Pen shown delivers 0.25 mg or 0.5 mg per injection.

Adult patients with type 2 diabetes, treated with diet and exercise, should expect more...
Indication and Limitations of Use

Ozempic® (semaglutide) injection 0.5 mg or 1 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

- Ozempic® is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic® is not a substitute for insulin. Ozempic® is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.

Important Safety Information

**WARNING: RISK OF THYROID C-CELL TUMORS**

- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.

Please see Brief Summary of Prescribing Information, including Boxed Warning, on adjacent pages.

Pen shown delivers 0.25 mg or 0.5 mg per injection.

Ozempic® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2018 Novo Nordisk. Printed in the U.S.A. US1802M00014 May 2018.
OZEMPIC® (semaglutide) injection

BRIEF SUMMARY: Please consult package insert for full prescribing information.

WARNING: RISK OF THYROID C-CELL TUMORS: In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions]. OZEMPIC® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC® [see Contraindications and Warnings and Precautions].

INDICATIONS AND USAGE: OZEMPIC® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: OZEMPIC® is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans [see Warnings and Precautions]. OZEMPIC® has not been studied in patients with a history of pancreatitis. Consider other anti-diabetic therapies in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.

CONTRAINDICATIONS: OZEMPIC® is contraindicated in patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions]; Known hypersensitivity to semaglutide or to any of the product components [see Warnings and Precautions].

WARNINGS AND PRECAUTIONS: Risk of Thyroid C-Cell Tumors: In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures. It is unknown whether OZEMPIC® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the relevance of rodent C-cell tumor findings to humans is uncertain. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC®. Monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC®. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin value may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated. Pancreatitis: In glycemic control trials, acute pancreatitis was confirmed by adjudication in 7 OZEMPIC®-treated patients (0.3 cases per 100 patient years) versus 3 in comparator-treated patients (0.2 cases per 100 patient years). One case of chronic pancreatitis was confirmed in an OZEMPIC®-treated patient. In a 2-year trial, acute pancreatitis was confirmed by adjudication in 8 OZEMPIC®-treated patients (0.27 cases per 100 patient years) and 10 placebo-treated patients (0.33 cases per 100 patient years), both on a background of standard of care. After initiation of OZEMPIC®, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be associated with vomiting). If acute pancreatitis is confirmed, OZEMPIC® should be discontinued and appropriate management initiated; if confirmed, OZEMPIC® should not be restarted. Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC® (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC® 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC® 0.7%, placebo 0.4%). Rapid improvement in glycemic control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. Never Share an OZEMPIC® Pen Between Patients: OZEMPIC® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: The risk of hypoglycemia is increased when OZEMPIC® is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Patients may require a lower dose of the secretagogue or insulin to reduce the risk of hypoglycemia. In a setting [see Adverse Reactions, Drug Interactions]. Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of OZEMPIC® in patients reporting severe adverse gastrointestinal reactions. Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of OZEMPIC®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity to OZEMPIC® [see Contraindications]. Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with OZEMPIC®. Macrovacular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with OZEMPIC®.

ADVERSE REACTIONS: The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-Cell Tumors [see Warnings and Precautions], Pancreatitis [see Warnings and Precautions], Diabetic Retinopathy Complications [see Warnings and Precautions], Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions], Acute Kidney Injury [see Warnings and Precautions], Hypersensitivity [see Warnings and Precautions]. Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Pool of Placebo-Controlled Trials: The data in Table 1 are derived from 9 placebo-controlled trials (T monotherapy trial and 9 trial in combination with basal insulin) in patients with type 2 diabetes. These data reflect exposure of 521 patients to OZEMPIC® and a mean duration of exposure to OZEMPIC® (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC® 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC® 0.7%, placebo 0.4%). Rapid improvement in glycemic control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. Never Share an OZEMPIC® Pen Between Patients: OZEMPIC® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: The risk of hypoglycemia is increased when OZEMPIC® is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Patients may require a lower dose of the secretagogue or insulin to reduce the risk of hypoglycemia. In a setting [see Adverse Reactions, Drug Interactions]. Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of OZEMPIC® in patients reporting severe adverse gastrointestinal reactions. Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of OZEMPIC®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity to OZEMPIC® [see Contraindications]. Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with OZEMPIC®. Macrovacular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with OZEMPIC®.
adverse reactions, excluding hypoglycemia, associated with the use of OZEMPIC® in placebo-controlled trials. The incidence of events related to hypoglycemia by various definitions in these trials and occurred in at least 5% of patients treated with OZEMPIC®. Common Adverse Reactions: Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of OZEMPIC® in the placebo-controlled trials. These adverse reactions occurred more commonly on OZEMPIC® than on placebo, and occurred in at least 5% of patients treated with OZEMPIC®.

Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC®-Treated Patients with Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Placebo (N=262)</th>
<th>OZEMPIC® 0.5 mg (N=260)</th>
<th>OZEMPIC® 1 mg (N=261)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>6.1</td>
<td>15.8</td>
<td>20.3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2.3</td>
<td>5.0</td>
<td>9.2</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1.9</td>
<td>8.5</td>
<td>8.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4.6</td>
<td>7.3</td>
<td>5.7</td>
</tr>
<tr>
<td>Constipation</td>
<td>1.5</td>
<td>5.0</td>
<td>3.1</td>
</tr>
</tbody>
</table>

In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1. Gastrointestinal Adverse Reactions: In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC® than placebo (placebo 15.3%, OZEMPIC® 0.5 mg 32.7%, OZEMPIC® 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving OZEMPIC® 0.5 mg (31%) and OZEMPIC® 1 mg (38%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of >5% were associated with OZEMPIC® (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.6%, 0.8%, 0.4%). Other Adverse Reactions: Hypoglycemia: Table 2 summarizes the incidence of events related to hypoglycemia by various definitions in the placebo-controlled trials.

Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials In Patients with Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Monotherapy</th>
<th>Placebo</th>
<th>OZEMPIC® 0.5 mg</th>
<th>OZEMPIC® 1 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>(30 weeks)</td>
<td>N=129</td>
<td>N=127</td>
<td>N=130</td>
</tr>
<tr>
<td>Severe†</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Documented symptomatic (≤70 mg/dL glucose threshold)</td>
<td>0%</td>
<td>1.6%</td>
<td>3.8%</td>
</tr>
<tr>
<td>Severe† or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)</td>
<td>1.6%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Add-on to Basal Insulin with or without Metformin</td>
<td>5.3%</td>
<td>8.3%</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

“Severe” hypoglycemia adverse reactions are episodes requiring the assistance of another person. Hypoglycemia was more frequent when OZEMPIC® was used in combination with a sulfonylurea [see Warnings and Precautions]. Severe hypoglycemia occurred in 0.8% and 1.2% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Documented symptomatic hypoglycemia occurred in 17.9% and 24.4% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Severe or blood glucose confirmed symptomatic hypoglycemia occurred in 6.5% and 10.4% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Injection Site Reactions: In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC®-treated patients. Increases in Amylase and Lipase: In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with OZEMPIC® 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients. Increases in Heart Rate: In placebo-controlled trials, OZEMPIC® 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats per minute. There was a mean decrease in heart rate of 0.3 beats per minute in placebo-treated patients. Hypoglycemia: Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC® include fatigue, dysgeusia and dizziness. Immunogenicity: Consistent with the potential immunogenic properties of protein and peptide pharmaceuticals, patients treated with OZEMPIC® may develop anti-semaglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to semaglutide in the studies described below cannot be directly compared with the incidence of antibodies in other studies or to other products. Across the placebo- and active-controlled glycemic control trials, 32 (1.0%) OZEMPIC®-treated patients developed anti-drug antibodies (ADAs) to the active ingredient in OZEMPIC® (i.e., semaglutide). Of the 32 semaglutide-treated patients that developed semaglutide ADAs, 19 patients (0.6% of the overall population) developed antibodies cross-reacting with native GLP-1. The in vitro neutralizing activity of the antibodies is uncertain at this time.

DRUG INTERACTIONS: Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin: The risk of hypoglycemia is increased when OZEMPIC® is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions]. Oral
Medications: OZEMPIC® causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree. Nonetheless, caution should be exercised when oral medications are concomitantly administered with OZEMPIC®.

USE IN SPECIFIC POPULATIONS: Pregnancy: Risk Summary: There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. OZEMPIC® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at maternal exposures below the maximum recommended human dose (MRHD) based on AUC. In rabbits and cynomolgous monkeys administered semaglutide during organogenesis, early pregnancy losses and structural abnormalities were observed at below the MRHD (rabbit) and ≥5-fold the MRHD (monkey). These findings coincided with a marked maternal body weight loss in both animal species (see Data).

The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c >7 and has been reported to be as high as 20–25% in women with a HbA1c >10. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations: Disease associated maternal and fetal risk. Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data: Animal Data: In a combined fertility and embryofetal development study in rats, subcutaneous doses of 0.01, 0.03 and 0.09 mg/kg/day (0.1-, 0.4-, and 1.1-fold the MRHD) were administered to males for 4 weeks prior to and throughout mating and to females for 2 weeks prior to mating, and throughout organogenesis to Gestation Day 17. In parental animals, pharmacologically mediated reductions in body weight gain and food consumption were observed at all dose levels. In the offspring, reduced growth and fetuses with visceral (heart blood vessels) and skeletal (cranial bones, vertebra, ribs) abnormalities were observed at the human exposure. In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.001, 0.0025 or 0.0075 mg/kg/day (0.03-, 0.3-, and 2.3-fold the MRHD) were administered throughout organogenesis from Gestation Day 6 to 19. Pharmacologically mediated reductions in maternal body weight gain and food consumption were observed at all dose levels. Early pregnancy losses and increased incidences of minor visceral (kidney, liver) and skeletal (sternbra) fetal abnormalities were observed at ≥0.0025 mg/kg/day, at clinically relevant exposures. In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (1.0-, 5.2-, and 14.9-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50. Pharmacologically mediated, marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with the occurrence of sporadic abnormalities (vertebra, sternbra, ribs) at ≥0.075 mg/kg twice weekly (≥5X human exposure). In a pre- and postnatal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (0.7-, 3.3-, and 7.2-fold the MRHD) were administered from Gestation Day 16 to 140. Pharmacologically mediated marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with an increase in early pregnancy losses and led to delivery of slightly smaller offspring at ≥0.075 mg/kg twice weekly (≥3X human exposure). Lactation: Risk Summary: There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Semaglutide was present in the milk of lactating rats, however, due to species-specific differences in lactation physiology, the clinical relevance of these data are not clear (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OZEMPIC® and any potential adverse effects on the breastfed infant from OZEMPIC® or from the underlying maternal condition. Data: In lactating rats, semaglutide was detected in milk at levels 3-12 fold lower than in maternal plasma. Females and Males of Reproductive Potential: Discontinue OZEMPIC® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide (see Use in Specific Populations).

Pediatric Use: Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years). Geriatric Use: In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC®-treated patients were 65 years of age and over and 102 OZEMPIC®-treated patients (3.2%) were 75 years of age and over. In SUSTAIN 6, the cardiovascul ar outcome trial, 788 (48.0%) OZEMPIC®-treated patients were 65 years of age and over and 157 OZEMPIC®-treated patients (9.6%) were 75 years of age and over. No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Renal Impairment: No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no clinically relevant change in semaglutide pharmacokinetics (PK) was observed. Hepatic Impairment: No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. In a study in subjects with different degrees of hepatic impairment, no clinically relevant change in semaglutide pharmacokinetics (PK) was observed.

OVERDOSAGE: In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of OZEMPIC® of approximately 1 week.

More detailed information is available upon request.

For information about OZEMPIC® contact: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, 1-888-693-6742 Date of Issue: December 2017 Version: 1 Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark OZEMPIC® and NovoFine® are registered trademarks of Novo Nordisk A/S.

(This page left intentionally blank)
Final Program

78th Scientific Sessions
June 22-26, 2018
Orange County Convention Center
Orlando, Florida
78th Scientific Sessions Educational Support

This activity is supported, in part, by unrestricted educational grants from the following companies:

Merck

Merck/Pfizer Alliance

The Leona M. and Harry B. Helmsley Charitable Trust
Table of Contents

Welcome ........................................................................................................................................................................... 1

Abstracts
General Poster Sessions ......................................................................................................................... 89, 124, 156
Moderated Poster Discussions ...................................................................................................................... 90-93, 125-126, 157
Abstract Author Index ........................................................................................................................................ 319-401
Abstract Reviewers ........................................................................................................................................... 32-34
Poster Session Titles ........................................................................................................................................... 200-318

Association Leadership ........................................................................................................................................... 2-4
Association Officers Leadership and Service Recognition ........................................................................ 9, 16-17

Award Recipients
Banting Medal for Scientific Achievement .................................................................................................. 10, 122
Outstanding Scientific Achievement Award .................................................................................................. 10, 153
Albert Renold Award ......................................................................................................................................... 11
Outstanding Achievement in Clinical Diabetes Research Award ................................................................. 11
Outstanding Educator in Diabetes Award ........................................................................................................ 12, 87
Outstanding Physician Clinician in Diabetes Award ..................................................................................... 12
Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes ..................................... 13
Kelly West Award for Outstanding Achievement in Epidemiology .............................................................. 13, 127
Richard R. Rubin Award .................................................................................................................................. 14, 94
Roger Pecoraro Award ....................................................................................................................................... 14, 103
Norbert Freinkel Award ..................................................................................................................................... 15, 104
Edwin Bierman Award ....................................................................................................................................... 15, 161
Young Investigator Travel Grant Award Recipients ..................................................................................... 28-29
Abstract Award Recipients ..................................................................................................................................... 30

Continuing Education
Learning Objectives and Target Audience .................................................................................................. 43
Accreditation Statements .................................................................................................................................. 44-45
Continuing Education Credit ............................................................................................................................ 46
Personal Session Tracking Worksheet ........................................................................................................... 47-55

Corporate Symposia ............................................................................................................................................. 402-408

Exhibit Hall
Exhibitors ............................................................................................................................................................... 417-429
Exhibitors by Product Category/Booth Number ............................................................................................... 430-433

General Information ........................................................................................................................................... 35-42

Journal Editors ......................................................................................................................................................... 8

Presidential Addresses
President, Health Care & Education Address .................................................................................................. 87
President, Medicine & Science Address ............................................................................................................. 122

Product Theaters ..................................................................................................................................................... 409-416

Program Information
Friday, June 22 .................................................................................................................................................. 56-75
Saturday, June 23 ........................................................................................................................................... 76-109
Sunday, June 24 ............................................................................................................................................. 110-139
Monday, June 25 ............................................................................................................................................ 140-175
Tuesday, June 26 .......................................................................................................................................... 176-181
Networking Reception ........................................................................................................................................ 39, 75
National Scientific & Health Care Achievement Awards Presentation .................................................................. 153

Scientific Sessions Meeting Planning Committee .......................................................................................... 31
Scientific Sessions Meeting Planning Committee Disclosures ...................................................................... 434-435

Speakers
Invited Speaker Index .......................................................................................................................................... 182-199
Invited Speaker Disclosure Information ......................................................................................................... 436-451
78th Scientific Sessions Commercial Support

The ADA is grateful for the continued support and generosity of the following companies:

- **Abstracts on USB**
  - Sanofi

- **Albert Renold Award**
  - Merck

- **Bus Fleets**
  - Abbott

- **Exhibit Hall Aisle Signs**
  - Akcea Therapeutics;
    - Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA;
    - Sanofi and Lexicon Pharmaceuticals Inc.

- **Exhibit Hall Stepping Stone**
  - Floor Graphics
  - Merck

- **Final Program**
  - Novo Nordisk A/S

- **Hotel Key Cards**
  - Novo Nordisk Inc.

- **Interactive Online Posters (ePosters)**
  - Sanofi

- **Kelly West Award for Outstanding Achievement in Epidemiology**
  - Merck

- **Meeting App**
  - Sanofi

- **Patron Sponsors**
  - Merck;
    - The Leona M. and Harry B. Helmsley Charitable Trust

- **Welcome Carpet**
  - Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA;
    - Sanofi and Lexicon Pharmaceuticals Inc.

- **5K@ADA Fun Run/Walk**
  - Novo Nordisk Inc.
Welcome from the Officers of the American Diabetes Association

It is our pleasure to welcome you to the ADA’s 78th Scientific Sessions. As the world’s largest meeting on diabetes, the Scientific Sessions is both a leading educational gathering and a unique opportunity to network with colleagues from all 50 states and 111 countries.

The 34-member Scientific Sessions Meeting Planning Committee, chaired by Dr. Maureen A. Gannon, has developed an exciting and informative educational program. The five-day schedule will feature the most recent and significant advances in basic science and the prevention, diagnosis, and treatment of diabetes and its complications.

The Association will honor recipients of its highest National Scientific and Health Care Achievement Awards. Special lectures will be given by recipients of the Banting Medal for Scientific Achievement, the Outstanding Scientific Achievement Award, the Outstanding Educator in Diabetes Award, and the Kelly West Award for Outstanding Achievement in Epidemiology. The Scientific Sessions will also feature special award lectureships sponsored by the Professional Interest Groups.

We encourage you to visit the Poster Hall to view cutting-edge research and have one-on-one conversations with poster presenters in a convenient and relaxed environment. Or, join one of the many moderated poster discussions where you can listen in as poster presenters share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators.

Be sure to take advantage of the world’s largest exposition of diabetes-related products, services, and technology by visiting the Exhibit Hall. More than 150 companies will showcase the latest and most innovative technology and resources available.

Do you have an idea for a session that you would like to see featured at next year’s Scientific Sessions? The Scientific Sessions Meeting Planning Committee is soliciting high quality, innovative session proposals for the 79th Scientific Sessions. The committee encourages submissions that are innovative, challenge current treatment paradigms, and represent the latest advances in basic, clinical, and translational science. This is your opportunity to shape the scientific program and help ensure that the most relevant spectrum of topics is presented at the meeting. Visit www.sciencesessions.diabetes.org for more information.

The caliber of scientific exchange, quality of the presenters, and engaged attendees are what make the Scientific Sessions unique. Thank you for joining us this year in Orlando.

Karen Talmadge, PhD
Chair of the Board

Felicia Hill-Briggs, PhD, ABPP
President, Health Care & Education

Jane E.B. Reusch, MD
President, Medicine & Science

Michael Ching, CPA
Secretary/Treasurer

Tracey D. Brown, MBA, BChE
Chief Executive Officer
Officers of the American Diabetes Association

Chair of the Board
Karen Talmadge, PhD

President, Health Care & Education
Felicia Hill-Briggs, PhD, ABPP

Chair of the Board-Elect
David Herrick, MBA

President-Elect, Health Care & Education
Gretchen A. Youssef, MS, RD, CDE

Chief Executive Officer
Tracey D. Brown, MBA, BChE
President, Medicine & Science
Jane E.B. Reusch, MD

Secretary/Treasurer
Michael Ching, CPA

President-Elect, Medicine & Science
Louis H. Philipson, MD, PhD, FACP

Secretary/Treasurer-Elect
Brian Bertha, JD, MBA
Officers and Board of Directors of the American Diabetes Association

Chair of the Board  Karen Talmadge, PhD
President, Health Care & Education  Felicia Hill-Briggs, PhD, ABPP
President, Medicine & Science  Jane E.B. Reusch, MD
Secretary/Treasurer  Michael Ching, CPA
Chair of the Board-Elect  David Herrick, MBA
President-Elect, Health Care & Education  Gretchen A. Youssef, MS, RD, CDE
President-Elect, Medicine & Science  Louis H. Philipson, MD, PhD, FACP
Secretary/Treasurer-Elect  Brian Bertha, JD, MBA
Chief Executive Officer  Tracey D. Brown, MBA, BChE

At-Large Members

Janet Brown Friday, RN, MSN, MPH  Sherita Golden, MD, MHS
Martha Clark, MBA  C. Ronald Kahn, MD
Mary de Groot, PhD  Cynthia Muñoz, PhD, MPH
Robert H. Eckel, MD  Christopher Ralston, JD
Past Officers of the American Diabetes Association

Past Chairs of the Board

1973-1974 Gail Patrick Velde
1974-1977 Wendell Mayes, Jr.
1977-1979 Myles H. Tanenbaum
1979-1981 Benjamin Greenspoon
1981-1983 Harlan L. Hanson
1983-1984 Gordon T. Stulberg
1984-1985 Joseph H. Davis
1985-1986 Henry M. Rivera
1986-1987 Sam A. Gallo
1987-1988 S. Douglas Dodd
1988-1989 William A. Mamrack
1989-1990 Sterling Tucker
1990-1991 Arnold Bereson
1991-1992 Todd E. Leigh
1993-1994 Michael A. Greene
1994-1995 Douglas E. Lund
1995-1996 David H. McClure
1996-1997 Alan Altschuler
1997-1998 Stephen J. Satalino
1998-1999 Jane Camporeale
1999-2000 Edward T. Hawthorne
2000-2001 Charles F. Baer
2001-2002 Stephen H. Smith
2002-2003 Michael A. Weiss
2003-2004 James A. Horbowicz
2004-2005 Larry K. Ellingson, RPh
2005-2006 Lawrence T. Smith
2007 Darlene L. Cain
2008 R. Stewart Perry
2009 George J. Huntley, CPA
2010 Nash M. Childs, PE
2011 John W. Griffin, Jr.
2012 L. Hunter Limbaugh
2013 Karen Talmadge, PhD
2014 Dwight Holing
2015 Janel L. Wright, JD
2016 Robin J. Richardson
2017 David A. DeMarco, PhD

Past Presidents, Health Care & Education*

1976-1979 Patricia A. Lawrence, RN, MA
1979-1981 Barbara Prater, RD, PhD
1982-1983 Florence R. Ruhland, RN, MEd
1984-1986 Patricia A. Schultz, RN, MS, CDE
1987-1988 Linda S. Hurwitz, RN, MS
1988-1989 Alan D. Cherrington, PhD
1989-1990 Mary Louise Maras, RD, CDE
1990-1991 Charlene Freeman, RN, CDE
1992-1994 Patricia D. Stenger, RN, CDE
1994-1995 Linda M. Siminerio, RN, MS, CDE, PhD
1996-1997 Belinda P. Childs, ARNP, MN, CDE
1997-1998 Christine A. Beebe, MS, RD, CDE, LD
1998-1999 Linda B. Haas, PhC, RN, CDE
1999-2000 Elizabeth A. Walker, DNSc, RN, CDE
2000-2001 Lee J. Sanders, DPM
2001-2002 Anne E. Daly, MS, RD, BC-ADM, CDE
2002-2003 Martha M. Funnell, MS, RN, CDE
2003-2004 Carole R. Mensing, RN, MA, CDE
2004-2005 Catherine J. Tibbetts, RN, MPH, CDE
2005-2006 Karmeen Kulkarni, MS, RD, BC-ADM, CDE
2006-2007 Richard R. Rubin, PhD, CDE
2008 Ann L. Albright, PhD, RD
2009 Sue McLaughlin, BS, RD, CDE, CPT
2010 Christine T. Tobin, MS, MBA, CDE
2011 Elizabeth Mayer-Davis, MSPH, PhD, RD
2012 Geralyn R. Spollett, MSN, ANP-CS, BC-ADM
2013 Lurelean B. Gaines, RN, MSN
2014 Marjorie Cypress, PhD, C-ANP, CDE
2015 David G. Marrero, PhD
2016 Margaret A. Powers, PhD, RD, CDE
2017 Brenda Montgomery, RN, MSHS, CDE

*New title effective July 1, 1996. Past titles included Vice President, Health Professional, and Senior Vice President.
### Past Presidents, Medicine & Science

<table>
<thead>
<tr>
<th>Years</th>
<th>Name</th>
<th>Years</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1940-1941</td>
<td>Cecil Striker, MD</td>
<td>1980-1981</td>
<td>Donald I. Bell, MD</td>
</tr>
<tr>
<td>1941-1942</td>
<td>Herman O. Monsenthal, MD</td>
<td>1981-1982</td>
<td>Oscar B. Crofford, MD</td>
</tr>
<tr>
<td>1942-1944</td>
<td>Joseph T. Beardwood, Jr., MD</td>
<td>1982-1983</td>
<td>Irving L. Sparrt, MD</td>
</tr>
<tr>
<td>1944-1946</td>
<td>Joseph H. Barach, MD</td>
<td>1983-1984</td>
<td>Allan L. Drash, MD</td>
</tr>
<tr>
<td>1946-1947</td>
<td>Russell M. Wilder, MD</td>
<td>1984-1985</td>
<td>Karl E. Sussman, MD</td>
</tr>
<tr>
<td>1947-1948</td>
<td>Edward S. Dillon, MD</td>
<td>1985-1986</td>
<td>Harold Rifkin, MD</td>
</tr>
<tr>
<td>1949-1950</td>
<td>Howard F. Root, MD</td>
<td>1987-1988</td>
<td>John A. Colwell, MD, PhD</td>
</tr>
<tr>
<td>1951-1952</td>
<td>Arthur R. Colwell, Sr., MD</td>
<td>1989-1990</td>
<td>Sherman M. Holvey, MD</td>
</tr>
<tr>
<td>1956-1957</td>
<td>Frederick W. Williams, MD</td>
<td>1994-1995</td>
<td>Kathleen L. Wishner, PhD, MD</td>
</tr>
<tr>
<td>1957-1958</td>
<td>John A. Reed, MD</td>
<td>1995-1996</td>
<td>Frank Vinicor, MD, MPH</td>
</tr>
<tr>
<td>1960-1961</td>
<td>Franklin B. Peck, Sr., MD</td>
<td>1998-1999</td>
<td>Gerald Bernstein, MD</td>
</tr>
<tr>
<td>1961-1962</td>
<td>Blair Holcomb, MD</td>
<td>1999-2000</td>
<td>Bruce R. Zimmerman, MD</td>
</tr>
<tr>
<td>1963-1964</td>
<td>Thomas P. Sharkey, MD</td>
<td>2001-2002</td>
<td>Christopher D. Saudek, MD</td>
</tr>
<tr>
<td>1964-1965</td>
<td>Rachmiel Levine, MD</td>
<td>2002-2003</td>
<td>Francine R. Kaufman, MD</td>
</tr>
<tr>
<td>1965-1966</td>
<td>T.S. Danowski, MD</td>
<td>2003-2004</td>
<td>Eugene J. Barrett, MD, PhD</td>
</tr>
<tr>
<td>1966-1967</td>
<td>L.O. Underdahl, MD</td>
<td>2004-2005</td>
<td>Alan D. Cherrington, PhD</td>
</tr>
<tr>
<td>1968-1969</td>
<td>Harvey C. Knowles, Jr., MD</td>
<td>2006-2007</td>
<td>Larry C. Deeb, MD</td>
</tr>
<tr>
<td>1969-1970</td>
<td>Robert C. Hardin, MD</td>
<td>2008</td>
<td>John B. Buse, MD, PhD</td>
</tr>
<tr>
<td>1970-1971</td>
<td>James B. Hurd, MD</td>
<td>2009</td>
<td>R. Paul Robertson, MD</td>
</tr>
<tr>
<td>1971-1972</td>
<td>Stefan S. Fajans, MD</td>
<td>2010</td>
<td>Richard M. Bergenstal, MD</td>
</tr>
<tr>
<td>1972-1973</td>
<td>William H. Grishaw, MD</td>
<td>2011</td>
<td>Robert R. Henry, MD</td>
</tr>
<tr>
<td>1973-1974</td>
<td>Addison B. Scoville, Jr., MD</td>
<td>2012</td>
<td>Vivian Fonseca, MD</td>
</tr>
<tr>
<td>1974-1975</td>
<td>Max Ellenberg, MD</td>
<td>2013</td>
<td>John E. Anderson, MD</td>
</tr>
<tr>
<td>1975-1976</td>
<td>George F. Cahill, Jr., MD</td>
<td>2014</td>
<td>Elizabeth R. Seaquist, MD</td>
</tr>
<tr>
<td>1977-1978</td>
<td>Norbert Freinkel, MD</td>
<td>2016</td>
<td>Desmond Schatz, MD</td>
</tr>
<tr>
<td>1978-1979</td>
<td>Fred W. Whitehouse, MD</td>
<td>2017</td>
<td>Alvin C. Powers, MD</td>
</tr>
<tr>
<td>1979-1980</td>
<td>Ronald A. Arky, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>Secretary</td>
<td>Treasurer</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------</td>
<td>------------------------------------</td>
<td></td>
</tr>
<tr>
<td>1971-1972</td>
<td>John I. Murphy</td>
<td>Walter S. Morris</td>
<td></td>
</tr>
<tr>
<td>1972-1975</td>
<td>William O. Stoufer</td>
<td>Myles H. Tanenbaum</td>
<td></td>
</tr>
<tr>
<td>1975-1976</td>
<td>Virginia C. Coyle</td>
<td>Eric G. Dunkley</td>
<td></td>
</tr>
<tr>
<td>1977-1980</td>
<td>Dorothy Kaplan</td>
<td>Michael C. Salapka</td>
<td></td>
</tr>
<tr>
<td>1980-1981</td>
<td>Sydelle Feinman</td>
<td>Norman F. Rickeman</td>
<td></td>
</tr>
<tr>
<td>1985-1987</td>
<td>Frank Rosenhoover</td>
<td>Stephen J. Satalino</td>
<td></td>
</tr>
<tr>
<td>1987-1989</td>
<td>Gloria Hirsch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990-1992</td>
<td>Marilyn Moore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994-1996</td>
<td>Denise Dodero</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Dwight Holing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>Pearson C. Cummin III, MBA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Patrick L. Shuler, CPA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Robert J. Singley, MBA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Richard Farber, MBA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Lorrie Welker Liang</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Umesh Verma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Secretary and Treasurer merged to Secretary/Treasurer effective July 1, 1996.**
Journal Editors

**Diabetes Editors-in-Chief**

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1952-1955</td>
<td>Frank N. Allan, MD</td>
</tr>
<tr>
<td>1956-1960</td>
<td>William C. Stadie, MD</td>
</tr>
<tr>
<td>1961-1966</td>
<td>Irving Graef, MD</td>
</tr>
<tr>
<td>1967-1972</td>
<td>Harvey C. Knowles, Jr., MD</td>
</tr>
<tr>
<td>1973-1978</td>
<td>David M. Kipnis, MD</td>
</tr>
<tr>
<td>1979-1983</td>
<td>Daniel W. Foster, MD</td>
</tr>
<tr>
<td>1984-1986</td>
<td>Charles J. Goodner, MD</td>
</tr>
<tr>
<td>1987-1991</td>
<td>R. Paul Robertson, MD</td>
</tr>
<tr>
<td>1992-1995</td>
<td>Philip E. Cryer, MD</td>
</tr>
<tr>
<td>1996</td>
<td>Julio V. Santiago, MD</td>
</tr>
<tr>
<td>1997-2001</td>
<td>Gordon C. Weir, MD</td>
</tr>
<tr>
<td>2002-2006</td>
<td>Franz M. Matschinsky, MD</td>
</tr>
<tr>
<td>2007-2011</td>
<td>Peter C. Butler, MD</td>
</tr>
<tr>
<td>2012-2016</td>
<td>K. Sreekumaran Nair, MD, PhD</td>
</tr>
<tr>
<td>Current</td>
<td>Martin G. Myers, Jr., MD, PhD</td>
</tr>
</tbody>
</table>

**Diabetes Care Editors-in-Chief**

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1978-1982</td>
<td>Jay S. Skyler, MD</td>
</tr>
<tr>
<td>1983-1987</td>
<td>F. John Service, MD</td>
</tr>
<tr>
<td>1988-1991</td>
<td>David C. Robbins, MD</td>
</tr>
<tr>
<td>1992-1996</td>
<td>Allan L. Drash, MD</td>
</tr>
<tr>
<td>1997-2001</td>
<td>Charles M. Clark, Jr., MD</td>
</tr>
<tr>
<td>2002-2006</td>
<td>Mayer B. Davidson, MD</td>
</tr>
<tr>
<td>2007-2011</td>
<td>Vivian Fonseca, MD</td>
</tr>
<tr>
<td>2012-2017</td>
<td>William T. Cefalu, MD</td>
</tr>
<tr>
<td>Current</td>
<td>Matthew C. Riddle, MD</td>
</tr>
</tbody>
</table>

**Clinical Diabetes Editors-in-Chief**

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983-1987</td>
<td>Philip Raskin, MD</td>
</tr>
<tr>
<td>1988-1992</td>
<td>Marvin E. Levin, MD</td>
</tr>
<tr>
<td>1993-1997</td>
<td>Alan J. Garber, MD, PhD</td>
</tr>
<tr>
<td>1998-2002</td>
<td>Irl B. Hirsch, MD</td>
</tr>
<tr>
<td>2003-2006</td>
<td>Jennifer B. Marks, MD, FACP, FACE</td>
</tr>
<tr>
<td>2007-2011</td>
<td>Tom A. Elasy, MD, MPH</td>
</tr>
<tr>
<td>2012-2016</td>
<td>Davida F. Kruger, MSN, APRN-BC, BC-ADM</td>
</tr>
<tr>
<td>Current</td>
<td>Stephen A. Brunton, MD</td>
</tr>
</tbody>
</table>

**Diabetes Spectrum Editors-in-Chief**

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988-1992</td>
<td>Patricia A. Lawrence, RN, MA</td>
</tr>
<tr>
<td>1993-1995</td>
<td>Elizabeth A. Walker, DNsC, RN, CDE</td>
</tr>
<tr>
<td>1996-2000</td>
<td>Linda M. Siminerio, MS, RN, CDE</td>
</tr>
<tr>
<td>2001-2005</td>
<td>Belinda P. Childs, MN, ARNP, CDE</td>
</tr>
<tr>
<td>2006-2008</td>
<td>Davida F. Kruger, MSN, APN-BC, BC-ADM</td>
</tr>
<tr>
<td>2009-2013</td>
<td>Jackie Boucher, MS, RD, LD, CDE</td>
</tr>
<tr>
<td>Current</td>
<td>Joshua J. Neumiller, PharmD, CDE, CGP, FASCP</td>
</tr>
</tbody>
</table>

**Diabetes Forecast Editors-in-Chief**

<table>
<thead>
<tr>
<th>Year</th>
<th>Editor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1985-1988</td>
<td>Arthur Krosnick, MD</td>
</tr>
<tr>
<td>1989-1993</td>
<td>Philip Levy, MD</td>
</tr>
<tr>
<td>1994-1998</td>
<td>Neal Friedman, MD</td>
</tr>
<tr>
<td>1999-2001</td>
<td>Michael A. Pfeifer, MD</td>
</tr>
<tr>
<td>2002</td>
<td>Robert J. Tanenberg, MD, FACP</td>
</tr>
<tr>
<td>2002-2006</td>
<td>Linda M. Siminerio, RN, PhD, CDE</td>
</tr>
<tr>
<td>2007</td>
<td>M. Sue Kirkman, MD</td>
</tr>
<tr>
<td>Current</td>
<td>Paris Roach, MD</td>
</tr>
</tbody>
</table>
Award Recipients

National Scientific & Health Care Achievement Award Recipients

Banting Medal for Scientific Achievement ................................................................. Gerald I. Shulman, MD, PhD, FACP, MACE
Outstanding Scientific Achievement Award ................................................................. Lora K. Heisler, PhD
Albert Renold Award ............................................................................................... Mark A. Atkinson, PhD
Outstanding Achievement in Clinical Diabetes Research Award ........................ Rury R. Holman, FRCP, FMedSci
Outstanding Educator in Diabetes Award ................................................................. Jackie L. Boucher, MS, RDN
Outstanding Physician Clinician in Diabetes Award ................................................ Andrew J. Ahmann, MD
Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes ................................................................. Viswanathan Mohan, MD, PhD, DSc
Kelly West Award for Outstanding Achievement in Epidemiology ........................ Catherine C. Cowie, PhD, MPH

Professional Interest Group Award Recipients

Richard R. Rubin Award ......................................................................................... Tim Wysocki, PhD, ABPP
Roger Pecoraro Award ........................................................................................ Edgar J.G. Peters, MD, PhD
Norbert Freinkel Award ....................................................................................... Linda (Lynn) A. Barbour, MD, MSPH, FACP
Edwin Bierman Award ........................................................................................ Alessandro Doria, MD, PhD, MPH

Association Officers Leadership and Service Recognition

Charles H. Best Medal for Leadership and Service .................................................. Karen Talmadge, PhD
Rachmiel Levine Medal for Leadership and Service ................................................ Felicia Hill-Briggs, PhD, ABPP
Banting Medal for Leadership and Service ............................................................. Jane E.B. Reusch, MD
Charles Kopke Medal for Leadership and Service .................................................. Michael Ching, CPA
National Scientific & Health Care Achievement Award Recipients

**Banting Medal for Scientific Achievement**
Gerald I. Shulman, MD, PhD, FACP, MACE

**Banting Medal Lecture**

*Mechanisms of Insulin Resistance—Implications for Obesity, Lipodystrophy, and Type 2 Diabetes*

Gerald I. Shulman, MD, PhD, FACP, MACE, is the recipient of the 2018 Banting Medal for Scientific Achievement. This award recognizes significant, long-term contributions to the understanding, treatment, or prevention of diabetes. Dr. Shulman will present the Banting Medal Lecture on Sunday, June 24.

Currently the George R. Cowgill Professor of Medicine and Cellular and Molecular Physiology at Yale University School of Medicine and Co-Director of the Yale Diabetes Research Center, Dr. Shulman is a Howard Hughes Medical Institute Investigator renowned for transformative studies examining the molecular mechanisms of insulin resistance in humans that have been paradigm shifting in our understanding of the pathogenesis of type 2 diabetes.

A clinical investigator with acute focus, he developed and implemented novel tools to elucidate the underpinnings of human metabolic physiology, leading to cutting-edge discoveries that have challenged dogma and stimulated new directions in the field. His groundbreaking application of magnetic resonance spectroscopy made it possible to directly examine intracellular glucose and lipid metabolism in humans thus providing a dynamic view of intracellular metabolism not before possible. Using this approach, he found that defects in insulin-stimulated muscle glycogen synthesis, due to defects in glucose transport activity, was the major factor responsible for muscle insulin resistance in individuals with type 2 diabetes and prediabetes. In another pivotal series of studies, he developed novel methods to measure hepatic glycogenolysis and gluconeogenesis in humans for the first time and demonstrated that increased hepatic gluconeogenesis is the major factor responsible for fasting hyperglycemia in type 2 diabetes.

With a body of work reflected in more than 450 publications and election to the National Academy of Medicine and the National Academy of Sciences, Dr. Shulman is a leader in translating basic science into clinical physiology.

Please join us in celebrating Dr. Shulman’s outstanding contributions to diabetes research.

---

**Outstanding Scientific Achievement Award**
Lora K. Heisler, PhD

**Outstanding Scientific Achievement Award Lecture**

*Harnessing Brain Circuits to Improve Type 2 Diabetes*

Lora K. Heisler, PhD, is the recipient of the 2018 Outstanding Scientific Achievement Award. This prestigious award recognizes research in diabetes that demonstrates particular independence of thought and originality. Dr. Heisler will present the Outstanding Scientific Achievement Award Lecture on Monday, June 25.

Dr. Heisler is Professor, Chair in Human Nutrition and Head of the Obesity and Food Choice Division of the Rowett Institute at the University of Aberdeen, Scotland as well as an elected Fellow of the Royal Society of Edinburgh. Dr. Heisler’s scientific contributions include seminal discoveries in the neurobiology of energy and glucose homeostasis that demonstrate her innovation.

In particular, Dr. Heisler has elucidated novel approaches to harness serotonin’s activity in the treatment of obesity and type 2 diabetes. Notably, she defined the mechanism through which the obesity medication d-fenfluramine exerts its beneficial effects—a clinically significant finding that contributed to the development of new obesity drugs targeting specific serotonin receptors. She also identified a mechanistically novel target for type 2 diabetes treatment, a subtype of serotonin receptors in the brain. Dr. Heisler further discovered substantially enhanced metabolic benefits by combining medications that target multiple components of the brain serotonin system.

Dr. Heisler exhibits a remarkable ability to apply basic science to clinically impactful work. Please join us in celebrating Lora K. Heisler, PhD, for her transformative contributions to diabetes research.
Outstanding Achievement in Clinical Diabetes Research Award
Rury R. Holman, FRCP, FMedSci

Rury R. Holman, FRCP, FMedSci, is the recipient of the 2018 Outstanding Achievement in Clinical Diabetes Research Award. This award recognizes exceptional contributions in patient-oriented clinical outcomes research that have had a significant impact on diabetes prevention and treatment.

Dr. Holman is Professor of Diabetic Medicine at the University of Oxford, Director of the University of Oxford Diabetes Trial Unit, and an NIHR Senior Investigator. Having delivered landmark clinical outcome trials over more than four decades, Dr. Holman is an exemplary clinical scientist and global leader in the field of diabetes.

Among his major accomplishments are pioneering studies in the use of basal insulin therapy for type 2 diabetes mellitus; co-invention of the first automated fingerpricker enabling home blood glucose monitoring and the first automated insulin pen, and instigator of the HOMA Calculator; co-design and operation of the 20-year UK Prospective Diabetes Study (UKPDS), which ushered in the modern era of diabetes risk factor management; and direction of the 10-year UKPDS post-trial monitoring program that identified the glucose “legacy effect,” which led guidelines worldwide to recommend targeting optimal blood glucose control immediately upon diagnosis of diabetes.

With more than 300 publications and more than 55,000 citations, Dr. Holman has been recognized as one of the top 400 living biomedical researchers and one of the world’s most influential scientific minds.

Please join us in celebrating Rury R. Holman, FRCP, FMedSci, for remarkable contributions that have substantially influenced the clinical care of diabetes.

Albert Renold Award
Mark A. Atkinson, PhD

Mark A. Atkinson, PhD, is the recipient of the 2018 Albert Renold Award. Supported by an unrestricted grant from Merck, this award is presented to an individual whose career is distinguished by outstanding achievements in the development of communities of scientists to enhance diabetes research.

Dr. Atkinson is the Jeffrey Keene Family Professor, American Diabetes Association Eminent Scholar for Diabetes Research, and Director of the Diabetes Institute at the University of Florida. With more than three decades dedicated to investigating the pathogenesis and natural history of type 1 diabetes (T1D), he has created a robust, collaborative environment for diabetes research that has contributed to significant advancements in our understanding of this disease.

Notably, Dr. Atkinson founded the Network for Pancreatic Organ donors with Diabetes (nPOD), a groundbreaking nation-wide effort that collects and distributes tissues from organ donors with T1D and those at risk for developing the disease to investigators throughout the world. Through nPOD, Dr. Atkinson has helped facilitate the performance of nearly 230 projects by 350 investigators in 20 countries to answer key T1D research questions. Furthermore, Dr. Atkinson has been active in training the next generation of diabetes researchers, including mentoring more than 30 graduate students, fellows and junior faculty, and serving on the American Diabetes Association’s Pathway to Stop Diabetes Mentor Advisory Group.

Please join us in celebrating Mark A. Atkinson, PhD, for outstanding contributions to developing strong scientific communities working collaboratively to advance diabetes-related discoveries.
Outstanding Physician Clinician in Diabetes Award
Andrew J. Ahmann, MD

Andrew J. Ahmann, MD, is the recipient of the 2018 Outstanding Physician Clinician in Diabetes Award. This award is presented to an individual to reward and honor meritorious contributions to diabetes clinical practice.

Dr. Ahmann is Professor of Medicine at Oregon Health & Science University (OHSU) and Director of the Harold Schnitzer Diabetes Health Center. In 2007, he led the transformation of the OHSU diabetes clinic into a comprehensive center serving more than 5,000 individuals with diabetes of all ages and socioeconomic circumstances. Among many contributions to the local diabetes community are long-term service as president of the ADA Leadership Council, chairing the Oregon Diabetes Coalition’s nutrition position statement, and decades of volunteering at diabetes camps.

Nationally, Dr. Ahmann has contributed to the *ADA Standards of Medical Care in Diabetes*, guidelines for inpatient management of hyperglycemia and guidelines on the use of diabetes technology. He currently serves on the ADA Scientific Sessions Planning Committee and was on the editorial board of *Diabetes Care*. Other scientific activities include numerous diabetes publications and clinical research projects, including the ongoing Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study and the Type 1 Diabetes Exchange.

Dr. Ahmann highly values training and mentorship of medical students, residents, and fellows, inspiring many to pursue diabetes research and practice.

Please join us in celebrating Andrew J. Ahmann, MD, for outstanding accomplishments in diabetes care.

Outstanding Educator in Diabetes Award
Jackie L. Boucher, MS, RDN

Outstanding Educator in Diabetes Award Lecture
*Connectedness—How Technology and Social Networks are Advancing Diabetes Nutrition Care*

Jackie L. Boucher, MS, RDN, is the recipient of the 2018 Outstanding Educator in Diabetes Award. This award recognizes a distinguished health professional who has made outstanding educational efforts in the field of diabetes and has demonstrated significant contributions to the understanding of diabetes education. Ms. Boucher will present the Outstanding Educator in Diabetes Award Lecture on Saturday, June 23.

As President of Children’s HeartLink in Minneapolis, Minnesota, Ms. Boucher leads a global organization with the mission of training doctors and nurses in underserved parts of the world to diagnose and treat children with heart disease. Ms. Boucher began contributing to the diabetes literature early in her career. In addition to her contributions to more than 75 publications, she has served on the editorial board for *Practical Diabetology*, as editor-in-chief of *Diabetes Spectrum*, and as a reviewer for the *Journal of the Academy of Nutrition and Dietetics* and *Diabetes Care*. She co-chaired the American Diabetes Association’s nutrition position statement, published in 2013, and served as a content expert panel member for the Advanced Diabetes Management credential.

Demonstrating her passion for improving health for all, Ms. Boucher was a lead investigator and continues as a co-investigator on Hearts Beat Back: The Heart of New Ulm Project, a 10-year demonstration project with a goal of decreasing the disease burden of diabetes and cardiovascular disease in a rural Minnesota community.

Please join us in celebrating Jackie L. Boucher, MS, RDN, for outstanding contributions to diabetes education and care.
Kelly West Award for Outstanding Achievement in Epidemiology
Catherine C. Cowie, PhD, MPH

Kelly West Award for Outstanding Achievement in Epidemiology Lecture
Diabetes Diagnosis and Control—Missed Opportunities to Improve Health
Catherine C. Cowie, PhD, MPH, is the recipient of the 2018 Kelly West Award for Outstanding Achievement in Epidemiology. Supported by an unrestricted educational grant from Merck, this award recognizes significant contributions to the field of diabetes epidemiology. Dr. Cowie will deliver the Kelly West Award Lecture on Sunday, June 24.

Having served most of her career at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Dr. Cowie is now Senior Advisor for the NIDDK Diabetes Epidemiology Program. Her body of work is described in more than 110 original research articles and book chapters. Her research spans the entire terrain of type 1 and type 2 diabetes epidemiology, including landmark studies in diabetes disparities in renal disease, discovery of the link between diabetes and hearing loss, and multiple reports, particularly in national data, on the prevalence of diabetes, prediabetes, diabetes care patterns, and diabetes complications.

Dr. Cowie’s current duties include developing national survey components and analyzing and publishing resultant data. She is the NIDDK project scientist for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study, and past project scientist for the Diabetes Prevention Trial—Type 1 Diabetes and TrialNet. She chairs the NIDDK Epidemiology Group Committee and edits the book Diabetes in America, now in its third edition. Beyond this, Dr. Cowie has dedicated much of her time expanding the pipeline of well-trained scientists in diabetes epidemiology through mentorship.

Please join us in recognizing Catherine C. Cowie, PhD, MPH, for outstanding contributions to diabetes epidemiology.
Professional Interest Group Award Recipients

Richard R. Rubin Award
Tim Wysocki, PhD, ABPP

Richard R. Rubin Award Lecture
_Diabetes and Behavior in the 21st Century—Things That Make You Go “Hmmmm”_

Tim Wysocki, PhD, ABPP, is the recipient of the 2018 Richard R. Rubin Award. This award recognizes a behavioral researcher who has made outstanding, innovative contributions to the study and understanding of behavioral aspects of diabetes in diverse populations. Dr. Wysocki will deliver the Richard R. Rubin Award Lecture on Saturday, June 23.

Dr. Wysocki is Co-Director of the Center for Health Care Delivery Science and Principal Research Scientist at Nemours Children’s Health System in Jacksonville, Florida. He has earned continuous NIH and other external funding since 1992 for his research on adaptation of children and adolescents with type 1 diabetes and their families to the challenges of living with this chronic condition. His research has explored interventions to promote family management of diabetes, family teamwork in diabetes management, youth and parent coping with knowledge about long term complications, and mechanisms of benefit among patients and families incorporating new diabetes technologies into their regimens.

Dr. Wysocki has published 158 journal articles and 155 other publications in the field, including the American Diabetes Association book, _The Ten Keys to Helping Your Child Grow Up with Diabetes_. He has been involved in the multidisciplinary clinical care of youth with type 1 diabetes and their families, and mentoring of post-doctoral fellows and early-career pediatric psychologists. Dr. Wysocki’s contributions have been recognized in national awards from the Society of Pediatric Psychology and JDRF.

Please join us in celebrating Tim Wysocki, PhD, ABPP, for his contributions in behavioral medicine and diabetes.

Roger Pecoraro Award
Edgar J.G. Peters, MD, PhD

Roger Pecoraro Award Lecture
_The Ghosts of Diabetic Foot Infection—Past, Present, and Yet to Come_

Edgar J.G. Peters, MD, PhD, is the recipient of the 2018 Roger Pecoraro Award. This award recognizes a researcher who has made scientific contributions and demonstrates an uniring commitment to improving the understanding of the detection, treatment, and prevention of diabetic foot complications. Dr. Peters will deliver the Roger Pecoraro Award Lecture on Saturday, June 23.

Currently, Dr. Peters is Director of the Infectious Diseases Fellowship Program and Head of the Outpatient Department of Internal Medicine at the VU University Medical Center in Amsterdam. He also serves as an Internist in Infectious Diseases and Acute Medicine. The author of more than 90 journal articles and book chapters, Dr. Peters has significantly advanced our understanding of diabetic foot care. His research was instrumental in the development of the International Working Group of the Diabetic Foot’s practice guidelines on diabetic foot infection. Additionally, he played an integral role in writing the Dutch Diabetic Foot Infection Guidelines.

Finally, Dr. Peters has maintained leadership roles in various committees focused on diabetic foot care, including the Wound Healing Society of America, International Working Group of the Diabetic Foot, Dutch Internist Society, and Annual Dutch Diabetes Research Meeting, as well as is a founding member of the Board of Charcot-NET, a network for guideline development and clinical excellence in acute Charcot arthropathy.

Please join us in recognizing Edgar J.G. Peters, MD, PhD, for his contributions and commitment to improving the understanding of detection, treatment, and prevention of diabetic foot complications.
Norbert Freinkel Award
Linda (Lynn) A. Barbour, MD, MSPH, FACP

Norbert Freinkel Award Lecture
Metabolic Culprits in Obese Pregnancies and Gestational Diabetes—Big Babies, Big Twists, Big Picture

Linda (Lynn) A. Barbour, MD, MSPH, FACP, is the recipient of the 2018 Norbert Freinkel Award, given in memory of Norbert Freinkel, a dedicated investigator and thought leader. This award honors a researcher who has made outstanding contributions to the understanding and treatment of diabetes in pregnancy. Dr. Barbour will deliver the Norbert Freinkel Award Lecture on Saturday, June 23.

Dr. Barbour is a tenured Professor in Endocrinology, Metabolism, and Diabetes and Maternal-Fetal Medicine at the University of Colorado School of Medicine. She is Medical Director of the OB Diabetes and High-Risk Clinics at her university’s hospital and serves on the Editorial Board for Diabetes Care.

Dr. Barbour is a clinician/translational scientist in the management of obesity in pregnancy and gestational diabetes. She has made several seminal observations on the hormonal and signaling changes that increase insulin resistance in pregnancy and the intrauterine and dietary factors that contribute to nutrient excess and affect newborn body composition. Her NIH and ADA-funded studies have prompted guideline changes to improve maternal/fetal health and she has published more than 100 manuscripts, book chapters, and guidelines.

As previous CME Director, Dr. Barbour loves to teach Medicine and OB students, residents, fellows, and faculty and supervises treatment for the majority of mothers with type 1 and type 2 diabetes. She is a dedicated mentor for junior investigators across neonatology, maternal-fetal medicine, and endocrinology, and helped to build a Colorado translational research program in Maternal and Child Metabolic Health.

Please join us in celebrating Linda (Lynn) A. Barbour, MD, MSPH, FACP, for outstanding contributions to the understanding and treatment of diabetes in pregnancy.

Edwin Bierman Award
Alessandro Doria, MD, PhD, MPH

Edwin Bierman Award Lecture
Leveraging Genetics to Improve Cardiovascular Health in Diabetes

Alessandro Doria, MD, PhD, MPH, is the recipient of the 2018 Edwin Bierman Award. This award recognizes a leading scientist who has made outstanding contributions in the field of diabetes-related macrovascular complications and related risk factors. Dr. Doria will deliver the Edwin Bierman Award Lecture on Monday, June 25.

Currently an Associate Professor of Medicine at Harvard Medical School, as well as Senior Investigator in the Section on Genetics and Epidemiology and Co-Director of the Molecular Phenotyping and Genotyping Core at the Joslin Diabetes Center, Dr. Doria is a world expert in the genetic epidemiology of coronary heart disease in diabetes.

With more than 100 original publications, Dr. Doria’s research has had a major impact on our understanding of coronary heart disease in diabetes, paving the way for innovative diagnostic and therapeutic approaches. The overarching concept of his research has been that the risk of coronary heart disease in people with diabetes is determined by a synergism between exposure to the diabetic milieu and permissive genetic factors. He has persistently worked to identify these genetic factors and turn this knowledge into novel approaches to prevent, stop, or reverse the macrovascular complications of diabetes.

Furthermore, Dr. Doria serves as an Associate Editor of the American Diabetes Association’s journal, Diabetes, and is a dedicated mentor to young researchers in the fields of epidemiology, genetics, and macrovascular complications.

Please join us in celebrating Alessandro Doria, MD, PhD, MPH, for outstanding contributions in the field of diabetes-related macrovascular complications.
Association Officers Leadership and Service Recognition

**Charles H. Best Medal for Leadership and Service**  
Karen Talmadge, PhD

The Charles H. Best Medal for Leadership and Service will be presented to Karen Talmadge, PhD, to honor her service as Chair of the Board of the American Diabetes Association.

Dr. Talmadge is an award-winning entrepreneur, executive, and scientist in the biomedical industry. She currently serves as President of Nabu Strategic Advisors, a Silicon Valley-based consulting business she started in 2011 to advise entrepreneurs and early-stage companies in health care. Dr. Talmadge was a Bakken Fellow following her 2009 induction into the Bakken Society, Medtronic’s highest scientific and technical honor. In 1994, Dr. Talmadge co-founded Kyphon, a minimally invasive orthopaedic spine medical device company, and served as a Board member, its chief executive officer for the first five years, and in other executive positions until its acquisition by Medtronic in 2007.

Inspired by her daughter with type 1 diabetes from the age of 25 months, Dr. Talmadge has volunteered for the Association since 1994. In addition to her role as Chair of the Board, she currently serves as Vice Chair of the Research Foundation and as a member the Mentor Advisory Group for the Association’s Pathway to Stop Diabetes research grant program. She was instrumental in the creation of Pathway and was also a founding philanthropic supporter.

Dr. Talmadge previously served as Chair of the Board in 2013, on the Executive Committee from 2011 to 2013, and on the Board of Directors in 2014 as well as from 2004 to 2007. Dr. Talmadge also volunteers for the Association in the Silicon Valley area, where she helped to establish an annual networking lunch that has raised more than $4 million in support of the work of the Association.

Please join us in honoring Karen Talmadge, PhD, for her outstanding leadership and service to the American Diabetes Association.

**Rachmiel Levine Medal for Leadership and Service**  
Felicia Hill-Briggs, PhD, ABPP

The Rachmiel Levine Medal for Leadership and Service will be presented to Felicia Hill-Briggs, PhD, ABPP, in recognition of her service as President, Health Care & Education of the American Diabetes Association.

Dr. Hill-Briggs is Professor of Medicine, Physical Medicine and Rehabilitation, and Acute and Chronic Care at the Johns Hopkins University and Senior Director of Population Health Research and Development for Johns Hopkins HealthCare, LLC. She is Director of Behavior and Cognition for the Health Care and Population Science Core of the Johns Hopkins-University of Maryland Diabetes Research Center and Core Faculty of the Welch Center for Prevention, Epidemiology, and Clinical Research.

As a behavioral scientist and clinical psychologist, Dr. Hill-Briggs works to bring quality care to populations with diabetes within health care settings, communities, and through international population health initiatives in regions including the Caribbean and Middle East. Her research focuses on design of behavioral interventions that improve diabetes self-management and outcomes within underserved and high-risk populations. In 2017, she was elected to the National Academy of Medicine.

Dr. Hill-Briggs is a past Chair of the Association’s Council on Behavioral Medicine and Psychology. She has served as a member of the Research Grant Review Committee, Scientific Sessions Meeting Planning Committee, Research Policy Committee, and Strategic Planning Committee. She currently serves on the Association’s Awards Committee.

Please join us in honoring Felicia Hill-Briggs, PhD, ABPP, for her outstanding leadership and service to the American Diabetes Association.
Charles Kopke Medal for Leadership and Service
Michael Ching, CPA

The Charles Kopke Medal for Leadership and Service will be presented to Michael Ching, CPA, to honor his service as Secretary/Treasurer of the American Diabetes Association.

Mr. Ching is an Executive Vice President of First Hawaiian Bank and serves as the Chief Financial Officer and Treasurer, overseeing all finance, accounting, and treasury functions of the bank. First Hawaiian Bank is the largest bank headquartered in Hawaii in terms of assets, loans, deposits, and net income. Prior to this role, Mr. Ching served at Ernst & Young for 22 years, rising to Office Managing Partner in the Honolulu office, providing assurance and advisory services to clients in Hawaii and the United States mainland. He also led the firm’s efforts to develop a financial services practice amongst the Phoenix, Denver, and Las Vegas offices.

Active in the community, Mr. Ching currently serves on non-profit boards including the Aloha Council—Boy Scouts of America, Hawaii Theatre, Hawaiian Humane Society, and the Chinese Chamber of Commerce. He also currently serves as a member of the American Diabetes Association’s Finance Committee as well as the Association’s Honolulu Community Leadership Board. Mr. Ching previously served on the Association’s Board of Directors from 2012 to 2014.

Please join us in honoring Michael Ching, CPA, for his outstanding leadership and service to the American Diabetes Association.

Banting Medal for Leadership and Service
Jane E.B. Reusch, MD

The Banting Medal for Leadership and Service will be presented to Jane E.B. Reusch, MD, to honor her service as President, Medicine & Science of the American Diabetes Association.

Dr. Reusch is a Professor of Medicine, Biochemistry, and Bioengineering and Associate Director of the Center for Women's Health Research at the University of Colorado School of Medicine Anschutz Medical Campus. She directs the Diabetes Care Team and the PEERS diabetes education program at the Denver VA Medical Center.

Dr. Reusch is a translational diabetes researcher with both clinical and basic research programs. Her career has been dedicated to research in the prevention of diabetes complications focused currently on cardiovascular disease and exercise impairments. Her research accomplishments have been recognized by election to the ASCI and AAP, continuous funding, more than 130 publications and, most importantly, highly successful trainees now conducting independent research in diabetes.

In addition to her research and clinical practice, she has provided local, regional, and national leadership for the recruitment and retention of new researchers to the fields of diabetes and women's health research and public policy to support research and the careers of scientists, particularly clinician scientists. Dr. Reusch has been a volunteer of the Association for more than 25 years. She currently serves on the Association's Finance and Strategic Planning Committees and is a past member of the Research Policy Committee. Dr. Reusch is a member of the Association’s Pinnacle Society and was honored with the Association’s Women of Valor Award for Colorado in 2001.

Please join us in honoring Jane E.B. Reusch, MD, for her outstanding leadership and service to the American Diabetes Association.
Call for Nominations

The ADA is seeking applications for the National Scientific & Health Care Achievement Awards. These awards provide an opportunity to recognize exceptional leadership of individuals who have made significant contributions in the field of diabetes research and care.

**National Scientific & Health Care Achievement Award Categories**

- Banting Medal for Scientific Achievement
- Outstanding Scientific Achievement Award
- Albert Renold Award
- Outstanding Achievement in Clinical Diabetes Research Award
- Outstanding Educator in Diabetes Award
- Outstanding Physician Clinician in Diabetes Award
- Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
- Kelly West Award for Outstanding Achievement in Epidemiology

**Nominations for the 2019 National Scientific & Health Care Achievement Awards closes September 14, 2018.**

For questions regarding the National Scientific & Health Care Achievement Awards, contact Gedeon Topacio at gtopacio@diabetes.org or visit www.professional.diabetes.org.

**Note:** The ADA is reorganizing its Professional Interest Groups. Nominations for the 2019 Professional Interest Group Awards, including the Richard R. Rubin Award, Roger Pecoraro Award, Norbert Freinkel Award, and Edwin Bierman Award will open later in 2018.
Previous National Scientific & Health Care Achievement Award Recipients

**Banting Medal for Scientific Achievement***

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1941</td>
<td>Elliott P. Joslin, MD</td>
</tr>
<tr>
<td>1942</td>
<td>William Muhlhberg, MD</td>
</tr>
<tr>
<td>1943</td>
<td>Fred W. Hipwell, MD</td>
</tr>
<tr>
<td>1944</td>
<td>Leonard G. Rowntree, MD</td>
</tr>
<tr>
<td>1945</td>
<td>25th Anniversary of Insulin Program</td>
</tr>
<tr>
<td></td>
<td>Bernardo A. Houssay, MD</td>
</tr>
<tr>
<td></td>
<td>H.C. Hagedorn, MD</td>
</tr>
<tr>
<td></td>
<td>R.D. Lawrence, MD</td>
</tr>
<tr>
<td></td>
<td>Eugene Opie, MD</td>
</tr>
<tr>
<td></td>
<td>University of Toronto</td>
</tr>
<tr>
<td>1947</td>
<td>G.H.A. Clowes, PhD</td>
</tr>
<tr>
<td>1948</td>
<td>Rollin T. Woodyatt, MD</td>
</tr>
<tr>
<td>1949</td>
<td>Herbert M. Evans, MD</td>
</tr>
<tr>
<td></td>
<td>Frederick M. Allen, MD</td>
</tr>
<tr>
<td>1950</td>
<td>F.G. Young, DCs</td>
</tr>
<tr>
<td>1951</td>
<td>C.N.H. Long, MD</td>
</tr>
<tr>
<td>1952</td>
<td>R.R. Bensley, MD</td>
</tr>
<tr>
<td>1953</td>
<td>Shields Warren, MD</td>
</tr>
<tr>
<td></td>
<td>Walter R. Campbell, MD</td>
</tr>
<tr>
<td></td>
<td>A. Almon Fletcher, MD</td>
</tr>
<tr>
<td>1954</td>
<td>Sir Henry H. Dale, MD</td>
</tr>
<tr>
<td>1955</td>
<td>Carl F. Cori, MD</td>
</tr>
<tr>
<td></td>
<td>Eugene F. DuBois, MD</td>
</tr>
<tr>
<td>1956</td>
<td>William C. Stadie, MD</td>
</tr>
<tr>
<td>1957</td>
<td>DeWitt Stetten, Jr., MD, PhD</td>
</tr>
<tr>
<td></td>
<td>John R. Murlin, PhD, DSc</td>
</tr>
<tr>
<td>1958</td>
<td>Jerome W. Conn, MD</td>
</tr>
<tr>
<td></td>
<td>William H. Olmsted, MD</td>
</tr>
<tr>
<td>1959</td>
<td>George W. Thorn, MD</td>
</tr>
<tr>
<td></td>
<td>E.T. Bell, MD</td>
</tr>
<tr>
<td>1960</td>
<td>Priscilla White, MD</td>
</tr>
<tr>
<td></td>
<td>J.P. Collip, MD</td>
</tr>
<tr>
<td>1961</td>
<td>Rachmiel Levine, MD</td>
</tr>
<tr>
<td>1962</td>
<td>A. Baird Hastings, PhD</td>
</tr>
<tr>
<td>1963</td>
<td>Bernardo A. Houssay, MD</td>
</tr>
<tr>
<td>1964</td>
<td>Garfield G. Duncan, MD</td>
</tr>
<tr>
<td>1965</td>
<td>Francis D.W. Lukens, MD</td>
</tr>
<tr>
<td></td>
<td>Moses Barron, MD</td>
</tr>
<tr>
<td></td>
<td>Joseph P. Hoet, MD</td>
</tr>
<tr>
<td></td>
<td>Leland S. McKittrick, MD</td>
</tr>
<tr>
<td></td>
<td>Peter J. Maloney, PhD</td>
</tr>
<tr>
<td></td>
<td>David A. Scott, PhD</td>
</tr>
<tr>
<td>1966</td>
<td>Ernst Wertheimer, MD</td>
</tr>
<tr>
<td>1967</td>
<td>Solomon A. Berson, MD</td>
</tr>
<tr>
<td>1968</td>
<td>I. Arthur Mirsky, MD</td>
</tr>
<tr>
<td>1969</td>
<td>Robert H. Williams, MD</td>
</tr>
<tr>
<td>1970</td>
<td>Alexander Marble, MD</td>
</tr>
<tr>
<td>1971</td>
<td>Arthur R. Colwell, MD</td>
</tr>
<tr>
<td>1972</td>
<td>Earl W. Sutherland, MD</td>
</tr>
<tr>
<td>1973</td>
<td>Robert L. Jackson, MD</td>
</tr>
<tr>
<td>1974</td>
<td>William C. Stadie, MD</td>
</tr>
<tr>
<td>1975</td>
<td>DeWitt Stetten, Jr., MD, PhD</td>
</tr>
<tr>
<td>1976</td>
<td>James B. Field, MD</td>
</tr>
<tr>
<td>1977</td>
<td>Marvin D. Siperstein, MD, PhD</td>
</tr>
<tr>
<td>1978</td>
<td>Albert E. Renold, MD</td>
</tr>
<tr>
<td>1979</td>
<td>Eugene F. DuBois, MD</td>
</tr>
<tr>
<td>1980</td>
<td>Lawrence M. Rubenstein, MD</td>
</tr>
<tr>
<td></td>
<td>Donald F. Steinier, MD</td>
</tr>
<tr>
<td>1981</td>
<td>Robert H. Williams, MD</td>
</tr>
<tr>
<td>1982</td>
<td>Charles R. Park, MD</td>
</tr>
<tr>
<td>1983</td>
<td>Jesse Roth, MD</td>
</tr>
<tr>
<td>1984</td>
<td>Arthurr H. Rubenstein, MD</td>
</tr>
<tr>
<td>1985</td>
<td>Bjorn Nerup, MD</td>
</tr>
<tr>
<td>1986</td>
<td>Albert I. Winegrad, MD</td>
</tr>
<tr>
<td>1987</td>
<td>Joseph Larner, MD, PhD</td>
</tr>
<tr>
<td>1988</td>
<td>M. Reaven, MD</td>
</tr>
<tr>
<td>1989</td>
<td>Ora Rosen, MD</td>
</tr>
<tr>
<td>1990</td>
<td>Daniel Porte, Jr., MD</td>
</tr>
<tr>
<td>1991</td>
<td>Miladen Vranic, MD</td>
</tr>
<tr>
<td>1992</td>
<td>Gian Franco Bottazzo, MD</td>
</tr>
<tr>
<td>1993</td>
<td>C. Ronald Kahn, MD</td>
</tr>
<tr>
<td>1994</td>
<td>Philip E. Coyer, MD</td>
</tr>
<tr>
<td>1995</td>
<td>Franco M. Mateschinsky, MD</td>
</tr>
<tr>
<td>1996</td>
<td>Peter H. Bennett, MD, PhD</td>
</tr>
<tr>
<td>1997</td>
<td>Alan D. Cherrington, PhD</td>
</tr>
<tr>
<td>1998</td>
<td>Anthony Cerami, PhD</td>
</tr>
<tr>
<td>1999</td>
<td>Michael F. Czech, PhD</td>
</tr>
<tr>
<td>2000</td>
<td>J. Denis McGarry, PhD</td>
</tr>
<tr>
<td>2001</td>
<td>Samuel W. Cushman, PhD</td>
</tr>
<tr>
<td>2002</td>
<td>Aldo A. Rossini, MD</td>
</tr>
<tr>
<td>2003</td>
<td>Michael A. Brownlee, MD</td>
</tr>
<tr>
<td>2004</td>
<td>Jeffrey S. Flier, MD</td>
</tr>
<tr>
<td>2005</td>
<td>Richard N. Bergman, PhD</td>
</tr>
<tr>
<td>2006</td>
<td>Robert S. Sherwin, MD</td>
</tr>
<tr>
<td>2007</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>2008</td>
<td>George S. Eisenbarth, MD, PhD</td>
</tr>
<tr>
<td>2009</td>
<td>Robert A. Rizza, MD</td>
</tr>
<tr>
<td>2010</td>
<td>Barbara A. Corkey, PhD</td>
</tr>
<tr>
<td>2011</td>
<td>Bruce M. Spiegelman, PhD</td>
</tr>
<tr>
<td>2012</td>
<td>J. Denis McGarry, PhD</td>
</tr>
<tr>
<td>2013</td>
<td>Graeme I. Bell, PhD</td>
</tr>
<tr>
<td>2014</td>
<td>Daniel J. Drucker, MD</td>
</tr>
<tr>
<td>2015</td>
<td>Philipp E. Scherer, PhD</td>
</tr>
<tr>
<td>2016</td>
<td>Barbara B. Kahn, MD</td>
</tr>
<tr>
<td>2017</td>
<td>Domenico Accili, MD</td>
</tr>
</tbody>
</table>

*Prior to 1972, the Association recognized multiple award recipients in a single year. The list above includes all who received the Banting Medal for Scientific Achievement. In those years when more than one medal was bestowed, the medal recipient listed first delivered the Banting Lecture.

**Outstanding Scientific Achievement Award**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1957</td>
<td>Solomon A. Berson, MD</td>
</tr>
<tr>
<td>1958</td>
<td>James B. Field, MD</td>
</tr>
<tr>
<td>1959</td>
<td>Marvin D. Siperstein, MD, PhD</td>
</tr>
<tr>
<td>1960</td>
<td>Albert E. Renold, MD</td>
</tr>
<tr>
<td>1961</td>
<td>Rosalyn S. Yalow, PhD</td>
</tr>
<tr>
<td>1962</td>
<td>Harry N. Antoniades, PhD</td>
</tr>
<tr>
<td>1963</td>
<td>James M.B. Bloodworth, Jr., MD</td>
</tr>
<tr>
<td>1964</td>
<td>Roger H. Unger, MD</td>
</tr>
<tr>
<td>1965</td>
<td>George F. Cahill, Jr., MD</td>
</tr>
<tr>
<td>1966</td>
<td>Norbert Freinkel, MD</td>
</tr>
<tr>
<td>1967</td>
<td>David M. Kipnis, MD</td>
</tr>
<tr>
<td>1968</td>
<td>Robert G. Spiro, MD</td>
</tr>
<tr>
<td>1969</td>
<td>Donald F. Steiner, MD</td>
</tr>
<tr>
<td>1970</td>
<td>Daniel Porte, Jr., MD</td>
</tr>
<tr>
<td>1971</td>
<td>Jesse Roth, MD</td>
</tr>
<tr>
<td>1972</td>
<td>Pedro Cuatrecasas, MD</td>
</tr>
<tr>
<td>1973</td>
<td>Philip Felig, MD</td>
</tr>
<tr>
<td>1974</td>
<td>Peter H. Bennett, MD</td>
</tr>
<tr>
<td>1975</td>
<td>J. Denis McGarry, PhD</td>
</tr>
<tr>
<td>1976</td>
<td>Leonard S. Jefferson, PhD</td>
</tr>
<tr>
<td>1977</td>
<td>Jerrold M. Olefsky, MD</td>
</tr>
<tr>
<td>1978</td>
<td>C. Ronald Kahn, MD</td>
</tr>
<tr>
<td>1979</td>
<td>Jerrold M. Olefsky, MD</td>
</tr>
<tr>
<td>1980</td>
<td>C. Ronald Kahn, MD</td>
</tr>
<tr>
<td>1981</td>
<td>C. Ronald Kahn, MD</td>
</tr>
<tr>
<td>1982</td>
<td>Michael P. Czech, PhD</td>
</tr>
<tr>
<td>1983</td>
<td>Howard S. Tager, PhD</td>
</tr>
<tr>
<td>1984</td>
<td>Alan D. Cherrington, PhD</td>
</tr>
<tr>
<td>1985</td>
<td>Steven J. Jacobs, MD</td>
</tr>
<tr>
<td>1986</td>
<td>George S. Eisenbarth, MD, PhD</td>
</tr>
<tr>
<td>1987</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>1988</td>
<td>John E. Gerich, MD</td>
</tr>
<tr>
<td>1989</td>
<td>Richard N. Bergman, PhD</td>
</tr>
<tr>
<td>1990</td>
<td>Graeme I. Bell, PhD</td>
</tr>
<tr>
<td>1991</td>
<td>Jeffrey S. Flier, MD</td>
</tr>
<tr>
<td>1992</td>
<td>Simeon Taylor, MD, PhD</td>
</tr>
</tbody>
</table>
1993 Michael A. Brownlee, MD
1994 Kenneth S. Polonsky, MD
1995 Barbara B. Kahn, MD
1996 Jeffrey E. Pessin, PhD
1997 Gerald I. Shulman, MD, PhD
1998 Michael M. Mueckler, PhD
1999 Morris F. White, PhD
2000 Luciano Rossetti, MD
2001 Christopher B. Newgard, PhD
2002 Camillo Ricordi, MD
2003 Domenico Accili, MD
2004 Mark A. Atkinson, PhD
2005 Philipp E. Scherer, PhD
2006 Markus Stoffel, MD, PhD
2007 Göökhan S. Hotamisligil, MD, PhD
2008 Matthias G. von Herrath, MD
2009 Randy J. Seeley, PhD
2010 Martin G. Myers, Jr., MD, PhD

1992 Peter H. Forsham, MD
1993 Jesse Roth, MD
1994 Harold E. Lebovitz, MD
1995 Daniel Porte, Jr., MD
1996 George F. Cahill, Jr., MD
1997 R. Paul Robertson, MD
1998 C. Ronald Kahn, MD
1999 Phillip Gorden, MD
2000 Reubin Andres, MD
2001 Ralph A. DeFronzo, MD
2002 Gerald M. Reaven, MD
2003 Michael P. Czech, PhD
2004 Mladen Vranic, MD, DSc, FRSC, FRCP
2005 Donald F. Steiner, MD
2006 Neil B. Ruderman, MD
2007 Christopher B. Newgard, PhD
2008 Jeffrey S. Flier, MD
2009 Aldo A. Rossini, MD
2010 Philip E. Cryer, MD

1993 Michael A. Brownlee, RN, MS
1994 Barbara M. Prater, PhD, RD
1995 Diana Guthrie, RN, PhD
1996 Carelyn P. Fylling, RN, MS
1997 Barbara Christman Adair, RN, MSN
1998 Myrtis A. McSweeney, RN
1999 Maria Alogna, RN, MPH
1980 Margaret C. Yarborough, RPh
1981 Barbara M. Prater, PhD, RD
1982 Marion Franz, RD, MS
1983 Deborah A. Hinnen, RN, MN
1984 Madelyn L. Wheeler, MS, RD, CDE
1985 Phyllis R. Crapo, RD, PhD
1986 R. Keith Campbell, RPh
1987 Margaret A. Powers, RD, MS
1988 Judith Wylie-Rosett, RD, EdD
1989 Helen R. Bowlin, RN, CDE
1990 Barbara J. Maschak-Carey, RNCS, MSN, CDE
2002 Jean E. Betschart, MN, RN, CDE
2003 Linda B. Haas, MN, RN, CDE, PhD
2004 Ruth Farkas-Hirsch, MS, RN, CDE
1997 Richard R. Rubin, PhD, CDE
1998 Anne S. Daly, MS, CDE, RD
1999 Martha M. Funnell, MS, CDE, RN
2000 Robert M. Anderson, EdD
2001 Lawrence B. Harkless, DPM
2002 Karmeen Kulkarni, MS, RD, CD, CDE, BC-ADM
2003 Barbara J. Anderson, PhD
2004 Marjorie L. Cypress, CDE, RN, ANP
2005 Melinda D. Maryniuk, MEd, RD, FADA, CDE
2006 Geralyn Spollett, MSN, CDE, ANP

Albert Renold Award

1992 Peter H. Forsham, MD
1993 Jesse Roth, MD
1994 Harold E. Lebovitz, MD
1995 Daniel Porte, Jr., MD
1996 George F. Cahill, Jr., MD
1997 R. Paul Robertson, MD
1998 C. Ronald Kahn, MD
1999 Phillip Gorden, MD
2000 Reubin Andres, MD
2001 Ralph A. DeFronzo, MD
2002 Gerald M. Reaven, MD
2003 Michael P. Czech, PhD
2004 Mladen Vranic, MD, DSc, FRSC, FRCP
2005 Donald F. Steiner, MD
2006 Neil B. Ruderman, MD
2007 Christopher B. Newgard, PhD
2008 Jeffrey S. Flier, MD
2009 Aldo A. Rossini, MD
2010 Philip E. Cryer, MD

Outstanding Educator in Diabetes Award
### Outstanding Physician Clinician in Diabetes Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td>Edgar A. Haunz, MD</td>
</tr>
<tr>
<td>1976</td>
<td>David Hurwitz, MD</td>
</tr>
<tr>
<td>1977</td>
<td>Henry E. Oppenheimer, MD</td>
</tr>
<tr>
<td>1978</td>
<td>Priscilla White, MD</td>
</tr>
<tr>
<td>1979</td>
<td>Marvin E. Levin, MD</td>
</tr>
<tr>
<td>1980</td>
<td>Harold Rifkin, MD</td>
</tr>
<tr>
<td>1981</td>
<td>James M. Moss, MD</td>
</tr>
<tr>
<td>1982</td>
<td>George P. Heftner, MD</td>
</tr>
<tr>
<td>1983</td>
<td>Harvey C. Knowles, Jr., MD</td>
</tr>
<tr>
<td>1984</td>
<td>Alan L. Graber, MD</td>
</tr>
<tr>
<td>1985</td>
<td>Burritt L. Haag, MD</td>
</tr>
<tr>
<td>1986</td>
<td>Holbrooke S. Seltzer, MD</td>
</tr>
<tr>
<td>1987</td>
<td>O. Peter Schumacher, MD</td>
</tr>
<tr>
<td>1988</td>
<td>Allan L. Drash, MD</td>
</tr>
<tr>
<td>1989</td>
<td>Fred W. Whitehouse, MD</td>
</tr>
<tr>
<td>1990</td>
<td>James R. Gavin III, MD</td>
</tr>
<tr>
<td>1991</td>
<td>Christopher D. Saudek, MD</td>
</tr>
<tr>
<td>1992</td>
<td>Saul M. Genuth, MD</td>
</tr>
<tr>
<td>1993</td>
<td>Alice N. Bessman, MD</td>
</tr>
<tr>
<td>1994</td>
<td>Lester Baker, MD</td>
</tr>
<tr>
<td>1995</td>
<td>Lois Jovanovic, MD</td>
</tr>
<tr>
<td>1996</td>
<td>F. Xavier Pi-Sunyer, MD</td>
</tr>
<tr>
<td>1997</td>
<td>Bruce R. Zimmerman, MD</td>
</tr>
<tr>
<td>1998</td>
<td>Julio V. Santiago, MD</td>
</tr>
<tr>
<td>1999</td>
<td>Lloyd M. Aiello, MD</td>
</tr>
<tr>
<td>2000</td>
<td>Robert A. Rizza, MD</td>
</tr>
<tr>
<td>2001</td>
<td>H. Peter Chase, MD</td>
</tr>
<tr>
<td>2002</td>
<td>David M. Nathan, MD</td>
</tr>
<tr>
<td>2003</td>
<td>Richard A. Guthrie, MD</td>
</tr>
<tr>
<td>2004</td>
<td>Irl B. Hirsch, MD</td>
</tr>
<tr>
<td>2005</td>
<td>Matthew C. Riddle, MD</td>
</tr>
<tr>
<td>2006</td>
<td>Bernard Zinman, MD, FACP, FRCP</td>
</tr>
<tr>
<td>2007</td>
<td>Richard M. Bergenstal, MD</td>
</tr>
<tr>
<td>2008</td>
<td>Anne L. Peters, MD, FACP, CDE</td>
</tr>
<tr>
<td>2009</td>
<td>Daniel L. Lorber, MD, FACP, CDE</td>
</tr>
</tbody>
</table>

### Outstanding Physician Educator in Diabetes Award**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td>Alexander Marble, MD</td>
</tr>
<tr>
<td>1976</td>
<td>Leona V. Miller, MD</td>
</tr>
<tr>
<td>1977</td>
<td>Philip W. Felts, MD</td>
</tr>
<tr>
<td>1978</td>
<td>Frederick C. Goetz, MD</td>
</tr>
<tr>
<td>1979</td>
<td>John K. Davidson, MD</td>
</tr>
<tr>
<td>1980</td>
<td>Leon P. Krall, MD</td>
</tr>
<tr>
<td>1981</td>
<td>John W. Runyan, MD</td>
</tr>
<tr>
<td>1982</td>
<td>Ann Lawrence, MD, PhD</td>
</tr>
<tr>
<td>1983</td>
<td>Donnell D. Etzwiler, MD</td>
</tr>
<tr>
<td>1984</td>
<td>H. St. George Tucker, Jr., MD</td>
</tr>
<tr>
<td>1985</td>
<td>Charles R. Shuman, MD</td>
</tr>
<tr>
<td>1986</td>
<td>J. Stuart Soeldner, MD</td>
</tr>
<tr>
<td>1987</td>
<td>Ronald A. Arky, MD</td>
</tr>
<tr>
<td>1988</td>
<td>Daniel W. Foster, MD</td>
</tr>
<tr>
<td>1989</td>
<td>Oscar B. Crofford, MD</td>
</tr>
<tr>
<td>1990</td>
<td>Mayer B. Davidson, MD</td>
</tr>
<tr>
<td>1991</td>
<td>Marvin E. Levin, MD</td>
</tr>
<tr>
<td>1992</td>
<td>John A. Colwell, MD, PhD</td>
</tr>
<tr>
<td>1993</td>
<td>John H. Karam, MD</td>
</tr>
<tr>
<td>1994</td>
<td>Fred Whitehouse, MD</td>
</tr>
<tr>
<td>1995</td>
<td>Luther B. Travis, MD</td>
</tr>
<tr>
<td>1996</td>
<td>Edward S. Horton, MD</td>
</tr>
<tr>
<td>1997</td>
<td>Mark E. Molitch, MD</td>
</tr>
<tr>
<td>1998</td>
<td>Arthur Krosnick, MD, CDE</td>
</tr>
</tbody>
</table>

**This award was merged with the Outstanding Clinician Award in 1999.

### Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Harold Rifkin, MD</td>
</tr>
<tr>
<td>1992</td>
<td>Harry Keen, MD</td>
</tr>
<tr>
<td>1993</td>
<td>Leo P. Krall, MD</td>
</tr>
<tr>
<td>1994</td>
<td>Wendell Mayes, Jr., MSc, MD</td>
</tr>
<tr>
<td>1995</td>
<td>Hilary King, MSc, MD, MFPHM, DSc</td>
</tr>
<tr>
<td>1996</td>
<td>Meng H. Tan, MD</td>
</tr>
<tr>
<td>1997</td>
<td>K.G.M.M. Alberti, DPhil</td>
</tr>
<tr>
<td>1998</td>
<td>Enrol Morrison, MD</td>
</tr>
<tr>
<td>1999</td>
<td>Michael Berger, MD</td>
</tr>
<tr>
<td>2000</td>
<td>Maria de Alva</td>
</tr>
<tr>
<td>2001</td>
<td>Sterling Tucker</td>
</tr>
<tr>
<td>2002</td>
<td>Paul Zimet, MD, PhD</td>
</tr>
<tr>
<td>2003</td>
<td>Linda M. Siminerio, RN, PhD</td>
</tr>
<tr>
<td>2004</td>
<td>Jean-Claude Mbanya, MD</td>
</tr>
<tr>
<td>2005</td>
<td>Insulin for Life</td>
</tr>
<tr>
<td>2006</td>
<td>Jaime A. Davidson, MD</td>
</tr>
<tr>
<td>2007</td>
<td>Martin Silink, AM, MD, FRACP</td>
</tr>
<tr>
<td>2008</td>
<td>Andrew J.M. Boulton, MD, FRCP</td>
</tr>
<tr>
<td>2009</td>
<td>Mahmoud Ashraf Ibrahim, MD</td>
</tr>
<tr>
<td>2010</td>
<td>Peter H. Bennett, MB, ChB, FRCP, FFPH</td>
</tr>
<tr>
<td>2011</td>
<td>Rury R. Holman, FRCP</td>
</tr>
<tr>
<td>2012</td>
<td>Pierre J. LeFévère, MD, PhD, FRCP, MAE</td>
</tr>
<tr>
<td>2013</td>
<td>Graham Ogle, MBBS, FRACP</td>
</tr>
<tr>
<td>2014</td>
<td>Jaakko Tuomilehto, MD, MA, PhD, FRCP Edin</td>
</tr>
<tr>
<td>2015</td>
<td>Carl Erik Mogensen, MD</td>
</tr>
<tr>
<td>2016</td>
<td>Yutaka Saito, MD, PhD</td>
</tr>
<tr>
<td>2017</td>
<td>Roger S. Mazze, PhD</td>
</tr>
</tbody>
</table>
Kelly West Award for Outstanding Achievement in Epidemiology

1986  Peter H. Bennett, MD
1987  Elizabeth L. Barrett-Connor, MD
1988  Ronald E. LaPorte, PhD
1989  Harry Keen, MD
1990  Michael Stern, MD
1991  Paul Zimmet, MD, PhD
1992  Maureen I. Harris, PhD
1993  Trevor J. Orchard, MD
1994  Ronald Klein, MD, MPH
1995  William C. Knowler, MD, DrPh
1996  Richard F. Hamman, MD, DrPh
1997  Steven M. Haffner, MD

1998  Jaakko Tuomilehto, MD, PhD
1999  Wilfred Y. Fujimoto, MD
2000  Eveline Eschwege, MD
2001  John H. Fuller, MD
2002  David H. Pettitt, MD
2003  Barbara V. Howard, PhD
2004  Michael Engelgau, MD, MS
2005  Marian J. Rewers, MD, PhD
2006  William H. Herman, MD, MPH
2007  Beverley Balkau, PhD, BSC, DipEd
2008  Markku Laakso, MD, PhD
2009  James B. Meigs, MD, MPH
2010  Frank B. Hu, MD, PhD
2011  Frederick L. Brancati, MD, MHS, FACP
2012  Knut Borch-Johnsen, MD, PhD
2013  Edward J. Boyko, MD, MPH
2014  Andrzej S. Krolewski, MD, PhD
2015  K.M. Venkat Narayan, MD, MSc, MBA
2016  Edward W. Gregg, PhD
2017  Dana Dabelea, MD, PhD
## Previous Professional Interest Group Award Recipients

### Richard R. Rubin Award*

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Daniel J. Cox, PhD</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Russell E. Glasgow, PhD</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Suzanne B. Johnson, PhD</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Rena R. Wing, PhD</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Patrick J. Lustman, PhD</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Richard R. Rubin, PhD, CDE</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Barbara J. Anderson, PhD</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>Lawrence Fisher, PhD, ABPP</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Margaret Grey, DrPH, RN, FAAN</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>William H. Polonsky, PhD, CDE</td>
<td></td>
</tr>
</tbody>
</table>

*Formerly the Behavioral Medicine and Psychology Distinguished Contributions Award, this award was renamed in honor of Richard R. Rubin, PhD, CDE, who passed away on March 25, 2013. The award is to honor his remarkable service to the Association as both a volunteer and health care professional.

### Roger Pecoraro Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>Michael E. Edmonds, MD, FRCP</td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>Jean-Philippe Assal, MD</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>Paul W. Brand, MD, CBE</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>Andrew J.M. Boulton, MD</td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>Gary W. Gibbons, MD</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>Jan Apleqivist, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>Michael E. Edmonds, MD, FRCP</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>Gayle Reiber, PhD, MPH</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Peter R. Cavanaugh, PhD, Dsc</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Lawrence B. Harkless, DPM FACFAS</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Aristidis Veves, MD</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Frank LoGerfo, MD, FACS</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Michael J. Mueller, PT, PhD, FAPTA</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Lawrence A. Lavery, DPM, MPH</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>David Sinacore, PT, PhD</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>James A. Birke, PT, PhD</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>David G. Armstrong, DPM, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Robert G. Frykberg, DPM, MPH</td>
<td></td>
</tr>
</tbody>
</table>

### Norbert Freinkel Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>John Bell, MD</td>
<td></td>
</tr>
<tr>
<td>1992</td>
<td>Lars Mosted-Pedersen, MD</td>
<td></td>
</tr>
<tr>
<td>1993</td>
<td>Boyd E. Metzger, MD</td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>John A. O’Sullivan, MD</td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>Ulf J. Eriksson, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td>John L. Kitzmiller, MD</td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td>Donald R. Coustan, MD</td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td>David Pettitt, MD</td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td>Thomas A. Buchanan, MD</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>Patrick M. Catalano, MD</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Lois Jovanovic, MD</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Jorge H. Mestman, MD</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Oded Langer, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>F. André Van Assche, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Steven G. Gabbe, MD</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>David R. Hadden, MD</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Emilio Herrera, PhD</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>David A. Sacks, MD</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Sir L. Kjos, MD</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Sylvie Hauguel-de Mouzon, PhD</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Peter Damm, MD, DMSc</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>E. Albert Reece, MD, PhD, MBA</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Caroline A. Crowther, MD, FRANZCOG, FRCOG, CMFM</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Jacob E. (Jed) Friedman, PhD</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>Elisabeth R. Mathiesen, MD, DMSc</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>H. David McIntyre, MD, FRACP</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Gernot Desoye, PhD</td>
<td></td>
</tr>
</tbody>
</table>

### Edwin Bierman Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>Barbara V. Howard, PhD</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>John A. Colwell, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td>Maria Lopes-Virella, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td>Helen Vlassara, MD</td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td>Alan Chait, MD</td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>Marja-Riitta Taskinen, MD</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>John D. Brunzell, MD</td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>Robert H. Eckel, MD,</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td>Henry N. Ginsberg, MD</td>
<td></td>
</tr>
<tr>
<td>2008</td>
<td>Scott M. Grundy, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2009</td>
<td>Steven M. Haffner, MD</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>Ira J. Goldberg, MD</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>Theodore Mazzone, MD, FACP</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>Ronald M. Krauss, MD</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>Joseph L. Witztum, MD</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>Karin E. Bornfeldt, PhD</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>George L. King, MD</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>Clay F. Semenkovich, MD</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>Mark Emmanuel Cooper, MBBS, PhD</td>
<td></td>
</tr>
</tbody>
</table>
Previous National Service Achievement Award Recipients

C. Everett Koop Medal for Health Promotion and Awareness

- 1990  C. Everett Koop, MD
- 1991  Ted Turner
- 1992  Governor Michael N. Castle
- 1993  Governor Lowell P. Weicker
- 1994  First Lady, Hillary Rodham Clinton
- 1995  Ronald Kotulak
- 1996  The Honorable Jake Garn
- 1999  Nicole Johnson (Miss America 1999)
- 2000  National Council of La Raza
- 2001  Anita Manning
- 2002  Secretary of Health and Human Services, Tommy G. Thompson
- 2003  American College of Cardiology
- 2004  Michael Jacobson
- 2005  National Committee on Quality Assurance (NCQA)
- 2006  Governor Mike Huckabee
- 2007  AARP
- 2008  Thomas R. Frieden, MD, MPH (Commissioner, NYC Department of Health & Mental Hygiene)
- 2010  Kelly J. Acton, MD, MPH, FACP, CAPT, USPHS

Wendell Mayes, Jr. Award for Lifetime Service

- 1986  Wendell Mayes, Jr.
- 1987  Benjamin Greenspoon
- 1988  Dorothea Sims
- 1989  Lee Iacocca
- 1990  William F. Talbert
- 1991  Maria L. de Alva
- 1992  Lee Ducat
- 1993  Tom Parks
- 1994  Wade Wilson
- 1995  Henry Rivera
- 1996  Todd E. Leigh
- 1997  Ross V. Hickey, Jr.
- 1998  Sterling Tucker
- 1999  Wayne Parker
- 2000  Michael A. Greene
- 2001  Stephen J. Satalino
- 2002  Alan Altschuler
- 2003  Davida F. Kruger, MSN, APRN, BC-ADM
- 2004  Charles and Verda Kopke
- 2005  Robert J. Singley
- 2006  Stephen H. Smith
- 2007  James A. Horbowicz
- 2008  Lawrence T. Smith
- 2010  Stanley Panasewicz, CMA
- 2011  Darlene L. Cain
- 2012  Stewart Perry
- 2013  Larry Ellingson, RPh

Public Policy Leadership Award

- 1995  Assemblyman Robert K. Sweeney and Senator Nicholas A. Spano
- 1996  The Honorable Elizabeth Furse
- 1998  The Honorable George R. Nethercutt, Jr.
- 1999  Diabetes Advocates (represented by Hal Storey, Paula M. Yutzy, RN, CDE, Crystal Jackson, and Sandy Pope)
- 2000  Senator Susan M. Collins
- 2001  The Honorable Henry Bonilla
- 2002  The Honorable Bruce B. Howell
- 2003  The Honorable Dennis J. Hastert
- 2004  State Senator Robert Duncan
- 2005  Senator Pete Domenici
- 2006  Senator Edward M. Kennedy
- 2007  Senator Edward M. Kennedy
- 2008  Senator Edward M. Kennedy
- 2009  Senator Edward M. Kennedy
- 2010  Kapche Litigation Team (represented by Jeffrey S. Kapche, Katherine L. Butler, JD, James R. Gavin II, MD, PhD, and Desmond A. Schatz, MD)
- 2011  Representative Diana DeGette
- 2012  Senator Ben Nevers and Representative Matt Ramsey
- 2013  Senator Al Franken

Ross Hickey Award for Outstanding Service in Diabetes Research Funding

- 1999  Davida F. Kruger, MSN, RN, CS, CDE
- 2000  PacifiCare Foundation
- 2001  Order of the Amaranth and Amaranth Diabetes Foundation
- 2002  Anonymous
- 2003  Terry Gregg and Louise Cotting-Gregg
- 2004  Donald and Arleen Wagner
- 2005  Edsel and Cynthia Ford
- 2006  Richard and Susan Smith
- 2007  The Hickey Family
- 2008  Valerie and Peter Kompaniez
- 2010  Ginger L. Graham, MBA
- 2012  Delores and William Brehm
Addison B. Scoville Award for Outstanding Volunteer Service

1975  Ernest M. Frost, EdD
1977  Wendell Mayes, Jr.
1981  Alvin Z. Levine
1984  Robert L. Kroc, PhD
1986  Annette Shapiro
1987  Oscar B. Crofford, MD
1988  Virginia Hanson-Ullom
1989  Sandra Segal Polin, MPA
1990  Jaime A. Davidson, MD
1991  Frederick C. Goetz, MD
1992  Charles H. Kopke
1993  Deborah Hinnen, RN, CDE
1994  Denise Dodero
1995  Sydelle Feinman
1996  Michael J. DeMarea, Jr.
1997  David L. Shaw
1998  Sara Nelson
1999  Sanford J. Spitzer
2000  Darlene L. Cain
2001  Lawrence T. Smith
2002  George J. Huntley, CPA
2003  Cherrel A. Christian, RN, CDE
2004  R. Stewart Perry
2005  Victor H. Gonzalez, MD
2006  John W. Griffin, Jr.
2007  Robert E. Sevier, MD
2008  Yvette Roubideaux, MD, MPH
2009  Joseph A. Stankaitis, MD, MPH
2010  Cynthia Levy
2011  Kermit R. Crawford, RPh

Excellence in Health Communications Award

2012  Kelly Close

Health Professional Award for Volunteer Service

2012  Ho Luong Tran, MD, MPH  2013  Brenda Montgomery, RN, MS, CDE

Charles H. Best Medal for Distinguished Service in the Cause of Diabetes*

1974  Senator Gale W. McGee
1975  Ray A. Kroc
1976  Representative Louis Stokes
1977  Wayne Newton
1978  President Gerald R. Ford
1979  Jim (Catfish) Hunter
1980  David M. Kipnis
1981  Daniel T. Gillespie Family
1982  J. William Flynn, MD
1983  Ronald Reagan
1984  James M. Fowler, DDS
1985  Everett J. Grindstaff
1986  Keatha K. Krueger, PhD
1987  Senator Richard Schweiker
1988  Wayne Parker
1989  Robert S. Bolan
1990  Premiere Committee, Los Angeles
1991  Eva R. Saxl
1992  Rachmiel Levine, MD
1993  Holiday Sales Program
1994  Diabetes Control and Complications Trial (DCCT) Study Group
1995  Charles and Verda Kopke
1996  Order of the Amaranth, Inc.
1997  Diabetes Care & Education Practice Group of the American Dietetic Association
1998  Honorable Newt Gingrich
1999  Barbara Fleming, MD, PhD
2000  Saul M. Genuth, MD
2001  Marion J. Franz, MS, RD, CDE
2002  Sherman M. Holvey, MD
2003  Equal Employment Opportunity Commission
2004  Gila River Indian Tribe
2005  National Diabetes Education Program
2006  People’s Republic of Bangladesh and The United Nations
2007  Donald and Arleen Wagner
2008  Nicole Johnson
2009  Richard Kahn, PhD
2010  Karen Talaladze, PhD
2011  Kermit R. Crawford, RPh

*While this award is no longer bestowed, the Association continues to honor its past recipients for their distinguished service.
AMERICAN DIABETES ASSOCIATION

Association Officers Leadership and Service Recognition

Charles H. Best Medal for Leadership and Service

1974 Gail Velde
1978 Wendell Mayes, Jr.
1979 Myles H. Tanenbaum
1981 Benjamin Greenspoon
1983 Harlan L. Hanson
1984 Gordon Stulberg
1985 Joseph H. Davis
1986 Henry Rivera
1987 Sam A. Gallo
1988 S. Douglas Dodd
1989 William A. Mannrakk
1990 Sterling Tucker
1991 Arnold Bereson
1992 Todd E. Leigh
1993 Ross V. Hickey, Jr.
1994 Michael A. Greene
1995 Douglas E. Lund
1996 David H. McClure
1997 Alan Altschuler
1998 Stephen J. Satalino
1999 Jane Camporeale
2000 Edward T. Hawthorne
2001 Charles F. Baer
2002 Stephen H. Smith
2003 Michael A. Weiss
2004 James A. Horbowicz
2005 Larry K. Ellingson, RPh
2006 Lawrence T. Smith
2007 Darlene L. Cain
2008 R. Stewart Perry
2009 George J. Huntley, CPA
2010 Nash M. Childs, PE
2011 John W. Griffin, Jr.
2012 L. Hunter Limbaugh
2013 Karen Talmadge, PhD
2014 Dwight Holing
2015 Janel L. Wright, JD
2016 Robin J. Richardson
2017 David A. DeMarco, PhD

Rachmiel Levine Medal for Leadership and Service

1979 Patricia A. Lawrence, RN, MA
1981 Barbara Prater, RD, PhD
1983 Florence R. Ruhrland, RN, MEd
1986 Patricia A. Schultz, RN, MS
1988 Linda S. Hurwitz, RN, MS
1989 Alan D. Cherrington, PhD
1990 Mary Louise Maras, RD, CDE
1991 Charlene Freeman, RN, CDE
1992 Madelyn L. Wheeler, MS, RD, CDE
1994 Patricia D. Stenger, RN, CDE
1995 Linda M. Siminerio, RN, MS, CDE
1996 Davida F. Kruger, MSN, RN, CS, CDE
1997 Belinda P. Childs, RN, MN, CDE
1998 Christine A. Beebe, MS, RD, CDE, LD
1999 Linda B. Haas, PhC, RN, CDE
2000 Elizabeth A. Walker, DNSc, RN, CDE
2001 Lee J. Sanders, DPM
2002 Anne E. Daly, MS, RD, BC-ADM, CDE
2003 Martha M. Funnell, MS, RN, CDE
2004 Catherine J. Tibbetts, RN, MPH, CDE
2005 Carolé R. Mensing, RN, MA, CDE
2006 Karmeen Kulkami, MS, RD, BC-ADM, CDE
2007 Richard R. Rubin, PhD, CDE
2008 Ann L. Albright, PhD, RD
2009 Sue McLaughlin, BS, RD, CDE, CPT
2010 Christine T. Tobin, MS, MBA, CDE
2011 Elizabeth Mayer-Davis, MSPH, PhD, RD
2012 Gerald R. Spollett, MSN, ANP-CS, CDE
2013 Lurelean B. Gaines, RN, MSN
2014 Marjorie Cypress, PhD, C-ANP, CDE
2015 David G. Marrero, PhD
2016 Margaret A. Powers, PhD, RD, CDE
2017 Brenda Montgomery, RN, MSHS, CDE

Banting Medal for Leadership and Service

1977 Donnell D. Etzwiler, MD
1978 Norbert Freinkel, MD
1979 Fred W. Whitehouse, MD
1980 Ronald A. Arky, MD
1981 Donald I. Bell, MD
1982 Oscar B. Crofford, MD
1983 Irving L. Spratt, MD
1984 Allan L. Drash, MD
1985 Karl E. Sussman, MD
1986 Harold Rifkin, MD
1987 Daniel Porte, Jr., MD
1988 John A. Colwell, MD, PhD
1989 Charles M. Clark, Jr., MD
1990 Sherman M. Holvey, MD
1991 Edward S. Horton, MD
1992 Jay S. Skyler, MD
1993 F. Xavier Pi-Sunyer, MD
1994 James R. Gavin II, MD, PhD
1995 Kathleen L. Wishner, MD, PhD
1996 Frank Vinicor, MD, MPH
1997 Philip E. Cryer, MD
1998 Mayer B. Davidson, MD
1999 Gerald Bernstein, MD
2000 Bruce R. Zimmerman, MD
2001 Robert S. Sherwin, MD
2002 Christopher D. Saudek, MD
2003 Francine R. Kaufman, MD
2004 Eugene J. Barrett, MD, PhD
2005 Alan D. Cherrington, PhD
2006 Robert A. Rizza, MD
2007 Larry C. Deeb, MD
2008 John B. Buse, MD, PhD
2009 R. Paul Robertson, MD
2010 Richard M. Bergenstal, MD
2011 Robert R. Henry, MD
2012 Vivian Fonseca, MD
2013 John E. Anderson, MD
2014 Elizabeth R. Seagrist, MD
2015 Samuel Dagogo-Jack, MD
2016 Desmond Schatz, MD
2017 Alvin C. Powers, MD
<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>George W. Booker II, CPA</td>
<td>2011</td>
<td>Dwight Holing</td>
<td>2015</td>
<td>Richard Farber, MBA</td>
</tr>
</tbody>
</table>

**Charles Kopke Medal for Leadership and Service**
Young Investigator Travel Grant Award Recipients

The following abstract authors have been awarded Young Investigator Travel Grants. The ADA funds this program to support promising young scientists presenting their research at the Scientific Sessions and to encourage new and emerging investigators in the field of diabetes research and care.

Ali Asmar, MD, PhD
Bispebjerg Hospital,
University Hospital of Copenhagen
Copenhagen, Denmark
144-OR: Extracellular Volume Expansion Uncovers a Natriuretic Action of Glucagon-Like Peptide-1

Giorgio Basile, PhD
Joslin Diabetes Center
Boston, MA
49-OR: Identification of Pancreatic Elastase Inhibitors That Can Stimulate Beta-Cell Proliferation

Gourav Bhardwaj, PhD
University of Iowa
Iowa City, IA
187-OR: Loss of Insulin/IGF-1 Receptors in Muscle Cooperately Downregulates Mitochondrial Metabolism and Alters Mitophagy via Fox Transcription Factors

Bruna B. Brandao, PhD
Joslin Diabetes Center
Boston, MA
354-OR: Serum Exosomal Proteins—A New Component of Intercellular Communication in Metabolism

Persis V. Commissariat, PhD
Joslin Diabetes Center
Boston, MA
795-P: Establishing a Clinical Cut-Point for the PAID-Peds (Problem Areas in Diabetes-Pediatric) Survey

Baqiyyah Conway, PhD
University of Texas Health Science Center at Tyler
Tyler, TX
178-OR: Diabetes and Liver Cancer Risk—A Stronger Effect in Whites than Blacks?

Hassan S. Dashti, PhD, RD
Massachusetts General Hospital
Boston, MA
176-OR: Multitrait Genome-Wide Association Analysis of Macronutrient Intake Identifies 12 Novel Loci for Dietary Intake and Unravels Genetic Overlap with Lifestyle Traits and Cardiometabolic Diseases

Laerke S. Gasbjerg, MD
University of Copenhagen
Copenhagen, Denmark
145-OR: Extracellular Volume Expansion Uncovers a Natriuretic Action of Glucagon-Like Peptide-1

Cristy R. Geno Rasmussen, PhD, MPH
Barbara Davis Center for Diabetes
Aurora, CO
182-OR: Population Screening for T1D and Celiac Disease—Autoimmunity Screening for Kids (ASK)

Veronique Gingras, PhD, RD
Harvard Medical School
Boston, MA
137-OR: Dietary Behaviors throughout Childhood Are Associated with Body Mass Index and Estimated Insulin Resistance in Adolescence—A Longitudinal Study

Christine Hockett, PhD
Colorado School of Public Health
Aurora, CO
179-OR: Adiposity and Cardiovascular Markers in Offspring of Women with Diabetes during Pregnancy—The EPOCH Study

Heba M. Ismail, MB, BCh, MSc, PhD
Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center
Pittsburgh, PA
1693-P: The Influence of Parental Type 1 Diabetes (T1D) on the Progression to T1D in Autoantibody-Positive Offspring

Rabab Z. Jafri, MD
Massachusetts General Hospital
Boston, MA
14-OR: A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense CGM Devices in an Outpatient Study of Subjects with Type 1 Diabetes

Prapaporn Jungtrakoon, PhD
Mahidol University
Bangkok, Thailand
262-OR: Malate Dehydrogenase 2 (MDH2) as a New Diabetogene Causing Hyperglycemia in Families with Multigenerational Diabetes

Noriko Kodani, MD
Keio University School of Medicine
Tokyo, Japan
191-OR: Foxo1 Corepressor (FCoR) and Foxo1 Regulate a-Cell and β-Cell Identity

Andrea Laurenzi, MD
Diabetes Research Institute, San Raffaele Hospital
Milan, Italy
898-P: Frequency of Flash Glucose Monitoring Scans and Hemoglobin A1C in Real Life
Michael Laxy, PhD, MSc, MPH
Centers for Disease Control and Prevention
Atlanta, GA
170-OR: Cost-Effectiveness of Structured Lifestyle Programs for Diabetes Prevention in the Medicaid Population

Yan Liu, PhD
University of Michigan Medical School
Ann Arbor, MI
185-OR: Hepatic Insulin/Snail1 Axis Protects against Liver Steatosis and Insulin Resistance through Epigenetically Suppressing Lipogenesis

Ana Leda Longhini, PhD
University of Alabama at Birmingham
Birmingham, AL
238-OR: Loss of Hypothalamic Somatostatin (SST) Contributes to Bone Marrow (BM) Dysfunction and Diabetic Retinopathy (DR) in Type 2 Diabetic Rats

Nicolai A. Lund-Blix, PhD
Barbara Davis Center for Diabetes
Aurora, CO
136-OR: Gluten Intake and Risk of Islet Autoimmunity and Progression to Type 1 Diabetes in Children at Increased Risk of Disease

Tracy C.S. Mak, PhD
MRC London Institute of Medical Sciences
London, United Kingdom
52-OR: Generation of a Novel Mouse Model to Study Pancreatic Beta-Cell Dedifferentiation

Amy McKenzie, PhD
Virta Health
San Francisco, CA
293-OR: Continuous Remote Care Model Utilizing Nutritional Ketosis Improves Type 2 Diabetes Risk Factors in Patients with Prediabetes

Natalie Ritchie, PhD
Denver Health
Denver, CO
246-OR: Presessions to the National Diabetes Prevention Program Are a Promising Strategy to Improve Attendance and Weight Loss Outcomes

Hui Shao, MBBS, MHA, PhD
Centers for Disease Control and Prevention
Atlanta, GA
3-OR: Influence of Diabetes Complications on the Cost-Effectiveness of A1C Treatment Goals in Older U.S. Adults

Ana B.A. Wagner, PhD
Joslin Diabetes Center
Boston, MA
64-OR: Maternal and Paternal Exercise Regulates Offspring Metabolic Health and Beta-Cell Phenotype

David V. Wagner, PhD
Oregon Health & Science University
Portland, OR
881-P: HbA1c (You Later)—What Happens to Glycemic Control while Waiting for NICH?

Chih-Hao Wang, PhD
Joslin Diabetes Center
Boston, MA
273-OR: CRISPR-Engineered Human Brown-Like Adipocytes Promotes Metabolic Homeostasis through Activation of Endogenous Brown Fat
Abstract Award Recipients

Marvin Levin Travel Scholarships

The young scientists listed below have been awarded the Marvin Levin Travel Scholarships. These scholarships are awarded each year by the Professional Interest Group on Foot Care, in honor of Dr. Levin, who is internationally known for his contributions to the understanding of diabetic foot disorders.

Are We Misdiagnosing Diabetic Foot Osteomyelitis?
Peter A. Crisologo, DPM
Dallas, TX

Outcomes of Split Thickness Skin Grafting on Lower Extremity Wounds in Diabetics
Elliot Walters, MD
Washington, DC

Michaela Modan Memorial Award

The group of scientists listed below have been awarded the Michaela Modan Memorial Award given in honor of Dr. Michaela Modan, an Israeli epidemiologist who made major contributions to the understanding of type 2 diabetes mellitus, insulin resistance, hypertension, and diabetic complications.

The Pros and Cons of Gastric Bypass Surgery in Obese Individuals with Type 2 Diabetes—Nationwide, Matched, Observational Cohort Study
Vasileios Liakopoulos, MD, MSc; Ann-Marie Svensson, PhD; Ingmar Naslund, MD, PhD; Bjorn Eliasson, MD, PhD
Gothenburg, Sweden, Orebro, Sweden

The Vivian Fonseca and Nagendran Family Diabetes Research Award

The individual listed below has been awarded the Vivian Fonseca and Nagendran Family Diabetes Research Award. This award recognizes diabetes research focused on the South Asian, Asian American, Native Hawaiian, and Pacific Islander populations and/or research by a scientist from these areas of the world. Supported by a grant from Suku Nagendran, MD, and Anne Nagendran, the Vivian Fonseca and Nagendran Family Diabetes Research Award is given in honor of Mr. P. Nagendran and recognizes the contributions of Dr. Vivian Fonseca, a former President, Medicine & Science of the American Diabetes Association, who has been a mentor and role model to many researchers and clinicians.

The Relationship of Acculturation to Cardiometabolic Risk Factors among U.S. South Asians—Findings from the MASALA Study
Rita Rastogi Kalyani, MD, MHS
Baltimore, MD

Abstract Co-Authors: Mohammed Al-Sofiani, MBBS, MSc; Susan J. Langan, MS, MPH; Alka M. Kanaya, MD; Namratha R. Kandula, MD, MPH; Belinda Needham, PhD; Catherine Kim, MD, MPH; Diane M. Becker, MPH, ScD; Dhananjay Vaidya, MBBS, PhD, MPH; Sherita Golden, MD, MHS; Clare Lee, MD, MHS
Baltimore, MD, San Francisco, CA, Chicago, IL, Ann Arbor, MI
Professional Interest Group Chairs

The Professional Interest Groups provide a forum for the exchange of information in specific areas of diabetes research and care. The Professional Interest Group Chairs are listed below:

Behavioral Medicine and Psychology ................................................................. Michael A. Harris, PhD
Clinical Centers and Programs ........................................................................ Boris Draznin, MD, PhD
Clinical Endocrinology, Health Care Delivery, and Public Health ................ Thomas Songer, PhD, MSc, MPH
Complications ...................................................................................................... Jennifer B. Green, MD
Diabetes in Youth ................................................................................................ Ingrid M. Libman, MD, PhD
Education ............................................................................................................ Curtis L. Triplitt, PharmD, CDE
Epidemiology and Statistics ................................................................................ Kasia J. Lipska, MD, MHS, BS
Exercise ................................................................................................................ Jeffrey F. Horowitz, PhD
Foot Care ............................................................................................................. George T. Liu, DPM, FACFAS
Immunology, Immunogenetics, and Transplantation ....................................... Massimo Pietropaolo, MD
Nutritional Science and Metabolism ................................................................. Elizabeth J. Mayer-Davis, PhD
Pregnancy and Reproductive Health ............................................................... Rebecca A. Simmons, MD

Scientific Sessions Meeting Planning Committee

The Scientific Sessions Meeting Planning Committee is responsible for the development and content of the meeting. They volunteer countless hours to ensure the meeting offers world-class science and education. The ADA would like to thank the members of the committee for their dedication and leadership in planning this year’s scientific program:

Maureen A. Gannon, PhD (Chair) Andrew J. Ahmann, MD Laura C. Alonso, MD Rita Basu, MD Joni Beck, PharmD, BC-ADM, CDE Melena Bellin, MD Richard K.P. Benninger, PhD Sudha Biddinger, MD, PhD Julia V. Busik, PhD Brian C. Callaghan, MD, MS Luiza Caramori, MD, MSc, PhD Kenneth Feingold, MD Brian N. Finck, PhD Adolfo Garcia-Ocaña, PhD Jennifer B. Green, MD Michael A. Harris, PhD Andrea L. Hevener, PhD Jeffrey F. Horowitz, PhD William C. Hsu, MD Erin E. Kershaw, MD Ingrid M. Libman, MD, PhD Ildiko Lingvay, MD, MPH, MScS Kasia J. Lipska, MD, MHS, BS George T. Liu, DPM, FACFAS Elizabeth J. Mayer-Davis, PhD Amir Moheet, MBBS Timothy F. Osborne, PhD Massimo Pietropaolo, MD Toni I. Pollin, MS, PhD, CGC Guy A. Rutter, PhD Jane Jeffrie Seley, DNP, MSN, MPH, BC-ADM, CDE, CDTC, FAADE, FAAN Thomas Songer, PhD, MSc, MPH Curtis L. Triplitt, PharmD, CDE

For Scientific Sessions Meeting Planning Committee disclosure information, see page 434.
Abstract Reviewers

The Scientific Sessions program received more than 3,000 abstract submissions, which were put through a blind, peer-reviewed process, carried out by a panel of reviewers who play a critical role in designing a strong scientific program.

More than 350 reviewers volunteered their time and expertise, helping to ensure that the abstracts being presented were selected on the basis of rigorous review and of the highest scientific quality.

The ADA and the Scientific Sessions Meeting Planning Committee would like to thank the following abstract reviewers for their contributions to this year’s Scientific Sessions:

Muhammad Abdul-Ghani, MD, PhD
Martin J. Abrahamson, MD
Grazia Abreu, MD
Grazia Aleppo, MD
Rebecca Allen, MD, RD/LD, CDE
Pamela Allweiss, MD, MPH
Jaime Almendzo, MD
John W. Apolzan, PhD
Vanita R. Aroda, MD
Tandy Aye, MD
Madona Azar, MD
Fida Bacha, MD
David Baidal, MD
Christie M. Ballantyne, MD
Linda A. Barbour, MD, MSPH, FACP
Eugene J. Barrett, MD, PhD
Joshua I. Barzilay, MD
Ananda Basu, MD
Lydia Bazzano, MD, PhD
Dorothy J. Becker, MD
Martin Beinborn, MD, PhD
Richard M. Bergenstal, MD
Ernesto Bernal-Mizrachi, MD
Deloris A. Berrien-Jones, MD
Rudy Bilous, MD
Petter Bjornstad, MD
Jonathan Bogan, MD
Karen Bolderman, RD, LDN, CDE
Fatima Bosch, PhD
Julie K. Bower, PhD, MPH
Rose Briars, ND, PNP-BC, CDE
J. Mark Brown, PhD
Lisa Brown, RD, LD, CDE
Clinton Bruce, PhD
Charles F. Burant, MD, PhD
Kyle Burger, MPH, RD, PhD
John B. Buse, MD, PhD
Andrew A. Butler, PhD
Nigel A. Calcult, PhD
Ruth B. Caldwell, PhD
Judith A. Callan, PhD, RN
Sonia Caprio, MD
Anders Carlson, MD
Mercedes R. Carnethon, PhD
April P. Carson, PhD, MSPH
Gregory D. Cartee, PhD
Jessica R. Castle, MD
Patrick M. Catalano, MD
Ilaria Cavallari, MD
Alan Chait, MD
Laura Chalmers, MD
Rane Chatterjee, MD, MPH
Lisa Chow, MD
Paul M. Coen, PhD
Fran Cogen, MD
Ronald Cohen, MD
Robert V. Considine, PhD
John A. Corbett, PhD
Susan Cornell, PharmD, CDE, FAPhA
Daniela Costa, MD
Tessa L. Crume, PhD, MSPH
Philip E. Cryer, MD
Aaron M. Cypess, MD, PhD, MMSc
Dana Dabelea, MD, PhD
Peter Damm, DMSc
Kirstie K. Danielson, PhD
Barbara de Courtens, MD, PhD, MPH, FRACP
Carolyn F. Deacon, PhD
Amy DeGueme, MD, ECNU
Stefano Del Prato, MD
Jean-Pierre Després, PhD
Jane K. Dickinson, RN, PhD, CDE
Thanh Dinh, DPM
Luc Djousse, MD
Kim C. Donahue, MBBS, PhD
Amy C. Donihi, PharmD, BCPS
Kimberly A. Driscoll, PhD
Daniel J. Drucker, MD
John J. Dubé, PhD
Kathleen M. Dungan, MD, MPH
Fredrick Dunn, MD
Patti Duprey, MSN, APRN, CDE
Justin Basile Echouffo Tcheugui, MD, PhD
Steven V. Edelman, PhD
Decio L. Eizirik, MD, PhD
Jennifer L. Estall, PhD
Carmella Evans-Molina, MD, PhD
Yong Fan, PhD
Denise S. Feig, MD, MSc, FRCP
Assiamira Ferrara, MD, PhD
Simon J. Fisher, MD, PhD
Jose C. Florez, MD, PhD
Elena O. Flowers, PhD, RN
Vivian Fonseca, MD
Alessia Fornoni, MD, PhD
Krystle Frahm, PhD
Marion J. Franz, MS, RD, LD, CDE
Roy L. Freeman, MD
Juan P. Frias, MD
Vera Fridman, MD
Jacob E. Friedman, PhD
Robert A. Gabbay, MD, PhD
Dymphna Gallagher, EdD
Om Ganda, MD
Abhimanyu Garg, MD
Rajesh Garg, MD
Satish K. Garg, MD
Amalia Gastaldelli, PhD
Kyle Gauton, PhD
Minu George, MD
Senta Georgia, PhD
Luigi Gnudi, MD, PhD, FRCP, FASN
Jeffrey S. Gonzalez, PhD
Morgan E. Grams, MD, PhD, MHS
Maria B. Grant, MD
Carla J. Greenbaum, MD
M. Carol Greenlee, MD, FACE, FACP
Leif C. Groop, MD, PhD
Gabriella Gruden, MD
Guoqiang Gu, PhD
Kirk M. Habbegger, PhD
Samy Hadjadj, MD
Rebecca A. Haeusler, PhD
Jeffrey B. Halter, MD
Osama Hamdy, MD, PhD
Rens Hanewinckel, MD
Torben Hansen, MD, PhD
Manami Hara, DDS, PhD
Charles Harris, PhD
Mary Elizabeth Hartnett, MD
Monique Hedden, PhD
Robert R. Henry, MD
William H. Herman, MD, MPH
Abstracts on USB
Sponsored by Sanofi

Abstracts on USB contain searchable electronic copies of all abstracts from the 78th Scientific Sessions. This compact and easily portable format provides enduring access to abstracts. Visit the Sanofi Exhibit at booth 803 in the Exhibit Hall to pick up your free USB.

ADA Daily
Share in the excitement of the 78th Scientific Sessions with the official meeting newspaper—ADA Daily. Get the latest updates on upcoming sessions as well as a recap of sessions from previous days. Pick up your free copy at newsstands located throughout the convention center or view it online at www.adadaily.org

ADA Exhibit
Hall WA1-WA3 (Exhibit Hall)

Visit the ADA Exhibit at booth 1453 in the Exhibit Hall and get the latest tools to help you and your patients better manage and prevent diabetes. Pick up free copies of our professional journals and the latest issue of Diabetes Forecast®. Learn about the Association’s patient materials and programs, recognized education program, and other professional resources. You’ll also be able to join our Advocacy program’s efforts to bring down barriers for people with diabetes and encourage the funding of diabetes research.

Badges
Each registered attendee and exhibitor attending the Scientific Sessions will be issued an official identification badge. Anyone wishing to enter session rooms, the Exhibit Hall, or Poster Hall must wear a valid badge for entrance. You will be stopped and asked to present your badge if it is not in view of room monitors or security personnel. If there are any errors on your badge, visit Assisted Registration located in the Level 1 Lobby so it can be corrected. Lost badges will be replaced at a cost of $50/badge.

Business Center/FedEx
Hall C Lobby

The Business Center offers photocopying, faxing, shipping, and sale of office supplies. The Business Center can also produce posters onsite for presenters with any last-minute updates.

Career Center
Level 1 Lobby

Stop by the DiabetesPro Career Center to see or post the latest job openings in diabetes care, research, and education. You can also get individualized recommendations for enhancing your resume and curriculum vitae, and receive complimentary headshots.

Childcare
ADA does not provide childcare during the Scientific Sessions. If you are interested in securing childcare during your stay, contact the concierge in your hotel for a list of local childcare providers. Note: ADA assumes no liability and is not responsible for any expenses related to childcare during the Scientific Sessions. Due to safety concerns and insurance liability, children under the age of 18 are not allowed in session rooms, the Exhibit Hall, or Poster Hall. Exceptions will be made for nursing mothers if the child does not disrupt the session. For safety reasons, strollers are not allowed in session rooms, the Exhibit Hall, or Poster Hall.
Coat/Luggage Check

Level 1 Lobby

Coat and luggage check is available at a cost of $3.00 per item.

Hours of operation:

Friday, June 22 ................................................................. 9:00 a.m.-6:30 p.m.
Saturday, June 23 ............................................................ 7:30 a.m.-6:15 p.m.
Sunday, June 24 ............................................................... 7:30 a.m.-6:45 p.m.
Monday, June 25 ............................................................... 7:30 a.m.-6:45 p.m.
Tuesday, June 26 ............................................................. 7:30 a.m.-12:45 p.m.

Continuing Education

To obtain continuing education credit, you must complete the online evaluation that will be available at www.scientificsessions.diabetes.org from June 22 to July 27, 2018. For attendees practicing outside the U.S. who do not wish to obtain credit, you can pick up a Certificate of Attendance from your tour group leader or at one of the two Information/CE Desks located in the Level 1 and Level 2 Lobbies.

DiabetesInsight™ Monthly Audio CME Program

Level 1 Lobby

DiabetesInsight™ is the most convenient way for clinicians and care team members to prepare themselves for the daily challenges of diabetes care. Listen anytime, anywhere with online access from your computer, tablet, or smartphone.

Diabetes education is rapidly evolving and changing. Stay on top of the field with exclusive interviews from leading diabetes experts. Access the latest and most effective information on the clinical care of diabetes direct from the American Diabetes Association and other major organizations and institutions. Recent topics include trial outcomes and what they mean to the clinician, breakthroughs in lipid and hypertension control, and preventing and treating diabetes complications—from CVD to retinopathy and beyond.

Subscribe today for new low prices! Visit our booth in the Level 1 Lobby to learn more or visit us online at www.audiodigest.org/DI.

E-mail Stations

Level 1 Lobby

E-mail stations are available to help you keep in touch with the office, develop your personal meeting itinerary, or plan your time in Orlando.

Emergencies

ADA staff in red shirts and security personnel located at most session room entrances can assist you in case of any emergency. To report an emergency, please dial 911 or dial 407-685-9828 for convention center security. Stay on the line and be prepared to give the type of emergency along with the location.

Evacuation

In certain circumstances, an emergency requiring evacuation may occur. If the emergency is minor, security and safety personnel will move attendees to a safer location. If the emergency is greater, attendees will be advised via the public-address system to stay in place, move to another area, or evacuate until the emergency is resolved.
Exhibit Hall
Hall WA1-WA3

The Exhibit Hall is a vital part of the Scientific Sessions. This unparalleled venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care.

*Children under the age of 18 will not be admitted into the Exhibit Hall. Exceptions will be made for nursing mothers, but for safety reasons, strollers are not allowed in the Exhibit Hall.*

*Taking photographs in the Exhibit Hall is not permitted. Security will confiscate all cameras used by non-authorized photographers or attendees on the exhibit floor.*

Hours of operation:

- Saturday, June 23: 10:00 a.m.-4:00 p.m.
- Sunday, June 24: 10:00 a.m.-4:00 p.m.
- Monday, June 25: 10:00 a.m.-2:00 p.m.

First Aid Station
Level 1 Lobby

A First Aid Station will be open during regular meeting hours. Ask ADA staff members in red shirts if you need assistance in locating the First Aid Station. First Aid is available in the event of medical emergencies, large or small. First Aid, as well as building security will notify the police, fire department, or EMS company for any emergency requiring additional assistance.

Food and Refreshments
Various Locations

A variety of food and beverage carts are available throughout the convention center.

Two food courts are located in the Level 1 Lobby. Please note that the food options in these food courts are provided by the convention center. A variety of food and beverage carts/concession stands are also available throughout the convention center.

Enjoy lunch on us! All registered full-meeting attendees and those with a Saturday, Sunday, or Monday One-Day Registration will receive a ticket worth $10 with their badge to purchase food or refreshments at concession stands located throughout the Exhibit Hall only. Tickets have no cash value, no change is given, and the unused portion is forfeited.

General Poster Sessions
Hall WA4-WB2 (Poster Hall)

All posters will be displayed Saturday, Sunday, and Monday. Poster presenters will be available for discussion at their posters during one of three General Poster Sessions, scheduled from 11:30 a.m. to 12:30 p.m. on Saturday, and from 12:00 p.m. to 1:00 p.m. on Sunday and Monday.

Please check the presentation schedules on pages 89, 124, and 156 for the abstract categories presented during the General Poster Sessions.

All Late Breaking posters, regardless of category, will be presented on Monday during the General Poster Session.

GlucoseZone Exercise for Diabetes
Hall C Lobby

Join us in the Hall C Lobby from 6:00 p.m. to 6:25 p.m. for a fun and interactive exercise session! After your exciting day of learning, come in the clothes that you are wearing to see how GlucoseZone is revolutionizing exercise for diabetes. The GlucoseZone program is designed to meet the needs of your patients with diabetes or prediabetes by providing exercise guidance that is specific to helping people take control of their diabetes. GlucoseZone is designed to increase insulin sensitivity, lower A1C, reduce body weight, and redefine how diabetes is managed through exercise.
Guest Services
Level 1 Lobby and Hall C Lobby

Have a question regarding Orlando, restaurants, or tour information? Visit the Guest Services Desk where helpful locals from Visit Orlando are eager to assist you!

Hotel Information Desk
Level 1 Lobby

If you have any questions or concerns regarding your hotel reservation made through ADA’s official housing company, CMR, please stop by the Hotel Information Desk for assistance.

Information/CE Desks
Level 1 and Level 2 Lobbies

Have a question about the meeting or need help locating something? Stop by an Information Desk for assistance. ADA Staff wearing red shirts will also be available throughout the convention center to assist you.

Interactive Online Posters (ePosters)
Sponsored by Sanofi

Navigate the virtual Poster Hall from anywhere in the world. The ePosters platform provides a convenient and valuable year-round tool that enables you to view full-scale electronic reproductions of posters presented at the Scientific Sessions. Visit the Sanofi Exhibit at booth 803 in the Exhibit Hall to pick up your free webkey for online access. Computer kiosks are also located within the Poster Hall for electronic poster viewing.

Lost and Found
Room: W102

If you lose an item, or find one, please stop by ADA’s Lost and Found. If a lost item has not yet been turned in, we will take your name and number and contact you if the item is found. Unclaimed items will be returned to ADA’s home office at the end of the meeting. Inquiries after June 26 should be directed to the Convention Operations Department at conventionoperations@diabetes.org.

Hours of operation:
Friday, June 22 .............................................................................................................................................9:00 a.m.-6:15 p.m.
Saturday, June 23 ........................................................................................................................................8:00 a.m.-6:00 p.m.
Sunday, June 24 ...........................................................................................................................................8:00 a.m.-6:30 p.m.
Monday, June 25..........................................................................................................................................8:00 a.m.-6:30 p.m.
Tuesday, June 26........................................................................................................................................8:00 a.m.-12:15 p.m.

Membership Lounge
Level 1 Lobby

ADA Membership Department staff will be available to assist you with renewing your membership, processing new applications, updating addresses, verifying membership status, and answering questions about member benefits.

Are you a long-time attendee of the Scientific Sessions? If you’ve attended five or more years, stop by to pick up a complimentary anniversary pin.

Visit the Membership Lounge for complimentary beverages/snacks, network with other professional members, charge your phone or device, or just relax. Note: Only ADA Professional Members (those wearing Member ribbons) will have access to the Membership Lounge.
Meeting App
Sponsored by Sanofi

Put the Scientific Sessions in the palm of your hand! Use the meeting app for on-the-go access to meeting information on your smartphone or handheld device. Features include meeting program and schedules, a customizable calendar and itinerary builder, exhibitor listing with booth map, social media interaction, and special meeting alerts.

Download the meeting app from Google Play or the App Store. You can also visit m.core-apps.com/tristar_ada_events.

Need help? Visit the Meeting App Help Desk located in the Level 1 Lobby for assistance.

Moderated Poster Discussions
Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and discussions with session moderators.

Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedules listed on pages 90-93, 125-126, and 157.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Networking Reception
Level 4 Foyer

Join us Friday evening from 6:30 p.m. to 8:30 p.m. on the Level 4 Foyer of the convention center for a networking reception. Enjoy complimentary beverages and hors d’oeuvres from a sampling of recipes from the ADA’s award-winning cookbooks while catching up with your colleagues from across the country and around the world.

Nursing Mothers/Prayer Rooms
Level 1 Lobby (Rooms: 13 and 14)

Rooms have been set aside for use by women traveling with a pump or those needing a few minutes of privacy. You may pick up a key to the rooms from the receptionist located in front of the rooms.

Personal Information

Attendee badges have a barcode on the badge to assist exhibitors and corporate symposia planners in contacting you. The barcode, accessible only via handheld scanner devices, contains your name, organization, mailing address, phone, fax, area of expertise, e-mail address, and credentials. It is your choice to have your badge scanned by exhibitors and meeting hosts.
Personal Safety
Follow these tips to make your stay both safe and enjoyable:

- Remove your badge when exiting buses at your hotel or when walking throughout the city.
- Do not carry your Scientific Sessions registration bag during the evening.
- Always walk in groups.
- Talk to your hotel concierge or security regarding the surrounding neighborhoods and any safety concerns.
- Map your route before leaving your hotel.
- Always use auxiliary-locking devices on doors and windows.
- Never leave money, checks, credit cards, passports, extra room keys, or car keys in the room—take them with you or leave them in the hotel safety deposit box or in-room safe.
- If you are the victim of a crime, call the police and report the crime immediately. Dial 911 from any phone to be connected with the police department.

Photography/Social Media Policy

- **Photography:** Allowing photographs of presentation slides at the Scientific Sessions will be at the discretion of the presenter/study author. Each presenter/study author will announce, verbally and visually on a slide at the beginning of their presentation, whether or not he/she approves of photos being taken of his/her slides. If allowed, attendees may take photographs during presentations provided that the photographs are for personal, non-commercial use and are not for publication or rebroadcast without the express written permission of the author. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience. **Photography is not permitted in the Exhibit Hall or Poster Hall.**
- **Social Media:** The ADA encourages the use of social media, when following the above photo policy and within embargo restrictions, to update followers on the latest news coming from the Scientific Sessions.

Poster Barcodes

**Hall WA4-WB2 (Poster Hall)**

Each poster in the Poster Hall has a corresponding barcode on its board. Scanning the code with a smartphone or camera equipped tablet will allow you to access an electronic version of the poster, corresponding abstract, and audio commentary by the presenter (if provided). To view barcodes, you will need to download a reader. We suggest searching your App Store for a free reader.

Poster Hall Hours

**Hall WA4-WB2 (Poster Hall)**

Hours of operation:
- Saturday, June 23: 10:00 a.m.-6:00 p.m.
- Sunday, June 24: 7:30 a.m.-6:30 p.m.
- Monday, June 25: 7:30 a.m.-2:00 p.m.

Poster Presenters

Plan to hang your poster on Friday, June 22 between the hours of 11:00 a.m. and 6:00 p.m. **Note:** All posters and materials must be removed from the Poster Hall on Monday, June 25 between 2:00 p.m. and 4:30 p.m. or they will be discarded. Poster presenters will not be allowed access into the Poster Hall after 4:30 p.m. on Monday, June 25.

Press Office

**Room: W109B**

The Press Office provides a workplace for credentialed media representatives. ADA staff will arrange all interviews and news conferences pertaining to the Scientific Sessions. Presenters are urged to check their voice mail daily for messages from media, and to contact the Press Office immediately if they receive an interview request. All questions regarding interviews and/or Press Office operations should be directed to Michelle Kirkwood, Vice President, Strategic Communications and Media Relations at 407-685-4010.
Registration

Level 1 Lobby

If you have any additional questions after picking up your badge and materials, visit Assisted Registration (blue counters) for assistance.

Session Room Capacity

The ADA has made every effort to assign sessions to the appropriate room. Attendance is on a first-come, first-served basis. We ask that attendees use all available seating before standing.

Shop Diabetes Store

Level 1 Lobby

- Books
- Webcasts
- Gifts

Save up to 30% off books and show your support with exclusive ADA gear. Every purchase in the store supports diabetes research, advocacy, awareness, and educational programs.

Shuttle Bus Transportation

Shuttle bus transportation will be provided from hotels outside of walking distance to the convention center. If you reserved a room via ADA’s official housing company, CMR, you are entitled to ride the shuttles free of charge and should have received a shuttle pass when you picked up your badge. Hang it on your badge lanyard as you will be required to show the shuttle pass for the return trip from the convention center to your hotel.

If you booked your hotel through ADA’s housing company and did not receive a shuttle pass, stop by Assisted Registration located in the Level 1 Lobby to pick one up. If you did not book your hotel through ADA’s housing company, you may purchase a pass for $75 at Assisted Registration. Limited shuttle bus transportation will be provided to/from the 5K@ADA Fun Run/Walk.

Shuttle schedules are available at your hotel and at Information Desks located in the convention center.

Speaker Ready Room

Room: W205

The Speaker Ready Room is reserved for use by those presenting at the Scientific Sessions. Speakers are required to check in with ADA staff a minimum of two hours before their presentation. Computer workstations will be available for any last-minute updates to presentations. Speakers can also sit for a free professional headshot.

Two areas within the Speaker Ready Room will be available to presenters to practice their presentations. Presenters will be able to reserve these areas in 30-minute increments. A sign-up sheet will be available at the Information Desk in the Speaker Ready Room. Note: Scheduling is on a first-come, first-served basis.

Virtual Reality Tour of Non-Statin LDL-C-Lowering Agents that Decrease Cardiovascular Risk for Patients with Persistent Hypercholesterolemia

Booth 952C (Exhibit Hall)

Visit booth 952C in the Exhibit Hall for a virtual reality learning experience where participants will have the opportunity to wear Oculus Virtual Reality headsets and be completely immersed in a 360-degree virtual world inside a blood vessel. The learners will virtually experience what the patient is going through in terms of disease symptoms and treatment effects, which will help them learn the importance of personalized treatment, physician patient communication, and patient-reported outcomes. This learning experience will be broken into several virtual themes including:

- The Role of LDL-C in the pathophysiology of cardiovascular disease.

Wear Red to Stop Diabetes

Wear red on Sunday, June 24 to show your support of the ADA and our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Together, we can achieve a world free of diabetes and all its burdens. Red merchandise is available for purchase at the Shop Diabetes Store. Every purchase supports diabetes research, advocacy, awareness, and educational programs.
Webcasts (Session Recordings)
Webcasts from all symposia, oral presentations, and major lectures and addresses will be available following the meeting, subject to individual speaker authorization.

Registered attendees who are ADA Professional Members receive FREE online only access to all webcasts at www.professional.diabetes.org/webcasts. Online access for non-ADA members is available for purchase in the Shop Diabetes Store, located in the Level 1 Lobby.

WiFi
Complimentary WiFi is available throughout the public space and meeting rooms of the convention center.

World Cup Lounge
Level 1 Lobby
You don’t have to miss sessions to keep up with the FIFA World Cup. Visit the World Cup Lounge between sessions to see how your favorite team is doing.

#2018ADA on Social Media
The Scientific Sessions is on Twitter and Instagram! For the latest information and to network with fellow attendees, follow @AmDiabetesAssn and @ADA_DiabetesPro on Twitter, as well as @AmDiabetesAssn on Instagram. Be sure to use the official meeting hashtag, #2018ADA, in all your posts.

5K@ADA Fun Run/Walk
Sponsored by Novo Nordisk
Join us for the 5K@ADA Fun Run/Walk on Sunday, June 24. This fun event gives you the opportunity to raise public awareness about the importance of a healthy lifestyle. Registration opens at 6:00 a.m. and the warm up begins at 6:15 a.m. The race will take place at the West Concourse of the Orange County Convention Center and will begin promptly at 6:30 a.m.

To register or pick up your race number, visit the 5K@ADA booth located in the Level 1 Lobby on Thursday or Friday, or visit the Novo Nordisk Exhibit at booth 823 in the Exhibit Hall on Saturday beginning at 10:00 a.m. Limited shuttle bus service will be provided to and from the event.

Want to race in style sporting a 5K@ADA running shirt? Shirts are available in the Shop Diabetes Store located in the Level 1 Lobby for $25. Quantities are limited, so hurry and get yours today!

79th Scientific Sessions—Save the Date
June 7-11, 2019
Moscone Center
San Francisco, California
Visit the San Francisco 2019 Desk located in the Level 1 Lobby to find out more about the host city for next year’s 79th Scientific Sessions. A representative from San Francisco will be available to answer questions.

Do you have an idea for a session that you would like to see featured at next year’s Scientific Sessions? The Scientific Sessions Meeting Planning Committee is soliciting high quality, innovative session proposals for the 79th Scientific Sessions. The committee encourages submissions that are innovative, challenge current treatment paradigms, and represent the latest advances in basic, clinical, and translational science. This is your opportunity to shape the scientific program and help ensure that the most relevant spectrum of topics is presented at the meeting. Visit www.scientificsessions.diabetes.org for more information.

Registration and Housing for the 79th Scientific Sessions will open in early December 2018.
Learning Objectives and Target Audience

The ADA’s Scientific Sessions offers five days of comprehensive educational programming covering the latest in the field of diabetes. The program is designed for physicians, scientists, researchers, physician assistants, nurse practitioners, nurses, dietitians, pharmacists, psychologists, and other members of the health care team.

New developments in clinical and basic research are presented in symposia, state-of-the-art lectures, current issue sessions, oral presentations, and poster discussions. The sessions are designed to improve care of the patient with diabetes by providing members of the health care team with an educational program enhancing their knowledge, advancing their skills, and apprising them of the latest research developments.

At the conclusion of this activity attendees will be able to:

- Identify the 2018 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes.
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia.
- Apply clinical decision-making tools to the assessment and treatment of the complications related to diabetes.
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes.
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes.
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients.
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, transplantation, and islet biology as they relate to diabetes.
Accreditation Statements

Physicians
The American Diabetes Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Diabetes Association designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Family Physicians
This live activity, 78th Scientific Sessions, with a beginning date of 06/22/2018, has been reviewed and is acceptable for up to 35.00 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Doctors of Osteopathy
Category 2 Credit will be awarded for formal educational programs that are ACCME-accredited or AAFP approved.

Physician Assistants
AAAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 35 hours of Category 1 Credit™ for completing this program.

International Physicians
The American Medical Association has determined that physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.

European Union of Medical Specialists
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby:

1) European physicians attending an event in the USA had their credits recognized in Europe and
2) American physicians attending an event in Europe had their credits recognized in the USA.

The American Diabetes Association designates this educational activity for a maximum of 35 AMA PRA Category 1 Credit(s)™ for the Association's 78th Scientific Sessions. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. These credits can be converted by the EACCME into European CME credits and/or into National credits by the European National Authorities.

Nurses
The American Diabetes Association is accredited as a provider of continuing education by the American Nurses Credentialing Center’s COA.

This activity offers a total of 35 contact hours, which includes a maximum of 28 pharmacology-related contact hours.

Dietitians
The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians will receive 35 continuing professional education units (CPEUs) for completion of this program/material. Activity Number: 138560.
Pharmacists
The American Diabetes Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The American Diabetes Association designates these sessions as Knowledge-based per ACPE guidelines. To view the UANs and learning objectives for each session, please visit www.scientificsessions.diabetes.org and click “Continuing Education.”

Psychologist Continuing Education
Postgraduate Institute for Medicine (PIM) is approved by the American Psychological Association to sponsor continuing education for psychologists. PIM maintains responsibility for this program and its content.

Credit: This program offers 35 continuing education credits for psychologists.

Certified Diabetes Educators
To satisfy the requirement for renewal of certification by continuing education for the National Certification Board for Diabetes Educators (NCBDE), continuing education activities must be diabetes related and approved by a provider on the NCBDE List of Approved Providers (www.ncbde.org). NCBDE does not approve continuing education. The American Diabetes Association is on the NCBDE List of Approved Providers.
Continuing Education

Information/CE Desks

Level 1 and Level 2 Lobbies

Hours of operation:

- Thursday, June 21: 3:00 p.m.-7:00 p.m.
- Friday, June 22: 9:00 a.m.-6:30 p.m.
- Saturday, June 23: 7:00 a.m.-6:15 p.m.
- Sunday, June 24: 7:30 a.m.-6:45 p.m.
- Monday, June 25: 7:30 a.m.-6:45 p.m.
- Tuesday, June 26: 7:30 a.m.-12:30 p.m.

Obtaining a Certificate

The continuing education evaluation system will be available beginning on Friday, June 22.

All registered attendees will receive an email for participation. The evaluation will also be posted on our website, www.scientificsessions.diabetes.org. The online evaluation will only be available through Friday, July 27. For attendees practicing outside the U.S., please pick up your certificate of attendance from your tour group leader or at one of two Information/CE Desks located in the Level 1 or Level 2 Lobbies.

Should you have any questions, please contact the continuing education staff onsite or by e-mail at professionaleducation@diabetes.org.

Continuing Education Opportunities

Continuing education credits are available for health care professionals who treat patients with diabetes. For more information, visit the Association’s professional education website at www.professional.diabetes.org/ce.

Take advantage of the variety of continuing education activities and materials for health care professionals. Each activity has been developed by leaders in the field of diabetes with the goal of providing cutting-edge education to advance knowledge and strategies to improve clinical practice and patient outcomes.

Educational offerings include:

- Live programs (fee may apply).
- Webcasts.
- Self-assessment programs (free of charge).

and more…

Continuing education credits are available for physicians, nurses, dietitians, pharmacists, certified diabetes educators, and other health care professionals. Please view the individual activities to see which continuing education credits are offered.
# Personal Session Tracking Worksheet

Double credit will not be awarded for sessions occurring at the same time.

## FRIDAY, JUNE 22, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.-12:30 p.m. sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measuring Neuropathy—Is Corneal Confocal Microscopy Ready for Prime Time?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biofilm—Real Wound Problem or Just a Buzzword?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tech and Teens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myth or Science? Current Fads and Evidence in Diet and Nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Innovations in Diabetes Pregnancy Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New-Onset Type 2 Diabetes in the Youngest and the Oldest</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Emerging Role of Neoeptopes in the Dialogue between T Cells and Beta Cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Banting Exchange—New Concepts in the Pathogenesis of Diabetes and Metabolic Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Regulators of Beta-Cell Identity</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 11:30 a.m.-12:30 p.m. sessions</strong></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 p.m.-1:45 p.m. sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveillance of Kidney Disease and Comorbidities among People with Diabetes—What We Can Learn from the CDC’s Chronic Kidney Disease Surveillance System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding Hybrid Closed-Loop Pump</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Youth-Onset Type 2 Diabetes and Exercise—Outcomes and Challenges</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improving Patient-Provider Communication in the Management of Diabetes in Culturally Diverse Populations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Better Ways to Build Diabetes Population Health Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challenging Times for Youth with Type 1 Diabetes—How Do We Approach Them?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Future of Islet Transplant—Towards a Renewable Source of Beta Cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Near, Far, Wherever You Are—Obesity-Related Defects in Insulin Signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Of Mice, Mongrels, and Men—Commonalities and Differences in Metabolic Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 12:45 p.m.-1:45 p.m. sessions</strong></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m.-4:00 p.m. sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Antiplatelet and Antithrombotic Therapies in Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreasing Risk for Type 2 Diabetes with Foods</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Artificial Pancreas and Decision Support Approaches</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Real-World Evidence in Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health Disorders and Diabetes Distress among Adults with Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine, Paracrine Signaling Affecting Adipocyte Function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Exosome Superhighway in Energy and Metabolic Homeostasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transformational Technologies in Islet Biology—From Omics to Imaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 2:00 p.m.-4:00 p.m. sessions</strong></td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Many Faces of Hypoglycemia—Impact on Patient Health and Well-Being</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data, Data, Everywhere and Not a Pattern to Be Found</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Cardiovascular Outcomes Trials (CVOTs) in Diabetes—Shall We Continue or Change Course?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Dynamic Approaches to Improve Glycemic Control and Primary Diabetes Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose Monitoring—Advances, Pitfalls, and Clinical Relevance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Should Metformin Remain the First-Line Therapy for Type 2 Diabetes?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetics, Adipose Tissue, Obesity, and Type 2 Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel Approaches to Advancing Islet Transplantation—Basic Science</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adipose Differentiation and Function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiRECT Links between Hepatic Metabolism, Glucagon Action, and Glucose Turnover</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balancing Proliferation and Maturation in the Islet (With ADA Presidents' Select Abstract)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Maximum total credit for 4:15 p.m.-6:15 p.m. sessions** 2

**Maximum total credit for Friday** 6

(*) Denotes ANCC pharmacotherapeutics contact hours.
### SATURDAY, JUNE 23, 2018

#### 8:00 a.m.-10:00 a.m. sessions

<table>
<thead>
<tr>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is It Osteomyelitis or Not? Diagnostic and Treatment Dilemmas in Bone Infection</td>
<td>✗</td>
</tr>
<tr>
<td>What’s New in Diabetic Neuropathy? Equal Parts Clinical and Basic Science</td>
<td>✗</td>
</tr>
<tr>
<td>ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability</td>
<td>✗</td>
</tr>
<tr>
<td>Effects of Exercise on Metabolic Health in Type 1 and Type 2 Diabetes (With ADA Presidents’ Select Abstract)</td>
<td>✗</td>
</tr>
<tr>
<td>Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus</td>
<td>✗</td>
</tr>
<tr>
<td>Genetics and Type 2 Diabetes in Youth (**)</td>
<td>✗</td>
</tr>
<tr>
<td>ADA Diabetes Care Symposium—Using Continuous Glucose Monitoring and Smart Devices to Control Glucose when It Matters Most (**)</td>
<td>✗</td>
</tr>
<tr>
<td>Emerging Targets for Diabetes Treatment (**)</td>
<td>✗</td>
</tr>
<tr>
<td>HIV and Diabetes—The Double Whammy (**)</td>
<td>✗</td>
</tr>
<tr>
<td>Overcoming Challenges in Islet Transplantation—Engineering and Protecting Beta Cells</td>
<td>✗</td>
</tr>
<tr>
<td>Hepatokines and Metabolic Regulation—A Liver-Centric Point of View</td>
<td>✗</td>
</tr>
<tr>
<td>Turning Up the Heat—New Regulators of Thermogenesis in Mice and Humans</td>
<td>✗</td>
</tr>
<tr>
<td>Targeting Beta-Cell Apoptosis and Death</td>
<td>✗</td>
</tr>
</tbody>
</table>

**Maximum total credit for 8:00 a.m.-10:00 a.m. sessions** 2

#### 10:15 a.m.-11:15 a.m. session

<table>
<thead>
<tr>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>President, Health Care &amp; Education Address and Outstanding Educator in Diabetes Award Lecture</td>
<td>✗</td>
</tr>
</tbody>
</table>

**Maximum total credit for 10:15 a.m.-11:15 a.m. session** 1

#### 11:30 a.m.-12:30 p.m. sessions

<table>
<thead>
<tr>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>(*) The Best and Worst Practices in Managing the Diabetic Foot</td>
<td>✗</td>
</tr>
<tr>
<td>Update on Nonnutritive Sweeteners and Cardiometabolic Health</td>
<td>✗</td>
</tr>
<tr>
<td>Reframing Exercise—The Surprising Science behind Motivating Patients to Be More Physically Active</td>
<td>✗</td>
</tr>
<tr>
<td>Quantifying Diabetes—Genomics, Electronic Health Records, and Automated Control</td>
<td>✗</td>
</tr>
</tbody>
</table>

**Maximum total credit for 11:30 a.m.-12:30 p.m. sessions** 1

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>Time</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1:45 p.m.-3:45 p.m. sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Resurgence of Triglyceride-Rich Lipoproteins as an Important Target in the Treatment of Dyslipidemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>What Is New in Diabetic Kidney Disease? (With State-of-the-Art Lecture and ADA Presidents’ Select Abstract)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Making a Difference in Five Minutes—Interventions in Diabetes for Anyone (With Richard R. Rubin Award Lecture)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of Exercise in Regulating Mitochondrial Dynamics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Implementation and Dissemination of Research to Improve Patient Safety and Reduce Hypoglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Diabetes Do-It-Yourself (DIY) Revolution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Exploring the Next Frontier in Diabetes Pharmacology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lessons Learned from the Environmental Determinants of Diabetes in the Young (TEDDY) Study—Insights into Early Autoimmune Type 1 Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monogenic Diabetes Testing Is Ready for Prime Time—Integrating Genetics into Your Practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Insights into the Immunology of Human Type 1 Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Intestine in the Regulation of Metabolism, Immunity, and Insulin Sensitivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Steering the Right Course for Diabetes Management—Clinical Perspectives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-Cell Dedifferentiation—True or False?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 1:45 p.m.-3:45 p.m. sessions</strong></td>
<td><strong>2</strong></td>
<td></td>
</tr>
<tr>
<td><strong>4:00 p.m.-6:00 p.m. sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Hypoglycemia—Reducing the Risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Advances in the Diabetic Foot (With Roger Pecoraro Award Lecture)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrition and the Gut Microbiome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Online and Mobile Support—Wading through the Noise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint ADA/Chinese Diabetes Society Symposium—Glucose and Lipid Metabolism—Novel Mechanisms and Targets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>It’s Not Too Late, Baby—Outcomes in Gestational Diabetes Mellitus (With Norbert Freinkel Award Lecture)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Updates from Type 2 Diabetes Trials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) The Impact of Diabetes Interventions and Behaviors on Outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Progress in Islet Transplantation—Clinical Science</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial Dynamics, Metabolism, and Insulin Action</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G is for GLP, GIP, and Glucagon—A NOD to the Gut-Liver Axis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscling In on the Heart of Metabolism and Insulin Sensitivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurotransmitters in the Islet</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 4:00 p.m.-6:00 p.m. sessions</strong></td>
<td><strong>2</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for Saturday</strong></td>
<td><strong>8</strong></td>
<td></td>
</tr>
</tbody>
</table>

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>8:00 a.m.-10:00 a.m. sessions</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Where and Why of Diabetic Neuropathy</td>
<td>3</td>
<td>□</td>
</tr>
<tr>
<td>Blood Flow to the Toe</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>(*) Prediction and Prevention of Cardiovascular Disease</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Building a Case for Getting Reimbursement or Payment for Behavioral Health in Diabetes</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>NDEP Symposium—Diabetes Prevention, Care, and Education in the Digital Age</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Unrecognized (Occult) Metabolic Conditions in Women with Gestational Diabetes Mellitus that Predict Metabolic Complications Later in Life</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>(*) Prioritizing Injectable Therapies in Type 2 Diabetes</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Enhancing the Use of Diabetes Prevention and Cardiovascular Risk Factor Control</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Diabetes Complications and Risk Factors</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Challenges and Hope in Finding a Cure for Type 1 Diabetes</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Molecular Mechanisms of Insulin Action and Resistance in Peripheral Tissues</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>(*) Precision Medicine in Diabetes</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>ADA Diabetes Symposium—Emerging Areas of Islet Biology</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Novel Signaling Pathways in the Islet</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td><strong>Maximum total credit for 8:00 a.m.-10:00 a.m. sessions</strong></td>
<td><strong>2</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:15 a.m.-11:45 a.m. session</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>President, Medicine &amp; Science Address and Banting Medal for Scientific Achievement</td>
<td>1.5</td>
<td>□</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:00 p.m.-1:00 p.m. sessions</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Importance of the Functional Characteristics of HDL</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Update on Diabetic Retinopathy Clinical Trials</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Moving Past the Randomized Controlled Trial—Understanding the Need for Implementation Science in Diabetes Care</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>The Future of Diabetes Education—“Live” Educator and “Virtual” Coach Partners in Care</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Beyond HbA1c in Pediatric Diabetes—Is It Time to Look at Other Outcomes?</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>(*) Clinical Centers and Programs Session I</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td>Update on the Genetics of Type 1 and Type 2 Diabetes</td>
<td></td>
<td>□</td>
</tr>
<tr>
<td><strong>Maximum total credit for 12:00 p.m.-1:00 p.m. sessions</strong></td>
<td><strong>1</strong></td>
<td></td>
</tr>
</tbody>
</table>

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>2:15 p.m.-4:15 p.m. sessions</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>(*) Joint ADA/ASN Symposium—Management of Patients with Progressing Diabetic Kidney Disease (DKD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Insights into the Mechanisms of Defective Hypoglycemia Counterregulation in Diabetes (With ADA Presidents’ Select Abstract)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Innovative Strategies to Improve the Inpatient Experience</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aerobic Exercise in the Prevention of Cognitive Decline in Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The National Diabetes Prevention Program—From Research to Practice to National Policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Joint ADA/JDRF Symposium—Current Management of Type 1 Diabetes in Youth—What Are the Options?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Addressing Unique Challenges in Diabetes Management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials in Type 1 Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kelly West Award for Outstanding Achievement in Epidemiology Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint ADA/Diabetes UK Symposium—Cell Therapy for Diabetes—International Progress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fuel Driving Function—Lipidic Roles in Different Tissues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ordering from the Weight-Loss Menu in the Era of Precision Medicine for Obesity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>More to Mitochondria in the Beta Cell</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Maximum total credit for 2:15 p.m.-4:15 p.m. sessions**: 2

<table>
<thead>
<tr>
<th>4:30 p.m.-6:30 p.m. sessions</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuro- and Gial-Vascular Effects in the Pathogenesis of Diabetic Retinopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) The Veterans Affairs Diabetes Trial (VADT) at 15 Years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-Carbohydrate Diets—Potential Benefits, Risks, and Costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High Risk Behavioral and Psychosocial Issues in Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) Diabetes Prevention—What Are We Preventing?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint ADA/AACC Symposium—Refining Measurement of A1C—Do We Know What It Means?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basic and Translational Mechanisms in Gestational Diabetes Mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*) From Progression to Management in Type 1 Diabetes—What Is New? (With ADA Presidents’ Select Abstract)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Academia-Industry Collaborations—Key Considerations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beyond Single Nucleotide Polymorphisms—Building on Knowledge of the Genetic Architecture of Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel Pathogenetic Pathways in Type 1 Diabetes—What Can We Learn from Cancer Immunotherapy?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Angles in Adipose Biology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint ADA/EASD Symposium—Central Control of Glucose Homeostasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alpha Cells—New Sources of Beta Cells?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Maximum total credit for 4:30 p.m.-6:30 p.m. sessions**: 2

**Maximum total credit for Sunday**: 8.5

(*) Denotes ANCC pharmacotherapeutics contact hours.
### MONDAY, JUNE 25, 2018

<table>
<thead>
<tr>
<th>Time Range</th>
<th>Total Credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8:00 a.m.-10:00 a.m. sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of the Kidney in Heart Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Insights into the Pathogenesis of Diabetic Retinopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intervening in the Lived Experiences and Social Context of Those with Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Self-Management Education and Support—Embracing Data and Digital Dialogue Advances</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Who Do You Think You Are? Heterogeneity of Obesity and Gestational Diabetes Mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 Diabetes in Youth—Update on the Current State of Knowledge on Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effectiveness of Telemedicine in Underserved Communities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*') SGLT2 Inhibitors—From Mechanisms to Clinical Trials (With ADA Presidents’ Select Abstract)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*') Genetic and Ethnic Heterogeneity and the Road to Precision Medicine in Diabetes (With ADA Presidents’ Select Abstract)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(*') Clinical Trials for Type 1 Diabetes—Current, Emerging, and Novel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adipose Browning and Energy Expenditure (With State-of-the-Art Lecture)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recognition of Depression, Diabetes, and Dementia—Resetting Clinical Priorities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novel Mediators and Mechanisms of Obesity Pathogenesis in Animals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and the Beta Cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 8:00 a.m.-10:00 a.m. sessions</strong></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>10:10 a.m.-11:45 a.m. session</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 10:10 a.m.-11:45 a.m. session</strong></td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>12:00 p.m.-1:00 p.m. sessions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special Topics in Hypoglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overcoming Gender Gaps in Science</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Lancet Commission on Diabetes—Societal Solutions to Combat Diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Should All Pregnant Women with Type 1 Diabetes Use Continuous Glucose Monitoring from Planning Pregnancy until after Breastfeeding?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Centers and Programs Session II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Defining a Healthy Diet—Do Fats or Carbohydrates Matter More?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunopathogenesis of Type 1 Diabetes—Is It Autoimmunity?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maximum total credit for 12:00 p.m.-1:00 p.m. sessions</strong></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>Session Time</th>
<th>Event Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-4:15 p.m.</td>
<td>Evolving Mechanisms in Cardiovascular Complications (With Edwin Bierman Award Lecture)</td>
</tr>
<tr>
<td></td>
<td>(*) Easing Disease Management Burden for Older Adults</td>
</tr>
<tr>
<td></td>
<td>Nutrition 2018—New Data, New Perspectives</td>
</tr>
<tr>
<td></td>
<td>Cost-Related Nonadherence to Diabetes Care</td>
</tr>
<tr>
<td></td>
<td>(*) The Restoring Insulin Secretion (RISE) Study in Youth and Adults—Baseline Data and Results of the Pediatric Medication Study</td>
</tr>
<tr>
<td></td>
<td>(*) Preventing and Treating Hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>Race and Societal Influences on Diabetes (With Vivian Fonseca and Nagendran Family Diabetes Research Award Presentation)</td>
</tr>
<tr>
<td></td>
<td>Translational Immunology in Type 1 Diabetes—A Look at the Future</td>
</tr>
<tr>
<td></td>
<td>Adipose Signaling and the Central Nervous System in the Control of Obesity</td>
</tr>
<tr>
<td></td>
<td>Diversity Affairs—Impact of Genetic Variability and Sex on Integrative Metabolism and Disease Risk</td>
</tr>
<tr>
<td></td>
<td>Regulation of Islet Function in Health and Disease</td>
</tr>
<tr>
<td></td>
<td>Maximum total credit for 2:15 p.m.-4:15 p.m. sessions</td>
</tr>
<tr>
<td>4:30 p.m.-6:30 p.m.</td>
<td>(*) Albuminuria—Two Debates</td>
</tr>
<tr>
<td></td>
<td>(*) Clinical Strategies for Prevention and Management of Hypoglycemia</td>
</tr>
<tr>
<td></td>
<td>New Insights into Lipid and Lipoprotein Alterations in Patients with Diabetes</td>
</tr>
<tr>
<td></td>
<td>Diabetes and Psychosocial Risk Factors in the Hispanic Community Health Study/Study of Latinos</td>
</tr>
<tr>
<td></td>
<td>Using mHealth for Obesity Treatment and Weight Management</td>
</tr>
<tr>
<td></td>
<td>(*) Insulin Therapy—To the Future and Back</td>
</tr>
<tr>
<td></td>
<td>Adiposity, Insulin Resistance, and Type 2 Diabetes Mellitus—What Is New in Risk Factors and Biomarkers?</td>
</tr>
<tr>
<td></td>
<td>(*) Innovations in Insulin Formulation and Delivery</td>
</tr>
<tr>
<td></td>
<td>(*) Mechanistic Insights from Rare Conditions and Opportunities for Novel Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Clinical Updates in Beta-Cell Replacement Therapy</td>
</tr>
<tr>
<td></td>
<td>Novel Aspects of Metabolic Regulation (With ADA Presidents’ Select Abstract)</td>
</tr>
<tr>
<td></td>
<td>Human Obesity Pathogenesis—from Brain to Peripheral Organs</td>
</tr>
<tr>
<td></td>
<td>Alphabet Soup—GABA, FGF, ERα—Recipe for Central Nervous System Control of Metabolic Homeostasis and Diabetes Remission (With State-of-the-Art Lecture)</td>
</tr>
<tr>
<td></td>
<td>The Islet in Type 1 Diabetes—What’s New?</td>
</tr>
<tr>
<td></td>
<td>Maximum total credit for 4:30 p.m.-6:30 p.m. sessions</td>
</tr>
<tr>
<td></td>
<td>Maximum total credit for Monday</td>
</tr>
</tbody>
</table>

(*) Denotes ANCC pharmacotherapeutics contact hours.
<table>
<thead>
<tr>
<th>8:00 a.m.-10:00 a.m. sessions</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>(*) Cardiorenal Effects of Glucose-Lowering Therapies</td>
<td>3</td>
<td>☑️</td>
</tr>
<tr>
<td>Multigenerational Effects of Exercise</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>(*) Management of Diabetes in a Surgical Patient</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>Obesity in Type 1 Diabetes—An Evolving Challenge</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>(*) Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>Diabetes in Rural America</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>Aging and Insulin Sensitivity</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>Nutrient Sensing and Signaling in the Regulation of Metabolic Homeostasis</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td>G-Protein-Coupled Receptors—Structural Insights to Therapeutic Options</td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td><strong>Maximum total credit for 8:00 a.m.-10:00 a.m. sessions</strong></td>
<td><strong>2</strong></td>
<td><strong>☑️</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10:15 a.m.-12:15 p.m. session</th>
<th>Total credit</th>
<th>Attended</th>
</tr>
</thead>
<tbody>
<tr>
<td>(*) SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?</td>
<td>2</td>
<td>☑️</td>
</tr>
<tr>
<td><strong>Maximum total credit for 10:15 a.m.-12:15 p.m. session</strong></td>
<td><strong>2</strong></td>
<td><strong>☑️</strong></td>
</tr>
</tbody>
</table>

**Maximum total credit for Tuesday**

**Maximum total credit for entire meeting**

(*) Denotes ANCC pharmacotherapeutics contact hours.
### FRIDAY, JUNE 22, 2018—DAY-AT-A-GLANCE SCHEDULE

**Registration Hours:** 9:00 a.m.-6:30 p.m.
**Shop Diabetes Store Hours:** 9:00 a.m.-6:30 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 11:30 a.m.-12:30 p.m. | **Mini-Symposium** Measuring Neuropathy—Is Corneal Confocal Microscopy Ready for Prime Time?  
Room: W208 | **Mini-Symposium** Tech and Teens  
Room: W414 | **Mini-Symposium** Innovations in Diabetes Pregnancy Care  
Room: W308 | **Mini-Symposium** New-Onset Type 2 Diabetes in the Youngest and the Oldest  
Room: W304E-H |
|             | **Mini-Symposium** Biofilm—Real Wound Problem or Just a Buzzword?  
Room: W204 | **Mini-Symposium** Myth or Science? Current Fads and Evidence in Diet and Nutrition  
Room: W209 | | |
| 12:45 p.m.-1:45 p.m. | **Mini-Symposium** Surveillance of Kidney Disease and Comorbidities among People with Diabetes—What We Can Learn from the CDC's Chronic Kidney Disease Surveillance System  
Room: W311 | **Mini-Symposium** Understanding Hybrid Closed-Loop Pump  
Room: W304E-H | **Mini-Symposium** Better Ways to Build Diabetes Population Health Management  
Room: W208 | **Mini-Symposium** Of Mice, Mongrels, and Men—Commonalities and Differences in Metabolic Research  
Room: W304A-D |
|             | | **Mini-Symposium** Youth-Onset Type 2 Diabetes and Exercise—Outcomes and Challenges  
Room: W414 | **Mini-Symposium** Challenging Times for Youth with Type 1 Diabetes—How Do We Approach Them?  
Room: W312 | |
<table>
<thead>
<tr>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Emerging Role of Neoepitopes in the Dialogue between T Cells and Beta Cells</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W206</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Future of Islet Transplant—Towards a Renewable Source of Beta Cells</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W206</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The Bantering Exchange—New Concepts in the Pathogenesis of Diabetes and Metabolic Disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W304A-D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Regulators of Beta-Cell Identity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W312</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FRIDAY—DAY-AT-A-GLANCE**
## Registration Hours: 9:00 a.m.-6:30 p.m.
Shop Diabetes Store Hours: 9:00 a.m.-6:30 p.m.

### 2:00 p.m.-4:00 p.m.

**Symposium**  
Acute and Chronic Complications  
**Antiplatelet and Antithrombotic Therapies in Diabetes**  
Room: W414

**Symposium**  
Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
**Decreasing Risk for Type 2 Diabetes with Foods**  
Room: W315

**Symposium**  
Clinical Diabetes/Therapeutics  
**Artificial Pancreas and Decision Support Approaches**  
Room: W311

**Symposium**  
Epidemiology/Genetics  
**Real-World Evidence in Diabetes**  
Room: W415B  
(Valencia Ballroom)

### 4:15 p.m.-6:15 p.m.

**Symposium**  
Acute and Chronic Complications  
**The Many Faces of Hypoglycemia—Impact on Patient Health and Well-Being**  
Room: W308

**Symposium**  
Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
**Data, Data, Everywhere and Not a Pattern to Be Found**  
Room: W315

**Current Issues**  
Clinical Diabetes/Therapeutics  
**Cardiovascular Outcomes Trials (CVOTs) in Diabetes—Shall We Continue or Change Course?**  
Room: W415B  
(Valencia Ballroom)

**Oral Presentations**  
Epidemiology/Genetics  
**Genetics, Adipose Tissue, Obesity, and Type 2 Diabetes**  
Room: W304E-H

### 6:30 p.m.-8:30 p.m.

**Networking Reception**  
Orange County Convention Center (Level 4 Foyer)
<table>
<thead>
<tr>
<th>Immunology/ Transplantation</th>
<th>Insulin Action/ Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/ Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Endocrine, Paracrine</td>
<td>Endocrine, Paracrine</td>
<td>Endocrine, Paracrine</td>
<td>Endocrine, Paracrine</td>
</tr>
<tr>
<td>Signaling Affecting</td>
<td>Signaling Affecting</td>
<td>Signaling Affecting</td>
<td>Signaling Affecting</td>
</tr>
<tr>
<td>Adipocyte Function</td>
<td>Adipocyte Function</td>
<td>Adipocyte Function</td>
<td>Adipocyte Function</td>
</tr>
<tr>
<td>Room: W209</td>
<td>Room: W209</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>Novel Approaches</td>
<td>Novel Approaches</td>
<td>Novel Approaches</td>
<td>Novel Approaches</td>
</tr>
<tr>
<td>to Advancing Islet</td>
<td>to Advancing Islet</td>
<td>to Advancing Islet</td>
<td>to Advancing Islet</td>
</tr>
<tr>
<td>Transplantation—Basic</td>
<td>Transplantation—Basic</td>
<td>Transplantation—Basic</td>
<td>Transplantation—Basic</td>
</tr>
<tr>
<td>Science</td>
<td>Science</td>
<td>Science</td>
<td>Science</td>
</tr>
<tr>
<td>Room: W206</td>
<td>Room: W206</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>Adipose Differentiation</td>
<td>Adipose Differentiation</td>
<td>Adipose Differentiation</td>
<td>Adipose Differentiation</td>
</tr>
<tr>
<td>and Function</td>
<td>and Function</td>
<td>and Function</td>
<td>and Function</td>
</tr>
<tr>
<td>Room: W209</td>
<td>Room: W209</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>DIRECT Links between</td>
<td>DIRECT Links between</td>
<td>DIRECT Links between</td>
<td>DIRECT Links between</td>
</tr>
<tr>
<td>Hepatic Metabolism,</td>
<td>Hepatic Metabolism,</td>
<td>Hepatic Metabolism,</td>
<td>Hepatic Metabolism,</td>
</tr>
<tr>
<td>Glucagon Action, and</td>
<td>Glucagon Action, and</td>
<td>Glucagon Action, and</td>
<td>Glucagon Action, and</td>
</tr>
<tr>
<td>Glucose Turnover</td>
<td>Glucose Turnover</td>
<td>Glucose Turnover</td>
<td>Glucose Turnover</td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>Balancing Proliferation</td>
<td>Balancing Proliferation</td>
<td>Balancing Proliferation</td>
<td>Balancing Proliferation</td>
</tr>
<tr>
<td>and Maturation in the Islet</td>
<td>and Maturation in the Islet</td>
<td>and Maturation in the Islet</td>
<td>and Maturation in the Islet</td>
</tr>
<tr>
<td>(With ADA Presidents’</td>
<td>(With ADA Presidents’</td>
<td>(With ADA Presidents’</td>
<td>(With ADA Presidents’</td>
</tr>
<tr>
<td>Select Abstract)</td>
<td>Select Abstract)</td>
<td>Select Abstract)</td>
<td>Select Abstract)</td>
</tr>
<tr>
<td>Room: W312</td>
<td>Room: W312</td>
<td>Room: W312</td>
<td>Room: W312</td>
</tr>
</tbody>
</table>
**Mini-Symposium**  
*Theme Area: Acute and Chronic Complications*  
**Measuring Neuropathy—Is Corneal Confocal Microscopy Ready for Prime Time?**  
Room: W208  
Chair: Dinesh Selvarajah, MB, ChB, MRCP, PhD  
11:30 a.m.-11:50 a.m. **Yes, Corneal Confocal Microscopy Is Ready for Clinical Trials and Practice**  
Bruce A. Perkins, MD, MPH  
11:50 a.m.-12:10 p.m. **Not So Fast, Corneal Microscopy Is Not as Good as the Tried and True**  
J. Robinson Singleton, MD  
12:10 p.m.-12:30 p.m. **Question and Discussion Period**

**Mini-Symposium**  
*Theme Area: Acute and Chronic Complications*  
**Biofilm—Real Wound Problem or Just a Buzzword?**  
Room: W204  
Chair: Javier La Fontaine, DPM, MS  
11:30 a.m.-11:50 a.m. **Biofilm—Invisible Barrier to Wound Healing**  
Elizabeth A. Grice, PhD  
11:50 a.m.-12:10 p.m. **Biofilm—It’s Invisible Because It’s Not There**  
Lawrence A. Lavery, DPM  
12:10 p.m.-12:30 p.m. **Question and Discussion Period**

**Mini-Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
**Tech and Teens**  
Room: W414  
Chair: Shelagh A. Mulvaney, PhD  
11:30 a.m.-11:45 a.m. **Texting Teens to Improve Management and Reduce Diabetic Ketoacidosis**  
David V. Wagner, PhD  
11:45 a.m.-12:00 p.m. **The Value of Apps, or Lack Thereof, for Teens with Diabetes**  
Sarah S. Jaser, PhD  
12:00 p.m.-12:15 p.m. **To Share or Not to Share, Do Teens Care?**  
Korey K. Hood, PhD  
12:15 p.m.-12:30 p.m. **Question and Discussion Period**

**Mini-Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
**Myth or Science? Current Fads and Evidence in Diet and Nutrition**  
Room: W209  
Chair: Hope Warshaw, MMSc, RD, CDE  
11:30 a.m.-12:30 p.m. **Panel Discussion**  
Catherine M. Champagne, PhD, RDN, LDN, FADA, FAND, FTOS  
Melinda D. Maryniuk, MEd, RD, CDE
Mini-Symposium
Theme Area: Clinical Diabetes/Therapeutics
Innovations in Diabetes Pregnancy Care
Room: W308
Chair: David Simmons, FRCP, FRACP, MD
11:30 a.m.-11:50 a.m.  Community Models of Care
   Maribeth Inturrisi, RN, MS, CNS, CDE
11:50 a.m.-12:10 p.m.  Healthy Mothers on the Move—A Community Health Worker-Led Diabetes Prevention Intervention for Pregnant and Postpartum Latinas
   Edith C. Kieffer, PhD, MPH
12:10 p.m.-12:30 p.m.  Question and Discussion Period

Mini-Symposium
Theme Area: Epidemiology/Genetics
New-Onset Type 2 Diabetes in the Youngest and the Oldest
Room: W304E-H
Chair: Rita Rastogi Kalyani, MD, MHS
11:30 a.m.-11:50 a.m.  Type 2 Diabetes in Children, Adolescents, and Young Adults
   Sharon Saydah, PhD
11:50 a.m.-12:10 p.m.  New-Onset Type 2 Diabetes among the Elderly
   Hermes Florez, MD
12:10 p.m.-12:30 p.m.  Question and Discussion Period

Mini-Symposium
Theme Area: Immunology/Transplantation
The Emerging Role of Neoepitopes in the Dialogue between T Cells and Beta Cells
Room: W206
Chair: Hubert M. Tse, PhD
11:30 a.m.-11:50 a.m.  Posttranslational Modifications in Type 1 Diabetes and Other Autoimmune Disorders
   Mark J. Mamula, PhD
11:50 a.m.-12:10 p.m.  Generation and Recognition of Neoepitopes in Subjects with Type 1 Diabetes
   Eddie A. James, PhD
12:10 p.m.-12:30 p.m.  Question and Discussion Period

Mini-Symposium
Theme Area: Integrated Physiology/Obesity
The Banting Exchange—New Concepts in the Pathogenesis of Diabetes and Metabolic Disease
Room: W304A-D
Co-Chairs: Sonia Caprio, MD and Andrea L. Hevener, PhD
11:30 a.m.-12:00 p.m.  Panel Discussion
   Richard N. Bergman, PhD
   Barbara E. Corkey, PhD
12:00 p.m.-12:30 p.m.  Question and Discussion Period

Mini-Symposium
Theme Area: Islet Biology/Insulin Secretion
New Regulators of Beta-Cell Identity
Room: W312
Chair: Piero Marchetti, MD, PhD
11:30 a.m.-11:50 a.m.  3-D Chromatin Maps, Beta-Cell Identity, and Diabetes
   Jorge Ferrer, MD, PhD
11:50 a.m.-12:10 p.m.  Lineage Dynamics of Pancreatic Endocrine Development at Single-Cell Resolution
   Julie B. Sneddon, PhD
12:10 p.m.-12:30 p.m.  Question and Discussion Period
**Mini-Symposium**  
*Theme Area: Acute and Chronic Complications*

**Surveillance of Kidney Disease and Comorbidities among People with Diabetes—What We Can Learn from the CDC’s Chronic Kidney Disease Surveillance System**

Room: W311  
Chair: Nilka Ríos Burrows, MT, MPH

- **12:45 p.m.-1:05 p.m.**  
  *Prevalence and Awareness of Chronic Kidney Disease among People with Diabetes*  
  Rajiv Saran, MBBS, DTCD, MD, MRCP, MS

- **1:05 p.m.-1:25 p.m.**  
  *Cardiovascular Comorbidity among People with Diabetes and Chronic Kidney Disease*  
  Meda E. Pavkov, MD, PhD

- **1:25 p.m.-1:45 p.m.**  
  *Question and Discussion Period*

---

**Mini-Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Understanding Hybrid Closed-Loop Pump**

Room: W304E-H  
Chair: Neesha Ramchandani, PNP, CDE, CDTC

- **12:45 p.m.-1:05 p.m.**  
  *What Clinicians Need to Know*  
  Elizabeth Ann Doyle, DNP, APRN, CDE

- **1:05 p.m.-1:25 p.m.**  
  *What Patients Need to Know*  
  Laurel H. Messer, RN, MPH, CDE

- **1:25 p.m.-1:45 p.m.**  
  *Question and Discussion Period*

---

**Mini-Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Youth-Onset Type 2 Diabetes and Exercise—Outcomes and Challenges**

Room: W414  
Chair: Kevin Short, PhD

- **12:45 p.m.-1:05 p.m.**  
  *Exercise Dose and Diabetes Risk in Overweight and Obese Children*  
  Catherine L. Davis, PhD

- **1:05 p.m.-1:25 p.m.**  
  *Changing the School of Thought on Metabolic Health in Children by Creating an ACTIVE Classroom*  
  Rebecca E. Hasson, PhD

- **1:25 p.m.-1:45 p.m.**  
  *Question and Discussion Period*

---

**Mini-Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Improving Patient-Provider Communication in the Management of Diabetes in Culturally Diverse Populations**

Room: W308  
Chair: A. Enrique Caballero, MD

- **12:45 p.m.-12:55 p.m.**  
  *Effective, Culturally Oriented Patient-Provider Communication—Challenges and Opportunities*  
  A. Enrique Caballero, MD

- **12:55 p.m.-1:05 p.m.**  
  *Role Play—A Common Scenario of the Interaction of Patients and Providers from Different Cultural Backgrounds*  
  Melinda D. Maryniuk, MEd, RD, CDE  
  Betsy Rodriguez, BSN, MSN, CDE

- **1:05 p.m.-1:30 p.m.**  
  *Audience Participation/Panel Discussion*

- **1:30 p.m.-1:40 p.m.**  
  *Audience Participation/Question and Discussion Period*

- **1:40 p.m.-1:45 p.m.**  
  *Take Home Messages*  
  A. Enrique Caballero, MD
12:45 p.m.-1:45 p.m.  
(continued)

**Mini-Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
**Better Ways to Build Diabetes Population Health Management**  
Room: W208  
Chair: Athena Philis-Tsimikas, MD  
12:45 p.m.-1:05 p.m. **Population Health Management in Underserved Communities**  
Luigi F. Meneghini, MD, MBA  
1:05 p.m.-1:25 p.m. **Nurse Care Managers and Medical Assistant Coaches to Improve Quality Outcomes**  
Addie L. Fortmann, PhD  
1:25 p.m.-1:45 p.m. **Question and Discussion Period**

**Mini-Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
**Challenging Times for Youth with Type 1 Diabetes—How Do We Approach Them?**  
Room: W312  
Co-Chairs: Sarah Lyons, MD and Jamie R. Wood, MD  
12:45 p.m.-1:05 p.m. **The Toddler Years—Depending on Parental/Guardian Support**  
Michelle A. Van Name, MD  
1:05 p.m.-1:25 p.m. **Being a Young Adult and Transitioning to Adult Care**  
Katharine C. Garvey, MD, MPH  
1:25 p.m.-1:45 p.m. **Question and Discussion Period**

**Mini-Symposium**  
Theme Area: Immunology/Transplantation  
**The Future of Islet Transplant—Towards a Renewable Source of Beta Cells**  
Room: W206  
Chair: Michael R. Rickels, MD, MS  
12:45 p.m.-1:05 p.m. **Stem Cells Will Be the Future Source of Beta Cells**  
Jon S. Odorico, MD, FACS  
1:05 p.m.-1:25 p.m. **Genetically-Engineered Pigs Will Be the Future Source of Beta Cells**  
David K.C. Cooper, MD, PhD, FRCS  
1:25 p.m.-1:45 p.m. **Question and Discussion Period**

**Mini-Symposium**  
Theme Area: Insulin Action/Molecular Metabolism  
**Near, Far, Wherever You Are—Obesity-Related Defects in Insulin Signaling**  
Room: W209  
Chair: Samuel Klein, MD  
12:45 p.m.-1:05 p.m. **Proximal Mechanisms Mediate Impaired Responses to Insulin**  
Varman Samuel, MD, PhD  
1:05 p.m.-1:25 p.m. **Downstream Defects in Insulin Signaling in Obesity**  
Michael P. Czech, PhD  
1:25 p.m.-1:45 p.m. **Question and Discussion Period**
12:45 p.m.-1:45 p.m.
(continued)

Mini-Symposium
Theme Area: Integrated Physiology/Obesity
Of Mice, Mongrels, and Men—Commonalities and Differences in Metabolic Research
Room: W304A-D
Chair: Ananda Basu, MBBS, MD
12:45 p.m.-1:00 p.m. Mouse Models in Research—How Translatable Are the Data?
   Jason K. Kim, PhD
1:00 p.m.-1:15 p.m. Dogs, Pigs, and Primates—A Bridge Between Mice and Men
   Dale S. Edgerton, PhD
1:15 p.m.-1:30 p.m. Are Humans Becoming the Optimum Model for Diabetes Research?
   Eugene J. Barrett, MD, PhD
1:30 p.m.-1:45 p.m. Question and Discussion Period

2:00 p.m.-4:00 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Antiplatelet and Antithrombotic Therapies in Diabetes
Room: W414
Chair: Darren K. McGuire, MD, MHSc
2:00 p.m.-2:40 p.m. Aspirin for Primary Cardiovascular Risk Intervention—What’s the Evidence in Patients with Diabetes?
   Rita Rastogi Kalyani, MD, MHS
2:40 p.m.-3:20 p.m. Utility of Combination Antiplatelet Therapies in Diabetes
   Deepak L. Bhatt, MD, MPH
3:20 p.m.-4:00 p.m. Update on Novel Anticoagulants
   Jacob A. Udell, MD, MPH, FRCPC

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Decreasing Risk for Type 2 Diabetes with Foods
Room: W315
Chair: Osama Hamdy, MD, PhD
2:00 p.m.-2:30 p.m. Mediterranean Diet to Reduce Risk for Type 2 Diabetes
   Catherine Itsiopoulos, BSc, BSc (Hons), Grad Dip Diet, MPH, PhD, APD, AN
2:30 p.m.-3:00 p.m. The Role of Dairy Food in Diabetes Risk Reduction
   Joanna Mitri, MD, MS
3:00 p.m.-3:30 p.m. Plant-Based Diets to Reduce Risk for Type 2 Diabetes
   David Jacobs, PhD
3:30 p.m.-4:00 p.m. Red and Processed Meats—Do They Really Increase Risk for Type 2 Diabetes?
   Sylvia H. Ley, PhD, RD
2:00 p.m.-4:00 p.m.  
(continued)

Symposium  
Theme Area: Clinical Diabetes/Therapeutics  
**Artificial Pancreas and Decision Support Approaches**  
Room: W311  
Co-Chairs: Peter G. Jacobs, PhD and Jennifer Sherr, MD, PhD  
2:00 p.m.-2:20 p.m.  
**Advanced Treatments for Type 1 Diabetes—Adapting to Meals and Exercise**  
Jessica R. Castle, MD  
2:20 p.m.-2:40 p.m.  
**Continuous Glucose Monitoring-Based Decision Support for Type 1 Diabetes**  
Marc D. Breton, PhD  
2:40 p.m.-3:00 p.m.  
**The Path to a Medical Internet of Things (IoT) and Human-Centric Design of an Artificial Pancreas**  
Eyal Dassau, PhD  
3:00 p.m.-3:20 p.m.  
**Automated Adjustment of Basal-Bolus Insulin Therapy Using Run-to-Run Control and Case-Based Reasoning**  
Pau Herrero-Viñas, PhD  
3:20 p.m.-3:40 p.m.  
**Multivariable Adaptive Artificial Pancreas Systems**  
Ali Cinar, PhD  
3:40 p.m.-4:00 p.m.  
**Question and Discussion Period**

Symposium  
Theme Area: Clinical Diabetes/Therapeutics  
**Real-World Evidence in Diabetes**  
Room: W415B (Valencia Ballroom)  
Chair: Edward W. Gregg, PhD  
2:00 p.m.-2:20 p.m.  
**Closing the Evidence Gaps with Real-World Evidence in Diabetes**  
Kamlesh Khunti, MD, PhD, FRCPG, FRCP, FMedSci  
2:20 p.m.-2:40 p.m.  
**Real-World Evidence Studies—Methodological Approaches to Overcome Bias**  
Sean D. Sullivan, BSc Pharm, PhD  
2:40 p.m.-3:00 p.m.  
**Combining Methodological Approaches to Assess Efficacy and Safety of Gla-300 vs. First-Generation Basal Insulins—A Case Study**  
Timothy S. Bailey, MD, FACE, CPI  
3:00 p.m.-3:20 p.m.  
**From Traditional to Innovative Methodological Approaches to Assess Efficacy and Safety of Gla-300 vs. Other Second-Generation Basal Insulins—A Case Study**  
Lawrence Blonde, MD  
3:20 p.m.-3:40 p.m.  
**Complementing Randomized Controlled Trials with Real-World Evidence—A Comprehensive Evidence-Generation Program in Patients with Diabetes**  
Stewart Harris, CM, MD, MPH, FCFP, FACPM  
3:40 p.m.-4:00 p.m.  
**Panel Discussion**

Symposium  
Theme Area: Epidemiology/Genetics  
**Mental Health Disorders and Diabetes Distress among Adults with Diabetes**  
Room: W304E-H  
Chair: Mary Beth Weber, PhD, MPH  
2:00 p.m.-2:30 p.m.  
**The Epidemiology and Impact of Mental Health Disorders among Adults with Diabetes**  
Mary de Groot, PhD  
2:30 p.m.-3:00 p.m.  
**Diabetes among Patients with Complex Mental Health Disorders and with Use of Antipsychotic Medications—Implications for Screening and Management**  
John W. Newcomer, MD  
3:00 p.m.-3:30 p.m.  
**Caring for the Whole Patient—Best Practices for Managing Mental Health Disorders and Diabetes**  
Mark D. Williams, MD  
3:30 p.m.-4:00 p.m.  
**Diabetes Distress—Epidemiology, Impact, and Treatment**  
Kathryn Evans Kreider, DNP, FNP-BC, BC-ADM
2:00 p.m.-4:00 p.m.
(continued)

**Symposium**
**Theme Area: Insulin Action/Molecular Metabolism**
**Endocrine, Paracrine Signaling Affecting Adipocyte Function**
Room: W209
Chair: Alan R. Saltiel, PhD

2:00 p.m.-2:30 p.m.  **Cardiac-Adipocyte Cross Talk through Natriuretic Peptide Signaling**
Sheila Collins, PhD

2:30 p.m.-3:00 p.m.  **Brain-Derived Neurotrophic Factor and Brain-Adipocyte Cross Talk**
Lei Cao, PhD

3:00 p.m.-3:30 p.m.  **Sympathetic Input Regulating Lipolysis and Thermogenesis in White and Brown Adipose Tissue**
Kristin I. Stanford, PhD

3:30 p.m.-4:00 p.m.  **Beta-Adrenergic Signaling Regulates a Concerted Thermogenic Response in Brown Adipose Tissue and Subcutaneous White Adipose Tissue**
Juro Sakai, MD, PhD

**Symposium**
**Theme Area: Integrated Physiology/Obesity**
**The Exosome Superhighway in Energy and Metabolic Homeostasis**
Room: W304A-D
Chair: Anthony W. Ferrante, Jr., MD, PhD

2:00 p.m.-2:30 p.m.  **Adipose-Derived Exosomal MicroRNAs Regulate Gene Expression in Other Tissues**
C. Ronald Kahn, MD

2:30 p.m.-3:00 p.m.  **Islet-Derived Extracellular Vesicles and Their Immunological Potential**
Steven Paraskevas, MD, PhD

3:00 p.m.-3:30 p.m.  **Exosomes as Mediators of the Systemic Adaptation to Endurance Exercise**
Mark A. Tarnopolsky, MD, PhD, FRCPC

3:30 p.m.-4:00 p.m.  **Circulating MicroRNAs in Polycystic Ovary Syndrome**
Louise T. Dalgaard, PhD, MSc

**Symposium**
**Theme Area: Islet Biology/Insulin Secretion**
**Transformational Technologies in Islet Biology—From Omics to Imaging**
Room: W312
Chair: Alvin C. Powers, MD

2:00 p.m.-2:30 p.m.  **The Visible Pancreas Project—Islets in Health and Diabetes**
Martha L. Campbell-Thompson, DVM, PhD

2:30 p.m.-3:00 p.m.  **Imaging Mass Spectrometry—Molecular Microscopy in the New Age of Discovery**
Richard Caprioli, PhD

3:00 p.m.-3:30 p.m.  **Single Cell Omics**
Åsa Segerstolpe, PhD

3:30 p.m.-4:00 p.m.  **In Situ and In Vivo Imaging of Human Islet Cell Physiology**
Stephan Speier, PhD
4:15 p.m.-5:10 p.m.

**Current Issues**

*Theme Area: Clinical Diabetes/Therapeutics*

**Cardiovascular Outcomes Trials (CVOTs) in Diabetes—Shall We Continue or Change Course?**

Room: W415B (Valencia Ballroom)

Co-Chairs: Ildiko Lingvay, MD, MPH, MSCS and Bernard Zinman, MD

- 4:15 p.m.-4:35 p.m. *Continue—CVOTs Are Worth the Expense for the Knowledge Gained*
  - Steven P. Marso, MD
- 4:35 p.m.-4:55 p.m. *Change Course—We Need to Refocus Our Approach and Questions*
  - Darren K. McGuire, MD, MHSc
- 4:55 p.m.-5:10 p.m. *Question and Discussion Period*

4:15 p.m.-6:15 p.m.

**Symposium**

*Theme Area: Acute and Chronic Complications*

**The Many Faces of Hypoglycemia—Impact on Patient Health and Well-Being**

Room: W308

Co-Chairs: Meredith A. Hawkins, MD, MS and Simon R. Heller, MD, FRCP

- 4:15 p.m.-4:45 p.m. *Hypoglycemia and Cardiovascular Mortality*
  - Stephen N. Davis, MBBS
- 4:45 p.m.-5:15 p.m. *The Link between Hypoglycemia and Arrhythmias*
  - Simon J. Fisher, MD, PhD
- 5:15 p.m.-5:45 p.m. *Impact of Hypoglycemia on the Brain—Insights from Structural and Functional Neuroimaging*
  - Silvia Mangia, PhD
- 5:45 p.m.-6:15 p.m. *Impact of Hypoglycemia on Patient-Reported Outcomes and Quality of Life*
  - Linda Gonder-Frederick, PhD

**Symposium**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Data, Data, Everywhere and Not a Pattern to Be Found**

Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust

Room: W315

Chair: Davida F. Kruger, MSN, APN-BC, BC-ADM

- 4:15 p.m.-4:40 p.m. *Blood Glucose Meter—Interpreting Clinical Data*
  - Alison B. Evert, MS, RD, CDE
- 4:40 p.m.-5:05 p.m. *Ambulatory Glucose Profile (AGP)—The Picture Says It All*
  - Mary L. Johnson, RN, BS, CDE
- 5:05 p.m.-5:30 p.m. *Professional Continuous Glucose Monitoring—Avoiding Pitfalls and Optimizing Outcomes*
  - Patricia Knutsen, NP-C, RN, MSN, ACNS-BC, CDE
- 5:30 p.m.-5:55 p.m. *Personal-Use Continuous Glucose Monitoring—Constructive Conversations with Your Patients*
  - Margaret Pellizzari, MS, MBA, RN, CDE, CDTC
- 5:55 p.m.-6:15 p.m. *Panel Discussion*
Oral Presentations
4:15 p.m.-6:15 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Dynamic Approaches to Improve Glycemic Control and Primary Diabetes Care
Room: W204
Chair: Pamela Allweiss, MD, MPH

4:15 p.m.-4:30 p.m.
1-OR Characterizing Clinical Inertia in a Large, National Database
CORI R. RATTELMAN, ANUPAMA ARORA, JOHN K. CUDDEBACK, ELIZABETH L. CIEMINS, Alexandria, VA

4:30 p.m.-4:45 p.m.
2-OR Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control
DARBY M. HERKERT, PAVITHRA VIJAYAKUMAR, JING LUO, JEREMY SCHWARTZ, TRACY L. RABIN, EUNICE M. DE Filippo, KASIA J. LIPSKA, New Haven, CT; Boston, MA, West Haven, CT

4:45 p.m.-5:00 p.m.
3-OR Influence of Diabetes Complications on the Cost-Effectiveness of A1C Treatment Goals in Older U.S. Adults
HUJI SHAO, DEBORAH B. ROLKA, EDWARD W. GREGG, PING ZHANG, Atlanta, GA

5:00 p.m.-5:15 p.m.
4-OR The Clinical and Economic Effects of Switching Medicare Beneficiaries with Type 2 Diabetes from Analog to Human Insulin
JING LUO, NAZLEEN F. KHAN, THOMAS MANETTI, JAMES J. ROSE, ANI KALOGHLIAN, BALU GADHE, SACHIN H. JAIN, JOSHUA GAGNE, AARON KESSELHEIM, Boston, MA, Cerritos, CA

5:15 p.m.-5:30 p.m.
5-OR Dietary Intervention for Inpatient Glycemic Control
SARA CROMER, MAGDALENA M. BOGUN, New York, NY

5:30 p.m.-5:45 p.m.
6-OR Management of Patients with Type 2 Diabetes Shared between a Specialized Outpatient Clinic and General Practice Was Noninferior to Mono Management in a Specialized Outpatient Clinic—A Prospective, Randomized, Noninferiority Trial
LENE MUNCH, BIRGITTE B. BENNICH, DORTHE OVERGAARD, HANNE KONRADSEN, HELLE V. MIDD ELFART, NIELS KAARSBERG, FILIP K. KNOP, TINA VILSBOLL, MICHAEL RØDER, Gentofte, Denmark; Hellerup, Denmark; Copenhagen, Denmark; Huddinge, Sweden; Holte, Denmark

5:45 p.m.-6:00 p.m.
7-OR Diabetes Inside—Following the Long-Term Impact of a Diabetes Quality Improvement (QI) Initiative in Primary Care
UMA GUNASEKARAN, ROY E. FURMAN, KELLIE M. RODRIGUEZ, E. ELIZABETH OBI ALO, SENTA YEHU KASSA, NOEL O. SANTINI, ELISE FURMAN, LUIGI MENEGHINI, Dallas, TX; Bala Cynwyd, PA

6:00 p.m.-6:15 p.m.
8-OR Economic Evaluation of Group Medical Visits for Adults with Diabetes in Community Health Centers
WEN WAN, ERIN M. STAAB, SANDRA A. HAM, AMANDA CAMPBELL, CYNTHIA T. SCHAEFER, MICHAEL T. QU INN, ARSHIYA BAIG, Chicago, IL; East Lansing, MI; Evansville, IN
**Oral Presentations**

4:15 p.m.-6:15 p.m.

(continued)

_Theme Area: Clinical Diabetes/Therapeutics_

**Glucose Monitoring—Advances, Pitfalls, and Clinical Relevance**

Room: W311

Chair: Anders Carlson, MD

4:15 p.m.-4:30 p.m.

9-OR Performance of Cleared Blood Glucose Monitor Systems

FRAYA G. KING, DAVID T. AHN, VICTORIA HSIAO, TRAVIS PORCO, DAVID C. KLONOFF, New Orleans, LA, Los Angeles, CA, San Francisco, CA, San Mateo, CA

4:30 p.m.-4:45 p.m.

10-OR Analysis of Prevalence, Magnitude, and Timing of the Dawn Phenomenon in Type 1 Diabetes—Descriptive Analysis of Two Insulin Pump Trials

ILIA OSTROVSKI, LEIF ERIK LOVBLOM, DANIEL SCARR, ALANNA WEISMANN, ANDREJ ORSZAG, EMILIE D’AOUST, AHMAD HAIDAR, RÉMI RABASA-LHORET, LAURENT LEGAULT, BRUCE A. PERKINS, Toronto, ON, Canada, Montreal, QC, Canada

4:45 p.m.-5:00 p.m.

11-OR Distinct Patterns of Daily Glucose Variation by Pubertal Stage in Youth with Type 1 Diabetes (T1D)

JIA ZHU, LISA VOLKENING, MICHELLE KATZ, LORI M. LAFFEL, Boston, MA

5:00 p.m.-5:15 p.m.

12-OR What Is the Role of A1C in Comorbidities?

JORDAN E. PERLMAN, JENNIFER L. ROSENBAUM, BRIDGET K. MCNULTY, IRL B. HIRSCH, Seattle, WA

5:15 p.m.-5:30 p.m.

13-OR First Assessment of the Performance of an Implantable CGM System through 180 Days in a Primarily Adolescent Population with Type 1 Diabetes

RONNIE ARONSON, RAVI RASTOGI, COLLEEN MDINGI, XIAOXIAO CHEN, KATHERINE TWEDEN, Toronto, ON, Canada, Germantown, MD

5:30 p.m.-5:45 p.m.

14-OR A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics EverSense CGM Devices in an Outpatient Study of Subjects with Type 1 Diabetes

RABAB Z. JAFRI, COURTNEY A. BALLEIRO, FIRAS EL-KHATIB, MICHELE MAHENO, MALLORY A. HILLARD, ALEXANDER J. O’DONOVAN, RAJENDRANATH SELAGAMSETTY, HUI ZHENG, EDWARD DAMIANO, STEVEN J. RUSSELL, Boston, MA

5:45 p.m.-6:00 p.m.

15-OR Efficacy of a Novel Interim Intervention Technique (IIT) with Retrospective Flash Glucose Monitoring to Improve Glycemic Control

AKSHAY B. JAIN, Mumbai, India

6:00 p.m.-6:15 p.m.

16-OR Real-World Assessment of Sugar.IQ with Watson—A Cognitive Computing-Based Diabetes Management Solution

YUXIANG ZHONG, SIDDHARTH ARUNACHALAM, PRATIK AGRAWAL, HUZEA NEEMUCHWALA, TONI L. CORDERO, FRANCINE R. KAUFMAN, Northridge, CA
Oral Presentations
4:15 p.m.-6:15 p.m.
(continued)

Theme Area: Epidemiology/Genetics
Genetics, Adipose Tissue, Obesity, and Type 2 Diabetes
Room: W304E-H
Chair: Kyle Gaulton, PhD

4:15 p.m.-4:30 p.m.
17-OR The Maternal Impact of AdGHRKO Mice on Glucose Metabolism
XIAOSHUANG WANG, AI MI, YANSHUANG LIU, DAN WANG, LIYUAN RAN, YINGJIE WU, Dalian, China

4:30 p.m.-4:45 p.m.
18-OR Shared Genetic Influence on Early Growth and Type 2 Diabetes in Adulthood
FASIL TEKOLA-AYELE, ANTHONY LEE, TSEGASELASSIE WORKALEMAHU, DEEPika SHRESTHA, Bethesda, MD, Rockville, MD

4:45 p.m.-5:00 p.m.
19-OR Genetically Regulated Mechanisms of Insulin Resistance in Adipose Tissue
NEERAJ K. SHARMA, CHIA-CHI C. KEY, MARY E. COMEAU, CARL D. LANGEFELD, JOHN S. PARKS, SWAPAN K. DAS, Winston-Salem, NC

5:00 p.m.-5:15 p.m.
20-OR Genome-Wide and Abdominal Imaging Data Characterizes Common Alleles Associated with Higher BMI and Subcutaneous Fat but Less Liver Fat and Lower Risk of Type 2 Diabetes
HANIEH YAGHOOTKAR, YINGJIE JI, ANDRIANOS M. YIORKAS, FRANCESCA FRAU, DENNIS MOOK-KANAMORI, RENÉE DE MUTSERT, JESSICA TYRRELL, SAMUEL E. JONES, ROBERT BEAUMONT, ANDREW R. WOOD, LOUISE THOMAS, KARLA V. ALLEBRANDT, NORBERT STEFAN, HARALD STAIGER, EWAN PEARSON, ALEX I. BLAKEMORE, JIMMY D. BELL, TIMOTHY M. FRAYLING, Exeter, United Kingdom, London, United Kingdom, Frankfurt, Germany, Leiden, Netherlands, Tübingen, Germany, Dundee, United Kingdom, Uxbridge, United Kingdom

5:15 p.m.-5:30 p.m.
21-OR Dietary Fat Quality and Genetic Risk of Type 2 Diabetes
JORDI MERINO, HASSAN S. DASHTI, MARTA GUASCH, CHRISTINA ELLERVIK, CAREN SMITH, TUOMAS O. KILPE-LAINEN, DANIEL CHASMAN, JOSE C. FLOREZ, Boston, MA, Copenhagen, Denmark

5:30 p.m.-5:45 p.m.
22-OR MicroRNA Drivers of the Effects of High-Fat Diet and Bariatric Surgery on the Intestine
PRAVEEN SETHUPATHY, Ithaca, NY

5:45 p.m.-6:00 p.m.
23-OR Physical Inactivity and Sleep Inefficiency Accentuate the Genetic Risk of Obesity
ANDREW R. WOOD, SAMUEL E. JONES, REBECCA RICHMOND, SHAFAQAT AHMAD, HANIEH YAGHOOTKAR, ROBERT BEAUMONT, KATHERINE S. RUTH, MARCUS TUKE, ANNA MURRAY, RACHEL M. FREATHY, GEORGE DAVEY SMITH, I-MIN LEE, NIC TIMPSON, DANIEL CHASMAN, ZOLTAN KUTALIK, MICHAEL N. WEDDON, JESSICA TYRRELL, TIMOTHY M. FRAYLING, Exeter, United Kingdom, Bristol, United Kingdom, Boston, MA, Lausanne, Switzerland

6:00 p.m.-6:15 p.m.
24-OR Whole Genome Sequence Association Analysis and Diabetes-centric Functional Annotation of Type 2 Diabetes
JENNIFER WESSEL, JENNIFER A. BRODY, ALISA MANNING, TOPMED DIABETES WORKING GROUP, Indianapolis, IN, Seattle, WA, Cambridge, MA

ADA-Supported Research
Oral Presentations  
4:15 p.m.-6:15 p.m.  
(continued)

Theme Area: Immunology/Transplantation

Novel Approaches to Advancing Islet Transplantation—Basic Science  
Room: W206  
Chair: Hongjun Wang, PhD

4:15 p.m.-4:30 p.m.  
25-OR  
Newly Designed Alginate-Based Microcapsules (AgMc) for the Molecular Therapy of Type 1 Diabetes  
RICCARDO CALAFIORE, PIA MONTANUCCI, GIUSEPPE P. BASTA, GIUSEPPE NOCENTINI, TERESA PESCARA, CARLO RICCARDI, Perugia, Italy

4:30 p.m.-4:45 p.m.  
26-OR  
Subcutaneous Transplantation of MIN6 Beta Cells Embedded in mPEG-Ala Hydrogel  
JYUHN-HUARNG JUANG, HSIU-CHAO LIN, CHEN-YI CHEN, CHEN-WEI KAO, SHU-TING WU, SUNG-HAN LIN, CHIA-RUI SHEN, JIUN-JIE WANG, I-MING CHU, Taoyuan, Taiwan, Hsinchu, Taiwan

4:45 p.m.-5:00 p.m.  
27-OR  
Predicting Insulin Secretion Profiles for Immunoisolating Devices with Transplanted Islets  
PETER BUCHWALD, ALICE A. TOMEI, CHERIE L. STABLER, Miami, FL, Gainesville, FL

5:00 p.m.-5:15 p.m.  
28-OR  
Comparison of Xenogeneic Encapsulated Islet Transplantation in Nonhuman Primates With and Without Immunosuppression  
EUN YOUNG LEE, HEON SEOK PARK, JIWON KIM, YEOREE YANG, JAYOUNG LIM, HUN-SUNG KIM, SEUNG-HWAN LEE, JAE HYOUNG CHO, BONG YUN CHA, KUN-HO YOON, Seoul, Republic of Korea

5:15 p.m.-5:30 p.m.  
29-OR  
Tannic Acid-Encapsulated Islets Suppress Autoimmunity and Restore Euglycemia following Transplantation  
JESSIE BARRA, HUBERT M. TSE, Birmingham, AL

5:30 p.m.-5:45 p.m.  
30-OR  
Prolongation of Allograft Survival by Intrathymic Introduction of Allogeneic Thymic Epithelial Cells  
ISHA PRADHAN, STEPHANIE WONG-NOONAN, SUZANNE BERTERA, ROBERT J. LAKOMY, HENRY COHEN, DERRICK WELLS, MASSIMO TRUCCO, YONG FAN, Pittsburgh, PA

5:45 p.m.-6:00 p.m.  
31-OR  
Immunosuppressive PLGA TGF-β1 Microparticles Induce Antigen-Specific T-Cell Tolerance for Enhancing Islet Transplantation Outcomes  
YING LI, ANTHONY FREI, STEVEN D. BARASH, CHERIE L. STABLER, Gainesville, FL

6:00 p.m.-6:15 p.m.  
32-OR  
Acceptance of Murine Islet Allografts without Immunosuppression in the Inguinal Subcutaneous White Adipose Tissue Pretreated with bFGF  
YUKI NAKAFUSA, NAOYOSHI NITTA, MASAFUNI NAKAMURA, YOHICHI YASUNAMI, Fukuoka, Japan

ADA-Supported Research
Oral Presentations
4:15 p.m.-6:15 p.m.
(continued)

Theme Area: Insulin Action/Molecular Metabolism

Adipose Differentiation and Function
Room: W209
Chair: Jacqueline M. Stephens, PhD

4:15 p.m.-4:30 p.m.
33-OR Functional Roles of Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) in Adipocytes
JUN EGUCHI, JUN WADA, Okayama, Japan

4:30 p.m.-4:45 p.m.
34-OR ▲ Adipocyte mTORC1 Suppresses Treg Cell Development and Browning of White Adipose Tissue through CRTC2/COX-2/PGs Pathway
XING ZHANG, YAN LUO, XIAOFENG DING, CHUNQING WANG, XUEXIAN YANG, MEILIAN LIU, Albuquerque, NM

4:45 p.m.-5:00 p.m.
35-OR The Adipose-Derived Insulin Sensitizer Adiponectin Can Activate Intracellular Signaling Independent of the Well Known AdipoR1 or AdipoR2 Receptors
JOSEPH W. GUNNET, WENYU LI, YUANPING WANG, JOSE A. CHAVEZ, MATT HUSOVSKY, RONG MENG, WENSH-ENG LANG, JEY R. JEEASEELAN, GARY W. CALDWELL, SPRING HOUSE, PA, SAN DIEGO, CA

36-OR ▲ WITHDRAWN
5:00 p.m.-5:15 p.m.
37-OR GIP Signaling Integrates with Insulin Signaling to Regulate Glucose and Lipid Metabolism in Human Adipocytes
AJIT REGMI, MELISSA K. THOMAS, M. DODSON MICHAEL, WILLIAM C. ROELL, Indianapolis, IN

5:15 p.m.-5:30 p.m.
38-OR The Cell Junction Protein Afadin Negatively Regulates Insulin Action and Modulates Adipose Tissue Function
MORTEN LUNDH, MARIE S. ISIDOR, KAJA PLUCINSKA, FARNAZ SHAMSI, PATRICIA PETERSEN, YU-HUA TSENG, BRICE EMANUELLI, Copenhagen, Denmark, Boston, MA

5:30 p.m.-5:45 p.m.
39-OR ▲ Insulin Sensitizing Effects of Vitamin D Mediated through Reduced Adipose Tissue Inflammation and Fibrosis
ERIC LONTCHI-YIMAGOU, SONA KANG, KEHAO ZHANG, AKANKASHA GOYAL, JEE YOUNG YOU, PREETI KISHORE, EVAN ROSEN, MEREDITH HAWKINS, Bronx, NY, Berkeley, CA, New York, NY, Boston, MA
Oral Presentations
4:15 p.m.–6:15 p.m.
(continued)

Theme Area: Integrated Physiology/Obesity

**DiRECT Links between Hepatic Metabolism, Glucagon Action, and Glucose Turnover**
Room: W304A-D
Co-Chairs: Michael R. Rickels, MD, MS and Matthew J. Watt, PhD

4:15 p.m.–4:30 p.m.
40-OR Pathophysiology of Remission in Type 2 Diabetes—The Diabetes Remission Clinical Trial (DiRECT)
ROY TAYLOR, AHMAD AL-MRABEH, SVIATLANA V. ZHYZHNEUSKAYA, CARL PETERS, ALISON C. BARNES, BENJAMIN ARIBISALA, KIEREN G. HOLLINGSWORTH, NAVEED SATTAR, MICHAEL E. LEAN, Newcastle upon Tyne, United Kingdom, Lagos, Nigeria, Glasgow, United Kingdom

4:30 p.m.–4:45 p.m.
41-OR Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose Tolerant Subjects—Role of Glucagon and Gluconeogenic Substrates
DEVJIT TRIPATHY, AURORA MEROVCI, ENRIQUE R. MALDONADO CORCHADO, RITA BASU, RALPH A. DEFRONZO, San Antonio, TX, Charlottesville, VA

4:45 p.m.–5:00 p.m.
42-OR Diabetes Remission Clinical Trial (DiRECT)—Changes in Hepatic VLDL1-TG Production and Intrapancreatic Fat during Weight Maintenance Phase
AHMAD AL-MRABEH, SVIATLANA V. ZHYZHNEUSKAYA, CARL PETERS, ALISON C. BARNES, BENJAMIN ARIBISALA, KIEREN G. HOLLINGSWORTH, NAVEED SATTAR, MICHAEL E. LEAN, ROY TAYLOR, Newcastle upon Tyne, United Kingdom, Lagos, Nigeria, Glasgow, United Kingdom

5:00 p.m.–5:15 p.m.
43-OR Amino Acid Metabolism Is Regulated by Glucagon Receptor Signaling in Mice
MARIE WINOTHER-SORENSEN, KATRINE D. GALSGAARD, RUNE E. KUHRE, JENS PEDERSEN, NICOLAI J. WEVER ALBRECHTSEN, JENS J. HOLST, Copenhagen, Denmark

5:15 p.m.–5:30 p.m.
44-OR Effect of Glucagon on Nocturnal Rates of Endogenous Glucose Production in Type 2 Diabetes
ANANDA BASU, HUALING ZHAI, RICKEY CARTER, RITA BASU, Charlottesville, VA, Shanghai, China, Jacksonville, FL

5:30 p.m.–5:45 p.m.
45-OR Effects of Hyperglycemia and Hyperinsulinemia on Glucose Turnover during Exercise in Type 1 Diabetes
DAVIDE ROMERES, ANANDA BASU, MICHELE SCHIAVON, CLAUDIO COBELLI, CHIARA DALLA MAN, RITA BASU, Padova, Italy, Charlottesville, VA

5:45 p.m.–6:00 p.m.
46-OR NREP Bridges TGF-β Signaling and Lipid Metabolism in the Epigenetic Reprogramming of NAFLD in the Offspring of Insulin-Resistant Parents
DARIO F. DE JESUS, KAZUKI ORIME, CHIH-HAO WANG, JIANG HU, ERCUMENT DIRICE, AMÉLIA M. SILVA, YU-HUA TSENG, JUSSI PIHLAJAMAKI, ROHIT KULKARNI, Boston, MA, Vila Real, Portugal, Kuopio, Finland

6:00 p.m.–6:15 p.m.
47-OR Effects of NAFLD on Acetyl-CoA Partitioning and Ketone Kinetics in Response to a 24-Hour Fast
JUSTIN A. FLETCHER, STANISLAW DEJA, SHAWN C. BURGESS, JEFFREY BROWNING, Dallas, TX
**Oral Presentations**

4:15 p.m.-6:15 p.m.
(continued)

**Theme Area: Islet Biology/Insulin Secretion**

**Balancing Proliferation and Maturation in the Islet (With ADA Presidents’ Select Abstract)**

Room: W312

Chair: Emilyn Alejandro, PhD

4:15 p.m.-4:30 p.m.

48-OR  ADA Presidents’ Select Abstract: CRISPR-cas9 Gene Editing Restores Beta-Cell Differentiation and Function in Patient-Specific iPSCs

KATELYN MILLETTE, KYLE R. VOGT, ANDREW SALAS, PISIT PITUKCHEEWANONT, JULIANA AUSTIN, MARTIN MARTIN, SENTA GEORGIA, Los Angeles, CA

4:30 p.m.-4:45 p.m.

49-OR  Identification of Pancreatic Elastase Inhibitors That Can Stimulate Beta-Cell Proliferation

GIORGIO BASILE, AMEDEO VETERE, JIANG HU, BRIDGET WAGNER, ROHIT KULKARNI, Boston, MA, Cambridge, MA

4:45 p.m.-5:00 p.m.

50-OR  DNA Hydroxymethylation Regulates Beta-Cell Maturation and Expansion

TATYANA GURLO, SENTA GEORGIA, SANGEETA DHAWAN, Los Angeles, CA, Duarte, CA

5:00 p.m.-5:15 p.m.

51-OR  Serpin B13 Plays a Role in Beta-Cell Development and Progression to Insulin-Dependent Diabetes

YURY KRYVALAP, MATTHEW L. JIANG, NADZEYA KRYVALAP, KYLE A. MUELLER, JAN CZYZYK, Rochester, NY, Webster, NY

5:15 p.m.-5:30 p.m.

52-OR  Generation of a Novel Mouse Model to Study Pancreatic Beta-Cell Dedifferentiation

TRACY C.S. MAK, MATHIEU LATREILLE, London, United Kingdom

5:30 p.m.-5:45 p.m.

53-OR  SAD-A Promotes Pancreatic β-Cell Proliferation by Regulating β-Cell Cycle as a Downstream Target of mTORC1 Signaling

JIA NIE, NICOLAS MUSI, YUGUANG SHI, San Antonio, TX

5:45 p.m.-6:00 p.m.

54-OR  Interaction of Exocrine and Endocrine Pancreas in Obesity Ciliopathies

TIMOTHY L. HOSTELLEY, JR., JESSICA DUNLEAVEY, NORANN A. ZAGHLoul, Baltimore, MD

6:00 p.m.-6:15 p.m.

55-OR  Intrauterine Growth Retardation Induced Long-Term Gene Dysregulation Is Associated with Altered Histone Modifications in Rat Islets

YU-CHIN LIEN, PAUL WANG, REBECCA A. SIMMONS, Philadelphia, PA

**ADA-Supported Research**
5:20 p.m.-6:15 p.m.

Current Issues
Theme Area: Clinical Diabetes-Therapeutics
Should Metformin Remain the First-Line Therapy for Type 2 Diabetes?
Room: W415B (Valencia Ballroom)
Co-Chairs: Ildiko Lingvay, MD, MPH, MSCS and Joanna Mitri, MD, MS
5:20 p.m.-5:40 p.m.  Yes—Metformin’s Efficacy, Safety, and Role as Initial Therapy Are Well Established
Vanita R. Aroda, MD
5:40 p.m.-6:00 p.m.  No—Change Is Overdue—Better Options Are Available
Alice Y.Y. Cheng, MD, FRCPC
6:00 p.m.-6:15 p.m.  Question and Discussion Period

6:30 p.m.-8:30 p.m.
Networking Reception
Orange County Convention Center
(Level 4 Foyer)
(see page 39 for details)
### SATURDAY, JUNE 23, 2018—DAY-AT-A-GLANCE SCHEDULE

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 8:00 a.m.-10:00 a.m. | **Symposium** Is It Osteomyelitis or Not? Diagnostic and Treatment Dilemmas in Bone Infection  
Room: W315 | **Symposium** ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability  
Room: W203 | **Symposium** Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus  
Room: W307 | **Symposium** HIV and Diabetes—The Double Whammy  
Room: W308 |
| 10:15 a.m.-11:15 a.m. | **President, Health Care & Education Address and Outstanding Educator in Diabetes Award Lecture**—Room: W311 | | | |
| 11:30 a.m.-12:30 p.m. | **Professional Interest Group Session** The Best and Worst Practices in Managing the Diabetic Foot  
Room: W304A-D | **Professional Interest Group Session** Update on Nonnutritive Sweeteners and Cardiometabolic Health  
Room: W304E-H | **Mini-Symposium** Quantifying Diabetes—Genomics, Electronic Health Records, and Automated Control  
Room: W312 | |
| 11:30 a.m.-12:30 p.m. | **General Poster Session**—Hall WA4-WB2 (Poster Hall) | | | |
| 11:30 a.m.-1:30 p.m. | **Moderated Poster Discussions**—Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall) | | | |

Registration Hours: 7:00 a.m.-6:30 p.m.  
Shop Diabetes Store Hours: 7:30 a.m.-6:15 p.m.
<table>
<thead>
<tr>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td><em>Symposium</em></td>
<td><strong>Symposium</strong></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>Overcoming Challenges in Islet Transplantation—Engineering and Protecting Beta Cells</td>
<td>Hepatokines and Metabolic Regulation—A Liver-Centric Point of View</td>
<td>Turning Up the Heat—New Regulators of Thermogenesis in Mice and Humans</td>
<td>Targeting Beta-Cell Apoptosis and Death</td>
</tr>
<tr>
<td>Room: W206</td>
<td>Room: W209</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
</tr>
</tbody>
</table>
### SATURDAY, JUNE 23, 2018—DAY-AT-A-GLANCE SCHEDULE (CONTINUED)

**Registration Hours:** 7:00 a.m.-6:30 p.m.  
**Shop Diabetes Store Hours:** 7:30 a.m.-6:15 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 1:45 p.m.-3:45 p.m. | **Symposium**  
The Resurgence of Triglyceride-Rich Lipoproteins as an Important Target in the Treatment of Dyslipidemia  
*Room: W308* | **Symposium**  
Making a Difference in Five Minutes—Interventions in Diabetes for Anyone  
(With Richard R. Rubin Award Lecture)  
*Room: W414* | **Symposium**  
National Implementation and Dissemination of Research to Improve Patient Safety and Reduce Hypoglycemia  
*Room: W203* | **Case Studies**  
Monogenic Diabetes Testing Is Ready for Prime Time—Integrating Genetics into Your Practice  
*Room: W304E-H* |
|               | **Oral Presentations**  
What Is New in Diabetic Kidney Disease? (With State-of-the-Art Lecture and ADA Presidents’ Select Abstract)  
*Room: W304A-D* | **Symposium**  
Role of Exercise in Regulating Mitochondrial Dynamics  
*Room: W315* | **Symposium**  
The Diabetes Do-It-Yourself (DIY) Revolution  
*Room: W415C*  
(Valencia Ballroom) | **Symposium**  
Exploring the Next Frontier in Diabetes Pharmacology  
*Room: W307* |
|               | **Symposium**  
Lessons Learned from the Environmental Determinants of Diabetes in the Young (TEDDY) Study—Insights into Early Autoimmune Type 1 Diabetes  
*Room: W415B*  
(Valencia Ballroom) | **Symposium**  
Mitochondrial Dynamics, Metabolism, and Insulin Action  
*Room: W209* | **Symposium**  
Beta-Cell Dedifferentiation—True or False?  
*Room: W312* |
| 4:00 p.m.-6:00 p.m. | **Oral Presentations**  
Hypoglycemia—Reducing the Risk  
*Room: W208* | **Symposium**  
Nutrition and the Gut Microbiome  
*Room: W414* | **Symposium**  
Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?  
*Room: W311* | **Oral Presentations**  
The Impact of Diabetes Interventions and Behaviors on Outcomes  
*Room: W304E-H* |
|               | **Oral Presentations**  
Research Advances in the Diabetic Foot (With Roger Pecoraro Award Lecture)  
*Room: W204* | **Symposium**  
Online and Mobile Support—Wading through the Noise  
*Room: W304A-D* | **Symposium**  
Joint ADA/Chinese Diabetes Society Symposium—Glucose and Lipid Metabolism—Novel Mechanisms and Targets  
*Room: W203* | **Oral Presentations**  
It’s Not Too Late, Baby—Outcomes in Gestational Diabetes Mellitus (With Norbert Freinkel Award Lecture)  
*Room: W307* |
|               | **Oral Presentations**  
Updates from Type 2 Diabetes Trials  
*Room: W415B*  
(Valencia Ballroom) | **Oral Presentations**  
Updates from Type 2 Diabetes Trials  
*Room: W415B*  
(Valencia Ballroom) | **Symposium**  
Steering the Right Course for Diabetes Management—Clinical Perspectives  
*Room: W311* |
<table>
<thead>
<tr>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>New Insights into the</td>
<td>The Intestine in the Regulation</td>
<td>Steering the Right Course for</td>
<td>Beta-Cell Dedifferentiation—</td>
</tr>
<tr>
<td>Immunology of Human Type 1</td>
<td>of Metabolism, Immunity, and</td>
<td>Diabetes Management—Clinical</td>
<td>True or False?</td>
</tr>
<tr>
<td>Diabetes</td>
<td>Insulin Sensitivity</td>
<td>Perspectives</td>
<td>Room: W312</td>
</tr>
<tr>
<td>Room: W206</td>
<td>Room: W209</td>
<td>Room: W311</td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Progress in Islet</td>
<td>Mitochondrial Dynamics, Metabolism,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transplantation—Clinical</td>
<td>and Insulin Action</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Science</td>
<td>Room: W209</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W206</td>
<td>Room: W209</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>G is for GLP, GIP, and</td>
<td>Steering the Right Course for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucagon—A NOD to the</td>
<td>Diabetes Management—Clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gut-Liver Axis</td>
<td>Perspectives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W308</td>
<td>Room: W311</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscling In on the Heart</td>
<td>Neurotransmitters in the Islet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>of Metabolism and Insulin</td>
<td>Room: W312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>Room: W312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room: W315</td>
<td>Room: W312</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Scientific Sessions
8:00 a.m.-10:00 a.m.

Symposium
Theme Area: Acute and Chronic Complications
Is It Osteomyelitis or Not? Diagnostic and Treatment Dilemmas in Bone Infection
Room: W315
Chair: Lawrence A. Lavery, DPM
8:00 a.m.-8:20 a.m. The Science of Osteomyelitis—What Do We Know about the Interaction between Bacteria and Bone?
John M. Embil, MD
8:20 a.m.-8:40 a.m. The Best Diagnostic Imaging Tools—Is There One Imaging Modality That Says Yes, It Is Osteomyelitis?
William B. Morrison, MD
8:40 a.m.-9:00 a.m. Evaluating Our Treatment Metric in Osteomyelitis—What Do We Mean When We Say the Patient is Cured?
Eric Senneville, MD, PhD
9:00 a.m.-9:20 a.m. Antibiotic Duration for the Treatment of Osteomyelitis—Who Said Six Weeks Was Enough?
Edgar J.G. Peters, MD, PhD
9:20 a.m.-9:40 a.m. When In Vivo Stainless Steel Is the Best Antibiotic
F. Javier Aragón-Sánchez, MD, PhD
9:40 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
ADA Education Recognition Program Symposium—Implementing Technology-Enabled Diabetes Care Management Processes for Population Health—Conception, Build, Implementation, Outcomes, and Sustainability
Room: W203
Chair: Lori Blanton, MS, CHES, CDE
8:00 a.m.-8:30 a.m. Setting the Stage
Michelle F. Magee, MD, MB, BCh, LRCPSI
8:30 a.m.-9:00 a.m. Implementation of the Diabetes Boot Camp in a Multipayer System
Gretchen A. Youssef, MS, RD, CDE
9:00 a.m.-9:30 a.m. Learning from Outcomes, Sustainability, and Spread
Carine M. Nassar, MS, RD, CDE
9:30 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Have You Seen Your Mother, Baby? Placenta-Derived Biomarkers of Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
Room: W307
Chair: Mary R. Loeken, PhD
8:00 a.m.-8:30 a.m. Circulating Exosomes in Gestational Diabetes Mellitus—Potential Role on Insulin Sensitivity during Gestation
Carlos Salomen, PhD, DMedSc, MSc
8:30 a.m.-9:00 a.m. MicroRNAs in Maternal-Placenta-Fetal Communication and Pregnancy Health
Yoel Sadovsky, MD
9:00 a.m.-9:30 a.m. Lipid Metabolism and How It Affects Fetal Growth
Perrie F. O’Tierney-Ginn, PhD
9:30 a.m.-10:00 a.m. The Placenta Microbiome
Samuel Parry, MD
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Genetics and Type 2 Diabetes in Youth
Room: W414
Chair: Jeanie B. Tryggestad, MD
8:00 a.m.-8:30 a.m.  Monogenic Diabetes—Results from SEARCH
                    Catherine Pihoker, MD
8:30 a.m.-9:00 a.m.  Prevalence of Monogenic Diabetes in Youth with Type 2 Diabetes—Results from the
                    TODAY Study
                    Rachelle Gandica, MD
9:00 a.m.-9:30 a.m.  All Type 2 Diabetes Isn’t the Same, but When Is It Atypical?
                    Siri Atma W. Greeley, MD, PhD
9:30 a.m.-10:00 a.m. Metformin Response among Youth with Type 2 Diabetes—Impact of Ethnicity/Genes
                    Elvira Isganaitis, MD, MPH

Symposium
Theme Area: Clinical Diabetes/Therapeutics
ADA Diabetes Care Symposium—Using Continuous Glucose Monitoring and Smart Devices to
Control Glucose when It Matters Most
Room: W311
Co-Chairs: Matthew C. Riddle, MD and William V. Tamborlane, MD
8:00 a.m.-8:30 a.m.  Intensive Glycemic Treatment during Pregnancy
                    Helen R. Murphy, MD, FRACP
8:30 a.m.-9:00 a.m.  Continuous Glucose Monitoring and CSII in the Hospital
                    Guillermo E. Umpierrez, MD, CDE, FACP, FACE
9:00 a.m.-9:30 a.m.  Closed-Loop Systems for Type 1 Diabetes in Youth—Children Are Not Just Small Adults
                    Jennifer Sherr, MD, PhD
9:30 a.m.-10:00 a.m. “Profiles in Progress” Plaque Presentations

Symposium
Theme Area: Epidemiology/Genetics
HIV and Diabetes—The Double Whammy
Room: W308
Chair: Kasia J. Lipska, MD, MHS, BS
8:00 a.m.-8:30 a.m.  Epidemiology of Diabetes Mellitus among People Living with HIV
                    Phyllis Tien, MD
8:30 a.m.-9:00 a.m.  HIV and the Heart
                    Priscilla Hsue, MD
9:00 a.m.-9:30 a.m.  Antiretroviral Therapy, Lipodystrophy, and Dyslipidemia
                    Carl Grunfeld, MD, PhD
9:30 a.m.-10:00 a.m. Management of Diabetes in HIV
                    Todd T. Brown, MD, PhD
8:00 a.m.-10:00 a.m.  
(continued)

Symposium
Theme Area: Immunology/Transplantation
Overcoming Challenges in Islet Transplantation—Engineering and Protecting Beta Cells
Room: W206
Chair: Christian Schuetz, MD
8:00 a.m.-8:30 a.m.  Engineering the Biohub—Clinical Use of Alternate Transplant Sites  
David Baidal, MD
8:30 a.m.-9:00 a.m.  Physiologic Demands, a Challenge for Stem-Cell Generated Beta-Cell Implants  
Daniel Pipeleers, MD, PhD
9:00 a.m.-9:30 a.m.  Overcoming the Immunosuppression Barrier in Islet Transplant—Modulating the Local Environment to Protect Transplanted Cells  
Lonnie D. Shea, PhD
9:30 a.m.-10:00 a.m.  Novel Encapsulation Approaches to Prevent Rejection and Recurrent Autoimmunity  
Tejal Desai, PhD

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Hepatokines and Metabolic Regulation—A Liver-Centric Point of View
Room: W209
Chair: Brian N. Finck, PhD
8:00 a.m.-8:30 a.m.  Fetuin B Links Hepatic Steatosis to Altered Glucose Homeostasis  
Matthew J. Watt, PhD
8:30 a.m.-9:00 a.m.  New Insights into the Physiology and Pharmacology of FGF-21  
Steven Kliewer, PhD
9:00 a.m.-9:30 a.m.  ApoJ Is a Novel Hepatokine Regulating Muscle Glucose Metabolism and Insulin Sensitivity  
Young-Bum Kim, PhD
9:30 a.m.-10:00 a.m.  Foxo-Regulated Hepatokines Regulate Hepatic Insulin Resistance  
Morris F. White, PhD

Symposium
Theme Area: Integrated Physiology/Obesity
Turning Up the Heat—New Regulators of Thermogenesis in Mice and Humans
Room: W304A-D
Chair: Erin E. Kershaw, MD
8:00 a.m.-8:30 a.m.  Blocking Follicle-Stimulating Hormone (FSH) Induces Thermogenic Adipose Tissue and Reduces Body Fat  
Mone Zaidi, MD, PhD
8:30 a.m.-9:00 a.m.  Lipolysis in Brown Adipose Tissue Is Not Essential for Cold-Induced Thermogenesis in Mice  
Liqing Yu, MD, PhD
9:00 a.m.-9:30 a.m.  Critical Review of the Energy Sources of Brown Adipose Tissue Thermogenesis in Humans  
André C. Carpentier, MD
9:30 a.m.-10:00 a.m.  Cold-Induced Adipokines in Thermogenesis and Metabolism  
Yu-Hua Tseng, PhD
Oral Presentations  
8:00 a.m.-10:00 a.m.  
(continued)

Theme Area: Acute and Chronic Complications
What’s New in Diabetic Neuropathy? Equal Parts Clinical and Basic Science
Room: W208  
Chair: Vera Fridman, MD

8:00 a.m.-8:15 a.m.  
56-OR  
A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes  
YALING TANG, JOSYF MYCHALECKYI, BRUCE A. PERKINS, RODICA POP-BUSUI, MICHAEL J. WAGNER, ALISON MOTSINGER-REIF, JOHN B. BUSE, HETAL SHAH, ALESSANDRO DORIA, Boston, MA, Charlottesville, VA, Toronto, ON, Canada, Ann Arbor, MI, Chapel Hill, NC, Raleigh, NC

8:15 a.m.-8:30 a.m.  
57-OR  
Increased Deacetylation of Proteins in Sensory Neurons by Sirtuin 1 Protein Overexpression Reverses T2D Peripheral Neuropathy  
KRISH CHANDRASEKARAN, CHENG-YING HO, MOHAMMAD SALIMIAN, PRANITH H. KUMAR, SAI SRUTHI REDDY KONDURU, JAMES W. RUSSELL, Baltimore, MD

8:30 a.m.-8:45 a.m.  
58-OR  
Muscarinic Receptor Antagonist Improves Nerve Fiber Function in Subjects with Type 2 Diabetes and Peripheral Neuropathy  
AARON I. VINIK, NIGEL A. CALCUTT, JOSHUA F. EDWARDS, JESSICA R. WEAVER, MICHAEL D. BAILEY, PAUL FERNYHOUGH, LINDSEY B. CUNDRA, KATIE E. FRIZZI, HENRI PARSON, CAROLINA M. CASELLINI, Norfolk, VA, La Jolla, CA, Winnipeg, MB, Canada

8:45 a.m.-9:00 a.m.  
59-OR  
Effect of Sacubitril/Valsartan vs. Valsartan on Vascular and Neural Complications in Type 2 Diabetic Rats  
MARK A. YOREK, Iowa City, IA

9:00 a.m.-9:15 a.m.  
60-OR  
High-Fat Diet Induces Mitochondrial Dysfunction in Saphenous Nerve Axons—A Study by Confocal Microscopy In Vivo  
MARIJA SAJIC, ANISH KANHAI, GIACOMO DENTONI, SHARLINI VARATHARAJAH, LUCY M. HINDER, AMY RUMORA, EVA L. FELDMAN, KENNETH SMITH, London, United Kingdom, Leiden, Netherlands, Stockholm, Sweden, Ann Arbor, MI

9:15 a.m.-9:30 a.m.  
61-OR  
Alterations in Somatomotor Network Functional Connectivity in Painful Diabetic Neuropathy—A Resting State Functional Magnetic Resonance Imaging Study  
DINESH SELVARAJAH, MOHAMED AWADH, RAJIV GANDHI, IAIN D. WILKINSON, SOLOMON TESFAYE, Sheffield, United Kingdom

9:30 a.m.-9:45 a.m.  
62-OR  
Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes (T1D)—Findings from the T1D Exchange  
KARA R. MIZOKAMI-STOUT, CLAIRE T. BOYLE, VIRAL N. SHAH, GRAZIA ALEPPO, JANET B. MCGILL, RICHARD PRATLEY, ELENA TOSCHI, LYNN ANG, RODICA POP-BUSUI, Ann Arbor, MI, Tampa, Fl, Aurora, CO, Chicago, IL, St. Louis, MO, Orlando, FL, Boston, MA

9:45 a.m.-10:00 a.m.  
63-OR  
Differential Association of Inflammatory Markers and Growth Factors with Type 2 Diabetes and Polyneuropathy—A Multimarker Approach  
GIDON J. BÖNHOF, ALEXANDER STROM, WOLFGANG RATHMANN, MARGIT HEIER, CHRISTA MEISINGER, ANNETTE PETERS, MICHAEL RODEN, BARBARA THORAND, CHRISTIAN HERDER, DAN ZIEGLER, Düsseldorf, Germany, Munich, Germany
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise

Effects of Exercise on Metabolic Health in Type 1 and Type 2 Diabetes (With ADA Presidents’ Select Abstract)
Room: W204
Chair: Lauren M. Sparks, PhD

8:00 a.m.-8:15 a.m.
64-OR  ▲  ADA Presidents’ Select Abstract: Maternal and Paternal Exercise Regulates Offspring Metabolic Health and Beta-Cell Phenotype
JIA ZHENG, ANA B.A. WAGNER, NOAH B. PRINCE, KAWAI SO, JORAM MUL, ERCUMENT DIRICE, MICHAEL F. HIRSHMAN, KRISTIN I. STANFORD, ROHIT KULKARNI, LAURIE J. GOODYEAR, Beijing, China, Boston, MA, Worcester, MA, Amsterdam, Netherlands, Columbus, OH

8:15 a.m.-8:30 a.m.
65-OR  Reducing Basal Insulin 90 Minutes before Exercise Protects Against Hypoglycemia Better than Insulin Suspension at Exercise Onset in T1D—The OmniTIME Results
DESSI ZAHARIEVA, SARAH M. MCGAUGH, RUBIN POONI, TODD VIENNEAU, TRANG T. LY, MICHAEL RIDDELL, Toronto, ON, Canada, Oakville, ON, Canada, Billerica, MA

8:30 a.m.-8:45 a.m.
66-OR  Exercise Regulates the Concentration of Novel Circulating Factors in Humans
ROELAND MIDDELBEEK, JEFFREY J. RICHARD, NOAH B. PRINCE, LESLIE ROWLAND, JONATHAN DREYFUSS, HUI PAN, LAURIE J. GOODYEAR, Boston, MA

8:45 a.m.-9:00 a.m.
67-OR  GDF15 Is a Contraction-Induced Myokine That Regulates Pancreatic β-Cell Function
HUI ZHANG, ANNY MULYA, STEPHAN NIEUWOUDT, RUTH MCDOWELL, JOHN P. KIRWAN, Cleveland, OH

9:00 a.m.-9:15 a.m.
68-OR  Exercise Prevents High-Fat Diet-Induced Impairment of Insulin-Induced Vasodilatation of Muscle Arterioles in Mice by Browning Perivascular Adipose Tissue of Mice
BEATRIZ C.S. BOA, FERNANDA M. FERRÃO, ISABELA M. GONZAGA, LUIS FELIPE R. PINTO, VICTOR W.M. VAN HINSBERGH, ETTO C. ERINGA, Amsterdam, Netherlands, Rio de Janeiro, Brazil

9:15 a.m.-9:30 a.m.
69-OR  Effects on Insulin Sensitivity, but Not on Mitochondrial Function Are Dependent on Insulin Resistance Status after High Intensity Interval Training
MARIA APOSTOLOPOULOU, DOMINIK PESTA, YANISLAVA KARUSHEVA, SOFIYA GANCHEVA, TOMAS JELENIK, ALESSANDRA BIERWAGEN, KARSTEN MÜSSIG, JULIA SZENDROEDI, MICHAEL RODEN, Düsseldorf, Germany

9:30 a.m.-9:45 a.m.
70-OR  ▲  Aerobic Training Remodels Muscle Lipid Composition and Improves Intrinsic Mitochondrial Function in Men with Type 2 Diabetes
MARIA F. PINO, NATALIE STEPHENS, FANCHAO YI, ANDREW P. HODGES, RICHARD E. PRATLEY, STEVEN R. SMITH, BRET H. GOOPDASTER, LAUREN M. SPARKS, Orlando, FL, Cambridge, MA, La Jolla, CA

9:45 a.m.-10:00 a.m.
71-OR  MicroRNA Regulated Transcriptomic Changes during Aging in Human Skeletal Muscle Are Reversible with Exercise Training
JOE VALENTINE, SANGETHA GHOSH, BRANDON MILHOLLAND, JONATHAN A. GELFOND, NICOLAS MUSI, San Antonio, TX, Boyds, MD, Bronx, NY

▲ ADA-Supported Research
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Emerging Targets for Diabetes Treatment
Room: W304E-H
Co-Chairs: Marconi Abreu, MD and Sadia Ali, MD

8:00 a.m.-8:15 a.m.
72-OR Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes
BRITTA GOEBEL, MICHELE SCHIAVON, ROBERTO VISENTIN, MICHELA RIZ, CHIARA DALLA MAN, CLAUDIO COBELLI, THOMAS KLABUNDE, Frankfurt, Germany, Padova, Italy

8:15 a.m.-8:30 a.m.
73-OR Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin
JEREMY PETTUS, ERIC G. VAJDA, JAMES PIPKIN, GRETCHEN WILLIAMSON, MIRIAM A. ZANGMEISTER, YONGXI LI, ROBERT R. HENRY, DAVID D’ALESSIO, JUAN P. FRIAS, LIN ZHI, KEITH MARSCHKE, San Diego, CA, Cincinnati, OH, Durham, NC, Los Angeles, CA

8:30 a.m.-8:45 a.m.
74-OR Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension
JOHN P. HANRAHAN, JAMES D. WAKEFIELD, PHEBE J. WILSON, PAUL MILLER, JENNIFER CHICKERING, LINDA MORROW, MICHAEL L. HALL, MARK CURRIE, G. TODD MILNE, ALBERT T. PROFY, Cambridge, MA, Raleigh, NC, Chula Vista, CA

8:45 a.m.-9:00 a.m.
75-OR Oral Sodium Nitrite Improves Insulin Sensitivity, Blood Pressure, and Arterial Thickening in Adults with Uncontrolled Hypertension and Metabolic Syndrome
KARA S. HUGHAN, NICOLE L. HELBLING, STEVEN J. ANTHONY, JAMES DELANY, BRET H. GOODPASTER, MARK GLADWIN, Pittsburgh, PA, Orlando, FL

9:00 a.m.-9:15 a.m.
76-OR BZ043, a Novel Amylin Analog, in a Fixed Combination with Insulin Glargine—Nonclinical Results
CAIO V.F. NASCIMENTO, PAULO G. LACATIVA, FRANÇOIS BRIAND, LUIS M.T.R. LIMA, Rio de Janeiro, Brazil, Labège, France

9:15 a.m.-9:30 a.m.
77-OR Novel Combination of a Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) and Once-Weekly Basal Insulin (HM12460A) Offers Improved Glucose Lowering and Weight Loss in a Diabetic Animal Model
JUNG KUK KIM, JONG SUK LEE, JAEHYUK CHOI, SUNG YOUB JUNG, SANG HYUN LEE, IN YOUNG CHOI, SUN JIN KIM, Seoul, Republic of Korea

9:30 a.m.-9:45 a.m.
78-OR MEDI0382, a GLP/Glucagon Receptor Dual Agonist, Significantly Reduces Hepatic Fat Content in Subjects with Type 2 Diabetes Mellitus
MEENA JAIN, LAN-FENG TSAI, DARREN ROBERTSON, BOAZ HIRSHBERG, PAUL HOOKINGS, LARS JOHANSSON, PHILIP AMBERY, Cambridge, United Kingdom, Gaithersburg, MD, Mölndal, Sweden

9:45 a.m.-10:00 a.m.
79-OR Effects of MEDI0382 on Pancreatic and Incretin Hormones
VICTORIA E.R. PARKER, LAN-FENG TSAI, DARREN ROBERTSON, MARCELLA PETRONE, CRISTINA RONDINONE, BOAZ HIRSHBERG, LUTZ JERMUTUS, PHILIP AMBERY, Cambridge, United Kingdom, Gaithersburg, MD
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

**Theme Area: Islet Biology/Insulin Secretion**

**Targeting Beta-Cell Apoptosis and Death**
Room: W312
Chair: Maria S. Remedi, PhD

8:00 a.m.-8:15 a.m.
**80-OR** miR-128 Targets Thioredoxin-Interacting Protein 3’UTR and Downregulates Its Expression in Pancreatic Beta Cells
GU JING, JUNQIN CHEN, GUANLAN XU, ANATH SHALEV, Birmingham, AL

8:15 a.m.-8:30 a.m.
**81-OR** Imeglimin Protects INS-1 Cells and Human Islets against High Glucose- and High Fructose-Induced Cell Death by Inhibiting the Mitochondrial PTP Opening
SANDRINE LABLANCHE, EMILY TUBBS, CÉCILE COTTET-ROUSSELLE, FREDERIC LAMARCHE, ANAÏCK MOISAN, VIRGINIE PERSOONS, PIERRE Y. BENHAMOU, SOPHIE HALLAKOU-BOZEC, ERIC FONTAINE, Grenoble, France, Saint-Martin d’Hères, France, Saint-Ismier, France, Lyon, France

8:30 a.m.-8:45 a.m.
**82-OR** Evidence for Necroptosis as a Mechanism of Islet Amyloid-Induced Beta-Cell Death
ANDREW T. TEMPLIN, MEGHAN F. HOGAN, NATHALIE ESSER, SAKENEH ZRAIKA, REBECCA L. HULL, STEVEN E. KAHN, Seattle, WA

8:45 a.m.-9:00 a.m.
**83-OR** Pancreatic Beta Cell O-GlcNAc Transferase Overexpression Increases Susceptibility to Streptozotocin- and High-Fat Diet-Induced Diabetes in Female Mice
RAMKUMAR MOHAN, HAI-BIN RUAN, XIAOYONG YANG, EMILYN ALEJANDRO, Minneapolis, MN, New Haven, CT

9:00 a.m.-9:15 a.m.
**84-OR** Caveolin-1 Deficiency Protects Pancreatic β Cells against Palmitate-Induced Dysfunction and Apoptosis
WEN ZENG, KUNYING LIU, JIANSONG TANG, HAICHENG LI, HAIXIA XU, HONGYUN LU, HANGYA PENG, CHUWEN LIN, RILI GAO, SHOU LIN, KEYI LIN, YAN JIANG, LONGYI ZENG, Guangzhou, China

9:15 a.m.-9:30 a.m.
**85-OR** Grp78 Is Critical for Beta-Cell Maturation and Survival
ROHIT B. SHARMA, XIAOYING ZHENG, BRIAN GABLASKI, JASON K. KIM, AMY S. LEE, LAURA C. ALONSO, Worcester, MA, Los Angeles, CA

9:30 a.m.-9:45 a.m.
**86-OR** Pancreatic Islets in Short Duration Type 2 Diabetes (T2D) Show Macrophage Infiltration and Increased Inflammatory Signaling
JOHN T. WALKER, SHRISTI SHRESTHA, NRIPESH PRASAD, TIFFANY RICHARDSON, RADHIKA ARAMANDLA, GREG POFFENBERGER, RITA BOTTINO, MARCELA BRISSOVA, ALVIN C. POWERS, Nashville, TN, Huntsville, AL, Pittsburgh, PA

9:45 a.m.-10:00 a.m.
**87-OR** Novel Small Molecule TXNIP Inhibitor Protects against Diabetes
LANCE THIELEN, JUNQIN CHEN, GUANLAN XU, GU JING, TRUMAN GRAYSON, SEONGHO JO, ANATH SHALEV, Birmingham, AL
10:15 a.m.-11:15 a.m.
President, Health Care & Education Address

*The American Diabetes Association in the Era of Health Care Transformation*
Felicia Hill-Briggs, PhD, ABPP

and

**Outstanding Educator in Diabetes Award Lecture**

*Connectedness—How Technology and Social Networks are Advancing Diabetes Nutrition Care*
Jackie L. Boucher, MS, RDN
Room: W311

11:30 a.m.-12:30 p.m.

**Professional Interest Group Session**
Theme Area: Acute and Chronic Complications

**The Best and Worst Practices in Managing the Diabetic Foot**
Room: W304A-D
Chair: Barry Rosenblum, DPM
11:30 a.m.-11:35 a.m.  Opening Remarks
Barry Rosenblum, DPM
11:35 a.m.-12:30 p.m.  Panel Discussion
Neal R. Barshes, MD, MPH
Lawrence A. Lavery, DPM
Misaki Kiguchi, MD, MBA
Edgar J.G. Peters, MD, PhD

**Professional Interest Group Session**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise

**Update on Nonnutritive Sweeteners and Cardiometabolic Health**
Room: W304E-H
Chair: Alison B. Evert, MS, RD, CDE
11:30 a.m.-12:00 p.m.  Evidence for Effect of Nonnutritive Sweeteners on Cardiometabolic Health in Adults
Judith Wylie-Rosett, EdD, RD
12:00 p.m.-12:30 p.m.  Potential Effects of Early Life Exposure to Nonnutritive Sweeteners
Dylan Mackay, MSc, PhD

**Professional Interest Group Session**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise

**Reframing Exercise—The Surprising Science behind Motivating Patients to Be More Physically Active**
Room: W308
Chair: Caroline R. Richardson, MD
11:30 a.m.-12:30 p.m.  Concepts and Science
Michelle Segar, PhD, MPH
Mini-Symposium
Theme Area: Clinical Diabetes/Therapeutics
Quantifying Diabetes—Genomics, Electronic Health Records, and Automated Control
Room: W312
Chair: Boris P. Kovatchev, PhD
11:30 a.m.-11:45 a.m. The Type 2 Diabetes Knowledge Portal
    Jason A. Flannick, PhD
11:45 a.m.-12:00 p.m. Diabetes Data Science—Linking Genotype, Electronic Health Records, and Real-Time Monitoring
    Philip E. Bourne, PhD, FACMI
12:00 p.m.-12:15 p.m. Adaptive Automated Control of Diabetes
    Eyal Dassau, PhD
12:15 p.m.-12:30 p.m. Question and Discussion Period
11:30 a.m.-12:30 p.m.
(continued)

General Poster Session
Hall WA4-WB2 (Poster Hall)

All posters will be displayed Saturday, Sunday, and Monday. Poster presenters in the following categories will be at their posters during this period for questions and discussion with attendees.

Presented Categories

**Theme Area: Acute and Chronic Complications**
- **Complications—Hypoglycemia**
  - Posters: 376-P to 406-P
- **Complications—Nephropathy—Basic and Experimental Science**
  - Posters: 491-P to 516-P
- **Complications—Nephropathy—Clinical and Translational Research**
  - Posters: 517-P to 546-P
- **Complications—Neuropathy**
  - Posters: 547-P to 588-P
- **Complications—Retinopathy**
  - Posters: 589-P to 608-P
- **Diabetic Dyslipidemia**
  - Posters: 609-P to 629-P
- **Clinical Therapeutics/New Technology—Glucose Monitoring and Sensing**
  - Posters: 898-P to 959-P
- **Clinical Therapeutics/New Technology—Insulins**
  - Posters: 997-P to 1059-P
- **Clinical Therapeutics/New Technology—Pharmacologic Treatment of Complications**
  - Posters: 1216-P to 1244-P

**Theme Area: Epidemiology/Genetics**
- **Epidemiology—Aging**
  - Posters: 1466-P to 1482-P
- **Epidemiology—Nutrition**
  - Posters: 1598-P to 1611-P
- **Epidemiology—Type 1 Diabetes**
  - Posters: 1686-P to 1699-P
- **Epidemiology—Type 1 Diabetes**
  - Posters: 1726-P to 1739-P
- **Epidemiology—Type 1 Diabetes**
  - Posters: 1740-P to 1747-P
- **Epidemiology—Central Nervous System Regulation of Metabolism**
  - Posters: 1788-P to 1807-P
- **Epidemiology—Muscle**
  - Posters: 1902-P to 1937-P
- **Epidemiology—Other Hormones**
  - Posters: 1938-P to 1977-P
11:30 a.m.-12:30 p.m. (continued)

Moderated Poster Discussions
Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators.

Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedule listed below.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

**Theme Area: Clinical Diabetes/Therapeutics**
New Concepts in Oral Therapies
Posters: 1116-P to 1121-P
Location: Exhibit Hall (ePoster Theater A)
Moderator: Matthew P. Gilbert, DO, MPH

**Theme Area: Clinical Diabetes/Therapeutics**
Clinical/Epidemiology Topics in Gestational Diabetes Mellitus
Posters: 1414-P to 1419-P
Location: Exhibit Hall (ePoster Theater B)
Moderator: Helen R. Murphy, MD, FRACP

**Theme Area: Acute and Chronic Complications**
Predictors and Mediators of Cardiovascular Risk
Posters: 407-P to 412-P
Location: Poster Hall (First poster in discussion)
Moderator: Sotirios Tsimikas, MD, FACC, FAHA, FSCAI

**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**
Implementing Best Practices and Innovative Interventions into Diabetes Self-Management Education and Support
Posters: 648-P to 653-P
Location: Poster Hall (First poster in discussion)
Moderator: Laura B. Hieronymus, DNP, MSED, RN, MLDE, BC-ADM, CDE, FAADE

**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**
Assessing and Intervening on the Impact of Diabetes Distress on Individuals with Diabetes
Posters: 794-P to 799-P
Location: Poster Hall (First poster in discussion)
Moderator: Danielle M. Hessler, PhD

**Theme Area: Clinical Diabetes/Therapeutics**
Cost-Effective Strategies to Improve Diabetes Care
Posters: 1245-P to 1250-P
Location: Poster Hall (First poster in discussion)
Moderator: Thomas Songer, PhD, MSc, MPH

**Theme Area: Clinical Diabetes/Therapeutics**
Metabolic Parameters—Risk Factors for Type 2 Diabetes, Cardiovascular Disease, and Cognitive Development?
Posters: 1334-P to 1339-P
Location: Poster Hall (First poster in discussion)
Moderator: Elvira Isganaitis, MD, MPH

**Theme Area: Epidemiology/Genetics**
Clinical Diagnosis and Screening of Diabetes
Posters: 1497-P to 1502-P
Location: Poster Hall (First poster in discussion)
Moderator: Elizabeth Selvin, PhD, MPH

(continued on next page)
11:30 a.m.-12:30 p.m.  
(continued)

Moderated Poster Discussions

Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators.

Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedule listed below.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

Theme Area: Insulin Action/Molecular Metabolism

Fat Is Where Insulin’s At
Posters: 1748-P to 1753-P
Location: Poster Hall (First poster in discussion)
Moderator: Matthew Steinhauser, MD

Theme Area: Integrated Physiology/Obesity

Integrated Physiology of Insulin Secretion In Vivo
Posters: 1808-P to 1813-P
Location: Poster Hall (First poster in discussion)
Moderator: Sangeeta Kashyap, MD

Theme Area: Integrated Physiology/Obesity

Obesity Pathogenesis and Treatment—Insights from Animal Studies
Posters: 1978-P to 1983-P
Location: Poster Hall (First poster in discussion)
Moderator: Michael J. Jurczak, PhD

Theme Area: Islet Biology/Insulin Secretion

Islet Biology—Apoptosis
Posters: 2102-P to 2107-P
Location: Poster Hall (First poster in discussion)
Moderator: Carmella Evans-Molina, MD, PhD
12:30 p.m.-1:30 p.m.

Moderated Poster Discussions

Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators.

Follow the steps below to attend a Moderated Poster Discussion:

• Identify the discussion you are interested in attending from the schedule listed below.
• Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
• Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

**Theme Area: Clinical Diabetes/Therapeutics**

Clinical Studies with Noninsulin Injectables
Posters: 1060-P to 1065-P
Location: Exhibit Hall (ePoster Theater A)
Moderator: Philip Raskin, MD

Clinical Outcomes with Oral Therapies
Posters: 1122-P to 1127-P
Location: Exhibit Hall (ePoster Theater B)
Moderator: Sadia Ali, MD

**Theme Area: Acute and Chronic Complications**

Modulators of Endothelial and Myocardial Dysfunction
Posters: 470-P to 475-P
Location: Poster Hall (First poster in discussion)
Moderator: George L. King, MD

**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

Targeting People and Educational Barriers to Improve Outcomes
Posters: 654-P to 659-P
Location: Poster Hall (First poster in discussion)
Moderator: Susan Cornell, PharmD, CDE, FAPhA

(continued on next page)
12:30 p.m.-1:30 p.m.
(continued)

Moderated Poster Discussions

Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators. Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedule listed below.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

Theme Area: Epidemiology/Genetics
Diabetes Complications
Posters: 1550-P to 1555-P
Location: Poster Hall (First poster in discussion)
Moderator: Neda Laiteerapong, MD, MS

Theme Area: Epidemiology/Genetics
Type 2 Diabetes—Risk Factors and Complications
Posters: 1612-P to 1617-P
Location: Poster Hall (First poster in discussion)
Moderator: Neda Rasouli, MD

Theme Area: Epidemiology/Genetics
Delving into Type 2 Diabetes Genetics
Posters: 1703-P to 1708-P
Location: Poster Hall (First poster in discussion)
Moderator: Jose C. Florez, MD, PhD

Theme Area: Integrated Physiology/Obesity
Integrated Physiology of Macronutrient Metabolism and Food Intake
Posters: 1884-P to 1889-P
Location: Poster Hall (First poster in discussion)
Moderator: Karen K. Ryan, PhD
Symposium
Theme Area: Acute and Chronic Complications
The Resurgence of Triglyceride-Rich Lipoproteins as an Important Target in the Treatment of Dyslipidemia
Room: W308
Chair: Carl Grunfeld, MD, PhD
1:45 p.m.-2:15 p.m. New Insights into the Metabolism of Triglyceride-Rich Lipoproteins
Ira J. Goldberg, MD
2:15 p.m.-2:45 p.m. Do Triglyceride-Rich Lipoproteins Cause Atherosclerosis?
Anne Tybjærg-Hansen, MD, DMSc
2:45 p.m.-3:15 p.m. The Chylomicronemia Syndrome—A Potentially Fatal Complication of Elevations in Triglyceride-Rich Lipoproteins in Patients with Diabetes
Alan Chait, MD
3:15 p.m.-3:45 p.m. New and Old Approaches to Lower Triglyceride-Rich Lipoproteins
Sotirios Tsimikas, MD, FACC, FAHA, FSCAI

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Making a Difference in Five Minutes—Interventions in Diabetes for Anyone (With Richard R. Rubin Award Lecture)
Room: W414
Chair: Michael A. Harris, PhD
1:45 p.m.-2:15 p.m. Richard R. Rubin Award Lecture—Diabetes and Behavior in the 21st Century—Things That Make You Go “Hmmm”
Tim Wysocki, PhD, ABPP
2:15 p.m.-2:35 p.m. Five-Minute ABS (Adherence, Bite-Sized)
Andrew Riley, PhD
2:35 p.m.-2:55 p.m. Intervening in Diabetes Distress
Lawrence Fisher, PhD, ABPP
2:55 p.m.-3:15 p.m. Chasing and Talking about Numbers—It’s Not a Game
Jill Weissberg-Benchell, PhD, CDE
3:15 p.m.-3:35 p.m. Working with Couples and Diabetes—I’m Not a Child and You’re Not My Parent
Paula M. Trief, PhD
3:35 p.m.-3:45 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Role of Exercise in Regulating Mitochondrial Dynamics
Room: W315
Chair: Andrea L. Hevener, PhD
1:45 p.m.-2:15 p.m. Overview—Metabolic Regulation of Mitochondrial Dynamics
David C. Chan, MD, PhD
2:15 p.m.-2:45 p.m. Exercise and Mitochondrial Turnover
David A. Hood, PhD
2:45 p.m.-3:15 p.m. Mitofusin 2 as a Driver of Energy Metabolism and Insulin Signaling
Antonio Zorzano, PhD
3:15 p.m.-3:45 p.m. Regulation of Skeletal Muscle Mitochondrial Remodeling in Type 2 Diabetes
John P. Kirwan, PhD
1:45 p.m.-3:45 p.m.  
(continued)

**Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
National Implementation and Dissemination of Research to Improve Patient Safety and Reduce Hypoglycemia  
Room: W203  
Chair: Clydette Powell, MD, MPH, FAAP

1:45 p.m.-2:05 p.m.  
**Introduction—Federal Role in Patient Safety and Hypoglycemia**  
Christine S. Lee, PharmD, PhD

2:05 p.m.-2:25 p.m.  
**National Population Health Management of Hypoglycemia**  
Damian Everhart, RN, PhD

2:25 p.m.-2:45 p.m.  
**Implementing the Risk Prediction Algorithm for Hypoglycemia into Routine Clinical Practice**  
Nilay D. Shah, PhD

2:45 p.m.-3:05 p.m.  
**Development of an Outcome-Based Hypoglycemia Performance Measure to Optimize Patient Health**  
Matthew Pickering, PharmD

3:05 p.m.-3:25 p.m.  
**Implementing the National Action Plan in the Transforming Clinical Practice Initiative**  
M. Carol Greenlee, MD, FACE, FACP

3:25 p.m.-3:45 p.m.  
**Question and Discussion Period**

---

**Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
The Diabetes Do-It-Yourself (DIY) Revolution  
Room: W415C (Valencia Ballroom)  
Co-Chairs: William C. Hsu, MD and Joshua D. Miller, MD, MPH

1:45 p.m.-2:15 p.m.  
**The Diabetes DIY Technology Revolution—How Patients Are Changing the Innovation Pipeline and Care**  
Jason B. Wittmer, MD, FCCP

2:15 p.m.-2:45 p.m.  
**Supporting and Communicating with Patients about DIY Diabetes—The Clinician's Role**  
Lorenzo Sandini, MD

2:45 p.m.-3:15 p.m.  
**The Data behind DIY Diabetes—Opportunities for Collaboration and Ongoing Research**  
Dana M. Lewis, BA

3:15 p.m.-3:45 p.m.  
**The Front Lines of DIY Diabetes—State of the State and Closing the Loop**  
Joyce M. Lee, MD, MPH

---

**Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
Exploring the Next Frontier in Diabetes Pharmacology  
Room: W307  
Co-Chairs: Joni Beck, PharmD, BC-ADM, CDE and Ildiko Lingvay, MD, MPH, MSCS

1:45 p.m.-2:15 p.m.  
**Stretching It Out—Very-Long-Acting Agents and Implantable Technologies for Drug Delivery in Diabetes**  
Carlos A. Alvarez, PharmD, MSc, MSCS, BCPS

2:15 p.m.-2:45 p.m.  
**Peptides Gone “Oral” or Other Delivery Routes (Transnasal, Transdermal, Inhaled, etc.) for Glucose-Lowering Agents**  
Hugh Smyth, PhD

2:45 p.m.-3:15 p.m.  
**“Smart” (Glucose-Sensing) Insulins—Nanotechnology and Other Approaches**  
Arturo J. Vegas, PhD

3:15 p.m.-3:45 p.m.  
**The Dual/Triple Peptides—Premise, Technologies, and Clinical Promise**  
Richard DiMarchi, PhD
1:45 p.m.-3:45 p.m. (continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics

Lessons Learned from the Environmental Determinants of Diabetes in the Young (TEDDY) Study—Insights into Early Autoimmune Type 1 Diabetes
Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust
Room: W415B (Valencia Ballroom)
Chair: Marian Rewers, MD, PhD
1:45 p.m.-2:05 p.m. The First-Appearing Islet Autoantibodies—Genetics and Prospects of Different Etiologies
Jeffrey Krischer, PhD
2:05 p.m.-2:25 p.m. Maternal Dietary Supplement Use and the Development of Islet Autoimmunity in the Offspring
Jill M. Norris, PhD
2:25 p.m.-2:45 p.m. Gestational Infections and the Trigger of Islet Autoimmunity
Kristian F. Lynch, PhD
2:45 p.m.-3:05 p.m. Association between Gastrointestinal Infections and Onset of Islet Autoimmunity in the TEDDY Study
Maria Lönnrot, MD, PhD
3:05 p.m.-3:25 p.m. Family History of Diabetes and Other Autoimmune Diseases—Effect on Development of Islet Autoimmunity and Type 1 Diabetes in TEDDY Children
Riitta Veijola, MD, PhD
3:25 p.m.-3:45 p.m. My Child Is Islet Autoantibody Positive—Impact on Parent Understanding of Their Child’s Diabetes Risk
Suzanne Bennett Johnson, PhD

Case Studies
Theme Area: Epidemiology/Genetics

Monogenic Diabetes Testing Is Ready for Prime Time—Integrating Genetics into Your Practice
Room: W304E-H
Chair: Rochelle N. Naylor, MD
1:45 p.m.-2:15 p.m. Recognizing and Diagnosing Monogenic Diabetes
Louis H. Philipson, MD, PhD
2:15 p.m.-2:45 p.m. Genetic Testing for Monogenic Diabetes—Whom to Test, What and How to Order?
Miriam Udler, MD, PhD
2:45 p.m.-3:15 p.m. Genetic Testing for Monogenic Diabetes—What Do the Results Mean, What Do I Do Next?
Liana K. Billings, MD, MMSc
3:15 p.m.-3:45 p.m. Genetic Testing for Monogenic Diabetes—How Does It Impact the Patient?
Susie Perkowitz

Symposium
Theme Area: Insulin Action/Molecular Metabolism

The Intestine in the Regulation of Metabolism, Immunity, and Insulin Sensitivity
Room: W209
Chair: George A. Kyriazis, PhD
1:45 p.m.-2:15 p.m. The Intestine, the Gut Microbiome, and Insulin Sensitivity
Frank J. Gonzalez, PhD
2:15 p.m.-2:45 p.m. The Role of the Gut in Regulating Whole-Body Metabolism—Insights from Bariatric Surgery
Darleen A. Sandoval, PhD
2:45 p.m.-3:15 p.m. Enteroendocrine Functions of the Intestine
Daniel J. Drucker, MD
3:15 p.m.-3:45 p.m. Fishing for Regulators—Live Imaging of Intestinal Lipid Flux through Lipoproteins and Lipid Droplets Using the Zebrafish
Steven A. Farber, PhD
1:45 p.m.-3:45 p.m.
(continued)

**Symposium**  
*Theme Area: Integrated Physiology/Obesity*

**Steering the Right Course for Diabetes Management—Clinical Perspectives**  
*Room: W311*  
*Co-Chairs: Linong Ji, MD and Eugene Wright, Jr., MD*

1:45 p.m.-2:10 p.m.  
**What’s Next after Metformin Is the Wrong Question—Type 2 Diabetes Remission as a New Treatment Paradigm**  
Hertzel C. Gerstein, MD, MSc, FRCPC

2:10 p.m.-2:35 p.m.  
**What Is the Best Diet? Building a Portfolio of Nutritional Recommendations Based on Current Evidence**  
Donald D. Hensrud, MD, MPH

2:35 p.m.-3:00 p.m.  
**What Is the Best Activity/Exercise? Recommendations for Healthy Living**  
Sheri R. Colberg, PhD, FACSM

3:00 p.m.-3:25 p.m.  
**Do We Know Enough? Why We Need More Rigorous Prospective Randomized Studies**  
David M. Nathan, MD

3:25 p.m.-3:45 p.m.  
**Question and Discussion Period**

**Symposium**  
*Theme Area: Islet Biology/Insulin Secretion*

**Beta-Cell Dedifferentiation—True or False?**  
*Room: W312*  
*Co-Chairs: Guy A. Rutter, PhD and Lori Sussel, PhD*

1:45 p.m.-2:15 p.m.  
**Why Do Beta Cells in Type 2 Diabetes Survive So Long?**  
Peter C. Butler, MD

2:15 p.m.-2:45 p.m.  
**Beta-Cell Dedifferentiation—One-Way or Round Trip?**  
Piero Marchetti, MD, PhD

2:45 p.m.-3:15 p.m.  
**Fragile Beta-Cell Identity—From Metabolic Stress to Loss of Beta-Cell Transcription Factors**  
Avital Swisa, PhD

3:15 p.m.-3:45 p.m.  
**Beta-Cell Stress and Dedifferentiation—Moving Beyond Semantics**  
Mark A. Magnuson, MD
Oral Presentations
1:45 p.m.-3:45 p.m.
(continued)

Theme Area: Acute and Chronic Complications

What Is New in Diabetic Kidney Disease? (With State-of-the-Art Lecture and ADA Presidents’ Select Abstract)
Room: W304A-D
Chair: Subramaniam Pennathur, MD

1:45 p.m.-2:15 p.m.
State-of-the-Art Lecture
The NIDDK’s Kidney Precision Medicine Project—What It Means for Diabetic Kidney Disease
Robert A. Star, MD

2:15 p.m.-2:30 p.m.
88-OR ADA Presidents’ Select Abstract: Proteomic Profile of Circulating Inflammatory Proteins Associated with 10-Year Risk of ESRD in T1 and T2 Diabetes—Enrichment for TNF Receptor Superfamily Members
MONIKA NIEWCZAS, JAN K. SKUPIEN, VIJI NAIR, ADAM SMILES, JIHWAN PARK, EIICHIRO SATEKE, CHRISTOPHER A. SIMEONE, JOHN TSAY, WENJUN JU, MATTHIAS KRETZLER, KATALIN SUSZTAK, ANDRZEJ KROLEWSKI, Boston, MA, Kraków, Poland, Ann Arbor, MI, Philadelphia, PA, Princeton, NJ

2:30 p.m.-2:45 p.m.
89-OR Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
KENGO KIDOKORO, YUJI SOGAWA, DAVID CHERNEY, VATHANY KULASINGAM, HAJIME NAGASU, MINORU SATOH, TAMAKI SASAKI, NAOKI KASHIHARA, Kurashiki, Japan, Okayama, Japan, Toronto, ON, Canada

2:45 p.m.-3:00 p.m.
90-OR Luseogliflozin Inhibits HIF-1α Expression in Renal Proximal Tubular Epithelial Cells
RYOICHI BESSHO, YUMI TAKIYAMA, TSUGUHITO OTA, Asahikawa, Japan

3:00 p.m.-3:15 p.m.
91-OR Activation of PKM2 Protects against Diabetic Kidney Disease from Mice to Men
DANIEL GORDIN, TAKANORI SHINJO, RONALD ST-LOUIS, WEIER QI, LIANE J. TINSLEY, DAVID M. POBER, MEGAN J. BRISSETT, MONIKA NIEWCZAS, JONATHAN DREYFUSS, HUI PAN, THORSTEN SADOWSKI, AIMO KANNT, HETAL SHAH, HILLARY A. KEENAN, ANDRZEJ KROLEWSKI, GEORGE L. KING, Boston, MA, Frankfurt, Germany

3:15 p.m.-3:30 p.m.
92-OR Short-Chain Fatty Acids Prevent Diabetic Nephropathy In Vivo and In Vitro
WEI HUANG, YONG XU, YOUHUA XU, LUPING ZHOU, CHENLIN GAO, Luzhou, China, Macau, Macao

3:30 p.m.-3:45 p.m.
93-OR Serum Galectin-3 and All-Cause Mortality in Type 2 Diabetes
KATHRYN C.B. TAN, SAMMY SHIU, JOANNE K.Y. LAM, ALAN C. LEE, YING WONG, Hong Kong, China
Oral Presentations
1:45 p.m.-3:45 p.m.
(continued)

Theme Area: Immunology/Transplantation

New Insights into the Immunology of Human Type 1 Diabetes
Room: W206
Chair: Peter Gottlieb, MD

1:45 p.m.-2:00 p.m.
94-OR  Metabolic Markers Associated with Increased Risk for Progression from Single to Multiple Autoantibodies in Type 1 Diabetes Relatives
EMANUELE BOSI, SUSAN GEYER, JAY SOSENKO, DOROTHY J. BECKER, MANUELA BATOLLUA, HEBA M. ISMAIL, MARK A. ATKINSON, LOUIS H. PHILIPSON, JERRY P. PALMER, CARMELLA EVANS-MOLINA, Milan, Italy, Tampa, FL, Miami, FL, Pittsburgh, PA, Gainesville, FL, Chicago, IL, Seattle, WA, Indianapolis, IN

2:00 p.m.-2:15 p.m.
95-OR  Identification of Cross Reactive Insulin Immunogenic Epitopes from Commensal Gut Microbes
EMRAH ALTINDIS, ANTHONY N. VOMUND, I-TING CHOW, MARCOS DAMASIO, WILLIAM KWOK, EMIL R. UNANUE, C. RONALD KAHN, Boston, MA, St. Louis, MO, Seattle, WA

2:15 p.m.-2:30 p.m.
96-OR  Costimulatory Molecules CD226 and TIGIT Impact CD8+ T-Cell Activity and Function during Type 1 Diabetes
WEN-I YEH, HOWARD SEAY, CLAYTON E. MATHEWS, TODD M. BRUSKO, Gainesville, FL

2:30 p.m.-2:45 p.m.
97-OR  Decrease in Proportion of CD24hiCD38hi Beta Cells and Impairment of Their Regulatory Capacity in Type 1 Diabetes Patients
YUESHU WANG, XING WANG, YAO QIN, MEI ZHANG, Nanjing, China

2:45 p.m.-3:00 p.m.
98-OR  Characterization of T Cells Reactive to Hybrid Insulin Peptides in the Peripheral Blood of Type 1 Diabetes Patients
ROCKY L. BAKER, THOMAS DELONG, PETER GOTTLIEB, KATHRYN M. HASKINS, Denver, CO, Aurora, CO

3:00 p.m.-3:15 p.m.
99-OR  Supramolecular Biomaterials as a Biomimetic Platform for Investigating Immunopathological Processes of Human Type 1 Diabetes
MATTHEW BECKER, DILLON SEROSKI, SCOTT STIMPSON, CLAYTON E. MATHEWS, GREG HUDALLA, EDWARD A. PHELPS, Gainesville, FL

3:15 p.m.-3:30 p.m.
100-OR  Distinct Phenotypes of Islet Antigen-Specific CD4+ T Cells among the Three Subtypes of Type 1 Diabetes
DAISUKE CHUJO, AKITSU KAWABE, NOBUYUKI TAKAHASHI, MAYA MATSUSHITA, CHIHARU TSUTSUMI, FUMITAKA HASEDA, AKIHISA IMAGAWA, TOSHIKI HANAFUSA, KUNIMASA YAGI, MASAYUKI SHIMODA, KOHJIRO UEKI, HIROSHI KAJIO, Tokyo, Japan, Takatsuki, Japan, Sakai, Japan, Toyama, Japan

3:30 p.m.-3:45 p.m.
101-OR  Low-Dose IL-2 Signaling Is Specifically Impaired in Regulatory T Cells from T1D Patients
BARBARA PRIETL, SELINA KOFLER, STEFANIE STANZER, BARBARA M. OBERMAYER-PIETSCH, THOMAS R. PIEBER, HARALD SOURIJ, Graz, Austria
Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Nutrition and the Gut Microbiome
Room: W414
Chair: Jill M. Norris, PhD
4:00 p.m.-4:40 p.m. State-of-the-Art Lecture—Nutrition and the Gut Microbiome
Nadim J. Ajami, PhD
4:40 p.m.-5:20 p.m. Gut Microbiome in Relation to Autoimmunity and Type 1 Diabetes
Tommi Vatanen, PhD
5:20 p.m.-6:00 p.m. Impact of the Gut Microbiome on Energy Regulation, Weight Management, and Eating Disorders
Ian Carroll, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Online and Mobile Support—Wading through the Noise
Room: W304A-D
Chair: David T. Ahn, MD
4:00 p.m.-4:30 p.m. Can Diabetes Apps Make Our Lives Easier?
Adam Brown, BS
4:30 p.m.-5:00 p.m. Evaluating Mobile Apps for Disease Self-Management
David Fedele, PhD
5:00 p.m.-5:30 p.m. Building Cybersecurity into Connected Diabetes Devices
David C. Klonoff, MD
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Joint ADA/ISPAD Symposium—25 Years after the Announcement of the DCCT Results—What Is the Status of Type 1 Diabetes in Youth, and How Can We Do Better?
Room: W311
Co-Chairs: Kim C. Donaghue, MBBS, PhD and Ingrid M. Libman, MD, PhD
4:00 p.m.-4:30 p.m. State of Pediatric Type 1 Diabetes Mellitus in the United States
Joseph Wolfsdorf, MB, BCh
4:30 p.m.-5:00 p.m. State of Pediatric Type 1 Diabetes Mellitus in the World
Sabine E. Hofer, MD, PhD
5:00 p.m.-5:30 p.m. What Can We Do Differently? The European Experience
Knut Dahl-Jørgensen, MD, PhD
5:30 p.m.-6:00 p.m. Where Do We Go from Here? Lessons Learned after 25 Years of the DCCT
Rose Gubitosi-Klug, MD, PhD
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Joint ADA/Chinese Diabetes Society Symposium—Glucose and Lipid Metabolism—Novel Mechanisms and Targets
Room: W203
Co-Chairs: Weiping Jia, MD, PhD and Ling Qi, PhD
4:00 p.m.-6:00 p.m.
4:00 p.m.-4:20 p.m.  cGAS Pathway Activation in Obesity-Induced Metabolic Dysfunction
   Feng Liu, MD, PhD
4:20 p.m.-4:40 p.m.  Mitochondrial Dynamics and Hepatic Metabolism
   Chih-Hao Lee, PhD
4:40 p.m.-5:00 p.m.  The Role of SGLT2 in Diabetes-Associated Hypertension
   Zhiming Zhu, MD
5:00 p.m.-5:20 p.m.  The Role of Ubiquitination Regulation in Insulin Resistance
   Xiaoying Li, MD, PhD
5:20 p.m.-5:40 p.m.  Ameliorating Diabetic Nephropathy by Transcriptional Suppression of TGFβ1
   Junli Liu, PhD
5:40 p.m.-6:00 p.m.  Question and Discussion Period

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Mitochondrial Dynamics, Metabolism, and Insulin Action
Room: W209
Chair: Michael J. Jurczak, PhD
4:00 p.m.-4:30 p.m.  Transcriptional Control of Mitochondrial Biogenesis and Function
   Anastasia Kralli, PhD
4:30 p.m.-5:00 p.m.  Role of Mitochondrial Dynamics in Neuronal Energy Sensing
   Sabrina Diano, PhD
5:00 p.m.-5:30 p.m.  Fanning the Flames—Mitochondrial Flux in Diabetes and Fatty Liver Disease
   Shawn C. Burgess, PhD
5:30 p.m.-6:00 p.m.  Phospholipid Turnover and Mitochondrial Metabolism in Skeletal Muscle
   Katsu Funai, PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Neurotransmitters in the Islet
Room: W312
Chair: Alejandro Caicedo, PhD
4:00 p.m.-4:30 p.m.  GABA Signaling in the Context of Beta-Cell Neogenesis
   Patrick Collombat, PhD
4:30 p.m.-5:00 p.m.  Glutamate Action (Serotonin, Dopamine)
   Siegfried Ussar, PhD
5:00 p.m.-5:30 p.m.  GABA Synthesis in the Islet
   Edward Phelps, PhD
5:30 p.m.-6:00 p.m.  Glutamate in the Beta Cell, from Metabolism to Signaling
   Pierre Maechler, PhD
### Oral Presentations

**Theme Area: Acute and Chronic Complications**

#### Hypoglycemia—Reducing the Risk

<table>
<thead>
<tr>
<th>Room: W208</th>
<th>Chair: Kamlesh Khunti, MD, PhD, FRCGP, FRCP, FMedSci</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>4:00 p.m.-4:15 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>102-OR</strong> Low Doses of Dasiglucagon Consistently Increase Plasma Glucose (PG) Levels in Hypoglycemia and Euglycemia in People with Type 1 Diabetes Mellitus (T1DM)</td>
<td></td>
</tr>
<tr>
<td>ULRIKE HOVELMANN, MINNA BRAENDHOLT OLSEN, ULRIK MOURITZEN, DANIELA LAMERS, BIRGIT KRONSHAGE, TIM HEISE, Neuss, Germany, Glostrup, Denmark</td>
<td></td>
</tr>
<tr>
<td><strong>4:15 p.m.-4:30 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>103-OR</strong> Glycemic Management as the Primary Determinant of One-Year Mortality after CABG</td>
<td></td>
</tr>
<tr>
<td>LUCAS HELLER, MARGARET ZUPA, PETER L. PERREIAH, R. HARSHA RAO, Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td><strong>4:30 p.m.-4:45 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>104-OR</strong> Metoclopramide Restores the Sympathoadrenal Response to Hypoglycemia in a Novel Model of HAAF</td>
<td></td>
</tr>
<tr>
<td>ADRIANA VIEIRA DE ABREU, RAHUL AGRAWAL, PARKER HOWE, SIMON J. FISHER, Salt Lake City, UT</td>
<td></td>
</tr>
<tr>
<td><strong>5:00 p.m.-5:15 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>105-OR</strong> Prediction of Nonsevere Hypoglycemia—The Influence of Glycemic Variability in the HypoAna Study</td>
<td></td>
</tr>
<tr>
<td>RIKKE M. AGESSEN, PETER L. KRISTENSEN, SR., HENNING BECK-NIELSEN, SR., KIRSTEN NØRGAARD, TONNY JENSEN, SR., BIRGER THORSTEINSSON, SR., LISE TARNOW, ULRIK PEDERSEN-BJERGAARD, Hillerød, Denmark, Odense, Denmark, Copenhagen, Denmark</td>
<td></td>
</tr>
<tr>
<td><strong>5:15 p.m.-5:30 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>106-OR</strong> Prevalence of Impaired Awareness of Hypoglycemia and Severe Hypoglycemia among People with Type 2 Diabetes Treated with Insulin—The Dutch Diabetes Pearl Cohort</td>
<td></td>
</tr>
<tr>
<td>LIAN VAN MEIJEL, FEMMIE DE VEGT, CORNELIS TACK, EVERTINE J. ABBINK, FEMKE RUTTERS, JACQUELINE M. DEKKER, BRUCE H. WOLFFENBUTTEL, FRITS HOLLEMAN, J. HANS DEVRIES, NATHALIE MASUREL, HANNO PIJL, BEHIYE OZCAN, BIANCA SILVIUS, BASTIAAN E. DE GALAN, Nijmegen, Netherlands, Amsterdam, Netherlands, Groningen, Netherlands, Leiden, Netherlands, Rotterdam, Netherlands, Utrecht, Netherlands</td>
<td></td>
</tr>
<tr>
<td><strong>5:30 p.m.-5:45 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>107-OR</strong> Insulin Degludec Has Lower Hypoglycemia Risk than Insulin Glargine U100 in Older People with Type 2 Diabetes (T2D)</td>
<td></td>
</tr>
<tr>
<td>SIMON R. HELLER, J. HANS DEVRIES, CAROL H. WYSHAM, CHARLOTTE T. HANSEN, MELISSA V. HANSEN, BRIAN M. FRIER, Sheffield, United Kingdom, Amsterdam, Netherlands, Spokane, WA, Søborg, Denmark, Edinburgh, United Kingdom</td>
<td></td>
</tr>
<tr>
<td><strong>5:45 p.m.-6:00 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>108-OR</strong> Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (&gt;85 Years) with Type 2 Diabetes (T2D)—Observations from DEVOTE</td>
<td></td>
</tr>
<tr>
<td>RICHARD E. PRATLEY, SCOTT S. EMERSON, EDWARD FRANEK, MATTHEW P. GILBERT, STEVEN P. MARSO, DARREN K. MCGUIRE, THOMAS R. PIEBER, NEIL R. POULTER, CHARLOTTE T. HANSEN, MELISSA V. HANSEN, THOMAS MARK, ALAN C. MOSES, BERNARD ZINMAN, ON BEHALF OF THE DEVOTE STUDY GROUP, Orlando, FL, Seattle, WA, Warsaw, Poland, South Burlington, VT, Kansas City, MO, Dallas, TX, Graz, Austria, London, United Kingdom, Søborg, Denmark, Plainsboro, NJ, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td><strong>5:45 p.m.-6:00 p.m.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>109-OR</strong> Effect of Combination Therapy with Liraglutide plus Canagliflozin on HGP and HbA1c vs. Each Therapy Alone in T2DM</td>
<td></td>
</tr>
<tr>
<td>MUHAMMAD ABDUL-GHANI, ALI M. ALI, ROBERT A. MARTINEZ, JOHN M. ADAMS II, EUGENIO CERSOSIMO, CURTIS L. TRIPLITT, RALPH A. DERFONZO, San Antonio, TX</td>
<td></td>
</tr>
</tbody>
</table>
Oral Presentations
4:00 p.m.-6:00 p.m.
(continued)

Theme Area: Acute and Chronic Complications
Research Advances in the Diabetic Foot (With Roger Pecoraro Award Lecture)
Room: W204
Chair: Lawrence A. Lavery, DPM

4:00 p.m.-4:30 p.m.
Roger Pecoraro Award Lecture
The Ghosts of Diabetic Foot Infection—Past, Present, and Yet to Come
Edgar J.G. Peters, MD, PhD

4:30 p.m.-4:45 p.m.
110-OR Are We Misdiagnosing Diabetic Foot Osteomyelitis?
PETER A. CRISOLOGO, JAVIER LA FONTAINE, KATHRYN DAVIS, LAWRENCE A. LAVERY, Dallas, TX

4:45 p.m.-5:00 p.m.
111-OR Outcomes of Split Thickness Skin Grafting on Lower Extremity Wounds in Diabetics
ELLiot WALTERS, GREG STIMAC, NEHA RAJPAL, IRAM NAZ, TAMMER ELMARSAFI, JOHN STEINBERG, KAREN EVANS, CHRISTOPHER ATTINGER, PAUL KIM, Washington, DC

5:00 p.m.-5:15 p.m.
112-OR Bedside Blind Bone Biopsy (B4) for Suspected Diabetic Foot Osteitis—A Reliable Tool to Manage Medical Treatment?
FLORINE FÉRON, DIANE-CÉCILE GAUTHIER, JEAN-FRANÇOIS GAUTIER, JEAN-PHILIPPE KEVORKIAN, Paris, France

5:15 p.m.-5:30 p.m.
113-OR Risk of Foot Ulcer and Lower Extremity Amputation among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC)
EDWARD J. BOYKO, LEILA ZELNICK, BARBARA BRAFFETT, RODICA POP-BUSUI, CATHERINE C. COWIE, GAYLE M. LORENZI, ROSE GUBITOSI-KLUG, BERNARD ZINMAN, IAN DE BOER, Seattle, WA, Rockville, MD, Ann Arbor, MI, Bethesda, MD, La Jolla, CA, Cleveland, OH, Toronto, ON, Canada

5:30 p.m.-5:45 p.m.
114-OR Accuracy of Daily Foot Temperature Monitoring for Patients with Recently Healed Diabetic Foot Ulcers or History of Amputation
IAN L. GORDON, AKSONE NOUVONG, BIJAN NAJAFI, GARY M. ROTHENBERG, BRIAN PETERSEN, JONATHAN D. BLOOM, ROBERT FRYKBERG, Long Beach, CA, Sylmar, CA, Houston, TX, Ann Arbor, MI, Somerville, MA, Phoenix, AZ

5:45 p.m.-6:00 p.m.
115-OR Increased Rates of Readmission, Reoperation, and Mortality following Open Reduction and Internal Fixation of Ankle Fractures Are Associated with Diabetes Mellitus
JENNIFER LIU, JUNHO AHN, KATHERINE M. RASPOVIC, DANE WUKICH III, Dallas, TX
Oral Presentations
4:00 p.m.-6:00 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics

It’s Not Too Late, Baby—Outcomes in Gestational Diabetes Mellitus (With Norbert Freinkel Award Lecture)
Room: W307
Co-Chairs: Peter Damm, DMSc and Monique Hederson, PhD

4:00 p.m.-4:30 p.m.

Norbert Freinkel Award Lecture

Metabolic Culprits in Obese Pregnancies and Gestational Diabetes—
Big Babies, Big Twists, Big Picture
Linda (Lynn) A. Barbour, MD, MSPH, FACP

4:30 p.m.-4:45 p.m.

116-OR Gestational Diabetes (GDM) and Childhood Disorders of Glucose Metabolism—Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study (HAPO FUS)
WENDY BRICKMAN, PATRICK CATALANAL, PETER E. CLAYTON, CHAIHARN DEERCHANAWONG, JILL HAMILTON, PAULA M. LASHLEY, JEAN M. LAWRENCE, YAEL LEBENTHAL, DAVID R. MCCANCE, WING H. TAM, ALAN KUANG, LYNN P. LOWE, BOYD E. METZGER, DENISE SCHOLTENS, WILLIAM LOWE, JR., HAPO FOLLOW-UP STUDY COOPERATIVE RESEARCH GROUP, Chicago, IL, Cleveland, OH, Manchester, United Kingdom, Bangkok, Thailand, Toronto, ON, Canada, Saint George, Barbados, Pasadena, CA, Tel Aviv, Israel, Belfast, United Kingdom, Hong Kong, China

4:45 p.m.-5:00 p.m.

117-OR Maternal Type 1 Diabetes and Risk of Autism in Offspring
ANNY XIANG, XINHUI WANG, MAYRA P. MARTINEZ, KATHLEEN A. PAGE, THOMAS A. BUCHANAN, Pasadena, CA, Los Angeles, CA

5:00 p.m.-5:15 p.m.

118-OR Pregnancy Glycemia Reflects Life Course Glycemia of the Mother
NILAM S. MEMANE, DATTATRAY BHAT, DEEPA A. RAUT, SOMNATH J. BONDARDE, RASIA LADKAT, PALLAVI C. YAJNIK, CAROLINE FALL, CHITTARANJAN S. YAJNIK, Pune, India, Southampton, United Kingdom

5:15 p.m.-5:30 p.m.

119-OR Changing Glucose Tolerance during Pregnancy—Implications for Diagnosis of Gestational Diabetes Mellitus (GDM)
WILLIAM C. KNOWLER, KIMBERLY DREWS, LEANNE REDMAN, KAUMUDI J. JOSHI, S. SONIA ARTEAGA, XAVIER PI-SUNYER, LINDA VAN HORN, RENA R. WING, SAMUEL KLEIN, LIFE-MOMS RESEARCH GROUP, Phoenix, AZ, Rockville, MD, Baton Rouge, LA, San Juan, PR, Bethesda, MD, New York, NY, Chicago, IL, Providence, RI, St. Louis, MO

5:30 p.m.-5:45 p.m.

120-OR Placental DNA Methylation of miR-548 and WWTR1 Genes Influence Insulin Sensitivity during Pregnancy
MARIE-FRANCE HIVERT, CATHERINE M. BRIGGS, ANDRES CARDENAS, PATRICE PERRON, LUIGI BOUCHARD, Boston, MA, Brookline, MA, Sherbrooke, QC, Canada

5:45 p.m.-6:00 p.m.

TAO ZHOU, DIANJIANI SUN, XIANG LI, YORIKO HEIANZA, HOIRUN NISA, GANG HU, XIAOFANG PEI, XIAOYUN SHANG, LU QI, New Orleans, LA, Baton Rouge, LA, Chengdu, China, Marrero, LA

ADA-Supported Research
Oral Presentations
4:00 p.m.–6:00 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Updates from Type 2 Diabetes Trials
Room: W415B (Valencia Ballroom)
Chair: Tricia Santos Cavaioia, MD

4:00 p.m.–4:15 p.m.
122-OR
Efficacy of Semaglutide vs. Dulaglutide across Baseline HbA₁c in SUSTAIN 7
RICHARD E. PRATLEY, JUAN P. FRIAS, HARISH KUMAR, JOHN PÉTRIE, ANDREA NAVARRIA, MORTEN ABILD-LUND NIELSEN, WOLFGANG E. SCHMIDT, Orlando, FL, Los Angeles, CA, Kochi, India, Glasgow, United Kingdom, Søborg, Denmark, Aalborg, Denmark, Bochum, Germany

4:15 p.m.–4:30 p.m.
123-OR
Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study
MUHAMMAD ABDUL-GHANI, CURTISS L. PUCKETT, JR., CURTIS L. TRIPLITT, DAVID MAGGS, JOHN M. ADAMS II, EUGENIO CERSOSIMO, RALPH A. DEFRONZO, San Antonio, TX, Lexington, MA

4:30 p.m.–4:45 p.m.
124-OR
Comparing Treatment Strategies for Patients with Very Elevated HbA1c—A Randomized Trial
MARCONI ABREU, ANNA TUMYAN, AHMED ELHASSAN, OLIVIA PAPACOSTEA, KATHERINE PEICHER, PERIHAN DIMACKIE, MUHAMMAD S. SIDIQIUI, BEVERLEY ADAMS-HUET, XILON LI, LAURENTIU POP, ILDIKO LINGVAY, Dallas, TX, Redlands, CA, Oklahoma City, OK, McKinney, TX

4:45 p.m.–5:00 p.m.
125-OR
Remission of Type 2 Diabetes in 12% (16 of 133) Hypogonadal Men Receiving Long-Term Testosterone Therapy in a Real-Life Registry Study
AHMAD HAIDER, KARIM S. HAIDER, FARID SAAD, Bremerhaven, Germany, Berlin, Germany

5:00 p.m.–5:15 p.m.
126-OR
Efficacy and Safety of an Expanded Dulaglutide Dose Range—A Phase 2, Placebo-Controlled Trial in T2D Patients on Metformin
JUAN P. FRIAS, ALAN G. WYNNE, BEATA MATYJASZEK-MATUSZEK, DAGMAR BARTASKOVA, DAVID COX, BRAD WOODWARD, GRACE LI, ZVONKO MILICEVIC, Los Angeles, CA, Topeka, KS, Lublin, Poland, Prague, Czech Republic, Indianapolis, IN, Vienna, Austria

5:15 p.m.–5:30 p.m.
127-OR
Superior Efficacy of Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) as Add-On to Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) ± Oral Antidiabetic Drug (OAD) Therapy in Patients with Type 2 Diabetes (T2D)—DUAL IX Trial
ATHENA PHILIS-TSMIKAIS, LIANA BILLINGS, ROBERT S. BUSCH, CRISTOBAL MORALES PORTILLO, RAKESH SAHAY, NATALIE HALLADIN, RUTA GRÖNSKYTE JUHL, STEWART HARRIS, San Diego, CA, Evanston, IL, Albany, NY, Gelves, Spain, Hyderabad, India, Søborg, Denmark, London, ON, Canada

5:30 p.m.–5:45 p.m.
128-OR
Efficacy and Safety of Evolocumab in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia or Mixed Dyslipidemia
ROBERT S. ROSENSON, MARTHA L. DAVIGLUS, PETER REAVEN, PAOLO POZZILLI, HAROLD BAYS, MARIA LAURA MONSALVO, MARY ELLIOTT, RANSI SOMARATNE, YEHUDA HANDELSMAN, New York, NY, Chicago, IL, Phoenix, AZ, Rome, Italy, Louisville, KY, Thousand Oaks, CA, Cambridge, United Kingdom, Tarzana, CA

5:45 p.m.–6:00 p.m.
129-OR
More Subjects Achieved Composite Reductions of ≥1% HbA₁c, ≥5% Body Weight, and ≥5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)
KATHLEEN M. DUNGAN, VANITA ARODA, FILIP K. KNOP, LAWRENCE A. LEITER, NANNA L. LAUSVIG, SØREN LINDBERG, JURIS J. MEIER, Columbus, OH, Hyattsville, MD, Hellenburg, Denmark, Toronto, ON, Canada, Søborg, Denmark, Bochum, Germany
**Theme Area: Epidemiology/Genetics**

**The Impact of Diabetes Interventions and Behaviors on Outcomes**

Room: W304E-H  
Chair: Rene Rodriguez-Gutierrez, MD

- **4:00 p.m.-4:15 p.m.**  
  **130-OR**  
  Lifestyle Interventions Lower Cardiovascular Disease in Chinese Adults with IGT—Thirty-Year Follow-Up of Da Qing Diabetes Prevention Study  
  QIUHONG GONG, PING ZHANG, JIXIANG MA, JINPING WANG, YALI AN, YILING J. CHENG, BO ZHANG, HUI LI, YANYAN CHEN, YINGHUA HU, EDWARD W. GREGG, PETER H. BENNETT, GUANGWEI LI, Beijing, China, Atlanta, GA, Daqing, China, Phoenix, AZ

- **4:15 p.m.-4:30 p.m.**  
  **131-OR**  
  The Pros and Cons of Gastric Bypass Surgery in Obese Individuals with Type 2 Diabetes—Nationwide, Matched, Observational Cohort Study  
  VASILEIOS LIAKOPOULOS, ANN-MARIE SVENSSON, INGMAR NASLUND, BJORN ELIASSON, Gothenburg, Sweden, Orebro, Sweden

- **4:30 p.m.-4:45 p.m.**  
  **132-OR**  
  Cost and Cost-Effectiveness of a Faith-Based Lifestyle Intervention for Diabetes Prevention among African-Americans—A Within-Trial Analysis  
  ELIZABETH C. RHODES, EESHWAR CHANDrasekar, SHIVANI PATEL, K.M. VENKAT NARAYAN, THOMAS V. JOSHUA, LUCY MARION, LOVORIA B. WILLIAMS, MOHAMMED K. ALI, Atlanta, GA, Augusta, GA

- **4:45 p.m.-5:00 p.m.**  
  **133-OR**  
  Long-Acting Insulin Analogues and Risk of Breast Cancer—Meta-analysis  
  MARIA BOTA, PHILIPPE AUTIER, PETER BOYLE, Écully, France, Lyon, France

- **5:00 p.m.-5:15 p.m.**  
  **134-OR**  
  Association of Intensive Lifestyle Intervention and Metformin with Frailty in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS)  
  HELEN P. HAZUDA, QING PAN, JILL P. CRANDALL, HERMES FLOREZ, JOSE A. LUCHSINGER, ELIZABETH M. VENDITTI, ANDREA KRISKA, SHERITA GOLDEN, GEORGE BRAY, DPP RESEARCH GROUP, San Antonio, TX, Washington, DC, Bronx, NY, Miami, FL, New York, NV, Pittsburgh, PA, Baltimore, MD, Baton Rouge, LA, Rockville, MD

- **5:15 p.m.-5:30 p.m.**  
  **135-OR**  
  Evaluation of Treatment Persistence in Individuals with Type 2 Diabetes in a Real-World Setting  
  WILLIAM T. CEFALU, TAMARA DARSOW, MATT PETERSEN, LIISA PALMER, ELLEN THIEL, LISA LATTS, Arlington, VA, Baltimore, MD, Ann Arbor, MI, Denver, CO

- **5:30 p.m.-5:45 p.m.**  
  **136-OR**  
  Gluten Intake and Risk of Islet Autoimmunity and Progression to Type 1 Diabetes in Children at Increased Risk of Disease  
  NICOLAI A. LUND-BLIX, FRAN DONG, KARL MARILD, ANNA E. BARON, JENNIFER A. SEIFERT, KATHLEEN WAUGH, GEIR JONER, KETIL STORDAL, GERMAN TAPIA, LARS C. STENE, RANDI K. JOHNSON, MARIAN REWERS, JILL NORRIS, Aurora, CO, Denver, CO, Oslo, Norway

- **5:45 p.m.-6:00 p.m.**  
  **137-OR**  
  Dietary Behaviors throughout Childhood Are Associated with Body Mass Index and Estimated Insulin Resistance in Adolescence—A Longitudinal Study  
  VERONIQUE GINGRAS, SHERYL RIFAS-SHIMAN, ELSIE M. TAVERAS, EMILY OKEN, MARIE-FRANCE HIVERT, Boston, MA
Oral Presentations
4:00 p.m.-6:00 p.m.
(continued)

Theme Area: Immunology/Transplantation
Clinical Progress in Islet Transplantation—Clinical Science
Room: W206
Co-Chairs: David Baidal, MD and Kirstie K. Danielson, PhD

4:00 p.m.-4:15 p.m.
138-OR Initial Clinical Evaluation of VC-01T™ Combination Product—A Stem Cell-Derived Islet Replacement for Type 1 Diabetes (T1D)
ROBERT R. HENRY, JEREMY PETTUS, JON WILENSKY, A.M. JAMES SHAPIRO, PETER A. SENIOR, BART ROEP, RICHARD WANG, EVERT J. KROON, MICHAEL SCOTT, KEVIN D’AMOUR, HOWARD L. FOYT, San Diego, CA, Edmonton, AB, Canada, Duarte, CA, North York, ON, Canada

4:15 p.m.-4:30 p.m.
139-OR Clinical Islet Transplantation Outcomes Are Comparable in Obese Type 1 Diabetes Recipients
ANNA LAM, KATHRYN J. POTTER, SHAREEN FORBES, SHARLEEN IMES, ANDREW J. MALCOLM, ANDREA HAQQ, A.M. JAMES SHAPIRO, PETER A. SENIOR, Edmonton, AB, Canada, Edinburgh, United Kingdom

4:30 p.m.-4:45 p.m.
140-OR Long-Term Function of Islet Allografts Transplanted on the Omentum Using a Biological Scaffold
DAVID BAIDAL, CAMILLO RICORDI, DORA M. BERMAN, ANTONELLO PIEGGI, ANA M. ALVAREZ GIL, NATHALIA PADILLA, GAETANO CIANCIO, ELINA LINETSKY, RODOLFO ALEJANDRO, Miami, FL

4:45 p.m.-5:00 p.m.
141-OR Enhanced Recipient Cardiovascular Health Pretransplant Predicts Better Clinical Outcomes following Islet Cell Transplant for Type 1 Diabetes
KIRSTIE K. DANIELSON, REBECCA S. MONSON, YI LI, BRETT RYDZON, Chicago, IL

5:00 p.m.-5:15 p.m.
142-OR Persistence of Allosensitization after Islet Allograft Failure
PAOLA RIOS, DAVID BAIDAL, NATHALIA PADILLA, ANA M. ALVAREZ GIL, SRIGITA MADIRAJU, JONATHAN AMBUT, ALEJANDRO M. MANTERO, SHARI MESSINGER CAYETANO, CAMILLO RICORDI, RODOLFO ALEJANDRO, Miami, FL, Homestead, FL

5:15 p.m.-5:30 p.m.
143-OR CGM Shows Islet Transplantation Prevents Hypoglycemia, Correcting Time in Range and Reducing Glycemic Variability, Despite Subnormal Beta-Cell Function
SHAREEN FORBES, TOLU OLUTOYIN OLANEJU, ANNA LAM, JOHN CASEY, JOHN CAMPBELL, LAURA REID, RICHARD A. ORAM, ANDREW J. MALCOLM, A.M. JAMES SHAPIRO, PETER A. SENIOR, Edinburgh, United Kingdom, Edmonton, AB, Canada, Exeter, United Kingdom

ADA-Supported Research
Oral Presentations
4:00 p.m.-6:00 p.m.
(continued)

Theme Area: Integrated Physiology/Obesity

G is for GLP, GIP, and Glucagon—A NOD to the Gut-Liver Axis
Room: W308
Co-Chairs: Carolyn F. Deacon, PhD, DMSc and Carrie McCurdy, PhD

4:00 p.m.-4:15 p.m.
144-OR Extracellular Volume Expansion Uncovers a Natriuretic Action of Glucagon-Like Peptide-1
ALI ASMAR, PER K. CRAMON, LENE SIMONSEN, MEENA ASMAR, CHARLOTTE M. SORENSEN, STEN MADSBAD, SR., CEDRIC MORO, BOLETTE HARTMANN, JENS J. HOLST, BOYE L. JENSEN, JENS BÜLOW, Copenhagen, Denmark, Toulouse, France, Odense, Denmark

4:15 p.m.-4:30 p.m.
145-OR Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects
LÆRKE S. GASBJERG, MADS M. HELSTED, ALEXANDER H. SPARRE-ULRICH, AMALIE R. LANNING, SIGNE STENSEN, METTE HØY JAKOBSEN, BOLETTE HARTMANN, MIKKEL B. CHRISTENSEN, JENS J. HOLST, TINA VILSBØLL, METTE M. ROSENKILDE, FILIP K. KNØP, Copenhagen, Denmark, Hellerup, Denmark, Gentofte, Denmark

4:30 p.m.-4:45 p.m.
146-OR Mechanisms by Which Glucagon Acutely Stimulates Hepatic Mitochondrial Oxidation and Gluconeogenesis
RACHEL J. PERRY, YONGLIANG WANG, ALLISON L. BRILL, LIANG PENG, DONGYAN ZHANG, SYLVIE DUFOUR, YE ZHANG, XIAN-MAN ZHANG, YUICHI NOZAKI, GARY CLINE, BARBARA E. EHLRICH, KITT PETERSEN, GERALD I. SHULMAN, New Haven, CT, Beijing, China

4:45 p.m.-5:00 p.m.
147-OR Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis
MALTE P. SUPPLI, JONATAN I. BAGGER, ASGER B. LUND, NICOLAI J. WEWER ALBRECHTSEN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNØP, Hellerup, Denmark, Copenhagen, Denmark, Gentofte, Denmark

5:00 p.m.-5:15 p.m.
148-OR NOD1 Mediates Insulin Resistance in Response to Circulating Free Fatty Acids
SYDNEY L. RIVERS, LUCY SHU NG A YEUNG, KENNY L. CHAN, YUSAKU MORI, DANA PHILPOTT, AMIRA KLIP, ADRIA GIACCA, Toronto, ON, Canada

5:15 p.m.-5:30 p.m.
149-OR Targeting Ketohexokinase (KHK) with a Novel Antisense Oligonucleotide (ASO) Decreases De Novo Lipogenesis and Improves Insulin-Mediated Whole Body Glucose Metabolism
DONGQING LIU, JOHN A. STERPKA, DANIEL F. VATNER, MELANIE BELL, SUE MURRAY, SANJAY BHANOT, GARY CLINE, VARMAN SAMUEL, New Haven, CT, Carlsbad, CA, West Haven, CT

5:30 p.m.-5:45 p.m.
150-OR Early Effects of Sleeve Gastrectomy (SG) on Systemic and Organ-Specific Dietary Fatty Acid Uptake, Postprandial Free Fatty Acids (FFA), and Glucose Metabolism in Type 2 Diabetes (T2D)
ANNE-MARIE CARREAU, CHRISTOPHE NOLL, BRIGITTE GUERIN, LAURENT BERTHO, ERIC E. TURCOTTE, ANDRE TCHERNOF, ANDRÉ CARPENTIER, Sherbrooke, QC, Canada, Quebec City, QC, Canada

5:45 p.m.-6:00 p.m.
151-OR Ileum-Specific Transgenic Expression of Human Chimeric Intestinal Alkaline Phosphatase (IAP) Attenuates Western Diet (WD)-Induced Barrier Dysfunction and Glucose Intolerance
HONGLIANG HE, SIDDHARTHA S. GHOSH, PAUL J. YANNIE II, JING WANG, SHOBHA GHOSH, Richmond, VA

ADA-Supported Research
Oral Presentations
4:00 p.m.–6:00 p.m.
(continued)

Theme Area: Integrated Physiology/Obesity
Muscling In on the Heart of Metabolism and Insulin Sensitivity
Room: W315
Co-Chairs: Bret H. Goodpaster, PhD and Juleen R. Zierath, PhD

4:00 p.m.–4:15 p.m.
152-OR Activation of Cardiac Mitochondrial Akt Signaling Improved Diabetic Cardiomyopathy and Induced Liver Metabolic Remodeling
ALBERT TA, YU-HAN CHEN, YUMAY CHEN, HYE-JIN LEE, HUGO YOU-HSIEN LIN, PING H. WANG, Irvine, CA, Seoul, Republic of Korea

4:15 p.m.–4:30 p.m.
153-OR Caloric Restriction Increases the Resistance of Aged Heart to Myocardial Ischemia/Reperfusion Injury
ZHIJIA GUO, THOMAS ROUSSELLE, JI LI, Taiyuan, China, Jackson, MS

4:30 p.m.–4:45 p.m.
154-OR Effects of Hormone-Sensitive Lipase Overexpression on Lipotoxic Cardiomyopathy in Mice Lacking Adipose Triglyceride Lipase
MIKA YAMADA, JINYA SUZUKI, MASAMICHI HIROSE, TAKAHIRO NAKAYA, MAI ICHIKAWA, SATSUKI SATO, MICHIKO IMAGAWA, YASUO ZENIMARU, FREDRIC B. KRAEMER, TADASHI KONOSHITA, TAMOTSU ISHIZUKA, Fukui, Japan, Iwate, Japan, Stanford, CA

4:45 p.m.–5:00 p.m.
155-OR Mitochondrial Glycerol 3-Phosphate Dehydrogenase Improves Skeletal Muscle Regeneration in Obesity and Diabetes
HUA QU, YI ZHENG, Chongqing, China

5:00 p.m.–5:15 p.m.
156-OR Epigenetic and Metabolic Changes in Skeletal Muscle Underlying the Improvement of Insulin Sensitivity after Bariatric Surgery in Humans
SOFIYA GANCHEVA, MERIEM OUNI, CHRYSI KOLIAKI, TOMAS JELENIK, DANIEL F. MARKGRAF, JULIA SZEN- DROEDI, MATTHIAS SCHLENSAK, ANNETTE SCHUERMANN, MICHAEL RODEN, Düsseldorf, Germany, Potsdam

5:15 p.m.–5:30 p.m.
157-OR Effect of Metformin on Mitochondrial Pathways in Human Skeletal Muscle Cells
JESSICA SACKS, ANNY MULYA, CIARAN E. FEALY, KELLY M. FITZGERALD, EMILY HUANG, JOHN P. KIRWAN, Cleveland, OH

5:30 p.m.–5:45 p.m.
158-OR Sex Differences in Insulin Sensitivity Are Related to Muscle Tissue Acylcarnitines and Serum Lysosphosphatidylcholines but Not Subcellular Lipid Distribution in Humans
JOSIANE L. BROUSSARD, LEIGH PERREAULT, SEAN A. NEWSOM, DARCY E. KAHN, ANNA KEREGE, KATHLEEN A. HARRISON, BRYAN BERGMAN, Boulder, CO, Aurora, CO, Corvallis, OR

5:45 p.m.–6:00 p.m.
159-OR IRAK-1/IRS-1 Signaling Cross Talk in Human Skeletal Muscle—Role in Insulin Resistance
THEODORE P. CIARALDI, SUnder MUDALIAR, LIWU LI, ROSARIO SCALIA, XIAO JIAN SUN, ROBERT R. HENRY, MICHAEL QUON, La Jolla, CA, San Diego, CA, Blacksburg, VA, Philadelphia, PA, Baltimore, MD
### SUNDAY, JUNE 24, 2018—DAY-AT-A-GLANCE SCHEDULE

**Registration Hours:** 7:30 a.m.-5:00 p.m.  
**Shop Diabetes Store Hours:** 7:30 a.m.-6:45 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| **8:00 a.m. - 10:00 a.m.** | **Symposium**  
The Where and Why of Diabetic Neuropathy  
*Room: W208* | **Symposium**  
Building a Case for Getting Reimbursement or Payment for Behavioral Health in Diabetes  
*Room: W307* | **Symposium**  
Unrecognized (Occult) Metabolic Conditions in Women with Gestational Diabetes Mellitus that Predict Metabolic Complications Later in Life  
*Room: W311* | **Oral Presentations**  
Diabetes Complications and Risk Factors  
*Room: W304E-H* |
|               | **Symposium**  
Blood Flow to the Toe  
*Room: W315* | **Symposium**  
NDEP Symposium—Diabetes Prevention, Care, and Education in the Digital Age  
*Room: W204* | | |
|               | **Oral Presentations**  
Prediction and Prevention of Cardiovascular Disease  
*Room: W203* | | | |
| **10:15 a.m. - 11:45 a.m.** | | | | **President, Medicine & Science Address and Banting Medal for Scientific Achievement—*Room: Hall WB4*** |
| **12:00 p.m. - 1:00 p.m.** | **Mini-Symposium**  
The Importance of the Functional Characteristics of HDL  
*Room: W203* | **Professional Interest Group Session**  
Moving Past the Randomized Controlled Trial—Understanding the Need for Implementation Science in Diabetes Care  
*Room: W312* | **Professional Interest Group Session**  
Beyond HbA1c in Pediatric Diabetes—Is It Time to Look at Other Outcomes?  
*Room: W307* | **Mini-Symposium**  
Update on the Genetics of Type 1 and Type 2 Diabetes  
*Room: W308* |
|               | **Mini-Symposium**  
Update on Diabetic Retinopathy Clinical Trials  
*Room: W204* | **Professional Interest Group Session**  
The Future of Diabetes Education—“Live” Educator and “Virtual” Coach Partners in Care  
*Room: W315* | | |
| **1:00 p.m. - 2:00 p.m.** | **General Poster Session/Moderated Poster Discussions—Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)** | | | **Session Break (Take this opportunity to visit the Exhibit and Poster Halls)** |
### WEAR RED DAY

**Exhibit Hall Hours:** 10:00 a.m.-4:00 p.m.
**Poster Hall Hours:** 7:30 a.m.-6:30 p.m.

<table>
<thead>
<tr>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Challenges and Hope in Finding a Cure for Type 1 Diabetes</td>
<td></td>
<td></td>
<td>ADA Diabetes Symposium—Emerging Areas of Islet Biology</td>
</tr>
<tr>
<td><em>Room: W206</em></td>
<td></td>
<td></td>
<td><em>Room: W304A-D</em></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
<td><strong>Oral Presentations</strong></td>
</tr>
<tr>
<td>Molecular Mechanisms of Insulin Action and Resistance in Peripheral Tissues</td>
<td></td>
<td></td>
<td>Novel Signaling Pathways in the Islet</td>
</tr>
<tr>
<td><em>Room: W209</em></td>
<td></td>
<td></td>
<td><em>Room: W312</em></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td></td>
<td></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Precision Medicine in Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Room: W414</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m.-</td>
<td><strong>Symposium</strong> Joint ADA/ASN Symposum—Management of Patients with Progressing Diabetic Kidney Disease (OKD)</td>
<td><strong>Symposium</strong> Innovative Strategies to Improve the Inpatient Experience Room: W315</td>
<td><strong>Symposium</strong> The National Diabetes Prevention Program—From Research to Practice to National Policy Room: W204</td>
<td><strong>(2:15 p.m.-3:00 p.m.)</strong> Kelly West Award for Outstanding Achievement in Epidemiology Lecture Room: W304E-H</td>
</tr>
<tr>
<td>4:15 p.m.</td>
<td>(Valencia Ballroom)</td>
<td><strong>Symposium</strong> Aerobic Exercise in the Prevention of Cognitive Decline in Diabetes Room: W307</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong> New Insights into the Mechanisms of Defective Hypoglycemia Counterregulation in Diabetes (With ADA Presidents’ Select Abstract) Room: W208</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong> Basic and Translational Mechanisms in Gestational Diabetes Mellitus Room: W308</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentations</strong> From Progression to Management in Type 1 Diabetes—What Is New? (With ADA Presidents’ Select Abstract) Room: W204</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunology/Transplantation</td>
<td>Insulin Action/Molecular Metabolism</td>
<td>Integrated Physiology/Obesity</td>
<td>Islet Biology/Insulin Secretion</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>Joint ADA/Diabetes</td>
<td>Joint ADA/Diabetes</td>
<td>Joint ADA/EASD</td>
<td>Joint ADA/Diabetes</td>
<td></td>
</tr>
<tr>
<td>for Diabetes—International Progress</td>
<td>Room: W206</td>
<td>Room: W204A-D</td>
<td>Room: W206</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>Novel Pathogenetic</td>
<td>New Angles in Adipose Biology</td>
<td>Joint ADA/EASD</td>
<td>Alpha Cells—New Sources of Beta Cells?</td>
<td></td>
</tr>
<tr>
<td>Pathways in Type 1 Diabetes—What Can We Learn from Cancer Immunotherapy?</td>
<td>Room: W209</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
<td></td>
</tr>
<tr>
<td>Room: W206</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Scientific Sessions
8:00 a.m.-10:00 a.m.

Symposium
Theme Area: Acute and Chronic Complications
The Where and Why of Diabetic Neuropathy
Room: W208
Chair: Solomon Tesfaye, MB, ChB, MD, FRCP
8:00 a.m.-8:30 a.m.  Insight into the Why—The Importance of Sphingolipids
                     Vera Fridman, MD
8:30 a.m.-9:00 a.m.  Insight into the Why—The Importance of Bioenergetic Deficits
                     Lucy M. Hinder, PhD
9:00 a.m.-9:30 a.m.  Seeing What They Are Feeling—Central Nervous System Neuroimaging
                     Dinesh Selvarajah, MB, ChB, MRCP, PhD
9:30 a.m.-10:00 a.m. Seeing What They Are Feeling—Peripheral Nervous System Neuroimaging
                     Niels Ejskjaer, MD, PhD

Symposium
Theme Area: Acute and Chronic Complications
Blood Flow to the Toe
Room: W315
Chair: Neal R. Barshes, MD, MPH
8:00 a.m.-8:30 a.m.  Diabetes Mellitus and Peripheral Arterial Disease
                     Michael H. Criqui, MD, MPH
8:30 a.m.-9:00 a.m.  Role of Cardiology and the Diabetic Foot—Addressing the Heart of the Problem
                     Carlos Mena, MD, FACC, FSCAI
9:00 a.m.-9:30 a.m.  Endovascular Revascularization—How Low Do You Need to Go?
                     Neal R. Barshes, MD, MPH
9:30 a.m.-10:00 a.m. Vascular Bypass Is Not a Thing of the Past—The Limitations of Endovascular
                     Revascularization
                     Misaki Kiguchi, MD, MBA

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Building a Case for Getting Reimbursement or Payment for Behavioral Health in Diabetes
Room: W307
Chair: Jennifer Raymond, MD, MCR
8:00 a.m.-8:30 a.m.  Using Economic Data to Build the Case for Behavioral Health Care
                     David Janicke, PhD, ABPP
8:30 a.m.-9:00 a.m.  Implementing a System for Reimbursement of Psychosocial Screening in Diabetes Care
                     Danny C. Duke, PhD
9:00 a.m.-9:30 a.m.  Cost-Effectiveness Evaluations—How to Evaluate the Financial Impact of Care
                     Dmitry Dukhovny, MD, MPH
9:30 a.m.-10:00 a.m. Building a Reimbursement Model to Support Behavioral Health in a Pediatric Obesity Clinic
                     Marilyn Sampilo, PhD, MPH
Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
NDEP Symposium—Diabetes Prevention, Care, and Education in the Digital Age
Room: W204
Chair: M. Sue Kirkman, MD
8:00 a.m.-8:05 a.m. Welcome/Introductions
M. Sue Kirkman, MD
8:05 a.m.-8:25 a.m. Preventing Type 2 Diabetes in the Digital Age—The National Diabetes Prevention Program
Ann L. Albright, PhD, RD
8:25 a.m.-8:40 a.m. Telemedicine for Improvements in Diabetes Care and Education Outcomes
Linda M. Siminerio, RN, PhD, CDE
8:40 a.m.-9:10 a.m. Improving Diabetes Treatment Access and Outcomes Using Mobile Health Tools—Examples of Evidence-Based Solutions
John D. Piette, PhD
9:10 a.m.-9:35 a.m. Digital Tools and Technology for Optimizing Diabetes Care among Latinos
Athena Philis-Tsimikas, MD
9:35 a.m.-9:45 a.m. Future Research/Concluding Remarks
Judith E. Fradkin, MD
9:45 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Unrecognized (Occult) Metabolic Conditions in Women with Gestational Diabetes Mellitus that Predict Metabolic Complications Later in Life
Room: W311
Co-Chairs: Assiamira Ferrara, MD, PhD and Kathleen A. Page, MD
8:00 a.m.-8:30 a.m. Obesity during Pregnancy—Long-Term Cardiometabolic Consequences for Mother and Child
Susan Ozanne, PhD
8:30 a.m.-9:00 a.m. Sleep and Glucose Metabolism in Pregnancy
Sirimon Reutrakul, MD
9:00 a.m.-9:30 a.m. Adverse Childhood Experiences, Weight during Pregnancy, and Gestational Diabetes
Susan Marshall Mason, PhD, MPH
9:30 a.m.-10:00 a.m. Gestational Diabetes and Depression—Co-occurrence, Prediction, Later Complications, and Intervention
Beth Bailey, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Prioritizing Injectable Therapies in Type 2 Diabetes
Room: W415B (Valencia Ballroom)
Chair: John (Jack) L. Leahy, MD
8:00 a.m.-8:30 a.m. Basal Insulin or GLP-1 Agonist—Which Agent First, When?
Juan P. Frias, MD
8:30 a.m.-9:00 a.m. Therapy Progression after Basal Insulin—GLP-1 Agonist vs. Prandial Insulin vs. Premixed Insulins
Helena W. Rodbard, MD
9:00 a.m.-9:30 a.m. How Differences in GLP-1 Agonists Impact Treatment, With or Without Basal Insulin
Juris Meier, MD
9:30 a.m.-10:00 a.m. When Should Fixed-Ratio Basal Insulin/GLP-1 Agonists Be Considered?
Vivian Fonseca, MD
Symposium
Theme Area: Immunology/Transplantation
Challenges and Hope in Finding a Cure for Type 1 Diabetes
Room: W206
Chair: Carla J. Greenbaum, MD
8:00 a.m.-8:30 a.m. The Challenge of Dose Selection
Marc A. Gavin, PhD
8:30 a.m.-9:00 a.m. The Challenge of Heterogeneity in Disease Progression
Todd M. Brusko, PhD
9:00 a.m.-9:30 a.m. Harnessing Heterogeneity in Response to Therapy
Matthew Dufort, PhD
9:30 a.m.-10:00 a.m. Applying Mechanistic Insights from Natural History to Therapy
Martin J. Hessner, PhD

Symposium
Theme Area: Integrated Physiology/Obesity
Precision Medicine in Diabetes
Room: W414
Chair: Rita Basu, MD
8:00 a.m.-8:20 a.m. Emerging Imaging Modalities (Muscle, Brain, Liver, Pancreas) in Diabetes
Michael Roden, MD
8:20 a.m.-8:40 a.m. Measure What Is Measurable and Make Measurable What Is Not
Claudio Cobelli, PhD
8:40 a.m.-9:00 a.m. Genetics and Precision Medicine for Diabetes
Stephen S. Rich, PhD
9:00 a.m.-9:20 a.m. VIP Therapeutics—Individualized Treatment Based on a Virtual Image of the Patient—Researcher Perspective
Boris P. Kovatchev, PhD
9:20 a.m.-9:40 a.m. Bench to Bedside—Precision Individualized Medicine for Diabetes—A Clinician’s Perspective
Ananda Basu, MBBS, MD
9:40 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Islet Biology/Insulin Secretion
ADA Diabetes Symposium—Emerging Areas of Islet Biology
Room: W304A-D
Chair: Maureen A. Gannon, PhD
8:00 a.m.-8:40 a.m. LncRNA Regulation of Islet Biology
Lori Sussel, PhD
8:40 a.m.-9:20 a.m. Checkpoint Inhibitor-Induced Diabetes
Kevan C. Herold, MD
9:20 a.m.-9:40 a.m. Question and Discussion Period
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Acute and Chronic Complications
Prediction and Prevention of Cardiovascular Disease
Room: W203
Chair: John M. Stafford, MD, PhD

8:00 a.m.-8:15 a.m.
160-OR Betatrophin Predicts Cardiovascular Events Independently from the Presence of Type 2 Diabetes and Coronary Artery Disease
ANDREAS LEIHERER, AXEL MUENDLEIN, KATHRIN GEIGER, CHRISTOPH H. SAELY, EVA-MARIA BRANDTNER, JANINE EBNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, HEINZ DREXEL, Triesen, Liechtenstein, Feldkirch, Austria, Berne, Switzerland, Philadelphia, PA

8:15 a.m.-8:30 a.m.
161-OR Predictive Utilities of Blood Pressure Variables on Coronary Artery Disease in Type 1 Diabetes
JINGCHUAN GUO, TREVOR J. ORCHARD, Pittsburgh, PA

8:30 a.m.-8:45 a.m.
162-OR A Cost Analysis of Intensified vs. Conventional Multifactorial Therapy of Patients with Type 2 Diabetes—The Steno 2 Study
JOACHIM GÆDE, JENS OELLGAARD, RIKKE IBSEN, PETER GÆDE, EMIL NOERTOFT, JAKOB KJELLBERG, OLUF PEDESEN, SR., Copenhagen, Denmark, Slagelse, Denmark, Aarhus, Denmark, Sæborg, Denmark

8:45 a.m.-9:00 a.m.
163-OR Both Diabetes Duration and Cumulative Hyperglycemic Exposure Promote Myocardial Fibrosis and Increase Coronary Microvascular Resistance Evaluated by Comprehensive Myocardial CT Perfusion
SHENGPU CHOU, MIKIKO HARAGUCHI, YUSUKE FUJINO, NOBUO TOMIZAWA, TAKESHI NOJO, SUNAO NAKAMURA, Chiba, Japan

9:00 a.m.-9:15 a.m.
164-OR SGLT2 Inhibitors Suppress NLRP3 Inflammasome Activity via Changes in Ketones and Insulin in Type 2 Diabetes and Cardiovascular Diseases
YONG-HO LEE, SO RA KIM, JAEHYUN BAE, BYUNG-WAN LEE, EUN SEOK KANG, CHUL WOO AHN, BONG-SOO CHA, Seoul, Republic of Korea, Goyang, Republic of Korea

9:15 a.m.-9:30 a.m.
165-OR SGLT2 Inhibitors and Stroke Risk in Patients with Type 2 Diabetes—A Systematic Review and Meta-analysis
MAN GUO, YONG XU, CHENLIN GAO, Luzhou, China

9:30 a.m.-9:45 a.m.
166-OR Serum Fibroblast Growth Factor-21 Is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Incident Atherosclerotic Cardiovascular Diseases
LIANG WU, LINGLING QIAN, HUATING LI, WEIPING JIA, Shanghai, China

9:45 a.m.-10:00 a.m.
167-OR Metformin Regresses Left Ventricular Hypertrophy in Normotensive Patients with Coronary Artery Disease without Type 2 Diabetes Mellitus—The MET-REMODEL Trial
MOHAPRADEEP MOHAN, SHAWEEN AL-TALABANY, ANGELA M. MCKINNIE, IFY MORDI, JAGDEEP S. SINGH, STEPHEN J. GANDY, ANNAMARIA CHOI, JOHN G. HOUSTON, JACOB GEORGE, ALLAN D. STRUTHERS, CHIM C. LANG, MET-REMODEL INVESTIGATORS, Dundee, United Kingdom
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Enhancing the Use of Diabetes Prevention and Cardiovascular Risk Factor Control
Room: W308
Chair: Ranee Chatterjee MD, MPH

8:00 a.m.-8:15 a.m.
168-OR Shared Decision-Making for Diabetes Prevention—One-Year Results from the Prediabetes Informed Decision and Education (PRIDE) Study
TANNAZ MOIN, NORMAN TURK, CAROL MANGIONE, YELBA CASTELLON-LOPEZ, KIA SKRINE JEFFERS, KEITH C. NORRIS, CHIHONG TSENG, O. KENRIK DURU, Los Angeles, CA

8:15 a.m.-8:30 a.m.
169-OR Medicare Diabetes Prevention Program Final Rules May Limit Beneficiary Access and Widen Health Disparities
NATALIE RITCHIE, MARK GRITZ, Denver, CO, Aurora, CO

8:30 a.m.-8:45 a.m.
170-OR Cost-Effectiveness of Structured Lifestyle Programs for Diabetes Prevention in the Medicaid Population
MICHAEL LAXY, PING ZHANG, HUI SHAO, BOON PENG NG, MOHAMMED K. ALI, EDWARD W. GREGG, Atlanta, GA

8:45 a.m.-9:00 a.m.
171-OR Cost-Effectiveness of Structured Lifestyle Intervention in Overweight and Obese Adults with Type 2 Diabetes—Results from the Action for Health in Diabetes (Look AHEAD) Study
PING ZHANG, HAIYING CHEN, MARK ESPELAND, RENA R. WING, MARIA G. MONTEZ, PETER J. HUCKFELDT, MARY EVANS, EDWARD W. GREGG, WILLIAM C. KNOWLER, Atlanta, GA, Winston-Salem, NC, Providence, RI, San Antonio, TX, Minneapolis, MN, Washington, DC, Phoenix, AZ

9:00 a.m.-9:15 a.m.
172-OR A Comparison of the Impact of the 2017 ACC/AHA Hypertension Guidelines on Primary Care Populations With and Without Diabetes
JOANN M. SPERL-HILLEN, JEFFREY P. ANDERSON, JAY R. DESAI, KAREN L. MARGOLIS, A. LAUREN CRAIN, PATRICK J. O’CONNOR, Bloomington, MN, Minneapolis, MN

9:15 a.m.-9:30 a.m.
173-OR New 2017 ACC/AHA Hypertension Guidelines—Cost-Effectiveness among U.S. Adults with Type 2 Diabetes
HUI SHAO, MICHAEL LAXY, DEBORAH B. ROLKA, EDWARD W. GREGG, PING ZHANG, Atlanta, GA, Munich, Germany

174-OR WITHDRAWN

9:30 a.m.-9:45 a.m.
175-OR Ten-Year Trends in Consumer-Directed Health Plan Enrollment and Out-of-Pocket Costs among Commercially Insured Members with Diabetes
LAURA F. GARABEDIAN, DENNIS ROSS-DEGNAN, FANG ZHANG, MATTHEW X. CALLAHAN, ROBERT LECATES, JAMIE WALLACE, STEPHEN B. SOUMERAI, JAMES F. WHARAM, Boston, MA, Waban, MA
Oral Presentations  
8:00 a.m.-10:00 a.m.  
(continued)

Theme Area: Epidemiology/Genetics  
Diabetes Complications and Risk Factors  
Room: W304E-H  
Chair: Julie K. Bower, PhD, MPH

8:00 a.m.-8:15 a.m.  
176-OR  Multitrait Genome-Wide Association Analysis of Macronutrient Intake Identifies 12 Novel Loci for Dietary Intake and Unravels Genetic Overlap with Lifestyle Traits and Cardiometabolic Diseases  
HASSAN S. DASHTI, JORDI MERINO, JACQUELINE M. LANE, JOSE C. FLOREZ, MARTIN K. RUTTER, RICHA SAXENA, Boston, MA, Manchester, United Kingdom

8:15 a.m.-8:30 a.m.  
177-OR  Use of Oral Contraceptives at Child-Bearing Age Are Associated with the Prevalence of Diabetes in Postmenopausal Women  
SUNG-WOO KIM, REBECCA KIM, EONJU JEON, JI-HYUN LEE, HO-SANG SHON, Daegu, Republic of Korea, Gumi, Republic of Korea

8:30 a.m.-8:45 a.m.  
178-OR  Diabetes and Liver Cancer Risk—A Stronger Effect in Whites than Blacks?  
BAQIYYAH CONWAY, WILLIAM J. BLOT, Tyler, TX, Nashville, TN

8:45 a.m.-9:00 a.m.  
179-OR  Adiposity and Cardiovascular Markers in Offspring of Women with Diabetes during Pregnancy—The EPOCH Study  
CHRISTINE HOCKETT, ANNE P. STARLING, ANNA BELLATORRE, JENNY AALBORG, KATHERINE A. SAUDER, KAVITA GARG, BRANDY RINGHAM, DEBORAH H. GLUECK, DANA DABELEA, Aurora, CO

9:00 a.m.-9:15 a.m.  
180-OR  The Risk of Breast Cancer in Women with Diabetes  
MARIA BOTA, PHILIPPE AUTIER, PETER BOYLE, Écully, France, Lyon, France

9:15 a.m.-9:30 a.m.  
181-OR  Impact of Diabetes Age of Onset and Duration on Outcomes  
JUDY ZHONG, JINKYUNG HA, CAROLINE BLAUM, MOHAMMED KABETO, CHRISTINE CIGOLLE, New York, NY, Ann Arbor, MI

9:30 a.m.-9:45 a.m.  
182-OR  Population Screening for T1D and Celiac Disease—Autoimmunity Screening for Kids (ASK)  
CRISTY R. GENO RASMUSSEN, MARIAN REWERS, JUDITH BAXTER, KATHLEEN WAUGH, ANDREA STECK, BRIGITTE I. FROHNERT, LIPING YU, EDWIN LIU, Aurora, CO, Denver, CO

9:45 a.m.-10:00 a.m.  
183-OR  Risk Factors for Major Atherosclerotic Cardiovascular Events (MACE) in Type 1 Diabetes (T1D)—The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study  
RACHEL G. MILLER, TREVOR J. ORCHARD, Pittsburgh, PA
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Insulin Action/Molecular Metabolism
Molecular Mechanisms of Insulin Action and Resistance in Peripheral Tissues
Room: W209
Chair: Morris F. White, PhD

8:00 a.m.-8:15 a.m.
184-OR  Hepatic Insulin Signaling Regulates Hepatokines to Coordinate Energy Expenditure and Weight Gain through Irs2 in Sim1 Neurons
RONGYA TAO, KYLE D. COPPS, OLIVER STOEHR, MORRIS F. WHITE, Boston, MA

8:15 a.m.-8:30 a.m.
185-OR  Hepatic Insulin/Snail1 Axis Protects against Liver Steatosis and Insulin Resistance through Epigenetically Suppressing Lipogenesis
YAN LIU, NICOLE M. IRELAND, LIN JIANG, LIANGYOU RUI, Ann Arbor, MI

8:30 a.m.-8:45 a.m.
186-OR  Characterization of the G2L1 Interactome Leads to the Discovery That CLIP2, G2L1, and EB1 Undergo Insulin-Stimulated Phosphorylation
NATALIE K. BARKER, JAMES L. KRANTZ, SARA PARKER, GHASSAN MOUENEIMNE, PAUL R. LANGLAIS, Tucson, AZ

8:45 a.m.-9:00 a.m.
187-OR  Loss of Insulin/IGF-1 Receptors in Muscle Coordinately Downregulates Mitochondrial Metabolism and Alters Mitophagy via Foxo Transcription Factors
GOURAV BHARDWAJ, CHRISTIE M. PENNIMAN, PABLO A. SUAREZ BELTRAN, COLLIN M. FOSTER, BRIAN T. O’NEILL, Iowa City, IA

9:00 a.m.-9:15 a.m.
188-OR  Insulin Signaling in Adipocytes Controls Systemic Insulin Sensitivity through the 5-LO-LTB4 Axis
TETSUYA HOSOOKA, WATARU OGAWA, Kobe, Japan

9:15 a.m.-9:30 a.m.
189-OR  Mfge8 Binding of the αvβ5 Integrin Promotes Insulin Resistance in Mice
RITWIK DATTA, AMIN KHALIFEH-SOLTANI, ARNOLD HA, KAMRAN ATABAI, San Francisco, CA
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Islet Biology/Insulin Secretion

Novel Signaling Pathways in the Islet
Room: W312
Chair: Jonathan Rocheleau, PhD

8:00 a.m.-8:15 a.m.
190-OR Sensory Innervation of the Pancreatic Islet
MADINA MAKHMUTOVA, JONATHAN WEITZ, RAYNER RODRIGUEZ DIAZ, JOANA ALMACA, ERNESTO BERNAL-MIZRACHI, ALEJANDRO CAICEDO, Miami, FL

8:15 a.m.-8:30 a.m.
191-OR Foxo1 Corepressor (FCoR) and Foxo1 Regulate α-Cell and β-Cell Identity
NORIKO KODANI, JUN NAKAE, HIROSHI ITOH, Tokyo, Japan

8:30 a.m.-8:45 a.m.
192-OR Localization of ChREBPα and ChREBPβ in Pancreatic β Cells
LIORA S. KATZ, ANIL K. LAXMAN, PILI ZHANG, DONALD SCOTT, New York, NY, Salt Lake City, UT

8:45 a.m.-9:00 a.m.
193-OR Assessment of Proinflammatory Mediators of Beta-Cell Circadian Clock Dysfunction in Diabetes
NAUREEN JAVEED, KUNTOL RAKSHIT, ALEKSEY MATVEYENKO, Rochester, MN

9:00 a.m.-9:15 a.m.
194-OR Reduced β Cell SPCA1 Leads to Impaired Calcium Oscillations and Decreased Autophagy
ROBERT N. BONE, TATSUYOSHI KONO, CARMELLA EVANS-MOLINA, Indianapolis, IN

9:15 a.m.-9:30 a.m.
195-OR Deletion of OGIcNAc Transferase in Pancreatic Progenitors Causes Partial Pancreas Agenesis and Diabetes Independent of p53 in Mice
EMILYN ALEJANDRO, DANIEL BAUMLANN, SEOKWON JQ, BRIAN AKHAPHONG, AMBER D. LOCKRIDGE, RAMKUMAR MOHAN, Minneapolis, MN, Saint Paul, MN

9:30 a.m.-9:45 a.m.
196-OR Role of ROCK1 in Pancreatic β Cells
BYUNG-JUN SUNG, KYU YEON HUR, JAE HYEON KIM, YOUNG-BUM KIM, MOON-KYU LEE, Seoul, Republic of Korea, Boston, MA

9:45 a.m.-10:00 a.m.
197-OR Anti-inflammatory Cholinergic Signals Inhibit Islet Resident Macrophage Responses to ATP in Living Pancreatic Tissue Slices
JONATHAN WEITZ, RAYNER RODRIGUEZ DIAZ, JOANA ALMACA, MADINA MAKHMUTOVA, ALEJANDRO CAICEDO, Miami, FL
10:15 a.m.-11:45 a.m.
President, Medicine & Science Address
24/7/365—Tell the Diabetes Story
Jane E.B. Reusch, MD
and
Banting Medal for Scientific Achievement
Mechanisms of Insulin Resistance—Implications for Obesity, Lipodystrophy, and Type 2 Diabetes
Gerald I. Shulman, MD, PhD, FACP, MACE
Room: Hall WB4

12:00 p.m.-1:00 p.m.
Mini-Symposium
Theme Area: Acute and Chronic Complications
The Importance of the Functional Characteristics of HDL
Room: W203
Chair: Alan Chait, MD
12:00 p.m.-12:20 p.m. Importance of the Antioxidant/Anti-inflammatory Effects of HDL in Preventing Atherosclerosis
Robert S. Rosenson, MD
12:20 p.m.-12:40 p.m. Importance of Reverse Cholesterol Transport in Preventing Atherosclerosis
Alan T. Remaley, MD
12:40 p.m.-1:00 p.m. Question and Discussion Period

Mini-Symposium
Theme Area: Acute and Chronic Complications
Update on Diabetic Retinopathy Clinical Trials
Room: W204
Chair: Maria B. Grant, MD
12:00 p.m.-12:20 p.m. DRCR.net Update on Anti-VEGF and Steroids
Jennifer K. Sun, MD, MPH
12:20 p.m.-12:40 p.m. Update on Retinopathy Outcomes in GLP-1RA Trials
Wiley A. Chambers II, MD
12:40 p.m.-1:00 p.m. Question and Discussion Period

Professional Interest Group Session
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Moving Past the Randomized Controlled Trial—Understanding the Need for Implementation Science in Diabetes Care
Room: W312
Co-Chairs: Felicia Hill-Briggs, PhD, ABPP and Elizabeth Pyatak, PhD
12:00 p.m.-12:20 p.m. The Uptake of Behavioral Diabetes Research into Routine Health Care
Gretchen A. Piatt, PhD, MPH
12:20 p.m.-12:40 p.m. Use of Pragmatic Trials in Diabetes Prevention and Control
Laura A. Young, MD, PhD
12:40 p.m.-1:00 p.m. Scale Up, Spread, and Sustainability of Diabetes Prevention Programs
Rachel G.A. Tabak, PhD, RD
12:00 p.m.-1:00 p.m. (continued)

Professional Interest Group Session
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
The Future of Diabetes Education—“Live” Educator and “Virtual” Coach Partners in Care
Room: W315
Chair: Curtis L. Triplitt, PharmD, CDE
12:00 p.m.-1:00 p.m. The Marriage of a “Live” Educator and “Virtual” Coach
Neesha Ramchandani, PNP, CDE, CDTC
12:15 p.m.-12:30 p.m. A Voice-Enabled Diabetes Self-Management Program That Addresses Mood—The DiaBetty Experience
Olusika Ajilore, MD, PhD
12:30 p.m.-12:45 p.m. Your Virtual Diabetes GluCoach—Always Ready
Anil Verma
12:45 p.m.-1:00 p.m. Question and Discussion Period

Professional Interest Group Session
Theme Area: Clinical Diabetes/Therapeutics
Beyond HbA1c in Pediatric Diabetes—Is It Time to Look at Other Outcomes?
Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust
Room: W307
Co-Chairs: Mark A. Clements, MD, PhD, CPI and Linda A. DiMeglio, MD, MPH
12:00 p.m.-12:20 p.m. It Is Time to Incorporate Other Glycemic Outcomes
Roy W. Beck, MD, PhD
12:20 p.m.-12:40 p.m. HbA1c Is Still a Key Measure
William V. Tamborlane, MD
12:40 p.m.-1:00 p.m. It Is Time to Stress Nonglycemic Outcomes
Lori Laffel, MD, MPH

Professional Interest Group Session
Theme Area: Clinical Diabetes/Therapeutics
Clinical Centers and Programs Session I
Room: W209
Chair: Boris Draznin, MD, PhD
12:00 p.m.-12:15 p.m. Diabetes Management in Hospitalized Patients with End-Stage Renal Disease/Dialysis
Jennifer Wyckoff, MD
12:15 p.m.-12:30 p.m. A Multidisciplinary Team’s Approach to Reduce Inpatient Insulin-Related Hypoglycemia
Celeste C. Thomas, MD, MS
12:30 p.m.-12:45 p.m. Improving Glycemic Control and Decreasing the Risk of Hypoglycemia in Diabetic Patients in a Long-Term Care Facility
Janice L. Gilden, MD, MS, FCP, FACE, FAAS
12:45 p.m.-1:00 p.m. Piloting a Quality Improvement Project in an Advanced Practice Provider-Led Hospitalist Team to Standardize Perioperative Insulin Management in Patients with Acute Diabetic Foot Ulcers and/or Infections
Luigi F. Meneghini, MD, MBA

Mini-Symposium
Theme Area: Epidemiology/Genetics
Update on the Genetics of Type 1 and Type 2 Diabetes
Room: W308
Chair: Alisa Manning, PhD
12:00 p.m.-12:20 p.m. Update on the Genetics of Type 1 Diabetes
Grant Morahan, BSc (Hons), PhD
12:20 p.m.-12:40 p.m. Update on the Genetics of Type 2 Diabetes
Mark McCarthy, MD
12:40 p.m.-1:00 p.m. Question and Discussion Period
General Poster Session
Hall WA4-WB2 (Poster Hall)

All posters will be displayed Saturday, Sunday, and Monday. Poster presenters in the following categories will be at their posters during this period for questions and discussion with attendees.

Presented Categories

Theme Area: Acute and Chronic Complications
Foot Care—Lower Extremities
Posters: 630-P to 647-P

Theme Area: Clinical Diabetes/Therapeutics
Clinical Therapeutics/New Technology—Insulin Delivery Systems
Posters: 960-P to 996-P

Theme Area: Clinical Diabetes/Therapeutics
Clinical Therapeutics/New Technology—Noninsulin Injectables
Posters: 1060-P to 1115-P

Theme Area: Clinical Diabetes/Therapeutics
Clinical Therapeutics/New Technology—Oral Agents
Posters: 1116-P to 1215-P

Theme Area: Clinical Diabetes/Therapeutics
Health Care Delivery—Economics/Quality Improvement
Posters: 1245-P to 1333-P

Theme Area: Clinical Diabetes/Therapeutics
Pregnancy—Basic Science/Translational
Posters: 1397-P to 1413-P

Theme Area: Clinical Diabetes/Therapeutics
Pregnancy—Clinical/Epidemiology
Posters: 1414-P to 1465-P

Theme Area: Epidemiology/Genetics
Epidemiology—Cardiovascular Disease
Posters: 1483-P to 1496-P

Theme Area: Epidemiology/Genetics
Epidemiology—Clinical—Diagnosis and Screening
Posters: 1497-P to 1549-P

Theme Area: Epidemiology/Genetics
Epidemiology—Diabetes Complications
Posters: 1550-P to 1597-P

Theme Area: Epidemiology/Genetics
Epidemiology—Other
Posters: 1612-P to 1685-P

Theme Area: Insulin Action/Molecular Metabolism
Insulin Action—Adipocyte Biology
Posters: 1748-P to 1764-P

Theme Area: Insulin Action/Molecular Metabolism
Insulin Action—Signal Transduction, Insulin, and Other Hormones
Posters: 1780-P to 1787-P

Theme Area: Integrated Physiology/Obesity
Obesity—Animal
Posters: 1978-P to 2043-P

Theme Area: Integrated Physiology/Obesity
Obesity—Human
Posters: 2044-P to 2101-P

Theme Area: Islet Biology/Insulin Secretion
Islet Biology—Beta Cell—Stimulus-Secretion Coupling and Metabolism
Posters: 2140-P to 2163-P

Theme Area: Islet Biology/Insulin Secretion
Islet Biology—Signal Transduction
Posters: 2164-P to 2174-P
12:00 p.m.-1:00 p.m.  
(continued)

Moderated Poster Discussions

Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators. Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedule listed below.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

<table>
<thead>
<tr>
<th>Theme Area: All Categories</th>
<th>Evolving Concepts in Clinical Management Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 1-LB to 6-LB</td>
<td>Location: Exhibit Hall (ePoster Theater A)</td>
</tr>
<tr>
<td>Moderator: Robert H. Eckel, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Clinical Diabetes/Therapeutics</th>
<th>Insulin Marches On</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 997-P to 1002-P</td>
<td>Location: Exhibit Hall (ePoster Theater B)</td>
</tr>
<tr>
<td>Moderator: Athena Philis-Tsimikas, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>Hypoglycemia—Prediction, Perception, and Prevention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 376-P to 381-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Rozalina G. McCoy, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>Mechanisms of Diabetic Kidney Disease in Humans and in Animal Models of Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 491-P to 496-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Katherine R. Tuttle, MD, FACP, FASN, FNKF</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Exercise Effects on Human Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 730-P to 735-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Steven K. Malin, PhD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Nutrition 2018—New Approaches and Practical Realities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 760-P to 765-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Barbora de Courten, MD, PhD, MPH, FRACP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Epidemiology/Genetics</th>
<th>Dietary Influences of Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 1598-P to 1603-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Jill M. Norris, PhD</td>
<td></td>
</tr>
</tbody>
</table>

(continued on next page)
12:00 p.m.-1:00 p.m.
(continued)

Moderated Poster Discussions
Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators.

Follow the steps below to attend a Moderated Poster Discussion:

• Identify the discussion you are interested in attending from the schedule listed below.
• Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
• Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

Theme Area: Epidemiology/Genetics
Type 1 Diabetes Autoimmunity
Posters: 1686-P to 1691-P
Location: Poster Hall (First poster in discussion)
Moderator: Jennifer Sherr, MD, PhD

Inflammation and Immunity in Diabetes
Posters: 1726-P to 1731-P
Location: Poster Hall (First poster in discussion)
Moderator: Eddie A. James, PhD

Theme Area: Immunology/Transplantation
Islet Transplantation
Posters: 1740-P to 1745-P
Location: Poster Hall (First poster in discussion)
Moderator: Amisha Wallia, MD

Theme Area: Insulin Action/Molecular Metabolism
Insulin Action—Cellular and Molecular Metabolism
Posters: 1765-P to 1770-P
Location: Poster Hall (First poster in discussion)
Moderator: Ronald N. Cohen, MD

Integrated Physiology/Obesity
Integrated Physiology of the Liver
Posters: 1833-P to 1838-P
Location: Poster Hall (First poster in discussion)
Moderator: Brian N. Finck, PhD

Beta-Cell Development and Postnatal Growth
Posters: 2116-P to 2121-P
Location: Poster Hall (First poster in discussion)
Moderator: Franck Mauvais-Jarvis, MD, PhD
1:00 p.m.-2:00 p.m.
Session Break
Take this opportunity to visit the Exhibit and Poster Halls

2:15 p.m.-3:00 p.m.
Kelly West Award for Outstanding Achievement in Epidemiology Lecture
Supported by an unrestricted educational grant from Merck
Diabetes Diagnosis and Control—Missed Opportunities to Improve Health
Catherine C. Cowie, PhD, MPH
Room: W304E-H

2:15 p.m.-4:15 p.m.
Symposium
Theme Area: Acute and Chronic Complications
Joint ADA/ASN Symposium—Management of Patients with Progressing Diabetic Kidney Disease (DKD)
Room: W415C (Valencia Ballroom)
Co-Chairs: Luiza Caramori, MD, MSc, PhD and Subramaniam Pennathur, MD
2:15 p.m.-2:45 p.m.  Pathophysiology of DKD and Glycemic Goals in Patient with Low Glomerular Filtration Rate
Bernard Zinman, MD
2:45 p.m.-3:15 p.m.  How and When to Modify Diabetes Medications as Glomerular Filtration Rate Declines
Mark E. Molitch, MD
3:15 p.m.-3:45 p.m.  Specific Considerations for Lipid Lowering in DKD
Christoph Wanner, MD
3:45 p.m.-4:15 p.m.  Specific Considerations for Blood Pressure Control in DKD
George Bakris, MD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Innovative Strategies to Improve the Inpatient Experience
Room: W315
Chair: Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAADE, FAAN
2:15 p.m.-2:45 p.m.  Patients’ Own Diabetes Devices—To Wear or Not to Wear?
Donna Jornsay, MS, BSN, CPNP, CNS, CDE, CDTC, BC-ADM
2:45 p.m.-3:15 p.m.  Diabetes Care Coordination—When the Hospital and Home Regimen Are at Odds
Laura B. Hieronymus, DNP, MSED, RN, MLDE, BC-ADM, CDE, FAADE
3:15 p.m.-3:45 p.m.  Implementing a Patient-Centered Interdisciplinary Diabetes Care Model
Sandra Hardee, PharmD, CDE
3:45 p.m.-4:15 p.m.  Building an Inpatient Glycemic Management Team
Stacey A. Seggelke, DNP, ACNS-BC, BC-ADM, CDE

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Aerobic Exercise in the Prevention of Cognitive Decline in Diabetes
Room: W307
Chair: Jacob M. Haus, PhD
2:15 p.m.-2:45 p.m.  Genetic and Metabolic Factors in Progression of Alzheimer’s Disease
Jill Morris, PhD
2:45 p.m.-3:15 p.m.  Exercise-Mediated Improvements in Memory and Cognition
Henriette van Praag, PhD
3:15 p.m.-3:45 p.m.  The Effects of Aerobic Exercise on the Brain in Older Adults with Prediabetes
Christina E. Hugenschmidt, PhD
3:45 p.m.-4:15 p.m.  Impaired Cerebral Blood Flow during Exercise in Type 2 Diabetes Mellitus
Johannes van Lieshout, MD
Symposium
Theme Area: Clinical Diabetes/Therapeutics
The National Diabetes Prevention Program—From Research to Practice to National Policy
Room: W204
Chair: David G. Marrero, PhD
2:15 p.m.-2:45 p.m. Status of the National Diabetes Prevention Program—From Access to Uptake
Ann L. Albright, PhD, RD
2:45 p.m.-3:15 p.m. Implementing the New Medicare Diabetes Prevention Program Service
Elizabeth Matthews, MPA
3:15 p.m.-3:45 p.m. CDC Recognition—What You Need to Know
Elizabeth K. Ely, MS
3:45 p.m.-4:15 p.m. Where Are We with Medicaid Coverage?
Patricia Shea, MPH, MA

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Joint ADA/JDRF Symposium—Current Management of Type 1 Diabetes in Youth—What Are the Options?
Room: W414
Co-Chairs: Aaron J. Kowalski, PhD and Maria J. Redondo, MD, PhD, MPH
2:15 p.m.-2:40 p.m. Insulin Therapy in Youth with Type 1 Diabetes Mellitus—Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion?
Hood Thabit, MD, PhD
2:40 p.m.-3:05 p.m. Monitoring Glycemia in Youth with Type 1 Diabetes Mellitus—Meter Blood Glucose, Continuous Glucose Monitoring, or Both?
Gregory P. Forlenza, MD
3:05 p.m.-3:30 p.m. Psycho/Social Support—The Sometimes Forgotten Part of the Management
Maureen Monaghan, PhD
3:30 p.m.-3:55 p.m. Beyond HbA1c—How Are We Managing Type 1 Diabetes Mellitus Comorbidities?
Petter Bjornstad, MD
3:55 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Addressing Unique Challenges in Diabetes Management
Room: W311
Co-Chairs: Andrew J. Ahmann, MD and Boris Draznin, MD, PhD
2:15 p.m.-2:45 p.m. An Update on Cystic Fibrosis-Related Diabetes and Its Treatment
Antoinette Moran, MD
2:45 p.m.-3:15 p.m. Glycemic Issues and Therapeutic Approaches in Patients Receiving Cancer Therapy
Tahseen A. Chowdhury, MD, FRCP
3:15 p.m.-3:45 p.m. Managing the Stroke Patient with Diabetes
Walter Kernan, MD
3:45 p.m.-4:15 p.m. Heart Failure Outcomes in Diabetes Cardiovascular Outcomes Trials—An Evolving Landscape
Javed Butler, MD, MPH, MBA
2:15 p.m.-4:15 p.m. (continued)

**Symposium**
*Theme Area: Immunology/Transplantation*

**Joint ADA/Diabetes UK Symposium—Cell Therapy for Diabetes—International Progress**
Room: W206
Chair: James A.M. Shaw, MB, ChB, PhD, FRCP, BSc

2:15 p.m.-2:45 p.m.  
The UK Islet Transplant Consortium—Utilizing Centralized Islet Isolation and Expanded Donor Criteria  
Shareen Forbes, MB, ChB, PhD, FRCP

2:45 p.m.-3:15 p.m.  
Progress towards Islets as a Clinically Approved Therapy in the U.S.  
Jose Oberholzer, MD

3:15 p.m.-3:45 p.m.  
Utilizing Diabetes Technology in Transplantation—Is There a Role for Continuous Glucose Monitors?  
Marie-Christine Vantyghem, MD, PhD

3:45 p.m.-4:15 p.m.  
Islet Transplant to Reduce Progression of Microvascular Complications  
David M. Thompson, MD

**Symposium**
*Theme Area: Insulin Action/Molecular Metabolism*

**Fuel Driving Function—Lipidic Roles in Different Tissues**
Room: W209
Chair: M. Mahmood Hussain, PhD

2:15 p.m.-2:45 p.m.  
Lipid Metabolism and Angiogenesis in the Retina  
Lois E.H. Smith, MD, PhD

2:45 p.m.-3:15 p.m.  
Muscle Lipid Uptake during Exercise  
Peter Plomgaard, MD, PhD

3:15 p.m.-3:45 p.m.  
Regulation of Lipid Metabolism by ANGPTL4  
Carlos Fernández-Hernando, PhD

3:45 p.m.-4:15 p.m.  
Molecular Mechanisms Underlying Intravascular Lipolysis  
Anne Beigneux, PhD

**Symposium**
*Theme Area: Integrated Physiology/Obesity*

**Ordering from the Weight-Loss Menu in the Era of Precision Medicine for Obesity**
Room: W304A-D
Chair: Erin E. Kershaw, MD

2:15 p.m.-2:45 p.m.  
Predicting Obesity Using Genetic Information  
Ruth Loos, PhD

2:45 p.m.-3:15 p.m.  
Precision Nutrition—Using Gene-Diet Interaction Data to Guide Nutrition Therapy  
Lu Qi, MD, PhD

3:15 p.m.-3:45 p.m.  
Lifestyle Precision Medicine—Using Genetic and Behavioral Data to Guide Lifestyle Interventions  
Jeanne M. McCaffery, PhD

3:45 p.m.-4:15 p.m.  
Toward More Precise Surgical Approaches  
Anita P. Courcoulas, MD, MPH
Symposium
Theme Area: Islet Biology/Insulin Secretion
More to Mitochondria in the Beta Cell
Room: W312
Chair: Matthew J. Merrins, PhD

2:15 p.m.-2:45 p.m.  The Bioenergetics of the Beta Cell—Should Coupling Factors Be Reevaluated?
   David G. Nicholls, PhD

2:45 p.m.-3:15 p.m.  Intrinsic and Extrinsic Signals Governing Beta-Cell Mitochondrial Quality Control
   Scott A. Soleimanpour, MD

3:15 p.m.-3:45 p.m.  Drp1 Is Required for the Metabolic Amplifying Pathway of Insulin Secretion
   Gregory Ku, MD, PhD

3:45 p.m.-4:15 p.m.  Effects of Genetic Variations on Mitochondrial Function and Morphology
   Simone E. Baltrusch, PhD
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Acute and Chronic Complications
New Insights into the Mechanisms of Defective Hypoglycemia Counterregulation in Diabetes (With ADA Presidents’ Select Abstract)
Room: W208
Chair: Jason J. Winnick, PhD

2:15 p.m.-2:30 p.m.
198-OR ADA Presidents’ Select Abstract: Effects of Epinephrine on Atherothrombotic Responses and In Vivo Endothelial Function in Healthy Humans
MAIA MIKELADZE, MAKA HEDRINGTON, SOFIO DUMBADZE, VANESSA J. BRISCOE, DONNA TATE, EVAN THAYER, STEPHEN DAVIS, Baltimore, MD

2:30 p.m.-2:45 p.m.
199-OR The Vagus Nerve Mediates Severe Hypoglycemia-Induced Fatal Cardiac Arrhythmias
CANDACE M. RENO, ALLIE J. SKINNER, JUSTIN BAYLES, SIMON J. FISHER, Salt Lake City, UT

2:45 p.m.-3:00 p.m.
200-OR Carvedilol Prevents Counterregulatory Failure in Recurrently Hypoglycemic Rats
RAWAD FARHAT, GONG SU, OWEN CHAN, Salt Lake City, UT

3:00 p.m.-3:15 p.m.
201-OR Hypothalamic Glucose Concentrations Are Higher in Subjects with Type 1 Diabetes (T1D) and Impaired Awareness of Glycemia (IAH) than in T1D without IAH
AMIR MOHEET, DINESH DEELCHAND, ANJALI KUMAR, GULIN OZ, ELIZABETH R. SEAQUIST, Minneapolis, MN

3:15 p.m.-3:30 p.m.
202-OR Identification of VMN Cckbr Neurons as Crucial Mediators of the Counterregulatory Response to Hypoglycemia
JONATHAN N. FLAK, AHSAN ANSARI, PAUL SABATINI, PAULETTE B. GOFORTH, CHIEN LI, DARLEEN A. SANDOVAL, DAVID OLSON, MARTIN G. MYERS, JR., Ann Arbor, MI, Seattle, WA

3:30 p.m.-3:45 p.m.
203-OR Glycogen Is the Major Source of Lactate in the Ventromedial Hypothalamus of Recurrently Hypoglycemic Rats
GONG SU, OWEN CHAN, RAWAD FARHAT, KIMBERLY CHAPMAN, Salt Lake City, UT

3:45 p.m.-4:00 p.m.
204-OR Increased Glycemic Variability Is Associated with Augmented Brain Glucose Transport amongst Poorly Controlled T1DM Individuals
JANICE HWANG, LIHONG JIANG, WAI LAM, ELIZABETH SANCHEZ RANEGEL, DOUGLAS L. ROTHMAN, GRAEME F. MASON, ROBERT SHERWIN, New Haven, CT

4:00 p.m.-4:15 p.m.
205-OR Acute Caloric Restriction Leads to Loss of Hypoglycemic Counterregulation in Mice following Short-Term Refeeding
DAVID MCDougAL, Baton Rouge, LA

ADA-Supported Research
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Clinical Trials in Type 1 Diabetes
Room: W308
Chair: David Sparling, MD, PhD

2:15 p.m.-2:30 p.m.
206-OR
Overnight Insulin Delivery and Glucose in Children Using the MiniMed™ 670G System
ANIRBAN ROY, BENYAMIN GROSMAN, NEHA PARikh, DI WU, SCOTT W. LEE, FRANCINE R. KAUfMAN, Northridge, CA, Los Angeles, CA

2:30 p.m.-2:45 p.m.
207-OR
Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions
BRUCE A. BUCKINGHAM, JENNIFER SHERR, THOMAS A. PEYSER, JOON BOK LEE, JASON B. OCONNOR, BONNIE DUMAIS, LAUREN M. HUYETT, JENNIFER E. LAYNE, TRANG T. LY, Palo Alto, CA, New Haven, CT, Aurora, CO, Billerica, MA

2:45 p.m.-3:00 p.m.
208-OR
Twelve-Week Home Use of Hybrid Closed-Loop Insulin Delivery System vs. Sensor-Assisted Pump Therapy in Adults with Type 1 Diabetes—Intermediate Results of the Multicenter Randomised Crossover Diabeloop WP7 Trial
SYLVIA FRANC, PIERRE Y. BENHAMOU, SOFIE BOROT, LUCY CHAILLOUS, BRIGITTE DELEMER, BRUNO GUERCI, HÉLÈNE HANAIRE, NATHALIE M. JEANDIDIER,  SR., ERIC RENARD, YVES REZNIK, PAULINE SCHAEPELYNCK, CHARLES THIVOLET, GILLES CHARPENTIER, Corbeil-Essonnes, France, Grenoble, France, Besançon, France, Nantes, France, Reims, France, Vaudavive-lès-Nancy, France, Toulouse, France, Strasbourg, France, Montpellier, France, Caen, France, Marseille, France, Lyon, France

3:00 p.m.-3:15 p.m.
209-OR
Real-World Data from the MiniMed™ 670G System Commercial Launch—Patients Previously Using MDI Therapy
SHWETA GOPALAKRISHNAN, PRATIK AGRAWAL, MICHAEL STONE, CATHERINE FOGEL, SCOTT W. LEE, Northridge, CA

3:15 p.m.-3:30 p.m.
210-OR
Insulin-plus-Pramlintide Artificial Pancreas in Type 1 Diabetes—Randomized Controlled Trial
AHMAD HAIDAR, MICHAEL TSOUKAS, SARAH TWARDY, NATALIA STRAUSS, JEAN FRANCOIS YALE, JOANNA RUTKOWSKI, ANNE BOSSY, EVELYNE PYTKA, HIEU T. NGUYEN, LAURENT LEGAULT, Montreal, QC, Canada, Pincourt, QC, Canada

3:30 p.m.-3:45 p.m.
211-OR
rtCGM Usage Is Associated with a Significant Reduction of Time Spent in Hypoglycemia in Patients with Type 1 Diabetes Treated with Multiple Daily Injections—Results of the HypoDE Study
LUTZ HEINEMANN, GUIDO FRECKMANN, DELIA WALDENMAIER, DOMINIC EHRMANN, NORBERT HERMANNs, Düsseldorf, Germany, Ulm, Germany, Bad Mergentheim, Germany

3:45 p.m.-4:00 p.m.
212-OR
Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)
JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, TIMOTHY S. BAILEY, PHILLIP L. BANKS, BRUCE W. BODE, THOMAS DANNE, JAKE A. KUSHNER, WENDY LANE, PABLO LAPUERTA, DARREN K. MCGUIRE, ANNE L. Peters, JOHN H. REED, SANDEE SAWHNEY, PAUL STRUMPH, Chapel Hill, NC, Aurora, CO, Dallas, TX, Escondido, CA, The Woodlands, TX, Atlanta, GA, Hannover, Germany, Houston, TX, Asheville, NC, Basking Ridge, NJ, Los Angeles, CA, Roswell, GA

4:00 p.m.-4:15 p.m.
213-OR
Efficacy and Safety of Dagegliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study
CHANTAL MATHIEU, PARESH DANDONA, PIETER A. SENIOR, CHRISTOPH HASSLACHER, EIICHI ARAKI, MARCUS LIND, STEPHEN C. BAIN, SERGE JABBOUR, NIKI ARYA, FREDRIK A. THOREN, ANNA MARIA LANGKILDE, ON BEHALF OF THE DEPICT-2 INVESTIGATORS, Leuven, Belgium, Buffalo, NY, Edmonton, AB, Canada, Heidelberg, Germany, Kumamoto, Japan, Gothenburg, Sweden, Swansea, United Kingdom, Philadelphia, PA, Gaithersburg, MD, Mölndal, Sweden
4:30 p.m.-6:30 p.m.

**Symposium**  
Theme Area: Acute and Chronic Complications  
**Neuro- and Glial-Vascular Effects in the Pathogenesis of Diabetic Retinopathy**  
Room: W208  
Co-Chairs: Mary Elizabeth Hartnett, MD and John S. Penn, PhD  
4:30 p.m.-5:00 p.m.  
Proteomic Analysis of Neurodegenerative Changes in Preclinical Diabetic Retinopathy  
Jeffrey M. Sundstrom, MD, PhD  
5:00 p.m.-5:30 p.m.  
Vascular Effects on Glia and Neurons using OCTA  
Amani Fawzi, MD  
5:30 p.m.-6:00 p.m.  
Müller Cells and Their Effect on Vasculature and Neuronal Cells  
Susanne Mohr, PhD  
6:00 p.m.-6:30 p.m.  
The Role of Photoreceptors and Photoreceptor Metabolic Modulation with Light Therapy in Diabetic Retinopathy  
Timothy S. Kern, PhD

**Symposium**  
Theme Area: Acute and Chronic Complications  
**The Veterans Affairs Diabetes Trial (VADT) at 15 Years**  
Room: W414  
Chair: Jennifer B. Marks, MD  
4:30 p.m.-4:50 p.m.  
Design of the VADT and VADT Follow-up Study  
Wyndy L. Wiitala, PhD  
4:50 p.m.-5:15 p.m.  
Macrovascular Events in the VADT-F Study  
Peter D. Reaven, MD  
5:15 p.m.-5:35 p.m.  
Renal and Other Microvascular Outcomes in the VADT-F Study  
Nicholas V. Emanuele, MD  
5:35 p.m.-6:00 p.m.  
Clinical Perspective  
Hertzel C. Gerstein, MD, MSc, FRCPC  
6:00 p.m.-6:30 p.m.  
Question and Discussion Period

**Symposium**  
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
**Low-Carbohydrate Diets—Potential Benefits, Risks, and Costs**  
Room: W315  
Chair: Elizabeth J. Mayer-Davis, PhD  
4:30 p.m.-5:00 p.m.  
Low-Carbohydrate Diets for the Metabolic Management of Adults with Type 2 Diabetes  
Jeannie Tay, PhD  
5:00 p.m.-5:30 p.m.  
Low-Carbohydrate Diets for Children—Impacts and Potential Risks of Dietary Restriction  
Martin I. de Bock, FRACP  
5:30 p.m.-6:00 p.m.  
Environmental Sustainability and Impact of Low-Carbohydrate Diets  
Timothy Griffin, PhD  
6:00 p.m.-6:30 p.m.  
Panel Discussion

**Symposium**  
Theme Area: Clinical Diabetes/Therapeutics  
**Diabetes Prevention—What Are We Preventing?**  
Room: W415B (Valencia Ballroom)  
Chair: Robert E. Ratner, MD  
4:30 p.m.-5:00 p.m.  
Preventing Diabetes vs. Treating Prediabetes  
Leigh Perreault, MD  
5:00 p.m.-5:30 p.m.  
Preventing Microvascular Disease  
Lena Carlsson Ekander, MD, PhD  
5:30 p.m.-6:00 p.m.  
Preventing Macrovascular Disease  
Jean-Louis Chiasson, MD  
6:00 p.m.-6:30 p.m.  
Preventing Cancer, Cognitive Decline, and Physical Impairment  
Jill P. Crandall, MD
4:30 p.m.-6:30 p.m.
(continued)

**Symposium**
Theme Area: Clinical Diabetes/Therapeutics
**Joint ADA/AACC Symposium—Refining Measurement of A1C—Do We Know What It Means?**
Room: W307
Chair: M. Sue Kirkman, MD

4:30 p.m.-5:00 p.m.  *What A1C Results Don’t Tell You (about Risk for Complications)*
Richard M. Bergenstal, MD

5:00 p.m.-5:30 p.m.  *Correcting A1C Results for Erythrocyte Lifespan—Problem Solved?*
John M. Higgins, MD

5:30 p.m.-6:00 p.m.  *Assessment of A1C in Patients with Hemoglobin Disorders*
David B. Sacks, MB, ChB

6:00 p.m.-6:30 p.m.  *Should A1C Targets Differ among Ethnic Groups?*
Robert M. Cohen, MD

---

**Symposium**
Theme Area: Epidemiology/Genetics
**Academia-Industry Collaborations—Key Considerations**
Room: W415C (Valencia Ballroom)
Chair: Kasia J. Lipska, MD, MHS, BS

4:30 p.m.-5:00 p.m.  *Clinical Research Outcomes*
Joel Lexchin, MD

5:00 p.m.-5:30 p.m.  *Challenges and Opportunities in Nutrition Research*
W. Timothy Garvey, MD

5:30 p.m.-6:00 p.m.  *Academia-Industry Collaborations in Diabetes Trials*
John B. Buse, MD, PhD

6:00 p.m.-6:30 p.m.  *Addressing Potential Bias and Conflicts of Interest*
Ameet Sarpatwari, JD, PhD

---

**Symposium**
Theme Area: Epidemiology/Genetics
**Beyond Single Nucleotide Polymorphisms—Building on Knowledge of the Genetic Architecture of Diabetes**
Room: W304E-H
Chair: Mark McCarthy, MD

4:30 p.m.-5:00 p.m.  *Type 2 Diabetes in the Trans-Omics for Precision Medicine (TOPMed) Program*
Alisa Manning, PhD

5:00 p.m.-5:30 p.m.  *Do Epigenetic Mechanisms Affect the Pathogenesis of Type 2 Diabetes?*
Charlotte Ling, PhD

5:30 p.m.-6:00 p.m.  *Pharmacogenetics*
Amber L. Beitelshees, PharmD, MPH, FAHA, FCCP

6:00 p.m.-6:30 p.m.  *Applications of the Type 1 Diabetes Risk Score*
Richard A. Oram, MD, PhD
4:30 p.m.-6:30 p.m.  
(continued)

**Symposium**  
Theme Area: Immunology/Transplantation  
**Novel Pathogenetic Pathways in Type 1 Diabetes—What Can We Learn from Cancer Immunotherapy?**  
Room: W206  
Chair: Massimo Pietropaolo, MD

4:30 p.m.-5:10 p.m.  
*Immune Checkpoints in Cardiovascular Disease*  
Andrew H. Lichtman, MD, PhD

5:10 p.m.-5:50 p.m.  
*Cancer Immunotherapy-Induced Autoimmune Diabetes and Endocrinopathies—The Memorial Sloan-Kettering Cancer Center Experience*  
Monica Girotra, MD

5:50 p.m.-6:30 p.m.  
*Checkpoint Inhibitor-Induced Type 1 Diabetes—The University of Texas MD Anderson Case Studies*  
Conor J. Best, MD

**Symposium**  
Theme Area: Insulin Action/Molecular Metabolism  
**New Angles in Adipose Biology**  
Room: W209  
Chair: C. Ronald Kahn, MD

4:30 p.m.-5:00 p.m.  
*Adipocyte Turnover, Aging, and Insulin Resistance*  
Matthew Steinhauer, MD

5:00 p.m.-5:30 p.m.  
*Phosphoproteomic Analysis of Insulin Resistant Adipocytes*  
David E. James, PhD

5:30 p.m.-6:00 p.m.  
*Adipose Tissue Lipolysis in Humans*  
Michael D. Jensen, MD

6:00 p.m.-6:30 p.m.  
*CEACAM1 along the Adipocyte-Hepatocyte Axis and Systemic Metabolism*  
Sonia M. Najjar, PhD

**Symposium**  
Theme Area: Integrated Physiology/Obesity  
**Joint ADA/EASD Symposium—Central Control of Glucose Homeostasis**  
Room: W304A-D  
Chair: Robert S. Sherwin, MD and Juleen R. Zierath, PhD

4:30 p.m.-5:00 p.m.  
*Central Nervous System Neurons That Control Glucose Production*  
Martin G. Myers, Jr., MD, PhD

5:00 p.m.-5:30 p.m.  
*Central Nervous System That Control Glucose Production*  
Jens C. Brüning, MD

5:30 p.m.-6:00 p.m.  
*Central Glucose Sensing in the Defense against Hypoglycemia*  
Bernard Thorens, PhD

6:00 p.m.-6:30 p.m.  
*Leptin Action on POMC Neurons Regulates the Coordinated Metabolic Responses to Fasting*  
Joel K. Elmquist, DVM, PhD
Symposium
Theme Area: Islet Biology/Insulin Secretion
Alpha Cells—New Sources of Beta Cells?
Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust
Room: W312
Chair: George K. Gittes, MD
4:30 p.m.-5:00 p.m.  A Hepatic-Islet-Alpha-Cell Axis Integrates Amino Acid Availability with Alpha-Cell Mass
                      Danielle Dean, PhD
5:00 p.m.-5:30 p.m.  Alpha-Cell Transdifferentiation
                      Kenichiro Furuyama, MD, PhD
5:30 p.m.-6:00 p.m.  Regulation of Alpha-Cell Mass and Function by Nutrient Signaling
                      Ernesto Bernal-Mizrachi, MD
6:00 p.m.-6:30 p.m.  Transcriptional Control of Alpha-Cell Fate
                      Takaaki Matsuoka, MD, PhD
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued)

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
High Risk Behavioral and Psychosocial Issues in Diabetes
Room: W203
Chair: Deborah Young-Hyman, PhD

4:30 p.m.-4:45 p.m.
214-OR Youth with Avoidable DKA—Going from Bad to Worse without NICH
RAJKARAN SACHDEJ, NATAFIE C. KOSKELA, DAVID V. WAGNER, SAMANTHA A. BARRY, CELESTE JENISCH, MICHAEL A. HARRIS, Portland, OR, Worcester, MA

4:45 p.m.-5:00 p.m.
215-OR Suicidal Screening in Youth with T1D—Risk or Benefit?
HARPETT NAGRA, DANNY C. DUKE, MELINDA JONES, KIMBERLY KRAUS, MICHAEL A. HARRIS, Portland, OR

5:00 p.m.-5:15 p.m.
216-OR Substance Use in Adults with Type 1 Diabetes in the T1D Exchange
NANCY PETRY, NICOLE C. FOSTER, EDA CENGIZ, WILLIAM V. TAMBORLANE, JULIE WAGNER, SARIT POLSKY, Farmington, CT, Tampa, FL, New Haven, CT, Aurora, CO

5:15 p.m.-5:30 p.m.
217-OR Diabetes-Specific Risk Taking—Psychometric Properties of a Measure for Adolescents with Type 1 Diabetes (T1D)
RACHEL M. WASSERMAN, SUSANA R. PATTON, MARK A. CLEMENTS, JONATHAN H. FINCH, KELSEY BOSCHERT, DAVID D. SCHWARTZ, BARBARA ANDERSON, Orlando, FL, Kansas City, KS, Kansas City, MO, Leawood, KS, Houston, TX, Charlottesville, VA

5:30 p.m.-5:45 p.m.
218-OR The Association of Dispositional Mindfulness and Adverse Childhood Experiences with Glycemic Control among Young Adults with Type 1 Diabetes

5:45 p.m.-6:00 p.m.
219-OR Few Pediatric Diabetes Patients Access Outpatient Psychotherapy following Screening and Referral
JOANNA TSIKIS, JESSICA M. VALENZUELA, ARETI VASSILOPOULOS, CHELSEA WILCOCKS, LITAL REITBLAT, ERNESTO J. BLANCO, SHELLEY NICHOLS, RISA WOLF, Davie, FL, Fort Lauderdale, FL, Baltimore, MD

6:00 p.m.-6:15 p.m.
220-OR Associations between Executive Dysfunction and Disordered Eating Behavior (DEB) Risk in Teens with Type 1 Diabetes (T1D)
RAQUEL CECILIA-COSTA, MEREL HANSMANN, KARA R. HARRINGTON, LISA VOLKENING, LORI M. LAFFEL, Boston, MA

6:15 p.m.-6:30 p.m.
221-OR Key Factors for Overcoming Psychological Insulin Resistance—An Examination of a Large International Sample through Content Analysis
HEATHER L. STUCKEY, WILLIAM POLONSKY, LAWRENCE FISHER, DANIELLE M. HESSLER, FRANK J. SNOEK, TRICIA S. TANG, NORBERT HERMANNS, XAVIER MUNDET, MARIA ELIZABETH R. SILVA, JACKIE A. STURT, KENTARO OKAZAKI, DACHUANG CAO, IRENE HADJYIANNI, JASMINA I. IVANOVA, URVI DESAI, MAGALY PEREZ-NIEVES, Hershey, PA, Del Mar, CA, San Francisco, CA, Amsterdam, Netherlands, Vancouver, BC, Canada, Bad Mergentheim, Germany, Barcelona, Spain, São Paulo, Brazil, London, United Kingdom, Nagoya, Japan, Charlotte, NC, Bad Homburg, Germany, New York, NY, Boston, MA, Indianapolis, IN
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Basic and Translational Mechanisms in Gestational Diabetes Mellitus
Room: W308
Chair: Jacob E. Friedman, PhD

4:30 p.m.-4:45 p.m.
222-OR Maternal High-Fat Diet Persistently Alters Bone Marrow Immune Cell Proportions and Function in a Nonhuman Primate Model
MICHAEL J. NASH, TAYLOR K. SODERBORG, RACHEL C. JANSSEN, ERIC M. PIETRAS, JACOB E. FRIEDMAN, Aurora, CO

4:45 p.m.-5:00 p.m.
223-OR Air Pollution Exposure during Pregnancy and Lactation Induces Obesity and Glucose Intolerance in the Offspring
OLIVIA P. ZORDÃO, LAÍS W. CLARO, PAULO S. SALDIVA, JOSE DONATO JR., MARIANA VERAS, PATRICIA O. PRADA, Campinas, Brazil, São Paulo, Brazil

5:00 p.m.-5:15 p.m.
224-OR Activation of Browning Adipose Tissues by Placental Growth Factor
RUILI YIN, JING ZHOU, CHUANHAI ZHANG, CEN YAN, WEI MA, NANNAN WU, DONG ZHAO, YINGMEI FENG, Beijing, China

5:15 p.m.-5:30 p.m.
225-OR Free Fatty Acids-Mediated Inflammation and Insulin Resistance/Insulin Production in Healthy and Gestational Diabetes Pregnant Women
XINHUA CHEN, THOMAS P. STEIN, THERESA O. SCHOLL, ROBERT A. STEER, Stratford, NJ

5:30 p.m.-5:45 p.m.
226-OR The Mitochondrial Cholesterol Transporter TSPO—Gatekeeper of Gestational Progesterone Production
MARICELA HAGHIAC, JUDI MINIUM, YELENNA SKOMOROVSKA-PROKVOLIT, PATRICK CATALANO, SYLVIE HAUGUEL DE MOUZON, Cleveland, OH

5:45 p.m.-6:00 p.m.
227-OR Maternal Obesity Is Associated with Reduced Hippocampal Volume in Children
KATHLEEN A. PAGE, SHAN LUO, XINHUI WANG, JASMIN ALVES, MAYRA P. MARTINEZ, ANNY XIANG, Los Angeles, CA, Pasadena, CA

6:00 p.m.-6:15 p.m.
228-OR Maternal Diabetes Induces Congenital Heart Defects by Suppressing Mitochondrial Fusion through the miR140 Mitofusin 1 Circuit
XI CHEN, WEI-BIN SHEN, PEIXIN YANG, Baltimore, MD

6:15 p.m.-6:30 p.m.
229-OR Survivin from Flk1+ Endothelial Progenitor Cells in the Developing Embryo Ameliorates Maternal Diabetes-Induced Neural Tube Defects through Exosome
SONGYING CAO, WEI-BIN SHEN, PEIXIN YANG, Baltimore, MD

ADA-Supported Research
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
From Progression to Management in Type 1 Diabetes—What Is New? (With ADA Presidents’ Select Abstract)
Room: W204
Co-Chairs: Eda Cengiz, MD, MHS and David M. Maahs, MD, PhD

4:30 p.m.-4:45 p.m.
230-OR ADA Presidents’ Select Abstract: Gut Microbiome Dysbiosis and Increased Intestinal Permeability in Australian Children with Islet Autoimmunity and Type 1 Diabetes
JESSICA E. HARBISON, ALEXANDRA J. ROTH-SCHULZE, SIMON C. BARRY, CUONG D. TRAN, KATRINA NGUI, MEGAN A. PENNO, JOHN WENTWORTH, PETER G. COLMAN, REBECCA THOMSON, MARIA E. CRAIG, ANTHONY T. PAPENFUSS, LYNNE GILES, LEONARD C. HARRISON, JENNY COUPER, Adelaide, Australia, Melbourne, Australia, Parkville, Australia, Westmead, Australia

4:45 p.m.-5:00 p.m.
231-OR Comparison of Novel MicroRNA and Cell-Free DNA Biomarkers of Beta-Cell Death and Diabetes Progression
MUGDHA JOGLEKAR, RYAN FARR, WILSON WONG, KRISTINA ROTHER, ALICIA JENKINS, CHITTARANJAN S. YAJNIK, RONALD C. MA, MARIA E. CRAIG, TIM JONES, ANAND HARDIKAR, PREDICT T1D STUDY GROUP, Sydney, Australia, Geelong, Australia, Bethesda, MD, Pune, India, Hong Kong, China, Westmead, Australia, Perth, Australia

5:00 p.m.-5:15 p.m.
232-OR The Pathological Evolution of Glucose Response Curves (GRCs) during the Progression to Type 1 Diabetes (T1D) in the TrialNet Pathway to Prevention Study
HEBA M. ISMAIL, PING XU, DOROTHY J. BECKER, INGRID LIBMAN, JENNIFER B. MARKS, JAY S. SKYLER, JERRY P. PALMER, JAY SOSENKO, Pittsburgh, PA, Tampa, FL, Miami, FL, Seattle, WA

5:15 p.m.-5:30 p.m.
233-OR Pancreas Volume Declines over the First Year after Diagnosis with Type 1 Diabetes (T1D)
JACK VIROSTKO, MELISSA A. HILMES, JONATHAN M. WILLIAMS, JORDAN WRIGHT, LIPING DU, HAKMOOK KANG, WILLIAM E. RUSSELL, DANIEL J. MOORE, ALVIN C. POWERS, Austin, TX, Nashville, TN

5:30 p.m.-5:45 p.m.
234-OR Metformin Improves Insulin Resistance (IR) and Vascular Health in Youth with Type 1 Diabetes (T1D)
KRISTEN J. NADEAU, PETTER BJORNSTAD, MICHAL SCHÄFER, LORNABROWNE, AMY BAUMGARTNER, YES-NIA GARCIA REYES, ARISTIDES MANIATIS, R. PAUL WADWA, SUNIL NAYAK, LAURA PYLE, MELANIE CREE-GREEN, JANE E. REUSCH, Aurora, CO, Denver, CO, Centennial, CO, Greenwood Village, CO

5:45 p.m.-6:00 p.m.
235-OR Alpha-1 Antitrypsin Therapy in Recent-Onset Type 1 Diabetes
YAELEBENTHAL, AVIVIT BRENER, ELI HERSHKOVITZ, NAIM SHEHADEH, SHLOMIT SHALITIN, SHARON GAI-CASTRO, MICHAL STEIN, NAVEHTOV, MARIANNA RACHMIEL, Tel Aviv, Israel, Beersheba, Israel, Harifa, Israel, Petah Tikva, Israel, Rehovot, Israel, Zerifin, Israel

6:00 p.m.-6:15 p.m.
236-OR Overnight to Early-Morning Glycemic Outcomes in Children Using the MiniMed™ 670G Hybrid Closed-Loop (HCL) System
GREGORY P. FORLENZA, DOROTHY I. SHULMAN, MICHAEL A. WOOD, TIMOTHY S. BAILEY, BRUCE W. BODE, BRUCE BUCKINGHAM, SUIYING HUANG, JOHN SHIN, SCOTT W. LEE, TONI L. CORDERO, FRANCINE R. KAUFMAN, Aurora, CO, Tampa, FL, Ann Arbor, MI, Escondido, CA, Atlanta, GA, Palo Alto, CA, Northridge, CA

6:15 p.m.-6:30 p.m.
237-OR Timing of CGM Initiation in Pediatric Diabetes—The CGM TIME Trial
MARGARET L. LAWSON, JENNILEA COURTNEY, BRENDA J. BRADLEY, KAREN MCSASSEY, CHERIL CLARSON, SUSAN E. KIRSCH, JACQUELINE CURTIS, FARID H. MAHMUD, CHRISTINE RICHARDSON, TAMMY COOPER, KEN TANG, THE CGM TIME TRIAL STUDY GROUP, JDRF CANADIAN CLINICAL TRIAL NETWORK CCTN1101, Ottawa, ON, Canada, Hamilton, ON, Canada, London, ON, Canada, Markham, ON, Canada, Toronto, ON, Canada

ADA-Supported Research
### MONDAY, JUNE 25, 2018—DAY-AT-A-GLANCE SCHEDULE

Registration Hours: 7:30 a.m.-4:00 p.m.  
Shop Diabetes Store Hours: 7:30 a.m.-6:45 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 8:00 a.m.-10:00 a.m.| **Symposium**  
Role of the Kidney in Heart Health  
*Room: W308*  
**Oral Presentations**  
New Insights into the Pathogenesis of Diabetic Retinopathy  
*Room: W208*  
** Symposium**  
Intervening in the Lived Experiences and Social Context of Those with Diabetes  
*Room: W315*  
**Oral Presentations**  
Diabetes Self-Management Education and Support—Embracing Data and Digital Dialogue Advances  
*Room: W204* | **Symposium**  
Who Do You Think You Are? Heterogeneity of Obesity and Gestational Diabetes Mellitus  
*Room: W414*  
** Symposium**  
Type 2 Diabetes in Youth—Update on the Current State of Knowledge on Complications  
*Room: W307*  
** Symposium**  
Effectiveness of Telemedicine in Underserved Communities  
*Room: W311*  
**Oral Presentations**  
SGLT2 Inhibitors—From Mechanisms to Clinical Trials (With ADA Presidents’ Select Abstract)  
*Room: W415B*  
(Valencia Ballroom) | ** Symposium**  
Genetic and Ethnic Heterogeneity and the Road to Precision Medicine in Diabetes  
(With ADA Presidents’ Select Abstract)  
*Room: W206* |

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 a.m.-11:45 a.m.</td>
<td><strong>National Scientific &amp; Health Care Achievement Awards Presentation and Outstanding Scientific Achievement Award Lecture—Room: Hall WB4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 12:00 p.m.-1:00 p.m.| **Mini-Symposium**  
Special Topics in Hypoglycemia  
*Room: W307*  
**Mini-Symposium**  
Overcoming Gender Gaps in Science  
*Room: W304E-H*  
**Professional Interest Group Session**  
The Lancet Commission on Diabetes—Societal Solutions to Combat Diabetes  
*Room: W204*  
**Professional Interest Group Session**  
Should All Pregnant Women with Type 1 Diabetes Use Continuous Glucose Monitoring from Planning Pregnancy until after Breastfeeding?  
*Room: W304A-D*  
**Professional Interest Group Session**  
Clinical Centers and Programs Session II | ** Professional Interest Group Session**  
Defining a Healthy Diet—Do Fats or Carbohydrates Matter More?  
*Room: W315* |

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m.-1:00 p.m.</td>
<td><strong>General Poster Session/Moderated Poster Discussions—Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m.-2:00 p.m.</td>
<td><strong>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunology/Transplantation</td>
<td>Insulin Action/Molecular Metabolism</td>
<td>Integrated Physiology/Obsesity</td>
<td>Islet Biology/Insulin Secretion</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>Symposium</td>
<td>Oral Presentations</td>
<td>Symposium</td>
<td>Symposium</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials for Type 1 Diabetes—Current, Emerging, and Novel</td>
<td>Adipose Browning and Energy Expenditure (With State-of-the-Art Lecture)</td>
<td>Recognition of Depression, Diabetes, and Dementia—Resetting Clinical Priorities</td>
<td>Metabolism and the Beta Cell</td>
<td></td>
</tr>
<tr>
<td>Room: W304E-H</td>
<td>Room: W209</td>
<td>Room: W304A-D</td>
<td>Room: W312</td>
<td></td>
</tr>
</tbody>
</table>

**Professional Interest Group Session**
- Immunopathogenesis of Type 1 Diabetes—Is It Autoimmunity?
- Room: W206
<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 2:15 p.m.-4:15 p.m. | Oral Presentations | Evolving Mechanisms in Cardiovascular Complications  
(With Edwin Bierman Award Lecture)  
*Room: W208* | Symposium  
Easing Disease Management Burden for Older Adults  
*Room: W307* | Symposium  
Cost-Related Nonadherence to Diabetes Care  
*Room: W315* | Oral Presentations  
Race and Societal Influences on Diabetes  
(With Vivian Fonseca and Nagendran Family Diabetes Research Award Presentation)  
*Room: W304E-H* |
| 4:30 p.m.-6:30 p.m. | Current Issues  
Albuminuria—Two Debates  
*Room: W308* | Symposium  
Diabetes and Psychosocial Risk Factors in the Hispanic Community Health Study/Study of Latinos  
*Room: W414* | Symposium  
Insulin Therapy—To the Future and Back  
*Room: W415B* (Valencia Ballroom) | Symposium  
Mechanistic Insights from Rare Conditions and Opportunities for Novel Therapeutics  
*Room: W304E-H* |
| | Symposium  
Clinical Strategies for Prevention and Management of Hypoglycemia  
*Room: W311* | Symposium  
Using mHealth for Obesity Treatment and Weight Management  
*Room: W307* | Oral Presentations  
Adiposity, Insulin Resistance, and Type 2 Diabetes Mellitus—What Is New in Risk Factors and Biomarkers?  
*Room: W203* |  |
| | Oral Presentations  
New Insights into Lipid and Lipoprotein Alterations in Patients with Diabetes  
*Room: W208* |  | Oral Presentations  
Innovations in Insulin Formulation and Delivery  
*Room: W415C* (Valencia Ballroom) |  |
| |  |  | Oral Presentations  
Novel Aspects of Metabolic Regulation  
(With ADA Presidents’ Select Abstract)  
*Room: W209* |  |  |
| |  |  | Oral Presentations  
Alphabet Soup—GABA, FGF, ERα—Recipe for Central Nervous System Control of Metabolic Homeostasis and Diabetes Remission  
(With State-of-the-Art Lecture)  
*Room: W204* |  |  |
| |  |  | Symposium  
Mechanistic Insights from Rare Conditions and Opportunities for Novel Therapeutics  
*Room: W304E-H* |  |  |
<table>
<thead>
<tr>
<th>Immunology/ Transplantation</th>
<th>Insulin Action/ Molecular Metabolism</th>
<th>Integrated Physiology/Obsesity</th>
<th>Islet Biology/ Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td>Translational Immunology in Type 1 Diabetes— A Look at the Future Room: W206</td>
<td>Adipose Signaling and the Central Nervous System in the Control of Obesity Room: W209</td>
<td>Regulation of Islet Function in Health and Disease Room: W312</td>
<td></td>
</tr>
<tr>
<td><strong>Symposium</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td><strong>Symposium</strong></td>
</tr>
<tr>
<td><strong>Oral Presentations</strong></td>
<td><strong>Oral Presentations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alphabet Soup—GABA, FGF, ERα—Recipe for Central Nervous System Control of Metabolic Homeostasis and Diabetes Remission (With State-of-the-Art Lecture) Room: W204</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exhibit Hall Hours: 10:00 a.m.-2:00 p.m.
Foster Hall Hours: 7:30 a.m.-2:00 p.m.
Scientific Sessions
8:00 a.m.-10:00 a.m.

**Symposium**
*Theme Area: Acute and Chronic Complications*

**Role of the Kidney in Heart Health**
Room: W308
Chair: Christoph Wanner, MD

- 8:00 a.m.-8:30 a.m. **Natural History of Nephropathy and Associated Cardiovascular Risk**
  - Julia Scialla, MD
- 8:30 a.m.-9:00 a.m. **Sodium-Hydrogen Exchange and the Cardiorenal Axis**
  - Julie A. Lovshin, MD, PhD
- 9:00 a.m.-9:30 a.m. **Impact of Tubuloglomerular Feedback**
  - Christopher T. Chan, MD, FRCPC
- 9:30 a.m.-10:00 a.m. **Cardiovascular Risk Reduction in the Patient with Nephropathy**
  - Janani Rangaswami, MD, FACP

**Symposium**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Intervening in the Lived Experiences and Social Context of Those with Diabetes**
Room: W315
Chair: Jill Weissberg-Benchell, PhD, CDE

- 8:00 a.m.-8:30 a.m. **Understanding the Social Context of Managing Diabetes—What’s Life Really Like?**
  - Evan A. Los, MD
- 8:30 a.m.-9:00 a.m. **Intervention Targeting the Social Determinants of Health in Youth with Repeat Diabetic Ketoacidosis—Novel Interventions in Children’s Healthcare (NICH) Works**
  - Lena Teplitsky, MPH
- 9:00 a.m.-9:30 a.m. **Integrating Social and Behavioral Interventions for Diabetes in Primary Care**
  - Danielle M. Hessler, PhD
- 9:30 a.m.-10:00 a.m. **Question and Discussion Period**

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*

**Who Do You Think You Are? Heterogeneity of Obesity and Gestational Diabetes Mellitus**
Room: W414
Co-Chairs: Linda (Lynn) A. Barbour, MD, MSPH, FACP and Patrick M. Catalano, MD

- 8:00 a.m.-8:30 a.m. **Heterogeneity of Gestational Diabetes—Physiologic and Genetic Characterization**
  - Marie-France Hivert, MD
- 8:30 a.m.-9:00 a.m. **Heterogeneity in Gestational Diabetes Mellitus—A View from the Beta Cell**
  - Thomas A. Buchanan, MD
- 9:00 a.m.-9:30 a.m. **Metabolic Heterogeneity in Obese Pregnancies—Looks Can Be Deceiving**
  - Teri L. Hernandez, PhD, RN
- 9:30 a.m.-10:00 a.m. **Treatment of Gestational Diabetes Mellitus Based on Underlying Pathophysiology**
  - Maisa N. Feghali, MD
8:00 a.m.-10:00 a.m.  
(continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
**Type 2 Diabetes in Youth—Update on the Current State of Knowledge on Complications**  
Room: W307  
Co-Chairs: Tamara S. Hannon, MD, MS and Philip S. Zeitler, MD, PhD  
8:00 a.m.-8:30 a.m.  
*Natural History of Type 2 Diabetes Mellitus in Youth—Different than in Adults?*  
Fida Bacha, MD  
8:30 a.m.-9:00 a.m.  
*Cardiovascular Disease Risk Factors in Youth with Type 2 Diabetes Mellitus—Time to Be More Aggressive in the Management?*  
Amy S. Shah, MD  
9:00 a.m.-9:30 a.m.  
*Microvascular Complications in Youth with Type 2 Diabetes Mellitus—How Common Are They and When Do We Treat?*  
Amy K. Mottl, MD  
9:30 a.m.-10:00 a.m.  
*Psychosocial and Behavioral Self-Care Challenges in Youth with Type 2 Diabetes Mellitus—The Not So Hidden Iceberg*  
Elizabeth M. Venditti, PhD

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
**Effectiveness of Telemedicine in Underserved Communities**  
Room: W311  
Chair: Ruth S. Weinstock, MD, PhD  
8:00 a.m.-8:30 a.m.  
*Project Extension for Community Healthcare Outcomes (ECHO)—Diabetes Education and Training*  
Evan Klass, MD  
8:30 a.m.-9:00 a.m.  
*Success of Telehealth Eye Care in Indian Health Service*  
Mark B. Horton, OD, MD  
9:00 a.m.-9:30 a.m.  
*Telemedicine Care in Rural Communities*  
Michele Heisler, MD, MPA  
9:30 a.m.-10:00 a.m.  
*eHealth for Diabetes Care in Latino Communities*  
A. Enrique Caballero, MD

**Symposium**  
*Theme Area: Immunology/Transplantation*  
**Clinical Trials for Type 1 Diabetes—Current, Emerging, and Novel**  
Room: W304E-H  
Co-Chairs: Chantal Mathieu, MD, PhD and Emily K. Sims, MD  
8:00 a.m.-8:30 a.m.  
*What We Have Learned and Plan to Learn from TrialNet Studies*  
Manuela Battaglia, PhD  
8:30 a.m.-9:00 a.m.  
*Increasing the Pace of Research—Novel Clinical Trial Designs*  
Jeffrey Krischer, PhD  
9:00 a.m.-9:30 a.m.  
*Combination Immunotherapy for Type 1 Diabetes—The TrialNet ATG/GCSF Study*  
Michael Haller, MD  
9:30 a.m.-10:00 a.m.  
*From Mechanism to Clinical Trial—Methyldopa for Type 1 Diabetes Prevention*  
Aaron Michels, MD
8:00 a.m.-10:00 a.m. (continued)

Symposium
Theme Area: Integrated Physiology/Obesity
Recognition of Depression, Diabetes, and Dementia—Resetting Clinical Priorities
Room: W304A-D
Chair: Linda Gonder-Frederick, PhD
8:00 a.m.-8:25 a.m. Neuroimaging and Neuromodulation in Obesity and Type 2 Diabetes
Maria A. Guzzardi, PhD
8:25 a.m.-8:50 a.m. Insulin Resistance and Cognition
Sophia Frangou, MD, MSc, PhD, FRCPsych
8:50 a.m.-9:15 a.m. Research Perspective of Diabetes and Depression—The Neuroendocrine Link
Sherita Golden, MD, MHS
9:15 a.m.-9:40 a.m. What Is the Role of Diabetes Treatments in the Treatment of Psychiatric Disorders?
Roger S. McIntyre, MD, FRCPC
9:40 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Islet Biology/Insulin Secretion
Metabolism and the Beta Cell
Room: W312
Chair: Donald Scott, PhD
8:00 a.m.-8:30 a.m. Disallowed Genes
Timothy Pullen, PhD
8:30 a.m.-9:00 a.m. Glucose Metabolism
Richard G. Kibbey, MD, PhD
9:00 a.m.-9:30 a.m. Regulation of Islet Beta-Cell Glucose Cycling by IGRP/G6PC2
Richard M. O’Brien, PhD
9:30 a.m.-10:00 a.m. Functional and Metabolomic Consequences of KATP Channel Inactivation in Human Islets
Diva D. De León-Crutchlow, MD, MSCE
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Acute and Chronic Complications
New Insights into the Pathogenesis of Diabetic Retinopathy
Room: W208
Chair: Wenbo Zhang, PhD

8:00 a.m.-8:15 a.m.
238 -OR Loss of Hypothalamic Somatostatin (SST) Contributes to Bone Marrow (BM) Dysfunction and Diabetic Retinopathy (DR) in Type 2 Diabetic Rats
ANA LEDA LONGHINI, JEFFREY THINSCHMIDT, MICHAEL BOULTON, MICHAEL A. KING, MARIA B. GRANT, Birmingham, AL, Gainesville, FL

8:15 a.m.-8:30 a.m.
239 -OR Epigenetics and Mitochondrial Stability in Diabetic Retinopathy
RENU KOWLURU, MANISH MISHRA, Detroit, MI

8:30 a.m.-8:45 a.m.
240 -OR MALAT1 and HOTAIR—Key Epigenetic Regulators in Diabetic Retinopathy
SAUMIK BISWAS, ANU A. THOMAS, BIAO FENG, SHALI CHEN, ERFAN AREF-ESHGHI, JOHN GONDER, BEKIM SADIKOVIC, SUBRATA CHAKRABARTI, London, ON, Canada

8:45 a.m.-9:00 a.m.
241 -OR Effects of Diabetes on Retinal Protein Lysine Malonylation
STEVEN F. ABCOUWER, SUMATHI SHANMUGAM, HEATHER M. HAGER, CHENG-MAO LIN, PATRICE E. FORT, THOMAS W. GARDNER, KELLI SAS, SUBRAMANIAM P N E N N A T H U R, Ann Arbor, MI

9:00 a.m.-9:15 a.m.
242 -OR ▲ Deletion of REDD1 Prevents Hyperglycemia-Induced Reactive Oxygen Species Accumulation and Retinal Cell Death
WILLIAM P. MILLER, ALLYSON TORO, MICHAEL D. DENNIS, Hershey, PA

9:15 a.m.-9:30 a.m.
243 -OR Epsin Deficiency Promotes Lymphangiogenesis through Regulation of VEGFR3 Degradation in Diabetes
HONG CHEN, Boston, MA

9:30 a.m.-9:45 a.m.
244 -OR Longitudinal Association of Microaneurysm Wall Characteristics with Perfusion and Local Neuroretinal Pathology
JENNIFER K. SUN, OMAR ABU-QAMAR, KONSTANTINA SAMPANI, WARD FICKWEILER, LLOYD P. AIELLO, Boston, MA

9:45 a.m.-10:00 a.m.
245 -OR Diabetic Retinopathy Reversed by Intravitreous Application of Retinol Binding Protein 3
HISASHI YOKOMIZO, KYOUNGMIN PARK, ALLEN CLERMONT, YASUTAKA MAEDA, WARD FICKWEILER, ATSUSHI ISHIKADO, QIAN LI, Liane J. TINSLEY, DAVID M. POBER, I-HSIEN WU, LLOYD P. AIELLO, HILLARY A. KEENAN, JENNIFER SUN, GEORGE L. KING, Boston, MA, Takatsuki, Japan

▲ ADA-Supported Research
MONDAY, JUNE 25, 2018

Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise

Diabetes Self-Management Education and Support—Embracing Data and Digital Dialogue Advances
Room: W204
Chair: Carolina Solis-Herrera, MD

8:00 a.m.-8:15 a.m.
246-OR Presessions to the National Diabetes Prevention Program Are a Promising Strategy to Improve Attendance and Weight Loss Outcomes
NATALIE RITCHIE, PETER G. KAUFMANN, MARK GRITZ, JODI S. HOLTROP, Denver, CO, Aurora, CO

8:15 a.m.-8:30 a.m.
247-OR Mediating Role of Acculturation and Lifestyle Behaviors on Cardiometabolic Risks among Asian Indians in the United States
NITHA MATHEW JOSEPH, RANJITA MISRA, JING WANG, STANLEY CRON, PADMAVATHY RAMASWAMY, Houston, TX, Morgantown, WV

8:30 a.m.-8:45 a.m.
248-OR Enabling Data-Driven Decision Making for Personalized Care in Type 2 Diabetes with Clinical and Lifestyle Journey Data Using a Digital Therapeutic
RAJEEV CHAWLA, MAAZ SHAikh, ABHISHEK SHAH, BANSHI D. SABoo, BRIJ M. MAKkar, JOTHyDEV KESAvADEv, SHILPA JOSHI, NEETA DESHPANDE, SANJAY AGARWA, ANUJ MAHESHWARI, ARAVIND R. SOSALE, SR., SV MADHU, New Delhi, India, Mumbai, India, Ahmedabad, India, Delhi, India, Trivandrum, India, Belgaum, India, Pune, India, Lucknow, India, Bangalore, India

8:45 a.m.-9:00 a.m.
249-OR Innovative Tailored Microlearning Approach to Insulin Self-Management Education Shows High Engagement Levels among Diverse Adults

9:00 a.m.-9:15 a.m.
250-OR On Time—An Innovative Online Discussion Tool to Overcome Barriers to Insulin Initiation
JEREMY GILBERT, GAIL MACNEILL, ELAINE M. COOKE, PIERRE FILTEAU, MICHAEL VALLIS, MÉLANIE GROLEAU, PASHA JAVADI, CYNTHIA LEOBOVICS, Toronto, ON, Canada, Maple Ridge, BC, Canada, Saint-Marc-des-Carrières, QC, Canada, Halifax, NS, Canada, Laval, QC, Canada, Paris, France

9:15 a.m.-9:30 a.m.
251-OR CoMac Communication System—A Feasibility Implementation of Language-Centered Intervention for T2DM
ULLA M. CONNOR, ROBERT SANDY, MARY DE GROOT, ROBERT S. MACNEILL, JR., Indianapolis, IN

9:30 a.m.-9:45 a.m.
252-OR Impacts of a Two-Part Multidisciplinary Diabetes Education Program on Glycemic Control and Hospital Use
HEATHER P.Q. WHITLEY, ANGELA STALLWORTH, DEEPTHI DESAI, COURTNEY HANSON, Montgomery, AL, Tuscaloosa, AL

9:45 a.m.-10:00 a.m.
253-OR Diabetes Educator Impact in Value-Based Care Models
JANICE L. KOSHINSKY, JODI KRALL, KRISTINE RUPPERT, JUSTIN KANTER, FRANCIS X. SOLANO, JR., LINDA M. SIMINERIO, Pittsburgh, PA
Theme Area: Clinical Diabetes/Therapeutics

SGLT2 Inhibitors—From Mechanisms to Clinical Trials (With ADA Presidents’ Select Abstract)
Room: W415B (Valencia Ballroom)
Co-Chairs: Satish K. Garg, MD and John (Jack) Leahy, MD

Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

8:00 a.m.-8:15 a.m.
254-OR ADA Presidents’ Select Abstract: Mechanism by Which Dapagliflozin Induces Euglycemic Ketonacidosis in Rats
RACHEL J. PERRY, JOONGYU D. SONG, YONGLIANG WANG, GERALD I. SHULMAN, New Haven, CT

8:15 a.m.-8:30 a.m.
255-OR SGLT2 Inhibitor Ipragliflozin Induces Breast Cancer Apoptosis via Membrane Hyperpolarization and Mitochondria Dysfunction
SHIHO KOMATSU, TAKASHI NOMIYAMA, TOMOHIRO NUMATA, TAKAKO KAWANAMI, YURIKO HAMAGUCHI, TOMOKO TANAKA, RYUJI INOUE, TOSHIHIKO YANASE, Fukuoka, Japan

8:30 a.m.-8:45 a.m.
256-OR Research into the Effect of Sodium-Glucose Linked Transporter 2 Inhibition on Left Ventricular Remodeling in Patients with Heart Failure and Diabetes Mellitus
JAGDEEP S.S. SINGH, IFY MORDI, MOHAPRADEEP MOHAN, STEPHEN J. GANDY, EWAN PEARSON, JOHN G. HOUSTON, ALLAN D. STRUTHERS, CHIM C. LANG, Dundee, United Kingdom

8:45 a.m.-9:00 a.m.
257-OR Comparing the Effects of Ipragliflozin and Metformin on Visceral Fat Reduction in Patients with Type 2 Diabetes Inadequately Controlled with Sitagliptin—A Prospective, Multicenter, Blinded-Endpoint, Randomized Controlled Study in Japan (PRIME-V Study)
MASAYA KOSHIZAKA, KO ISHIKAWA, RYOICHI ISHIBASHI, YOSHIRO MAEZAWA, KENICHI SAKAMOTO, DAIGAKU UCHIDA, SUSUMU NAKAMURA, HIDETAKA YOKOH, AKINA KOBAYASHI, SHUNICHIRO ONISHI, KAZUKI KOYAMA, JUN OGINO, HIROTAKI TAKAYAMA, FUMIO SHIMADA, EMI OHARA, TAKAHIRO ISHIKAWA, MAYUMI SHOJI, KANA IDE, SHINTARO IDE, YUSUKE NAKAMURA, TAKURO ISHIKAWA, CHIBA, Japan

9:00 a.m.-9:15 a.m.
258-OR Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease
BRENDON L. NEUEN, TOSHIKI OHKUMA, BRUCE NEAL, DAVID R. MATTHEWS, DICK DE ZEEUW, KENNETH W. MAHAFFEY, GREG FULCHER, MEHUL DESAI, QIANG LI, YUHWA LEE, NORM ROSENTHAL, MEG JARDINE, GEORGE BAKRIS, VLADO PERKOVIC, Sydney, Australia, Oxford, United Kingdom, Groningen, Netherlands, Stanford, CA, Raritan, NJ, China

9:15 a.m.-9:30 a.m.
259-OR Overall Safety of Canagliflozin (CANA) in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program
PRISCILLA HOLLANDER, VISWANATHAN MOHAN, VINCENT C. WOO, RICHARD OH, GREG FULCHER, Dallas, TX, Chennai, India, Winnipeg, MB, Canada, Raritan, NJ, Sydney, Australia

9:30 a.m.-9:45 a.m.
260-OR Dapagliflozin plus Saxagliptin Shows Noninferior A1C Reduction vs. Insulin Glargine in Patients with Type 2 Diabetes Inadequately Controlled by Metformin With or Without Sulfonylurea
TINA VILSBØLL, ELLA EKHOLM, EVA K. JOHNSSON, NALINA DRONAMRAJU, SERGE JABBOUR, MARCUS LIND, Copenhagen, Denmark, Möln达尔, Sweden, Gaithersburg, MD, Philadelphia, PA, Gothenburg, Sweden

9:45 a.m.-10:00 a.m.
261-OR Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
JUAN P. FRIAS, GUILLERMO GONZALEZ-GALVEZ, EVA K. JOHNSSON, JILL MAASKE, ANNE PETERS, Los Angeles, CA, Guadalajara, Mexico, Möln达尔, Sweden, Gaithersburg, MD
MONDAY, JUNE 25, 2018

Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Epidemiology/Genetics
Genetic and Ethnic Heterogeneity and the Road to Precision Medicine in Diabetes (With ADA Presidents’ Select Abstract)
Room: W206
Chair: Stephen S. Rich, PhD

8:00 a.m.-8:15 a.m.
262-OR ADA Presidents’ Select Abstract: Malate Dehydrogenase 2 (MDH2) as a New Diabetogene Causing Hyperglycemia in Families with Multigenerational Diabetes
PRAPAPORN JUNGTRAKOON, SERENA PEZZILLI, ANTONELLA MARUCCI, LUCA PANNONE, ELISABETTA FLEX, TOMMASO BIAGINI, PATINUT BURANASUPKAJORN, ORNELLA LUDOVICO, LUANA MERCURI, TIMOTHY HASTINGS, ROSA DI PAOLA, FEDERICA ALBERICO, CHRISTINE MENDONCA, JULIAN CERON, MONTSSERRAT PORTA DE LA RIVA, LORELLA MARSELLI, SIMONE MARTINELLI, VINCENZO TRISCHITTA, ALESSANDRO DORIA, SABRINA PRUDENTE, Bangkok, Thailand, Rome, Italy, San Giovanni Rotondo, Italy, Boston, MA, Barcelona, Spain, Pisa, Italy

8:15 a.m.-8:30 a.m.
263-OR Genotypic Associations with C-Peptide Persistence in People with Type 1 Diabetes
PAUL MCKEIGUE, ATHINA SPILOPOULOU, STUART MCGURNAGHAN, MARCO COLOMBO, TIMOTHY J. MCDONALD, HELEN COLHOUN, ON BEHALF OF THE SDRNT1BIO INVESTIGATORS, Edinburgh, United Kingdom, Exeter, United Kingdom

8:30 a.m.-8:45 a.m.
264-OR Clinical Utility of the T1D Genetic Risk Score—Examples from the U.S. Monogenic Diabetes Registry
MAY SANYOURA, LISA R. LETOURNEAU, ROCHELLE N. NAYLOR, LOUIS H. PHILIPSON, MICHAEL N. WEDDON, RICHARD A. ORAM, SIRI ATMA W. GREELEY, Chicago, IL, Exeter, United Kingdom

8:45 a.m.-9:00 a.m.
265-OR HLA-C Position 275, a Novel HLA Locus Identified in Autoantibody-Positive Type 1 Diabetes of Chinese Han Population Based on a Genome-Wide Association Study
KUANFENG XU, YANG CHEN, YONG GU, MENG ZHU, MEI ZHANG, MIN SUN, XINYU XU, HSIANG-TING HSU, HENG CHEN, YUN SHI, YUN CAI, HAO DAI, SHUAI ZHENG, XUQIN ZHENG, HONGWEN ZHOU, LI-PING YU, ZHIBIN HU, ZHIGUANG ZHOU, JIANPING WENG, HONGBING SHEN, TAO YANG, Nanjing, China, Shanghai, China, Guangzhou, China, Jiangsu, China

9:00 a.m.-9:15 a.m.
266-OR A Nonsynonymous Variant in GLP-1R Is Associated with Decreased Risk of Type 2 Diabetes in Koreans
SOO HEON KWAK, JEESOO CHAE, JIWON YOON, SUNGHEE CHOI, SOO LIM, MIN KYONG MOON, YOUNG MIN CHO, HAK CHUL JANG, YOON SHIN CHO, HYUN MIN KANG, JONG-IL KIM, KYONG SOO PARK, Seoul, Republic of Korea, Seongnam, Republic of Korea, Chuncheon, Republic of Korea, Ann Arbor, MI

9:15 a.m.-9:30 a.m.
267-OR Identifying Pathogenic Variants of Monogenic Diabetes Using Targeted Exome Sequencing
SEUNG SHIN PARK, SE SONG JANG, YOUNG AH LEE, YOUNG MIN CHO, HAK CHUL JANG, KYONG SOO PARK, SOO HEON KWAK, Seoul, Republic of Korea, Seongnam, Republic of Korea

9:30 a.m.-9:45 a.m.
268-OR Monogenic Diabetes in the Progress for Diabetes Genetics in Youth (ProDiGy) Collaboration
JENNIFER TODD, JEFFREY W. KLEINBERGER, SHYLAJA SRINIVASAN, SHERIDA E. TOLLEFSSEN, LYNNNE L. LEVITSKY, LORRAINE E. KATZ, JEANIE B. TRYGGESTAD, FIDA BACHA, GIUSEPPINA IMPERATORE, JEAN M. LAWRENCE, CATHERINE PIHOKER, JASMIN DIVERS, JASON FLANNICK, DANIELE ABELE, JOSE C. FLOREZ, TONI I. POLLIN, Boston, MA, Baltimore, MD, San Francisco, CA, St. Louis, MO, Philadelphia, PA, Oklahoma City, OK, Houston, TX, Atlanta, GA, Pasadena, CA, Seattle, WA, Winston-Salem, NC, Cambridge, MA, Aurora, CO

9:45 a.m.-10:00 a.m.
269-OR Digenic Mutations in the FGF-21 Signaling Pathway Found in an Adolescent with Extreme Insulin Resistance
STEPHEN I. STONE, ELIZABETH A. ADESANYA, DANIEL J. WEGNER, JENNIFER A. WAMBACH, F. SESSIONS COLE, DAVID M. ORNITZ, FUMIHIKO URANO, St. Louis, MO
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Insulin Action/Molecular Metabolism
Adipose Browning and Energy Expenditure (With State-of-the-Art Lecture)
Room: W209
Chair: Kristin I. Stanford, PhD

8:00 a.m.-8:30 a.m.
State-of-the-Art Lecture
Identification and Function of Brown Adipose Tissue in Humans
Aaron M. Cypess, MD, PhD, MMSc

8:30 a.m.-8:45 a.m.
270-OR NFIA Colocalizes with PPARgamma and Activates the Cell-Type-Specific Enhancers to Control the Brown Fat Gene Program
YUTA HIRAIKE, HIRONORI WAKI, SHUICHI TSUTSUMI, HIROYUKI ABURATANI, TOSHIMASA YAMAUCHI, TAKASHI KADOWAKI, Tokyo, Japan

8:45 a.m.-9:00 a.m.
271-OR STAT5 Deficiency in Mature Adipocytes Results in Metabolically Healthy Adiposity, Reduced Growth Hormone Signaling in Adipose Tissue, and Decreased Energy Expenditure
ALLISON J. RICHARD, HARDY HANG, TIMOTHY D. ALLERTON, CARRIE M. ELKS, JACQUELINE M. STEPHENS, Baton Rouge, LA

9:00 a.m.-9:15 a.m.
272-OR Reprogramming of Human Adipocytes to a Briter Phenotype—Enhanced Fatty Acid Oxidation and Lipid Droplet Remodeling
MI-JEONG LEE, SUKANTA JASH, VISHWAJEET PURI, SUSAN K. FRIED, New York, NY, Athens, OH

9:15 a.m.-9:30 a.m.
273-OR CRISPR-Engineered Human Brown-Like Adipocytes Promotes Metabolic Homeostasis through Activation of Endogenous Brown Fat
CHIH-HAO WANG, MORTEN LUNDH, ROKUS KRISZT, TIAN LIAN HUANG, LUIZ O. LEIRIA, FARNAZ SHAMSI, MATT LYNES, JUSTIN DARCY, BRICE EMANUELLI, MICHAEL KIEBISH, YU-HUA TSENG, Boston, MA, Copenhagen, Denmark, Singapore, Singapore, Framingham, MA

9:30 a.m.-9:45 a.m.
274-OR Sirt5 Plays a Critical Role in Mitochondrial Protein Acylation and Mitochondrial Metabolic Homeostasis in Brown Fat
GUOXIAO WANG, JESSE G. MEYER, WEIKANG CAI, MENGYAO E. LI, SAMIR SOFTIC, C. RONALD KAHN, Boston, MA, Novato, CA

9:45 a.m.-10:00 a.m.
275-OR BAF60a Orchestrates Thermogenic Chromatin Accessibility in Brown Fat
SIMING LI, TONGYU LIU, LIN MI, ZHUOXIAN MENG, JIANDIE LIN, Ann Arbor, MI, Hangzhou, China
Oral Presentations
8:00 a.m.-10:00 a.m.
(continued)

Theme Area: Integrated Physiology/Obesity

Novel Mediators and Mechanisms of Obesity Pathogenesis in Animals
Room: W203
Chair: Kevin Williams, PhD

8:00 a.m.-8:15 a.m.
276-OR Targeting the Amyloid Precursor Protein (APP) to Mitochondria of White Adipose Tissues Triggers Mitochondrial Dysfunction and Obesity
YU A. AN, PHILIPP E. SCHERER, Dallas, TX

8:15 a.m.-8:30 a.m.
277-OR ▲ Fibroblast Growth Factor-9 Regulates Adaptive Brown Adipose Tissue Mass Expansion
FARNAZ SHAMSI, TIAN LIAN HUANG, YU-HUA TSENG, Boston, MA

8:30 a.m.-8:45 a.m.
278-OR Endoplasmic Reticulum Membrane Protein Complex 10 (EMC10), a Novel Circulating Factor for Systemic Energy and Metabolic Homeostasis
XUANCHUN WANG, GUIFEN QIANG, YANLIANG LI, XINYI CAO, VICTORIA GIL, SHENGXIAN LI, KUANGYANG CHEN, XINRU WANG, MATTHIAS BLUHER, CHONG WEE LIEW, Shanghai, China, Beijing, China, Chicago, IL, Leipzig, Germany

8:45 a.m.-9:00 a.m.
279-OR HOXC10 Maintains White Adipose Tissue Identity and Its Loss Leads to Enhanced Browning of White Adipose Tissues
ANGELINE H.Y. TAN, SINYEE GUN, WEIPING HAN, Singapore, Singapore, Coppell, TX

9:00 a.m.-9:15 a.m.
280-OR A UCP1 Near-Infrared Reporter System for Monitoring Adipose “Browning” In Vivo Using Photoacoustic Imaging
DERRYN XIN HUI CHAN, SHIGEKI SUGII, WEIPING HAN, Singapore, Singapore, Coppell, TX

9:15 a.m.-9:30 a.m.
281-OR Ablation of Adipose CREB3L3 Protects Mice from Obesity-Induced Metabolic Dysfunction
MAXIMILIAN A. MCCANN, GUIFEN QIANG, VICTORIA GIL, HYERIM WHANG KONG, KEZHONG ZHANG, CHONG WEE LIEW, Chicago, IL, Beijing, China, Detroit, MI

9:30 a.m.-9:45 a.m.
282-OR Androgens Activate Myeloid Cells during High-Fat Diet Exposure Promoting Sex Differences in Metabolic Disease
CAMERON A. GRIFFIN, SIMIN ABRISHAMI, MITA VARGHESE, KANAKADURGA SINGER, Ann Arbor, MI

9:45 a.m.-10:00 a.m.
283-OR Targeting Intestinal Macrophages as a Potential Therapeutic Option in Obesity
THERESA V. ROHM, SHEFAA ALASFOOR, ANGELA J. BOSCH, CLAUDIA CAVELTI-WEDER, Basel, Switzerland
10:10 a.m.-11:45 a.m.
National Scientific & Health Care Achievement Awards Presentation

and

Outstanding Scientific Achievement Award Lecture
Harnessing Brain Circuits to Improve Type 2 Diabetes
Lora K. Heisler, PhD
Room: Hall WB4

12:00 p.m.-1:00 p.m.

Mini-Symposium
Theme Area: Acute and Chronic Complications
Special Topics in Hypoglycemia
Room: W307
Chair: Lisa Chow, MD
12:00 p.m.-12:20 p.m. New Definition of Hypoglycemia—Why Does It Matter?
Simon R. Heller, MD, FRCP
12:20 p.m.-12:40 p.m. Economic Impact of Severe Hypoglycemia
Philip C. McEwan, PhD
12:40 p.m.-1:00 p.m. Question and Discussion Period

Mini-Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Overcoming Gender Gaps in Science
Room: W304E-H
Chair: Maureen A. Gannon, PhD
12:00 p.m.-12:20 p.m. Gender Gaps in Science—The Clinician Scientist Perspective
Elizabeth R. Seaquist, MD
12:20 p.m.-12:40 p.m. Overcoming Gender Gaps in Science—A Health Education and Behavioral Discipline Perspective
Felicia Hill-Briggs, PhD, ABPP
12:40 p.m.-1:00 p.m. Gender Gaps in Science—Panel Discussion
Jane E.B. Reusch, MD
Professional Interest Group Session
Theme Area: Clinical Diabetes/Therapeutics
The Lancet Commission on Diabetes—Societal Solutions to Combat Diabetes
Supported by a grant from The Leona M. and Harry B. Helmsley Charitable Trust
Room: W204
Co-Chairs: Anne L. Peters, MD and Jennifer Sargent, PhD
12:00 p.m.-12:15 p.m.  Diabetes—A Global Epidemic Requiring Societal Solutions
   Edward W. Gregg, PhD
12:15 p.m.-12:30 p.m.  Act Now to Change Environments for Preventing Diabetes and Evaluate Impacts
   Nicholas Wareham, PhD
12:30 p.m.-12:45 p.m.  Strengthening the System to Improve Diabetes Care and Access to Cost-Effective Drugs
   Juliana C.N. Chan, MD
12:45 p.m.-1:00 p.m.  Population and Health System Surveillance
   Jonathan E. Shaw, MD, FRACP, FRCP (UK), FAAHMS

Professional Interest Group Session
Theme Area: Clinical Diabetes/Therapeutics
Should All Pregnant Women with Type 1 Diabetes Use Continuous Glucose Monitoring from Planning Pregnancy until after Breastfeeding?
Room: W304A-D
Chair: Rebecca A. Simmons, MD
12:00 p.m.-12:30 p.m.  Pro
   Denice S. Feig, MD, MSc, FRCPC
12:30 p.m.-1:00 p.m.  Con
   Elisabeth R. Mathiesen, MD, DMS

Professional Interest Group Session
Theme Area: Clinical Diabetes/Therapeutics
Clinical Centers and Programs Session II
Room: W209
Chair: Boris Draznin, MD, PhD
12:00 p.m.-12:15 p.m.  Endocrinology Telehealth Consultation Improved Glycemic Control Similar to Face-to-Face Visits in Veterans
   Neda Rasouli, MD
12:15 p.m.-12:30 p.m.  Diabetes Telemedicine Development in the Great Plains
   Leslie Eiland, MD
12:30 p.m.-12:45 p.m.  A Feasibility Study using Polaris, an Automated Lifestyle Health Navigator Mobile App, to Optimize Metabolic Index
   Ping H. Wang, MD
12:45 p.m.-1:00 p.m.  Integrating Technology with Remote Diabetes Management
   Joseph A. Aloi, MD

Professional Interest Group Session
Theme Area: Epidemiology/Genetics
Defining a Healthy Diet—Do Fats or Carbohydrates Matter More?
Room: W315
Chair: Karen R. Siegel, PhD, MPH
12:00 p.m.-12:30 p.m.  It's All about the Fats!
   Allison Sylvetsky, PhD
12:30 p.m.-1:00 p.m.  It's All about the Carbs!
   Viswanathan Mohan, MD, PhD, DSc
12:00 p.m.-1:00 p.m.  
(continued)

Professional Interest Group Session  
Theme Area: Immunology/Transplantation  
Immunopathogenesis of Type 1 Diabetes—Is It Autoimmunity?  
Room: W206  
Chair: Mark A. Atkinson, PhD  
12:00 p.m.-12:20 p.m.  Type 1 Diabetes Is an Autoimmune Disease  
Hubert M. Tse, PhD  
12:20 p.m.-12:40 p.m.  Type 1 Diabetes Is More than Just Autoimmunity  
Raghavendra G. Mirmira, MD, PhD  
12:40 p.m.-1:00 p.m.  Question and Discussion Period
12:00 p.m.-1:00 p.m.  
(continued)

General Poster Session  
Hall WA4-WB2 (Poster Hall)

All posters will be displayed Saturday, Sunday, and Monday. Poster presenters in the following categories will be at their posters during this period for questions and discussion with attendees.

Presented Categories

Theme Area: Acute and Chronic Complications  
Complications—Macrovascular—Atherosclerotic Cardiovascular Disease and Human Diabetes  
Posters: 407-P to 469-P

Theme Area: Acute and Chronic Complications  
Complications—Macrovascular—Cellular Mechanisms of Atherogenesis in Diabetes  
Posters: 470-P to 490-P

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Diabetes Education  
Posters: 648-P to 729-P

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Exercise  
Posters: 730-P to 759-P

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Nutrition—Clinical  
Posters: 760-P to 793-P

Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Psychosocial, Behavioral Medicine  
Posters: 794-P to 897-P

Theme Area: Clinical Diabetes/Therapeutics  
Pediatrics—Obesity and Type 2 Diabetes  
Posters: 1334-P to 1365-P

Theme Area: Clinical Diabetes/Therapeutics  
Pediatrics—Type 1 Diabetes  
Posters: 1366-P to 1396-P

Theme Area: Epidemiology/Genetics  
Genetics—Type 2 Diabetes  
Posters: 1703-P to 1725-P

Theme Area: Insulin Action/Molecular Metabolism  
Insulin Action—Cellular and Molecular Metabolism  
Posters: 1765-P to 1775-P

Theme Area: Insulin Action/Molecular Metabolism  
Insulin Action—Glucose Transport and Insulin Resistance In Vitro  
Posters: 1776-P to 1779-P

Theme Area: Integrated Physiology/Obesity  
Integrated Physiology—Insulin Secretion In Vivo  
Posters: 1808-P to 1832-P

Theme Area: Integrated Physiology/Obesity  
Integrated Physiology—Liver  
Posters: 1833-P to 1883-P

Theme Area: Integrated Physiology/Obesity  
Integrated Physiology—Macronutrient Metabolism and Food Intake  
Posters: 1884-P to 1901-P

Theme Area: Islet Biology/Insulin Secretion  
Islet Biology—Apoptosis  
Posters: 2102-P to 2115-P

Theme Area: Islet Biology/Insulin Secretion  
Islet Biology—Beta Cell—Development and Postnatal Growth  
Posters: 2116-P to 2139-P

Theme Area: All Categories  
Late Breaking Posters  
Posters: 1-LB to 317-LB
12:00 p.m.-1:00 p.m.
(continued)

Moderated Poster Discussions
Hall WA4-WB2 (Poster Hall)/Hall WA1-WA3 (Exhibit Hall)

Continuing Education Credit is not awarded for Moderated Poster Discussions.

Explore the Poster Hall with a Moderated Poster Discussion. Poster presenters will share their perspectives and highlight novel or recent developments in question and answer discussions with session moderators. Follow the steps below to attend a Moderated Poster Discussion:

- Identify the discussion you are interested in attending from the schedule listed below.
- Note the location of the discussion. Discussions will start at the first poster board number in the discussion, OR in one of two ePoster Theaters located within the Exhibit Hall (booth 952).
- Proceed to the location of the session at least 5 minutes before the start of the discussion.

There is no required sign-up to attend a discussion, however space and equipment is available on a first-come, first-served basis.

Presented Discussions

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>New Insights from Continuous Glucose Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 898-P to 903-P</td>
<td>Location: Exhibit Hall (ePoster Theater A)</td>
</tr>
<tr>
<td>Moderator: Joseph El Youssef, MBBS</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Clinical Diabetes/Therapeutics</th>
<th>Innovative Insulin Delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 960-P to 965-P</td>
<td>Location: Exhibit Hall (ePoster Theater B)</td>
</tr>
<tr>
<td>Moderator: Joshua D. Miller, MD, MPH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>Clinical and Translational Studies in Diabetic Kidney Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 517-P to 522-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Sally Marshall, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>Latest Breakthroughs in the Clinical and Basic Science of Diabetic Neuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 547-P to 552-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Lucy M. Hinder, PhD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Theme Area: Acute and Chronic Complications</th>
<th>Role of Systemic and Retinal-Specific Factors in Diabetic Retinopathy Pathogenesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters: 589-P to 594-P</td>
<td>Location: Poster Hall (First poster in discussion)</td>
</tr>
<tr>
<td>Moderator: Yaqian Duan, MD, PhD</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY, JUNE 25, 2018

1:00 p.m.-2:00 p.m.
Session Break
Take this opportunity to visit the Exhibit and Poster Halls

2:15 p.m.-4:15 p.m.

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Easing Disease Management Burden for Older Adults
Room: W307
Chair: Susan Cornell, PharmD, CDE, FAPhA
2:15 p.m.-2:45 p.m. Assessing Functional Decline in Older Adults—Influences in Decision Making
Barbara Resnick, PhD, RN, CRNP
2:45 p.m.-3:15 p.m. Polypharmacy and the Older Adult—Easing the Medication Burden
Leigh Ann Mike, PharmD, BCPS, BCGP
3:15 p.m.-3:45 p.m. Tailoring the Diabetes Regimen—One Size Does Not Fit All
Mary C. Ballin, GNP-BC, CDE
3:45 p.m.-4:15 p.m. Creating Educational Interventions for Older Adults
Elizabeth A. Beverly, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Cost-Related Nonadherence to Diabetes Care
Room: W315
Chair: Elbert S. Huang, MD, MPH, FACP
2:15 p.m.-2:35 p.m. Introduction—Financial Incentives in Health Insurance—What Is Their Role?
A. Mark Fendrick, MD
2:35 p.m.-2:55 p.m. Cost-Related Nonadherence in Medicare Beneficiaries
Carol M. Mangione, MD, MSPH
2:55 p.m.-3:15 p.m. Social Determinants of Cost-Related Nonadherence with Diabetes Care
Minal R. Patel, PhD, MPH
3:15 p.m.-3:35 p.m. Effect of High-Deductible Health Insurance on Diabetes Care and Outcomes
J. Frank Wharam, MB, BCh, BAO, MPH
3:35 p.m.-3:55 p.m. Level of Deductible in an Insurance Plan Affects Medical Care Use in Individuals with Diabetes
Anuradha Jetty, MPH
3:55 p.m.-4:15 p.m. Question and Discussion Period
Symposium
Theme Area: Clinical Diabetes/Therapeutics
The Restoring Insulin Secretion (RISE) Study in Youth and Adults—Baseline Data and Results of the Pediatric Medication Study
Room: W415B (Valencia Ballroom)
Co-Chairs: Judith E. Fradkin, MD and Steven E. Kahn, MB, ChB
2:15 p.m.-2:20 p.m. General Introduction
Griffin P. Rodgers, MD
Background
2:20 p.m.-2:30 p.m. Rationale for Intervention Studies Addressing the Pathophysiology of Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes in Youth and Adults
David A. Ehrmann, MD
2:30 p.m.-2:40 p.m. Study Designs—Pediatric Medication, Adult Medication, and Adult Surgery Protocols
Sharon L. Edelstein, ScM
Baseline Data Comparing Youth and Adults
2:40 p.m.-2:55 p.m. Demographics, Insulin Sensitivity, and Cardiovascular Disease Risk Factors
Kieren J. Mather, MD
2:55 p.m.-3:10 p.m. Contrasts in Beta-Cell Function Based on the Hyperglycemic Clamp and OGTT
Silva A. Arslanian, MD
RISE Pediatric Medication Study Results
3:10 p.m.-3:20 p.m. Comparisons of Baseline Data by Intervention Arms
Tamara S. Hannon, MD, MS
3:20 p.m.-3:35 p.m. Primary Outcome
Kristen J. Nadeau, MD, MS
3:35 p.m.-3:50 p.m. Secondary Outcomes and Adverse Events
Philip S. Zeitler, MD, PhD
3:50 p.m.-4:05 p.m. From Disease Mechanisms to Clinical Implications
Sonia Caprio, MD
4:05 p.m.-4:15 p.m. Independent Commentary
John B. Buse, MD, PhD
Symposium
Theme Area: Insulin Action/Molecular Metabolism
Adipose Signaling and the Central Nervous System in the Control of Obesity
Room: W209
Chair: Sheila Collins, PhD
2:15 p.m.-2:45 p.m. Astrocytes and the Regulation of Energy Homeostasis
Kate Ellacott, PhD
2:45 p.m.-3:15 p.m. New Cell Types Involved in Hypothalamic Obesity
Linus T.-Y. Tsai, MD, PhD
3:15 p.m.-3:45 p.m. IKKβ, from Atherogenesis to Adipogenesis and Beyond
Changcheng Zhou, PhD
3:45 p.m.-4:15 p.m. Adipose Inflammation
Ajay Chawla, MD, PhD
Symposium
Theme Area: Integrated Physiology/Obesity
Diversity Affairs—Impact of Genetic Variability and Sex on Integrative Metabolism and Disease Risk
Room: W304A-D
Chair: Miklos Peterfy, PhD
2:15 p.m.-2:45 p.m. Genetic Heterogeneity in Murine Responses to High-Fat Diet
Brian Parks, PhD
2:45 p.m.-3:15 p.m. Genetic Diversity of Lifespan Modulation in Mice
Colin Selman, PhD
3:15 p.m.-3:45 p.m. Systems Network Modeling of Genetic Risks of Metabolic Diseases
Xia Yang, PhD
3:45 p.m.-4:15 p.m. Dissecting the Role of Estrogen Receptors in the Regulation of Metabolic Homeostasis in Muscle
Espen E. Spangenburg, PhD
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Acute and Chronic Complications

Evolving Mechanisms in Cardiovascular Complications (With Edwin Bierman Award Lecture)
Room: W208
Chair: Willa Hsueh, MD

2:15 p.m.-2:45 p.m.

Edwin Bierman Award Lecture

Leveraging Genetics to Improve Cardiovascular Health in Diabetes
Alessandro Doria, MD, PhD, MPH

2:45 p.m.-3:00 p.m.

284-OR Insulin Resistance and Type 2 Diabetes Mellitus Are Associated with Impaired Mitochondrial Function in Human Ventricular Myocardium
ELRIC ZWECK, DANIEL SCHEIBER, TOMAS JELENIK, PATRICK HORN, SOPHIE ALBERMANN, UDO BOEKEN, DIYAR SAEED, MALTE KELM, MICHAEL RODEN, RALF WESTENFELD, JULIA SZENDROEDI, Düsseldorf, Germany

3:00 p.m.-3:15 p.m.

285-OR The Novel Adipokine C1QTNF1 Significantly Predicts the Incidence of Future Major Cardiovascular Events in Patients with Type 2 Diabetes
AXEL MUENDEL, ANDREAS LEIHERER, CHRISTOPH H. SAELY, KATHRIN GEIGER, JANINE EBNER, EVA-MARIA BRANDTNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, HEINZ DREXEL, Feldkirch, Austria, Triesen, Liechtenstein, Bern, Switzerland, Philadelphia, PA

3:15 p.m.-3:30 p.m.

286-OR Endothelial/Nitric Oxide Regulation of Brown Adipose Tissue Activating Lipokine, 12, 13-diHOME and Its Antiatherogenic Actions
Kyoungmin Park, Qian Li, Matt Lynes, Hisashi Yokomizo, Takanori Shinjo, Ronald St-Louis, Jialin Fu, Christian Rask-Madsen, Yu-Hua Tseng, George L. King, Boston, MA

3:30 p.m.-3:45 p.m.

287-OR Modified Mesenchymal Stromal Cells Promote Multiple Metabolic Benefits in Obese Diabetic Mice
Cleyton C. Domingues, Nabanita Kundu, Yana Kropotova, Neeki Ahmadi, Sabyasachi Sen, Washington, DC

3:45 p.m.-4:00 p.m.

288-OR Loss of Insulin Actions on Arterial Smooth Muscle Cells May Enhance Unstable Atherosclerotic Plaque Formation
Qian Li, Jialin Fu, Kyoungmin Park, Christian Rask-Madsen, George L. King, Boston, MA

4:00 p.m.-4:15 p.m.

289-OR Liraglutide Suppresses Atherosclerosis via AMP-Activated Protein Kinase Dependent and Independent Mechanisms in Diabetic Apolipoprotein Enulf Mice
Masakazu Koshibu, Yusaku Mori, Hideki Kushima, Munenori Hiromura, Kyoko Kohashi, Michi-Ishige Terasaki, Tsutomu Hirano, Tokyo, Japan
**Oral Presentations**  
2:15 p.m.-4:15 p.m.  
(continued)

**Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise**  
**Nutrition 2018—New Data, New Perspectives**  
Room: W203  
Chair: Kyle Burger, PhD

2:15 p.m.-2:30 p.m.  
**290-OR**  
Relationship between Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes  
KIRSTINE BELL, SALLY DUKE, KYLIE M. ALEXANDER, MARGARET MCGILL, JENCIA WONG, GREGORY FULCHER, STEPHEN M. TWIGG, JENNIE BRAND-MILLER, GARRY M. STEIL, Sydney, Australia, Boston, MA

2:30 p.m.-2:45 p.m.  
**291-OR**  
Baseline Predictors and Influence of Early Weight Loss during an Intensive Weight Management Programme on Remission of Type 2 Diabetes after 12 Months—Post-Hoc Analysis of the Diabetes Remission Clinical Trial (DIRECT)  
MICHAEL E.J. LEAN, WILMA S. LESLIE, NAVEED SATTAR, GEORGE THOM, ELIZABETH L. MCCOMBIE, NAOMI T. BROSNAHAN, ALISON C. BARNES, ROY TAYLOR, ALEX MCCONNACHIE, FOR THE DIRECT STUDY TEAM, Glasgow, United Kingdom, Newcastle upon Tyne, United Kingdom

2:45 p.m.-3:00 p.m.  
**292-OR**  
Acute Insulin Secretory Effects of a Classic Ketogenic Meal in Healthy Subjects  
SIMONA BERTOLI, ANGELA SPADAFRANCA, RAMONA DE AMICIS, ALESSANDRO LEONE, ANDREA MARI, ALBERTO BATTEZZATI, Piacenza, Italy, Milan, Italy, Padova, Italy

3:00 p.m.-3:15 p.m.  
**293-OR**  
Continuous Remote Care Model Utilizing Nutritional Ketosis Improves Type 2 Diabetes Risk Factors in Patients with Prediabetes  
AMY MCKENZIE, SARAH HALLBERG, NASIR H. BHANPUR, SHAMINIE J. ATINARAYANAN, JACKSON MCCUE, JAMES P. MCCARTER, JEFF VOLEK, STEPHEN PHINNEY, San Francisco, CA, Columbus, OH

3:15 p.m.-3:30 p.m.  
**294-OR**  
A Plant-Based Diet Improves Beta-Cell Function and Insulin Resistance in Overweight Adults—A 16-Week Randomized Clinical Trial  
HANA KAHLEOVA, ANDREA TURA, MARTIN HILL, RICHARD HOLUBKOV, NEAL BARNARD, Washington, DC, Padua, Italy, Prague, Czech Republic, Salt Lake City, UT

3:30 p.m.-3:45 p.m.  
**295-OR**  
The Common Food Additive Carrageenan Increases Intestinal Permeability without Affecting Whole-Body Insulin Sensitivity in Humans—Results from a Randomized, Double-Blind Crossover Study  
ROBERT WAGNER, JANINE BÜTTNER, MARTIN HENI, LOUISE FRITSCH, STEPHANIE KULLMANN, MORITZ WAGMÜLLER, ANDREAS PETER, HUBERT PREISSL, JUERGEN MACHANN, ULRICH-FRANK PAPE, GERRIT VAN HALL, PETER PLOMGAAARD, REINHILD KLEIN, ANDREAS FRITSCH, HANS-ULRICH HAERING, NORBERT STEFAN, Tübingen, Germany, Berlin, Germany, Copenhagen, Denmark

3:45 p.m.-4:00 p.m.  
**296-OR**  
Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men  
MICHAEL KRUSE, MARGRIT KEMPER, SOFYA GANCHEVA, DIRK DANNENBERGER, DANIEL F. MARKGRAF, MICHAEL RODEN, ANDREAS F. PFEIFFER, Nuthetal, Germany, Düsseldorf, Germany, Dummerstorf, Germany, Berlin, Germany

4:00 p.m.-4:15 p.m.  
**297-OR**  
Gut Microbiota Metabolites, Amino Acid Metabolites, and Improvements in Diabetes-Related Traits—The POUNDS Lost Trial  
YORIKO HEIANZA, DIANJIAN YI SUN, GEORGE BRAY, LU OI, New Orleans, LA, Baton Rouge, LA
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Preventing and Treating Hypoglycemia
Room: W311
Co-Chairs: Anne L. Peters, MD and Heather P.Q. Whitley, PharmD

2:15 p.m.-2:30 p.m.
298-OR Predictors of Hypoglycemia Avoidance in a Randomized Controlled rtCGM Trial (HypoDE)
NORBERT HERMANNS, LUTZ HEINEMANN, GUIDO FRECKMANN, DELIA WALDENMAIER, DOMINIC EH RMANN, Bad Mergentheim, Germany, Düsseldorf, Germany, Ulm, Germany

2:30 p.m.-2:45 p.m.
299-OR Differential Effects of the Insulin-Only and Bihormonal Configurations of the Bionic Pancreas on Mean Glucose and Hypoglycemia during the Daytime and Nighttime
JORDAN SHERWOOD, COURTNEY A. BALLIRO, RABAB Z. JAFRI, FIRAS EL-KHATIB, MICHELE MAHENO, MALLORY A. HILLARD, ALEXANDER J. O’DONOVAN, RAJENDRANATH SELAGAMSETTY, HUI ZHENG, EDWARD DAMIANO, STEVEN J. RUSSELL, Boston, MA

2:45 p.m.-3:00 p.m.
300-OR Relationship between A1C and Hypoglycemia Risk in Individual Patients Comparing Insulin Degludec with Insulin Glargine U100
ATHENA PHILIS-TSIMIKAS, WENDY LANE, ULRIK PEDERSEN-BJERGAARD, CAROL H. WYSHAM, LARS BARDTRUM, SIGNE H. ØSTOFT, SIMON HELLER, San Diego, CA, Asheville, NC, Hillerød, Denmark, Spokane, WA, Søborg, Denmark, Sheffield, United Kingdom

3:00 p.m.-3:15 p.m.
301-OR Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (IDeg-100) in Insulin-Naïve T2DM on Antihyperglycemic Drugs ± GLP-1 RAs—The BRIGHT Randomized Study
ALICE Y.Y. CHENG, JULIO ROSENSTOCK, ROBERT RITZEL, ZSOLT BOSNYAK, CHRISTINE DEVISME, PETER STELLA, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, GEREMIA B. BOLLI, Mississauga, ON, Canada, Dallas, TX, Munich, Germany, Paris, France, Boulogne-Billancourt, France, Tokyo, Japan, Beijing, China, Los Angeles, CA, Perugia, Italy

3:15 p.m.-3:30 p.m.
302-OR Efficacy and Safety of Insulin Degludec and Insulin Glargine U-100 in Hospitalized Patients with Type 2 Diabetes—An Open-Label, Randomized Controlled Study
JUN SUZUKI, TADASHI YAMAKAWA, MINORI SHINODA, RIKA SAKAMOTO, KENICHIRO TAKAHASHI, YASUO TERAUCHI, Yokohama, Japan

3:30 p.m.-3:45 p.m.
303-OR Self- vs. Physician-Led Titration of Insulin Glargine 300 U/mL (Gla-300)—Improved or Comparable Efficacy at Week 24 without Increased Risk of Hypoglycemia, Irrespective of Age (<65 or ≥65 Years)—TAKE CONTROL
KRZYSZTOF STROJEK, GREGORY BIGOT, MIREILLE BONNEMAIRE, ELIAS DELGADO, VIERA DONICOVA, MILAN KVAPEL, NIKOLAOS PAPANAS, LUIZA POPESCU, ROBERT RITZEL, BERND SCHULTES, LEA DUVNJAK, Zabrze, Poland, Levallois-Perret, France, Paris, France, Oviedo, Spain, Kosice, Slovakia, Prague, Czech Republic, Alexandroupolis, Greece, Bucharest, Romania, Munich, Germany, St. Gallen, Switzerland, Zagreb, Croatia

3:45 p.m.-4:00 p.m.
304-OR A Phase 3 Comparison of a Novel Liquid Glucagon Autoinjector to Glucagon Emergency Kit for the Symptomatic Relief of Severe Hypoglycemia
MARK P. CHRISTIANSEN, MARTIN J. CUMMINS, STEVEN J. PRESTRELSKI, POUL STRANGE, Walnut Creek, CA, Chicago, IL, Princeton Junction, NJ

4:00 p.m.-4:15 p.m.
305-OR BioChaperone Glucagon (BCG), a Stable Ready-to-Use Liquid Glucagon Formulation, Is Well Tolerated and Quickly Restores Euglycemia after Insulin-Induced Hypoglycemia
STANISLAV GLEZER, ULRIKE HOVELMANN, SOPHIE TENG, DANIELA LAMERS, MARION ODOUL, JOSÉ CORREIA, ERIC ZIJLSTRA, MARTIN GAUDIER, OLIVER SOULA, DAVID DURACHER, Skillman, NJ, Neuss, Germany, Lyon, France
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Epidemiology/Genetics
Race and Societal Influences on Diabetes (With Vivian Fonseca and Nagendran Family Diabetes Research Award Presentation)
Room: W304E-H
Chair: Ambar Kulshreshtha, MD, PhD

2:15 p.m.-2:30 p.m.

Vivian Fonseca and Nagendran Family Diabetes Research Award Presentation
Rita Rastogi Kalyani, MD, MHS

306-OR The Relationship of Acculturation to Cardiometabolic Risk Factors among U.S. South Asians—Findings from the MASALA Study
MOHAMMED AL-SOFIANI, SUSAN J. LANGAN, ALKA M. KANAYA, NAMRATHA R. KANDULA, BELINDA NEEDHAM, CATHERINE KIM, DIANE M. BECKER, DHANANJAY VAIDYA, SHERITA GOLDEN, CLARE LEE, Baltimore, MD, San Francisco, CA, Chicago, IL, Ann Arbor, MI

2:30 p.m.-2:45 p.m.

307-OR Mediators of the Racial Disparity in Diabetes Incidence—The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
APRIL P. CARSON, D. LEANN LONG, ANDREA CHERRINGTON, GARETH R. DUTTON, VIRGINIA J. HOWARD, TODD BROWN, CLAUDIA MOY, MARY CUSHMAN, MONIKA SAFFORD, GEORGE HOWARD, Birmingham, AL, Bethesda, MD, Burlington, VT, New York, NY

2:45 p.m.-3:00 p.m.

308-OR Socioeconomic Profiles as Predictors of Glycemic Control in Youth with Type 1 Diabetes
MELANIE W. SUTHERLAND, XIAONAN MA, JASON A. MENDOZA, BETHANY A. BELL, BETH A. REBOUSSIN, ANNA R. KAHKOSKA, KATHERINE A. SAUER, CATHERINE PIHOKER, ANGELA D. LIESE, COLUMBIA, SC, SEATTLE, WA, WINSTON-SALEM, NC, CHAPEL HILL, NC, AURORA, CO

3:00 p.m.-3:15 p.m.

309-OR Neighborhood Walkability and Diabetes-Related Complications
REEMA SHAH, JIN LUO, HERTZEL C. GERSTEIN, GILLIAN BOOTH, Hamilton, ON, Canada, Toronto, ON, Canada

3:15 p.m.-3:30 p.m.

YILING J. CHENG, ALKA M. KANAYA, SHARON SAYDAH, MARIA ROSARIO ARANETA, HENRY S. KAHN, GIUSEPPIA IMPERATORE, ATLANTA, GA, SAN FRANCISCO, CA, HYATTSVILLE, MD, LA JOLLA, CA

3:30 p.m.-3:45 p.m.

311-OR Food Insecurity in Older Adults with Diabetes
EMILY B. SCHROEDER, CHAN ZENG, ANDREW STERRETT, TINA K. KIMPO, ANDREA R. PAOLINO, JOHN STEINER, DENVER, CO

3:45 p.m.-4:00 p.m.

312-OR Racial and Socioeconomic Disparities in Meeting Goals of Care in Adults with Type 1 Diabetes
J. SONIA HAW, LIMIN PENG, FRANCISCO J. PASQUEL, PRIYATHAMA VELLANKI, MAYA FAYFMAN, GEORGIA DAVIS, GUILLERMO E. UMPIERREZ, ATLANTA, GA

4:00 p.m.-4:15 p.m.

313-OR Ethnicity and Common Genetic Variants Modulate Nonalcoholic Fatty Liver Disease (NAFLD) Metabolic Phenotype in Obese Youth
DOMENICO TRICO, SONIA CAPRIO, GIUSEPPINA R. UMANO, ALFONSO GALDERISI, MARIANA M. MATA, JESSICA NOUWS, BRIDGET PIERPONT, GRACE KIM, NICOLA SANTORO, NEW HAVEN, CT, SEATTLE, WA
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Immunology/Transplantation
Translational Immunology in Type 1 Diabetes—A Look at the Future
Room: W206
Co-Chairs: Maria Bettini, PhD and Matthew Bettini, PhD

2:15 p.m.-2:30 p.m. 314-OR Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins
LILIANE KHORYATI, SWARNIMA KUMARI, THI MINH NGUYET PHAM, MARIKA BOGDANI, MARC GAVIN, Seattle, WA

2:30 p.m.-2:45 p.m. 315-OR ▲ Hybrid Insulin Peptides Form in Islets of Nondiabetes Prone Mice
TIMOTHY WILES, KATHRYN M. HASKINS, THOMAS DE LONG, Aurora, CO, Denver, CO

2:45 p.m.-3:00 p.m. 316-OR ▲ Thymic Development of Beta-Cell Specific Regulatory T Cells in Neonatal NOD Mice
YONG LIN, THOMAS LEE, MARIA BETTINI, MATTHEW BETTINI, Houston, TX

3:00 p.m.-3:15 p.m. 317-OR ▲ Investigating the Role of CD137 Ligand in the Pathogenesis of Type 1 Diabetes
BARDEES FODA, MATTHEW H. FORSBERG, ASHLEY E. CIECKO, KEVIN W. MUELLER, ARON GEURTS, YI-GUANG CHEN, Milwaukee, WI, Madison, WI

3:15 p.m.-3:30 p.m. 318-OR CD19+IgM+ Cells from NOD Mice Demonstrate Enhanced Therapeutic Efficacy in Type 1 Diabetes Mellitus
ANDREW D. VONBERG, MASSIMO PIETROPAOLO, Houston, TX

3:30 p.m.-3:45 p.m. 319-OR Contrast Enhanced Ultrasound with Submicron-Sized Contrast Agents Detects Diabetes Progression in Mouse Models of Type 1 Diabetes
DAVID RAMIREZ, RICHARD K. BENNINGER, Denver, CO, Aurora, CO

3:45 p.m.-4:00 p.m. 320-OR CD70 Modulates Thymocyte Development and Type 1 Diabetes in NOD Mice
CHENG YE, JOHN DRIVER, MICHAEL V. WILES, DAVE SERREZE, Gainesville, FL, Bar Harbor, ME

4:00 p.m.-4:15 p.m. 321-OR Stem Cell-Derived Tissue-Associated Regulatory T Cells Suppress Autoimmune Diabetes
JIAXUN J. SONG, College Station, TX

▲ ADA-Supported Research
Oral Presentations
2:15 p.m.-4:15 p.m.
(continued)

Theme Area: Islet Biology/Insulin Secretion
Regulation of Islet Function in Health and Disease
Room: W312
Chair: David Jacobson, PhD

2:15 p.m.-2:30 p.m.
322-OR Glucocorticoid Receptor Is Instrumental for the Mechanism of Beta-Cell Compensation for Insulin Resistance in Dietary Obesity
JUN YAMAUCHI, SOJIN LEE, HENRY DONG, Pittsburgh, PA

2:30 p.m.-2:45 p.m.
323-OR Dapagliflozin Treatment Impacts β, but Not α, Cell Function in Normal Human Islets

2:45 p.m.-3:00 p.m.
324-OR Foxo1-Expressing Cells in the Gut as a Source of Insulin for Diabetes Treatment
WENDY MCKIMPSON, TAIYI KUO, DOMENICO ACCILI, New York, NY

3:00 p.m.-3:15 p.m.
325-OR Maintenance of β-Cell Heterogeneity Is Required for Normal Islet Function
DANIELA NASTESKA, GUY A. RUTTER, QIAO ZHOU, DAVID HODSON, Birmingham, United Kingdom, London, United Kingdom, Cambridge, MA, Edgbaston, United Kingdom

3:15 p.m.-3:30 p.m.
326-OR Molecular Mechanism of Androgen Receptor Stimulation of Insulin Secretion in Male β Cells
WEIWEI XU, FIONA B. ASHFORD, DAVID HODSON, FRANCK MAUVAIS-JARVIS, New Orleans, LA, Birmingham, United Kingdom, Edgbaston, United Kingdom

3:30 p.m.-3:45 p.m.
327-OR Beta-Cell Glucotoxicity in K_ATP-Induced Diabetes Is Alleviated by Genetic Reduction of Glucose Metabolism
MANUELA FORTUNATO, ZIHAN YAN, ZEENAT A. SHYR, HANNAH E. CONWAY, MARIA S. REMEDI, St. Louis, MO

3:45 p.m.-4:00 p.m.
328-OR DAG Accumulation due to Type 1 DGK Inhibition Has Contradictory Dual Effect on Ca^{2+} Signaling in Pancreatic β Cells
TOSHIAKI SAWATANI, YUKIKO K. KANEKO, TOMOHIRA ISHIKAWA, Shizuoka, Japan

4:00 p.m.-4:15 p.m.
329-OR Adiponectin Increases Glucose-Dependent Electrical Activity and Insulin Secretion in Mouse Pancreatic β Cells
JOANA I. REAL, BELEN CHANCLON GARCIA, INGRID WERNSTEDT ASTERHOLM, PATRIK RORSMAN, Gothenburg, Sweden, Oxford, United Kingdom
4:30 p.m.-6:30 p.m.

**Current Issues**  
*Theme Area: Acute and Chronic Complications*  
**Albuminuria—Two Debates**  
Room: W308  
Chair: Katherine R. Tuttle, MD, FACP, FASN, FNKF  
Should Patients with Microalbuminuria and Normal Blood Pressure be Treated with Renin Angiotensin Aldosterone System Blockade?  
4:30 p.m.-5:00 p.m.  
Yes, All Patients Should Be Treated  
Peter Rossing, MD  
5:00 p.m.-5:30 p.m.  
No, Not All Patients Should Be Treated  
Robert Nelson, MD, PhD  
Should the Level of Albuminuria be a Treatment Target?  
5:30 p.m.-6:00 p.m.  
Yes, Albuminuria Should Be a Therapeutic Target  
Dick de Zeeuw, MD, PhD  
6:00 p.m.-6:30 p.m.  
No, Albuminuria Should Not Be a Therapeutic Target  
Merlin Thomas, MB, ChB, PhD, FRACP  

**Symposium**  
*Theme Area: Acute and Chronic Complications*  
**Clinical Strategies for Prevention and Management of Hypoglycemia**  
Room: W311  
Chair: Elizabeth R. Seaquist, MD  
4:30 p.m.-5:00 p.m.  
Hypoglycemia—Who Is at Risk and Who Is Most Likely to Be Harmed?  
Emily B. Schroeder, MD, PhD  
5:00 p.m.-5:30 p.m.  
Preventing Hypoglycemia in Type 1 Diabetes through Patient Education  
Stephanie A. Amiel, MD, FRCP  
5:30 p.m.-6:00 p.m.  
Preventing Hypoglycemia in Type 2 Diabetes through More Appropriate Treatments  
Geremia B. Bolli, MD  
6:00 p.m.-6:30 p.m.  
Leveraging Technology to Detect, Prevent, and Treat Hypoglycemia  
Bruce A. Buckingham, MD  

**Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
**Diabetes and Psychosocial Risk Factors in the Hispanic Community Health Study/Study of Latinos**  
Room: W414  
Chair: Jeffrey S. Gonzalez, PhD  
4:30 p.m.-5:10 p.m.  
Diabetes Awareness, Treatment, Glycemic Control, and Access to Health Insurance—Longitudinal Relationships from the Hispanic Community Health Study/Study of Latinos  
Neil Schneiderman, PhD  
5:10 p.m.-5:50 p.m.  
Health Behaviors, Psychosocial Factors, Obesity, and Risk for Type 2 Diabetes—Findings from the Hispanic Community Health Study/Study of Latino Youth  
Alan M. Delamater, PhD  
5:50 p.m.-6:30 p.m.  
Cultural and Psychosocial Risk Factors for Type 2 Diabetes and Metabolic Syndrome in the Hispanic Community Health Study/Sociocultural Ancillary Study  
Carmen R. Isasi, MD, PhD
4:30 p.m.-6:30 p.m.  
(continued)

Symposium  
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Using mHealth for Obesity Treatment and Weight Management  
Room: W307  
Chair: Bruce R. King, MD, PhD, FRACP
4:30 p.m.-5:00 p.m.  State-of-the-Art—Perspectives towards Sustained Behavior Change  
Deborah Tate, PhD
5:00 p.m.-5:30 p.m.  Digital DPP—Evaluation of mHealth for Outcomes and Cost of Diabetes Prevention  
Rick Chapman, PhD, MS
5:30 p.m.-6:00 p.m.  Utilization and Perception—Behavioral Components of the Practice-Based Opportunities for Weight Reduction Hopkins Trial  
Janelle Coughlin, PhD
6:00 p.m.-6:30 p.m.  Panel Discussion

Symposium  
Theme Area: Clinical Diabetes/Therapeutics  
Insulin Therapy—To the Future and Back  
Room: W415B (Valencia Ballroom)  
Chair: Bernard Zinman, MD
4:30 p.m.-5:00 p.m.  Fast and Furious or just Marketing Fiction? Expectations from New and Developing Rapid Acting Insulins  
Tim Heise, MD
5:00 p.m.-5:30 p.m.  Which Patients Should Receive New Ultra-Long-Acting Basal Insulin Products?  
Carol H. Wysham, MD
5:30 p.m.-6:00 p.m.  When and How to Use Neutral Protamine Hagedorn and Regular in Patients with Type 2 or Type 1  
Dace Trence, MD
6:00 p.m.-6:30 p.m.  Concentrated Insulin Products  
Wendy S. Lane, MD

Symposium  
Theme Area: Epidemiology/Genetics  
Mechanistic Insights from Rare Conditions and Opportunities for Novel Therapeutics  
Room: W304E-H  
Chair: Norann A. Zaghloul, PhD
4:30 p.m.-5:00 p.m.  Modeling Insulin Variants  
Fabrizio Barbetti, MD, PhD
5:00 p.m.-5:30 p.m.  Wolfram Syndrome and Wolfram Spectrum Disorder  
Fumihiko Urano, MD, PhD
5:30 p.m.-6:00 p.m.  Lipodystrophies  
Atul Chopra, MD, PhD
6:00 p.m.-6:30 p.m.  Severe Obesity  
Sadaf Farooqi, PhD, FRCP, FMedSci
**Symposium**

**Theme Area: Immunology/Transplantation**

**Clinical Updates in Beta-Cell Replacement Therapy**

Room: W206

Chair: Rodolfo Alejandro, MD

4:30 p.m.-5:00 p.m.  *Defining Outcomes for Beta-Cell Replacement Therapy—A Summary from the 2017 IPITA/EPITA Igls Consensus Workshop*

Michael R. Rickels, MD, MS

5:00 p.m.-5:30 p.m.  *An Update from the CIT-07 Trials—Quality of Life and Metabolic Outcomes of Islet Allotransplant*

Camillo Ricordi, MD

5:30 p.m.-6:00 p.m.  *Who Is the Ideal Patient for Alloislet Transplant? Predictive Models for Successful Transplant Outcomes from the CITR*

Franca B. Barton, MS

6:00 p.m.-6:30 p.m.  *Challenges in Islet Transplantation—Risks and Barriers to Islet Transplant for Type 1 Diabetes*

Peter A. Senior, MBBS, PhD

---

**Symposium**

**Theme Area: Islet Biology/Insulin Secretion**

**The Islet in Type 1 Diabetes—What’s New?**

Room: W312

Chair: Laura C. Alonso, MD

4:30 p.m.-5:00 p.m.  *tRNA Hypomethylation—A Novel Mechanism of Beta-Cell Demise in Diabetes*

Miriam Cnop, MD, PhD

5:00 p.m.-5:30 p.m.  *Islet Resident Macrophages/T Cells*

David M. Harlan, MD

5:30 p.m.-6:00 p.m.  *KIRA8, Shift Back to Adaptive UPR in Type 1 Diabetes*

Feroz R. Papa, MD, PhD

6:00 p.m.-6:30 p.m.  *Losing It? Islet Beta-Cell Mass in Type 1 Diabetes*

Anath Shalev, MD
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued)

Theme Area: Acute and Chronic Complications

New Insights into Lipid and Lipoprotein Alterations in Patients with Diabetes
Room: W208
Chair: John M. Stafford, MD, PhD

4:30 p.m.-4:45 p.m.
330-OR Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia
LAWRENCE LEITER, HWEE TEOH, DAVID KALLEN, R. SCOTT WRIGHT, ULF LANDMESSER, PETER L. WIJNGAARD, JOHN J. KASTELEIN, KAUSIK K. RAY, Toronto, ON, Canada, Zürich, Switzerland, Rochester, MN, Berlin, Germany, Parsippany, NJ, Amsterdam, Netherlands, London, United Kingdom

4:45 p.m.-5:00 p.m.
331-OR Angiopoietin-Like Protein 3 Directly Regulates HDL Metabolism and Function
LONGYAN YANG, YAN WANG, YING FU, JIANAN LANG, DONG ZHAO, YINGMEI FENG, Beijing, China

5:00 p.m.-5:15 p.m.
332-OR Prevalence and Predictors of Residual Hypertriglyceridemia According to Statin Use in U.S. Adults with Diabetes
WENJUN FAN, SEPHY PHILIP, CRAIG B. GRANOWITZ, PETER P. TOOTH, NATHAN D. WONG, Irvine, CA, Bedminster, NJ, Sterling, IL

5:15 p.m.-5:30 p.m.
333-OR Circulating ANGPTL8 and ANGPTL4 Levels Are Increased in Patients with Hyperglycemia Combined Dyslipidemia
XUEFENG YU, PUHAN LU, XI CHEN, Wuhan, China

5:30 p.m.-5:45 p.m.
334-OR Hypertriglyceridemia per se Is Not an Independent Risk Factor for Beta-Cell Dysfunction
JUN YAMANUCI, TING ZHANG, SOJIN LEE, HENRY DONG, Pittsburgh, PA

5:45 p.m.-6:00 p.m.
335-OR Unaltered Fatty Acid Uptake, Utilization, and Mitochondrial Respiration in Right Atrial Appendage of Type 2 Diabetic Human Heart
NANDINI RJ, RAJI SR, VIVEK V. PILLAI, JAYAKUMAR K., SRINIVAS GOPALA, Thiruvananthapuram, India

6:00 p.m.-6:15 p.m.
336-OR Effect of a New Type of Nanomaterial on Glucose and Lipid Metabolism
JIN WU, YINGBO CHEN, LIPEING LIU, QING YAO, XIAOCEN LIU, YINGJIE WU, Dalian, China, Jinan, China

6:15 p.m.-6:30 p.m.
337-OR Glycation and Deamidation Result in HDL Dysfunction in Patients with Type 2 Diabetes
TAKHAR KASUMOV, MAKAN GOLIZEH, SANGEETA KASHYAP, Rootstown, OH, Montreal, QC, Canada, Cleveland, OH

ADA-Supported Research
Oral Presentations
4:30 p.m.–6:30 p.m.
(continued)

Theme Area: Clinical Diabetes/Therapeutics
Adiposity, Insulin Resistance, and Type 2 Diabetes Mellitus—What Is New in Risk Factors and Biomarkers?
Room: W203
Chair: Lorraine E.L. Katz, MD

4:30 p.m.–4:45 p.m.
338-OR Adipocyte Insulin Resistance Index in Youth along the Span of Glycemia from Normal Glucose Tolerance (NGT) to Impaired Glucose Tolerance (IGT) to Type 2 Diabetes (T2D)
JOON YOUNG KIM, FIDA BACHA, HALA TFAYLI, SARA MICHALISZYN, SILVA ARSLANIAN, Pittsburgh, PA, Houston, TX, Beirut, Lebanon, Youngstown, OH

4:45 p.m.–5:00 p.m.
339-OR Serum Uric Acid (SUA), Urinary Albumin Excretion (UAE), and Hypertension (HTN) in Adolescents with Type 2 Diabetes (T2D) in the TODAY Study
PETTER BJORNSTAD, LORI M. LAFFEL, JANE L. LYNCH, LAURE EL GHORMLI, RUTH S. WEINSTOCK, SHERIDA E. TOLLEFSEN, KRISTEN J. NADEAU, Aurora, CO, Boston, MA, San Antonio, TX, Rockville, MD, Syracuse, NY, St. Louis, MO, Denver, CO

5:00 p.m.–5:15 p.m.
340-OR The TCF7L2 Variant rs7903146 Affects the Risk of Youth-Onset Type 2 Diabetes by Reducing the Incretin Effect on Insulin Secretion
ALFONSO GALDERISI, BRIDGET PIERPONT, DAVID D’ALESSIO, NICOLA SANTORO, SONIA CAPRIO, New Haven, CT, Durham, NC

5:15 p.m.–5:30 p.m.
341-OR Nonalcoholic Fatty Liver Disease (NAFLD) Outcome Post-Bariatric Surgery in the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Consortium
FIDA BACHA, RESMI GUPTA, TODD M. JENKINS, MARY BRANDT, THOMAS H. INGE, DAVID KLEINER, STAVRA XANTHAKOS, TEEN-LABS CONSORTIUM, Houston, TX, Cincinnati, OH, Aurora, CO, Bethesda, MD

5:30 p.m.–5:45 p.m.
342-OR DNA Methylation at Birth Is Associated with Adiposity and Infant Growth during the First Six Months of Life in the Healthy Start Study
SARAH J. BORENGASSER, ANNE P. STARLING, WEIMING ZHANG, JACOB FRIEDMAN, RICHARD F. HAMMAN, IVANA YANG, KATERINA KECHRIS, DANA DABELEA, Aurora, CO

5:45 p.m.–6:00 p.m.
343-OR Risk Factors of Youth Type 2 Diabetes (Y-T2DM) and Prevalence of Dysglycemia (DG)
MOHAMMED SALEH, JOON YOUNG KIM, CHRISTINE MARCH, SHAHWAR YOUSUF, SILVA ARSLANIAN, Pittsburgh, PA

6:00 p.m.–6:15 p.m.
344-OR Maternal Obesity, Diabetes during Pregnancy, Gestational Weight Gain, Breastfeeding, and Child’s BMI Growth Trajectory from Ages 2 to 6 Years
XINHUI WANG, MAYRA P. MARTINEZ, ANNY XIANG, Pasadena, CA

6:15 p.m.–6:30 p.m.
345-OR The Role of Exosomes in Improvement of Insulin Sensitivity in Obese Adolescents following Bariatric Surgery
AHLEE KIM, KAZUTOSHI MURAKAMI, VISHNUPRIYA J. BORRA, LAWRENCE M. DOLAN, AMY SHAH, TAKAHISA NAKAMURA, Cincinnati, OH
Oral Presentations
4:30 p.m.-6:30 p.m. (continued)

Theme Area: Clinical Diabetes/Therapeutics
Innovations in Insulin Formulation and Delivery
Room: W415C (Valencia Ballroom)
Chair: Elena Toschi, MD

4:30 p.m.-4:45 p.m.

346-OR Pharmacodynamic Effect of Novel Oral Insulin Tregopil in Relation to Meal Composition in Type 2 Diabetes Mellitus Patients
ANAND P. KHEDKAR, VINU JOSE, HAROLD E. LEOBOWITZ, ALAN D. CHERINGTON, GILBERT ALEXANDER FLEMING, SANDEEP N. ATHALYE, ASHWINI VISHWESWARAMURTHY, Bangalore, India, Brooklyn, NY, Nashville, TN; Harpers Ferry, WV

4:45 p.m.-5:00 p.m.

347-OR Basal Oral Insulin Analog I338 Enhances Meal-Related Hepatic Glucose Disposal
MARY C. MOORE, ERICA NISHIMURA, CHRISTIAN L. BRAND, THOMAS KJELDSEN, PETER MADSEN, HANNE H. REFSGAARD, KARSTEN WASSERMANN, SANNE GRAM-NIELSEN, MARTA S. SMITH, L. MERKLE MOORE, BEN FARMER, JON R. HASTINGS, PHILLIP E. WILLIAMS, ALAN D. CHERINGTON, Nashville, TN, Måløv, Denmark, Copenhagen, Denmark, Seborg, Denmark

5:00 p.m.-5:15 p.m.

348-OR Improved Postprandial Blood Glucose (PPBG) Excursions with Technosphere Inhaled Insulin (TI) Compared with Aspart in T1D Patients—STAT Study
HALIS K. AKTURK, JANET K. SNELL-BERGEON, AMANDA REWERS, LESLIE J. KLAFF, ANNE PETERS, BRUCE W. BODE, TIMOTHY S. BAILEY, SATISH K. GARG, Aurora, CO, Denver, CO, Renton, WA, Los Angeles, CA, Atlanta, GA, Escondido, CA

5:15 p.m.-5:30 p.m.

349-OR BioChaperone Technology Enables the Development of Pramlintide-Prandial Insulin Combinations
GRÉGORY MEIFFREN, ALEXANDRE GEISSLER, YVES MEYER, AYMERIC RANSON, CHARLES FORTIER, OLIVIER SOULA, RÉMI SOULA, BERTRAND ALLUIS, RICHARD CHARVET, Lyon, France

5:30 p.m.-5:45 p.m.

350-OR Fully Closed-Loop Glucose Control in Noncritical Care Settings—A Randomised, Controlled Two-Centre Study
LIA BALLY, HOOD THABIT, SARA HARTNELL, EVELINE ANDEREGGEN, YUE RUAN, MALGORZATA E. WILINSKA, MARK EVANS, MARIA M. WERTLI, ANTHONY P. COLL, CHRISTOPH STETTLER, ROMAN HOVORKA, Berne, Switzerland, Manchester, United Kingdom, Cambridge, United Kingdom, Oxford, United Kingdom

5:45 p.m.-6:00 p.m.

351-OR Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study—All Randomized Population
GEORGE GRUNBERGER, ANUJ BHARGAVA, TRANG T. LY, HOWARD ZISSER, LIZA ILAG, JAMES K. MALONE, SHUYU ZHANG, JENNAL JOHNSON, Bloomfield Hills, MI, West Des Moines, IA, Billerica, MA, Santa Barbara, CA, Indianapolis, IN

6:00 p.m.-6:15 p.m.

352-OR Improvements in A1c and Time-in-Range in DIY Closed-Loop (OpenAPS) Users
DANA M. LEWIS, RICHARD S. SWAIN, THOMAS W. DONNER, Seattle, WA, College Park, MD, Baltimore, MD

6:15 p.m.-6:30 p.m.

353-OR Digitally Enhanced Insulin Therapy—A Multicenter Clinical Trial
ISRAEL HODISH, RICHARD M. BERGENSTAL, MARY L. JOHNSON, REBECCA A. PASSI, ANUJ BHARGAVA, NATALIE YOUNG, DAVIDA F. KRUGER, ANGELA HAILEY, EMILY UNGER, ERAN BASHAN, Ann Arbor, MI, Minneapolis, MN, West Des Moines, IA, Detroit, MI, Livonia, MI
Oral Presentations  
4:30 p.m.-6:30 p.m.  
(continued)

Theme Area: Insulin Action/Molecular Metabolism  
Novel Aspects of Metabolic Regulation (With ADA Presidents’ Select Abstract)  
Room: W209  
Chair: Kyle S. McCommis, PhD

4:30 p.m.-4:45 p.m.  
354-OR  ADA Presidents’ Select Abstract: Serum Exosomal Proteins—A New Component of Intercellular Communication in Metabolism  
BRUNA B. BRANDAO, EMRAH ALTINDIS, RUBEN GARCIA MARTIN, C. RONALD KAHN, Boston MA

4:45 p.m.-5:00 p.m.  
355-OR  The Role of GLP-1 Receptor Expressed in Pancreatic α-Cells in Regulating Glucagon Secretion  
YANQING ZHANG, KESHAB R. PARAJULI, GENEVIEVE E. SMITH, RAJESH GUPTA, WEIWEI XU, LAUREN U. NGUYEN, ANADIL F. ZAKARIA, FRANCK MAUVAIS-JARVIS, VIVIAN FONSECA, KYLE W. SLOOP, HONGJU WU, New Orleans, LA, Toledo, OH, Konner, LA, Indianapolis, IN

5:00 p.m.-5:15 p.m.  
356-OR  FoxK1/K2 Are New, Important Components of IR and IGF1R Signaling and Control of Cell Proliferation and Metabolism  
MASAJI SAKAGUCHI, WEIKANG CAI, CHIH-HAO WANG, THIAGO M. BATISTA, EIICHI ARAKI, C. RONALD KAHN, Kumamoto, Japan, Boston, MA

5:15 p.m.-5:30 p.m.  
357-OR  Loss of CEACAM1 in Endothelial Cells Contributes to the Development of Cardiac Fibrosis  
HARRISON T. MUTURI, HILDA E. GHADIEH, SAJA S. KHUDER, SUKANTA JASH, RAGHD ABU HELAI, NIGEL A. DANIELS, JAMES LIU, VISHWAJEET PURI, GUILLERMO VAZQUEZ, RAJESH GUPTA, SONIA M. NAJJAR, Athens, OH, Toledo, OH, Baltimore, MD

5:30 p.m.-5:45 p.m.  
358-OR  Hepatic Overexpression of Retinoic Acid Receptor β Downregulates Mitochondrial Pyruvate Carrier 1 and Protects from Metabolic Dysregulation in ob/ob Mice  
FARNAZ KEYHANI NEJAD, DONGHWAN LEE, HANQING CHEN, ZERONG LIANG, NICOLAS MUSI, MENGWEI ZANG, San Antonio, TX

5:45 p.m.-6:00 p.m.  
359-OR  Macrophages React to Postprandial Signals and Regulate the Response to Feeding through Akt-mTOR-Dependent Production of IL-10  
GOTARO TODA, NOZOMU KAMEI, KOTARO SOEDA, YUKARI MASUDA, YOSHIIKO IZUMIDA, NAOKI KOBAYASHI, TAKAYOSI SASAKO, KAZUYUKI TOBE, MORRIS J. BIRNBAUM, TAKASHI KADOWAKI, KOHURO UEKI, Tokyo, Japan, Hiroshima, Japan, Toyama, Japan, Philadelphia, PA

6:00 p.m.-6:15 p.m.  
360-OR  NAD-Mediated Metabolic Reprogramming Epigenetically Regulates Gene Expression to Promote Preadipocyte Differentiation  
KEISUKE OKABE, ISAO USUI, ALLAH NAWAZ, SHIHO FUJISAKA, TOMONOBU KADO, YOSHIKO IGARASHI, KUNI-MASA YAGI, KAZUYUKI TOBE, TAKASHI NAKAGAWA, Toyama, Japan, Shimotsuga, Japan

6:15 p.m.-6:30 p.m.  
361-OR  CMHX008, a Novel Thiazolidinedione-Like PPARγ Partial Agonist, Enhances Insulin Sensitivity with Minor Influences on Bone Loss  
XIAOQIU XIAO, YI HOU, XUEMEI CAO, JIAYU LI, Chongqing, China
Oral Presentations
4:30 p.m.-6:30 p.m.
(continued)

Theme Area: Integrated Physiology/Obesity
Human Obesity Pathogenesis—From Brain to Peripheral Organs
Room: W304A-D
Chair: Frederico G.S. Toledo, MD

4:30 p.m.-4:45 p.m.
362-OR Cognitive Function and Brain Plasticity in Obese Patients—The Impact of Bariatric Surgery
ANGELA DARDANO, GIUSEPPE DANIELE, CLAUDIA LUNghi, ANNAMARIA CIcCARONE, FERRUCCIO SANTINI,
GIOVANNI CECCARini, CARLO MORETTO, GIUSEPPE PENNO, ROBERTO MICCOLI, MARIA CONCETTA MORRONE,
STEFANO DEL PRATO, Pisa, Italy

4:45 p.m.-5:00 p.m.
363-OR Effects of High BMI on Synaptic Function and Metabolic Connectivity in the Brain—Evidence of Gender
Difference
ARIANNA SALA, MAURA MALPETTI, ANNA FERRULLI, LUIGI GIANOLLI, LIVIO LUZ1, DANIELE PERANI, Milan, Italy,
San Donato Milanese, Italy

5:00 p.m.-5:15 p.m.
364-OR Brain Insulin Sensitivity Predicts Adiposity—Nine-Year Results of the Tulip Study
VERA SCHMID, OTTO TSCHRITTER, JÜRGEN MACHANN, ROBERT WAGNER, NORBERT STEFAN, HUBERT PRE-
ISSLI, HANS-ULRICH HAERING, ANDREAS FRITSCH, MARTIN HENI, Tübingen, Germany, Stuttgart, Germany

5:15 p.m.-5:30 p.m.
365-OR Hyperinsulinemia Invokes Greater Brain Perfusion in Reward and Motivation Regions in Obesity
DEREK GROSkreutz, RAJITA SINHA, CHERYL LACADIE, WAI LAM, MUHAMMAD HAMZA, CHRISTIAN P.
SCHMIDT, DONGJU seo, JANICE HWANG, RENATA BELFORT-DEAGUIAR, JESSICA LEVENTHAL, SAMUEL ROSEN-
BERG, LISA PARiKH, TODD CONSTANT, ROBERT SHERWIN, ANIA M. JASTREBOFF, New Haven, CT

5:30 p.m.-5:45 p.m.
366-OR Intestinal Epigenetic Reprogramming Relates to Glycemic Improvement after Roux-en-Y Gastric Bypass
Surgery
MARGARET A. STEFATER, COURTNEY PANCIOTTI, HENRY A. FELDMAN, WILLIAM F. GOURASH, ELEANOR SHIR-
LEY, ANITA COUCOULAS, NICHOLAS STYLOPOULOS, Boston, MA, Pittsburgh, PA

5:45 p.m.-6:00 p.m.
367-OR Glucagon-Like Peptide-1 (GLP-1) Increases Skeletal and Cardiac Muscle, Microvascular Perfusion, and
Improves Metabolic Insulin Action in Obese Humans
NASUI WANG, AlVIN WAI KIT TAN, LINDA JAHN, LEE HARTLINE, KEVIN W. AYLOR, EUGENE BARRETT, ZHENQI
LIU, Charlottesville, VA, Singapore, Singapore

6:00 p.m.-6:15 p.m.
368-OR Regulation of Lipocalin 2 by Estrogen in Human Adipose Tissue—A Link between ERβ Pathway and Insulin
Resistance
PRASAD G. KAMBLE, MARIA J. PEREIRA, GRETHA J. BOERSMA, KRISTINA E. ALMBY, JAN W. ERIKSSON,
Uppsala, Sweden

6:15 p.m.-6:30 p.m.
369-OR Functional and Developmental Heterogeneity in Human Adipose Tissue Depots
JAMES W. JOHNSON, CHERYL CERO, ALANA O’MARA, JOYCE D. LINDERMAN, ALISON S. BASKIN, AARON
CYPESS, Bethesda, MD

ADA-Supported Research
Oral Presentations 4:30 p.m.-6:30 p.m. (continued)

**Theme Area: Integrated Physiology/Obesity**

**Alphabet Soup—GABA, FGF, ERα—Recipe for Central Nervous System Control of Metabolic Homeostasis and Diabetes Remission (With State-of-the-Art Lecture)**

Room: W204
Chair: Joel K. Elmquist, DVM, PhD

4:30 p.m.-5:00 p.m.

**State-of-the-Art Lecture**

*Metabolic Impact of the Central Nervous System in Rodents and Humans*
Tony K.T. Lam, PhD

5:00 p.m.-5:15 p.m.

370-OR ▲ Deciphering a GABAergic Neural Circuit in Critical Control of Leptin-Mediated Feeding, Body Weight, and Glucose Homeostasis
QI WU, YONG HAN, Houston, TX

5:15 p.m.-5:30 p.m.

371-OR ▲ Microglia Activation Regulates Systemic Glucose Tolerance
JOHN DOUGLASS, MARTIN VALDEARCOS, SR., SUNEIL K. KOLIWAD, JOSH THALER, Seattle, WA, San Francisco, CA

5:30 p.m.-5:45 p.m.

372-OR An Action in the Hypothalamic Arcuate Nucleus Is Sufficient to Explain the Sustained Remission of Diabetes Induced by Central Administration of Fibroblast Growth Factor-1 (FGF-1)
JENNY M. BROWN, JARRAD SCARLETT, MILES E. MATSEN, ANNA SECHER, RASMUS JORGENSEN, GREGORY J. MORTON, MICHAEL W. SCHWARTZ, Seattle, WA, Måløv, Denmark

5:45 p.m.-6:00 p.m.

373-OR Sustained Diabetes Remission Induced by the Central Action of Fibroblast Growth Factor-1 (FGF-1) Requires Activation of Integrin Receptor αvβ3
JARRAD SCARLETT, JENNY M. BROWN, BAO ANH N. PHAN, EDDIE L. KHAV, MILES E. MATSEN, NIHIL K. ACHARYA, HONG T. NGUYEN, ANNA SECHER, RASMUS JORGENSEN, GREGORY J. MORTON, MICHAEL W. SCHWARTZ, Seattle, WA, Glendale, AZ, Måløv, Denmark

6:00 p.m.-6:15 p.m.

374-OR ▲ Estrogen-Responsive Neurons in the Ventrolateral VMH Regulate Glucose Balance
YANLIN HE, PINGWEN XU, YANN XIA, YONGJIE YANG, XING CAI, ILIRJANA HYSNI, YONG XU, Houston, TX

6:15 p.m.-6:30 p.m.

375-OR A Single-Cell Transcriptomics Roadmap to Investigate Diabetes Remission Induced by the Central Action of Fibroblast Growth Factor-1 (FGF-1)
MARIE A. BENTSEN, DYLAN RAUSCH, JARRAD SCARLETT, KIMBERLY M. ALONGE, PASCAL N. TIMSHEL, ZAMAN MIRZADEH, ANNA SECHER, RASMUS JORGENSEN, TUNE PERS, MICHAEL W. SCHWARTZ, Seattle, WA, Copenhagen, Denmark, Phoenix, AZ, Måløv, Denmark, Gentofte, Denmark
### TUESDAY, JUNE 26, 2018—DAY-AT-A-GLANCE SCHEDULE

**Registration Hours:** 7:30 a.m.-10:30 a.m.  
**Shop Diabetes Store Hours:** 7:30 a.m.-12:30 p.m.

<table>
<thead>
<tr>
<th>Time</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
</table>
| 8:00 a.m.-10:00 a.m. | **Symposium** Cardiorenal Effects of Glucose-Lowering Therapies  
Room: W308          | **Symposium** Multigenerational Effects of Exercise  
Room: W208                                               | **Symposium** Management of Diabetes in a Surgical Patient  
Room: W315                                               | **Symposium** Diabetes in Rural America  
Room: W304E-H                                               |
| 10:15 a.m.-12:15 p.m. | **Symposium** Multigenerational Effects of Exercise  
Room: W208                                               | **Symposium** Management of Diabetes in a Surgical Patient  
Room: W315                                               | **Symposium** Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018  
Room: W414                                               | **Symposium** Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018  
Room: W414                                               |
|               | **Symposium** SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?  
Room: W415C (Valencia Ballroom) | **Symposium** Management of Diabetes in a Surgical Patient  
Room: W315                                               | **Symposium** Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018  
Room: W414                                               | **Symposium** Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018  
Room: W414                                               |
<table>
<thead>
<tr>
<th>Immunology/Transplantation</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Integrated Physiology/Obesity</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
</table>
| **Symposium** Aging and Insulin Sensitivity  
_Room: W209_ | **Symposium** Nutrient Sensing and Signaling in the Regulation of Metabolic Homeostasis  
_Room: W304A-D_ | **Symposium** G-Protein-Coupled Receptors—Structural Insights to Therapeutic Options  
_Room: W312_ | |
**Symposium**  
*Theme Area: Acute and Chronic Complications*  
**Cardiorenal Effects of Glucose-Lowering Therapies**  
Room: W308  
Chair: Maryam Afkarian, MD, PhD  
8:00 a.m.-8:30 a.m.  
*SGLT2i, GLP-1RA, and DPP-4i and Effects on Proteinuria—From Physiology to Clinical Practice*  
Hiddo Lambers Heerspink, PhD  
8:30 a.m.-9:00 a.m.  
*Other Renal Protective Agents—Endothelin Antagonists, Mineralocorticoid Antagonists, and Novel Potassium Binders*  
Daniël H. van Raalte, MD, PhD  
9:00 a.m.-9:30 a.m.  
*Heart Failure Management in the Era of EMPA-REG Outcome and CANVAS Program*  
Mikhail N. Kosiborod, MD  
9:30 a.m.-10:00 a.m.  
*How to Put the Pieces Together—How Will SGLT2i and GLP-1RA/DPP-4i Agents Work Together, and with Other Newer Agents?*  
David Cherney, MD, PhD

**Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
**Multigenerational Effects of Exercise**  
Room: W208  
Chair: Kristin I. Stanford, PhD  
8:00 a.m.-8:30 a.m.  
*Epigenetic Effects of Exercise on Metabolism*  
Romain Barrés, PhD  
8:30 a.m.-9:00 a.m.  
*Early-Life and Multigenerational Programming of Physical Activity*  
Theodore Garland, Jr., PhD  
9:00 a.m.-9:30 a.m.  
*Maternal Exercise and Diabetes Risk in Future Generations*  
Laurie J. Goodyear, PhD  
9:30 a.m.-10:00 a.m.  
*Fit Fathers—Epigenetic Reprogramming of Sperm by Exercise*  
Alexander K. Murashov, MD, PhD

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
**Management of Diabetes in a Surgical Patient**  
Room: W315  
Chair: Guillermo E. Umpierrez, MD, CDE, FACP, FACE  
8:00 a.m.-8:30 a.m.  
*Preparation for Elective Surgery*  
Rajesh Garg, MD  
8:30 a.m.-9:00 a.m.  
*Glucose Management in the Operating Room*  
Jesse Ehrenfeld, MD, MPH  
9:00 a.m.-9:30 a.m.  
*Postoperative Hyperglycemia*  
Francisco J. Pasquel, MD, MPH  
9:30 a.m.-10:00 a.m.  
*Reducing Readmissions after Surgery*  
Kathleen M. Dungan, MD, MPH
8:00 a.m.-10:00 a.m.
(continued)

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*

**Obesity in Type 1 Diabetes—An Evolving Challenge**

*Room: W307*

*Chair: Osama Hamdy, MD, PhD*

8:00 a.m.-8:20 a.m.  
**Epidemiology and Physiology**  
Cynthia L. Ogden, PhD

8:20 a.m.-8:40 a.m.  
**Nutrition and Exercise Recommendations**  
Jackie L. Boucher, MS, RDN

8:40 a.m.-9:00 a.m.  
**Challenges of Insulin Use in the Obese Patient with Type 1 Diabetes**  
David Russell-Jones, MD

9:00 a.m.-9:20 a.m.  
**Pharmacotherapy for Obesity in Type 1 Diabetes**  
Jennifer N. Clements, PharmD, FCCP, BCPS, CDE, BCACP

9:20 a.m.-9:40 a.m.  
**Bariatric Surgery in Patients with Type 1 Diabetes—What Do We Know?**  
Ali Aminian, MD, FACS

9:40 a.m.-10:00 a.m.  
**Question and Discussion Period**

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*

**Management of Hyperglycemia in Type 2 Diabetes—Draft ADA/EASD Consensus Report 2018**

*Room: W414*

*Co-Chairs: John B. Buse, MD, PhD and Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP*

8:00 a.m.-8:20 a.m.  
**Introduction and Methods**  
Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP

8:20 a.m.-8:40 a.m.  
**The Rationale and Importance of Antihyperglycemic Treatment**  
Judith E. Fradkin, MD
Apostolos Tsapas, MD, PhD, MSc

8:40 a.m.-9:00 a.m.  
**Personalized Approach Based on Patient Characteristics and Comorbidities**  
Peter Rossing, MD
Deborah J. Wexler, MD, MSc

9:00 a.m.-9:20 a.m.  
**Therapeutic Options—Lifestyle Management and Pharmacologic Treatment**  
Walter Kernan, MD
Geltrude Mingrone, MD, PhD

9:20 a.m.-9:40 a.m.  
**Strategies for Implementing Antihyperglycemic Treatment Plan**  
David D’Alessio, MD
Chantal Mathieu, MD, PhD

9:40 a.m.-10:00 a.m.  
**Key Knowledge Gaps, Question and Discussion Period**  
John B. Buse, MD, PhD

**Symposium**
*Theme Area: Epidemiology/Genetics*

**Diabetes in Rural America**

*Room: W304E-H*

*Chair: Rozalina G. McCoy, MD, MS*

8:00 a.m.-8:30 a.m.  
**Disparities in the Prevention and Management of Diabetes in Rural America**  
Shivani A. Patel, PhD

8:30 a.m.-9:00 a.m.  
**Burden of Diabetes and Its Complications among American Indians and Alaska Natives**  
Spero M. Manson, PhD

9:00 a.m.-9:30 a.m.  
**How to Improve Access in Rural America?**  
Matthew F. Bouchonville II, MD

9:30 a.m.-10:00 a.m.  
**Policy Solutions to Improve Diabetes Care in Rural America**  
Janice C. Probst, PhD
Symposium
Theme Area: Insulin Action/Molecular Metabolism
Aging and Insulin Sensitivity
Room: W209
Chair: Bret H. Goodpaster, PhD

8:00 a.m.-8:30 a.m. Metformin Action in Aging and Cancer
Alexander Soukas, MD, PhD

8:30 a.m.-9:00 a.m. Caloric Restriction and Aging—A Focus on Metabolism
Rozalyn M. Anderson, PhD

9:00 a.m.-9:30 a.m. Metabolic Defects Induced by the Lifespan-Extending Drug Rapamycin
Joseph A. Baur, PhD

9:30 a.m.-10:00 a.m. Mitochondria and Aging
Jennifer L. Estall, PhD

Symposium
Theme Area: Integrated Physiology/Obesity
Nutrient Sensing and Signaling in the Regulation of Metabolic Homeostasis
Room: W304A-D
Chair: Peter A. Crawford, MD, PhD

8:00 a.m.-8:20 a.m. Amino Acids and Metabolic Health
Mark A. Herman, MD

8:20 a.m.-8:40 a.m. Mechanisms of High-Fructose Diet-Induced Pathology in the Liver
Dean R. Tolan, PhD

8:40 a.m.-9:00 a.m. Exposure to a Maternal Western-Style Diet during Early Development Impairs Offspring Skeletal Muscle Mitochondrial Metabolism in Juvenile Nonhuman Primates
Carrie McCurdy, PhD

9:00 a.m.-9:20 a.m. Nicotinamide Adenine Dinucleotide Metabolism and Energy Homeostasis
Charles Brenner, PhD

9:20 a.m.-9:40 a.m. Nutrient Sensing and Oxidative Stress
Danica Chen, PhD

9:40 a.m.-10:00 a.m. Question and Discussion Period

Symposium
Theme Area: Islet Biology/Insulin Secretion
G-Protein-Coupled Receptors—Structural Insights to Therapeutic Options
Room: W312
Chair: Patrick R. Griffin, PhD

8:00 a.m.-8:30 a.m. Leveraging G-Protein-Coupled Receptors and Structural Insights
Roger K. Sunahara, PhD

8:30 a.m.-9:00 a.m. Designer G-Protein-Coupled Receptors to Dissect Metabolic Pathways
Jürgen Wess, PhD

9:00 a.m.-9:30 a.m. Inhibition of Secretion by GPCR Regulation of the Exocytotic Fusion Machinery
Heidi E. Hamm, PhD

9:30 a.m.-10:00 a.m. Targeting GLP-1 Receptor Trafficking to Improve Agonist Efficacy
Alejandra Tomas, PhD
10:15 a.m.-12:15 p.m.

Symposium
Theme Area: Clinical Diabetes/Therapeutics
SGLT Inhibition for Type 1 Diabetes Mellitus Management—How Far Have We Gone?
Room: W415C (Valencia Ballroom)
Chair: William T. Cefalu, MD

10:15 a.m.-10:35 a.m.  Understanding Metabolic Effects of SGLT Inhibition in Type 1 Diabetes to Explain and Avoid Increased Risk of Diabetic Ketoacidosis  
Ele Ferrannini, MD

10:35 a.m.-10:55 a.m.  Clinical Efficacy and Safety of Dapagliflozin in Type 1 Diabetes—Evidence to Date!  
Paresh Dandona, MD

10:55 a.m.-11:15 a.m.  Empagliflozin “Ease” Development Program to Support Regulatory Approval  
Julio Rosenstock, MD

11:15 a.m.-11:35 a.m.  Sotagliflozin “In Tandem” Development Program to Support Regulatory Approval  
John B. Buse, MD, PhD

11:35 a.m.-11:55 a.m.  Should a Cardiovascular-Renal Prevention Outcome Trial with an SGLT Inhibitor Be Warranted in Type 1 Diabetes Mellitus?  
David Cherney, MD, PhD

11:55 a.m.-12:15 p.m.  Panel Discussion
# Invited Speaker Index

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajami, Nadim J., PhD</td>
<td>Baylor College of Medicine, Houston, TX</td>
<td>100</td>
</tr>
<tr>
<td>Ajilore, Olusika, MD, PhD</td>
<td>University of Illinois, Chicago, IL</td>
<td>123</td>
</tr>
<tr>
<td>Albright, Ann L., PhD, RD</td>
<td>Centers for Disease Control and Prevention, Atlanta, GA</td>
<td>115, 128</td>
</tr>
<tr>
<td>Aloï, Joseph A., MD</td>
<td>Wake Forest University School of Medicine, Winston-Salem, NC</td>
<td>154</td>
</tr>
<tr>
<td>Alvarez, Carlos A., PharmD, MSc, MSCS, BCPS</td>
<td>Texas Tech University Health Sciences Center, Dallas, TX</td>
<td>95</td>
</tr>
<tr>
<td>Amiel, Stephanie A., MD, FRCP</td>
<td>Kings College London, London, United Kingdom</td>
<td>167</td>
</tr>
<tr>
<td>Aminian, Ali, MD, FACS</td>
<td>Cleveland Clinic, Cleveland, OH</td>
<td>179</td>
</tr>
<tr>
<td>Anderson, Rozalyn M., PhD</td>
<td>University of Wisconsin, Madison, WI</td>
<td>180</td>
</tr>
<tr>
<td>Aragón-Sánchez, F. Javier, MD, PhD</td>
<td>La Paloma Hospital, Las Palmas, de Gran Canaria, Spain</td>
<td>80</td>
</tr>
<tr>
<td>Aroda, Vanita R., MD</td>
<td>Brigham and Women’s Hospital, Boston, MA</td>
<td>75</td>
</tr>
<tr>
<td>Arslanian, Silva A., MD</td>
<td>Children’s Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA</td>
<td>159</td>
</tr>
<tr>
<td>Bacha, Fida, MD</td>
<td>Baylor College of Medicine, Houston, TX</td>
<td>145</td>
</tr>
<tr>
<td>Baidal, David, MD</td>
<td>University of Miami, Miami, FL</td>
<td>82</td>
</tr>
<tr>
<td>Bailey, Beth, PhD</td>
<td>University of Colorado Denver, Aurora, CO</td>
<td>115</td>
</tr>
<tr>
<td>Bailey, Timothy S., MD, FACE, CPI</td>
<td>AMCR Institute, Inc., Escondido, CA</td>
<td>65</td>
</tr>
<tr>
<td>Bakris, George, MD</td>
<td>University of Chicago Medicine, Chicago, IL</td>
<td>127</td>
</tr>
<tr>
<td>Ballin, Mary C., GNP-BC, CDE</td>
<td>New York Presbyterian Hospital, New York, NY</td>
<td>158</td>
</tr>
<tr>
<td>Baltrusch, Simone E., PhD</td>
<td>University of Rostock, Rostock, Germany</td>
<td>130</td>
</tr>
<tr>
<td>Barbetti, Fabrizio, MD, PhD</td>
<td>University of Rome Tor Vergata, Rome, Italy</td>
<td>168</td>
</tr>
<tr>
<td>Barbour, Linda (Lynn) A., MD, MSPH, FACP</td>
<td>University of Colorado Anschutz Medical Campus, Aurora, CO</td>
<td>104</td>
</tr>
<tr>
<td>Barrés, Romain, PhD</td>
<td>University of Copenhagen, Copenhagen, Denmark</td>
<td>178</td>
</tr>
<tr>
<td>Barrett, Eugene J., MD, PhD</td>
<td>University of Virginia, Charlottesville, VA</td>
<td>64</td>
</tr>
<tr>
<td>Barsches, Neal R., MD, MPH</td>
<td>Baylor College of Medicine, Houston, TX</td>
<td>87, 114</td>
</tr>
<tr>
<td>Barton, Franca B., MS</td>
<td>Emmes Corporation, Rockville, MD</td>
<td>169</td>
</tr>
<tr>
<td>Basu, Ananda, MBBS, MD</td>
<td>University of Virginia, Charlottesville, VA</td>
<td>116</td>
</tr>
<tr>
<td>Battaglia, Manuela, PhD</td>
<td>Diabetes Research Institute-San Raffaele Hospital, Milan, Italy</td>
<td>145</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Baur, Joseph A., PhD</td>
<td>University of Pennsylvania</td>
<td>p.180</td>
</tr>
<tr>
<td>Beck, Roy W., MD, PhD</td>
<td>Jaeb Center for Health Research</td>
<td>p.123</td>
</tr>
<tr>
<td>Beigneux, Anne, PhD</td>
<td>University of California, Los Angeles</td>
<td>p.129</td>
</tr>
<tr>
<td>Beitelshees, Amber L., PharmD, MPH, FAHA, FCCP</td>
<td>University of Maryland School of Medicine</td>
<td>p.134</td>
</tr>
<tr>
<td>Bergenstal, Richard M., MD</td>
<td>International Diabetes Center</td>
<td>p.134</td>
</tr>
<tr>
<td>Bergman, Richard N., PhD</td>
<td>Cedars-Sinai</td>
<td>p.61</td>
</tr>
<tr>
<td>Bernal-Mizrachi, Ernesto, MD</td>
<td>University of Miami</td>
<td>p.139</td>
</tr>
<tr>
<td>Best, Conor J., MD</td>
<td>MD Anderson Cancer Center</td>
<td>p.135</td>
</tr>
<tr>
<td>Beverley, Elizabeth A., PhD</td>
<td>Ohio University Heritage College of Osteopathic Medicine</td>
<td>p.158</td>
</tr>
<tr>
<td>Bhatt, Deepak L., MD, MPH</td>
<td>Brigham and Women's Hospital/ Harvard Medical School</td>
<td>p.64</td>
</tr>
<tr>
<td>Billings, Liana K., MD, MMSc</td>
<td>NorthShore University HealthSystem</td>
<td>p.96</td>
</tr>
<tr>
<td>Bjornstad, Petter, MD</td>
<td>Children's Hospital Colorado</td>
<td>p.128</td>
</tr>
<tr>
<td>Blonde, Lawrence, MD</td>
<td>Ochsner Medical Center</td>
<td>p.65</td>
</tr>
<tr>
<td>Bolli, Geremia B., MD</td>
<td>University of Perugia</td>
<td>p.167</td>
</tr>
<tr>
<td>Boucher, Jackie L., MS, RDN</td>
<td>Children's HeartLink</td>
<td>p.87, 179</td>
</tr>
<tr>
<td>Bouchonville, Matthew F., II</td>
<td>University of New Mexico School of Medicine</td>
<td>p.179</td>
</tr>
<tr>
<td>Bourne, Philip E., PhD, FACMI</td>
<td>University of Virginia</td>
<td>p.88</td>
</tr>
<tr>
<td>Brenner, Charles, PhD</td>
<td>University of Iowa</td>
<td>p.180</td>
</tr>
<tr>
<td>Breton, Marc D., PhD</td>
<td>University of Virginia</td>
<td>p.65</td>
</tr>
<tr>
<td>Brown, Adam, BS</td>
<td>diaTribe</td>
<td>p.100</td>
</tr>
<tr>
<td>Brown, Todd T., MD, PhD</td>
<td>Johns Hopkins Bloomberg School of Public Health</td>
<td>p.81</td>
</tr>
<tr>
<td>Brüning, Jens C., MD</td>
<td>Max Planck Institute for Metabolism Research</td>
<td>p.135</td>
</tr>
<tr>
<td>Brusko, Todd M., PhD</td>
<td>University of Florida</td>
<td>p.116</td>
</tr>
<tr>
<td>Buchanan, Thomas A., MD</td>
<td>University of Southern California</td>
<td>p.144</td>
</tr>
<tr>
<td>Buckingham, Bruce A., MD</td>
<td>Stanford University</td>
<td>p.167</td>
</tr>
<tr>
<td>Burgess, Shawn C., PhD</td>
<td>University of Texas Southwestern Medical Center</td>
<td>p.101</td>
</tr>
<tr>
<td>Buse, John B., MD, PhD</td>
<td>University of North Carolina School of Medicine</td>
<td>p.134, 159, 179, 181</td>
</tr>
<tr>
<td>Butler, Javed, MD, MPH, MBA</td>
<td>University of Mississippi</td>
<td>p.128</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Institution/Location</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Butler, Peter C., MD</td>
<td></td>
<td>University of California, Los Angeles, CA</td>
</tr>
<tr>
<td>Caballero, A. Enrique, MD</td>
<td></td>
<td>Harvard Medical School, Boston, MA</td>
</tr>
<tr>
<td>Campbell-Thompson, Martha L., DVM, PhD</td>
<td></td>
<td>University of Florida, Gainesville, FL</td>
</tr>
<tr>
<td>Cao, Lei, PhD</td>
<td></td>
<td>The Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>Caprio, Sonia MD</td>
<td></td>
<td>Yale University School of Medicine, New Haven, CT</td>
</tr>
<tr>
<td>Caprioli, Richard, PhD</td>
<td></td>
<td>Vanderbilt University School of Medicine, Nashvile, TN</td>
</tr>
<tr>
<td>Carlsson Ekander, Lena, MD, PhD</td>
<td></td>
<td>University of Gothenburg, Gothenburg, Sweden</td>
</tr>
<tr>
<td>Carpentier, André C., MD</td>
<td></td>
<td>Université de Sherbrooke, Sherbrooke, QC, Canada</td>
</tr>
<tr>
<td>Carroll, Ian, PhD</td>
<td></td>
<td>University of North Carolina at Chapel Hill, Chapel Hill, NC</td>
</tr>
<tr>
<td>Castle, Jessica R., MD</td>
<td></td>
<td>Oregon Health &amp; Science University, Portland, OR</td>
</tr>
<tr>
<td>Chait, Alan, MD</td>
<td></td>
<td>University of Washington, Seattle, WA</td>
</tr>
<tr>
<td>Chambers, Wiley A., II, MD</td>
<td></td>
<td>U.S. Food and Drug Administration, Silver Spring, MD</td>
</tr>
<tr>
<td>Champagne, Catherine M., PhD, RDN, LDN, FADA, FAND, FTOS</td>
<td></td>
<td>Pennington Biomedical Research Center, Baton Rouge, LA</td>
</tr>
<tr>
<td>Chan, David C., MD, PhD</td>
<td></td>
<td>California Institute of Technology, Pasadena, CA</td>
</tr>
<tr>
<td>Chan, Juliana C.N., MD</td>
<td></td>
<td>Chinese University of Hong Kong, Hong Kong, China</td>
</tr>
<tr>
<td>Chapman, Rick, PhD, MS</td>
<td></td>
<td>Institute for Clinical and Economic Review, Boston, MA</td>
</tr>
<tr>
<td>Chawla, Ajay, MD, PhD</td>
<td></td>
<td>University of California, San Francisco, San Francisco, CA</td>
</tr>
<tr>
<td>Chen, Danica, PhD</td>
<td></td>
<td>University of California, Berkeley, Berkeley, CA</td>
</tr>
<tr>
<td>Cheng, Alice Y.Y., MD, FRCPC</td>
<td></td>
<td>University of Toronto, Mississauga, ON, Canada</td>
</tr>
<tr>
<td>Cherney, David, MD, PhD</td>
<td></td>
<td>University Health Network/University of Toronto, Toronto, ON, Canada</td>
</tr>
<tr>
<td>Chiaisson, Jean-Louis, MD</td>
<td></td>
<td>University of Montréal, Montréal, QC, Canada</td>
</tr>
<tr>
<td>Chopra, Atul, MD, PhD</td>
<td></td>
<td>Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td>Chowdhury, Tahseen A., MD, FRCP</td>
<td></td>
<td>Barts and The London School of Medicine and Dentistry, London, United Kingdom</td>
</tr>
<tr>
<td>Cinar, Ali, PhD</td>
<td></td>
<td>Illinois Institute of Technology, Chicago, IL</td>
</tr>
<tr>
<td>Clements, Jennifer N., PharmD, FCCP, BCPS, CDE, BCACP</td>
<td></td>
<td>Presbyterian College School of Pharmacy, Clinton, SC</td>
</tr>
<tr>
<td>Crog, Miriam, MD, PhD</td>
<td></td>
<td>Université Libre de Bruxelles, Brussels, Belgium</td>
</tr>
<tr>
<td>Cobelli, Claudio, PhD</td>
<td></td>
<td>University of Padova, Padova, Italy</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Cohen, Robert M., MD</td>
<td>University of Cincinnati College of Medicine</td>
<td>134</td>
</tr>
<tr>
<td>Colberg, Sheri R., PhD, FACSM</td>
<td>Old Dominion University</td>
<td>97</td>
</tr>
<tr>
<td>Collins, Sheila, PhD</td>
<td>Vanderbilt University Medical Center</td>
<td>66</td>
</tr>
<tr>
<td>Collombat, Patrick, PhD</td>
<td>INSERM</td>
<td>101</td>
</tr>
<tr>
<td>Cooper, David K.C., MD, PhD, FRCS</td>
<td>University of Alabama at Birmingham</td>
<td>63</td>
</tr>
<tr>
<td>Corkey, Barbara E., PhD</td>
<td>Boston University School of Medicine</td>
<td>61</td>
</tr>
<tr>
<td>Coughlin, Janelle, PhD</td>
<td>Johns Hopkins University School of Medicine</td>
<td>168</td>
</tr>
<tr>
<td>Courcoulas, Anita P., MD, MPH</td>
<td>University of Pittsburgh Medical Center</td>
<td>129</td>
</tr>
<tr>
<td>Cowie, Catherine C., PhD, MPH</td>
<td>National Institute of Diabetes and Digestive and Kidney Diseases</td>
<td>127</td>
</tr>
<tr>
<td>Crandall, Jill P., MD</td>
<td>Albert Einstein College of Medicine</td>
<td>133</td>
</tr>
<tr>
<td>Criqui, Michael H., MD, MPH</td>
<td>University of California, San Diego</td>
<td>114</td>
</tr>
<tr>
<td>Cypess, Aaron M., MD, PhD, MMSc</td>
<td>National Institutes of Health</td>
<td>151</td>
</tr>
<tr>
<td>Czech, Michael P., PhD</td>
<td>University of Massachusetts Medical School</td>
<td>63</td>
</tr>
<tr>
<td>D’Alessio, David, MD</td>
<td>Duke University Medical Center</td>
<td>179</td>
</tr>
<tr>
<td>Dahl-Jørgensen, Knut, MD, PhD</td>
<td>Oslo University Hospital</td>
<td>100</td>
</tr>
<tr>
<td>Dalgaard, Louise T., PhD, MSc</td>
<td>Roskilde University</td>
<td>66</td>
</tr>
<tr>
<td>Dandona, Paresh, MD</td>
<td>State University of New York at Buffalo</td>
<td>181</td>
</tr>
<tr>
<td>Dassau, Eyal, PhD</td>
<td>Harvard University</td>
<td>65, 88</td>
</tr>
<tr>
<td>Davies, Melanie J., CBE, MB, ChB, MD, FRCP, FRCGP</td>
<td>University of Leicester</td>
<td>179</td>
</tr>
<tr>
<td>Davis, Catherine L., PhD</td>
<td>Augusta University</td>
<td>62</td>
</tr>
<tr>
<td>Davis, Stephen N., MBBS</td>
<td>University of Maryland School of Medicine</td>
<td>67</td>
</tr>
<tr>
<td>de Bock, Martin I., FRACP</td>
<td>Princess Margaret Hospital</td>
<td>133</td>
</tr>
<tr>
<td>de Groot, Mary, PhD</td>
<td>Indiana University School of Medicine</td>
<td>65</td>
</tr>
<tr>
<td>de León-Crutchlow, Diva D., MD, MSCE</td>
<td>Children’s Hospital of Philadelphia</td>
<td>146</td>
</tr>
<tr>
<td>de Zeeuw, Dick, MD, PhD</td>
<td>University of Groningen</td>
<td>167</td>
</tr>
<tr>
<td>Dean, Danielle, PhD</td>
<td>Vanderbilt University School of Medicine</td>
<td>136</td>
</tr>
<tr>
<td>Delamater, Alan M., PhD</td>
<td>University of Miami Miller School of Medicine</td>
<td>167</td>
</tr>
<tr>
<td>Desai, Tejal, PhD</td>
<td>University of California, San Francisco</td>
<td>82</td>
</tr>
</tbody>
</table>

INVITED SPEAKER INDEX
Diano, Sabrina, PhD ............................................ p.101
Yale University School of Medicine
New Haven, CT

DiMarchi, Richard, PhD ......................................... p.95
Indiana University
Bloomington, IN

Doria, Alessandro, MD, PhD, MPH ......................... p.161
Joslin Diabetes Center
Boston, MA

Duke, Danny C., PhD ........................................ p.114
Oregon Health & Science University
Portland, OR

Dufort, Matthew, PhD ........................................ p.116
Benaroya Research Institute at Virginia Mason
Seattle, WA

Dukhovny, Dmitry, MD, MPH .............................. p.114
Oregon Health & Science University
Portland, OR

Dungan, Kathleen M., MD, MPH ......................... p.178
The Ohio State University
Columbus, OH

Edelstein, Sharon L., ScM ................................ p.159
George Washington University
Rockville, MD

Edgerton, Dale S., PhD ........................................ p.64
Vanderbilt University School of Medicine
Nashville, TN

Ehrenfeld, Jesse, MD, MPH ................................. p.178
Vanderbilt University Medical Center
Nashville, TN

Ehrmann, David A., MD ....................................... p.159
University of Chicago
Chicago, IL

Eiland, Leslie, MD ............................................. p.154
University of Nebraska Medical Center
Omaha, NE

Ejskjaer, Niels, MD, PhD ................................. p.114
Aalborg University Hospital
Aalborg, Denmark

Ellacott, Kate, PhD ......................................... p.159
University of Exeter
Exeter, United Kingdom

Elmquist, Joel K., DVM, PhD ............................ p.135
University of Texas Southwestern Medical Center
Dallas, TX

Ely, Elizabeth K., MD ....................................... p.128
Centers for Disease Control and Prevention
Atlanta, GA

Emanuele, Nicholas V., MD ............................. p.133
VA Hospital/Loyola University Chicago
Stritch School of Medicine
Hines, IL

Embil, John M., MD ......................................... p.80
University of Manitoba
Winnipeg, MB, Canada

Estall, Jennifer L., PhD ...................................... p.180
Institut de recherches cliniques de Montréal
Montréal, QC, Canada

Everhart, Damian, RN, PhD ............................... p.95
Centers for Medicare and Medicaid
Woodlawn, MD

Evert, Alison B., MS, RD, CDE ............................ p.67
University of Washington Neighborhood Clinics
Seattle, WA

Farber, Steven A., PhD ....................................... p.96
Carnegie Institution for Science
Baltimore, MD

Farooqi, Sadaf, PhD, FRCP, FMedSci ........................ p.168
Cambridge Neuroscience
Cambridge, United Kingdom

Fawzi, Amani, MD ......................................... p.133
Northwestern University
Chicago, IL

Fedele, David, PhD ......................................... p.100
University of Florida
Gainesville, FL

Feghali, Maisa N., MD ...................................... p.144
University of Pittsburgh
Pittsburgh, PA
Feig, Denice S., MD, MSc, FRCPC.......................... p.154
Mount Sinai Hospital
Toronto, ON, Canada

Fendrick, A. Mark, MD................................. p.158
University of Michigan
Ann Arbor, MI

Fernández-Hernando, Carlos, PhD.................. p.129
Yale University School of Medicine
New Haven, CT

Ferrannini, Ele, MD...................................... p.181
National Research Council
Pisa, Italy

Ferrer, Jorge, MD, PhD............................... p.61
CIBERDE, IDIBAPS
Barcelona, Spain
Imperial College London
London, United Kingdom

Fisher, Lawrence, PhD, ABPP....................... p.94
University of California, San Francisco
San Francisco, CA

Fisher, Simon J., MD, PhD.......................... p.67
University of Utah
Salt Lake City, UT

Flannick, Jason A., PhD.............................. p.88
Broad Institute
Cambridge, MA

Florez, Hermes, MD.................................... p.61
University of Miami Geriatric Research Education
and Clinical Center
Miami, FL

Fonseca, Vivian, MD................................. p.115
Tulane University
New Orleans, LA

Forbes, Shareen, MB, ChB, PhD, FRCP............ p.129
University of Edinburgh
Edinburgh, United Kingdom

Forlenza, Gregory P., MD......................... p.128
Barbara Davis Center for Diabetes
Aurora, CO

Fortmann, Addie L., PhD............................. p.63
Scripps Whittier Diabetes Institute-Scripps Health
San Diego, CA

Fradkin, Judith E., MD................................ p.115, 179
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD

Frangou, Sophia, MD, MSc, PhD,
FRCpsych............................................. p.146
Icahn School of Medicine at Mount Sinai
New York, NY

Frias, Juan P., MD..................................... p.115
National Research Institute
Los Angeles, CA

Fridman, Vera, MD................................. p.114
University of Colorado Anschutz Medical Campus
Aurora, CO

Funai, Katsu, PhD................................. p.101
University of Utah
Salt Lake City, UT

Furuyama, Kenichiro, MD, PhD.................... p.136
University of Geneva
Geneva, Switzerland

Gandica, Rachelle, MD.............................. p.81
Naomi Berrie Diabetes Center of Columbia
University
New York, NY

Garg, Rajesh, MD................................. p.178
University of Miami
Coral Gables, FL

Garland, Theodore, Jr., PhD...................... p.178
University of California, Riverside
Riverside, CA

Garvey, Katharine C., MD, MPH................... p.63
Boston Children’s Hospital
Boston, MA

Garvey, W. Timothy, MD......................... p.134
University of Alabama at Birmingham
Birmingham, AL

Gavin, Marc A., PhD................................ p.116
Benaroya Research Institute at Virginia Mason
Seattle, WA

Gerstein, Hertzel C., MD, MSc, FRCPC........ p.97, 133
McMaster University
Hamilton, ON, Canada
Gilden, Janice L., MD, MS, FCP, FACE, FAAS .................................................. p.123
Chicago Medical School at Rosalind Franklin University of Medicine and Science North Chicago, IL

Girotra, Monica, MD .......................................................... p.135
Memorial Sloan Kettering Cancer Center New York, NY

Goldberg, Ira J., MD .......................................................... p.94
New York University Langone Health New York, NY

Golden, Sherita, MD, MHS .................................................. p.146
Johns Hopkins University School of Medicine Baltimore, MD

Gonder-Frederick, Linda, PhD .................................................. p.67
University of Virginia Charlottesville, VA

Gonzalez, Frank J., PhD .................................................. p.96
National Cancer Institute Bethesda, MD

Goodyear, Laurie J., PhD .................................................. p.178
Joslin Diabetes Center Boston, MA

Greeley, Siri Atma W., MD, PhD ................................................. p.81
University of Chicago Chicago, IL

Greenlee, M. Carol, MD, FACE, FACP ................................................. p.95
Western Slope Endocrinology Grand Junction, CO

Gregg, Edward W., PhD .......................................................... p.154
Centers for Disease Control and Prevention Atlanta, GA

Grice, Elizabeth A., PhD .................................................. p.60
University of Pennsylvania Philadelphia, PA

Griffin, Timothy, PhD .......................................................... p.133
Tufts University, Friedman School of Nutrition Science and Policy Boston, MA

Grunfeld, Carl, MD, PhD .................................................. p.81
University of California, San Francisco San Francisco, CA

Gubitsos-Klug, Rose, MD, PhD .................................................. p.100
Rainbow Babies and Children's Hospital/Case Western Reserve University School of Medicine Cleveland, OH

Guzzardi, Maria A., PhD .................................................. p.146
Institute of Clinical Physiology, National Research Council Pisa, Italy

Haller, Michael, MD .......................................................... p.145
University of Florida Gainesville, FL

Hamm, Heidi E., PhD .................................................. p.180
Vanderbilt University School of Medicine Nashville, TN

Hannan, Tamara S., MD, MS .................................................. p.159
Indiana University School of Medicine Indianapolis, IN

Hardee, Sandra, PharmD, CDE .................................................. p.127
Vidant Medical Center Greenville, NC

Harlan, David M., MD .......................................................... p.169
University of Massachusetts Medical School Worcester, MA

Harris, Stewart, CM, MD, MPH, FCFP, FACPM .................................................. p.65
Western University London, ON, Canada

Hasson, Rebecca E., PhD .................................................. p.62
University of Michigan Ann Arbor, MI

Heerspink, Hiddo Lambers, PhD .................................................. p.178
University Medical Center Groningen Groningen, Netherlands

Heise, Tim, MD .......................................................... p.168
Profil Neuss, Germany

Heisler, Lora K., PhD .................................................. p.153
University of Aberdeen Cambridge, United Kingdom

Heisler, Michele, MD, MPA .................................................. p.145
University of Michigan Ann Arbor, MI

Heller, Simon R., MD, FRCP .................................................. p.153
University of Sheffield Sheffield, United Kingdom
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hensrud, Donald D., MD, MPH</td>
<td>Mayo Clinic Rochester, MN</td>
<td>p.97</td>
</tr>
<tr>
<td>Herman, Mark A., MD</td>
<td>Duke University Durham, NC</td>
<td>p.180</td>
</tr>
<tr>
<td>Hernandez, Teri L., PhD, RN</td>
<td>University of Colorado Anschutz Medical Campus Aurora, CO</td>
<td>p.144</td>
</tr>
<tr>
<td>Herold, Kevan C., MD</td>
<td>Yale University New Haven, CT</td>
<td>p.116</td>
</tr>
<tr>
<td>Herrero-Viñas, Pau, PhD</td>
<td>Imperial College London London, United Kingdom</td>
<td>p.65</td>
</tr>
<tr>
<td>Hessner, Martin J., PhD</td>
<td>Medical College of Wisconsin Milwaukee, WI</td>
<td>p.116</td>
</tr>
<tr>
<td>Hieronymus, Laura B., DNP, MSc, RN, MLDE, BC-ADM, CDE, FAFADE</td>
<td>University of Kentucky Barnstable Brown Diabetes Center Lexington, KY</td>
<td>p.127</td>
</tr>
<tr>
<td>Higgins, John M., MD</td>
<td>Massachusetts General Hospital Boston, MA</td>
<td>p.134</td>
</tr>
<tr>
<td>Hill-Briggs, Felicia, PhD, ABPP</td>
<td>Johns Hopkins University School of Medicine Baltimore, MD</td>
<td>p.87, 153</td>
</tr>
<tr>
<td>Hinder, Lucy M., PhD</td>
<td>University of Michigan Ann Arbor, MI</td>
<td>p.114</td>
</tr>
<tr>
<td>Hivet, Marie-France, MD</td>
<td>Harvard Medical School Boston, MA</td>
<td>p.144</td>
</tr>
<tr>
<td>Hofer, Sabine E., MD, PhD</td>
<td>Medical University of Innsbruck Innsbruck, Austria</td>
<td>p.100</td>
</tr>
<tr>
<td>Hood, David A., PhD</td>
<td>York University Toronto, ON, Canada</td>
<td>p.94</td>
</tr>
<tr>
<td>Hood, Korey K., PhD</td>
<td>Stanford University Stanford, CA</td>
<td>p.60</td>
</tr>
<tr>
<td>Horton, Mark B., OD, MD</td>
<td>Indian Health Service Phoenix, AZ</td>
<td>p.145</td>
</tr>
<tr>
<td>Hsue, Priscilla, MD</td>
<td>University of California, San Francisco School of Medicine San Francisco, CA</td>
<td>p.81</td>
</tr>
<tr>
<td>Hugenschmidt, Christina E., PhD</td>
<td>Wake Forest School of Medicine Winston-Salem, NC</td>
<td>p.127</td>
</tr>
<tr>
<td>Inturri, Maribeth, RN, MS, CNS, CDE</td>
<td>Sweet Success Extension Program San Francisco, CA</td>
<td>p.61</td>
</tr>
<tr>
<td>Isasi, Carmen R., MD, PhD</td>
<td>Albert Einstein College of Medicine Bronx, NY</td>
<td>p.167</td>
</tr>
<tr>
<td>Itsiopoulos, Catherine, BSc, BSc (Hons), Grad Dip Diet, MPH, PhD, APD, AN</td>
<td>Joslin Diabetes Center/Harvard Medical School Boston, MA</td>
<td>p.64</td>
</tr>
<tr>
<td>Jacobs, David, PhD</td>
<td>University of Minnesota School of Public Health Minneapolis, MN</td>
<td>p.64</td>
</tr>
<tr>
<td>James, David E., PhD</td>
<td>University of Sydney New South Wales, Australia</td>
<td>p.135</td>
</tr>
<tr>
<td>James, Eddie A., PhD</td>
<td>Benaroya Research Institute Seattle, WA</td>
<td>p.61</td>
</tr>
<tr>
<td>Janicke, David, PhD, ABPP</td>
<td>University of Florida Gainesville, FL</td>
<td>p.114</td>
</tr>
<tr>
<td>Jaser, Sarah S., PhD</td>
<td>Vanderbilt University School of Medicine Nashville, TN</td>
<td>p.60</td>
</tr>
<tr>
<td>Jensen, Michael D., MD</td>
<td>Mayo Clinic Rochester, MN</td>
<td>p.135</td>
</tr>
</tbody>
</table>
Jetty, Anuradha, MPH ........................................ p.158
Robert Graham Center
Washington, DC

Johnson, Mary L., RN, BS, CDE ........................................ p.67
International Diabetes Center
Minneapolis, MN

Johnson, Suzanne Bennett, PhD ........................................ p.96
Florida State University College of Medicine
Tallahassee, FL

Jornsay, Donna, MS, BSN, CPNP, CNS, CDE, CDT, BC-ADM ......................................... p.127
Mills-Peninsula Medical Center
Burlingame, CA

Kahn, C. Ronald, MD ...................................................... p.66
Joslin Diabetes Center
Boston, MA

Kalyani, Rita Rastogi, MD, MHS ........................................ p.64, 164
Johns Hopkins University School of Medicine
Baltimore, MD

Kern, Timothy S., PhD .................................................... p.133
Case Western Reserve University
Cleveland, OH

Kernan, Walter, MD ...................................................... p.128, 179
Yale School of Medicine
New Haven, CT

Khunti, Kamlesh, MD, PhD, FRCGP, FRCP, FMedSci ......................................................... p.65
University of Leicester
Leicester, United Kingdom

Kibbey, Richard G., MD, PhD ............................................. p.146
Yale School of Medicine
New Haven, CT

Kieffer, Edith C., PhD, MPH ............................................... p.61
University of Michigan School of Social Work
Ann Arbor, MI

Kiguchi, Misaki, MD, MBA ................................................ p.87, 114
MedStar Health
Washington, DC

Kim, Jason K., PhD ...................................................... p.64
University of Massachusetts Medical School
Worcester, MA

Kim, Young-Bum, PhD .................................................... p.82
Beth Israel Deaconess Medical Center/
Harvard Medical School
Boston, MA

Kirkman, M. Sue, MD .................................................... p.115
University of North Carolina
Chapel Hill, NC

Kirwan, John P., PhD .................................................... p.94
Pennington Biomedical Research Center
Baton Rouge, LA

Klass, Evan, MD ........................................................ p.145
University of Nevada, Reno School of Medicine
Reno, NV

Klemewer, Steven, PhD .................................................... p.82
University of Texas Southwestern Medical Center
Dallas, TX

Klonoff, David C., MD .................................................... p.100
Mills-Peninsula Health Services
San Mateo, CA

Knutsen, Patricia, NP-C, RN, MSN, ACNS-BC, CDE ............................................. p.67
Washington University School of Medicine
St. Louis, MO

Kosiborod, Mikhail N., MD ............................................. p.178
Saint Luke's Mid America Heart Institute/
University of Missouri-Kansas City
Kansas City, MO

Kovatchev, Boris P., PhD ................................................... p.116
University of Virginia School of Medicine
Charlottesville, VA

Kralli, Anastasia, PhD .................................................... p.101
Johns Hopkins University School of Medicine
Baltimore, MD

Kreider, Kathryn Evans, DNP, FNP-BC, BC-ADM ............................................. p.65
Duke University School of Nursing
Durham, NC

Krischer, Jeffrey, PhD .................................................... p.96, 145
University of South Florida
Tampa, FL

Ku, Gregory, MD, PhD .................................................... p.130
University of California, San Francisco
San Francisco, CA

Laffel, Lori, MD, MPH .................................................... p.123
Joslin Diabetes Center
Boston, MA

Lam, Tony K.T., PhD .................................................... p.175
University of Toronto
Toronto, ON, Canada
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lane, Wendy S., MD</td>
<td>Mountain Diabetes and Endocrine Center</td>
<td>168</td>
</tr>
<tr>
<td></td>
<td>Asheville, NC</td>
<td></td>
</tr>
<tr>
<td>Lavery, Lawrence A., DPM</td>
<td>University of Texas Southwestern Medical Center</td>
<td>60, 87</td>
</tr>
<tr>
<td></td>
<td>Dallas, TX</td>
<td></td>
</tr>
<tr>
<td>Lee, Chih-Hao, PhD</td>
<td>Harvard T.H. Chan School of Public Health</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Lee, Christine S., PharmD, PhD</td>
<td>U.S. Food &amp; Drug Administration</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Silver Spring, MD</td>
<td></td>
</tr>
<tr>
<td>Lee, Joyce M., MD, MPH</td>
<td>University of Michigan</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>Lewis, Dana M., BA</td>
<td>OpenAPS</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td>Seattle, WA</td>
<td></td>
</tr>
<tr>
<td>Lexchin, Joel, MD</td>
<td>York University</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td>Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>Ley, Sylvia H., PhD, RD</td>
<td>Harvard T.H. Chan School of Public Health/</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Li, Xiaoying, MD, PhD</td>
<td>Zhongshan Hospital, Fudan University</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>Lichtman, Andrew H., MD, PhD</td>
<td>Brigham and Women's Hospital</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Boston, MA</td>
<td></td>
</tr>
<tr>
<td>Ling, Charlotte, PhD</td>
<td>Lund University Diabetes Center</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td>Malmo, Sweden</td>
<td></td>
</tr>
<tr>
<td>Liu, Feng, MD, PhD</td>
<td>Metabolic Syndrome Research Center, Second Xiangya Hospital, Central South University</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Changsha, China</td>
<td></td>
</tr>
<tr>
<td>Liu, Junli, PhD</td>
<td>Shanghai Sixth People's Hospital</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>Lönnrot, Maria, MD, PhD</td>
<td>University of Tampere</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Tampere, Finland</td>
<td></td>
</tr>
<tr>
<td>Loos, Ruth, PhD</td>
<td>Mount Sinai School of Medicine</td>
<td>129</td>
</tr>
<tr>
<td></td>
<td>New York, NY</td>
<td></td>
</tr>
<tr>
<td>Los, Evan A., MD</td>
<td>East Tennessee State University</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>Johnson City, TN</td>
<td></td>
</tr>
<tr>
<td>Lovshin, Julie A., MD, PhD</td>
<td>Sunnybrook Health Sciences Centre</td>
<td>144</td>
</tr>
<tr>
<td></td>
<td>Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>Lynch, Kristian F., PhD</td>
<td>University of South Florida</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Tampa, FL</td>
<td></td>
</tr>
<tr>
<td>Mackay, Dylan, MSc, PhD</td>
<td>University of Manitoba</td>
<td>87</td>
</tr>
<tr>
<td></td>
<td>Winnipeg, MB, Canada</td>
<td></td>
</tr>
<tr>
<td>Maechler, Pierre, PhD</td>
<td>University of Geneva Medical School</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Geneva, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Magee, Michelle F., MD, MB, BCh, LRCPSI</td>
<td>MedStar Health Diabetes &amp; Research Institutes</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Washington, DC</td>
<td></td>
</tr>
<tr>
<td>Magnuson, Mark A., MD</td>
<td>Vanderbilt University School of Medicine</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Nashville, TN</td>
<td></td>
</tr>
<tr>
<td>Mamula, Mark J., PhD</td>
<td>Yale University</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>New Haven, CT</td>
<td></td>
</tr>
<tr>
<td>Mangia, Silvia, PhD</td>
<td>University of Minnesota</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Minneapolis, MN</td>
<td></td>
</tr>
<tr>
<td>Mangione, Carol M., MD, MSPH</td>
<td>University of California, Los Angeles</td>
<td>158</td>
</tr>
<tr>
<td></td>
<td>Los Angeles</td>
<td></td>
</tr>
<tr>
<td>Manning, Alisa, PhD</td>
<td>Broad Institute</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td>Cambridge, MA</td>
<td></td>
</tr>
<tr>
<td>Manson, Spero M., PhD</td>
<td>Colorado School of Public Health/University of</td>
<td>179</td>
</tr>
<tr>
<td></td>
<td>Colorado Anschutz Medical Campus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aurora, CO</td>
<td></td>
</tr>
<tr>
<td>Marchetti, Piero, MD, PhD</td>
<td>University of Pisa</td>
<td>97</td>
</tr>
<tr>
<td></td>
<td>Pisa, Italy</td>
<td></td>
</tr>
</tbody>
</table>
Marso, Steven P., MD ........................................ p.67
HCA Midwest Health
Kansas City, MO

Maryniuk, Melinda D., MEd, RD, CDE .......... p.60, 62
Melinda Maryniuk & Associates
Boston, MA

Mason, Susan Marshall, PhD, MPH .......... p.115
University of Minnesota School of Public Health
Minneapolis, MN

Mather, Kieren J., MD .......... p.159
Indiana University School of Medicine
Indianapolis, IN

Mathiesen, Elisabeth R., MD, DMSc .......... p.154
Center for Pregnant Women with Diabetes
Copenhagen, Denmark

Mathieu, Chantal, MD, PhD .......... p.179
UZ Leuven
Leuven, Belgium

Matsuoka, Takaaki, MD, PhD .......... p.163
Osaka University
Suita, Japan

Matthews, Elizabeth, MPA .......... p.128
Center for Medicare and Medicaid Innovation
Baltimore, MD

McCaffery, Jeanne M., PhD .......... p.129
Allied Health Sciences at the University of
Connecticut
Storrs, CT

McCarty, Mark, MD .......... p.123
Oxford Centre for Diabetes, Endocrinology and
Metabolism
Oxford, United Kingdom

McCurdy, Carrie, PhD .......... p.180
University of Oregon
Eugene, OR

McEwan, Philip C., PhD .......... p.153
Health Economics and Outcomes
Research Ltd.
Cardiff, United Kingdom

McGuire, Darren K., MD, MHSc .......... p.67
University of Texas Southwestern Medical Center
Dallas, TX

McIntyre, Roger S., MD, FRCPA .......... p.146
University of Toronto
Toronto, ON, Canada

Meier, Juris, MD .......... p.115
St. Josef-Hospital
Bochum, Germany

Mena, Carlos, MD, FACC, FSCAI .......... p.114
Yale University
New Haven, CT

Meneghini, Luigi F., MD, MBA .......... p.63, 123
University of Texas Southwestern Medical Center
Dallas, TX

Messer, Laurel H., RN, MPH, CDE .......... p.62
University of Colorado Anschutz Medical Campus
Aurora, CO

Michels, Aaron, MD .......... p.145
University of Colorado Anschutz Medical Campus
Aurora, CO

Mike, Leigh Ann, PharmD, BCPS, BCGP .......... p.158
University of Washington
Seattle, WA

Mingrone, Geltrude, MD, PhD .......... p.179
Università Cattolica delSacro Cuore
Rome, Italy

Mirmira, Raghavendra G., MD, PhD .......... p.155
Indiana University School of Medicine
Indianapolis, IN

Mitri, Joanna, MD, MS .......... p.64
Joslin Diabetes Center
Boston, MA

Mohan, Viswanathan, MD, PhD, DSc .......... p.154
Madras Diabetes Research Foundation/
Dr. Mohan’s Diabetes Specialties Centre
Chennai, India

Mohr, Susanne, PhD .......... p.133
Michigan State University
East Lansing, MI

Molitch, Mark E., MD .......... p.127
Northwestern University Feinberg School of Medicine
Chicago, IL

Monaghan, Maureen, PhD .......... p.128
Children’s National Health System
Washington, DC

Morahan, Grant, BSc (Hons), PhD .......... p.123
Harry Perkins Institute of Medical Research
Perth, Australia
Moran, Antoinette, MD ........................................ p.128
University of Minnesota
Minneapolis, MN

Morris, Jill, PhD ........................................... p.127
University of Kansas Medical Center
Kansas City, KS

Morrison, William B., MD ................................. p.80
Thomas Jefferson University Hospital
Philadelphia, PA

Mottl, Amy K., MD ........................................ p.145
University of North Carolina
Chapel Hill, NC

Murashov, Alexander K., MD, PhD ................ p.178
Brody School of Medicine at East Carolina University
Greenville, NC

Murphy, Helen R., MD, FRACP ......................... p.81
University of East Anglia, Norwich/
Kings College London
Norwich, United Kingdom

Myers, Martin G., Jr., MD, PhD ......................... p.135
University of Michigan
Ann Arbor, MI

Nadeau, Kristen J., MD, MS ............................ p.159
University of Colorado Anschutz Medical Campus
Aurora, CO

Najjar, Sonia M., PhD .................................. p.135
Ohio University
Athens, OH

Nassar, Carine M., MS, RD, CDE ....................... p.80
MedStar Health Diabetes & Research Institutes
Washington, DC

Nathan, David M., MD ................................ p.97
Massachusetts General Hospital
Boston, MA

Nelson, Robert, MD, PhD ................................. p.167
National Institute of Diabetes and Digestive and Kidney Diseases
Phoenix, AZ

Newcomer, John W., MD ................................. p.65
Florida Atlantic University
Boca Raton, FL

Nicholls, David G., PhD ................................. p.130
Buck Institute for Research on Aging
Novato, CA

Norris, Jill M., PhD ........................................ p.96
Colorado School of Public Health
Aurora, CO

O’Brien, Richard M., PhD ............................... p.146
Vanderbilt University School of Medicine
Nashville, TN

O’Tierney-Ginn, Perrie F., PhD ....................... p.80
Tufts Medical Center
Boston, MA

Oberholzer, Jose, MD ......................................... p.129
University of Virginia
Charlottesville, VA

Odagiri, Jon S., MD, FACS .............................. p.63
University of Wisconsin School of Medicine and Public Health
Madison, WI

Ogden, Cynthia L., PhD ................................. p.179
Centers for Disease Control and Prevention
Hyattsville, MD

Oram, Richard A., MD, PhD ............................. p.134
University of Exeter
Exeter, United Kingdom

Ozanne, Susan, PhD ................................. p.115
University of Cambridge
Cambridge, United Kingdom

Papa, Feroz R., MD, PhD ............................. p.169
University of California, San Francisco
San Francisco, CA

Paraskevas, Steven, MD, PhD ....................... p.66
McGill University Health Centre
Montréal, QC, Canada

Parks, Brian, PhD ........................................... p.160
University of Wisconsin-Madison
Madison, WI

Parry, Samuel, MD ......................................... p.80
University of Pennsylvania School of Medicine
Philadelphia, PA

Pasquel, Francisco J., MD, MPH ....................... p.178
Emory University
Decatur, GA

Patel, Minal R., PhD, MPH .............................. p.158
University of Michigan School of Public Health
Ann Arbor, MI
Patel, Shivani A., PhD ........................................ p.179
Emory University
Atlanta, GA

Pavkov, Meda E., MD, PhD ........................................ p.62
Centers for Disease Control and Prevention
Atlanta, GA

Pellizzari, Margaret, MS, MBA, RN, CDE, CDTC ........................................................ p.67
Northwell Health
New York, NY

Perkins, Bruce A., MD, MPH ........................................ p.60
University of Toronto
Toronto, ON, Canada

Perkowitz, Susie ................................................ p.96
Deerfield, IL

Perreault, Leigh, MD ........................................ p.133
University of Colorado Anschutz Medical Campus
Aurora, CO

Peters, Edgar J.G., MD, PhD ................ p.80, 87, 103
VU University Medical Center
Amsterdam, Netherlands

Phelps, Edward, PhD ........................................ p.101
University of Florida
Gainesville, FL

Philipson, Louis H., MD, PhD ................ p.96
University of Chicago
Chicago, IL

Philis-Tsimikas, Athena, MD ................ p.115
Scripps Whittier Diabetes Institute-Scripps Health
San Diego, CA

Piatt, Gretchen A., PhD, MPH .................... p.122
University of Michigan
Ann Arbor, MI

Pickering, Matthew, PharmD .................. p.95
Pharmacy Quality Alliance
Alexandria, VA

Piette, John D., PhD ........................................ p.115
University of Michigan School of Public Health
Ann Arbor, MI

Piikker, Catherine, MD ........................................ p.81
University of Washington
Seattle, WA

Pipeleers, Daniel, MD, PhD ...................... p.82
Vrije Universiteit Brussel
Brussels, Belgium

Plomgaard, Peter, MD, PhD .................... p.129
Centre of Inflammation and Metabolism
Copenhagen, Denmark

Probst, Janice C., PhD ........................................ p.179
University of South Carolina
Columbia, SC

Pullen, Timothy, PhD ........................................ p.146
Imperial College
London, United Kingdom

Qi, Lu, MD, PhD ........................................ p.129
Tulane University
New Orleans, LA

Ramchandani, Neesha, PNP, CDE, CDTC ...... p.123
New York University Rory Meyers College of Nursing
New York, NY

Rangaswami, Janani, MD, FACP ................ p.144
Einstein Medical Center
Philadelphia, PA

Rasouli, Neda, MD ........................................ p.154
University of Colorado School of Medicine/
Eastern Colorado VA Health Care System
Denver, CO

Reaven, Peter D., MD ........................................ p.133
Phoenix VA Health Care System
Phoenix, AZ

Remaley, Alan T., MD ...................................... p.122
National Institutes of Health
Bethesda, MD

Resnick, Barbara, PhD, RN, CRNP .............. p.158
University of Maryland School of Medicine
Baltimore, MD

Reusch, Jane E.B., MD ...................................... p.122, 153
University of Colorado Anschutz Medical Campus
Denver, CO

Reutrakul, Sirimon, MD ......................... p.115
University of Illinois at Chicago
Chicago, IL

Rich, Stephen S., PhD ............................. p.116
University of Virginia
Charlottesville, VA

Rickels, Michael R., MD, MS ................. p.169
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Ricordi, Camillo, MD ........................................ p.169
University of Miami Diabetes Research Institute
Miami, FL

Riley, Andrew, PhD ........................................ p.94
Oregon Health & Science University
Portland, OR

Rodbard, Helena W., MD .................... p.115
Endocrine and Metabolic Consultants
Rockville, MD

Roden, Michael, MD ..................... p.116, 175
German Diabetes Center, University of
Düsseldorf
Düsseldorf, Germany

Rodgers, Griffin P., MD .................. p.159
National Institute of Diabetes and
Digestive and Kidney Diseases
Bethesda, MD

Rodriguez, Betsy, BSN, MSN, CDE .... p.62
Centers for Disease Control and Prevention
Atlanta, GA

Rosenblum, Barry, DPM .................... p.87
Beth Israel Deaconess Medical Center
Boston, MA

Rosenstock, Julio, MD .................. p.181
Dallas Diabetes Research Center
Dallas, TX

Rossing, Peter, MD ...................... p.167, 179
Steno Diabetes Center Copenhagen
Gentofte, Denmark

Russell-Jones, David, MD ............... p.179
Royal Surrey County Hospital
Guildford, United Kingdom

Sacks, David B., MB, ChB .............. p.134
National Institutes of Health
Bethesda, MD

Sadovsky, Yoel, MD ................. p.80
Magee-Women’s Research Institute
Pittsburgh, PA

Sakai, Juro, MD, PhD ................. p.66
Tohoku University
Tokyo, Japan

Salomon, Carlos, PhD, DMedSc, MSc ..... p.80
The University of Queensland
Brisbane, Australia

Sampilo, Marilyn, PhD, MPH .......... p.114
The Ohio State University
Columbus, OH

Samuel, Varman, MD, PhD ........ p.63
Yale University/VA Medical Center West Haven
West Haven, CT

Sandini, Lorenzo, MD ................ p.95
Central Hospital of South Carelia
Lappeenranta, Finland

Sandoval, Darleen A., PhD .......... p.96
University of Michigan
Ann Arbor, MI

Saran, Rajiv, MBBS, DTCD, MD, MRCP, MS ........... p.62
University of Michigan
Ann Arbor, MI

Sarpatwari, Ameet, JD, PhD .......... p.134
Brigham and Women’s Hospital
Boston, MA

Saydah, Sharon, PhD ................ p.61
Centers for Disease Control and Prevention
Hyattsville, MD

Schneiderman, Neil, PhD .......... p.167
University of Miami
Miami, FL

Schroeder, Emily B., MD, PhD .......... p.167
Kaiser Permanente
Denver, CO

Scialla, Julia, MD .................. p.144
Duke University School of Medicine
Durham, NC

Seaquist, Elizabeth R., MD .......... p.153
University of Minnesota
Minneapolis, MN

Segar, Michelle, PhD, MPH .......... p.87
University of Michigan
Ann Arbor, MI

Segerstolpe, Åsa, PhD ............. p.66
Karolinska Institutet
Stockholm, Sweden
Seggelke, Stacey A., DNP, ACNS-BC, BC-ADM, CDE ........................................... p.127
University of Colorado Hospital
Aurora, CO

Selman, Colin, PhD ............................................. p.160
University of Glasgow
Glasgow, United Kingdom

Selvarajah, Dinesh, MB, ChB, MRCP, PhD ................................ p.114
University of Sheffield
Sheffield, United Kingdom

Senior, Peter A., MBBS, PhD ........................................... p.169
University of Alberta
Edmonton, AB, Canada

Senneville, Eric, MD, PhD ........................................... p.80
Dron Hospital
Tourcoing, France

Shah, Amy S., MD ................................................. p.145
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Shah, Nilay D., PhD ................................................ p.95
Mayo Clinic
Rochester, MN

Shalev, Anath, MD ................................................ p.169
University of Alabama at Birmingham
Birmingham, AL

Shaw, Jonathan E., MD, FRACP, FRCP (UK), FAAHMS ........................................ p.154
Baker IDI Heart and Diabetes Institute
Melbourne, Australia

Shea, Lonnie D., PhD ................................................. p.82
University of Michigan
Ann Arbor, MI

Shea, Patricia, MPH, MA ............................................ p.128
Centers for Disease Control and Prevention
Atlanta, GA

Sherr, Jennifer, MD, PhD ........................................... p.81
Yale University School of Medicine
New Haven, CT

Shulman, Gerald I., MD, PhD, FACP, MACE ................................................. p.122
Yale University School of Medicine
New Haven, CT

Siminerio, Linda M., RN, PhD, CDE ............................................. p.115
University of Pittsburgh
Pittsburgh, PA

Singleton, J. Robinson, MD ........................................... p.60
University of Utah
Salt Lake City, UT

Smith, Lois E.H., MD, PhD ........................................... p.129
Boston Children’s Hospital
Boston, MA

Smyth, Hugh, PhD ................................................. p.95
University of Texas at Austin
Austin, TX

Sneddon, Julie B., PhD ............................................. p.61
University of California, San Francisco
San Francisco, CA

Soleimanpour, Scott A., MD ........................................... p.130
University of Michigan Medical School
Ann Arbor, MI

Soukas, Alexander, MD, PhD ........................................... p.180
Massachusetts General Hospital
Boston, MA

Spangenburg, Espen E., PhD ........................................... p.160
East Carolina Diabetes and Obesity Institute
Greenville, NC

Speier, Stephan, PhD ................................................ p.66
Technische Universität Dresden
Dresden, Germany

Stanford, Kristin I., PhD ............................................. p.66
The Ohio State University
Columbus, OH

Star, Robert A., MD ................................................. p.98
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD

Steinhauser, Matthew, MD ........................................... p.135
Brigham and Women’s Hospital
Boston, MA

Sullivan, Sean D., BSc Pharm, PhD ........................................... p.65
University of Washington
Seattle, WA

Sun, Jennifer K., MD, MPH ........................................... p.122
Joslin Diabetes Center
Boston, MA
Sunahara, Roger K., PhD .................................. p.180
University of California, San Diego
La Jolla, CA

Sundstrom, Jeffrey M., MD, PhD .................... p.133
Penn State Hershey Eye Center
Hershey, PA

Sussel, Lori, PhD ........................................ p.116
University of Colorado Anschutz Medical Campus
Aurora, CO

Swisa, Avital, PhD ........................................... p.97
Hebrew University of Jerusalem
Jerusalem, Israel

Sylvetsky, Allison, PhD .................... p.154
George Washington University
Washington, DC

Tabak, Rachel G.A., PhD, RD ........ p.122
Washington University in St. Louis
St. Louis, MO

Tamborlane, William V., MD .................... p.123
Yale University
New Haven, CT

Tarnopolsky, Mark A., MD, PhD, FRCP ........ p.66
McMaster University
Hamilton, ON, Canada

Tate, Deborah, PhD .................... p.168
University of North Carolina Gillings School of Global Public Health
Chapel Hill, NC

Tay, Jeannie, PhD .................... p.133
University of Alabama at Birmingham
Birmingham, AL

Teplitsky, Lena, MPH .................... p.144
Oregon Health & Science University
Portland, OR

Thabit, Hood, MD, PhD .................... p.128
Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom

Thomas, Celeste C., MD, MS .................... p.123
University of Chicago
Chicago, IL

Thomas, Merlin, MB, ChB, PhD, FRACP ........ p.167
Monash University
Melbourne, Australia

Thompson, David M., MD .................... p.129
University of British Columbia
Vancouver, BC, Canada

Thorens, Bernard, PhD .................... p.135
University of Lausanne
Lausanne, Switzerland

Tien, Phyllis, MD .................... p.81
University of California, San Francisco School of Medicine
San Francisco, CA

Tolan, Dean R., PhD .................... p.180
Boston University
Boston, MA

Tomas, Alejandra, PhD .................... p.180
Imperial College
London, United Kingdom

Trence, Dace, MD .................... p.168
University of Washington
Seattle, WA

Trief, Paula M., PhD .................... p.94
State University of New York Upstate Medical University
Syracuse, NY

Tsai, Linus T.-Y., MD, PhD .................... p.159
Beth Israel Deaconess Medical Center
Boston, MA

Tsapas, Apostolos, MD, PhD, MSc ........ p.179
Aristotle University of Thessaloniki
Thessaloniki, Greece

Tse, Hubert M., PhD .................... p.155
University of Alabama at Birmingham
Birmingham, AL

Tseng, Yu-Hua, PhD .................... p.82
Joslin Diabetes Center/Harvard Medical School
Boston, MA

Tsimikas, Sotirios, MD, FAC, FAHA,
FSCAI ........................................ p.94
University of California, San Diego
La Jolla, CA

Tybjærg-Hansen, Anne, MD, DMSc ........ p.94
University of Copenhagen
Copenhagen, Denmark
INVITED SPEAKER INDEX

Udell, Jacob A., MD, MPH, FRCPC ........................................... p.64
Women’s College Hospital/Toronto General Hospital, University of Toronto
Toronto, ON, Canada

Udler, Miriam, MD, PhD ...................................................... p.96
Massachusetts General Hospital
Boston, MA

Umpierrez, Guillermo E., MD, CDE, FACP, FACE ............... p.81
Emory University School of Medicine
Atlanta, GA

Urano, Fumihiko, MD, PhD .................................................. p.168
Washington University School of Medicine
St. Louis, MO

Ussar, Siegfried, PhD ............................................................ p.101
Helmholtz Center München
München, Germany

van Lieshout, Johannes, MD .............................................. p.127
University of Amsterdam
Amsterdam, Netherlands

Van Name, Michelle A., MD ................................................ p.63
Yale School of Medicine
New Haven, CT

van Praag, Henriette, PhD ................................................... p.127
National Institute on Aging/National Institutes
of Health Biomedical Research Center
Baltimore, MD

van Raalte, Daniël H., MD, PhD ........................................... p.178
VU University Medical Center
Amsterdam, Netherlands

Van't Vygem, Marie-Christine, MD, PhD ......................... p.129
University of Lille
Lille, France

Vatanen, Tommi, PhD .......................................................... p.100
Broad Institute of MIT and Harvard
Cambridge, MA

Vegas, Arturo J., PhD .......................................................... p.95
Boston University
Boston, MA

Veijola, Riitta, MD, PhD ...................................................... p.96
University of Oulu
Oulu, Finland

Venditti, Elizabeth M., PhD .................................................. p.145
University of Pittsburgh
Pittsburgh, PA

Verma, Anil .............................................................................. p.123
HCL Technologies
New York, NY

Wagner, David V., PhD ........................................................ p.60
Oregon Health & Science University
Portland, OR

Wang, Ping H., MD .............................................................. p.154
University of California, Irvine
Irvine, CA

Wanner, Christoph, MD ...................................................... p.127
University Hospital of Würzburg
Würzburg, Germany

Wareham, Nicholas, PhD .................................................... p.154
Institute of Metabolic Science
Cambridge, United Kingdom

Watt, Matthew J., PhD ........................................................ p.82
The University of Melbourne
Melbourne, Australia

Weissberg-Benchell, Jill, PhD, CDE ................................. p.94
Lurie Children’s Hospital
Chicago, IL

Wess, Jürgen, PhD ............................................................... p.180
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD

Wexler, Deborah J., MD, MSc .......................................... p.179
Massachusetts General Hospital
Boston, MA

Wharam, J. Frank, MB, BCh, BAO, MPH ......................... p.158
Harvard Medical School
Boston, MA

White, Morris F., PhD ......................................................... p.82
Boston Children’s Hospital
Boston, MA

Wiitala, Wyndy L., PhD ....................................................... p.133
VA Center for Clinical Management Research
Ann Arbor, MI

Williams, Mark D., MD ....................................................... p.65
Mayo Clinic
Rochester, MN

Wittmer, Jason B., MD, FCCP .......................................... p.95
Des Moines, IA
Wolfsdorf, Joseph, MB, BCh..........................p.100
Boston Children’s Hospital
Boston, MA

Wyckoff, Jennifer, MD .........................p.123
University of Michigan
Ann Arbor, MI

Wylie-Rosett, Judith, EdD, RD ..................p.87
Albert Einstein College of Medicine
Bronx, NY

Wysham, Carol H., MD .......................p.168
University of Washington/Multicare Rockwood
Clinic
Spokane, WA

Wysocki, Tim, PhD, ABPP......................p.94
Nemours Children’s Health System
Jacksonville, FL

Yang, Xia, PhD ........................................p.160
University of California, Los Angeles
Los Angeles, CA

Young, Laura A., MD, PhD .................p.122
University of North Carolina School of Medicine
Chapel Hill, NC

Yousef, Gretchen A., MS, RD, CDE ..........p.80
MedStar Health
Washington, DC

Yu, Liqing, MD, PhD ..................p.82
Georgia State University
Atlanta, GA

Zaidi, Mone, MD, PhD ......................p.82
Icahn School of Medicine at Mount Sinai
New York, NY

Zeitler, Philip S., MD, PhD ..................p.159
University of Colorado Anschutz Medical
Campus
Aurora, CO

Zhou, Changcheng, PhD ..................p.159
University of Kentucky
Lexington, KY

Zhu, Zhiming, MD .......................p.101
Daping Hospital
Chongqing, China

Zinman, Bernard, MD .....................p.127
Mount Sinai Hospital, University of Toronto
Toronto, ON, Canada

Zorzano, Antonio, PhD ..................p.94
University of Barcelona
Barcelona, Spain
COMPLICATIONS—HYPOGLYCEMIA

Moderated Poster Discussion: Hypoglycemia—Prediction, Perception, and Prevention (Posters: 376-P to 381-P), see page 125.

376-P Continuous Glucose Monitoring in Patients With or Without Symptoms of Hypoglycemia after Bariatric Surgery. CLARE LEE, TODD BROWN, MICHAEL SCHWEITZER, THOMAS MAGNUSON, JEANNE CLARK, Baltimore, MD

377-P Real-World Risk Indicators of Severe Hypoglycemia in T2D—Results of the InHypo-DM Study. ALEXANDRIA RAZTIKI-LEEWING, STEWART HARRIS, SELAM MEQUANINT, NATALIE H. AU, JASON E. BLACK, SONJA M. REICHERT, JUDITH B. BROWN, BRIDGET L. RYAN, London, ON, Canada

378-P Correlates of Hypoglycemia among Youth with Type 1 Diabetes (T1D) and Suboptimal Glycemic Control. ANNA R. KAHKOSKA, JAMIE CRANDELL, KIMBERLY A. DRISCOLL, MICHAEL R. KOSOROK, DAVID M. MAAHS, ELIZABETH J. MAYER-DAVIS, Chapel Hill, NC, Aurora, CO, Stanford, CA

379-P Does Hypoglycemia Awareness Status on Gold and Clark Questionnaires Predict Hormonal and Symptomatic Responses to Hypoglycemia (HG) in Type 1 Diabetes (T1D)? NATHAN RUBIN, AMIR MOHEET, LYNN E. EBERLY, ANJALI KUMAR, SILVIA MANGIA, ELIZABETH R. SEAQUIST, Minneapolis, MN

380-P Impact of Aging on Risk of Hypoglycemia in Patients with Type 1 Diabetes. MEDHA MUNSHI, CHRISTINE SYLVE, ASTRID ATAKOV-CASILLO, JORDAN GREENBERG, TORI GREAVES, SAM P. CARL, ELENA TOSCHI, Boston, MA

381-P Hospitalization and Emergency Department Visits for Severe Hypoglycemia among U.S. Adults with Diabetes and Serious Comorbid Conditions. ROZALINA G. MCCOY, HOLLY VAN HOUTEN, KASIA J. LIPSKA, NILAY SHAH, Rochester, MN, New Haven, CT

382-P Beta-Blocker Usage and Hypoglycemia in Hospitalized Patients with Diabetes Mellitus. JENNIFER MERRILL, KATHLEEN M. DUNGAN, Columbus, OH

383-P Inadequate Use of Glucagon in Patients with T1D. MOREY W. HAYMOND, JINGWEN LIU, JEFFREY BISPHAM, AILEEN HICKEY, ALICIA H. MCAULIFFE-FOGARTY, Houston, TX, Boston, MA

384-P Factors Associated with Severe Hypoglycemia among Patients with Type 2 Diabetes Treated with Insulin. MANJIRI PAWASKAR, JINAN LIU, R. RAVI SHANKAR, SWAPNIL RAJPATHAK, North Wales, PA, Rahway, NJ


386-P Heart Rate Variability in Patients with Type 1 Diabetes and Hypoglycemia with Different Control of Diabetes Mellitus. KATERYNA MOSHENETS, NATALIIA PERSEVA, Dnipr, Ukraine

387-P Limited Availability of Glucagon by Emergency Personnel. PETER KAHN, NICOLE WAGNER, ROBERT A. GABBAY, New Haven, CT, Boston, MA

388-P Effect of Hypoglycemia during Intensive Insulin Therapy on Long-Term Glycemic Control in Patients with Newly Diagnosed Type 2 Diabetes. LIJUAN XU, YANBING LI, Guangzhou, China

389-P iDegAsp Improves Glycemic Control with Minimal Hypoglycemia—An Indian Real-World Study in T2D Subjects. JOTHIYDEV KESAVEDEV, BANSHI D. SABOO, ARUN SHANKAR, ASHWIN DAVID, ROHIT WARRIER, GOPAL KISHNAN, LAKSHMY RAMACHANDRAN, SUNITHA JOTHIYDEV, Trivandrum, India, Ahmedabad, India, Kochi, India

390-P WITHDRAWN

391-P Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials. CAROL H. WYSHAM, WENDY LANE, STEEN LADELUND, DENIZ TUTKUNKARDAS, SIMON HELLER, Spokane, WA, Asheville, NC, Søborg, Denmark, Sheffield, United Kingdom
392-P Hypoglycemia in Patients with Diabetes in an Australian Public Hospital Setting. MILAN K. PIYA, REETU ZARORA, THERESE FLETCHER, DAVID SIMMONS, Campbelltown, Australia

393-P Insulin Acts in Ventromedial Hypothalamus to Regulate the Sympathoadrenal Response to Hypoglycemia in Rats. RAHUL AGRAWAL, ADRIANA VIEIRA DE ABREU, GRIFFIN T. DURUPT, SIMON J. FISHER, Salt Lake City, UT

394-P Somatostatin Receptor II Antagonism Improves Glucagon Counterregulatory Responses to Recurrent Hypoglycemia in Male Sprague-Dawley Rats. MICHAEL RIDDELL, MAHSA JAHANGIRIESMAILI, ERIN R. MANDEL, CAYLEE A. GREENBERG, AOIBHE M. PASIEKA, TREVOR TEICH, OWEN CHAN, RICHARD T. LIGGINS, Toronto, ON, Canada, Salt Lake City, UT, Vancouver, BC, Canada

395-P A Novel Continuous Glucose Monitoring System Accurately Detects Existing and Impending Hypoglycemia. PETER CALHOUN, TERRI JOHNSON, ANDREW BALO, DAVID A. PRICE, San Diego, CA

396-P Machine Learning Identification of Multiple Predictively Equivalent Risk Models for Severe Hypoglycemia in Patients with Type 2 Diabetes. SISI MA, PAMELA SCHREINER, RACHEL ZMORA, ELIZABETH R. SEAQUIST, LISA S. CHOW, Minneapolis, MN

397-P Sustainability of a Real-Time Informatics Alert to Prevent Inpatient Severe Hypoglycemia. MICHAEL ELLIOTT, MARY C. BLACKBURN, KEVIN M. HEARD, PAUL E. MILLIGAN, PAULINA CRUZ BRAVO, GARRY T. TOBIN, St. Louis, MO, High Ridge, MO

398-P C-Peptide Levels Are Associated with Glycemic Variability and Hypoglycemia in Insulin-Treated Type 2 Diabetes. MERETE B. CHRISTENSEN, ANDERS GOTFREDSSEN, KIRSTEN NØRGAARD, Hvidovre, Denmark, Gentofte, Denmark

399-P Severe Hypoglycemia Rates Are Highest among those with Suboptimal Reporting Behaviour—Results from the InHypo-DM Study. ALEXANDRIA RATZKI-LEEWING, JASON E. BLACK, SELAM MEQUANTINT, NATALIE H. AU, BRIDGET L. RYAN, SONJA M. REICHERT, Judith B. Brown, STEWART HARRIS, London, ON, Canada

400-P Decreasing Incidence of Postinsulin Hypoglycemia for Hyperkalemia Treatment. HEIDEMARIE W. MACMASTER, ALLEN TRAN, BRADLEY MONASH, SARA G. MURRAY, PRIYA A. PRASAD, ROBERT J. RUSHAKOFF, San Francisco, CA

401-P Clinical Outcomes and Mortality among Patients Hospitalized with Hypoglycemia and End-Stage Renal Disease in the U.S. RODOLFO J. GALINDO, CAROLINA R. HURTADO, FRANCISCO J. PASQUEL, PRIYATHAMA VELLANKI, GUILLERMO E. UMPIERREZ, Atlanta, GA, New York, NY

402-P Increased Fluctuation of Measured Glucose in Critically Ill Patients Is an Independent Predictor of Mortality. NAGA SASIDHAR KANAPARTHY, SHERIN ELSA MATHEWS, KAMALA RAMYA KALLUR, Valhalla, NY, Jersey City, NJ, New York, NY

403-P Postprandial Insulin Initiation—Evaluation of Adverse Outcomes in Older Veterans. CHIN-LIN TSENG, ORSYA SOROKA, LEONARD POGACH, East Orange, NJ

404-P Intensive Hypoglycemia Avoidance and Improved Awareness of Hypoglycemia Associated with Partial Recovery Activation Lost in Hypoglycemia Unaware Patients with Type 1 Diabetes. PRATIK CHOUDHARY, MUNACHISO NWOKOLO, OWEN O’DALY, STEPHANIE A. AMIEL, FERNANDO O. ZELAYA, London, United Kingdom

405-P Risk of Hypoglycemia in Aging Population with Insulin-Requiring Diabetes. MEDHA MUNSHI, CHRISTINE SLYNE, ASTRIDATAKOV-CASTILLO, JORDANGREENBERG, TORIGREAVES, SAM P. CARL, ELENA TOSCHI, Boston, MA

406-P Incidence of Hypoglycemia Events in a Large, Real-World Diabetes Population. JENNIFER BOLLKY, WEI LU, JENNIFER SCHNEIDER, Mountain View, CA
COMPLICATIONS—MACROVASCULAR—ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND HUMAN DIABETES

Moderated Poster Discussion: Predictors and Mediators of Cardiovascular Risk (Posters: 407-P to 412-P), see page 90.

407-P The Impact of Fatty Liver Disease and Metabolic Syndrome on the Progression of Coronary Artery Calcification. YUN KYUNG CHO, YU MI KANG, CHEOL-YOUNG PARK, SUNG-WOO PARK, WOO JE LEE, JOONG-YEOL PARK, CHANG HEE JUNG, Seoul, Republic of Korea

408-P Inhibition of Drp1-Mediated Mitochondrial Fission Protects Diabetic Heart against Ischemia-Reperfusion Injury. MINGGE DING, JIAHAO FENG, ZEYANG LI, FENG FU, Xi’an, China

409-P A Risk Prediction Model for Heart Failure Hospitalization among Patients with Type 2 Diabetes. BRENTH WILLIAMS, PRANAV GANDHI, Danville, PA, Ridgefield, CT

410-P Pro-B-Type Natriuretic Peptide Strongly Predicts Future Cardiovascular Events in Cardiovascular Disease Patients with Type 2 Diabetes as Well as in Those Without Type 2 Diabetes. CHRISTOPH H. SAELY, ALEXANDER VONBANK, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDLEIN, HEINZ DREXEL, Bern, Switzerland, Feldkirch, Austria, Triesen, Liechtenstein, Philadelphia, PA

411-P Effects of Glucose and Blood Pressure Variability on Oxidative Stress in Type 2 Diabetes with Hypertension. MAKOTO OHARA, HIROE NAGAIKE, TAKESHI YAMAMOTO, TOSHIYUKI HAYASHI, TOMOYASU FUKUI, TSUTOMU HIRANO, Tokyo, Japan

412-P The Effect of Bariatric Surgery on Neprilysin and Vasoactive Factors. PARESH DANDONA, HUSAM GHANIM, SCOTT MONTE, KELLY GREEN, JOSEPH A. CARUANA, Williamsville, NY, Buffalo, NY, Orchard Park, NY

413-P Electrophysiological Assessment of Cardiac Complication in Chronic Diabetic Minipigs. ALAIN STRICKER-KRONGRAD, JASON LIU, GUY BOUCHARD, Auxvasse, MO

414-P Update in Cardiovascular Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes—A Mixed Treatment Comparison Meta-analysis of Randomized Controlled Trials. OSAMAH ALFAYEZ, MAJED S. AL YAMI, RAZAN ALSHEIKH, Tucson, AZ, Riyadh, Saudi Arabia

415-P A Novel Therapeutic Approach to Intensive Statin Therapy-Resistant Vulnerable Plaque of Coronary Artery in Diabetic Patients by Use of Anti-PCSK9 Antibody and Coronary CT Angiography (CCTA). AIZAN HIRAI, KOJI FUJIMURA, SEIYA KONDO, TAKENORI SAKAI, SHIN IGEJIMA, HIRANOD TANIAI, KELLI HIRAI, KAZUYA MURATA, ATSUSHI SHIRAKAMI, KAZUTOSHI OKUZAKI, TAKAHIRO KAGEYAMA, Ichihara, Japan, Chiba, Japan, Usuki, Japan, Yawatahama, Japan, Odate, Japan, Yurituchiyo, Japan, Saitama, Japan, Ise, Japan, Tokushima, Japan

416-P Diabetes Mellitus and High Triglycerides Are Significant Predictors of Major Cardiovascular Events and Increased Health Care Costs and Resource Utilization—A Real-World Analysis of High-Risk Statin-Treated Patients. PETER P. TOOTH, CRAIG B. GRANOWITZ, MICHAEL HULL, SEPHY PHILIP, Sterling, IL, Bedminster, NJ, Eden Prairie, MN

417-P The Effects of Cardiovascular Risk Factor Combined Antiplatelet Therapy and the Risk of Cerebrovascular Events in Patients with T2DM in an Urban Community over 96-Month Follow-Up—The Beijing Communities Diabetes Study 19. XUE LIAN ZHANG, SHEN YUAN YUAN, BCDS GROUP, Beijing, China

418-P Relationship between Sleep Disordered Breathing during Rapid Eye Movement Sleep and Coronary Risk Factors in Patients with Type 2 Diabetes Mellitus. TAKAYASU UCHIDA, AKIHIRO NISHIMURA, SHOTA KIKUNO, KAZUYA MURATA, ATSUSHI SHIRAKAMI, KAZUTOSHI OKUZAKI, TAKAHIRO KAGEYAMA, Ichihara, Japan, Chiba, Japan, Usuki, Japan, Yawatahama, Japan, Odate, Japan, Yurituchiyo, Japan, Saitama, Japan, Ise, Japan, Tokushima, Japan

419-P Total Oxidative Index Is Associated with Glycated Hemoglobin, Low-Grade Inflammation, and Non-HDL Cholesterol in Type 2 Diabetes. RINKOO DALAN, LIUH LING GOH, XIN TANG, DANIEL E.K. CHEW, BERNHARD BOEHM, Singapore, Singapore

420-P Prevalence of Preexisting Dysglycaemia among Inpatients with Acute Coronary Syndrome and Associations with Outcomes. DINESH MAHENDRAN, GARRY HAMILTON, JEREMY WEISS, JEREMY LEW, KAYLYN KOH, ELIF I. EKINCI, Carnegie, Australia, Melbourne, Australia, Heidelberg, Australia

Moderated Poster Discussion poster
421-P Next Generation of Spontaneous Diabetic Model of ZDSD Rats with Intact Leptin Signaling Develop Cardiac Dysfunction and Compromised Cardiac Reserve. GAO SUN, GUODONG ZHANG, YIXIN WANG, Taicang, China

422-P Plasma Omentin Levels Are Associated with Atherosclerosis in Patients with Type 2 Diabetes. MASAMI HATAMORI, TOMOAKI MORIYOKA, MARIKO SENDA, MARIKO ASADA, YOSHINORI KAKUTANI, YUKO YAMAZAKI, KOKA MOTOYAMA, KATSUHIITO MORI, SHIYHA FUKUMOTO, ATSUSHI SHIOJI, TETSUO SHOJI, MASANORI EMOTO, MASAAKI INABA, Osaka, Japan

423-P Plasma Omentin Levels Are Associated with Vascular Endothelial Function in Patients with Type 2 Diabetes and Cardiovascular Diseases. MARIKO SENDA, TOMOAKI MORIYOKA, MARIKO ASADA, YOSHINORI KAKUTANI, YUKO YAMAZAKI, KOKA MOTOYAMA, KATSUHIITO MORI, SHIYHA FUKUMOTO, ATSUSHI SHIOJI, TETSUO SHOJI, MASANORI EMOTO, MASAAKI INABA, Osaka, Japan

424-P Early Vascular Parameters in the Micro- and Macrocirculation in Type 2 Diabetes. ROLAND E. SCHMIEDER, DENNIS KANNENKERIL, MARINA V. KARG, AGNES BOSCH, JOANNA M. HARAZNY, SR., CHRISTIAN OTT, Erlangen, Germany

425-P Contribution of Serum FGF-21 Level to the Identification of Left Ventricular Systolic Dysfunction and Cardiac Death. YUQIAN BAO, YUN SHEN, XUELI ZHANG, XIAOPENG PAN, YITING XU, QIN XIONG, ZHIGANG LU, XIAOJING MA, Shanghai, China

426-P Serum FGF-21 Is Associated with Future Cardiovascular Events in Patients with Coronary Artery Disease—Results from a Median Follow-Up of 4.8 Years Study. YUQIAN BAO, YUN SHEN, XUELI ZHANG, YITING XU, QIN XIONG, ZHIGANG LU, XIAOJING MA, Shanghai, China

427-P Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists—A Network Meta-Analysis. ALISTAIR J. RODDICK, SEAN ZHENG, London, United Kingdom

428-P Long-Term Prognostic Value of Coronary Computed Tomography Angiography in Asymptomatic Elderly Population Including Diabetic Patients. SUN JOON MOON, DONG-HWA LEE, TAE JUNG OH, KYOUNG MIN KIM, SUNGHEE CHOI, HAK CHUL JANG, SOO LIM, Seoul, Republic of Korea, Seongnam, Republic of Korea

429-P Elevated Fibroblast Growth Factor-21 Protect Endothelial Function in Type 2 Diabetes Patients. YANJIN HU, YUAN XU, GUANG WANG, Beijing, China

430-P Pre-Apoptotic and Inflammatory Markers Enhance the Ability of MDA-LDL in Circulating Immune Complex to Predict Acute Myocardial Infarction in the VADT Study. MARIA F.L. LOPES-VIRELLA, KELLY J. HUNT, RASHI AGARWAL, NATHANIEL L. BAKER, GABRIEL VIRELLA, VADT INVESTIGATORS, Charleston, SC

431-P ▲ Serum Uromodulin (SUMOD) Inversely Correlates with Aortic Stiffness in Type 1 Diabetes (T1D) Youth. PATTARA WIROMRAT, PETTER BJORNSTAD, CARLOS ALBERTO RONCAL-JIMENEZ, SR., MICHAL SCHAFER, AMY BAUMGARTNER, LAURA PYLE, MELANIE CREE-GREEN, YESENIA GARCIA REYES, LORNA BROWNE, RICHARD JOHNSTON, KRISTEN J. NADEAU, Aurora, CO, Denver, CO

432-P Prevalent Prediabetes at Admission due to Acute Myocardial Infarction Does Not Affect One-Year Mortality Rates of Patients Who Were Discharged Alive. IE BYUNG PARK, DAE HO LEE, SEUNG HEE YU, KIYOUNG LEE, Incheon, Republic of Korea

433-P ▲ High Prevalence of Asymptomatic Coronary Artery Disease (CAD) Evaluated by Intravascular Ultrasound (IVUS) in a Norwegian Cohort with Type 2 Diabetes (T2D) as Compared with Asymptomatic Controls without T2D—A Cross-Sectional Study. ANNE P. OFSTAD, SATISH ARORA, GEIR R. ULIMOEN, KARE I. BIRKELAND, KNUT ENDRESEN, LARS L. GULLESTAD, ODD ERIK JOHANSEN, Rud Norway, Oslo, Norway, Lorenskog, Norway

434-P Skin Autofluorescence, a Marker of Glycaemic Memory in Type 2 Diabetes. RIGO MARINE, MON-LUN MARIE, KAMEL MOHAMMEDI, LAURENCE BLANCO, VINCENT RIGALLEAU, Pessac, France, Bordeaux, France

435-P Impact of Human vs. Analog Insulins on Occurrence of Death and Major Cardiovascular Events. EMILY B. SCHROEDER, PATRICK J. O’CONNOR, JULIE SCHMITTDEIL, KRISTI REYNOLDS, JAY R. DESAI, MICHAEL HO, GABRIELA VAZQUEZ BENITEZ, JEFFREY P. ANDERSON, NOEL PIMENTEL, LINDA M. LOES, ROMAIN NEUGEBAUER, Denver, CO, Bloomington, MN, Oakland, CA, Pasadena, CA
436-P Different Augmentation of Left Ventricular Contractility of Mice during Myocardial Infarction following Glipitin and Sulfonylurea Treatment. ELIAS HA-JEYIA, SEBASTIAN DIEBOLD, JULIA MOELLMANN, FLORIAN KAHLES, THOMAS KLEIN, MICHAEL MARK, NIKOLAUS MARK, MICHAEL LEHRKE, Aachen, Germany, Biberach, Germany

437-P Glycemic Variation and Cardiovascular Risk during the VADT. JIN ZHOU, DAWN SCHWENKE, PETER REAVEN, Tucson, AZ, Phoenix, AZ

438-P Liraglutide Effects in Insulin-Treated Patients in LEADER. CORNELIS TACK, STEPHAN JACOB, CYRUS DESOÜZA, STEPHEN C. BAIN, MICHAEL A. NAUCK, JOHN PETRIE, NEIL R. POULTER, RICHARD E. PRATLEY, HELEN VANYA BIERING, KJAER STEGMANN, HEIDRUN BOSCH-TRABERG, ELENA STARTSEVA, BERNARD ZINMAN, LEADER PUBLICATION COMMITTEE AND INVESTIGATORS, Nijmegen, Netherlands, Villingen, Germany, Osaka, NE, Swansea, United Kingdom, Bochum, Germany, Glasgow, United Kingdom, London, United Kingdom, Orlando, FL, Søborg, Denmark, Copenhagen, Denmark, Toronto, ON, Canada

439-P Do Greenlandic Carriers of the TBC1D4 p.Arg684Ter Variant Have Increased Risk of Cardiovascular Disease? MARIT E. JØRGENSEN, MARIA TVEMOOSEGAARD, PERNILLE F. RØNN, PETER BJERREGAARD, INGER K. DAHL-PETERSEN, CHRISTINA V. LARSEN, MICHAEL L. PEDERSEN II, ANDERS ALBRECHTSEN, IDA MOLTKE, NIELS GRARUP, TORBEN HANSEN, Gentofte, Denmark, Copenhagen, Denmark, Nuuk, Greenland

440-P Relationship between Fasting Insulin Concentration as a Risk Factor for Cardiovascular Disease and High-Density Lipoprotein Cholesterol Levels in Patients with Chronic Hepatitis C. RAMONA MARIA DRAGUT, EMILIA RUSU, RALUCA CURSARU, FLORIN RUSU, ADRIAN CURSARU, HORATIU POPESCU, GABRIELA RADULIAN, Pitesti, Romania, Bucharest, Romania

441-P Association between Arterial Stiffness and Cardiovascular Autonomic Neuropathy in Youth with Type 2 Diabetes—SEARCH for Diabetes in Youth Study. MAMTA JAIWAL, JASMINE DIVERS, DANA DABELEA, JEAN M. LAWRENCE, GRACE KIM, ANGELA D. LIESE, ELAINE M. URBINA, Ann Arbor, MI, Winston-Salem, NC, Aurora, CO, Pasadena, CA, Seattle, WA, Columbus, SC, Cincinnati, OH

442-P Effect of Number of Achieved Targets for Risk Factors on Coronary Artery Disease? KAZUYA FUJIIHARA, YASUHIRO MATSUBAYASHI, MASAKI HIROYASU, SEIDA, KIMINORI KATO, SATORU KODAMA, HIROYASU SEIDA, KIMINORI KATO, SATORU KODAMA, HIROYASU SEIDA, KIMINORI KATO, SATORU KODAMA, HIROYASU SEIDA, Japan

443-P Albuminuria Is More Closely Associated with Vascular Endothelial Function than eGFR in Type 2 Diabetes with Diabetic Kidney Disease. YOSHINORI KAKUTANI, MASANORI EMOTO, YUKO YAMAZAKI, KOKA MOTOLA, TOMOAKI MOKIOKA, KATSUHITO MORI, SHINYA YAMASHITA, ATSUSHI SHIOI, TETSUO SHIOJI, MASAKI INABA, Tokyo, Japan

444-P Effects of Treatment-Achieved HbA1c on Incidence of Micro-/Macrovascular Complications in Patients with Diabetes Mellitus. MAYUKO HARADA, KAZUYA FUJIHARA, TAEKO OSAWA, MASAKI HIROYASU, SATOSHI MITSUNAGA, TAKAHO YAMADA, NAUTA YAMANAKA, HIROYASU SEIDA, SATORU KODAMA, HIROYASU SEIDA, SATORU KODAMA, HIROYASU SEIDA, SATORU KODAMA, HIROYASU SEIDA, SATORU KODAMA, HIROYASU SEIDA, SATORU KODAMA, Japan

445-P Roles of Histone Deacetylases in Arteriovenous Fistula Failure Under Disturbed Flow. JENG-JIANN CHIU, TUNG-LIN YANG, Miao, Taiwan

446-P Severe Hypoglycemia and Clinical Cardiovascular Events in Cohorts with No vs. Early Microvascular Complications. ELKE R. FAHRMANN, LAURA J. ADKINS, HENRY DRISCOLL, Huntington, WV

447-P Coronary Artery Calcium Trajectory Predicts Coronary Artery Disease Events—The CACTI Study. JANET K. SNELL-BERGEON, AMENA KESHAWARZ, GREGORY L. KINNEY, IRENE E. SCHAUER, VIRAL N. SHAH, LAURA PYLE, Aurora, CO

448-P Treatment for Diabetes and Cardiovascular Risk Factors in a Predominantly Minority Urban Cohort of Kidney Transplant Recipients. EFFIE TSOMOS, SANDRA ALEKSIK, SARA ZAHEDPOUR ANARAKI, EMILY JAPP, LAXMI UPADHYAY, MARIA AJAIMY, JOEL ZONSZEN, ENVER AKALIN, Bronx, NY, New Rochelle, NY

449-P Asymptomatic Coronary Artery Disease (CAD) in a Norwegian Cohort with Type 2 Diabetes (T2D)—A Prospective Invasive Coronary Angiographic (ICA) Study. ANNE P. OFSTAD, SATISH ARORA, GEIR R. ULIMOEN, KARE I. BIRKELAND, KNUD ENDRESEN, Lars L. GULLESTAD, ODD ERIK JOHANSEN, Rud, Norway, Oslo, Norway, Lorenskog, Norway
450-P Skin Autofluorescence Predicts Macrovascular Events in Type 1 Diabetes. CHRISTELE BLANC-BISSON, FRITZ-LINE VELAYOUDOM CEPHISE, CATHERINE HELMER, LAURENCE BLANCO, KAMEL MOHAMMEDI, MARIE MONLUN, VINCENT RIGALLEAU, Pessac, France, Abymes, Guadeloupe, Bordeaux, France

451-P Wavelet Phase Coherence Analysis between the Respiratory Activity and the Microcirculation—The Effects of Type 1 Diabetes. ANTONIA PERRELLA, MICHELE SORELLI, PIERGIOVANNI FRANZIA, LAURA STEVENS, YULIYA LOKHNYGINA, RENATO D. LOPES, AMANDA ADLER, DARREN K. MCGUIRE, ERIC PETERSON, RURY R. HOLMAN, Oxford, United Kingdom, Graz, Austria, Durham, NC, Cambridge, United Kingdom, Dallas, TX

452-P Insulin Deficiency Is a Major Contributor to Atrial Fibrillation. ZAHRA MARIA, ALLISON CAMPOLO, BENJAMIN J. SCHERLAG, JERRY W. RITCHIE, VERONIQUE LACOMBE, Stillwater, OK, Oklahoma City, OK

453-P Insulin Rescues Diabetes-Induced Pulmonary Complications. ALLISON CAMPOLO, ZAHRA MARIA, MYRON HINSDALE, LIN LIU, VERONIQUE LACOMBE, Stillwater, OK

454-P High Serum Branched-Chain Amino Acids Level Independently Predicts Incident Heart Failure—The Hong Kong Diabetes Register. LEE-LING LIM, ERIC S.H. LAU, ANDREA LUK, ELAINE CHOW, HEUNG MAN LEE, RONALD C. MA, JULIANA C. CHAN, ALICE P. KONG, Hong Kong, China

455-P Impact of Type 2 Diabetes Mellitus and Myocardial Perfusion on Long-Term Risk of Heart Failure and All-Cause Mortality following Interventional Treatment of ST-Elevation Myocardial Infarction. ANDREJ TOMASIK, KATARZYNA NABRDALIK, HANNA KWIENDACZ, TOMASZ SAWCZYN, MICHAŁ KUKLA, EDYTA RADZIK, KATARZYNA PIGON, TOMASZ MYŁAŁ, JANUSZ GUMPRECHT, WALDYSLAW GRZESZCZAK, EWA NOWALANY-KOZIELSKA, Zabrze, Poland, Katowice, Poland

456-P Cardiovascular Event Hazards over Time in TECOS. M. ANGELYN BETHEL, HARALD SOURIJ, SUSANNA R. STEVENS, RENATO D. LOPES, AMANDA ADLER, DARREN K. MCGUIRE, ERIC PETERSON, RURY R. HOLMAN, Oxford, United Kingdom, Graz, Austria, Durham, NC, Cambridge, United Kingdom, Dallas, TX

457-P Type 2 Diabetes Mellitus Is Not Associated with the Incidence or the Outcome of Pneumonia in Patients with Acute Ischemic Stroke. MARIANTHI PAPAGIANNI, KONSTANTINOS TZIOMAKOS, STAVROULA KOSTAKI, STELLA-MARIA ANGELOPOULOU, KONSTANTINOS CHRISTOU, ARETI SOFOGIANNI, STELLINA ALKAGIET, TRIANTAFYLLOPSIDANGELOS, CHRISTOS SAVOPOULOS, APOSTOLOS I. HATZITOLIOS, Thessaloniki, Greece

458-P The Effect of Hypercholesterolemia on the Characteristics of Cerebral Microvasculature. YUSUKE TODATE, YASUSHI ISHIKAKI, Morioka, Japan

459-P Relationship of Serum Sestrin2 Level with Metabolic Risk Factors in Newly Diagnosed Drug-Naive Type 2 Diabetes Patients with Chronic Heart Failure. EVA STOLARIKOVA, JAN KOPECKY, JR., JIRI VELEBA, KATERINA VELEBOVA, LENKA BELINOVA, VOJTECH MELENOVSKY, JAN KOPECKY, SR., TEREZIE PELIKANOVA, Prague, Czech Republic
466-P Novel "Dual Hit" Rat Model of Diabetic Cardiomyopathy. LOUISE THISTED, ROSS T. LINDSAY, KELD FOSGERAU, THOMAS SECHER, MORTEN B. THOMSEN, THOMAS JESPERSEN, ANDREW J. MURRAY, PHILIP J. PEDERSEN, NIELS VRANG, LISBETH N. FINK, TANJA X. PEDERSEN, NORA E. ZOIS, Harsholm, Denmark, Cambridge, United Kingdom, Copenhagen, Denmark

467-P Impaired Gastric Emptying Is Associated with a Higher Incidence of Coronary Heart Disease in Subjects with Diabetes. SEON-YOUNG PARK, JIN OOK CHUNG, DONG HYEOK CHO, DONG JIN CHUNG, MIN YOUNG CHUNG, Gwangju, Republic of Korea

468-P A Comparative Study of the Associations between Modified Low-Density Lipoproteins and Vascular Function in African-American Diabetic Patients. AJIBOLA M. ADEDAYO, AYOBAMI ELUWOLE, FASIKA TEDLA, ARYE KREMER, NICOLE MASTROGIOVANNI, CARL ROSENBERG, PAUL DREIZEN, JOHN LAROSA, LOUIS SALCICCIOLI, MOHAMED BOUTJDIR, MARY ANN BANERJI, CLINTON BROWN, MORO SALIFU, JASON LAZAR, AHMED BAKILLAH, Brooklyn, NY

469-P The Role of Epicardial Adipose Tissue Lymphocytes in Low-Grade Inflammation and Coronary Artery Disease. MILOS MRAZ, ANNA CINKAJZLOVA, ZDENKA LACINOVÁ, JANA KLOUCKOVA, HELENA KRATOCHVILOVÁ, MICHAL LIPS, PETR KOPECKY, MICHAL PORIŽKA, JAROSLAV LINDNER, MARTIN HALUZÍK, Prague, Czech Republic

COMPLICATIONS—MACROVASCULAR—CELLULAR MECHANISMS OF ATHEROGENESIS IN DIABETES

Moderated Poster Discussion: Modulators of Endothelial and Myocardial Dysfunction (Posters: 470-P to 475-P), see page 92.

470-P WITHDRAWN

471-P CXCR7 Agonist TC14012 Improves Angiogenic Function of Endothelial Progenitor Cells in Diabetic Limb Ischemia. KAI WANG, XIAOZHEN DAI, JING CHEN, PAUL N. EPSSTEIN, LU CAI, KUPPER A. WINTERGERST, YAN QIAN, YI TAN, Louisville, KY, Wenzhou, China

472-P Intermittent Hypoxia Induces Expression of Epiregulin mRNA via Upregulation of Interleukin-6 in Human Coronary Artery Smooth Muscle Cells. YOJI KYOTANI, JING ZHAO, ASAKO ITAYA-HIRONAKA, AKIYO YAMAUCHI, SUMIYO SAKURAMOTO-TSUCHIDA, MAI MAKINO, SHIN TAKASAWA, MASNORI YOSHIZUMI, Kashihara, Japan

473-P Long Noncoding RNA Zfas1 in Diabetic Cardiomyopathy. BIAO FENG, SHALI CHEN, SUBRATA CHAKRABARTI, London, ON, Canada

474-P Protective Role of L-Cysteine Against High Glucose Induces G6PD-Deficiency and Endothelial Dysfunction. RAJESH PARSAKAR, SUSHIL K. JAIN, Shreveport, LA

475-P Nrf2 Exaggerates Cardiomyopathy Associated with Type 1 Diabetes in Mice. HUI M. ZANG, WEIWEI WU, LEI QI, CHRISTOPHER BOWEN, TAIXING CUI, PRAKASH NAGARKATTI, MITZI NAGARKATTI, Columbia, SC

476-P ROCK2 Regulates the Expression of Cell Adhesion Molecules and Cell-to-Cell Adhesion in Vascular Endothelial Cells. YUSUKE TAKEDA, KEICHIRO MATOBA, DAIJI KAWANAMI, YOSUKE NAGAI, TOMOYO AKAMINE, SHO ISHIZAWA, YASUSHI KANAZAWA, TAMOTSU YOKOTA, KAZUNORI UTSONOYAMA, Tokyo, Japan

477-P Gemigliptin Inhibits IL-1β-Induced Endothelial-Mesenchymal Transition via BMP2/Smad/ MAPK/Runx2 Pathway. HYUK-SANG KWON, OAKKEE HONG, YANGGYO KANG, HEE SUN KWON, SOON JIB YOO, Seoul, Republic of Korea, Bucheon, Republic of Korea, Busan, Republic of Korea

478-P Poldip2 Affects Collagen I Accumulation by Regulating the Expression of Zyxin in Vascular Smooth Muscle Cells. MASAKAZU FUJII, NORIYUKI SONODA, MISATO OKAMOTO, HIDETAKA MORINAGA, YOSHIHIRO OGAWA, KATHY GRIENDLING, Fukuoka, Japan, Atlanta, GA

479-P WITHDRAWN

480-P Diabetes-Induced Vascular Dysfunction Can Be Attenuated with a Naked G7 Polyamidoamine Dendrimer In Vivo. SAGHIR AKHTAR, BINDU CHANDRASEKHAR, AHMED Z. EL-HASHIM, IBRAHIM BENTER, Doha, Qatar, Kuwait City, Kuwait, Famagusta, Cyprus
481-P  Canagliflozin Inhibits Human Endothelial Cell Inflammation via the Induction of Heme Oxygenase-1. KELLY J. PEYTON, GHAZALEH BEHNAMMANESH, WILLIAM DURANTE, Columbia, MO

482-P  Vasoprotective Effects of Vildagliptin in Mice Is Masked by Metformin—Overlapping Mechanisms Implied. HIDEKI KUSHIMA, YUSAKU MORI, MASAKAZU KOSHIBU, MUNENORI HIROMURA, KYOKO KOHASHI, MICHISHIGE TERASAKI, TSUTOMU HIRANO, Tokyo, Japan

483-P  Inhibition of NF-κB Pathway with IKK-16 or Linagliptin Attenuates the Cardiac Dysfunction Associated with Polymicrobial Sepsis in Mice with Preexisting Type 2 Diabetes Mellitus (TZDM). SURA AL ZOUBI, JIANMIN CHEN, LUKAS MARTIN, CATHERINE MURPHY, GARETH S. PURVIS, FAUSTO CHIAZZA, DEBORA COLLOTTA, MASSIMO COLLINO, CHRISTOPH THIEMERMANN, London, United Kingdom, Torina, Italy

484-P  The Effect of Resveratrol on Reducing Neointimal Growth after Femoral Artery Injury in AMPKα2 Knockout Mice Given High-Fat Diet. LIWEI ZHOU, JUNE GUO, HANGJUN ZHANG, SCOTT HEXIMER, ADRIA GIACCA, Toronto, ON, Canada

485-P  NMR-Based Lipidomic Analysis of Red Blood Cells Membranes in Type 2 Diabetes. CHRISTINA KOSTARA, ELENI BAIRAKTARI, MOSES ELISAF, VASILEIOS TSIMIHODIMOS, Ioannina, Greece

486-P  Tofogliflozin Suppresses the Progression of Atherosclerosis and Reduces Inflammation in Macrophages of STZ-Diabetic ApoE KO Mice due to Improvement of Glucose Tolerance. MASAHIKO IWAMOTO, NAOTO KUBOTA, TETSUYA KUBOTA, YOSHITAKA SAKURAI, NOBUHIRO WADA, ISEKI TAKAMOTO, SEIJI SHIODA, KODAI TAKAMOTO, Tokyo, Japan

487-P  Actions of Liraglutide on Vascular Endothelial Cells Play a Central Role in the Suppression of Atherosclerosis in Diabetic Mice. MUNENORI HIROMURA, YUSAKU MORI, MASAKAZU KOSHIBU, HIDEKI KUSHIMA, KYOKO KOHASHI, MICHISHIGE TERASAKI, TSUTOMU HIRANO, Tokyo, Japan

488-P  Role of Hyaluronic Acid on Apolipoprotein A1 and HDL-Mediated Cholesterol Efflux in Macrophages. KOTA MATSUKI, MASATSUNE OGURA, MARIKO HARADA-SHIBA, Suita, Japan

489-P  Association between Glycated Lipoproteins and Vascular Function in African-American Diabetic Patients. AYOBAMI ELUWOLE, AJIBOLA M. ADENSI, FARIAOBA KADUM, FERHAN S. SIDDIQI, SYAMANTAK MAJUMDER, ANDREW ADVANI, MARY ANN BANERJI, CARL ROSENBERG, PAUL DREIZEN, JOHN LAROSA, LOUIS SALCICCIOLI, BROOKLYN, NY

490-P  Coronary Microvascular Smooth Muscle Cells Contribute to Heart Failure in Diabetes Mellitus by Increasing Methylglyoxal Flux. KESHORE BIDASEE, Omaha, NE

COMPLICATIONS—NEPHROPATHY—BASIC AND EXPERIMENTAL SCIENCE

Moderated Poster Discussion: Mechanisms of Diabetic Kidney Disease in Humans and in Animal Models of Diabetes (Posters: 491-P to 496-P), see page 125.

491-P  Renin-Angiotensin System Inhibition Alters Triacylglycerol Metabolism in Diabetic Kidney Disease. KELLY SAS, JIAHE LIN, VIJI NAIR, MATTHIAS KRETZLER, FRANK BROSJUS, SUBRAMANIAM PEN-NATHAN, Ann Arbor, MI, Tucson, AZ

492-P  Histone H3 Serine 10 Phosphorylation Facilitates Endothelial Activation in Diabetic Kidney Disease. TAMADHER ALGHAMDI, SRI NAGARJUN BATCHU, MITCHELL J. HADDEN, YOUMAN LIU, BRIDGIT BOWSKILL, LAURETTE GELDENHUYS, FERHAN S. SIDDIQI, SYAMANTAK MAJUMDER, ANDREW ADVANI, Toronto, ON, Canada, Halifax, NS, Canada


494-P  Hyposialylated Angiopoietin-4 Induces Podocyte Apoptosis via a3β1 Integrin/FAK Signalling in Diabetic Nephropathy. HAIBING CHEN, KAIFENG GUO, PAN PAN, Shanghai, China

495-P  Renal Mitochondrial Oxidative Stress Induced by NAD+-Dependent Sirt3 Inactivation via Overexpression of CD38 (NADase) in Diabetic Kidney Disease. YOSHIO OGURA, MUNEOHI KITADA, ITARU MONNO, AI WATANABE, DAISUKE KOYA, Ishikawa, Japan
496-P Mechanistic Role of Mitochondrial AKT1 in Kidney Injury and Diabetic Nephropathy. HUGO YOU-HSIEN LIN, YUMAY CHEN, YU-HAN CHEN, ALBERT TA, HSIAOCHEN LEE, PING H. WANG, Irvine, CA

497-P Activation of Brown Adipose Tissue Attenuates Diabetic Nephropathy in Mice. MEIPING GUAN, YINGYING CAI, SHAOZHOU ZOU, Guangzhou, China

498-P Rho-Kinase Induces CTGF Expression through Actin Dynamics in Mesangial Cells. YOSUKE NAGAI, DALJI KAWANAMI, KEICHIRO MATOBA, YUSUKE TAKEDA, TOMOYO AKAMINE, SHO ISHIZAWA, YASUSHI KANAZAWA, TAMOTSU YOKOTA, KAZUNORI UTSUNOMIYA, Tokyo, Japan

499-P Sweet-Taste Receptors Mediated ROS-NLRP3 Inflammasome Signaling Activation—Implications for Diabetic Nephropathy. LUPING ZHOU, WEI HUANG, YONG XU, CHENLIN GAO, Luzhou, China

500-P Backcross db Gene into CD-1 Background Results in Novel Type 2 Diabetic Mouse Model with Progressive Kidney Fibrosis. YUIKO MIZUNUMA, KYOKO NITTA, SUSUMU TAKAGI, KEIZO KANASAKI, DAISUKE KOYA, Kahoku, Japan

501-P Carbohydrate Response Element Binding Protein (ChREBP) Promotes Inflammation and Apoptosis of Mesangial Cells. YAN CHEN, SHUJIE ZHAO, YANJUN WANG, Changchun, China

502-P Novel Rat Models of Diabetic Nephropathy Promoting Pronounced Tubular Fibrosis and Glomerular Alterations. THOMAS SECHER, THEA T. JOHANSEN, METTE V. OESTERGAARD, PHILIP J. PEDERSEN, NORA E. ZOU, TANJA X. PEDERSEN, NIELS VRANG, KELD FOSGERAU, LISBETH N. FINK, Harsholm, Denmark

503-P PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-3 Expression, and Inflammatory Cell Infiltration in ob/ob Mouse Model. JEAN-CHRISTOPHE SIMARD, MARIE-PIER CLOUTIER, ALEXANDRE LAVERRURE, JONATHAN RICHARD, LIETTE GERVAIS, PIERRE LAURIN, TIMO LUCAS, FRANÇOIS A. LEBLOND, LYNE GAGNON, Laval, QC, Canada

504-P Early Growth Response Protein 1 Mediates Long Noncoding RNA Arid2-IR to Promote Extracellular Matrix Production in Diabetic Kidney Disease. YAN-LIN YANG, FANG HU, YIJIE JIA, MEINA ZOU, YAO-MING XUE, Guangzhou, China

505-P Early Growth Response 1 (Egr1) Is a Transcriptional Activator of RAAS in Diabetic Kidney Disease. YAO-MING XUE, Guangzhou, China

506-P Changes of Plasma and Urine hsa-miR-223-3p Was Correlated with the Severity in Different Stages of Diabetes Kidney Disease of Type 2 Diabetes Patients in China. JUNYI HE, RONG LI, LAN LI, YANAN WU, QIUPING YANG, LIHUA ZHANG, Kunming, China

507-P Klotho Prevented Epithelial-to-Mesenchymal Transition in High-Fat Diet/Streptozotocin-Induced Mice by Targeting NFkB/Microrna-21/Smad7 Signaling Pathway. MENG XUE, FANG HU, YIJIE JIA, YAO-MING XUE, Guangzhou, China

508-P Empagliflozin and Linagliptin Alleviated Glomerular Changes in a Model of Diabetic Nephropathy. ANTON I. KORBUT, VADIM KILMONT, IULIJA TASKAEVA, NATALIYA P. BGATOVA, IRINA ISCHENKO, NOVOSIBIRSK, Russian Federation

509-P TRIM29 Is a New Gene That Regulates IRS-1 to Induce Insulin Resistance in Diabetes. SAMY L. HABIB, San Antonio, TX
514-P  A Low-Protein Calorie-Restricted Diet Attenuates Renal Injury and Facilitates Podocyte Autophagy in Type 2 Diabetic Rats. GUOFANG CHEN, YAN GENG, CHAO LUI, Nanjing, China, Jiangsu, China

515-P  Identifying a New Pathway to Regulate Autophagy in HK2 Cells. EIJIRO YAMADA, SHUICHI OKADA, MASANOBU YAMADA, Maebashi, Japan

516-P  Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy. TANJA X. PEDERSEN, THEA T. JOHANSEN, LISBETH N. FINK, NIELS VRANG, THOMAS SECHER, Harsholm, Denmark

COMPLICATIONS—NEPHROPATHY—CLINICAL AND TRANSLATIONAL RESEARCH

Moderated Poster Discussion: Clinical and Translational Studies in Diabetic Kidney Disease (Posters: 517-P to 522-P, see page 157).

517-P  Renal Hemodynamic Function at the Extremes of T1D Duration—Adolescents vs. Adults with T1D for ≥50 Years. YULIYA LYTVYN, PETTER BJORNSTAD, JULIE A. LOVSHIN, GENEVIEVE BOULET, MOHAMMED FAROQDI, VESTA S. LAI, JOSEPHINE M. TSE, LESLIE CHAM, LEIF ERIK LOVBLOM, ALANNA WEISSMAN, HILLARY A. KEENAN, MICHAEL H. BRENT, NARINDER PAUL, VERA BRIL, ANDREW ADVANI, ETIENNE B. SCHETT, BRUCE A. PERKINS, DAVID CHERNEY, Toronto, ON, Canada, Aurora, CO, Boston, MA, London, ON, Canada

518-P  Apolipoprotein C3 and Cardiovascular Disease in Patients with Type 1 Diabetes and Diabetic Nephropathy. LARS STECHEMESSER, CAROL FORSBLOM, RAIMUND WEITGASSER, PER-HENRIK GROOP, Salzburg, Austria, Helsinki, Finland

519-P  Circulating MicroRNAs Associated with Incident End-Stage Renal Disease in Chinese with Type 2 Diabetes. BAQI FAN, HEUNG MAN LEE, CADMON K.P. LIM, RICHARD CHOIY, JULIANA C. CHAN, ANDREA LUK, RONALD C. MA, Hong Kong, China

520-P  Elevated Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Intrarenal Hemodynamic Dysfunction in Type 1 Diabetes (T1D). PETTER BJORNSTAD, JANET K. SNELL-BERGEN, JULIE A. LOVSHIN, SUNIKA K. SINGH, LEIF ERIK LOVBLOM, JOSEPHINE M. TSE, ANDREJ ORSZAG, YULIYA LYTVYN, MICHAEL H. BRENT, NARINDER PAUL, ALANNA WEISSMAN, HILLARY A. KEENAN, LESLIE CHAM, VERA BRIL, BRUCE A. PERKINS, DAVID CHERNEY, Aurora, CO, Toronto, ON, Canada, London, ON, Canada, Boston, MA

521-P  Advanced Glycation End Products (AGES)—Role in Development and Progression of Kidney Disease in Type 1 Diabetes in DCC7/EDIC. PAUL J. BEISSWENGER, IONUT BEBU, SCOTT HOWELL, JOHN LACHIN, Hanover, NH, Washington, DC, Lebanon, NH, Rockville, MD

522-P  Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). M. ANGELYN BETHEL, ROBERT J. MENTZ, PETER MERRILL, JOHN B. BUSE, JULIANA C. CHAN, SHAUN G. GOODMAN, NAYYAR IQBAL, NELI JAKUBONIENE, BRIAN G. KATONA, YULIYA LOKHNYGINA, RENATO D. LOPES, ALDO P. MAGGIONI, PETER K. OHMAN, NEIL R. POULTER, AMBADY RAMACHANDRAN, TSVELATINA TANKOVA, BERNARD ZINMAN, ADRIAN F. HERNANDEZ, RURY R. HOLMAN, Oxford, United Kingdom, Durham, NC, Chapel Hill, NC, Hong Kong, China, Toronto, ON, Canada, Malmö, Sweden, Kaunas, Lithuania, Gaithersburg, MD, Florence, Italy, London, United Kingdom, Chennai, India, Sofia, Bulgaria

523-P  Significant Association of TGF-Beta1 C-T Transition in Codon 10 of the Gene with Posttransplant Diabetes. MOHAMED M.J. JAHROMI ESQ., Kuwait City, Kuwait

524-P  Empagliflozin Improves Renal Outcomes irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. CHRISTOPH WANNER, MARK E. COOPER, SILVIO INZUCHI, BERNARD ZINMAN, UWE HENKNE, MAXIMILIAN VON EYNATTEN, AUDREY KOKITA-WEBER, Würzburg, Germany, Melbourne, Australia, New Haven, CT, Toronto, ON, Canada, Ingelheim, Germany, Biberach, Germany

525-P  Urinary NGAL and KIM-1 are Significantly Elevated in Young Adults (YA) with Type 1 (T1D) and Type 2 (T2D) Diabetes. NICOLE M. SHEANON, AMY K. MOTT, RAFAL DAGOSTINO, JR., CYNTHIA SUIERKEN, MARYAM AFKARIAN, DANA DABELEA, GIUSEPPINA IMPERATORE, SANTICA M. MARCOVINA, DAVID J. PETERITT, SHARON SAYDAH, LAWRENCE M. DOLAN, Cincinnati, OH, Chapel Hill, NC, Winston-Salem, NC, Davis, CA, Aurora, CO, Atlanta, GA, Seattle, WA, Santa Barbara, CA, Hyattsville, MD

Presence of Carotid Artery Plaque Is Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes and Normal Baseline Renal Function. DA HEA SEO, SO HUN KIM, SEONG HEE AHN, SEONGBIN HONG, MOONSUK NAM, JEONG-TAEK WOO, SEI HYUN BAIK, KWANWOO LEE, YOUNG SEOL KIM, YONGSOO PARK, Incheon, Republic of Korea, Seoul, Republic of Korea, Suwon, Republic of Korea, Seongnam, Republic of Korea, Champaign, IL


The Risk Factors for Rapid Decline of Renal Function in Japanese Patients with Diabetes Mellitus. MUNEHIDE MATSUHISA, HIROYASU MORI, MAMI OHISHI, MASASHI ISHIZU, REIKO SUZUKI, INEKO TAKAWA, SATOSHI TANIGUCHI, MOOTOYUKI TAMAKI, YUKO AKEHI, KIYOE KURAHASHI, SUMIKO YOSHIDA, ITSURO ENDO, KEN-ICHI AIHARA, MAKOTO FUNAKI, AKIO KURODA, Tokushima, Japan

Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)—DEVOTE Results. ASLAM AMOD, SCOTT S. EMERSON, STEVEN P. MARSO, DARREN K. MCGUIRE, THOMAS R. PIEBER, RODICA POP-BUSUI, RICHARD E. PRATLEY, BERNARD ZINMAN, MELISSA V. HANSEN, TING JIA, THOMAS MARK, NEIL R. POULET, ON BEHALF OF THE DEVOTE STUDY GROUP, Durham, South Africa, Seatttle, WA, Kansas City, MO, Dallas, TX, Graz, Austria, Ann Arbor, MI, Orlando, FL, Toronto, ON, Canada, Saborig, Denmark, London, United Kingdom

Elevated Baseline Glomerular Filtration Rate Is Associated with a More Rapid Decline in Chinese Patients with Type 2 Diabetes with Normoalbuminuria. JING WAN, HAIBING CHEN, Shanghai, China

Effect of Thiazolidinediones on Renal Outcomes in Type 2 Diabetes—The VADT Study. KELLY J. HUNT, MIRAN A. JAFFA, SARA M. GARRETT, DEIRDRÉ K. LUTTRELL, KENNETH E. LIPSON, MARIA F. LOPES-VIRELLA, LOUIS M. LUTTRELL, AYAD A. JAFFA, VADT INVESTIGATORS, Charleston, SC, Beinut, Lebanon, San Francisco, CA

Serum Adipocyte Fatty Acid-Binding Protein Levels Are Linked to Rapid Renal Function Decline in Patients with Type 2 Diabetes and Normal Renal Function. DA HEA SEO, SO HUN KIM, SEONG HEE AHN, SEONGBIN HONG, MOONSUK NAM, Incheon, Republic of Korea

Structure Equation Modeling Analysis of Risk Factors and the Pathway Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes. TAO-CHUN LEE, FU-MEI CHUNG, Pingtung, Taiwan, Kaohsiung, Taiwan

Glycemic Fluctuation and the Risk of Hypoglycemia Unawareness Associated with Hemodialysis in Type 2 Diabetic Renal Failure. AKINORI HAYASHI, AKARI MOMOZONO, SAYUKI KAWAI, TSUGUTO MASAKI, SONOMI YOSHINO, AKIFUMI OGAWA, KOJI TAKANO, MASAYOSHI SHICHIRI, Sagamihara, Japan

Treatment Patterns in Type 2 Diabetes Patients with Chronic Kidney Disease—A Cohort Study. MICHAEL BLANKENBURG, CSABA P. KOVESDY, SELINE EISENRING, ANNE FETT, EMILE W. SCHOKKER, JONATHAN KORN, ALAIN GAY, Berlin, Germany, Memphis, TN, Zürich, Switzerland, Frankfurt, Germany, Somerville, MA

Estimating Glomerular Filtration Rate Calculated by Serum Creatinine Lacks Precision and Accuracy in Adults with Type 2 Diabetes with Preserved Renal Function. JULIE A. LOVSHIN, LEIF ERIK LOVBLOM, PETTER BJORNSTAD, YULIYA LYTVYN, HARIENDRA RAJASEKERAN, DANIEL SCCARR, BRUCE A. PERKINS, DAVID CHERNEY, Toronto, ON, Canada, Aurora, CO

Plasma Uric Acid (PUA), Renal Hemodynamic Function, and Arterial Stiffness at the Extremes of T1D Duration—Adolescents vs. Adults with T1D for ≥50 Years. YULIYA LYTVYN, PETTER BJORNSTAD, JULIE A. LOVSHIN, GENEVIEVE BOULET, MOHAMMED FAROOQI, VESTA S. LAI, JOSEPHINE M. TSE, LESLIE CHAM, LEIF ERIK LOVBLOM, ALANNA WEISMAN, HILLARY A. KEENAN, MICHAEL H. BRENT, NARINDER PAUL, VERA BRIL, ANDREW ADVANI, ETIENNE B. SOCHETT, BRUCE A. PERKINS, DAVID CHERNEY, Toronto, ON, Canada, Aurora, CO, Boston, MA, London, ON, Canada

Artificial Intelligence Predicts Progress of Diabetic Kidney Disease—Novel Prediction Model Construction with Big Data Machine Learning. MASAKI MAKINO, MASAKI ONO, TOSHINARI ITOKO, TAKAYUKI KATSUKI, AKIRA KOSEKI, MICHIHARU KUDO, KYOICHI HAIUDA, JUN KURODA, RYOSUKE YANAGIYA, ATSUSHI SUZUKI, Toyoake, Japan, Tokyo, Japan
540-P Factors Responsible for Progression of Microalbuminuria in Japanese Patients with Type 2 Diabetes—Retrospective Analysis. SODAI KUBOTA, HITOSHI KUWATA, DAISUKE YABE, KENTA MUROTANI, YOSHIYUKI HAMAMOTO, TAKESHI KUROSE, YUTAKA SEINO, Osaka, Japan, Kobe, Japan, Nagakute, Japan

541-P Clinical Variables and Outcomes of Kidney Transplant Recipients with Type 2 Diabetes and New-Onset Diabetes after Transplantation in a Predominantly Minority Urban Population. SANDRA ALEKSIC, SARA ZAHEDPOUR ANARAKI, EFFIE TSOMOS, LAXMI UPADHYAY, EMILY JAPP, MARIA AJAIMY, ENVER AKALIN, JOEL ZONSZEIN, Bronx, NY, New Rochelle, NY

542-P Wider Peripheral Retinal Vessel Predicts Renal Dysfunction in Adolescents with Type 1 Diabetes. VALLIMAYIL VELAYUTHAM, MARIA E. CRAIG, GERALD LIEW, TIEN Y. WONG, ALICIA JENKINS, KIM C. DONAGHUE, Campbelltown, Australia, Westmead, Australia, Sydney, Australia, Singapore, Singapore

543-P Superior Glycaemic Control Effects with Dulaglutide (Dula), a Once-Weekly Glucagon-Like Peptide Receptor-Antagonist (GLP-1RA), to Liraglutide (Lira) in Diabetic Hemodialysis Patients Assessed by Continuous Glucose Monitoring (CGM). SATOSHI FUNAKOSHI, MASATOSHI HAYASHIDA, KENJI SAWASE, JYUNICHIRO HASHIGUCHI, RICA ETOH, YUTAKA MORI, KAZUNORI UTSUNOMIYA, TAKASHI HARADA, Nagasaki, Japan, Tokyo, Japan

544-P CKD Prevalence and Risk Are Higher in Adults with Type 2 vs. Type 1 Diabetes—An Assessment of 1.5 Million Patients Recently Evaluated in U.S. Clinical Practices. MICHAEL CRESSMAN, JENNIFER L. ENNIS, BARRY J. GOLDSTEIN, LOUKAS GOURGIOTIS, DAJIE LUO, MALA PURI, BARBARA GILLESPIE, Princeton, NJ, Chicago, IL, Maidenhead, United Kingdom, Durham, NC, Cary, NC

545-P Clinical Characteristics and Outcomes in Patients Admitted with Diabetic Ketoacidosis (DKA) and End-Stage Renal Disease (ESRD). RODOLFO J. GALINDO, FRANCISCO J. PASQUEL, KATERINA G. TSEGKA, SAUMETH CARDONA, NEIL DHRUV, PRIYATHAMA VELLANKI, MAYA FAYFMAN, J. SONYA HAW, ALEXANDRA MIGDAL, SHAILESH NAIR, HEQIONG WANG, GUILLERMO E. UMPIERREZ, Atlanta, GA

546-P WITHDRAWN

COMPLICATIONS—NEUROPATHY

Moderated Poster Discussion: Latest Breakthroughs in the Clinical and Basic Science of Diabetic Neuropathy (Posters: 547-P to 552-P), see page 157.

547-P Genetically Reduced Chondroitin Sulfate Prevents the Progression of Diabetic Neuropathy. HAJIME ISHIGURO, TAKASHI USHIKI, ASAMI KAWASAKI, KAORI CHO, MASAYOSHI MASUKO, KAZUNORI SANGO, MICHIIRO IGARASHI, HIROHITO SONE, Niigata, Japan, Tokyo, Japan

548-P Two-Way Orthogonal Partial Least Squares (O2PLS) Analysis of the Lipidome and Transcriptome in Prediabetic and Diabetic Neuropathy. KAI GUO, EVA L. FELDMAN, JUNGUK HUR, Grand Forks, ND, Ann Arbor, MI

549-P Beneficial Effects of Xanthine Oxidase Inhibitor, Topiloxostat, on Experimental Diabetic Neuropathy in Mice. HIROKI MIZUKAMI, REMINA KOYAMA, KAZUHISA TAKAHASHI, SHO OSONOI, SAORI OGASAWARA, SOROKU YAGIHASHI, Hiroaki, Japan

550-P A Magnetic Resonance Imaging Volumetry Study of Regional Brain Atrophy in Diabetic Peripheral Neuropathy. DINESH SELVARAJAH, FRANCESCA HEIBERG-GIBBONS, IAIN D. WILKINSON, RAJIV GANDHI, SOLOMON TESFAYE, Sheffield, United Kingdom

551-P Large-Scale DNA Methylation Profiling of Human Diabetic Peripheral Neuropathy in Subjects with Type 2 Diabetes Mellitus. KAI GUO, SARAH ELZINGA, STEPHANIE EID, CLAUDIA FIGUEROA-ROMERO, BRETT A. MCGREGOR, GUILLERMO DE ANDA-JAUREGUI, CRYSTAL PACUT, EVA L. FELDMAN, JUNGUK HUR, Grand Forks, ND, Ann Arbor, MI

552-P Prevalence of Peripheral Neuropathy in Prediabetes. UAZMAN ALAM, DIABETES AND ENDOCRINE RESEARCH GROUP, UNIVERSITY OF LIVERPOOL, EARLY NEUROPATHY ASSESSMENT GROUP, MANCHESTER, Liverpool, United Kingdom

553-P LXRs Protect DRG Neurons from High-Fat Diet-Induced ER Stress and Allodynia. VIRGINIE AUBERT, Chicago, IL
554-P Mechanisms of Therapeutic Effects of Conditioned Media from Cultured Dental Pulp Stem Cells on Diabetic Polyneuropathy. ERIKO MAKINO, NOBUHISA NAKAMURA, MEGUMI MIYABE, MIZUHO ITO, SAKI KANADA, MASAKI HATA, TOMOKAZU SAIKI, HIDEKI KAMIYA, JIRO NAKAMURA, KEN MIYAZAWA, SHIGEMI GOTO, TATSUHIKO MATSUBARAI, KEIKO NARUSE, Nagoya, Japan, Nagakute, Japan.

555-P The Impact of Normoglycemia in Reducing Microvascular Complications in Patients with Type 2 Diabetes—A Follow-Up Study. MITRA TAVAKOLI, FUKASHI ISHIBASHI, Exeter, United Kingdom, Hatsukaichi, Japan.

556-P Vitamin D Supplementation and Microcirculation Parameters in Diabetic Patients with Neuropathy. ANNA P. STEFANOVA, TATYANA L. KARONOVA, EDWARD B. JUDE, Saint Petersburg, Russian Federation, Manchester, United Kingdom.

557-P The Effect and Molecular Mechanism of Pancreatic Kallikrein in Painful Diabetic Neuropathy Based on CX3CL1/CX3CR1 Pathway. XU XIANG, JIN HUI, XU LAN, Wuxi, China.

558-P Effect of Diabetes on Peripheral Neuropathy in an Adult U.S. Population. MUIDEEN T. OLAIYA, ROBERT L. HANSON, KAREN G. KAVENA, MADHUMITA SINHA, ROBERT NELSON, WILLIAM C. KNOWLER, Phoenix, AZ.

559-P Prevalence of Cardiovascular Autonomic Neuropathy and Gastroparesis Symptoms among Adults with Type 2 Diabetes Who Attend a Primary Health Care Center. LINA ALOLAIWI, TURKI ALHARBI, AYLA TOURKMANI, Riyadh, Saudi Arabia.

560-P Sex Differences in Neuropathy and Neuropathic Pain in Long-Standing Diabetes—Results from the Canadian Study of Longevity in Type 1 Diabetes. NANCY CARDINEZ, LEIF ERIK LOVBLOM, JOHNNY-WEI BAI, ALON ABRAHAM, EVAN J. LEWIS, DANIEL SCARR, JULIE A. LOVSHIN, YULIYA LYTVYN, GEN-EVIEVE BOULET, MOHAMMED FAROOQI, ANDREJ ORSZAG, ALANNA WEISMAN, HILLARY A. KEENAN, MICHAEL H. BREN'T, NARINDER PAUL, VERA BRIL, DAVID CHERNEY, BRUCE A. PERKINS, Toronto, ON, Canada, Hamilton, ON, Canada, Boston, MA, London, ON, Canada.

561-P Sensory Cutoff Value for Predicting Postural Instability in People with Peripheral Neuropathy Secondary to Diabetes. NAY LINN AUNG, STACEY A. MEARDON, CHIA-CHENG LIN, ROBERT J. TANENBERG, Greenville, NC.

562-P The Prevalence and Characteristics of Diabetic Polyneuropathy in Japanese Type 2 Diabetic Patient. HIDEKI KAMIYA, ATSUKO WATARAI, MASAYUKI BABA, RIMEI NISHIMURA, NAOKO TAJIMA, JIRO NAKAMURA, Nagakute, Japan, Nagoya, Japan, Aomori, Japan, Tokyo, Japan.

563-P Usefulness of a Point-of-Care Sural Nerve Conduction Device (DPNCheck™) for Evaluation of Diabetic Symmetric Sensorimotor Polyneuropathy in Japan. YUKA SHIBATA, HIDEKI KAMIYA, TATSUHITO HIMENO, MIKIO MOTEKI, HIROMI SHIMODA, MAKOTO KATO, YUICHIRO YAMADA, EMIRI MIURA-YUURA, MASAKI KONDO, SHIN TSUNEKAWA, YOSHIRO KATO, JIRO NAKAMURA, Nagakute, Japan.

564-P Palmitoylethanolamide in Add-On to Alpha Lipoic Acid for Control of Symptoms of Diabetic Peripheral Neuropathy. ERNESTO MADALONI, ANNA RITA MAURIZI, ALESSANDRA MINUTOLO, ELVIRA FIORITI, ROSELLA DEL TORO, ANDA MIHAELA NACIU, SILVIA PIERALICE, MILENA M. ROSATI, SILVIA MANFRINI, PAOLO POZZILLI, Rome, Italy.

565-P A Novel Severity Classification of Diabetic Polyneuropathy Based on Nerve Conduction Study and ECG. HIROMI SHIMODA, HIDEKI KAMIYA, ATSUKO WATARAI, TATSUHITO HIMEINO, YUKA SHIBATA, MIKIO MOTEKI, MAKOTO KATO, YUICHIRO YAMADA, EMIRI MIURA-YUURA, MASAKI KONDO, SHIN TSUNEKAWA, YOSHIRO KATO, JIRO NAKAMURA, Nagakute, Japan, Nagoya, Japan.

566-P Secreted Factors from Dental Pulp Stem Cells Ameliorated Diabetic Polyneuropathy in Streptozotocin-Induced Diabetic Mice. EMIRI MIURA-YUURA, SHIN TSUNEKAWA, TATSUHITO HIMEINO, KEIKO NARUSE, MIKIO MOTEKI, HIROMI SHIMODA, MAKOTO KATO, YUICHIRO YAMADA, MASAKI KONDO, YOSHIRO KATO, HIDEKI KAMIYA, JIRO NAKAMURA, Nagakute, Japan, Nagoya, Japan.

568-P Impaired Hemodynamic Response to Thermal Pain in Painful Diabetic Neuropathy. MARNI GREIG, IAIN D. WILKINSON, DINESH SELVARAJAH, PALLAI RAPPAI SHILLO, RAJIV GANDHI, SOLOMON TESFAYE, Sheffield, United Kingdom

569-P Amelioration of Peripheral Neuropathy in Mouse Models of Diabetes by Dietary Reversal. PHIL-LIPE D. O’BRIEN, KAI GUO, LUCY M. HINDER, JOHN M. HAYES, FAYE MENDELSOHN, MAEGAN A. TABBEY, JUN-GUK HUR, EVA L. FELDMAN, Ann Arbor, MI, Grand Forks, ND

570-P PGC-1α Determines the Formation of Neuronal Respiratory Chain Supercomplexes That Regulate Mitochondrial Function. JOUNGIL CHOI, MOHAMMAD SALIMIAN, SAI SRUTHI REDDY KONDURU, JAMES RUSSELL, Baltimore, MD

571-P Eyekon Is a Novel Diagnostic Tool for Diabetic Neuropathy. MOUFIDA BEN NASR, ELENA GIULIANI, FRANCESCA D’ADADIO, ANNA MAESTRONI, VERA USUELLI, STEFANIA BIANCHI MARZOLI, PAOLO FIORINA, Boston, MA, Italy

572-P The Association between Urinary N-Acetyl-β-D-Glucosaminidase and Cardiovascular Autonomic Neuropathy in Patients with Diabetes. MIN SUN CHOI, JI EUN JUN, GYURI KIM, SANG-MAN JIN, KYU YEON HUR, MOON-KYU LEE, JAE HYEON KIM, Seoul, Republic of Korea

573-P Monounsaturated Fatty Acids Prevent Saturated Fatty Acid-Induced Impairment of Mitochondrial Trafficking in Dorsal Root Ganglion Sensory Neurons. AMY RUMORA, GIOVANNI LOGRASSO, JULIA A. HAIDAR, JUSTIN DOLKOWSKI, STEPHEN I. LENTZ, EVA L. FELDMAN, Ann Arbor, MI

574-P Comparison of Cognitive Function, Depression, and Sleep Quality among Type 2 Diabetes Mellitus Patients With and Without Diabetic Neuropathy. CHANDNI RADHAKRISHNAN, RINU R. CR, SREEJITH K, ANJUSHA UT, Manjeri, India, Kozhikode, India

575-P Suppression of Neuropathy Development in Diabetic Rage-Deficient Mice Is Associated with Absence of M1/M2 Macrophage Skewing in the Sciatic Nerve. SHO OSONOI, HIROKI MIZUKAMI, SAORI OGASAWARA, KAZUHISA TAKAHASHI, KAZUNORI SANGO, SOROKU YAGIHASHI, Hiroaki; Japan, Tokyo, Japan

576-P Exercise Training to Target Gait Unsteadiness in People with Diabetes. STEVEN J. BROWN, ANDREW J.M. BOULTON, FRANK L. BOWLING, NEIL D. REEVES, Manchester, United Kingdom

577-P Analysis of Different Methods for the Diagnosis of Subclinical and Clinical Stages Polyneuropathy in Patients with Type 2 Diabetes Mellitus. ANASTASIIA FOKINA, ALEXEY ZILOV, IGOR STROKOV, ZOYA SURNINA, Moscow, Russian Federation

578-P Cardiovascular Autonomic Neuropathy and Uric Acid in Subjects with Type 1 Diabetes—Preventing Early Renal Loss (PERL) in Type 1 Diabetes Trial. MAMTA JAISWAL, ALESSANDRO DORIA, MICHAEL MAUER, RODICA POP-BUSUI, Ann Arbor, MI, Boston, MA, Minneapolis, MN

579-P Impaired Baroreflex Sensitivity in Patients with Recent-Onset Type 2 Diabetes. GIDON J. BÖNHOF, ALEXANDER STROM, KALMÁN BÓDIS, KARSTEN MÜSSLIG, JULIA SZENDROEDI, MICHAEL RÖDEN, DAN ZIEGLER, Düsseldorf, Germany

580-P The Reference Distribution of Annual Change in Corneal Nerve Fibre Length in Diabetes Mellitus. EVAN J.H. LEWIS, MITRA TAVAKOLI, LEIF ERIK LOVBLOM, ELISE M. HALPERN, MARIA JEZIORSKA, DANIELÉ PACAUD, NICOLA PRITCHARD, RONI M. SHTEIN, NATHAN EFRON, VERA BRIL, RAYAZ A. MALIK, BRUCE A. PERKINS, Toronto, ON, Canada, Exeter, United Kingdom, Manchester, United Kingdom, Calgary, AB, Canada, Brisbane, Australia, Ann Arbor, MI, Doha, Qatar

581-P Mast Cell Precursors and Diabetic Neuropathy—Is Immunity the Connection? MARIA SAMBATARO, LUISA SAMBADO, ENRICA TREVISIOL, AGOSTINO PACCAGNELLA, Castelfranco Veneto, Italy, Treviso, Italy

582-P Clinical Application of Photoacoustic Imaging to the Evaluation of Diabetic Polyneuropathy. SOROKU YAGIHASHI, Chiba, Japan

583-P Alterations in Histone Acetylation in Diabetic Painful Neuropathy. MUNMUN CHATTOPADHYAY, VIKRAM THAKUR, El Paso, TX

584-P WITHDRAWN
585-P  Insulin Resistance, Cardiovascular Autonomic Neuropathy, and Left Ventricular Hypertrophy in Patients with Congenital Generalized Lipodystrophy. VIRGINIA O. FERNANDES, CLARISSE M.M. PONTE, MARIA HELANE C. GURGEL, ANA PAULA D.R. MONTENEGRO, LIVIA A.A. BATISTA, CRISTIANE B.R. LIBERATO, CATARINA B. D’ALVA, RENAN M. MONTENEGRO, JR., BRAZILIAN LIPODYSTROPHY STUDY GROUP (BRAZLIPO), Fortaleza, Brazil

586-P  Clinical Association between Diabetic Peripheral Neuropathy and Diabetic Retinopathy. ZYDEN JARRY, VINAYAK JOSHI, MARIA VAHTEL, MARK R. BURGE, PETER SOLIZ, Albuquerque, NM

587-P  Vestibular Deficits with Type 2 Diabetes Assayed by Motion Perception Thresholds. SUSAN KING, DEBORAH J. WEXLER, TANIA LEEDER, FAISAL KARMALI, Boston, MA

588-P  hBMSC-TERT in Cutaneous Diabetic Wound—Histological Analysis and Metalloproteinases. ÂNGELA M. LEAL, São Carlos, Brazil

COMPLICATIONS—RETINOPATHY

Moderated Poster Discussion: Role of Systemic and Retinal-Specific Factors in Diabetic Retinopathy Pathogenesis (Posters: 589-P to 594-P), see page 157.

589-P  Persistent C-Peptide Levels and Proliferative Retinopathy in Childhood-Onset Type 1 Diabetes (T1D). KATHERINE WILLIAMS, TINA COSTACOU, DOROTHY J. BECKER, TREVOR J. ORCHARD, Pittsburgh, PA

590-P  Neutrophil Elastase Contributes to the Early Molecular Abnormalities of the Retina in Diabetes. HAITAO LIU, TIMOTHY KERN, Cleveland, OH

591-P  Anemia as a Risk Factor for Diabetic Retinopathy (DR) with Special Reference to Nutritional Etiology. JYOTHI IDICULLA, SUNEETHA NITHYANANDAM, MARY JOSEPH, CHRISTEENA J., Bangalore, India

592-P  Angiotensin-(1-7) Attenuates Protein O-GlcNAcylation in the Retina of Mice Fed a High-Fat Diet. SADIE DIERSCHKE, AMY C. ARNOLD, ALISTAIR J. BARBER, MICHAEL D. DENNIS, Hershey, PA

593-P  Abnormal Electroretinography in Patients with Long-Duration Diabetes but No Retinopathy. BELINDA BROOKS, DENNIS YUE, ELLEN LANDY, YI SHI, Camperdown, Australia, Sydney, Australia

594-P  Test Strip-Positive Proteinuria and Its Combination with Low eGFR Are Predictive of Treatment-Required Eye Diseases in Japanese Patients with Diabetes Mellitus. CHIKA HORIKAWA, REI AIDA, SHIRO TANAKA, YUKIO YOSHIMURA, TATSUMI MORIYA, ATSUSHI ARAKI, HIROHITO SONE, Niigata, Japan, Tokyo, Japan

595-P  Statins Decrease VEGF Expression in Retinal Pigment Epithelial Cells by Downregulation of Receptor for AGE (RAGE). HIROKI TSUJINAKA, ASAKO ITAYA-HIRONAKA, AKIYO YAMAUCHI, SUMIYO SAKURAMOTO-TSUCHIDA, MIYUKO HARADA, HIROSHI SUZUKI, HIROHIRO SEIDA, NAUTA YAMANAKA, YASUHIRO MATSUBAYASHI, HIROHIRO SONE, Niigata, Japan

596-P  Screening for Diabetic Retinopathy in African Immigrants—The Africans in America Study. PANOS G. CHRISTAKIS, JEAN DAMASCENE KABAKAMBIRA, SARA M. BRIKER, CHRISTOPHER DUBOSE, ANNE E. SUMNER, EMILY CHEW, Bethesda, MD

597-P  Impact of Vitamin B6 Intake on the Risk of Diabetic Retinopathy—Analysis from Multicenter Prospective Study of Japanese Patients with Type 2 Diabetes. HIROKI TSUJINAKA, ASAKO ITAYA-HIRONAKA, RYOOGO SHOBATAKE, NAONORI MASUDA, HIROMASA HIRAI, NAOKO OGATA, SHIN TAKASAWA, Kashihara, Japan

598-P  Knowledge, Attitudes, and Practices Related to Diabetes Eye Complications among Diabetes Mellitus Patients at a Referral Hospital in Zimbabwe. MELLISA SITHOLE, ALICE MATIMBA, RICHMOND WOODWARD, Harare, Zimbabwe, New York, NY

599-P  Male Type 2 Diabetic Patients Have Higher Diabetic Retinopathy Prevalence. SARA CHERCHI, ALFONSO GIAGANTE, PIERPAOLO CONTINI, DANILA PISTIS, ROSANGELA M. PILOSU, MARIA A. SPANU, MARIA A. FOIS, ALESSIO LALI, GISELLA MELONI, GIANNCARLO TONOLO, Olbia, Italy, Nuoro, Italy, Cagliari, Italy, Sassari, Italy, Isili, Italy, Lanusei, Italy
600-P The Relationships between Retinopathy and Other Vascular Complications in Adults with Long-Standing Diabetes—Results from the Canadian Study of Longevity in Type 1 Diabetes (T1D). JULIE A. LOVSHIN, LEIF ERIK LOVBLOM, PETTER BJORNSTAD, YULIYA LYTYYIN, GENEVIEVE BOULET, ALANNA WEISMAN, VESTA S. LAI, JOSEPHINE M. TSE, LESLIE CHAM, ANDREJ ORSZAG, HILLARY A. KEENAN, NARINDER PAUL, VERA BRIL, MICHAEL H. BRENT, BRUCE A. PERKINS, DAVID CHERNEY, Toronto, ON, Canada, Aurora, CO, Boston, MA, London, ON, Canada

601-P Ranibizumab-Induced Diabetic Retinopathy Improvement—Results from Patients at High Risk for Vision Loss in RIDE/RISE and Protocol S. VRINDA HERSHBERGER, LAUREN F. HILL, LISA L. TUOMI, AVANTI GHANEKAR, Melbourne, FL, South San Francisco, CA, St. Louis, MO

602-P Extreme Hyperglycemia Causes Vascular Hypoperfusion at Optic Nerve Head in Diabetic Patients (DM). TAKAKO MITSUMATSU, FUMIHIKO YAGI, YUKO KONDO, AYAKO ANRAKU, SUMIE OKAHATA, KENTARO SAKAMOTO, GOJI TOMITA, TERUO SHIBA, Tokyo, Japan

603-P Diabetic Retinopathy Grade as a Predictive Marker of Stroke and Mortality in Type 2 Diabetes Mellitus Patients with Amputations—Seven-Year Follow-Up. KIRAN SHAH, NATARAJAN SUNDARAM, ABHAY A. RAUT, SR., KARTHIK RAO, NAVNEET WADHWA, Mumbai, India, Delhi, India

604-P Role of Xanthine Oxidoreductase from Mesenchymal Cells in Retinal Inflammation after Pericyte Breakdown. AKIFUMI KUSHIYAMA, TAKAKO KIKUCHI, HIROKI YAMAZAKI, TAKESHI YAMAMOTOYA, HIKEIYUKI SAKODA, MIDORI FUJISHIRO, YUSUKE NAKATSU, AKIYOSHI UEMURA, TAKASHI SHIRAKURA, TOMOICHIRO ASANO, YASUHIKO IWAMOTO, Tokyo, Japan, Hiroshima, Japan, Miyazaki, Japan, Nagoya, Japan

605-P Identification of Proliferative Diabetic Retinopathy to Asymptomatic Coronary Heart Disease in Chinese T2D Individuals—The IPAD Reach Study. JIANBO ZHOU, JINKUI YANG, Beijing, China

606-P Macular Choroidal Thickness in Pregnant Women with Type 1, Type 2, and Gestational Diabetic Mellitus. CAMILA Z. BENIFICA, TERESINHA ZANELLA, LUCAS B. FARIAS, MARIA LUCIA R. OPPERMANN, LUIS H.S. CANANI, DANIEL LAVINSKY, Porto Alegre, Brazil

607-P High-Fat Diet/Palmitate-Induced ER Stress Promotes Protein O-GlcNAcylation in Retina and Retinal Müller Cells. WEIWEI DAI, ALLYSON TORO, SADIE K. DIERSCHKE, MICHAEL D. DENNIS, Hershey, PA

608-P Identification of Early Biochemical Changes in the Diabetic Retina Using an Unbiased Proteomics Approach. SARAH R. WEBER, YUANJUN ZHAO, ALEXANDER J. BARBER, CRISTINA HERNÁNDEZ, OLGA SIMÓ-SERVAT, THOMAS W. GARDNER, RAFAEL SIMÓ, JEFFREY M. SUNDSTROM, Hershey, PA, Barcelona, Spain, Ann Arbor, MI

DIABETIC DYSLIPIDEMIA

Moderated Poster Discussion: Key Role of Lipids [Posters: 609-P to 614-P], see page 157.

609-P FFAR1 Agonism Restores Insulin Secretion in Rodents, Human Islets, and Diabetic Monkeys. JIANYING LIU, SEUNGHUN P. LEE, TONYA MARTIN, BRIAN RADY, SANATH MEEGALLA, HUI HUANG, MICHAEL P. WINTERS, LISA D. NORQUAY, JENSON QI, FU YONG DU, ANDREA R. NAWROCKI, MARK PLAYER, ALESSANDRO POCAI, Spring House, PA, Phoenixville, PA

610-P WITHDRAWN

611-P Relationship between Nitrated High-Density Lipoproteins and Vascular Function in African-American Diabetic Patients. AJIBOLA M. ADEDAYO, AYOBAWI ELOWWO, FASIKA TEDLA, ARIE KREMER, NICOLE MASTROGIANNI, CARL ROSENBERG, PAUL DREIZEN, JOHN LAROSA, LOUIS SALCICCIOLI, MOHAMED BOUTJDIR, MARY ANN BANERJI, CLINTON BROWN, MORO SALIFU, JASON LAZAR, AHMED BAKILLAH, Brooklyn, NY

612-P Relationship between the Triglyceride Glucose Index and the Presence and Fibrosis of Nonalcoholic Fatty Liver Disease in Korean Adults. MIN KYUNG KIM, JUNG HYE KIM, KAHUI PARK, SANG BAE LEE, JI SUN NAM, SHINAE KANG, JONG SUK PARK, CHUL WOO AHN, YU SIK KIM, Seoul, Republic of Korea

613-P Expression of ApoE Attenuates Differentiation of the White Adipose Tissue from ApoE-Knockout Diabetic Mice. JIANMIN RAN, XIAMING PAN, RUYI ZHANG, PING ZHU, RONGSHAO TAN, YAN LIU, Guangzhou, China
614-P Lipoprotein(a) Levels Are Twice as High in Left-Handed T2DM Patients. MICHEL P. HERMANS, SYLVIE A. AHN, MICHEL F. ROUSSEAU, Brussels, Belgium

615-P Atorvastatin Increases Fatty Acid Desaturases (FADs) and Elongation of Very-Long-Chain Fatty Acids (ELOVLs) through Geranylatedgeranyl Pyrophosphate (GGPP)-Dependent Rho Kinase Pathway in HepG2 Cells. ICHIRO TATSUNO, SHOU TANAKA, NORIKO ISHIHARA, Sakura, Japan

616-P Prevalence of Lipid Abnormalities in Progressive Stages of Diabetes Mellitus. BIN GUI, EVAN SIAU, LOUIS F. AMÓROSA, New Brunswick, NJ, Bronx, NY

617-P Association between Metabolic Syndrome Components and Indices of Liver Steatosis and Stiffness by Transient Elastography in Patients with Type 2 Diabetes and Imaging-Confirmed Nonalcoholic Fatty Liver Disease. ZHIMIN HUANG, CHI HO LEE, HO YI FONG, KAREN S. LAM, Guangzhou, China, Hong Kong, China

618-P Independent Association of a Metabolic Syndrome Severity Score with All-Cause Mortality in Type 1 Diabetes—A 10-Year Follow-Up. GIUSEPPE PENNO, MONIA GAROFOLO, ROSA GIANNARELLI, FABRIZIO CAMPI, DANIELA LUCCHESI, LAURA GIUSTI, VERONICA SANCHO-BORNEZ, ANGELA DARDANO, GIUSEPPE DANIELE, ROBERTO MICCOLI, STEFANO DEL PRATO, Pisa, Italy

619-P Increased Angiopoietin Like Proteins 4 (ANGPTL4) Is Associated with Higher Concentration of LDL-Triglycerides in Type 2 Diabetes. HIROE NAGAIKE, TOSHIYUKI HAYASHI, NORIKO NAKANISHI, MAKOTO OHARA, TAKESHI YAMAMOTO, TOMOYASU FUKUI, TSUTOMU HIRANO, Tokyo, Japan

620-P Progressive Improvement in Endothelial Nitric Oxide Release due to Synthase Dimer Formation with LDL Reductions below 70 mg/dL during Hyperglycemia. R. PRESTON MASON, HAZEM E. DAWOOD, SR., SAMUEL SHERRATT, TADEUSZ MALINSKI, Beverly, MA, Athens, OH

622-P A Neural Signature of Metabolic Syndrome—Preliminary Results. EITHAN KOTKOWSKI, CRYSTAL FRANKLIN, SAINT ANTONIO, TX

623-P ApoC-III Levels Correlate with Insulin Resistance and HbA1c in Familial Partial Lipodystrophy—Observations from the Broaden Study. RASIMCAN MERAL, ANDRES DIGENIO, ADAM H. NEIDERT, JOSEPH TAMI, ELIF A. ORAL, ON BEHALF OF THE BROADEN STUDY INVESTIGATORS, Ann Arbor, MI, Cambridge, MA, Carlsbad, CA

624-P Effects of Gly-LDL on LRP5/DKK1 Pathway in MC3T3-E1 Osteoblasts. TAO LEI, LIN CHEN, BINGYU ZHANG, WENJUN TANG, Shanghai, China

625-P Effect of Ezetimibe Add-On Therapy on Non-HDL-C in Type 2 Diabetes Subjects—A Post-Hoc Analysis of RESEARCH Study. KENTARO SAKAMOTO, MITSUNOBU KAWAMURA, YASUMICHI MORI, TERUO SHIBA, RESEARCH STUDY GROUP, Tokyo, Japan

626-P Analysis of the Association between PCSK9 Levels and Plasma Lipid Levels in Cameroonians with Type 2 Diabetes. CAMILLE B.M. MBA, WILFRED F. MBACHAM, JEAN CLAUDE MBANYA, Yaoundé, Cameroon

627-P Enhancement of Insulin Sensitivity Contributes to Polychlorinated Biphenyl-126-Induced Hepatic Steatosis and Injury. XIN WANG, SR., XI’AN, China
FOOT CARE—LOWER EXTREMITIES

Moderated Poster Discussion: Stepping Forward on the Diabetic Foot (Posters: 630-P to 635-P), see page 157.

630-P Insulin or Metformin for Glucose Control during Wound Healing in Diabetes? BEATA MROZIKIEWICZ-RAKOWSKA, MATEUSZ MIECZKOWSKI, TOMASZ SIWKO, MAGDALENA BUJALSKA-ZADROZNY, TOMASZ GRZELA, RENATA WOLINSKA, ANNA E. DE CORDE, PIOTR FOLTYNSKI, LESZEK CZUPRYNIAK, Warsaw, Poland

631-P Depression and Anxiety Associated with Complications after Foot and Ankle Surgery in Diabetic Patients—Comparison with a Nondiabetic Population. KRISTIN KIRBY, KIMBERLEE HOBIZAL, RENEE SHEPHERD, TRESA WIZE, Beaver, PA

632-P 3D Microstructural Fiber Tracking of the Human Calf Muscles in Individuals With and Without Type 2 Diabetes during Rest and Exercise. MOHAMMAD EDALATI, CHRISTOPHER J. SORENSEN, MARY HASTINGS, MOHAMED A. ZAYED, MICHAEL J. MUELLER, JIE ZHENG, St. Louis, MO

633-P Renal Function as a Predictor of Reamputation after Initial Transmetatarsal Amputation in the Perioperative Period—An ACS-NSQIP Study. JUNHO AHN, KATHERINE M. RASPOVIC, TRAPPER LALLI, GEORGE T. LIU, MICHAEL D. VANPELT, DANE WUKICH III, Dallas, TX

634-P Critical Regulation of Angiogenesis by Nrf2 Signaling Is Absent in Diabetic Wound Healing. PIUL S. RABBANI, JOSHUA A. DAVID, DARREN L. SULTAN, ALVARO P. VILLARREAL-PONCE, JENNIFER KWONG, JASMINE LEE, CHEN SHEN, SALMA A. ABDOU, DANIEL CERADINI, New York, NY

635-P Comparison of Microbiological Results of Two Bone Sampling Methods in Diabetic Foot Osteomyelitis—Debridement vs. Operation. MENGCHEN ZOU, PING HU, YANLING PAN, XANGRONG LUO, YA JIANG, YAO-MING XUE, YING CAO, FANG GAO, Guangzhou, China

636-P Feasibility of Creating a Diagnosis-Based Diabetic Foot Registry in a Large Health Care Provider. AVIVIT CAHN, TALYA ALTARAS, TAL AGAMI, SR., ORI LIRAN, COLETTE E. TOUATY, RENA POLLACK, ITA-MAR RAZ, GABRIEL CHODICK, INBAR ZUCKER, Jerusalem, Israel, Rehovot, Israel, Modiin, Israel, Tel Aviv, Israel, Ramat Gan, Israel

637-P Incidence and Risk Factors for Amputation in Patients with Diabetes in Japan—Historical Cohort Study Using a Nationwide Claims Database. MASANORI KANEKO, KAZUYA FUJIHARA, MASAHIKO YAMAMOTO, MASARU KITAZAWA, MASAHIRO ISHIZAWA, TAEKO OSAWA, MAYUKO HARADA, YASUHIRO MATSUBAYASHI, TAKAHO YAMADA, HIROHITO SONE, Niigata, Japan

638-P The Leucopatch® System in the Management of Hard-to-Heal Diabetic Foot Ulcers—A Multi-centre, Multinational, Observer-Blinded, Randomised Controlled Trial. FRANCES GAME, WILLIAM JEFFCOATE, LISE TARNOW, JUDITH L. JACOBSEN, DIANE J. WHITHAM, ELEANOR F. HARRISON, SHARON J. ELLENBERGER, MAGNUS LONDAHL, Derby, United Kingdom, Nottingham, United Kingdom, Hillerød, Denmark, Kokkedal, Denmark, Lund, Sweden

639-P Gender and Risk of Cardiovacular Events in Patients with Diabetic Foot. ROBERTO ANICHINI, LAURA POLICARDO, PAOLO FRANCESCONI, PIERGIORGIO FRANCIA, ALESSANDRA DE BELLIS, MASSIMO GULISANO, GIUSEPPE SEGHERI, Pistoia, Italy, Florence, Italy

640-P Microstructure Dysfunction May Be More Severe in Diabetes than in Peripheral Arterial Disease—a M111 Diffusion Tensor Imaging Study. MOHAMMAD EDALATI, CHRISTOPHER J. SORENSEN, MARY HASTINGS, MOHAMED A. ZAYED, MICHAEL J. MUELLER, JIE ZHENG, St. Louis, MO

641-P Cortisol Synthesis Enzyme CYP11B1 as Tissue Biomarker for Diabetic Foot Ulcers. LORETTA VILEIKYTE, BIING-JUIN SHEN, IRENA PASTAR, ANDREW J.M. BOULTON, ROBERT KIRSNER, MARJANA TOMIC-CANIC, MATTHEW HARDMAN, Manchester, United Kingdom, Singapore, Singapore, Miami, FL, Hull, United Kingdom

642-P The Roles of NLRP3 Inflammasome and ADAR1 in Diabetic Foot Ulcer. FANG WANG, LILING ZHAO, WENJUN YANG, HONGHUI HE, ZHAOHUI MO, Changsha, China

643-P Study on the Effect of Cerium Oxide Nanocubes on Full-Thickness Cutaneous Wound Healing of Type 2 Diabetic Rats. YANFEI HAN, LINDONG LI, YANJUN LIU, YOU WANG, CHUNHUA YAN, LINGDONG SUN, Peking, China, Beijing, China
644‑P Keap1‑Mediated Nrf2 Dysfunction as a Source of Oxidative Damage in Human Diabetic Wounds. JOSHUA A. DAVID, ALVARO P. VILLARREAL‑PONCE, SALMA A. ABDOU, DARREN L. SULTAN, WILLIAM J. RIFKIN, JENNIFER KWONG, PIUL S. RABBANI, DANIEL CERADINI, New York, NY

645‑P Diabetes Foot Wound Healing—A Collaborative Approach. JACQUELINE N. MCNULTY, BRANDON J. LEWIS, JAVIER LA FONTAINE, APRIL ROSE, MIRIAM GOMEZ, LUIGI MENEGHINI, UMA GUNASEKARAN, MARIA S. RUÍZ, Dallas, TX

646‑P Osteomyelitis and Neuropathic Ulcers in Forefoot—Amputation Is the Only Surgical Intervention Resolving? DIMITRIOS SKOUTAS, FARES SAYEGH, SYMEON METALLIDIS, SOKRATIS SGOUTZAKOS, IOANNIS KATSANOS, STAMATA GEORGA, ATHANASIOS NIKOLAIDIS, SR., LOUKAS DOUKAS, JR., ELENA MATOPOULOU, SOLOMON TESFAYE, CHRISTOS MANES, GLYKERIA TZATZAGOU, Thessaloniki, Greece, Sheffield, United Kingdom

647‑P Single Cell RNA‑Seq Analyses of Healthy Lower Extremity Skin and Diabetic Foot Ulcers Uncover Distinct Immune Landscape of Diabetic Wound Healing. GEORGIOS THEOCHARIDIS, SWATI S. BHASIN, KONSTANTINOS KOUNAS, MANOJ K. BHASIN, ARISTIDIS VEVES, Boston, MA

DIABETES EDUCATION

Moderated Poster Discussion: Implementing Best Practices and Innovative Interventions into Diabetes Self‑Management Education and Support (Posters: 648‑P to 653‑P), see page 90.

648‑P Evaluating Evidence‑Based Strategies to Build and Support Lifestyle Change Programs for People at High Risk for Type 2 Diabetes. YVONNE MENSA‑WILMOT, SHELLY‑ANN BOWEN, ROSS I. BROWN, TIMÉTHIA BONNER, KIMBERLY D. FARRIS, GIA E. RUTLEDGE, Atlanta, GA

649‑P Bridging the Gap of Diabetes Education—The IDF School of Diabetes. SAMEER PATHAN, ANNE WIEBKE OHLROGGE, BELMA MALANDA, ELS SUNG, LORENZO PIEMONTE, Brussels, Belgium

650‑P Diabetes Self‑Management Education via Telemedicine in the United States Air Force. NINA WATSON, DORIS G. ACUNA, JANA L. WARDIAN, ELLEN C. COBB, DAVID BEAVERS, TOM J. SAUERWEIN, San Antonio, TX, Universal City, TX

651‑P Employee Health: Diabetes Self‑Management with Wireless Meter. JOHN BRUCH, MICHELLE D. STANCI, JESSICA M. ODOM, BRYCE A. NELSON, LINDSAY S. REULBACH, REBECCA RUSS‑SELLERS, ALYSON GHIZZONI BURNS, MAINE R. LINDHOLM, JONDA DAWSON, NATHAN A. SCHWECKE, Greenville, SC

652‑P Diabetes Knowledge and Numeracy among Under‑ or Uninsured Latinos with Type 2 Diabetes. YA‑CHING HUANG, ALEXANDRA A. GARCIA, JULIE A. ZUNIGA, Austin, TX

653‑P Tu Puedes—An Exploratory Usability Pilot of a Postpartum Education “App” for Latina Women with Previous Gestational Diabetes. KRISTIN CASTORINO, SILVIA ALVAREZ, HANNAH M. MATHERS, ARIANNA J. LAREZ, CEARA AXELROD, Santa Barbara, CA

Moderated Poster Discussion: Targeting People and Educational Barriers to Improve Outcomes (Posters: 654‑P to 659‑P), see page 92.

654‑P Barriers and Facilitators to Perceived Diabetes Self‑Management in Arab Americans with Diabetes. DANA EL MASRI, GRETCHEN PIATT, NIKOLAS J. KOSCIELNIAK, LINDA JABEL, Detroit, MI, Ann Arbor, MI

655‑P Results of a Culturally Tailored Multidisciplinary Intervention on Diabetes Self‑Care and Glycemic Outcome in Lebanese Patients with Type 2 Diabetes. OLA SUKKARIEH‑HARATY, MAYA BASSIL, LEONARD E. EGEDE, Byblos, Lebanon, Beirut, Lebanon, Milwaukee, WI

656‑P Can Practice Redesign Improve Diabetes Self‑Management Education (DSME) Referrals? JODI KRALL, JUSTIN KANTER, VINCENT C. ARENA, KRISTINE RUPPERT, FRANCIS X. SOLANO, JR., LINDA M. SIMINERIO, Pittsburgh, PA

657‑P Parents with Type 1 Diabetes—Children’s Role in Self‑Management. JODI KRALL, VICKI HELGESON, MEREDITH VAN VLEET, EUNJIN LEE, MARYJANE SIMMS, MARY T. KORYTKOWSKI, CYNTHIA BERG, Pittsburgh, PA, Salt Lake City, UT
658-P<br>Diabetes Self-Management Education Program Effect on Glycemic Control and Insulin Dosing in Poor Diabetes Literacy Patients from Urban Areas in Mexico City—Therapeutic Education Underuse and Insulin Overuse. RUBÉN SILVA-TINOCA, DANIELA G. MEZA, DAVID GARCIA MARTINEZ, JAVIER OROZCO, MARÍA ELENA ROMERO-IBARGUENGOTÍA, VIRIDIANA A. DE LA TORRE-SALDAÑ, JESÚS A. RAMOS GARCÍA, MARÍA C. DOLORES, ENEDINA TERESA CUATECONTZI, Mexico City, Mexico

659-P<br>Combining Insulin and Incretins in T2DM Management—Effect of Case-Based Online Education on Physician Knowledge and Competence.<br>ROTEM, ILAN GOFER, EFRAT SHADMI, CALANIT KEY, NOMY LEVIN-IAINA, ALENA STRIZEK, BECCA S. FELDMAN, VICI, MAYA LEVENTER-ROBERTS, BRADLEY CURTIS, XUANYAO HE, AMICHAY AKRIV, MOSHE B. HOSHEN, MINA ROTEM, ILAN GOFER, EFRAT SHADMI, CALANIT KEY, NØMY LEVIN-IAINA, ALENA STRIZEK, BECCA S. FELDMAN, Haifa, Israel, Tel Aviv, Israel, Sydney, Australia, Indianapolis, IN, Rishon Le Zion, Israel, Raanana, Israel

660-P<br>Promoters of and Barriers to Engagement in Type 2 Diabetes Mellitus (T2DM) Populations with Real-World Technological Interventions. KEVIN R. DUVALL, ANJALI TRASY, ERIN MURRAY, ROBERT MILAM, TOBIAS SAYRE, ANNE C. BEAL, Bridgewater, NJ, Santa Monica, CA

661-P<br>Multidisciplinary Predialysis Team Education for Patients with Diabetic Nephropathy Reduced Cost for Admission at the Induction of Hemodialysis, and Subsequent Mortality. MAMIKO HITOMI, TERUKO SATO, TATSUMI MORIYA, Sagamihara, Japan, Tokyo, Japan

662-P<br>Type 1 Diabetes—The Comic Book. MAYANK B. PATEL, PARTHA KAR, DANIEL G. MCLAUGHLIN, Southampton, United Kingdom, Cosham, United Kingdom, Denry, United Kingdom

663-P<br>The Use of Quality Improvement Continuing Medical Education to Improve the Evaluation of Diabetic Retinopathy. KATIE ROBINSON, ROBERT A. ESgro, Thornofare, NJ

664-P<br>Feasibility of Mother-Daughter Dysgical Gestational Diabetes (GDM) Risk Reduction Intervention for American Indian and Alaska Native (AIAN) Teens. KELLY R. MOORE, SARAH A. STOTZ, KRISTEN J. NADEAU, SUSAN M. SERREIKA, YESENIA GARCIA REYES, HOWARD R. STEIN, DENISE CHARRON-PROCHOWNIK, Aurora, CO, Pittsburgh, PA

665-P<br>An Evaluation of the Diabetes Conversation Map Program—Health Outcomes and Health Care Utilization during a Four-Year Follow-Up. EIAV SRULOVICI, MAYA LEVENTER-ROBERTS, BRADLEY CURTIS, XUANYAO HE, MOSHE B. HOSHEN, MINA ROTEM, ILAN GOFER, EFRAT SHADMI, CALANIT KEY, NØMY LEVIN-IAINA, ALENA STRIZEK, BECCA S. FELDMAN, Haifa, Israel, Tel Aviv, Israel, Sydney, Australia, Indianapolis, IN, Rishon Le Zion, Israel, Raanana, Israel

666-P<br>An Evaluation of the Diabetes Conversation Map™ Program—Are Program Factors Associated with Health Outcomes and Health Care Utilization at 12 Months Post-Enrollment? EIAV SRULOVICI, MAYA LEVENTER-ROBERTS, BRADLEY CURTIS, XUANYAO HE, AMICHAY AKRIV, MOSHE B. HOSHEN, MINA ROTEM, ILAN GOFER, EFRAT SHADMI, CALANIT KEY, NØMY LEVIN-IAINA, ALENA STRIZEK, BECCA S. FELDMAN, Haifa, Israel, Tel Aviv, Israel, Sydney, Australia, Indianapolis, IN, Rishon Le Zion, Israel, Raanana, Israel

667-P<br>Digging Deep into Glycemic Control in Diabetic Patients in a Resident-Run Clinic. SARA HAWATMEH, MAGGIE MEIER, OSMAN QAIYUM, MUHAMMAD FARHAN ASGHAR, AMIR TALEBIAN, HARINDERJEET KAUR, RAMZA HAQUE, RAJAT SHAILLY, HAMEEM KAWSAR, St. Louis, MO, Chesterfield, MO

668-P<br>Novel Insulins and Fixed-Ratio Combinations—Effect of Case-Based Online Education on Physician Knowledge and Competence. ATHENA PHILIS-TSIMIKAS, GILLIAN A. GRIFFITH, JOACHIM TRIER, San Diego, CA, Edinburgh, United Kingdom, New York, NY

669-P<br>Combining Insulin and Incretins in T2DM Management—Effect of Online Education on Physician Knowledge and Competence. JOACHIM TRIER, ROBERT F. MCCARTHY, STEPHEN COLAGIURI, New York, NY, Camperdown, Australia

670-P<br>Ocho Pasos a la Buena Salud (Eight Steps to Better Health)—A Diabetes Education Program for Low-Literacy Latinos With or at Risk for Type 2 Diabetes (T2D). JAMIE CREASON, MARY M. CONNEELEY, CEARA AXELROD, WENDY C. BEVIER, JENIFER SWARTZENTRUBER, DAVID KERR, India, Bad Mergentheim, Germany

671-P<br>More Patients with Optimal Glycemic Control after Participation in a CSII-Specific Education Program (INPUT)—Results from a Randomized Controlled Study. BERNHARD KULZER, DOMINIC EHRMANN, MELANIE SCHIFFER, BERNHARD LIPPIMANN-GROB, THOMAS HAAK, NORBERT HERMANNS, Bad Mergentheim, Germany

---

Moderated Poster Discussion poster 219
672-P  Marketing and Communication Strategies to Increase Enrollment in National Diabetes Prevention Program—Implications for Evaluation of Technical Assistance. YVONNE MENSA-WILMOT, SHELLY-ANN BOWEN, SHARANYA THUMMALAPALLY, MONICA D. MURPHY, GIA E. RUTLEDGE, Atlanta, GA

673-P  Novel Approach to Sarcopenia in Diabetic Patients Treated with GLP-1 Receptor Agonists (GLP-1RA). SHIN IKEJIMA, SEIYA KONDO, TAKENORI SAKAI, HISANORI TANAI, TOMOMI TAKAHASHI, JUNKO UMEZU, MAMI ISEKA, MAYA INOUE, HARUMI NISHIHARA, KAZUYA MURATA, AIZAN HIRAI, Odate, Japan, Usuki, Japan, Yawatahama, Japan, Yurihonjo, Japan, Tokyo, Japan, Minano, Japan, Tsukuba, Japan, Ichihara, Japan, Ise, Japan

674-P  The Impact of Lifestyle Intervention on Stage of Change toward Healthy Eating and Development of Diabetes in Prediabetic Individuals in Precontemplation Stage. NAOKI SAKANE, SHIN-SUKE NIRENGI, KAORU TAKAHASHI, AKIKO SUGANUMA, KENTARO OKAZAKI, KAZUO IZUMI, MITSUHIKO NODA, HIDESHI KUZUYA, Kyoto, Japan, Nagoya, Japan, Tokyo, Japan, Saitama, Japan

675-P  Weight Loss among Adults with Type 2 Diabetes Participating in the Diabetes Prevention Program. DOROTA CARPENEDO, SARAH M. BROKAW, SONJA TYSK, JESSIE FERNANDES, STEVEN D. HELGERSON, TODD S. HARWELL, MONTANA DIABETES PREVENTION PROGRAM STUDY GROUP, Helena, MT, Seattle, WA

676-P  Weight Loss Achieved by Participants with Hypertension/Elevated Blood Pressure in a Diabetes Prevention Program. SARAH M. BROKAW, DOROTA CARPENEDO, SONJA TYSK, JESSIE FERNANDES, STEVEN D. HELGERSON, TODD S. HARWELL, MONTANA DIABETES PREVENTION PROGRAM STUDY GROUP, Helena, MT, Seattle, WA


679-P  The Alarming Inadequacy of Adult Vaccination—Vaccination Rates in Diabetic Patients. GÜNEŞ FEYIZOĞLU, ASLI KARSLI, AYTEKIN ÖGUZ, Istanbul, Turkey

680-P  The Influence of Outpatients’ Wait Times and Health Care Professionals’ Communication Behaviors on Treatment Satisfaction and the Intention to Drop Out. SHIHIRO SATO, TAKAHIRO TOSAKI, CHIE OSIRO, AYAE KUDARA, AKEMI INAGAKI, MASAKI KONDO, SHIN TSUNEKAWA, YOSHIRO KATO, HIDEKI KAMIYA, JIRO NAKAMURA, Nagoya, Japan, Nagakute, Japan

681-P  Diabetes Self-Management Education (DSME) and Diabetes Preventive Care Practices among People With and Without Vision Impairment. SWATHI SEKAR, ROBERT B. GERZOFF, JINAN B. SAAD-DINE, MAGON M. SAUNDERS, Atlanta, GA

682-P  Provider Experience Drives Clinical Decision Making in T2DM—Insights from Realistic Training Simulations. KATIE ROBINSON, ROBERT A. ESGRO, DOUGLAS SEIFERT, Thorofare, NJ, Exton, PA

683-P  Results from the First Culturally Tailored, Multidisciplinary Diabetes Education in Lebanon—Effect on Cardiovascular Risk Factors. MAYA BASSIL, OLA SUKKARIEH-HARATY, JOELLE L. ABI KHARMA, LEONARD E. EGGEDE, Beirut, Lebanon, Byblos, Lebanon, Milwaukee, WI

684-P  HCP and Patient Perspectives on Basal Insulin Titration. CHIOMA UZOIGWE-SMITH, MARGARITA LEVIN, DOUGLAS B. PFAFF, MICHELLE MOCARSKI, CAROL M. HAMERSKY, WILLIAM POLONSKY, Plainsboro, NJ, New York, NY, Del Mar, CA

685-P  Are Complications Preventable with Periodic Education via Telemedicine? A Study of 414 Compliant T2D Patients Followed Up for 19 Years. JOTHYDEV KESAVADEV, ARUN SHANKAR, ASHWIN DAVID, GOPIKA KRISHNAN, NEETHU A. AJAJI, GEETHU SANAL, JAYSREE AJITH, SOUMYA JAYANTHI, LAKSHMY RAMACHANDRAN, SUNITHA JOTHYDEV, Trivandrum, India, Kochi, India

687-P Interdisciplinary Educational Structured Diabetes Program Effect on Health-Related Quality of Life and Anxiety/Depression Perception in Patients Attending a Primary Care Diabetes Clinic in Mexico City. RUBÉN SILVA-TINOCO, ENEDINA TERESA CUATECONTZI, AMAYRANI GÓMEZ ALONSO, MARIA ELENA ROMERO-IBARGUENGUITA, VIRIDIANA A. DE LA TORRE-SALDAÑ, MARIA DOLORES D. CABRERA-GERARDO, EILEEN B. GUZMÁN OLVERA, ENRIQUE GONZÁLEZ, DANIELA G. MEZA, Mexico City, Mexico

688-P Virtual Simulation Improves Clinical Decision-Making in Managing Type 2 Diabetes. AMY LARKIN, KELLY L. HANLEY, MARTIN WARTERS, GWEN S. LITTMAN, New York, NY, Durham, NC

689-P The Impact of Restricted Gestational Weight Gain on Fetal Growth during Dietary Treatment in Women with Gestational Diabetes Mellitus. LISE KURTZHALS, SIDSE NØRGAARD, HELLE RONNEBY, ANNA L. SECHER, ANN TABOR, H. DAVID MCINTYRE, PETER DAMM, ELISABETH R. MATHIESEN, Copenhagen, Denmark, South Brisbane, Australia

690-P Evaluating the Effect That Diabetes Education Has on Acute-Care Nurses’ Knowledge Level. JACKIE KUCHTA, Sioux City, IA

691-P Durability of Glycemic Control in a Diabetes Education Insurer-Based Intervention in Primary Care. MARGARET ZUPA, VINCENT C. ARENA, MARGARET B. THEARLE, PATRICIA A. JOHNSON, LINDA M. SIMINERIO, Pittsburgh, PA

692-P User Experience with a New Smartphone Application for Blood Glucose Monitoring (BGM) in an Information-Motivation-Behavioral Skills (IMB) Model Study. WILLIAM FISHER, ANDREAS STUHR, JANE WALLACE, SERGEY ZHUPLATOV, TIMOTHY S. BAILEY, SCOTT PARDO, London, ON, Canada, Parsippany, NJ, Escondido, CA

693-P Impact of Certified Diabetes Educators following Preapproved Protocols on Diabetes Self-Care Behaviors—Results of the REMEDIES 4D Trial. KRY S. M. JOHNSON, MARKKU MALMI, JR., SHIH-CHEN KUO, JANICE C. ZGIBOR, Tampa, FL, Lutz, FL, Ann Arbor, MI

694-P Evidence-Based Interventions to Control Diabetes by Local Health Departments in the United States. RACHEL G. TABAK, RENEE G. PARKS, PEG M. ALLEN, REBEKAH R. JACOB, STEPHANIE MAZZUCCA, KATHERINE STAMATAKIS, MARSHALL CHIN, ROSS BROWNSON, St. Louis, MO, Chicago, IL

695-P National Snapshot of State Health Department Outcomes and Lessons Learned from Implementing Diabetes Self-Management Education and Support Programs and National Diabetes Prevention Programs. GIA E. RUTLEDGE, MEENU ANAND, YVONNE MENSA-WILMOT, Atlanta, GA

696-P Assessing the Evaluability of Type 2 Diabetes Prevention and Diabetes Management Interventions Focusing on Underserved Populations. KIMBERLY D. FARRIS, TIMETHIA BONNER, GIA E. RUTLEDGE, BRYCE SMITH, Atlanta, GA

697-P Free Weight-Loss Apps and Diabetes Management for the Patient. GLORIA WU, LAURA BILLARD, VY-VY NGO, AMY DOAN, ELENA MURO, BRYAN LE, San Francisco, CA, Santa Barbara, CA, Irvine, CA, Davis, CA, Tampa, FL, San Diego, CA

698-P Cardiovascular Disease (CVD) Decision Aid for Youth with Type 1 Diabetes (T1DM)—Perspectives of Health Care Providers (HCPs) with Pediatric-Onset T1DM. JODI KRALL, INGRID LIBMAN, SAMINA AFREEN, LINDA M. SIMINERIO, Pittsburgh, PA

699-P Training Nursing Staff to Improve Diabetes Care for Long-Term Care Facility (LTCF) Residents. ABEGAIL L. HUBBERD, CHRISTINA M. HERNANDEZ, San Antonio, TX

700-P An Interdisciplinary Team Approach to Managing Diabetes in a Patient-Centered Medical Home. STEVEN M. LAMIE, JANET C. BAILLOD, STUART D. ROCKAFELLOW, MARYLIN B. GIBBS, DEBRA SCHEPPERLY, Traverse City, MI

701-P Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). HUI SHAO, SHUANG YANG, VIVIAN FONSECA, XU JI, LIZHENG SHI, New Orleans, LA, Atlanta, GA

702-P You Can Build It, and They Will Come—Working with Industry Allies to Build Successful Continuing Education Programs for Your Hospital. KELLIE ANTINORI-LENT, JOANNE F. TURKA, KATHRYN HAWKINS, Pittsburgh, PA, McDonald, PA
703-P Cost-Effectiveness of Diabetes Self-Management Education and Support in the Community—
Projections from a Randomized Controlled Trial. GRETCHEN PIATT, WEN YE, SHIHCHEN KUO, BRANDY R.
SINCO, WILLIAM H. HERMAN, MICHAEL S. SPENCER, GLORIA PALMISANO, MICHELE HEISLER, EDITH C.
KIEFFER, Ann Arbor, MI, Detroit, MI

704-P Introduction of a Web-Based Computerized Personal Diabetes Educational System. KWANG-
WEN CHEN, YUH-JUE CHUANG, CHAO KUN LIU, YU-YEN CHIU, HAN-YI LIN, JR., Taoyuan, Taiwan, Taipei, Taiwan

705-P The Efficacy of Registered Dietitian Interventions in Type 2 Diabetes Management in a Family
Practice Clinic in North Alabama. BRITTANNIE H. CHESTER, WAYNE G. STANLEY, GEETHA THANGIAH,
Auburn, AL, Florence, AL

706-P Virtual Education for Older Adults with Type 2 Diabetes during Transitions. CHRISTINA R. WHITE-
HOUSE, JUDITH A. LONG, LORI MCLEER MALONEY, DAVID A. HOROWITZ, KATHRYN BOWLES, Philadelphia, PA

707-P Younger Patients with Type 2 Diabetes Have Poorer Self-Care Practices Compared with Older
Patients—Results from the Australian National Diabetes Audit. NATALIE NANAYAKKARA,
ANTHONY J. PEASE, SANJEEVA RANASINHA, NATALIE WISCHER, BARBORA DE COURTEN, SOPHIA ZOUNGAS,
Melbourne, Australia, Clayton, Australia, Ghin Ghin, Australia

708-P Implementation and Evaluation of Gestational Diabetes Management Using Mobile Health
Care Service—A Pilot Study. MINKYUNG LEE, CHEOL-YOUNG PARK, SUNG-WOO PARK, DA YOUNG LEE,
JI-HEE SUNG, Gyeonggi, Republic of Korea, Seoul, Republic of Korea

709-P Factors Associated with Medication Adherence among Type 2 Diabetes Mellitus Patients in
Nepal. PUSHPAJALI SHAKYA, BIRAJ M. KARMACHARYA, ARCHANA SHRESTHA, BAARD E. KULSENG,
Dhulikhel, Nepal, Boston, MA, Trondheim, Norway

710-P Insulin Titration Algorithms Incorporated into a Patient Glucose Profile Result in Significant
Improvements in Glucose Profiles and A1C. MARY L. JOHNSON, DARLENE M. DREON, BRIAN L. LEVY,
RICHARD M. BERGENSTAL, Minneapolis, MN, Menlo Park, CA, Wayne, PA

711-P Dietary Education via Teacher-Diabetologist Cooperation. SHIZUKA KANEKO, YUMI ONOGI, RYOKO
MICHIBATA, Takatsuki, Japan, Ikeda, Japan

712-P The Role of Diabetes Educators in Reduction the Risk of Hypoglycemia in Type 1 Patients dur-
ing Fasting Ramadan. SAHAR MOURAD, Kuwait City, Kuwait

713-P What Is Deterring DSME Service? Perspectives of Diabetes Educators. LINDA M. SIMINERIO,
MEGAN HAMM, JODI KRALL, Pittsburgh, PA

714-P Atypical Antipsychotics and Metabolic Complications. MUNAZA AKUNJEE, SHRUTI M. GANDHI,
ERIC NYLEN, Washington, DC

715-P Use of Continuous Glucose Monitoring during Dose Adjustment for Normal Eating Course
Favors the Emergence of Positive Patient-Provider Language Code. MARCELO DOS SANTOS
MAMED, GIACOMO GASTALDI, SR., Lausanne, Switzerland, Geneva, Switzerland

716-P Rapid Improvement of Metabolic Control in Type 1 Diabetes after Transition from Paediatic
Clinics to an Adult Diabetes Center. ANNA RITA MAURIZI, SILVIA PIERALICE, DARIO TUCINARDI, CHI-
ARA GUGLIELMI, ANGELO LAURIA, ERNESTO MADDALONI, ELVIRA FIORITI, SILVIA MANFRINI, PAOLO POZZILLI,
Rome, Italy

717-P Medical Student Knowledge of Current Recommendations for Glucose Screening and Obesity-
Related Risk Assessment in Children. EMILY H. GUSEMAN, JONATHON WHIPPS, LAURA L. JENSEN,
ELIZABETH A. BEVERLY, Athens, OH

718-P Collaborative Formative Evaluation for Implementation of Primary Care-Based Peer Support in
the Shanghai Integration Model. MUCHIEH M. COUFAL, PATRICK Y. TANG, EDWIN B. FISHER, WEIPING
JIA, Plano, TX, Chapel Hill, NC, Shanghai, China

719-P “It Was All Trial and Error”—The Perspective of Parents of Emerging Adults with Type 1 Dia-
betes during the Transition to Independence. ANASTASIA ALBANESE-O’NEILL, SARAH C. WESTEN,
NICOLE T. THOMAS, MICHAEL J. HALLER, DESMOND SCHATZ, Gainesville, FL, Orlando, FL
720-P: Findings from a Diabetes Support Group—A Pilot Study. LORI MCLEER MALONEY, JEREMY FLOOD, NAJI ALAMUDDIN, MONA AL MUKADDAM, Philadelphia, PA

721-P: Narrative Medicine in Diabetes—A Randomized Trial. FRANCISCO ROSÁRIO, SR., ISABEL CORREIA, JORGE OLIVEIRA, JOAO RAPOSO, Lisbon, Portugal

722-P: Prevalence of Impaired Glucose Tolerance in Adolescent Patients with Polycystic Ovary Syndrome in an Urban Health Care Center. JYOTSNA GUPTA, ZOLTAN ANTAL, MARISA CENSAI, New York, NY

723-P: Adherence to Insulin Therapy Assistance Program (iTAP) among Indian Type 2 Diabetes Mellitus (T2DM) Patients. PRAVEEN RAJ, DILIP PAWAR, SARAH JABEEN, SHIVARAM VS, Bangalore, India

724-P: Examining the Association between Treatment Satisfaction and Medication Adherence among Patients with Poorly Controlled Type 2 Diabetes. NNADOZIE EMEECHEBE, NGOZICHUKWUKA AGU, MARKKU MALMI, JR., JANICE C. ZGIBOR, Tampa, FL

725-P: The Prevalence of Impaired Glucose Tolerance in Adolescent Patients with Polycystic Ovary Syndrome in an Urban Health Care Center. JYOTSNA GUPTA, ZOLTAN ANTAL, MARISA CENSAI, New York, NY

726-P: Adherence to Insulin Therapy Assistance Program (iTAP) among Indian Type 2 Diabetes Mellitus (T2DM) Patients. PRAVEEN RAJ, DILIP PAWAR, SARAH JABEEN, SHIVARAM VS, Bangalore, India

727-P: Exploring the Type 2 Diabetes Mellitus Experience from the Patient Perspective. KRISTINA YU-ISENBERG, GEOF D. GRAY, CATHERINE FOLEY, JONATHAN T. STOKES, ALAN SHIELDS, GAVIN DICKIE, ROGER LAMOUREUX, CLARK V. JACKSON, BRAD PADILLA, WILLIAM POLONSKY, Boston, MA, Surabaya, Indonesia, Del Mar, CA

728-P: Patient Perspectives on the Burden of Type 2 Diabetes Mellitus Treatment. KRISTINA YU-ISENBERG, GEOF D. GRAY, CATHERINE FOLEY, JONATHAN T. STOKES, ALAN SHIELDS, GAVIN DICKIE, ROGER LAMOUREUX, CLARK V. JACKSON, BRAD PADILLA, WILLIAM POLONSKY, Boston, MA, Surabaya, Indonesia, Del Mar, CA

729-P: Effect of Preadmission Diabetes Intervention (PREHAB) on Postoperative Patient Outcomes in Cardiac Surgery. AMEL ARNAOUT, SANDHYA GOGE, Ottawa, ON, Canada

720-P: Exercise Performance Is Not Impaired by Hyperglycemia in Type 1 Diabetes. KAREN ROTHACKER, SAM ARMSTRONG, GRANT J. SMITH, NAT BENJANUVATRA, BRENDAN S. LAY, PAUL A. FOURNIER, PETER ADOLFSSON, TIM JONES, ELIZABETH A. DAVIS, Subiaco, Australia, Crawley, Australia, Kungsbacka, Sweden

731-P: Upregulation of Skeletal Muscle FGF-21 Is Linked to Weight Loss following a Lifestyle Intervention in Humans with Obesity. ANNY MULYA, HUI ZHANG, JOHN P. KIRWAN, Cleveland, OH

732-P: Optimal Insulin Correction Factor (ICF) for Post-exercise Hyperglycemia following High-Intensity Training in Adults with Type 1 Diabetes (T1D)—The FIT Study. RONNIE ARONSON, RUTH E. BROWN, MICHAEL RIDDELL, Toronto, ON, Canada

733-P: Acute Resistance Exercise Improves Postprandial Lipid Metabolism in Men with Obesity and Prediabetes. ADAM BITTEL, DANIEL BITTEL, BRUCE W. PATTERSON, BETTINA MITTENDORFER, WILLIAM T. CADE, St. Louis, MO

734-P: Physically Active Diabetics Report Lower Rates of Impaired Cognitive Function—Findings from the 2012 National Health Interview Survey. ZHUO FU, MATTHEW KOMELSKI, AAKSHAY KUMAR, Charlottesville, VA, Christiansburg, VA

735-P: INHIBITORY EFFECTS OF INTRANASAL INSULIN ADMINISTRATION ON FAT OXIDATION DURING EXERCISE ARE DIMINISHED IN OVERWEIGHT YOUNG INDIVIDUALS. HISAYO YOKOYAMA, RYOSUKE TAKEDA, ERIKAI KAWAI, AKEMI OTA, EMIKO MORITA, DAIIKI IMAI, YUTA SUZUKI, TOMOOAKI MORIOTA, MASANORI EMOTO, MASAAKI INABA, KAZUNOBU OKAZAKI, Osaka, Japan

EXERCISE

Moderated Poster Discussion: Exercise Effects on Human Health (Posters: 730-P to 735-P), see page 125.
737-P Provider Perspectives on Exercise in Children with Type 1 Diabetes. JENIECE ILKOWITZ, MARY PAT GALLAGHER, New York, NY

738-P Predicting Future Glucose Fluctuations Using Machine Learning and Wearable Sensor Data. AMIR HAYERI, West Vancouver, BC, Canada

739-P Identification of >150 Novel Exercise-Regulated Circulating Factors. LESLIE ROWLAND, ROELAND MIDDELBEEK, HUI PAN, JONATHAN DREYFUSS, LAURIE J. GOODYEAR, Boston, MA

740-P Short-Term Aerobic and Interval Training Improves Muscle Mitochondrial Function and Reveals a New Role for an Old Protein. STEPHANIE PARSONS, MARIA F. PINO, ANDREW P. HODGES, FANCHAQ YI, ELVIS A. CARNERO, RICHARD E. PRATLEY, STEVEN R. SMITH, LAUREN M. SPARKS, Orlando, FL, La Jolla, CA

741-P Maintenance of Changes in Glycemic Control and Blood Lipids following 12 Weeks of Underwater Treadmill Training in Adults with Type 2 Diabetes. RYAN T. CONNERS, JOHN M. COONS, DANA K. FULLER, YOUNGDEOK KIM, ROBBIE G. COCHRUM, DON W. MORGAN, Huntsville, AL, Murfreesboro, TN, Lubbock, TX, Nashville, TN

742-P Combination of Canagliflozin and Exercise Training Leads to Lipid-Dependent Energy Expenditure in Skeletal Muscle in Obese Diabetic Mice. KENICHI TANAKA, HIROKAZU TAKAHASHI, KAZUYO SASAKI, KANAKO INOUE, YAYOI MATSUDA, YUICHIRO EGUCHI, KEIZO ANZAI, Saga, Japan, Osaka, Japan

743-P High-Intensity Interval Training and Hypoglycemia Minimization in Adults with Type 1 Diabetes (HIIT HYPO T1D Study). ANGELA S. LEE, KIMBERLEY L. WAY, NATHAN A. JOHNSON, STEPHEN M. TWIGG, Sydney, Australia

744-P Variability and Reproducibility in the Rise in Blood Glucose Levels in Response to High-Intensity Interval Training (HIIT) in Type 1 Diabetes (T1D)—The FIT Reproducibility Study. MICHAEL RIDDELL, RUBIN POONI, RUTH E. BROWN, LOREN YAVELBERG, ZOEY LI, CRAIG KOLLMAN, RONNIE ARONSON, Toronto, ON, Canada, Tampa, FL

745-P Moderate- and High-Intensity Exercise Training Improve “Free-Living” Glycemic Control Independently of Weight Loss. MICHAEL W. SCHLEH, BENJAMIN J. RYAN, JENNA B. GILLEN, ALISON LUDZKI, JEFFREY F. HOROWITZ, Ann Arbor, MI

746-P Constant-Moderate and High-Intensity Interval Training Induce Differential Metabolic Benefits on Insulin-Sensitive Tissues in High-Fat Fed Mice. SERGIO F. MARTINEZ-HUENCHULLAN, LINDA A. BAN, LUISA F. OLAYA, BABU R. MAHARJAN, CHARMAINE TAM, SUSAN MCLENNAN, STEPHEN M. TWIGG, Sydney, Australia

747-P Short Sprints during Exercise Reduce Exercise-Mediated Hypoglycaemia in Type 1 Diabetes in a Real-Life Setting. TARINI CHETTY, HEATHER ROBY, NIRUBASINI PARAMALINGAM, JULIE DART, WAYNE SOON, GRANT J. SMITH, VINUTHA B. SHETTY, PAUL A. FOURNIER, TIM JONES, ELIZABETH A. DAVIS, Perth, Australia

748-P Relationship of Physical Activity Behavior with Insulin Sensitivity over Five Years after Diagnosis of Type 2 Diabetes. DOMINIK PESTA, PAVEL BOBROV, OANA P. ZAHARIA, KÁLMÁN BÓDIS, YAN-ISLAVA KARUSHEVA, DANIEL F. MARKGRAF, VOLKER BURKART, KARSTEN MÜSSIG, KLAUS STRASSBURGER, JULIA SZENDROEDI, MICHAEL RODEN, Düsseldorf, Germany

749-P Exercise Training Alters Sorbin and SH3 Domain Containing 3 DNA Methylation in Human Skeletal Muscle. SAMANTHA E. DAY, LUIS GARCIA, RICHARD L. COLETTA, ELEANNA DEFILIPPIS, LAWRENCE MANDARINO, DAWN K. COLETTA, Phoenix, AZ, Tucson, AZ, Scottsdale, AZ

750-P Conversational Artificial Intelligence for Achieving Activity Targets through Routine Physical Activity—Longitudinal Observational Study among People with Type 2 Diabetes. BRU M. MAKKAR, MAAZ SHAHRI, ABHISHEK SHAH, SHILPA JOSHI, BANSHI D. SABDO, ARAVIND R. SOSALE, SR., SV MADHU, RAJIV KOV, TEJAS SHAH, MANOJ S. CHAWLA, RAJEEV CHHAWLA, JOTHDEV KESAVADEV, Delhi, India, Mumbai, India, Ahmedabad, India, Bangalore, India, New Delhi, India, Trivandrum, India

751-P Predicting Exercise-Related Changes in Glucose in People with Type 1 Diabetes Using Linear Models and Incorporating Knowledge of Prior Exercise. NICHOLE S. TYLER, RAVI REDDY, JOSEPH EL YOUSSEF, JESSICA R. CASTLE, PETER G. JACOBS, Portland, OR
752-P  Branched-Chain Amino Acid (BCAA) Metabolism, Insulin Sensitivity (IS), and Liver Fat Response to Exercise Training in Sedentary Prediabetic and Normoglycemic Men. SINDRE LEE, HANNE L. GULSETH, HELGA REFJEM, TORGRIIM M. LANGLEITE, TORGRIIM HOLEN, JØRGEN JENSEN, CHRISTIAN A. DREVON, KARE I. BIRKELAND, Oslo, Norway

753-P  Improved Metabolic Flexibility Postbreakfast after Exercise Intervention in People with T2DM. ELVIS A. CARNERO, CHRISTOPHER P. BOCK, NATALIE STEPHENS, RICHARD E. PRATLEY, STEVEN R. SMITH, LAUREN M. SPARKS, Orlando, FL, Cambridge, MA

754-P  Two Weeks of Interval vs. Continuous Exercise Training on Endothelial Function in Adults with Prediabetes. STEVEN K. MALIN, NICOLE M. GILBERTSON, NATALIE EICHNER, EMILY M. HEISTON, EUGENE BARRETT, ARTHUR WELTMAN, STEPHANIE L. MILLER, Charlottesville, VA

755-P  Short-Term Interval and Continuous Training Improves Pancreatic β-Cell Function Adjusted for Skeletal Muscle Insulin Resistance in Adults with Prediabetes. MONIQUE E. FRANCOIS, NATALIE EICHNER, NICOLE M. GILBERTSON, EMILY M. HEISTON, EUGENE BARRETT, STEVEN K. MALIN, Charlottesville, VA

756-P  Effect of Exercise on Glycemic Control in Type 1 Diabetes. RAVI REDDY, AMANDA WITTMENBERG, DEBORAH BRANIGAN, KERRI WINTERS-STONE, JESSICA R. CASTLE, JOSEPH EL YOUSSEF, PETER G. JACOBS, Portland, OR

757-P  Two Mechanisms Mediating Enhanced Glucose Tolerance with Regulator of GS Protein 14 Disruption; Increased Exercise Capacity and Increased Brown Adipose Tissue. MARKO OYDANICH, JIE ZHANG, DOROTHY E. VATNER, STEPHEN F. VATNER, Newark, NJ

758-P  Sexual-Dimorphism in Exercise-Induced Beiging and Altered Mitochondrial Function in Inguinal White Adipose Tissue (iWAT) from the Mouse. PASQUALE NIGRO, ROELAND MIDDELBEEK, CHRIS-TIANO R. ALVES, BRENT G. ALBERTSON, LESLIE A. ROWLAND, ANA B. WAGNER, NOAH B. PRINCE, MICHAEL F. HIRSHMAN, LAURIE J. GOODYEAR, Boston, MA

759-P  Two Years Supervised Resistance Training Prevented Diabetes Incidence in People with Prediabetes—A Randomized Control Trial. XIAODAN YUAN, QINGQING LOU, Nanjing, China

NUTRITION—CLINICAL

Moderated Poster Discussion: Nutrition 2018—New Approaches and Practical Realities (Posters: 760-P to 765-P), see page 125.

760-P  Effect of Dairy Consumption and Its Fat Content on Glycemic Control and Cardiovascular Risk Factors in Patients with Type 2 Diabetes—A Randomized Controlled Study. ADHAM MOT-TALIB, JOANNA MITRI, VERONICA SALSBERT, SAHAR ASHRAFZADEH, TAHAN ELSEAYDY, SHAHENA TOMAH, KHALED ALSIBAI, NOOR MAHMOUD, OSAMA HAMDY, Boston, MA

761-P  Comparison of Effects of Low-Carbohydrate Diet and Calorie-Restricted Diet on Nonalco-holic Fatty Liver Disease in Japanese Patients with Type 2 Diabetes. EITA NISHIMORI, SATOSHI OGATA, MOTOJI NAKA, Nagano, Japan

762-P  Dietary Protein Intake Is Not Associated with Progression of Diabetic Nephropathy in Patients without Macroaluminuria. AYUMI KAJI, YOSHITAKA HASHIMOTO, RYOSUKE SAKAI, TAKURO OKAMURA, KOSHIRO YAMAZAKI, MICHIAKI FUKUI, Kyoto, Japan

763-P  Evaluation of Dietary Macronutrients in Adults with Different A1c Levels. OWEN KELLY, JESSICA L. KROK-SCHOEN, MENGJUA LUO, CHRISTOPHER A. TAYLOR, Columbus, OH

764-P  Impact of the ENHANCED (diEtitiaNs Helping pAtieNts CarE for Diabetes) Trial on Optimal Care Outcomes in Adults with Type 2 Diabetes. GRETHEN BENSON, ABBEY SIDEBOTTOM, JOY HAYES, JACKIE L. BOUCHER, MARC VAQUER, MICHAEL D. MIEDEMA, ARTHUR SILLAH, JEFFREY VANWORMER, Minneapolis, MN, Seattle, WA, Marshfield, WI

765-P  Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study—A Contemporary Prediabetes Cohort. ERIN LEBLANC, RICHARD E. PRATLEY, BESS DAWSON-HUGHES, MYRELENE A. STATEN, PATRICIA R. SHEEHAN, MICHAEL R. LEWIS, ANNE L. PETERS, SUN H. KIM, RANEE CHATTERJEE, VANITA ARODA, CHHAVI CHADHA, ANASTASSIADIS PITTAS, Portland, OR, Orlando, FL, Boston, MA, Madison, VA, Burlington, VT, Los Angeles, CA, Stanford, CA, Durham, NC, Hyattsville, MD, Saint Paul, MN
766-P Clinical Study of Astaxanthin on Glucose Tolerance in Nondiabetic Subjects. MASAHARU URAKAZE, CHIKAAKI KOBASHI, YUKIHIRO SATOU, MASATOSHI TAKAGI, KOUICHI SHIGETA, MASAHIRO TOSHIMA, JIRO TAKAHASHI, MITSUNORI NISHIDA, Toyama, Japan

767-P Digital Dietitian—Pilot Study of a Novel Smartphone Application. CHRISTIAN C. FARFAN, CEARA AXELROD, DONNA L. FRASE, ANDREW MACKENZIE, GAL HAROUSH, KRISTIN CASTORINO, Santa Barbara, CA, Goleta, CA

768-P Safer Glycemic Control Using Fructose-Based Enteral Formula—A Randomized Crossover Clinical Trial. MAGALI KUMBIER, CASSIANO TEIXEIRA, LUCAS HELAL, JUSSARA ALMEIDA, Porto Alegre, Brazil

769-P Relationship of Vitamin B12 and Homocysteine Status with Nephropathy and Neuropathy in Metformin-Treated Patients with Type 2 Diabetes. SHIVAJIRAO PATIL, ROMAN PAWLAK, APARNA THOMBARE, RICHARD BARTALO, KRISTIE HICKS, DOYLE M. CUMMINGS, Greenville, NC

770-P Impact of the No-Carrageenan Diet on Glucose Tolerance and Insulin Resistance in Adults with Prediabetes. JOANNE K. TOBACMAN, Chicago, IL

771-P Saccharin Does Not Affect Insulin Resistance in 14 Overweight Adults without Diabetes. KARIN RADHOLM, KENNY KALIN, MARIA WENNBORG, MARK WOODWARD ESQ., FREDRIK BÄCKHED, OLOV ROLANDSSON, Linköping, Sweden, Umeå, Sweden, Oxford, United Kingdom, Gothenburg, Sweden

772-P Effect of High β-Glucan Barley on Postprandial Plasma Glucose Levels in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. MARIKO HIGA, AYANA HASHIMOTO, MOE HAYASAKA, MAI HIJIKATA, AYAMI UEDA, KENZABURU ODA, DAIKU KATO, TAKAMASA YAMAZAKI, Yokohama, Japan

773-P Effect of Reduced Intake of Branched-Chain Amino Acids (BCAA) on Insulin Sensitivity in Type 2 Diabetes. YANISLAVA KARUSHEVA, THERESA VAN GEMERT, MARIE-CHRISTINE SIMON, DANIEL F. MARKGRAF, KLAUS STRASSBURGER, DIETER SCHMOLL, VOLKER BURKART, KARSTEN MÜSSLIG, JULIA SZENDROEDI, MICHAEL RODEN, Düsseldorf, Germany, Bonn, Germany, Frankfurt, Germany

774-P Total Energy Expenditure Evaluated by Doubly Labeled Water Method in Japanese Patients with Diabetes Mellitus—Clinical Evaluation of Energy Requirements in Patients with Diabetes Mellitus (CLEVER-DM) Study. TAKURO OKAMURA, YOSHITAKA HASHIMOTO, RYOSUKE SAKAI, EMI USHIGOME, MASAHIDE HAMAGUCHI, MASAHIRO YAMAZAKI, MICHIAKI FUKUI, Kyoto, Japan

775-P Energy Intake and Energy Expenditure in Japanese Patients with Diabetes Mellitus—Clinical Evaluation of Energy Requirements in Patients with Diabetes Mellitus (CLEVER-DM) Study. KEIKO KONDO, KATSUTARO MORINO, SHIGEHO TANAKA, KAIKU FUSE, AKIKO OHI, MIKA KURISHITA, MASAYA SASAKI, FUMINORI KATSUKAWA, HIROSHI MAEGAWA, Otsu, Japan, Shinjuku, Japan, Shiga, Japan, Yokohama, Japan

776-P Effect of Fiber Intake on Glycemia, Insulin Secretion, and Inflammation in Patients with Type 2 Diabetes. CHI TANG, HUSAM GHANIM, KELLY GREEN, ANTOINE MAKDISSI, MANAV BATRA, AJAY CHAUDHURI, PARESH DANDONA, Ansonia, CT, Buffalo, NY, Williamsburg, NY

777-P Carnosine Supplementation Improves Serum Resistin Concentrations in Overweight or Obese but Otherwise Healthy Sedentary Adults—Results From Randomised Controlled Trial. BARBARA DE TACCHARYY, LEONID FEFERMAN, Chicago, IL

778-P Carnosine Supplementation Reduces Plasma Soluble Transferrin Receptor in Healthy Overweight or Obese Individuals—A Pilot Randomised Trial. BARBARA DE TACCHARYY, LEONID FEFERMAN, BARTOSLAVA SLOVAKIA, Melbourne, Australia, Milan, Italy

779-P Correlations between Serum 25-Hydroxyvitamin D and Pancreatic Islet Function in Type 2 Diabetics. NAN LI, MING CHEN, JIAQI DONG, WENSONG YANG, YANRU WANG, HANG SUN, SHEN QU, Shanghai, China

780-P Increase in Galectin-3 Contributes to Glucose Intolerance and Insulin Resistance following Exposure to the Common Food Additive Carrageenan. JOANNE K. TOBACMAN, SUMIT BHATTACHARYYA, LEONID FEFERMAN, Chicago, IL

American Diabetes Association
Behavioral, Nutrition, Education, Exercise
POSTERS
781-P Dietary Energy Density (DED) Is Significantly Associated with Obesity in Japanese Patients with Type 2 Diabetes Mellitus (T2DM). YASUNAGA TAKEDA, KAZUYA FUJIIHARA, SAKIKO Y. MORIKAWA, CHIKA HÖRKAWA, MARIKO HATTA, DAI ISHI, REIKO HIRASAWA, YOKO YACHI, HIROHITO SONE, Niigata, Japan, Tokushima, Japan, Yamanashi, Japan, Chiba, Japan

782-P Changes of the Bone Metabolism Markers and Body Composition in Nonalcoholic Fatty Liver Disease by the SGLT2 inhibitor. CHIZURU WATANABE, NORIO AKUTA, YOSHIYUKI SUZUKI, MASAHIRO KOBAYASHI, YASUMICHI MORI, HIROMITSU KUMADA, Kanagawa, Japan, Tokyo, Japan

783-P Excess Nicotinamide Induces Reactive Oxygen Species Generation, Insulin Resistance, and Epigenetic Change in Rats and Humans. YIMING ZHOU, NANA CHEN, DA LI, WUPING SUN, SHI-SHENG ZHOU, Boston, MA, Nagoya, Japan, Shenyang, China, Shenzhen, China, Dalian, China

784-P The Effect of Two Isocaloric and Energy-Matched Plant-Based and Processed-Meat Meals on Glucose Metabolism, Gastrointestinal Hormones, and Satiety in Subjects with T2D, Obese Subjects, and Healthy Controls—A Randomized Crossover Study. MARTA KLEMENTOVA, LENKA BELINOVA, MARTIN HALUZIK, RENATA PAVLOVICOVA, MARTIN HILL, TEREZIE PELIKANOVA, HANA KAHLHOVA, Prague, Czech Republic, Washington, DC

785-P Protein-Restricted Diet Is Effective in Decreasing Glycemia, HbA1c, and Cholesterol in Type 2 Diabetic Subjects by the Activation of the GCN2 Pathway. RAFAEL C. FERRAZ, REBECA A. BERALDO, PATRICIA GOMES, MILTON C. FOSS, MARIA CRISTINA FOSS-FREITAS, Ribeirão Preto, Brazil

786-P Baseline Vitamin D as a Surrogate Marker for Type 2 Diabetes Remission and Weight Loss following Sleeve Gastrectomy. ALANOUD ALADEL, MILAN K. PIYA, SAHAR AZHARIAN, MARK CHRISTIAN, VINOD MENON, PHILIP G. MCTERNAN, Coventry, United Kingdom, Sydney, Australia, Nottingham, United Kingdom

787-P Impact of Carbohydrate Intake on Obesity in Japanese Patients with Type 2 Diabetes—An Analysis of the JDCP Registry. SATOSHI MATSUNAGA, HIROHITO SONE, KINSUKE TSUDA, YOSHIHARU OSHIDA, SATOSHI SASAKI, JO SATOH, YASUAKI HAYASHINO, RIMEI NISHIMURA, NAOKO TAJIMA, Niigata, Japan, Sakai, Japan, Nagoya, Japan, Tokyo, Japan, Sendai, Japan, Nara, Japan

788-P WITHDRAWN

789-P Ascorbic Acid Supplementation Improves Postprandial Glucose and Blood Pressure in People with Type 2 Diabetes. SHAUN MASON, BODIL RASMUSSEN, GLENN D. WADLEY, Melbourne, Australia, Burwood, Australia

790-P Effect of Stevia on Glycemic and Insulin Responses in Obese Patients—A Randomized, Double-Blind, Placebo-Controlled Crossover Study. PARINYA SAMAKKARNTHAI, MANAPORN PAYANUNDANA, NATTAPOL SATHAVARODOM, CHONPITI SIRIWAN, APUSANEE BOONYAVARAKUL, Bangkok, Thailand

791-P Effect of a Novel Ficus Carica (Fig) Fruit Extract Standardized in Abscisic Acid on the Glycemic and Insulinemic Responses in Healthy Human Subjects. ANDREA ZANGARA, Mollet del Vallès, Spain

792-P Effect of Resistant Starch on Postprandial Glucose Levels in Sedentary, Abdominally Obese Persons. TONGYU MA, CHONG-DÔ LEE, Phoenix, AZ

793-P Contribution of Eating Behaviours to Glycemic Dysmetabolism. SIMONA BERTOLI, ALESSANDRO LEONE, RAMONA DE AMICIS, ALBERTO BATTEZZATI, Piacenza, Italy, Milan, Italy

PSYCHOSOCIAL, BEHAVIORAL MEDICINE

Moderated Poster Discussion: Assessing and Intervening on the Impact of Diabetes Distress on Individuals with Diabetes (Posters: 794-P to 799-P), see page 90.
796-P Diabetes Distress and All ‑Cause Mortality in Patients with Type 2 Diabetes—A Prospective Cohort Study. YASUAKI HAYASHINO, SHINTARO OKAMURA, SATORU TSUJII, HITOSHI ISHII, Nara, Japan, Tanri, Japan, Kashihara, Japan

797-P T1 ‑REDEEM—An RCT to Reduce Diabetes Distress in Adults with Type 1 Diabetes. LAWRENCE FISHER, DANIELLE M. HESSLER, WILLIAM POLONSKY, UMESH MASHARANI, SUSAN GUZMAN, VICKY BOWYER, LISA A. STRYCKER, San Francisco, CA, Del Mar, CA, San Diego, CA, Eugene, OR

798-P High Prevalence of Distress among Patients with Type 2 Diabetes (T2DM)—A Hospital ‑Based, Cross ‑Sectional Study from South India. PRASANTH SANKAR, PRIYANKA SASKUMAR, RITUNA MEDAYIL, RITTIN JACOB, SARANYA SASIDHARAN, Pathanamthitta, India

799-P Shared Responsibility Moderates Relations between Psychological Distress and Self ‑Care among Adolescents with T1D. HIBA ABUJARADEH, VICKI HELGESON, SUSAN M. COHEN, SUSAN M. SEREIKA, Pittsburgh, PA

Moderated Poster Discussion: Interventions and Outcomes of Behavioral and Psychosocial Factors in Diabetes (Posters: 800-P to 805-P), see page 92.

800-P Behavior Change of Participants in Group vs. Individual DPP Weight Loss Interventions—The SHINE Study. PAULA M. TRIEF, LINDA M. DELAHANTY, DONALD A. CIBULA, RUTH S. WEINSTOCK, Syracuse, NY, Boston, MA

801-P Successful Health Care Provider Strategies to Overcome Psychological Insulin Resistance in U.S. and Canada. TRICIA S. TANG, DANIELLE M. HESSLER, WILLIAM POLONSKY, LAWRENCE FISHER, IRENE HADJYIANNI, DACHUANG CAO, BEVERLY REED, SAMANEH KALIRAI, TANYA IRANI, JASMINA I. IVA ‑NOVA, URVI DESAI, MAGALY PEREZ ‑NIEVES, Vancouver, BC, Canada, San Francisco, CA, Del Mar, CA, Bad Homburg, Germany, Charlotte, NC, Indianapolis, IN, Toronto, ON, Canada, New York, NY, Boston, MA

802-P Motivational Interviewing to Improve Insulin Acceptance in Insulin ‑Naïve Korean Patients with Type 2 Diabetes. YOUNGSHIN SONG, JEONGHWA CHO, HYUNJIN LEE, KEUMOK PARK, YOONHEE LEE, BOHYUN KIM, KAWOUN SEO, ANCHO LIM, YOUNGHEE JUN, SOOHYUN NAM, Daejeon, Republic of Korea, West Haven, CT

803-P Psychosocial Benefits of Structured Support for Self ‑Care in Teens with Type 1 Diabetes (T1D)—Results of an RCT. PERSIS V. COMMISSARIAT, LISA VOLKENING, DEBORAH A. BUTLER, BARBARA ANDERSON, LORI M. LAFFEL, Boston, MA, Charlottesville, VA

804-P Cognitive Behavioral Intervention Produces Comparable Reductions in Regimen ‑Related Distress in Insulin Users and Nonusers—Twelve ‑Month Results from COMRADE. KERRY LITTLE ‑WOOD, SHIVAJIRAO PATIL, DOYLE M. CUMMINGS, LESLEY LUTES, BERTHA HAMBIDGE, MARISSA CARRAWAY, ALYSSA ADAMS, CHELSEY SOLAR, SHEILA EDWARDS, PEGGY GATLIN, Tampa, FL, Greenville, NC, Kelowna, BC, Canada

805-P Ketones to Success—Does NICH Involvement Influence DKA Discharge Presentation? DAVID V. WAGNER, ROSE CHUONG, NATALIE C. KOSKELA, HANNAH LUZOD, ERYNN BEESON, INES GUTT ‑MANN ‑BAUMAN, MICHAEL A. HARRIS, Portland, OR

806-P Factors Affecting Noninsulin Antidiabetic Drug Adherence in Patients with Type 2 Diabetes. LINDSAY PETRENCHIK, F. ELLEN LOH, New York, NY

807-P Engaging Hispanic Adolescents with Type 2 Diabetes or Obesity in Personalized Exercise. MELISSA S. FAULKNER, SARA MICHALISZYN, Atlanta, GA, Youngstown, OH

808-P Clinical Relevance of the Behavioral Stages of Change with the Efficacy of Multifaceted Interventions on the Drop ‑Out from Regular Medical Care in Patients with Diabetes—The Japan Diabetes Outcome Intervention Trial ‑2 (J ‑DOIT2). RYOTARO BOUCHI, MITSUHIKO NODA, YASUAKI HAYASHINO, KATSUYA YAMAZAKI, HIKARI SUZUKI, ATSUSHI GOTO, TOSHI A. FURUKAWA, KAZUO IZUMI, MASASHI KOBAYASHI, J ‑DOIT2 STUDY GROUP, Tokyo, Japan, Saitama, Japan, Nara, Japan, Tsukuba, Japan, Takaoka, Japan, Kyoto, Japan

809-P Stigmatization of Adults with Type 1 Diabetes in Asia. AMANDA Y.R. LAM, DAPHNE GARDNER, SURESH RAMA CHANDRAN, EDMUND P. TEO, LING ZHU, GERALD KOH, SU ‑YEN GOH, Singapore, Singapore
810-P Patient-Reported Outcomes in T2D Patients Inadequately Controlled by Metformin Are More Favorable for Dapagliflozin plus Saxagliptin vs. Insulin Glargine. MARCIA A. TESTA, DONALD C. SIMONSON, ELLA EKHOIM, MAXWELL SU, EVA K. JOHNSSON, Boston, MA, Malmö, Sweden

811-P Sleep Quality and Heart Rate Variability in Adolescents with Type 1 or Type 2 Diabetes. MELISSA S. FAULKNER, ASHLEY HÉLVIG, Atlanta, GA

812-P Blog Use Is Associated with Lower Hemoglobin A1c in Adults with Type 1 Diabetes. SEAN M. OSER, TAMARA OSER, ERIN L. MCGINLEY, ARTHUR BERG, HEATHER L. STUCKEY, Hershey, PA

813-P Diabetes Distress and Glycemic Control in Working People with Type 1 Diabetes—The Role of Intentional Hyperglycemia at Work. ULLA M. HANSEN, KASPER OLESEN, TIMOTHY C. SKINNER, INGRID WILLAING, Gentofte, Denmark, Copenhagen, Denmark

814-P Sleep and Glycemia in Adolescents with Type 1 Diabetes. MARGARET GREY, KAITLYN RECHENBERG, West Haven, CT

815-P Anxiety in Adolescents with Type 1 Diabetes. KAITLYN RECHENBERG, LOIS S. SADLER, MARGARET GREY, West Haven, CT, Orange, CT

816-P Distress, Depression, or Both? Exploring Differences in the DDS-17 and the PHQ-9 in Diabetes Specialty Clinic. JANA L. WARDIAN, KATHRYN E. KANZLER, TOM J. SAUERWEIN, MARK W. TRUE, MICHAEL A. GLOTTELTER, San Antonio, TX, Dayton, OH

817-P Impact of Intensive Lifestyle Intervention for Weight Management on Self-Reported Cognitive Function—The Action for Health in Diabetes (Look AHEAD) Randomized Controlled Trial. GARETH R. DUTTON, MARK ESPELAND, REBECCA H. NEIBERG, OWEN CARMICHAEL, KATHLEEN M. HAYDEN, KAREN C. JOHNSON, ROBERT W. JEFFERY, DELILAH COOK, DALANE KITZMAN, STEVE R. RAPP, Birmingham, AL, Winston-Salem, NC, Baton Rouge, LA, Memphis, TN, Minneapolis, MN

818-P WITHDRAWN

819-P How Does Risk Screening for Kidney Disease Influence Diabetes Distress? LENE E. JOENSEN, KRISTOFFER P. MADSEN, MARIE FRIMODT-MOLLER, NETE TOFTE, INGRID WILLAING, MORTEN LINDHARDT, PETER ROSSING, Gentofte, Denmark, Copenhagen, Denmark

820-P Diabetic Complications Associated with Poor Sleep Quality in Type 2 Diabetes. DUGHYUN CHOI, BO-YEON KIM, CHAN-HEE JUNG, CHUL-HEE KIM, SUNG-KOO KANG, JI-OH MOK, Bucheon, Republic of Korea

821-P Relationship between Weight Change Patterns and Health Satisfaction in the CANadian Canagliflozin Registry (CanCARE) Study. VINCENT C. WOO, HARPREET S. BAJAJ, MAUREEN A. CLEMENT, FERNANDO CAMACHO, SHANA TRAINA, NATASHA GEORGIJEV, JENNIFER B. ROSE, DELNA SORAJJI, ALAN D. BELL, Winnipeg, MB, Canada, Brampton, ON, Canada, Coldstream, BC, Canada, Waterloo, ON, Canada, Ranitan, NJ, Toronto, ON, Canada

822-P Cognitive Function Is Impaired in Recently Diagnosed Type 2 Diabetes, but Not in Type 1 Diabetes. THERESA VAN GEMERT, WOLFGANG WÖLWER, KATHARINA S. WEBER, ANNIKA HOYER, KLAUS STRAS-SBURGER, NORA T. BOHNAU, MARIE BRÜGGEN, KATHARINA OVELGOENNE, EVA-MARIA GÖSSMANN, VOLKER BURKART, JULIA SZENDROEID, MICHAEL RODEN, KARSTEN MÜSSIG, Düsseldorf, Germany

823-P Education for Family Members Is Effective for Improved Glycemic Control of Patients with Type 2 Rather than Type 1 Diabetes Mellitus—A Meta-analysis. SATORU KODAMA, SR., KAZUYA FUJIIHARA, HAJIME ISHIKIHARA, CHIKU HIRAI, YOKO YACHI, MASASHIRO ISIHARA, SATOSHI MATSU-NAGA, SHIRO TANAKA, KIMINORI KATO, HIROHITO SONE, NIIGATA, Japan, Chiba, Japan, Kyoto, Japan

824-P Impact of rtCGM Usage on a Combined Patient Reported Outcome—A Post-Hoc Analysis of the HypoDE Study. DOMINIC EHRMANN, LUTZ HEINEMANN, GUIDO FRECKMANN, DELIA WALDENMAIER, NORBERT HERMANN, Bad Mergentheim, Germany, Düsseldorf, Germany, Ulm, Germany

825-P Comprehensive Diabetes Stigma Scale—Associations with Patient Characteristics and Outcomes. LAUREN B. BEACH, SHYAM KANKOTIA, CHRISTINE U. DINV, TOM ELASY, LINDSAY S. MAYBERRY, KENNETH WALLSTON, GREGORY PHILLIPS II, PATRICK JANULIS, KERRI CAVANAUGH, Chicago, IL, Providence, RI, Iowa City, IA, Nashville, TN, Pisgah Forest, NC
826-P Acceptability of a Self-Regulation Theory-Based mHealth Behavior Intervention for Older Adults with Type 2 Diabetes and Obesity. YAGUANG ZHENG, KATIE WEINGER, MATT C. GREGAS, JORDAN GREENBERG, ZHUXIN LI, LORA E. BURKE, CHENFANG QI, CHRISTINE SLYNE, TORI GREAVES, MEDHA MUNISHI, Chestnut Hill, MA, Boston, MA, Brighton, MA, Pittsburgh, PA

827-P Adherence and Associated Follow-Ups for Diabetic Eye Examinations in Japan. HIROSHI MURAKAMI, HIDEYUKI OTAKA, MASAYA MURABAYASHI, SATORU MIZUSHIRI, AYA KAMBA, YUKI MATSUBASHI, MIYUKI YANAGIMACHI, HIROFUMI NAKAYAMA, MAKOTO DAIMON, Hirosaki, Japan, Hachinohe, Japan

828-P Prevalence and Factors Associated with Sleep Disorders in Japanese Patients with Type 2 Diabetes. HIDEYUKI OTAKA, HIROSHI MURAKAMI, SATORU MIZUSHIRI, AYA KAMBA, MAKOTO DAIMON, Hirosaki, Japan, Hachinohe, Japan

829-P Impact of Diabetes-Related Distress on Predicted Cardiovascular Complications in Patients with Type 2 Diabetes. CLIPPER YOUNG, JOY A. DUGAN, ANDREW J. RAY, JAY H. SHUBROOK, Vallejo, CA

830-P Health Mindset and Health Outcomes for Adolescents with Type 1 Diabetes. LAURA NALLY, CLAUDIA MUELLER, Stanford, CA

831-P Gender Differences in Psychosocial Factors Influencing Glycemic Control among Chinese Adults with Type 2 Diabetes Mellitus. KEKE LIN, LAURIE T. QUINN, Beijing, China, Chicago, IL

832-P Positive Impact of Integrative Medicine Approaches on Diabetes Related Care. JEONG-HEE KU, MATTHEW FREEBY, RASHMI S. MULLUR, Los Angeles, CA

833-P Exploring Psychological Aspects of Hyperglycemia in People with Type 2 Diabetes. METTE A. NEXO, BRYAN CLEAL, INGRID WILLAING, Gentofte, Denmark

834-P Increasing Daily Step Count Results in an Improvement in BMI and Aortic Blood Pressure in Patients with Type 2 Diabetes Mellitus. CHERNGJYE SEOW, LIAN XIA, JANET S. TAN, XIN TANG, BING SUN, RINKOO DALAN, Singapore, Singapore

835-P Markup Methodology to Culturally Tailor Preexisting Preconception Counseling (PC) Program for Latina Adolescent Girls with Diabetes and Their Mothers. HIBA ABUJARADEH, FRANCES M. PETERSON-BURCH, ELLEN OLSHANSKY, KEIRSTEN MONTGOMERY, DENISE CHARRON-PROCHOWNIK, Pittsburgh, PA, Irvine, CA, Tustin, CA

836-P How Improving Stress Improves Glucose Control. SAAD SAKKAL, Milton, FL

837-P Differences in Patient Perspectives of Type 2 Diabetes Management and Care by Current A1C. MERYL BROD, KENNETH J. TOMASZEWSKI, AMY ALLEN, DAVIDA F. KRUGER, MICHAEL K. HEILE, MICHELLE MOCARSKI, ALISA SCHIFFMAN, YEHUDA HANDELSMAN, Mill Valley, CA, Honeye Rot, NY, Detroit, MI, Cincinnati, OH, Plainsboro, NJ, Tarzana, CA

838-P Attitudes among Adults with Type 2 Diabetes Affecting Insulin Initiation and Discontinuation. DANIELLE M. HESSLER, WILLIAM POLONSKY, LAWRENCE FISHER, FRANK J. SNOEK, IRENE HADJIYIANNI, DACHUANG CAO, JASMINA I. IVANOVA, URVI DESAI, MAGALY PEREZ-NIEVES, San Francisco, CA, Del Mar, CA, Amsterdam, Netherlands, Bad Homburg, Germany, Charlotte, NC, New York, NY, Boston, MA, Indianapolis, IN

839-P From Research to Action—Impactful Intervention Arenas. A. DAVID NAPIER, NIELS LUND, MALENE BAGGER, BJORNE B. JENSEN, London, United Kingdom, Bagsværd, Denmark, Gentofte, Denmark

840-P Effectiveness of Digital Interventions for Improving Glycemic Control in Persons with Poorly Controlled Type 2 Diabetes—A Systematic Review and Meta-Regression Analysis. MIHIRETU M. KEBEDE, HAJO ZEEB, MANUELA PETERS, THOMAS L. HEISE, CLAUDIA R. PISCHKE, Bremen, Germany

841-P Family Impact Module and Type 1 Diabetes. JENIECE ILKOWITZ, MARY PAT GALLAGHER, BECKY LOIS, MORGAN L. PACHECO, ANNE ZELENIUCH-JACQUOTTE, New York, NY, Manhattan, NY

842-P The Three I’s of Diabetes Integration in Emerging Adulthood—Developing a Framework to Individualize Diabetes Care. BENJAMIN MARKOWITZ, CHERYL PRITLOVE, GEETHA MUKERJI, JAMES V. LAVERY, JANET A. PARSONS, ANDREW ADVANI, Toronto, ON, Canada, Atlanta, GA
843-P Identifying Recommendations of Health Care Providers (HCP) for Developing an Evidence-Based Reproductive Health (RH) Educational Intervention for Adolescent and Young Adult (AYA) Males with TID. ANDREA F.R. FISCHL, INGRID LIBMAN, DANA L. ROFEY, DENISE CHARRON-PROCHOWNIK, Pittsburgh, PA

844-P A Content Analysis of Text Messages in a Type 1 Diabetes Peer Mentoring Program—The Importance of Shared Interests. ASHBY F. WALKER, CATHRYN JOHNSON, CLAUDIA ANEZ-ZABALA, SARAH R. DORVL, MICHAEL J. HALLER, MATTHEW J. GUERKA, BRITTANY S. BRUGGEAN, DANIELLE GÜIFFRE, MARK A. ATKINSON, ILYSSA SCHATZ, DESMOND SCHATZ, Gainesville, FL, Atlanta, GA, Decatur, GA

845-P Comparing Perceptions of Concerns Regarding Complications Including Reproductive Health (RH) in Male and Female Adolescents and Young Adults (AYA) with TID. ANDREA F.R. FISCHL, DENISE CHARRON-PROCHOWNIK, SUSAN M. SEREIKA, DANA L. ROFEY, DOROTHY J. BECKER, JESSICA FINNEY, ANA M. DIAZ, INGRID LIBMAN, Pittsburgh, PA

846-P Examination of Accuracy of Self-Reported Blood Glucose Using mHealth Data Collection. JENNIFER WARNICK, SARAH C. WESTEN, ANASTASIA ALBANESE-O’NEILL, DESMOND SCHATZ, MICHAEL J. HALLER, DAVID JANICKE, Gainesville, FL

847-P Poor Adherence in Adolescents with Type 1 Diabetes Associated with Distress, Fear of Hypoglycemia, and Executive Functioning. SARAH C. WESTEN, JENNIFER WARNICK, MINA ENTESSARI, ANASTASIA ALBANESE-O’NEILL, DESMOND SCHATZ, MICHAEL J. HALLER, DAVID M. JANICKE, Gainesville, FL

848-P What Is Health-Related Quality of Life? Perspectives from Diabetes Care Providers. VIENA T. CAO, SAHAR S. ESHTEHARDI, BRET M. MCKINNEY, BARBARA ANDERSON, DAVID G. MARRERO, DEBBE THOMPSON, MARISA E. HILLIARD, Houston, TX, Indianapolis, IN, Charlottesville, VA, Tucson, AZ

849-P The Effects of a Sleep Extension Intervention on Glucose Control in Youth with Type 1 Diabetes. MICHELLE PERFECT, SARA FRYE, GRAI P. BLUEZ, Tucson, AZ

850-P Factors Affecting Long-Term Healthy Behaviors and Posttraumatic Growth in Type 2 Diabetes Patients. AYAKO KAYANO, MASAHIRO YAMAZAKI, KANAKO TAKU, RYOSUKE SAKAI, NAKO HIGO, MAI ASANO, TOYOSHI HOSOKAWA, MASATOSHI KAWASE, MICHIKI FUKUI, Kyoto, Japan, Rochester, MI

851-P Evaluation of a Web-Based Tool for Parents of Teens with Type 1 Diabetes. ROBIN WHITTEMORE, JULIA L. COLEMAN, ROBERTA DELVY, BERNET KATO, JAMES A. AMBROSOLI, MICHAEL P. MAURAO, REBEKAH ZINCAVAGE, LISA MARCEAU, West Haven, CT, Watertown, MA

852-P The Influence of Daily Stress on Glycemic Control and Mortality in Adults with Diabetes. REBEKAH J. WALKER, EMMA GARACCI, JENNIFER A. CAMPBELL, LEONARD E. EGEDE, Milwaukee, WI

853-P Glycemic Factors Related to Depression in Adults with Type 1 Diabetes. IFEOMA EGBUONU, PAULA M. TREF, CHERYL A. ROE, RUTH S. WEINSTOCK, Syracuse, NY

854-P Correlates of Perceived Stress in Parents of Teens with Type 1 Diabetes. ROBIN WHITTEMORE, ROBERTA DELVY, JULIA L. COLEMAN, BERNET KATO, JAMES A. AMBROSOLI, MICHAEL P. MAURAO, REBEKAH ZINCAVAGE, LISA MARCEAU, West Haven, CT, Watertown, MA

855-P Affective Communication in Routine Diabetes Care for Adolescents and Young Adults. KIRSTEN HOMMA, FRAN R. COGEN, RANDI STREISAND, MAUREEN MONAGHAN, Milwaukee, WI

856-P Increased Perceived Effort during Low-Intensity Exercise Linked to Type 2 Diabetes. AMY G. HUEBSCHMANN, MATTHEW WAHL, REBECCA L. SCALZO, DEIRDRE RAFFERTY, JUDITH G. REGENSTEINER, Aurora, CO

857-P Effects of Mindfulness-Based Stress Reduction on Insulin-Treated Diabetes. RAQUEL REIN, MEGHAN SEARL, SHREYA BHANDARI, KATHRYN E. COTE, ISRA HASHMI, KAYLA L. DEL VALLE, MARIE E. MCDONNELL, Boston, MA

858-P A Nurse-Led Diabetes Navigation Program for Rural Appalachian Ohio. ELIZABETH A. BEVERLY, EMILY H. GUSEMAN, KARIE A. COOK, MELISSA STANDLEY, Athens, OH

859-P The Relationship between Brain Volume Loss and Cognition in Subjects with T2DM. LEANNE HUNT, DINESH SELVARAJAH, SOLOMON TESFAYE, IAIN D. WILKINSON, Sheffield, United Kingdom
860-P The Design and Preliminary Evaluation of a Mobile Health Application TangTangQuan in Management of Type 1 Diabetes in China. PING LING, SIHUI LUO, JINHUA YAN, XUEYING ZHENG, DAIZHI YANG, XIFENG ZENG, JIANPING WENG, Guangzhou, China, Shenzhen, China

861-P Dispelling Misperceptions—Family Satisfaction with Behavioral Health Screening. DANNY C. DUKE, HARPREET NAGRA, MELINDA JONES, MORGAN BOLEN, MICHAEL A. HARRIS, Portland, OR

862-P Predicting MDD with a Semistructured Depression Symptom Severity Interview in Type 2 Diabetes. AMIT SHAPIRA, VANCE ZEMON, STEVEN SAFREN, JEFFREY S. GONZALEZ, Bronx, NY, Miami, FL

863-P Neuropathy-Related Unsteadiness and Psychosocial Outcomes in Diabetes—Preliminary Findings. STEVEN J. BROWN, ANDREW J.M. BOULTON, LORETTA VILEIKYTE, NEIL D. REEVES, Manchester, United Kingdom

864-P Does Gender Moderate the Relations between Shared Responsibility and Health Outcomes among Adolescents with T1D? HIBA ABUJARADEH, SUSAN M. SEREIKA, SUSAN M. COHEN, VICKI HELGESON, Pittsburgh, PA

865-P Psychological Distress Mediates the Association between Poor Sleep Quality and Prediabetes. LI LI, Birmingham, AL

866-P Real-World Effectiveness of a Digital Therapeutic in Improving Glycaemic Control in South Asians Living with Type 2 Diabetes. ARAVIND R. SOSALE, SR., MAAZ SHAikh, ABHISHEK SHAH, RAJEEV CHAWLA, BRIJ M. MAKKAR, JOTHIEV KESAVadeV, SHILPA JOSHI, NEETA DESHPANDE, SANJAY AGARWAL, ANUJ MAHESHWARI, SV MADHU, BANSHI D. SABoo, Bangalore, India, Mumbai, India, New Delhi, India, Delhi, India, Trivandrum, India, Belgaum, India, Pune, India, Lucknow, India, Ahmedabad, India

867-P Randomized Trial of a Tailored Cognitive Behavioral Intervention in Type 2 Diabetes with Comorbid Depressive and/or Distress Symptoms—Twelve-Month Outcomes from COMRADE. DOYLE M. CUMMINGS, LESLEY LUTES, SHIVAJIEF PATIL, BERTHA HAMBIDGE, MARISSA CARRAWAY, KERRY LITTLEWOOD, ALYSSA ADAMS, CHELSEY SOLAR, SHEILA EDWARDS, PEGGY GATLIN, Greenville, NC, Kelowna, BC, Canada, Tampa, FL

868-P Hypoglycemia Contributes to Increased CVD Mortality with HbA1c <6.0%. MARY RHEE, KATHERINE E. KURGANSKY, YUK-LAM HO, DAVID R. GAGNON, SRIDHARAN RAGHAVAN, JASON L. VASSY, KELLY CHO, ADRIANA GONZALEZ, FARAH N. KHAN, LISA R. STAIMEZ, CHRISTOPHER N. FORD, PETER W. WILSON, LAWRENCE S. PHILLIPS, Decatur, GA, Boston, MA, Denver, CO, Atlanta, GA

869-P Which Relationships Really Matter for Blood Glucose Control? PATRICIA N.E. ROBERSON, MELANIE MILLER, KATHERINE M. RASPOVIC, JAVIER LA FONTAINE, FRANK FINCHAM, DANE WUKICH III, Davis, CA, Dallas, TX, Tallahassee, FL

870-P Family, Marital, and Friend Relationship and Diabetics Psychological Quality of Life. PATRICIA N.E. ROBERSON, MELANIE MILLER, KATHERINE M. RASPOVIC, JAVIER LA FONTAINE, FRANK FINCHAM, DANE WUKICH III, Davis, CA, Dallas, TX, Tallahassee, FL

871-P Building Infrastructure for Diabetes Self-Management Support in Church-Based Settings—Results of a 15-Month Cluster-Randomized Controlled Trial. NIKOLAS J. KOSCIELNIAK, MARTHA FUNNEll, GRETCHEN PIATT, Ann Arbor, MI

872-P Raising a Child with Type 1 Diabetes and Autism—Using Social Media to Identify Barriers and Facilitators. TAMARA OSER, SEAN M. OSER, KANTHI BANGALORE KRISHNA, DANIEL E. HALE, Hershey, PA

873-P The Emotional Side of Diabetes and Glycemic Control in a Brazilian Sample of Adults with Type 1 Diabetes. MÔNICA S.V.M. SILVEIRA, MARIA C. PARISI, SR., KRISTINE RUPPERT, ARNALDO MOURA NETO, LINDA M. SIMINERIO, ANDREI C. SPOSITO, MARTHA FUNNEll, ELIZABETH J. PAVIN, SR., LAWRENCE FISHER, Campinas, Brazil, Pittsburgh, PA, Ann Arbor, MI, San Francisco, CA

874-P Clinical Practice Factors That Define Insulin Pump Readiness. CASSIDY PUCKETT, JENISE C. WONG, Atlanta, GA, San Francisco, CA

875-P Empowerment, Motivation, and Medical Adherence (EMMA)—Results of an RCT in Patients with Poorly Regulated Type 2 Diabetes. ANNEMARIE R. VARMING, KASPER OLESEN, INGRID WILLAING, Gentofte, Denmark
876-P  Improved Diabetes Medication Convenience in Persons with Type 2 Diabetes after Switching to Insulin Glargine 300 U/mL (U-300)—The Observational OPTIN-D Study. THOMAS H. WIERINGA, MAARITJE DE WIT, JOS TWISK, FRANK J. SNOEK, Amsterdam, Netherlands

877-P  Gender Differences in Contributions of Mutable and Immutable Factors on Quality of Life in Adults with Type 2 Diabetes. JONI S. WILLIAMS, LEONARD E. EGEDE, Milwaukee, WI

878-P  Timely Initiation of Human Insulins—Interim Analysis on Knowledge and Attitude from Indian Human Insulin Registry (INHIRIT). DILIP PAWAR, SAPTARSHI BOSE, SARAH JABEEN, SANDEEP S., VEER-ANNA KARADI, Bangalore, India

879-P  A Reimbursable Counseling Intervention Improves Physical Activity and Function for Primary Care Patients with Type 2 Diabetes. AMY G. HUEBSCHMANN, IAN M. LEAVITT, RUSSELL GLASGOW, JUDITH G. REGENSTEINER, ANDREA L. DUNN, Aurora, CO, Loveland, CO

880-P  Program ACTIVE II—Glycemic Improvements Are Sustained over 12 Months with Combination Therapy for MDD in Adults with T2DM. MARY DE GROOT, W. GUYTON HORNSBY, JR., CHANDAN K. SAHA, ZIYI YANG, YEGAN PILLAY, KAREN M. FITZPATRICK, KIEREN J. MATHER, JAY H. SHUBROOK, Indianapolis, IN, Morgantown, WV, Athens, OH, Fairfield, CA

881-P  HbA1c (You Later)—What Happens to Glycemic Control while Waiting for NICH? DAVID V. WAGNER, RAJKARAN SACHDEJ, NATALIE C. KOSKELA, SAMANTHA A. BARRY, HANNAH LUZOD, ELIZA JAMES-UNREIN, MICHAEL A. HARRIS, Portland, OR, Worcester, MA

882-P  Predictors of Depressive Symptoms in a Clinical Sample of Individuals with Type 1 Diabetes. KELLY R. STANEK, SHIDEH MAJIDI, JO M. VOGELEI, KIMBERLY A. DRISCOLL, Aurora, CO

883-P  Clinic-Wide Screening of Fear of Hypoglycemia in Mothers and Fathers of Children with Type 1 Diabetes. SHIDEH MAJIDI, HOLLY O’DONNELL, KYLIE BENSON, KIMBERLY A. DRISCOLL, Aurora, CO

884-P  A Real-World Evidence in Understanding the Barriers and Behaviours of Insulin Therapy among Indian Type 2 Diabetes Mellitus (T2DM) Patients. PRAVEEN RAJ, DILIP PAWAR, SARAH JABEEN, SHIVARAM VS, Bangalore, India

885-P  Determination of Risk for Suboptimal Glycemic Control in New-Onset Type 1 Diabetes. SHIDEH MAJIDI, JO M. VOGELEI, KIMBERLY A. DRISCOLL, Aurora, CO

886-P  RCT of Tailored Cognitive Behavioral Intervention Reduces Regimen-Related Distress—Relationship to Change in Medication Adherence and Glycemic Control at 12-Month Follow-Up. LESLEY LUTES, DOYLE M. CUMMINGS, BERTHA HAMBIDGE, MARISSA CARRAWAY, SHIVAJIRAO PATIL, ALYSSA ADAMS, CHELSLEY SOLAR, KERRY LITTLEWOOD, SHEILA EDWARDS, PEGGY GATLIN, Kelowna, BC, Canada, Greenville, NC, Tampa, FL

887-P  An Examination of the Presence of Mental Health Diagnoses in a Clinical Sample of Individuals with Type 1 Diabetes. KELLY R. STANEK, SHIDEH MAJIDI, ERIN M. YOUNGKIN, JO M. VOGELEI, KIMBERLY A. DRISCOLL, Aurora, CO

888-P  Determination of Risk for Suboptimal Glycemic Control in New-Onset Type 1 Diabetes. SHIDEH MAJIDI, JO M. VOGELEI, KIMBERLY A. DRISCOLL, Aurora, CO

889-P  Preferences for Health Information and Decision-Making Autonomy among Chinese Patients with T2DM in the mHealth Era. LISA NIE, BO XIE, YAN YANG, SHARON A. BROWN, Austin, TX, Chengdu, China

890-P  Insulin Adherence Is a Mechanism Underlying Disparities in A1c for Younger Adults with Type 2 Diabetes. LINDSAY SEARS, ASHLEY HIRSCH, JENNIFER RAYMOND, MARK HEYMAN, RACHEL HEAD, JEFF DACHIS, Nashville, TN, Los Angeles, CA, New York, NY

891-P  Assessment of Diabetes Distress in Appalachian Ohio. ELIZABETH A. BEVERLY, EMILY H. GUSEMAN, KARIE A. COOK, AMBER M. HEALY, Athens, OH

892-P  Shared Telemedicine Appointments for Young Adults with T1D and Depressive Symptoms—Improved Attendance and Symptom Regulation. MARK W. REID, JENNIFER RAYMOND, JOHN F. THOMAS IV, Los Angeles, CA, Aurora, CO
893-P Experiences of Enrolling in the U.S. Monogenic Diabetes Registry. SALLY S. LADSARIA, JAZZMYNE MONTGOMERY, KATHERINE L. LINDAUER, ROCHELLE N. NAYLOR, Chicago, IL

894-P Long-Term Use of Closed-Loop Control—Patient-Reported Experience. LINDA GONDER-FREDERICK, SUE A. BROWN, JACLYN SHEPARD, LAURA L. KOLLAR, BORIS KOVATCHEV, Charlottesvile, VA, Jeffersonson, VA

895-P Quality of Life Assessment in Patients with HNF1A- and GCK-MODY Compared with T1DM. MAGDALENA SZOPA, Krakow, Poland

896-P Perceived Health and Mental Well-Being of College Students with Type 1 Diabetes. JENNIFER SAYLOR, SARA LEE, JODIE M. AMBROSINO, EMILY IKE, MICHELLE NESS, Newark, DE, Cleveland, OH, New Haven, CT, Boston, MA

897-P Diabetes Prevention within a Large Health Care System. KRISTEN M.J. AZAR, CATHERINE NASRALLAH, NINA SZWERINSKI, VIDITA CHOPRA, MEGHAN HALLEY, ROBERT ROMANELLI, Walnut Creek, CA, Palo Alto, CA

CLINICAL THERAPEUTICS/NEW TECHNOLOGY—GLUCOSE MONITORING AND SENSING

Moderated Poster Discussion: New Insights from Continuous Glucose Monitoring (Posters: 898-P to 903-P), see page 157.

898-P Frequency of Flash Glucose Monitoring Scans and Hemoglobin A1c in Real Life. ANDREA LAURENZI, AMELIA CARETTO, MARILUCE BARRASSO, ANDREA MARIO BOLLA, CHIARA MOLINARI, ANNA ZANARDINI, NICOLETTA C. DOZIO, ELENA MENEGHINI, EMANUELE BOSI, MARINA SCAVINI, Milan, Italy, Cinisello Balsamo, Italy

899-P Associations between A1C and Continuous Glucose Monitoring-Derived Glycemic Parameters. PETER CALHOUN, TERRI JOHNSON, JOHN WELSH, TOMAS C. WALKER, DAVID A. PRICE, San Diego, CA

900-P Effect of Remote Glucose Monitoring Utilizing Computerized Insulin Dose Adjustment Algorithms on A1C Levels—A Preliminary Report. MAYER B. DAVIDSON, JOSH DAVIDSON, Los Angeles, CA

901-P Interim Analysis of an Implantable CGM System Longevity during a 365-Day Study. SORIN IOACARA, RAVI RASTOGI, COLLEEN MDINGI, XIAOXIAO CHEN, KATHERINE TWEDEN, Bucharest, Romania, Germantown, MD

902-P Changes in Self-Care Behavior (Summary of Diabetes Self-Care Activities Measure) Using Real-Time Blood Glucose Monitoring with the Free Style Libre. AYAE KUDARA, TAKAHIRO TOSAKI, SHIORI SATO, AKEMI INAGAKI, MASAKI KONDO, SHIN TSUNEKAWA, YOSHIRO KATO, HIDEKI KAMIYA, JIRO NAKAMURA, Nagoya, Japan, Nagakute, Japan

903-P Benefits of Use of Professional CGM in Low Socioeconomic Population. SULMAN HASHMI, McKeesport, PA

904-P WITHDRAWN

905-P Continuous Glucose Monitoring Glycemic Variability Profiles Are More Favorable for Dapagliflozin plus Saxagliptin Compared with Insulin Glargine in Type 2 Diabetes. DONALD C. SIMONSON, TINA VILSBØLL, ELLA EKHOLM, EVA K. JOHNSON, MARCIA A. TESTA, SERGE JABBOUR, MARCUS LIND, Boston, MA, Copenhagen, Denmark, Malmöld, Sweden, Philadelphia, PA, Gothenburg, Sweden

906-P A Feasibility Study to Detect Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring. LAURA M. NALLY, NICHOLAS W. BONDY, JASMINE DOIEV, BRUCE BUCKINGHAM, DARRELL WILSON, Stanford, CA

907-P Automated Integration of Glucometer Data into the Electronic Health Record. JAKE WEATHERLY, SANIYA S. KISHNANI, TANDY AYE, Palo Alto, CA, Stanford, CA

908-P Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial. MARIANNA YARON, EYTAN ROITMAN, GENYA AHARON-HANANEL, ZOHAR LANDAU, TALI GANZ, MOSHE KARP, MAYA ISH-SHALOM, JOELLE SINGER, JULIO WAINSTEIN, SR., ITAMAR RAZ, Tel Aviv, Israel, Holon, Israel, Jerusalem, Israel
909-P  
**HbA1c Trends with Treatment Intensification following Inadequate Response to Two Oral Agents in Patients with Type 2 Diabetes.**  
KIBUM KIM, SUDHIR UNNI, DIANA BRIXNER, SHEILA THOMAS, CODY J. OLSEN, KIMBERLY L. STERLING, MATT MITCHELL, CARRIE MCADAM-MARX, Salt Lake City, UT, Bridge-water, NJ, Murray, UT, Indianapolis, IN, Little Rock, AR

910-P  
**WITHDRAWN**

911-P  
**Near-Infrared Spectroscopic Method for Noninvasive Blood Glucose Prediction without Using Multivariate Analyses.**  
KATSUHIKO MARUO, YUKIO YAMADA, Ehime, Japan, Chofu, Japan

912-P  
**Comparison of Glycemic Control between Experienced Users of Flash Glucose Monitoring vs. Flash-Naïve Patients.**  
DOMINIC EHRMANN, MELANIE SCHIPFER, THOMAS HAAK, BERNHARD KULZER, NORBERT HERMANNS, Bad Mergentheim, Germany

913-P  
**Equivalent Efficacy of Intensive Self-Monitoring of Blood Glucose to Real-Time Continuous Glycemic Monitoring in Adults with Type 2 Diabetes.**  
YUYA TAKANO, YULIA NAMIKI, HIROSHI TAKAHASHI, YUKINO KATAKURA, KEIKO FUJIE, YOSHIKO NAKATA, KOICHI HASHIMOTO, HIROAKI YAGYU, Ibaraki, Japan, Tsukuba, Japan

914-P  
**Comparison of Satisfaction with Their Glucose Monitoring Device in Patients Using Flash Glucose Monitoring vs. Patients Using SMBG.**  
MIAKI TANIZAWA, HIROSHI TAKAHASHI, YUKINO KATAKURA, KEIKO FUJIE, YOSHIKO NAKATA, KOICHI HASHIMOTO, HIROAKI YAGYU, Ibaraki, Japan, Tsukuba, Japan

915-P  
**Development and Validation of a Pattern-Recognition Engine for Visualization of Glycemic Patterns in Individuals Performing Low-Frequency SMBG.**  
GIACOMO VESPASIANI, ANTONIO NICO-LUCCI, MILENA SALEH, JÖCHEN SIEBER, GIUSEPPE PROSPERINI, CONCETTA SURACI, MARIANNA GALETTA, GIORGIO GRASSI, Rome, Italy, Pescara, Italy, Frankfurt, Germany, San Benedetto del Tronto, Italy, Tunin, Italy

916-P  
**Comparison of Glycemic Control in Type 2 Diabetic Patients on SAP Therapy.**  
ANA MARIA GOMEZ, Bogotá, Colombia

917-P  
**Factors Associated with High Glycemic Variability Defined by Coefficient of Variation in Hypoglycemic Type 2 Diabetes.**  
RYO KUMAGAI, AIKO MURAMATSU, MASANAO FUJII, YUKINO KATAKURA, KEIKO FUJIE, YOSHIKO NAKATA, KOICHI HASHIMOTO, HIROAKI YAGYU, Ibaraki, Japan, Tsukuba, Japan

918-P  
**Use of Automated Clinical Decision Support (CDS) to Effect Glycemic Control in Elderly Patients with T1D.**  
BOYI JIANG, SADAF SOLEYMANI, ROBERT VIGERSKY, ASHLEY SULLIVAN, YUXIANG ZHONG, PRATIK AGRAWAL, FRANCINE R. KAUFMAN, Northridge, CA

919-P  
**Impact of Continuous Glucose Monitors’ Accuracy on Their Clinical Utility—A Quantitative Assessment.**  
SCOTT PARDO, SERGEY ZHUPLATOV, JANE WALLACE, TIMOTHY S. BAILEY, Parsippany, NJ, Escondido, CA
925-P Use of the New Smartphone Application for Blood Glucose Monitoring (BGM) with Information-Motivation-Behavioral Skills (IMB) Model Has an Impact on Diabetes Control Parameters. SCOTT PARDO, SERGEY ZHUPLATOV, JANE WALLACE, TIMOTHY S. BAILEY, Parsippany, NJ, Escondido, CA

926-P A Novel Composite Glucose Index (COGI) for Evaluating Closed-Loop Performance in Type 1 Diabetes. LALANTHA LEELARATHNA, HOOD THABIT, LIA BALLY, MALGORZATA E. WILINSKA, JULIA K. MADER, THOMAS R. PIEBER, MARK EVANS, ROMAN HOVORKA, Manchester, United Kingdom, Berne, Switzerland, Cambridge, United Kingdom, Graz, Austria


928-P Efficacy of Average Daily Risk Range (ADRR) to Estimate Glycemic Kinetics during Nighttime in Japanese Patients with Type 1 Diabetes Mellitus. FUKI IKEDA, AKIO KANAZAWA, MAYU IIDA, HI DEYOSHI KAGA, NAOKO TAKAYANAGI, TOMOAKI SHIMIZU, CHIE SHIRAKAWA, HIROTAKA WATADA, Tokyo, Japan

929-P Effectiveness and Tolerability of Vildagliptin plus Metformin Compared with Other Oral Antidiabetes Agents in Baseline HbA1c Patients with Type 2 Diabetes—A Real-World Study (China PDS). DAQING HU, YING HAN, LIXIAN CHEN, HUI JIN, NAILONG YANG, XIAOYUN SHI, QUANMIN LI, LINLANG LIANG, LI ZANG, MINGMING LIU, JAMES HE, YIMING MU, Wuhan, China, Tianjin, China, Nanjing, China, Qingdao, China, Beijing, China, Shenyang, China, Shanghai, China

930-P A Wireless, Integrated, Extremely Miniaturized Continuous Glucose Monitoring System. MUHAMMAD MUJEEB-U-RAHMAN, MEISAM HONARVAR NAZARI, MEHMET SENCAN, Irvine, CA

931-P Mobile Technology for Behavioral Feedback on Glycemic Excursions—A Qualitative Study. MARILYN D. RITHOLZ, OWEN HENN, ASTRID ATAKOV-CASTILLO, LAWRENCE FISHER, ELENA TOSCHI, Boston, MA, San Francisco, CA

932-P Adults with Type 1 Diabetes (T1D) Using Continuous Glucose Monitoring (CGM) Report Disease Has Little Impact on Daily Functioning—T1D Exchange. LUDI FAN, COLLEEN GAREY, JINGWEN LIU, BETH MITCHELL, JEOFFREY BISPHAM, ALICIA H. MCAULIFFE-FOGARTY, Indianapolis, IN, Boston, MA

933-P Randomized, Multicentric, Prospective Study Assessing the Effect of Adding VILDaglptin to Insulin in Hemodialysed Type 2 Diabetic Patients—The VILDDIAL Study. MARION MUNCH, AGNÉS SMAGALA, LAURENT MEYER, NICOLAS MEYER, ODILE VERIER, DOMINIQUE I. FLEURY, SR., BRUNO GUERCI, THIERRY HANNE DUOUCHE, JOELLE CRIDLIG, SR., PHILIPPE BALTZINGER, DIDIER DUCLOUX, SOPHIE BOROT, KRISTIAN W. KUNZ, FARIDEH ALENABI, PATRICE WINISZEWSKI, FRANCOIS CHANTREL, LAURENCE KESSLER, Strasbourg, France, Colmar, France, Valenciennes, France, Vandeuvre-lès-Nancy, France, Besançon, France, Mulhouse, France

934-P Relationship between Frequency of Blood Glucose Testing and Reduction in HbA1c and Body Weight during Intensive Lifestyle Intervention in Patients with Type 2 Diabetes and Obesity. SHAHEEN TOMAH, NOOR MAHMOUD, ADHAM MOTTALIB, KHALED ALSIBAI, SAHAR ASHRAFZADEH, TAHASE AIDY, OSAMA HAMDY, Boston, MA

935-P Performance of the GLUCOCARD® Shine XL Blood Glucose Monitoring System Compared with FDA 2016 Guidance Accuracy Criteria. JULIE WALKER, PATRICIA GILL, DANIELLE MAHER, JOHN M. GLEISNER, Minneapolis, MN, Edina, MN

936-P Fourth-Generation Glucose Sensor with an Advanced Algorithm Featuring No Calibrations and Optional Calibration Modes of Operation. TALY ENGEL, PETER AJEMBA, JEFFREY NISHIDA, KEITH NOGUEIRA, BENYAMIN GROSMAN, ANDY TSAI, YUNFENG LU, ASHLEY SULLIVAN, ANDREA VARSAVSKY, Northridge, CA

937-P Adaptive Modeling of Glucose Measurements with Unannounced Meals and Exercise. IMAN HAJIZADEH, MUDASSIR RASHID, ALI CINAR, Chicago, IL

938-P Improvement of Glycemic Control after Three Months’ Use of the Predictive Low-Glucose Management System and Persisting for 18 Months in Patients with Diabetes Mellitus Type 1. TRIANTAFYLLOS DIDANGELOS, PARTHENA GIANNOU LAKI, ELENI KARLAFITI, EVANGELIA KOTZAKI OULAFI, ZISI S KONTONINAS, CONSTANTINOS TZIOMALOS, APOSTOLOS I. HATZITOLIOS, Thessaloniki, Greece
939-P Intermittently Scanned Continuous Glucose Monitoring (isCGM)—Examination in Pediatric Patients With and Without Ketoadcidoses. GABRIELA A. BOU, MICHAEL WURM, BARBARA C. HANSEN, KARL OTFRIED SCHWAB, Tampa, FL, Freiburg, Germany

940-P Use of the Tidepool Platform to Collect, Integrate, and Visualize Diabetes Device Data in a Pediatric Clinic Setting. JENISE C. WONG, ZARA IZADI, SHANNON M. SCHROEDER, MARIE NADER, HYO-JIN J. MIN, AARON B. NEINSTEIN, SALEH ADI, San Francisco, CA

941-P Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials. MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, JOHANNA F. HAYES, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA

942-P The Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 Diabetes. GRY H. DØRFLINGER, JAKOB A. ØSTERGAARD, SANNE FISKER, SOREN T. KNUDSEN, TROELS K. HANSEN, Aarhus, Denmark

943-P Effects of Basal Doses of Insulin Treatment in Type 1 Diabetes Evaluated by Continuous Glucose Monitoring on Glucose Variability. ADRIAN E. PROIETTI, SR., ANDREA V. DAGHERO, SR., NICOLAS PANEI, SR., MARIA L. SCAPUZZI, SR., ANDREA E. JOKIEL, SR., MARIA LAURA IGLESIAS, SR., JULIETA VELAZQUEZ, JUAN P. NOGUEIRA, SR., Buenos Aires, Argentina, Caba, Argentina, Formosa, Argentina

944-P Study of the Correlation between Tear Glucose Concentrations and Blood Glucose Concentrations. MASAKAZU AIHARA, NAOTO KUBOTA, TAKASHI KADOWAKI, Tokyo, Japan

945-P A Novel, Nonenzymatic Strategy for Stable, Optical Glucose Detection in Small Volumes of Fluid. BING WANG, GUILLERMO BAZAN, SUMITA PENNATHUR, B.N. QUEENAN, KAREN SCIDA, Santa Barbara, CA

946-P Flash Glucose Monitoring in Children—One-Year Experience. ANISSA MESSAAOUI, SYLVIE TENOUTASSE, LAURENT CRENIER, Brussels, Belgium

947-P Characteristics of Children Discontinuing Flash Glucose Monitoring. ANISSA MESSAAOUI, SYLVIE TENOUTASSE, LAURENT CRENIER, Brussels, Belgium

948-P Noninvasive Tissue Glucose Prediction in Patients with Type 1 Diabetes. ANDREAS PFÜTZNER, FILIZ DEMIRCIK, ALEXANDER LIER, SANJA RAMLIJAK, Mainz, Germany

949-P Unique Digital Care Interactions of Diabetes Patients with Remote Health Coach through Apollo Sugar App to Achieve Positive Glycemic Control Outcomes. SANJIV SHAH, RABINDER NATH MEHROTRA, SAMBIT DAS, RAVI S. ERUKULAPATI, SURYA P. REDDY, JANA JAYAPRAKASHSAI, KALPANA DASH, BANJAJI JAGANMOHAN, USHA AYYAGARI, SUREKHA TIPPISETTY, VAMSÍ K. KOLUKULA, SHASHANK JOSHI, Mumbai, India, Hyderabad, India, Bhutan, India, Dhaka, Bangladesh, India, Chennai, India

950-P Assessing Glucose Trend Accuracy with a Novel Continuous Glucose Monitoring System. TERRI JOHNSON, KARLA BRAZUN, ANDREW BALO, San Diego, CA

951-P WITHDRAWN

952-P Retrospective Flash Glucose Monitoring Analysis in Patients with Type 2 DM, Closer to Target. MANOJ S. CHAWLA, PURVI M. CHAWLA, MIKHIL C. KOTHARI, AMBARI F. SHAIKH, NAVNEET WADHWA, Mumbai, India, Delhi, India

953-P Real-World Avoidance of Glucose Excursions with the Guardian Connect CGM System’s Predictive Alerts. OHAD COHEN, SINU BESSY ABRAHAM, CHANTAL M. MCMAHON, PRATIK AGRAWAL, ROBERT VIGERSKY, Toluca, Mexico, Northridge, CA

954-P Use of Continuous Glucose Monitoring Data for Defining Glucose Control in Insulin-Treated Patients. TZVETELINA TOTOMIROVA, IVONA DASKALOVA, MILA ARNAUDOVA, Sofia, Bulgaria

955-P Safety of Microdose Dexamethasone Acetate in the Eversense® Long-Term Implantable Continuous Glucose Monitoring System. E.L. KELLEY, HARITHA HARIDAS, CARRIE LORENZ, Germantown, MD

956-P WITHDRAWN

957-P Impact of a Noninvasive Blood Glucose Device on Glycemic Control and Daily Routine Measurement Aspects—Results of a Pilot Study. ANDREAS PFÜTZNER, ALEXANDER LIER, SANJA RAMLIJAK, FILIZ DEMIRCIK, Mainz, Germany
### Beneficial Effect of Flash Glucose Monitoring Persists in a Two-Year Perspective—A Clinical Follow-Up Study of 334 Individuals with Type 1 Diabetes.
Magnus Londoahl, Katarina Fagher, Per Katzman, Karin Filipsson, Lund, Sweden

### Use of Real Time Continuous Glucose Monitoring (CGM) in Real Life Clinical Practice Compared with Finger-Stick Glucose Monitoring.
Elena Toschi, Christine Slynë, Astrid Atakovsky-Castillo, Jordan Greenberg, Tori Greaves, Sam P. Carl, Medha Munshi, Boston, MA

## Clinical Therapeutics/New Technology—Insulin Delivery Systems

**Moderated Poster Discussion:** Innovative Insulin Delivery (Posters: 960-P to 965-P), see page 157.

### Real-World Data from the MiniMed™ 670G System Commercial Launch
Pratik Agrawal, Michael Stone, Shweta Gopalakrishnan, Catherine Fogel, Scott W. Lee, Francine R. Kaufman, Northridge, CA

### Artificial Pancreas with Glucose Prediction Trust Index Improves Time-in-Target Glucose Range vs. Sensor-Augmented Pump Therapy
Jordan E. Pinsker, Alejandro J. Laguna Sanz, Mei Mei Church, Joon Bok Lee, Laura Lindsey, Camille C. Andre, Francis J. Doyle III, Yyal Dassau, Santa Barbara, CA, Cambridge, MA

### THE MINIMED™ 670G HYBRID CLOSED-LOOP (HCL) SYSTEM AND PATIENT-REPORTED OUTCOMES CONCERNING QUALITY OF LIFE MEASURES
Shweta Gopalakrishnan, Catherine Fogel, John Mueckler, Northridge, CA

### Open Artificial Pancreas System Reduced Hypoglycemia and Improved Glycemic Control in Patients with Type 1 Diabetes
Soo Bong Choi, Eun Shil Hong, Yun Hee Noh, Seoul, Republic of Korea

### Preference Differences between Insulin Glargine and MK-1293 Pens among Patients with Diabetes and Certified Diabetes Educators
Berhanu Alemayehu, Marco Dibona Ventura, Allison M. Nguyen, Michael Crutchlow, Kenilworth, NJ, New York, NY, North Wales, PA, Upper Gwynedd, PA

### Patient Reported Outcomes (PRO) in a Study of Human Regular U-500 Insulin (U-500R) Delivered by Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI) in Patients with T2D
Xiaomei Peng, Jieling Chen, Ludì Fan, Liza Ilag, Trang T. Ly, Jennal Johnson, Indianapolis, IN, Billerica, MA

### Delivery of Low Basal Rates in Different Insulin Pumps—An Accuracy Evaluation
Ralph Ziegler, Ulrike Kamecke, Delia Waldenmaier, Cornelia Haug, Guido Freckmann, Ulm, Germany, Münster, Germany

### Looking Beyond HbA1c—Evaluating Glycaemic Control during Closed-Loop Use in Type 1 Diabetes
Hood Thabit, Lalantha Leelarathna, Malgorzata E. Wilinska, Carsten Benesch, Sabine Arnolds, Julia K. Mader, Thomas R. Pieber, Mark Evans, Roman Hovorka, Manchester, United Kingdom, Cambridge, United Kingdom, Neuss, Germany, Graz, Austria
974-P Effect of Medicare (CMS) Insulin Pump Policies in T1D. NICHOLAS B. ARGENTO, JINGWEN LIU, AILEEN HICKEY, ELDA GAUTSCHI, ALICIA H. MCAULIFFE-FOGARTY, Columbia, MD, Boston, MA

975-P CSII Use in Hospitalized Patients—Adherence to Policy and Safety of Use. KATHERINE YANG, MOHAMMAD B. ATEYA, ROMA GIANCHANDANI, Ann Arbor, MI

976-P Glucose-Responsive Insulin Delivery with Fast Response Using Charge-Switchable Polymeric Depot. ZHEN GU, Apex, NC

977-P Real-World Use of Hybrid Closed-Loop Therapy in Pediatric Patients with Type 1 Diabetes. CARI BERGET, LAUREL H. MESSER, LAURA PYLE, EMILY WESTFALL, GREGORY P. FORLENZA, KIMBERLY A. DRISCOLL, Aurora, CO

978-P Meta-analysis vs. Single Trial (OptT2mise Study) Data to Assess Cost-Effectiveness of Simple CSII Devices in T2DM in the U.S. PETER WAHLOVIST, JAY L. WARNER, JOHN C. PICKUP, Cardiff, United Kingdom, Marlborough, MA, London, United Kingdom

979-P Dosing Time of Insulin Tregopil, a Novel Oral Insulin, in Type 2 Diabetes Mellitus Patients and Its Pharmacodynamic Effect. ANAND P. KHEDKAR, VINU JOSE, HAROLD E. LEOVITZ, ALAN D. CERRINGTON, GILBERT ALEXANDER FLEMING, SANDEEP N. ATHALYE, ASHWINI VISHWESWARUMURTHY, Bangalore, India, Brooklyn, NY, Nashville, TN, Harpers Ferry, WV


981-P Insulin Pump Therapy—Patient and Provider Perceptions. MAGALY PEREZ-NIEVES, COLLEEN GAREY, LUDI FAN, ALICIA H. MCAULIFFE-FOGARTY, Indianapolis, IN, Boston, MA

982-P Multiple Oral Insulin (ORMD-0801) Doses Elicit a Cumulative Effect on Glucose Control in T2DM Patients. ROY ELDROR, JOEL NEUTEL, KENNETH E. HOMER, MIRIAM KIDRON, Tel Aviv, Israel, Tustin, CA, Jerusalem, Israel

983-P Learning to Close the Loop. HAMISH CROCKET, Hamilton, New Zealand

984-P Evaluating Human Factors and Design Variables on Pen Injection Technique. CHRISTOPHER RINI, BRUCE C. ROBERTS, DIDIER MOREL, RICK KUG, BENJAMIN L. SELVAGE, RONALD J. PETTIS, Research Triangle Park, NC, Meylan, France

985-P Intradermal Administration Improves the Kinetics of Faster-Acting Insulin. SAHAN RANAMUKHA, IMAN MANSOOR, KIMBERLEY FENG, BORIS STOEBER, MOHAMED WEHBE, RORY ST CLAIR, CLAUDE PICHÉ, JEAN-PIERRE MÉROUÉ, Vancouver, BC, Canada, Montreal, QC, Canada, Riga, QC, Canada

986-P Glucose Control Using a Standard vs. an Enhanced Hybrid Closed-Loop System—A Pilot Study. BARBORA PALDUS, MELISSA H. LEE, HANNAH JONES, SYBIL A. MCAULEY, JODIE C. HORSBURGH, KERRYN L. ROEM, GLENN WARD, RICHARD MACISAAC, WILMA COLEMAN, PETER G. COLMAN, ALICIA JENKINS, DAVID N. O’NEAL, Melbourne, Australia, Parkville, Australia, Sydney, Australia

987-P Optimizing Basal-Bolus Therapy in T2D—A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch vs. an Insulin Pen. RICHARD M. BERGENSTAL, MARK PEYROT, DARLENE M. DREON, VANITA ARORA, TIMOTHY S. BAILEY, RONALD L. BRAZG, JUAN P. FRIAS, MARY L. JOHN-SON, DAVID C. KLOOFF, DAVIDA F. KRUGER, SHENAZ RAMTOOLA, JULIO ROSENOstock, PIERRE SERUSCLAT, RUTH S. WEINSTOCK, RAMACHANDRA G. NAIK, DAVID M. SHEARER, VIVIEN ZRAICK, BRIAN L. LEBOVITZ, Indianapolis, IN, Baltimore, MD, Menlo Park, CA, Hyattsville, MD, Escondida, CA, Renton, WA, Los Angeles, CA, San Mateo, CA, Detroit, MI, Blackburn, United Kingdom, Dallas, TX, Vénissieux, France, Syracuse, NY, Philadelphia, PA, Wayne, PA, San Francisco, CA

988-P Effectiveness of V-Go Wearable Insulin Delivery for Basal-Bolus Therapy: A Multicenter, Retrospective Real-World Evaluation in Type 2 Diabetes. RIPU S. HUNDAL, STEPHAN KOWALYK, JANE CASES, AMER AL-KARADSHEH, AMANDA P. WAKIM, MELISSA DOYLE, JOHN H. SINK II, ADRIENNE SPENCE, JAMIE L. BREWER, CARLA C. NIKKEL, Newark, DE, Greensburg, PA, Marietta, OH, Houston, TX, Wheeling, WV, Erwin, NC, Macon, GA, Picayune, MS, Jackson, MS, Edmond, OK
998-P  
Fasting Plasma Glucose Indicates Reversibility of Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes of Various Duration. LIEHUA LIU, SIYUE YANG, JIANBIN LIU, LI HAI, JUAN LIU, YANBING LI, Guangzhou, China, Hong Kong, China, Melbourne, Australia

1000-P  
Efficacy and Safety of Faster Aspart Compared with Insulin Aspart Both with Insulin Degludec in Adults with T1D. JOHN B. BUSE, ANDERS CARLSON, MITSUISHA KOMATSU, OFRI MOSENZON, LUDGER ROSE, BO LIANG, HIROSHI HORIO, TAKASHI KADOWAKI, Chapel Hill, NC, Minneapolis, MN, Nagano, Japan, Jerusalem, Israel, Münster, Germany, Søborg, Denmark, Tokyo, Japan
1001-P Better Postprandial Glucose (PPG) Control with BioChaperone Combo (BC Combo) than with Lispro Mix25 (LMx) or Separate Glargine and Lispro (G+L) Administrations in Subjects with Type 2 Diabetes (T2DM). TIM HEISE, LEONA PLUM-MOERSCHEL, CLAIRE MÉGRE, THERESA HERBRAND, VÉRONIQUE VACHER, ERNESTOS ANASTASSIADIS, OLIVER KLEIN, MARTIN GAUDIER, OLIVIER SOULA, STANISLAV GLEZER, BERTRAND ALLUIS, GRÉGORY MEIFFREN, Neuss, Germany, Mainz, Germany, Lyon, France, Skillman, NJ

1002-P Effect of the Combination Therapy of Tiraglutide, a GLP-1 Receptor Analog, and IDegAsp in Patients with Type 2 Diabetes. MARINA HARADA, MINORI SHINODA, RIKA SAKAMOTO, JUN SUZUKI, KENICHIRO TAKASHASHI, TADASHI YAMAKAWA, Yokohama, Japan

1003-P Comparison of Ultra-Rapid-Acting Insulin’s Effect—Randomised, Triple Crossover Study. SOICHICHI TAKEISHI, HIROKI TSUBOI, SHODO TAKEKOSHI, Inuyama, Japan

1004-P Improving Appropriate Basal Insulin Use in Clinical Practice—Impact of Physician Education on T2D Clinical Management. AMY LARKIN, MICHAEL LACOUTURE, ANNE LE, New York, NY

1005-P Follow-On Basal Insulin—Can Online CME Improve Clinical Knowledge and Ability to Use Effectively? AMY LARKIN, JESS DROPPIN, ANNE LE, New York, NY

1006-P Ultra-rapid Lispro (URLi) Shows Faster Absorption of Insulin Lispro vs. Humalog® during Insulin Pump (CSII) Use in Patients with T1D. CHRISTOF M. KAZDA, JENNIFER LEOHR, RONG LIU, THOMAS HARDY, SHOBHA REDDY, SHANE P.C. CHUA, XIAONAN GUO, ULRIKE HOVELMANN, CHRISTOPH KAPITZA, Vagnas, France, Indianapolis, IN, Singapore, Neuss, Germany

1007-P Treatment Effects of Once-Weekly Dulaglutide vs. Insulin Glargine in Patients with Different Baseline Glycemic Patterns (Based on High/Low Fasting or High/Low Postprandial Glucose)—A Post-Hoc Analysis of the AWARD-2 Clinical Trial. FRANCESCO GIORGINO, MARIA YU, AXEL HAUP, ZVONKO MILICEVIC, LUIS-EMILIO GARCIA-PEREZ, Bar, Italy, Toronto, ON, Canada, Indianapolis, IN, Vienna, Austria

1008-P The Effect of Temperature on the Stability of In-Use Insulin Pens. TANAWAN KONGMALAI, LUKANA PREECHASUK, SARAWUT JUNNU, SIRIPHAN MANOCHEEWA, CHATCHAWAN SRSAWAT, APIRADEE SRIWIJIT-KAMOL, Bangkok, Thailand

1009-P Ultra-rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T2D at Multiple Meal-to-Dose Timing Intervals. CHRISTOPH KAPITZA, JENNIFER LEOHR, RONG LIU, SHOBHA REDDY, MARY A. DELLVA, MARK MATZPOULOS, MARY P. KNADLER, MEI TENG LOH, THOMAS HARDY, CHRISTOF M. KAZDA, Neuss, Germany, Indianapolis, IN, London, United Kingdom, Singapore, Singapore, Vagnas, France

1010-P Ultra-rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T1D at Multiple Meal-to-Dose Timing Intervals. LEONA PLUM-MOERSCHEL, JENNIFER LEOHR, RONG LIU, SHOBHA REDDY, MARY A. DELLVA, SHUFEN LIM, MEI TENG LOH, MARY P. KNADLER, THOMAS HARDY, CHRISTOF M. KAZDA, Mainz, Germany, Indianapolis, IN, Singapore, Vagnas, France

1011-P Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with T2D—The VIVID Study, Primary Population. GEORGE GRUNBERGER, ANUJ BHARGAVA, TRANG T. LY, HOWARD ZISSER, LIZA ILAG, JAMES K. MALONE, SHUYU ZHANG, JENNAL JOHN-SON, Bloomfield Hills, MI, West Des Moines, IA, Billerica, MA, Santa Barbara, CA, Indianapolis, IN

1012-P WITHDRAWN

1013-P Continuous Glucose Monitoring Guided Assessment of Concentrated U200 r-DNA Human Premix 30/70 Insulin. HEMANT THACKER, JOTHYDEV KESAVADEV, GURSIMRAN SINGH, KIRTI SHUKLA, GAURAV PUPPALWAR, RUPAL SHIRMANKER, Mumbai, India, Trivandrum, India

1014-P Switching to Insulin Degludec from Insulin Glargine U100 Improves Glycemic Control in People with Type 1 (T1D) or Type 2 Diabetes (T2D) in a Real-World Setting. SOREN T. KNUDSEN, NIKOLAOS TENTOLOURIS, BERND SCHULTES, ANNUNZIATA LAPOLLA, MARKUS EIDENMUELLER, RUDOLF PRAGER, ANDREI-MIRCEA CATARIG, MICHAEL L. WOLDEN, THORSTEN SIEGMUND, Aarhus, Denmark, Athens, Greece, St. Gallen, Switzerland, Padova, Italy, Marburg, Germany, Vienna, Austria, Copenhagen, Denmark, Saborg, Denmark, Munich, Germany

1015-P WITHDRAWN

1016-P WITHDRAWN
1017-P Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients—STAT Study. JANET K. SNELL-BERGEON, HALIS K. AKTURK, AMANDA REVERS, BRUCE W. BODE, LESLIE J. KLAFF, ANNE PETERS, TIMOTHY S. BAILEY, SATISH K. GARG, Aurora, CO, Denver, CO, Atlanta, GA, Renton, WA, Los Angeles, CA, Escondido, CA

1018-P Is It Possible to Predict the Onset of Nocturnal Severe Asymptomatic Hypoglycemia Using CGM Data of Previous Day and Next Morning in Type 1 Diabetic Patients Receiving Insulin Degludec? HIROSHI TAKAHASHI, RIMEI NISHIMURA, KAZUNORI UTSUNOMIYA, Tokyo, Japan

1019-P One-Year Safety and Effectiveness of Insulin Degludec in Patients with Diabetes Mellitus in Routine Clinical Practice in India—TRUST (Tresiba Real-World Use Study). JOTHYDEV KESAVADEV, L. SREENIVASA MURTHY, SR., BANSHI D. SABOO, SADASIVA RAO YALAMANCHI, BALAMURUGAN RAMANATHAN, SUNIL GUPTA, SANJAY CHATTERJEE, MANJUNATHA REVANNA, HARSHA KASETTY, Trivandrum, India, Bangalore, India, Ahmedabad, India, Vijayawada, India, Coimbatore, India, Nagpur, India, Kolkata, India

1020-P Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients (Pts) with Type 2 Diabetes (T2DM) on Basal Insulin Supported Oral Therapy (BOT). JOCHEM SEUFERT, ANDREAS FRITSCH, HELMUT ANDERTEN, KATRIN PEGELOW, STEFAN PSCHERER, MARTIN PFÖHL, Freiburg, Germany, Tübingen, Germany, Hildesheim, Germany, Berlin, Germany, Weimar, Germany, Duisburg, Germany

1021-P Treatment Patterns in Patients with Type 2 Diabetes Treated with Human Regular U-500 Insulin—A Retrospective Claims Database Analysis. JIELING CHEN, XUANYAO HE, CHRISTI Y. KAO, JEFFREY A. JACKSON, Indianapolis, IN

1022-P Basal Insulin in Clinical Practice—Can Virtual Patient Simulation Improve Use in T2D? AMY LARKIN, MICHAEL LACOUTURE, MARTIN WARTERS, GWEN S. LITTMAN, New York, NY, Durham, NC

1023-P Pharmacodynamics of 100 vs. 200 Units of U500 Regular Insulin in Obese Subjects with T2DM. ANJALI KUMAR, RUPENDRA T. SHRESTHA, ABDISA S. TADESE, AMIR MOHEET, AMEER KHAWAJA, EVAN A. OLAWSKY, LYNN E. EBERLY, ELIZABETH R. SEAQUIST, Minneapolis, MN, Chaska, MN

1024-P BioChaperone 222 (BC222), the New Excipient Enabling the Ultra-rapid BioChaperone Lispro (BCLIS) Formulation, Is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection. GREGORY MEIFFREN, LEONA PLUM-MOERSCHL, AYMERIC RANSON, ERNESTOS ANASTASSIADIS, CYRIL SEROUSSI, JOSÉ CORREIA, GRIT ANDERSEN, MARTIN GAUDIER, OLIVIER SOULA, STANISLAV GLEZER, BERTRAND ALLUIS, Lyon, France, Mainz, Germany, Neuss, Germany, Skillman, NJ

1025-P Lower Day-to-Day Fasting Self-Measured Plasma Glucose (SMPG) Variability with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine 100 Units/mL (IGlar U100). IDIKO LINGVAY, ANKUR DOSHI, PEDRO A. GARCIA-HERNANDEZ, JUAN FRANCISCO MERINO TORRES, MELANIE RODACKI, FREDY A. JACKSON,技能 diversity, India, Bangalore, India, Chennai, India, Dubai, United Arab Emirates, Yaoundé, Cameroon, Moscow, Russian Federation, Paris, France, Hong Kong, China

1026-P Reasons for Discontinuation of Insulin Therapy—Results from the International Diabetes Management Practices Study (IDMPS). PABLO ASCHNER, JUAN J. GAGLIARDINO, HASAN M. ILKOV, FERNANDO J. LAVALLE-GONZALEZ, SR., AMBADY RAMACHANDRAN, GAHIDA KADDAHA, JEAN CLAUDE MBANYA, MARINA V. SHESTAKOVA, JEAN-MARC CHANTELOT, JULIANA C. CHAN,技能 diversity, Brazil, Seborg, Denmark, Hannover, Germany

1027-P Initiating Basal Insulin Supported Oral Therapy (BOT) with Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control in Patients (Pts) with Type 2 Diabetes (T2DM) without Increasing Hypoglycemia Risk. MARTIN PFÖHL, ANDREAS FRITSCH, HELMUT ANDERTEN, KATRIN PEGELOW, STEFAN PSCHERER, JOCHEM SEUFERT, Duisburg, Germany, Tübingen, Germany, Hildesheim, Germany, Berlin, Germany, Weimar, Germany, Freiburg, Germany

1028-P Self-Managed Titration with Insulin Glargine 300 U/mL (Gla-300) Can Achieve Similar Efficacy to Physician-Led Titration Regardless of Prior Insulin Status in People with T2DM—Results from TAKE CONTROL. ELIAS DELGADO, MIREILLE BONNEMAIRE, ARNAUD DAUCHY, VIERA DONICOLA, MILAN KVAPIL, NIKOLAOS TENTOLOURIS, LUIZA POPESCU, DAVID RUSSELL-JONES, Oviedo, Spain, Paris, France, Kosice, Slovakia, Prague, Czech Republic, Athens, Greece, Bucharest, Romania, Guildford, United Kingdom
1029-P Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People with T2DM from the BRIGHT Randomized Study. RONAN ROUSSEL, JULIO ROSENSTOCK, JEREMY PETTUS, ROBERT RITZEL, ALICE CHENG, ZSOLT BOSNYAK, CHRISTINE DEVISME, ANNA M. CALI, XIANGLING WANG, GERMERIA B. BOLLI, Paris, France, Dallas, TX, San Diego, CA, Munich, Germany, Mississauga, ON, Canada, Boulogne-Billancourt, France, Tokyo, Japan, Beijing, China, Perugia, Italy

1030-P Nonachievement of Glycemic Target—Results from the International Diabetes Management Practices Study (IDMPS). PABLO ASCHNER, JUAN J. GAGLIARDINO, HASAN M. ILKOVA, FERNANDO J. LAVALLE-GONZALEZ, SR., AMBADY RAMACHANDRAN, GHAIDA KADDAHA, JEAN CLAUDE MBANYA, MARINA V. SHESTAKOVA, JEAN-MARC CHANTELOT, JULIANA C. CHAN, Bogota, Colombia, La Plata, Argentina, Istanbul, Turkey, Monterrey, Mexico, Chennai, India, Dubai, United Arab Emirates, Yaoundé, Cameroon, Moscow, Russian Federation, Paris, France, Hong Kong, China

1031-P Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control after Failure of Nonachievement of Glycemic Target—Results from the International Diabetes Management Practices Study (IDMPS). STOCK, ELLE BOELLE-LE CORFEC, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, JULIO ROSENSTOCK, EMANUELE BOELLE-LE CORFEC, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, JULIO ROSENSTOCK, Perugia, Italy, Mississauga, ON, Canada, Paris, France, Chilly-Mazarin, France, Tokyo, Japan, Beijing, China, Los Angeles, CA, Dallas, TX

1032-P Lower Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM on Oral Antihyperglycemic Therapy ± GLP-1RA—The BRIGHT Randomized Study. GERMERIA B. BOLLI, ALICE CHENG, ZSOLT BOSNYAK, EMANUELE BOELLE-LE CORFEC, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, JULIO ROSENSTOCK, Perugia, Italy, Mississauga, ON, Canada, Paris, France, Chilly-Mazarin, France, Tokyo, Japan, Beijing, China, Los Angeles, CA, Dallas, TX

1033-P Comparison of Different Self-Adjustment Regimens of Basal Insulin in Outpatients with T2DM. XILING HU, XUBIN YANG, WEN XU, HONG R. DENG, XIAODI GUO, BIN YAO, LONGYI ZENG, JIANPING WENG, Guangzhou, China

1034-P WITHDRAWN

1035-P The Ultra-Rapid Insulin (URI) BioChaperone Lispro (BCLIS) Shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs. Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII). BRUCE W. BODE, OLIVER KLEIN, CYRIL SEROUSSI, AYMERIC RANSON, JORGE ARRUBLA, JOSÉ CORREA, MARTIN GAUDIER, OLIVIER SOULA, RÉMI SOULA, BERTRAND ALLUIS, GRÉGORY MEIFFREN, STANISLAV GLEZER, TIM HEISE, Atlanta, GA, Neuss, Germany, Lyon, France, Skillman, NJ

1036-P Similar Variability of Fasting and 24-h Self-Measured Plasma Glucose (SMPG) with Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve Adults with T2DM—The Randomized BRIGHT Trial. ALICE Y.Y. CHENG, ROBERT RITZEL, ZSOLT BOSNYAK, EMANUELE BOELLE-LE CORFEC, ANNA M. CALI, XIANGLING WANG, JUAN P. FRIAS, RONAN ROUSSEL, GERMERIA B. BOLLI, Mississauga, ON, Canada, Munich, Germany, Paris, France, Chilly-Mazarin, France, Tokyo, Japan, Beijing, China, Los Angeles, CA, Perugia, Italy

1037-P Change in Insulin Dose and HbA₁c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study. DIDAC MAURICIO, LUIGI MENEGHINI, EMANUELA ORSI, VADIM KILIMONTOV, JUKKA WESTERBACKA, LYDIE MELAS-MELT, VALERIE PILORET, RICCARDO PERFETTI, KAMLESH KHUNTI, Badalona, Spain, Dallas, TX, Milan, Italy, Novosibirsk, Russian Federation, Paris, France, Levallois-Perret, France, Bridgewater, NJ, Leicester, United Kingdom

1038-P Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSI) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements. XIAOUS MA, RANDY P. PRESCELLA, SHUYU ZHANG, HELLE LINNEBJERG, LINDA MORROW, JEFFREY A. JACKSON, JENNAL JOHNSON, DEREK LEISHMAN, Indianapolis, IN, Chula Vista, CA

1039-P Achievement of Individualized HbA₁c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study. LORI BEARD, DIDAC MAURICIO, KAMLESH KHUNTI, DENISE R. FRANCO, JUKKA WESTERBACKA, CHRISTOPHE CANDELAS, VALERIE PILORET, RICCARDO PERFETTI, LUIGI MENEGHINI, Winnipeg, MB, Canada, Badalona, Spain, Leicester, United Kingdom, Sao Paulo, Brazil, Paris, France, Chilly-Mazarin, France, Bridgewater, NJ, Dallas, TX
1040-P Short-Term Effects of Basal-Plus Insulin Therapy on Early Remission of Newly Diagnosed Type 2 Diabetes. EMMA WOKS, MARTINE CLAUDE ETÖA NDZIE ETÖGA, RAICHA NAMBA, JEAN CLAUDE NJABOU KATTE, JEAN CLAUDE MBANYA, EUGÈNE SOBNGWI, Yaoundé, Cameroon

1041-P Efficacy and Safety of Biphasic Insulin Aspart Treatment in Hospitalized Patients with T2DM—A Real-World Study. RAVI S. ERUKULAPATI, APARNA YERRAMILLI, VISALAKSHI KANCHELRA, GOPALA RAO S. SREELALITHA, ANITHA POOJARI, FATHIMA Z. KHAN, KRISHNA REDDY CHAPPIDI, Hyderabad, India

1042-P Lower Pharmacokinetic and Pharmacodynamic Within-Day Variability of Individual Clinical Doses of Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in T1DM. CARMINE FANELLI, PAOLA LUCIDI, PAOLA CANDELORO, PATRIZIA CIOLI, ANNA MARINELLI ANDREOLI, GEREMIA B. BOLLI, FRANCESCA PORCELLATI, Perugia, Italy

1043-P The Influencing Factors of Continuous Subcutaneous Insulin Infusion in Newly Diagnosed T2DM Patients. WEIJIAN KE, LIEHUA LIU, YANBING LI, Guangzhou, China

1044-P The Effect of Age on Short-Term Insulin Intensive Therapy for Patients with New Diagnosis Type 2 Diabetes. XUESI WAN, ZHIMIN HUANG, LIJUAN XU, YANBING LI, Guangzhou, China

1045-P The Characteristics of Patients with Long Remission after Short-Term Insulin Intensive Therapy. XUESI WAN, LIU JUAN, ZHIMIN HUANG, LIEHUA LIU, YANBING LI, Guangzhou, China

1046-P High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c < 7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL. DAVID R. OWENS, WOLFGANG LANDGRAF, MEI ZHANG, BRIAN M. FRIER, LUIGI MENEGHINI, PHILIP HOME, GEREMIA B. BOLLI, Swansea, United Kingdom, Frankfurt, Germany, Bridgewater, NJ, Edinburgh, United Kingdom, Dallas, TX, Newcastle upon Tyne, United Kingdom, Perugia, Italy

1047-P Insulin Therapy in Type 3c Diabetes—More Common in Chronic Rather than Acute Pancreatitis. WILLIAM HINTON, MICHAEL FEHER, NEIL M. MUNRO, RACHEL M. COYLE, SIMON DE LUSIGNAN, Guildford, United Kingdom

1048-P Self-Titration with Insulin Glargine 300 or 100 U/mL has Improved Efficacy vs. Physician-Led Titration—Comparison of the TAKE-CONTROL, AT.LANTUS, and ATLAS Studies in People with Type 2 Diabetes (T2DM). MELANIE JANE DAVIES, EMMANUELLE BOELLE-LE CORFEC, MIREILLE BONNEMAIRE, MASATO ODOWARA, LUIZA POPESCU, JOCHEN SIEBER, DAVID RUSSELL-JONES, KRYSZTOF STROJEK, NIKOLAOS TENTOLOURIS, Leicester, United Kingdom, Chilly-Mazarin, France, Paris, France, Tokyo, Japan, Bucharest, Romania, Frankfurt, Germany, Guildford, United Kingdom, Zabrze, Poland, Athens, Greece

1049-P Effectiveness of Insulin Glargine U300 Used as Part of Basal Bolus Therapy in People with T2DM—Toujeo 6 Months Real-World Data From Hungary. TIBOR HIDVEGI, PETER STELLA, Győr, Hungary, Paris, France

1050-P The Use of Supportive Tools and Education Enables Self-Titration with Insulin Glargine 300 (Gla-300) or 100 U/mL (Gla-100) in People with Type 2 Diabetes (T2DM)—Results from TAKE CONTROL, INNOVATE, and AUTOMATIX. MILAN KVAPIL, MIREILLE BONNEMAIRE, HARMONIE GOYEAU, NIKOLAOS PAPANAS, LUIZA POPESCU, BERND SCHULTES, JOCHEN SIEBER, LEA DUVNJAK, Prague, Czech Republic, Paris, France, Chilly-Mazarin, France, Alexandroupolis, Greece, Bucharest, Romania, St. Gallen, Switzerland, Frankfurt, Germany, Zagreb, Croatia

1051-P Impact of Endogenous Insulin Adjustment Methods on the Assessment of Insulin Pharmacokinetics and Pharmacodynamics. SANG M. CHUNG, JUSTIN A. PENZENSTADLER, MANOJ KHURANA, CHANDRAHAS SAHAIJWALLA, Silver Spring, MD

1052-P Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry—The REALITY Study. ALEXANDER ABITBOL, RUTH E. BROWN, DISHAY JIAN-DANI, LUC Sauriol, RONNIE ARONSON, Toronto, ON, Canada, Laval, QC, Canada

1053-P Electron Microscopic Findings of Insulin-Induced Local Amyloidosis. SULEYMAN SENDUR, KUBRA KATIPOGLU, OZGE KOCKARA, OZAY GÖKÖZ, FIGEN KAYMAZ, SELCUK DAGDELEN, Ankara, Turkey

1054-P The Impact of Different Initial Insulin Dose Regimens in Short-Term Intensive Insulin Therapy. HUANG XINWEI, Guangzhou, China
1055-P The Challenges and Potential of Digital Therapeutic Solutions for Long-Acting Insulin Management. ARATI KANCHI, LINDA PARKS, TONG SHENG, JANE LEA SMITH, MICHAEL GREENFIELD, Mountain View, CA, Del Mar, CA

1056-P Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ SEAN D. SULLIVAN, TIMOTHY S. BAILEY, RONAN ROUSSEL, FANG L. ZHOU, ZSOLT BOSNYAK, RON PREBLICK, JUKKA WESTERBACKA, RISHAB GUPTA, LAWRENCE BLONDE, SEATTLE, WA, Escondido, CA, Paris, France, Bridgewater, NJ, Florham Park, NJ, New Orleans, LA

1057-P Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses. SEAN D. SULLIVAN, TIMOTHY S. BAILEY, RONAN ROUSSEL, FANG L. ZHOU, ZSOLT BOSNYAK, RON PREBLICK, JUKKA WESTERBACKA, RISHAB GUPTA, LAWRENCE BLONDE, SEATTLE, WA, Escondido, CA, Paris, France, Bridgewater, NJ, Florham Park, NJ, New Orleans, LA

1058-P Mobile-Based Artificial Intelligence Significantly Improves Type 1 Diabetes Management. JOHN DOPIS, VASILIKI PAPANDREOPOULOU, SPYRIDOULA GLYKOFRIDI, VASILEIOS ANDRIANESIS, Athens, Greece

1059-P Impact of Insulin Therapy Assistance Program, a Patient Support Program, on 10,426 Indian T2DM Patients to Assess Safety and Efficacy with Biosimilar Insulin. SARAH JABEEN, DILIP PAWAR, SHIVARAM VS, PRAVEEN RAJ, Bangalore, India

CLINICAL THERAPEUTICS/NEW TECHNOLOGY—NONINSULIN INJECTABLES

Moderated Poster Discussion: Clinical Studies with Noninsulin Injectables (Posters: 1060-P to 1065-P), see page 92.

1060-P LXisenatide and Renal Outcomes in Patients with Type 2 Diabetes—A Post-Hoc Analysis of the ELIXA Trial. MARCEL A. MUSKIET, LENNART TONNELICK, YAO HUANG, MINZHI LIU, ARAMESH SAREMI, HIDDO LAMBERS, HEERSPINK, DANIEL H. VAN RAALTE, Amsterdam, Netherlands, Somerset, NJ, Pluckemin, NJ, Groningen, Netherlands

1061-P ITCA 650 Provides Consistent Efficacy in T2D Irrespective of Baseline Characteristics—Results of a Pooled Subgroup Analysis. PRAKASH PRABHAKAR, LISE L. KJEMS, HOLLY HUANG, BRIAN SCHWARTZ, MICHELLE A. BARON, Boston, MA, Morristown, NJ

1062-P Durability of Combination Therapy with Exenatide and Pioglitazone vs. Basal Bolus Insulin in Poorly Controlled T2DM Patients—Three-Year Follow-Up of the QATAR Study. MUHAMMAD ABDUL-GHANI, OSAMA MIGAHID, SR., AYMAN MEGAHED, SR., MOHAMMAD FAWAZ. MOHAMMAD, RALPH A. DEFRONZO, AMIN JAYYOUSI, Sao Antonio, TX, Doha, Qatar

1063-P Progression from Prediabetes to Type 2 Diabetes (T2DM) in 303 Hypogonadal Men With and Without Testosterone Treatment—Eight-Year Real-Life Data from a Registry. FARID SAAD, AHMAD HAIDER, KARIM S. HAIDER, Berlin, Germany, Bremerhaven, Germany

1064-P Identification of Subpopulations Exhibiting the Greatest Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide-1 Receptor Agonists—A Combined Analysis of Large Cardiovascular Outcome Trials. YU MI KANG, YUN KYUNG CHO, JONG HAN CHOI, CHANGYUN WOO, WOO JE LEE, JOONG-YEOL PARK, CHANG HEE JUNG, Seoul, Republic of Korea

1065-P Rates of Major Adverse Cardiovascular (CV) Events (MACE) and Mortality with Basal Insulin by Liraglutide Use—A DEVOTE Subanalysis. KIRSTINE BROWN-FRANDSEN, SCOTT S. EMERSON, STEVEN P. MARSO, DARREN K. MCGUIRE, THOMAS R. PIEBER, NEIL R. POULTER, BERNARD ZINMAN, RANDI GRØN, MARTIN LANGE, ALAN C. MOSES, PETRA ÖRBY, MATTIS F. RANTHE, RICHARD E. PRATLEY, ON BEHALF OF THE DEVOTE STUDY GROUP, Seborg, Denmark, Seattle, WA, Kansas City, MO, Dallas, TX, Graz, Austria, London, United Kingdom, Toronto, ON, Canada, Plainsboro, NJ, Orlando, FL

1066-P Lesser eGFR Decline with Dulaglutide Regardless of Weight Changes in People with Type 2 Diabetes and Moderate to Severe Chronic Kidney Disease (AWARD-7). KATHERINE R. TUTTLE, MARK LAKSHMANAN, BRIAN L. RAYNER, ROBERT S. BUSCH, ALAN G. ZIMMERMANN, BRAD WOODWARD, FADY T. BOTROS, Spokane, WA, Indianapolis, IN, Cape Town, South Africa, Albany, NY
1067-P | Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes. PHILIP AMBERY, MICHAEL W. STUMVOLL, MAXIMILIAN G. POSCH, TIM HEISE, LEONA PLUM-MOERSCHEL, LAN-FENG TSAI, DARREN ROBERTSON, MARCELLA PETRONE, CRISTINA RONDINONE, VICTORIA E. PARKER, BOAZ HIRSHBERG, LUTZ JERMUTUS, Cambridge, United Kingdom, Leipzig, Germany, Berlin, Germany, Neuss, Germany, Mainz, Germany, Gaithersburg, MD

1068-P | Relative Contribution of Basal and Postprandial Hyperglycemia Stratified by A1c Categories Before and After Treatment Intensification with Dulaglutide. GUILLERMO E. UMPIERREZ, KEVIN M. PANTALONE, CHARLES ATISSO, LAURA FERNANDEZ LANDO, HIREN PATEL, Atlanta, GA, Cleveland, OH, Indianapolis, IN

1069-P | Achieving Composite Endpoint of A1C <7.0% without Weight Gain or Hypoglycemia with Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes—Post-Hoc Analysis. XINHUA XIAO, CHANGJIANG WANG, FENG WANG, PENGFEI LI, LIQUN GU, Beijing, China, Hefei, China, Shanghai, China

1070-P | MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes—A Multiple-Ascending-Dose Study. DARREN ROBERTSON, MICHAEL W. STUMVOLL, MAXIMILIAN G. POSCH, TIM HEISE, LEONA PLUM-MOERSCHEL, GERNOT KLEIN, LAN-FENG TSAI, MARCELLA PETRONE, BOAZ HIRSHBERG, CRISTINA RONDINONE, VICTORIA E. PARKER, LUTZ JERMUTUS, PHILIP AMBERY, Cambridge, United Kingdom, Leipzig, Germany, Berlin, Germany, Neuss, Germany, Mainz, Germany, Munich, Germany, Gaithersburg, MD

1071-P | Comparative Glycemic Effectiveness of Dulaglutide vs. Liraglutide and Exenatide QW in a U.S. Real-World Setting. REEMA MOODY, QING HUANG, MARIA YU, HIREN PATEL, RUIZHI ZHAO, MICHAEL GRABNER, LAURA FERNANDEZ LANDO, Indianapolis, IN, Wilmington, DE, Toronto, ON, Canada

1072-P | Relationship of Ethnicity to Clinical Outcomes in iGlarLixi-Treated Patients with Type 2 Diabetes. PABLO MORA, JASON CHAO, ARAMESH SAREMI, TERRY A. DEX, MICHELLE ROBERTS, GUILLERMO E. UMPIERREZ, Dallas, TX, Bridgewater, NJ, Atlanta, GA

1073-P | Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM). JULIO ROSENSTOCK, ANTONIO J. NINO, JOSEPH SOFFER, JASON M. MALLORY, LOIS M. ERSKINE, ANDRE ACUSTA, JO F. DOLE, MOLLY CARR, PHILLIP HOME, Dallas, TX, Chester Springs, PA, Collegeville, PA, King of Prussia, PA, Newcastle upon Tyne, United Kingdom

1074-P | Short Duration of Diabetes Should Be Associated with More Prominent Effect of Liraglutide—Titrated from Insulin Degludec plus Liraglutide Combination Therapy. KOJI KASHIMA, HIROYUKI SHIMIZU, MASANOBU YAMADA, Kyus, Japan, Maebashi, Japan

1075-P | Effect of Single Dose of Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) on Postprandial Glucodynamic Response in Japanese Patients with Type 2 Diabetes Mellitus. MEGUMI INOUE, MARTIN LORENZ, HIDEYA MUTO, YASUHIRO HASHIMOTO, KIRIYAMA, Tokyo, Japan

1076-P | Treatment and Clinical Measures after Initiation of Injectable Therapy for Type 2 Diabetes—A Real-World Observational Cohort Study. ORNA REGES, MAYA LEVENTER-ROBERTS, BRADLEY CURTIS, ILAN GOFER, XUANYAO HE, TOMAS KARPATI, GIL RUBIN, MORTON LEIBOWITZ, ALENA STRIZEK, BECCA S. FELDMAN, Tel Aviv, Israel, Sydney, Australia, Indianapolis, IN, Raanana, Israel

1077-P | Medication Compliance on Glycemic Control in Patients with Elevated HbA1c. AHMED ELHASAN, MARCONI ABREU, ANNA TUMYAN, OLIVIA PACAPOSTEA, KATHERINE PEICHER, PERIHAH DIMACHKIE, MUHAMMAD S. SIDIQUI, BEVERLEY ADAMS-HUET, XILONG LI, LAURENTIU POP, ILDIKO LINGVAY, DALLAS, TX, Redlands, CA, Oklahoma City, OK, McKinney, TX

1078-P | Safety and Efficacy of Exenatide Therapy for the Management of Hospitalized Patients with Type 2 Diabetes—Exenatide Hospital Trial. MAYA FAYFMAN, DARA L. MIZE, DANIEL J. RUBIN, ISABEL ANZOLA, MARIA A. URRUTIA, CLEMENTINA RAMOS, FRANCISCO J. PASQUEL, J. SONYA HAW, PRIYATHAMA VELLANKI, HEQIONG WANG, KATHERINE E. JOHEY, ABHIJANA KARUNAKARAN, BONNIE S. ALBURY, RITA WEAVER, LAVANYA VISWANATHAN, SHUCHIE JAGGI, RODOLFO J. GALINDO, GUILLERMO E. UMPIERREZ, Atlanta, GA, Nashville, TN, Philadelphia, PA, Decatur, GA, Pittsburgh, PA

1079-P | Effect of Dulaglutide and Long-Acting Insulin Combination Therapy in Patients with Type 2 Diabetes. KOHEI ITO, YOSHI NOBU KONDO, SHINOBU SATOH, YASUO TERAUCHI, Chigasaki, Japan, Yokohama, Japan
1080-P Effects of Dulaglutide and Trelagliptin on Beta-Cell Function in Patients with Type 2 Diabetes—The DUET-Beta Study. YOSHINOBU KONDO, SHINOBU SATOH, YASUO TERAUCHI, Yokohama, Japan, Chigasaki, Japan

1081-P Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis. JULIO ROSENSTOCK, LOUIS B. CHAYKIN, JOERG LUEDEMANN, STEN MADSBAD, SR., JULIE F. LARSEN, EMRE YILDIRIM, STEPHEN C. BAIN, Dallas, TX, Bradenton, Fl, Falkensee, Germany, Copenhagen, Denmark, Saborg, Denmark, Swansea, United Kingdom

1082-P LIRA-PRIME Trial Design and Baseline Data—Efficacy in Controlling Glycemia with Liraglutide in a Primary Care Setting. JEFF UNGER, DEER LOWE, GERRI MURPHY, JAYANT KUMAR PANDA, MEHMET SARGIN, MARGIT KALTOFT, MARIANNE TREPPENDAHL, MAROUAN ZOGHBI, Rancho Cucamonga, CA, Surrey, BC, Canada, Mount Pearl, NL, Canada, Cuttack, India, Istanbul, Turkey, Saborg, Denmark, Beirut, Lebanon

1083-P Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7. ADIE VILJOEN, MATTHIAS BLUHER, FRANCIS C.C. CHOW, CAREL LE ROUX, JULIO ROSENSTOCK, NANNIA L. LAUSVIG, EMRE YILDIRIM, ILDIKO LINGVAY, Stevenage, United Kingdom, Leipzig, Germany, Hong Kong, China, Dublin, Ireland, Dallas, TX, Saborg, Denmark

1084-P Semaglutide Treatment and Renal Function in the SUSTAIN 6 Trial. TINA VILSBØLL, JANUSZ GUMPRECHT, ROBERT J. SILVER, THOMAS HANSEN, JONAS PETTERSSON, JOHN P. WILDING, Hellerup, Denmark, Zabrze, Poland, Nashua, NH, Saborg, Denmark, Liverpool, United Kingdom

1085-P Semaglutide Consistently Reduces Cardiovascular Events in Both Male and Female Subjects with Type 2 Diabetes. IRENE HRAMIAK, CYRUS DESOUZA, JOCHEN SEUFERT, THOMAS HANSEN, DESIREE THIELKE, ILDIKO LINGVAY, London, ON, Canada, Omega, NE, Freiburg, Germany, Saborg, Denmark, Dallas, TX

1086-P Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer—A Meta-analysis with Trial Sequential Analysis. LANA C. PINTO, DIMITRIS V. RADOS, MARIANA R. FALCETTA, CRISTIANE B. LEITAO, Porto Alegre, Brazil

1087-P Dulaglutide—Combined Conventional Insulin Therapy Contributes to Ideal Glycemic Control in Noncritically Ill Hospitalized Patients. NOBUTOSHI FUSHIMI, TAKASHI SHIBUYA, YOHEI YOSHIDA, SHUN ITO, HIROKI HACHIYA, AKIHIRO MORI, Ichinomiya, Japan

1088-P Long-Term Use of GLP-1 Receptor Agonists Alter GLP-1 Receptor mRNA Expression in Hindbrain Pathways That Regulate Gastric Motility in Mice. PEILI WANG, RAMANAIHA MAMILLAPALLI, WANLING ZHU, OWEN CHAN, New Haven, CT, Salt Lake City, UT

1089-P A1C Target Attainment in Patients with T2D Receiving iGlarLixi Who Reach PPG and FPG Targets in the Lixilan-L Trial. LAWRENCE A. LEITER, JASON CHAO, ARAMESH SAREMI, TERRY A. DEX, JAIME A. DAVIDSON IV, Toronto, ON, Canada, Bridgewater, NJ, Pluckemin, NJ, Dallas, TX

1090-P In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists. IN YOUNG CHOI, MI JIN MOON, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI, Seoul, Republic of Korea, Chula Vista, CA, Bridgewater, NJ

1091-P Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide. YOUNG JIN PARK, IN YOUNG CHOI, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, CHRISTOPHER H. SORLI, Seoul, Republic of Korea, Chula Vista, CA, Bridgewater, NJ

1092-P Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%—Analyses from the DUAL Program. DANNY SUGIMOTO, JUAN P. FRIAS, DIDIER GOUET, RÖBERT TAKÁCS, TING JIA, PETRA ÖRSY, STEPHEN C. BAIN, Chicago, IL, Los Angeles, CA, La Rochelle, France, Szeged, Hungary, Saborg, Denmark, Swansea, United Kingdom

1093-P Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi. CYRUS DESOUZA, VIVIAN FONSECA, JUAN P. FRIAS, LUC VAN GAAL, FRANCESCO GIORGINO, JASON CHAO, TERRY A., DEX, MICHELLE ROBERTS, ARAMESH SAREMI, LAWRENCE A. LEITER, Omaha, NE, New Orleans, LA, Los Angeles, CA, Antwerp, Belgium, Bari, Italy, Bridgewater, NJ, Readington, NJ, Pluckemin, NJ, Toronto, ON, Canada

1094-P Impact of Type 2 Diabetes (T2D) Duration on Response to iGlarLixi vs. iGlra—A Subanalysis of LixiLan-L. LAWRENCE BLONDE, LORI BERARD, ARAMESH SAREMI, YAO HUANG, VANITA ARODA, DENIS RACCAH, New Orleans, LA, Winnipeg, MB, Canada, Pluckemin, NJ, Somerset, NJ, Hyattsville, MD, Marseille, France
9095-P iGlarLixi Effectively Reduces Residual Hyperglycemia in Patients with Type 2 Diabetes on Basal Insulin—A Post-Hoc Analysis from the LixiLan-L Study. FRANCESCO GIORGINO, RAVI RETNAKARAN, JOSEP VIDAL, VANITA ARODA, ARAMESH SAREMI, MINZHI LIU, Bari, Italy, Toronto, ON, Canada, Barcelona, Spain, Hyattsville, MD, Pluckemin, NJ, Somerset, NJ

9096-P Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP‐1RA) in Patients with Type 2 Diabetes—PROGRESS-DIABETES Study. RUTH E. BROWN, ALEXANDER ABITBOL, HARPREET S. BAJAJ, HASNAIN KHANDWALA, RONALD GOLDBERG, SUZAN ABDEL-SALAM, RONNIE ARONDON, Toronto, ON, Canada, Brampton, ON, Canada, Thornhill, ON, Canada, Barrie, ON, Canada

9097-P Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies. STEFANO DEL PRATO, IN YOUNG CHOI, JAHOON KANG, MICHAEL E. TRAUTMANN, KUN-HO YOON, CHRISTOPHER H. SORLI, Pisa, Italy, Seoul, Republic of Korea, Chula Vista, CA, Bridgewater, NJ

9098-P Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide. MICHAEL E. TRAUTMANN, IN YOUNG CHOI, JUNG KUK KIM, CHRISTOPHER H. SORLI, Chula Vista, CA, Seoul, Republic of Korea, Bridgewater, NJ

9099-P Predictive Factors of Insulin Discontinuation after Adding a GLP-1 Receptor Agonist in Patients with Type 2 Diabetes Treated with Insulin in Combination with Oral Antihyperglycemic Agents. JUAN J. GORGOJO-MARTINEZ, Alcorcón, Spain

1100-P Effect of Biased GLP-1/Glucagon Receptor Co-agonists on Insulin Secretion. GALA FAROOQ, BEN JONES, JAMES S. MINNION, STEPHEN R. BLOOM, London, United Kingdom

1101-P Dulaglutide Has Favorable Outcomes in Elderly or Renal Impairment Patients with Type 2 Diabetes. SHIZUKA KANEKO, YOUEI UEDA, YUMIKO TAHARA, Takatsuki, Japan

1102-P Exploring Two Dose Regimens of ITCA 650 to Switch from Stable Liraglutide Therapy in Type 2 Diabetes (T2D). NEDA RASOULI, JULIO ROSENSTOCK, SAMER NAKHLE, BRIAN SCHWARTZ, PRAKASH PRABHAKAR, SYDNEY L. KRUGER, HOLLY HUANG, MICHELLE A. BARON, Denver, CO, Dallas, TX, Las Vegas, NV, Boston, MA, Morristown, NJ

1103-P Efficacy and Safety of ITCA 650, an Injection-Free GLP-1RA, in T2D Patients—A Pooled Analysis of Phase 3 Studies. LISE L. KJEMS, PRAKASH PRABHAKAR, BRIAN SCHWARTZ, HOLLY HUANG, MICHELLE A. BARON, Boston, MA, Morristown, NJ

1104-P Qualitative and Quantitative Effect of IDegLira Compared with the Nonfixed Administration of Degludec and Liraglutide. ANASTASIOS KOUTSOVASILIS, ALEXIOS SOTIROPOULOS, DESPINA PAPADAKI, EVOXIA BLETSAS, GEORGIOS KOKOTOS, IOANNIS KOUNELAKIS, STAVROS BOUSBOULAS, THEODOROS PEPPAS, Athens, Greece

1105-P Bone Protective Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in an Animal Model. SANGDON LEE, YU-YON KIM, JONG SUK LEE, SANG HYUN LEE, YOUNG HOON KIM, IN YOUNG CHOI, SUN JIN KIM, Seoul, Republic of Korea

1106-P Efficacy of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model. IN YOUNG CHOI, JUNG KUK KIM, JONG SUK LEE, EUNJIN PARK, YOUNG HOON KIM, SUNG YOUB JUNG, SUN JIN KIM, Seoul, Republic of Korea

1107-P Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models. JEONG A. KIM, SANGDON LEE, SANG HYUN LEE, SUNG YOUB JUNG, YOUNG HOON KIM, IN YOUNG CHOI, SUN JIN KIM, Seoul, Republic of Korea

1108-P Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus—A Systematic Review and Meta-analysis. MUNIZA M. SATTI, TIMOTHY O’BRIEN, AARON LIEW, Galway, Ireland

1109-P Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program. LUIGI MENEGHINI, SULTAN LINJAWI, PIERRE SERUSCLAT, TINA VILSBOLL, BUE F. AGNER, TRINE HANSEN, LAWRENCE A. LEITER, Dallas, TX, Coft's Harbour, Australia, Vénissieux, France, Hellerup, Denmark, Sæborg, Denmark, Toronto, ON, Canada
1110-P  Possibility of Lirolaglutide for Prevention of Dementia Progression in Patients with Type 2 Diabetes. MAMI YOSHIDA, TAKAKO MORIMOTO, ERIKO OH, NAOUME YAMAMOTO, KOJUI NAGATA, AKIO SAeki, EUN SASAKI, SHIGERU YOSHIDA, TAKESHI KUZUYA, NAKAII OHSAWI, MASAKAZU SUGINO, Ibaraki, Japan, Osaka, Japan, Otsu, Japan, Shimona, Japan

1111-P  Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies. JULIO ROSENSTOCK, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOO KANG, KUN-HO YOON, CHRISTOPHER H. SORLI, Dallas, TX, Chula Vista, CA, Seoul, Republic of Korea, Bridgewater, NJ

1112-P  Heterologous Adipose-Derived Mesenchymal Stem Cells and Vitamin D Supplementation in Patients with Recent-Onset Type 1 Diabetes Mellitus—Six Months Follow-Up. JOANA R. DANTAS, DEBORA A. CABRAL, SR., KARINA PEREIRA, MARIA F. PEREIRA, DEBORA L. SOUTO, MATHEUS NOLASCO, MARINA O. SOARES, MONICA GABBY, CARLOS E. COURI, CESAR S. CLAUDIO-DA-SILVA, CARMEN K. REBELATTO, SERGIO A. DIB, JOSE EGIIDO P. OLIVEIRA, LENITA ZAJDENVERG, MELANIE RODACKI, Rio de Janeiro, Brazil, São Paulo, Brazil, Ribeirão Preto, Brazil, Paranà, Brazil

1113-P  Cholesterol 7 Alpha-Hydroxylase (CYP7A1) Activity and 7-Alpha-Hydroxy-4-Cholesten-3-One (C4) Are Not Translatable Biomarkers of Glucagon Receptor (GCGR) Activation. RAUL CAMACHO, WENYU LI, THOMAS KIRCHNER, RUI ZHANG, FAN YONILLA, WENYING JIAN, BIN GAO, RANABIR SINHAROY, JAMES LEONARD, THOMAS CONNOLLY, Spring House, PA, Rantant, NJ

1114-P  Health State Utilities Associated with Attributes of Weekly Injection Devices and Subdermal Implant for Treatment of Type 2 Diabetes. ANNEN M. RENTZ, KATELYN CUTTS, KELLIE WASHINGTON, MAUD BEILLAT, SR., KRISTINA YU-ISENBERG, Bethesda, MD, Suresnes, France, Boston, MA

1115-P  IMPG-1 Is Able to Normalize Blood Glucose Levels by Inhibiting Glucagon Levels in a Type 2 Diabetic Rat Model. JONATHAN B. POLLETT, NGOC THAI, Devon, PA

CLINICAL THERAPEUTICS/NEW TECHNOLOGY—ORAL AGENTS

Moderated Poster Discussion: New Concepts in Oral Therapies (Posters: 1116-P to 1121-P), see page 90.

1116-P  Dapagliflozin Suppresses Plasma Hepcidin Concentrations. HUSAM GHANIM, JEANNE M. HEJNA, SANAA ABUAYSHEH, TANVI SHAH, JAGDESH KUMAR, MANAV BATRA, PARESH DANDONA, Buffalo, NY, Williamsville, NY

1117-P  An Allosteric Glucagon Receptor Antagonist, LGD-6972, Displays Biased Receptor Signaling. ERIC G. VAJDA, LIN ZHI, KEITH MARCHSKE, San Diego, CA

1118-P  OWL833, an Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys. TAKAHIRO KAWAI, FUJIMIHO TANINO, MASANORI FUKAZAWA, KOTARO OGAWA, SHUNSUKE NAGAO, HITOSHI MAMI YOSHIDA, TAKAKO MORIMOTO, ERIKO OH, NAOMUNE YAMAMOTO, KOJUI NAGATA, AKIO SAEKI, EUN SASAKI, SHIGERU YOSHIDA, TAKESHI KUZUYA, NAKAII OHSAWI, MASAKAZU SUGINO, Ibaraki, Japan, Osaka, Japan, Otsu, Japan, Shimona, Japan

1119-P  Alteration of Gut Microbiota Induced by DPP-4i Treatment Improves Glucose Homeostasis. XIAOYU LIAO, HONGTING ZHENG, Chongqing, China

1120-P  Pioglitazone Alters the Cargo Composition of Circulating Exosomes in Subjects with Type 2 Diabetes. YURY O. NUNEZ LOPEZ, RICHARD E. PRATLEY, Orlando, FL

1121-P  FTY720 Treatment Rejuvenates β-Cell Function and Improves Cardiac Function in Diabetic Nonhuman Primates (NHPs). YIXIN WANG, YONGQIANG LIU, QIAO WEI, XIAOLI WANG, GAO SUN, YONGFU XIAO, GUOLIANG YU, ZHONGMIN A. MA, Taicang, China, Suzhou, China, Great Neck, NY

Moderated Poster Discussion: Clinical Outcomes with Oral Therapies (Posters: 1122-P to 1127-P), see page 92.

1122-P  Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study). THOMAS DANNE, BERTRAND CARIOU, PHILLIP L. BANKS, MICHAEL BRANDLE, HELMUT BRATH, EDWARD FRANEK, JAKE A. KUSHNER, PABLO LAPUERTA, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH, Hannover, Germany, Nantes, France, The Woodlands, TX, Kantonsspital St. Gallen, Switzerland, Vienna, Austria, Warsaw, Poland, Houston, TX, Basking Ridge, NJ, Dallas, TX, Los Angeles, CA
1123-P Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. DAVID H. FITCHETT, BENJAMIN M. SCIRICA, SILVIO INZUCCHI, CHRISTOPHER P. CANNON, DARREN K. MCGUIRE, ODD ERIK JOHANSEN, STEVEN SAMBEVSKI, UWE HEHNKE, JYOTIHS T. GEORGE, BERNARD ZINMAN, Toronto, ON, Canada, Boston, MA, New Haven, CT, Dallas, TX, Askar, Norway, Ingelheim, Germany

1124-P Cumulative Delays in Treatment Intensification over Three Typical Stages of Antihyperglycemic Treatment. SUMA VUPPUTURI, Rockville, MD

1125-P The Comparative Cardiovascular Effectiveness of Six Antidiabetic Medications among Insured Adults with Type 2 Diabetes. MATTHEW O’BRIEN, SUSAN L. KARAM, AMISHA WALLIA, RAYMOND KANG, ANDREW J. COOPER, NICOLA LANCKI, MARGARET R. MORAN, DAVID T. LISS, THEODORE A. PROSPECT, RONALD T. ACKERMANN, Chicago, IL, Minneapolis, MN

1126-P Systems Medicine Derived Biomarkers to Assess How Canagliflozin Delays Progression of Diabetic Kidney Disease. HIDDO LAMBERS, HEERSPINK, PAUL PERCO, JOHANNES LEIERER, MICHAEL K. HANSEN, ANDREAS HEINZEL, GERT MAYER, Groningen, Netherlands, Innsbruck, Austria, Spring House, PA, Vienna, Austria

1127-P Short-Term Effects of a Sodium–Glucose Linked Transporter 2 Inhibitor on Left Ventricular Relaxation in Non diabetic Hypertensive Patients. EBO ETOUA KRISTEL KELLY, JEAN CLAUDE MBANYA, EUGÈNE SOBNGWI, MFELUEKU KUATE LILIANE, Yaoundé, Cameroon

1128-P Sodium–Glucose Cotransporter 2 Inhibitors for Type 1 Diabetes Mellitus—Systematic Review and Meta-analysis. TOMOHIDE YAMADA, JUN HOSOE, NOBUHIRO SHOJIMA, TOSHIMASA YAMAUCHI, TAKASHI KADOWAKI, Tokyo, Japan

1129-P Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy—104-Week VERTIS MET Trial. SILVINA GALLO, BERNARD CHARBONNEL, ALLISON GOLDMAN, HARRY SHI, SUSAN HUYCK, AMANDA DAREKAR, BRETT LAURING, STEVEN TERRA, Berlin, Germany, Nantes, France, Collegeville, PA, New York, NY, Kenilworth, NJ, Tadworth, United Kingdom, Rahway, NJ, Andover, MA

1130-P Gemigliptin in Diabetic Kidney Disease in Asian Indians with Type 2 Diabetes in Real-Life Scenarios—Insights from Gem Study. KIRAN SHAH, SONALI A. PATANGE, ALKA P. GANDHI, Mumbai, India

1131-P A Phase 3 Study to Assess the Efficacy and Safety of Ipragliflozin in Russian Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin. MARINA V. SHESTAKOVA, JOHN P. WILDING, WIM WILPSHAAR, REINER N. TRETTER, VALERIA L. ORLOVA, ANDREY F. VERBOVOY, Moscow, Russian Federation, Livermore, United Kingdom, Leiden, Netherlands, Saint Petersburg, Russian Federation, Samara, Russian Federation

1132-P Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM). JIE LIU, LISA TARASENKO, ANNPEY PONG, SUSAN HUYCK, LARRY WU, JAMES P. MANCUSO, STEVEN TERRA, BRETT LAURING, Rahway, NJ, New York, NY, Kenilworth, NJ, Groton, CT, Andover, MA

1133-P Combination of SGLT2 Inhibitor and Novel Selective PPARα Modulator, Tofogliflozin (Tofo) and Pemafibrate (Pema), Improves Survival Rate in STAM Mice as a Diabetic NASH Model. WATARU YANO, TOSHIKAZU TAKIZAWA, YUSUKE SAKASI, MASATO ASAHIIYAMA, WAKANA KAMIYA, TAKASHI NAKAGAWA, HIROYUKI YAMAZAKI, KEISUKE INOUE, KEN MIZUNO, JURO SAKAI, TATSUHIKO KODAMA, TOSHIYA TANAKA, Tokyo, Japan, Fuji, Japan

1134-P Which Is Better? High-Dose Metformin Alone or Combination of Low-Dose Metformin and Linagliptin on Glycemic Variability in Japanese Type 2 Diabetes Patients with Insufficient Glycemic Control with Low-Dose Metformin Alone—A Randomized, Crossover, Pilot Study. HIROSHI TAKAHASHI, RIMEI NISHIMURA, KAZUNORI UTSUNOMIYA, Tokyo, Japan

1135-P Oral Semaglutide Does Not Affect the Bioavailability of the Combined Oral Contraceptive Ethinyloestradiol/Levonorgestrel. ANDREAS BÖRSTING JORDY, ASTRID BREITSCHAF, ERIK CHRISTIANSEN, CHARLOTTE GRANHALL, CILE W. HANSEN, AZADEH HOUSHMAND-DREGAARD, TINE A. BAEKDAL, Søborg, Denmark, Berlin, Germany
1136-P Apabetalone (RVX-208) Lowers Major Adverse Cardiovascular Events (MACE) in Diabetes Mellitus Patients with CVD by Attenuating Monocyte Adhesion to Endothelial Cells. LAURA TSUJI-KAWA, EWELINA KULIKOWSKI, CYRUS CALOSING, SYLVIA WASIAK, DEAN GILHAM, CHRISTOPHER HALLIDAY, JAN O. JOHANSSON, MICHAEL SWEENEY, NORMAN C. WONG, Calgary, AB, Canada, San Francisco, CA

1137-P Duodenal Mucosal Resurfacing Elicits Improvement in Glycemic and Hepatic Parameters in Type 2 Diabetes—One-Year Multicenter Study Results. ANNEKE C.G. VAN BAAR, MAX NIEUWDORP, FRITS HOLLEMAN, JACQUES DEVIERE, LAURENT CRENER, REHAN HAIDRY, RACHEL L. BATTERHAM, DAVID HOPKINS, LEONARDO RODRIGUEZ GRUNERT, MANOEL GALVAO NETO, PAULINA VIGNOLO, GUIDO COSTA-MAGNA, JACQUES J. BERGMAN, Amsterdam, Netherlands, Brussels, Belgium, London, United Kingdom, Santiago, Chile, Miami, Fl, Rome, Italy

1138-P Comparison of the Effect of Empagliflozin and Glimepiride on the Endothelial Function in Patients with Type 2 Diabetes—A Randomized Study. HARUKA TAMURA, YOSHINOBU KONDO, KOHEI ITO, SHINOBU SATŌ, YASUO TERAUCHI, Chigasaki, Japan, Yokohama, Japan

1139-P Mortality Risk of Noninsulin Glucose-Lowering Drugs in Type 2 Diabetes—A Network Meta-analysis of Observational Trials. BRENDÁ BONGARTS, LENA M. LINDNER, ANNKA HOYER, OLIVER KUSS, CHRISTIAN HERDER, HADI AL-HASANI, SR., KARSTEN MÜSSIG, MICHAEL RODEN, WOLFGANG RATHMANN, Düsseldorf, Germany

1140-P A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin. ROBERTO A. CALLE, JIE LIU, SUSAN HUYCK, LARRY WU, ANNEPY PONG, JAMES P. MANCUSO, STEVEN TERRA, BRETT LAURING, Cambridge, MA, Kenilworth, NJ, Groton, CT, Andover, MA

1141-P Temporal Trends in the Use of Sodium–Glucose Cotransporter 2 Inhibitors—The Global DISCOVER Study. MIKHAIL KOSIBOROD, HUNGTA CHEN, JAVIER CID-RUZAFÁ, PETER FENICI, MARILIA B. GOMES, NIKLAS HAMMAR, KAMLESH KHUNTI, STUART POCOCK, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, FILIP SURMONT, FENGMING TANG, LINONG JI, Kansas City, MO, Gathersburg, MD, Barcelona, Spain, Cambridge, United Kingdom, Rio de Janeiro, Brazil, Mönndal, Sweden, Leicester, United Kingdom, London, United Kingdom, Moscow, Russian Federation, Osaka, Japan, Luton, United Kingdom, Beijing, China


1144-P Efficacy and Safety of Sitagliptin (SITA)-Based Dual and Triple Combination Therapy in Older Chinese People with T2D. XIANGYANG LIU, LI WANG, YING XING, SAMUEL S. ENGEL, GUOJUAN CHEN, YE ZHANG, RUYA ZHANG, SHU LIU, JIANPING WENG, QIUHE JI, Xi’an, China, Kenilworth, NJ, Shanghai, China, Beijing, China, Guandzhou, China

1145-P Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. MARY A. HICKMAN, ROBERT FREDERICH, SHRITA M. PATIL, SILVINA GALLO, BRETT LAURING, STEVEN TERRA, SUSAN L. JOHNSON, URSZULA MASIUKIEWICZ, SUSAN HUYCK, JAMES P. MANCUSO, Groton, CT, Collegeville, PA, North Wales, PA, Berlin, Germany, Rahway, NJ, Andover, MA, Durham, NC, Kenilworth, NJ

1146-P Physiological Responses to Daily Use of Beta-Three Adrenergic Receptor Agonist, Mirabegron. ALANA O’MARA, AARON CYPESS, CHERYL CERO, JAMES W. JOHNSON, JÖYCE D. LINDERMANN, BROOKS LEITNER, LARA FLETCHER, ROBERT BRYCHTA, DEVIKA KAPURIA, SUZANNE MCGHEE, YARON ROTMAN, Bethesda, MD

1147-P Development of an Innovative Screening Tool and Identification of Novel β-Cell Protective Drugs. SMITHAMOL SITHARA, BHAVISHA PATIL, MEGAN K. ELLIS, TAMSYN CROWNLEY, KEN WALDER, KATHRYN ASTON-MOURNEY, Waurn Ponds, Australia
1148-P The Effect of Gliptins to Improve Functional Outcome after Stroke in Mice Is Mediated by the CXCR4/SDF-1α Pathway. FAUSTO CHIAZZA, HARALD TAMMEN, HIRANYA PINTANA, GRAZYNA LIETZAU, MASSIMO COLLINO, SR., THOMAS NYSTROM, THOMAS KLEIN, VLADIMER DARSALIA, CESARE PATRONE, Stockholm, Sweden; Hannover, Germany; Torino, Italy; Biberach, Germany

1149-P Triple vs. Dual Therapy with Low-Dose Dapagliflozin plus Saxagliptin vs. Each Monocomponent Added to Metformin in Uncontrolled Type 2 Diabetes. JULIO ROSENSTOCK, SHIRA PERL, EVA K. JOHNSON, STEPHAN JACOB, Dallas, TX; Gaithersburg, MD; Malmö, Sweden; Villingen, Germany

1150-P Safety and Tolerability of Empagliflozin in East Asian Patients with Type 2 Diabetes—Pooled Analysis of Phase I-III Clinical Trials. ATSUTAKA YASUI, DAISUKE YABE, LINONG JI, MOON-KYU LEE, RONALD C. MA, TIEN-JYUN CHANG, TOMOO OKAMURA, CORDULA ZELLER, STEFAN KASPERS, JISOO LEE, SVEN KOHLER, YUTAKA SEINO, Tokyo, Japan; Kobe, Japan; Beijing, China; Seoul, Republic of Korea; Hong Kong, China; Taipei, Taiwan; Biberach, Germany; Ingelheim, Germany; Osaka, Japan

1151-P WITHDRAWN

1152-P The SGLT2 Inhibitor Tofogliflozin Reduces Weight in People with Type 2 Diabetes due to Fluid Loss Initially and to Lipolysis in Late. AKIHIRO YOSHIDA, HIROMI KUSAKABE, TOSHINARI TAKAMURA, KOHEI KAKU, HIDEKI SUGANAMI, Tokyo, Japan; Kanazawa, Japan; Kurashiki, Japan

1153-P Tofogliflozin and Pemafibrate Combination Therapy Prevents Nonalcoholic Steatohepatitis (NASH) Development of Novel Metabolic Syndrome-Related NASH Model Mice. YUSUKE SASAKI, MASATO ASAHIYAMA, WAKANA KAMIYA, JURO SAKAI, TATSUHIKO KODAMA, TOSHIYA TANAKA, Tokyo, Japan; Fuji, Japan

1154-P Influence of SGLT2 Inhibitor on Resting Heart Rate (RHR) and Factors Related to Its Changes. YASUHIRO MATSUBAYASHI, TOSHIKI NOJIMA, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, TAKAHI YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROMI KUSAKABE, TOSHINARI TAKAMURA, ATSUTAKA YASUI, DAISUKE YABE, YUSUKE SAKAI, TATSUHIKO KODAMA, TOSHIYA TANAKA, Tokyo, Japan; Kyoto, Japan

1155-P The Novel Use of Nanotechnology Structured Water Magnalife to Control Blood Glucose Level in Type 2 Diabetic Patients. ALI K.M. SAMI, KAWA H. AMIN, MOHAMMED T. KURMANJI, Sulaymany, Iraq

1156-P Initial Beta-Hydroxybutyrate Elevation in Relation to Subsequent Weight Loss in Type 2 Diabetes via the SGLT2 Inhibitor Tofogliflozin. YUICHI SATO, KIYOHIDE NUNO, KOHEI KAKU, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, Kurume, Japan; Kurashiki, Japan; Tokyo, Japan

1157-P SGLT2 Inhibitors Increase Bone Strength by Increasing Procollagen Type 1 Amino-Terminal Propeptide in Patients with Type 2 Diabetes. MASATAKA KUSUNOKI, YUKIE NATSUME, TETSURO MIYATA, YOSHIHARU OSHIDA, Nagoya, Japan; Tokyo, Japan

1158-P Discovery and Development of HGR4113 as a Novel Antidiabetes Oral Agent. KYUNGIL KIM, SANG-KU YOO, IN GEUN JO, KEUN-WAN LIM, Suwon, Republic of Korea

1159-P Systematic Literature Review and Network Meta-analysis (NMA) of SGLT2i as Monotherapy for Type 2 Diabetes Mellitus (T2DM). GLENN M. DAVIES, ANN MARIE MCNEILL, ELIZA KRUGER, STACEY L. KOWAL, FLAVIA EJZYKOWICZ, HAKIMA HANNACHI, NILO B. CATER, EUAN MCLEOD, North Wales, PA, San Francisco, CA; Shelby Township, MI; Kenilworth, NJ; New York, NY; Tedworth, United Kingdom

1160-P SGLT2i Dual Therapy with Metformin (Met) for Type 2 Diabetes Mellitus (T2DM)—Systematic Literature Review and Network Meta-analysis (NMA). ANN MARIE MCNEILL, GLENN M. DAVIES, ELIZA KRUGER, TIMOTHY REASON, FLAVIA EJZYKOWICZ, HAKIMA HANNACHI, NILO B. CATER, EUAN MCLEOD, North Wales, PA; San Francisco, CA; London, United Kingdom; Kenilworth, NJ; New York, NY; Tedworth, United Kingdom

1161-P Type 2 Diabetes Mellitus (T2DM) Patients with Inadequate A1C Control on Metformin (MET) + DPP-4i—A Network Meta-analysis (NMA) of the Efficacy and Safety of SGLT2i, GLP-1 Analogs, and Insulin. ANN MARIE MCNEILL, GLENN M. DAVIES, ELIZA KRUGER, STACEY L. KOWAL, FLAVIA EJZYKOWICZ, HAKIMA HANNACHI, NILO B. CATER, EUAN MCLEOD, North Wales, PA; San Francisco, CA; Shelby Township, MI; Kenilworth, NJ; New York, NY; Tedworth, United Kingdom

1162-P Central Obesity but Not BMI Related to Hypoglycemic Efficacy of Metformin—Subanalysis of MARCH Study. ZHAOJUN YANG, XIN WANG, NA WANG, XIAN JIN, JINPING ZHANG, XUELIAN ZHANG, WENYING YANG, Beijing, China
1163-P Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes—The Energize Study. SURYA PANICKER RAJEEV, CARL A. ROBERTS, DANIEL J. CUTHBERTSON, VICTORIA S. SPRUNG, EMILY BROWN, JASON C. HALFORD, JR., JOANNE A. HARROLD, GRAHAM J. KEMP, ANDREJ STANCAK, JOHN P. WILDING, Liverpool, United Kingdom

1164-P Effect of SGLT2 Inhibition on Body Water Distribution and Its Relevance to Body Composition Measures. HITOMI NAKAYAMA, SHIMPEI IWATA, TSUYOSHI OHKI, AYAKO NAGAYAMA, KENTARO YAMADA, YUJI TAJIRI, MASATOSHI NOMURA, Kuruma, Japan, Asakura, Japan

1165-P An Observational Study to Evaluate Change in Dose Requirement of Standard Glucose Lowering, Lipid Lowering, and Antihypertensive Therapy Treated with SGLT2 Inhibitor (Canagliflozin) over One Year, in Fifty T2DM Patients. VISHAL GUPTA, VAISHALI TELI, Mumbai, India

1166-P WITHDRAWN

1167-P Changes in Blood Glucose Levels and Body Weight in Patients Administered Sodium-Glucose Cotransporter 2 Inhibitors. HUN-SUNG KIM, EUN YOUNG LEE, KUN-HO YOON, Seoul, Republic of Korea

1168-P Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. SHRITA M. PATEL, MARY A. HICKMAN, ROBERT FREDERICH, BRETT LAURING, STEVEN TERRA, SUSAN L. JOHNSON, SUSAN HUYCK, JAMES P. MANCUSO, North Wales, PA, Groton, CT, Collegeville, PA, Rahway, NJ, Andover, MA, Durham, NC, Kenilworth, NJ

1169-P Evaluation of Osmotic Diuresis and Volume Depletion Events in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. SHRITA M. PATEL, MARY A. HICKMAN, ROBERT FREDERICH, BRETT LAURING, STEVEN TERRA, SUSAN L. JOHNSON, SUSAN HUYCK, JAMES P. MANCUSO, North Wales, PA, Groton, CT, Collegeville, PA, Rahway, NJ, Andover, MA, Durham, NC, Kenilworth, NJ

1170-P Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin (DAPA) in Combination with Insulin in Japanese Patients with T1D. HIROTAKA WATADA, MASANARI SHIRAMOTO, SHINYA UEDA, WEIFENG TANG, MICHIKO ASANO, FREDRIK A. THOREN, HYOSUNG KIM, TOSHITAKA YAJIMA, DAVID W. BOULTON, EIICHI ARAKI, Tokyo, Japan, Fukuoka, Japan, Osaka, Japan, Gaithersburg, MD, Möln达尔, Sweden, Kumamoto, Japan

1171-P Modulation of Dapagliflozin-Associated Genital Tract Infections by Saxagliptin—A Pooled Safety Analysis. STEFANO DEL PRATO, EVA K. JOHNSON, RICARDO GARCIA-SANCHEZ, CLAIRE MORGAN, PETER SARTIPY, RAISA KURLYANDSKAYA, NAYYAR IQBAL, CHANTAL MATHIEU, Pisa, Italy, Möln达尔, Sweden, Gaithersburg, MD, Warsaw, Poland, Leuven, Belgium

1172-P A Pilot, Head-to-Head Comparison of Hydroxychloroquine (HCQ) with Pioglitazone (PIO) as Third-Line Agents in Type 2 Diabetic Patients Failing Metformin and a Sulfonylurea (SU). STANLEY H. HSIA, PETRA DURAN, MAYER B. DAVIDSON, Los Angeles, CA

1173-P Improvements in Liver Enzymes with Empagliflozin in the EMPA-REG OUTCOME Trial. NAVEED SATTAR, DAVID H. FITCHETT, STEFAN HANTEL, JYOTHSI T. GEORGE, BERNARD ZINMAN, Glasgow, United Kingdom, Toronto, ON, Canada, Biberach, Germany, Ingelheim, Germany

1174-P Dapagliflozin Exposure Response in Japanese vs. Non-Japanese Patients with Type 1 Diabetes. VICTOR SOKOLOV, TATIANA YAKOVLEVA, SHINYA UEDA, JOANNA R. PARKINSON, ROBERT C. PENLAND, DAVID W. BOULTON, WEIFENG TANG, Moscow, Russian Federation, Osaka, Japan, Möln达尔, Sweden, Waltham, MA, Gaithersburg, MD

1175-P Dapagliflozin plus Saxagliptin Add-On to Metformin Reduces Liver Fat and Adipose Tissue Volume in Patients with Type 2 Diabetes. JOHN P. WILDING, PAUL HOCKINGS, EVA K. JOHNSON, JILL MAASKE, RICARDO GARCIA-SANCHEZ, LARS JOHANSSON, Liverpool, United Kingdom, Möln达尔, Sweden, Gaithersburg, MD

1176-P Reduced Postprandial Hepatic Insulin Clearance via the DPP-4 Inhibitor Anagliptin Contributed to Improvement in Hyperglycemia in Patients with Type 2 Diabetes Mellitus. YASUHIRO MATSUBAYASHI, TAKAHIRO ABE, SAYAKA MURAGISHI, AKIHIRO YOSHIDA, HIDEKI SUGANAMI, KENICHI FURUWAWA, TAKAHO YAMADA, KAZUYA FUJIHARA, SHIRO TANAKA, KOHEI KAKU, HIROHITO SONE, NIIGATA, Japan, Tokyo, Japan, Nagoya, Japan, Kyoto, Japan, Kurashiki, Japan
1177-P Canagliflozin Improves a Left Ventricular Diastolic Dysfunction without Affecting Baroreflex Sensitivity in Type 2 Diabetes. DAISUKE MATSUTANI, MASAYA SAKAMOTO, YOSUKE KAYAMA, KAZUNORI TUNSUNOMIYA, Tokyo, Japan

1178-P The Elevation of Hematocrit after Administration of SGLT2 Inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes. YOSHIIHARU WADA, YOSHIYUKI HAMAMOTO, YORIIHIRO IWASAKI, YOSHIHISA NAKATANI, JUN FUJIKAWA, SACHIKO HONJO, MEGUMI AIZAWA-ABE, AKIHIRÔ HAMASAKI, Osaka, Japan, Osakasayama, Japan

1179-P Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2). THOMAS DANNE, BERTRAND CARIOU, JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, PHILIP L. BANKS, JAKE A. KUSHNER, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH, Hannover, Germany, Nantes, France, Chapel Hill, NC, Aurora, CO, Dallas, TX, The Woodlands, TX, Houston, TX, Los Angeles, CA

1180-P Efficacy and Safety of Long-Term Administration of Dapagliflozin for Japanese Patients with Type 2 Diabetes Mellitus. MASAIRO YAMAZAKI, RYOSUKE SAKAI, TAKURO OKAMURA, MICHIAKI FUKUI, Kyoto, Japan

1181-P Durability of Glycemic Control with Dapagliflozin vs. Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes. CLIFFORD J. BAILEY, STEFANO DEL PRATO, CHERYL WEI, GABRIELA LUPORINI SARAINA, Birmingham, United Kingdom, Pisa, Italy, Gaithersburg, MD

1182-P Baseline Characteristics of Participants in the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness Study (GRADE). DEBORAH J. WEXLER, HEIDI KRAUSE-STEINRAUF, ALEXANDER KUHN, JILL P. CRANDALL, HERMES FLOREZ, CHANTAL UNDERSKOFLER, SOPHIA H. HOX, MICHAEL C. BACKMAN, VANITA ARORA, GRADE RESEARCH GROUP, Boston, MA, Rockville, MD, Hyattsville, MD, Bronx, NY, Miami, FL, Aurora, CO, Honolulu, HI, Washington, DC

1183-P Real-World Impact of HbA1c Reduction on Treatment Intensification and HbA1c Goal Attainment in T2DM Patients Initiated on SGLT2i. STEPHEN BRUNTON, HEATHER M. ROZJABEK, DOMINIC PILON, MARIE-HELENE LAFILEU, RHIANNON L. KAMSTRA, WILLY WYNANT, BRAHIM BOOKHART, PATRICK LEFEVRE, Lakeview Terrace, CA, Columbus, NJ, Montreal, QC, Canada, Titusville, NJ

1184-P CANadian CANagliflozin REgistry (CanCARE)—A Prospective, Observational Assessment of Canagliflozin (CANA) Treatment in Type 2 Diabetes Mellitus (T2DM)—Twelve-Month Results. VINCENT C. WOO, ALAN D. BELL, MAUREEN A. CLEMENT, FERNANDO CAMACHO, NATASHA GEORGIJEV, JENNIFFER B. ROSE, WALLY RAPATTONI, HARPREET S. BAJAJ, Winnipeg, MB, Canada, Toronto, ON, Canada, Coldstream, BC, Canada, Waterloo, ON, Canada, Laval, QC, Canada, Brampton, ON, Canada

1185-P Exploring Hepatic Safety of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Vildagliptin in a Real-World Setting. RACHEL WILLIAMS, WOLFGANG KOTHNY, CARMEN SERBAN, PAIVI M. PALTANNI, RAYMOND SCHLIEGER, London, United Kingdom, Basel, Switzerland

1186-P HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in U.K. Primary Care Patients with Type 2 Diabetes. JOHN P. WILDING, UNA RIGNEY, BETINA T. BLAK, STEPHEN T. NOLAN, PETER FENICI, JESUS MEDINA, Liverpool, United Kingdom, Luton, United Kingdom, Cambridge, United Kingdom, Madrid, Spain

1187-P Effects of SGLT2 Inhibitors on Insulin Secretion and Insulin Resistance—Results from a Cross-Sectional Study. NAOKO WASEDA, HIROAKI SATOH, CHISA YOSHIDA, FUKI IKEDA, AKIO KANA ZAWA, HIROTAKA WATADA, Tokyo, Japan

1188-P Disparity of the Efficacy of DPP-4 Inhibitors in Combination with Metformin vs. High Dose Metformin as Initial Treatment between Asian and Caucasian T2DM Patients. XIUTING HUANG, XUEYING GAO, XIAOLING CAI, LINONG JI, Beijing, China

1189-P Discovery of CPL207-280CA, an Effective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes. KATARZYNA BAZYDLO, PAWEŁ BUDA, MATEUSZ MACH, RADOSŁAW DZIDA, FILIP STELMACH, KRZYŻSZTOF K. DUBIEL, JERZY S. PIEZYKOLAN, MACIEJ WIECZOREK, Kiel, Poland

1190-P Dose-Response and Exposure-Response (HbA1c) of Dapagliflozin in T1DM Patients. JOANNA R. PARKINSON, JOHANNA MELIN, MAGNUS ÅSTRAND, BENGT HAMREN, DAVID W. BOULTON, WEIFENG TANG, Gothenburg, Sweden, Gaithersburg, MD
1204-P Antidiabetes Drug Prescription in Indian Scenario—A Cross-Sectional Analysis from a Large, Pan India Database of Type 2 Diabetes. KRISHNA G. SESHAHARI, VENKATARAMAN S., MANIKANDAN RM, DWARAKANATH CS, BOOCHANDRAN TS, NARAYANAN NK, JAYASREE GOPAL, SHANTHARAM DUVURU, USHA AYYAGARI, ANISH BEHL, APOLLO SUGAR RESEARCH GROUP, Chennai, India, Madurai, India, Bangalore, India, Mysore, India

1205-P The Efficacy of Teneligliptin with Metformin in Drug-Naïve Type 2 Subjects. DIPAK B. CHUDASAMA, BANSHI D. SABOO, DHARMENDRA PANCHAL, FENY PATEL, MAHIRA SAiyED, DHRUVI HASNANI, VIIPUL CHAVDA, HARDIK CHANDARANA, RUTUL GOKLANI, Ahmedabad, India

1206-P Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANA) Program Irrespective of Baseline (BL) Body Mass Index (BMI). HAROLD BAYS, LUC VAN GAAL, S.R. ARAVIN, NARESH AGGARWAL, RAFAEL VIOLANTE, APRIL SLEE, WAYNE SHAW, KENNETH W. MAHAFFEY, DICK DE ZEEUW, DAVID R. MATTHEWS, Louisville, KY, Antwerp, Belgium, Bangalore, India, Brampton, ON, Canada, Tampico, Mexico, Seattle, WA, Rantian, NJ, Stanford, CA, Groningen, Netherlands, Oxford, United Kingdom

1207-P Rapid Dose Escalation Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension. JOHN P. HANRAHAN, JAMES D. WAKEFIELD, PHEBE J. WILSON, DANIEL P. ZIMMER, MARINA MIHOVA, JENNIFER CHICKERING, DENNIS RUFF, MICHAEL L. HALL, MARK CURRIE, T. TODD MILNE, ALBERT T. PROFY, Cambridge, MA, Raleigh, NC, San Antonio, TX

1208-P Effects of Teneligliptin (Teneli) on Glycemic Indices in Type 2 Diabetes (T2DM) Subjects Uncontrolled with Metformin (Met) and Glimepiride (Glim) Combination. HARIBALLAV MAHAPATRA, SUSANT MISHRA, MONALISA KHUNTA, BISWARANJAN JENA, SREEYA DAS, APURBA R. JENA, RAJESH K. PADHI, ABHAY K. SAHOO, RAMABALLAV MAHAPATRA, LAXMINARAYAN MAHAPATRA, Puri, India, Bhubaneswar, India

1209-P Real-Life Investigation of Effectiveness and Tolerability of Hydroxychloroquine in Type 2 Diabetes Mellitus Patients in India. MANOJ S. CHAWLA, PURVI M. CHAWLA, PAYAL GUPTA, Mumbai, India

1210-P Improvements in Blood Pressure (BP) and Markers of Arterial Stiffness with Canagliflozin (CANA) in the CANagliflozin CardioVascular Assessment Study (CANA) Program. RAYMOND TOWNSEND, MALA DHARMALINGAM, STEFANO GENOVESE, ANDREW STEELE, JOSE L. ARENAS, SR., APRIL SLEE, ELISA FABBIN, KENNETH W. MAHAFFEY, Philadelphia, PA, Bangalore, India, Milan, Italy, Oshawa, ON, Canada, San Luis, Mexico, Seattle, WA, Rantian, NJ, Stanford, CA

1211-P The Effect of Empagliflozin on Metabolic Parameters in Nonobese Nondiabetic Model of Metabolic Syndrome. JAROSLAVA TRNOVSKA, MARTINA HUUTLI, IRENA MARKOVA, OLENA OLYARNYK, HANA MALINSKA, LUDMILA KADZOVA, MARTIN HLUZIK, Prague, Czech Republic

1212-P The Effect of Saxagliptin on Adipose Tissue Inflammation in Overweight and Obese Nondiabetic Subjects. JURAJ KOSKA, TRACY OSREDKAR, KAREN D’SOUZA, SANDEEP SINHA, CHRISTIAN MEYER, PETER REAVEN, Phoenix, AZ

1213-P Effect of Metformin on Lymphoid Cancer Cells. NEEKI AHMADI, SABYASACHI SEN, Washington, DC

1214-P IMG-1 Lowers Insulin Resistance by Decreasing Hepatic Glucose Production in a DIO Mouse Clamp Test. JONATHAN B. POLLETT, HYE LIM NOH, JASON K. KIM, NGOC THAI, Devon, PA, Worcester, MA

1215-P IMG-1 Reduces Blood Glucose Levels in Type 1 Diabetic Animal Models. JONATHAN B. POLLETT, HYE LIM NOH, JASON K. KIM, NGOC THAI, Devon, PA, Worcester, MA

CLINICAL THERAPEUTICS/NEW TECHNOLOGY—PHARMACOLOGIC TREATMENT OF COMPLICATIONS

1216-P Canagliflozin Ameliorates Arterial Stiffness by Reducing Serum Uric Acid in Type 2 Diabetic Patients. RAMIRO A. SANCHEZ, MARIA J. SANCHEZ, AGUSTIN J. RAMIREZ, Buenos Aires, Argentina, Caba, Argentina

1217-P Cardiometabolic Management—Success of Online CME at Expanding Diabetes Management Past Glycemic Control. AMY LARKIN, MICHAEL LACOUTURE, ANNE LE, New York, NY

1218-P Success of Interactive, Case-Based Education on Improving Physician Clinical Competence. AMY LARKIN, KELLY L. HANLEY, COLLEEN S. HEALY, ANNE LE, New York, NY
1219-P WITHDRAWN

1220-P Consistent Accuracy over 10 Days with a Factory-Calibrated Continuous Glucose Monitoring System in Children and Adults. XIAOHE ZHANG, TERRI JOHNSON, DAVID A. PRICE, ANDREW BALO, San Diego, CA

1221-P WITHDRAWN

1222-P Linagliptin Reduced Renal Injury and Proteinuria in a Rat Model of Crescentic Nephritis. ANNA-LENA MAYER, KERSTIN U. AMANN, THOMAS KLEIN, CHRISTOPH DANIEL, Erlangen, Germany, Biberach, Germany

1223-P Role of Vitamin E for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients with T2DM—A Randomized, Controlled Trial. FERNANDO BRIL, DIANE M. BIERNACKI, ROMINA LOMONACO, SRILAXMI KALAVALAPalli, SREEVIDYA K. SUBBARAYAN, JINPING LAI, FERMIN O. TIO, AMITABH SUMAN, BEVERLY K. ORSAK, JOAN HECHT, KENNETH CUSI, Gainesville, FL, San Antonio, TX

1224-P Suppressive Effect of Angiotensin II Receptor Blockers on Progression of Atherosclerosis as Assessed by 3-Dimensional Carotid Ultrasound. KENTARO TAKI, RIMEI NISHIMURA, MAKIKO NISHIOKA, YUMI MIYASHITA, TAMOTSU YOKOTA, TSUJINO DAISUKE, AYA MORIMOTO, NAOKO TAJIMA, KAZUNORI UTSUNOMIYA, Tokyo, Japan

1225-P (R)-ND-336 as a Therapeutic Agent for Diabetic Wound Healing. MAYLAND CHANG, Notre Dame, IN

1226-P Metformin Activates AMPK Signaling but Inhibits Mitophagy in the Mouse Heart. YAWEN ZHANG, MICHAEL M. CHANG, POLINA R. PINKHASOVA, FENGYI ZHAO, TAMAYO KOBAYASHI, YUAN HUANG, SATORU KOBAYASHI, QIANGRONG LIANG, Old Westbury, NY, Brooklyn, NY, New York, NY

1227-P Combined Treatment with Exendin-4 and Metformin Attenuates Breast Cancer Growth. CHIKAYO IWAYA, TAKASHI NAKAMATe, TAKAKO KAWANAMI, YURIKO HAMAGUCHI, TOMOKO TANAKA, TSUJINO DAISUKE, AYA MORIMOTO, GAKKEN, Tokyo, Japan

1228-P Empagliflozin Exhibits Therapeutic Effect in Preclinical Model of Liver Disease (NASH). ERIC MAYOUX, THOMAS KLEIN, MICHAEL MARK, Ingelheim, Germany, Biberach, Germany

1229-P Identification of Glucosepane Cross-Link Breaking Enzymes. MATTHEW STREETER, TYLER N. GODDARD, JASON M. CRAWFORD, DAVID A. SPIEGEL, New Haven, CT, West Haven, CT

1230-P Long-Term Safety and Tolerability of Dasiglucagon, a Stable-in-Solution Glucagon Analog. JESSICA R. CASTLE, MIKAEL ELANDER, SEAN A. O’HALLORAN, Portland, OR, Glostrup, Denmark, Harrogate, United Kingdom

1231-P Embryonic Cell Extracts Ameliorate Wound Healing in Diabetic Mice. CRISTIAN LORETELLI, MICHAEL S. BISCHLER, Thèse, France, Guglielmo B. SCHNEIDER, Girona, Spain

1232-P Adiponectin Attenuates NLRP3 Inflammasome by Modulating AMPK-ROS Pathway. FANG WANG, LINGHAO WANG, YUXING LIU, JINGJING YUAN, ZHAOHUI MO, Changsha, China

1233-P Compound C Inhibits NLRP3 Inflammasome through an AMPK-Independent Mechanism. FANG WANG, WENJUN YANG, LINGHAO WANG, YUXING LIU, ZHAOHUI MO, Changsha, China

1234-P Glucokinase-MODY Frequently Misdiagnosed and Inappropriately Treated. SEAN BOYD, MARIA M. BYRNE, Dublin, Ireland

1235-P The Effect of Lisinatide and Dapagliflozin in Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus Compared with Sitagliptin and Pioglitazone. ANASTASIOS KOUTSOVASILIS, ALEXIOS SIOUTOPOULOS, MARIA PAPPA, DESPINA PAPADAKI, VASILIS KORDINAS, NIKOS KORDONIS, THOMAS G. KALAPETAS, NIKOS KORDONIS, Athens, Greece

1236-P FoxO1 Inhibition Potentiates Endothelial Function and Ischemic Angiogenesis in Diabetes via Suppression of ROCK1/Drp1-Mediated Mitochondrial Fission. LU TIE, YUNDI SHI, DI WANG, Beijing, China
AMERICAN DIABETES ASSOCIATION

Clinical Diabetes/Therapeutics

POSTERS

1237-P Simplified Transition Algorithm from Intravenous to Subcutaneous Insulin in Nondiabetic Cardiac Surgery Patients with Stress Hyperglycemia. SAUMETH CARDONA, RODOLFO J. GALINDO, KATERINA G. TSEGKA, MARIA A. URRUTIA, PRIYATHAMA VELLANKI, MAYA FAYFMAN, J. SONYA HAW, FRANCISCO J. PASQUEL, LIMIN PENG, GUILLERMO E. UMPIERREZ, Atlanta, GA

1238-P The Effect of Metformin and Dapagliflozin on Epicardial Adipose Tissue in Prediabetes and Type 2 Diabetic Patients. SHAWEEEN AL-TALABANY, JONATHAN WEIR-MCCALL, MOHAPRADEEP MOHAN, JAGDEEP S. SINGH, IFY MORDI, STEPHEN J. GANDY, FAISEL KHAN, ANNAMARIA CHOY, JOHN G. HOUSTON, EWAN PEARSON, JACOB GEORGE, ALLAN D. STRUTHERS, CHIM C. LANG, Dundee, United Kingdom

1239-P A Phase 3 Comparison of a Novel Liquid Glucagon Autoinjector to Glucagon Emergency Kit for the Treatment of Severe Hypoglycemia. MARK P. CHRISTIANSEN, MARTIN J. CUMMINS, STEVEN J. PRESTRELSKI, POUL STRANGE, POUL STRANGE, Walnut Creek, CA, Chicago, IL, Princeton Junction, NJ

1240-P Effectiveness and Safety of Oral Hypoglycemic Agents as Initial Treatment in Comparison to Insulin Injection in Newly Diagnosed Type 2 Diabetes Mellitus. XI CHEN, YUFAN WANG, AIFANG ZHANG, NIANG WANG, NA LI, Shanghai, China

1241-P Liquid Room Temperature Stable Glucagon—Glucose Response in Pediatric Type 1 Diabetes Patients. BRUCE BUCKINGHAM, MARTIN J. CUMMINS, STEVEN J. PRESTRELSKI, POUL STRANGE, Palo Alto, CA, Chicago, IL, Princeton Junction, NJ

1242-P Effect of Testosterone Therapy on Renal and Endothelial Functions in Men with Type 2 Diabetes Mellitus. IRINA A. KHRIPUN, ELENA V. BOVA, SERGEY V. VOROBYEV, Rostov on Don, Russian Federation

1243-P L-Carnitine and Resveratrol Action on Oxidative Response and Differentiation in H9c2 Rat Cardiomyocytes. ILEANA TERRUZZI, PAMELA SENESI, ANNA MONTESANO, FERNANDA VACCANTE, LIVIO LUZI, Milan, Italy

1244-P Telmisartan Combination with Amlodipine Inhibits RAGE. SWETHA SRIRAMOJU, KERRY GOETZ, Ardsley, NY, Bethesda, MD

HEALTH CARE DELIVERY—ECONOMICS/QUALITY IMPROVEMENT

Moderated Poster Discussion: Cost-Effective Strategies to Improve Diabetes Care (Posters: 1245-P to 1250-P), see page 90.

1245-P Cost-Effectiveness of Interventions to Prevent and Manage Diabetes—A Systematic Review and Update. KAREN R. SIEGEL, XILIN ZHOU, BOON PENG NG, SHAWN JAWANDA, KRISTA PROIA, XUANPING ZHANG, PING ZHANG, Atlanta, GA, Chamblee, GA

1246-P Health Economics Analysis of Point-of-Care HbA1c Monitoring in Belgian, German, and Swiss Patients with Diabetes Mellitus Type 2. ARTEM T. BOLTYENKOV, FELIPE NAVARRO, ROK HREN, Erlangen, Germany, Norwood, MA, Ljubljana, Slovenia

1247-P Modeling Long-Term Cost-Effectiveness of Sitagliptin and SGLT2i Combination Therapy for the Treatment of Type 2 Diabetes. MANJIRI PAWASKAR, S. PINAR BILIR, ANNA GRABER-NAIDICH, CLAUDIO D. GONZALEZ, SWAPNIL RAJPATHAK, GLENN M. DAVIES, North Wales, PA, San Francisco, CA, Kenilworth, NJ

1248-P WITHDRAWN

1249-P Cost-Effectiveness of Telephone-Delivered Behavioral Skills Intervention for African-American Adults with Diabetes. LEONARD E. EGEDE, CLARA DISMUKE, CHRISTIAN EILER, REBEKAH J. WALKER, Milwaukee, WI, Charleston, SC

1250-P Cost-Effectiveness Analysis of the EndoBarrier Device in Patients with Type 2 Diabetes. PIYA SEN GUPTA, STEPHANIE ARMSTRONG, STEPHANIE A. AMIEL, ROBERT E. RYDER, MARK W. PENNINGTON, London, United Kingdom, Birmingham, United Kingdom

Moderated Poster Discussion: Health Care Strategies for Improving Glycemic Control (Posters: 1251-P to 1256-P), see page 92.

1251-P Divergence in Perceptions of Diabetes Control among Patients with T2DM and Health Care Professionals (HCPs). MERYL BROD, KENNETH J. TOMASZEWSKI, AMY ALLEN, DAVIDA F. KRUGER, MICHAEL K. HEILE, MICHELLE MOCCARSKI, ALISA SCHIFFMAN, YEHUDA HANDELSMAN, Mill Valley, CA, Honeoye Falls, NY, Detroit, Mi, Cincinnati, OH, Plainsboro, NJ, Tarzana, CA
1252-P ☝ Physician Feedback on the Quality of Diabetes Care—An Important Strategy with Moderate Impact. PARMIDA ZAREI, SANDRA A. HAM, AVIVA NATHAN, LUISA SEPULVEDA, ROBERT M. SARGIS, MICHAEL T. QUINN, ELBERT HUANG, NEDA LAITERAPONG, Chicago, IL

1253-P ☝ Health Care Access, Utilization, and Glycemic Control in Youth and Young Adults with Diabetes in South Carolina. ANGELA D. LIESE, XIAONAN MA, LAUREN REID, JAN M. EBERTH, BETHANY A. BELL, JANICE PROBST, CHRISTINE B. TURLEY, ELIZABETH J. MAYER-DAVIS, Columbia, SC, Chapel Hill, NC

1254-P ☝ Cost as the Main Driver of T2D Treatment Patterns—Lessons from Real-World Data and Physician Focus Groups. SZE-JUNG WU, AMIT D. RAVAL, JUDITH J. STEPHENSON, XIAOMEI PENG, HARRY WEISMAN, DOUGLAS E. FARIÉS, Wilmington, DE, Indianapolis, IN, Los Angeles, CA

1255-P ☝ A Clinical Training Program for Hybrid Closed-Loop Therapy in a Pediatric Diabetes Clinic. CARI BERGET, SARAH THOMAS, LAUREL H. MESSER, SUSAN OWEN, KATIE THIVENER, ROBERT H. SLOVER, R. PAUL WADWA, GUY T. ALONSO, Aurora, CO, Denver, CO

1256-P ☝ Basal-Bolus Insulin Therapy May Not Be the Optimal Strategy in a “Real-World” Hospital Setting for Inpatient Hyperglycemia Management. ARCHANA R. SADHU, BHARGAVI PATHAM, AISHA VADHARIYA, MICHAEL L. JOHNSON, Houston, TX

1257-P Improving Multidisciplinary Care in Pediatric Diabetes Clinic. DANIEL J. DESALVO, SARAH K. BARTZ, CURTIS YEE, RONA SONABEND, Houston, TX

1258-P Delays in Antihyperglycemic Treatment Intensification and Risk of Diabetes Complications. GREGORY NICHOLS, VICTORIA J. ROMO-LETORNEAU, SUMA VUPPUTURI, SHEILA THOMAS, Portland, OR, Encinitas, CA, Rockridge, MD, Bridgewater, NJ

1259-P Drug Copay and Hospitalizations in Elderly Patients with Type 2 Diabetes. LIOU XU, MANJIRI PAWASKAR, YUEXIN TANG, GARY PUCKREIN, SWAPNIL RAJPATHAK, BRUCE C. STUART, Washington, DC, North Wales, PA, Baltimore, MD

1260-P Factors Associated with Secondary Nonadherence to Oral Antihyperglycemic Agents among Patients with T2DM. SHARON LARSON, YUEXIN TANG, H. LESTER KIRCHNER, Wynnewood, PA, North Wales, PA, Danville, PA

1261-P Duration of Insulin Supply in Type 1 Diabetes—Is 90 Days Better or Worse than 30 Days? MARY A.M. ROGERS, CATHERINE KIM, RENUKA TIPIRNENI, TANIMA BANERJEE, JOYCE LEE, Ann Arbor, MI

1262-P WITHDRAWN

1263-P Severe Hypoglycemia (SH) and Diabetic Ketoacidosis (DKA) Hospitalization Rates—Twenty-Five Years in the Epidemiology of Diabetes Complications (EDC) Study. GEORGIA PAMBIANCO, TREvor J. ORCHARD, Pittsburgh, PA

1264-P Dulaglutide Has Higher Adherence and Persistence than Liraglutide and Exenatide QW—One-Year Follow-Up from U.S. Real-World Data. REEMA MODY, QING HUANG, MARIA YU, RUIZHI ZHAO, HIREN PATEL, MICHAEL GRABNER, LAURA FERNANDEZ LANDO, Indianapolis, IN, Wilmington, DE, Toronto, ON, Canada

1265-P Cost Effectiveness of DPP-4i and SGLT2i Combination Therapy for the Treatment of Type 2 Diabetes in the U.S. MANJIRI PAWASKAR, S. PINAR BILIR, ANNA GRABER-NAIDICH, CLAUDIO D. GONZALEZ, SWAPNIL RAJPATHAK, GLENN M. DAVIES, North Wales, PA, San Francisco, CA, Kenilworth, NJ

1266-P Embedding Diabetes Expertise within Primary Care. JOHN N. CLORE, LINDA THURBY-HAY, Mechanicsville, VA, Richmond, VA

1267-P Impact of a Structured Patient-Support Program on Adherence and Persistence with Basal Insulin Therapy at 12 Months. FANG L. ZHOU, JASON YEAW, SWAPNA KARKARE, MITCH DEKOVEN, TIMOTHY S. REID, Bridgewater, NJ, Denver, CO, Deerfield, IL, Fairfax, VA, Janesville, WI

1268-P Institutional Inpatient Diabetes Management—We’re Still Not Doing It Right. MARIA KRAVCHENKO, JANNA L. WARDIAN, SKY GRAYBILL, San Antonio, TX

1269-P Characterization of Patients Requiring High-Dose Insulin Infusion for the Management of Hyperglycemia. AFOMIA A. FELEKE, RACHAEL C. FULLER, REEM ISMAIL, MEGAN CADIZ, Royal Oak, MI
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1270-P</td>
<td>Preserving Vision by Empowering Patients.</td>
<td>Almira J. Yang, Van T. La, Chibuzo U. Eke, Anthony Firek, Moreno Valley, CA, Riverside, CA</td>
</tr>
<tr>
<td>1271-P</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>1272-P</td>
<td>Assessing the Value of Canagliflozin (CANA) vs. Sitagliptin (SITA) as Second-Line Therapy in</td>
<td>Michael Willis, Cheryl Neslusian, Andreas Nilsson, Christian Asseburg, Lund, Sweden, Rantian, NJ</td>
</tr>
<tr>
<td></td>
<td>the U.S.—The Importance of Considering Evidence from the CANVAS Program</td>
<td></td>
</tr>
<tr>
<td>1273-P</td>
<td>Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health</td>
<td>Marc Evans, Pierre Johansen, Hrvoje Vrazic, Cardiff, United Kingdom, Søborg, Denmark</td>
</tr>
<tr>
<td></td>
<td>Benefits for Patients with Type 2 Diabetes.</td>
<td></td>
</tr>
<tr>
<td>1274-P</td>
<td>A Model of Good Inpatient Diabetes Care with Consistently Low Levels of Medication Errors.</td>
<td>Meenakshi Parsad, Kimberley D. Lambert, Diane Arden, Abigail C. Mezzullo, Winchester, United Kingdom</td>
</tr>
<tr>
<td>1275-P</td>
<td>Electronic Messaging Use via a Patient Portal Is Associated with Primary Care Utilization in</td>
<td>Rann Sun, Susan M. Sereika, Melissa Saul, Mary T. Korytkowski, Dan Li, Lora E. Burke, Pittsburgh, PA</td>
</tr>
<tr>
<td></td>
<td>Patients with Type 2 Diabetes.</td>
<td></td>
</tr>
<tr>
<td>1276-P</td>
<td>Medical Costs of Diabetic Ketoacidosis Presenting at Diagnosis of Diabetes among Privately</td>
<td>Sundar Shrestha, Ping Zhang, Giuseppina Imperatore, Atlanta, GA</td>
</tr>
<tr>
<td></td>
<td>Insured Youth, 2016.</td>
<td></td>
</tr>
<tr>
<td>1277-P</td>
<td>Excess Medical Expenditures Associated with Diabetes-Related Complications among Adult</td>
<td>Boon Peng Ng, Sundar Shrestha, Robin Soler, Bryce Smith, Ping Zhang, Chamblee, GA, Atlanta, GA</td>
</tr>
<tr>
<td></td>
<td>Medicaid Enrollees in Eight U.S. States.</td>
<td></td>
</tr>
<tr>
<td>1278-P</td>
<td>Improving Diabetes Outcomes in Rural Dominican Republic.</td>
<td>Elizabeth A. Walker, Henry J. Dethlefs IV, Rachel A. Dowd, Clyde Schechter, Charles Filipi, Bronx, NY, Omaha, NE</td>
</tr>
<tr>
<td>1279-P</td>
<td>Risk Factors for Hospital Readmission following Implementation of a Diabetic Ketoacidosis</td>
<td>Neha Karajigkar, Amy Donihi, Rose A. Salata, Ronald Codario, Runa Acharaya, Pooja Manroa, Mary T. Korytkowski, Pittsburgh, PA, Syracuse, NY</td>
</tr>
<tr>
<td></td>
<td>(DKA) Power Plan.</td>
<td></td>
</tr>
<tr>
<td>1280-P</td>
<td>The Effectiveness of Text Message Support for Weight Loss to Reduce Diabetes Risk.</td>
<td>Henry Fischer, Silvia Raghunath, Josh Durfee, Natalie Ritchie, Denver, CO</td>
</tr>
<tr>
<td>1281-P</td>
<td>Racial Disparities in the Burden of End-Stage Renal Disease due to Diabetes among Medicare</td>
<td>Namino M. Glantz, Ian Duncan, Tamim Ahmed, David Kerr, Santa Barbara, CA, Glastonbury, CT</td>
</tr>
<tr>
<td></td>
<td>Beneficiaries.</td>
<td></td>
</tr>
<tr>
<td>1282-P</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>1283-P</td>
<td>Comparing Diabetes Screening Strategies in China—An Agent-Based Modeling Approach.</td>
<td>Xiaolei Xie, Bowen Pang, Yan Li, Beijing, China, New York, NY</td>
</tr>
<tr>
<td>1284-P</td>
<td>Patient-Reported Outcome Labeling for Antidiabetic Agents Approved in the United States,</td>
<td>Marjorie E. Zettler, Renato Sandoval, Overland Park, KS, Lee’s Summit, MO</td>
</tr>
<tr>
<td>1285-P</td>
<td>Evaluation of Liraglutide Usage for Treatment of Type 2 Diabetes at a Veterans Affairs Medical</td>
<td>Rikki L. Ryche, Mary Beth Low, Sharon A. Watts, Corinna Falck-Ytter, Kristina M. Pasuzzi, Alessandra Lyman, Cleveland, OH, Dover, NH</td>
</tr>
<tr>
<td></td>
<td>Center.</td>
<td></td>
</tr>
<tr>
<td>1286-P</td>
<td>Use of a Machine Learning Algorithm Improves Prediction of Progression to Diabetes.</td>
<td>Avivit Cahn, Avi Shoshan, Tal Sagiv, Rachel Yesharim, Itamar Raz, Ran Goshen, Jerusalem, Israel, Kfar Malal, Israel</td>
</tr>
<tr>
<td>1287-P</td>
<td>Key Clinical Risk Factors Identify Adverse Glycemia in Hospitalized Patients.</td>
<td>Mervyn Kyi, Jane E. Reid, Alexandra Gorelik, Shanal S. Kumar, Anna Galligan, Lois M. Rowan, Alison J. Nankervis, Katie A. Marley, David M. Russell, Paul R. Wraith, Peter G. Colman, Spiros Fourlanos, Melbourne, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**American Diabetes Association**

Clinical Diabetes/Therapeutics

Posters
1289-P Quality of Diabetes Care—Comparisons between Rzeszow, Podkarpacie, Poland, and Waukesha, Wisconsin, U.S. JOHN IDSO, GRZEGORZ TELEGA, MARIUSZ DąBROWSKI, SRIVIDYA KIDAMBI, Milwaukee, WI, Rzeszów, Poland

1290-P Physician-Targeted Education for Management of Chinese T2DM Patients Receiving Basal Insulin—BEYOND II Study Results. JIANPING WENG, JIAJUN ZHAO, ZHIGUANG ZHOU, XIAOHUI GUO, XUEYING ZHENG, SIHUI LUO, THE BEYOND II STUDY GROUP, Guangzhou, China, Jinan, China, Changsha, China, Beijing, China

1291-P Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting. CRAIG I. COLEMAN, WILLIAM H. HERMAN, SHIVANI PANDYA, LI WANG, ONUR BASER, JENNIFER CAI, BRAHIM BOOKHART, Storrs, CT, Ann Arbor, MI, Plano, TX, New York, NY, Titusville, NJ

1292-P Different Sampling and Modeling Strategies Affect Analyses of Readmission Risk among Diabetes Patients. HUAQING ZHAO, SAMUEL TANNER, SHERITA GOLDEN, SUSAN G. FISHER, DANIEL J. RUBIN, Philadelphia, PA, Baltimore, MD

1293-P Individualized Diabetes Risk Prediction in Women with a History of Gestational Diabetes. BERNICE MAN, ALAN SCHWARTZ, YINGLIN XIA, BEN S. GERBER, Chicago, IL

1294-P Cost-Effectiveness Analysis of Empagliflozin Compared with Canagliflozin or Standard of Care (SoC) in Patients with T2DM and Established Cardiovascular (CV) Disease. ANURAAG KANSAL, ODETTE REIFSNIDER, JOSEPH LEE, KYLE FAHRBACH, PRANAV GANDHI, EGNON PFARR, ANASTASIA V. USTUGOVA, Bethesda, MD, San Francisco, CA, Waltham, MA, Ridgefield, CT, Ingelheim, Germany

1295-P The Association of Glucose Values at Hospital Discharge with 30-Day Readmission and Post-discharge Mortality Rates in Patients with Diabetes. ELIAS SPANAKIS, GUILLERMO E. UMPIERREZ, TARIQ SIDDIQUI, MIN ZHAN, SOREN SNITKER, JEFFREY C. FINK, JOHN D. SORKIN, Baltimore, MD, Atlanta, GA

1296-P WITHDRAWN

1297-P Economic Evaluation of Dapagliflozin as Add-On to Metformin in T2DM in the Israeli Health Care Setting. SHAI MOSHEL, MICHAL HIRSCH VEXBERG, OREN SHAVIT, YOEL TOLEDANO, Tel Aviv, Israel

1298-P Outcomes of Telehealth in the Management of Type 2 Diabetes—A Systematic Review and Meta-analysis of Randomised Controlled Trials. NISHA NANGRANI, USMAN MALABU, VENKAT VAN-GAVETI, Townsville, Australia, Douglas, Australia

1299-P Regional Variations in Case Fatality following a Major Coronary or Cerebrovascular Event in People with Type 2 Diabetes—Evidence from the ADVANCE Trial and TECOS Trial. PHILIP M. CLARKE, XINYANG HUA, JOHN CHALMERS, MARK WOODWARD ESQ., RUTH L. COLEMAN, JENNIFER B. GREEN, DARREN K. MCGUIRE, RURY R. HOLMAN, Melbourne, Australia, Sydney, Australia, Oxford, United Kingdom, Durham, NC, Dallas, TX

1300-P Safe Ramadan Fasting Is Possible for Subjects with Poorly Controlled Type 2 Diabetes Mellitus. YING JIE CHEE, SHONDA NG, KEVIN J. KWEK, SHAikh ABDUL KADER ABDUL SHAKOOR, Singapore, Singapore

1301-P Awareness of Preconception Care for Women with Type 1 Diabetes—From Family Members’ Perspective. CHAOFAN WANG, SIHUI LUO, XUEYING ZHENG, XILINGHU, JINHUA YAN, YAN GUO, SHANSHAN XIONG, DAIZHI YANG, LILING QIU, BIN YAO, JIANPING WENG, Guangzhou, China, Zhongshan, China

1302-P A Population-Based Program Improving Diabetes Care. ALDO MARIOTTO, ARIELLA DE MONTE, Trieste, Italy

1303-P Documentation of Continuous Subcutaneous Insulin Infusion (CSII) Use in the Emergency Department (ED). ROBERT J. RUSHAKOFF, JESSICA ZOOK, HEIDEMARIE W. MACMASTER, San Francisco, CA

1304-P Inpatient Use of Insulin Pens—Eliminating Risk for Inappropriate Use of Pen on More than One Patient. HEIDEMARIE W. MACMASTER, ANDREW MARUOKA, CRAIG SAN LUIS, SABINA GONZALEZ, ROBERT J. RUSHAKOFF, San Francisco, CA

1305-P HbA1c Screening Characterizes Undiagnosed Dysglycemia in Surgical Patients. ELIZABETH W. DUGGAN, VIKAS N. O’REILLY-SHAH, KATERINA G. TSEGKA, RODOLFO J. GALINDO, GUILLERMO E. UMPIERREZ, Atlanta, GA
1306-P The Pro-Diab Perioperative Study — A Structured Perioperative Diabetes Management Plan Improves Medication Usage and Glycemia in Elective Surgery. OI YANG DAMIEN OI, ELIZABETH J. PEMBERTON, MERVYN KYI, PETER G. COLMAN, SPIRO FOURLANOS, Melbourne, Australia

1307-P Improving the Management and Recognition of Elevated Blood Pressure among Youth with Type 1 Diabetes. KAJAL GANDHI, DON A. BUCKINGHAM, SR., JESSICA HEHMEYER, ALYSSA M. KRAMER, KATHRYN OBRYNBA, JUSTIN A. INDYK, MANMOHAN K. KAMBOJ, Columbus, OH

1308-P Patient-Centered Outcomes of a Randomized Trial of Blood Glucose Monitoring Technology and Family-Centered Goal Setting. JILLIAN B. HALPER, TAMARA HANNON, LISA YAZEL-SMITH, Indianapolis, IN

1309-P Incorporating Depression Screening into Diabetes Clinics across the T1DX Learning Collaborative. SHIDEH MAJIDI, MARY C. JOLLY, GUY T. ALONSO, DON A. BUCKINGHAM, SR., ALYSSA B. CABRERA, MARK A. CLEMENTS, ASHLEY GARRITY, KATE A. GIBBS, BETHANY GLICK, K. MING HONG, MANMOHAN K. KAMBOJ, KATHRYN L. LAMBERT, JOYCE LEE, PRASHANT V. NADKARNI, RYAN MCDONOUGH, AMY L. OHMER, NICOLE RIOLES, KELLY R. STANEK, SARAH THOMAS, RUTH S. WEINSTOCK, SARAH CORATHERS, Aurora, CO, Cincinnati, OH, Denver, CO, Columbus, OH, Boston, MA, Kansas City, MO, Ann Arbor, MI, Syracuse, NY

1310-P Pharmacist-Led Digital Care Improved Community Diabetes Control in China — An Observational Study in a Large Population Sample. JIUMEI CAO, YINGJIE LI, WEI WANG, ZHEN WANG, DONGXING LI, HONGGUANG ZHANG, KAI LIU, Shanghai, China

1311-P Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control? KASIA J. LIPSKA, MELISSA M. PARKER, HOWARD H. MOFFET, ELBERT HUANG, ANDREW J. KARTER, New Haven, CT, Oakland, CA, Chicago, IL

1312-P Managing Diabetic Patients with Hypertension Comorbidity by Retail Pharmacists Using a Digital Solution in China. WEI WANG, YINGJIE LI, ZHEN WANG, DONGXING LI, HONGGUANG ZHANG, KAI LIU, JIUMEI CAO, Shanghai, China

1313-P Application of a Cloud-Based Medication Adherence Improvement (MAI) System to Assist Diabetic Care in China. YINGJIE LI, JIUMEI CAO, WEI WANG, ZHEN WANG, DONGXING LI, HONGGUANG ZHANG, KAI LIU, Shanghai, China

1314-P Economic Evaluation of Dapagliflozin vs. Other Oral Hypoglycemic Drugs in China via Idealized Model. JUAN ZHENG, LU LONG, ZI YE, LULU CHEN, Wuhan, China, Shanghai, China

1315-P An Assessment of Protocol Utilization and Efficacy when Transitioning from Infusion to Subcutaneous Insulin at an Academic Medical Center. LAUREN VINCENT, KEVIN BOX, KRISTEN KULASA, San Diego, CA

1316-P Predictors of Achieving Glycemic Targets among People with Type 2 Diabetes — The CARRS Trial. MUHAMMAD Q. MASOOD, KAVITA SINGH, MINAZ Z. MAWANI, MOHAMMED K. ALI, RAJ DEVARAJAN, DIMPLE KONDAL, ROOPA SHIVASHANKAR, VAMADEVAN S. AJAY, PREMLATA K. VARTHAKAVI, MALLA DHARMALINGAM, RAKESH SAHAY, USHA MENON, VIJAY VISWANATHAN, GANAPATHI BANTWAL, RAJESH KHANDGAWAT, ANKUSH DESAI, BIPIN SETHI, MUHAMMAD M. KADIR, K.M. VENKAT NARAYAN, DORAIRAJ PRABHAKARAN, NIKHIL TANDON, Karachi, Pakistan, New Delhi, India, Atlanta, GA, Mumbai, India, Bangalore, India, Hyderabad, India, Kochi, India, Chennai, India, Goa, India


1318-P Comparison of Adult and Pediatric Resources for Type 1 Diabetes Care among T1D Exchange Centers. SHIVANI AGARWAL, EMILY HIRSCHFELD, ASHLEY GARRITY, AVNI SHAH, SARAH CORATHERS, RUTH S. WEINSTOCK, KATHRYN L. LAMBERT, CRAIG BOBIK, ALYSSA B. CABRERA, NICOLE RIOLES, JOYCE LEE, Philadelplhia, PA, Ann Arbor, MI, Portola Valley, CA, Cincinnati, OH, Syracuse, NY, Land O’ Lakes, FL, Boston, MA

1319-P EXSCEL—Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. SHELBY D. REED, YANHONG LI, HELEN A. DAKIN, FRAUKE BECKER, JOSE LEAL, STEPHANIE GUSTAVSON, BERNT KARTMAN, ERIC T. WITTBRODT, ROBERT J. MENTZ, NEHA PAGIDIPATI, M. ANGELYN BETHEL, ALASTAIR M. GRAY, RURY R. HOLMAN, ADRIAN F. HERNANDEZ, Durham, NC, Oxford, United Kingdom, Gaithersburg, MD, Mölndal, Sweden, Wilmington, DE
1320-P Implementation Strategy for a Digital Health Tool Influences User Engagement. MANSUR SHOMALI, MALINDA PEEPLES, Baltimore, MD, Columbia, MD

1321-P Establishment of the Type 1 Diabetes Exchange QI Learning Collaborative (T1DX-LC). AVNI SHAH, SARAH CORATHERS, GUY T. ALONSO, DON A. BUCKINGHAM, SR., ALYSSA B. CABRERA, MARK A. CLEMENTS, DANIEL J. DESALVO, MANMOHAN K. KAMBOJ, KATHRYN L. LAMBERT, SANJEEV N. MEHTA, AMY L. OHMER, NICOLE RIOLES, RONA SONABEND, JOYCE LEE, Portola Valley, CA, Cincinnati, OH, Denver, CO, Columbus, OH, Boston, MA, Kansas City, MO, Houston, TX, Syracuse, NY, Ann Arbor, MI

1322-P An Innovative Cost-Effective Model of Using Advanced Care Practitioners (ACPs) in Improving Glycemic Control and LOS in a Large Hospital System. RENU JOSHI, AMY HELMUTH, Mechanicsburg, PA, Harrisburg, PA

1323-P Development of a Clinical Screening Tool for Undiagnosed Diabetes in a Hospital Observation Unit. REBECCA M. NOONAN, WILFRIDO J. CASTILLO, GABRIEL M. SAFFRAN, COLLIN B. MONTGOMERY, GANESH PHAYAL, RONALD H. SEE-MANGAL, NINA KOHN, ALLISON TIBERIO, ELISSA WOLFF, RIFKA SCHULMAN, ROBERT SILVERMAN, Hempstead, NY, New Hyde Park, NY, Great Neck, NY

1324-P Shared Telemedicine Appointments in Young Adults with T1D—An Economic Evaluation of the CoYoT1 Trial. WEN WAN, REZA SKANDARI, AVIVA NATHAN, PARMIDA ZAREI, MARK W. REID, JENNIFER RAYMOND, ELBERT HUANG, Chicago, IL, Los Angeles, CA

1325-P Feasibility of Shared Telemedicine Appointments for Low SES Adolescents and Young Adults with T1D. JAQUELIN J. FLORES GARCIA, WILFRIDO J. CASTILLO, GABRIEL M. SAFFRAN, COLLIN B. MONTGOMERY, REBECCA M. NOONAN, NINA KOHN, ALLISON TIBERIO, ELISSA WOLFF, RIFKA SCHULMAN, ROBERT SILVERMAN, Hempstead, NY, New Hyde Park, NY

1326-P Cost Savings Associated with Digitally Enhanced Insulin Therapy. ISRAEL HODISH, STANLEY G. BISGAIER, EMILY UNGER, MARY M. AUSTIN, Ann Arbor, MI, Livonia, MI

1327-P Blue Index—The Diabetes Health Score. DHARMENDRA PANCHAL, SANJEEV PHATAK, PADMANABH ZINZUWADIA, BANSHI D. SABOO, DHARUVI HASNANI, SANJAY KALRA, A.K. DAS, SHIVANGI DWIVEDI, Ahmedabad, India, Kanal, India, Pondicherry, India

1328-P Culturally Specific Diabetes Care Reduces Disparities in Metabolic Control. KA HEI KAREN LAU, DAVID M. POBER, SANJEEV N. MEHTA, WILLIAM C. HSU, GEORGE L. KING, Boston, MA

1329-P WITHDRAWN

1330-P Cost Savings Associated with Usage and Blood Glucose Control for Members of the Livongo for Diabetes Program. JENNIFER BOLLYKY, WEI LU, JENNIFER SCHNEIDER, CHRISTOPHER WHALEY, Mountain View, CA, Santa Monica, CA

1331-P Patient Quality of Life and Benefits of Leptin Replacement Therapy (LRT) in Generalized and Partial Lipodystrophy (GL, PL). OMER A. ALI, KEZIAH COOK, KRISTINA S. SHAMPANIER, EDWARD TUTTLE, CHARLES GERRITS, REBECCA BROWN, Menlo Park, CA, Boston, MA, Cambridge, MA, Bethesda, MD

1332-P Impact of Hyperglycemia on 30-Day Readmission Rates. MARY GAINES, RICHARD E. PRATLEY, Maitland, FL, Orlando, FL

1333-P Impact of Diabetes Mellitus on Outcomes of Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma in the U.S. KRISHMITA SIWAKOTI, SMITH GIRI, VIJAY BHATT, New Haven, CT, Omaha, NE

PEDIATRICS—OBESITY AND TYPE 2 DIABETES

Moderated Poster Discussion: Metabolic Parameters—Risk Factors for Type 2 Diabetes, Cardiovascular Disease, and Cognitive Development? (Posters: 1334-P to 1339-P), see page 90.

1334-P ◇ Childhood Metabolic Markers Are Associated with Performance on Cognitive Tasks in Young Children—The Healthy Start Study. ALLISON L.B. SHAPO, GRETA WILKENING, JASON R. TREGELLA, JENNY AALBORG, BRANDY RINGHAM, ALEXANDRA V. STAMATOIU, ALEXIS BANNING, DANA DABELEA, Aurora, CO, Denver, CO

1335-P ◇ Time to Glucose Peak during Oral Glucose Tolerance Test (OGTT) and Pathophysiological Biomarkers of Type 2 Diabetes in Obese Youth. JOON YOUNG KIM, HALA TFAYLI, FIDA BACHA, SARA MICHALISZYN, SILVA ARSLANIAN, Pittsburgh, PA, Beirut, Lebanon, Houston, TX, Youngstown, OH
1336-P Metabolic Differences among Children of Different Ethnicities Are Magnified when Hepatic Insulin Extraction Is Included. FRANCESCA PICCININI, BARBARA GOWER, JOSE R. FERNANDEZ, RICHARD N. BERGMAN, Los Angeles, CA, Birmingham, AL

1337-P Complement and Cardiometabolic Risk in Adolescents. ROBERT P. HOFFMAN, MELANIE M. COPENHAVER, CHACK-YUNG YU, Columbus, OH

1338-P Valine Metabolism Is Altered in Obese Adolescents with Polycystic Ovary Syndrome and Relates to Insulin Sensitivity. ANNE-MARIE CARREAU, HASEEB RAHAT, YESENIA GARCIA REYES, LAURA PYLE, KRISTEN J. NADEAU, MELANIE CREE-GREEN, Aurora, CO

1339-P Childhood Habitual Sleep Duration Modifies the Polygenic Risk for Obesity through Leptin Pathway—A Longitudinal Study. MING LI, JUNLING FU, LANWEN HAN, GE LI, SHAN GAO, STRUAN F. GRANT, BCAMS GROUP, Beijing, China, Philadelphia, PA

1340-P T1D and T2D Youth in the Pediatric Diabetes Consortium (PDC) Registries—Comparing Clinical Characteristics and Glycemic Control. WILLIAM V. TAMBORLANE, PEIYAO CHENG, ROBIN L. GAL, CRAIG KOLLMAN, MICHELLE A. VAN NAME, JANE L. LYNCH, BRYCE A. NELSON, New Haven, CT, Tampa, Fl, San Antonio, TX, Greenville, SC

1341-P Rosiglitazone Increases Visceral and Subcutaneous Fat in Youth with Type 2 Diabetes (T2D) in the TODAY Study. RUBAN DHALIWAL, JOHN A. SHEPHERD, LAURE EL GHORMLI, KENNETH C. COPELAND, MITCHELL GEFFN, JANINE HIGGINS, LYNNE L. LEVITSKY, KRISTEN J. NADEAU, RUTH S. WEINSTOCK, NEIL H. WHITE, Syracuse, NY, Honolulu, HI, Rockville, MD, Oklahoma City, OK, Los Angeles, CA, Aurora, CO, Boston, MA, Denver, CO, St. Louis, MO

1342-P Management of Hypertension and Hyperlipidemia in Youth with T2D. LINDSEY C. BEAULIEU, PEIYAO CHENG, MICHELLE KATZ, LORI M. LAFELL, WILLIAM V. TAMBORLANE, MICHELLE A. VAN NAME, NIDHI BANSAL, CRAIG KOLLMAN, ROBIN L. GAL, Tampa, FL, Boston, MA, New Haven, CT, Iowa City, IA

1343-P Transforming Pediatric T2D Clinical Research—A Network Model. ROBIN L. GAL, LINDSEY C. BEAULIEU, KIMBERLY D. KEELIN, JOANE E. LESS, BRYCE A. NELSON, KUPPER A. WINTERGERST, GEORGEANNA J. KLENGENSCHMIT, WILLIAM V. TAMBORLANE, Tampa, Fl, Oklahoma City, OK, Greenville, SC, Louisville, KY, Aurora, CO, New Haven, CT

1344-P Effect of Liraglutide, Metformin, and Gliclazide on Body Composition in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease—A Randomised Trial. WENHUAN FENG, YAN BI, PING LI, TINSTING YIN, CAIXIA GAO, SHANMEI SHEN, LIJUN GAO, CAN JIANG, DALONG ZHU, Nanjing, China, Yani’an, China, Shandong, China

1345-P Maternal Gestational Diabetes and Childhood Obesity—A Large Observational Study. JING WANG, LEISHEN WANG, SHUANG ZHANG, HUIKUN LIU, JUNHONG LENG, WEIQIN LI, TAO ZHANG, NAN LI, WEI LI, ANDREA BACCARELLI, LIFANG HOU, GANG HU, Tianjin, China, New York, NY, Chicago, IL, Baton Rouge, LA

1346-P The Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth with Type 2 Diabetes. PETTER BJORNSTAD, LORI M. LAFELL, WILLIAM V. TAMBORLANE, GUDRUN SIMONS, STEFAN HANTEL, MAXIMILIAN VON EYNATTEN, JYOTHSI T. GEORGE, JAN MARQUARD, DAVID CHERNEY, Aurora, CO, Boston, MA, New Haven, CT, Biberach, Germany, Ingelheim, Germany, Toronto, ON, Canada

1347-P Estimating Plasma Glucose with FreeStyle Libre Pro CGM during OGTT in Youth. NEJLA GHANE, MIRANDA BROADNEY, SHAVONNE M. COLLINS, ELISABETH K. DAVIS, SHEILA BRADY, JACK A. YANOFSKI, Bethesda, MD

1348-P Longitudinal Predictors of Insulin Sensitivity and Secretion during Puberty. MEGAN M. KELSEY, LAURA PYLE, ALLISON M. HILKIN, AIMEE JOHNSON, PHIL ZEITLER, Aurora, CO, Denver, CO

1349-P Genotype-Phenotype Correlations and Structural Basis of INSR and IGF1R Mutations Causing Severe Insulin/IGF-1 Resistance. JUN HOSOE, HIROKO KADOWAKI, FUYUKI MIYA, MINAKA TAKAKURA, TATSUHIKO TSUNODA, NOBUHIRO SHOJIMA, TOSHIYASU YAMAUCHI, TAKASHI KADOWAKI, Tokyo, Japan

1350-P Withdrawn

1351-P Identification of Gastric Mucosa Key Pathways and Genes in Obesity and Obesity-Related Diabetes via Gene Microarray Analysis. XIN WEN, YI ZHANG, RUI J. WU, CUILING ZHU, RAN CUI, YOU HUI, FANG Y. MEI, JINGYANG GAO, SHEN QU, LE BU, Shanghai, China
1352-P Increased Glucagon, but Reduced GIP Secretion, in Adolescents with Obesity and T2DM.
HJALTI KRISTINSSON, HANNES MANELL, MONICA VILHELMSSON, JENNY PRESTO, CAROLINA GÄREDAL,
HANNA RITZÉN, ANDERS H. FORSLUND, SR., PETER BERGSTEN, Uppsala, Sweden

1353-P Variation in Phenotypic Features of Two Siblings with PC1/3 Deficiency—Obesity and Hyperproinsulinemia. ELISABETH K. DAVIS, MIRANDA BROADNEY, REBECCA PERSKY, AHMED TORKY, JACK A.
YANOVSKI, Bethesda, MD

1354-P Adolescents at High-Risk for Developing Type 2 Diabetes and/or Polycystic Ovary Syndrome Can Be Identified Using a Simple Questionnaire while in High School. SIDIKA KARAKAS, Sacramento, CA

1355-P Evaluation of a Family-Based Interactive Lifestyle Intervention to Reduce the Risk of Developing Type 2 Diabetes in the Future (PRE-START Intervention). EMER M. BRADY, LAURA J. GRAY,
SUSANN WEIHRAUCH-BLÜHER, CHARLOTTE EDWARDSON, DEIRDRE HARRINGTON, ROGÉRIO T. RIBEIRO,
ANDRIANI VAZEOU, ALISON L. NORTHERN, ELENA ALUSTIZA, MELANIE JANE DAVIES, Leicester, United Kingdom, Leipzig, Germany, Lisboa, Portugal, Athens, Greece, San Sebastian, Spain

1356-P The Association between Breakfast Skipping and the Risk of Obesity, Diabetes, Hypertension, or Dyslipidemia—A Meta-analysis from 44 Trials Including 65,233 Cases and 381,051 Controls. XIU M. MA, YONG XU, Luzhou, China

1357-P Perceptions of Physical Activity in American-Indian Youth at Risk for Diabetes. HEATHER KIMBLEY, JENNIFER CHADWICK, CHARLOTTE L. COLEMAN, MARY A. TULLIER, LISA D. WOLBERT, KENNETH C. COPLELAND, KEVIN R. SHORT, Oklahoma City, OK, Talihina, OK, Soper, OK

1358-P KIAA2022, a Candidate Gene for Syndromic Diabetes. CAROLINE STEKELENBURG, JEAN-LOUIS BLOUIN, FRED SANTONI, ELIZABETH A. O’HARE, NORANN A. ZAGHLoul, VALERIE SCHWITZGEBEL, Geneva, Switzerland, Lausanne, Switzerland, Towson, MD, Baltimore, MD

1359-P Obstructive Sleep Apnea in Pediatric Type 2 Diabetes—Prevalence, Demographics, and Screening Practices. KRISTAL A. MATLOCK, YUPING GUO, JANE C. KHOURY, NEEPA GURBANI, NANCY A. CRIMMINS, Cincinnati, OH

1360-P Complement C3 and C4 Genetics and Cardiometabolic Risk in Adolescents. ROBERT P. HOFFMAN, MELANIE M. COPENHAVER, CHACK-YUNG YU, Columbus, OH

1361-P Late Reactive Hypoglycemia (RHG) as a Common Early Sign of Glycemic Dysfunction in Obese Adolescent Girls. ANNE-MARIE CARREAU, HASEEB RAHAT, YESENIA GARCIA REYES, LAURA PYLE, KRISTEN J. NADEAU, MELANIE CREE-GREEN, Denver, CO

1362-P Alterations in Novel Signals in the Gut-Adipose Axis—A Pilot Study in Insulin-Resistant Children with Obesity and Biopsy-Proven Nonalcoholic Steatohepatitis. MATTHEW D. DI GUGLIELMO, SANA MANSOOR, VIKAS ÚPPAL, KÁTRYN N. FURUYA, SEEMA KUMAR, P. BABU BALAGOPAL, Wilmington, DE, Rochester, MN, Jacksonville, FL

1363-P Paternal Bisphenol A Exposure Alters Offspring Glucose Tolerance in a Time, Dose, and Sex-Specific Manner. CETEWAYO S. RASHID, AMITA BANSAL, REBECCA A. SIMMONS, Philadelphia, PA

1364-P Utility of Fibroscan in Screening Overweight and Obese Children at Risk for Nonalcoholic Fatty Liver Disease. KRISTIN A. DAYTON, FERNANDO BRIL, KENNETH CUSI, Gainesville, FL

1365-P Vitamin D Levels Are Associated with Risk Factors for Type 2 Diabetes and Metabolic Syndrome in Chinese Youths. SHAN GAO, LANWEN HAN, JUNLING FU, GE LI, MING LI, STEVEN M. WILLI, Beijing, China, Philadelphia, PA
Clinical Diabetes/Therapeutics
POSTERS

1366-P Co-Occurrence of 2+ Early Complications in Type 1 Diabetes—SEARCH for Diabetes in Youth. KATHERINE A. SAUDER, JEANETTE M. STAFFORD, ELIZABETH J. MAYER-DAVIS, ELIZABETH T. JENSEN, SHARON SAYDAH, AMY K. MOTTI, LAWRENCE M. DOLAN, RICHARD F. HAMMAN, JEAN M. LAWRENCE, CATHERINE PIHOKER, SANTICA M. MARCOVINA, RALPH DAGOSTINO, JR., DANA DABELEA, SEARCH FOR DIABETES IN YOUTH STUDY GROUP, Aurora, CO, Winston-Salem, NC, Chapel Hill, NC, Hyattsville, MD, Cincinnati, OH, Pasadena, CA, Seattle, WA

1367-P Diabetes Retinopathy (DR) Relates to Complication Risk in Young Persons with T1D. MICHELINE KATZ, GEORGE L. KING, JENNIFER SUN, LORI M. LAFFEL, Boston, MA

1368-P Grazing in Young Children with Type 1 Diabetes Is Associated with Higher HbA1c. ROWEN L. SECKOLD, PETER HOWLEY, BRUCE R. KING, KIRSTINE BELL, CARMEL SMART, Newcastle, Australia, Callaghan, Australia, Sydney, Australia

1369-P Novel, Culturally Sensitive Shared Group Appointment Program for Hispanic Pediatric Type 1 Diabetes Patients Is Feasible, Improves Technology Uptake, and Has Promising Results on Better Diabetes Outcomes. ANDREA GERARD GONZALEZ, ANDREA CAROLINA BRADY, GEORGEANNA J. KLINGENSMITH, LAURA PYLE, JESSICA THURSTON, Aurora, CO

1370-P Impact of Intensive Remote Monitoring on Blood Glucose Measurements in a Cohort of T1D Pediatric Patients. LAURA M. GANDRUD, TIMOTHY L. BARNES, DAVID A. WATSON, Saint Paul, MN, Minneapolis, MN

1371-P Promoting Health Equity in Type 1 Diabetes through Peer Mentorship—Findings from the All for ONE Randomized Controlled Trial. ASHBY F. WALKER, MICHAEL J. HALLER, MATTHEW J. GURKA, HEATHER L. MORRIS, CLAUDIA ANEZ-ZABALA, BRITTANY S. BRUGGMAN, DANIELLE GUIFFRE, HENRY ROHRS III, MARK A. ATKINSON, DESMOND SCHATZ, Gainesville, FL

1372-P Motivational Stage at CGM Initiation Is Less Important than Timing of CGM Initiation in Predicting CGM Adherence. KATE VERBEETEN, JASON CHAN, NADIA SOURIAL, MARGARET L. LAWSON, CGM TIME TRIAL STUDY GROUP, JDRF CANADIAN CLINICAL TRIALS NETWORK, Ottawa, ON, Canada, Montreal, QC, Canada

1373-P Impact of Target HbA1c Change in Pediatric Participants in the T1D Exchange Clinic Registry. JAMIE WOOD, CLAIRE BOYLE, MARYANNE QUINN, JENISE C. WONG, MICHAEL J. HALLER, BRYCE A. NELSON, MICHAEL J. HALLER, DESMOND SCHATZ, WILLIAM V. TAMBORLANE, LARRY FOX, PRIYA PRAPHALA, SARAH CORATHERS, DAVID M. MAAHS, GUY T. ALONSO, DANIEL J. DESALVO, PAUL WADWA, LINDA DIMEGLIO, Cleveland, OH, Tampa, FL, Boston, MA, San Francisco, CA, Gainesville, FL, Greenville, SC, New Haven, CT, Jackson-ville, FL, Stanford, CA, Cincinnati, OH, Denver, CO, Houston, TX, Aurora, CO, Indianapolis, IN

1374-P Early and Later C-Peptide Responses during Oral Glucose Tolerance Testing (OGTT) Are Independently and Oppositely Predictive of Type 1 Diabetes (T1D) in Autoantibody-Positive (Ab+) Individuals. HEBA M. ISMAIL, DOROTHY J. BECKER, SUSAN GEVERY, PING XIU, INGRID LIBMAN, KEVIN C. HEROLD, MARK A. ATKINSON, MARIA J. REDONDO, JERRY P. PALMER, JAY SOSENKO, Pittsburgh, PA, Tampa, FL, New Haven, CT, Gainesville, FL, Houston, TX, Seattle, WA, Miami, FL

1375-P Associations of Executive Function (EF) with Diabetes Management and Glycemic Control in Teens with Type 1 Diabetes (T1D). MEREL HANSMANN, ZIJING GUO, LISA VOLKENING, LORI M. LAFFEL, Boston, MA

1376-P Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions. GREGORY P. FORLENZA, BRUCE BUCKINGHAM, JENNIFER SHERR, THOMAS A. PEYSER, JOON BOK LEE, JASON B. OCONNOR, BONNIE DUMAIS, LAUREN M. HUYETT, JENNIFER E. LAYNE, TRANG T. LY, Aurora, CO, Palo Alto, CA, New Haven, CT, Biltenica, MA

1377-P Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions. JENNIFER SHERR, GREGORY P. FORLENZA, BRUCE BUCKINGHAM, THOMAS A. PEYSER, JOON BOK LEE, JASON B. OCONNOR, BONNIE DUMAIS, LAUREN M. HUYETT, JENNIFER E. LAYNE, TRANG T. LY, New Haven, CT, Aurora, CO, Palo Alto, CA, Biltenica, MA
1378-P Family History of Diabetes Is Associated with Increased Risk of Recurrent DKA in Pediatric Patients in Rhode Island. JANAKI D. VAKHARIA, SUNGEETA AGRAWAL, JANINE BACIC, LISA S. TOPOR, Providence, RI, Boston, MA

1379-P Insulin Treatment and Clinical Outcomes in 67 Participants with Infancy-Onset Diabetes. LISA R. LETOURNEAU, DAVID CARMDY, ANNA M. DENSOn, MAY SANYOURA, ROCHELLE N. NAYLOR, LOUIS H. PHILIPSON, SIRI ATMA W. GREELEY, Chicago, IL, Singapore, Singapore

1380-P Impact of Family-Centered Tailoring of Pediatric T1D Self-Management Resources. ROSANNA V. FIALLO-SCHARER, VICTORIA P. RAJAMANICKAM, BETTY A. CHEWINING, MARI PALTA, TOSHA B. WETTERNECK, TIM WYSOCKI, ELIZABETH D. COX, Milwaukee, WI, Madison, WI, Jacksonville, FL

1381-P Socioeconomic Disparities in Outpatient Diabetes Care Patterns for Young Adults with Type 1 Diabetes. SHIVANI AGARWAL, HANNAH L. VIROSLAV, JACK N. EIEL, JUDITH A. LONG, Philadelphia, PA, Dallas, TX

1382-P Type 1 Diabetes Transition Program at a Children’s Hospital—Lessons Learned and Future Directions. HOLLY CORNWELL, SEVKET YIGIT, RADHIKA PURUSHOTHAMAN, Portland, OR

1383-P Analysis of the Social Network and Physical Activity Performed as Perceived by Young Patients with Type 1 Diabetes. PIERGIORGIO FRANCIA, BARBARA PICCINI, UGO SANTOSUSSO, GIULIA IANNONE, LAURA CAPIRCHIO, ALESSANDRO VITTO R, MASSIMO GUlisANO, SONIA TONI, Florence, Italy

1384-P Association of Age, Sex, and Weight with Moderate-to-Vigorous Physical Activity in a Pediatric Type 1 Diabetes Population. NELS E. THOMPSON, DAVID A. WATSON, TIMOTHY L. BARNES, LAURA M. GANDRUD, Minneapolis, MN, Saint Paul, MN

1385-P Relationship between Mean Glucose and A1c by Pubertal Stage in Youth with Type 1 Diabetes (T1D). JIA ZHU, LISA VOLKENING, MICHELLE KATZ, LORI M. LAFFEL, Boston, MA

1386-P Effect of Significant Family Life Events in the First Year of Type 1 Diabetes (T1D). KELLY R. STANEK, SHIDEH MAJIDI, ERIN M. YOUNGKIN, AMY NOSER, MARK A. CLEMENTS, SUSANA R. PATTON, Aurora, CO, Lawrence, KS, Kansas City, MO, Kansas City, KS

1387-P Higher Weekly Physical Activity in T1D Pediatric Patients Is Associated with Improved Target Glucose Levels—Findings from Six Months of Fitbit-Monitored Activity. TIMOTHY L. BARNES, DAVID A. WATSON, LAURA M. GANDRUD, Minneapolis, MN, Saint Paul, MN

1388-P A Paradoxical Relationship between Physical Activity and HbA1c in Pediatric T1D Patients. DAVID A. WATSON, TIMOTHY L. BARNES, LAURA M. GANDRUD, Minneapolis, MN, Saint Paul, MN

1389-P Five-Year Experience with Telemedicine Clinics for Youth with Type 1 Diabetes (T1D). R. PAUL WADWA, JOHN STACY, TYLER REZNICK-LIPINA, ROBERT H. SLOVER, JOHN F. THOMAS IV, Aurora, CO, Grand Forks, ND

1390-P Sustained CGM Use in Low Income Youth following Insurance Coverage. PRIYA PRAHALAD, BRUCE BUCKINGHAM, DARRELL WILSON, DAVID M. MAAMS, Stanford, CA, Palo Alto, CA

1391-P Parental Hypoglycemia Fear and Adoption of Pump Therapy in Youth with New-Onset Type 1 Diabetes (T1D). ERIN M. YOUNGKIN, SHIDEH MAJIDI, AMY NOSER, KELLY R. STANEK, JONATHAN H. FINCH, MARK A. CLEMENTS, SUSANA R. PATTON, Aurora, CO, Lawrence, KS, Kansas City, MO, Kansas City, MO

1392-P Longitudinal Assessment of Disordered Eating Behavior (DEB) Risk in Teens with Type 1 Diabetes (T1D). RAQUEL CECILIA-COSTA, ZIJING GUO, KARA R. HARRINGTON, LISA VOLKENING, LORI M. LAFFEL, Boston, MA

1393-P Inhibition of Nox-1 Activity Attenuates Diabetic Ketoadasosis-Induced Blood Brain Barrier Permeability and Edema Formation. GABRIELA MARTINEZ-REVOLLAR, Ann Arbor, MI

1394-P Establishing a Clinically Meaningful Cut-Point for the PAID-PR (Problem Areas in Diabetes-Parent Revised) Survey. LIANE J. TINSLEY, PERSIS V. COMMISSARIAT, LISA VOLKENING, BARBARA ANDER SON, MICHELLE KATZ, LORI M. LAFFEL, Boston, MA, Charlottesville, VA
1396-P  Racial Ethnic Disparities in Diabetes Youth Participating in Diabetes Summer Camps. JESSICA M. VALENZUELA, MEGAN T. MARTIN, SAM RECORDS, KELLY O’NEAL, KELLY MUELLER, RISA M. WOLF, Davie, FL, Arlington, VA, Baltimore, MD

PREGNANCY—BASIC SCIENCE/TRANSLATIONAL

Moderated Poster Discussion: Basic Science/Translational Topics in Gestational Diabetes Mellitus  (Posters: 1397-P to 1402-P), see page 92.

1397-P  Effects of Modified Lipoproteins on Human Trophoblast Cells—A Role in Preeclampsia in Pregnancies Complicated by Diabetes. REBECCA H. MCLEESE, JIAWU ZHAO, JEREMY YU, DEREK BRAZIL, TIMOTHY LYONS, Charleston, SC, Belfast, United Kingdom

1398-P  Olive Oil Supplementation Reduces Proinflammatory Markers in the Placenta in a GDM Rat Model Induced by Intrauterine Programming. DALMIRO L. GÓMEZ RIBOT, EVANGELINA CAPOBIANCO, CECILIA P. LEVIEUX, DAIANA FORNES, ALICIA JAWERBAUM, Buenos Aires, Argentina

1399-P  PKC Modulates sFlt1 Production by Human Placental Trophoblasts in Response to Oxidized LDL. REBECCA P. CHOW, JIAWU ZHAO, JEREMY YU, Charleston, SC, Belfast, United Kingdom

1400-P  Pancreatic β-Cell Mass Is Determined by β-Cell Size after Parturition in Mice. MASAYA TAKAHASHI, TAKESHI MIYATSUKA, MIWA HIRURO, LUKA SUZUKI, MASAKI MIURA, TAKEHIRO KATAHIRA, YUYA NISHIDA, ATSUYO ITAKURA, HIROTAKA WATADA, Tokyo, Japan

1401-P  Regulation and Role of Human Resistin in Diabetes during Pregnancy. SHAONING JIANG, APRIL M. TEAGUE, JEANIE B. TRYGGESTAD, TIMOTHY LYONS, STEVEN CHERNAUSEK, Oklahoma City, OK, Charleston, SC

1402-P  Fetal Brain Activity in Pregnancy of Women with Type 1 Diabetes Mellitus. ELLEN FEHLERT, FRANZISKA SCHLEGER, KATARZYNA LINDER, MARTIN HENI, HANS-ULRICH HAERING, HUBERT FREISST, Tübingen, Germany

1403-P  Family History of Diabetes Delays Fetal Brain Activity. FRANZISKA SCHLEGER, LAURA WALTER, MARTIN HENI, SARA Y. BRUCKER, HANS-ULRICH HAERING, ANDREAS FREISST, HUBERT FREISST, Tübingen, Germany

1404-P  High Maternal DHA Levels in Hawaiian Women Decrease Insulin Resistance. FERNANDA ALVARADO, PAI-JONG TSAI, JUDI MINIMUM, PATRICK CATALANO, PERRIE O’TIERNEY-GINN, Cleveland, OH, Honolulu, HI

1405-P  Haptoglobin Concentration, Pregnancy, and Preeclampsia in Women with Type 1 Diabetes. CLARE B. KELLY, JEREMY YU, ALICIA JENKINS, ALISON J. NANKERVIS, KRISTIAN F. HANSSSEN, SATISH K. GARG, CHRISTOPHER E. ASTON, TIMOTHY LYONS, Charleston, SC, Sydney, Australia, Parkville, Australia, Oslo, Norway, Aurora, CO, Oklahoma City, OK

1406-P  Longitudinal Changes in Amino Acid (AA) Turnover in Pregnancy in Women with Normal Glucose Tolerance (NGT) and GDM—Relationship to Fetal Growth. PATRICK CATALANO, LARRAINE PRESLEY, SYLVIE HAUQUEL DE MOUZON, SATISH KALHAN, Cleveland, OH

1407-P  Is Gestational Weight Gain Associated with Change in Ectopic Lipid Stores? KIMBERLY VESCO, MICHAEL C. LEO, MELANIE FRANCISCO, ERIC BAETSCHER, WILLIAM ROONEY, NICOLE E. MARSHALL, JONATHAN Q. PURNELL, Portland, OR

1408-P  Are Changes in Whole-Body Insulin Sensitivity during Pregnancy Related to Changes in Ectopic Fat Stores? KIMBERLY VESCO, NICOLE E. MARSHALL, WILLIAM ROONEY, MICHAEL C. LEO, ERIC BAETSCHER, MELANIE FRANCISCO, JONATHAN Q. PURNELL, Portland, OR

1409-P  Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women with Type 1 Diabetes. CLARE B. KELLY, JEREMY YU, ALICIA JENKINS, ALISON J. NANKERVIS, KRISTIAN F. HANSSSEN, SATISH K. GARG, CHRISTOPHER E. ASTON, TIMOTHY LYONS, Charleston, SC, Sydney, Australia, Parkville, Australia, Oslo, Norway, Aurora, CO, Oklahoma City, OK

1410-P  Adipose Tissue Health Associates with the Development of Gestational Diabetes Mellitus in Nonobese Women. DEMIDMAA R. TUVDENDORJ, BATBAYAR TUMURBAATAR, AARON POOLE, SHWETHA THUKUNTILA, GAYLE O. KOUTROUELIS, NICOLA ABATE, Galveston, TX, Portsmouth, VA, League City, TX

1411-P  IRS1 Is a Target of MicroRNA-126. JEANIE B. TRYGGESTAD, APRIL M. TEAGUE, STEVEN CHERNAUSEK, Oklahoma City, OK
1412-P IGFs and IGF-Binding Proteins in Pregnancy and Gestational Diabetes Mellitus. KATERINA ANDERLOVÁ, PATRIK SIMJAK, ANNA CINKAJZLOVÁ, JANÁ KLOUCKOVA, HELENA KRATOVILLIOVA, ZDENA LACINOVÁ, PETRA KAVÁLKOVÁ, HANA KREJCI, MILOS MRAZ, MARTIN HALUZIK, MICHAL KRSEK, Prague, Czech Republic

1413-P Subclinical Inflammation and Lymphocytes in Subcutaneous and Visceral Adipose Tissue—The Influence of Pregnancy and Gestational Diabetes Mellitus. ANNA CINKAJZLOVÁ, KATERINA ANDERLOVÁ, ZDENA LACINOVÁ, JANÁ KLOUCKOVA, HELENA KRATOVILLIOVA, HANA KREJCI, MILOS MRAZ, MARTIN HALUZIK, MICHAL KRSEK, Prague, Czech Republic

PREGNANCY—CLINICAL/EPIDEMIOLOGY

Moderated Poster Discussion: Clinical/Epidemiology Topics in Gestational Diabetes Mellitus (Posters: 1414-P to 1419-P), see page 90.

1414-P Metformin and Dietary Advice for Pregnant Women Who Are Overweight or Obese to Promote Gestational Restriction of Weight—The GROW Randomized Trial. JOHANNA M. DODD, JENNIE LOUISE, ANDREA R. DEUSSEN, THE GROW RANDOMIZED TRIAL GROUP, North Adelaide, Australia

1415-P The Association of Pregnancy Number and Outcome with Mortality in Type 1 Diabetes. TINA COSTACOU, DEBRA RUBINSTEIN, TREVOR J. ORCHARD, Pittsburgh, PA

1416-P A Reduction in Sedentary Behavior in Obese Women Reduces Neonatal Adiposity—The DALI Randomized Controlled Trial. MIREILLE VAN POPPEL, DAVID SIMMONS, GERNOT DESOYE, DALI CORE INVESTIGATOR GROUP, Graz, Austria, Campbelltown, Australia

1417-P Associations of a Preconception Biomarker Risk Score with Future Gestational Diabetes. SYLVIA E. BADON, ASSIAMIRA FERRARA, YEJI ZHU, SNEHA B. SRIDHAR, CATHERINE LEE, SAMANTHA EHRlich, CHARLES QUEENEBERRY, MONIQUE HEDDERSON, Oakland, CA, Knoxville, TN

1418-P Comparison of Cardiometabolic Risk Factors in Offspring of Diabetic Mothers (ODM) and Non-diabetic Mothers (OND) in India. SONALI S. WAGLE, KALYNARAMAN KUMARAN, RASIKA LADKAT, DATTATRAY BHAT, PALAVI C. YAJNik, CHITTARANJAN S. YAJNik, Pune, India, Southampton, United Kingdom

1419-P The Association between Free Fatty Acid Level at Mid-pregnancy and Postpartum Glucose Intolerance in Women with Gestational Diabetes Mellitus. KYUNG-SOO KIM, SOO-KYUNG KIM, YONG-WOOK CHO, SEOK WON PARK, Seongnam, Republic of Korea

1420-P Gestational Diabetes Mellitus (GDM) Predicts Future Risk of Serious Liver Disease. RAVI RETNAKARAN, JIN LUO, BAIJU R. SHAH, Toronto, ON, Canada

1421-P Implementation of an Electronic Screening Tool to Detect Early GDM Uncovers Deficiencies. RACHEL RODEL, SHANE A. REEVES, LINDA A. BARBOUR, Aurora, CO

1422-P Maternal Postprandial Triglycerides in the Home Setting. HELEN L. BARRETT, MARLOES NITERT DEKKER, SUSAN J. DE JERSEY, MICHAEL C. D’EMOEN, LEONIE CALLAWAY, H. DAVID MINTYRE, South Brisbane, Australia, St. Lucia, Australia, Brisbane, Australia, Herston, Australia

1423-P The Skin Autofluorescence of Pregnant Women with Diabetes Predicts Macrosomia in Their Newborns. NINON FOSSARD, CATHERINE HELMER, CONCEPCION GONZALEZ, LAURENCE BLANCO, KAMEL MOHAMMEDI, VINCENT RIGALLEAU, Bordeaux, France, Lormont, France, Pessac, France

1424-P Breastfeeding at Night Is Rarely Followed by Hypoglycemia in Puerperal Women with Type 1 Diabetes Using Carbohydrate Counting and Modern Insulin Treatment. LENE RINGHOLM, ANN B. ROSKJÆR, SUSANNE ENGBERG, HENRIK U. ANDERSEN, EVA HOMMEL, ANNA L. SECHER, PETER DANNM, ELISABETH R. MATHIESEN, Gentofte, Denmark, Copenhagen, Denmark

1425-P WITHDRAWN

1426-P Plasma Triglyceride Concentrations during Pregnancy Are Associated with Fetal Hyperinsulinemia, Insulin Resistance, and Birth Weight Independent of Maternal Hyperglycemia and Insulin Resistance. KUAN YU CHEN, HUNG-YUAN LI, Hsinchu, Taiwan, Taipei, Taiwan

1427-P Labor Induction and Cesarean Delivery Risk in Women with Gestational Diabetes Mellitus. MAUREEN S. HAMEL, MARTHA B. KOLE, DWIGHT ROUSE, ERIKA WERNER, Providence, RI
1428-P Sleep Disordered Breathing—An Unrecognized Contributor to Abnormal Glycemic Profiles in Pregnancy. SARAH S. FARABI, LINDA A. BARBOUR, TERI L. HERNANDEZ, Aurora, CO

1429-P Maternal Metabolites during Pregnancy Are Associated with Newborn Outcomes. RACHEL KADAKIA, MICHAEL NODZENSKI, OCTAVIOUS TALBOT, ALAN KUANG, JAMES R. BAIN, MICHAEL MUEHLBAUER, OLGA ILKAYEVA, SARA K. O’NEAL, LYNN P. LOWE, BOYD E. METZGER, DENISE SCHOLTENS, WILLIAM LOWE, JR., HAPO STUDY COOPERATIVE RESEARCH GROUP, Chicago, IL, Durham, NC

1430-P Maternal Central Obesity and Birth Size—A Mendelian Randomization Analysis. TAO HUANG, BEIJING, China, Singapore, Singapore

1431-P In Early Pregnancy, a High Proportion of Women with Type 2 Diabetes Have Lower Daily Carbohydrate Consumption than Recommended by the Institute of Medicine. BJÖRG ÁSBJÖRNSDÓTTIR, HELLE RONNEBY, MARIANNE VESTGAARD, LENE RINGHOLM, DORTE M. JENSEN, ANNE RABEN, PETER DAMM, ELISABETH R. MATHIESEN, Copenhagen, Denmark, Gentofte, Denmark, Odense, Denmark, Frederiksberg, Denmark

1432-P Adaptability of Closed-Loop during Labor, Delivery, and Postpartum—A Secondary Analysis of Data From Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. JENNIFER M. YAMAMOTO, ZOE A. STEWART, MALGORZATA E. WILINSKA, SARA HARTNELL, ROMAN HOVKORKA, HELEN R. MURPHY, Calgary, AB, Canada, Cambridge, United Kingdom, Norwich, United Kingdom

1433-P Gestational Diabetes and Diabetes and Prediabetes Risks Postpartum—A Large Observational Study. YUN SHEN, PENG WANG, LEISHEN WANG, SHUANG ZHANG, HUIKUN LIU, WEIQIN LI, NAN LI, WEI LI, JUNHONG LENG, JING WANG, HUIGUANG TIAN, CUILIN ZHANG, XILIN YANG, ZHIJIE M. YU, GANG HU, Baton Rouge, LA, Tranjin, China, Bethesda, MD, Halifax, NS, Canada

1434-P Sex Hormone-Binding Globulin, Cardiometabolic Biomarkers, and Gestational Diabetes—A Longitudinal Pregnancy Cohort Study and a Meta-analysis. MENG YING LI, SHRISTI RAWAL, STEFANIE HINKLE, SIMIN LIU, FASIL TEKOLA-AYELE, CUILIN ZHANG, Bethesda, MD, Newark, NJ, Providence, RI

1435-P Is Screening for Early Gestational Diabetes Mellitus Associated with a Better Prognosis? An Observational Study Including 8,713 Women. EMMANUEL COSSON, DORIAN SANDRE BANON, FRANÇOISE GARY, ISABELLE PHARISIEN, JEAN-JACQUES PORTAL, PAUL VALENSE, LIONEL CARBILLON, Bondy, France, Paris, France

1436-P How Important Is Early Diagnosis and Intense Insulin Therapy in In Vitro Fertilization Pregnancies Complicated by Gestational Diabetes Mellitus? PETROS THOMAKOS, OLGA KEPAPTSOGLOU, ANASTASIA TROUVA, CAROL BARETTO, DIMITRIS TROUVAS, IBRAHIM TARAOUNE, ASTERIS KORANTZIS, CRISTOS ZOPAS, Athens, Greece

1437-P Vitamin D Status during Pregnancy and the Risk of Gestational Diabetes Mellitus—A Longitudinal Study in a Multiracial Cohort. JIN XIA, YIQING SONG, SHRISTI RAWAL, JINHUA LU, JIANRONG HE, HUIMIN XIA, XIU QIU, KRISHNARAJAH NIRANTHARA-KUMAR, Guangzhou, China, Birmingham, United Kingdom

1438-P Postpartum Relapse in Diet Quality among Women Diagnosed with Gestational Diabetes. ROSETTE J. CHAKKALAKAL, AMBER J. HACKSTADT, HEIDI J. SILVER, TN

1439-P Insulin Secretory Response Is Enhanced in Early Pregnancy. CAMILLE E. POWE, JESSICA S. TANGREN, AARON LEONG, SHANANSSA PERCY, SCOTT KRINSKY, JULIANA ARENAS, MELODY CAYFORD, JOSE C. FLOREZ, MARIE-FRANCE HİVERT, RAVI THADHANI, Boston, MA

1441-P impact of Maternal Metabolic Parameters on Birth Weight and Cord Blood Insulin Concentration—Findings from the Born in Guangzhou Study. JINGYA WANG, YASHU KUANG, MALCOLM J. PRICE, JINHUA LU, JIANRONG HE, HUIMIN XIA, XIU QIU, KAR KEUNG CHENG, KRISHNARAJAH NIRANTHARA-KUMAR, Guangzhou, China, Birmingham, United Kingdom

1443-P Nocturnal Insulin Requirements Are Higher in Pregnant Hispanic Women with Type 2 DM. JESSICA C. EHRRIG, AMANDA A. ALLSHOUSE, LINDA A. BARBOUR, Aurora, CO
1444-P Fatty Liver Disease among Adolescent Offspring Born to Women with Pregestational Type 1 Diabetes (The EPICOM Study). SINE KNORR, BIRGITTE BYTOFT, ZUZANA LOHSE, TINE D. CLAUSEN, RIKKE B. JENSEN, PETER DAMM, HENNING BECK-NIELSEN, CLAUS H. GRAVHOLT, DORTE M. JENSEN, Aarhus, Denmark, Copenhagen, Denmark, Odense, Denmark, Virum, Denmark

1445-P Failure of Maternal Glucose-Insulin Adjustments in Pregnancy Might Contribute to Poor Fetal Growth in India. MADHURA KISHOR DESHMUKH, HEMANT DAMLE, DATTATRAY BHAT, NILAM S. MEMANE, DEEPA A. RAUT, ABOLI A. BHALERAO, SOMNATH J. BONDARDE, CHITTARANJAN S. YAJNIK, Pune, India

1446-P Association between Glyburide Dose and Adverse Neonatal Outcomes in Women with Gestational Diabetes. MAISA N. FEGHALI, STEVE CARITIS, JANET M. CATOV, CHRISTINA M. SCIFRES, Pittsburgh, PA, Oklahoma City, OK

1447-P Predicting Diabetes in the First Two Years Postpartum among Women with Recent Gestational Diabetes—The Linda-Brasil Study. CRISTINA D. CASTILHOS, RUBEN LADWIG, MICHELE DREHMER, BRUCE B. DUNCAN, CRISTINA FACANHA, MARIA I. SCHMIDT, Porto Alegre, Brazil, Fortaleza, Brazil

1448-P Association of First-Trimester Fasting Plasma Glucose with Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes. PING LI, SHUO LIN, LING LI, JINHUI CUI, JIANGHUI FAN, Guangzhou, China

1449-P Free Thyroxin T4 in Early Pregnancy and Risk of Gestational Diabetes Mellitus. PING LI, SHUO LIN, LING LI, LIPING OUYANG, JIANGHUI FAN, Guangzhou, China

1450-P Risk Factors for Pregnancy Hypertensive Disorders in a Cohort of Women with Pregestational Diabetes. MARIA LUCIA R. OPPERMANN, JANINE ALESSI, VANIA N. HIRAKATA, DANIELA WIEGAND, ANGELA J. REICHETT, Porto Alegre, Brazil

1451-P Knowledge of Gestational Diabetes Mellitus among Women of Reproductive Age in Rivers State—Implications for Prevention and Control. ROSEMARY OGU, OMOSIVIE MADUKA, VETTY R. AGALA, IBIMONYE PORBENI, MEDICAL WOMEN’S ASSOCIATION OF NIGERIA, RIVERS STATE, Port Harcourt, Nigeria

1452-P White Coat Hypertension in Early Pregnancy Is Prevalent in Women with Type 1 and Type 2 Diabetes. MARIANNE VESTGAARD, BJÖRG ÆSBJØRNSDOTTIR, LENE RINGHOLM, DORTE M. JENSEN, LISE LOTTE TORVIN ANDERSEN, PETER DAMM, ELISABETH R. MATHIESEN, Copenhagen, Denmark, Gentofte, Denmark, Odense, Denmark

1453-P Management of GCK-MODY in Pregnancy—Does Clinical Practice Follow Current Recommendations? LAURA T. DICKENS, LISA R. LETOURNEAU, LOUIS H. PHILIPSON, SIRI ATMA W. GREELEY, ROCHELLE N. NAYLOR, Chicago, IL

1454-P Effect of Preconceptional Care on Maternal and Fetal Outcomes in Type 1 Diabetes. BELEN DALAMA, ANA ORTIZ DE URBINA, MARIA GOYA, SILVIA AREVALO, CARLOTA RODRIGUES, JORDI MESA, Barcelona, Spain

1455-P Medical Nutrition Therapy for Gestational Diabetes Mellitus (GDM) Based on Mediterranean Diet Principles. ALEJANDRA DURAN, CARLA ASSAF-BALUT, NURIA GARCIA DE LA TORRE, MANUEL FUENTES, ELENA BORDIU, LAURA DEL VALLE, ANA M. BARABASH, MARTIN CUESTA, MIGUEL A. RUBIO, ALFONSO L. CALLE, Madrid, Spain

1456-P Is Gestational Weight Gain below That Recommended by IOM for Obese Women with Insulin Treated Gestational Diabetes Safe? DELIA BOGDANET, PAULA M. O’SHEA, FIDELMA P. DUNNE, Galway, Ireland

1457-P Intensive Metabolic Control of T1D Pregnant Women in CSII vs. MDI—A Retrospective Analysis. SARA PARRETTINI, IRENE GIARDINA, FRANCESCA CARDINI, ELISABETTA TORGHI, Perugia, Italy

1458-P Treatment of Gestational Diabetes and Offspring Early Childhood Growth. MAISA N. FEGHALI, JAQUELINE ALTASS, STEVE CARITIS, JANET M. CATOV, CHRISTINA M. SCIFRES, Pittsburgh, PA, Oklahoma City, OK

1459-P Prevalence of Gestational Diabetes and Preexisting Type 2 Diabetes in a 10-Year Multistate Hospital Discharge Cohort. CYNTHIA J. HERRICK, MATTHEW KELLER, MARGARET A. OLSEN, St. Louis, MO

1460-P Should We Perform an OGTT in All Latino Pregnant Women? The Negative Predictive Value of a Fasting Blood Glucose. LEONARDO G. MANCELLAS-ADAME, CAMILO D. GONZALEZ, JOSE A. VILLAREAL, DONATO SALDIVAR-RODRIGUEZ, FERNANDO J. LAVALL-GONZALEZ, RENÉ RODRIGUEZ-GUTIERREZ, JOSE G. GONZALEZ-GONZALEZ, Monterrey, Mexico
1461-P Maternal Diabetes during Pregnancy and Early Childhood Obesity—A Population-Level Analysis. SAMANTHA L. BOWKER, ANAMARIA SAVU, ROSEANNE O. YEUNG, EDMOND A. RYAN, PADMA KAUL, Edmonton, AB, Canada

1462-P Plasma Metabolomics Reveal Novel Metabolites in Early Pregnancy in Association with Gestational Diabetes Risk. CUILIN ZHANG, YEN-CHEN ANNE FENG, OLIVER FIEHN, MICHAEL Y. TSAI, YEYI ZHU, PAUL ALBERT, LIMING LIANG, Bethesda, MD, Boston, MA, Davis, CA, Minneapolis, MN, Oakland, CA

1463-P WITHDRAWN

1464-P WITHDRAWN

1465-P GLP-1 Receptor Agonist Liraglutide Increased IVF Pregnancy Rates in Obese Women with PCOS and Previous Poor Response to First-Line Reproductive Treatments. ANDREJ JANEZ, MOJCA JENSTERLE, Ljubljana, Slovenia

1466-P Relationship between Executive Functioning and Glycemic Controls in Patients with Type 2 Diabetes. TAICHI MINAMI, MASAYO YAMADA, YUZURU ITO, RYUTARO FURUTA, SHO KATSURAGAWA, SAKIKO TERUI, TOMOAKI AKIYAMA, FUYUKI MINAGAWA, YASUO TERAUCHI, Yokohama, Japan

1467-P Serum Sclerostin, Body Composition, and Physical Function in Postmenopausal Women with Type 2 Diabetes. FRANCISCO BANDEIRA, CONCEIÇAO D. CHAVES, MARIA ELBA BANDEIRA FARIAS, LARISSA B. PIMENTEL, LEONARDO FARIAS, Recife, Brazil, Natal, Brazil

1468-P Frailty and Health Care Utilization among Community-Dwelling Older Patients with Diabetes Mellitus. SHIVANI PRIYADARSHNI, SRUTHI NELLURI, ZUBAIR RAHAMAN, MICHAEL J. MINTZER, STUTI DANG, WILLY MARCOS VALENCIA, JORG G. RUIZ, Miami, FL

1469-P Association between Dementia and Glycemic Control in Elderly Patients. TAKUMA YASUDA, SEIJI Muro, HARUKA FUJITA, MASAKI FUJIMURA, TOMONOBU HATOKO, EISAKU MORI, SHIN YONEMITSU, Osaka, Japan

1470-P History of Falls in the Previous Year Predicts Frailty among Community-Dwelling Older Patients with Diabetes Mellitus. WILLY MARCOS VALENCIA, NIMA MOGHADAM, JAVIER BALDA-CANIZARES, MICHAEL J. MINTZER, STUTI DANG, JORG G. RUIZ, Miami, FL

1471-P Long-Term Effects of Lifestyle Intervention and Metformin during DPP on Appendicular Lean Mass. ANN V. SCHWARTZ, QING PAN, HELEN P. HAZUDA, EDWARD HORTON, MARY A. HOSKIN, RITA R. KALY-ANI, WILLIAM C. KNOWLER, ANDREA KRISKA, CHRISTOPHER S. PIROMALLI, MARINELLA TEMPROSA, HERMES FLOREZ, DPP RESEARCH GROUP, San Francisco, CA, Washington, DC, San Antonio, TX, Brookline, MA, Phoenix, AZ, Baltimore, MD, Pittsburgh, PA, Zürich, Switzerland, Miami, FL, Rockville, MD

1472-P Metformin and Lifestyle Interventions in DPP Do Not Have Long-Term Effects on Bone Density or Falls. ANN V. SCHWARTZ, QING PAN, VANITA ARODA, JILL P. CRANDALL, ANDREA KRISKA, CHRISTOPHER S. PIROMALLI, MARINELLA TEMPROSA, HERMES FLOREZ, DPP RESEARCH GROUP, San Francisco, CA, Washington, DC, Hyattsville, MD, Bronx, NY, Pittsburgh, PA, Anchorage, AK, Rockville, MD, Miami, FL

1473-P Progression of Coronary Artery Calcification Is Associated with Clinically Relevant Cognitive Impairment in Type 1 Diabetes. JINGCHUAN GUO, KAREN NUNLEY, CATERINA ROSANO, TREvor J. ORCHARD, Pittsburgh, PA

1474-P Life-Course Glucose Trajectory and Cognitive Function in Middle Age—Evidence from the Bogalusa Heart Study. PATRICK STUCHLIK, OWEN CARMICHAEL, EMILY HARVILLE, HUA HE, MARYELLEN ROMERO, JEANETTE GUSTAT, VIVIAN FONSECA, LYDIA A. BAZZANO, New Orleans, LA, Baton Rouge, LA

1475-P Joint Associations of Diabetes and Sarcopenia on All-Cause Mortality among U.S. Older Adults. JIN XIA, YIQING SONG, Indianapolis, IN

1476-P Secular Trend for Cancer Incidence in Type 2 Diabetic Patients and the Association between Type 2 Diabetic Patients and Cancer between 2004 and 2014. QI GUO, HUILIN XU, DONGLI XU, Shang-hai, China

1477-P Trajectories of Health-Related Quality of Life (HR-QoL) in Older Adults with Diabetes. SUNHEE PARK, TAEWHANA LEE, Seoul, Republic of Korea
1478-P Cognitive Impairment and Glycemic Status among U.S. Adults. SARAH CASAGRANDE, CATHERINE C. COWIE, Silver Spring, MD, Bethesda, MD

1479-P The Burden of Aging with Diabetes and the Impact of Cognitive Decline. BRITTANY L. SMALLS, SHOSHANA H. BARDACH, NANCY SCHOENBERG, Lexington, KY

1480-P Obese and Overweight Ex-smokers Live Longer Overall but Spend More Years with Type 2 Diabetes than Normal Weight Smokers. ERALDA ASLLANAJ, TRUDY VOORTMAN, MARIJA GLISIC, OSCAR FRANCO, TAULANT MUKA, SR., Rotterdam, Netherlands

1481-P Association between Diabetes Mellitus and Urinary Incontinence in Elderly Patients. HUYEN T. VU, Hanoi, Vietnam

1482-P Chronic Sleep Disturbances Are Predictive of Incident Diabetes in Older Adults—Variations by Gender and Race/Ethnicity. HEIDI GUYER, Ann Arbor, MI

EPIDEMIOLOGY—CARDIOVASCULAR DISEASE

1483-P Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes—The ADVANCE Trial. TOSHIAKI OHKUMA, MIN JUN, MARK WOODWARD ESQ., JOHN CHALMERS, VLADO PERKOVIC, ANTHONY RODGERS, Camperdown, Australia, Newtown, Australia, Oxford, United Kingdom, Sydney, Australia

1484-P Elevated Parathyroid Hormone Is Associated with an Increased Mortality Risk in Type 2 Diabetes. AXEL MUENDELEIN, ANDREAS LEIHERER, CHRISTOPH H. SAEY, KATHRIN GEIGER, EVA-MARIA BRANDTNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, MARCUS KLEBER, ALEXANDER DRESSEL, WINFRIED MAERZ, HEINZ DREXEL, Feldkirch, Austria, Triesen, Liechtenstein, Berne, Switzerland, Mannheim, Germany, Hamburg, Germany, Philadelphia, PA

1485-P Increased Cardiovascular Risk in Patients with Diabetes, Statin-Controlled LDL Cholesterol, and Residual Hypertriglyceridemia. GREGORY NICHOLS, SEPHY PHILIP, CRAIG B. GRANOWITZ, KRISTI REYNOLDS, SERGIO FAZIO, Portland, OR, Bedminster, NJ, Pasadena, CA


1487-P Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. NATHAN D. WONG, YANG SONG, SUZANNE V. ARNOLD, LAURENCE SPERLING, CHRISTOPHER P. CANNON, SILVIO INZUCCHI, MIKHAIL KOSIBOROD, Irene, CA, Boston, MA, Kansas City, MO, Atlanta, GA, New Haven, CT

1488-P Impact of Prior Coronary Artery Disease (CAD) and Glucose Tolerance Status (GTS) on Incident CAD in Japanese Men. MASARU KITAZAWA, KAZUYA FUJIHARA, MAYUKO HARADA, MASAHIRO ISHIZAWA, MASAHIKO YAMAMOTO, MASANORI KANEKO, TAEKO OSAWA, TAKAHO YAMADA, YASUHIRO MATSUBAYASHI, HIROHITO SONE, Niigata, Japan

1489-P The Extent of Severe Periodontal Disease as a Predictor of Cardiovascular Complications and Mortality in Type 1 Diabetes (T1D). TUMADER KHOUJA, RACHEL G. MILLER, PAUL A. MOORE, TREVOR J. ORCHARD, TINA COSTACOU, Pittsburgh, PA

1490-P Sex Differences in Coronary Artery Disease Patients With and in Those Without Type 2 Diabetes. CHRISTOPH H. SAEY, ALEXANDER VONBANK, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDELEIN, HEINZ DREXEL, Berne, Switzerland, Feldkirch, Austria, Triesen, Liechtenstein, Philadelphia, PA

1491-P The Relationship between Immigration Status and Cardiovascular Disease Risk Factors in United States Adults with Diabetes—A 14-Year Study. APRILL DAWSON, EMMA GARACCI, MUKOSO N. OZIEH, REBEKAH J. WALKER, LEONARD E. EGEOE, Milwaukee, WI

1492-P Comparative Cardiovascular Effectiveness of SGLT2 Inhibitors vs. Liraglutide in Routine Care. ELISABETTA PATORNO, BRENDAN M. EVERETT, SEBASTIAN SCHNEEWEISS, ROBERT J. GLYNN, JUN LIU, SEY-OUNG C. KIM, Boston, MA
1493-P A Real-World Evaluation of the Association between Cardiovascular Outcomes and T2D Therapy. ELLEN THIEL, WILLIAM D. MARDER, WILLIAM T. CEFALU, TAMARA DARSAW, MATT PETERSEN, LISA LATTS, Ann Arbor, MI, Cambridge, MA, Arlington, VA, Denver, CO.

1494-P Epicatechin Modulates Vasoreactivity and Mitochondrial Function in Endothelium. AMY C. KELLER, SARA E. HULL, LESLIE KNAUB, ASPEN JOHNSTON, JANE E. REUSCH, Aurora, CO, Tucson, AZ, Denver, CO.

1495-P Epigenetic Link between Statin Use and Diabetes. CAROLINA OCHOA-ROSALES, ELIANA PORTILLA-FERNANDEZ, RORY WILSON, JANA NANO, MOHSEN GHANBARI, OSCAR L. RUEDA-OCHOA, SR., TERHO LEHTIMÄKI, SR., XU GAO, BENJAMIN LEHNE, TRUDY VOORTMAN, OSCAR FRANCO, TAULANT MUKA, SR., Rotterdam, Netherlands, Munich, Germany, Tampere, Finland, Heidelberg, Germany, London, United Kingdom.

1496-P Pericardial Adipose Tissue and Coronary Calcium in Type 1 Diabetes—The CACTI Study. AMENA KESHAWARZ, LAURA PYLE, AMY C. ALMAN, CAPRICE SASSANO, ELIZABETH WESTFELDT, RACHEL M. SIPPL, JANET K. SNELL-BERGEON, Aurora, CO, Tampa, Fl.

EPIDEMIOLOGY—CLINICAL—DIAGNOSIS AND SCREENING

Moderated Poster Discussion: Clinical Diagnosis and Screening of Diabetes (Posters: 1497-P to 1502-P), see page 90.

1497-P Derivation of an EMR-Based Dysglycemia Risk Score. MICHAEL E. BOWEN, JOANNE SANDERS, SONG ZHANG, NOEL O. SANTINI, ILDIKO LINGVAY, ETHAN HALM, Dallas, TX.

1498-P Incidence and Risk of Celiac Disease in Individuals with Type 1 Diabetes over the Lifetime—A Population-Based Cohort Study Using the Health Improvement Network Database. MARY ELLEN VAJRAVELU, DIVA DE LEON, DAVID R. WEBER, RON KEREN, MICHELLE R. DENBURG, RITU VERMA, Philadelphia, PA, Rochester, NY.

1499-P Screening Patients for Diabetes in a Large, National Clinical Database. NIKITA STEMPNIE-WICZ, JOHN K. CUDDEBACK, CORI R. RATTELMAN, ELIZABETH L. CIEMINS, Alexandria, VA.

1500-P One-Hour Oral Glucose Tolerance Tests (OGTTs) for the Prediction and Diagnostic Surveillance of Type 1 Diabetes (T1D). KIMBER SIMMONS, JAY SOSENKO, HEBA M. ISMAIL, HELENA ELDIG-LARSSON, ANDREA STECK, Aurora, CO, Miami, FL, Pittsburgh, PA, Malmö, Sweden.

1501-P Higher HbA1c Levels Should Be Used to Diagnose Diabetes and Prediabetes in Blacks. LISA R. STAIMEZ, CHRISTOPHER N. FORD, LAUREN DANIELS, ADRIANA GONZALEZ, FARAH N. KHAN, MARY RHEE, PETER W. WILSON, LAWRENCE S. PHILLIPS, Atlanta, GA, Decatur, GA.

1502-P Clinical and Socioeconomic Characteristics Associated with Ketoacidosis at Diagnosis of Type 1 Diabetes in Italian Children—Nationwide Survey, 2014-2016. VALENTINO CHERUBINI, RICCARDO BONFANTI, EDILIRA SKRAMI, ROSARIA GESUITA, STUDY GROUP FOR DKA IN ITALY, Ancona, Italy, Milan, Italy.

1503-P Duplicate Oral Glucose Tolerance Tests Provide Highly Reproducible Results for the Diagnosis of Diabetes in Africans—The Africans in America Study. SARA M. BRIKER, JEAN DAMASCENE KABAKAMBIRA, RAFEAL L. BAKER, JR., CHRISTOPHER DUBOSE, LILIAN MABUNDO, STEPHANIE T. CHUNG, JEAN N. UTUMATWISHIMA, ANNE E. SUMNER, Bethesda, MD, Musanze, Rwanda.

1504-P Combining A1C with Glycated Albumin Improves Detection of Abnormal Glucose Tolerance in Nonobese Africans—The Africans in America Study. JEAN DAMASCENE KABAKAMBIRA, SARA M. BRIKER, RAFEAL L. BAKER, JR., CHRISTOPHER DUBOSE, LILIAN MABUNDO, STEPHANIE T. CHUNG, DAVID B. SACKS, ANNE E. SUMNER, Bethesda, MD.

1505-P Serum Total Adiponectin Level Is Associated with Incident Prediabetes in Japanese Workers. AKIKO HATA, MASASHI MIYOSHI, TAKAYUKI NAKAO, TAKAKO ICHIHARA, YUKO TAMURA, TAKAKO MINABAWA, YUMI KUWAMURA, MAKOTO FUNAKI, Tokushima, Japan, Takamatsu, Japan.

1506-P WITHDRAWN

1507-P Heterogeneity between Pharmacoepidemiological Studies Using the Clinical Practice Research DataLink (CPRD). ALICE KOECHLIN, PETER BOYLE, PHILIPPE AUTIER, Écully, France, Lyon, France.

1508-P Novel Nomogram for Screening the Risk of Developing Diabetes in a Korean Population. SEUNG MIN CHUNG, JUN SUNG MOON, JI SUNG YOON, KYU CHANG WON, Daegu, Republic of Korea.
1522-P Concordance of Glucose-Based and of HbA1c-Based Diagnoses of Diabetes in Patients with Peripheral Artery Disease—A Comparison between Two Age Groups. CHRISTOPH H. SAELEY, ALEXANDER VONBANK, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDELEIN, HEINZ DREXEL, Berne, Switzerland, Feldkirch, Austria, Triesen, Liechtenstein, Philadelphia, PA

1523-P Using MetS Severity to Track Risk for T2D during Intervention with Lifestyle and Metformin. MARK D. DEBOER, STEPHANIE L. FILIPP, MATTHEW J. GURKA, Charlottesville, VA, Gainesville, FL

1524-P Cardiometabolic Risk Disparities Associated with Health Insurance Status in a Latino Community in California. CEARA AXELROD, ELOISA CHAVEZ, WENDY C. BEVIER, JAMIE CREASON, KRISTIN CASTORINO, DAVID KERR, Santa Barbara, CA

1525-P Estimation of Population Insulin Sensitivity (S) from Sparsely Sampled Oral Glucose Tolerance Test (OGTT) Data. DARKO STEFANOVSKI, GUILLERMO E. UMPIERREZ, PRIYATHAMA VELLANKI, Philadelphia, PA, Atlanta, GA

1526-P Performance of Clinical/Proteomic Biomarker Panels to Predict Coronary Artery Disease Presence or Cardiovascular Prognosis in Patients With and Without Diabetes Mellitus. SHREYA SHRESTHA, CIAN P. MCCARTHY, NASRIEN E. IBRAHIM, ROLAND VAN KIMMENADE, HANNA GAGGIN, RENATA MUKAI, CRAIG A. MAGARET, GRADY BARNES, RHONDA F. RHYNE, JAMES JANUZZI, JR., Boston, MA, Nijmegen, Netherlands, Kirkland, WA

1527-P A Novel Ceruloplasmin Mutation Causing Aceruloplasminemia with Diabetes in China. YUANYUAN XIAO, Shanghai, China

1528-P Simple Screening for Glucose Intolerance Based on Myoinositol Levels in Self-Collected Urine Samples at Home. MISAKI TAKAKADO, YASUNORI TAKATA, RYOICHI KAWAMURA, HARUHIKO OSAWA, Toon, Japan

1529-P Maturity-Onset Diabetes of the Young (MODY) in a Racially Diverse Pediatric Population. SHILPI RELAN, FRANCES C. HESSEL, KELLY D. TIMMONS, RONA SONABEND, MARIA J. REDONDO, Houston, TX

1530-P Impact of “Mismatches” in HbA1c vs. Glucose on Diagnosis as Diabetes or Prediabetes. ADRIANA GONZALEZ, XIAOGONG CUI, LISA R. STAIMEZ, CHRISTOPHER N. FORD, FARAH N. KHAN, PETER W. WILSON, LAWRENCE S. PHILLIPS, MARY RHEE, Decatur, GA, Atlanta, GA

1531-P Screening for Cystic Fibrosis-Related Diabetes and Prediabetes—Evaluating 1,5-Anhydroglucitol, Fructosamine, Glycated Albumin, and Hemoglobin A1c. KALIE L. TOMMERDAHL, JOHN T. BRINTON, TIM B. VIGERS, KRISTEN J. NADEAU, PHIL ZEITLER, CHRISTINE L. CHAN, Aurora, CO, Denver, CO

1532-P Study on the Screening and Influence Factors for Prediabetes or Diabetes in Primary Health Care Centers of Shanghai. CHENG YINGLING, Shanghai, China

1533-P Are Diabetes Risk Scores the Best Way to Identify Those Who Will Benefit Most from Lifestyle Prevention? CAROLINA I. SARI, DIANNA J. MAGLIANO, PAUL Z. ZIMMET ESQ., JAAKKO TUOMILEHTO, KOWLESSUR SDHIRSEN, STEFAN SÖDERBERG, JONATHAN E. SHAW, Melbourne, Australia, Dasman, Kuwait, Port Louis, Mauritius, Umeå, Sweden

1534-P Metabolic Syndrome and Prediabetes Fail to Detect a High Prevalence of Early Insulin Resistance—The PREMIER Study. DAVID P. CISTOLA, ALOK K. DWIWEDI, JAMY D. ARD, El Paso, TX, Winston-Salem, NC

1535-P Circulating Netrin-1 as a Novel Biomarker for Impaired Fasting Glucose and Newly Diagnosed Type 2 Diabetes Mellitus. HYE-IN JUNG, JAEHYUN BAE, EUGENE HAN, YUJI KIM, JI-YEON LEE, SO RA KIM, BYUNG-WAN LEE, EUN SEOK KANG, CHUL WOO AHN, BONG-SOO CHA, YONG-HO LEE, Seoul, Republic of Korea, Daegu, Republic of Korea, Goyang, Republic of Korea

1536-P The Visceral Adiposity Index Is a Significantly Stronger Predictor of Incident Diabetes in Men than in Women. CHRISTOPH H. SAELEY, ALEXANDER VONBANK, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDELEIN, HEINZ DREXEL, Berne, Switzerland, Feldkirch, Austria, Triesen, Liechtenstein, Philadelphia, PA

1537-P One-Hour Post-OGTT Glucose Improves the Early Prediction of Type 2 Diabetes beyond Metabolic Markers. GOPAL PEDDINTI, TINAMAIJA TUOMI, MICHAEL BERGMAN, LEIF GROOP, Espoo, Finland, Helsinki, Finland, New York, NY

1539-P Plasma Lipidomic Profiles in Relation to Incident Type 2 Diabetes among Women with a History of Gestational Diabetes Mellitus. JUN LI, TIMING LIANG, FRANK HU, CUILIN ZHANG, DEIRDRE TOBIAS, Boston, MA, Bethesda, MD

1540-P Clinical Importance of One-Hour Plasma Glucose in Relation to Diabetes and Metabolic Syndrome in an Obese Population. LIEN HAVERALS, KRISTOF P.S. VAN DESSEL, AN VERRUIKEN, EVELINE L. DIRINCK, FRIDA W. PEIFFER, LUC VAN GAAL, CHRISTOPHE DE BLOCK, Edegem, Belgium, Antwerp, Belgium

1541-P Large Relative Skeletal Muscle Mass May Protect against Diabetes Irrespective of Glycemic Metabolic Parameters. GYURI KIM, MIN SUN CHOI, SANG-MAN JIN, MOON-KYU LEE, JAE HYEON KIM, Seoul, Republic of Korea

1542-P Glucose Variability of Individuals without Diabetes Using a Long-Term Continuous Glucose Monitoring System. DOROTHEE DEISS, TAHMID ABTAHI, RAVI RASTOGI, E.L. KELLEY, Berlin, Germany, Germantown, MD

1543-P Exocrine Pancreatic Function as a Novel Biomarker in Pre-T1D. JAMES J. ROSS, CLIVE WASSERFALL, DANIEL J. PERRY, KIERAN M. MCGRAIL, AMANDA L. POSGAI, TODD M. BRUSKO, DESMOND SCHATZ, MICHAEL J. HALLER, MARK A. ATKINSON, Ocala, FL, Gainesville, FL

1544-P Racial Differences in the Correlation of HbA1c to Early and Late Postprandial Glycemic Responses in Adults with Prediabetes. DANIEL S. HSIA, KARA MARLATT, COURTNEY M. PETERSON, ERIC RAVUSSIN, Baton Rouge, LA, Birmingham, AL

1545-P Diagnostic Accuracy in LADA—Low Correlation between Primary Care Physicians (PCPs) and an Endocrinologist. ALDO DE FERRARI, FERNANDO OVALLE, Birmingham, AL

1546-P The Progression of Hyperglycemia and Diabetes Before and After Lung Transplant. DIVYA AKSHINTALA, EVANA VALENZUELA SCHERKER, ANDRES PELAEZ, SATISH CHANDRASHEKARAN, TIAGO MACHUCA, JULIO A. LEY, Gainesville, FL

1547-P Falsely Decreased HbA1c in Diabetic Patient due to Dapsone. KHALED ALJENAAE, SULAIMAN HAJI ALI, AGNIESZKA PAZDERSKA, Dublin, Ireland

1548-P Cardiometabolic Disease Risk Assessment Predicts Incident Diabetes in a Large and Diverse Population. LUA WILKINSON, TAPAN MEHTA, W. TIMOTHY GARVEY, Birmingham, AL

1549-P Impact of the Structured, Comprehensive Clinic-Led, Population-Targeted Diabetes Intervention Program as Compared with the Standard Care Approach. INDUMATHI KUBERAN, SAMEER RAO, NAVNEET WADHWA, Mumbai, India, Delhi, India

EPIDEMIOLOGY—DIABETES COMPLICATIONS

Moderated Poster Discussion: Diabetes Complications (Posters: 1550-P to 1555-P), see page 93.

1550-P Higher Rates of Celiac Disease Serology and Biopsy Positivity in Adults with Type 1 Diabetes. FARID H. MAHMUD, ANTOINE B. CLARKE, KARIYM C. JOACHIM, ESTHER ASSOR, AMISH PARikh, ANDREW ADVANI, BRUCE A. PERKINS, BAJU R. SHAH, CAROLINE S. ZUIJDWIJK, CHARLOTTE MCDONALD, DAVID MACK, DROR KOLTIN, EUGÈNE HSIEH, EVA M. SZENTGYORGYI, SR., FRED SAIBIL, GEETHA MUKERJI, HEATHER A. LOCHNAN, JEREMY GILBERT, KEVIN BAX, MARGARET L. LAWSON, MELANIE D. BEATO, NAV A. SALOOGJEE, OLIVIA LOU, PATRICIA H. GALLEGÓ, ROBYN L. HOULDEN, RONNIE ARONSON, SUSAN E. KIRSCH, WILLIAM G. PATERSON, ZUBIN PUNTHAKEE, MARGARET A. MARCON, Toronto, ON, Canada, Mississauga, ON, Canada, Ottawa, ON, Canada, London, ON, Canada, New York, NY, Kingston, ON, Canada, Markham, ON, Canada, Hamilton, ON, Canada

1551-P Different Course of the Microvascular Complications of Diabetes Mellitus in Kidney Transplant Recipients with Posttransplant Diabetes—A Longitudinal Study. THIZA M. LONDONO GAI, LUANA S. GIARETTA, ROBERTO C. MANFRO, LUIS H. CANANI, DANIEL LAVINSKY, CRISTIANE B. LEITAO, ANDREA BAUER, Porto Alegre, Brazil
1552-P  ♦ Cis-Vaccenic Acid Is Associated with Lower HOMA-IR and Incident T2D in Participants from the MESA Cohort. NATALIE L. WEIR, LISA JOHNSON, WEIHUA GUAN, BRIAN STEFFEN, LUC DJOUSSE, KENNETH J. MUKAMAL, MICHAEL Y. TSAI, Minneapolis, MN, Plymouth, MN, Boston, MA, Brookline, MA

1553-P  ♦ Type 2 Diabetes Mellitus and Renal Impairment in Real-World with Large Outpatient Electronic Medical Records—Antihyperglycemic Medication Dose Adjustment. SANG MO HONG, CHEOL-YOUNG PARK, Gyeonggi, Republic of Korea, Seoul, Republic of Korea

1554-P  WITHDRAWN

1555-P  ♦ Twenty-Year Secular Trend of Diabetes Comorbidities in the United States, 1997-2016. DIAN-JIAN YI SUN, TAO ZHOU, XIANG LI, YORIKO HEIANZA, XIAOYUN SHANG, VIVIAN FONSECA, LU QI, New Orleans, LA, Marrero, LA

1556-P  Incidence of Chronic Kidney Disease and Progression of Renal Dysfunction in Type 2 Diabetes—The Role of Albuminuria. GREGORY NICHOLS, ANOUK DERUAZ-LUYET, SIBYLLLE HAUSKE, KIMBERLY BRODOVICZ, Portland, OR, Ingelheim, Germany, Ridgefield, CT

1557-P  Effects of Dugalglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting. KRISTINA BOYE, REEMA MOODY, JIANMIN WU, MAUREEN J. LAGE, FADY T. BOTROS, BRAD WOODWARD, Greenwood, IN, Indianapolis, IN, Bonita Springs, FL

1558-P  Causes of Mortality in Patients with Type 2 Diabetes, 2009-2014. CARRON MENEY, ANDREW COLLIER, MARIO D. HAIR, LYALL CAMERON, CHAD BISAMBAR, JUNAID ILYAS, Ayr, United Kingdom, Port Glasgow, United Kingdom

1559-P  Incidence and Prevalence of Bile Duct and Gallbladder Disease in Patients with Diabetes in the U.S. AYAD K. ALI, OMOLARA R. ADETUNJI, Indianapolis, IN, Surrey, United Kingdom

1560-P  Omega-6 Eicosadienoic Acid Is Associated with Lower HOMA-IR and Incident T2D in Participants from the MESA Cohort. NATALIE L. WEIR, WEIHUA GUAN, BRIAN STEFFEN, LYN M. STEFFEN, AMY B. KARGER, MICHAEL Y. TSAI, Minneapolis, MN, Plymouth, MN

1561-P  Higher Dietary Intake of Vitamin D Is Associated with Lower Incidence of Diabetic Nephropathy in Japanese Patients with Type 2 Diabetes. CHIKA HORIKAWA, REI AIDA, SHIRO TANAKA, SACHIKO TANAKA, CHIEMI KAMADA, YUKIO YOSHIMURA, ATSUSHI ARAKI, TATSUMI MORIYA, SHIGEHIRO KAYATAKAYAMA, HIROKITO SONE, Niigata, Japan, Kyoto, Japan, Shiga, Japan, Tokushima, Japan, Tokyo, Japan, Sagamihara, Japan, Kawagoe, Japan

1562-P  Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy—The DISCOVER Study. MIKHAIL KOSIBOROD, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, MARILIA B. GOMES, KAMELSH KHUNTI, STUART POCCOCK, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, ICHIRO SHIMOMURA, FILIP SURMONT, FENGMING TANG, HIROTAKA WATADA, LINONG JI, NIKLAS HAMMAR, Kansas City, MO, Gaithersburg, MD, Barcelona, Spain, Cambridge, United Kingdom, Rio de Janeiro, Brazil, Leicester, United Kingdom, London, United Kingdom, Düsseldorf, Germany, Moscow, Russian Federation, Osaka, Japan, Luton, United Kingdom, Tokyo, Japan, Beijing, China, Malmö, Sweden

1563-P  Long-Term Incidence of Liver Disease in the Diabetes Population in Israel. INBAL GOLDShtein, GAIL FERNANDES, AVRAHAM KARASIK, SWAPNIL RAjPATrAK, GABRIEL CHODick, Tel Aviv, Israel, Kenilworth, NJ, Tel Hashomer, Israel

1564-P  Risk of Nonalcoholic Fatty Liver Disease (NAFLD)-Related Liver Complications in the Diabetic Population in Israel. INBAL GOLDShtein, GAIL FERNANDES, GABRIEL CHODick, SWAPNIL RAjPATrAK, AVRAHAM KARASIK, Tel Aviv, Israel, Kenilworth, NJ, Ramat Gan, Israel

1565-P  Meta-analysis of Serum Uric Acid (SUA) and Cardiovascular Events in Diabetes Population. YIXUE SHAO, HUI SHAO, LIZHENG SHI, New Orleans, LA

1566-P  Trends of Nontraumatic Lower Extremity Amputation in End-Stage Renal Disease and Diabetes, U.S. 2000-2014. JESSICA L. HARDING, MEDA E. PAVKOV, NILKA BURROWS, EDWARD W. GREGG, ISRAEL A. HORA, Atlanta, GA

1567-P  Reduced Lower-Limb Muscle Strength in Type 2 Diabetes Patients with Arthritis Is Associated with Impaired Beta-Cell Function. OANA P. ZAHARIA, DOMINIK PESTA, PAVEL BOBOV, YULIYA KUPRIYANOVA, KALMÁN BÓDIS, VOLKER BURKART, JONG-HEE HWANG, KARSTEN MÜSSIG, MICHAEL RODEN, JULIA SZENDROEDI, Düsseldorf, Germany

---

**Epidemiology/Genetics POSTERS**

278
1581-P The Number of Teeth Is Associated with Diabetic Nephropathy. WATARU KURIHARA, TERUKI MIYAKE, SHINYA FURUKAWA, HIDENORI SENBA, SHIN YAMAMOTO, YOSHIDA SAKIKO, KOJII JOKO, TERUISHI UEDA, TETSUJI NIYII, HIROAKI MIYAOKA, BUNZO MATSUURA, YOICHI HIASA, Matsuyama, Japan, Toon, Japan

1582-P Cardiovascular Outcomes and Mortality in Type 2 Diabetes with Associated Cardio-Renal-Metabolic Comorbidities. SUZANNE V. ARNOLD, PHILLIP R. HUNT, HUNGTA CHEN, SHARON MACLACHLAN, ENRICO REPETTO, JITEN VORA, MIKHAIL KOSIBOROD, Kansas City, MO, Waltham, MA, Gaithersburg, MD, London, United Kingdom, Liverpool, United Kingdom

1583-P No Improvement in Glycemic Control or Rates of Diabetes-Related Complications for People with Type 2 Diabetes—Results from 10 Years of the International Diabetes Management Practices Study (IDMPS). PABLO ASCHNER, JUAN J. GAGLIARDINO, HASAN M. ILKOVA, FERNANDO J. LAVALLE-GONZALEZ, AMBADY RAMACHANDRAN, GHAIDA KADDAHA, JEAN CLAUBE MBANYA, MARINA V. SHESTAKOVA, JEAN-MARC CHANTELOT, JULIANA C. CHAN, Bogota, Colombia, La Plata, Argentina, Istanbul, Turkey, Monterrey, Mexico, Chennai, India, Dubai, United Arab Emirates, Yaounde, Cameroon, Moscow, Russian Federation, Paris, France, Hong Kong, China

1584-P Frequency of Diabetes-Related Complications in Type 1 and Type 2 Diabetes—Results from the International Diabetes Management Practices Study (IDMPS). JUAN J. GAGLIARDINO, PABLO ASCHNER, HASAN M. ILKOVA, FERNANDO J. LAVALLE-GONZALEZ, SR., AMBADY RAMACHANDRAN, GHAIDA KADDAHA, JEAN CLAUBE MBANYA, MARINA V. SHESTAKOVA, JEAN-MARC CHANTELOT, JULIANA C. CHAN, La Plata, Argentina, Bogota, Colombia, Istanbul, Turkey, Monterrey, Mexico, Chennai, India, Dubai, United Arab Emirates, Yaounde, Cameroon, Moscow, Russian Federation, Paris, France, Hong Kong, China

1585-P Protection from Severe Periodontal Disease among People with Type 1 Diabetes with Duration of 50 Years or Longer. TAKANORI SHINJO, ATSUSHI ISHIKADO, HATICE HASTURK, LIANE J. TINSLEY, DAVID M. POBER, I-HSIEN WU, THOMAS E. VAN DYKE, ROBERT J. GENCO, GEORGE L. KING, Japan, Cambridge, MA, Buffalo, NY

1586-P Projections of Prevalence of Diabetes With and Without CKD in Southwestern American-Indians. MEDA E. PAVKOV, ANNIKA HOYER, EDWARD W. GREGG, RALPH BRINKS, PETER H. BENNETT, Atlanta, GA, Düsseldorf, Germany, Phoenix, AZ

1587-P Characteristics and Mortality of Recurrent Diabetic Ketoacidosis (DKA) in Adults and Children with Type 1 Diabetes (T1D). PRIYATHAMA VELLANKI, LIMIN PENG, NEIL DHRUVA, CLEMENTINA RAMOS, J. SONYA HAW, RODOLFO J. GALINDO, GEORGIA DAVIS, MAYA FAYFMAN, FRANCISCO J. PASQUEL, GUILLERMO E. UMPIERREZ, Atlanta, GA

1588-P Glycemic Control and Infections among U.S. Hemodialysis Patients with Diabetes Mellitus. JINNIE J. RHEE, YUANCHAO ZHENG, MARIA MONTEZ-RATH, WOLFGANG WINKELMAYER, Palo Alto, CA, Houston, TX

1589-P The Impact of Sarcopenia and Diabetes on Postoperative Complications in Abdominal Surgery Patients. GEORGIA DAVIS, MAYA FAYFMAN, ADAM SINGER, MONICA UMPIERREZ, APARNA KAKARALA, LIMIN PENG, SHAILESH NAIR, FRANCISCO J. PASQUEL, GUILLERMO E. UMPIERREZ, Atlanta, GA

1590-P Prospective Study on Incidence of Cardiovascular-Renal Diseases, Severe Hypoglycaemia, and Death in Chinese with Latent Autoimmune Diabetes in Adults. ANDREA LUK, ERIC S. LAU, CADMION K.P. LIM, ELAINE CHOW, RONALD C. MA, ALICE P. KONG, JULIANA C. CHAN, Hong Kong, China

1591-P Cutaneous Reactions to Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion Devices in Type 1 Diabetes. RACHEL K. SEVERIN, RACHELE GANDICA, LAURA E. LEVIN, DONALD V. BELSITO, MARIA C. GARZON, KRISTEN M. WILLIAMS, New York, NY

1592-P Impact of Glycaemic Control on Bone Metabolism in Adult Patients with Type 1 Diabetes Mellitus. ELEFTHERIA BARMAPA, MARIANNA VLYCHOU, STELIOS TIGAS, GEORGE N. KOUKOLIS, ALEXANDRA BARGIOTA, Lanissa, Greece, Ioannina, Greece, Athens, Greece

1593-P Racial Variation in the Relationship of Diabetes with Pancreatic Cancer Risk. BAQIYYAH CONWAY, WILLIAM J. BLOT, Tyler, TX, Nashville, TN

1594-P Altered Neural Dynamics during a Flanker Attention Task in Patients with Type 1 Diabetes. CHRISTINE M. EMBURY, TIMOTHY J. MCDERMOTT, ALEX I. WIESMAN, KAITLIN BRAU, CYRUS DESOUZA, ANDJELA DRINCIC, TONY W. WILSON, Omaha, NE

1596-P Depressive Symptoms and Glycemic Control among Puerto Rican Adults with Diabetes. JOSIEMER MATTEI, LUIS M. FALCON, KATHERINE L. TUCKER, Boston, MA, Lowell, MA

1597-P Differences in Risk Factor Profile between Carotid Intimal Medial Thickness and Pulse Wave Velocity in African-Americans with Type 2 Diabetes. AYOBAI ELUWOLE, AJIBOLA M. ADEDAYO, FASIKA TEDLA, ARYE KREMER, NICOLE MASTROGIOVANNI, CARL ROSENBERG, PAUL DREIZEN, JOHN LAROSA, LOUIS SALCICCIOLI, MOHAMED BOUTJOIR, MARY ANN BANERJI, CLINTON BROWN, MORO SALIFU, AHMED BAKILLAH, JASON LAZAR, Brooklyn, NY

EPIDEMIOLOGY—NUTRITION

Moderated Poster Discussion: Dietary Influences of Diabetes (Posters: 1598-P to 1603-P), see page 125.

1598-P Copper Is Associated with Metabolic Syndrome and Fasting Blood Glucose in Non-Hispanic Black—Results from National Health and Nutrition Examination Survey. XIAOWEI HE, JR., YUN YU, SR., QINGLIN LOU, SR., WEI TANG, SR., Nanjing, China

1599-P Development of an Inflammatory Food Index and Association with Inflammatory Markers and Diabetes—Longitudinal Study of Adult Health (ELSA-Brasil). BARBARA P. RIBOLDI, VIVIAN C. LUFT, MARIA I. SCHMIDT, BRUCE B. DUNCAN, Porto Alegre, Brazil

1600-P WITHDRAWN

1601-P Dietary Fiber Intake and Glycemic Control—Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. ARPIA BASU, AMY C. ALMAN, JANET K. SNELL-BERGEON, Las Vegas, NV, Tampa, FL, Aurora, CO

1602-P Vitamin D, Prediabetes, and Diabetes—Bidirectional Mendelian Randomization Analysis. NINGJIAN WANG, LI ZHAO, CHI CHEN, YINGLI LU, Shanghai, China

1603-P WITHDRAWN

1604-P WITHDRAWN

1605-P Nutrient-Dependent Association of Cdk5 Regulatory Associated Protein 1-Like 1 Gene with Insulin Secretion. SATORU MIZUSHIRI, MAKOTO DAIMON, HIROSHI MURAKAMI, AYA KAMBA, HIDEYUKI OTAKA, MASAYA MURABAYASHI, Hirotsuki, Japan, Hachinohe, Japan

1606-P The Impact of Obesity and Lifestyle Status on Cardiovascular Risk Factors in Children and Adolescents with Type 1 Diabetes (T1D). ANNA-MARIA LAMPOUSI, DIMITRIOS E. DELIS, SR., MARIA XATZIPSALTI, ANDRIANI VAZEOU, Athens, Greece

1607-P Correlation between Niacin and Iron Consumption and Diabetes Prevalence among Different Sex, Age, and Ethnic Groups in the U.S. YIMING ZHOU, NANA CHEN, DA LI, WUPING SUN, SHI-SHENG ZHOU, Boston, MA, Nagoya, Japan, Shenyang, China, Shenzhen, China, Dalian, China

1608-P Dietary and Media Habits of Young Children in Mumbai. JASREENA NJJAR, ANNA C. REVETTE, Boston, MA

1609-P Skipping Breakfast and Eating Fast Could Be Associated with Metabolic Syndrome—Clinical Cohort Study in Japan. HIDENORI SENBA, TERUKI MIYAKE, WATARU KURIHARA, YOSHIDA SAKIKO, SHIN YAMAMOTO, SHINYA FURUKAWA, MASANORI ABE, BUNZO MATSUURA, YOICHI HIASA, Toon, Japan, Matsuomega, Japan, Ehime, Japan

1610-P Hemodialysis (HD)-Mediated Improvements in Insulin Resistance Are Correlated with Nutritional Status in Patients with Type 2 Diabetes. SATOSHI FUNAKOSHI, JYUNICHIRO HASHIGUCHI, MASATOSHI HAYASHIDA, RICA ETOH, KENJI SAWASE, YUTAKA MORI, KAZUNORI UTSUNOMIYA, TAKASHI HARADA, Nagasaki, Japan, Tokyo, Japan

1611-P Comorbidity of Diabetes and Chronic Sleep Disturbances and Consumption of a Mediterranean-Style Diet. HEIDI GUYER, Ann Arbor, MI
1612-P The Impact of Obesity on Incidence of Type 2 Diabetes Mellitus (T2DM) among Women with Polycystic Ovary Syndrome (PCOS). NADIRA SULTANA KAKOLY, ARUL EARNEST, HELENA TEEDE, LISA MORAN, DEBORAH LUXTON, ANJU E. JOHAM, Melbourne, Australia

1613-P Insulin Therapy and Breast Cancer Risk. CECILE PIZOT, MIRUNA DRAGOMIR, PETER BOYLE, PHILIPPE AUTIER, Écully, France, Lyon, France

1614-P Thiazolidinediones and Reduced Risk of Incident Bacterial Abscess in Adults with Type 2 Diabetes—A Population-Based Cohort Study. CHIA-HSUIIN CHANG, JIUN-LING WANG, YAA-HUI DONG, WEN-CHIEN KO, LI-CHIU WU, LEE-MING CHUANG, PAU-CHUNG CHEN, Taipei, Taiwan, Tainan, Taiwan

1615-P Twelve-Month Changes in HbA1c, Fasting Plasma Glucose, and Weight among Patients with Type 2 Diabetes in 37 Countries—DISCOVER. BERNARD CHARBONNEL, FABRICE BONNET, HUNGTA CHEN, JAVIER CID-RUZAF, PETER FENICI, MARILIA B. GOMES, NIKLAS HAMMAR, LINONG JI, KEVIN KENNEDY, MIKHAIL KOSIBOROD, STUART POCOCK, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, FILIP SURMONT, KAMLESH KHUNTI, MICHIO MORIMOTO, TONGTONG WANG, YUZHI XI, ROBERT N. LUBWAMA, CAROL KORO, Kenilworth, Moreno Valley, Moreno Valley, CA, Tainan, Taiwan


1617-P Association of Visceral Fat and Liver Fat, Not Thigh Muscle Area nor Attenuation, with the Incidence of Type 2 Diabetes. KYOKO SATO, SHINICHIRO UEHARA, MIKIKO SHIBATA, YONEZO HIKITA, WILFRED Y. FUJIMOTO, EDWARD J. BOYKO, TOMOSHIGE HAYASHI, Osaka, Japan, Seattle, WA

1618-P Chronic Kidney Disease (CKD) in U.S. Adults with Self-Reported Cardiovascular Disease (CVD)—A National Estimate of Prevalence by KDIGO 2012 Classification. TONGTONG WANG, YUZHI XI, ROBERT N. LUBWAMA, CAROL KORO, Kenilworth, NJ, Chapel Hill, NC, North Wales, PA

1619-P No Increased Risk of Breast Cancer in Patients Exposed to Insulin Glargine Compared with Human NPH Insulin. PETER BOYLE, CHUNTAO WU, KRISTEN SHARMA, STEPHEN L. LIN, JUHAERI JUHAERI, Lyon, France, Bridgewater, NJ

1620-P The Waist Circumference That Predicts Insulin Resistance in Africans Is Higher in Women than Men—A Population-Specific Study. JEAN DAMASCENE KABAKAMBIRA, SARA M. BRIKER, RAFAEL L. BAKER, JR., AMBER B. COURVILLE, LILIAN MABUNDO, CHRISTOPHER DUBOSE, STEPHANIE T. CHUNG, MD, MIZANUR RAHMAN, ANNE E. SUMNER, Bethesda, MD, Tokyo, Japan

1621-P Efficacy of A1C in the Presence of HbC Trait Needs Evaluation. SARA M. BRIKER, JEAN DAMASCENE KABAKAMBIRA, RAFAEL L. BAKER, JR., CHRISTOPHER DUBOSE, LILIAN MABUNDO, STEPHANIE T. CHUNG, DAVID B. SACKS, ANNE E. SUMNER, Bethesda, MD

1622-P Metformin and Risk of Hepatocellular Carcinoma in Taiwanese Patients with Type 2 Diabetes. CHIN-HSIAO TSENG, Taipei, Taiwan

1623-P Health Disparity in Diabetes Care—Impact of Community Health Representative-Led Patient Activation and Engagement. VALLABH SHAH, VERNON S. PANKRATZ, DONICA M. GHAHATE, JEANETTE BOBELU, ROBERT NELSON, Albuquerque, NM, Zuni, NM, Phoenix, AZ

1624-P The Association between Lipid Profile Abnormalities and the Risk of Proteinuria in Japanese Men with Impaired Fasting Glucose or Type 2 Diabetes. SHINICHIRO UEHARA, KYOKO SATO, MIKIKO SHIBATA, KEIKO OUE, HIROSHI KAMBE, MICHIO MORIMOTO, TOMOSHIGE HAYASHI, Osaka, Japan

1625-P The Prevalence and Impact of Diabetes Mellitus among Undocumented Immigrants in an Indigent Care Program in Riverside, California. HAYLEY LEE, BISHOY L. ZAKHARY, MATTHEW A. FIREK, HEIDI LANGE, CLAUDIN A. GOMEZ, ANTHONY FIREK, Moreno Valley, CA
1626-P Risk Factors for Sleep Apnea Syndrome in Diabetic Patients with a Focus on Comorbidities.
SATSUKI KAWASAKI, HARUO MISAWA, RYO KANEDA, TETSURI KONDO, YOSHINOBU KONDO, YASUO TERAUCHI, Fujiwara, Japan, Yokohama, Japan

1627-P Effect of Vitamin D Supplementation on Glucose Metabolism Biomarkers—A Meta-analysis of Randomized Controlled Trials.
CECILE PIZOT, PATRICK MULLIE, ALINA MACACU, MIRUNA DRAGOMIR, PETER BOYLE, PHILIPPE AUTIER, Écully, France, Lyon, France

1628-P Distance from Glycemic Target at the Time of Add-On Initiation in Patients with Type 2 Diabetes (T2D) Failing Metformin Monotherapy in the United States.
GAIL FERNANDES, HAKIMA HANNACHI, JINAN LIU, TONGTONG WANG, ANN MARIE MCNEILL, ALEX Z. FU, SWAPNIL RAJPATIKA, North Wales, PA, Kenilworth, NJ, Chapel Hill, NC, Washington, DC

1629-P Individualized HbA1c Targets in People with Type 2 Diabetes Initiating Second-Line Therapy—The Global DISCOVER Study.
KAMLESH KHUNTI, HUNGTA CHEN, JAVIER CID-RUZAF, PETER FENICI, MARILIA B. GOMÉS, NIKLAS HAMMAR, KEVIN KENNEDY, MIKHAIL KOSIBOROD, STUART POCOCK, MARINA V. SHESTAKOVA, ICHIRO SHIMOMURA, FILIP SURMONT, LINONG JI, Leicester, United Kingdom, Gaithersburg, MD, Barcelona, Spain, Cambridge, United Kingdom, Rio de Janeiro, Brazil, Malmö, Sweden, Kansas City, MO, London, United Kingdom, Moscow, Russian Federation, Osaka, Japan, Luton, United Kingdom, Beijing, China

1630-P Prediction of Adverse Pregnancy Outcomes among Women with Type 1 Diabetes.
TINA COSTACOU, DEBRA RUBINSTEIN, TREVOR J. ORCHARD, Pittsburgh, PA

1631-P Racial Patterns of Comorbidities in Patients with Cardiovascular Disease and Type 2 Diabetes.
KRISTY IGLAY, HAKIMA HANNACHI, SAMUEL S. ENGEL, XUEYING LI, DAVID J. O’CONNELL, LORI M. MOORE, SWAPNIL RAJPATIKA, Kenilworth, NJ

1633-P The Adiponectin-Mortality Paradox—A Systematic Review and Meta-analysis.
MARIA GIOVANNA SCARALE, ANDREA FONTANA, VINCENZO TRISCHITTA, MASSIMILIANO COPETTI, CLAUDIA MENZAGHI, San Giovanni Rotondo, Italy, Rome, Italy

1634-P Prediabetes Is Associated with Increased Long-Term Mortality Regardless of Subsequent Glycemic Progression.
YU CHO WOO, CHI HO LEE, HO YI FONG, MAN YI YEUNG, KAREN S.L. LAM, Hong Kong, China

1635-P Impacts of the Kumamoto Earthquake 2016 on Glycemic Control in Diabetic Patients.
TATSUYA KONDO, NOBUKAZU MIYAKAWA, HIROYUKI MOTOISHIMA, NORIO ISHIH, MOTOYUKI IGATA, KAYO YOSHINAGA, DAISUKE KUKIDOME, TAKAFUMI SENOKUCHI, JUNJI KAWASHIMA, TAKESHI MATSUMURA, EIICHI ARAKI, Kumamoto, Japan

1636-P The Ratio of Liver to Spleen (L/S Ratio) for CT Attenuation Value Is Associated with the Onset of Diabetes Mellitus in a Community-Based Sample of Japanese Men—The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA).
KEIKO FUSE, AYA KADOTA, KEIKO KONDO, AKIRA FUJIOYSHI, TAKASHI HISAMATSU, SAYAKA KADOWA, HIROSHI MIGAWA, TAKESHI MATSUMURA, EIICHI ARAKI, Kumamoto, Japan

1637-P Fasting Plasma Mannose Level Is Associated with Insulin Sensitivity Independent of BMI in Japanese Individuals with Diabetes.
ERI AMANO, SHOGO FUNAKOSHI, KUMIKO YOSHIMURA, SEIKI HIRANO, SATOKO OHMI, YOSHIO TERADA, SHIMPEI FUJIMOTO, Nankoku, Japan

1638-P Long-Term Survival in 200 Patients with Advanced Stage of Colorectal Carcinoma and Diabetic Mellitus—A Single Institution Experience.
NIKA SATEJ, NIKOLA BESIC, ANA PAVLIC, MILA KERIN POVSIC, Ljubljana, Slovenia

1639-P Immigrants from Sub-Saharan Africa and the Caribbean Experience Different Rates of Obesity but Similar Rates of Diabetes—The New York City Community Health Survey.
MARGARET F. HORLYCK-ROMANOVSKY, ANNE E. SUMNER, TERRY HUANG, New York, NY, Bethesda, MD
1640-P Clinical Profile of Adults with Nonalcoholic Steatohepatitis (NASH) With and Without Type 2 Diabetes Mellitus (T2DM). KENNETH CUSI, ALFRED S. BARRITT IV, VIRGINIA CLARK, ROBERTO J. FIRPI, SAMUEL KLEIN, ANNA LOK, ROHIT LOOMBA, LAURA MALAHIAS, BRENT NEUSCHWANDER-TETRI, CHERYL SCOHEN, K. RAJENDER REDDY, JAWAHAR L. TAUNK, KATHLEEN WYNE, ARUN J. SANYAL, Gainesville, FL, Chapel Hill, NC, St. Louis, MO, Ann Arbor, MI, San Diego, CA, Philadelphia, PA, Palm Harbor, FL, Columbus, OH, Richmond, VA

1641-P Impact of Early Intensification with Sitagliptin on Glycemic Goal Attainment among Patients with Metformin Monotherapy Failure. FLAVIA EJZYKOWICZ, JINAN LIU, SAMUEL S. ENGEL, SWAPNIL RAJPATHAK, North Wales, PA, Kenilworth, NJ

1642-P Study on the Correlation between Cholecystectomy and Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. LU YE, HAIBING CHEN, Shanghai, China

1643-P Sleep Disturbances Are Associated with Poorer Glycemia and Increased Obesity in Youth at Risk for or with Early Type 2 Diabetes (T2D). BABAK MOHLESI, KARLA A. TEMPLE, ASHLEY N. HOGAN, SHARON EDELSTEIN, KRISTEN J. NADEAU, SUSAN SAM, TAMARA HANNON, KRISTINA UTZSCHNEIDER, ELENA BARENGOLTS, SHALINI MANCHANDA, DAVID A. EHRMANN, EVE VAN CAUTER, RISE CONSORTIUM, Chicago, IL, Rockville, MD, Denver, CO, Indianapolis, IN, Seattle, WA

1644-P Self-Reported Sleep and Circadian Measures Are Not Associated with Glycemia in Adults with Prediabetes or Early Untreated Type 2 Diabetes (T2D). BABAK MOHLESI, KARLA A. TEMPLE, ASHLEY N. HOGAN, SHARON EDELSTEIN, KRISTINA UTZSCHNEIDER, KRISTEN J. NADEAU, TAMARA HANNON, SUSAN SAM, ELENA BARENGOLTS, SHALINI MANCHANDA, DAVID A. EHRMANN, EVE VAN CAUTER, RISE CONSORTIUM, Chicago, IL, Rockville, MD, Seattle, WA, Denver, CO, Indianapolis, IN

1645-P The Impact of Diabetes and Hyperglycemia in Patients Hospitalized for Dengue. ELVIO D. BUENO COLMAN, SR., YESSIKA A. POZZO, GUILLERMO E. UMPIERREZ, URSULA B. MEDINA, ALDO BENITEZ, SUSANA N. MARIN, San Lorenzo, Paraguay, Atlanta, GA, Asuncion, Paraguay

1646-P Multiple Chronic Comorbidities in a T2DM Mediterranean Population. JOSEP FRANCH-NADAL, MANEL MATA-CASES, JORDI REAL, KARINE FERREIRA DE CAMPOS, MARTA CEDENILLA, ANTON GOMEZ, DIDAC MAURICIO, Barcelona, Spain, Madrid, Spain, Badalona, Spain

1647-P Diabetes Treatment in Patients with Renal Disease—How Many Are Receiving Contraindi- cated Drugs? MANEL MATA-CASES, JOSEP FRANCH-NADAL, JORDI REAL, KARINE FERREIRA DE CAMPOS, MARTA CEDENILLA, ANTON GOMEZ, DIDAC MAURICIO, Barcelona, Spain, Madrid, Spain, Badalona, Spain

1648-P Treatment Patterns in Patients with Newly Diagnosed Type 2 Diabetes in 2015. JIANMIN WU, JIN XIE, SIEW HOONG WONG-JACOBSON, VIRGINIA S. HAYNES, ZHENXIANG ZHAO, Indianapolis, IN

1649-P Burden of Hospitalization in Young-Onset Type 2 Diabetes—The Hong Kong Diabetes Register. CALVIN KE, ERIC S.H. LAU, ANDREA LUK, RONALD C. MA, ALICE P. KONG, ELAINE CHOW, PHILIP M. CLARKE, JULIANA C. CHAN, Toronto, ON, Canada, Hong Kong, China, Melbourne, Australia

1650-P Diabetes Risk Behaviors Are Higher among Sexual Minority U.S. High School Students. LAUREN B. BEACH, BLAIR TURNER, RACHEL MARRO, GREGORY PHILLIPS II, Chicago, IL

1651-P Rate of Diabetes in Maricopa County, AZ. SHARON H. JAYCOX, SABINA PAGLIALUNGA, Tempe, AZ

1652-P High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions. ROZALINA G. MCCOY, HOLLY VAN HOUTEN, KASIA J. LIPSKA, NILAY SHAH, Rochester, NY, New Haven, CT

1653-P Presentation and Clinical Characteristics of Patients with Maturity Onset Diabetes of the Young (MODY) at Women and Children’s Hospital of Buffalo. LINA SAADEH, LUCY D. MASTRAN- DREA, Buffalo, NY

1654-P Effects of Lifestyle Intervention on Metabolism Profile in People with Impaired Glucose Tolerance—The China Da Qing Diabetes Prevention Study. XIN QIAN, YANYAN CHEN, HONG-MEI JIA, ZHONG-MEI ZOU, GIUHONG GONG, YALI AN, JINPING WANG, HUI LI, NA SHI, GUANGWEI LI, Beijing, China, Daqing, China

1655-P Association of Urinary Normetanephrine Levels with Increased Insulin Resistance in a General Population. MASAYA MURABAYASHI, MAKOTO DAIMON, HIROSHI MURAKAMI, AYA KAMBA, SATORU MIZUSHIRI, Hiroaki, Japan, Hachinohe, Japan
1656-P Poor Glycemic Control in People with T1D and T2D—Results from the International Diabetes Management Practices Study (IDMPS). PABLO ASCHNER, JUAN J. GAGLIARDINO, HASAN M. ILKOVA, FERNANDO J. LAVALLE-GONZALEZ, SR., AMBADY RAMACHANDRAN, GHAIDA KADDADA, JEAN CLAUDE MBANYA, MARINA V. SHESTAKOVA, JEAN-MARC CHANTELOT, JULIANA C. CHAN, Bogotá, Colombia, La Plata, Argentina, Istanbul, Turkey, Monterrey, Mexico, Chennai, India, Dubai, United Arab Emirates, Yaoundé, Cameroon, Moscow, Russian Federation, Paris, France, Hong Kong, China

1657-P Prevalence of Prediabetes and Undiagnosed Diabetes among Adults Aged 18 to 70 Years in France—The CONSTANCES Cohort. SONSOLES FUENTES, SANDRINE FOSSE-EDORH, NOLWENN REGNAULT, MARCEL GOLDBERG, EMMANUEL COSSON, Paris, France, Saint Maurice, France, Villejuif, France, Bondy, France

1658-P Conformance to Type 2 Diabetes (T2D) Guidelines in a Large U.S. Health Plan. RAJESH MEHTA, ALISON EDWARDS, SWAPNIL RAJPATHAK, AJAY SHARMA, KENNETH J. SNOW, KRISTY IGLAY, New York, NY, Kenilworth, NJ

1659-P Trends in Type 2 Diabetes Mellitus Complications, Drug Utilization, and Laboratory Outcomes, 2012-2017. RADHIKA NAIR, ZHENXIANG ZHAO, YONG LI, KIMBERLY BRODOVICZ, YUNUS A. MEAH, SAMANEH KALIRAI, CHAD MORETZ, MICHELE MACKENZIE, BRADLEY CURTIS, TODD G. PREWITT, Louisville, KY, Indianapolis, IN, Ridgefield, CT, Sydney, Australia

1660-P Impact of Diabetes on Colorectal Cancer Screening Rates in U.S. Adults. JENNIFER A. CAMPBELL, REBEKAH J. WALKER, CHRISTIAN EILER, LEONARD E. EGEDE, Milwaukee, WI

1661-P Metabolic Function in 5,047 Adults with Type 2 Diabetes on Metformin Alone Based on Oral Glucose Tolerance Test (OGTT) Data from the GRADE Cohort. KRISTINA UTZSCHNEIDER, MARY ANN BANERJI, JOSHUA I. BARZILAY, ERICA V. GONZALEZ, FARAMARZ ISMAIL-BEIGI, KIEREN J. MATHER, PHILIP RASKIN, NAJY YOUNES, STEVEN E. KAHN, GRADE RESEARCH GROUP, Seattle, WA, Brooklyn, NY, Duluth, GA, Houston, TX, Shaker Heights, OH, Indianapolis, IN, Dallas, TX, Rockville, MD, Washington, DC

1662-P Evaluating the Combination of Metabolic Syndrome and Different Body Mass Index Categories to Predict Risk for Mortality among U.S. Adults. TING HUAI SHI, SUNDAR NATARAJAN, New York, NY

1663-P Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B—The Strong Heart Family Study. ROZENN N. LEMAITRE, CHAOYU YU, ANDREW HOOFNAGLE, HARI NAIR, PAUL N. JENSEN, AMANDA M. FRETTS, JASON G. UMANS, COLLEEN SITLANI, DAVID SISCOVICK, IRENA KING, NONA SOTOODEHNIA, BARBARA MCKNIGHT, Seattle, WA, Framingham, MA, Hyattsville, MD, New York, NY, Albuquerque, NM

1664-P Analysis of the Effect of the Lowest SpO2 on Nocturnal Blood Glucose Fluctuation in Type 2 Diabetes Measured by WatchPAT and Continuous Glucose Monitoring. MINORI SHINODA, TADASHI YAMAKAWA, RIKA SAKAMOTO, JUN SUZUKI, KENICHIRO TAKAHASHI, YASUO TERAUCHI, Yokohama, Japan

1665-P Antiplatelet Therapy as a Primary Prevention Strategy for Cardiovascular Disease in Type 2 Diabetes Mellitus in Taiwan—A Population-Based Study. YI-CHUN YEH, PEI-YIN CHEN, YEN-YU CHEN, Changhua, Taiwan, Tainan, Taiwan

1666-P Advanced Nonalcoholic Steatohepatitis Is Associated with Low Serum Lipoprotein(a) Concentrations. KANAKO KONISHI, TERUKI MIYAKE, HIDENORI SENBA, SHIN YAMAMOTO, SHINYA FURUKAWA, TAKAO WATANABE, YOHEI KOIZUMI, OSAMU YOSHIDA, MASASHI HIROOKA, TERU KUMAGI, MASANORI ABE, BUNZO MATSUURA, YOICHI HIASA, Toon, Japan

1667-P SGLT2 Inhibitors Suppress Alpha-Adrenergic Tone and Morning Elevation of Plasma Glucose Levels. KEISHI YAMAUCHI, Nagan, Japan

1668-P Type 2 Diabetes Remission—Analysis of Three Population-Level Historical Cohorts. SRIKANTH TANGELLOJU, GIANG VU, HUNTER CHAVIS-BLAKELY, BERT B. LITTLE, Louisville, KY

1669-P The Number of Metabolic Syndrome Components and Incidence Rates of Type 2 Diabetes—A Korean National Sample Cohort Study. MIN-KYUNG LEE, HYUK-SANG KWON, Gyeonggi, Republic of Korea, Seoul, Republic of Korea
1670-P Gamma Glutamyltransferase and Risk of Dementia in Normal, Prediabetes, and Diabetes Populations—A Nationwide Cohort Study with 6.5 Million People. EUGENE HAN, MINYOUNG LEE, YONG-GIN CHO, BYUNG-WAN LEE, CHUL WOO AHN, BONG-SOO CHA, YONG-HO LEE, Daegu, Republic of Korea, Seoul, Republic of Korea

1671-P Nationwide Analysis of Excess Deaths Attributable to Diabetes in Brazil. PAULA BRACCO, EDWARD W. GREGG, DEBORAH B. ROLKA, MARIA I. SCHMIDT, SANDHI MARIA BARRETO, PAULO A. LOTUFO, ENIRTES C. MELO, BRUCE B. DUNCAN, Porto Alegre, Brazil, Atlanta, GA, Belo Horizonte, Brazil, São Paulo, Brazil, Rio de Janeiro, Brazil

1672-P Plasma Strontium and Interactions between Calcium and Strontium for Type 2 Diabetes—A Hospital-Based Case-Control Study. LIANGKAI CHEN, QIANG WANG, XIAOLI HU, XIAOQIAN WANG, TAOPING SUN, WEI BAO, LIEGANG LIU, Wuhan, China, Iowa City, IA

1673-P Socioeconomic Relationship Trends between Diabetes and Postcodes in NSW, Australia. KHARISS BURNS, TIEN-MING HNG, NGAI WAH CHEUNG, Westmead, Australia, Blacktown, Australia

1674-P Parental Type 2 Diabetes and Obesity Development from Childhood to Early Adulthood. JANNIE NIELSEN, ADAM HULMAN, SOLVEIG A. CUNNINGHAM, Atlanta, GA, Aarhus, Denmark

1675-P Subjective Sleep Debt Is Correlated with Body Fat Percentage Independent of Sleep Duration. XIAO TAN, CHRISTIAN BENEDICT, Uppsala, Sweden

1676-P Diabetes Prevalence in North America and Caribbean Region in 2017 and 2045. YADI HUANG, SUVI KARURANGA, EDWARD J. BOYKO, BELMA MALANDA, Brussels, Belgium, Uccle, Belgium, Seattle, WA

1677-P Seasonal Trends in HbA1c Level in Adult Patients with Type 1 Diabetes Treated with Personal Insulin Pumps. BARTOMIEJ MATEJKO, BEATA KIEC-WILK, SANDRA MROZINSKA, TOMASZ KLUPA, MACIEJ MALECKI, Kraków, Poland


1681-P Inverse Associations between Circulating SFRP5 and Adiposity among African-Caribbean Men. HIRA ALI, JOSEPH M. ZMUDA, RYAN CVEJKUS, ERIN E. KERSHAW, ALLISON L. KUIPERS, CLAREANN H. BUNKER, IVA MILJKOVIC, Pittsburgh, PA

1682-P Prognostic Cut Points for Prediabetes Glucose Levels and HbA1c Values in Predicting All-Cause Mortality—A Systematic Review and Meta-analysis. MINXUAN HUANG, UNJALI GUJRAL, SIRAN HE, RAM JAGANNATHAN, JINGKAI WEI, LISA R. STAIMEZ, K.M. VENKAT NARAYAN, Atlanta, GA, Chapel Hill, NC

1683-P Serum Levels of Soluble LR11 Are Associated with Insulin Resistance in the Patients with Type 2 Diabetes Mellitus. HIROYUKI UNOKI-KUBOTA, MEIZI JIANG, HIROSHI KAJIO, RITSUKO YAMAMOTO-HONDA, KAZUYUKI TOBE, MITSUHIKO NODA, HIDEAKI BUJO, YASUSHI KABURAGI, Tokyo, Japan, Sakura, Japan, Toyama, Japan, Saitama, Japan

1684-P Association between Polycystic Ovarian Syndrome and Bone Mineral Density—A Systematic Review and Meta-analysis. SIKARIN UPALA, DAVID A. EHRMANN, Chicago, IL

1685-P Trends in Glycemic Control Based on A1C Factorisation across Different Clinical Settings. PURVI M. CHAWLA, CHANDRASHEKHAR ASHTEKAR, RAHUL M. DHOPE, AMBARI FIRDOUS, SHAIKH, MIKHIL C. KOTHARI, MANOJ S. CHAWLA, Mumbai, India, Latur, India, Pune, India
**Epidemiology—Type 1 Diabetes**

**Moderated Poster Discussion:** Type 1 Diabetes Autoimmunity (Posters: 1686-P to 1691-P), see page 126.

**1686-P** 🔴 Residual Beta-Cell Function in Long Duration Type 1 Diabetes (T1D). ROSE GUBITOSI-KLUG, BARBARA BRAFFETT, SUSAN M. HITT, VALERIE ARENDS, MICHAEL STEFFES, AMY K. SAENGER, JOHN LACHIN, JERRY P. PALMER, Cleveland, OH, Rockville, MD, Columbia, MO, Minneapolis, MN, Seattle, WA

**1687-P** 🔴 Risk of Islet and Celiac Autoimmunity in Cotwins of Probands with Type 1 Diabetes. TAYLOR M. TRIOLO, ALEXANDRA R. FOUTS, LAURA PYLE, LIPING YU, PETER GOTTLIEB, ANDREA STECK, Aurora, CO

**1688-P** 🔴 Time-to-Peak C-Peptide and Peak Glucose during an Oral Glucose Tolerance Test (OGTT) Are Independent Risk Factors for Type 1 Diabetes (T1D) in Antibody-Positive (Ab+) Individuals. HEBA M. ISMAIL, PING XU, CARMELLA EVANS-MOLINA, JERRY P. PALMER, JAY SOSENKO, Pittsburgh, PA, Tampa, Fl, Indianapolis, IN, Seattle, WA, Miami, Fl

**1689-P** 🔴 Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network. NICOLE C. FOSTER, KELLEE MILLER, LINDA DIMEGLIO, DAVID M. MAÅHS, WILLIAM V. TAMBORLANE, RICHARD M. BERGENSTAL, MARK A. CLEMENTS, MICHAEL R. RICKELS, ELIZABETH SMITH, BETH A. OLSON, ROY BECK, Tampa, Fl, Indianapolis, IN, Stanford, CA, New Haven, CT, Minneapolis, MN, Kansas City, MO, Philadelphia, PA

**1690-P** 🔴 Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody-Positive Children. ANDREA STECK, FRAN DONG, IMAN TAKI, MICHELLE R. HOFFMAN, KIMBER SIMMONS, BRIGITTE I. FROHNERT, MARIAN REVERS, Aurora, CO, Denver, CO, Highlands Ranch, CO

**1691-P** 🔴 Individuals with Single Islet Autoantibody Positivity (SA+) at Type 1 Diabetes (T1D) Diagnosis Have Distinct Characteristics. MARIA J. REDONDO, JAY SOSENKO, INGRID LIBMAN, JENNIFER J. MOVEAN, MARK A. ATKINSON, DOROTHY J. BECKER, SUSAN GEYER, THE TYPE 1 DIABETES TRIALNET STUDY GROUP, Houston, TX, Miami, Fl, Pittsburgh, PA, Minneapolis, MN, Gainesville, Fl, Tampa, Fl

**1692-P** A Comparison of HbA1c and Index 60 Thresholds for Identifying Autoantibody Positive Individuals at High Risk for Type 1 Diabetes (T1D). LAURA M. JACOBSEN, HEBA M. ISMAIL, MARK A. CLEMENTS, DESMOND SCHATZ, JAY SOSENKO, Gainesville, Fl, Pittsburgh, PA, Kansas City, MO, Miami, Fl

**1693-P** The Influence of Parental Type 1 Diabetes (T1D) on the Progression to T1D in Autoantibody-Positive Offspring. HEBA M. ISMAIL, EMILY K. SIMS, SUSAN GEYER, MARIA J. REDONDO, CARMELLA EVANS-MOLINA, INGRID LIBMAN, LINDA DIMEGLIO, DOROTHY J. BECKER, JERRY P. PALMER, JAY S. SKYLER, JEFFREY KRISCHER, DESMOND SCHATZ, ALBERTO PUGLIESE, JAY SOSENKO, Pittsburgh, PA, Indianapolis, IN, Tampa, Fl, Houston, TX, Seattle, WA, Miami, Fl, Gainesville, Fl

**1694-P** Estimated Glucose Disposal Rate as a Predictor of All-Cause Mortality in Type 1 Diabetes—A 10-Year Follow-Up Study. MONIA GAROFOLI, ALESSANDRABERTOLOTTI, FABRIZIO CAMP, DANIELA LUCCHESI, LAURA GIUSTI, VERONICA SANCHEZ-BORNEZ, ANGELA DARDANO, ROBERTO MICCOLI, GIUSEPPE PENNO, STEFANO DEL PRATO, Pisa, Italy

**1695-P** Reduced Rate of Acute Complications with Tubeless Insulin Pump Use—Data from 2,640 Patients in the German/Austrian DPV Registry. TORBEN BIESTER, THOMAS DANNE, ESTHER BOLLLOW, ANKE SCHWANDT, BETTINA HEIDTMANN, BIRGIT RAMI-MERHAR, THOMAS HAAK, REINHARD W. HOLL, Hannoover, Germany, Ulm, Germany, Hamburg, Germany, Vienna, Austria, Bad Mergentheim, Germany

**1696-P** Overweight Individuals with Type 1 Diabetes Are Less Likely to Present with Diabetic Ketoacidosiss—Data from the After Diabetes Diagnosis Research Support System (ADDRESS-2) Cohort. SHIVANI MISRA, AKAAL KAUR, IAN F. GODSLAND, HELEN C. WALKEY, DESMOND G. JOHNSTON ESQ., NICK OLIVER, London, United Kingdom

**1697-P** Burden of Cardiovascular Risk Factors and Disease in Type 1 Diabetes—Results of the Australian National Diabetes Audit (ANDA). ANTHONY J. PEASE, ARUL EARNEST, NATALIE NANYAKKARA, SANJEEVA ZOUNGAS, ANNA K. ASLANIDIS, JEFF R. FLACK, WENDY A. DAVIS, GLORIA M. KILMARTIN, NATALIE WISCHER, SOPHIE ZHOU, Melbourne, Australia, Clayton, Australia, Bankstown, Australia, Fremantle, Australia, Shepparton, Australia, Shin Shin, Australia

**1698-P** Teraspanin 7 Autoantibodies in Type 1 Diabetes and Latent Autoimmune Diabetes in Adult. ZHIGUANG ZHOU, XIAJIE SHI, PEILIN ZHENG, GAN HUANG, YUNFEI WANG, CHAO DENG, Changsha, China
1699-P  Hidden Epidemic—Half of T1DM Is Diagnosed in Adulthood. MAAMOUN SALAM, YICHERG BAO, CYNTHIA J. HERRICK, JANET B. MCGILL, JING HUGHES, St. Louis, MO, Kansas City, MO

GENETICS—TYPE 1 DIABETES

1700-P  Association of Anti-GAD Antibody Positivity Measured by RIA and ELISA with Clinical Characteristics in Patients with Type 1 Diabetes. SATOSHI TAKAGI, JUNNOSUKE MIURA, SARI HOSHINA, YASUKO UCHIGATA, TETSUYA BABAZONO, Tokyo, Japan

1701-P  Sclerostin Resistance Protects Bone Mass and Retards the Onset of Metabolic Abnormalities in a Mouse Model of Type 1 Diabetes. GIULIA LEANZA, ROCKY STROLLO, PAOLO POZZILLI, ROBERTO CIVITELLI, NICOLA NAPOLI, Rome, Italy, St. Louis, MO

1702-P  Functional Evaluation of RNLS, a Gene Harboring Risk Variants for Type 1 Diabetes in European and African Ancestry Subjects. SUNA ONENGUT-GUMUSCU, NOAH VOGLER, MARIA FAIDAS, REBECCA R. PICKIN, ELAINE GERSZ, STEPHEN S. RICH, Charlottesville, VA

GENETICS—TYPE 2 DIABETES

Moderated Poster Discussion: Delving into Type 2 Diabetes Genetics (Posters: 1703-P to 1708-P), see page 93.

1703-P  The First Genome-Wide Association Study (GWAS) for Type 2 Diabetes in Youth from the Progress in Diabetics Genetics in Youth (ProDIGY) Collaboration. SHYLAJA SRINIVASAN, JENNIFER TODD, LING CHEN, JASMIN DIVERS, SAM GIDDING, STEVEN CHERNAUSEK, ROSE GUBITOSI-KLUG, MEGAN M. KELSEY, RACHANA SHAH, MARY HELEN BLACK, LYNNE E. WAGENKNECHT, JOSE M. MERCADER, ALISA MANNING, JASON FLANNICK, DANA DABELEA, STEPHEN PARKER, FUSION TISSUE STUDY, Boston, MA, CHARGE EPIGENETICS WORKING GROUP, CHARGE DIABETES WORKING GROUP, Boston, MA, PRODIGY WORKING GROUP, ROCKVILLE, MD, CHARGE EPIDEMIOLOGY/GENETICS WORKING GROUP, CHARGE GENETICS WORKING GROUP, ROCKVILLE, MD


1705-P  A High Resolution Capture-C Promoter “Interactome” Implicates Causal Genes at Type 2 Diabetes GWAS Loci. ELISABETTA MANDUCHI, MATTHEW JOHNSON, MICHELLE LEONARD, SUMEI LU, KENYAITA M. HODGE, ALESSANDRA CHESI, ANDREW D. WELLS, STRUAN F.A. GRANT, Ann Arbor, MI, Berkeley, CA, New York, NY, St. Louis, MO, Durham, NC, Minneapolis, MN, New York, NY, St. Louis, MO, Minneapolis, MN, St. Louis, MO

1706-P  Genetic Effects on Enhancer Activity in Human Pancreatic Islets. ARUSHI VARSHNEY, STEPHEN PARKER, FUSION TISSUE STUDY, Ann Arbor, MI

1707-P  Mendelian Randomization Suggests Causal Influence of Glycemic Traits on DNA Methylation. DANIEL A. DICORPO, SAMANTHA LENT, WEIHUA GUAN, MARIE-FRANCE HIVERT, JAMES S. PANKOW, CHARGE EPIGENETICS WORKING GROUP, CHARGE DIABETES WORKING GROUP, Boston, MA, Minneapolis, MN

1708-P  Characterization of a Type 2 Diabetes-Associated Islet-Specific Enhancer Cluster in STARD10 by Genome Editing of EndoC-βH1 Cells. MING HU, PAUL GADUE, GUY A. RUTTER, London, United Kingdom, Philadelphia, PA

1709-P  Genetics of Circulating HbA1c Long-Term Change over Time in Nondiabetic Subjects—The Long Life Family Study. PING AN, PETRA LENZINI, BHARAT THYAGARAJAN, JOSEPH H. LEE, JOSEPH M. ZMUDA, BADRI N. VARDARAJAN, IVA MILKOVIC, ANATOLIY I. YASHIN, KAARE CHRISTENSEN, TOM PERLS, MICHAEL PROVINCE, St. Louis, MO, Minneapolis, MN, New York, NY, Pittsburgh, PA, Durham, NC, Odense, Denmark, Boston, MA

1710-P  Targeted Metabolomics Identifies Elevated Serotonin Levels in Carriers of a TCF7L2 Diabetes Risk Allele. ANDREAS LEIHERER, ALEX MUENDELEIN, KATHRIN GEIGER, CHRISTOPH H. SAEY, EVA-MARIA BRANDTNER, JANINE EBNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, HEINZ DREXEL, Triesen, Liechtenstein, Feldkirch, Austria, Berne, Switzerland, Philadelphia, PA

1712-P Ancestral Differences in Hemoglobin A1C (A1C) Associations of Erythrocyte Genes Using NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole Genome Sequence (WGS) Data. CHLOÉ SARNOWSKI, AARON LEONG, LAURA RAFFIELD, TOPMED DIABETES WORKING GROUP, Boston, MA, Chapel Hill, NC

1713-P Genome-Wide Association Study of Inflammatory Cytokines in Southwestern Native Americans Identifies Novel Association between WWOX and Serum TNF-α Levels. LAUREN E. WEDEKIND, MARY WALTER, SAYUKO KOBES, PENG CHEN, WEN-CHI HSUEH, ROBERT NELSON, LESLIE BAIER, WILLIAM C. KNOWLER, ROBERT L. HANSON, Phoenix, AZ, Bethesda, MD

1714-P CRISPR Mediated Deletion of a Proxy 19.2kb Distal to the T2D GWAS-Implicated SLC30A8 R325W Variant Impacts RAD21 and UTP23 Gene Expression in HepG2 Cells. KENYAÏTA M. HODGE, SUMEI LU, MICHELLE LEONARD, JAMES A. PIPPIN, ALESSANDRA CHESI, ANDREW D. WELLS, MATTHEW JOHNSON, STRUAN F. GRANT, Philadelphia, PA

1715-P A Comprehensive Type 1 Diabetes Genetic Risk Score Is Associated with Type 2 Diabetes in the Framingham Heart Study. SHYLAIA SRINIVASAN, AARON LEONG, MIRIAM UDLER, BIANCA C. PORNEALA, JAMES B. MEIGS, STEPHEN S. RICH, JOSEE DUPUIS, San Francisco, CA, Boston, MA, Charlottesville, VA

1716-P Heme Deficiency Causes Impaired Glycogen Synthesis in Skeletal Muscle Leading to Insulin Resistance. OSAMU NAKAJIMA, SHINICHI SAI TOH, TOMOHIRO KIMURA, TSUKASA OSAKI, KELLY P. VINCENT, KI WAMU TAKA HASHI, TOHRU TANAKA, MOTOWO NAKAJIMA, Yamagata, Japan, Dublin, Ireland, Tokyo, Japan

1717-P SNP x SNP Interactions Elucidate TCF7L2’s Physiology Conveying Incretin Action. BENJAMIN JAGHUTRIZ, MARTIN HENI, STEFAN Z. LUTZ, HARALD STAIGER, ANDREAS PETER, HANS-ULRICH HAERING, ANDREAS FRITSCH, ROBERT WAGNER, Tübingen, Germany

1718-P Effects of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects with Type 2 Diabetes. DEBORA OLIO SO, MARCO DAURIZ, ELISABETTA BACCHI, CARLO NEGRI, ENZO BONORA, PAOLO MOGHE TTI, Verona, Italy

1719-P Association of CREBFRF Variants with BMI and Diabetes in Pacific Islanders. ROBERT L. HANSON, SAI ED SAFABAKHSH, JEFFREY CURTIS, DARIN K. MAH KEE, LESLIE BAIER, WILLIAM C. KNOWLER, ROBERT NELSON, WEN-CHI HSUEH, Phoenix, AZ, Sinajana, Guam

1720-P Serum Resistin Was Inversely Associated with Physical Activity in the C/C Genotype of SNP-420 in the General Japanese Population—The Toon Genome Study. RYOICHI KAWAMURA, YASUHARU TABARA, YASUNORI TAKATA, MISAKI TAKAKADO, YUMI MATSUSHITA, TOSHIHIRO HADATE, HIROSHI ONUMA, KOUTATSU MARUYAMA, TAKESHI TANIGAWA, ISAO SAI TO, HARUHIKO OSAWA, Toon, Japan, Kyoto, Japan, Yachiyo, Japan, Matsuyama, Japan, Tokyo, Japan

1721-P A Missense (c.T1424C:p.L475P) Mutation of ZYG11A Causes Maturity-Onset Diabetes of the Young. CHUTIMA CHAROENSUK, PRAPAPORN JUNGTRAKOON, WATIP TANGJITTIPOKIN, JATUPORN SUJJITJOON, NATTACHET PLENGVIDHYA, PA-THAI YENCHITSOMANUS, Bangkok, Thailand

1722-P The Different Effect of Sucrose on Transcriptomic Profile in Adipose and Muscle Tissues in Model of Metabolic Syndrome and Insulin Resistance. MARTINA HÜTTLI, IRENA MARKOVA, HANA MALINSKA, LUDMILA KAZDOVA, ONDREJ SEDA, Prague, Czech Republic

1723-P Hepatic Transcriptomic Signature of High-Sucrose Diet in Nonobese Model of Metabolic Syndrome and Prediabetes. IRENA MARKOVA, MARTINA HÜTTLI, HANA MALINSKA, ONDREJ SEDA, LUDMILA KAZDOVA, Prague, Czech Republic

1724-P TOPMed Whole Genome Sequence Combined with Pancreatic-Specific Annotation for Rare Variants Tests of Type 2 Diabetes Risk. ALISA MANNING, TIM MAJARIAN, PAUL S. DE VRIES, JENNIFER WESSEL, JAMES B. MEIGS, TOPMED DIABETES WORKING GROUP, Cambridge, MA, Houston, TX, Indianapolis, IN, Boston, MA
1725-P No Evidence of a Causal Association between Diabetes-Related Phenotypes and Atrial Fibrillation. HADI HARATI, DANIELA ZANETTI, ERIK INGELSSON, JOSH KNOWLES, Palo Alto, CA, Stanford, CA

IMMUNOLOGY

Moderated Poster Discussion: Inflammation and Immunity in Diabetes (Posters: 1726-P to 1731-P), see page 126.

1726-P Chronic Low Grade Inflammation in Type 2 Diabetes—Activation of the Inflammasomes by Circulating Metabolites. MARIE MONLUN, VINCENT RIGALLEAU, LAURENCE BLANCO, KAMEL MOHAMMEDI, PATRICK BLANCO, Bordeaux, France, Pessac, France

1727-P ILC1s Alteration in Type 2 Diabetes Patients. FANGCEN LIU, YAN BI, HONGDONG WANG, Nanjing, China

1728-P Spontaneous Diabetic FATZO Mice with Intact Leptin Signaling Develop Peripheral Immune Cell Responses Similar to T2D and Obese Patients. GAO SUN, WEIWEI YE, XIAOYU AN, YONG-FU XIAO, YIXIN WANG, Taicang, China

1729-P WITHDRAWN

1730-P TNF-α in Combination with Palmitate Enhances IL-8 Production via TLR4-Dependent Signaling Pathway—Potential Relevance to Metabolic Inflammation. RASHEED AHMAD, NADEEM AKHTER, SHIHAB P. KOCHUMON, AREEJ ABU ALROUB, REEBY S. THOMAS, SARDAR T. SINDHU, Kuwait City, Kuwait, Dasman, Kuwait

1731-P A Pilot Study of Preproinsulin Peptides Reactivity in Chinese Type 1 Diabetic Patients. YINGXIN XIAN, HAIXIA XU, JING LV, YIFANG GAO, WENQIAN REN, QIANWEN HUANG, ZIYU JIANG, JINHUA YAN, BIN YAO, JIANPING WENG, Guangzhou, China

1732-P Pharmacological Inhibition of Neutrophil Elastase Attenuates Insulitis and Autoimmune Diabetes in Mice. SHU LINGLING, LING ZHONG, RLC HOO, AIMIN XU, Hong Kong, China

1733-P The MultiPepT1De Study—Examining the Safety of Peptide Immunotherapy Using Multiple Islet Antigens in Recent-Onset Type 1 Diabetes. YUK-FUN LIU, JAKE K. POWRIE, SEFINA ARIF, NIKOLAOS FOUNTOULAKIS, MAMTA JOSHI, EMMA L. SMITH, FOTEINI STRIMENOPOLOU, MOIRA THOMSON, MARK PEAKMAN, London, United Kingdom, Slough, United Kingdom

1734-P Measure Real-Time cAMP Signaling in the Living Cell. XIPING LIU, SEAN HONG, SHIJUAN WU, ZHI WEN YAO, QIANG X. YAO, Irvine, CA, Culver City, CA

1735-P A Cut-Off Value for Anti-GAD Ab ELISA Test for Predicting Future Insulin Dependency in SPIDDM May Not Exist. YOICHI OIKAWA, TAKESHI KATSUKI, TOSHIHIDE KAWAI, AKIRA SHIMADA, Saitama, Japan, Tokyo, Japan

1736-P Change in Circulating Monocyte Profile with Foot Ulcer Healing in Diabetic Patients. DANQING MIN, VANESSA L. NUBE, ANH TAO, XIN YUAN, BELINDA BROOKS, JENCIA WONG, STEPHEN M. TWIGG, SUSAN MCLENNAN, Sydney, Australia

1737-P Renal C3 Production Drives Acute Kidney Injury and Acute Kidney Disease in Diabetics with Sepsis. LYNN M. FRYDRYCH, GUOWU BIAN, SR., PETER A. WARD, MARKUS BITZER, MATTHEW DELANO, Ann Arbor, MI

1738-P Mucosal Gamma/Delta T Cells Increased by i.n. Administration of Gliadin to Four-Week-Old NOD Mice Suggest Diabetes in the NOD-SCID Model of Adoptive Cotransfer of Diabetes. DAVID FUNDA, JARoslAV GOLIAS, MARTIN HAUPT-JORGENSEN, KARSTEN BUSCHARD, Prague, Czech Republic, Copenhagen, Denmark

1739-P Glycolysis-Dependent Inflammasome Activation by Carbon Monoxide. DAENEON KIM, SUNG WAN CHUN, YEOJOO KIM, SANG JIN KIM, JONG-SEOK MOON, Cheonan, Republic of Korea
TRANSPLANTATION

Moderated Poster Discussion: Islet Transplantation (Posters: 1740-P to 1745-P), see page 126.

1740-P 无忧 Flash Glucose Monitoring Reflects Graft Function after Clinical Islet Transplantation—An Initial Report. ANNA LAM, SHAREEN FORBES, CECILIA HAMMING, ANDREW J. MALCOLM, A.M. JAMES SHAPIRO, PETER A. SENIOR, Edmonton, AB, Canada, Edinburgh, United Kingdom

1741-P 无忧 Alpha-1 Antitrypsin (AAT) Promotes Islets Graft Survival by Modulating Macrophage Activation. WENYU GOU, JINGJING WANG, DO-SUNG KIM, LILI SONG, CHARLIE STRANGE, DAVID ADAMS, KATHERINE MORGAN, HONGJUN WANG, Charleston, SC

1742-P 无忧 Pax4 Gene Transfer Induces α-to-β Transdifferentiation and Improves the Therapeutic Efficacy of Islet Transplantation. KESHAB R. PARAJULI, YANQING ZHANG, HONGJU WU, New Orleans, LA

1743-P 无忧 Development of Perfluorodecalin Contained Microcapsules for Islet Survival and Function. JIWON KIM, HEON SEOK PARK, KUN-HO YOON, EUN YOUNG LEE, Seoul, Republic of Korea

1744-P 无忧 Protective Effect of NecroX-7 on Islets against Oxidative Stress and Inflammation. YOUNGSANG KWON, HAN SIN LEE, HYUNJIN KIM, GYURI KIM, SANG-MAN JIN, MOON-KYU LEE, JAE HYEON KIM, Seoul, Republic of Korea

1745-P 无忧 Synergistic Effect of Islet Magnetic Resonance Imaging Using Direct Linking of Ferumoxytol to Surface of PEGylated Islet. HAN SIN LEE, YOUNGSANG KWON, HYUNJIN KIM, MUHAMMAD R. HAQUE, GYURI KIM, SANG-MAN JIN, MOON-KYU LEE, JAE HYEON BYUN, JAE HYEON KIM, Seoul, Republic of Korea

1746-P Intraperitoneally Administered Neo-Islets, Aggregates of Mesenchymal Stem Cells, and Cultured Islet Cells Improve Glycemic Control of Spontaneously Occurring Insulin-Dependent Diabetes Mellitus in Pet Dogs—A Pilot Study, INAD 012-776. CHRISTOF WESTENFELDER, ANNA GOOCH, NATASHA K. LOY SON, NICOLE AVILA, JULIE R. FISCHER, Salt Lake City, UT, San Diego, CA, San Marcos, CA

INSULIN ACTION—ADIPOCYTE BIOLOGY

Moderated Poster Discussion: Fat Is Where Insulin’s At (Posters: 1748-P to 1753-P), see page 91.

1748-P 无忧 ▲ Impaired Insulin Resistance in IF1-Deficient Mice Subjected to a High-Fat Diet with Reduced-Fat Mass and Skeletal Muscle Lipid Accumulation. FENGYUAN HUANG, KEVIN YANG, KAMALAMMA SAJA, YICHENG HUANG, QINGQIANG LONG, MASASUKE YOSHIDA, QINGLIN YANG, Birmingham, AL, Thiruvananthapuram, India, Wuhan, China, Kyoto, Japan

1749-P 无忧 ▲ Depletion of CD206 M2-Like Macrophages Promotes the Browning of the White Adipose Tissue. ALLAH NAVAZ, SHIHO FUJISAKA, ISAO USUI, KUNIMASA YAGI, TAKASHI NAKAGAWA, TOMONOBU KADO, KAZUYUKI TOBE, YOSHIKO IGARASHI, KEISUKE OKABE, KUMIKO SAEKI, Toyama, Japan, Shimotsuga, Japan, Tokyo, Japan

1750-P 无忧 ▲ Inhibition of PPARγ, Adipogenesis, and Insulin Sensitivity by MAGED1. QINGHUA WANG, JING TANG, XIANG GAO, HAI-BIN RUAN, Nantong, China, Nanjing, China, Minneapolis, MN

1751-P 无忧 ▲ Adipocyte EGFL6 Expression from Subcutaneous Adipose Tissue Alters Glucose Homeostasis and Affects Human Obesity. DAVID BRADLEY, ZHENG YIN, JOEY Z. LIU, ALECIA M. BLASZCZAK, STEPHEN T. WONG, WILLA HSUEH, Columbus, OH, Houston, TX

1752-P 无忧 ▲ Phosphoregulation Profiles of Transcription Factors during Early Stage of Thermogenesis in Brown Fat. XIAOJING GAO, Shanghai, China

1753-P 无忧 ▲ Adipose Tissue-Specific Knockout of AMPK alpha1/alpha2 Results in Normal AICAR Tolerance and Glucose Metabolism. RAN HEE CHOI, ABBIGAIL MCCONAHAY, MACKENZIE B. JOHNSON, HO-JIN KOH, Columbia, SC
1754‑P Role of Adenylyl Cyclase‑Associated Protein 1 (CAP1) in Mediating Resistin Actions in Mouse Liver Cells. DIMITER AVTANSKI, ANABEL GARCIA, PRIYANTHAN THANGESWARAN, BEATRIZ CARABALLO BORDON, LEONID PORETSKY, New York, NY

1755‑P Fibroblast Growth Factor‑21 Maintains Glucose Homeostasis through Influencing the Expansion and Function of Subcutaneous Adipose Tissue. HUATING LI, LINGLING QIAN, LIANG WU, Shang‑hai, China

1756‑P Early Changes in Glucose Homeostasis after Gastric Bypass Surgery in Patients with T2DM—Role of Adipose Tissue Mechanisms? PETROS KATSOGIANNOS, GRETHA J. BOERSMA, PRASAD G. KAMBLE, MARIA J. PEREIRA, PER LUNDKVIST, ANDERS KARLSSON, SR., MAGNUS SUNDBOM, JAN W. ERIKSSON, Uppsala, Sweden

1757‑P Siah2 Expression in Adipocyte Progenitor Cells. THANH DANG, GAIL E. KILROY, JESSICA L. TAYLOR, YONGMEI YU, ELIZABETH FLOYD, Baton Rouge, LA

1758‑P Fat Shadows from DEXA for Documentation of Fat Distribution in Patients with Lipodystrophy. RASIMCAN MERAL, BENJAMIN J. RYAN, JEFFREY F. HOROWITZ, ELIF A. ORAL, Ann Arbor, MI

1759‑P Comprehensive Analysis of the Characteristics and Differences in Adult and Newborn Brown Adipose Tissue. CHUANHAI ZHANG, RUILI YIN, YAO SHENG, CUI YANG, XIAOYUN HE, WENTAO XU, KUNLUN HUANG, Beijing, China

1760‑P Adipose Tissue Transferrin and Insulin Resistance. DON MCCLAIN, NEERAJ K. SHARMA, FELIPE LORENZO, SHALINI JAIN, CARL D. LANGEFELD, MARY E. COMEAU, SWAPAN K. DAS, Winston-Salem, NC

1761‑P DBC1, Deleted in Breast Cancer 1, Is a Nuclear STAT5A-Interacting Protein in Adipocytes, but Its Primary Effects on GLUT4 Gene Expression and Lipolysis Are STAT5 Independent. ASHLEY ABLE, ALLISON J. RICHARD, JACQUELINE M. STEPHENS, Baton Rouge, LA

1762‑P Insulin Receptor‑Mediated Signaling Regulates Pluripotency Markers and Lineage Differentiation. MANOJ K. GUPTA, DARIO F. DE JESUS, SEVIM KAHRAMAN, FARNAZ SHAMSI, JIANG HU, YU-HUA TSENG, ROHIT KULKARNI, Boston, MA

1763‑P Evidence against Pathway‑Selective Hepatic Insulin Resistance in Mice. DANIEL F. VATNER, MAX C. PETERSEN, XIRUO LI, JILLIAN C. ROGERS, GARY CLINE, WARREN SAMUEL, GERALD I. SHULMAN, New Haven, CT, West Haven, CT

1764‑P Silencing Mediator of Retinoid and Thyroid Hormone Receptors (SMRT)—A Link between Adipocytes, Inflammation, and Glucose Intolerance. JONATHAN KAHN, ANNA A. GODDI, RONALD N. COHEN, Chicago, IL

INsulin ACTION—CELLULAR AND MOLECULAR Metabolism

Moderated Poster Discussion: Insulin Action—Cellular and Molecular Metabolism (Posters: 1765‑P to 1770‑P), see page 126.

1765‑P Insulin Receptor‑Mediated Signaling Regulates Pluripotency Markers and Lineage Differentiation. MANOJ K. GUPTA, DARIO F. DE JESUS, SEVIM KAHRAMAN, FARNAZ SHAMSI, JIANG HU, YU-HUA TSENG, ROHIT KULKARNI, Boston, MA

1766‑P Evidence against Pathway‑Selective Hepatic Insulin Resistance in Mice. DANIEL F. VATNER, MAX C. PETERSEN, XIRUO LI, JILLIAN C. ROGERS, GARY CLINE, WARREN SAMUEL, GERALD I. SHULMAN, New Haven, CT, West Haven, CT

1767‑P A Positive AllostERIC Modulator Enhances the Ability of Beta Cell M3 Muscarinic Receptors to Simulate Insulin Secretion In Vitro and In Vivo. LU ZHU, JÜRGEN WESS, Bethesda, MD

1768‑P Remodeling of Myocardial Metabolism by Cardiac Mitochondrial Akt Signaling through Modulation of Pyruvate Dehydrogenase Complex. YU-HAN CHEN, YUMAY CHEN, ALBERT TA, HSIAO‑CHEN LEE, HUGO YOU-HSIEN LIN, PING H. WANG, Irvine, CA

1769‑P Polymorphic Role of P2Y1 Receptor in Insulin Sensitive Organs—Adipose Tissue and Skeletal Muscle. SHANU JAIN, JÜRGEN WESS, KENNETH A. JACOBSON, Bethesda, MD
1770-P Identification of Mitochondrial Pyruvate Carrier Modulators to Treat Diabetes. KYLE S. MCCOMMIS, WESLEY T. HODGES, YANA CHEN, KARI CHAMBERS, BRIAN N. FINCK, St. Louis, MO

1771-P Absence of Changes in Galectin-3 with Insulin Sensitization and Anti-Inflammation. PARESH DANDONA, HUSAM GHANIM, MANASI S. SHAH, KELLY GREEN, ANTOINE MAKDISSI, AJAY CHAUDHURI, Williamsville, NY, Buffalo, NY

1772-P Regulation of Insulin Sensitivity by Phosphorus. YI LIN, LINDSEY BERGER, ZHONGJIE SUN, Oklahoma City, OK

1773-P Differential Impacts of Insulin Analogos Lispro and Glulisine on Glucose and Lipid Homeostasis during Hyperinsulinemic Euglycemic Clamp in Streptozotocin-Induced Diabetic Rats. FRANÇOIS BRIAND, EMMANUEL BOURSSEAU, RÉMY BURCELIN, THIERRY SULPICE, Labège, France, Toulouse, France

1774-P An Oral Glucose Load Decreases Post-Prandial Microparticles in Obese Adults With and Without Prediabetes. NATALIE EICHNER, NICOLE M. GILBERTSON, LUCA MUSANTE, SABRINA LA SALVIA, EUGENE BARRETT, ARTHUR WELTMAN, STEVEN K. MALIN, Charlottesville, VA

1775-P Mechanism Mediated by S6 Kinase Resulting in both Sufficient Glucose Metabolism Improvement and Insufficient Weight Loss by Glucose Excretion against Fat Load. TAKAKO KIKUCHI, AKIFUMI KUSHIYAMA, MIDORI FUJISHIRO, HIDEYUKI SAKODA, TOMOICHIRO ASANO, YASUHIKO IWAMOTO, Tokyo, Japan, Miyazaki, Japan, Hiroshima, Japan

INSULIN ACTION—GLUCOSE TRANSPORT AND INSULIN RESISTANCE IN VITRO

1776-P Impact of Blood Sugar Control on Metabolites and Carbohydrate Metabolism in Type 1 Diabetess. WILLEM KUHTREIBER, SOPHIE E. JANES, MICHAEL W. YANG, DENISE L. FAUSTMAN, Charlestown, MA, Boston, MA

1777-P Actions of Apolipoprotein A-IV on Insulin-Independent Glucose Control and Activation of Akt in Mouse Liver. JING HE, JING ZHAO, ZIYU YANG, JIANBO ZHANG, SHU GUANG WEI, SHENG BIN LI, XIAMING LI, Xian, China

1778-P Pharmacologic Uncoupling of Skeletal Muscle Mitochondria Promotes Glucose Metabolism. MICHAELA E. HULL, CHRISTOPHER L. AXELROD, KELLY M. FITZGERALD, JESSICA SACKS, JOHN P. KIRWAN, Cleveland, OH, Baton Rouge, LA

1779-P Isoform-Selective Targeting of Facilitative Glucose Transporters with Small Molecule Inhibitors. MONIQUE HEITMEIER, RICHARD C. HRESKO, MALA SHANMUGAM, PAUL W. HRUZ, St. Louis, MO, Atlanta, GA

INSULIN ACTION—GLUCOSE TRANSPORT AND INSULIN RESISTANCE IN VITRO

1780-P Generation of a Novel Gene Therapy Vector Encoding Beta-Cell-Specific Insulin for Diabetes Treatment. ELIF O. SAHIN, FULYA EREN DOR, MUSTAFA KEMAL BALCI, SALIH SANLI OGLU, Antalya, Turkey

1781-P Aquaporins-1 and -3 Play Novel, Distinct Roles in Normal Balanced Insulin Signaling. XIANGDONG WU, KEVIN JON WILLIAMS, Philadelphia, PA

1782-P Preserved Beta-Cell Function during Acute DKA in Ketosis-Prone Diabetes. PARAS B. MEHTA, SURYA N. MULUKUTLA, JEAN W. HSU, KELLY R. KEENE, NALINI RAM, ASHOK BALASUBRAMANYAM, Houston, TX, Sugar Land, TX

1783-P Mitochondrial DNA DAMPs Induce Inflammation and Insulin Resistance. LARYSA YUZEOFYCH, VIKTOR M. PASTUKH, LYUDMILA RACHEK, Mobile, AL

1784-P Modeling the Spectrum of Human Insulin Resistance Using Induced Pluripotent Stem Cells. JASMIN LEBASTCHI, THIAGO M. BATISTA, IVAN CARCAMO-DRIVE, ANNA KROOK, JULIEN R. ZIERATH, JOSH KNOWLES, C. RONALD KAHN, Boston, MA, Stanford, CA, Stockholm, Sweden

1785-P Dissection of Insulin-Dependent Pathways in Skeletal Muscle under Physiological and Diabetic Conditions. THIAGO M. BATISTA, RUBEN GARCIA MARTIN, WEIKANG CAI, SUJIN SUK, HYE LIM NOH, JASON K. KIM, C. RONALD KAHN, Boston, MA, Worcester, MA
1786-P Persistence with Insulin Glargine 300 IU/ml Compared with Other Basal Insulins—A Canadian Retrospective Cohort Study. KOBINA A. QUANSAH, LUC SAURIOL, ATIF A. KUKASWADIA, SAMANTHA BREMNER, BRADLEY MILLSON, Mississauga, ON, Canada, Laval, QC, Canada, Kanata, ON, Canada

1787-P Adipocyte Overexpression of p55cx Subunit of PI3k Improves Systemic Glucose Metabolism in Lean Mice. ZACHARY S. CLAYTON, CARRIE MCCURDY, Eugene, OR

INTEGRATED PHYSIOLOGY—CENTRAL NERVOUS SYSTEM REGULATION OF METABOLISM

1788-P MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Enhances Leptin-Mediated pSTAT3 Induction in Key Neuronal Regions That Regulate Metabolism. HANI JOUIHAN, PERNILLE BARKHOLT, RIkke GRÖNLUND, JAMES TREvASKIS, Gaithersburg, MD, Hørsholm, Denmark

1789-P Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Strongly Predict Whole-Body Insulin Resistance in the Development of Type 2 Diabetes. GRETHA J. BOERSMA, KERSTIN HEURL-ING, MARIA J. PEREIRA, EMIL JOHANSSON, MARK LUBBERINK, PETROS KATSOGIANNOS, STANKO SKRTIC, JOEL KULLBERG, HÅKAN AHLSTRÖM, SR., JAN W. ERIKSSON, Uppsala, Sweden, Gothenburg, Sweden

1790-P Lack of Brain Insulin Receptor Substrate-1 (IRS1) Causes Growth Retardation via Growth Hormone Releasing Hormone (GHRH). TAKANORI HAYASHI, NAOTO KUBOTA, TETSUYA KADOWAKI, Tokyo, Japan

1791-P Effect of Bariatric Surgery on Neuroplasticity in Humans. GIUSEPPE DANIELE, ANGELA DARDANO, CLAUDIA LUNGHI, PAOLA BINGA, ANNAMARIA CICCARONE, FERRUCCIO SANTINI, GIOVANNI CECARINI, LAURA GIUSTI, ROSARIO BELLINI, MARTA SEGHIERI, Pisa, Italy

1792-P Insulin Acutely Regulates Gene Expression in Brain—A New Potential Major Level of Control of Metabolism and Neurotransmission. WEIKANG CAI, ALFRED RAMIREZ, JONATHAN DREYFUSS, THIAGO M. BATISTA, RUBEN MARTIN, HUI PAN, NAOYUKI LI, BRIAN T. O’NEILL, JASON K. KIM, C. RONALD KAHN, Boston, MA, Iowa City, IA, West Palm Beach, FL, Memphis, TN

1793-P Improving Sleep by Trazodone Improves Glucose Control. SAAD SAKKAL, Milton, FL

1794-P DBS Surgery Improved the T2DM Rats Glucose Homeostasis, Elevated the Glucose Utilization, and the GLUT3 Expression in Brain. RUIYAN PAN, NA LI, TINGKUN ZHAO, HUAJIE WANG, BIN JIANG, QINGTAO YAN, ZHIQIN GAO, WEIFANG, China

1795-P Cerebral Blood Flow Abnormalities in Brain Regions Responsible for Cognitive Function in Type 2 Diabetes. LEANNE HUNT, DINESH SELVARAJAH, SOLOMON TESFAYE, SHEFFIELD, United Kingdom

1796-P Hierarchical Brain and Physiological Responses to Hypoglycemia and HAAF. JOHN J. LEE, AARON TANENBAUM, ANA MARIA ARBELAEZ, SHEFFIELD, United Kingdom

1797-P Sympathetic Innervation of Human Alpha Cells. ELIZABETH A. BUTTERWORTH, LITH H. NASIF, KAMAL NASIF, KATELYN N. CARY, CLAYTON E. MATHEWS, MARK A. ATKINSON, IVAN C. GERLING, MARThA CAMP-BELL-THOMPSON, Gainesville, FL, West Palm Beach, FL, Memphis, TN

1800-P Hypothalamic Spexin and Galanin Receptor 2 Are Novel Regulators of Energy Balance in Mice. NA-HEE HA, NAM HOON KIM, CHANG-HOON KIM, MUN-GYU SONG, HYE-JIN LEE, MI-RAE PARK, JAE YOUNG SEONG, SONG KIM, SEOUL, Republic of Korea

1801-P Hypothalamic HSP10 Impacts Mitochondrial Dynamics, Insulin Signaling, and Liver Glycogen Content. KRISTINA WAREDMANN, JOSE PEDRO CASTRO, MICHAELA RATH, JÜRGEN WEß, ANNETTE SCHUERMANN, ANDRE KLEINRIDDERS, Nuthetal, Germany, Düsseldorf, Germany
1802-P Short-Term Weight Loss Undermines Brain Regulation of Food Consumption. WAI LAM, DONGJU SEO, CHERYL LACADIE, CHRISTIAN P. SCHMIDT, SAMUEL ROSENBERG, HAI HOANG, JANICE HWANG, TODD CONSTABLE, MARY SAVOYE, RAJITA SINHA, ROBERT SHERWIN, RENATA BELFORT-DEAGUIAR, New Haven, CT

1803-P ▲ Central K<sub>ATP</sub> Channels Modulate Glucose Effectiveness. WILLIAM G. MITCHELL, ERIC LONTCHI-YIMAGOU, SARAH A. REDA, MICHELLE CAREY, KEHAO ZHANG, SANDRA ALEKSIC, DEREK HUFFMAN, MEREDITH HAWKINS, Bronx, NY

1804-P Neuronal Deletion of the Mammalian Indy Homolog (Slc13a5) Increases Energy Expenditure in Mice. ANICA KURZBACH, DIANA M. WILLMES, TINA SCHUMANN, CHRISTINE HENKE, NERMEEN EL-AGROUDY, ANDRE KLEINRIDDERS, ANDREAS L. BIRKENFELD, Dresden, Germany; Nuthetal, Germany

1805-P Novel Function of Increased Ventromedial Hypothalamus (VMH) Norepinephrine (NE) to Block Local VMH Hyperglycemia Sensing Coupled to Increased Insulin Action. CARL STOELZEL, ANTHONY CINCOTTA, Tiverton, RI

1806-P Glucagon Regulates Energy Balance via FGF-21 Signaling in the Brain. SHELLY NASON, TEAYOUN KIM, JESSICA P. ANTIPENKO, JODI PAUL, BRIAN FINAN, RICHARD DIMARCHI, KIRK M. HABEGGER, Birmingham, AL, Indianapolis, IN, Bloomington, IN

1807-P ▲ Amygdala Glucose-Sensing Neurons Regulate Glucose Metabolism. KAVYA DEVARAKONDA, MITCHELL BAYNE, ALEXANDRA ALVARSSON, SARAH STANLEY, New York, NY

INTEGRATED PHYSIOLOGY—INSULIN SECRETION IN VIVO

Moderated Poster Discussion: Integrated Physiology of Insulin Secretion In Vivo (Posters: 1808-P to 1813-P), see page 91.

1808-P ▲ Elevated Glucose Concentrations 60 Minutes after an Oral Challenge in Subjects with Normal Glucose Tolerance Are Not Explained by the Rate of Meal-Derived Glucose Appearance. J.D. ADAMS, GERLIES TREIBER, MARIA D. HURTADO, MARCELLO C. LAURENTI, CHIARA DALLA MAN, CLAUDIO COBELLI, ROBERT A. RIZZA, ADRIAN VELLA, Rochester, MN, Graz, Austria; Albuzzano, Italy; Padova, Italy

1809-P ▲ Transient Hyperglycemia Alters Pancreatic Function and Peripheral Insulin Signaling in Preterm Baboons. CYNTHIA BLANCO, AMY QUINN, LAURYN A. WINTER, JOE VALENTINE, NICOLAS MUSI, RALPH A. DEFRONZO, San Antonio, TX

1810-P ▲ Differential Beta-Cell Response to Intravenous Exenatide (EXEN) and Arginine (ARG) in Prediabetic Subjects with Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT). TOMOKO TERASAWA, CURTIS L. TRIPLITT, JOHN M. ADAMS II, EUGENIO CERSOSIMO, RALPH A. DEFRONZO, ALBERTO O. CHAVEZ VELAZQUEZ, San Antonio, TX

1811-P ▲ Does the Shape of the OGTT Glucose Curve Reflect Metabolic Function in Individuals with Type 2 Diabetes? Baseline Data from the GRADE Cohort. KRISTINA UTZSCHNEIDER, MARY ANN BANERJII, JOSHUA L. BARZILAY, ERICA V. GONZALEZ, KEREN J. MATHER, PHILIP RASKIN, NAJI YOUNES, STEVEN E. KAHN, GRADE RESEARCH GROUP, Seattle, WA, Brooklyn, NY, Duluth, GA, Houston, TX, Shaker Heights, OH, Indianapolis, IN, Dallas, TX, Rockville, MD, Washington, DC

1812-P ▲ The Relationship of Fasting Free Fatty Acids, Adipose Tissue, Insulin Resistance, and Fasting Glucose Concentrations with Subsequent β-Cell Function in Nondiabetic Subjects. MARIA D. HURTADO, J.D. ADAMS, MARCELLO C. LAURENTI, CHIARA DALLA MAN, CLAUDIO COBELLI, ROBERT A. RIZZA, MICHAEL D. JENSEN, ADRIAN VELLA, Rochester, MN, Albuzzano, Italy; Padova, Italy

1813-P ▲ Altering Glucose Variability with Low- or High-Glycemic-Index Diets in Adults with Prediabetes Does Not Affect Beta-Cell Function or Markers of Oxidative Stress. KRISTINA UTZSCHNEIDER, TONYA N. JOHNSON, KARA BREYMEYER, MARIAN L. NEUHOUSER, Seattle, WA

1814-P ▲ The Role of Incretins and Insulin in Postprandial Hyperinsulinemia in Black Women—The Federal Women Study. STEPHANIE T. CHUNG, AMBER B. COURVILLE, POOLA C. ALDANA, ANTHONY ONUZURUIKE, SHANNA BERNSTEIN, MIRELLA GALVAN-DE LA CRUZ, LILIAN MABUNDO, MARY WALTER, ANNE E. SUMMER, Bethesda, MD; Baltimore, MD

1815-P Treatment of Hyperglycemia with Empagliflozin, With or Without Metformin, Improves Islet Endothelial Cell Health and Insulin Secretion in db/db Diabetic Mice. MEGHAN F. HOGAN, DARYL J. HACKNEY, ALFRED APIN, THOMAS O. MUNDINGER, SAKENEH ZRAIKA, REBECCA L. HULL, Seattle, WA
1816-P Relative Pancreas Volume Is Reduced in Autoantibody Negative First-Degree Relatives and Subjects with Pre-Type 1 Diabetes. MARTHA CAMPBELL-THOMPSON, MARK A. ATKINSON, STEPHANIE L. FILIPP, MATTHEW J. GURKA, RICHARD BEEGLE, DESMOND SCHATZ, MICHAEL J. HALLER, TYPE 1 DIABETES STUDY GROUP, Gainesville, FL

1817-P PBI-4547 Prevents Progression of Prediabetic Condition to Type 1 Diabetes in NOD Mice. FRANÇOIS A. LEBlOND, KATHY HINCE, FRANÇOIS SARRA-BOURNET, WILLIAM GAGNON, MIKAEL TREMBLAY, MARIE-PIER CLOUTIER, SYLVIE LÉTOURNEAU, JEAN-CHRISTOPHE SIMARD, MARTIN LEDUC, BRIGITTE GROUIX, PIERRE LAURIN, LYNE GAGNON, Laval, QC, Canada

1818-P Normal Glucose Tolerance (NGT) in Obese African-Americans (AA) with Ketosis-Prone Diabetes (KPDM). PRIYATHAMA VELLANKI, DARKO STEFANOVSKI, VISHAL NARWANI, ISABEL ANZOLA, LIMIN PENG, DAWN SMILEY-BYRD, GUILLERMO E. UMPIERREZ, Atlanta, GA, Philadelphia, PA

1819-P Association of Pancreas Fat with Impaired Insulin Secretion Depends on Liver Fat and Circulating Fatty Acids. BENJAMIN JAGHUTRIZ, ROBERT WAGNER, JÜRGEN MACHANN, NORBERT STEFAN, ANDREAS PETER, DOROTHEA I. SIEGEL-AXEL, FELICIA GERST, SUSANNE ULRICH, SUSANNE ULLRICH, ANDREAS FRITSCHE, HANS-ULRICH HAERING, MARTIN HENI, Tübingen, Germany

1820-P Effects of GLP-1 and GIP on Insulin Secretion in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis. JACk N. EIeL, SARAH NYIRJESY, AMY J. PELECKIS, DIVA DE LEON, DENIS HADJIILADIS, CHRISTINA KUBRAK, ABIGAIL TAMi, SABA SHEIKH, RONALD C. RUBENSTEIN, ANDREA KELLY, MICHAEL R. RICKELS, Philadelphia, PA

1821-P Glucose Metabolism after Overnight and Prolonged Fasting in Healthy Subjects. NORBERT J. TRIPOLT, SLAVEN STEKOVIC, JASMIN URL, FELIX ABERER, PETER N. PFERSCHY, REGINA RIEDL, BARBARA M. OBERMAYER-PIETSCH, THOMAS R. PIEBER, FRANK MADEO, HARALD SOURIJ, Graz, Austria

1822-P Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. NEDA RASOULI, ROBERT M. COHEN, RALPH A. DEFRONZO, SILVIO INZUCCHI, FARAMARZ ISMAEL-BEGI, STEVEN E. KAHN, KRISTINA UTZSCHNEIDER, JOHN LACHIN, NAJI YOUNES, GRADE RESEARCH GROUP, Denver, CO, Cincinnati, OH, San Antonio, TX, New Haven, CT, Shaker Heights, OH, Seattle, WA, Rockville, MD, Washington, DC

1823-P Beta-Cell Function after Gastric Bypass. ANKIT SHAH, KIARRA LEVESQUE, MICHAEL AHLERS, MARLENA M. HOLTER, FATIMA ALAM, ESMeRALDA PIERINI, BETSY L. ROJAS, VICTORIA MARk, KAPiLA PATEL, ROKANNE DUTiA, EUGENIUS J. HARVEY, KOJI PArk, NINAN KOShY, SCOTT J. BELSLEY, JAMES J. MCBINTY, BLANDINE LAFERRERE, New York, NY

1824-P Beta-Cell SCHAD Deficiency Causes Hypoglycemia in Mice. JOHANNA LUDEKE, KELLY M. VELASCO, DARIo F. DE JESUS, BRITTANY A. SLIPP, JIANG HU, SOLRUN J. STEINE, GEIR HELGELAND, PÅL RASMUS NJØLSTAD, ROHIT KULKARNI, ANDERS MOLVEN, Bergen, Norway, Boston, MA, Lier, Norway

1825-P Pharmacological Neprilysin Inhibition Improves Glucose Homeostasis in a Mouse Model of Type 2 Diabetes. JACQUELINE H. PARILLA, STEVE MONGOVIN, BRENANNE BARROW, NATHALIE ESSEr, SAKENEH ZRAIKA, Seattle, WA

1826-P Retinol Binding Protein 4 Impairs Pancreatic Beta-Cell Function, Leading to the Development of Type 2 Diabetes. RONG HUANG, XINXIU BAI, XUEYAN LI, LINA ZHAO, Min XIA, Guangzhou, China

1827-P Mild Physiologic Hyperglycemia Impairs Beta-Cell Function and Induces Insulin Resistance in Healthy Normal Glucose Tolerant Subjects. AURORA MEROVICI, ENRIQUE R. MALDONADO COrCHADO, RALPH A. DEFRONZO, San Antonio, TX

1828-P Metabolic Clearance Rate of Insulin Is Not Saturable within the Physiological Range. ISAAC ASARE BEDIAKO, REBECCA L. PASZKIEWICZ, ORISON O. WOOLCOTT, RICHARD N. BERGMAN, Los Angeles, CA

1829-P Sodium-Glucose Cotransporter 2 Inhibitors Improve Pancreatic β-Cell Function by the Relief of β-Cell Distress in Japanese Type 2 Diabetes. TSUNEHIKO YAMAMOTO, Amagasaki, Japan

1830-P Insulin Resistance Impairs Cognitive Performance Even in Healthy Subjects at Risk for Diabetes Mellitus. GIAN PIO SORICE, ILARIA IMPROTA, TERESA MEZZA, SARA GRIONI, GIOVANNA MASONE IACOBUCCHI, SIMONA MOFFA, ANDREA MARI, CAMILLO MARRA, ANDREA GIACCARI, Rome, Italy, Milan, Italy, Padova, Italy
1831-P The Postprandial C-peptide-to-Glucose Ratio Correlated with Beta-Cell Function in Japanese Patients with Type 2 Diabetes Mellitus. YUKI MATSUHASHI, SHINJI CHIKAZAWA, HIROFUMI NAKAYAMA, MASAYA MURABAYASHI, SATORU MIZUSHIRI, SHO OSONO, KAZUHIKA TAKAHASHI, HIDEYUKI OTAKA, MIYUKI YANAGIMACHI, HIROSHI MURAKAMI, MAKOTO DAISON, Hirosaki, Japan

1832-P Hepatic Sulfate of β Cells Regulates Insulin Secretion and Contributes to Normal Glucose Homeostasis. TAKURO MATSUIZWA, TAKED YOSHITAKA, AKIRA SUGAWARA, KAZUHIKO YANAI, Sandai, Japan

INTEGRATED PHYSIOLOGY—LIVER

Moderated Poster Discussion: Integrated Physiology of the Liver (Posters: 1833-P to 1838-P), see page 126.

1833-P IGFBP2 Is Increased after Gastric Bypass in Humans—Potential Impact on Hepatic Metabolism. YIXING YUCHI, WEIKANG CAI, TUKIYO TAKAGI, HUI PAN, JONATHAN DREYFUSS, KATHLEEN FOSTER, ASHLEY H. VERNON, DONALD C. SIMONSON, ALLISON GOLDFINE, ANDREAS HOEFELICH, MARY E. PATTI, Boston, MA, Cambridge, MA, Dummerstorf, Germany

1834-P Diabetes Remission Clinical Trial (DIRECT)—Plasma Liver Function Tests Reflect Change in Liver Fat Content in Early Type 2 Diabetes. SVITLANA V. ZHYZHNEUSKAYA, AHMAD AL-MRABEH, CARL PETERS, ALISON C. BARNES, KIEREN G. HOLLINGSWORTH, HELEN PILKINGTON, PAUL WELSH, NAVEED SATTAR, MICHAEL E. LEAN, ROY TAYLOR, Newcastle upon Tyne, United Kingdom, Glasgow, United Kingdom

1835-P Hepatic Lipid Profiling in Fatty Liver Disease—Degree of Saturation Matters. MELISSA L. ERICKSON, JACOB M. HAUS, CHRIS FLASK, JOHN P. KIRWAN, Cleveland, OH, Ann Arbor, MI

1836-P The SGLT2 Inhibitor Canagliflozin Induces Catabolic Transcriptional and Metabolic Switching and Increases FGF-21 in Mice with Dietary Obesity. SORAVIS OSATAPHAN, CHIARA MACCHI, VICENCIA SALES, CHISAYO KOZUKA, JEREMY I. CHIMÈNE-WEISS, YANIN TANGJAROENPAISAN, JORDAN MORNINGSTAR, ROBERT GERSZTEN, MARY E. PATTI, Boston, MA, Milan, Italy, Cambridge, MA, Nottingham, United Kingdom, Somerville, MA, Brookline, MA

1837-P Increased Gluconeogenesis Is Not an Early Feature of Whole-Body Insulin Resistance in Black Women—The Federal Women Study. STEPHANIE T. CHUNG, MOREY W. HAYMOND, ANTHONY ONUZURUIKE, LILIAN MABUNDO, H. MARTIN GARRAFFO, AMBER B. COURVILLE, AHMED M. GHARIB, SHAJI CHACKO, ANNE E. SUMNER, Bethesda, MD, Eden, UT, Houston, TX

1838-P Palmitic Acid Esters of Hydroxy Stearic Acids Are Hepatic Insulin Sensitizers in Chow and High-Fat Diet (HFD)-Fed Mice. ANNA SANTORO, PENG ZHUO, ODILE D. PERONI, ISMAIL SYED, ANDREW T. NELSON, DIONICIO SIEGEL, ALAN SAGHATELIAN, BARBARA KAHN, Boston, MA, La Jolla, CA

1839-P A Porcine Placental Extract Alleviates Lipotoxicity-Induced NASH by Polarizing M2 Macrophages and Attenuating Stellate Cell Activation in Mice. GUANLIANG CHEN, LIANG XU, NAOTO NAGATA, MAYUMI NAGASHIMADA, TSUGUHITO OTA, Kanazawa, Japan, Asahikawa, Japan

1840-P Hepatic G0S2 Exacerbates Hepatic Insulin Resistance in Estrogen-Deficient Female Wistar Rats. HIROAKI SATOH, YOSHIYUKI SUGAYA, CHIHIRO T. MORIYA, TAKESHI MIYATSUKA, HIROTAKA WATADA, HIROSHI MURAKAMI, MAKOTO DAIMON, Hirosaki, Japan

1841-P MED10382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH. MICHELLE BEATON, SILVIA GUIONAUD, JAMES P. CONWAY, JOE GRIMSBY, CHRISTOPHER J. RHODES, LUTZ JERMUTUS, JAMES TREVASKIS, Gaithersburg, MD, Cambridge, United Kingdom

1842-P Low Hepatic Fat and Stearoyl-CoA Desaturase Activity Contribute to Paradoxically Normal Triglyceride-Rich Lipoproteins in Insulin Resistant Black Women—The Federal Women Study. STEPHANIE T. CHUNG, MIRELLA GALVAN-DE LA CRUZ, SHANNA BERNSTEIN, ANTHONY ONUZURUIKE, NURUPA R. MATTHAN, RONALD OUWERKERK, LILIAN MABUNDO, MAUREEN L. Sampson, AMBER B. COURVILLE, AHMED M. GHARIB, ALICE H. LICHTENSTEIN, ALAN SAGHATELIAN, BARBARA KAHN, Boston, MA

1843-P mGPDH Depresses Hepatic Lipogenesis by Inhibition of ER Stress. YI ZHENG, HONGTING ZHENG, Chongqing, China

1844-P Ethnic Differences in Hepatic Insulin Clearance Seen since Childhood Suggest a Genetic Basis. FRANCESCA PICCININI, DAVID POLIDORI, BARBARA GOWER, JOSE R. FERNANDEZ, RICHARD N. BERGMAN, Los Angeles, CA, San Diego, CA, Birmingham, AL
1845-P The Molecular Role of WNT5A and Its Antagonist SFRP5 in Gluconeogenesis and Inflammation in Human Hepatocytes. MAREN CARSTENSEN-KIRBERG, CORINNA NIERSMANN, KARIN ROEHRRG, MICHAEL RODEN, CHRISTIAN HERDER, Düsseldorf, Germany

1846-P Exenatide Treatment Improves Mitochondrial Metabolism and Hepatic Insulin Sensitivity in Mice with Nonalcoholic Steatohepatitis (NASH). SRILAXMI KALVALAPALI, FERNANDO BRIL, ARIANA VERGARA, NISHANTH SUNNY, KENNETH CUSI, Gainesville, FL, College Park, MD

1847-P Use of Plasma Metabolomics and Lipidomics for the Diagnosis of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. FERNANDO BRIL, SRILAXMI KALVALAPALI, KEVIN L. DUFFIN, MARK L. HARTMAN, YU CHEN, QIAN YANG, JOSEPH V. HAAS, PAUL L. MILLIGAN, JR., KENNETH D. ROTH, KENNETH CUSI, Gainesville, FL, Indianapolis, IN

1848-P Mechanisms of Hepatic Steatosis and Insulin Resistance Induced by Sleep Deprivation in Mice. FUMIKA SHIGIYAMA, NAOKI KUMASHIRO, FUKUMI YOSHIKAWA, YOUSUKE TSUNEOKA, HIROMASA FUNATO, TAKAHIRO HIROSE, Tokyo, Japan

1849-P Canagliflozin, an SGLT2 Inhibitor, Prevents Development of Hepatocellular Carcinoma (HCC) from Nonalcoholic Steatohepatitis (NASH) in a Mouse Model of NASH-HCC Under Diabetic State. TERUO JOJIMA, SYO WAKAMATU, TOSHI HIJIMA, ISAO USUI, YOSHIMASA ASO, Mibu, Japan, Shimosugita, Japan

1850-P Liver-Specific Overexpression of NOS1AP Alleviates Hepatic Insulin Resistance in Obese Mice. CHEN WANG, KAIDA MU, TIANXUE ZHAO, HUI ZHU, WEIPING JIA, Shanghai, China

1851-P Hypothalamic Orexin Is Essential for Estrogenic Action on Glucose and Energy Metabolism in Diet-Induced Obese Mice. KANTA KON, HIROSHI TSUNEKI, SHINJIRO TAKATA, TAKAHIRO MAEDA, TSUTOMU WADA, TOSHIHIRO ASAO, Tohoku, Japan

1852-P Lactobacillus Pentosus Strain S-PT84 Attenuates Insulin Resistance and Steatohepatitis by Maintaining Gut Permeability and Polarizing M2 Macrophages. YURIKO SAKAI, MAYUMI NAGASHIMADA, TSUGUHITO OTA, Kanazawa, Japan, Asahikawa, Japan

1853-P Elevated Serum Cytokeratin-18 Levels in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. TAO-CHUN LEE, Pingtung, Taiwan

1854-P Fatty Liver Is a Better Marker of Muscle Insulin Resistance than Visceral Fat Accumulation in Nonobese Japanese Men. SATOSHI KADOWAKI, YOSHIFUMI TAMURA, YUKI SOMEYA, KAGEUMI TAKENO, TAKASHI FUNAYAMA, YASUHIKI KAGA, RUIKO SUZUKI, DAIHIGAKU SUGIMOTO, RYUZO KAWAMORI, HIROTAKA WATADA, Tokyo, Japan

1855-P Withdrawn

1856-P Metabolic Activity of the Liver during Exercise—A Metabolomics Approach. PETER PLOMGÅRD, CHUNXIU HU, JAKOB S. HANSEN, XINJIE ZHAO, MIRIAM HOENE, XIAOLIN WANG, NIELS SECHER, HANS-ULRICH HAERING, RAINER LEHMANN, GUOWANG XU, CORA WEIGERT, Copenhagen, Denmark, Dalian, China, Tübingen, Germany

1857-P Development of In Vitro NASH Model with Mechanically Compliant Substrate. MASAKI MORISHIMA, KAZUKI HORIKAWA, MAKOTO FUNAKI, Tokushima, Japan

1858-P PBI-4547 Improves Glucose Metabolism and Insulin Resistance, and Reduces Liver Damage in a High-Fat Mouse Model of Obesity and Metabolic Syndrome. MARTIN LEDUC, BRIGITTE GROUIX, MIKAEL TREMLAY, LIETTE GERVAIS, FRANÇOIS SARRA-BOURNET, ALEXANDRA FELTON, JEAN-CHRISTOPHE SIMARD, FRANÇOIS A. LEBLOND, PIERRE LAURIN, LYNÉE GAGNON, Laval, QC, Canada

1859-P A Novel Role for SerpinB1, a Protease Inhibitor, in Hepatic Biology. KAZUKI ORIME, DARIO F. DE JESUS, ROHIT KULKARNI, Boston, MA

1860-P Growth Differentiation Factor 15 Ameliorates Nonalcoholic Steatohepatitis Associated with Metabolic Syndrome in Mice. MYUNG-SHIK LEE, YONG-HO LEE, SEOONG HUN KIM, KOOK HWAN KIM, Seoul, Republic of Korea
1861-P Liver-Specific siRNA Inhibition of Class 2a Histone Deacetylases (HDACs) Reduces Expression of Genes Regulating Gluconeogenesis in Primary Human and Mouse Hepatocytes, but Not in Mice. SVEN W. GÖRGENS, SURYAPRAKSH RAICHUR, PAULUS WOHLFART, BODO BRUNNER, NORBERT TENNAGELS, MAXIMILIAN BIELOHUBY, Frankfurt, Germany, Göttingen, Germany

1862-P Difference in Hepatic Steatosis and Pancreatic Beta-Cell Mass between Dapagliflozin and Insulin Glargine Treatment at Comparable Levels of Glycemic Control. KAZUNO OMORI, AKINOBU NAKAMURA, HIDEKI MIYOSHI, KIYOHIKO TAKASHASHI, NAOYUKI KITAO, YASUO TERAUCHI, TATSUYA ATSUMI, Sapporo, Japan, Yokohama, Japan

1863-P Regulation of Hepatic Insulin Sensitivity and Hepatic Steatosis by ULK1. YOUNGDO KOO, MICHAEL P. GARNEAU, QUANJIANG ZHANG, E. DALE ABEL, Iowa City, IA

1864-P Genetic Ablation of Liver CPT-1A Gene Protects Mice against High-Fat Diet-Induced Obesity and Insulin Resistance. DONGHAI WU, Guangzhou, China

1865-P WITHDRAWN

1866-P The Role of Adipocyte Fatty Acid Binding Protein in the Development of Liver Fibrosis. XIAOPING WU, LINGLING SHU, KAREN S. LAM, AIMIN XU, RLC HOO, Hong Kong, China

1867-P cGMP-Dependent Protein Kinase I (cGKI) Modulates Human Hepatic Stellate Cell Activation. ANDRAS FRANKO, MARKETA KOVAROVA, ROBERT WAGNER, CORA WEIGERT, ROBERT FEIL, SUSANNE FEIL, HANS-ULRICH HAERING, STEFAN Z. LUTZ, ANDREAS PETER, Tübingen, Germany

1868-P WITHDRAWN

1869-P Lean Subjects with Fatty Liver Show Decreased GLP-1 and GIP Response during OGTT. AMALIA GASTALDELLI, JESUS GARDUNO-GARCIA, RALPH A. DEFRONZO, JENS J. HOLST, NICOLAS MUSI, San Antonio, TX, Copenhagen, Denmark

1870-P Short-Term Exercise Improves Hepatic Insulin Extraction in Individuals with Nonalcoholic Fatty Liver Disease. ADITHYA HARI, CIARAN E. FEALY, JOHN P. KIRWAN, Cleveland, OH

1871-P Liver-Specific Overexpression of 17β-HSD13 Causes Hepatic Steatosis in Mice. WEN SU, YOUFEI GUAN, Shenzhen, China, Dalian, China

1872-P A Role for Macrophage Adenosine 2A Receptor in Diet-Induced Nonalcoholic Fatty Liver Disease. JING ZHOU, HONGGUI LI, XIANJUN LUO, LINQIANG MA, CHAODONG WU, College Station, TX

1873-P Metabolic Dysfunction within Brown Adipose Tissue and Skeletal Muscle Caused by Complete Hepatic Insulin Resistance Is Reversible by FGF-21 Treatment. OLIVER STOEHR, RONGYA TAO, KYLE D. COPPS, MORRIS F. WHITE, Boston, MA

1874-P Integration of BCAA and Lipid Metabolism by the BCKDH Kinase and Phosphatase. PHILLIP J. WHITE, ROBERT W. MCGARRAH III, PAUL A. GRIMSRUD, WEN-HSUAN YANG, GUO-FANG ZHANG, JONATHAN M. HALDEMAN, MICHELLE ARLOTTO, OLGA ILKAYEVA, RICHARD M. WYNN, DAVID T. CHUANG, CHRISTOPHER B. NEWGARD, Durham, NC, Dallas, TX

1875-P Estrogen Improves Insulin Sensitivity and Suppresses Hepatic Glucose Production via the Transcription Factor Foxo1. HUI YAN, FENGHUA ZOU, WANGBAO YANG, QUAN PAN, ZHENH SHEN, GUICHUN HAN, KIMBERLY ALLRED, CLINTON ALLRED, YONG XU, SHAODONG GUO, College Station, TX, Guangzhou, China, Houston, TX

1876-P Simultaneous 2H and 13C Metabolic Flux Analysis of Liver Metabolism Using NMR and GC-MS—Methods Validation and New Applications. STANISLAW DEJA, JUSTIN A. FLETCHER, BLANKA KUCEJJOVA, XIAORONG FU, JAMEY YOUNG, SHAWN C. BURGESS, Dallas, TX, Nashville, TN

1877-P Differential Effects of Niacin on High-Fat Diet-Induced Adipose Tissue Inflammation and Nonalcoholic Fatty Liver Disease in C57BL6/J and B6129SF2/J Mice. HAN FANG, EMILY GRAFF, ZHUOYUE LI, ROBERT L. JUDD, Auburn, AL

1878-P Glutathione Deficiency Induces Epigenetic Alterations of Vitamin D Metabolism Genes in the Liver of High-Fat Diet-Induced Type 2 Diabetic Mice. RAJESH PARSANATHAN, SUSHIL K. JAIN, Shreveport, LA
1879-P Impact of Hepatic Mig6 on Glucose Homeostasis and Oxidative Stress. JOSE M. IRIMIA-DOMINGUEZ, ANDREW J. LUTKEWITTE, PATRICK T. FUEGER, Duarte, CA, St. Louis, MO

1880-P A Novel Mechanism by Foxo1 Phosphorylation Mediates Glucagon Signaling in Control of Glucose Homeostasis. YUXIN WU, HUI YAN, QUAN PAN, HONGTING ZHENG, SUDATH A. DAHANAYAKA, YUXIANG SUN, AIMIN ZHOU, LIN ZHANG, SHAODONG GUO, Belfast, United Kingdom, College Station, TX, Chongqing, China, Cleveland, OH, Indianapolis, IN

1881-P Protection of Progression of Nonalcoholic Steatohepatitis in Diet-Induced Obese Mice by a Low-Iron Diet. LIPIKA SALAYE, IELIZAVETA BYCHKOVA, FELIPE LORENZO, SANDY T. SINK, DON McCLAIN, Winston-Salem, NC, Salt Lake City, UT

1882-P Pyruvate Carboxylase Is Required for Hepatic Gluconeogenesis and TCA Cycle Function. DAVID CAPPEL, STANISLAW DEJA, XIAORONG FU, SHAWN C. BURGESS, Dallas, TX

1883-P Foxo1-Ser253 Phosphorylation Regulates Glucose Homeostasis in Mice. HUI YAN, YUXIN WU, QUAN PAN, ZHENG SHEN, HONGTING ZHENG, MORRIS F. WHITE, YUXIANG SUN, AIMIN ZHOU, LIN ZHANG, SHAODONG GUO, College Station, TX, Belfast, United Kingdom, Chongqing, China, Boston, MA

INTEGRATED PHYSIOLOGY—MACRONUTRIENT METABOLISM AND FOOD INTAKE

Moderated Poster Discussion: Integrated Physiology of Macronutrient Metabolism and Food Intake (Posters: 1884-P to 1889-P), see page 93.

1884-P Sex Differences in the Response of C57BL/6 Mice to Ketogenic Diets. JESSE COCHRAN, PAUL V. TAUFALELE, KEVIN D. LIN, YUAN ZHANG, E. DALE ABEL, Iowa City, IA, Nashville, TN

1885-P Protein and Glucose Absorption and Gastrointestinal Hormone Secretion Differ between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. MARIA S. SVANE, KIRSTINE N. BOJSEN-MOLLER, CHRISTOFFER MARTINUSSEN, CARSTEN DIRKSEN, SØREN REITELSEDER, LARS HOLM, VIGGO B. KRISTIANSEN, GERRIT VAN HALL, JENS J. HOLST, STEN MADSBAD, SR., Hvidovre, Denmark, Copenhagen, Denmark, Birmingham, United Kingdom

1886-P Praliciguat, a Clinical-Stage sGC Stimulator, Improved Glucose Tolerance and Insulin Sensitivity and Lowered Triglycerides in a Mouse Diet-Induced Obesity Model. CHAD D. SCHWARTZ-KOPF, JOHN HADCOCK, JULI E. JONES, MARK CURRIE, GEORGE T. MILNE, JAIME MASFERRER, Cambridge, MA

1887-P Impact of Type 1 Diabetes on 24-Hour Energy Expenditure and Metabolic Flexibility. ELVIS A. CARNERO, KAREN D. CORBIN, CHRISTOPHER P. BOCK, STEVEN R. SMITH, RICHARD E. PRATLEY, Orlando, FL

1888-P Meal Intake Is Suppressive of Ketogenesis in Patients with Type 1 Diabetes. HUSAM GHANIM, KELLY GREEN, JEANNE M. HEJNA, NITESH D. KUHADIYA, MANAV BATRA, AJAY CHAUDHURI, BUFFALO, NY, Williamsville, NY, Reno, NV

1889-P Relating Disinhibited Eating Behaviors to Resting State Functional Connectivity in Young Children. ALLISON L.B. SHAPIRO, SUSAN L. JOHNSON, BRIANNE MOHL, GRETA WILKENING, KRISTINA T. LEGGET, DANA DABELEA, JASON R. TREGELLAS, Aurora, CO

1890-P Evaluating the Sub-chronic Effects of MEDI0382, a GLP-1/GLucagon Receptor Dual Agonist, on Weight Loss in Male ob/ob Mice. STEPHANIE OLDHAM, CHRISTOPHER D. CHURCH, SARAH WILL, ANISH KONKAR, JAMES TREVASKIS, GRAEME R. DAVIES, Gaithersburg, MD, Cambridge, United Kingdom, Frankfurt, Germany

1891-P MEDI0382, a GLP-1/GLucagon Receptor Dual Agonist, Acutely Inhibits Food Intake in Leptin-Deficient ob/ob Mice and Leptin Receptor-Deficient fa/fa Rats. VICTOR G. HOWARD, STEPHANIE OLDHAM, ANISH KONKAR, JAMES TREVASKIS, SARAH WILL, Gaithersburg, MD, Frankfurt, Germany

1892-P Diabetes Prevention Using a Simulation Model That Explains Individual Variability in Response to Diet Change. JULIA H. CHEN, MOMOKO FUKASAWA, QIAN CHEN, SAMUEL P. BURNS, KEI KUMAR, SHINSUKE NIRENGI, SR., KARU TAKAHASHI, AKIKO SUGANUMA, HIDESHI KUZUYA, NAOKI SAKANE, GAURAV DWIVEDI, New York, NY, Tokyo, Japan, Jersey City, NJ, Philadelphia, PA, Kyoto, Japan, Boston, MA
1893-P Comparison of Dietary Fat Intake Using Food Records vs. RBC Fatty Acid Biomarkers in a Multiethnic Population—The Federal Women Study. AMBER B. COURVILLE, SHANNA BERNSTEIN, MIRELLA GALVAN-DE LA CRUZ, ANTHONY ONUZURUIKE, NIRUPA R. MATTHAN, ALICE H. LICHTENSTEIN, ANNE E. SUMNER, STEPHANIE T. CHUNG, Bethesda, MD, Boston, MA

1894-P The Different Effects of Sodium Glucose Cotransporter 2 Inhibitor on Obese Diabetic Mice Fed a Normal or Low-Carbohydrate Diet. FUTOSHI FURUYA, YOSHIIITO FUJITA, NAOMI MATSUO, YASUO OGURI, HIROTO MINAMINO, KAORI IKEDA, SHINICHI HARASHIMA, YU WANG, YANYAN LIU, NOBUYA INAGAKI, Kyoto, Japan

1895-P Dietary Supplementation with Galactooligosaccharide (GOS) Attenuates High-Fat, High-Cholesterol Containing Western Diet (WD)-Induced Glucose Intolerance. HONGLIANG HE, SID-DHARTHA S. GHOSH, PAUL J. YANNIE II, JING WANG, SHOBHA GHOSH, Richmond, VA

1896-P Effects of Sucrose vs. Fructose-and-Glucose Intakes on Gut Abundance of Akkermansia Muciniphila and Serum Kidney Injury Molecule-1 in Rats. GRZEGORZ WYSTRYCHOWSKI, EWA PIKULSKA-CHROBAK, JAKUB WOJCIK, MAGDALENA KOZUBSKA, WANDA TRAUTSOLT, SYLVIA GORCZYNSKA-KOSIORZ, ROMAN KUJWIECZ, EWA ZUKOWSKA-SZCZEWSKA, WLADYSLAW GRZESZCZAK, ANTONI WYSTRYCHOWSKI, Zabrze, Poland, Katowice, Poland, Sosnowiec, Poland, Debowiec, Poland

1897-P White- and Brown-Rice Supplementation Improves Insulin Tolerance, Brown Fat Activation, Energy Expenditure, and Changes the Gut Microflora in Diet-Induced Obesity. HIASHI YOKOMIZO, ATSUSHI ISHIKADO, TAKANORI SHINJO, KYOUNGMIN PARK, YASUTAKA MAEDA, I-HSIEN WU, DAVID M. POBER, SUZANNE DEVKOTA, MOTONOBU MATSUMOTO, ALEKSANDAR KOSTIC, GEORGE L. KING, Boston, MA, Takatsuki, Japan, Los Angeles, CA

1898-P The Effect of Nutritional Transition on the Differentiation of Bone Marrow Stem Cells and the Therapeutic Effect of GLP-1. WENFANG XIA, LULU CHEN, QING ZHANG, Wuhan, China

1899-P Angiotensin-Converting Enzyme 2 Deficiency Increases Translocation of Gut Bacteria by Depletion of Bone Marrow-Derived Circulating Angiogenic Cells. YAOQING DUAN, DONGNI FENG, ELENI BELI, SERGIO LI CALZI, ANA LEDA F. LONGHINI, REGINA LAMENDELLA, JUSTIN R. WRIGHT, TROY A. MARKEL, ALEXANDER G. OBUKHOV, MARIA B. GRANT, Indianapolis, IN, Birmingham, AL, Huntingdon, PA

1900-P Westernized Diet-Induced Insulin Resistance in Mice Is Associated with Focal Duodenal Hyperplasia. SOUMITRA GHOSH, FRANCESCO RUBINO, PERNILLE WISMANN, KRISTOFFER RIBGOLT, HARITH RAJAGOPALAN, DAVID MAGGS, San Diego, CA, London, United Kingdom, Harsholm, Denmark, Lexington, MA

1901-P Txnip Deficiency in the Intestinal Epithelial Cells Prevents against the High-Fat Diet-Induced Fructose Uptake. ANU SHAH, SEZIN DAGDEVIREN, HENNA HUNDAL, RICHARD LEE, Cambridge, MA

INTEGRATED PHYSIOLOGY—MUSCLE

Moderated Poster Discussion: Integrated Physiology of Muscle (Posters: 1902-P to 1907-P), see page 157.

1902-P Potential Autocrine Effects of Type 2 Diabetes-Related Myokines on Human Skeletal Muscle. YIFAT AMIR LEVY, THEODORE P. CIARALDI, SUDDER MUDALIAR, ROBERT R. HENRY, San Diego, CA, La Jolla, CA

1903-P Overexpression of Perilipin 2 Induces Cardiac Steatosis and Atrial Fibrillation via Connexin 43 Remodeling. SATOSHI SATO, JINZA SUZUKI, MASAMICHI HIROSE, TAKAHIRO NAKAYA, MIKA YAMADA, MAI ICHIKAWA, MICHIKO IMAGAWA, YASUO ZENIMARU, SADAO TAKASHASHI, TADASHI KONOSHITA, TAMOTSU ISHIZUKA, Fukui, Japan, Iwate, Japan, Saitama, Japan, Stanford, CA

1904-P The Sarcoplasmic Reticulum Calcium ATPase Pump Is a Major Regulator of Whole-Body Glucose Metabolism. ZAHRA MARIA, ALLISON CAMPOLO, SHANELL HOOP GRAY, STEVEN HARTSON, VERONIQUE LACOMBE, Stillwater, OK

1905-P Cause of Hyperglycemia in Postmenopausal Underweight Women with Impaired Glucose Tolerance. RURIKO SUZUKI, YOSHIFUMI TAMURA, YUKI SOMAYA, HIDEYOSHI KAGA, DAISUKE SUGimoto, SATOSHI KADOKAWA, SAORI KAKEHI, KAGEUMI TAKENO, TAKASHI FUNAYAMA, YASUHIKO FURUKAWA, JUNKO SATO, RUZO KAWAMORI, HIROTAKA WATADA, Tokyo, Japan, Izuokunishi, Japan
1906-P  ◀️ Heart-Specific Overexpression of HMG-CoA Synthase 2 Induces Mitochondrial Stress—Adaptation via the ATF4 Pathway. YASUO ZENIMARU, JINYA SUZUKI, TAKAHIRO NAKAYA, MIKA YAMADA, MAI ICHIKAWA, SATSUKI SATO, MICHIKO IMAGAWA, FREDRIC B. KRAEMER, TADASHI KONOSHITA, TAMOTSU ISHIIZUKA, Fukui, Japan, Stanford, CA

1907-P  ▶️ Exercise Is Required to Improve Mitochondrial Respiratory Capacity in Skeletal Muscle of Older Obese Subjects during Calorie Restriction-Induced Weight Loss to Improve Insulin Sensitivity. GIOVANNA DISTEFANO, ROBERT STANDLEY, JR., ELVIS A. CARNERO, PAUL M. COEN, RICK B. VEGA, BRET H. GOODPASTER, Orlando, FL

1908-P Long-Term Insulin Treatment Alters Muscle-Related Protein in OLETF Rat Skeletal Muscle. HYUK-SANG KWON, OAKKEE HONG, HEE SUN KWON, YANGGYO KANG, SEONG-SU LEE, SUNG RAE KIM, SOON JIB YOO, Seoul, Republic of Korea, Bucheon, Republic of Korea, Busan, Republic of Korea

1909-P Co-administration of GLP-1 and Y2R Receptor Agonists Synergize to Promote Muscle Glucose Uptake and Induce Diabetic Remission. BRANDON BOLAND, VICTOR G. HOWARD, MICHELLE BEATON, SARAH WILL, STEPHANIE OLDHAM, JAMES TREVASKIS, CHRISTOPHER J. RHODES, JOE GRIMSBY, Gaithersburg, MD

1910-P Hyperglycemia Promotes Muscle Atrophy through the WWP1/KLF15 Pathway. YU HIRATA, KAZUHIRO NOMURA, YOKO SENGU, MICHIIHIRO IMAMURA, SHIN’ICHI TAKEDA, YUKO OKADA, STEVEN J. BURDEN, TETSUYA HOSOKOA, WATARU OGAWA, Kobe, Japan, Kodaira, Japan, New York, NY

1911-P Exogenous Delta-Like 1 Homolog (DLK1)-Fc Treatment Attenuates Muscle Atrophy in Both Dexamethasone and High-Fat Diet-Induced Obesity Mice Models. JI YOUNG LEE, MINYOUNG LEE, HYE-IN JUNG, JI-YEON LEE, YONG-HO LEE, BONG-SOO CHA, Seoul, Republic of Korea

1912-P Iron Overload Plays an Important Role in ER Stress-Induced Insulin Resistance in Human Skeletal Muscle Cells. Kwanwoo Lee, RiJuA Cui, Dae Jung Kim, SunGe Choi, WHA Joung Lee, YUP Kang, Tae Ho Kim, Hyun UK Moon, Ja Young Jeon, Seung Jin Han, Hae Jin Kim, Suwon, Republic of Korea, Seoul, Republic of Korea

1913-P Prokineticin Receptor 1 Activation Induces Myogenesis and Ameliorates Insulin Resistance in Mouse Skeletal Muscle Cells. Mok JongSoO, Joonghoon Park, Pyeongchang, Republic of Korea, Kangwon, Republic of Korea

1914-P Clinical Significance of Insulin Sensitivity in Adipose Tissue in Apparently Healthy Nonobese Men. DAISUKE SUGIMOTO, YOSHIFUMI TAMURA, KAGEUMI TAKENO, HIDEYOSHI KAGA, YUKI SOMEYA, RURIKO SUZUKI, SATOSHI KADOWAKI, YASUHIKO FURUKAWA, HYUNUK KANG, HAE JIN KIM, Seoul, Republic of Korea

1915-P Mitochondrial Adaptation in Insulin Resistant Human Skeletal Muscle. CHRISTOPHER L. AXELROD, CIARAN E. FEALY, ANNY MULYA, EMILY HUANG, HISASHI FUJIOKA, BARTOLOME BURGUERA, CHARLES L. HOPPEL, JOHN P. KIRWAN, Baton Rouge, LA, Cleveland, OH

1916-P Age-Related Attenuation of Aerobic Exercise Training Adaptation in 24-Week Old Rats. REBECCA L. CALZO, GRAHAME F. EVANS, SARA E. HULL, LESLIE KNAUB, LORI A. WALKER, JANE E. REUSCH, Aurora, CO, Durham, NC, Denver, CO

1917-P Skeletal Muscle Clock Is Essential for Nutrient-Sensing and Interorgan Metabolic Fuel Partitioning. KE MA, SOMIK CHATTERJEE, HONGSHAN YIN, Duarte, CA, Houston, TX, Shijiazhuang, China

1918-P Effects of Diet/Exercise and Pioglitazone on the Association between Fitness and Intramyocellular FFA Trafficking. SAMYAH SHADID, ENDOCRINE RESEARCH UNIT, MAYO CLINIC, ROCHESTER, MN

1919-P Naturopetric Peptide Deficiency Causes Skeletal Muscle Insulin Resistance in Mice. CEDRIC MORO, Toulouse, France

1920-P Effects of Hyperglycemia on Skeletal Muscle Glucose Metabolism in Healthy Subjects. CHRIS SHANNON, AURORA MEROCVI, DEVJIT TRIPATHY, MUHAMMAD ABDUL-GHANI, LAKE NORTON, RALPH A. DEFRONZO, San Antonio, TX

1921-P Sarcolipin, an Uncoupler of SERCA, Protects Against Lipotoxicity and Insulin Resistance. SANTOSH K. MAURYA, Orlando, FL
1922-P NFκB Regulation of Mitochondrial Function in Skeletal and Cardiac Muscle. JOE VALENTINE, MENGYAO E. LI, NING ZHANG, STEVEN E. SHOELSON, NICOLAS MUSI, San Antonio, TX, Boston, MA

1923-P Diabetes and High-Fat Diet Induce Different Pathologies in Mouse Skeletal Muscle Extracellular Matrix. SERGIO F. MARTINEZ-HUENCHULLAN, LINDA A. BAN, ANH TAO, SURYA S. SUTANTO, CHARMAINE TAM, SUSAN MCLNNAN, STEPHEN M. TWIGG, Sydney, Australia

1924-P Multivitamin Reproducibility of Clamp-Derived Insulin Sensitivity in Free-Living Humans—Association with Incident Prediabetes in the POP-ABC Study. NKIRU A. UMKEW, DEIRDRE J. JAMES, SAMUEL DAGOGO-JACK, Memphis, TN

1925-P Skeletal Muscle Dysfunction and Metabolic Abnormalities in Individuals with Familial Partial Lipodystrophy Is Associated with Diminished Mitochondrial Fatty Acid Oxidation. VINAYA SIMHA, IAN R. LANZA, NATHAN LEBRASSEUR, KATHERINE KLAUS, JOHN PORT, MARCELLO C. LAURENTI, CLAUDIO COBELLI, K. SREEKUMARAN NAIR, Rochester, MN, Albuizzazione, Italy, Padova, Italy

1926-P Skeletal Muscle Lipid Composition Parallels Clinical Phenotype Extremes. LISA S. CHOW, DOUGLAS G. MASHEK, TYLER BOSCH, ANNE BANTLE, MAI PETTerson, DONALD R. DENGEL, MICHAEL D. JENSEN, Minneapolis, MN, Rochester, MN

1927-P Febuxostat Improves Insulin Resistance in the Skeletal Muscle In Vitro and In Vivo. CHIHIRO T. MORIYA, HIROAKI SATOH, HIROTAKA WATADA, Tokyo, Japan

1928-P Mechanism Underlying the Biphasic Effect of ADP on Succinate-Energized Muscle Mitochondrial Respiration. BRIAN FINK, LIPING YU, WILLIAM SIVITZ, Iowa City, IA

1929-P Prdx6 Prevents Diabetic Myopathy by Improving Skeletal Muscle Cell Differentiation. FRANCESCA PACIFICI, BARBARA CAPUANI, FRANCESCA PIEMARINI, DONATELLA PASTORE, ROBERTO ARRIGA, ANDREA COPPOLA, SILVIA REA, GIULIA DONADELL, ALFONSO BELLIA, DAVID DELLA-MORTE, DAVIDE LAURO, Rome, Italy

1930-P Mitophagy Receptor FUNDC1 Links Mitochondrial Quality Control to Muscle-Adipose Dialogue in Alleviating Dietary Obesity. TINGTING FU, ZHISHENG XU, LIN LIU, XIUJUN LIANG, DANXIA ZHOU, QIQI GUO, LIWEI XIAO, ZHENJI GAN, Nanjing, China

1931-P Serum Creatinine Progressively Decreases with Obesity and Type 2 Diabetes in Nonhuman Primates. UDDHAV K. CHAUDHARI, JENNIFER D. NEWCOMB, BARBARA C. HANSEN, Mumbai, India, Tampa, FL

1932-P Transient Activation of Skeletal Muscle Rac1 in Obesity-Related Insulin Resistance. HARRISON D. STIERWALT, BRYAN BERGMAN, SARAH E. EHRlicher, MATTHEW M. ROBINSON, SEAN A. NEWSOM, Corvallis, OR, Aurora, CO

1933-P Metabolomic Signatures of Insulin Resistance in Human Skeletal Muscle Are Exacerbated with Insulin Stimulation. SEAN A. NEWSOM, LEIGH PERREaut, ANNA KEREGE, KATHLEEN A. HARRISON, DARCY E. KAHN, TRAVIS NEMKOV, ANGELO D’ALESSANDRO, BRYAN BERGMAN, Corvallis, OR, Aurora, CO

1934-P Mitochondrial Function in High-Fat Fed and Exercise-Trained Mice Unable to Induce Autophagy. SARAH E. EHRlicher, HARRISON D. STIERWALT, SEAN A. NEWSOM, MATTHEW M. ROBINSON, Corvallis, OR

1935-P Deoxysphingolipids—Novel Skeletal Muscle Lipids Related to Insulin Resistance in Humans That Decrease Insulin Sensitivity In Vitro. SIMONA ZARINII, LEIGH PERREaut, SEAN A. NEWSOM, DARCY E. KAHN, ANNA KEREGE, KATHLEEN A. HARRISON, BRYAN BERGMAN, Aurora, CO, Corvallis, OR

1936-P Weight Loss and Exercise Decrease Saturation of Intramyocellular Lipid Species in Association with Improvements in Insulin Sensitivity. ROBERT STANDLEY, PAUL M. COEN, BRET H. GOODPASTER, Orlando, FL

1937-P Skeletal Muscle Mitochondrial Fission Is Increased after an Overnight Lipid Infusion in Healthy Humans. CIARAN E. FEALY, CHRISTOPHER L. AXELROD, MELISSA L. ERICKSON, EMILY HUANG, ADITHYA HARI, ANNY MULYA, HISASHI FUJIOKA, CHARLES L. HOPPEL, JOHN P. KIRwan, Cleveland, OH, Baton Rouge, LA
### INTEGRATED PHYSIOLOGY—OTHER HORMONES

<table>
<thead>
<tr>
<th>Posters</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1938-P</td>
<td>Circulating Pigment Epithelium-Derived-Factor Levels—Hyperglycemia vs. Insulin Resistance.</td>
<td>RAELENE E. MASER, JAMES LENHARD, RYAN POHLIG, P. BABU BALAGOPAL, Newark, DE, Wilmington, DE, Jacksonvill, FL</td>
</tr>
<tr>
<td>1939-P</td>
<td>Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption.</td>
<td>NATASHA C. BERGMANN, ASGER B. LUND, SEBASTIAN M. HEIMBÜRGER, LENE JESSEN, MIKKEL B. CHRISTENSEN, TINA VILSBØLL, FILIP K. KNØP, Gentofte, Denmark, Hellerup, Denmark, Glosstrup, Denmark, Copenhagen, Denmark</td>
</tr>
<tr>
<td>1940-P</td>
<td>Contribution of Pancreatic Alpha-Cell Function to Insulin Sensitivity and Glucose Variability in Type 1 Diabetes Patients.</td>
<td>NOBUYUKI TAKAHASHI, DAISUKE CHUJO, HIROSHI KAJIO, KOHJIRO UEKI, Shinjuku, Japan</td>
</tr>
<tr>
<td>1941-P</td>
<td>Assessment of Fasting Glucagon Levels in Subjects with Diabetes and Healthy Controls Using ELISA and RIA.</td>
<td>MARTINA BRUNNER, MAXIMILIAN HABERLANDER, EVA SVELIKOVA, KATHARINA EBERHARD, ELISABETH STACH, ROBERT LIPP, BARBARA M. OBERMAYER-PIETSCH, THOMAS R. PIEBER, HARALD SOURIJ, Graz, Austria</td>
</tr>
<tr>
<td>1942-P</td>
<td>Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition.</td>
<td>SOFIE HAEDERSDAL, ASGER B. LUND, HENRIK MAAGENSEN, ELISABETH NIELSEN-HANNERUP, JENS J. HOLST, FILIP K. KNØP, TINA VILSBØLL, Copenhagen, Denmark, Gentofte, Denmark, Hellerup, Denmark</td>
</tr>
<tr>
<td>1943-P</td>
<td>The Association between the Adipokine C1QTNF1 and Type 2 Diabetes Is Significantly Modulated by Obesity.</td>
<td>KATHRIN GEIGER, AXEL MUENDLEIN, ANDREAS LEHERER, CHRISTOPH H. SAEY, JANINE EBNER, ÉVA-MARIA BRANDTNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, HEINZ DRESKEL, Feldkirch, Austria, Triesen, Liechtenstein, Berne, Switzerland, Philadelphia, PA</td>
</tr>
<tr>
<td>1944-P</td>
<td>Risk of Breast Cancer According to Glycaemia and HbA1c Concentration—A Meta-analysis of Prospective Studies.</td>
<td>ALINA MACACU, CECILE PIZOT, PETER BOYLE, PHILIPPE AUTIER, Écully, France, Lyon, France</td>
</tr>
<tr>
<td>1945-P</td>
<td>Endo Soc-3- Decrease in AMP Kinase Expression and Activity in Diabetic Patients with Hypogonadism—Increase Following Testosterone Supplementation.</td>
<td>SANDEEP DHINDSA, HUSAM GHANIM, MANAV BATRA, AJAY CHAUDHURI, SANAA ABAJUSSHEH, PARESH DANDONA, St. Louis, MO, Buffalo, NY, Williamsville, NY</td>
</tr>
<tr>
<td>1946-P</td>
<td>Hepatic Insulin Clearance Is Increased in the Patients with Poorly Controlled Type 2 Diabetes.</td>
<td>TSUYOSHI OKURA, MARI ANNO, YUICHI ITO, SR., Yonago, Japan</td>
</tr>
<tr>
<td>1947-P</td>
<td>Metabolomics Shows an Association of Betatrophin with Bile Acids, Suggesting an Involvement of Betatrophin in Bile Acid-Mediated Metabolic Control.</td>
<td>ANDREAS LEHERER, AXEL MUENDLEIN, KATHRIN GEIGER, CHRISTOPH H. SAEY, JANINE EBNER, BARBARA LARCHER, ARTHUR MADER, PETER FRAUNBERGER, HEINZ DRESKEL, Triesen, Liechtenstein, Feldkirch, Austria, Berne, Switzerland, Philadelphia, PA</td>
</tr>
<tr>
<td>1948-P</td>
<td>Lactobacillus Gasseri in the Upper Small Intestine Impacts an ACSL3-Dependent Fatty Acid Sensing Pathway That Regulates Whole-Body Glucose Homeostasis.</td>
<td>PAIGE V. BAUER, FRANK DUCA, T.M. ZAVED WAISE, HELEN J. DRANSE, BRITTANY A. RASMUSSEN-SMALL, AKSHITA PURI, MOZHGAN RASTI, TONY K.T. LAM, Toronto, ON, Canada, Tucson, AZ</td>
</tr>
<tr>
<td>1949-P</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>1950-P</td>
<td>Comparative Study on Glucose Metabolism Before and After Surgery in Patients with Adrenal Cushion’s Syndrome.</td>
<td>KENGO MIYOSHI, YUYA TSURUTANI, AKIHIKO SUZUKI, TOMOKO TAKIGUCHI, CHIHO SUGISAWA, JUN SAITO, TETSUO NISHIKAWA, Yokohama, Japan</td>
</tr>
<tr>
<td>1951-P</td>
<td>Roles of Adipose Tissue VLDL-VLDLR Axis in Energy Metabolism.</td>
<td>JAE BUM KIM, KYUNG CHEUL SHIN, INJAE HWANG, SUNG SIK CHOE, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>1952-P</td>
<td>Regulation of Lipid Regulator ANGPTL8 Gene Transcript by Insulin Is Mediated by C/EBPβ, and ANGPTL8 Deficiency Improves Glucose Homeostasis in Mice.</td>
<td>LU ZHANG, MUHAMMAD ABDUL-GHANI, RALPH A. DEFRONZO, LUKE NORTON, San Antonio, TX</td>
</tr>
</tbody>
</table>
1953-P Fasting Glucagon Concentrations Predict Longitudinal Changes in β-Cell Function of Nondiabetic Humans. J.D. ADAMS, MARCELLO C. LAURENTI, MARIA D. HURTADO, CHIARA DALLA MAN, CLAUDIO COBELLI, ROBERT A. RIZZA, ADRIAN VELLA, Rochester, MN, Albuzzano, Italy, Padova, Italy

1954-P Exenatide and Saxagliptin Do Not Attenuate NFκB-Induced Inflammation in Prediabetic Humans. ABSALON D. GUTIERREZ, JR., KARLA BERMEUDEZ, VALA HAMIDI, KAYLA RIGGS, SARA COVERDALE, AMY DURST, NITYA K. KUMAR, MONIKA RUSCHEINSKY, Houston, TX, San Diego, CA, Dallas, TX

1955-P SGLT1 in Pancreatic α Cells Regulates Glucagon Secretion in Mice, Possibly Explaining the Distinct Effects of SGLT2 Inhibitors on Plasma Glucagon Levels. TAKAYOSHI SUGA, OSAMU KIKUCHI, MASAKI KOBAYASHI, SHO MATSUBA, HIROMI H. HASHIMOTO, TSUTOMU SASAKI, SATORU KAKIZAKI, MASANOBU YAMADA, TADAHIRO KITAMURA, Maebashi, Japan

1956-P Effects of Simple Carbohydrates on GLP-1 Responses in Gastric Bypass Patients and Matched Controls. CHRISTOFFER MARTINUSSEN, KIRSTINE N. BOJSEN-MOLLER, CARSTEN DIRKSEN, MARIA S. SVANE, JENS J. HOLST, STEN MADSBAD, SR., Copenhagen, Denmark, Hvidovre, Denmark

1957-P Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Prostate Cancer Cell Proliferation via Phosphorylation of MKP-1. TAKAKO KAWANAMI, TAKASHI NOMIYAMA, YURIKO HAMAGUCHI, TOMOKO TANAKA, TOSHIHIKO YANASE, Fukuoka, Japan

1958-P Forced Expressed GLP-1R Attenuates Prostate Cancer Growth. TORU SHIGEOKA, TAKASHI NOMIYAMA, TAKAKO KAWANAMI, YURIKO HAMAGUCHI, TOMOKO TANAKA, TOSHIHIKO YANASE, Fukuoka, Japan

1959-P The Hyperinsulinemic Isoglycemic Hyperlactemic Clamp. DMITRY ZARETSKY, ANDREW A. YOUNG, Durham, NC

1960-P The Simultaneous Changes of Endogenous Glucose Production, Postprandial Glucagon, and Fasting Glutamine during Weight Loss in Type 2 Diabetes. JULIA OTTEN, ANDREAS STOMBY, MARIA WALING, ELIN CHORELL, MATS RYBERG, MICHAEL B. SVENSSON, JENS J. HOLST, TOMMY OLSSON, Umeå, Sweden, Jönköping, Sweden, Copenhagen, Denmark


1962-P GLP-1 Integrates the Innate Immune System to Glucose Homeostasis. ELLEN M. DAVIS, CHELSEA HUTCH, KI-SUK KIM, BASMA MAERZ, KAREN J. ROELOFS, MICHAEL LEHRKE, DARLEEN A. SANDOVAL, Ann Arbor, MI, Allen Park, MI, Aachen, Germany

1963-P Glucagon-Like Peptide-1 Is a Significant Determinant of the Second-Meal Effect in Patients with Type 2 Diabetes. SIGRID BERGMANN, NATASHA C. BERGMANN, LÆRKE S. GASBJERG, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP, Hellerup, Denmark, Copenhagen, Denmark, Gentofte, Denmark

1964-P The Role of Visceral Adipocytes in Adrenergically Stimulated Adiponectin Secretion. SALIHA MUSOVIĆ, SANDRA NGUYEN, CHARLOTTE S. OLOFSSON, Gothenburg, Sweden

1965-P Gastrin—A Potential Predictor of Glucoregulation in Newly Diagnosed Type 2 Diabetes Patients. MAJA CIGROVSKI BERKOVIĆ, DAVORKA HERMAN MAHEČIĆ, INES BILCIC-CURCIC, Zagreb, Croatia

1966-P miR-494 Regulates Mitochondrial Biogenesis and Thermogenesis through PGC1-α Signaling in Beige Adipocytes. MENGISTU LEMECH, KATSUTARO MORINO, TAKESHI IMAMURA, HIROTAKA IWASAKI, NATSUO OHASHI, HIROTAKA YAMAMOTO, SATOSHI UGI, HIROSHI MAEGAWA, Otsu, Japan, Yonago, Japan

1967-P Insulin-Like Growth-Factor Axis Collectively Identifies Pre-Type 1 Diabetes. MELANIE SHAPIRO, CLIVE WASSERFALL, ANDREW R. SCHULTZ, SEAN M. MCPHAIL, MICHAEL J. HALLER, DESMOND SCHATZ, MARK A. ATKINSON, TODD M. BRUSKO, Gainesville, FL

1968-P GLP-1 Secretion Is Increased upon Blockade of the Somatostatin Receptor Subtype 2 and 5 Resulting in GLP-1 Receptor-Mediated Lowering of Blood Glucose in Mice. SARA L. JEPSEN, NICOLAI J. WEVER ALBRECHTSEN, JENS PEDERSEN, MAJA S. ENGELSTOFT, CAROLYN F. DEACON, JENS J. HOLST, Copenhagen, Denmark, New York, NY
1969-P The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes. LAURA S. HANSEN, LÆRKE S. GASBJERG, ANDREAS BRØNDEN, NIELS B. DALSGAARD, EMILIE BAHNE, PERNILLE H. SØRENSEN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNØP, Gentofte, Denmark, Copenhagen, Denmark, Hellerup, Denmark

1970-P Exendin-4, but Not Oleylethanolamide, Promotes Host-Mediated Alterations to the Gut Microbiome during Weight Loss. JACOB BROWN, VANDANA SHARMA, DAVID TRAN, SCOTT N. PETERSON, JULIO AYALA, Nashville, TN, La Jolla, CA

1971-P In Insulin-Resistant Subjects, Islet Functional Changes Might Represent an Attempt to Increase the Incretin Effect. TERESA MEZZA, SIMONA MOFFA, GIAN PIO SORICE, CHIARA MARIA ASSUNTA CEFALO, FRANCESCA CINTI, ANDREA MARI, ANDREA GIACCA, Rome, Italy, Padova, Italy

1972-P Association Between Body Fat Mass and Plasma Insulin Level in the Male Patients with Idiopathic Hypogonadotropic Hypogonadism and Normal Glucose Tolerance. XUBIN YANG, QIONGYAN LIN, XILING HU, WEN XU, HONG R. DENG, Guangzhou, China

1973-P Chronic Fructalkine Administration Exerts Durable Effects to Improve Glucose Tolerance with Specific Effects to Pancreatic Endocrine Function. YUN SOK LEE, La Jolla, CA

1974-P The Influence of Metabolic Surgery and Endoscopy on Serum Proteome in Subjects with Obesity and Type 2 Diabetes Mellitus. MILOS MRAZ, KAREL HARANT, HELENA KRATOCHVILOVA, ANNA CINKAJZLOVA, JANA KLOUCKOVA, PETRA KAVÁLKOVA, ZDENKA LACINOVÁ, MAREK BENES, ZUZANA VLASAKOVA, KARIN DOLEZALOVA, MARTIN FRIED, TEREZIE PELIKANOVA, MARTIN HALUZIK, Prague, Czech Republic

1975-P Improvement of Insulin Resistance and Cardiovascular Risk Factors with Treatment of Subclinical Hypothyroidism in Patients with Autoimmune Thyroiditis. CELESTINO NEVES, SOFIA C. OLIVEIRA, JOÃO SER NEVES, MIGUEL G. PEREIRA, OKSANA SOKHATSKA, ANA OLIVEIRA, JOSÉ LUIZ MEDINA, LUIS DELGADO, DAVIDE M. CARVALHO, Porta, Portugal

1976-P Iron Downregulates Leptin by Decreasing CREB O-GlcNAc Modification and CREB Occupancy of the Leptin Promoter. YOSHIRO KITAHARA, HARUKA KAWANABE, MAI HASUMURA, YUSUKE IWAI, YORIKO OKAMATSU, Kawasaki, Japan

1977-P The Preprohormone Expression Profile of Enteroendocrine Cells following Roux-en-Y Gastric Bypass in Rats. LISE BIEHL RUDKJAER, CHEN ZHANG, KRISTOFFER RIGBOLT, SOREN L. PEDERSEN, MECHTHILDE FALKENHAHN, THORSTEN SCHMIDT, NIELS VRANG, JACOB JELSING, Harsholm, Denmark, Frankfurt, Germany

OBESITY—ANIMAL

Moderated Poster Discussion: Obesity Pathogenesis and Treatment—Insights from Animal Studies

1978-P Glucagon-Receptor Signaling Regulates Mitochondrial Bioenergetics via Hepatic Farnesol X Receptor. TEAYOUN KIM, SHELLY NASON, JESSICA P. ANTIPENKO, CATHERINA S. VESTRI, KELLEY SMITH-JOHNSON, MARK E. PEPIN, ADAM R. WENDE, BRIAN FINAN, RICHARD DIMARCHI, DIEGO PEREZ-TILVE, DOUGLAS R. MOELLERING, KIRK M. HABEGGER, Birmingham, AL, Helena, AL, Indianapolis, IN, Bloomington, IN, Cincinnati, OH

1979-P Peripheral Melanocortin 3 Receptor (MC3R) Regulates Hepatic Autophagy in Obesity. YOO JUN JUN, ARNOLD Y. SEO, TUSHAR P. PATEL, ANDREW J. UHLMAN, NOAH J. LEVI, ROBIN ROBERSON, JACK A. YANOFSKY, Bethesda, MD, Ashburn, VA

1980-P Enterohepatic Circulation of Bile Acids Is Activated by Bariatric Surgery before Weight Loss Becomes Apparent. YOSHIRO KITAHARA, HARUKA KAWANABE, MAI HASUMURA, YUSUKE IWAI, YORIKO OKAMATSU, Kawasaki, Japan

1981-P The Preprohormone Expression Profile of Enteroendocrine Cells following Roux-en-Y Gastric Bypass in Rats. LISE BIEHL RUDKJAER, CHEN ZHANG, KRISTOFFER RIGBOLT, SOREN L. PEDERSEN, MECHTHILDE FALKENHAHN, THORSTEN SCHMIDT, NIELS VRANG, JACOB JELSING, Harsholm, Denmark, Frankfurt, Germany

1982-P APPL2 Promotes Inflammation in Mouse Liver by Negative Regulation of Adiponectin Signaling. JIYOON RYU, San Antonio, TX
1983-P ▲ The Regulation of BRD7 in the Insulin Signaling Pathway. SANG PARK, YOUNGAH HAN, MARIO A. SALAZAR HERNANDEZ, Boston, MA

1984-P The Transcription Factor ETV5 Regulates Adipogenesis through PPARg Signaling Pathway. ZHUO MAO, Shenzhen, China

1985-P Berberine Hydrochloride Protects Cytokine-Induced Inflammation through Multiple Pathways. ANIL POUDEL, JOSEPH ZHOU, SCOTT MASSEY, LIXIN LI, Auburn, AL, Mount Pleasant, MI, Lake Isabella, MI

1986-P Vitamin D3 Alleviates High-Fat Diet-Induced Endoplasmic Reticulum Stress and Insulin Resistance in Mice. LU LIU, XIAOHUA LI, Shanghai, China

1987-P ▲ Endothelial ULK1 Regulates High-Fat Diet-Induced Obesity via FGF-21. MANNA LI, MING QIAN, JIAN XU, Oklahoma City, OK

1988-P Anorexic Peptide Nesfatin-1 Exerts Vasoprotective Effects in Injured Arteries of Mice. YUSAKU MORI, HIROYUKI SHIMIZU, HIDEKI KUSHIMA, MICHISHIGE TERASAKI, MUNENORI HIROMURA, MASAKAZU KOSHIBU, KYOKO KOHASHI, TSUTOMU HIRANO, Tokyo, Japan, Maebashi, Japan

1989-P Loss of Fractalkine-CX3CR1 Signaling Exacerbates Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance through M1 Dominant Shift in Macrophages. MAYUMI NAGASHIMADA, YINHUA NI, TSUGUHITO OTA, Kanazawa, Japan, Hangzhou, China, Asahikawa, Japan

1990-P Bofutsushosan Improves Gut Barrier Function with a Bloom of Akkermansia Muciniphila and Improves Glucose Metabolism in Diet-Induced Obese Mice. SHIHO FUJISAKA, ISAO USUI, ALLAH NAZ, YOSHIKOSHI IGARASHI, TOMONOBU KADO, KEISUKE OKABE, YOSHIHIRO OGAWA, KAZUYUKI TOBE, Toyama, Japan, Shimotsuga, Japan

1991-P Glycolytic Activation Promotes PDGF-B Production in Adipose Tissue Macrophages during Obesity Development. YASUHIRO ONOGI, TSUTOMU WADA, TAKATOSHI MATSUZAWA, AKIRA OKEKAWA, ERI WATANABE, HIROSHI TSUNEKI, TOSHIYASU SASAOKA, Toyama, Japan

1992-P WITHDRAWN

1993-P Deficiency of Melanocortin 4 Receptor Promotes Vascular Vulnerability in Mice. KENTARO MORI, KIOICHIRO TSUCHIYA, SUGURU NAKAMURA, YASUTAKA MIYACHI, KUMIKO SHIBA, YOSHIHIRO OGAWA, KENICHIRO KITAMURA, Chuo, Japan, Kofu, Japan, Tokyo, Japan, Fukukota, Japan

1994-P ILDR2 Alters Hepatic Phospholipid Composition via MBOAT7—Effects on Liver Fat. KAZUHISA WATANABE, KAZUHIRO NAKAYAMA, KEN YOSHIDA, ELIZABETH J. MILLINGS, CHARLES A. LEDUC, RUDOLPH LEIBEL, SADAHIKO IWAMOTO, Chuo, Japan, Kofu, Japan, Tokyo, Japan, New York, NY

1995-P Sennoside A Improves Mitochondrial Function of Large Intestine in Diet-Induced Obese Mice to Preserve GLP-1 Expression through Induction of Short-Chain Fatty Acids. JIAMING YE, YONGNING SUN, Shanghai, China, Baton Rouge, LA

1996-P The Role of a Glucagon-Like Peptide-1 Receptor Agonist in Visceral and Subcutaneous Fat Redistribution. LI ZHAO, CHUNFANG ZHU, MENG LU, CHI CHEN, YINGLI LU, Shanghai, China

1997-P Continuous Subcutaneous Delivery of a Glucagon Analog, ICA6150349, to Rats and Nonhuman Primates Demonstrates Safety and Tolerability in a 14-Day Toxicity Study. DORIS ZANE, RONALD SINGH, JOSEPHINE SHELTON, SHANE ROLLER, MARK PAULIK, JAMES WAY, WILLIAM C. BLACKWELL III, VED SRIVASTAVA, REBECCA HODGE, PAUL L. FELDMAN, THOMAS R. ALESSI, Hayward, CA, Research Triangle Park, NC, Durham, NC

1998-P ICA6150349, a Highly Selective Glucagon Agonist, in Combination with Exenatide Significantly Reduces Weight and Glucose in Obese and Diabetic Rats. MARK PAULIK, TOM TLUSTY, MARY K. GRIZZLE, MARCI COPELAND, SHARON WENG, WILLIAM C. BLACKWELL III, VED SRIVASTAVA, JAMES WAY, SHANE ROLLER, DORIS ZANE, REBECCA HODGE, ANDREW A. YOUNG, PAUL L. FELDMAN, Research Triangle Park, NC, Durham, NC, Hayward, CA

2000-P PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, β-Oxidation and Fibrosis in Liver, and White Adipose Tissue in ob/ob Mice. LYNE GAGNON, ALEXANDRE LAVERDURE, FRANÇOIS SARRA-BOURNET, MARIE-PIER CLOUTIER, ALEXANDRA FELTON, MIKAËL TREMBLAY, JONATHAN RICHARD, LIETTE GERVAIS, PIERRE LAURIN, FRANÇOIS A. LEBLOND, BRIGITTE GROUIX, Laval, QC, Canada

2001-P Obesity-Associated Family with Sequence Similarity 13 Member A Gene Regulates Adipocyte Differentiation. JIAZHEN TANG, HONGYI ZHOU, JING YANG, WEIQIN CHEN, Nanchang, China, Augusta, GA, Urbana, IL

2002-P Small Proliferative Adipocytes, Newly Identified Adipose Progenitor, as the Precursors of Beige Cells. KOICHIRO TAGUCHI, KAZUO KAJITA, MASAYUKI FUMIYA, MOTOCHIKA ASANO, YOSHIHIKO KITADA, TAKAHIDE IKEDA, TATSUO ISHIHUKA, HIROYUKI MORITA, Gifu, Japan

2003-P Self-Assembled Hyaluronic Acid Nanoparticles Ameliorate Adipose Tissue Inflammation and Insulin Resistance in Diet-Induced Obese Mice. JUN GI RH, WANGHEE LEE, EUNYOUNG LEE, CHONG-TAE KIM, EUN K YUNG LEE, WOOK KIM, Suwon, Republic of Korea, Seoul, Republic of Korea

2004-P Zinc Alpha2 Glycoprotein Promotes Browning in Adipocytes. XIN-HUA XIAO, XIAO-YAN QI, YA-DI WANG, CAN-XIN XU, JIANG-HUA LIU, Hengyang, China, St. Louis, MO

2005-P The SDF1-CXCR4 Signals Regulate Adipose Tissue Expansion by Modulating Angiogenesis in Diet-Induced Obesity in Mice. TSUTOMU WADA, ERI WATANABE, YURI KOTERA, YASUHIRO ONOGI, HIROSHI TSUNEKI, TOSHIYASU SASAOKA, Toyama, Japan

2006-P Discover and Track Obesity Relevant Research Resources Using dkNET (NIDDK Information Network). KO-WEI LIN, ANITA BANDROWSKI, JAMES GO, IBRAHIM BURAK OZYURT, TOM GILLESPIE, JEFFREY S. GRETHE, MARYANN E. MARTONE, La Jolla, CA

2007-P LRP1 Regulates Adiposity by Controlling Energy Balance in MC4R Neurons. MIN-CHEOL KANG, JI A. SEO, HYUNSOO CHO, HYUNNHA LEE, YOUNG-BUM KIM, Boston, MA, Ansan, Republic of Korea

2008-P Interaction of Endothelial Cell Mineralocorticoid Receptor, Noncoding RNA, and Exosomes in Diet-Induced Vascular Stiffness and Insulin Resistance. GUANGHONG JIA, ANNAAYA R. AROOR, JAYAD HABIBI, ADAM WHALEY-CONNELL, JAMES SOWERS, Columbia, MO

2009-P Empagliflozin and Linagliptin Administered in Combination or as Serial Add-On Therapy Decreases Macrovascular and Microvascular Stiffening and Microalbuminuria in a Mouse Model of Diabetic Nephrophy. ANNAAYA R. AROOR, JAYAD HABIBI, GUANGHONG JIA, THOMAS KLEIN, ERIC MAYOUX, VINCENT DEMARCO, Columbia, MO, Biberach, Germany, Ingelheim, Germany, Rocheport, MO

2010-P Evidence of CB1-Receptor Antagonism in Fat-Fed Dogs Promoting Beiging of Adipose Tissue Mainly via Activation of Sarco/Endoplasmic Reticulum Ca2+ ATPase 2b and Ryanodine Receptor 2. REBECCA L. PASZKIEWICZ, RICHARD N. BERGMAN, JOYCE M. RICHEY, MALINI S. IYER, ORISON O. WOOLCOTT, CATHRYN M. KOLKA, DEBORAH CLEGG, MORVARID KABIR, Los Angeles, CA

2011-P Gender-Dependent EPO Action in Adipose Tissue. JEEYOUNG LEE, CONSTANCE T. NOGUCHI, Bethesda, MD

2012-P Impairment of M2a-Subtype Macrophage Activation by IL-1-Irs2 Pathway in Obesity. TETSUYA KUBOTA, MARIKO INOUE, NAOOTO KUBOTA, ISEKI TAKAMOTO, KOHJIRO UEKI, TOSHIMASA YAMAUCHI, TAKASHI KADOKAWA, Tokyo, Japan

2013-P Diet-Dependent Sex Differences in the Response to Bariatric Surgery. CHELSEA HUTCH, DARIA STELMAN, KANAKADURGA SINGER, DARLEEN A. SANDOVAL, Ann Arbor, MI

2014-P Siah2 in Adipocytes Promotes M2-Like Macrophage Activation in Adipose Tissue. GAIL E. KILROY, JESSICA L. TAYLOR, THANH DANG, YONGMEI YU, ELIZABETH FLOYD, Baton Rouge, LA
2015-P Dipeptidyl Peptidase-4 Inhibition with Linagliptin Promotes Angiogenesis/Vasculogenesis in the Hearts of Female Diabetic db/db Mice. RYAN TOEDEBUSCH, ANNAYYA R. AROOR, JAVAD HABIBI, THOMAS KLEIN, LAKSHMI PULAKAT, VINCENT DEMARCO, Columbia, MO, Biberach, Germany, Rocheport, MO

2016-P Combination Linagliptin and Empagliflozin Therapy Improves Diastolic Function in Female Diabetic db/db Mice. JAVAD HABIBI, ANNAYYA R. AROOR, THOMAS KLEIN, ERIC MAYOUX, VINCENT DEMARCO, Columbia, MO, Biberach, Germany, Ingelheim, Germany, Rocheport, MO

2017-P Liver-Specific Reactivation of MC3R Partially Reverses the Obesity of MC3R Deficiency. NOAH J. LEVI, JOO YUN JUN, TUSHAR P. PATEL, ANDREW J. UHLMAN, ROBIN ROBERSON, JACK A. YANOVSKI, Bethesda, MD

2018-P Mice Lacking Both Cannabinoid-1 and Cannabinoid-2 Receptors Are Resistant to Diet-Induced Obesity. OMAYMA ALSHAARAWY, EMILY KURJAN, NGUYEN TRUONG, LAWRENCE K. OLSON, East Lansing, MI

2019-P Compound C Protects Mice from Diet-Induced Obesity and Hepatosteatosis. FANG WANG, WEN-JUN YANG, RONG XIANG, JINGJING YUAN, YUXING LIU, KEZHU CHEN, ZHAOHUI MO, Changsha, China

2020-P The Ldb1 Transcriptional Coregulator Is Required for Brown Adipose Development and Function. JESSICA KEPPLE, YANPING LIU, TEAYOUN KIM, GLENN C. ROWE, KIRK M. HABEGGER, CHAD S. HUNTER, Birmingham, AL

2021-P Adipocyte Lipolysis Triggers CD11c-ATM Inflammation in Lean Females and Obese Males and Females. MITA VARGHESE, SIMIN ABRISHAMI, KANAKADURGA SINGER, Ann Arbor, MI

2022-P Identification of Novel Transcriptional Regulators of Uncoupling Protein 1 Using a Modified CRISPR-Cas9 Methodology. JUSTIN DARCY, CHIH-HAO WANG, MORTEN LUNDH, FARNAZ SHAMS, MATT LYNES, BRICE EMANUELLI, YU-HUA TSENG, Boston, MA, Copenhagen, Denmark

2023-P High Iron Feeding Modulates Glucose Metabolism in Duodenal-Jejunal Bypass Surgery but Not in Vertical Sleeve Gastrectomy in Mice. JINGJING NIU, JONATHAN D. DOROS II, JONATHAN CAMPBELL, MEGAN CAPOZZI, SARAH M. GRAY, FELIPE LORENZO, DAVID D’ALESSIO, DON MCCLAIN, JENNIFER TONG, Durham, NC, Winston-Salem, NC

2024-P Diet-Induced Adipose Tissue Inflammation and Hypoxia Are Reversed by GLP-1 Potentially via Improved Microcirculation. FEN XU, ZONGLAN CHEN, YINGXIN XIAN, HONG R. DENG, WEN XU, HUA LIANG, JIANPING WENG, Guangzhou, China, Jining, China

2025-P miR-34a Aggravates Obesity-Induced Adipose Inflammation and Metabolic Dysfunction via Blocking Polarization of Anti-inflammatory M2 Macrophage. YONG PAN, HANNAH HUI, SR., RLC HOO, TIANSHI FENG, KAREN S. LAM, AIMIN XU, Hong Kong, China

2026-P Characterization of AJ5012 as a Novel Peripheral Cannabinoid 1 Receptor Antagonist in Mouse Models of Obesity. JUNGEUN KIM, JUHWAN YOON, EUNHA KIM, SONG-HWA YOON, WOOK KIM, Suwon, Republic of Korea

2027-P Low-Dose FGF-21 Administration Decreases Obesity-Induced Hepatic Steatosis, but Has No Effect on Inflammation in Mice. SHALIGRAM SHARMA, SEAN JUNG, EMILY GRAFF, THOMAS W. GETTYS, DESIREE WANDERS, Atlanta, GA, Auburn, AL, Baton Rouge, LA
2032-P TLR4-Induced Local Adipose Inflammation Critically Regulates Glucose Homeostasis. SHAN-GANG ZHAO, PHILIPP E. SCHERER, Dallas, TX

2033-P Insulin Action on Endothelial Cells Limits Leukocyte-Endothelial Interaction through CXCR4 and Counteracts Intestinal Tumor Formation in Obesity. THOMAS RATHJEN, QIAN LI, KYOUNGMIN PARK, GRO POVLSEN, GRITH SKYTTE. OLSEN, GEORGE L. KING, CHRISTIAN RASK-MADSEN, Berlin, Germany, Boston, MA, Målen, Denmark

2034-P Adipocyte-Selective Deletion of β-Arrestin-1 in Mice Causes Adiposity, Impaired Glucose Tolerance, and Reduced Insulin Sensitivity. SAI PRASAD PYDI, JÜRGEN WESS, Bethesda, MD

2035-P The Metabolic Effect of Chronic Elevated Erythropoietin in Tg6 Mice. HEATHER ROGERS, OKSANA GAVRIFOVA, CONSTANCE T. NOGUCHI, Bethesda, MD

2036-P Silencing of Supramammillary Nucleus (SuMN) Dopaminergic Neuronal Activity Induces the Obese Glucose Intolerant State. YAHONG ZHANG, TSUNG-HUANG TSAI, MICHAEL EZROKH, CARL STOEL-ZEL, ANTHONY CINCOTTA, Tiverton, RI

2037-P ▲ STAT1 Ablation in CD11c+ Cells Protects Mice from Obesity-Induced Insulin Resistance. ANTU KALATHOOKUNNEL ANTONY, XIAOYUAN D. PERRARD, ZEQIN LIAN, JERRY PERRARD, LOTHAR HENNIGHAUSEN, CLIFTON W. SMITH, CHRISTIE M. BALLANTYNE, HUAIZHU WU, Houston, TX, Bethesda, MD

2038-P SRC-2 in POMC Neurons Mediates Energy Reserving Effects of Foxo1. YONGJIE YANG, YONG XU, Houston, TX

2039-P Challenging the Adipocyte Color Barrier—TR Activation Elicits White to Beige Transdifferentiation Independent of Beta-Adrenergic Signaling. YAN XIA, XIAOFEI LIANG, MARK E. LEE, KEVIN PHILLIPS, Houston, TX

2040-P ▲ Nr4a1 and Nr4a3 Knock Out Mice Have Impaired Glucose Clearance and Beta-Cell Function under High-Fat Feeding. COURTNEY J. SMITH, KYLE B. KENER, JEFFERY S. TESSEM, Prava, UT

2041-P WITHDRAWN

2042-P WITHDRAWN

2043-P Resistin Is Associated with Blood-Brain Barrier Disruption in Mice Resistant to Diet-Induced Obesity and Treated with Topiramate. THERESE S. SALAMEH, WILLIAM MORTELL, WILLIAM A. BANKS, Seattle, WA

OBESITY—HUMAN

Moderated Poster Discussion: Obesity Pathogenesis and Treatment—Insights from Human Studies (Posters: 2044-P to 2049-P), see page 157.

2044-P ▲ Bariatric Surgery in Patients with Type 1 Diabetes and Obesity—A Three-Year Observational Matched Cohort Study. ADHAM MOTTALIB, KHALED ALSIBAI, SHAHEEN TOMAH, TAHAA ELSEAIDY, JENAN R. HOLLEY-CUTHRELL, ROELAND MIDDELBEEK, NOOR MAHMOUD, SAHAR ASHRAFZADEH, FLORENCE M. BROWN, OSAMA HAMDY, Boston, MA, Chicago, IL

2045-P ▲ Preoperative Hemoglobin A1c Predicts Postoperative Weight Loss Following Bariatric Surgery in Patients with Diabetes. CAMILA B. ORTEGA, HUI-JIE LEE, DANA PORTENIER, ALFREDO D. GUERRON, JENNY TONG, Durham, NC

2046-P ▲ Acarbose and Pasireotide Reduce Hypoglycemia in Roux-en-Y Gastric Bypass Operated Subjects. CAROLINE OHRSTRÖM, URD KIELGAST, SR., JENS J. HOLST, DORTE WORM, DORTE L. HANSEN, Koge, Denmark, Copenhagen, Denmark, Gentofte, Denmark

2047-P ▲ Insulin Sensitivity Is an Independent Determinant of Bone Mineral Density in Overweight and Obese Individuals. NEGAN NADERPOOR, AYA MOUSA, BARBORA DE COURTEN, Melbourne, Australia, Clayton, Australia

2048-P ▲ Insulin Resistance and Its In Vivo Lipolytic Rate Are Positively Associated with Body Iron Stores in Obese Women. BENJAMIN J. RYAN, DOUGLAS W. VAN PELT, LISA M. GUTH, ALISON LUDZKI, RACHEL A. GIOSCIA-RYAN, CHIWOON AHN, JEFFREY F. HOROWITZ, Ann Arbor, MI
2049-P Stimulation of the β3-Adrenergic Receptor via Mirabegron Induces Lipolysis and Thermogenesis in Human Adipocytes. CHERYL CÉRO, ALANA O’MARA, JAMES W. JOHNSON, ALISON S. BASKIN, JOYCE D. LINDEMANN, AARON CYPESS, Bethesda, MD

2050-P Effects of Different Types of Oral Glucose-Lowering Drugs on Hepatic Fat Accumulation and Liver Function in Japanese Subjects with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—A Randomized, Open-Label, 3-Arm Active-Control Study. TOMOE KINOSHITA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOTSU MUNE, KOHEI KAKU, HIDEAKI KANETO, Kurashiki, Japan

2051-P Duodeno-Jejunal Bypass Liner for the Treatment of Diabetes Mellitus in Obese Patients—Completeness of Duodenal Blending as the Key Factor for Efficacy. MAREK BENES, PAVEL DRAS-TICH, TOMAS HUCL, Prague, Czech Republic

2052-P The Existence of Superficial Dorsocervical Brown Adipose Tissue in Women. LAURA FLETCHER, BROOKS LEITNER, KATHERINE I. KIM, SUZANNE MCGEHEE, ROBERT BRYCHTA, AARON CYPESS, KONG Y. CHEN, Bethesda, MD

2053-P Efficacy and Safety of HSG4112, a Novel Anti-Obesity Oral Agent in Diet-Induced Obesity (DIO) Mice. SANG-KU YOO, KYUNGIL KIM, IN GEUN JO, KEUN-WAN LIM, Suwon, Republic of Korea

2054-P Lower Stearoyl-CoA Desaturase and Hormone Sensitive Lipase Gene Expression in Superficial Subcutaneous Adipose Tissue of Male, but Not Female, Patients with Type 2 Diabetes. KÁLMÁN BÓDIS, JESPER LUNDBOM, TOMAS JELENIK, DANIEL F. MARKGRAF, ALEXANDER STROM, OANA P. ZAHARIA, YANISLAVA KARUSHEVA, VOLKER BURKART, CARSTEN DIRKSEN, Hvidovre, Denmark, Copenhagen, Denmark, Petaling Jaya, Malaysia, Penang, Malaysia

2055-P The Relationships between Serum Levels of Adipokines, Body Fat Distribution, and Subcutaneous Microvasculature in Type 2 Diabetic Subjects. VADIM KIMONTOV, DINARA BULUMBAEVA, NATALIYA P. BГATOVA, IULIIA TASKAEVA, OLGA FAZULLINA, NIKOLAI ORLOV, ANTON I. KORBUT, SERGEY SAVCHENKO, VLADIMIR KONENKO, Novosibirsk, Russian Federation

2056-P Five-Year Glycemic and Metabolic Outcomes after Bariatric Surgery in an Asian Population with Type 2 Diabetes. ZHONG HONG LIEW, AYE CHAN MAUNG, SONALI GANGULY, PHONG CHING LEE, KWANG-WEI THAM, Singapore, Singapore

2057-P Elevated Insulin Clearance Contributes to the Reduced Peripheral Insulin Concentration Observed in Obese Young Asian with Type 2 Diabetes. GIOVANNI PACINI, ANDREA TURA, CHEE PENG HOR, SHUEH LIN LIN, FLORENCE TAN, CHIN VOON TONG, JANET Y.H. HONG, FUZIAH MD ZAIN, JENS J. HOLST, WAN NAZAIMOON MOHAMUD, SR., TOH PENG YEOW, Padua, Italy, Bukit Mertajam, Malaysia, George Town, Malaysia, Kuching, Malaysia, Medaka, Malaysia, Putrajaya, Malaysia, Copenhagen, Denmark, Petaling Jaya, Malaysia, Penang, Malaysia

2058-P Laparoscopic Sleeve Gastrectomy Improves Serum Uric Acid Levels and Has Sex Difference in Severely Obese Patients. CUILING ZHU, JINGYANG GAO, FANGYUN MEI, XINGCHUN WANG, LIANG LI, LIESHEH GU, Donglei ZHUO, SHEN QU, Shanghai, China

2059-P After Roux-en-Y Gastric Bypass, Enterohpatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. ALEKSANDER EIKEN, STEFAN FUGLSANG ESQ., MARKUS LAUGE EIKEN L, EIKEN, MARIA S. SVANE, JENS J. HOLST, KIRSTINE N. BOJSEN-MOLLER, STEN MADSBAD, SR., JAN L. MADSEN, CARSTEN DIRKSEN, Hvidovre, Denmark, Copenhagen, Denmark

2060-P Thyroid Function Improved after Laparoscopic Sleeve Gastrectomy in Severe Obesity and Related to Inflammatory Changes. CUILING ZHU, FANGYUN MEI, JINGYANG GAO, XINGCHUN WANG, LIANG LI, LIESHEH GU, Donglei ZHUO, SHEN QU, Shanghai, China

2061-P Chemerin and Tissue Inhibitor of Metalloproteinases 2, a Potential Link to Nonalcoholic Fatty Liver Changes in Metabolic Syndrome. SADIA FATIMA, Karachi, Pakistan

2062-P Significant Bone Loss in Obese Patients with Acanthosis Nigricans after LSG—One-Year Follow-Up Study. YOUGANG ZHANG, ZHIYIN ZHANG, CUILING ZHU, SIQI SUN, YING YIN, RAN CUI, HUI SHENG, SHEN QU, Shanghai, China

2063-P WITHDRAWN
2064-P Visceral and Ectopic Fat Expansion and the Risk of Incident Type 2 Diabetes Mellitus. IAN J. NEELAND, COLBY AYERS, KERSHAW V. PATEL, PARAG H. JOSHI, DARREN K. MCGUIRE, SCOTT M. GRUNDY, ANAND ROHATGI, GLORIA L. VEGA, Dallas, TX

2065-P BMI Z-Score Trajectories in Youth with T1D—An International Comparison. MENGDI WU, HELEN PHELAN, ANKE SCHWANDT, NICOLE C. FOSTER, JENNY COUPER, CLAUDIA STEIGLEDER-SCHWEIGER, STEVEN M. WILLI, TIM JONES, PETER KROSCHWALD, DAVID M. MAAHS, NICOLE PRINZ, MARIA E. CRAIG, Tampa, FL, Newcastle, Australia, Ulm, Germany, North Adelaide, Australia, Salzburg, Austria, Philadelphia, PA, Perth, Australia, Neuruppin, Germany, Stanford, CA, Westmead, Australia

2066-P Lipid Accumulation Product and Sarcopenia in Korean Patients with Type 2 Diabetes. JANG YEL SHIN, Wonju, Republic of Korea

2067-P Impact of Laparoscopic Sleeve Gastroplasty & Sleeve Gastroplasty on Thyroid Function Profiles in Chinese Euthyroid Obese Patients. LIANG LI, XINGCHUN WANG, JINGYANG GAO, SHEN QU, Shanghai, China

2069-P Attitudes Regarding Weight Loss Strategies and Pregnancy Risk in Patients with Type 2 Diabetes and Prediabetes in a Military Health System. ALEXIS BEAUVAIS, JANA L. WARDIAN, TOM J. SAUERWEIN, San Antonio, TX

2070-P A Smartphone App-Based Lifestyle Intervention Promotes Weight Loss—Results of a Prospective, Randomized, Controlled Clinical Trial (RCT). CHERIE LISA VAZ, AKASHKUMAR G. SUTHAR, BOBAK T. POUSTI, SU M. AYE, KEVIN JON WILLIAMS, HUAQING ZHAO, Philadelphia, PA

2071-P Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results. MAHENDER YADAGIRI, FIONA Y. KINNEY, NATALEE ASHMAN, MICHAEL H. LANG, EDWARD FOGDEN, MARK ANDERSON, JOHN BLEASDALE, CHRISTOPHER WALTON, MICHAEL A. GREENSTONE, ROBERT E. RYDER, Birmingham, United Kingdom, Hull, United Kingdom

2072-P Incretin and Cardiovascular Effects of Weight Loss and Remission of Prediabetes. FRANKIE B. STENTZ, ANN AMMONS, Memphis, TN

2073-P Effects of Laparoscopic Sleeve Gastroplasty on Insulin Secretion Patterns in Young Obese Patients with Acanthosis Nigricans. CHUNHUA QIAN, SHEN QU, CUILING ZHU, JINGYANG GAO, FANGYUN MEI, LE BU, Shanghai, China

2074-P Sleep Quality Is Associated with Obesity in Patients with Type 2 Diabetes. TOMOE HIROTA, TOMOA KIYOHARA, KIYOTAKA YODA, NORIKAZU TOI, NORIYUKI HAYASHI, SAOHI MARUO, MASAOFumi KURAJOH, SHINSUKE YAMADA, TETSUO SHOJO, MASANORI EMOTO, MASAAMI INABA, Osaka, Japan

2075-P Increased Bile Acids and FGF-19 after Sleeve Gastroplasty and Roux-en-Y Gastric Bypass Correlate with Improvement in Type 2 Diabetes in a Randomized Trial. RINKI MURPHY, REZA NEMATI, DECH DOKPUANG, JUN LU, Auckland, New Zealand

2076-P A Systems Approach to ER Stress Pathway Dynamics Reveals the Impact of Freeze-Dried Broccoli Extract to Mitigate Inflammation in Human Adipocytes through the Mevalonate Pathway. ALICE MURPHY, SAHAR AZHARIAN, GYANENDRA TRIPATHI, GUY BARKER, MICHAEL J. CHAPPELL, PHILIP G. McTERNAN, Coventry, United Kingdom, London, United Kingdom, Nottingham, United Kingdom

2077-P Altered Brain Resting-State Functional Connectivity in Obese Patients Is Associated with Plasma Levels of Leptin. FRANCANTONIO DEVOTO, ANNA FERRULLI, LAURA ZAPAROLI, ROLANDO BONANDRINI, LUCA MARIA SCONFIENZA, GIUSEPPE BANFI, LIVIO LUZI, ERALDO PAULESU, Milan, Italy, San Donato Milanese, Italy

2078-P Lower Ectopic Fat Accumulation in Obese Women May Help Explain Sex Differences in the Magnitude of Insulin Resistance. JENNA B. GILLEN, BENJAMIN J. RYAN, RACHEL A. GIOSCIA-RYAN, ALISON LUZKI, THOMAS L. CHENEVERT, JEFFREY H. HOROWITZ, Ann Arbor, MI

2079-P Collaborative Intensive Lifestyle Weight (Wt) Loss Intervention in Underserved Predominantly African-American (AA) Patients in Chicago. CAROLINE POKU, BETTINA TAHSIN, LEON FOGEFELD, Chicago, IL
2080-P Human Brown Adipose Tissue Density Assessed by Near-Infrared Time-Resolved Spectroscopy Inversely Correlates with the Body Mass Index in Patients with Type 2 Diabetes. HIRONORI WAKI, NAOKO WATANABE, SAYURI FUSE, YUKO KUROSAWA, TOSHIMASA YAMAUCHI, RYOTARO KIME, TAKAFUMI HAMAOKA, TAKASHI KADOWAKI, Tokyo, Japan

2081-P The Association between Body Mass Index and All-Cause Mortality in Type 2 Diabetic Patients With and Without Diabetic Microangiopathy—A Retrospective Cohort. LI Y. HSUAN, I-TE LEE, Taichung, Taiwan

2082-P Improved Insulin Sensitivity and Irisin after a Dietary Weight-Lowering Program in Obese, Otherwise Healthy Subjects. ADELA PENESOVA, ZOFIA RADIKOVA, BORIS BAJER, MIROSLAV VLCEK, Bratislava, Slovakia

2083-P Influence of Race, Ethnicity, and Behavioral Factors on Childhood Obesity. PRISCILLA AYINE, EMILY P. PARRA, RAMESH B. JEGANATHAN, GEETHA THANGIAH, Auburn, AL

2084-P Role of Free Fatty Acids in the Alteration of Cardiovascular Autonomic Activity and Its Post-prandial Changes in Obese Patients with Glucose Intolerance. AMEL REZKI, MARINOS FYSEKIDIS, CHIHEB SABRINA, ISABELA BANU, EMMANUEL COSSON, PAUL VALENSI, Bandy, France, Bobigny, France

2085-P Impact of Diabetes on Outcomes of Diabetic Ketoacidosis—Results from the National Inpatient Sample. ARWA ELSHEIKH, ABDULLAH ABDULLAH, ABDUL WAHAB, GEORGE E. EIGBIRE, AMR SALAMA, KRISHNAKUMAR RAJAMANI, Rochester, NY

2086-P Endobarrier® Gastrointestinal Liner in Obese Subjects with Type 2 Diabetes—Short- and Mid-term Effects on Glucose Metabolism. NORBERT J. TRIPOLT, FELIX ABERER, JASMIN URI, PETER N. PFERSCHY, CHRISTOPH HÖGENAUER, FLORIAN SCHREIBER, ANDREAS EHERER, EVAS VEHLIKOA, CAREN SOURIJ, ANNA M. OBERMAYER, VANESSA STADLBAUER, HARALD SOURIJ, Graz, Austria

2087-P U.K. First National Health Service (NHS) Endobarrier (EB) Service—Outcomes in First 38 Patients to Reach Six Months after Device Explant. ROBERT E.J. RYDER, MAHENDER YADAGIRI, SUSAN P. IRWIN, WYN BURBRIDGE, MELISSA L. CULL, RACHAEL ALLDEN, JOHN BLEASDALE, EDWARD FOGDEN, MARK ANDERSON, PIYA SEN GUPTA, Birmingham, United Kingdom

2088-P Effects of Deep Transcranial Magnetic Stimulation (dTMS) on Anti-Inflammatory Gut Bacterial Species in Obesity. ANNA FERRULLI, MARCO TOSCANO, MICHELA ADAMO, ILEANA TERRUZZI, LORENZO DRAGO, LIVIO LUZI, San Donato Milanese, Italy, Milan, Italy

2089-P Beneficial Effects of RYGB on β-Cell Function and Hepatic and Peripheral Insulin Sensitivity Are Maintained Seven Years after Surgery in Both Diabetic and Nondiabetic Subjects. STEFANIA CAMASTRA, BRENNO D. ASTIARRAGA, CHIARA BARBIERI, MELANIA GAGGINI, MARIA PALUMBO, ROSANA BERTA, DEMETRIO CIOCIARO, MARCO ANSELMINO, ANDREA MARI, ELE FERRANNINI, AMALIA GASTALDELLI, Pisa, Italy, Padova, Italy, San Antonio, TX

2090-P WITHDRAWN

2091-P The Visceral Adiposity Index Predicts Cardiovascular Events Both in Cardiovascular Disease Patients With and in Those Without Diabetes. CHRISTOPH H. SAELY, ALEXANDER VONBANK, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDELEIN, HEINZ DREXEL, Berne, Switzerland, Feldkirch, Austria, Triesen, Liechtenstein, Philadelphia, PA

2092-P The A Body Shape Index and Type 2 Diabetes Are Mutually Independent Predictors of Cardiovascular Events in Patients with Peripheral Artery Disease. ALEXANDER VONBANK, CHRISTOPH H. SAELY, CHRISTINE HEINZLE, DANIELA ZANOLIN, BARBARA LARCHER, ARTHUR MADER, ANDREAS LEIHERER, AXEL MUENDELEIN, HEINZ DREXEL, Feldkirch, Austria, Berne, Switzerland, Triesen, Liechtenstein, Philadelphia, PA

2093-P Effect of Restricted Caloric Intake and Bariatric Surgery on PCSK9 Concentrations in Plasma. HUSAM GHANIM, SANAA ABUAYSHEH, SCOTT MONTE, PARESH DANDONA, Buffalo, NY, Orchard Park, NY, Williamsville, NY

2094-P Energy Expenditure during Sleep Is an Independent Marker of Insulin-Resistance—A Cross-Sectional Study of Overweight/Obese Subjects. DARIO TUCCINARDI, ERNESTO MADDALONI, ILARIA CAPASSO, LORENZO RAMPA, ANDREA SOARE, DARIO MAGGI, GIUSEPPE DEFEUDIS, SHADI KYANVASH, ANNA RITA MAURIZI, PAOLO POZZILLI, SILVIA MANFRINI, Rome, Italy
2095-P Impact of the Intragastric Balloon Associated with Diet on the Treatment of Diabetic Patients with Overweight or Grade I Obesity and Its influence on the Production of Enterohormones. SILVIA M. REIMAO, MARIA ELIZABETH R. DA SILVA, GABRIEL C. NUNES, LUÍZ HENRIQUE M. MESTIERI, ROSA F. SANTOS, EDUARDO G. DE MOURA, São Paulo, Brazil

2096-P WITHDRAWN

2097-P First Risk-Benefit Data from the Worldwide Endobarrier Registry. ROBERT E.J. RYDER, LYNNE MUNRO, JESSICA J. MCMASTER, JUSTIN BESSELL, JEANINE M. BASCOMB, JANE E. COLLINS, JUSTIN BESSELL, JESSICA J. MCMASTER, EDDIE G. DE MOURA, São Paulo, Brazil

2098-P The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 Inhibitors on Obese Patients with Noninsulin-Treated DM2. IOANNIS L. MATSOUKIS, ASIMINA GANOTOPOULOU, CHRYSOULA TRIANTAFILLOPOULOU, KONSTANTINA KANELLOPOULOU, THEODORA ATHANASOPOULOU, ALEXANDRA SIANNI, Athens, Greece, Piraeus, Greece

2099-P Racial Differences in Insulin Resistance, Secretion, and Clearance. SUN H. KIM, Stanford, CA

2100-P Wnt Pathway Inhibitor DKK1—A Potential Novel Biomarker for Ectopic Skeletal Muscle Adiposity. HIRA ALI, JOSEPH M. ZMUDA, RYAN CVEJKUS, ERIN E. KERSHAW, ALLISON L. KUIPERS, CLAREANN H. BUNKER, IVA MILJKOVIC, Pittsburgh, PA

2101-P Metabolic Surgery Counseling, Diabetes Remission, and A1c Control in Patients with Diabetes and Obesity. LEE-SHING CHANG, SHERVIN MALMASI, NAOSHI HOSOMURA, HUABING ZHANG, CHRISTOPHER J. BROWN, VICTOR J. LEI, ALEXA RUBIN, CLARA TING, KIMHOUY TONG, ALEXANDER TURCHIN, Boston, MA, Beijing, China

ISLET BIOLOGY—APOPTOSIS

Moderated Poster Discussion: Islet Biology—Apoptosis (Posters: 2102-P to 2107-P), see page 91.

2102-P Detection of Pancreatic Beta-Cell DNA in the Circulation Using the Dual Amplification Refractory Mutation System PCR. AKIO KURODA, MISUZU Y. YAMADA, YUKARI TOMINAGA, REIKO SUZUKI, MOTOYUKI TAMAKI, YUKO AKEHI, YUICHI TAKASHI, DAISUKE KOGA, EISUKE SHIMOKITA, FUMINORI TANIHARA, KIYOE KURAHASHI, SUMIKO YOSHIDA, ITSURO ENDO, KEN-ICHI AIHARA, MASAHIRO ABE, KEVIN FERRERI, MUNEHIDE MATSUHISA, Tokushima, Japan, Duarte, CA

2103-P IER3IP1 Regulates Beta-Cell Survival. JUAN SUN, KENNETH POLONSKY, DECHENG REN, Chicago, IL

2104-P Targeted Deletion of ATF4 in β Cells Leads to the Vulnerability and Dedifferentiation during ER Stress. KEIKUKE KITAKE, KIYOE KURAHASHI, MASATO MIYAKE, YOSHIHISA HAMADA, MIHO OYADOMARI, SEIICHI OYADOMARI, Tokyo, Japan

2105-P Metabolic Insufficiency Caused By Cellular Stresses Is Implicated in Beta-Cell Dedifferentiation in the Mouse Model of Wolfram Syndrome. KIKUKO AMO-SHIINOKI, KATSUYA TANABE, MASYUKI HATANAKA, YUKIO TANIZAWA, Ube, Japan

2106-P Injury Factors Alter miRNA Profiles of Exosomes Derived from Islets and Circulation. QI FU, HEMIN JIANG, TAO YANG, Nanjing, China, Jiangsu, China

2107-P Tissue Plasminogen Activator (tPA) Expression Is Increased by Islet Amyloid Formation In Vitro. NATALIE JESS, MEGHAN F. GOGAN, ANDREW T. TEMPLIN, MARK ZIEMANN, ASSAM EL-GSTA, SAKENEH ZRAIKA, REBECCA L. HULL, STEVEN E. KAHN, Seattle, WA, Melbourne, Australia

2108-P The Effect of nAChR Signaling on Terminal-Unfolded Protein Response under Endoplasmic Reticulum Stress in INS1 Cells. TATSUJA ISHIBASHI, SHUHEI MORITA, ASAKO DOI, HIROSHI IWAKURA, HIROYUKI ARIYASU, MASAO NISHI, HIROYUKI ARIYASU, TAKASHI AKAMIZU, Wakayama, Japan

2109-P GDF15 Is Induced by T1D-Associated Cytokines and ER Stress and Promotes Beta-Cell Apoptosis. GUANLAN XU, LANCE TIELENJIAI, JUNQIN CHEN, SEONGHO JO, ANATH SHALEV, Birmingham, AL
2110-P  **MODY Signal Pathway in the Endoplasmic Reticulum Stress and the Role of Nkx6.1 in the Glucolipotoxicity of INS-1-3 Cells.**  YANAN DONG, YUKUN LI, JIANGZHONG XIAO, Beijing, China, Shijiazhuang, China

2111-P  **Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice—“The Earlier and Longer, the Better.”**  TOMOHIKO KIMURA, MASASHI SHIMODA, SHUHEI NAKANISHI, TOMOATSU MUNE, KOHEI KAKU, HIDEAKI KANETO, Kurashiki, Japan

2112-P  **Targeting Cellular Calcium Homeostasis to Prevent Beta-Cell Death in Type 1 Diabetes.**  AMY L. CLARK, DAMIEN ABRUE, CRIS M. BROWN, FUMIHIKO URANO, St. Louis, MO

2113-P  **Alpha-1 Antitrypsin (AAT) Protects β Cells via Clathrin-Mediated Endocytosis.**  JINGJING WANG, DO-SUNG KIM, CHARLIE STRANGE, HONGJUN WANG, Charleston, SC

2114-P  **Functional Characterization of Wolfram Syndrome 1 Protein in β-Cell Function and Viability.**  DAMIEN ABRUE, ZENO LAVAGNINO, CRIS M. BROWN, DAVID W. PISTON, FUMIHIKO URANO, St. Louis, MO

2115-P  **Role of NumbL:Mig6 Interactions in Beta-Cell Death during Glucolipotoxicity.**  HALESHA D. BASA-VARAJAPPA, JOSE M. IRIMIA-DOMINGUEZ, PATRICK T. FUEGER, Duarte, CA

2116-P  **Altering β-Cell Proliferation In Vivo by Pharmacological Manipulation of the Nrf2 Pathway.**  LIORA S. KATZ, ADOLFO GARCIA-OCANA, DONALD SCOTT, New York, NY

2117-P  **Deletion of SLC4A4 in Pancreatic β Cells Protects from High-Fat Diet-Induced Glucose Intolerance and β-Cell Dysfunction.**  MATTHEW BROWN, HEATHER L. HOLMES, KUNTOL RAKSHIT, MICHAEL F. ROMERO, ALEKSEY MATVEYENKO, Rochester, MN

2118-P  **Use of Live Murine Pancreatic Slices for the Study of β-Cell Regeneration.**  FAHD QADIR, JONATHAN WEITZ, SILVIA ALVAREZ-CUBELA, DAGMAR KLEIN, GIACOMO LANZONI, CARLOS A. GARCIA-SANTANA, ABELARDO MONTALVO, CAMILLO RICORDI, LUCA INVERARDI, ALEJANDRO CAICEDO, RICARDO PASTORI, JUAN DOMÍNGUEZ-BENDALA, Miami, FL

2119-P  **WITHDRAWN**

2120-P  **The Patterning of Pancreatic Progenitors Is Regulated by the Temporal Control of NOTCH Signaling.**  MICHAEL A. BUKYS, JAN JENSEN, Cleveland, OH

2121-P  **Ctgf Promotes Differentiation, Regeneration, and Proliferation of β Cells.**  SHANNON E. TOWNSEND, RAYMOND PASEK, MATTHEW A. COTTAM, MAUREEN A. GANNON, Nashville, TN

2122-P  **Mig6 Is Required for Pancreas Development in Zebrafish.**  KIMBERLEY EL, PATRICK T. FUEGER, RYAN M. ANDERSON, Indianapolis, IN, Duarte, CA

2123-P  **Noninvasive Longitudinal Evaluation of GPR-119 Agonist Effects on β-Cell Mass Using GLP-1 Receptor-Targeting SPECT/CT.**  TAKAAKI MURAKAMI, HIROYUKI FUJIMOTO, NAOTAKA FUJITA, KEITA HAMAMATSU, KOJI MATSUMOTO, NOBUYA INAGAKI, Kyoto, Japan, Tokyo, Japan

2124-P  **Investigation on the Protective Effect of Canagliflozin on Pancreatic Beta-Cell Mass Using SPECT/CT Imaging with 111In-Labeled Exendin-4.**  KEITA HAMAMATSU, HIROYUKI FUJIMOTO, NOBUYA INAGAKI, NAOTAKA FUJITA, TAKAAKI MURAKAMI, MAESAKU SHIHOTANI, HIROYUKI FUJIMOTO, NAOTAKA FUJITA, TAKAAKI MURAKAMI, MASAHARU SHIHOTANI, HIDEKI HAMAMATSU, KOJI MATSUMOTO, NOBUYA INAGAKI, Kyoto, Japan, Tokyo, Japan

2125-P  **Suppression of STAT3 Signaling Promotes Acinar-to-β Reprogramming Induced by Distinct Transcription Factors.**  MASAKI MIURA, TAKESHI MIYATSUKA, SHUZO SAKAI, TAKEHIRO KATAHIRA, LUKA SUZUKI, MIWA HIJIRI, YUJIN NISHIDA, YOSHIO FUJITANI, TAKAAKI MURAKAMI, NAOTAKA FUJITA, KEITA HAMAMATSU, KOJI MATSUMOTO, NOBUYA INAGAKI, Kyoto, Japan, Tokyo, Japan

2126-P  **E-Cadherin Downregulation by Cathepsin L Plays a Role in the Proliferation of Insulin-Producing Cells following Inhibition of Serpin B13.**  CHI-WEN LO, TZONG-JEN SHEU, JAN CZYZYK, Rochester, NY
2127-P Unusual Duct-Like Cells in the Islet of Diabetic C414A-CRY1 Transgenic Mice. SATOSHI OKANO, AKIRA YASUI, SHIN-ICHIRO KANNO, KENNICHI SATOH, MASAHIKO IGARASHI, OSAMU NAKAJIMA, Yamagata, Japan, Sendai, Japan

2128-P Novel Spatiotemporal Analysis for Exploring α-Cell Differentiation. MIWA HIMURO, TAKESHI MIYATSUKA, LUKA SUZUKI, MASAKI MIURA, TAKEHIRO KATAHIRA, MASAYA TAKAHASHI, YUYA NISHIDA, SHIGERU OISHIA, RYUICHI OKAMOTO, HIROTAKA WATADA, Tokyo, Japan

2129-P Adverse Impact of Hashimoto's Thyroiditis on Pancreatic Beta-Cell Function in Type 2 Diabetic Patients. YUANYUAN ZHANG, RONGXIN SUN, LIJIE ZHANG, YUAN FANG, CAIGUO YU, SHASHA YUAN, YING-MEI FENG, DONG ZHAO, Beijing, China

2130-P GLP-1 Controls Pancreatic Endocrine Development. CORENTIN M.H. CRAS-MÉNEUR, RANDY J. SEELEY, Ann Arbor, MI

2131-P Functional Maturation of Pancreatic β Cells during Development. DIANA E. STANESCU, CHANGHONG LI, JUXIANG YANG, DAPHNE YAU, CHARLES A. STANLEY, Philadelphia, PA

2132-P Synergistic Effects of Long-Term Combination Therapy of DPP-4 Inhibitor and SGLT2 Inhibitor on the Preservation of Beta-Cell Volume in Rats with Type 2 Diabetes. HIROKI MIZUKAMI, DAN-YANG GUO, KAZUHISA TAKAHASHI, SHO OSONO, SAORI OGASAWARA, WATARU INABA, SOROKU YAGIHASHI, Hirosaki, Japan

2133-P Lactational Programming of Offspring Glucose Homeostasis and Body Composition by Early Postnatal Metformin Exposure. BRIGID GREGG, Ann Arbor, MI

2134-P No Compensatory Increase in Non-β-Hormone Expressing Cells in the Pancreatic Duct Glands in Type 1 Diabetes. SHWETA S. KULKARNI, MARK A. ATKINSON, ALEXANDRA BUTLER, Gainesville, FL, Doha, Qatar

2135-P Glis3 Regulates Pancreatic β-Cell Development in Part through Coordination with Other Islet Transcription Factors. DAVID SCOVILLE, Research Triangle Park, NC

2136-P Effects of a Healthy Postweaning Diet on Endocrine Defects Caused by In Utero High-Fat Diet Exposure in Mouse and Japanese Macaque. JOSEPH ELSAKR, PAUL KIEVIT, ALVIN C. POWERS, MAUREEN A. GANNON, RITA BOTTINO, DIANA L. TAKAHASHI, Nashville, TN, Portland, OR, Pittsburgh, PA, Hillsboro, OR

2137-P T3 and Glucose Increase Expression of ChREBPβ to Induce Expression of Phosphoenolpyruvate Carboxykinase (Pck1) Leading to Increased β-Cell Proliferation. LIORA S. KATZ, DONALD SCOTT, New York, NY

2138-P Identification of Candidate Targets in Transcriptome of Islets from Offspring Exposed to High Glucose In Utero. JOSE CASASNOVAS, XI RAO, KOK LIM KUA, Indianapolis, IN

2139-P Impact of Mig6 on β-Cell Regeneration and Repair. BRANDON M. BAUER, KIMBERLEY EL, PATRICK T. FUEGER, Duarte, CA, Indianapolis, IN

ISLET BIOLOGY—BETA CELL—STIMULUS-SECRETION COUPLING AND METABOLISM

Moderated Poster Discussion: Beta-Cell Stimulus-Secretion Coupling and Metabolism (Posters: 2140-P to 2145-P, see page 157.

2140-P Cdk2-Dependent Activation of β-Cell Metabolism Is Eclipsed by Its Inhibitory Effect on Plasma Membrane Excitability and Insulin Secretion. SOPHIA SDAO, CHETAN POUDEL, KARA M. MORTENSEN, MATTHEW J. MERRINS, Madison, WI, Cambridge, United Kingdom

2141-P Caveolin-1 Deficiency Inhibits Palmitate-Induced Intracellular Lipid Accumulation and Enhances Autophagy in Pancreatic β Cells via AMPK/mTOR Pathway. WEN ZENG, KUNYING LIU, JIASONG TANG, HANGYA PENG, CHUWEN LIN, SHUO LIN, KEYI LIN, YAN JIANG, LONGYI ZENG, Guangzhou, China

2142-P The Increment of Noradrenergic Fibers Correlates with the Density of Dedifferentiated β Cells in Humans. FRANCESCA CINTI, ILENIA SEVERI, MARA SULEIMAN, LORELLA MARSELLI, PIERO MARCHETTI, SAVERIO CINTI, DOMENICO ACCILI, Rome, Italy, Ancona, Italy, Pisa, Italy, New York, NY
2143-P 🍿 Tobacco Smoking Results in Reduced Pancreatic Islet Mass in Humans. MIKAËL CHETBOUN, JULIE A. KERR-CONTE, VALERY GMYR, DOROTHÉE THIILLIER, RIMED EZZOUAOUI, THOMAS HUBERT, VIOLETA RAVERDY, ANTONINO BONGIOVANNI, MEHDI DAOUFI, SR., MARIE-CHRISTINE VANTYGHEM, FRANÇOIS PAT-TOU, Lille, France

2144-P 🍿 Identification and Analysis of a Novel Glucose Toxicity-Sensitive Gene in Pancreatic β Cell. NAOKI SHIMO, TAKAAKI MATSUOKA, DAN KAWAMORI, SATOMI TAKEBE, TAKESHI MIYATSUKA, ICHIRO SHIMOMURA, Suita, Japan, Tokyo, Japan

2145-P 🍿 Novel Use of Agent ¹⁴C-PHNO for Pet CT Imaging of Pancreatic Beta-Cell Mass. ELIZABETH SANCHEZ RANGEL, JASON BINI, NABEEL B. NABULSI, YIYUN HUANG, KEVAN C. HEROLD, ROBERT SHERWIN, RICHARD E. CARSON, GARY CLINE, New Haven, CT

2146-P Liraglutide Inhibits Endoplasmic Reticulum Stress in Pancreatic Beta Cells via Regulation of the Homeodomain Transcription Factor Nkx6.1. YUKUN LI, YANAN DONG, LI SHILUN, PENG XUE, Shijiazhuang, China

2147-P Effects of Extra Virgin Olive Oil Polyphenols on Pancreatic Beta-Cell Function and Survival. ANNALISA NATALICCHIO, ROSARIA SPAGNUOLO, NICOLA MARRANO, GIUSEPPINA BIONDI, LUCIA DIPAOLA, ANGELO CIGNARELLI, SEBASTIO PERRINI, LUIGI LAVIOLA, FRANCESCO GIORGINO, Bari, Italy

2148-P WITHDRAWN

2149-P miR-204 Antagomir Enhances GLP-1 Receptor Function and Glucose Control. SEONGHO JO, JUN-QIN CHEN, GUANLAN XU, TRUMAN GRAYSON, LANCE THIELEN, ANATH SHALEV, Birmingham, AL

2150-P 🍿 A Novel Mediator of Arsenic-Induced Pancreatic Beta-Cell Dysfunction. CHRISTOPHER M. CARMEAN, NORIHIDE YOKOI, ANDREW G. KIRKLEY, HARUMI TAKAHASHI, ROBERT M. SARGIS, SUSUMU SEINO, Kobe, Japan, Chicago, IL

2151-P 🍿 Impaired Glucagon and Insulin Responses in Mice Lacking the Cl- Loader Nkcc2a. LISA E. KELLY, MAURICIO DIFULVIO, Dayton, OH

2152-P 🍿 Glucose Oxidation Depletes Cytosolic Citrate and Glutamate in the Amplifying Pathways of Insulin Secretion. SOPHIE L. LEWANDOWSKI, MATTHEW J. MERRINS, Madison, WI

2153-P FSTL3 Inhibition Restores Glucose Responsive Insulin Secretion in Nonfunctional Human Islets. ALAN SCHNEYER, MELISSA BROWN, Concord, MA, West Hartford, CT

2154-P Functional Role and Mechanism of UCP2 Uproregulation in Pancreatic β Cells. RYOTA INOUE, JUN SHIRAKAWA, YU TOGASHI, YASUO TERACHUCHI, Yokohama, Japan

2155-P Beneficial Effects of Tamoxifen Treatment in Type 1 Diabetes. JUAN ZHENG, MOHAMMAD ISHRAQ ZAFAR, LULU CHEN, XIN GUO, XIAOMING LI, Wuhan, China, Jinan, China, Toronto, ON, Canada

2156-P Insulin and Glucagon Interaction Studied by Separate and Combined Receptor Antagonism. KATRINE D. GALSGAARD, JENS J. HOLST, MARIE WINther-SORENSEN, NICOLAI J. WEWER ALBRECHTSEN, JENS PEDERSEN, Copenhagen, Denmark

2157-P Canagliflozin Improves Glycemic Control and Beta-Cell Mass in the TallyHo Polygenic Model of Type 2 Diabetes. IULIANA POPESCU, GEORGE M. MUSSMAN, COREY B. HUGHES, TERRANCE J. JANES, JR., PHIL RAY, R. CLAY BUNN, JOHN FOWLKES, KATHRYN M. THRAILKILL, Lexington, KY

2158-P Mechanisms Underlying the Progressive Loss of Beta-Cell Function and Mass in Neonatal Diabetes Are Reverted by Dapagliflozin Therapy. ZEENAT A. SHYR, ZIHAN YAN, ALESSANDRO USTIONE, MARIA S. REMEDI, St. Louis, MO

2159-P 🍿 The Complement-1q-Like-3 Inhibits Insulin Secretion by an Adhesion G-Protein Coupled Receptor, BAI3 in Pancreatic β Cells. RAJESH GUPTA, MIKE SCHAIM, MICHELLE E. KIMPLE, JAMES E. KOLTES, SUSHANT BHNATGAR, Birmingham, AL, Madison, WI, Ames, IA

2160-P Analysis of ~700 Human Tissue Samples Identifies microRNAs That Are Associated with, Predictive of, and Necessary for Insulin Gene Transcription. ANAND HARDIKAR, WILSON WONG, MUGDHA JOGLEKAR, LOUISE T. DALGAARD, ALICIA JENKINS, RONALD C. MA, THE MICRORNA ATLAS STUDY GROUP, Sydney, Australia, Roskilde, Denmark, Hong Kong, China
2161-P Newly Revealed Role for OGT in Obesity-Precipitated β-Cell Hyperinsulinemia. AMBER D. LOCKRIDGE, SEOKWON JO, NIKLAS E. DAMBERG, RAMKUMAR MOHAN, EMILYN ALEJANDRO, Saint Paul, MN, Minneapolis, MN

2162-P Synchronized Microfluidic System to Dynamically Assess Pancreatic Islet Function beyond Glucose-Stimulated Insulin Secretion. STEPHAN NIEUWOUDT, RUTH MCDOWELL, HUI ZHANG, JOHN P. KIRWAN, Cleveland, OH

2163-P Diminished Ca2+ Signaling, Ca1 Channel Expression, and Activity in Pancreatic Beta Cells Expressing Mutated DISC1 (Disrupted in Schizophrenia 1). PING LU, ROHIT B. SHARMA, LAURA C. ALONSO, RONGHUA ZHUGE, ANN R. RITTENHOUSE, AGATA JURCZYK, Worcester, MA

ISLET BIOLOGY—SIGNAL TRANSDUCTION

2164-P Glucagon Expression Is Regulated by Exendin-4 via CaMKK/AMPK/FoxO1 Pathway in Alpha TC1.6 Cells. JINGYA LYU, HITORI IMACHI, KENSUKU FUKUNAGA, SEISUKE SATO, TAO DONG, TOMOHIRO IBATA, TOSHIHIRO KOBAYASHI, KOJI MURAÔ, Kagawa, Japan, Kitagun, Japan

2165-P Generation of Insulin Expressing Cells in Mouse Small Intestine by Pdx1, MafA, and BET2/NeuroD. LEE SO HYUN, JIWON KIM, KUN-HO YOON, Seoul, Republic of Korea

2166-P Evaluation of CFTR Expression and Localisation in Human Pancreas. RASHMI R. MAHESHWARI, CLAIRE J. JONES, JAMES A.M. SHAW, MICHAEL G. WHITE, Newcastle upon Tyne, United Kingdom

2167-P Hyperproinsulinemia in OGlCNac Transferase Deficient Mice Is Associated with Loss of CPE and elf4G1, but β-Cell Deletion of elf4G1 Induces Glucose Intolerance Independent of CPE Dysregulation. SEOKWON JO, AMBER D. LOCKRIDGE, EMILYN ALEJANDRO, Minneapolis, MN, Saint Paul, MN

2168-P Quantitative Proteomic Analysis on Human Islets—New Markers of Cellular and Metabolic Dysfunction. CHIARA MARIA ASSUNTA CEFALO, TERESA MEZZA, ROHIT KULKARNI, ANDREA GIACCARI, Rome, Italy, Boston, MA

2169-P Type 1 Diabetes Development Is Modulated by Select Lipid Signaling Derived from Beta Cells and Immune Cells. ALEXANDER NELSON, MARGARET A. PARK, CHARLES CHALFANT, SASANKA RAMANADHAM, Birmingham, AL, Tampa, FL

2170-P The microRNA 199a Family Is Regulated by Glucose Levels in Pancreatic Beta Cells. JOAO PEDRO WERNECK DE CASTRO, MANOEL BLANDINO-ROSANO, ERNESTO BERNAL-MIRZACHI, Miami, FL

2171-P Towards Generating Spatiotemporal Multiscale Models of Human Pancreatic Beta Cells. KATE L. WHITE, KYLE MCCLARY, JITIN SINGLA, RAYMOND C. STEVENS, Los Angeles, CA

2172-P Exploring the Role of Calcium-Activated Potassium Channels in Alpha-Cell Function. MATTHEW DICKERSON, MOLLY K. ALTMAN, PRASANNA DADI, NICHOLAS C. VIERRA, DAVID JACOBSON, Nashville, TN, Davis, CA

2173-P Endocannabinoid Receptors Activity Modifies Insulin Secretion in Response to Glucose Exposure. ALONSO VILCHES-FLORES, GUADALupe M. GARCIA-LUNA, Mexico City, Mexico

2174-P STIM1/Orai1 Inhibition Reduces Store-Operated Ca2+ Entry and Modulates α-Cell Glucagon Secretion. MOLLY K. ALTMAN, PRASANNA DADI, DAVID JACOBSON, Nashville, TN
Abstract Author Index

The number following the author’s name refers to the abstract number, not a page number. A number in bold indicates the author is the abstract presenter. Please refer to the Abstract Book, the June supplement to the Association’s journal *Diabetes*, for all abstracts. For the Invited Speaker Index, please see page 151.

Aalborg, Jenny 179-OR, 1334-P
Abate, Nicola 1410-P
Abbink, Evertine J. 106-OR
Abcouwer, Steven F. 241-OR
Abdel-Salam, Suzan 1096-P
Abdel-Kader, Shaikh Abdul 1300-P
Abdullah, Abdullah 2085-P
Abe, Masahiro 2102-P
Abe, Masanori 1609-P, 1666-P
Abe, Takahiro 1176-P
Abel, E. Dale 1863-P, 1884-P
Aberer, Felix 1821-P, 2086-P, 2280-PUB, 2309-PUB
Abi Kharma, Joelle L. 683-P
Abildlund Nielsen, Morten 122-OR
Abitbol, Alexander 1052-P, 1096-P
Abou Alroub, Areej 1730-P
Abu Helal, Raghd 357-OR
Abu Kishk, Nada M. 686-P
Abuaysheh, Sanaa 1116-P, 1945-P, 2093-P
Abubakari, Abdul-Razak 2405-PUB
Abujaradeh, Hiba 799-P, 835-P, 864-P
Abu‑Qamar, Omar 244-OR
Abu‑Qamar, Omar 105-OR
Adedayo, Ajibola M. 468-P, 469-P, 611-P, 1597-P
Adesanya, Elizabeth A. 269-OR
Adetunji, Omolora R. 1559-P
Adi, Saleh 940-P
Adkins, Laura J. 446-P
Adler, Amanda 452-P
Adolfsson, Peter 730-P
Afar, Marios 625-P
Afrein, Samina 698-P
Agala, Vetty R. 1451-P
Agam, Tal, Sr. 636-P
Agarwal, Rashi 430-P
Agarwal, Sanjay 248-OR, 866-P
Agarwal, Shivani 1318-P, 1381-P
Agesen, Rikke M. 105-OR
Aggarwal, Naresh 1206-P
Agne, April A. 2330-PUB
Agner, Bue F. 1109-P
Agrawal, Rahul 104-OR, 393-P
Agrawal, Sungeeta 1378-P
Agu, Ngozichukwuka 724-P
Aguilar, Sofia 2316-PUB
Aharon-Hananel, Genya 908-P
Ahlers, Michael 1823-P
Ahlström, Håkan, Sr. 1790-P
Ahmad, Rasheed 1730-P
Ahmad, Shafqat 1213-P
Ahmed, Tamim 1281-P
Ahn, Chang Ho 2029-P
Ahn, Chul Wook 164-OR, 612-P, 1535-P, 1670-P, 2414-PUB
Ahn, David T. 9-OR
Ahn, Junho 115-OR, 633-P
Ahn, Kyu Jeung 1571-P
Ahn, Seong Hee 527-P, 533-P
Ahn, Sylvia A. 614-P
Ahola-Olli, Ari V. 1519-P
Aida, Rei 597-P, 1561-P, 2319-PUB
Aiello, Lloyd P. 244-OR, 245-OR
Aihara, Ken-Ichi 529-P, 2102-P
Aihara, Masakazu 944-P
Aimbire, Flavio 2365-PUB
Aizawa-Abi, Megumi 1178-P
Ajai, Neethu A. 685-P
Ajaimy, Maria 448-P, 541-P
Ajay, Vamadevan S. 1316-P, 2361-PUB
<table>
<thead>
<tr>
<th>Name</th>
<th>OR/PUB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajemba, Peter</td>
<td>936-P</td>
</tr>
<tr>
<td>Ajith, Jaysree</td>
<td>689-P</td>
</tr>
<tr>
<td>Akalin, Enver</td>
<td>448-P, 541-P</td>
</tr>
<tr>
<td>Akamine, Tomoyo</td>
<td>476-P, 498-P</td>
</tr>
<tr>
<td>Akamizu, Takashi</td>
<td>2108-P</td>
</tr>
<tr>
<td>Akehi, Yuki</td>
<td>529-P, 2102-P</td>
</tr>
<tr>
<td>Akhaphong, Brian</td>
<td>195-OR</td>
</tr>
<tr>
<td>Akhmetova, Saule B.</td>
<td>2223-PUB</td>
</tr>
<tr>
<td>Akhtar, Saghir</td>
<td>480-P</td>
</tr>
<tr>
<td>Akhter, Nadeem</td>
<td>1730-P</td>
</tr>
<tr>
<td>Akiyama, Tomoaki</td>
<td>1466-P</td>
</tr>
<tr>
<td>Akiv, Amichay</td>
<td>666-P</td>
</tr>
<tr>
<td>Akshintala, Divya</td>
<td>1546-P</td>
</tr>
<tr>
<td>Akturk, Halis K.</td>
<td>348-OR, 1017-P</td>
</tr>
<tr>
<td>Akunjee, Munaza</td>
<td>714-P</td>
</tr>
<tr>
<td>Akuta, Norio</td>
<td>782-P</td>
</tr>
<tr>
<td>Al Haj, Ghina</td>
<td>1231-P</td>
</tr>
<tr>
<td>Al Jobori, Hussein</td>
<td>1192-P</td>
</tr>
<tr>
<td>Al Mukaddam, Mona</td>
<td>720-P</td>
</tr>
<tr>
<td>Al Yami, Majed S.</td>
<td>414-P</td>
</tr>
<tr>
<td>Al Zoubi, Sura</td>
<td>483-P</td>
</tr>
<tr>
<td>Aladel, Alnoud</td>
<td>1586-P</td>
</tr>
<tr>
<td>Ala-Korpela, Mika</td>
<td>1519-P</td>
</tr>
<tr>
<td>Alam, Fatima</td>
<td>1823-P</td>
</tr>
<tr>
<td>Alam, Uazman</td>
<td>552-P</td>
</tr>
<tr>
<td>Alamuddin, Naji</td>
<td>720-P</td>
</tr>
<tr>
<td>AlAsfoor, Shefaa</td>
<td>283-OR, 2416-PUB</td>
</tr>
<tr>
<td>Albanese-O'Neill, Anastasia</td>
<td>719-P, 846-P, 847-P</td>
</tr>
<tr>
<td>Alberico, Federica</td>
<td>262-OR</td>
</tr>
<tr>
<td>Albermann, Sophie</td>
<td>284-OR</td>
</tr>
<tr>
<td>Albert, Paul</td>
<td>1462-P</td>
</tr>
<tr>
<td>Albertson, Brent G.</td>
<td>758-P</td>
</tr>
<tr>
<td>Albrechtsen, Anders</td>
<td>439-P</td>
</tr>
<tr>
<td>Albuquerque, Raquel Cristina M.</td>
<td>2365-PUB</td>
</tr>
<tr>
<td>Albury, Bonnie S.</td>
<td>1078-P</td>
</tr>
<tr>
<td>Aldana, Paola C.</td>
<td>1814-P</td>
</tr>
<tr>
<td>Aldini, Giancarlo</td>
<td>777-P, 778-P</td>
</tr>
<tr>
<td>Alejandro, Emilyn</td>
<td>83-OR, 195-OR, 2161-P, 2167-P</td>
</tr>
<tr>
<td>Alejandro, Rodolfo</td>
<td>140-OR, 142-OR</td>
</tr>
<tr>
<td>Aleksov, Sandra</td>
<td>448-P, 541-P, 1803-P</td>
</tr>
<tr>
<td>Alemayehu, Berhanu</td>
<td>966-P, 2272-PUB</td>
</tr>
<tr>
<td>Alenabi, Faridah</td>
<td>933-P</td>
</tr>
<tr>
<td>Alenazi, Aqeel M.</td>
<td>2250-PUB</td>
</tr>
<tr>
<td>Aleppo, Grazia</td>
<td>62-OR</td>
</tr>
<tr>
<td>Alessi, Janine</td>
<td>1450-P</td>
</tr>
<tr>
<td>Alessi, Thomas R.</td>
<td>1997-P</td>
</tr>
<tr>
<td>Alexander, Kylie M.</td>
<td>290-OR</td>
</tr>
<tr>
<td>Alexanderson-Rosas, Elvira G., Sr.</td>
<td>2362-PUB</td>
</tr>
<tr>
<td>Alfayez, Osamah</td>
<td>414-P</td>
</tr>
<tr>
<td>Alghamdi, Tamadher</td>
<td>492-P</td>
</tr>
<tr>
<td>Alharbi, Turki</td>
<td>559-P, 2458-PUB</td>
</tr>
<tr>
<td>Al-Hasani, Hadi, Sr.</td>
<td>1139-P</td>
</tr>
<tr>
<td>Ali, Ali M.</td>
<td>109-OR, 1192-P</td>
</tr>
<tr>
<td>Ali, Ayad K.</td>
<td>1559-P</td>
</tr>
<tr>
<td>Ali, Hira</td>
<td>1681-P, 2100-P</td>
</tr>
<tr>
<td>Ali, Khawla F.</td>
<td>2320-PUB</td>
</tr>
<tr>
<td>Ali, Mohammed K.</td>
<td>132-OR, 170-OR, 1316-P</td>
</tr>
<tr>
<td>Ali, Omer A.</td>
<td>1331-P</td>
</tr>
<tr>
<td>Aljenaee, Khaled</td>
<td>1547-P</td>
</tr>
<tr>
<td>Alkagiet, Stelina</td>
<td>459-P</td>
</tr>
<tr>
<td>Al-Karadsheh, Amer</td>
<td>988-P, 989-P, 990-P</td>
</tr>
<tr>
<td>Allden, Rachael</td>
<td>2087-P</td>
</tr>
<tr>
<td>Allebrandt, Karla V.</td>
<td>20-OR</td>
</tr>
<tr>
<td>Allen, Amy</td>
<td>837-P, 1251-P</td>
</tr>
<tr>
<td>Allen, Peg M.</td>
<td>694-P</td>
</tr>
<tr>
<td>Allerton, Timothy D.</td>
<td>271-OR</td>
</tr>
<tr>
<td>Allred, Clinton</td>
<td>1875-P</td>
</tr>
<tr>
<td>Allred, Kimberly</td>
<td>1875-P</td>
</tr>
<tr>
<td>Allshouse, Amanda A.</td>
<td>1443-P</td>
</tr>
<tr>
<td>Alluis, Bertrand</td>
<td>349-OR, 998-P, 1001-P, 1024-P, 1035-P</td>
</tr>
<tr>
<td>Almca, Joana</td>
<td>190-OR, 197-OR</td>
</tr>
<tr>
<td>Alman, Amy C.</td>
<td>1496-P, 1601-P</td>
</tr>
<tr>
<td>Almby, Kristina E.</td>
<td>368-OR</td>
</tr>
<tr>
<td>Almeida, Jussara</td>
<td>768-P</td>
</tr>
<tr>
<td>Almeida-Pfitto, Bianca</td>
<td>2360-PUB</td>
</tr>
<tr>
<td>Al-Mrabeh, Ahmad</td>
<td>40-OR, 42-OR, 1834-P</td>
</tr>
<tr>
<td>AlOlaiwi, Lina</td>
<td>559-P</td>
</tr>
<tr>
<td>AlJonge, Kimberly M.</td>
<td>375-OR</td>
</tr>
<tr>
<td>Alonso, Guy T.</td>
<td>1255-P, 1309-P, 1321-P, 1373-P</td>
</tr>
<tr>
<td>Alonso, Laura C.</td>
<td>85-OR, 2163-P</td>
</tr>
<tr>
<td>Alothman, Shaima</td>
<td>2250-PUB</td>
</tr>
<tr>
<td>Alshaarawy, Omanayma</td>
<td>2018-P</td>
</tr>
<tr>
<td>Alshehri, Mohammed</td>
<td>2250-PUB</td>
</tr>
<tr>
<td>Alsheikh, Razan</td>
<td>414-P</td>
</tr>
<tr>
<td>Alsibai, Khaled</td>
<td>760-P, 934-P, 2044-P</td>
</tr>
<tr>
<td>Al-Sofiani, Mohammed</td>
<td>306-OR</td>
</tr>
<tr>
<td>Al-Talabany, Shaween</td>
<td>167-OR, 1238-P</td>
</tr>
<tr>
<td>Altaras, Talya</td>
<td>636-P</td>
</tr>
<tr>
<td>Altitidis, Emrah</td>
<td>95-OR, 354-OR</td>
</tr>
<tr>
<td>Altman, Molly K.</td>
<td>2172-P, 2174-P</td>
</tr>
<tr>
<td>Altomari, Anna</td>
<td>2359-PUB</td>
</tr>
<tr>
<td>Altwaijri, Sulaiman</td>
<td>2458-PUB</td>
</tr>
<tr>
<td>Alustiza, Elena</td>
<td>1355-P</td>
</tr>
<tr>
<td>Alvarado, Fernanda</td>
<td>1404-P</td>
</tr>
<tr>
<td>Alvarez Condo, Graciela B.</td>
<td>526-P</td>
</tr>
<tr>
<td>Alvarez Gil, Ana M.</td>
<td>140-OR, 142-OR</td>
</tr>
<tr>
<td>Alvarez Guisasola, Fernado</td>
<td>2407-PUB</td>
</tr>
<tr>
<td>Alvarez, Kristin S.</td>
<td>2318-PUB</td>
</tr>
<tr>
<td>Alvarez, Silvia</td>
<td>653-P</td>
</tr>
<tr>
<td>Alvarez-Cubela, Silvia</td>
<td>2118-P</td>
</tr>
<tr>
<td>Alvarsson, Alexandra</td>
<td>1807-P</td>
</tr>
<tr>
<td>Alves, Christiano R.</td>
<td>758-P</td>
</tr>
<tr>
<td>Alves, Jasmin</td>
<td>227-OR</td>
</tr>
<tr>
<td>Amann, Kerstin U.</td>
<td>1222-P</td>
</tr>
<tr>
<td>Amano, Eri</td>
<td>1637-P</td>
</tr>
<tr>
<td>Amaro, Anastassia</td>
<td>2452-PUB</td>
</tr>
<tr>
<td>Ambalam, Chandrasekaran M.</td>
<td>2361-PUB</td>
</tr>
<tr>
<td>Amberry, Philip</td>
<td>78-OR, 79-OR, 1067-P, 1070-P</td>
</tr>
<tr>
<td>Ambrosine, Jodie M.</td>
<td>896-P</td>
</tr>
<tr>
<td>Ambrosoli, James A.</td>
<td>851-P, 854-P</td>
</tr>
<tr>
<td>Ambut, Jonathan</td>
<td>142-OR</td>
</tr>
<tr>
<td>Amiel, Stephanie A.</td>
<td>404-P, 1250-P</td>
</tr>
<tr>
<td>Amin, Kawa H.</td>
<td>1155-P</td>
</tr>
<tr>
<td>Amir Levy, Yifat</td>
<td>1902-P</td>
</tr>
<tr>
<td>Author</td>
<td>OR/Poster/Publication Only</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Ammons, Ann</td>
<td>2072-P</td>
</tr>
<tr>
<td>Amod, Aslam</td>
<td>530-P</td>
</tr>
<tr>
<td>Amorosa, Louis F.</td>
<td>616-P</td>
</tr>
<tr>
<td>Amo-Shinoki, Kikuko</td>
<td>2105-P</td>
</tr>
<tr>
<td>An, Ping</td>
<td>1709-P</td>
</tr>
<tr>
<td>An, Xiaoyu</td>
<td>1728-P</td>
</tr>
<tr>
<td>An, Yali</td>
<td>130-OR, 1654-P</td>
</tr>
<tr>
<td>An, Yu A.</td>
<td>276-OR</td>
</tr>
<tr>
<td>Anand, Meenu</td>
<td>695-P</td>
</tr>
<tr>
<td>Anand, Santosh, Sr.</td>
<td>2293-PUB</td>
</tr>
<tr>
<td>Anastassiadis, Erastos</td>
<td>1001-P, 1024-P</td>
</tr>
<tr>
<td>Andall-Bereton, Glennis M.</td>
<td>1511-P</td>
</tr>
<tr>
<td>Anderegggen, Eveline</td>
<td>350-OR</td>
</tr>
<tr>
<td>Anderlová, Katerína</td>
<td>1412-P, 1413-P</td>
</tr>
<tr>
<td>Andersen, Henrik U.</td>
<td>1424-P</td>
</tr>
<tr>
<td>Andersen, Lise Lotte Torvin</td>
<td>1452-P</td>
</tr>
<tr>
<td>Anderson, Barbara</td>
<td>217-OR, 795-P, 803-P, 848-P, 1395-P</td>
</tr>
<tr>
<td>Andersen, James H.</td>
<td>1518-P, 2370-PUB</td>
</tr>
<tr>
<td>Anderson, Jeffrey P.</td>
<td>172-OR, 435-P</td>
</tr>
<tr>
<td>Anderson, Mark</td>
<td>2071-P, 2087-P, 2097-P</td>
</tr>
<tr>
<td>Anderson, Pamela W.</td>
<td>2331-PUB</td>
</tr>
<tr>
<td>Anderson, Ryan M.</td>
<td>2122-P</td>
</tr>
<tr>
<td>Anderson, Stacey</td>
<td>992-P</td>
</tr>
<tr>
<td>Anderten, Helmut</td>
<td>1020-P, 1027-P, 1031-P, 2288-PUB</td>
</tr>
<tr>
<td>Andre, Camille C.</td>
<td>961-P</td>
</tr>
<tr>
<td>Andrianesis, Vasileios</td>
<td>1058-P</td>
</tr>
<tr>
<td>Anez-Zabala, Claudia</td>
<td>944-P, 1371-P</td>
</tr>
<tr>
<td>Ang, Lynn</td>
<td>62-OR</td>
</tr>
<tr>
<td>Angelopoulou, Stella-Maria</td>
<td>459-P</td>
</tr>
<tr>
<td>Anichini, Roberto</td>
<td>451-P, 639-P, 2222-PUB</td>
</tr>
<tr>
<td>Anno, Mari</td>
<td>1946-P</td>
</tr>
<tr>
<td>Anraku, Akayo</td>
<td>602-P</td>
</tr>
<tr>
<td>Ansari, Ahsan</td>
<td>202-OR</td>
</tr>
<tr>
<td>Anselmino, Marco</td>
<td>2089-P</td>
</tr>
<tr>
<td>Antal, Zoltan</td>
<td>722-P</td>
</tr>
<tr>
<td>Anthony, Steven J.</td>
<td>75-OR</td>
</tr>
<tr>
<td>Antinori-Lent, Kellie</td>
<td>702-P</td>
</tr>
<tr>
<td>Antipenko, Jessica P.</td>
<td>1806-P, 1978-P</td>
</tr>
<tr>
<td>Anzai, Keizo</td>
<td>742-P</td>
</tr>
<tr>
<td>Anzola, Isabel</td>
<td>1078-P, 1818-P</td>
</tr>
<tr>
<td>Aplin, Alfred</td>
<td>1815-P</td>
</tr>
<tr>
<td>Apostolopoulou, Maria</td>
<td>69-OR</td>
</tr>
<tr>
<td>Aragão, Ricardo E.M.</td>
<td>628-P</td>
</tr>
<tr>
<td>Aragona, Michele</td>
<td>1572-P</td>
</tr>
<tr>
<td>Araki, Atsushi</td>
<td>597-P, 1561-P, 2319-PUB</td>
</tr>
<tr>
<td>Araki, Eiichi</td>
<td>213-OR, 356-OR, 1170-P, 1635-P</td>
</tr>
<tr>
<td>Aramandla, Radhika</td>
<td>86-OR, 323-OR</td>
</tr>
<tr>
<td>Araneta, Maria Rosario</td>
<td>310-OR</td>
</tr>
<tr>
<td>Arase, Yasushi</td>
<td>2368-PUB</td>
</tr>
<tr>
<td>Aravind, S.R.</td>
<td>1206-P</td>
</tr>
<tr>
<td>Arbelaez, Ana Maria</td>
<td>1797-P</td>
</tr>
<tr>
<td>Ard, Jamy D.</td>
<td>1534-P</td>
</tr>
<tr>
<td>Ardern, Diane</td>
<td>1274-P</td>
</tr>
<tr>
<td>Aref-Estghiy, Erfan</td>
<td>240-OR</td>
</tr>
<tr>
<td>Arena, Vincent C.</td>
<td>656-P, 691-P</td>
</tr>
<tr>
<td>Arenas, Jose L., Sr.</td>
<td>1210-P</td>
</tr>
<tr>
<td>Arenas, Juliana</td>
<td>1440-P</td>
</tr>
<tr>
<td>Arends, Valerie</td>
<td>1686-P</td>
</tr>
<tr>
<td>Arévalo, Silvia</td>
<td>1454-P</td>
</tr>
<tr>
<td>Argento, Nicholas B.</td>
<td>974-P</td>
</tr>
<tr>
<td>Argerich, Maria Ines</td>
<td>2347-PUB</td>
</tr>
<tr>
<td>Arbisala, Benjamin</td>
<td>40-OR, 42-OR</td>
</tr>
<tr>
<td>Arif, Selina</td>
<td>1733-P</td>
</tr>
<tr>
<td>Arjia, Victoria</td>
<td>2316-PUB</td>
</tr>
<tr>
<td>Arima, Hisatomi</td>
<td>1199-P</td>
</tr>
<tr>
<td>Ariyasu, Hiroyuki</td>
<td>2108-P</td>
</tr>
<tr>
<td>Arlottto, Michelle</td>
<td>1874-P</td>
</tr>
<tr>
<td>Armstrong, Sam</td>
<td>730-P</td>
</tr>
<tr>
<td>Armstrong, Stephanie</td>
<td>1250-P</td>
</tr>
<tr>
<td>Arnaout, Amel</td>
<td>727-P</td>
</tr>
<tr>
<td>Arnaudova, Mila</td>
<td>954-P</td>
</tr>
<tr>
<td>Arnold, Amy C.</td>
<td>582-P</td>
</tr>
<tr>
<td>Arnold, Frances M.</td>
<td>2326-PUB</td>
</tr>
<tr>
<td>Arnold, Suzanne V.</td>
<td>1487-P, 1582-P</td>
</tr>
<tr>
<td>Arnoldis, Sabine</td>
<td>973-P</td>
</tr>
<tr>
<td>Arora, Anupama</td>
<td>1-OR</td>
</tr>
<tr>
<td>Arora, Satish</td>
<td>433-P, 449-P</td>
</tr>
<tr>
<td>Arriga, Roberto</td>
<td>1929-P</td>
</tr>
<tr>
<td>Arrubla, Jorge</td>
<td>1035-P</td>
</tr>
<tr>
<td>Arslanian, Silva A.</td>
<td>338-OR, 343-OR, 1335-P</td>
</tr>
<tr>
<td>Arteaga, S. Sonia</td>
<td>119-OR</td>
</tr>
<tr>
<td>Arterburn, David</td>
<td>1538-P</td>
</tr>
<tr>
<td>Arunachalam, Siddharth</td>
<td>16-OR</td>
</tr>
<tr>
<td>Arya, Niki</td>
<td>213-OR</td>
</tr>
<tr>
<td>Aryal, Krishna K.</td>
<td>1511-P</td>
</tr>
<tr>
<td>Asada, Mariko</td>
<td>422-P, 423-P</td>
</tr>
<tr>
<td>Ashford, Fiona B.</td>
<td>326-OR</td>
</tr>
<tr>
<td>Ashman, Natalie</td>
<td>2071-P</td>
</tr>
<tr>
<td>Ashtekar, Chandrashekhar</td>
<td>1685-P</td>
</tr>
<tr>
<td>Asicco, Laureano D.</td>
<td>493-P</td>
</tr>
<tr>
<td>Asllanaj, Eralda</td>
<td>1480-P</td>
</tr>
<tr>
<td>Asmar, Ali</td>
<td>144-OR</td>
</tr>
<tr>
<td>Asmar, Meena</td>
<td>144-OR</td>
</tr>
<tr>
<td>Aso, Yoshimasa</td>
<td>1849-P</td>
</tr>
<tr>
<td>Assaf-Balut, Carla</td>
<td>1455-P</td>
</tr>
<tr>
<td>Author Name</td>
<td>Affiliation</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Asseburg, Christian</td>
<td></td>
</tr>
<tr>
<td>Assi, Emma</td>
<td></td>
</tr>
<tr>
<td>Assor, Esther</td>
<td></td>
</tr>
<tr>
<td>Astiarraga, Brenno D.</td>
<td></td>
</tr>
<tr>
<td>Aston, Christopher E.</td>
<td></td>
</tr>
<tr>
<td>Aston-Mourney, Kathryn</td>
<td></td>
</tr>
<tr>
<td>Åstrand, Magnus</td>
<td></td>
</tr>
<tr>
<td>Atabai, Kamran</td>
<td></td>
</tr>
<tr>
<td>Atakov-Castillo, Astrid</td>
<td></td>
</tr>
<tr>
<td>Ateya, Mohammad B.</td>
<td></td>
</tr>
<tr>
<td>Athalye, Sandeep N.</td>
<td></td>
</tr>
<tr>
<td>Athanasopoulou, Theodora</td>
<td></td>
</tr>
<tr>
<td>Athinarayanan, Shaminie J.</td>
<td></td>
</tr>
<tr>
<td>Atisso, Charles</td>
<td></td>
</tr>
<tr>
<td>Atlassian, Jacqueline</td>
<td></td>
</tr>
<tr>
<td>Atsumi, Tatsuya</td>
<td></td>
</tr>
<tr>
<td>Attinger, Christopher</td>
<td></td>
</tr>
<tr>
<td>Au, Natalie H.</td>
<td></td>
</tr>
<tr>
<td>Aubert, Virginie</td>
<td></td>
</tr>
<tr>
<td>Aung, Nay Linn</td>
<td></td>
</tr>
<tr>
<td>Austin, Juliana</td>
<td></td>
</tr>
<tr>
<td>Austin, Mary M.</td>
<td></td>
</tr>
<tr>
<td>Autier, Philippe</td>
<td></td>
</tr>
<tr>
<td>Auvinen, Juha</td>
<td></td>
</tr>
<tr>
<td>Avila, Jonathan</td>
<td></td>
</tr>
<tr>
<td>Avila, Nicole</td>
<td></td>
</tr>
<tr>
<td>Avtanski, Dimiter</td>
<td></td>
</tr>
<tr>
<td>Awadw, Mohammed</td>
<td></td>
</tr>
<tr>
<td>Axelrod, Ceara</td>
<td></td>
</tr>
<tr>
<td>Axelrod, Christopher L.</td>
<td></td>
</tr>
<tr>
<td>Ayala, Julio</td>
<td></td>
</tr>
<tr>
<td>Aye, Su M.</td>
<td></td>
</tr>
<tr>
<td>Aye, Tandy</td>
<td></td>
</tr>
<tr>
<td>Ayers, Colby</td>
<td></td>
</tr>
<tr>
<td>Ayine, Priscilla</td>
<td></td>
</tr>
<tr>
<td>Aylor, Kevin W.</td>
<td></td>
</tr>
<tr>
<td>Ayyagani, Usha</td>
<td></td>
</tr>
<tr>
<td>Azar, Kristen M.</td>
<td></td>
</tr>
<tr>
<td>Azharian, Sahar</td>
<td></td>
</tr>
<tr>
<td>Aziz, Faisal</td>
<td></td>
</tr>
<tr>
<td>Baba, Masayuki</td>
<td></td>
</tr>
<tr>
<td>Baba, Yusuke</td>
<td></td>
</tr>
<tr>
<td>Babazono, Tetsuya</td>
<td></td>
</tr>
<tr>
<td>Babenko, Alina Y.</td>
<td></td>
</tr>
<tr>
<td>Baccarelli, Andrea</td>
<td></td>
</tr>
<tr>
<td>Bacchi, Elisabetta</td>
<td></td>
</tr>
<tr>
<td>Bacha, Fida</td>
<td></td>
</tr>
<tr>
<td>Bacic, Janine</td>
<td></td>
</tr>
<tr>
<td>Bäckhed, Fredrik</td>
<td></td>
</tr>
<tr>
<td>Backman, Michael C.</td>
<td></td>
</tr>
<tr>
<td>Badon, Sylvia E.</td>
<td></td>
</tr>
<tr>
<td>Bae, Jaehyun</td>
<td></td>
</tr>
<tr>
<td>Baekdal, Tine A.</td>
<td></td>
</tr>
<tr>
<td>Baetscher, Eric</td>
<td></td>
</tr>
<tr>
<td>Bagger, Jonatan I.</td>
<td></td>
</tr>
<tr>
<td>Bagga, Malene</td>
<td></td>
</tr>
<tr>
<td>Bahne, Emilie</td>
<td></td>
</tr>
<tr>
<td>Bai, Johnny-Wei</td>
<td></td>
</tr>
<tr>
<td>Bai, Xinxui</td>
<td></td>
</tr>
<tr>
<td>Bairal, David</td>
<td></td>
</tr>
<tr>
<td>Baier, Leslie</td>
<td></td>
</tr>
<tr>
<td>Baig, Arshiya</td>
<td></td>
</tr>
<tr>
<td>Baik, Sei Hwn</td>
<td></td>
</tr>
<tr>
<td>Bailey, Clifford J.</td>
<td></td>
</tr>
<tr>
<td>Bailey, Michael D.</td>
<td></td>
</tr>
<tr>
<td>Baillod, Janet C.</td>
<td></td>
</tr>
<tr>
<td>Bain, James R.</td>
<td></td>
</tr>
<tr>
<td>Bain, Stephen C.</td>
<td></td>
</tr>
<tr>
<td>Bairaktari, Eleni</td>
<td></td>
</tr>
<tr>
<td>Bajaj, Harpreet S.</td>
<td></td>
</tr>
<tr>
<td>Bajer, Boris</td>
<td></td>
</tr>
<tr>
<td>Baker, David</td>
<td></td>
</tr>
<tr>
<td>Baker, Laura D.</td>
<td></td>
</tr>
<tr>
<td>Baker, Nathaniel L.</td>
<td></td>
</tr>
<tr>
<td>Baker, Rocky L.</td>
<td></td>
</tr>
<tr>
<td>Bakillah, Ahmed</td>
<td></td>
</tr>
<tr>
<td>Bakris, George</td>
<td></td>
</tr>
<tr>
<td>Balagopal, P. Babu</td>
<td></td>
</tr>
<tr>
<td>Balasubramaniam, Ashok</td>
<td></td>
</tr>
<tr>
<td>Balci, Mustafa Kemal</td>
<td></td>
</tr>
<tr>
<td>Balda-Canizares, Javier</td>
<td></td>
</tr>
<tr>
<td>Ballantyne, Christie M.</td>
<td></td>
</tr>
<tr>
<td>Balliro, Courtney A.</td>
<td></td>
</tr>
<tr>
<td>Bally, Lia</td>
<td></td>
</tr>
<tr>
<td>Balo, Andrew</td>
<td></td>
</tr>
<tr>
<td>Baltaro, Richard</td>
<td></td>
</tr>
<tr>
<td>Baltzinger, Philippe</td>
<td></td>
</tr>
<tr>
<td>Ban, Linda A.</td>
<td></td>
</tr>
<tr>
<td>Bandeira Farias, Maria Elba</td>
<td></td>
</tr>
<tr>
<td>Bandeira, Francisco</td>
<td></td>
</tr>
<tr>
<td>Bandrowski, Anita</td>
<td></td>
</tr>
<tr>
<td>Bandyopadhyay, Debuddita</td>
<td></td>
</tr>
<tr>
<td>Banerjee, Sayani</td>
<td></td>
</tr>
<tr>
<td>Banerjee, Tanima</td>
<td></td>
</tr>
<tr>
<td>Banerji, Mary Ann</td>
<td></td>
</tr>
<tr>
<td>Banfi, Giuseppe</td>
<td></td>
</tr>
<tr>
<td>Bangalore Krishna, Kanthi</td>
<td></td>
</tr>
<tr>
<td>Banke Nordbeck, Elin</td>
<td></td>
</tr>
<tr>
<td>Banks, Phillip L.</td>
<td></td>
</tr>
<tr>
<td>Banks, William A.</td>
<td></td>
</tr>
<tr>
<td>Banning, Alexis</td>
<td></td>
</tr>
<tr>
<td>Bansal, Amita</td>
<td></td>
</tr>
<tr>
<td>Bansal, Nidhi</td>
<td></td>
</tr>
<tr>
<td>Bantle, Anne</td>
<td></td>
</tr>
<tr>
<td>Bantwal, Ganapathi</td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT AUTHOR INDEX

Banu, Isabela 2084-P, 2189-P
Bao, Wei 1672-P
Bao, Yicheng 1699-P
Bao, Yuqian 425-P, 426-P
Baqar, Sara 461-P
Bao, Wei 1672-P
Bao, Yicheng 1699-P
Bao, Yuqian 425-P, 426-P
Baqar, Sara 461-P, 2179-PUB
Barabash, Ana M. 1455-P
Barash, Steven D. 31-OR
Barbe, Francois 2398-PUB
Barber, Alistair J. 592-P, 608-P
Barbieri, Chiara 2089-P
Barbour, Linda A. 1421-P, 1428-P, 1443-P
Bardach, Shoshana H. 1479-P
Bardtrum, Lars 300-OR
Barengolts, Elena 1643-P, 1644-P
Bärenz, Felix 2030-P
Baretto, Carol 1436-P
Barger, Kelly 659-P
Bargiota, Alexandra 1592-P
Barker, Guy 2076-P
Barker, Natalie K. 186-OR
Barkholt, Pernille 1788-P
Barmpa, Eleftheria 1592-P
Barnard, Neal 294-OR
Barnes, Alison C. 40-OR, 42-OR, 291-OR, 1834-P
Barnes, Timothy L. 1370-P, 1384-P, 1387-P, 1388-P
Barnighausen, Till 1511-P
Baron, Anna E. 136-OR
Baron, Michelle A. 1061-P, 1102-P, 1103-P
Barra, Jessie 29-OR
Barraso, Mariluce 898-P
Barreto, Sandhi Maria 1671-P
Barrett, Eugene 367-OR, 754-P, 755-P, 1774-P
Barrett, Helen L. 1422-P
Barrett-Connor, Elizabeth 1704-P
Barrio, Francisco 2316-PUB
Barritt, Alfred S. IV 1640-P
Barry, Samantha A. 214-OR, 881-P
Barry, Simon C. 230-OR
Bartaszkova, Dagmar 126-OR
Bartels, Dorothee 2364-PUB
Bartonova, Lenka 1747-P
Bartz, Sara K. 1257-P
Barzalobre Geronimo, Raul 2465-PUB
Barzilay, Joshua I. 1661-P, 1811-P
Basavarajappa, Halesha D. 2115-PUB
Bascomb, Jeanine M. 2097-P
Basset, Christine 49-OR
Bascomb, Jeanine M. 2097-P
Basov, Anna 394-OR
Bassil, Maya 655-P, 683-P
Bast, Giuseppe P. 25-OR
Basu, Ananda 44-OR, 45-OR
Basu, Arpita 1601-P
Basu, Rita 41-OR, 44-OR, 45-OR
Batchu, Sri Nagarjun 492-P
Batista, Livia A.A. 585-P, 628-P, 2192-PUB
Batista, Thiago M. 356-OR, 1784-P, 1785-P, 1792-P
Batra, Manav 776-P, 1116-P, 1868-P, 1945-P
Battaglia, Manuela 94-OR
Batterham, Rachel L. 1137-P
Battezzati, Alberto 292-OR, 793-P
Bauer, Andrea 1551-P
Bauer, Brandon M. 2139-P
Bauer, Paige V. 1948-P
Baumann, Daniel 195-OR
Baumgartner, Amy 234-OR, 431-P
Baumgartner, Iris 458-P
Bax, Kevin 1550-P, 1578-P, 1579-P
Baxter, Judith 182-OR
Baye, Estifanos 777-P, 778-P
Bayes, Justin 199-OR
Bayne, Mitchell 1807-P
Bays, Harold 128-OR, 1206-P
Bazalinski, Dariusz 2256-PUB
Bazan, Guillermo 945-P
Bazydlo, Katarzyna 1189-P
Bazzano, Alessandra N. 1576-P
Bazzano, Lydia A. 1474-P
Beach, Lauren B. 825-P, 1650-P
Beal, Anne C. 249-OR, 660-P, 1595-P, 1616-P
Beaton, Melanie D. 1550-P, 1578-P, 1579-P
Beaton, Michelle 1841-P, 1909-P
Beaudin, Maryse 1595-P
Beaulieu, Lindsey C. 1342-P, 1343-P, 2332-PUB
Beaumont, Robert 20-OR, 23-OR
Beauvais, Alexis 2069-P
Beavers, David 650-P
Bebu, Ionut 521-P
Beck, Peter 2280-PUB
Beck, Roy 1689-P
Becker, Diane M. 306-OR
Becker, Frauke 1319-P
Becker, Matthew 99-OR
Beckles, Gloria L.A. 1680-P
Beck-Nielsen, Henning 105-OR, 1444-P
Beegle, Richard 1816-P
Beeson, Erynn 805-P
Befi, Anish 1204-P
Behmanmanesh, Ghazaleh 481-P
Beillat, Maud, Sr. 1114-P
Beisswenger, Paul J. 521-P
Belfort-DeAquijar, Renata 365-OR, 1802-P, 2427-PUB
Bell, Eleni 1899-P
Bell, Alan D. 821-P, 1184-P
Bell, Bethany A. 308-OR, 1253-P
Bell, Jimmy D. 20-OR
Bell, Kirstine 290-OR, 1368-P
Bell, Melanie 149-OR
Bellatorre, Anna 179-OR
Bellia, Alfonso 1929-P
Belsito, Donald V. 1591-P
Belsley, Scott J. 1823-P
Ben Amor, Nadia, Jr. 2327-PUB
Ben Mami, Faika 2327-PUB
Ben Nasr, Moufida 571-P
Benedict, Christian 1675-P
Benes, Marek 1974-P, 2051-P, 2097-P, 2449-PUB
Benesch, Carsten 973-P
Benfica, Camila Z. 606-P
Benhamou, Pierre Y. 81-OR, 208-OR
Benitez, Aldo 1645-P
Benitez, Sara G. 2340-PUB
Benjamin, Richard K. 319-OR
Benson, Gretchen 764-P
Benson, Kylie 883-P
Benter, Ibrahim 480-P
Bentsen, Marie A. 375-OR, 1094-P
Beraldo, Rebeca A. 785-P
Berard, Lori 1039-P, 1094-P
Beretta, Mileni V. 2255-PUB
Berg, Arthur 812-P
Berg, Cynthia 657-P
Bergman, Jacques J. 1137-P
Bergman, Michael 1537-P
Bergman, Natasha C. 1939-P, 1963-P, 2415-PUB
Bergmann, Sigrid 1963-P
Bergsten, Peter 1352-P
Berman, Dora M. 140-OR
Bermudez, Karla 1954-P
Bernal-Mizrachi, Ernesto 190-OR, 2170-P
Bernstein, Shanna 1814-P, 1842-P, 1893-P
Bhargava, Amit 2377-PUB
Bhattacharya, Arpandev 1193-P
Bhattacharya, Sumit 760-P
Bhattacharyya, Kingshuk 2293-PUB
Bhattacharyya, Samit 780-P
Biertho, Laurent 150-OR
Bierwagen, Alessandra 69-OR
Biehl Rudkjaer, Lise 1981-P
Bielsen, Mathias 1223-P
Billard, Laura 697-P, 2236-PUB
Billings, Liana 997-P
Binda, Paola 1791-P
Bini, Jason 2145-P
Binkowska-Bury, Monika 2256-PUB
Biondi, Giuseppina 2147-P
Birkeland, Kare I. 433-P, 449-P, 752-P
Birkenfeld, Andreas L. 1804-P
Birnbaum, Morris J. 359-OR
Birukova, Elena 2305-PUB
Bisagno, Michela 2378-PUB
Bisgaier, Stanley G. 1326-P
Bissel, Adam 733-P
Bittel, Daniel 733-P
Bitterman, Olimpia 2345-PUB
Bitzer, Markus 1737-P
Bjornstad, Petter 1558-P
Bilir, S. Pinar 1247-P, 1265-P
Billard, Laura 697-P, 2236-PUB
Billings, Liana 127-OR, 997-P
Bina, Paolo 1791-P
Black, Jason E. 377-P, 399-P
Black, Mary Helen 1703-P
Blackburn, Mary C. 397-P
Blak, Betina T. 1186-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Cynthia 1809-P
Blanco, Ernesto J. 219-OR
Blak, Betina T. 1186-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Cynthia 1809-P
Blanco, Ernesto J. 219-OR
Blanco, Mary Helen 1703-P
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Cynthia 1809-P
Blanco, Ernesto J. 219-OR
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
Blakemore, Alex I. 20-OR
Blanc-Bisson, Christele 450-P
Blanco, Laurence 434-P, 450-P, 1423-P, 1726-P
Blanco, Patrick 1726-P
ABSTRACT AUTHOR INDEX

Bowles, Kathryn  706-P
Bowling, Frank L.  578-P
Bowskill, Bridgit  492-P
Bowyer, Vicky  797-P
Box, Kevin  1315-P
Boyd, Sean  **1234-P**
Boye, Kristina  **1557-P**
Boya, Edward J.  **113-OR, 1574-P, 1617-P, 1676-P, 2373-PUB**
Boyle, Claire  **62-OR, 1373-P**
Boyle, Peter  **133-OR, 180-OR, 1507-P, 1613-P, 1619-P, 1627-P, 1944-P**
Bracco, Paula  **1671-P**
Brachs, Maria  **2030-P**
Brachs, Sebastien  **2030-P**
Bradley, Brenda J.  **237-OR**
Bradley, David  **1751-P**
Bradley, Donald  **2765-PUB**
Brandle, Michael  **1122-P**
Brand, Christian L.  **347-OR**
Brandão, Ana B.P.  **2365-PUB**
Brand, Sheila  **1347-P**
Braendholt Olsen, Minna  **102-OR**
Braffett, Barbara  **113-OR, 1686-P**
Branigan, Deborah  **756-P**
Brath, Helmut  **1122-P**
Bremner, Samantha  **1789-P**
Breymeyer, Kara  **1943-P, 2445-PUB**
Breitschaft, Astrid  **1135-P**
Brerez, Samanta  **1786-P**
Breiner, Avivit  **235-OR**
Brent, Michael H.  **517-P, 520-P, 538-P, 560-P, 600-P**
Breton, Marc D.  **992-P**
Breslau, Mary  **341-OR**
B्रেux, Brittani M.  **2314-PUB**
Brixner, Diana  **909-P**
Broadney, Miranda  **1347-P, 1353-P**
Broer, Meryl  **837-P, 1251-P**
Brodmann, Marianne  **2309-PUB**
Brodovitz, Kimberly  **1556-P, 1569-P, 2364-PUB**
Brod, Jennifer A.  **24-OR**
Brokaw, Sarah M.  **675-P, 676-P**
Brønden, Andreas  **1969-P**
Brooks, Belinda  **593-P, 1736-P**
Brosius, Frank  **491-P**
Broznahan, Naomi T.  **291-OR**
Broussard, Josiane L.  **158-OR, 2448-PUB**
Brousseau, Emmanuel  **1773-P**
Brown, Christopher J.  **2101-P**
Brown, Clinton  **489-P, 611-P, 1597-P**
Brown, Cris M.  **2112-P, 2114-P**
Brown, Emily  **1163-P**
Brown, Florence M.  **2044-P**
Brown, Jacob  **1970-P**
Brown, Jenny M.  **372-OR, 373-OR**
Brown, Judith B.  **377-P, 399-P**
Brown, Lee  **1789-P**
Brown, Matthew  **2117-P**
Brown, Melissa  **2153-P**
Brown, Rebecca  **1331-P**
Brown, Ross L.  **648-P**
Brown, Sharon A.  **888-P**
Brown, Steven J.  **576-P, 863-P**
Brown, Sue A.  **894-P**
Brown, Susan  **2322-PUB**
Brown, Todd  **307-OR**
Brown, Todd  **376-P, 2460-PUB**
Brown, Lorna  **234-OR, 431-P**
Brown-Brandi, Kirstine  **1065-P**
Brown, Jeffrey  **47-OR**
Brownson, Ross  **694-P**
Bruch, John  **651-P**
Brucker, Sara Y.  **1403-P**
Bruggeman, Britney S.  **844-P, 1371-P**
Brügger, Marie  **822-P**
Brugnara, Laura  **2410-PUB**
Bruin, Pedro F.C.  **2192-PUB**
Brunner, Bodo  **1861-P**
Brunner, Martina  **1941-P**
Brunner, Stephen  **1183-P**
Bruns, Todd M.  **96-OR, 1543-P, 1967-P**
Bryght, Robert  **1146-P, 2052-P**
Bue, Le  **1351-P, 2073-P, 2456-PUB**
Buchanan, Thomas A.  **117-OR**
Buchwald, Peter  **27-OR**
Buckingham, Don A., Sr.  **1307-P, 1309-P, 1321-P**
Buda, Pawel  **1189-P**
Bueno Colman, Elvio D., Sr.  **1645-P**
Bueno, Luis E., Sr.  **2185-PUB**
<table>
<thead>
<tr>
<th>Name</th>
<th>OR</th>
<th>P</th>
<th>PUB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chau, Christopher V.</td>
<td>2322-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chaudhari, Uddhav K.</td>
<td>1931-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chavanelle, Vivien</td>
<td>2312-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chavda, Vipul</td>
<td>1205-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chaves, Conceição D.</td>
<td>1467-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chavez Velaquez, Alberto O.</td>
<td>1810-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chavez, Eloisa</td>
<td>1524-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chavis-Blakely, Hunter</td>
<td>1668-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chawla, Manoj S.</td>
<td>750-P, 952-P, 1209-P, 1685-P, 2328-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chawla, Purvi M.</td>
<td>952-P, 1209-P, 1685-P, 2328-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chawla, Rajeev</td>
<td>248-OR, 866-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chaykin, Louis B.</td>
<td>1081-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chee, Ying Jie</td>
<td>1300-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Chen-Yi</td>
<td>26-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Chi</td>
<td>1602-P, 1996-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Guanliang</td>
<td>1839-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Guofang</td>
<td>514-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Guojian</td>
<td>1144-P, 2302-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Guoqing J.</td>
<td>2324-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Haiying</td>
<td>494-P, 531-P, 1642-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Haiying</td>
<td>171-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Hanqing</td>
<td>358-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Heng</td>
<td>265-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Hong</td>
<td>243-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Hungta</td>
<td>1141-P, 1562-P, 1582-P, 1615-P, 1629-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Jianmin</td>
<td>483-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Jieling</td>
<td>967-P, 1021-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Jing</td>
<td>471-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Julia H.</td>
<td>1892-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Junqin</td>
<td>80-OR, 87-OR, 2109-P, 2149-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Kezhu</td>
<td>2019-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Kong Y.</td>
<td>2052-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Kuan Yu</td>
<td>1426-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Kuangyang</td>
<td>278-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Kwang-Wen</td>
<td>704-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Li</td>
<td>1201-P, 2310-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Liangkai</td>
<td>1672-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Lin</td>
<td>624-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Ling</td>
<td>1703-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Lixian</td>
<td>929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Lulu</td>
<td>1314-P, 1898-P, 2155-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Ming</td>
<td>779-P, 2413-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Nana</td>
<td>783-P, 1607-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Pau-Chung</td>
<td>1614-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Pei Chin</td>
<td>2382-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Pei-Yin</td>
<td>1665-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Peng</td>
<td>1713-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Qian</td>
<td>1892-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Shali</td>
<td>240-OR, 473-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Weiqin</td>
<td>2001-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Xi</td>
<td>228-OR, 333-OR, 1240-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Xiaohao</td>
<td>13-OR, 901-P, 965-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Xinhua</td>
<td>225-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yan</td>
<td>501-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yana</td>
<td>1770-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yang</td>
<td>265-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yanyan</td>
<td>130-OR, 1654-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yen-Yu</td>
<td>1665-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yi</td>
<td>1602-P, 1996-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yi-Guang</td>
<td>317-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yii-Der Ida</td>
<td>2244-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yingbo</td>
<td>336-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yu</td>
<td>1847-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yu-Han</td>
<td>152-OR, 496-P, 1768-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yunmay</td>
<td>152-OR, 496-P, 1768-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Yunmei</td>
<td>2441-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen, Zonglan</td>
<td>2024-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chenevert, Thomas L.</td>
<td>2078-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Alice</td>
<td>301-OR, 1029-P, 1032-P, 1036-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Kar Keung</td>
<td>1442-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Kenneth K.Y.</td>
<td>2027-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Peiyao</td>
<td>1340-P, 1342-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Xiaoyun</td>
<td>2456-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheng, Yiling J.</td>
<td>130-OR, 310-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chengcheng, Qiao</td>
<td>2453-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chenghui, Zhang</td>
<td>2186-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cherchi, Sara</td>
<td>599-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chernausek, Steven</td>
<td>1401-P, 1411-P, 1703-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cherney, David</td>
<td>89-OR, 517-P, 520-P, 537-P, 538-P, 560-P, 600-P, 1346-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cherrington, Alan D.</td>
<td>346-OR, 347-OR, 979-P, 1961-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cherrington, Andrea</td>
<td>307-OR, 2330-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cherubini, Valentino</td>
<td>1502-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chesi, Alessandra</td>
<td>1705-P, 1714-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chester, Britannie H.</td>
<td>705-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chetboun, Mikael</td>
<td>2143-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chetty, Tarini</td>
<td>747-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cheung, Ngai Wah</td>
<td>1673-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chew, Daniel E.K.</td>
<td>419-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chew, Emily</td>
<td>596-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chewning, Betty A.</td>
<td>1380-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chhawla, Rajeev</td>
<td>750-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chiazza, Fausto</td>
<td>483-P, 1148-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chickeerring, Jennifer</td>
<td>74-OR, 1207-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chigusa, Yoshitsugu</td>
<td>2348-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chikazawa, Shinji</td>
<td>1831-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chimene-Weiss, Jeremy I.</td>
<td>1836-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chin, Marshall</td>
<td>694-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chisholm, Jacob</td>
<td>2097-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chiu, Jeng-Jiann</td>
<td>445-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chiu, Yu-Yen</td>
<td>704-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Dong Hyeok</td>
<td>467-P, 2404-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Hyunsoo</td>
<td>2007-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Jae Hyoung</td>
<td>28-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Jeonghwa</td>
<td>802-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Kaoi</td>
<td>547-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Kelly</td>
<td>868-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Pyone</td>
<td>2389-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Yongin</td>
<td>1670-P, 1911-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cho, Yong-Wook</td>
<td>1419-P</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cho, Yoon Shin  266-OR
Cho, Young Min  266-OR, 267-OR, 2029-P
Cho, Yun Kyung  407-P, 1064-P
Chodick, Gabriel  636-P, 1563-P, 1564-P, 2295-PUB
Choe, Sung Sik  1951-P
Choi, Dughyun  820-P
Choi, Hyo Sun  1200-P, 1202-P
Choi, Jaehyuk  77-OR
Choi, Jong Han  1064-P
Choi, Joungil  570-P
Choi, Kyung Mook  464-P
Choi, Min Sun  572-P, 1541-P
Choi, Ran Hee  1753-P
Choi, Soo Bong  984-P, 996-P
Choi, Sunge  1912-P
Choi, Sunghee  266-OR, 428-P
Chopra, Vidita  897-P
Choudhary, Pratik  404-P
Chow, Diem  2318-PUB
Chow, Elaine  455-P, 1590-P, 1649-P
Chow, Francis C.C.  1083-P
Chow, I-Ting  95-OR
Chow, Lisa S.  396-P, 1926-P
Chow, Rebecca P.  1399-P
Choy, Annamaria  167-OR, 1238-P
Choy, Richard  519-P
Christakis, Panos G.  596-P
Christensen, Kaare  1709-P
Christensen, Merete B.  1939-P
Christian, Anna  2338-PUB
Christian, Mark  786-P
Christiansen, Erik  1135-P
Christiansen, Mark P.  304-OR, 1239-P
Christophi, Costas A.  1574-P, 1704-P
Christou, Konstantinos  459-P
Chu, I-Ming  26-OR
Chua, Chin Lian  1198-P
Chua, Shane P.C.  1006-P
Chuang, David T.  1874-P
Chuang, Lee-Ming  1614-P
Chuang, Yuh-Jue  704-P
Chudasama, Dipak B.  1205-P, 2214-PUB
Chuju, Daisuke  100-OR, 1940-P
Chun, Ki Hong  1571-P, 2386-PUB
Chun, Sunghwan  1739-P
Chung, Dong Jin  467-P, 2404-PUB
Chung, Fu-Mei  534-P
Chung, Hye Soo  464-P
Chung, Jin Ouk  467-P, 2404-PUB
Chung, Min Young  467-P, 2404-PUB
Chung, Sung M.  1051-P
Chung, Seung Min  1508-P
Chuong, Rose  805-P
Church, Christopher D.  1890-P
Church, Mei Mei  961-P
Ciancio, Gaetano  140-OR
Ciaraldi, Theodore P.  159-OR, 1902-P
Cibula, Donald A.  800-P
Ciccarone, Annamaria  362-OR, 1791-P
Cid-Ruzafa, Javier  1141-P, 1562-P, 1615-P, 1629-P
Ciecko, Ashley E.  317-OR
Ciemens, Elizabeth L.  1-OR, 1499-P
Cignarelli, Angelo  2147-P, 2190-PUB
Cigolle, Christine  181-OR
Cigrovski Berkovic, Maja  1965-P, 2278-PUB
Cinar, Ali  937-P
Cincotta, Anthony  1805-P, 2036-P, 2429-PUB
Cinkajlova, Anna  469-P, 1412-P, 1413-P, 1974-P, 2449-PUB
Cinti, Francesca  1971-P, 2142-P
Cinti, Saverio  1242-P
Ciociaro, Demetrio  2089-P
Ciofi, Patrizia  1042-P
Cistola, David P.  1534-P
Civet, Alexandre  2398-PUB
Civitelli, Roberto  1701-P
Ck, Shahanas  2213-PUB
Clark, Amy L.  2112-P
Clark, Jeanne  376-P, 2460-PUB
Clark, Taylor  794-P, 2326-PUB
Clark, Virginia  1640-P
Clarke, Antoine B.  1550-P, 1578-P, 1579-P
Clarke, Philip M.  1299-P, 1649-P
Claro, Lais W.  223-OR
Clarson, Cheril  237-OR
Claudio-da-Silva, Cesar S.  1112-P
Claver, Gervase J.  1444-P
Clayton, Peter E.  116-OR
Clayton, Zachary S.  1787-P
Cleal, Bryan  833-P
Clegg, Deborah  2010-P
Clement, Maureen A.  821-P, 1184-P
Clément, Allen  245-OR
Cline, Gary  146-OR, 149-OR, 1766-P, 2145-P, 2427-PUB
Clore, John N.  1266-P
Cloutier, Marie-Pier  503-P, 1817-P, 2000-P
Cobb, Ellen C.  650-P
Cobelli, Claudio  45-OR, 72-OR, 1808-P, 1812-P, 1925-P, 1953-P
Cochran, Jesse  1884-P
Cochrum, Robbie G.  741-P
Codario, Ronald  1279-P
Codella, Roberto  2311-PUB
Coen, Paul M.  1907-P, 1936-P
Cogen, Fran R.  855-P

AMERICAN DIABETES ASSOCIATION
ABSTRACT AUTHOR INDEX

OR: Oral  P: Poster  PUB: Published Only

330
Cohen, Henry 30-OR
Cohen, Neale 986-P
Cohen, Ohad 953-P
Cohen, Robert M. 1822-P
Cohen, Ronald N. 1764A-P
Cohen, Susan M. 799-P, 864-P
Colagiuri, Stephen 689-P
Cole, F. Sessions 269-OR
Coleman, Charlotte L. 1357-P
Coleman, Craig I. 1287-P, 1291-P
Coleman, Julia L. 851-P, 854-P
Coleman, Ruth L. 1299-P
Coletta, Dawn K. 749-P
Coletta, Richard L. 749-P
Colhoun, Helen 263-OR
Coll, Anthony P. 350-OR
Collino, Massimo 483-P, 1148-P
Collins, Jane E. 2097-P
Collins, Shavonne M. 1347-P
Collotta, Debora 483-P
Colman, Peter G. 230-OR, 986-P, 1288-P, 1306-P
Colombo, Marco 263-OR
Comeau, Mary E. 19-OR, 1760-P
Commissariat, Persis V. 795-P, 803-P, 1395-P
Conneely, Mary M. 670-P
Conners, Ryan T. 741-P
Connolly, Thomas 1113-P
Connor, Ulla M. 251-OR
Constable, Todd 365-OR, 1802-P
Contini, Pierpaolo 599-P
Conway, Baqiyah 178-OR, 1593-P
Conway, James P. 1841-P
Cook, Delilah 817-P
Cook, Karie A. 858-P, 891-P
Cook, Keziah 1331-P
Cook, Elaine M. 250-OR
Cooney, Laura G. 2452-PUB
Coons, John M. 741-P
Cooper, Andrew J. 1125-P
Cooper, Mark E. 505-P, 524-P
Cooper, Tammy 237-OR
Copenhaver, Melanie M. 1337-P, 1360-P
Copetti, Massimiliano 1633-P
Copolla, Andrea 2410-PUB
Coppola, Andrea 1929-P
Copps, Kyle D. 184-OR, 1762-P, 1873-P
Corathors, Sarah 1309-P, 1318-P, 1321-P, 1373-P
Corbin, Karen D. 1887-P
Cordero, Toni L. 16-OR, 236-OR, 965-P
Corleto, Vito D. 2345-PUB
Cornwell, Holly 1382-P
Correia, Isabel 721-P
Correia, José 305-OR, 1024-P, 1035-P
Cortes, Tiffany M. 2243-PUB
Costa, Bernardo 2316-PUB
Costacou, Tina 589-P, 1415-P, 1489-P, 1630-P
Costamagna, Guido 1137-P
Cote, Kathryn E. 857-P
Cottam, Matthew A. 2121-P
Cotten, Shelia 2237-PUB
Cottet-Rousselle, Cécile 81-OR
Coufal, Muchieh M. 718-P
Couper, Jenny 230-OR, 2065-P
Courcoulas, Anita 366-OR
Couri, Carlos E. 1112-P
Courtney, Jennilea 237-OR
Courville, Amber B. 1620-P, 1814-P, 1837-P, 1842-P, 1893-P
Coverdale, Sara 1954-P
Cowie, Catherine C. 113-OR, 1478-P
Cox, David 126-OR
Cox, Elizabeth D. 1380-P
Coyle, Rachel M. 1047-P
Crib, Rinu R. 574-P, 2209-PUB
Craith, Maria E. 230-OR, 231-OR, 542-P, 2065-P
Craig, A. Lauren 172-OR
Cramon, Per K. 144-OR
Crandon, Jill P. 134-OR, 1182-P, 1472-P
Crandell, Jamie 378-P
Cras-Ménéur, Corentin M.H. 2130-P
Crawford, Andrew 2452-PUB
Crawford, Jason M. 1229-P
Creason, Jamie 2065-PUB
Cree-Green, Melanie 234-OR, 431-P, 1338-P, 1361-P
Crenier, Laurent 946-P, 947-P, 1137-P
Cressman, Michael 544-P
Cridlig, Joelle, Sr. 933-P
Crimmins, Nancy A. 1359-P
Crisologo, Peter A. 110-OR
Crispino, Giuseppe 993-P
Crocket, Hamish 983-P
Croser, Sara 5-OR
Cron, Stanley 247-OR
Crooks, Sarah 1511-P
Crowley, Tamsyn 1147-P
Crutchlow, Michael 966-P, 2272-PUB
Cruz Bravo, Paulina 397-P
Cruz-Estrada, Antonio 2362-PUB
Cs, Dwarkanath 1204-P
Cuadertonzti, Enedina Teresa 658-P, 687-P
Cuddeback, John K. 1-OR, 1499-P
Cuesta, Martin 1455-P
Cui, Jinhui 1448-P
Cui, Ran 1351-P, 2062-P

OR: Oral  P: Poster  PUB: Published Only
Cui, Rihua 1912-P
Cui, Taixing 475-P
Cui, Xiangqin 1530-P
Cull, Melissa L. 2087-P, 2097-P
Cummings, Doyle M. 769-P, 804-P, 867-P, 886-P
Cunha, Tatiana S. 2365-PUB
Cunningham, Solveig A. 1674-P
Currie, Mark 74-P, 1207-P, 1886-P
Cursaru, Adrian 440-P
Cursaru, Raluca 440-P
Dai, Aozhi 505-P
Dai, Chunhua 323-OR
Dai, Hao 265-OR
Dai, Weiwei 607-P
Dai, Xiaozhen 471-P
Daisuke, Tszjino 1224-P
Dakin, Helen A. 1319-P
Dalala, Belen 1454-P
Dalan, Rinkoo 419-P, 834-P
D'Alessandro, Angelo 1933-P
D'Alessio, David 73-OR, 340-OR, 2023-P
Dalay, Matthew F. 1538-P
Dalgaard, Louise T. 2160-P
Dalla Man, Chiara 45-OR, 72-OR, 1808-P, 1812-P, 1953-P
Dalsgaard, Niels B. 1969-P
D'Alva, Catarina B. 585-P, 2192-PUB
Damas, Lucy 1517-P
Damasio, Marcos 95-OR
Damberg, Niklas E. 2161-P
Damiano, Edward 14-OR, 299-OR
Damm, Peter 689-P, 1424-P, 1431-P, 1444-P, 1452-P
D'Amour, Kevin 138-OR
Dang, Stuti 1468-P, 1470-P
Dang, Thanh 1757-P, 2014-P
Daniel, Christoph 1222-P
Danielle, Giuseppe 362-OR, 618-P, 1572-P, 1791-P
Daniels, Lauren 1501-P
Daniels, Nigel A. 357-OR
Dannelsen, Kirstie K. 141-OR
Danne, Thomas 212-OR, 1122-P, 1179-P, 1695-P
Dannenberger, Dirk 296-OR
Dantas, Joana R. 1112-P
Daoudi, Mehdi, Sr. 2143-P
D'Autre, Emilie 10-OR
Darcy, Justin 273-OR, 2022-P
Dardano, Angela 362-OR, 618-P, 1694-P, 1791-P
Darekar, Amanda 1129-P
Daria, Chub 2194-PUB
Darsalia, Vladimir 1148-P
Darsow, Tamara 135-OR, 1493-P
Dart, Julie 747-P
Das, A.K. 1327-P
Das, Sambit 949-P
Das, Sreeya 1208-P
Dashti, Hassan S. 19-OR, 1760-P
Dasari, Surendra 2243-PUB
Dash, Kalpana 949-P
Dassau, Eyal 961-P, 2351-PUB
Datta, Ritwik 189-OR
Dauchy, Arnaud 1028-P
Dauriz, Marco 1718-P, 2359-PUB
Davey Smith, George 23-OR
David, Ashwin 389-P, 685-P
David, Joshua A. 634-P, 644-P
David, Raul Alejandro 2347-PUB
Davidson, Jaime A. IV 1089-P
Davidson, Josh 900-P
Davidson, Mayer B. 900-P, 1172-P
Davies, Glenn M. 1159-P, 1160-P, 1161-P, 1247-P, 1265-P
Davies, Graeme R. 1890-P
Davies, Justine I. 1511-P
Davies, Melanie Jane 1048-P, 1355-P
Davilgus, Martha L. 128-OR
Davis, Christian 2324-PUB
Davis, Elisabeth K. 1347-P, 1353-P
Davis, Elizabeth A.  730-P, 747-P  
Davis, Ellen M.  1962-P  
Davis, Georgia  312-OR, 1587-P, 1589-P  
Davis, Kaddy  1518-P  
Davis, Kathryn  110-OR  
Davis, Stephen  198-OR  
Davis, Wendy A.  1697-P  
Dawoud, Hazem E., Sr.  620-P  
Dawson, Aprill  1491-P  
Dawson, Jonda  651-P  
Dawson-Hughes, Bess  765-P  
Day, Samantha E.  749-P  
Dayton, Kristin A.  1364-P  
de Abreu, Isabel C.  2365-PUB  
de Anda-Jáuregui, Guillermo  551-P  
de Bellis, Alessandra  451-P, 639-P  
de Block, Christophe  1540-P  
de Corde, Anna E.  630-P  
de Courten, Barbora  707-P, 777-P, 778-P, 2047-P  
de Ferrari, Aldo  1545-P  
de Galan, Bastiaan E.  106-OR  
de Groot, Mary  251-OR, 880-P  
de Jersey, Susan J.  1422-P  
de La Torre-Saldañ, Viridiana A.  658-P, 687-P  
de Leon, Dína  1498-P, 1820-P  
de Lusignan, Simon  1047-P  
de Moura, Eduardo G.  2095-P  
de Mutsert, Renée  20-OR  
de Pascale, Angelo  2279-PUB  
de Veg, Femmke  106-OR  
de Vries, Paul S.  1724-P  
de Wit, Maartje  876-P  
de Zeeuw, Dick  258-PUB, 1191-P, 1193-P, 1206-P  
Deacon, Carolyn F.  1968-P  
dean, Danielle  323-OR  
Dearn-S-Westley, Tracy  218-OR  
DeBoer, Mark D.  1486-P, 1523-P  
Decuzzi, Paolo  2279-PUB  
Deechend, Dinesh  201-OR  
Deerocanawong, Chaiyarn  116-OR  
Defeudis, Giuseppe  2094-P  
DeFilippis, Eleanna  749-P  
DeFilippo, Ennica M.  2-OR  
del Re, Luigi  970-P  
Del Toro, Rossella  564-P  
Del Valle, Kayla L.  857-P  
Del Valle, Laura  1455-P  
Delahanty, Linda M.  800-P  
Delano, Matthew  1737-P  
DeLany, James  75-OR  
DeLeer, Brigitte  208-OR  
Delgado, Elias  303-OR, 1028-P  
Delgado, Luis  1975-P  
Delis, Dimitrios E., Sr.  1606-P  
Della-Morte, David  1929-P  
Delisa, Mary A.  1009-P, 1010-P  
Delong, Thomas  98-OR, 315-OR  
Delvy, Roberta  651-P, 854-P  
DeMarco, Vincent  2009-P, 2015-P, 2016-P  
de ‘Emden, Michael C.  1422-P  
Demircik, Filiz  948-P, 957-P  
Denburg, Michelle R.  1498-P  
Dendy, Jared  2409-PUB  
Deng, Chao  1698-P  
Deng, Hong P.  1033-P, 1972-P, 2024-P  
Deng, Hsiaowei  258-OR  
Dengel, Donald R.  1926-P  
Dennis, Michael D.  242-OR, 592-P, 607-P  
Denson, Anna M.  1379-P  
Dentoni, Giacomo  80-OR  
Dempner, Christopher M.  2448-PUB  
Deraus-Luyet, Anouk  1556-P  
Dervos, Thomas  2416-PUB  
Desai, Ankush  1316-P  
Desai, Deepthi  252-OR  
Desai, Jay R.  172-OR, 435-P, 1538-P  
Desai, Mehul  258-OR  
Desai, Nagaraj  2361-PUB  
Desai, Ranjita C.  1194-P  
Desai, Urvit  221-OR, 801-P, 838-P  
DeSalvo, Daniel J.  1257-P, 1321-P, 1373-P  
Deshmukh, Madhura Kishor  1445-P  
Deshpande, Neeta  248-OR, 866-P  
Desjardins, Donna  2351-PUB  
Desoysa, Gernot  1416-P  
Dethlefs, Henry J. IV  1278-P  
Deussens, Andrea R.  1414-P  
Devarajan, Raja  1316-P  
Devarakonda, Kavya  1807-P  
Devire, Jacques  1137-P  
Deviseme, Christine  301-OR, 1029-P  
Devkota, Suzanne  1897-P  
Devoto, Francantonio  2077-P  
DeVries, J. Hans  106-OR, 107-OR  
Dex, Terry A.  1072-P, 1089-P, 1093-P  
Dhilawal, Ruban  1341-PUB  
Dharmalingam, Mala  1210-P, 1316-P
<table>
<thead>
<tr>
<th>Author</th>
<th>Type</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dhawan, Sangeeta</td>
<td>OR</td>
<td>50</td>
</tr>
<tr>
<td>Dhindsa, Sandeep</td>
<td>1945-P</td>
<td></td>
</tr>
<tr>
<td>Dhope, Rahul M.</td>
<td>1685-P</td>
<td></td>
</tr>
<tr>
<td>Dhruv, Neil</td>
<td>545-P</td>
<td>1587-P</td>
</tr>
<tr>
<td>Di Guglielmo, Matthew D.</td>
<td>1362-P</td>
<td></td>
</tr>
<tr>
<td>Di Mascolo, Daniele</td>
<td>2279-PUB</td>
<td></td>
</tr>
<tr>
<td>Di Paola, Rosa</td>
<td>262-OR</td>
<td></td>
</tr>
<tr>
<td>Di Pino, Antonino</td>
<td>1192-P</td>
<td></td>
</tr>
<tr>
<td>Diah, Ana M.</td>
<td>845-P</td>
<td></td>
</tr>
<tr>
<td>Diaz, David</td>
<td>980-P</td>
<td></td>
</tr>
<tr>
<td>Dib, Sergio A.</td>
<td>1112-P</td>
<td></td>
</tr>
<tr>
<td>DiBonaventura, Marco</td>
<td>966-P</td>
<td>2272-PUB</td>
</tr>
<tr>
<td>Dickens, Laura T.</td>
<td>1453-P</td>
<td>2353-PUB</td>
</tr>
<tr>
<td>Dickerson, Matthew</td>
<td>2172-P</td>
<td></td>
</tr>
<tr>
<td>Dickie, Gavin</td>
<td>725-P</td>
<td>726-P</td>
</tr>
<tr>
<td>DiCorpo, Daniel A.</td>
<td>1707-P</td>
<td></td>
</tr>
<tr>
<td>Didangelos, Triantafylos</td>
<td>459-P</td>
<td>938-P, 2447-PUB</td>
</tr>
<tr>
<td>Diebold, Sebastien</td>
<td>436-P</td>
<td></td>
</tr>
<tr>
<td>Dierschke, Sadie</td>
<td>592-P</td>
<td>607-P</td>
</tr>
<tr>
<td>DiFulvio, Mauricio</td>
<td>2151-P</td>
<td></td>
</tr>
<tr>
<td>Digenio, Andres</td>
<td>623-P</td>
<td></td>
</tr>
<tr>
<td>Dimachkie, Perihan</td>
<td>124-OR</td>
<td>1077-P</td>
</tr>
<tr>
<td>DiMarchi, Richard</td>
<td>1806-P</td>
<td>1978-P</td>
</tr>
<tr>
<td>DiMeglio, Linda</td>
<td>1373-P</td>
<td>1689-P, 1693-P</td>
</tr>
<tr>
<td>Dimsity, Gudrun</td>
<td>2309-PUB</td>
<td></td>
</tr>
<tr>
<td>Dinesen, Aleksandr R.</td>
<td>980-P</td>
<td></td>
</tr>
<tr>
<td>Ding, Mingge</td>
<td>408-P</td>
<td></td>
</tr>
<tr>
<td>Ding, Xiaofeng</td>
<td>34-OR</td>
<td></td>
</tr>
<tr>
<td>Dinh, Christine U.</td>
<td>825-P</td>
<td></td>
</tr>
<tr>
<td>Dipaola, Lucia</td>
<td>2147-P</td>
<td></td>
</tr>
<tr>
<td>Dipp, Susana L.</td>
<td>2314-PUB</td>
<td></td>
</tr>
<tr>
<td>Dirice, Ercuent</td>
<td>46-OR</td>
<td>64-OR</td>
</tr>
<tr>
<td>Dirinck, Eveline L.</td>
<td>1540-P</td>
<td></td>
</tr>
<tr>
<td>Dirksen, Carsten</td>
<td>1885-P</td>
<td>1956-P, 2059-P</td>
</tr>
<tr>
<td>Dismuke, Clara</td>
<td>1249-P</td>
<td></td>
</tr>
<tr>
<td>Distefano, Giovanna</td>
<td>1907-P</td>
<td></td>
</tr>
<tr>
<td>Divers, Jasmin</td>
<td>268-OR</td>
<td>441-P, 1703-P</td>
</tr>
<tr>
<td>Divney, Anna A.</td>
<td>1678-P</td>
<td></td>
</tr>
<tr>
<td>Djousse, Luc</td>
<td>1552-P</td>
<td></td>
</tr>
<tr>
<td>Doan, Amy</td>
<td>697-P</td>
<td>2236-PUB</td>
</tr>
<tr>
<td>Dodd, Jodie M.</td>
<td>1414-P</td>
<td></td>
</tr>
<tr>
<td>Doi, Asako</td>
<td>2108-P</td>
<td></td>
</tr>
<tr>
<td>Doiev, Jasmine</td>
<td>906-P</td>
<td></td>
</tr>
<tr>
<td>Dokpuang, Dech</td>
<td>2075-P</td>
<td></td>
</tr>
<tr>
<td>Dokras, Anuja</td>
<td>2452-PUB</td>
<td></td>
</tr>
<tr>
<td>Dolan, Lawrence M.</td>
<td>345-OR</td>
<td>525-P, 1366-P</td>
</tr>
<tr>
<td>Dole, Jo F.</td>
<td>1073-P</td>
<td></td>
</tr>
<tr>
<td>Dolezalova, Karin</td>
<td>1974-P</td>
<td></td>
</tr>
<tr>
<td>Dolkowski, Justin</td>
<td>573-P</td>
<td></td>
</tr>
<tr>
<td>Dolores, Maria C.</td>
<td>658-P</td>
<td></td>
</tr>
<tr>
<td>Dominguez, Cleveyon C.</td>
<td>287-OR</td>
<td>493-P</td>
</tr>
<tr>
<td>Dominguez-Bendala, Juan</td>
<td>2118-P</td>
<td></td>
</tr>
<tr>
<td>Donadel, Giulia</td>
<td>1929-P</td>
<td></td>
</tr>
<tr>
<td>Donaghe, Kim C.</td>
<td>542-P</td>
<td></td>
</tr>
<tr>
<td>Donato, Jose, Jr.</td>
<td>223-OR</td>
<td></td>
</tr>
<tr>
<td>Dong, Fran</td>
<td>136-OR</td>
<td>1521-P, 1690-P</td>
</tr>
<tr>
<td>Dong, Henry</td>
<td>322-OR</td>
<td>334-OR, 2443-PUB</td>
</tr>
<tr>
<td>Dong, Jiaqi</td>
<td>779-P</td>
<td>2413-PUB</td>
</tr>
<tr>
<td>Dong, Tao</td>
<td>2164-P</td>
<td></td>
</tr>
<tr>
<td>Dong, Ya-Hui</td>
<td>1614-P</td>
<td></td>
</tr>
<tr>
<td>Dong, Yanan</td>
<td>2110-P</td>
<td>2146-P</td>
</tr>
<tr>
<td>Donicova, Viera</td>
<td>303-OR, 1028-P</td>
<td></td>
</tr>
<tr>
<td>Donihi, Amy</td>
<td>1279-P</td>
<td></td>
</tr>
<tr>
<td>Donner, Thomas W.</td>
<td>352-OR</td>
<td></td>
</tr>
<tr>
<td>Donovan, Lois E.</td>
<td>2346-PUB</td>
<td></td>
</tr>
<tr>
<td>Donsa, Klaus</td>
<td>2280-PUB</td>
<td></td>
</tr>
<tr>
<td>Dörfinger, Gry H.</td>
<td>942-P</td>
<td></td>
</tr>
<tr>
<td>Doria, Alessandro</td>
<td>56-OR, 262-OR, 578-P</td>
<td></td>
</tr>
<tr>
<td>D’Oria, Rossella</td>
<td>2190-PUB</td>
<td></td>
</tr>
<tr>
<td>Dovil, Sarah R.</td>
<td>844-P</td>
<td></td>
</tr>
<tr>
<td>Dos Santos Mamed, Marcelo</td>
<td>715-P</td>
<td></td>
</tr>
<tr>
<td>Doshi, Ankur</td>
<td>1025-P</td>
<td></td>
</tr>
<tr>
<td>Douglass, John</td>
<td>371-OR</td>
<td></td>
</tr>
<tr>
<td>Doukas, Loukas, Jr.</td>
<td>646-P</td>
<td></td>
</tr>
<tr>
<td>Doupis, John</td>
<td>1058-P</td>
<td></td>
</tr>
<tr>
<td>Douros, Jonathan D.</td>
<td>II 2023-P</td>
<td></td>
</tr>
<tr>
<td>Dowd, Rachel A.</td>
<td>1278-P</td>
<td></td>
</tr>
<tr>
<td>Doyle, Francis J.</td>
<td>961-P</td>
<td></td>
</tr>
<tr>
<td>Doyle, Melissa</td>
<td>988-P, 989-P, 990-P</td>
<td></td>
</tr>
<tr>
<td>Dozio, Nicoletta C.</td>
<td>988-P</td>
<td></td>
</tr>
<tr>
<td>Drago, Lorenzo</td>
<td>2088-P, 2345-PUB</td>
<td></td>
</tr>
<tr>
<td>Dragomir, Miruna</td>
<td>1613-P, 1627-P</td>
<td></td>
</tr>
<tr>
<td>Dragut, Ramona Maria</td>
<td>440-P</td>
<td></td>
</tr>
<tr>
<td>Dranse, Helen J.</td>
<td>1948-P</td>
<td></td>
</tr>
<tr>
<td>Drastich, Pavel</td>
<td>2051-P</td>
<td></td>
</tr>
<tr>
<td>Drehmer, Michele</td>
<td>1447-P</td>
<td></td>
</tr>
<tr>
<td>Dreizen, Paul</td>
<td>468-P, 488-P, 611-P, 1597-P</td>
<td></td>
</tr>
<tr>
<td>Dreon, Darlene M.</td>
<td>710-P, 987-P, 995-P</td>
<td></td>
</tr>
<tr>
<td>Dressel, Alexander</td>
<td>1484-P</td>
<td></td>
</tr>
<tr>
<td>Drevon, Christian A.</td>
<td>752-P</td>
<td></td>
</tr>
<tr>
<td>Drews, Kimberly</td>
<td>119-OR</td>
<td></td>
</tr>
<tr>
<td>Dreyfuss, Jonathan</td>
<td>66-OR, 91-OR, 739-P, 1792-P, 1833-P</td>
<td></td>
</tr>
<tr>
<td>Drezza, Lucia</td>
<td>2359-PUB</td>
<td></td>
</tr>
<tr>
<td>Drincic, Andjela</td>
<td>1594-P</td>
<td></td>
</tr>
<tr>
<td>Driscoll, Henry</td>
<td>446-P</td>
<td></td>
</tr>
<tr>
<td>Driver, John</td>
<td>320-OR</td>
<td></td>
</tr>
<tr>
<td>Dronamraju, Nalina</td>
<td>260-OR</td>
<td></td>
</tr>
<tr>
<td>Dropkin, Jess</td>
<td>1005-P</td>
<td></td>
</tr>
<tr>
<td>D’Souza, Karen</td>
<td>1212-P</td>
<td></td>
</tr>
<tr>
<td>Du, Daniel</td>
<td>2310-PUB</td>
<td></td>
</tr>
<tr>
<td>Du, Fuyong</td>
<td>609-P</td>
<td></td>
</tr>
<tr>
<td>Du, Liping</td>
<td>233-OR</td>
<td></td>
</tr>
<tr>
<td>Duan, Yaqian</td>
<td>1899-P</td>
<td></td>
</tr>
<tr>
<td>Dubey, Shweta</td>
<td>2417-PUB</td>
<td></td>
</tr>
<tr>
<td>Dubiel, Krzysztof K.</td>
<td>1189-P</td>
<td></td>
</tr>
<tr>
<td>DuBose, Christopher</td>
<td>596-P, 1503-P, 1504-P, 1620-P, 1621-P</td>
<td></td>
</tr>
<tr>
<td>Duca, Frank</td>
<td>1948-P</td>
<td></td>
</tr>
<tr>
<td>Author</td>
<td>OR:</td>
<td>P:</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----</td>
<td>----</td>
</tr>
<tr>
<td>Ducloux, Didier</td>
<td>933-OR</td>
<td></td>
</tr>
<tr>
<td>Dudda, Angela</td>
<td>2028-P</td>
<td></td>
</tr>
<tr>
<td>Duffin, Kevin L.</td>
<td>1847-OR</td>
<td></td>
</tr>
<tr>
<td>Dungan, Joy A.</td>
<td>829-P</td>
<td></td>
</tr>
<tr>
<td>Duggan, Elizabeth W.</td>
<td>1305-P</td>
<td></td>
</tr>
<tr>
<td>Duke, Danny C.</td>
<td>215-OR, 861-P</td>
<td></td>
</tr>
<tr>
<td>Duke, Sally</td>
<td>290-OR</td>
<td></td>
</tr>
<tr>
<td>Dumais, Bonnie</td>
<td>207-OR, 1376-P, 1377-P</td>
<td></td>
</tr>
<tr>
<td>Dumas, Richard</td>
<td>1191-P</td>
<td></td>
</tr>
<tr>
<td>Dumbadze, Sofio</td>
<td>198-OR</td>
<td></td>
</tr>
<tr>
<td>Duncan, Bruce B.</td>
<td>1447-P, 1599-P, 1671-P</td>
<td></td>
</tr>
<tr>
<td>Duncan, Ian</td>
<td>1281-P</td>
<td></td>
</tr>
<tr>
<td>Dungan, Kathleen M.</td>
<td>129-OR, 382-P</td>
<td></td>
</tr>
<tr>
<td>Dunleavey, Jessica</td>
<td>54-OR</td>
<td></td>
</tr>
<tr>
<td>Dun, Andrea L.</td>
<td>879-P</td>
<td></td>
</tr>
<tr>
<td>Dunne, Fidelma P.</td>
<td>1456-P</td>
<td></td>
</tr>
<tr>
<td>Duna, Komar</td>
<td>2322-PUB</td>
<td></td>
</tr>
<tr>
<td>Duvall, Kevin R.</td>
<td>660-P</td>
<td></td>
</tr>
<tr>
<td>Duvall, Emilie</td>
<td>2429-PUB</td>
<td></td>
</tr>
<tr>
<td>Duvnjak, Lea</td>
<td>303-OR, 1050-P</td>
<td></td>
</tr>
<tr>
<td>Duvuru, Shantharam</td>
<td>1204-P</td>
<td></td>
</tr>
<tr>
<td>Dwivedi, Alok K.</td>
<td>1534-P</td>
<td></td>
</tr>
<tr>
<td>Dwivedi, Gaurav</td>
<td>1892-P</td>
<td></td>
</tr>
<tr>
<td>Dwivedi, Rishabh</td>
<td>1327-P</td>
<td></td>
</tr>
<tr>
<td>Dzial, Radostka</td>
<td>1199-P</td>
<td></td>
</tr>
<tr>
<td>Earnest, Arul</td>
<td>1612-P, 1697-P</td>
<td></td>
</tr>
<tr>
<td>Eberhard, Katharina</td>
<td>1941-P</td>
<td></td>
</tr>
<tr>
<td>Ebner, Jan M.</td>
<td>1253-P</td>
<td></td>
</tr>
<tr>
<td>Echeverria, Sandra</td>
<td>1678-P</td>
<td></td>
</tr>
<tr>
<td>Eckel, Robert H.</td>
<td>2448-PUB</td>
<td></td>
</tr>
<tr>
<td>Edalati, Masoud</td>
<td>632-OR, 640-OR, 2242-PUB</td>
<td></td>
</tr>
<tr>
<td>Edavettal, Suzanne</td>
<td>35-OR</td>
<td></td>
</tr>
<tr>
<td>Edelen, Rachel C.</td>
<td>2332-PUB</td>
<td></td>
</tr>
<tr>
<td>Edelstein, Sharon</td>
<td>1643-P, 1644-P, 1704-P</td>
<td></td>
</tr>
<tr>
<td>Edgerton, Dale S.</td>
<td>1961-P</td>
<td></td>
</tr>
<tr>
<td>Edwards, Alison</td>
<td>1658-P</td>
<td></td>
</tr>
<tr>
<td>Edwards, Joshua F.</td>
<td>58-OR</td>
<td></td>
</tr>
<tr>
<td>Edwards, Sheila</td>
<td>804-P, 867-P, 886-P</td>
<td></td>
</tr>
<tr>
<td>Edwardson, Charlotte</td>
<td>1355-P</td>
<td></td>
</tr>
<tr>
<td>Efren, Nathan</td>
<td>580-P</td>
<td></td>
</tr>
<tr>
<td>Egbo, Ifeoma</td>
<td>853-P</td>
<td></td>
</tr>
<tr>
<td>Egbo, Lisa</td>
<td>249-OR</td>
<td></td>
</tr>
<tr>
<td>Eggert, Sarah</td>
<td>1025-P</td>
<td></td>
</tr>
<tr>
<td>Eguchi, Jun</td>
<td>33-OR</td>
<td></td>
</tr>
<tr>
<td>Eguchi, Yuichiro</td>
<td>742-P</td>
<td></td>
</tr>
<tr>
<td>Ehrer, Andreas</td>
<td>2086-P</td>
<td></td>
</tr>
<tr>
<td>Ehnhart, Nicole</td>
<td>2231-PUB</td>
<td></td>
</tr>
<tr>
<td>Ehrig, Jessica C.</td>
<td>1443-P</td>
<td></td>
</tr>
<tr>
<td>Ehrlich, Barbara E.</td>
<td>148-OR</td>
<td></td>
</tr>
<tr>
<td>Ehrlich, Samantha</td>
<td>1417-P</td>
<td></td>
</tr>
<tr>
<td>Ehrlrich, Sarah E.</td>
<td>1932-P, 1934-P</td>
<td></td>
</tr>
<tr>
<td>Ehrmann, David A.</td>
<td>1643-P, 1644-P, 1684-P</td>
<td></td>
</tr>
<tr>
<td>Ehrmann, Dominic</td>
<td>211-OR, 298-OR, 671-P, 824-P, 912-P, 914-P</td>
<td></td>
</tr>
<tr>
<td>Eichner, Natalie</td>
<td>754-P, 755-P, 1774-P</td>
<td></td>
</tr>
<tr>
<td>Eid, Stephanie</td>
<td>551-P</td>
<td></td>
</tr>
<tr>
<td>Eidenmueller, Markus</td>
<td>1014-P</td>
<td></td>
</tr>
<tr>
<td>Eiel, Jack N.</td>
<td>1381-P, 1820-P</td>
<td></td>
</tr>
<tr>
<td>Eibberger, George E.</td>
<td>2085-P</td>
<td></td>
</tr>
<tr>
<td>Eiken, Aleksander</td>
<td>2059-P</td>
<td></td>
</tr>
<tr>
<td>Eiken, Markus</td>
<td>2059-P</td>
<td></td>
</tr>
<tr>
<td>Eiler, Christian</td>
<td>1249-P, 1577-P, 1660-P</td>
<td></td>
</tr>
<tr>
<td>Eisenring, Selina</td>
<td>536-P</td>
<td></td>
</tr>
<tr>
<td>Eisler, Gabriella J.</td>
<td>980-P</td>
<td></td>
</tr>
<tr>
<td>Ejzykowicz, Flavia</td>
<td>1159-P, 1160-P, 1161-P, 1641-P</td>
<td></td>
</tr>
<tr>
<td>Eke, Chibuzo U.</td>
<td>1270-P</td>
<td></td>
</tr>
<tr>
<td>Ehlers, R.</td>
<td>992-P</td>
<td></td>
</tr>
<tr>
<td>Ekholm, E.</td>
<td>260-OR, 810-P, 905-P</td>
<td></td>
</tr>
<tr>
<td>Ekin, Elif I.</td>
<td>420-P, 481-P, 2179-PUB</td>
<td></td>
</tr>
<tr>
<td>El Ghorbel, Laure</td>
<td>339-OR, 1341-P</td>
<td></td>
</tr>
<tr>
<td>El Maqri, Fatema</td>
<td>654-P</td>
<td></td>
</tr>
<tr>
<td>El Youssef, Joseph</td>
<td>751-P, 756-P</td>
<td></td>
</tr>
<tr>
<td>El, Kimberley</td>
<td>2122-P, 2139-P</td>
<td></td>
</tr>
<tr>
<td>El, Michael</td>
<td>1804-P</td>
<td></td>
</tr>
<tr>
<td>Elander, Mikael</td>
<td>1230-P</td>
<td></td>
</tr>
<tr>
<td>Elasy, Tom</td>
<td>825-P, 1439-P</td>
<td></td>
</tr>
<tr>
<td>Elding Larssen, Helena</td>
<td>1500-P</td>
<td></td>
</tr>
<tr>
<td>Eldor, Roy</td>
<td>982-P</td>
<td></td>
</tr>
<tr>
<td>El-Hashim, Ahmed Z.</td>
<td>480-P</td>
<td></td>
</tr>
<tr>
<td>Ethassan, Mahmoud</td>
<td>124-OR, 1077-P</td>
<td></td>
</tr>
<tr>
<td>Eliasson, Bjorn</td>
<td>131-OR</td>
<td></td>
</tr>
<tr>
<td>Elsaf, Moses</td>
<td>485-P</td>
<td></td>
</tr>
<tr>
<td>El, Khatib, Firas</td>
<td>14-OR, 299-OR</td>
<td></td>
</tr>
<tr>
<td>Els, Carrie M.</td>
<td>271-OR</td>
<td></td>
</tr>
<tr>
<td>Ellender, Sharon J.</td>
<td>638-P</td>
<td></td>
</tr>
<tr>
<td>Ellervik, Christina</td>
<td>21-OR</td>
<td></td>
</tr>
<tr>
<td>Elliott, Mary</td>
<td>128-OR</td>
<td></td>
</tr>
<tr>
<td>Elliott, Michael</td>
<td>397-P</td>
<td></td>
</tr>
<tr>
<td>Ellis, Megan K.</td>
<td>1147-P</td>
<td></td>
</tr>
<tr>
<td>Ellison, Misos C.</td>
<td>1143-P</td>
<td></td>
</tr>
<tr>
<td>Elmaradi, Tamim</td>
<td>111-OR</td>
<td></td>
</tr>
<tr>
<td>El-Osta, Assam</td>
<td>2107-P</td>
<td></td>
</tr>
<tr>
<td>Elsa Mathews, Sherin</td>
<td>402-P</td>
<td></td>
</tr>
<tr>
<td>Elsakr, Joseph</td>
<td>2136-P</td>
<td></td>
</tr>
<tr>
<td>Elsayed, Hesham</td>
<td>2280-PUB</td>
<td></td>
</tr>
<tr>
<td>Elseady, Tahar</td>
<td>760-P, 934-P, 2044-P</td>
<td></td>
</tr>
</tbody>
</table>
Elshiekh, Arwa 2085-P
Eltabakh, Soad M.M. 1514-P
El-Tobgy, Eric 2371-PUB
Eluwole, Ayobami 489-P, 611-P, 1597-P
Elvert, Ralf 2028-P, 2030-P
Elzinga, Sarah 551-P
Emanuelli, Brice 38-OR, 273-OR, 2022-P
Embury, Christine M. 1594-P
Emery, Alasdair 2709-OR
Emoto, Masanori 422-P, 423-P, 443-P, 736-P, 2074-P, 2434-PUB
Endo, Itsuro 529-P, 2102-P
Endresen, Knut 433-P, 449-P
Engel, Taly 936-P
Engelstoft, Maja S. 1968-P
Englert, Daniel 2409-PUB
Ennis, Jennifer L. 544-P
Entessari, Mina 847-P
Epstein, Paul N. 471-P
Erdbruegger, Uta 1774-P
Eredor, Fulya 1780-P
Erickson, Melissa L. 1835-P, 1937-P
Ericksson, Jan W. 368-OR, 1756-P, 1790-P
Eringa, Etto C. 68-OR
Ernakova, Anastasia 2273-PUB
Erskine, Lois M. 1073-P
Ermakova, Anastasia 2273-PUB
Erskind, Knut 433-P, 449-P
Ertekin, Serkan 2030-P
Eshtehardi, Sahar S. 848-P
Espeland, Mark 171-OR, 817-P
Esser, Nathalie 82-OR, 1825-P, 2107-P
Estacio, Karen 2322-PUB
Estadilla, E toxins Martine Claude 1040-P
Estadilla, E toxins Martine Claude 1040-P
Etow, Rica 543-P, 1610-P, 2205-PUB
Euyoque, Johanna A. 794-P
Evans, Grahame F. 1916-P
Evans, Karen 11-OR
Evans, Mark 1273-P
Evans, Mark 350-OR, 926-P, 973-P
Evans, Mary 171-OR
Evans-Molina, Carmella 94-OR, 194-OR, 1688-P, 1693-P
Everett, Brendan M. 1492-P
Everett, Andreas 2028-P
Evert, Alison 2329-PUB
Ezekiel, Michael 2036-P, 2429-PUB
Ezzouaoui, Rimed 2143-P
Fabbrini, Elisa 1210-P
Fabicic, Dejan 2287-PUB
Facanha, Cristina 1447-P
Fagher, Katarina 958-P, 2225-PUB
Fahrbach, Kyle 1294-P
Fahrnman, Elke R. 446-P
Faidas, Maria 1702-P
Falcetta, Mariana R. 1086-P
Falck-Ytter, Corinna 1285-P
Falcon, Luis M. 1596-P
Falkenhahn, Mechthilde 1981-P
Fall, Caroline 118-OR
Fallon, Michael 2391-PUB
Fan, Baoqi 519-P
Fan, Jianhui 1448-P, 1449-P
Fan, Kesuo 2298-PUB
Fan, Ludi 932-P, 967-P, 981-P
Fan, Wenjun 332-OR
Fan, Yong 30-OR
Fanelli, Carmine 1042-P
Fang, Han 1877-P
Fang, Wei-Jin 2182-PUB
Fang, Yuan 2129-P
Farabi, Sarah S. 1428-P
Faravelli, Silvia 1231-P
Farfan, Christian C. 767-P
Farhat, Rawad 200-OR, 203-OR
Farias, Leonardo 1467-P
Farias, Lucas B. 606-P
Faries, Douglas E. 1254-P
Farmer, Ben 347-OR, 1961-P
Faroq, Gala 1100-P
Faroq, Mohammed 517-P, 538-P, 560-P
Farr, Ryan 231-OR
Farris, Kimberly D. 648-P, 696-P
Fatima, Sadi 2061-P
Faulkner, Melissa S. 807-P, 811-P
Faustman, Denise L. 1776-P, 2339-PUB
Fayman, Maya 312-OR, 545-P, 1078-P, 1237-P, 1587-P, 1589-P
Fazeli, Sasan 2231-PUB
Fazio, Sergio 1485-P
Fazullina, Olga 2055-P
Feferman, Leonid 780-P
Feghali, Maisa N. 1446-P, 1458-P
Feher, Michael 1047-P
Feilert, Ellen 1402-P
Feil, Robert 1867-P
Feil, Susanne 1867-P
Feldman, Becca S. 665-P, 666-P, 1076-P
Feldman, Paul L. 366-OR
Feldman, Janule V. 2255-PUB
Feldman, Paul L. 1997-P, 1998-P
Feleke, Afomia A. 1269-P
Felton, Alexandra 503-P, 1858-P, 2000-P
Feng, Biao 240-OR, 473-P
Feng, Dongni 1899-P
Feng, Jiahao 408-P
Feng, Kimberly 985-P
Feng, Tianshi 2025-P
Feng, Wenhuan 1344-P
<table>
<thead>
<tr>
<th>Author</th>
<th>Citations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feng, Yen-Chen Anne</td>
<td>1462-P</td>
</tr>
<tr>
<td>Feng, Yingmei</td>
<td>224-OR, 331-OR, 2129-P</td>
</tr>
<tr>
<td>Fenici, Peter</td>
<td>1141-P, 1186-P, 1562-P, 1615-P, 1629-P</td>
</tr>
<tr>
<td>Fernandez, Gail</td>
<td>1563-P, 1564-P, 1628-P, 2180-PUB, 2396-PUB</td>
</tr>
<tr>
<td>Fernandez, Jessie</td>
<td>675-P, 676-P</td>
</tr>
<tr>
<td>Fernandez, Priscila</td>
<td>2192-PUB</td>
</tr>
<tr>
<td>Fernandi, Ele</td>
<td>2089-P</td>
</tr>
<tr>
<td>Fernandes, Gail</td>
<td>1563-P, 1564-P, 2180-PUB</td>
</tr>
<tr>
<td>Fernandes, Gail</td>
<td>1563-P, 1564-P, 2180-PUB</td>
</tr>
<tr>
<td>Fernandes, Virginia</td>
<td>585-P, 628-P, 2192-PUB</td>
</tr>
<tr>
<td>Fernandes, Virginia</td>
<td>585-P, 628-P, 2192-PUB</td>
</tr>
<tr>
<td>Fernandes, Virginia</td>
<td>2192-PUB</td>
</tr>
<tr>
<td>Fernandez, Jose R.</td>
<td>1336-P, 1844-P</td>
</tr>
<tr>
<td>Feng, Annie</td>
<td>2439-PUB</td>
</tr>
<tr>
<td>Fernyhough, Paul</td>
<td>58-OR</td>
</tr>
<tr>
<td>Feron, Florine</td>
<td>112-OR</td>
</tr>
<tr>
<td>Festa, Camilla</td>
<td>2345-PUB</td>
</tr>
<tr>
<td>Fett, Anne</td>
<td>536-P</td>
</tr>
<tr>
<td>Feyzioğlu, Gunes</td>
<td>679-P</td>
</tr>
<tr>
<td>Fiallo-Scharer, Rosanna</td>
<td>1380-P</td>
</tr>
<tr>
<td>Fickweiler, Ward</td>
<td>244-OR, 245-OR</td>
</tr>
<tr>
<td>Filion, Oliver</td>
<td>1462-P</td>
</tr>
<tr>
<td>Figueroa-Romero, Claudia</td>
<td>551-P</td>
</tr>
<tr>
<td>Filippi, Charles</td>
<td>1278-P</td>
</tr>
<tr>
<td>Filipp, Stephanie</td>
<td>1486-P, 1523-P, 1816-P</td>
</tr>
<tr>
<td>Filipsson, Karin</td>
<td>958-P</td>
</tr>
<tr>
<td>Filofoz, Claudia M.</td>
<td>1570-P</td>
</tr>
<tr>
<td>Filliaux, Pierre</td>
<td>250-OR</td>
</tr>
<tr>
<td>Finan, Brian</td>
<td>1806-P, 1978-P</td>
</tr>
<tr>
<td>Finch, Jonathan H.</td>
<td>217-OR, 1391-P</td>
</tr>
<tr>
<td>Fincham, Frank</td>
<td>869-P, 870-P</td>
</tr>
<tr>
<td>Finck, Brian</td>
<td>1770-P</td>
</tr>
<tr>
<td>Fink, Brian</td>
<td>1928-P</td>
</tr>
<tr>
<td>Fink, Jeffrey C.</td>
<td>1295-P</td>
</tr>
<tr>
<td>Fink, Lisbeth N.</td>
<td>466-P, 502-P, 516-P</td>
</tr>
<tr>
<td>Finney, Jessica</td>
<td>845-P</td>
</tr>
<tr>
<td>Fiorina, Paolo</td>
<td>571-P, 1231-P</td>
</tr>
<tr>
<td>Fioriti, Elvira</td>
<td>564-P, 716-P</td>
</tr>
<tr>
<td>Firek, Anthony</td>
<td>1270-P, 1625-P</td>
</tr>
<tr>
<td>Firek, Matthew A.</td>
<td>1625-P</td>
</tr>
<tr>
<td>Firpi, Roberto J.</td>
<td>1640-P</td>
</tr>
<tr>
<td>Fischer, Henry</td>
<td>1280-P</td>
</tr>
<tr>
<td>Fischer, Julie R.</td>
<td>1746-P</td>
</tr>
<tr>
<td>Fischl, Andrea F.R.</td>
<td>843-P, 845-P</td>
</tr>
<tr>
<td>Fisher, Edwin B.</td>
<td>718-P</td>
</tr>
<tr>
<td>Fisher, Lawrence</td>
<td>221-OR, 797-P, 801-P, 838-P, 873-P, 931-P</td>
</tr>
<tr>
<td>Fisher, Simon J.</td>
<td>104-OR, 199-OR, 393-P</td>
</tr>
<tr>
<td>Fisher, Susan G.</td>
<td>1292-P</td>
</tr>
<tr>
<td>Fisher, William</td>
<td>692-P</td>
</tr>
<tr>
<td>Fisher-Hoch, Susan P.</td>
<td>2391-PUB, 2392-PUB</td>
</tr>
<tr>
<td>Fisker, Sanne</td>
<td>942-P</td>
</tr>
<tr>
<td>Fitchett, David H.</td>
<td>1123-P, 1173-P</td>
</tr>
<tr>
<td>Fitzgerald, Kelly M.</td>
<td>157-OR, 1778-P</td>
</tr>
<tr>
<td>Fitzpatrick, Karen M.</td>
<td>980-P</td>
</tr>
<tr>
<td>Fitzpatrick, Stephanie L.</td>
<td>1538-P</td>
</tr>
<tr>
<td>Flack, Jeff R.</td>
<td>1897-P</td>
</tr>
<tr>
<td>Flak, Jonathan N.</td>
<td>202-OR</td>
</tr>
<tr>
<td>Flannick, Jason</td>
<td>268-OR, 1703-P</td>
</tr>
<tr>
<td>Flax, Chris</td>
<td>1835-P</td>
</tr>
<tr>
<td>Fleming, Gilbert</td>
<td>346-OR, 979-P</td>
</tr>
<tr>
<td>Fletcher, Justin A.</td>
<td>47-OR, 1876-P</td>
</tr>
<tr>
<td>Fletcher, Laura</td>
<td>1146-P, 2052-P</td>
</tr>
<tr>
<td>Fletcher, Therese</td>
<td>392-P</td>
</tr>
<tr>
<td>Fleury, Dominique I.</td>
<td>933-P</td>
</tr>
<tr>
<td>Flex, Elisabeta</td>
<td>262-OR</td>
</tr>
<tr>
<td>Flood, Jeremy</td>
<td>720-P</td>
</tr>
<tr>
<td>Flores Garcia, Jaquelin J.</td>
<td>1325-P</td>
</tr>
<tr>
<td>Flores, Carlos A.</td>
<td>2392-PUB</td>
</tr>
<tr>
<td>Flores, Hermes</td>
<td>1182-P, 1471-P, 1472-P</td>
</tr>
<tr>
<td>Flores, Jose C.</td>
<td>21-OR, 176-OR, 268-OR, 1440-P, 1703-P, 1704-P, 1711-P</td>
</tr>
<tr>
<td>Floyd, Elizabeth</td>
<td>1757-P, 2014-P</td>
</tr>
<tr>
<td>Foda, Bardees</td>
<td>317-OR</td>
</tr>
<tr>
<td>Fogden, Edward</td>
<td>2071-P, 2087-P, 2097-P</td>
</tr>
<tr>
<td>Fogel, Catherine</td>
<td>209-OR, 960-P, 963-P, 994-P</td>
</tr>
<tr>
<td>Fogelfeld, Leon</td>
<td>2079-P</td>
</tr>
<tr>
<td>Fois, Maria A.</td>
<td>599-P</td>
</tr>
<tr>
<td>Fokina, Anastasia</td>
<td>577-P</td>
</tr>
<tr>
<td>Folchetti, Luciana</td>
<td>2360-PUB</td>
</tr>
<tr>
<td>Foley, Catherine</td>
<td>725-P, 726-P</td>
</tr>
<tr>
<td>Foltynski, Piotr</td>
<td>630-P</td>
</tr>
<tr>
<td>Fong, Ho Yi</td>
<td>617-P, 1634-P</td>
</tr>
<tr>
<td>Fong, Isabel</td>
<td>728-P</td>
</tr>
<tr>
<td>Fong, Regan</td>
<td>2338-PUB</td>
</tr>
<tr>
<td>Fontaine, Eric</td>
<td>81-OR</td>
</tr>
<tr>
<td>Fontana, Andrea</td>
<td>1633-P</td>
</tr>
<tr>
<td>Forbes, Shareen</td>
<td>139-OR, 143-OR, 1740-P</td>
</tr>
<tr>
<td>Ford, Christopher N.</td>
<td>868-P, 1501-P, 1530-P</td>
</tr>
<tr>
<td>Forlenza, Gregory P.</td>
<td>207-OR, 236-OR, 965-P, 977-P, 1376-P, 1377-P</td>
</tr>
<tr>
<td>Fornes, Daiana</td>
<td>1398-P</td>
</tr>
<tr>
<td>Forsberg, Matthew H.</td>
<td>317-OR</td>
</tr>
<tr>
<td>Forsblom, Carol</td>
<td>518-P</td>
</tr>
<tr>
<td>Forslund, Anders H., Sr.</td>
<td>1352-P</td>
</tr>
<tr>
<td>Fort, Patrice E.</td>
<td>241-OR</td>
</tr>
<tr>
<td>Fortier, Charles</td>
<td>349-OR</td>
</tr>
<tr>
<td>Fortmann, Addie L.</td>
<td>659-P, 794-P, 2326-PUB</td>
</tr>
<tr>
<td>Fortunato, Manuela</td>
<td>327-OR</td>
</tr>
<tr>
<td>Foschini, Luca</td>
<td>1616-P</td>
</tr>
<tr>
<td>Fosgerau, Keld</td>
<td>466-P, 502-P</td>
</tr>
<tr>
<td>Foss, Milton C.</td>
<td>785-P</td>
</tr>
<tr>
<td>Boss-Eodorh, Sandrine</td>
<td>1657-P</td>
</tr>
<tr>
<td>Foss-Freitas, Maria Cristina</td>
<td>785-P</td>
</tr>
<tr>
<td>Foster, Collin M.</td>
<td>187-OR</td>
</tr>
<tr>
<td>Name</td>
<td>Index</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Foster, Kathleen</td>
<td>1833-P</td>
</tr>
<tr>
<td>Foster, Nicole C.</td>
<td>216-OR, 1689-P, 2065-P</td>
</tr>
<tr>
<td>Fountas, Athanasios</td>
<td>2410-PUB</td>
</tr>
<tr>
<td>Fountoulakis, Nikolaos</td>
<td>1733-P</td>
</tr>
<tr>
<td>Fourlanos, Spiros</td>
<td>1288-P, 1306-P</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Foussard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Foote, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fourlanos, Spiros</td>
<td>1288-P, 1306-P</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Fournier, Paul A.</td>
<td>730-P, 747-P</td>
</tr>
<tr>
<td>Fouchard, Ninon</td>
<td>1423-P</td>
</tr>
<tr>
<td>Fout, Anna</td>
<td>2157-P</td>
</tr>
<tr>
<td>Fout, Pamella E.</td>
<td>2315-PUB</td>
</tr>
</tbody>
</table>

OR: Oral | P: Poster | PUB: Published Only
<table>
<thead>
<tr>
<th>Name</th>
<th>Index</th>
<th>Type</th>
<th>PubMed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastaldi, Giacomo, Sr.</td>
<td>715-P</td>
<td>2210-PUB</td>
<td></td>
</tr>
<tr>
<td>Gatlin, Peggy</td>
<td>804-P</td>
<td>867-P</td>
<td>886-P</td>
</tr>
<tr>
<td>Gaudier, Martin</td>
<td>305-OR</td>
<td>998-P</td>
<td>1001-P</td>
</tr>
<tr>
<td>Gauthier, Diane-Cécile</td>
<td>112-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gautier, Jean-François</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gauthsch, Edda</td>
<td>974-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gavin, Marc</td>
<td>314-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gavrilova, Oksana</td>
<td>2035-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gay, Alain</td>
<td>536-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gazaliyeva, Meruert A.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ge, Zhijuan</td>
<td>2349-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geffen, Mitchell</td>
<td>1341-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geiger, Kathrin</td>
<td>160-OR</td>
<td>285-OR</td>
<td>1484-P</td>
</tr>
<tr>
<td>Geissler, Alexandre</td>
<td>349-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geldenhuys, Laurette</td>
<td>492-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geldsetzer, Pascal</td>
<td>1511-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelfond, Jonathan A.</td>
<td>71-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genco, Robert J.</td>
<td>1585-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geng, Ying</td>
<td>514-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geng, Yan</td>
<td>1197-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geno Rasmussen, Cristy R.</td>
<td>182-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genovese, Stefano</td>
<td>1210-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Georgia, Stamatina</td>
<td>646-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>George, Jacob</td>
<td>167-OR</td>
<td>1238-P</td>
<td></td>
</tr>
<tr>
<td>George, Jytis T.</td>
<td>1123-P</td>
<td>1173-P</td>
<td>1346-P</td>
</tr>
<tr>
<td>Georgia, Senta</td>
<td>48-OR</td>
<td>50-OR</td>
<td></td>
</tr>
<tr>
<td>Geogiev, Natasha</td>
<td>821-P</td>
<td>1184-P</td>
<td></td>
</tr>
<tr>
<td>Gerard Gonzalez, Andrea</td>
<td>1369-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerber, Ben</td>
<td>1293-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerling, Ian C.</td>
<td>1799-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerrits, Charles</td>
<td>1331-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerst, Felicia</td>
<td>1819-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerstein, Hertz C.</td>
<td>309-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gesz, Elaine</td>
<td>1702-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerszten, Robert</td>
<td>1836-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gervais, Liette</td>
<td>503-P</td>
<td>1858-P</td>
<td>2000-P</td>
</tr>
<tr>
<td>Gerzoff, Robert B.</td>
<td>681-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gesueta, Rosaria</td>
<td>1502-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gettys, Thomas W.</td>
<td>2031-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geurts, Aron</td>
<td>317-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geyer, Susan</td>
<td>94-OR</td>
<td>1374-P</td>
<td>1691-P</td>
</tr>
<tr>
<td>Ghideh, Hilda E.</td>
<td>357-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gahate, Donica M.</td>
<td>1623-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghanbari, Mohsen</td>
<td>1495-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghane, Nejla</td>
<td>1347-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghanekar, Avanti</td>
<td>601-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghanim, Husam</td>
<td>412-P</td>
<td>776-P</td>
<td>1116-P</td>
</tr>
<tr>
<td>Gharib, Ahmed M.</td>
<td>1837-P</td>
<td>1842-P</td>
<td></td>
</tr>
<tr>
<td>Gheng, Yan</td>
<td>514-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghosh, Soumitra</td>
<td>1900-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giacca, Adria</td>
<td>148-OR</td>
<td>484-P</td>
<td></td>
</tr>
<tr>
<td>Giacca, Andrea</td>
<td>1830-P</td>
<td>1971-P</td>
<td>2168-P</td>
</tr>
<tr>
<td>Gianchandani, Roma</td>
<td>975-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giannarelli, Rosa</td>
<td>618-P</td>
<td>1572-P</td>
<td></td>
</tr>
<tr>
<td>Giannopoulou, Catherine, Sr.</td>
<td>2210-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giannoukaki, Panthena</td>
<td>938-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gioncoli, Luigi</td>
<td>363-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giardina, Irene</td>
<td>1457-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giaretta, Luana S.</td>
<td>1551-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gibb, Kate A.</td>
<td>1309-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gibb, Marilyn B.</td>
<td>700-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gidding, Sam</td>
<td>1703-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gigante, Alfonso</td>
<td>599-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gil, Victoria</td>
<td>278-OR</td>
<td>281-OR</td>
<td></td>
</tr>
<tr>
<td>Gilbert, Jeremy</td>
<td>250-OR</td>
<td>1550-P</td>
<td>1578-P</td>
</tr>
<tr>
<td>Gilbert, Matthew P.</td>
<td>108-OR</td>
<td>2283-PUB</td>
<td></td>
</tr>
<tr>
<td>Gilbertson, Nicole M.</td>
<td>754-P</td>
<td>755-P</td>
<td>1774-P</td>
</tr>
<tr>
<td>Giles, Lynne</td>
<td>230-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gilham, Dean</td>
<td>1136-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gill, Patricia</td>
<td>935-P</td>
<td>2264-PUB</td>
<td></td>
</tr>
<tr>
<td>Gillas, Pieter</td>
<td>213-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gillen, Jenna B.</td>
<td>745-P</td>
<td>2078-P</td>
<td></td>
</tr>
<tr>
<td>Gillespie, Barbara</td>
<td>544-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gillespie, Tom</td>
<td>2006-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gillum, Matthew</td>
<td>2415-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gingras, Veronique</td>
<td>137-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giorgino, Francesco</td>
<td>1007-P</td>
<td>1093-P</td>
<td>1095-P</td>
</tr>
<tr>
<td>Gioscia-Ryan, Rachel A.</td>
<td>2048-P</td>
<td>2078-P</td>
<td></td>
</tr>
<tr>
<td>Giri, Smith</td>
<td>1333-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giri, Suresh R.</td>
<td>1194-P</td>
<td>1203-P</td>
<td></td>
</tr>
<tr>
<td>Giroux, Isabelle T.</td>
<td>2346-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giuliani, Elena</td>
<td>571-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giusti, Laura</td>
<td>618-P</td>
<td>1572-P</td>
<td>1694-P</td>
</tr>
<tr>
<td>Gladwin, Mark</td>
<td>75-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glantz, Namino M.</td>
<td>1281-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glasgow, Russell</td>
<td>879-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gleisner, John M.</td>
<td>935-P</td>
<td>2264-PUB</td>
<td></td>
</tr>
<tr>
<td>Glenister, Kristen</td>
<td>1515-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gleizer, Stanislav</td>
<td>305-OR</td>
<td>998-P</td>
<td>1001-P</td>
</tr>
<tr>
<td>Gluck, Bethany</td>
<td>1309-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLisic, Marija</td>
<td>1480-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glotfelter, Michael A.</td>
<td>816-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glueck, Deborah H.</td>
<td>179-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glykofridi, Spiriouda</td>
<td>1058-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glynn, Robert J.</td>
<td>1492-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gmyr, Valery</td>
<td>2143-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Go, James</td>
<td>2006-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goddard, Tyler N.</td>
<td>1229-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goddi, Anna A.</td>
<td>1764A-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Godsland, Ian F.</td>
<td>1696-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goebel, Britta</td>
<td>72-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goetz, Kerry</td>
<td>1244-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goetzman, Eric</td>
<td>2443-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gofer, Ilan</td>
<td>665-P</td>
<td>666-P</td>
<td>1076-P</td>
</tr>
<tr>
<td>Goforth, Paulette B.</td>
<td>202-OR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Goge, Sandhya  727-P
Goh, Lih Ling  419-P
Goh, Su-Yen  809-P
Goklani, Rutul  1205-P, 2214-PUB
Göküz, Özay  1053-P
Goland, Robin  249-OR
Goldberg, Marcel  1657-P
Golden, Sherita  1096-P
Goldfine, Allison  1833-P
Goldman, Allison  1129-P
Goldshtein, Inbal  1563-P, 1564-P
Goldstein, Barry J.  544-P
Golias, Jaroslav  1738-P
Golizeh, Makan  337-OR
Gomes, Lorena M.A.  628-P
Gomes, Marilia B.  1141-P, 1562-P, 1615-P, 1629-P
Gomes, Patricia  785-P
Gomez Alonso, Amayrani  687-P
Gomez, Ana Maria  918-P
Gomez, Claudin A.  1625-P
Gomez, Miriam  645-P
Gomez, Ricardo  2344-PUB
Gomis, Ramon  2410-PUB
Gonder, John  240-OR
Gonder-Frederick, Linda  894-P
Gong, Qiuhong  130-OR, 1654-P
Gong, Zhenwei  2443-PUB
Gonzaga, Isabela M.  68-OR
Gonzalez Perez de Villar, Noemi  2232-PUB
Gonzalez, Adriana  888-P, 1501-P, 1530-P
Gonzalez, Camilo D.  1460-P
Gonzalez, Claudio D.  1247-P, 1265-P
Gonzalez, Concepcion  1423-P
González, Enrique  687-P
Gonzalez, Erica V.  1661-P, 1811-P
Gonzalez, Jeffrey S.  862-P
Gonzalez, Sabrina  1304-P
Gonzalez-Galvez, Guillermo  261-OR, 1191-P
Gonzalez-Gonzalez, Jose G.  1460-P
Gooch, Anna  1746-P
Goodarzi, Mark O.  2244-PUB
Goodman, Shaun G.  522-P
Goodpaster, Bret H.  70-OR, 75-OR, 1907-P, 1936-P
Goodyear, Laurie J.  64-OR, 66-OR, 739-P, 758-P
Gopakumar, Srinivas  335-OR
Gopalakrishnan, Chandrasekar  2364-PUB
Gopalakrishnan, Shweta  209-OR, 960-P, 963-P, 994-P
Gorczyńska-Kosior, Sylwia  1896-P
Gordin, Daniel  91-OR
Gordon, Ian L.  114-OR
Gorelik, Alexandra  1288-P
Görgens, Sven W.  1861-P
Gorgojo-Martinez, Juan J.  1099-P
Goschen, Ran  1286-P
Göttmann, Eva-Maria  822-P
Goswami, Parikshit J.  2380-PUB
Gottfredsen, Anders  398-P
Goto, Atsushi  808-P
Goto, Shigemi  554-P
Gottlieb, Peter  98-OR, 1687-P
Gou, Wenyu  1741-P
Gouet, Didier  1092-P
Gould, Michelle  1579-P
Gourash, William F.  366-OR
Gourggiotis, Loukas  544-P
Gower, Barbara  1336-P, 1844-P
Goya, Maria  1454-P
Goyal, Akankasha  39-OR
Goyau, Harmonie  1050-P
Grabar-Naidich, Anna  1247-P, 1265-P
Grabner, Michael  1071-P, 1264-P
Gradiser, Marina  2278-PUB
Graff, Emily  1877-P, 2031-P
Gram-Nielsen, Sanne  347-OR
Granhall, Charlotte  1135-P
Granowicz, Craig B.  332-OR, 416-P, 1485-P
Grant, Maria B.  238-OR, 1899-P
Grant, Struan F.  1339-P, 1705-P, 1714-P
Graup, Niels  439-P
Grassi, Giorgio  916-P
Gravholt, Claus H.  1444-P
Gray, Alastair M.  1319-P
Gray, Geof D.  725-P, 726-P
Gray, Laura J.  1355-P
Gray, Sarah M.  2023-P
Graybill, Sky  1268-P
Grayson, Truman  87-OR, 2149-P
Greaves, Tori  380-P, 405-P, 826-P, 921-P, 959-P
Greeley, Siri Atma W.  264-OR, 1379-P, 1453-P, 2353-PUB
Green, Jennifer B.  1299-P
Green, Kelly  412-P, 776-P, 1771-P, 1888-P
Greenberg, Caylee A.  394-P
Greenberg, Jordan  380-P, 405-P, 826-P, 921-P, 959-P
Greenberg, Michael E.  1595-P, 1616-P
Greenfield, Michael  1055-P
Greenstone, Michael A.  2071-P
Greenwood, Deborah A.  249-OR
Greig, Marni  568-P
Greig, Marni  568-P
Grein, Dale L.  323-OR
Grethe, Jeffrey S.  2006-P
Grey, Margaret  814-P, 815-P
Griendling, Kathy  478-P
Griep, Brian T.  1317-P
Griffin, Cameron A.  282-OR
Griffith, Gillian A. 668-P, 2228-PUB
Griffiths, Kayleigh 2201-PUB
Grigorescu, Florin 2410-PUB
Grimsby, Joe 1841-P, 1909-P
Grimsrud, Paul A. 1874-P
Grioni, Sara 1830-P
Gritz, Mark 169-OR, 246-OR
Grizzle, Mary K. 1998-P
Groleau, Mélanie 250-OR
Grøn, Randi 997-P, 1025-P, 1065-P
Gronbaek, Henning 2415-PUB
Grônlund, Rikke 1788-P
Groop, Leif 1537-P
Gröske, Derek 365-OR
Grønlund, Rikke 1788-P
Gu, Liqun 1069-P
Gu, Yong 265-OR
Gu, Zhen 976-P
Guadalupe, Mariana E. 526-P
Gu, Weiying 2193-PUB
Guo, Xiaodi 1033-P
Guo, Xiaohua 2419-PUB
Guo, Xiaohui 1290-P
Guo, Xiaonan 1006-P
Guo, Xin 2155-P
Guo, Xiuqing 2244-PUB
Guo, Yan 1301-P
Guo, Yong 2298-PUB
Guo, Yuning 1359-P
Guo, Zhijia 153-OR
Guo, Zijing 1375-P, 1392-P, 2274-PUB
Gupta, Aashima 1595-P
Gupta, Jyotsna 722-P
Gupta, Manoj K. 1765-P
Gupta, Payal 1209-P
Gupta, Rajesh 355-OR, 357-OR, 2159-P
Gupta, Resmi 341-OR
Gupta, Rishab 1056-P, 1057-P
Gupta, Sunil 1019-P
Gupta, Vipul 462-P, 2313-PUB
Gupta, Vishal 1165-P, 1513-P, 1516-P
Gurbani, Neepa 1359-P
Gurgel, Maria Helane C. 585-P
Guo, Matthew J. 844-P, 1371-P, 1486-P, 1523-P, 1816-P
Gurlo, Tatiana 50-OR
Gurung, Mongal S. 1511-P
Guseman, Emily H. 717-P, 858-P, 891-P
Gustav, Jeanette 1474-P
Gustavson, Stephanie 1319-P
Guth, Lisa M. 2048-P
Gutierrez, Absalom D., Jr. 1954-P, 2392-PUB
Guttmann-Bauman, Ines 805-P
Gwatsadam, David 1511-P
Guyer, Heidi 1482-P, 1611-P
Guzmán Olvera, Eileen B. 687-P
Guzman, Susan 797-P
Ha, Arnold 189-OR
Ha, Jinkyung 181-OR
Ha, Na-Hee 1800-P
Haack, Torsten 2028-P
Haak, Thomas 671-P, 912-P, 914-P, 1695-P
Haas, Joseph V. 1847-P
Haberlander, Maximilian 1941-P
Habib, Samy L. 513-P
Hachiya, Hiroki 1087-P
Hackett, Daryl J. 1815-P
Haddad, Amber J. 1439-P
Hadato, Toshimi 1720-P
Hadcock, John 1886-P
Hadden, Mitchell J. 492-P
Hadidi, Jean Christophe 2410-PUB
Hadjadi, Samy 2220-PUB, 2221-PUB
Hadjiliadis, Denis 1820-P
Hadjiyanni, Irene 221-OR, 801-P, 838-P  
Haedersdal, Sofie 1942-P  
Hafner, Franz 2308-PUB  
Hager, Heather M. 241-OR  
Haghia, Maricela 226-OR  
Hai, Li 999-P  
Haida, Kyoichi 539-P  
Haidar, Ahmad 10-OR, 210-OR  
Haidar, Ahmad 125-OR, 1063-P  
Haidar, Julia A. 573-P  
Haidry, Rehan 1137-P  
Hailey, Angela 353-OR  
Hair, Mario D. 1558-P  
Haj, Li 999-P  
Haj‑Yehia, Elias 436-P  
Hajian, Matine 2444-PUB  
Hajizadeh, Iman 937-P  
Haji Ali, Sulaiman 1547-P  
Haj‑Yehia, Elias 436-P  
Haldeman, Jonathan M. 1874-P  
Hale, Daniel E. 872-P  
Hall, Michael L. 74-OR, 1207-P  
Halladin, Natalie 127-OR, 997-P  
Hallakou‑Bozec, Sophie 81-OR  
Hallberg, Sarah 293-OR  
Halliday, Christopher 1136-P  
Halm, Ethan 1497-P  
Halper, Jillian B. 1308-P  
Halpern, Elise M. 580-P  
Ham, Sandra A. 8-OR, 1252-P  
Hamada, Yoshimasa 2104-P  
Hamaguchi, Masahide 774-P  
Hamaguchi, Yuriko 255-OR, 1227-P, 1957-P, 1958-P  
Hamamatsu, Keita 2123-P, 2124-P  
Hamamoto, Yoshiyuki 540-P, 1178-P, 2306-PUB  
Hamaoka, Takafumi 2080-P  
Hamasaki, Akihiro 1178-P  
Hambidge, Bertha 804-P, 867-P, 886-P  
Hamdy, Osama 760-P, 934-P, 2044-P  
Hamel, Maureen S. 1427-P  
Hamersky, Carol M. 684-P  
Hamidi, Vala 1954-P  
Hamilton, Garry 420-P  
Hamilton, Jill 116-OR  
Hamm, Megan 713-P  
Hamman, Richard F. 342-OR, 1366-P  
Hammar, Niklas 1141-P, 1562-P, 1615-P, 1629-P  
Hammers, David 2444-PUB  
Hamming, Cecilia 1740-P  
Hamren, Bengt 1190-P  
Hamza, Muhammad 365-OR, 2427-PUB  
Han, Eugene 1535-P, 1670-P  
Han, Guichun 1875-P  
Han, Lanwen 1339-P, 1365-P  
Han, Michelle 1287-P  
Han, Seung Jin 1571-P, 1912-P  
Han, Taesung 2265-PUB  
Han, Weiping 279-OR, 280-OR  
Han, Yanfei 643-P  
Han, Ying 929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB  
Han, Yong 370-OR  
Han, Youngah 1983-P  
Hanafusa, Toshiaki 100-OR  
Hanaire, Hélène 208-OR  
Handelsman, Yehuda 128-OR, 837-P, 1251-P  
Haneda, Keigo 2265-PUB  
Hang, Hardy 271-OR  
Hanley, Kelly L. 688-P, 1218-P  
Hannouche, Thierry 933-P  
Hannon, Tamara 1308-P, 1643-P, 1644-P  
Hanrahan, John P. 74-OR, 1207-P  
Hansen, Barbara C. 939-P, 1931-P  
Hansen, Charlotte T. 107-OR, 108-OR  
Hansen, Cilie W. 1135-P  
Hansen, Dorte L. 2046-P  
Hansen, Jakob S. 1856-P  
Hansen, Laura S. 1969-P  
Hansen, Melissa V. 107-OR, 108-OR, 530-P  
Hansen, Michael K. 1126-P  
Hansen, Thomas 1084-P, 1085-P  
Hansen, Torben 439-P  
Hansen, Trine 1109-P  
Hansen, Troels K. 942-P  
Hansen, Ulla M. 813-P  
Hansmann, Merel 220-OR, 1375-P  
Hanson, Courtney 252-OR  
Hanson, Robert L. 558-P, 1713-P, 1719-P  
Hanssen, Kristian F. 1405-P, 1409-P  
Hantel, Stefan 1173-P, 1346-P  
Hanzu, Felicia 2410-PUB  
Haqq, Andrea 139-OR  
Haque, Muhammad R. 1745-P  
Haque, Ramza 667-P  
Hara, Kenji 2240-PUB  
Harada, Marina 1002-P  
Harada, Mayuko 444-P, 594-P, 637-P, 1488-P, 2368-PUB, 2384-PUB  
Harada, Takashi 543-P, 1610-P, 2205-PUB  
Harada-Shiba, Mariko 488-P  
Haraguchi, Mikiko 163-OR  
Harant, Karel 1974-P  
Harashima, Shinichi 1894-P, 2348-PUB
<table>
<thead>
<tr>
<th>Author</th>
<th>Citation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hehmeyer, Jessica</td>
<td>1307-P</td>
</tr>
<tr>
<td>Hehnke, Uwe</td>
<td>524-P, 1123-P</td>
</tr>
<tr>
<td>Heianza, Yoriko</td>
<td>121-OR, 297-OR, 1565-P, 1580-P</td>
</tr>
<tr>
<td>Heiberg-Gibbons, Francesca</td>
<td>550-P</td>
</tr>
<tr>
<td>Heidtmann, Bettina</td>
<td>1699-P</td>
</tr>
<tr>
<td>Heier, Margit</td>
<td>63-OR</td>
</tr>
<tr>
<td>Heile, Michael K.</td>
<td>837-P, 1251-P</td>
</tr>
<tr>
<td>Heimberger, Sebastian M.</td>
<td>1939-P</td>
</tr>
<tr>
<td>Heinemann, Lutz</td>
<td>211-OR, 298-OR, 824-P</td>
</tr>
<tr>
<td>Heinel, Andreas</td>
<td>1126-P</td>
</tr>
<tr>
<td>Heise, Thomas L.</td>
<td>840-P</td>
</tr>
<tr>
<td>Heisler, Michele</td>
<td>703-P</td>
</tr>
<tr>
<td>Heiston, Emily M.</td>
<td>754-P, 755-P</td>
</tr>
<tr>
<td>Heitmeier, Monique</td>
<td>1779-P</td>
</tr>
<tr>
<td>Hejna, Jeanne M.</td>
<td>1116-P, 1888-P</td>
</tr>
<tr>
<td>Helal, Lucas</td>
<td>768-P</td>
</tr>
<tr>
<td>Helbling, Nicole L.</td>
<td>75-OR</td>
</tr>
<tr>
<td>Helgeland, Geir</td>
<td>1824-P</td>
</tr>
<tr>
<td>Helgerson, Steven D.</td>
<td>675-P, 676-P</td>
</tr>
<tr>
<td>Helgeson, Vicki</td>
<td>657-P, 799-P, 864-P</td>
</tr>
<tr>
<td>Heller, Lucas</td>
<td>103-OR</td>
</tr>
<tr>
<td>Heller, Simon R.</td>
<td>107-OR, 300-OR, 391-P</td>
</tr>
<tr>
<td>Helmer, Catherine</td>
<td>450-P, 1423-P</td>
</tr>
<tr>
<td>Helmut, Amy</td>
<td>1322-P</td>
</tr>
<tr>
<td>Helsted, Mads M.</td>
<td>145-OR</td>
</tr>
<tr>
<td>Helvig, Nicole L.</td>
<td>1490-P, 1522-P, 1536-P, 2091-P, 2092-P, 2187-PUB, 2402-PUB</td>
</tr>
<tr>
<td>Heni, Martin</td>
<td>295-OR, 364-OR, 1402-P, 1403-P, 1717-P, 1819-P</td>
</tr>
<tr>
<td>Henke, Christine</td>
<td>1804-P</td>
</tr>
<tr>
<td>Henn, Owen</td>
<td>931-P</td>
</tr>
<tr>
<td>Hennighausen, Lothar</td>
<td>2037-P</td>
</tr>
<tr>
<td>Henriksson, Trine</td>
<td>1575-P</td>
</tr>
<tr>
<td>Henry, Robert R.</td>
<td>73-OR, 138-OR, 159-OR, 1902-P</td>
</tr>
<tr>
<td>Herbrand, Theresa</td>
<td>1001-P</td>
</tr>
<tr>
<td>Herder, Christian</td>
<td>63-OR, 1139-P, 1845-P</td>
</tr>
<tr>
<td>Herkert, Darby M.</td>
<td>2-OR</td>
</tr>
<tr>
<td>Herman Mahecic, Davorka</td>
<td>1965-P</td>
</tr>
<tr>
<td>Herman, Allison N.</td>
<td>218-OR</td>
</tr>
<tr>
<td>Herman, William H.</td>
<td>703-P, 1287-P, 1291-P, 1704-P</td>
</tr>
<tr>
<td>Hermans, Norbert</td>
<td>211-OR, 221-OR, 298-OR, 671-P, 824-P, 912-P, 914-P</td>
</tr>
<tr>
<td>Hermans, Michel P.</td>
<td>614-P</td>
</tr>
<tr>
<td>Hernandez, Adrian F.</td>
<td>522-P, 1319-P</td>
</tr>
<tr>
<td>Hernandez, Christina M.</td>
<td>699-P</td>
</tr>
<tr>
<td>Hernández, Cristina M.</td>
<td>608-P</td>
</tr>
<tr>
<td>Hernandez, Tari L.</td>
<td>1428-P</td>
</tr>
<tr>
<td>Herold, Kevan C.</td>
<td>1374-P, 2145-P</td>
</tr>
<tr>
<td>Herranz, Lucrencia</td>
<td>2232-PUB</td>
</tr>
<tr>
<td>Herrick, Cynthia J.</td>
<td>1459-P, 1699-P</td>
</tr>
<tr>
<td>Hershberger, Vrinda</td>
<td>601-P</td>
</tr>
<tr>
<td>Hershey, Denise</td>
<td>2237-PUB</td>
</tr>
<tr>
<td>Hershkovitz, Eli</td>
<td>235-OR</td>
</tr>
<tr>
<td>Hessel, Frances C.</td>
<td>1529-P</td>
</tr>
<tr>
<td>Hessler, Danielle M.</td>
<td>221-OR, 797-P, 801-P, 838-P</td>
</tr>
<tr>
<td>Heurling, Kerstin</td>
<td>1790-P</td>
</tr>
<tr>
<td>Heximer, Scott</td>
<td>484-P</td>
</tr>
<tr>
<td>Heyman, Mark</td>
<td>889-P, 890-P</td>
</tr>
<tr>
<td>Heyward, Frankie D.</td>
<td>2430-PUB</td>
</tr>
<tr>
<td>Haasa, Yoichi</td>
<td>1581-P, 1609-P, 1666-P</td>
</tr>
<tr>
<td>Hickey, Aileen</td>
<td>383-P, 974-P</td>
</tr>
<tr>
<td>Hickman, Mary A.</td>
<td>1145-P, 1168-P, 1169-P</td>
</tr>
<tr>
<td>Hicks, Kristie</td>
<td>769-P</td>
</tr>
<tr>
<td>Hidvegi, Tibor</td>
<td>1049-P</td>
</tr>
<tr>
<td>Higa, Elisah M.</td>
<td>2365-PUB</td>
</tr>
<tr>
<td>Higa, Mariko</td>
<td>772-P</td>
</tr>
<tr>
<td>Higgins, Janine</td>
<td>1341-P, 2448-PUB</td>
</tr>
<tr>
<td>Higo, Naoko</td>
<td>850-P</td>
</tr>
<tr>
<td>Higuera-de la Tijera, Fatima, Sr.</td>
<td>2362-PUB</td>
</tr>
<tr>
<td>Hirragi, Hiroko</td>
<td>913-P, 2286-PUB</td>
</tr>
<tr>
<td>Hijikata, Mai</td>
<td>772-P</td>
</tr>
<tr>
<td>Hitkina, Yonezou</td>
<td>1617-P</td>
</tr>
<tr>
<td>Hilkin, Allison M.</td>
<td>1348-P</td>
</tr>
<tr>
<td>Hil, Lauren F.</td>
<td>601-P</td>
</tr>
<tr>
<td>Hill, Martin</td>
<td>294-OR, 784-P</td>
</tr>
<tr>
<td>Hillard, Mallory A.</td>
<td>14-OR, 299-OR</td>
</tr>
<tr>
<td>Hilliard, Marisa E.</td>
<td>848-P</td>
</tr>
<tr>
<td>Hillman, Natalia</td>
<td>2232-PUB</td>
</tr>
<tr>
<td>Hilmes, Melissa A.</td>
<td>233-OR</td>
</tr>
<tr>
<td>Himeno, Tatsuhito</td>
<td>563-P, 565-P, 566-P, 567-P</td>
</tr>
<tr>
<td>Himuro, Miwa</td>
<td>1400-P, 2125-P, 2128-P</td>
</tr>
<tr>
<td>Hince, Cathy</td>
<td>1817-P</td>
</tr>
<tr>
<td>Hinder, Lucy M.</td>
<td>60-OR, 569-P</td>
</tr>
<tr>
<td>Hinkle, Stefanie</td>
<td>1434-P, 1437-P</td>
</tr>
<tr>
<td>Hinsdale, Myron</td>
<td>454-P</td>
</tr>
<tr>
<td>Hinton, William</td>
<td>1047-P</td>
</tr>
<tr>
<td>Hirai, Aizan</td>
<td>415-P, 673-P</td>
</tr>
<tr>
<td>Hirai, Hiromasa</td>
<td>595-P</td>
</tr>
<tr>
<td>Hirai, Keiji</td>
<td>415-P</td>
</tr>
<tr>
<td>Hiraizke, Yuta</td>
<td>270-OR</td>
</tr>
<tr>
<td>Hirakata, Vánia N.</td>
<td>1450-P</td>
</tr>
<tr>
<td>Hirano, Seiki</td>
<td>1637-P</td>
</tr>
<tr>
<td>Hirasawa, Reiko</td>
<td>781-P</td>
</tr>
<tr>
<td>Hirata, Kazuto</td>
<td>2434-PUB</td>
</tr>
<tr>
<td>Hirata, Yu</td>
<td>1910-P</td>
</tr>
<tr>
<td>Hiromura, Munenori</td>
<td>289-OR, 482-P, 487-P, 1988-P</td>
</tr>
<tr>
<td>Hirooka, Masashi</td>
<td>1666-P</td>
</tr>
<tr>
<td>Hirose, Masamichi</td>
<td>154-OR, 1903-P</td>
</tr>
<tr>
<td>Hirose, Takahisa</td>
<td>1848-P</td>
</tr>
<tr>
<td>Hirota, Naoki</td>
<td>2208-PUB</td>
</tr>
<tr>
<td>Hirota, Tomoe</td>
<td>2074-P</td>
</tr>
<tr>
<td>Hirsch Vexberg, Michal</td>
<td>1297-P</td>
</tr>
<tr>
<td>Hirsch, Ashley</td>
<td>889-P, 890-P</td>
</tr>
<tr>
<td>Hirsch, Irl B.</td>
<td>12-OR, 927-P, 2329-PUB</td>
</tr>
<tr>
<td>Hirschfeld, Emily</td>
<td>1318-P</td>
</tr>
<tr>
<td>Hirschler, Valeria</td>
<td>2333-PUB</td>
</tr>
<tr>
<td>Hirshberg, Beaz</td>
<td>78-OR, 79-OR, 1067-P, 1070-P</td>
</tr>
</tbody>
</table>
Hirshman, Michael F. 64-OR, 758-P
Hisamatsu, Takashi 1636-P
Hitomi, Mamiko 661-P
Hitt, Susan M. 1686-P
Hivert, Marie-France 120-OR, 137-OR, 1440-P, 1704-P, 1707-P
Hng, Tien-Ming 1673-P
Ho, Cheng-Ying 57-OR
Ho, Michael 435-P
Ho, Yuk-Lam 868-P
Hoang, Hai 1802-P
Hobizal, Kimberlee 631-P
Hockett, Christine 179-OR
Hocking, Paul 78-OR, 1175-P
Hodge, Kenyaita M. 1705-P, 1714-P
Hodges, Wesley T. 1770-P
Hodish, Israel 353-OR, 1326-P
Hödl, Ronald 2309-PUB
Hodson, David 325-OR, 326-OR
Hoeflich, Andreas 1833-P
Hodges, Andrew P. 70-OR, 740-P
Hodges, Peter 1770-P
Hodd, Israel 353-OR, 1326-P
Högenauer, Christoph 2086-P
Hogg, Ruth E. 2201-PUB
Holen, Torgeir 752-P
Hollander, Priscilla 259-OR
Holleman, Frits 106-OR, 1137-P
Holley-Cuthrell, Jenan R. 2044-P
Hollingsworth, Kieren G. 40-OR, 42-OR, 1834-P
Hollingsworth, Rosalind C. 1616-P
Holm, Lars 1895-P
Holman, Rury R. 1643-P, 1644-P
Hogan, Ashley N. 1643-P, 1644-P
Hogan, Rebecca 1937-P, 1938-P
Hogan, Meghan F. 1815-P, 2107-P
Högenauer, Christoph 1137-P
Holl, Reinhard W. 1695-P
Hollander, Priscilla 259-OR
Hollemans, Frits 1137-P
Holley-Cuthrell, Jenan R. 2044-P
Hollingsworth, Kieren G. 40-OR, 42-OR, 1834-P
Hollingsworth, Rosalind C. 1616-P
Holm, Lars 1895-P
Holman, Rury R. 452-P, 522-P, 1299-P, 1319-P
Holmes, Heather L. 2117-P
Holt, Marlena M. 1823-P
Holtrop, Jodi S. 246-OR
Hovorka, Roman 350-OR, 926-P, 973-P, 1432-P
Howard, Alan B. 2283-PUB
Howard, George 307-OR
Howard, Victor G. 1891-P, 1909-P
Howard, Virginia J. 307-OR, 1680-P
Howe, Parker 104-OR
Howell, Scott 521-P
Howley, Peter 1368-P
Hox, Sophia H. 1182-P
Hoyer, Annika 822-P, 1139-P, 1586-P
Hramiak, Irene 1085-P, 2289-PUB
Hren, Rok 1246-P
Hresko, Richard C. 1779-P
Hruz, Paul W. 1779-P
Hsia, Daniel S. 1544-P
Hsia, Stanley 919-P, 1172-P
Hong, Sean 1734-P
Hong, Seongbin 527-P, 533-P
Hong, So-Hyeon 464-P
Hong, Tianpei 2302-PUB
Horjio, Sachiko 1178-P
Hoo, Rlc 1732-P, 1866-P, 2025-P
Hoofnagle, Andrew 1663-P
Hopkins, David 1137-P
Hoppel, Charles L. 1915-P, 1937-P
Hor, Chee Peng 2057-P
Hore, Israel A. 1566-P, 2389-PUB
Horberg, Michael A. 1538-P
Horikawa, Chika 597-P, 781-P, 823-P, 1561-P, 2319-PUB
Horikawa, Kazuki 1857-P
Horikoshi, Takuro 257-OR
Horio, Hiroshi 1000-P
Horlyck-Romanovsky, Margarethe F. 1639-P
Horn, Patrick 284-OR
Hornby, W. Guyton, Jr. 880-P
Horie, David A. 706-P
Horie, Jeffrey F. 745-P, 1758-P, 2048-P, 2078-P
Horsburgh, Jodie C. 986-P
Horton, Edward 1471-P
Hoshen, Moshe B. 665-P, 666-P
Hoshina, Sari 1700-P
Hoskin, Mary A. 1471-P
Hosoe, Jun 1128-P, 1349-P
Hosokawa, Naoshi 850-P
Hosomura, Naoshi 2101-P
Hosooka, Tetsuya 188-OR, 1910-P
Hostelley, Timothy L., Jr. 54-OR
Hou, Lifang 1345-P
Hou, Xinghua, Sr. 1201-P
Hou, Yi 361-OR
Houehanou, Corine 1511-P
Houinato, Dismand, Sr. 1511-P
Houinato, Dismand, Sr. 1511-P
Houlden, Robyn L. 1550-P, 1578-P, 1579-P
Houpland-Oregaard, Azadeh 1135-P
Houston, John G. 167-OR, 256-OR, 1238-P
Hoefelmann, Ulrike 102-OR, 305-OR, 1006-P
Hovorka, Roman 58-OR, 926-P, 973-P, 1432-P
Howard, Alan B. 2283-PUB
Howard, George 307-OR
Howard, Victor G. 1891-P, 1909-P
Howard, Virginia J. 307-OR, 1680-P
Howe, Parker 104-OR
Howell, Scott 521-P
Howley, Peter 1368-P
Hox, Sophia H. 1182-P
Hoyer, Annika 822-P, 1139-P, 1586-P
Hramiak, Irene 1085-P, 2289-PUB
Hren, Rok 1246-P
Hresko, Richard C. 1779-P
Hruz, Paul W. 1779-P
Hsia, Daniel S. 1544-P
Hsia, Stanley 919-P, 1172-P
Hsiao, Victoria 9-OR
Hsieh, Eugene 1550-P, 1578-P, 1579-P
Hsu, Hsiang-Ting 265-OR
Hsu, Jean W. 1782-P
Hsu, William C. 1328-P
Hsuan, Li Y. 2081-P
Hsueh, Wen-Chi 1713-P, 1719-P
Hsueh, Willa 1751-P, 2244-PUB
Hu, Cheng 1977-P
Hu, Chunjuxiu 1856-P
Hu, Daqing 929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB
Hu, Fang 504-P, 506-P, 509-P, 510-P
Hu, Frank 1539-P
Hu, Gang 121-OR, 1345-P, 1433-P, 1576-P
Hu, Jiang 46-OR, 49-OR, 1765-P, 1824-P
Hu, Jun 2349-PUB
Hu, Ming 1708-P
Hu, Ping 635-P
Hu, Xiaoli 1672-P
Hu, Xiling 1033-P, 1301-P, 1972-P
Hu, Yanji 429-P
Hu, Yinghua 130-OR
Hua, Xinyang 1299-P
Huang, Chien-Ning 2258-PUB
Huang, Chunteng 2444-PUB
Huang, Elbert 1252-P, 1311-P, 1324-P
Huang, Emily 157-OR, 1915-P, 1937-P
Huang, Fengyuan 1748-P
Huang, Gan 1698-P
Huang, Holly 1061-P, 1102-P, 1103-P
Huang, Kunlun 1759-P
Huang, Minxuan 1682-P
Huang, Qianwen 1731-P
Huang, Qing 1071-P, 1264-P
Huang, Rong 1826-P
Huang, Suiying 236-OR
Huang, Tao 1430-P
Huang, Terry 1639-P
Huang, Tian Lian 273-OR, 277-OR
Huang, Wei 92-OR, 499-P
Huang, Xiuting 1188-P, 2401-PUB
Huang, Ya-Ching 652-P
Huang, Yadi 1676-P
Huang, Yao 1060-P, 1094-P
Huang, Yicheng 1748-P
Huang, Yiyun 2145-P
Huang, Yuan 1226-P
Huang, Zuimin 617-P, 1044-P, 1045-P
Hubberd, Abigail L. 699-P
Hubert, Thomas 2143-P
Hübbschle, Thomas 1981-P
Huckfeldt, Peter J. 171-OR
Hucl, Tomas 2051-P
Hudalla, Greg 99-OR
Huebschmann, Amy G. 856-P, 879-P
Huffman, Derek 1803-P
Hughan, Kara S. 75-OR
Hughes, Corey B. 2157-P
Hughes, Jinhua 1699-P
Hui, Hannah, Sr. 2025-P
Hui, Jin 557-P
Hui, You 1351-P
Hull, Michael 416-P
Hull, Michaela E. 1778-P
Hull, Rebecca L. 82-OR, 1815-P, 2107-P
Hull, Sara E. 1494-P, 1916-P
Hulman, Adam 1674-P
Hulstein, Jeff 2318-PUB
Hundal, Henna 1901-P
Hundal, Ripu S. 988-P, 989-P, 990-P
Hunt, Kelly J. 430-P, 528-P
Hunt, Phillip R. 1582-P
Hunter, Chad S. 2020-P
Hu, Junguk 548-P, 551-P, 569-P
Hu, Kyu Yeon 196-OR, 572-P
Hurtado, Carolina R. 401-P
Hurtado, Maria D. 1808-P, 1812-P, 1953-P
Husemoen, Lise Lotte N. 2295-PUB
Huovovsky, Matt 35-OR
Hutch, Chelsea 1962-P, 2013-P
Hüttl, Martina 1211-P, 1722-P, 1723-P
Huyck, Susan 1129-P, 1132-P, 1140-P, 1145-P, 1145-P, 1168-P, 1169-P
Huyett, Lauren M. 207-OR, 1376-P, 1377-P
Hwang, Inajie 1951-P
Hwang, Janice 204-OR, 365-OR, 1802-P, 2427-PUB
Hwang, Jong-Hee 1509-P, 1567-P, 2054-P
Hyseri, Ilirjana 374-OR
Iannone, Giulia 1383-P, 2222-PUB
Ibata, Tomohiro 2164-P
Ibrahim, Nasrien E. 1526-P
Ibsen, Rikke 162-OR
Ichihara, Takako 1505-P
Ichijo, Takamasa 772-P
Ichikawa, Mai 154-OR, 1903-P, 1906-P
Iida, Shogo 1199-P
Ide, Kana 257-OR
Ide, Shintaro 257-OR
Idiculla, Jyothi 591-P
Idso, John 1289-P
Iff, Joel 2180-PUB
Igarashi, Masahiko 2127-P
Igarashi, Michihiro 547-P
Igarashi, Yoshiko 380-OR, 1749-P, 1990-P
Igata, Motoyuki 1635-P
Iglay, Kristy 1631-P, 1632-P, 1658-P, 2396-PUB
Iglesias, Maria Laura, Sr. 943-P
Igor, Tverdokhleb 2194-PUB
Iida, Mayu 928-P  
Iijima, Toshiie 1849-P  
Ike, Emily 896-P  
Ikeda, Daisuke 2233-PUB  
Ikeda, Fuki 928-P, 1187-P  
Ikeda, Kaori 1894-P  
Ikeda, Takahide 2002-P  
Ikejima, Shin 415-P, 673-P  
Ilag, Liza 351-OR, 967-P, 1011-P  
Ilkayeva, Olga 1429-P, 1874-P  
Ilkowitz, Jeniece 737-P, 841-P  
Ilyas, Junaid 1558-P  
Imachi, Hitomi 2164-P  
Imagawa, Akihisa 190-P  
Imagawa, Michiko 154-OR, 1903-P, 1906-P  
Imai, Daiki 736-P  
Imamura, Michihiro 1910-P  
Imamura, Takeshi 1966-P  
Imes, Sharleen 139-OR  
Immanuel, Julius N. 2226-PUB  
Imperatore, Giuseppina 268-OR, 310-OR, 525-P, 1276-P, 1680-P  
Improta, Ilaria 1830-P  
Inaba, Wataru 2132-P  
Inagaki, Akemi 1894-P, 2123-P, 2124-P  
Inagaki, Nobuya 1894-P, 2123-P, 2124-P  
Inamdar, Aniket 2366-PUB  
Inamdar, Manohar 2366-PUB  
Inashima, Kunikazu 1999-P  
Inazu, Koji 913-P, 2204-PUB  
Incalza, Maria Angela 2190-PUB  
Indyk, Justin A. 1307-P  
Inge, Thomas H. 341-OR  
Ingelesson, Erik 1725-P  
Ingham, Mike 1287-P  
Inoue, Hideka 1199-P  
Inoue, Kanako 742-P  
Inoue, Keisuke 1133-P  
Inoue, Mariko 2012-P  
Inoue, Megumi 1075-P  
Inoue, Ryota 2154-P  
Inoue, Ryuji 255-OR  
Inukai, Toshihiko 2240-PUB  
Inverardi, Luca 2118-P  
Inuzuchi, Silvio 524-P, 1123-P, 1487-P, 1822-P  
Ioacara, Sorin 901-P  
Iqbal, Nayyar 522-P, 1171-P  
Irani, Tanya 801-P  
Ireland, Nicole M. 185-OR  
Irigoien, Maria Claudia C. 2365-PUB  
Irinia-Dominguez, Jose M. 1879-P, 2115-P  
Irwin, Susan P. 2087-P, 2097-P  
Iseka, Mami 673-P  
Ishchenko, Irina 511-P  
Ishibashi, Fukashi 555-P  
Ishibashi, Ryoichi 257-OR  
Ishibashi, Tatsuya 2108-P  
Ishigaki, Yasushi 463-P  
Ishiguro, Hajime 547-P, 594-P, 823-P  
Ishihara, Noriko 615-P  
Ishi, Dai 781-P, 2368-PUB  
Ishi, Hitoshi 796-P  
Ishi, Norio 1635-P  
Ishikado, Atsushi 245-OR, 1585-P, 1897-P  
Ishikawa, Ko 257-OR  
Ishikawa, Takahiro 257-OR  
Ishikawa, Tomohisa 328-OR  
Ishizaka, Yuko 2369-PUB  
Ishizawa, Masahiro 594-P, 637-P, 823-P, 1488-P, 2368-PUB, 2384-PUB  
Ishizawa, Sho 476-P, 498-P  
Ishizu, Masashi 529-P  
Ishizuka, Tatsuo 1196-P, 2002-P  
Ish-Shalom, Maya 908-P  
Isidor, Marie S. 38-OR  
Ismail, Heba M. 94-OR, 232-OR, 1374-P, 1500-P, 1688-P, 1692-P, 1693-P  
Ismail, Reem 1269-P  
Ismail-Beigi, Faramarz 1661-P, 1811-P, 1822-P  
Itakura, Atsuo 1400-P  
Itaya-Hironaka, Asako 472-P, 595-P  
Ito, Arata 2208-PUB  
Ito, Kohei 1079-P, 1138-P  
Ito, Mizuho 554-P  
Ito, Satoshi 2204-PUB  
Ito, Shun 1087-P  
Ito, Yuichi, Sr. 1946-P  
Ito, Yuzuru 1466-P  
Itoh, Hiroshi 191-OR  
Itoh, Jun 2372-PUB  
Itoko, Toshinari 539-P  
Ivanova, Jasmina I. 221-OR, 801-P, 838-P  
Iwai, Yusuke 1980-P  
Iwakura, Hiroshi 2108-P  
Iwamoto, Masahiko 486-P  
Iwamoto, Sadahiko 1994-P  
Iwamoto, Yasuhiko 604-P, 1775-P  
Iwasaki, Hirota 1966-P  
Iwasaki, Tomoyuki 2204-PUB  
Iwasaki, Yorihito 1178-P  
Iwata, Shimpei 1164-P  
Iwaya, Chikayo 1227-P  
Iyer, Anand K. 1317-P  
Iyer, Malini S. 2010-P  
Iyer, Priyanka 1195-P  
Izadi, Zara 940-P  
Izumi, Kazuo 674-P, 808-P  
Izumida, Yoshihiko 359-OR
J., Christeena 591-P
Jaacks, Lindsay M. 1511-P
Jabbour, Serge 213-OR, 260-OR, 905-P
Jaber, Linda 654-P
Jablonski, Kathleen A. 1704-P, 1711-P
Jackson, Clark V. 725-P, 726-P
Jackson, Jeffrey A. 1021-P, 1038-P
Jacob, Rebekah R. 694-P
Jacob, Rittin 798-P, 2376-PUB
Jacob, Stephan 438-P, 1149-P
Jackson, Peter G. 751-P, 756-P, 991-P
Jabreel, Linda 654-P
Jablonski, Kathleen A. 1704-P, 1711-P
Jagenhoy, Laura M. 1692-P
Jacobson, David 2172-P, 2174-P
Jacobson, Kenneth A. 1769-P
Jaye, Ayad A. 528-P
Jaffa, Miran A. 528-P
Jafri, Rabab Z. 14-OR, 299-OR
Jaganmohan, Balaji 949-P
Jagtap, Mohan 2366-PUB
Jagtap, Mohan, Mahsa 394-P
Jahn, Linda 367-OR
Jahn-Hofmann, Kerstin 2030-P
Jahromi, Mohamed M.J. 523-P
Jain, Akshay B. 15-OR
Jain, Meena 78-OR
Jain, Sachin H. 4-OR
Jain, Shalini 1760-P
Jain, Shanu 1769-P
Jaiswal, Mamta 441-P, 578-P
Jakobson, Mette Hay 145-OR
Jakuboniene, Neli 522-P
James, Deirdre J. 1924-P
Janes, Sophie E. 1776-P, 2339-PUB
Janes, Terrance J., Jr. 2157-P
Jenisch, Celeste 214-OR
Jenkins, Alicia 231-OR, 542-P, 986-P, 1405-P, 1409-P, 2160-P
Jenkins, Jan 2120-P
Jensen, Boye L. 144-OR
Jensen, Elizabeth T. 1366-P
Jensen, Jan 2120-P
Jensen, Laura L. 717-P
Jensen, Michael D. 1812-P, 1918-P, 1926-P
Jensen, Paul N. 1663-P
Jensen, Rikke B. 1444-P
Jensen, Tonny, Sr. 105-OR
Jensterle, Mojca 1465-P
Jepson, Sara L. 1571-P, 1912-P
Jepson, Sangeun 1999-P
Jermendy, Gyorgy 2321-PUB
Jermann, Lutz 79-OR, 1067-P, 1070-P, 1841-P
Jespersen, Thomas 466-P
Jessen, Lene 1939-P
Jeyaseelan, Jay R. 35-OR
Jezioro, Maria 580-P
Jha, Jay C. 505-P
Jha, Sujeet 2377-PUB, 2417-PUB
Jhingan, Ashok Kumar 2257-PUB
Ji, Qiuhe 1144-P
Jia, Guanghong 2008-P, 2009-P
Jia, Hong-Mei 1654-P
Jia, Ting 530-P, 1092-P
Jia, Weiping 166-OR, 718-P, 1850-P, 1977-P
Jia, Yijie 530-P, 504-P, 509-P, 510-P, 2198-PUB

Jastreboff, Ania M. 365-OR
Javadi, Pasha 250-OR
Javeed, Naureen 193-OR
Jawanda, Shawn 1245-P
Jawerbaum, Alicia 1398-P
Jayanthi, Soumya 665-P
Jayaprakasam, Jana 949-P
Jaycox, Sharon H. 1651-P
Jayyousi, Amin 1062-P
Jeandidier, Nathalie M., Sr. 208-OR
Jeffcoate, William 638-P
Jeffery, Robert W. 817-P
Jeganathan, Ramesh B. 2083-P
Jelenik, Tomas 69-OR, 156-OR, 284-OR, 2054-P
Jelteboff, Nicole E. 249-OR
Jelsing, Jacob 1981-P
Jena, Apurba R. 1208-P
Jena, Biswaranjan 1208-P
Jenisch, Celeste 214-OR
Jenkins, Alicia 231-OR, 542-P, 986-P, 1405-P, 1409-P, 2160-P
Jenkins, Todd M. 341-OR
Jensen, Bjarne B. 839-P
Jensen, Boye L. 144-OR
Jensen, Dorte M. 1431-P, 1444-P, 1452-P
Jensen, Elizabeth T. 1366-P
Jensen, Jan 2120-P
Jensen, Jorgen 752-P
Jensen, Laura L. 717-P
Jensen, Michael D. 1812-P, 1918-P, 1926-P
Jensen, Paul N. 1663-P
Jensen, Rikke B. 1444-P
Jensen, Tonny, Sr. 105-OR
Jensterle, Mojca 1465-P
Jen, Jonju 177-OR
Jen, Ja Young 1571-P, 1912-P
Jegou, Sangeun 1999-P
Jepsen, Sara L. 1968-P
Jeffcoate, William 638-P
Jelteboff, Nicole E. 249-OR
Jelsing, Jacob 1981-P
Jena, Apurba R. 1208-P
Jena, Biswaranjan 1208-P
Jenisch, Celeste 214-OR
Jenkins, Alicia 231-OR, 542-P, 986-P, 1405-P, 1409-P, 2160-P
Jenkins, Todd M. 341-OR
Jensen, Bjarne B. 839-P
Jensen, Boye L. 144-OR
Jensen, Dorte M. 1431-P, 1444-P, 1452-P
Jensen, Elizabeth T. 1366-P
Jensen, Jan 2120-P
Jensen, Jorgen 752-P
Jensen, Laura L. 717-P
Jensen, Michael D. 1812-P, 1918-P, 1926-P
Jensen, Paul N. 1663-P
Jensen, Rikke B. 1444-P
Jensen, Tonny, Sr. 105-OR
Jensterle, Mojca 1465-P
Jen, Jonju 177-OR
Jen, Ja Young 1571-P, 1912-P
Jegou, Sangeun 1999-P
Jepsen, Sara L. 1968-P
Jermendy, Gyorgy 2321-PUB
Jermannus, Lutz 79-OR, 1067-P, 1070-P, 1841-P
Jespersen, Thomas 466-P
Jessen, Lene 1939-P
Jeyaseelan, Jay R. 35-OR
Jezioro, Maria 580-P
Jha, Jay C. 505-P
Jha, Sujeet 2377-PUB, 2417-PUB
Jhingan, Ashok Kumar 2257-PUB
Ji, Qiuhe 1144-P
Ji, Xu 701-P
Ji, Yingjie 20-OR
Jia, Guanghong 2008-P, 2009-P
Jia, Hong-Mei 1654-P
Jia, Ting 530-P, 1092-P
Jia, Weiping 166-OR, 718-P, 1850-P, 1977-P
Jia, Yijie 530-P, 504-P, 509-P, 510-P, 2198-PUB
**AMERICAN DIABETES ASSOCIATION**

<table>
<thead>
<tr>
<th>Name</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jiamiao, Yang</td>
<td>2453-PUB</td>
</tr>
<tr>
<td>Jian, Wenying</td>
<td>1113-P</td>
</tr>
<tr>
<td>Jiang, Bin</td>
<td>1794-P</td>
</tr>
<tr>
<td>Jiang, Boyi</td>
<td>920-P</td>
</tr>
<tr>
<td>Jiang, Can</td>
<td>1344-P</td>
</tr>
<tr>
<td>Jiang, Hemin</td>
<td>2106-P</td>
</tr>
<tr>
<td>Jiang, Lihong</td>
<td>204-OR, 2427-PUB</td>
</tr>
<tr>
<td>Jiang, Matthew</td>
<td>51-OR</td>
</tr>
<tr>
<td>Jiang, Meiiz</td>
<td>1683-P</td>
</tr>
<tr>
<td>Jiang, Ruihua</td>
<td>2443-PUB</td>
</tr>
<tr>
<td>Jiang, Shaoning</td>
<td>1401-P</td>
</tr>
<tr>
<td>Jiang, Ya</td>
<td>635-P</td>
</tr>
<tr>
<td>Jiang, Yan</td>
<td>84-OR, 2141-P</td>
</tr>
<tr>
<td>Jiang, Ziyu</td>
<td>1731-P</td>
</tr>
<tr>
<td>Jiayi, Liu</td>
<td>2453-PUB</td>
</tr>
<tr>
<td>Jimenez, Javier</td>
<td>2289-PUB</td>
</tr>
<tr>
<td>Jin, Bo-Heung</td>
<td>1800-P</td>
</tr>
<tr>
<td>Jin, Hui</td>
<td>929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB</td>
</tr>
<tr>
<td>Jin, Leigang</td>
<td>2027-P</td>
</tr>
<tr>
<td>Jin, Sang-Man</td>
<td>572-P, 1541-P, 1744-P, 1745-P</td>
</tr>
<tr>
<td>Jin, Xian</td>
<td>1162-P</td>
</tr>
<tr>
<td>Jing, Gu</td>
<td>80-OR, 87-OR</td>
</tr>
<tr>
<td>Jing, Shuqian</td>
<td>2298-PUB</td>
</tr>
<tr>
<td>Jing, Yi</td>
<td>2418-PUB</td>
</tr>
<tr>
<td>Jo, In Geun</td>
<td>1158-P, 2053-P</td>
</tr>
<tr>
<td>Jo, Seokwon</td>
<td>195-OR, 2161-P, 2167-P</td>
</tr>
<tr>
<td>Jo, SeongHo</td>
<td>87-OR, 2109-P, 2149-P</td>
</tr>
<tr>
<td>Joachim, Kariym</td>
<td>1550-P</td>
</tr>
<tr>
<td>Joehym, Nicole</td>
<td>2452-PUB</td>
</tr>
<tr>
<td>Jodar, Esteban</td>
<td>997-P</td>
</tr>
<tr>
<td>Joenssen, Lene</td>
<td>819-P</td>
</tr>
<tr>
<td>Joglekar, Mugdha</td>
<td>231-OR, 2160-P</td>
</tr>
<tr>
<td>Joham, Anju E.</td>
<td>1612-P</td>
</tr>
<tr>
<td>Johansen, Odd Erik</td>
<td>433-P, 449-P, 1123-P</td>
</tr>
<tr>
<td>Johansen, Pierre</td>
<td>1273-P</td>
</tr>
<tr>
<td>Johansen, Theo T.</td>
<td>502-P, 516-P</td>
</tr>
<tr>
<td>Johansson, Emil</td>
<td>1790-P</td>
</tr>
<tr>
<td>Johansson, Jan O.</td>
<td>1136-P</td>
</tr>
<tr>
<td>Johansson, Lars</td>
<td>78-OR, 1175-P</td>
</tr>
<tr>
<td>Johnson, Aimee</td>
<td>1348-P</td>
</tr>
<tr>
<td>Johnson, Cathryn</td>
<td>844-P</td>
</tr>
<tr>
<td>Johnson, James W.</td>
<td>369-OR, 1146-P, 2049-P</td>
</tr>
<tr>
<td>Johnson, Jennal</td>
<td>351-OR, 967-P, 1011-P, 1038-P</td>
</tr>
<tr>
<td>Johnson, Karen C.</td>
<td>817-P</td>
</tr>
<tr>
<td>Johnson, Krys M.</td>
<td>693-P</td>
</tr>
<tr>
<td>Johnson, Lisa</td>
<td>1552-P</td>
</tr>
<tr>
<td>Johnson, Mackenzie B.</td>
<td>1753-P</td>
</tr>
<tr>
<td>Johnson, Mary L.</td>
<td>353-OR, 710-P, 987-P, 995-P</td>
</tr>
<tr>
<td>Johnson, Matthew</td>
<td>1705-P, 1714-P</td>
</tr>
<tr>
<td>Johnson, Michael L.</td>
<td>1256-P</td>
</tr>
<tr>
<td>Johnson, Nathan A.</td>
<td>743-P</td>
</tr>
<tr>
<td>Johnson, Patricia A.</td>
<td>691-P</td>
</tr>
<tr>
<td>Johnson, Randi K.</td>
<td>136-OR</td>
</tr>
<tr>
<td>Johnson, Richard</td>
<td>431-P</td>
</tr>
<tr>
<td>Johnson, Susan L.</td>
<td>1145-P, 1168-P, 1169-P, 1889-P</td>
</tr>
<tr>
<td>Johnson, Terri</td>
<td>395-P, 899-P, 950-P, 1220-P</td>
</tr>
<tr>
<td>Johnson, Tonya N.</td>
<td>1813-P</td>
</tr>
<tr>
<td>Johnston, Aspen</td>
<td>1494-P</td>
</tr>
<tr>
<td>Johnston, Desmond G.</td>
<td>1696-P</td>
</tr>
<tr>
<td>Johnston, Joseph A.</td>
<td>2331-PUB</td>
</tr>
<tr>
<td>Jojima, Teruo</td>
<td>1849-P</td>
</tr>
<tr>
<td>Jokelainen, Jari J.</td>
<td>1519-P</td>
</tr>
<tr>
<td>Jokiel, Andrea E., Sr.</td>
<td>943-P</td>
</tr>
<tr>
<td>Joko, Kouji</td>
<td>1581-P</td>
</tr>
<tr>
<td>Jolly, Mary C.</td>
<td>1309-P</td>
</tr>
<tr>
<td>Joner, Geir</td>
<td>136-OR</td>
</tr>
<tr>
<td>Jones, Ben</td>
<td>1100-P</td>
</tr>
<tr>
<td>Jones, Claire J.</td>
<td>2166-P</td>
</tr>
<tr>
<td>Jones, Hannah</td>
<td>986-P</td>
</tr>
<tr>
<td>Jones, Juli E.</td>
<td>1886-P</td>
</tr>
<tr>
<td>Jones, Melinda</td>
<td>215-OR, 861-P</td>
</tr>
<tr>
<td>Jones, Samuel E.</td>
<td>20-OR, 23-OR</td>
</tr>
<tr>
<td>Jones, Stephen</td>
<td>1570-P</td>
</tr>
<tr>
<td>Jones, Tim</td>
<td>231-OR, 730-P, 747-P, 2065-P</td>
</tr>
<tr>
<td>Jongsoo, Mok</td>
<td>1913-P</td>
</tr>
<tr>
<td>Jordan, Michelle C.</td>
<td>2315-PUB</td>
</tr>
<tr>
<td>Jorgensen, Jutta M.</td>
<td>1511-P</td>
</tr>
<tr>
<td>Jørgensen, Marit E.</td>
<td>439-P</td>
</tr>
<tr>
<td>Jorgensen, Rasmus</td>
<td>372-OR, 373-OR, 375-OR</td>
</tr>
<tr>
<td>Joe, Vinu</td>
<td>346-OR, 979-P</td>
</tr>
<tr>
<td>Joseph, Jeffrey I.</td>
<td>980-P</td>
</tr>
<tr>
<td>Joseph, Kibachio</td>
<td>1511-P</td>
</tr>
<tr>
<td>Joseph, Mary</td>
<td>591-P</td>
</tr>
<tr>
<td>Joshee, Prakriti</td>
<td>460-P</td>
</tr>
<tr>
<td>Joshi, Ansumali</td>
<td>2259-PUB</td>
</tr>
<tr>
<td>Joshi, Mamta</td>
<td>1733-P</td>
</tr>
<tr>
<td>Joshi, Parag H.</td>
<td>2064-P</td>
</tr>
<tr>
<td>Joshi, Renu</td>
<td>1322-P</td>
</tr>
<tr>
<td>Joshi, Shashank</td>
<td>949-P, 2292-PUB</td>
</tr>
<tr>
<td>Joshi, Shilpa</td>
<td>248-OR, 750-P, 866-P</td>
</tr>
<tr>
<td>Joshi, Vinayak</td>
<td>586-P</td>
</tr>
<tr>
<td>Joshipura, Kaumudi J.</td>
<td>119-OR</td>
</tr>
<tr>
<td>Joshua, Thomas V.</td>
<td>132-OR</td>
</tr>
<tr>
<td>Jothaydev, Sunitha</td>
<td>389-P, 685-P</td>
</tr>
<tr>
<td>Jouihan, Hani</td>
<td>1788-P</td>
</tr>
<tr>
<td>Joyce, Catherine E.</td>
<td>1078-P</td>
</tr>
<tr>
<td>Ju, Wenjun</td>
<td>88-OR</td>
</tr>
<tr>
<td>Juang, Juyn-Huarrng</td>
<td>26-OR</td>
</tr>
<tr>
<td>Judd, Robert L.</td>
<td>1877-P</td>
</tr>
<tr>
<td>Jude, Edward B.</td>
<td>556-P</td>
</tr>
<tr>
<td>Juhaeri, Juhaeri</td>
<td>1619-P</td>
</tr>
<tr>
<td>Juhl, Ruta Gronskyte</td>
<td>127-OR</td>
</tr>
<tr>
<td>Jun, Ji Eun</td>
<td>572-P</td>
</tr>
<tr>
<td>Jun, Joo Yun</td>
<td>1979-P, 2017-P</td>
</tr>
<tr>
<td>Jun, Min</td>
<td>1483-P</td>
</tr>
<tr>
<td>Jun, Younghhee</td>
<td>802-P</td>
</tr>
<tr>
<td>Jung, Chang Hee</td>
<td>407-P, 1064-P</td>
</tr>
<tr>
<td>Jung, Chan-Hee</td>
<td>820-P</td>
</tr>
<tr>
<td>Jung, Hye-In</td>
<td>1535-P, 1911-P</td>
</tr>
</tbody>
</table>

**OR:** Oral  **P:** Poster  **PUB:** Published Only
Kanter, Justin 253-OR, 656-P
Kanzler, Kathryn E. 816-P
Kao, Chen-Wei 26-OR
Kao, Christi Y. 1021-P
Kapitza, Christoph 1006-P, 1009-P
Kapuria, Devika 1146-P
Kapuria, Devika 1146-P
Kapusta, Maria 2217-PUB
Kar, Partha 662-P
Karadi, Veeranna 887-P, 2293-PUB
Karajgikar, Neha 1279-P
Karajgikar, Neha 1279-P
Karakas, Sidika 1354-P
Karam, Susan L. 1125-P
Kapitza, Christoph 1006-P, 1009-P
Kapuria, Devika 1146-P
Kapusten, Maria 2217-PUB
Karsli, Asli 679-P
Karsli, Asli 679-P
Karter, Andrew J. 1311-P, 2322-PUB
Kartman, Bernt 1319-P
Karunakaran, Abhijana 1078-P
Karuranga, Suvi 1676-P
Karusheva, Yanislava 69-OR, 748-P, 773-P, 1509-P, 2054-P
Kasai, Takatoshi 418-P
Kasetty, Harsha 1019-P
Kashihara, Naoki 89-OR
Kashima, Koji 1074-P, 2297-PUB
Katahira, Takehiro 1400-P, 2125-P, 2128-P
Katsanos, Ioannis 646-P
Katsogiannos, Petros 1756-P, 1790-P
Katsukawa, Fuminori 775-P
Katsuki, Takayuki 539-P
Katsuki, Takeshi 1735-P
Katsuragawa, Sho 1486-P
Katz, Liora S. 192-OR, 2116-P, 2137-P
Katz, Lorraine E.L. 268-OR
Katz, Michelle 11-OR, 1342-P, 1367-P, 1385-P, 1395-P
Katzman, Per 958-P, 2225-PUB
Katzmarzyk, Peter T. 1576-P
Kaufman, Keith D. 1142-P
Kaufmann, Peter G. 246-OR
Kaul, Padma 1461-P
Kaur, Akaal 1696-P
Kaur, Harinderjeet 667-P
Kawabe, Akitsu 100-OR
Kawabe, Yoshikichi 1118-P
Kawai, Eriko 736-P
Kawai, Sayuki 535-P
Kawai, Takahiro 1118-P
Kawai, Yoshi 1735-P
Kawalec, Ewa 2217-PUB
Kawamori, Dan 2144-P
Kawamori, Ryuzo 1512-P, 1854-P, 1905-P, 1914-P
Kawamura, Mitsunobu 625-P
Kawamura, Ryoichi 1528-P, 1720-P
Kawanabe, Haruka 1980-P
Kawanami, Daisuji 476-P, 498-P
Kawano, Mai 2205-PUB
Kawasaki, Masatoshi 850-P
Kawashima, Junji 1635-P
Kawarabe, Hameen 667-P
Kawara, Yoshi 1177-P
Kayano, Ayako 850-P
Kaya, Yasu 1053-P
Kaymaz, Figen 1053-P
Kazda, Christof M. 1006-P, 1009-P, 1010-P
Kazdova, Ludmila 1211-P, 1722-P, 1723-P
Ke, Calvin 1649-P
Ke, Wei-jian 1043-P
Kebede, Mihretu M. 840-P
Keel, Stefanie 2028-P
Keller, Amy C. 1494-P
Keller, Matthew 1459-P
Kelley, E.L.  
Kelly, Andrea  1820-P  
Kelly, Clare B.  1405-P, 1409-P  
Kelly, Lisa E.  2151-P  
Kelly, Owen  763-P  
Kelm, Malte  284-OR  
Kelsey, Megan M.  1348-P, 1703-P  
Kemp, Graham J.  1163-P  
Kemper, Margrit  296-OR  
Kempler, Peter  2321-PUB  
Kempler, Peter  2321-PUB  
Kemp, Graham J.  1163-P  
Kener, Kyle B.  2040-P  
Kennedy, Chris  505-P  
Kennedy, Kevin  1615-P, 1629-P  
Kepaptsoglou, Olga  1436-P  
Kepple, Jessica  2020-P  
Kerege, Anna  158-OR, 1933-P, 1935-P  
Keren, Ron  1498-P  
Kerin Povsic, Milena  1638-P  
Kern, Timothy  590-P  
Kerr, David  760-P, 1281-P, 1524-P  
Kerr-Conte, Julie A.  2143-P  
Kershaw, Erin E.  1681-P, 2100-P  
Keshawarz, Amena  447-P, 1496-P  
Kesselheim, Aaron  4-OR  
Kessler, Laurence  933-P  
Kettunen, Johannes  1519-P  
Kevorkian, Jean-Philippe  112-OR  
Key, Calanit  665-P, 666-P  
Key, Chia-Chi C.  19-OR  
Keyhani Nejad, Farnaz  358-OR  
Khav, Eddie L.  373-OR  
Khedkar, Anand P.  346-OR, 979-P  
Khedr, Marwa  1514-P  
Khoo, Kaylyn  420-P  
Khoryati, Liliane  314-OR  
Khouja, Tumader  1489-P  
Khoury, Jane C.  1359-P  
Kho, Kaylyn  420-P  
Khantia, Monalisa  1208-P  
Khurana, Girish, Sr.  462-P, 2313-PUB  
Khurana, Hardik  2313-PUB  
Khurana, Manoj  1051-P  
Kidambi, Sridivya  1289-P  
Kidokoro, Ken  89-OR  
Kidron, Miriam  982-P  
Kieblish, Michael  273-OR  
Kiec-Wilk, Beata  1677-P  
Kiefler, Edith C.  703-P  
Kielgast, Urs, Sr.  2046-P  
Kievit, Paul  2136-P  
Kikuchi, Osamu  1955-P  
Kikuchi, Takako  604-P, 1775-P, 2385-PUB  
Kikuno, Shota  418-P  
Kilmartin, Gloria M.  1697-P  
Kilpelainen, Tuomas O.  21-OR  
Kilroy, Gail E.  1757-P, 2014-P  
Kim, Ahlee  345-OR  
Kim, Allison M.  1999-P  
Kim, Bohyun  802-P  
Kim, Bo-Yeon  820-P  
Kim, Catherine  306-OR, 1261-P, 1574-P  
Kim, Chang-Hoon  1800-P  
Kim, Chongtae  2003-P  
Kim, Chul-Hee  820-P  
Kim, Chun Hwa  1200-P, 1202-P  
Kim, Dae Jung  1912-P  
Kim, Daeheon  1200-P, 1202-P  
Kim, DaeYo  1739-P  
Kim, Dong-Hoon  1800-P  
Kim, Do-Yeon  1200-P, 1202-P  
Kim, Do-Sung  1741-P, 2113-P  
Kim, Eunha  2026-P  
Kim, Grace  313-OR, 441-P, 2341-PUB  
Kim, Gyuri  572-P, 1535-P, 1541-P, 1744-P, 1745-P  
Kim, Hae Jin  1571-P, 1912-P  
Kim, Hyun-Jin  1167-P  
Kim, Hyoung  1170-P  
Kim, Jae Bum  1951-P  
Kim, Jae Hyeon  196-OR, 572-P, 1541-P, 1744-P, 1745-P  
Kim, Jason A.  85-OR, 1214-P, 1215-P, 1785-P, 1792-P, 1999-P  
Kim, Jeong A.  1107-P  
Kim, Jiwan  28-OR, 1743-P, 2165-P  
Kim, Jong-Il  266-OR  
Kim, Joon Young  1338-OR, 343-OR, 1335-P  
Kim, Jung A.  464-P  
Kim, Jung Hye  612-P, 2414-PUB  
Kim, Jung Kuk  77-OR, 1098-P, 1106-P  
Kim, Jungeun  2026-P  
Kim, Katherine L.  2052-P  
Kim, Kibum  909-P  
Kim, Ki-Suk  1962-P  
Kim, Kook Hwan  1860-P  
Kim, Kyung Min  428-P  
Kim, Kyung  1158-P, 2053-P  
Kim, Kyung-Soo  1419-P  
Kim, Min Kyung  612-P, 2414-PUB
<table>
<thead>
<tr>
<th>Name</th>
<th>OR/PUB</th>
<th>OR/PUB</th>
<th>OR/PUB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim, Nam Hoon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Paul</td>
<td>111-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Rebecca</td>
<td>177-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sang Jin</td>
<td>1739-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Seong Hun</td>
<td>1680-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Seoyoung C.</td>
<td>1492-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sin Gom</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, So Hun</td>
<td>527-P, 533-P</td>
<td>184-P, 1535-P</td>
<td></td>
</tr>
<tr>
<td>Kim, So-Kyung</td>
<td>1419-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sooyoung C.</td>
<td>1999-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun H.</td>
<td>765-P, 2099-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun Jin</td>
<td>77-OR, 1105-P, 1106-P, 1107-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sung Rae</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sung-Young</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun Jin</td>
<td>77-OR, 1105-P, 1106-P, 1107-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun H.</td>
<td>765-P, 2099-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun H.</td>
<td>765-P, 2099-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Sun H.</td>
<td>765-P, 2099-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim, Suo-Moon</td>
<td>1800-P</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Kim, Suo-Moon         | 1800-
Kobayashi, Toshihiro 2164-P
Kobes, Sayuko 1713-P
Kochumon, Shihab P. 1730-P
Koceda, Tatsuhiko 1133-P, 1153-P, 823-PUB
Kočiara, Ozge 1053-P
Kodama, Satoru 442-P, 444-P, 823-PUB
Kodama, Tatsuhiko 2102-P
Koga, Daisuke 2102-P
Koh, Angela Fang Yung 2408-PUB
Koh, Gerald 809-P
Koh, Ho-Jin 1753-P
Kohler, Sven 1150-P
Kollman, Craig 744-P, 1340-P, 1342-P
Kolozs, James E. 2159-P
Koutin, Dror 1550-P, 1578-P, 1579-P
Kosiborod, Mikhail 1141-P, 1487-P, 1562-P, 1582-P, 1615-P, 1629-P
Kosinová, Lucie 1410-P
Kotera, Yuri 2005-P
Kothari, Mikhil C. 952-P, 1685-P, 2328-PUB
Kotkowski, Eithan 622-P
Koutrouvelis, Gayle O. 1410-P
Koutsovasilis, Anastasios 1104-P, 1235-P
Koval, Lilian 2097-P
Kowal, Stacey L. 1159-P, 1161-P
Kowalyk, Stephan 988-P, 989-P, 990-P
Kowluru, Renu 239-OR
Koya, Daisuke 495-P, 500-P
Kozekska, Magdalena 1896-P
Kozuka, Chisayo 1836-P
Kraemer, Fredric B. 154-P
Krafco, Guillaume 186-P
Kraemer, Fredric B. 154-OR, 1903-P, 1906-P
Kraemer, Guillaume 1961-P
Kral, Jodi 253-OR, 656-P, 657-P, 698-P, 713-P
Kramer, Alyssa M. 1307-P
Krantz, James L. 186-P
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kraus, Kimberly</td>
<td>215-OR</td>
<td></td>
</tr>
<tr>
<td>Krause-Steinaufer, Heidi</td>
<td>1182-P</td>
<td></td>
</tr>
<tr>
<td>Kravchenko, Maria</td>
<td>1268-P</td>
<td></td>
</tr>
<tr>
<td>Krejci, Hana</td>
<td>1412-P, 1413-P</td>
<td></td>
</tr>
<tr>
<td>Kremer, Arve</td>
<td>468-P, 489-P, 611-P, 1597-P</td>
<td></td>
</tr>
<tr>
<td>Kretzler, Matthias</td>
<td>88-OR, 491-P</td>
<td></td>
</tr>
<tr>
<td>Kriens, Scott</td>
<td>1400-P</td>
<td></td>
</tr>
<tr>
<td>Kirsch, Jeffrey</td>
<td>1693-P</td>
<td></td>
</tr>
<tr>
<td>Krishnal, Gopika</td>
<td>1268-P</td>
<td></td>
</tr>
<tr>
<td>Krejci, Hana</td>
<td>1412-P, 1413-P</td>
<td></td>
</tr>
<tr>
<td>Kremer, Arye</td>
<td>468-P, 489-P, 611-P, 1597-P</td>
<td></td>
</tr>
<tr>
<td>Kristensen, Peter L., Sr.</td>
<td>105-OR</td>
<td></td>
</tr>
<tr>
<td>Kristiansen, Viggo B.</td>
<td>1885-P</td>
<td></td>
</tr>
<tr>
<td>Kristinsson, Hjalte</td>
<td>1352-P</td>
<td></td>
</tr>
<tr>
<td>Krietzler, Matthias</td>
<td>88-OR, 491-P</td>
<td></td>
</tr>
<tr>
<td>Krich, Scott</td>
<td>1440-P</td>
<td></td>
</tr>
<tr>
<td>Krischer, Jeffrey</td>
<td>1693-P</td>
<td></td>
</tr>
<tr>
<td>Krishnan, Gopika</td>
<td>389-P, 685-P</td>
<td></td>
</tr>
<tr>
<td>Kreiski, Andrea</td>
<td>134-OR, 1471-P, 1472-P</td>
<td></td>
</tr>
<tr>
<td>Kretel, Matthias</td>
<td>88-OR, 491-P</td>
<td></td>
</tr>
<tr>
<td>Kroek, Anna</td>
<td>1784-P</td>
<td></td>
</tr>
<tr>
<td>Kroon, Evert J.</td>
<td>138-OR</td>
<td></td>
</tr>
<tr>
<td>Kroopotova, Yana</td>
<td>287-OR</td>
<td></td>
</tr>
<tr>
<td>Kroeschwald, Peter</td>
<td>2065-P</td>
<td></td>
</tr>
<tr>
<td>Kreck, Matthias</td>
<td>1412-P, 1413-P</td>
<td></td>
</tr>
<tr>
<td>Kruger, Davida F.</td>
<td>353-OR, 837-P, 987-P, 995-P, 1251-P</td>
<td></td>
</tr>
<tr>
<td>Kruger, Eliza</td>
<td>1159-P, 1160-P, 1161-P</td>
<td></td>
</tr>
<tr>
<td>Kruger, Sydney L.</td>
<td>1102-P</td>
<td></td>
</tr>
<tr>
<td>Kruse, Michael</td>
<td>296-OR</td>
<td></td>
</tr>
<tr>
<td>Kyroelis, Joczwa</td>
<td>763-P</td>
<td></td>
</tr>
<tr>
<td>Kroliwski, Andrzej</td>
<td>88-OR, 91-OR</td>
<td></td>
</tr>
<tr>
<td>Kronshage, Birgit</td>
<td>102-OR</td>
<td></td>
</tr>
<tr>
<td>Krook, Anna</td>
<td>1784-P</td>
<td></td>
</tr>
<tr>
<td>Kroon, Evert J.</td>
<td>138-OR</td>
<td></td>
</tr>
<tr>
<td>Kroopotova, Yana</td>
<td>287-OR</td>
<td></td>
</tr>
<tr>
<td>Kroeschwald, Peter</td>
<td>2065-P</td>
<td></td>
</tr>
<tr>
<td>Krukel, Matthias</td>
<td>1412-P, 1413-P</td>
<td></td>
</tr>
<tr>
<td>Kruizer, Bernhard</td>
<td>671-OR, 912-OR, 914-P</td>
<td></td>
</tr>
<tr>
<td>Kuma, Hiromitsu</td>
<td>782-P</td>
<td></td>
</tr>
<tr>
<td>Kumagai, Ryo</td>
<td>917-P</td>
<td></td>
</tr>
<tr>
<td>Kumagai, Teru</td>
<td>1666-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Aakshay</td>
<td>734-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Jagdesh</td>
<td>1116-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Kei</td>
<td>1892-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Nitya K.</td>
<td>1954-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Pranith H.</td>
<td>57-OR</td>
<td></td>
</tr>
<tr>
<td>Kumar, Pushkar</td>
<td>2352-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Seema</td>
<td>1362-P</td>
<td></td>
</tr>
<tr>
<td>Kumar, Shanil S.</td>
<td>1288-P</td>
<td></td>
</tr>
<tr>
<td>Kumaran, Kalyanaraman</td>
<td>1418-P</td>
<td></td>
</tr>
<tr>
<td>Kumpf, Kanchan</td>
<td>2351-PUB</td>
<td></td>
</tr>
<tr>
<td>Kumpf, Swamima</td>
<td>314-OR</td>
<td></td>
</tr>
<tr>
<td>Kuma, Naoki</td>
<td>1848-P</td>
<td></td>
</tr>
<tr>
<td>Kumbier, Magali</td>
<td>768-P</td>
<td></td>
</tr>
<tr>
<td>Kundo, Nabanaita</td>
<td>287-OR, 493-P</td>
<td></td>
</tr>
<tr>
<td>Kundo, Rakesh</td>
<td>2466-PUB</td>
<td></td>
</tr>
<tr>
<td>Kurz, Kristian W.</td>
<td>933-P</td>
<td></td>
</tr>
<tr>
<td>Kuo, Shihchen</td>
<td>693-P, 703-P</td>
<td></td>
</tr>
<tr>
<td>Kuo, Taiyi</td>
<td>324-OR</td>
<td></td>
</tr>
<tr>
<td>Kupriyanova, Yuliya</td>
<td>1509-P, 1567-P, 2054-P</td>
<td></td>
</tr>
<tr>
<td>Kurakashi, Kyoe</td>
<td>529-P, 2102-P, 2104-P</td>
<td></td>
</tr>
<tr>
<td>Kurajoh, Masafumi</td>
<td>2074-P</td>
<td></td>
</tr>
<tr>
<td>Kurgansky, Katherine E.</td>
<td>668-P</td>
<td></td>
</tr>
<tr>
<td>Kuriha, Mika</td>
<td>775-P</td>
<td></td>
</tr>
<tr>
<td>Kuriha, Wataro</td>
<td>1581-P, 1609-P</td>
<td></td>
</tr>
<tr>
<td>Kurian, Emily</td>
<td>2018-P</td>
<td></td>
</tr>
<tr>
<td>Kurljandekaja, Raisa</td>
<td>1171-P</td>
<td></td>
</tr>
<tr>
<td>Kurmanji, Mohammed T.</td>
<td>1155-P</td>
<td></td>
</tr>
<tr>
<td>Kuroda, Akio</td>
<td>529-P, 2102-P</td>
<td></td>
</tr>
<tr>
<td>Kuroda, Jun</td>
<td>539-P</td>
<td></td>
</tr>
<tr>
<td>Kurosawa, Yoko</td>
<td>2080-P</td>
<td></td>
</tr>
<tr>
<td>Kurose, Tatsuki</td>
<td>540-P, 2306-PUB</td>
<td></td>
</tr>
<tr>
<td>Kuzapl, Nisatoe</td>
<td>1575-P, 2385-PUB</td>
<td></td>
</tr>
<tr>
<td>Kusakabe, Hiroi</td>
<td>1152-P</td>
<td></td>
</tr>
<tr>
<td>Kusama, Minoru</td>
<td>2284-PUB</td>
<td></td>
</tr>
<tr>
<td>Kushima, Hideki</td>
<td>289-OR, 482-P, 487-P, 1988-P</td>
<td></td>
</tr>
<tr>
<td>Kushiya, Akihumi</td>
<td>604-P, 1775-P, 2385-PUB</td>
<td></td>
</tr>
<tr>
<td>Kuschnier, Jake A.</td>
<td>212-OR, 1122-P, 1179-P</td>
<td></td>
</tr>
<tr>
<td>Kuss, Oliver</td>
<td>1139-P</td>
<td></td>
</tr>
<tr>
<td>Kusunoki, Masatake</td>
<td>1157-P</td>
<td></td>
</tr>
<tr>
<td>Kutaik, Zoltan</td>
<td>23-OR</td>
<td></td>
</tr>
<tr>
<td>Kuwamura, Yuji</td>
<td>1505-P</td>
<td></td>
</tr>
<tr>
<td>Kuwata, Hitoshi</td>
<td>540-P, 2306-PUB</td>
<td></td>
</tr>
<tr>
<td>Kuzie, Roman</td>
<td>1896-P</td>
<td></td>
</tr>
<tr>
<td>Kuzuya, Hideshi</td>
<td>674-P, 1892-P</td>
<td></td>
</tr>
</tbody>
</table>
Kuzuya, Takeshi 1110-P
Kvapil, Milan 303-OR, 1028-P, 1050-P
Kwak, Soo Heon 266-OR, 267-OR, 2029-P
Kwek, William 95-OR
Kwon, Hee Sun 477-P, 1908-P
Kwon, Hyuk-Sang 1744-P, 1745-P
Kwong, Jennifer 634-P, 644-P
Kyanvash, Shadi 2094-P
Kyi, Mervyn 1288-P, 1306-P
Kyotani, Yoji 472-P
La Fontaine, Javier 110-OR, 645-P, 869-P, 870-P, 2218-PUB
La Salvia, Sabrina 1774-P
La, Van T. 1270-P
Labadarios, Demetre 1511-P
Lablanche, Sandrine 81-OR
Labrot, Ben B. 2371-PUB
Lacadie, Cheryl 365-OR, 1802-P
Lacativa, Paulo G. 76-OR
LaCouture, Michael 1004-P, 1022-P, 1217-P
Ladelund, Steen 391-P
Ladkat, Rasika 118-OR, 1418-P
Ladsaria, Sally S. 893-P
Ladwig, Ruben 1447-P
Laferrere, Blandine 1823-P
Laghe, Maureen J. 1557-P
Laguna Sanz, Alejandro J. 961-P
Lai, Alessio 599-P
Lai, Jinping 1223-P
Lai, Joanne K.Y. 93-OR
Lam, Amanda Y.R. 809-P
Lam, Anna 139-OR, 143-OR, 1740-P
Lam, David W. 992-P
Lamarche, Frederic 81-OR
Lambert, Kathyn L. 1309-P, 1318-P, 1321-P
Lambert, Kimberly D. 1274-P
Lamendella, Regina 1899-P
Lamers, Daniela 102-OR, 305-OR
Lamie, Steven M. 700-P
Lamoureux, Roger 725-P, 726-P
Lampousi, Anna-Maria 1606-P
Lan, Xu 557-P
Lancki, Nicola 1125-P
Landau, Zohar 908-P
Landgraf, Wolfgang 1046-P
Landmesser, Ulf 330-OR
Landy, Ellen 593-P
Lane, Jacqueline M. 176-OR
Lane, Wendy 212-OR, 300-OR, 391-P
Lang, Chin C. 167-OR, 256-OR, 1238-P
Lang, Jihan 331-OR
Lang, Michael H. 2071-P
Lang, Wensheng 35-OR
Langan, Susan J. 306-OR
Lange, Heidi 1625-P
Lange, Martin 1065-P
Langefeld, Carl D. 19-OR, 1760-P
Langer, Jakob 2319-PUB
Langkilde, Anna Maria 213-OR
Langlais, Paul R. 186-OR
Langleite, Torgrim M. 752-P
Lan, Xu 557-P
Lansang, M. Cecilia 2320-PUB, 2325-PUB
Lanza, Ian R. 1925-P
Lanzoni, Giacomo 2118-P
Lapointe, Jean-Martin 1789-P
Lapolla, Annunziata 1014-P
Lapuerta, Pablo 212-OR, 1122-P
Larey, Arianna J. 653-P
LaRosa, John 468-P, 489-P, 611-P, 1597-P
Larsen, Christina V. 439-P
Larsen, Julie F. 1081-P
Larsen, Philip J. 2028-P
Larson, Sharon 1260-P
Lascano, Jorge E. 2374-PUB
Lashkari, Nassim 2371-PUB
Lashley, Paula M. 116-OR
Latreille, Mathieu 52-OR
Latts, Lisa 135-OR, 1493-P
Lau, Eric S. 455-P, 1590-P, 1649-P
Lau, Ka Hei Karen 1328-P
Laureti, Marcello C. 1808-P, 1812-P, 1925-P, 1953-P
Laurenzi, Andrea 898-P
Lauria, Angelo 716-P
Laurin, Pierre 503-P, 1817-P, 1858-P, 2000-P
Lauring, Brett 1129-P, 1132-P, 1140-P, 1145-P, 1168-P, 1169-P
Lauro, Davide 1929-P, 2410-PUB

OR: Oral  P: Poster  PUB: Published Only
Lee, Wha Joung 1912-P
Lee, Woo Je 407-P, 1064-P
Lee, Yong-Ho 164-OR, 1535-P, 1670-P, 1860-P, 1911-P
Lee, Yoonhee 802-P
Lee, You-Bin 464-P
Lee, Yun Ah 267-OR
Lee, Yong-Ho 164-OR, 1535-P, 1670-P, 1860-P, 1911-P
Lee, Yoonhee 802-P
Lee, You-Bin 464-P
Lee, Yun Sok 1973-P
Lee, Yun Sok 1973-P
Leeder, Tania 587-P
Leelarathna, Lalantha 926-P, 973-P
Leey, Julio A. 1546-P, 2374-PUB
Lefebvre, Patrick 1183-P
Legault, Laurent 10-OR, 210-OR
Legget, Kristina T. 1889-P
Lehmann, Rainer 1856-P
Lehne, Benjamin 1495-P
Lehrke, Michael 436-P, 1962-P
Lehtimäki, Terho, Sr. 1495-P, 1519-P
Lei, Tao 624-P
Lei, Victor J. 2101-P
Lei, Yanping 2182-PUB
Leibel, Rudolph 1994-P
Leibowitz, Morton 1076-P
Leierer, Johannes 1126-P
Leiria, Luiz O. 273-OR
Leishman, Derek 1038-P
Leitao, Cristiane B. 1086-P, 1551-P
Leiter, Lawrence A. 1089-P, 1093-P, 1109-P
Leitner, Brooks 1146-P, 2052-P
Lemaitre, Rozenn N. 1663-P
Lemecha, Mengistu 1966-P
Leng, Junhong 1345-P, 1433-P
Lenhard, James 1938-P
Lent, Samantha 1707-P
Lentz, Stephen I. 573-P
Lenzini, Petra 1709-P
Leo, Michael C. 1407-P, 1408-P
Leohr, Jennifer 1006-P, 1009-P, 1010-P
Leonard, James 1113-P
Leonard, Michelle 1705-P, 1714-P
Leonardini, Anna 2190-PUB
Leone, Alessandro 292-OR, 793-P
Leonetti, Donna L. 2373-PUB
Leong, Aaron 1440-P, 1712-P, 1715-P
Leslie, Wilma S. 291-OR
Less, Joane E. 1343-P, 2322-PUB
Letizia, Teresa 1231-P
Letourneau, Lisa R. 264-OR, 1379-P, 1453-P, 2353-PUB
Létourneau, Sylvie 1817-P
Leventer-Roberts, Maya 665-P, 666-P, 1076-P
Leventhal, Jessica 365-OR
Levesque, Kiarra 1823-P
Levieux, Cecilia P. 1398-P
Levin, Laura E. 1591-P
Levin, Margarita 684-P
Levinaina, Nomy 665-P, 666-P
Levisen, Vinie H. 2261-PUB
Levister, Camilla M. 992-P
Levitsky, Lynne L. 268-OR, 1341-P
Levy, Brian L. 710-P, 987-P, 995-P
Levy, Carol J. 992-P, 2351-PUB
Lew, Jeremy 420-P
Lewandowsky, Sophie L. 2152-P
Lewis, Arthur R. 1789-P
Lewis, Brandon J. 645-P
Lewis, Dana M. 352-OR
Lewis, Evan J. 560-P, 580-P
Lewis, Michael R. 765-P
Li, Calzi, Sergio 1899-P
Li, Changhong 2131-P
Li, Chien 202-OR
Li, Da 783-P, 1607-P
Li, Dan 1275-P
Li, Dongxing 1310-P, 1312-P, 1313-P
Li, Ge 1339-P, 1365-P
Li, Grace 126-OR
Li, Guangwei 130-OR, 1654-P
Li, Haicheng 84-OR, 2423-PUB
Li, Hong 779-P, 2413-PUB
Li, Honggui 1872-P
Li, Huating 166-OR, 1755-P
Li, Hui 130-OR, 1654-P
Li, Hung-Yuan 1426-P, 1510-P
Li, Ji 153-OR
Li, Jian 1762-P
Li, Jayu 361-OR
Li, Jingjing 2349-PUB
Li, Jun 1539-P
Li, Lan 512-P
Li, Li 865-P
Li, Liang 2058-P, 2060-P, 2067-P, 2068-P, 2455-PUB, 2457-PUB
Li, Lindong 643-P
Li, Ling 1449-P, 1449-P
Li, Liwu 159-OR
Li, Lixin 1985-P
Li, Manna 1997-P
Li, Mengyao E. 274-OR, 1792-P, 1922-P
Li, Mengying 1434-P
Li, Ming 1339-P, 1365-P
Li, Na 1240-P, 1794-P
Li, Nan 779-P, 1345-P, 1433-P, 2413-PUB
Li, Pengfei 1069-P
Li, Ping 1344-P, 1448-P, 1449-P
Li, Qi 245-OR, 286-OR, 288-OR, 2033-P
Li, Qiwen 2391-PUB
Li, Quanmin 929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB
Li, Rong 512-P
<table>
<thead>
<tr>
<th>Name</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, Shengbin</td>
<td>1777-P</td>
</tr>
<tr>
<td>Li, Shengxian</td>
<td>278-OR</td>
</tr>
<tr>
<td>Li, Siming</td>
<td>275-OR</td>
</tr>
<tr>
<td>Li, Wei</td>
<td>1345-P, 1433-P</td>
</tr>
<tr>
<td>Li, Weiqin</td>
<td>1435-P, 1433-P</td>
</tr>
<tr>
<td>Li, Wenyu</td>
<td>35-OR, 1113-P</td>
</tr>
<tr>
<td>Li, Xiang</td>
<td>121-OR, 1555-P, 1580-P</td>
</tr>
<tr>
<td>Li, Xiaorui</td>
<td>1766-P</td>
</tr>
<tr>
<td>Li, Xuey</td>
<td>1926-P</td>
</tr>
<tr>
<td>Li, Xueying</td>
<td>1631-P, 1632-P</td>
</tr>
<tr>
<td>Li, Yan</td>
<td>1283-P, 2199-PUB</td>
</tr>
<tr>
<td>Li, Yanbing</td>
<td>388-P, 999-P, 1044-P, 1045-P</td>
</tr>
<tr>
<td>Li, Yang</td>
<td>509-P, 510-P</td>
</tr>
<tr>
<td>Li, Yanhong</td>
<td>1319-P</td>
</tr>
<tr>
<td>Li, Yi</td>
<td>141-OR</td>
</tr>
<tr>
<td>Li, Ying</td>
<td>31-OR</td>
</tr>
<tr>
<td>Li, Yingjie</td>
<td>1310-P, 1312-P, 1313-P</td>
</tr>
<tr>
<td>Li, Yong</td>
<td>1859-P</td>
</tr>
<tr>
<td>Li, Yong-Guo</td>
<td>1201-P</td>
</tr>
<tr>
<td>Li, Yong-Xi</td>
<td>73-OR</td>
</tr>
<tr>
<td>Li, Yukun</td>
<td>2110-P, 2146-P</td>
</tr>
<tr>
<td>Li, Zeyang</td>
<td>408-P</td>
</tr>
<tr>
<td>Li, Zhuo</td>
<td>2193-PUB</td>
</tr>
<tr>
<td>Li, Zhuoxin</td>
<td>826-P</td>
</tr>
<tr>
<td>Li, Zuoqiu</td>
<td>1877-P</td>
</tr>
<tr>
<td>Li, Zhey</td>
<td>744-P</td>
</tr>
<tr>
<td>Liakopoulos, Vasileios</td>
<td>131-OR</td>
</tr>
<tr>
<td>Liang, Bo</td>
<td>1000-P</td>
</tr>
<tr>
<td>Liang, Diefei</td>
<td>2199-PUB</td>
</tr>
<tr>
<td>Liang, Hua</td>
<td>2024-P</td>
</tr>
<tr>
<td>Liang, Liming</td>
<td>1462-P, 1539-P</td>
</tr>
<tr>
<td>Liang, Linlang</td>
<td>929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB</td>
</tr>
<tr>
<td>Liang, Qiangrong</td>
<td>1226-P</td>
</tr>
<tr>
<td>Liang, Weiwen</td>
<td>2198-PUB</td>
</tr>
<tr>
<td>Liang, Xiaofei</td>
<td>2039-P</td>
</tr>
<tr>
<td>Liang, Xijun</td>
<td>1930-P</td>
</tr>
<tr>
<td>Liang, Zerong</td>
<td>358-OR</td>
</tr>
<tr>
<td>Liao, Chun-Cheng</td>
<td>2373-PUB</td>
</tr>
<tr>
<td>Liao, Xiaoyo</td>
<td>1119-P</td>
</tr>
<tr>
<td>Liao, Yin-Kai</td>
<td>2258-PUB</td>
</tr>
<tr>
<td>Liberato, Cristiane</td>
<td>585-P</td>
</tr>
<tr>
<td>Libibanto, Renata</td>
<td>2179-PUB</td>
</tr>
<tr>
<td>Lichtenstein, Alice H.</td>
<td>1842-P, 1893-P</td>
</tr>
<tr>
<td>Lien, Yu-Chin</td>
<td>55-OR</td>
</tr>
<tr>
<td>Lier, Alexander</td>
<td>948-P, 957-P</td>
</tr>
<tr>
<td>Liese, Angela D.</td>
<td>308-OR, 441-P, 1253-P</td>
</tr>
<tr>
<td>Lietzau, Grazyna</td>
<td>1148-P</td>
</tr>
<tr>
<td>Liew, Aaron</td>
<td>1108-P</td>
</tr>
<tr>
<td>Liew, Chong Wee</td>
<td>278-OR, 281-OR</td>
</tr>
<tr>
<td>Liew, Gerald</td>
<td>542-P</td>
</tr>
<tr>
<td>Liew, Zhong Hong</td>
<td>2056-P</td>
</tr>
<tr>
<td>Liggins, Richard T.</td>
<td>394-P</td>
</tr>
<tr>
<td>Liliane, Mfeukeu Kuate</td>
<td>1127-P</td>
</tr>
<tr>
<td>Lim, Anho</td>
<td>802-P</td>
</tr>
<tr>
<td>Lim, Cadmon K.P.</td>
<td>519-P, 1590-P</td>
</tr>
<tr>
<td>Lim, Gwyneth J.</td>
<td>1198-P</td>
</tr>
<tr>
<td>Lim, Jayoung</td>
<td>28-OR</td>
</tr>
<tr>
<td>Lim, Keun-Wan</td>
<td>1158-P, 2053-P</td>
</tr>
<tr>
<td>Lim, Kwan Soo</td>
<td>1200-P, 1202-P</td>
</tr>
<tr>
<td>Lim, Lee-Ling</td>
<td>455-P</td>
</tr>
<tr>
<td>Lim, Shueh Lin</td>
<td>2057-P</td>
</tr>
<tr>
<td>Lim, Shufen</td>
<td>1010-P</td>
</tr>
<tr>
<td>Lim, Soo</td>
<td>268-OR, 428-P</td>
</tr>
<tr>
<td>Lim, Sun-Young</td>
<td>2403-PUB</td>
</tr>
<tr>
<td>Lima, Luis M.T.R.</td>
<td>76-OR</td>
</tr>
<tr>
<td>Lin, Cheng-Mao</td>
<td>241-OR</td>
</tr>
<tr>
<td>Lin, Chia-Cheng</td>
<td>561-P</td>
</tr>
<tr>
<td>Lin, Chia-Hung</td>
<td>1510-P</td>
</tr>
<tr>
<td>Lin, Chuwen</td>
<td>84-OR, 2141-P, 2423-PUB</td>
</tr>
<tr>
<td>Lin, Han-Yi, Jr.</td>
<td>704-P</td>
</tr>
<tr>
<td>Lin, Hsiu-Chao</td>
<td>26-OR</td>
</tr>
<tr>
<td>Lin, Hugo You-Hsien</td>
<td>152-OR, 496-P, 1768-P</td>
</tr>
<tr>
<td>Lin, Jiahe</td>
<td>491-P</td>
</tr>
<tr>
<td>Lin, Jiandie</td>
<td>275-OR</td>
</tr>
<tr>
<td>Lin, Keke</td>
<td>831-P</td>
</tr>
<tr>
<td>Lin, Kevin D.</td>
<td>1884-P</td>
</tr>
<tr>
<td>Lin, Keyi</td>
<td>84-OR, 2141-P, 2423-PUB</td>
</tr>
<tr>
<td>Lin, Ko-Wei</td>
<td>2006-P</td>
</tr>
<tr>
<td>Lin, Qiongyan</td>
<td>1972-P</td>
</tr>
<tr>
<td>Lin, Shuo</td>
<td>84-OR, 1448-P, 1449-P, 2141-P, 2423-PUB</td>
</tr>
<tr>
<td>Lin, Stephen L.</td>
<td>1619-P</td>
</tr>
<tr>
<td>Lin, Sung-Han</td>
<td>26-OR</td>
</tr>
<tr>
<td>Lin, Yi</td>
<td>1772-P</td>
</tr>
<tr>
<td>Lin, Yong</td>
<td>316-OR</td>
</tr>
<tr>
<td>Lin, Yuan</td>
<td>2182-PUB</td>
</tr>
<tr>
<td>Lind, Marcus</td>
<td>213-OR, 260-OR, 905-P</td>
</tr>
<tr>
<td>Lindauer, Katherine L.</td>
<td>893-P</td>
</tr>
<tr>
<td>Lindberg, Saren</td>
<td>129-OR</td>
</tr>
<tr>
<td>Lind, Katarzyna</td>
<td>1402-P</td>
</tr>
<tr>
<td>Linderman, Joyce D.</td>
<td>369-OR, 1146-P, 2049-P</td>
</tr>
<tr>
<td>Lindhardt, Morton</td>
<td>819-P</td>
</tr>
<tr>
<td>Lindholm, Maine R.</td>
<td>651-P</td>
</tr>
<tr>
<td>Lindner, Jaroslav</td>
<td>469-P</td>
</tr>
<tr>
<td>Lindner, Lena M.</td>
<td>1139-P</td>
</tr>
<tr>
<td>Lindsay, Ross T.</td>
<td>486-P</td>
</tr>
<tr>
<td>Lindsey, Laura</td>
<td>961-P</td>
</tr>
<tr>
<td>Lindstrom, Jaana</td>
<td>2316-PUB</td>
</tr>
<tr>
<td>Linetsky, Elina</td>
<td>140-OR</td>
</tr>
<tr>
<td>Ling, Ping</td>
<td>860-P, 2350-PUB</td>
</tr>
<tr>
<td>Lingling, Shu</td>
<td>1732-P</td>
</tr>
<tr>
<td>Lingvay, Ilidiko</td>
<td>124-OR, 1025-P, 1077-P, 1083-P, 1085-P, 1497-P</td>
</tr>
<tr>
<td>Linjawi, Sultan</td>
<td>1109-P</td>
</tr>
<tr>
<td>Linnebjerg, Helge</td>
<td>1038-P</td>
</tr>
<tr>
<td>Lipp, Robert</td>
<td>1941-P</td>
</tr>
<tr>
<td>Lippmann-Grob, Bernhard</td>
<td>671-P</td>
</tr>
<tr>
<td>Author</td>
<td>Type</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Lips, Michal</td>
<td>OR</td>
</tr>
<tr>
<td>Lipscombe, Lorraine</td>
<td>PUB</td>
</tr>
<tr>
<td>Lipska, Kasia J.</td>
<td>OR, PUB</td>
</tr>
<tr>
<td>Lipson, Kenneth E.</td>
<td>P</td>
</tr>
<tr>
<td>Liran, Ori</td>
<td>P</td>
</tr>
<tr>
<td>Liska, Jan</td>
<td>P</td>
</tr>
<tr>
<td>Liss, David T.</td>
<td>P</td>
</tr>
<tr>
<td>Little, Bert B.</td>
<td>P</td>
</tr>
<tr>
<td>Littlewood, Kerry</td>
<td>P</td>
</tr>
<tr>
<td>Littman, Gwen S.</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Chao</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Cho Aun</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Dongqing</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Edwin</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Fangcen</td>
<td>P</td>
</tr>
<tr>
<td>Liu, George T.</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Haijun</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Haitao</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Huijun</td>
<td>P</td>
</tr>
<tr>
<td>Liu, James</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jason</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jennifer</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Jianbin</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jianger-Hua</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jiaying</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Jie</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Jinan</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jingfang</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Jingwen</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Joey Z.</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Juan</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Juanhong</td>
<td>PUB</td>
</tr>
<tr>
<td>Liu, Jun</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Kai</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Kunying</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Liegang</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Liehui</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Lin</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Liping</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Lu</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Meilian</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Mengmei</td>
<td>PUB</td>
</tr>
<tr>
<td>Liu, Minkzi</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Rong</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Shanying</td>
<td>PUB</td>
</tr>
<tr>
<td>Liu, Shu</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Simin</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Tongyu</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Xiangyang</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Xiaocen</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Xiping</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Yan</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yanjun</td>
<td>P</td>
</tr>
<tr>
<td>Liu, Yanping</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yanshuang</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yanyan</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yongqiang</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Youan</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yu-Chun</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Yuxing</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Zhengji</td>
<td>OR</td>
</tr>
<tr>
<td>Liu, Zhiwen</td>
<td>PUB</td>
</tr>
<tr>
<td>Liu, Zhiyuan Hao</td>
<td>OR</td>
</tr>
<tr>
<td>Lo, Chi-Wen</td>
<td>P</td>
</tr>
<tr>
<td>Lockhan, Heather A.</td>
<td>OR</td>
</tr>
<tr>
<td>Lockridge, Amber D.</td>
<td>OR</td>
</tr>
<tr>
<td>Loebner, Sarah E.</td>
<td>OR</td>
</tr>
<tr>
<td>Loes, Linda M.</td>
<td>OR</td>
</tr>
<tr>
<td>Loeum, Channy</td>
<td>OR</td>
</tr>
<tr>
<td>LoGrasso, Giovanni</td>
<td>OR</td>
</tr>
<tr>
<td>Loh, F. Ellen</td>
<td>OR</td>
</tr>
<tr>
<td>Loh, Mei Teng</td>
<td>OR</td>
</tr>
<tr>
<td>Lohse, Zuzana</td>
<td>OR</td>
</tr>
<tr>
<td>Lois, Becky</td>
<td>OR</td>
</tr>
<tr>
<td>Lok, Anna</td>
<td>OR</td>
</tr>
<tr>
<td>Lohhngyna, Yuliya</td>
<td>OR</td>
</tr>
<tr>
<td>Lomonaco, Romina</td>
<td>OR</td>
</tr>
<tr>
<td>Londehl, Magnus</td>
<td>OR</td>
</tr>
<tr>
<td>Londero Gai, Thizé M.</td>
<td>OR</td>
</tr>
<tr>
<td>Long, D. Leann</td>
<td>OR</td>
</tr>
<tr>
<td>Long, Judith A.</td>
<td>OR</td>
</tr>
<tr>
<td>Long, Lu</td>
<td>OR</td>
</tr>
<tr>
<td>Long, Qingqiang</td>
<td>OR</td>
</tr>
<tr>
<td>Longhini, Ana Leda</td>
<td>OR</td>
</tr>
<tr>
<td>Longchi-Yimagu, Eric</td>
<td>OR</td>
</tr>
<tr>
<td>Loomba, Rohit</td>
<td>OR</td>
</tr>
<tr>
<td>Lopes, Renato D.</td>
<td>OR</td>
</tr>
<tr>
<td>Lopes-Virella, Maria F.</td>
<td>OR</td>
</tr>
<tr>
<td>Lorenz, Carrie</td>
<td>OR</td>
</tr>
<tr>
<td>Lorenz, Martin</td>
<td>OR</td>
</tr>
<tr>
<td>Lorenzi, Gayle M.</td>
<td>OR</td>
</tr>
<tr>
<td>Lorenzo, Felipe</td>
<td>OR</td>
</tr>
<tr>
<td>Lorenzelli, Cristian</td>
<td>OR</td>
</tr>
<tr>
<td>Lotufo, Paulo A.</td>
<td>OR</td>
</tr>
<tr>
<td>Lou, Olivia</td>
<td>OR</td>
</tr>
<tr>
<td>Lou, Qinglin, Sr.</td>
<td>OR</td>
</tr>
<tr>
<td>Lou, Qingqing</td>
<td>OR</td>
</tr>
<tr>
<td>Louise, Jennie</td>
<td>OR</td>
</tr>
<tr>
<td>Lovshin, Julie A.</td>
<td>OR</td>
</tr>
<tr>
<td>Low, Audrey K.</td>
<td>OR</td>
</tr>
<tr>
<td>Low, Kiat Mun Serena</td>
<td>OR</td>
</tr>
<tr>
<td>Low, Mary Beth</td>
<td>OR</td>
</tr>
<tr>
<td>Lowe, Derek</td>
<td>OR</td>
</tr>
<tr>
<td>Lowe, Lynn P.</td>
<td>OR</td>
</tr>
<tr>
<td>Lowe, William, Jr.</td>
<td>OR</td>
</tr>
<tr>
<td>Loxton, Deborah</td>
<td>OR</td>
</tr>
<tr>
<td>Loy Son, Natasha K.</td>
<td>OR</td>
</tr>
<tr>
<td>Lu, Hongyun</td>
<td>OR</td>
</tr>
<tr>
<td>Lu, Jing</td>
<td>PUB</td>
</tr>
<tr>
<td>Lu, Jinhua</td>
<td>OR</td>
</tr>
<tr>
<td>Lu, Jun</td>
<td>OR</td>
</tr>
<tr>
<td>Author Name</td>
<td>Publication Details</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Maerz, Basma</td>
<td>1962-P</td>
</tr>
<tr>
<td>Maerz, Winfried</td>
<td>1484-P</td>
</tr>
<tr>
<td>Maestro, Anna</td>
<td>571-P, 1231-P</td>
</tr>
<tr>
<td>Maezawa, Yoshiro</td>
<td>257-OR, 2355-PUB</td>
</tr>
<tr>
<td>Magaret, Craig A.</td>
<td>1526-P</td>
</tr>
<tr>
<td>Maged, Hala</td>
<td>1514-P</td>
</tr>
<tr>
<td>Magee, Michelle F.</td>
<td>249-OR</td>
</tr>
<tr>
<td>Maggi, Daria</td>
<td>2094-P</td>
</tr>
<tr>
<td>Maggioni, Aldo P.</td>
<td>522-P</td>
</tr>
<tr>
<td>Maggs, David</td>
<td>123-OR, 1900-P</td>
</tr>
<tr>
<td>Maglano, Dianna J.</td>
<td>1515-P, 1533-P</td>
</tr>
<tr>
<td>Magnad, Flore</td>
<td>2398-PUB</td>
</tr>
<tr>
<td>Magnone, Mirko</td>
<td>2279-PUB</td>
</tr>
<tr>
<td>Magnuson, Thomas</td>
<td>376-P, 2460-PUB</td>
</tr>
<tr>
<td>Mahaffey, Kenneth W.</td>
<td>258-OR, 1191-P, 1193-P, 1206-P, 1210-P</td>
</tr>
<tr>
<td>Mahapatra, Hariballav</td>
<td>1208-P</td>
</tr>
<tr>
<td>Mahapatra, Laxminarayan</td>
<td>1208-P</td>
</tr>
<tr>
<td>Mahapatra, Ramaballav</td>
<td>1208-P</td>
</tr>
<tr>
<td>Maharjan, Babu R.</td>
<td>746-P</td>
</tr>
<tr>
<td>Mahendran, Dinesh</td>
<td>420-P</td>
</tr>
<tr>
<td>Maheno, Michele</td>
<td>14-OR, 299-OR</td>
</tr>
<tr>
<td>Maher, Danielle</td>
<td>935-P, 2264-PUB</td>
</tr>
<tr>
<td>Maheshwari, Anuj</td>
<td>248-OR, 866-P, 2292-PUB</td>
</tr>
<tr>
<td>Maheshwari, Rashmi</td>
<td>R. 2166-P</td>
</tr>
<tr>
<td>Mahesri, Mufaddal</td>
<td>2364-PUB</td>
</tr>
<tr>
<td>Mahknee, Darin K.</td>
<td>1719-P</td>
</tr>
<tr>
<td>Mahmood, Noor</td>
<td>780-P, 934-P, 2044-P</td>
</tr>
<tr>
<td>Mahmud, Farid H.</td>
<td>237-OR, 1550-P, 1578-P, 1579-P</td>
</tr>
<tr>
<td>Mai, Knut</td>
<td>2030-P</td>
</tr>
<tr>
<td>Maioli, Antonio</td>
<td>993-P</td>
</tr>
<tr>
<td>Majarian, Tim</td>
<td>1724-P</td>
</tr>
<tr>
<td>Majumder, Syamantak</td>
<td>492-P</td>
</tr>
<tr>
<td>Mak, Tracy C.</td>
<td>52-OR</td>
</tr>
<tr>
<td>Makdisssi, Antoine</td>
<td>776-P, 1771-P</td>
</tr>
<tr>
<td>Makhmutova, Madina</td>
<td>190-OR, 197-OR</td>
</tr>
<tr>
<td>Makino, Eriko</td>
<td>554-P</td>
</tr>
<tr>
<td>Makino, Mai</td>
<td>472-P, 595-P</td>
</tr>
<tr>
<td>Makino, Masaki</td>
<td>539-P</td>
</tr>
<tr>
<td>Makkar, Brij M.</td>
<td>248-OR, 462-P, 750-P, 866-P, 2313-PUB</td>
</tr>
<tr>
<td>Malabu, Usman</td>
<td>1298-P</td>
</tr>
<tr>
<td>Malahias, Laura</td>
<td>1640-P</td>
</tr>
<tr>
<td>Malanda, Belma</td>
<td>649-P, 1676-P</td>
</tr>
<tr>
<td>Malcolm, Andrew J.</td>
<td>139-OR, 143-OR, 1740-P</td>
</tr>
<tr>
<td>Maldonado Corchado, Enrique R.</td>
<td>41-OR, 1827-P</td>
</tr>
<tr>
<td>Maldonado Fernandez, Miguel</td>
<td>2363-PUB</td>
</tr>
<tr>
<td>Malecki, Maciej</td>
<td>1677-P</td>
</tr>
<tr>
<td>Malik, Rayaz A.</td>
<td>580-P</td>
</tr>
<tr>
<td>Malin, Steven K.</td>
<td>754-P, 755-P, 1774-P</td>
</tr>
<tr>
<td>Malinska, Hana</td>
<td>1211-P, 1722-P, 1723-P</td>
</tr>
<tr>
<td>Malinski, Tadeusz</td>
<td>620-P</td>
</tr>
<tr>
<td>Mallory, Jason M.</td>
<td>1073-P</td>
</tr>
<tr>
<td>Malmasi, Shervin</td>
<td>2101-P</td>
</tr>
<tr>
<td>Malmi, Markku, Jr.</td>
<td>693-P, 724-P</td>
</tr>
<tr>
<td>Malone, James K.</td>
<td>351-OR, 1011-P</td>
</tr>
<tr>
<td>Malpetti, Maura</td>
<td>363-OR</td>
</tr>
<tr>
<td>Malvandi, Amir Mohammad</td>
<td>1231-P</td>
</tr>
<tr>
<td>Mambilapalli, Ramaniah</td>
<td>1088-P</td>
</tr>
<tr>
<td>Man, Bernice</td>
<td>1293-P</td>
</tr>
<tr>
<td>Manaliang, Milben</td>
<td>2370-PUB</td>
</tr>
<tr>
<td>Manchanda, Shalini</td>
<td>1643-P, 1644-P</td>
</tr>
<tr>
<td>Manchanda, Subhash C.</td>
<td>2361-PUB</td>
</tr>
<tr>
<td>Mancillas-Adame, Leonardo G.</td>
<td>1460-P</td>
</tr>
<tr>
<td>Mancini, Raffaele</td>
<td>993-P</td>
</tr>
<tr>
<td>Mancuso, James P.</td>
<td>1132-P, 1140-P, 1145-P, 1168-P, 1169-P</td>
</tr>
<tr>
<td>Mandarino, Lawrence</td>
<td>749-P</td>
</tr>
<tr>
<td>Mandel, Erin R.</td>
<td>394-P</td>
</tr>
<tr>
<td>Manduchi, Elisabetta</td>
<td>1705-P</td>
</tr>
<tr>
<td>Manell, Hannes</td>
<td>1352-P</td>
</tr>
<tr>
<td>Manes, Christos</td>
<td>646-P</td>
</tr>
<tr>
<td>Manetti, Thomas</td>
<td>4-OR</td>
</tr>
<tr>
<td>Manfrini, Silvia</td>
<td>564-P, 716-P, 2094-P</td>
</tr>
<tr>
<td>Manfron, Roberto C.</td>
<td>1551-P</td>
</tr>
<tr>
<td>Mangia, Silvia</td>
<td>379-P</td>
</tr>
<tr>
<td>Mangione, Carol</td>
<td>168-OR</td>
</tr>
<tr>
<td>Maniatis, Aristides</td>
<td>234-OR</td>
</tr>
<tr>
<td>Manikath, Neeraj</td>
<td>2209-PUB</td>
</tr>
<tr>
<td>Manne-Goehler, Jennifer</td>
<td>1511-P</td>
</tr>
<tr>
<td>Manning, Alisa</td>
<td>24-OR, 1703-P, 1724-P</td>
</tr>
<tr>
<td>Manocheewa, Siriphan</td>
<td>1008-P</td>
</tr>
<tr>
<td>Manroa, Pooja</td>
<td>1279-P</td>
</tr>
<tr>
<td>Mansoor, Imran</td>
<td>985-P</td>
</tr>
<tr>
<td>Mansoor, Sana</td>
<td>1362-P</td>
</tr>
<tr>
<td>Mantani, Naoki</td>
<td>2204-PUB</td>
</tr>
<tr>
<td>Mantero, Alejandro M.</td>
<td>142-OR</td>
</tr>
<tr>
<td>Mao, Zhuo</td>
<td>1984-P</td>
</tr>
<tr>
<td>Marceau, Lisa</td>
<td>851-P, 854-P</td>
</tr>
<tr>
<td>March, Christine</td>
<td>343-OR</td>
</tr>
<tr>
<td>Marchetti, Piero</td>
<td>2142-P</td>
</tr>
<tr>
<td>Marcon, Margaret A.</td>
<td>1550-P, 1578-P, 1579-P</td>
</tr>
<tr>
<td>Marcovina, Santica M.</td>
<td>525-P, 1366-P</td>
</tr>
<tr>
<td>Marder, William D.</td>
<td>1493-P</td>
</tr>
<tr>
<td>Margari, Vito</td>
<td>2190-PUB</td>
</tr>
<tr>
<td>Margerie, Daniel, Sr.</td>
<td>2030-P</td>
</tr>
<tr>
<td>Margolis, Karen L.</td>
<td>172-OR</td>
</tr>
<tr>
<td>Mari, Andrea</td>
<td>292-OR, 1830-P, 1971-P, 2089-P</td>
</tr>
<tr>
<td>Maria, Zahra</td>
<td>453-P, 454-P, 1904-P</td>
</tr>
<tr>
<td>Marialiash, Cary N.</td>
<td>2177-PUB</td>
</tr>
<tr>
<td>Marie, Monlun</td>
<td>434-P</td>
</tr>
<tr>
<td>Marild, Karl</td>
<td>136-OR</td>
</tr>
<tr>
<td>Marin, Susana N.</td>
<td>1645-P</td>
</tr>
<tr>
<td>Marine, Rigo</td>
<td>434-P</td>
</tr>
<tr>
<td>Marinelli Andreoli, Anna</td>
<td>1042-P</td>
</tr>
<tr>
<td>Marion, Lucy</td>
<td>132-OR</td>
</tr>
<tr>
<td>Mariotto, Aldo</td>
<td>1302-P</td>
</tr>
<tr>
<td>Mark, Michael</td>
<td>436-P, 1228-P</td>
</tr>
<tr>
<td>Mark, Thomas</td>
<td>108-OR, 530-P</td>
</tr>
<tr>
<td>Mark, Victoria</td>
<td>1823-P</td>
</tr>
<tr>
<td>Markel, Troy A.</td>
<td>1899-P</td>
</tr>
<tr>
<td>Markgraf, Daniel F.</td>
<td>156-OR, 296-OR, 748-P, 773-P, 1509-P, 2054-P</td>
</tr>
<tr>
<td>Marková, Irena</td>
<td>1211-P, 1722-P, 1723-P</td>
</tr>
</tbody>
</table>
Markowitz, Benjamin 842-P
Markowitz, Jessica T. 2338-PUB
Marks, Jennifer B. 232-OR
Markwald, Rachel 2448-PUB
Marlatt, Kara 1544-P
Marley, Katie A. 1288-P
Marmol, Fernando A., Sr. 2185-PUB
Marquard, Jan 1346-P
Marquis, Patrick 2338-PUB
Marra, Camillo 1830-P
Marrano, Nicola 2147-P
Marre, Michel 2220-PUB, 2221-PUB
Marrero, David G. 848-P
Marro, Rachel 1650-P
Marschke, Keith 73-OR, 1117-P
Martindale, Robert E. 185-OR, 1171-P
Marshall, Cassandra 2322-PUB
Marshall, Nicole E. 1407-P, 1408-P
Martin, Lukas 483-P
Martin, Benjamin 419-P
Martin, Amanda E. 898-P
Martin, John C. 2097-P
Martin, Mary 223-P
Martin, Michael 1812-P
Martin, Megan T. 1396-P
Martinelli, Silvia 262-OR
Martinez, Mayra P. 117-OR, 227-OR, 344-OR
Martinez, Robert A. 109-OR, 1192-P
Martinez-Huenchullan, Sergio F. 746-P, 1923-P
Martinez-Revelo, Gabriela 1394-P
Martins, Christoffer 1885-P, 1956-P
Martone, Maryann E. 2006-P
Marucchi, Antonella 262-OR
Maruo, Saori 2074-P
Maruoka, Andrew 1304-P
Maruthur, Nisa 2460-PUB
Matsen, Miles E. 372-OR, 373-OR
Matsoukis, Ioannis L. 2098-P, 2406-PUB
Matsubara, Tatsuki 554-P
Matsukawa, Satoshi 444-P, 787-P, 823-P
Matsuoka, Takaaki 2125-P, 2144-P
Matsushita, Maya 100-OR
Matsushita, Yuichi 1720-P
Matsumoto, Motonobu 1897-P
Matsumoto, Tatsuki, Takeshi 1365-P
Matsunaga, Satoshi 444-P, 787-P, 823-P
Matsuzawa, Takatoshi 1991-P
Matsuzawa, Takuro 1832-P
Mattei, Josiemer 1596-P
Matthan, Nirupa R. 1842-P, 1893-P
Matthews, David R. 258-OR, 1191-P, 1206-P
Mathieson, Aleksey 193-OR, 2117-P
Matyjaszek-Matuszek, Beata 126-OR
Matzopoulos, Mark 1009-P
Mauer, Michael 578-P
Mawani, Minaz Z. 1316-P
Maxwell, Taylor J. 1711-P
Mayberry, Lindsay S. 825-P
Mayer, Anna‑Lena 1222-P
Mayer, Gert 1126-P
Mayer-Davis, Elizabeth J. 378-P, 1253-P, 1366-P
Mayige, Mary T. 1511-P
Mayoux, Eric 1228-P, 2009-P, 2016-P
Mazza, Tommaso 262-OR
Mazzucca, Stephanie 634-P
Mba, Camille B.M. 626-P
Mbath, Wilfred F. 626-P
McAdam-Marx, Carrie 909-P
McAsey, Karen 237-OR
McAuley, Sybil A. 986-P
McAuliffe-Fogarty, Alicia H. 383-P, 932-P, 974-P, 981-P
McCallum, James 2326-PUB
McCance, David R. 116-OR
McCann, Maximilian A. 281-OR
McCarter, James P. 293-OR
McCarter, Rachel V. 2201-PUB
McCarthy, Cian P. 1526-P
McCarthy, Robert F. 669-P
McClain, Don 1760-P, 1881-P, 1976-P, 2023-P
McClary, Kyle 2171-P
McClellan,pars 1764-P
McCurdy, Carrie 1787-P
McDermott, Timothy J. 1594-P
McDonald, Charlotte 1550-P, 1578-P, 1579-P
McDonald, Timothy J. 263-OR
McDonnell, Marie E. 857-P, 2317-PUB
McDonough, Ryan 1309-P
McDougal, David 205-OR
McDowell, Ruth 67-OR, 2162-P
McGarrah, Robert W. III 1874-P
McGaugh, Sarah M. 65-OR
McGehee, Suzanne 1146-P, 2052-P
McGill, Janet B. 62-OR, 1699-P
McGill, Margaret 290-OR
McGinley, Erin L. 812-P
McGinty, James J. 1753-P
McGinn, Robert W. III 1874-P
McGarrah, Robert W. III 1874-P
McGraw, Kieran M. 1543-P
McGraw, Sean M. 1657-P
McGregor, Brett A. 551-P
McGurnaghan, Stuart 263-OR
McIntyre, H. David 689-P, 1422-P
McKay, Gareth J. 2201-PUB
McKeigue, Paul 263-OR
McKenzie, Amy 293-OR
McKimpson, Wendy 324-OR
McKinney, Brett M. 484-P
McKinnie, Angela M. 167-OR
McKnight, Barbara 1663-P
McLaughlin, Daniel G. 662-P
McLeer Maloney, Lori 706-P, 720-P
McLeese, Rebecca H. 1397-P
McLennan, Susan 746-P, 1736-P, 1923-P
McLeod, Euan 1159-P, 1160-P, 1161-P
McMahon, Ruth M. 2346-PUB
McMaster, Jessica J. 2097-P
McNeil, Anne Marie 1159-P, 1160-P, 1161-P, 1628-P
McNeil, Diana B. 249-OR
McNulty, Bridget K. 12-OR, 927-P
McNulty, Jacqueline N. 645-OR, 2315-PUB
McTernan, Jennifer J. 1691-P
Me, Yunus A. 1659-P
Meardon, Stacey A. 561-P
Mechley, Amy 1518-P, 2370-PUB
Medayil, Rituna 798-P, 2376-PUB
Medina, Jesus 1186-P
Medina, Jose Luis 1975-P
Medina, Ursula B. 1645-P
Meegalla, Sanath 609-P
Mehrotra, Rabinder Nath 949-P
Mehta, Paras B. 1782-P
Mehta, Rajesh 1658-P
Mehta, Sanjeev N. 1321-P, 1328-P, 2274-PUB
Mehta, Tapan 1548-P
Mei, Fang Y. 1351-P
Mei, Fangyun 2058-P, 2060-P, 2073-P, 2456-PUB
Meier, Maggie 667-P
Meilhac, Olivier 349-P, 998-P, 1001-P, 1024-P, 1035-P
Meigs, James B. 1715-P, 1724-P
Meilhac, Olivier 2220-PUB
Meisinger, Christa 63-OR
Melanson, Edward 2448-PUB
Melas-Melt, Lydie 1037-P
Melenovsky, Vojtech 465-P
Melin, Johanna 1190-P
Melto, Enirates C. 1671-P
Meloni, Gisella 599-P
Melzer Cohen, Cheli 2295-PUB
Memen, Nilam S. 118-OR, 1445-P
Mendelson, Faye 569-P
Mendez, Carlos E. 1577-P
Miyaoka, Hiroaki 1581-P  
Miyashita, Yumi 1224-P  
Miyata, Ayaka 2253-PUB  
Miyatsuka, Takeshi 1400-P, 1840-P, 2125-P, 2128-P, 2144-P  
Miyata, Tetsuro 1157-P  
Miyazawa, Itsuko 1199-P, 1636-P  
Miyazawa, Ken 554-P  
Miyoshi, Hideaki 1862-P  
Miyoshi, Kengo 1950-P  
Miyoshi, Masashi 1505-P  
Mize, Dara L. 1078-P  
Mizoguchi, Asako, Sr. 2271-PUB  
Mizokami-Stout, Kara R. 62-OR  
Mizuyama, Hiroki 549-P, 575-P, 2132-P  
Mizuno, Ken 1133-P  
Mizunuma, Yuiko 500-P  
Mlyn’Czak, Tomasz 456-P  
Mocarski, Michelle 684-P, 837-P, 1251-P, 2285-PUB  
Mody, Reema 1071-P, 1264-P, 1557-P  
Moellering, Douglas R. 1978-P  
Moellmann, Julia 436-P  
Moffa, Simona 1830-P, 1971-P  
Moffet, Howard H. 1311-P  
Moghadam, Nima 1470-P  
Moghetti, Paolo 1718-P  
Mohammad, Mohammad Fawaz 1062-P  
Mohamed, Wan Nazaimoon, Sr. 2057-P  
Mohan, Bishav 2361-PUB  
Mohan, Mohapradeep 167-OR, 256-OR, 1238-P  
Moreau, Jean-Pierre 985-P  
Morel, Didier 923-P, 984-P  
Moretto, Carlo 362-OR, 1791-P  
Moretz, Chad 1659-P  
Morgan, Claire 1171-P  
Morgan, Don W. 741-P  
Morgan, Jerry D. 1142-P  
Morgan, Katherine 1741-P  
Mori, Akihiro 1087-P  
Mori, Eisaku 1469-P  
Mori, Hiroyasu 529-P  
Mori, Ichiro 1196-P  
Mori, Katsuhito 422-P, 423-P, 443-P  
Mori, Kentaro 1993-P  
Mori, Yasumichi 418-P, 625-P, 782-P, 2368-PUB  
Mori, Yuusaku 418-OR, 289-OR, 482-P, 487-P, 1988-P  
Mori, Yutaka 543-P, 915-P, 1610-P, 2205-PUB, 2269-PUB, 2308-PUB  
Morikawa, Sakiko Y. 781-P  
Morimoto, Aya 1224-P  
Morimoto, Michio 1624-P  
Morimoto, Takako 1110-P  
Morinaga, Hidetaka 478-P  
Moreno, P. 1110-P, 1636-P, 1966-P  
Morikawa, Tatsuro 775-P, 1199-P, 1636-P, 1966-P  
Morishima, Masaki 1857‑P
Morita, Emiko 736‑P
Morita, Hiroyuki 1927‑P
Morita, Shuhei 2108‑P
Moriya, Chihiro T. 1840‑P , 1927‑P
Moriya, Hitomi 508‑P
Moriya, Tatsumi 597‑P , 661‑P , 1561‑P , 2319‑PUB
Morningstar, Jordan 1836‑P
Morris, Heather L. 1371‑P
Morrisey, Robin 659‑P , 2326‑PUB
Morrone, Maria Concetta 362‑OR, 1791‑P
Morrow, Linda 74‑OR, 1038‑P
Mortell, William 2043‑P
Mortensen, Kara M. 2140‑P
Morton, Gregory J. 372‑OR, 373‑OR
Morton, Tim 2319‑PUB
Mosenzon, Ofri 1000‑P
Moses, Alan C. 108‑OR, 1065‑P
Moshel, Shai 1297‑P
Moshenets, Kateryna 386‑P
Moskowitz, Keith 1518‑P , 2370‑PUB
Moss, Elizabeth 2318‑PUB
Motegi, Mikio 563‑P , 565‑P , 566‑P , 567‑P
Motoyama, Koka 422‑P , 423‑P , 443‑P , 2434‑PUB
Motsinger‑Reif, Alison 56‑OR
Mottalib, Adham 760‑P , 934‑P , 2044‑P
Mottl, Amy K. 525‑P , 1366‑P
Mouneimne, Ghassan 186‑OR
Moura Neto, Arnaldo 873‑P
Mourad, Sahar 712‑P
Mouritzen, Ulrik 102‑OR
Mousa, Aya 777‑P , 2047‑PUB
Moutairou, Abdul K. 2221‑PUB
Moy, Claudia 307‑OR
Mrozikiewicz‑Rakowska, Beata 630‑P
Mrozinska, Sandra 1677‑P
Mu, Kaida 1850‑P
Mu, YiMing 929‑P , 2266‑PUB, 2267‑PUB, 2268‑PUB, 2307‑PUB
Mudaliar, Sunder 159‑OR, 1902‑P
Mueckler, John 963‑P
Muehlbauer, Michael 1429‑P
Mueller, Claudia 830‑P
Mueller, Kelly 1396‑P
Mueller, Kevin W. 317‑OR
Mueller, Kyle A. 51‑OR
Mueller, Michael J. 632‑P , 640‑P , 2242‑PUB
Muir, Andrew 2176‑PUB
Mujeeb‑U‑Rahman, Muhammad 930‑P
Muka, Taulant, Sr. 1480‑P , 1495‑P
Mukai, Renata 1526‑P
Mukamal, Kenneth J. 1552‑P
Mukerji, Geetha 842‑P , 1550‑P , 1578‑P , 1579‑P
Mukhuty, Alpana, Jr. 2443‑PUB
Mun, Joram 64‑OR
Mullie, Patrick 1627‑P
Mullur, Rashmi S. 832‑P
Mulkutlia, Surya N. 1782‑P
Munch, Lene 6‑OR
Munch, Marion 933‑P
Mundet, Xavier 221‑OR
Mundinger, Thomas O. 1815‑P
Mune, Tomoatsu 2050‑P , 2111‑P
Munro, Lynne 2097‑P
Munro, Neil M. 1047‑P
Munshi, Medha 380‑P , 405‑P , 826‑P , 921‑P , 959‑P
Murabayashi, Masaya 827‑P , 1605‑P , 1655‑P , 1831‑P
Muragishi, Sayaka 1176‑P
Murakami, Kazutoshi 345‑OR
Murakami, Takaaki 2123‑P , 2124‑P
Muramatsu, Aiko 917‑P
Murao, Koji 2164‑P
Murata, Kazuya 415‑P , 673‑P
Muro, Elena 697‑P , 2236‑PUB
Muro, Seiji 1489‑P
Murohashi, Yuko 913‑P
Murotani, Kenta 540‑P , 2306‑PUB
Murphy, Alice 1573‑P , 2076‑P
Murphy, Catherine 483‑P
Murphy, Gerni 1082‑P
Murphy, Helen R. 1432‑P
Murphy, Monica D. 672‑P
Murphy, Rinki 2075‑P
Murray, Andrew J. 466‑P
Murray, Anna 23‑OR
Murray, Erin 660‑P
Murray, Katharine 2237‑PUB
Murray, Sara G. 400‑P
Murray, Sue 149‑OR, 2439‑PUB
Murthy, L. Sreenivasa, Sr. 1019‑P
Musante, Luca 1774‑P
Musasi, Nicolas 53‑OR, 71‑OR, 358‑OR, 1809‑P , 1869‑P , 1922‑P
Muskiet, Marcel A. 1060‑P
Musovic, Saliha 1964‑P , 2431‑PUB
Mussman, George M. 2157‑P
Mustelin, Linda 1519‑P
Mutluay, Ruya 2234‑PUB
Muto, Hideya 1075‑P
Muturi, Harrison T. 357‑OR
Muzumdar, Radhika 2443‑PUB
Mychaleckyj, Josyf 56‑OR
Myers, Lyle C. 919‑P
Myers, Martin G., Jr. 202‑OR
<table>
<thead>
<tr>
<th>Name</th>
<th>OR: Oral</th>
<th>P: Poster</th>
<th>PUB: Published Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nabrdalik, Katarzyna</td>
<td>456-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nabulsi, Nabeel B.</td>
<td>2145-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naciu, Anda Mihaela</td>
<td>564-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nader, Marie</td>
<td>940-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naderpoor, Negar</td>
<td>2047-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nadkarni, Prashant V.</td>
<td>1309-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagai, Yusuke</td>
<td>476-P, 498-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagaike, Hiroe</td>
<td>411-P, 619-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagao, Shunsuke</td>
<td>1118-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagar, Ron</td>
<td>2281-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagarkatti, Mitzi</td>
<td>475-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagarkatti, Prakash</td>
<td>475-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagasawa, Kaoru</td>
<td>418-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagashima, Kengo</td>
<td>257-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagashimada, Mayumi</td>
<td>1839-P, 1852-P, 1989-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagasu, Hajime</td>
<td>89-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagata, Kouji</td>
<td>1110-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagata, Naoto</td>
<td>1839-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagayama, Ayako</td>
<td>1164-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagel, Kathryn</td>
<td>218-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagra, Harpreet</td>
<td>215-OR, 861-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nagy, Laszlo</td>
<td>2444-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naik, Nisha</td>
<td>2274-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naik, Ramachandra G.</td>
<td>987-P, 995-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naik, Sapna</td>
<td>2392-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair, Hari</td>
<td>1663-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair, K. Sreekumaran</td>
<td>1925-P, 2243-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair, Radhika</td>
<td>1659-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair, Shailes</td>
<td>545-P, 1589-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nair, Viji</td>
<td>88-OR, 491-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Najafi, Bijan</td>
<td>114-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Najjar, Sonia M.</td>
<td>357-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naka, Motoji</td>
<td>761-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naka, Jun</td>
<td>191-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakafusa, Yuki</td>
<td>32-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakagami, Tomoko</td>
<td>2208-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakagawa, Takashi</td>
<td>380-OR, 1133-P, 1749-P, 1990-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakajima, Atsushi</td>
<td>2204-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakajima, Motowo</td>
<td>1716-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakajima, Osamu</td>
<td>1716-P, 2127-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Akinobu</td>
<td>1862-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Masafumi</td>
<td>32-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Nobuhisa</td>
<td>554-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Suguru</td>
<td>1993-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Sunao</td>
<td>163-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Susumu</td>
<td>257-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakamura, Takahisa</td>
<td>345-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakanishi, Noriko</td>
<td>619-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakanishi, Shuhei</td>
<td>2050-P, 2111-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakao, Takayuki</td>
<td>1505-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakata, Yoshio</td>
<td>917-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakatani, Yoshihisa</td>
<td>1178-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakatsu, Yusuke</td>
<td>604-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakaya, Takahiro</td>
<td>154-OR, 1903-P, 1906-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakayama, Hirofumi</td>
<td>827-P, 1831-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakayama, Hitomi</td>
<td>1164-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakayama, Kazuhiro</td>
<td>1994-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nakhle, Samer</td>
<td>1102-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nally, Laura</td>
<td>830-P, 906-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nam, Ji Sun</td>
<td>612-P, 2414-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nam, Moonsuk</td>
<td>527-P, 533-P, 1571-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nam, Soohyun</td>
<td>802-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namba, Raicha</td>
<td>1040-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namiki, Yulia</td>
<td>913-P, 2204-PUB, 2286-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nanayakkara, Natalie</td>
<td>707-P, 1697-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naggrani, Nisha</td>
<td>1298-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nankervis, Alison J.</td>
<td>1288-P, 1405-P, 1409-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nano, Jana</td>
<td>1495-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Napier, A. David</td>
<td>839-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Napoli, Angela</td>
<td>2345-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Napoli, Nicola</td>
<td>1701-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narasimhan, Calambur</td>
<td>2361-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narayan, K.M. Venkat</td>
<td>132-OR, 1316-P, 1682-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narui, Koji</td>
<td>418-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naruse, Keiko</td>
<td>554-P, 566-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naruse, Rika</td>
<td>2240-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narwani, Vishal</td>
<td>1818-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nascimento, Caio V.F.</td>
<td>76-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nash, Michael J.</td>
<td>222-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasif, Kamal</td>
<td>1799-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasif, Lith H.</td>
<td>1799-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naslund, Ingmar</td>
<td>131-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nason, Shellie</td>
<td>1806-P, 1978-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasrallah, Catherine</td>
<td>897-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nassar, Carine M.</td>
<td>249-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nassim, Maria</td>
<td>2180-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasteska, Daniela</td>
<td>325-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalicchio, Annalis</td>
<td>2147-P, 2190-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natarajan, S.</td>
<td>2361-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natarajan, Sundar</td>
<td>1662-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nathan, Aviva</td>
<td>1252-P, 1324-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nativel, Mathilde</td>
<td>2220-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natsume, Yukie</td>
<td>1157-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauck, Michael A.</td>
<td>438-P, 1961-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauman, Elizabeth</td>
<td>1576-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Navarria, Andrea</td>
<td>122-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Navarro, Felipe</td>
<td>1246-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Navarro-Estrada, Alicia, Jr.</td>
<td>2362-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nawaz, Allah</td>
<td>360-OR, 1749-P, 1990-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nawrocki, Andrea R.</td>
<td>609-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nayak, Sunil</td>
<td>234-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naylor, Rochelle N.</td>
<td>264-OR, 893-P, 1379-P, 1453-P, 2353-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naz, Iram</td>
<td>111-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neal, Bruce</td>
<td>258-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needham, Belinda</td>
<td>306-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neeland, Ian J.</td>
<td>2064-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neemuchwala, Huzefa</td>
<td>16-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negi, Prakash C.</td>
<td>2361-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author Name</td>
<td>ID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Numata, Tomohiro</td>
<td>255-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nunes de Melo, Emilia</td>
<td>1578-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nunes, Gabriel C.</td>
<td>2065-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nunez Lopez, Yury O.</td>
<td>1120-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nunley, Karen</td>
<td>1473-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nunoï, Kiyohide</td>
<td>1156-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuttall, Amy K.</td>
<td>2237-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nwokolo, Munachisco</td>
<td>404-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyirjesy, Sarah</td>
<td>1820-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nylen, Eric</td>
<td>714-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nystrom, Thomas</td>
<td>1148-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obermayer, Anna M.</td>
<td>2086-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obermayer-Pietsch, Barbara M.</td>
<td>101-OR, 1821-P , 1941-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obialo, E. Elizabeth</td>
<td>7-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Brien, Matthew</td>
<td>1125-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Brien, Philippe D.</td>
<td>569-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Brien, Timothy</td>
<td>1108-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obryna, Kathryn</td>
<td>1307-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obukhov, Alexander G.</td>
<td>1899-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ochoa-Rosales, Carolina</td>
<td>1495-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Connell, David J.</td>
<td>1631-P , 1632-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Connell, Kathleen K.</td>
<td>2315-PU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Connor, Jason B.</td>
<td>207-OR, 1376-P , 1377-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Connor, Patrick J.</td>
<td>172-OR, 435-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oda, Kenzaburo</td>
<td>772-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Daly, Owen</td>
<td>404-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odawara, Masato</td>
<td>1048-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odedosu, Kehinde</td>
<td>2315-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odom, Jessica M.</td>
<td>651-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Donnell, Holly</td>
<td>883-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Donovan, Alexander J.</td>
<td>14-OR, 299-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odoul, Marion</td>
<td>305-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oelgaard, Jens</td>
<td>162-OR, 1575-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oestergaard, Mette V.</td>
<td>502-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ofstad, Anne P.</td>
<td>433-P, 449-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogasawara, Saori</td>
<td>549-P, 575-P, 2132-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogata, Nahoiko</td>
<td>595-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogata, Satoshi</td>
<td>761-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogawa, Akifumi</td>
<td>535-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogawa, Kotaro</td>
<td>1118-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogawa, Wataru</td>
<td>188-OR, 1910-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogawa, Yoshihiro</td>
<td>478-P, 1993-P, 2372-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogino, Jun</td>
<td>257-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogu, Rosemary</td>
<td>1451-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogura, Masatsune</td>
<td>488-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ogura, Yoshio</td>
<td>495-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oguri, Yasuo</td>
<td>1894-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oguz, Aytek</td>
<td>679-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oguyaadu, Selassie J.</td>
<td>992-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oh, Eiko</td>
<td>1110-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oh, Richard</td>
<td>259-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oh, Tae Jung</td>
<td>428-P, 2029-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Halloran, Sean A.</td>
<td>1230-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohara, Emi</td>
<td>257-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohara, Makoto</td>
<td>411-P, 619-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Hare, Elizabeth A.</td>
<td>1398-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohashi, Natsuko</td>
<td>1199-P, 1966-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pandya, Shivani</td>
<td>1291-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Panei, Nicolas, Sr.</td>
<td>943-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pang, Bowen</td>
<td>1283-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pankow, James S.</td>
<td>1707-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pankratz, Vernon S.</td>
<td>1623-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pannone, Luca</td>
<td>262-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantalione, Kevin M.</td>
<td>1068-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paolino, Andrea R.</td>
<td>311-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papadaki, Despina</td>
<td>1104-P, 1235-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papagianni, Marianthi</td>
<td>459-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papandreopoulou, Vasiliki</td>
<td>1058-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papenfuss, Anthony T.</td>
<td>2190-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papel, Ulrich-Frank</td>
<td>295-OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papel, Min Ah</td>
<td>1200-P, 1202-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parajuli, Keshab R.</td>
<td>355-OR, 1742-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paramalingam, Nirubasini</td>
<td>747-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parikh, Lisa</td>
<td>365-OR, 2427-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parilla, Jacqueline H.</td>
<td>1825-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parisi, Maria C., Sr.</td>
<td>873-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park, Cheol-Young</td>
<td>407-P, 708-P, 1553-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park, Eunjin</td>
<td>1106-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题一</td>
<td>88-OR, 1743-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题二</td>
<td>692-P, 924-P, 925-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parikh, Neha</td>
<td>206-OR, 969-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parikh, Vegi</td>
<td>1823-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题三</td>
<td>266-OR, 286-OR, 288-OR, 1897-P, 2033-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题四</td>
<td>1219-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题五</td>
<td>1140-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patange, Sonali A.</td>
<td>1130-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patil,专题六</td>
<td>1147-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题七</td>
<td>1205-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题八</td>
<td>1194-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题九</td>
<td>1068-P, 1071-P, 1264-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题十</td>
<td>1823-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题十一</td>
<td>2380-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题十二</td>
<td>2144-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passi,专题十三</td>
<td>1145-P, 1168-P, 1169-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题十四</td>
<td>1540-P, 1578-P, 1579-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pathan,专题十五</td>
<td>1256-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patil,专题十六</td>
<td>649-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patil,专题十七</td>
<td>1747-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patil,专题十八</td>
<td>2218-PUB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题十九</td>
<td>300-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题二十</td>
<td>1386-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Park,专题二十一</td>
<td>2143-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul,专题二十二</td>
<td>1806-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul,专题二十三</td>
<td>517-P, 520-P, 538-P, 560-P, 600-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paulin,专题二十四</td>
<td>1997-P</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paulik,专题二十五</td>
<td>1998-P</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pavin, Elizabeth J., Sr. 873-P
Pavkov, Meda E. 1566-P, 1586-P
Pavic, Ana 1638-P
Pavlovicova, Renata 784-P
Pawar, Dilip 723-P, 878-P, 884-P, 1059-P, 2293-PUB
Pawaskar, Manjiri 384-P, 1247-P, 1259-P, 1265-P
Pawlak, Roman 769-P
Payanundana, Manaporn 790-P
Pazderska, Agnieszka 1547-P
Pazmiño Gomez, Betty J. 526-P
Peakman, Mark 1733-P
Pearson, Ewan 20-OR, 256-OR, 1238-P
Pearson, Thomas A. 1486-P
Pease, Anthony J. 707-P, 1697-P
Peddinti, Gopal 1537-P
Pedersen, Jens 43-OR, 1968-P, 2156-P
Pedersen, Michael L. II 439-P
Pedersen, Oluf, Sr. 162-OR, 1575-P
Pedersen, Philip J. 466-P, 502-P
Pedersen, Søren L. 1981-P
Pedersen, Tanja X. 466-P, 502-P, 516-P
Pedersen-Bjergaard, Ulrik 105-OR, 300-OR
Pedersen-Bjergaard, Ulrik 105-OR, 300-OR
Pedersen, Philip J. 466-P, 502-P, 516-P
Pedersen, Søren L. 1981-P
Pedersen, Tanja X. 466-P, 502-P, 516-P
Pedersen-Bjergaard, Ulrik 105-OR, 300-OR
Peleckis, Amy J. 1820-P
Pelaez, Andres 1546-P
Peleckis, Amy J. 1820-P
Peiffer, Frida W. 1540-P
Pelikanova, Terezie 465-P, 784-P, 1974-P, 2449-PUB
Pellegow, Katrin 1020-P, 1027-P, 1031-P, 2288-PUB
Pei, Xiaofang 121-OR
Peirce, Katherine 124-OR, 1077-P
Peiffer, Frida W. 1540-P
Pelletier, Sebastien 2312-PUB
Peiris, Sumita 945-P
Pennathur, Sumita 945-P
Penniman, Christie M. 187-OR
Pennington, Mark W. 1250-P
Penno, Giuseppe 362-OR, 784-P, 1572-P, 1694-P
Penno, Megan A. 230-OR
Penzenstadler, Justin A. 1051-P
Peip, Mark E. 1211-P
Pepin, Mark E. 1978-P
Peters, Anne 212-OR, 261-OR, 348-OR, 765-P, 1017-P, 1122-P, 1179-P, 2227-PUB
Peters, Annette 63-OR
Peters, Carl 40-OR, 42-OR, 1834-P
Peters, Annette 63-OR
Petersen, Brian 114-OR
Petersen, Kitt 146-OR
Petersen, Matt 135-OR, 1493-P
Petersen, Max C. 1766-P
Petersen, Patricia 38-OR
Petersen, Courtneym A. 1544-P
Petersen, Eric 452-P
Petersen, Scott N. 1970-P
Petersen-Burch, Frances M. 835-P
Pettis, James 923-P
Petrenchik, Lindsay 806-P
Petrie, John 122-OR, 438-P
Petrone, Marcella 79-OR, 1067-P, 1070-P
Petrik, Nikolay 2378-PUB
Petry, Nancy 216-OR
Pettersson, Jonas 1084-P
Petit, Ronald J. 984-P
Pettilt, David J. 525-P
Pettus, Jeremy 73-OR, 138-OR, 1029-P, 2289-PUB
Perez, Mayra A. 2461-PUB
Perez-Nieves, Magaly 221-OR, 801-P, 838-P, 981-P
Perez-Perez, Guillermo 1999-P
Perez-Tilve, Diego 1978-P
Perfett, Michelle 849-P
Perfetti, Riccardo 1037-P, 1039-P
Perkovic, Vlado 258-OR, 1483-P
Perl, Shira 1149-P
Perlis, Lauren 2294-PUB
Perlman, Jordan E. 12-OR, 927-P
Perls, Tom 1709-P
Peralta, Raechel 2439-PUB
Persky, Rebecca 1353-P
Persoons, Virginie 81-OR
Perseve, Natalia 386-P, 2194-PUB
Pescara, Teresa 25-OR
Pesta, Dominik 69-OR, 748-P, 1567-P
Peter, Andreas 295-OR, 1717-P, 1819-P, 1867-P
Peters, Anne 212-OR, 261-OR, 348-OR, 765-P, 1017-P, 1122-P, 1179-P, 2227-PUB
Peters, Annette 63-OR
Petersen, Brian 114-OR
Petersen, Matt 135-OR, 1493-P
Petersen, Max C. 1766-P
Petersen, Patricia 38-OR
Petersen, Courtneym A. 1544-P
Petersen, Eric 452-P
Petersen, Scott N. 1970-P
Petersen-Burch, Frances M. 835-P
Petisco, James 923-P
Petrenchik, Lindsay 806-P
Petrie, John 122-OR, 438-P
Petrone, Marcella 79-OR, 1067-P, 1070-P
Petrov, Nikolay 2378-PUB
Petry, Nancy 216-OR
Pettersson, Jonas 1084-P
Petit, Ronald J. 984-P
Pettilt, David J. 525-P
Pettus, Jeremy 73-OR, 138-OR, 1029-P, 2289-PUB
Quinn, Maryanne 1373-P  
Quinn, Michael T. 8-OR, 1252-P  
Quintana, Fernando G. 2461-PUB, 2462-PUB  
Quisel, Thomas 1616-P  
Quon, Michael T. 8-OR, 1252-P  
Quon, Michael 159-OR  
Quisl, Thomas 1616-P  
Quon, Michael 159-OR  
R., Prasad M. 2361-PUB  
Rábago-Escoto, Ruth, Jr. 2362-PUB  
Rabbani, Piul S. 634-P, 644-P  
Raben, Anne 1431-P  
Rabin, Tracy L. 2-OR  
Raccah, Denis 1094-P  
Rachmiel, Marianna 235-OR  
Rachek, Lyudmila 1783-P  
Radhakrishnan, Chandni 574-P, 2209-PUB, 2213-PUB  
Radilová, Monika 1468-P  
Rady, Brian 609-P  
Radj, Praveen 723-P, 884-P, 1059-P  
Rajagopalan, Harith 1900-P  
Rajamanickam, Victoria P. 1380-P  
Rajamani, Krishnakumar 2085-P  
Rajeev, Surya Panicker 1163-P  
Rajpal, Neha 111-OR  
Raj, Praveen 723-P, 884-P, 1059-P  
Rajgopal, Harith 1900-P  
Rajamani, Krishnakumar 2085-P  
Rajamanickam, Victoria P. 1380-P  
Rajasekaran, Harindra 537-P  
Rajeek, Surya Panicker 1163-P  
Raji, Annaswamy 1142-P, 1143-P  
Rajapal, Neha 111-OR  
Rakshit, Kuntol 193-OR, 2117-P  
Rao, R. Harsha 1549-P  
Rao, Xi 2138-P  
Rapoport, Wally 1184-P  
Ran, Liyuan 17-OR  
Rao, Karthik 603-P  
Ran, Jianmin 613-P  
Ram, Nalini 1782-P  
Rama Chandran, Suresh 1139-P, 1562-P, 1615-P  
Rath, Michaela 1801-P  
Rath, Akshyaya C. 1194-P, 1203-P  
Rath, Michaela 1801-P  
Rathjen, Thomas 2033-P  
Rathmann, Wolfgang 1616-P, 1811-P  
Rastogi Kalyani, Rita 306-OR, 1471-P, 1574-P  
Rastogi, Ravinder 13-OR, 1542-P  
Rath, Akshay 1194-P, 1203-P  
Rathod, Rohan M. 1194-P, 1203-P  
Rattelman, Cori R. 1-OR, 1499-P  
Ratzki-Leewing, Alexander 377-P, 399-P  
Rausch, Dylan 375-OR  
Ray, Andrew J. 829-P  
Ray, Kausik K. 330-OR  
Ray, Ravi 1245-P  
Ray, Phil 2157-P  
Raymond, Jennifer 899-P, 890-P, 892-P, 1324-P, 1325-P  
Rayner, Brian L. 1066-P  
Raz, Itamar 636-P, 908-P, 1286-P  
Rauf, Abhay A., Sr. 603-P  
Raut, Deepa A. 118-OR, 1445-P  
Raval, Amit D. 1254-P  
Ravindran, Meera 2201-PUB  
Ravussin, Eric 1544-P  
Rawal, Shrishi 1434-P, 1437-P  
Ray, Phil 2157-P  
Ray, Kausik K. 330-OR  
Ray, Phil 2157-P  
Raymond, Jennifer 899-P, 890-P, 892-P, 1324-P, 1325-P  
Rayner, Brian L. 1066-P  
Raz, Itamar 636-P, 908-P, 1286-P  
Rauf, Abhay A., Sr. 603-P  
Raut, Deepa A. 118-OR, 1445-P  
Raval, Amit D. 1254-P  
Ravindran, Meera 2201-PUB  
Ravussin, Eric 1544-P  
Rawal, Shrishi 1434-P, 1437-P  
Ray, Andrew J. 829-P  
Ray, Phil 2157-P  
Raymond, Jennifer 899-P, 890-P, 892-P, 1324-P, 1325-P  
Rayner, Brian L. 1066-P  
Raz, Itamar 636-P, 908-P, 1286-P  
Rea, Silvia 1929-P
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rivers, Sydney L.</td>
<td>148-OR</td>
</tr>
<tr>
<td>Riz, Michela</td>
<td>72-OR</td>
</tr>
<tr>
<td>Rizza, Robert A.</td>
<td>1808-P, 1812-P, 1953-P</td>
</tr>
<tr>
<td>RJ, Nandini</td>
<td>335-OR</td>
</tr>
<tr>
<td>Rim, Manikandan</td>
<td>1204-P</td>
</tr>
<tr>
<td>Robacker, Maire</td>
<td>659-P</td>
</tr>
<tr>
<td>Roberson, Patricia N.E.</td>
<td>869-P, 870-P</td>
</tr>
<tr>
<td>Roberson, Robin</td>
<td>1979-P, 2017-P</td>
</tr>
<tr>
<td>Roberts, Bruce C.</td>
<td>984-P</td>
</tr>
<tr>
<td>Roberts, Carl A.</td>
<td>1163-P</td>
</tr>
<tr>
<td>Roberts, Michelle</td>
<td>1072-P, 1093-P</td>
</tr>
<tr>
<td>Robertson, Darren</td>
<td>78-OR, 79-OR, 1067-P, 1070-P</td>
</tr>
<tr>
<td>Robinson, Katie</td>
<td>663-P, 682-P</td>
</tr>
<tr>
<td>Robinson, Matthew M.</td>
<td>1932-P, 1934-P, 2243-PUB</td>
</tr>
<tr>
<td>Roby, Heather</td>
<td>747-P</td>
</tr>
<tr>
<td>Rocchio, Francesca</td>
<td>1231-P</td>
</tr>
<tr>
<td>Rockafellow, Stuart D.</td>
<td>700-P</td>
</tr>
<tr>
<td>Rodacki, Melanie</td>
<td>1025-P, 1112-P</td>
</tr>
<tr>
<td>Rodas Neira, Edgar I.</td>
<td>526-P</td>
</tr>
<tr>
<td>Roddieck, Alistair J.</td>
<td>427-P</td>
</tr>
<tr>
<td>Rodel, Rachel</td>
<td>1421-P</td>
</tr>
<tr>
<td>Rodger, Anthony</td>
<td>1483-P</td>
</tr>
<tr>
<td>Rock, Carlota</td>
<td>1454-P</td>
</tr>
<tr>
<td>Rodrigues, Ticiania</td>
<td>2255-PUB</td>
</tr>
<tr>
<td>Rodriguez Diaz, Rayner</td>
<td>190-OR, 197-OR</td>
</tr>
<tr>
<td>Rodriguez Grunert, Leonardo</td>
<td>1137-P</td>
</tr>
<tr>
<td>Rodriguez, Kellie M.</td>
<td>7-OR</td>
</tr>
<tr>
<td>Rodriguez-Gutierrez, Rene</td>
<td>1460-P</td>
</tr>
<tr>
<td>Roe, Cheryl A.</td>
<td>853-P</td>
</tr>
<tr>
<td>Roehrig, Karin</td>
<td>1845-P</td>
</tr>
<tr>
<td>Roell, William C.</td>
<td>37-OR</td>
</tr>
<tr>
<td>Roelofs, Karen J.</td>
<td>1962-P</td>
</tr>
<tr>
<td>Roem, Kerryn L.</td>
<td>986-P</td>
</tr>
<tr>
<td>Roep, Bart</td>
<td>138-OR</td>
</tr>
<tr>
<td>Rofey, Dana L.</td>
<td>843-P, 845-P</td>
</tr>
<tr>
<td>Rogers, Heather</td>
<td>2035-P</td>
</tr>
<tr>
<td>Rogers, Jillian C.</td>
<td>1766-P</td>
</tr>
<tr>
<td>Rogers, Mary A.M.</td>
<td>1261-P</td>
</tr>
<tr>
<td>Roh, Eun</td>
<td>464-P</td>
</tr>
<tr>
<td>Rohatgi, Anand</td>
<td>2064-P</td>
</tr>
<tr>
<td>Rohm, Theresa V.</td>
<td>283-OR, 2416-P</td>
</tr>
<tr>
<td>Rohrs, Henry III</td>
<td>1371-P</td>
</tr>
<tr>
<td>Roitman, Eytan</td>
<td>908-P</td>
</tr>
<tr>
<td>Rojas, Betsy L.</td>
<td>1823-P</td>
</tr>
<tr>
<td>Rokszin, György</td>
<td>2321-PUB</td>
</tr>
<tr>
<td>Rolandsson, Olov</td>
<td>771-P</td>
</tr>
<tr>
<td>Rolka, Deborah B.</td>
<td>3-OR, 173-OR, 1671-P</td>
</tr>
<tr>
<td>Roller, Shane</td>
<td>1997-P, 1998-P</td>
</tr>
<tr>
<td>Rollot, Melissa</td>
<td>2398-PUB</td>
</tr>
<tr>
<td>Romanelli, Robert</td>
<td>897-P</td>
</tr>
<tr>
<td>Romeres, Davide</td>
<td>45-OR</td>
</tr>
<tr>
<td>Romero, Maryellen</td>
<td>1474-P</td>
</tr>
<tr>
<td>Romero, Michael F.</td>
<td>2117-P</td>
</tr>
<tr>
<td>Romero-Ibarguengoitia, Maria Elena</td>
<td>658-P, 687-P</td>
</tr>
<tr>
<td>Romo-LeTourneau, Victoria J.</td>
<td>1258-P</td>
</tr>
<tr>
<td>Roncal-Jimenez, Carlos Alberto, Sr.</td>
<td>431-P</td>
</tr>
<tr>
<td>Rondeau, Philippe</td>
<td>2220-PUB</td>
</tr>
<tr>
<td>Rondinone, Cristina</td>
<td>79-OR, 1067-P, 1070-P</td>
</tr>
<tr>
<td>Røren, Femille F.</td>
<td>439-P</td>
</tr>
<tr>
<td>Ronney, Helle</td>
<td>689-P, 1431-P</td>
</tr>
<tr>
<td>Rooney, William</td>
<td>1407-P, 1408-P</td>
</tr>
<tr>
<td>Rorsman, Patrik</td>
<td>329-OR, 2431-P</td>
</tr>
<tr>
<td>Rosano, Caterina</td>
<td>1473-P</td>
</tr>
<tr>
<td>Rosário, Francisco, Sr.</td>
<td>721-P</td>
</tr>
<tr>
<td>Rosati, Milena M.</td>
<td>564-P</td>
</tr>
<tr>
<td>Rose, April</td>
<td>645-P</td>
</tr>
<tr>
<td>Rose, James J.</td>
<td>4-OR</td>
</tr>
<tr>
<td>Rose, Jennifer B.</td>
<td>821-P, 1184-P</td>
</tr>
<tr>
<td>Rose, Ludger</td>
<td>1000-P</td>
</tr>
<tr>
<td>Rosen, Evan</td>
<td>39-OR, 2430-P</td>
</tr>
<tr>
<td>Rosenbaum, Jennifer L.</td>
<td>12-OR, 927-P</td>
</tr>
<tr>
<td>Rosenberg, Carl</td>
<td>468-P, 489-P, 611-P, 1597-P</td>
</tr>
<tr>
<td>Rosenberg, Samuel</td>
<td>365-OR, 1802-P</td>
</tr>
<tr>
<td>Rosenkilde, Mette M.</td>
<td>145-OR</td>
</tr>
<tr>
<td>Rosenson, Robert S.</td>
<td>128-OR</td>
</tr>
<tr>
<td>Rosenthal, Norm</td>
<td>258-OR</td>
</tr>
<tr>
<td>Roskjaer, Ann B.</td>
<td>1424-P</td>
</tr>
<tr>
<td>Ross, James J.</td>
<td>1543-P</td>
</tr>
<tr>
<td>Ross-Degnan, Dennis</td>
<td>175-OR</td>
</tr>
<tr>
<td>Rossing, Peter</td>
<td>819-P</td>
</tr>
<tr>
<td>Rotem, Mina</td>
<td>665-P, 666-P</td>
</tr>
<tr>
<td>Roth, Kenneth D.</td>
<td>1847-P</td>
</tr>
<tr>
<td>Rothacker, Karen</td>
<td>730-P</td>
</tr>
<tr>
<td>Rothenberg, Gary M.</td>
<td>114-OR</td>
</tr>
<tr>
<td>Rother, Kristina</td>
<td>231-OR</td>
</tr>
<tr>
<td>Rothman, Douglas L.</td>
<td>204-OR, 2427-P</td>
</tr>
<tr>
<td>Roth-Schulze, Alexandra J.</td>
<td>230-OR</td>
</tr>
<tr>
<td>Rotman, Yaron</td>
<td>1146-P</td>
</tr>
<tr>
<td>Rotter, Jerome I.</td>
<td>2244-PUB</td>
</tr>
<tr>
<td>Rouse, Dwight</td>
<td>1427-P</td>
</tr>
<tr>
<td>Rousseau, Michel F.</td>
<td>614-P</td>
</tr>
<tr>
<td>Roussel, Roman</td>
<td>301-OR, 1029-P, 1032-P, 1036-P, 1056-P, 1057-P, 2220-PUB, 2221-PUB</td>
</tr>
<tr>
<td>Rousselle, Thomas</td>
<td>153-OR</td>
</tr>
<tr>
<td>Rowan, Lois M.</td>
<td>1288-P</td>
</tr>
<tr>
<td>Rowe, Glenn C.</td>
<td>2020-P</td>
</tr>
<tr>
<td>Rowland, Leslie</td>
<td>66-OR, 739-P, 758-P</td>
</tr>
<tr>
<td>Roy, Ambuj</td>
<td>2361-PUB</td>
</tr>
<tr>
<td>Roy, Anirban</td>
<td>206-OR, 969-P</td>
</tr>
<tr>
<td>Roy, Margaux</td>
<td>2210-PUB</td>
</tr>
<tr>
<td>Rozjabeck, Heather M.</td>
<td>1183-P</td>
</tr>
<tr>
<td>Ruan, Hai-Bin</td>
<td>83-OR, 1750-P</td>
</tr>
<tr>
<td>Ruan, Yue</td>
<td>350-OR</td>
</tr>
<tr>
<td>Rubenstein, Ronald C.</td>
<td>1820-P</td>
</tr>
<tr>
<td>Rubin, Alexa</td>
<td>2101-P</td>
</tr>
<tr>
<td>Rubin, Daniel J.</td>
<td>1078-P, 1292-P</td>
</tr>
<tr>
<td>Rubin, Gil</td>
<td>1076-P</td>
</tr>
<tr>
<td>Name</td>
<td>OR/Poster/Publication Only</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Rubin, Nathan</td>
<td>379-P</td>
</tr>
<tr>
<td>Rubino, Francesco</td>
<td>1900-P</td>
</tr>
<tr>
<td>Rubinstein, Debra</td>
<td>1415-P, 1630-P</td>
</tr>
<tr>
<td>Rubio, Miguel A.</td>
<td>1455-P</td>
</tr>
<tr>
<td>Rueda-Ochoa, Oscar L., Sr.</td>
<td>1495-P</td>
</tr>
<tr>
<td>Ruelas, Valerie F.</td>
<td>2227-PUB</td>
</tr>
<tr>
<td>Ruff, Dennis</td>
<td>1207-P</td>
</tr>
<tr>
<td>Rui, Liangyou</td>
<td>185-OR</td>
</tr>
<tr>
<td>Ruiz Quintero, Manuel</td>
<td>2407-PUB</td>
</tr>
<tr>
<td>Ruiz, Jorge G.</td>
<td>1468-P, 1470-P</td>
</tr>
<tr>
<td>Ruiz, Maria S.</td>
<td>645-P</td>
</tr>
<tr>
<td>Rumora, Amy</td>
<td>60-OR, 573-P</td>
</tr>
<tr>
<td>Ruppert, Kristine</td>
<td>253-OR, 656-P, 873-P</td>
</tr>
<tr>
<td>Ruscheinisky, Monika</td>
<td>1954-P</td>
</tr>
<tr>
<td>Rushakoff, Robert J.</td>
<td>400-OR, 728-P, 1303-P, 1304-P</td>
</tr>
<tr>
<td>Russell, David M.</td>
<td>1288-P</td>
</tr>
<tr>
<td>Russell, James</td>
<td>57-OR, 750-P</td>
</tr>
<tr>
<td>Russell, Steven J.</td>
<td>14-OR, 299-OR</td>
</tr>
<tr>
<td>Russell, William E.</td>
<td>233-OR</td>
</tr>
<tr>
<td>Russell-Jones, David</td>
<td>1028-P, 1048-P</td>
</tr>
<tr>
<td>Russ-Sellers, Rebecca</td>
<td>651-P</td>
</tr>
<tr>
<td>Rusu, Emilia</td>
<td>440-P</td>
</tr>
<tr>
<td>Rusu, Florin</td>
<td>440-P</td>
</tr>
<tr>
<td>Ruth, Katherine S.</td>
<td>23-OR</td>
</tr>
<tr>
<td>Rutkowski, Joanna</td>
<td>210-OR</td>
</tr>
<tr>
<td>Rutledge, Gia E.</td>
<td>648-P, 672-P, 695-P, 696-P</td>
</tr>
<tr>
<td>Rutter, Guy A.</td>
<td>325-OR, 1708-P</td>
</tr>
<tr>
<td>Rutter, Martin K.</td>
<td>176-OR</td>
</tr>
<tr>
<td>Rutters, Femke</td>
<td>106-OR</td>
</tr>
<tr>
<td>Ryan, Benjamin J.</td>
<td>745-P, 1758-P, 2048-P, 2078-P</td>
</tr>
<tr>
<td>Ryan, Bridget L.</td>
<td>377-P, 399-P</td>
</tr>
<tr>
<td>Ryan, Edmond A.</td>
<td>1461-P</td>
</tr>
<tr>
<td>Ryberg, Mats</td>
<td>1960-P</td>
</tr>
<tr>
<td>Rychel, Rikki L.</td>
<td>1285-P</td>
</tr>
<tr>
<td>Rydzon, Brett</td>
<td>141-OR</td>
</tr>
<tr>
<td>Ryu, Jiyoon</td>
<td>1982-P</td>
</tr>
<tr>
<td>S., Bindu</td>
<td>2213-PUB</td>
</tr>
<tr>
<td>S., Sandeep</td>
<td>879-P, 2293-PUB</td>
</tr>
<tr>
<td>S., Venkataraman</td>
<td>1204-P</td>
</tr>
<tr>
<td>Saad, Farid</td>
<td>125-OR, 1063-P</td>
</tr>
<tr>
<td>Saaddine, Jnan B.</td>
<td>681-P</td>
</tr>
<tr>
<td>Saadeh, Lina</td>
<td>1653-P</td>
</tr>
<tr>
<td>Sabatini, Paul</td>
<td>202-OR</td>
</tr>
<tr>
<td>Sabrina, Chiheb</td>
<td>2084-P</td>
</tr>
<tr>
<td>Sachdej, Rajkaran</td>
<td>214-OR, 881-P</td>
</tr>
<tr>
<td>Sacks, David B.</td>
<td>1504-P, 1621-P</td>
</tr>
<tr>
<td>Sacks, Jessica</td>
<td>157-OR, 1778-P</td>
</tr>
<tr>
<td>Sacks, Naomi C.</td>
<td>2273-PUB</td>
</tr>
<tr>
<td>Sadananda, K.S.</td>
<td>2361-PUB</td>
</tr>
<tr>
<td>Sadhu, Archana R.</td>
<td>1256-P</td>
</tr>
<tr>
<td>Sadikovic, Bekim</td>
<td>240-OR</td>
</tr>
<tr>
<td>Sadler, Jennifer R.</td>
<td>2428-PUB</td>
</tr>
<tr>
<td>Sadler, Lois S.</td>
<td>815-P</td>
</tr>
<tr>
<td>Sadowski, Thorsten</td>
<td>91-OR</td>
</tr>
<tr>
<td>Saeed, Diyar</td>
<td>284-OR</td>
</tr>
<tr>
<td>Saeed, Zeb L.</td>
<td>2177-PUB</td>
</tr>
<tr>
<td>Saeki, Akio</td>
<td>1110-P</td>
</tr>
<tr>
<td>Saeki, Kumiko</td>
<td>1749-P</td>
</tr>
<tr>
<td>Saenger, Amy K.</td>
<td>1886-P</td>
</tr>
<tr>
<td>Saez De Ibarra, Lourdes</td>
<td>2232-PUB</td>
</tr>
<tr>
<td>Safabakhsh, Said</td>
<td>1719-P</td>
</tr>
<tr>
<td>Safford, Monika</td>
<td>307-OR</td>
</tr>
<tr>
<td>Safran, Gabriel M.</td>
<td>1323-P</td>
</tr>
<tr>
<td>Safren, Steven</td>
<td>862-P</td>
</tr>
<tr>
<td>Saghatelian, Alan</td>
<td>1838-P</td>
</tr>
<tr>
<td>Sagiv, Tal</td>
<td>1286-P</td>
</tr>
<tr>
<td>Saha, Chandan K.</td>
<td>880-P</td>
</tr>
<tr>
<td>Sahajwalla, Chandrahas</td>
<td>1051-P</td>
</tr>
<tr>
<td>Sahay, Rakesh</td>
<td>127-OR, 1316-P</td>
</tr>
<tr>
<td>Sahin, Elif O.</td>
<td>1780-P</td>
</tr>
<tr>
<td>Sahoo, Abhay K.</td>
<td>1208-P</td>
</tr>
<tr>
<td>Saibil, Fred</td>
<td>1505-P, 1578-P, 1579-P</td>
</tr>
<tr>
<td>Saiki, Tomokazu</td>
<td>554-P</td>
</tr>
<tr>
<td>Saito, Isao</td>
<td>1720-P</td>
</tr>
<tr>
<td>Saito, Jun</td>
<td>1950-P</td>
</tr>
<tr>
<td>Saito, Kazumi</td>
<td>2368-PUB</td>
</tr>
<tr>
<td>Saito, Nobumichi</td>
<td>508-P</td>
</tr>
<tr>
<td>Saitoh, Shinichi</td>
<td>1716-P</td>
</tr>
<tr>
<td>Saiyed, Mahira</td>
<td>1205-P, 2214-PUB</td>
</tr>
<tr>
<td>Saja, Kamalamama</td>
<td>1748-P</td>
</tr>
<tr>
<td>Saji, Hideo</td>
<td>2124-P</td>
</tr>
<tr>
<td>Sajic, Marija</td>
<td>60-OR</td>
</tr>
<tr>
<td>Sakaguchi, Masaji</td>
<td>356-OR</td>
</tr>
<tr>
<td>Sakai, Juro</td>
<td>1133-P, 1153-P</td>
</tr>
<tr>
<td>Sakai, Ryosuke</td>
<td>762-P, 774-P, 850-P, 1180-P</td>
</tr>
<tr>
<td>Sakai, Takenori</td>
<td>415-P, 673-P</td>
</tr>
<tr>
<td>Sakai, Yuriko</td>
<td>1852-P</td>
</tr>
<tr>
<td>Sakamoto, Kenichi</td>
<td>257-OR</td>
</tr>
<tr>
<td>Sakamoto, Kentaro</td>
<td>602-P, 625-P, 2369-PUB</td>
</tr>
<tr>
<td>Sakamoto, Masaya</td>
<td>1177-P</td>
</tr>
<tr>
<td>Sakamoto, Rika</td>
<td>302-OR, 1002-P, 1664-P, 2393-PUB</td>
</tr>
<tr>
<td>Sakane, Naoki</td>
<td>674-P, 1892-P</td>
</tr>
<tr>
<td>Sakiko, Yoshida</td>
<td>1581-P, 1609-P</td>
</tr>
<tr>
<td>Sakkal, Saad</td>
<td>836-P, 1793-P, 2241-PUB, 2270-PUB, 2282-PUB</td>
</tr>
<tr>
<td>Sakoda, Hideyuki</td>
<td>804-P, 1775-P, 2385-PUB</td>
</tr>
<tr>
<td>Sakurai, Yoshitaka</td>
<td>486-P</td>
</tr>
<tr>
<td>Sakuramoto-Tsuchida, Sumiyo</td>
<td>472-P, 595-P</td>
</tr>
<tr>
<td>Sala, Arianna</td>
<td>363-OR</td>
</tr>
<tr>
<td>Salam, Maamoun</td>
<td>1699-P</td>
</tr>
<tr>
<td>Salama, Amr</td>
<td>2085-P</td>
</tr>
<tr>
<td>Salameh, Therese S.</td>
<td>2043-P</td>
</tr>
<tr>
<td>Salas, Andrew</td>
<td>48-OR</td>
</tr>
<tr>
<td>Salata, Rose A.</td>
<td>1279-P</td>
</tr>
<tr>
<td>Salaye, Lipika</td>
<td>1760-P, 1881-P</td>
</tr>
<tr>
<td>Salazar Hernandez, Mario A.</td>
<td>1983-P</td>
</tr>
</tbody>
</table>
Salciccioli, Louis 468-P, 489-P, 611-P, 1597-P
Saldiva, Paulo 223-OR
Saldivar-Rodriguez, Donato 1460-P
Saldivar-Salazar, Sergio 941-P
Saleh, Milena 916-P
Saleh, Mohamed 343-OR
Sales, Vicencia 1836-P
Salifu, Moro 468-P, 489-P, 611-P, 1597-P
Salimian, Mohammad 57-OR, 570-P
Saliu, Drilon 923-P
Salt, Geethu 685-P
Sanchez Rangel, Elizabeth 204-OR, 2145-P, 2427-PUB
Sanchez, Maria J. 1216-P
Sanchez, Ramiro A. 1216-P
Sancho-Bornez, Veronica 362-OR, 1791-P
Sanders, Joanne 1497-P
Sandre Banon, Dorian 1435-P
Saran, Robert 251-OR
Sang, Kazunori 547-P, 575-P
Sankey, Prasanth 798-P, 2376-PUB
Sanlioglu, Salih 1780-P
Santini, Ferruccio 362-OR, 1791-P
Santoni, Fred 1358-P
Santoro, Anna 1838-P
Santoro, Nicola 313-OR, 340-OR
Santos, Leticia B. 2365-PUB
Santos, Marcio 2211-PUB
Santos, Rosa F. 2095-P
Santosuosso, Ugo 1383-P, 2222-PUB
Sanyou, May 264-OR, 1379-P, 2353-PUB
Sara, Heather 1961-P
Sargin, Mehmet 1082-P
Sargis, Robert M. 1252-P, 2150-P
Sari, Carolina I. 1533-P
Sarma, P.V. Raghava 2361-PUB
Sarnowski, Chloé 1712-P
Sarria-Bourn, François 1817-P, 1858-P, 2000-P

Sartipy, Peter 1171-P
Sas, Kelli 241-OR, 491-P
Sasaki, Eun 1110-P
Sasaki, Hiroto 913-P, 2204-PUB
Sasaki, Kazuya 742-P
Sasaki, Masaya 775-P
Sasaki, Satoshi 787-P
Sasaki, Shugo 2125-P
Sasaki, Tamaki 89-OR
Sasaki, Tsutomu 1955-P
Sasaki, Yusuke 1133-P, 1153-P
Sasako, Takayoshi 359-OR
Sasaoka, Toshiyasu 1851-P, 1991-P, 2005-P
Sasidharan, Saranya 798-P, 2376-PUB
Sasikumar, Priyanka 798-P, 2376-PUB
Sassano, Caprice 1496-P
Satake, Eiichiro 88-OR
Satej, Niku 1638-P
Sathavarodom, Nattapol 790-P
Sato, Daisuke 1199-P
Sato, Junko 1905-P
Sato, Kyoko 1617-P, 1624-P
Sato, Satsuki 154-OR, 1903-P, 1906-P
Sato, Seisuke 2164-P
Sato, Shiori 680-P, 902-P, 2304-PUB
Sato, Teruko 661-P
Sato, Yuichi 1156-P
Sato, Hiroaki 1187-P, 1840-P, 1927-P
Sato, Jo 787-P
Sato, Kennichi 2127-P
Sato, Minoru 89-OR
Sato, Shinobu 1138-P
Sato, Yukihiro 766-P
Sattar, Naveed 40-OR, 42-OR, 291-OR, 1173-P, 1834-P
Sattali, Muniza M. 1108-P
Sauerwein, Tom J. 650-P, 816-P, 2069-P
Saul, Melissa 1275-P
Saulnier, Pierre 2220-PUB, 2221-PUB
Saunders, Diane C. 323-OR
Saunders, Magon M. 681-P
Sauriol, Luc 1052-P, 1786-P
Savchenko, Sergey 2055-P
Savopoulos, Christos 459-P
Savoye, Mary 1802-P
Sawada, Anamaria 1461-P
Sawada, Kaicho 508-P
Sawase, Kenji 543-P, 1610-P, 2205-PUB
Sawatani, Toshiaki 328-OR
Sawczyn, Tomasz 456-P
Sawhney, Sangeeta 212-OR, 1122-P, 1179-P
Saxena, Richa 176-OR
Saydah, Sharon 310-OR, 525-P, 1366-P
Sayegh, Fares 646-P
Saylor, Jennifer 896-P
Sayre, Tobias 660-P
Sencan, Mehmet 930-P
Senda, Mariko 422-P, 423-P
Sendaydiego, Anne M. 2229-PUB
Sendur, Suleyman 1053-P
Senesi, Pamela 1243-P, 2311-PUB
Senga, Yoko 1910-P
Senior, Emmanuelle 2338-PUB
Senior, Peter A. 138-OR, 139-OR, 143-OR, 213-OR, 1740-P
Senokuchi, Takafumi 1635-P
Seo, Arnold Y. 2007-P
Seo, Da Hea 527-P, 533-P
Seo, Dongju 365-P, 1802-P
Seo, Ji A. 2007-P
Seo, Kawoun 802-P
Seong, Jae Young 1800-P
Seow, CherngJye 834-P
Sepulveda, Luisa 1252-P
Serban, Carmen 1185-P
Seroussi, Cyril 1024-P, 1035-P
Serreze, Dave 320-OR
Shah, Baiju R. 56-OR, 91-OR
Shah, Hetal 56-P, 1652-P
Shah, Kakul 91-OR
Shah, Kartikeya 1875-P
Shah, Manasi S. 1771-P
Shah, Neeraj K. 19-OR, 1760-P
Shah, Rohit 85-P, 2163-P
Shah, Sanjiv 248-OR, 750-P, 866-P
Shah, Shaligram 2031-P
Shah, Vandana 1970-P
Sharp, Arielle 2467-PUB
Shavit, Oren 1297-P
Shaw, James A.M. 2166-P
Shaw, Jonathan E. 1533-P
Shaw, Wayne 1193-P, 1206-P
Shaw, James A.M. 2166-P
Shea, M. 2329-PUB
Shear, Grace E. 2428-PUB
Sheehan, Patricia R. 765-P
Shehadeh, Naim 235-OR
Sheikh, Saba 1820-P
Shehata, John P. 2330-PUB
Shelton, Josephine 1997-P
Shen, Biing-Jiu 641-P
Shen, Chen 634-P
Shen, Chia-Rui 293-PUB
Shen, Wei-Bin 228-OR, 229-OR, 2454-PUB
Shen, Yun 305-P, 426-P, 1433-P, 1576-P
Shen, Zheng 1875-P, 1883-P, 2441-PUB, 2442-PUB
Sheng, Hui 2062-P
Sheng, Tong 1055-P
Sheng, Yao 1759-P
Shepard, Jaclyn 894-P
Shepherd, John A. 1341-P

OR: Oral  P: Poster  PUB: Published Only
<table>
<thead>
<tr>
<th>Author</th>
<th>Pub Type</th>
<th>Pub Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shepherd, Renee</td>
<td>OR:</td>
<td>631-P</td>
</tr>
<tr>
<td>Sherr, Jennifer</td>
<td>OR:</td>
<td>207-OR, 1376-P, 1377-P</td>
</tr>
<tr>
<td>Sherratt, Samuel</td>
<td>P:</td>
<td>620-P</td>
</tr>
<tr>
<td>Sherwin, Robert</td>
<td>PUB:</td>
<td>204-OR, 365-OR, 1802-P, 2145-P, 2427-PUB</td>
</tr>
<tr>
<td>Sherwood, Jordan</td>
<td>OR:</td>
<td>299-OR</td>
</tr>
<tr>
<td>Shetty, Vinutha B.</td>
<td>P:</td>
<td>747-P</td>
</tr>
<tr>
<td>Sheu, Tzong-Jen</td>
<td>OR:</td>
<td>2126-P</td>
</tr>
<tr>
<td>Shi, Harry</td>
<td>PUB:</td>
<td>1129-P</td>
</tr>
<tr>
<td>Shi, Lizheng</td>
<td>OR:</td>
<td>701-P, 1565-P, 1576-P</td>
</tr>
<tr>
<td>Shi, Na</td>
<td>P:</td>
<td>1654-P</td>
</tr>
<tr>
<td>Shi, Ting Huai</td>
<td>OR:</td>
<td>1662-P</td>
</tr>
<tr>
<td>Shi, Xiajie</td>
<td>PUB:</td>
<td>1698-P</td>
</tr>
<tr>
<td>Shi, Xiaoyun</td>
<td>OR:</td>
<td>929-P, 2266-PUB, 2267-PUB, 2268-PUB, 2307-PUB</td>
</tr>
<tr>
<td>Shi, Yi</td>
<td>OR:</td>
<td>593-P</td>
</tr>
<tr>
<td>Shi, Yuguang</td>
<td>OR:</td>
<td>53-OR</td>
</tr>
<tr>
<td>Shi, Yundi</td>
<td>OR:</td>
<td>1236-P</td>
</tr>
<tr>
<td>Shiba, Kumiko</td>
<td>OR:</td>
<td>1993-P</td>
</tr>
<tr>
<td>Shiba, Teruo</td>
<td>OR:</td>
<td>602-P, 625-P, 2369-PUB</td>
</tr>
<tr>
<td>Shibata, Mikiko</td>
<td>OR:</td>
<td>1617-P, 1624-P</td>
</tr>
<tr>
<td>Shibata, Yuka</td>
<td>OR:</td>
<td>563-P, 565-P</td>
</tr>
<tr>
<td>Shigetou, Nobuyuki</td>
<td>OR:</td>
<td>2265-PUB</td>
</tr>
<tr>
<td>Shigiyama, Fumika</td>
<td>OR:</td>
<td>1848-P</td>
</tr>
<tr>
<td>Shih, Harry</td>
<td>OR:</td>
<td>725-P, 726-P</td>
</tr>
<tr>
<td>Shigeta, Kouichi</td>
<td>OR:</td>
<td>766-P</td>
</tr>
<tr>
<td>Shigetou, Nobuyuki</td>
<td>OR:</td>
<td>568-P</td>
</tr>
<tr>
<td>Shilun, Li</td>
<td>OR:</td>
<td>2146-P</td>
</tr>
<tr>
<td>Shimada, Akira</td>
<td>OR:</td>
<td>1735-P, 2412-PUB</td>
</tr>
<tr>
<td>Shimada, Fumio</td>
<td>OR:</td>
<td>257-OR</td>
</tr>
<tr>
<td>Shimizu, Tomoaki</td>
<td>OR:</td>
<td>928-P</td>
</tr>
<tr>
<td>Shimo, Naoki</td>
<td>OR:</td>
<td>2144-P</td>
</tr>
<tr>
<td>Shimoda, Masashi</td>
<td>OR:</td>
<td>2050-P, 2111-P</td>
</tr>
<tr>
<td>Shimoda, Masayuki</td>
<td>OR:</td>
<td>100-OR</td>
</tr>
<tr>
<td>Shimofusa, Ryota</td>
<td>OR:</td>
<td>257-OR</td>
</tr>
<tr>
<td>Shimokita, Eiuke</td>
<td>OR:</td>
<td>2102-P</td>
</tr>
<tr>
<td>Shimomura, Ichiro</td>
<td>OR:</td>
<td>1141-P, 1562-P, 1615-P, 1629-P, 2144-P</td>
</tr>
<tr>
<td>Shin, Jang Yel</td>
<td>OR:</td>
<td>2066-P</td>
</tr>
<tr>
<td>Shin, John</td>
<td>OR:</td>
<td>236-OR, 965-P</td>
</tr>
<tr>
<td>Shin, Kyung Cheul</td>
<td>OR:</td>
<td>1951-P</td>
</tr>
<tr>
<td>Shinde, Rituparna S.</td>
<td>OR:</td>
<td>2394-PUB</td>
</tr>
<tr>
<td>Shinde, Suresh N.</td>
<td>OR:</td>
<td>2394-PUB</td>
</tr>
<tr>
<td>Shinoda, Takeo</td>
<td>OR:</td>
<td>91-OR, 286-OR, 1585-P, 1589-P</td>
</tr>
<tr>
<td>Shinoda, Minori</td>
<td>OR:</td>
<td>302-OR, 1002-P, 1664-P, 2393-PUB</td>
</tr>
<tr>
<td>Shinozaki, Hiroyuki</td>
<td>OR:</td>
<td>2240-PUB</td>
</tr>
<tr>
<td>Shioda, Seiji</td>
<td>OR:</td>
<td>486-P</td>
</tr>
<tr>
<td>Shioi, Atsushi</td>
<td>OR:</td>
<td>422-P, 423-P, 443-P</td>
</tr>
<tr>
<td>Shiotani, Masaharu</td>
<td>OR:</td>
<td>2124-P</td>
</tr>
<tr>
<td>Shihabashi, Chieo</td>
<td>OR:</td>
<td>928-P</td>
</tr>
<tr>
<td>Shira, Tsukasa</td>
<td>OR:</td>
<td>2154-P</td>
</tr>
<tr>
<td>Shirokura, Takashi</td>
<td>OR:</td>
<td>804-P</td>
</tr>
<tr>
<td>Shira, Tetsuo</td>
<td>OR:</td>
<td>422-P, 423-P, 443-P, 2074-P, 2434-PUB</td>
</tr>
<tr>
<td>Shojima, Nobuhiro</td>
<td>OR:</td>
<td>1128-P, 1349-P</td>
</tr>
<tr>
<td>Shomali, Mansur</td>
<td>OR:</td>
<td>1317-P, 1320-P</td>
</tr>
<tr>
<td>Shon, Ho-Sang</td>
<td>OR:</td>
<td>177-OR</td>
</tr>
<tr>
<td>Shoo, Gray, Shanell</td>
<td>OR:</td>
<td>1904-P</td>
</tr>
<tr>
<td>Short, Kevin R.</td>
<td>OR:</td>
<td>1357-P</td>
</tr>
<tr>
<td>Shosho, Avi</td>
<td>OR:</td>
<td>1268-P</td>
</tr>
<tr>
<td>Shostak, Alena</td>
<td>OR:</td>
<td>323-OR</td>
</tr>
<tr>
<td>Shrestha, Archana</td>
<td>OR:</td>
<td>709-P</td>
</tr>
<tr>
<td>Shrestha, Deepika</td>
<td>OR:</td>
<td>18-OR</td>
</tr>
<tr>
<td>Shrestha, Rupendra T.</td>
<td>OR:</td>
<td>1023-P</td>
</tr>
<tr>
<td>Shrestha, Shreyo</td>
<td>OR:</td>
<td>1526-P</td>
</tr>
<tr>
<td>Shrestha, Shrihari</td>
<td>OR:</td>
<td>86-OR</td>
</tr>
<tr>
<td>Shrestha, Sundar</td>
<td>OR:</td>
<td>1276-P, 1277-P</td>
</tr>
<tr>
<td>Shrimanker, Rupal</td>
<td>OR:</td>
<td>1013-P</td>
</tr>
<tr>
<td>Shrestha, Tetsuo</td>
<td>OR:</td>
<td>254-OR, 1766-P</td>
</tr>
<tr>
<td>Shultz, Leonard D.</td>
<td>OR:</td>
<td>323-OR</td>
</tr>
<tr>
<td>Shy, Zeenat A.</td>
<td>OR:</td>
<td>327-OR, 2158-P</td>
</tr>
<tr>
<td>Shian, Alexandra</td>
<td>OR:</td>
<td>2098-P, 2406-PUB</td>
</tr>
<tr>
<td>Shiu, Evan</td>
<td>OR:</td>
<td>616-P</td>
</tr>
<tr>
<td>Siddiqui, Ferhan S.</td>
<td>OR:</td>
<td>492-P</td>
</tr>
<tr>
<td>Siddiqui, Muhammad S.</td>
<td>OR:</td>
<td>124-OR, 1077-P</td>
</tr>
<tr>
<td>Siddiqui, Samreen</td>
<td>OR:</td>
<td>2377-PUB, 2417-PUB</td>
</tr>
<tr>
<td>Siddiqui, Tariq</td>
<td>OR:</td>
<td>1295-P</td>
</tr>
<tr>
<td>Sidebottom, Abbey</td>
<td>OR:</td>
<td>764-P</td>
</tr>
<tr>
<td>Sieber, Jochen</td>
<td>OR:</td>
<td>916-P, 1048-P, 1050-P</td>
</tr>
<tr>
<td>Siegel, Dionicio</td>
<td>OR:</td>
<td>1838-P</td>
</tr>
<tr>
<td>Siegel, Karen R.</td>
<td>OR:</td>
<td>1245-P</td>
</tr>
<tr>
<td>Siegel-Axel, Dorothea I.</td>
<td>OR:</td>
<td>1819-P</td>
</tr>
<tr>
<td>Siegmund, Thorsten</td>
<td>OR:</td>
<td>1014-P</td>
</tr>
<tr>
<td>Sieradzan, Ray</td>
<td>OR:</td>
<td>2273-PUB</td>
</tr>
<tr>
<td>Sillah, Arthur</td>
<td>OR:</td>
<td>764-P</td>
</tr>
<tr>
<td>Silva, Amélia M.</td>
<td>OR:</td>
<td>46-OR</td>
</tr>
<tr>
<td>Silva, Carla P.</td>
<td>OR:</td>
<td>2192-PUB</td>
</tr>
<tr>
<td>Silva, Isis T.</td>
<td>OR:</td>
<td>2380-PUB</td>
</tr>
<tr>
<td>Silva, Jairton V.</td>
<td>OR:</td>
<td>628-P</td>
</tr>
<tr>
<td>Silva, Maria Elizabeth R.</td>
<td>OR:</td>
<td>221-OR</td>
</tr>
<tr>
<td>Silva-Tinoco, Rubén</td>
<td>OR:</td>
<td>658-P, 687-P</td>
</tr>
<tr>
<td>Silveira, Mônica S.V.M.</td>
<td>OR:</td>
<td>873-P</td>
</tr>
</tbody>
</table>
Silver, Bahendeka K. 1511-P
Silver, Heidi J. 1439-P
Silver, Robert J. 1084-P
Silverman, Robert 1323-P
Silvius, Bianca 106-OR
Simard, Jean-Christophe 503-P, 1817-P, 1858-P
Simeone, Christopher A. 88-OR
Simjak, Patrik 1412-P, 1413-P
Simmons, David 392-P, 1416-P, 1515-P
Simmons, Kimber 1500-P, 1690-P
Simmons, Rebecca A. 55-OR, 1363-P
Simms, MaryJane 657-P
Simó, Rafael 608-P
Simon, Marie-Christine 773-P
Simons, Gudrun 1346-P
Simonsen, Lene 144-OR
Simonson, Donald C. 810-P, 905-P, 941-P, 1520-P, 1833-P
Simó-Servat, Olga 608-P
Sink, John H. II 988-P, 989-P, 990-P
Sink, Sandy T. 1881-P
Sippl, Rachel M. 460-P, 1496-P
Sirota, Valentina B. 2223-PUB
Skandari, Reza 1324-P
Skinner, Allie J. 199-OR
Skinner, Timothy C. 813-P
Skomorovska-Prokvolit, Yelenna 226-OR
Skoutas, Dimitrios 646-P
Skram, Edira 1502-P
Skrine, Jeffers, Kia 168-OR
Sklric, Stanko 1790-P
Skupien, Jan K. 88-OR
Skyler, Jay S. 232-OR, 1693-P
Slee, April 1191-P, 1193-P, 1206-P, 1210-P
Slipp, Brittany A. 1824-P
Sloop, Kyle W. 355-OR
Slofer, Robert H. 1255-P, 1389-P
Slyne, Christine 380-P, 405-P, 826-P, 921-P, 959-P
Smagala, Agnes 933-P
Smalls, Brittany L. 1479-P
Smart, Carmel E. 1368-P
Smiles, Adam 88-OR
Smiley-Byrd, Dawn 1818-P
Smith, Bryce 696-P, 1277-P
Smith, Caren 21-OR
Smith, Clifton W. 2037-P
Smith, Courtney J. 2040-P
Smith, Elizabeth 1689-P
Smith, Emma L. 1733-P
Smith, Genevieve E. 355-OR
Smith, Grant J. 730-P, 747-P
Smith, Hannah G. 218-OR
Smith, Jane Lea 1055-P
Smith, Kenneth 60-OR
Smith, Laura 2332-PUB
Smith, Marta S. 347-OR, 447-P, 460-P, 520-P, 1017-P, 1496-P, 1601-P
Smith‑Johnston, Kelley 1978-P
Snîtker, Soren 1295-P
So, Kawai 64-OR
Soares, Andrew 2094-P
Soares, Marina O. 1112-P
Sobngwi, Eugène 626-P, 1040-P, 1127-P
Sochet, Etienne B. 517-P, 538-P
Söderberg, Stefan 1533-P
Soderborg, Taylor K. 222-OR
Soeda, Kotaro 359-OR
Soffer, Joseph 1073-P
Sofogianni, Areti 459-P
Softic, Damir 274-OR
Sogawa, Yuji 89-OR
Sokhatska, Oksana 1975-P
Sokolov, Victor 1174-P
Solano, Francis X., Jr. 253-OR, 656-P
Solar, Chelsey 804-P, 867-P, 886-P
Sole, Claudette 2316-PUB
Soler, Robin 1277-P
Soleymani, Sadaf 920-P

OR: Oral  P: Poster  PUB: Published Only
Soliz, Peter 586-P
Somaratne, Ransi 128-OR
Someya, Yuki 1512-P, 1854-P, 1905-P, 1914-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Sonabend, Rona 1257-P, 1321-P, 1529-P
Song, Jianxun J. 321-OR
Song, Joongyu D. 254-OR
Song, Lili 1741-P
Song, Mun-Gyu 1800-P
Song, Yang 1487-P
Song, Yiqing 1437-P, 1475-P
Song, Youngshin 802-P
Song, Zijiao 2199-PUB
Soni, Divya 2361-PUB
Sonoda, Noriyuki 478-P, 2372-PUB
Soon, Wayne 747-P
Soota, Kirti, Jr. 462-P
Sorabji, Delna 821-P
Sorelli, Michele 451-P
Sorensen, Charlotte M. 144-OR
Sorensen, Christopher J. 632-P, 640-P, 2242-PUB
Sørensen, Pernille H. 1969-P
Sorice, Gian Pio 1830-P, 1971-P
Soroka, Orysya 403-P
Sorlini, N. 144-OR
Sourial, Nadia 1372-P
Sourij, Caren 2086-P
Souto, Debora L. 1112-P
Sowers, James 664-P
Spadafranca, Angela 292-OR
Sparling, David 1764-P
Sparr, Roxy 403-P
Sposino, Andrea C. 873-P
Spree, Joachim 2030-P
Sprague, Marlan L. 2418-PUB
Sprung, Victoria S. 1163-P
Spyropoulos, Jelena 2215-PUB
Srivastava, Brijesh K. 1194-P
Srivastava, Ved 1997-P, 1998-P
Srivijitkamol, Apiradee 1008-P
Srivulovic, Einar 665-P, 666-P
St Clair, Rory 985-P
Staab, Erin M. 8-OR
Stabler, C. 27-OR, 31-OR
Stach, Elisabeth 1941-P
Stacy, John 1389-P
Stadlbauer, Vanessa 2086-P
Stafford, Jeanette M. 1366-P
Staiger, Harald 20-OR, 1717-P
Staimetz, Lisa R. 868-P, 1501-P, 1530-P, 1682-P
Stallworth, Angela 252-OR
Stamatakis, Katherine 694-P
Stamatoiou, Alexandra V. 1334-P
Stancak, Andrej 1163-P
Stancil, Michelle D. 651-P
Standley, Melissa 658-P
Standley, Robert 1907-P, 1936-P
Stanescu, Diana E. 2131-P
Stanford, Kristin I. 64-OR
Stanford, Stephanie 2421-PUB
Stanley, Charles A. 2131-P
Stanley, Sarah 1807-P
Stanley, Wayne G. 705-P
Stanzel, Stefanie 101-OR
Staiger, Robert 1210-P
Startseva, Elena 438-P
Staten, Myrlene A. 765-P
Steinemesser, Lars 518-P
Steck, Andrea 182-OR, 1500-P, 1521-P, 1687-P, 1690-P
Steele, Andrew 1210-P
Steer, Robert A. 225-OR
Stefan, Norbert 20-OR, 295-OR, 342-OR
Stefanovski, Darko 1525-P, 1818-P
Steffen, Brian 1552-P, 1560-P
Steffen, Lyn M. 1560-P
Steffes, Michael 1688-P
Stegmann, Helen Vanya Biering Kjaer 438-P
Steigleder-Schweiger, Claudia 2065-P
Stein, Garry M. 290-OR, 921-P
Stein, Howard R. 664-P
Stein, Michal 235-OR
Stein, Thomas P. 225-OR
Steinberg, John 111-OR
Steine, Solrun J. 1824-P
Steiner, John 311-OR
Stekelenburg, Caroline 1358-P
Stekovic, Slaven 1821-P
Stella, Peter 301-OR, 1049-P
Stempieniewicz, Nikita 1499-P
Stene, Lars C. 136-OR
Stenov, Vibeke 2235-PUB
Stensen, Signe 145-OR
Stenov, Vibeke 2235-PUB
Stinov, Vibeke 2235-PUB
Stilova, Gabriela 424-P
Stoehr, Oliver 212-OR, 1122-P, 1179-P
Stoeckel, Boris 2309-PUB
Stroek, Dout 524-P
Stroeven, Peter 237-PUB
Sum, Chee Fang 1198-P
Sun, Bing 834-P
Sun, Dianjianyi 121-OR, 297-OR, 1555-P, 1580-P
Sun, Gao 421-P, 1121-P, 1728-P, 2195-PUB
Sun, Hang 779-P
Sun, Jennifer 244-OR, 245-OR, 1367-P
Sun, Juan 2103-P
Sun, Lingdong 643-P
Sun, Lucy 2180-PUB
Sun, Min 265-P
Sun, Ran 1275-P
Strom, Alexander 63-OR, 579-P, 2054-P
Stumpf, Paul 212-OR, 1122-P, 1179-P
Strunk, Dirk 2309-PUB
Struthers, Allan D. 167-OR, 256-OR, 1238-P
Stryczer, Lisa A. 797-P
Stryker, Matthew D. 2290-PUB
Strzok, Sara 2338-PUB
Stuart, Bruce C. 1259-P
Stuchlik, Patrick 1474-P
Stuckey, Heather L. 221-OR, 812-P
Stuhr, Andreas 692-P
Stumvoll, Michael W. 1067-P, 1070-P
Sturt, Jackie A. 221-OR
Stylopoulos, Nicholas 366-OR
Su, Gong 200-OR, 203-OR
Su, Kai 2443-PUB
Su, Maxwell 810-P, 941-P, 1520-P
Su, Wen 1871-P
Suarez Beitrán, Pablo A. 187-OR
Subbarayan, Sreevidya K. 1223-P
Subramanian, Savitha 2329-PUB
Sudhirsen, Kowlessur 1533-P
Suerken, Cynthia 525-P
Suttsugu, Mariko 2240-PUB
Suga, Takayoshi 1955-P
Suganami, Hideshi 1152-P, 1154-P, 1156-P, 1176-P
Suganuma, Akiko 674-P, 1892-P
Sugawara, Akira 1832-P
Sugaya, Yoshiyuki 1840-P
Sugi, Shigeki 280-OR
Sugimoto, Daisuke 1512-P, 1854-P, 1905-P, 1914-P
Sugimoto, Danny 1092-P
Susino, Masakazu 1110-P
Sugisawa, Chikoh 1950-P
Sujit, Jatuporn 1721-P
Suki, Sujin 779-P
Sukkarieh-Haraty, Ola 655-P, 683-P
Suleiman, Mara 1223-P
Sulikowski, Michal G. 1789-P
Sumner, Anne E. 1621-P, 1837-P, 1842-P, 1893-P
Sun, Bing 834-P
Sun, Dianjianyi 121-OR, 297-OR, 1555-P, 1580-P
Sun, Gao 421-P, 1121-P, 1728-P, 2195-PUB
Sun, Hang 779-P
Sun, Jennifer 244-OR, 245-OR, 1367-P
Sun, Juan 2103-P
Sun, Lingdong 643-P
Sun, Lucy 2180-PUB
Sun, Min 265-OR
Sun, Ran 1275-P
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun, Rongxin</td>
<td>2129-P</td>
</tr>
<tr>
<td>Sun, Siqi</td>
<td>2062-P</td>
</tr>
<tr>
<td>Sun, Taoping</td>
<td>1672-P</td>
</tr>
<tr>
<td>Sun, Wuping</td>
<td>783-P, 1607-P</td>
</tr>
<tr>
<td>Sun, Xiao Jian</td>
<td>159-OR</td>
</tr>
<tr>
<td>Sun, Yongning</td>
<td>1995-P, 2451-PUB</td>
</tr>
<tr>
<td>Sun, Yuxiang</td>
<td>2442-PUB</td>
</tr>
<tr>
<td>Sun, Zhongjie</td>
<td>1772-P</td>
</tr>
<tr>
<td>Sundar, Rajesh</td>
<td>1194-P</td>
</tr>
<tr>
<td>Sundaram, Natarajan</td>
<td>603-P</td>
</tr>
<tr>
<td>Sundbom, Magnus</td>
<td>1756-P</td>
</tr>
<tr>
<td>Sundstrom, Jeffrey M.</td>
<td>608-P</td>
</tr>
<tr>
<td>Sung, Byung-Jun</td>
<td>196-OR</td>
</tr>
<tr>
<td>Sung, Els</td>
<td>649-P</td>
</tr>
<tr>
<td>Sung, Ji-Hee</td>
<td>708-P</td>
</tr>
<tr>
<td>Sung, Nishanth</td>
<td>1846-P</td>
</tr>
<tr>
<td>Suppli, Malte R.</td>
<td>147-OR</td>
</tr>
<tr>
<td>Suraci, Concetta</td>
<td>916-P</td>
</tr>
<tr>
<td>Surmont, Filip</td>
<td>1141-P, 1562-P, 1615-P, 1629-P</td>
</tr>
<tr>
<td>Sunina, Zoya</td>
<td>577-P</td>
</tr>
<tr>
<td>Suruga, Kohei</td>
<td>2253-PUB</td>
</tr>
<tr>
<td>Suscha, Emily</td>
<td>1518-P, 2370-PUB</td>
</tr>
<tr>
<td>Susztak, Katalin</td>
<td>88-OR</td>
</tr>
<tr>
<td>Sutanto, Surya S.</td>
<td>1923-P</td>
</tr>
<tr>
<td>Suthar, Akashkumar G.</td>
<td>2070-P</td>
</tr>
<tr>
<td>Sutherland, Melanie W.</td>
<td>308-OR</td>
</tr>
<tr>
<td>Suyuan, Wang</td>
<td>2186-PUB</td>
</tr>
<tr>
<td>Suzuki, Akihiko</td>
<td>1950-P</td>
</tr>
<tr>
<td>Suzuki, Atsushi</td>
<td>539-P</td>
</tr>
<tr>
<td>Suzuki, Hikari</td>
<td>808-P</td>
</tr>
<tr>
<td>Suzuki, Hiroshi</td>
<td>594-P</td>
</tr>
<tr>
<td>Suzuki, Jinya</td>
<td>154-OR, 1903-P, 1906-P</td>
</tr>
<tr>
<td>Suzuki, Jun</td>
<td>302-OR, 1002-P, 1664-P, 2393-PUB</td>
</tr>
<tr>
<td>Suzuki, Katsunori</td>
<td>2263-PUB</td>
</tr>
<tr>
<td>Suzuki, Luka</td>
<td>1400-P, 2125-P, 2128-P</td>
</tr>
<tr>
<td>Suzuki, Reiko</td>
<td>529-P, 2102-P</td>
</tr>
<tr>
<td>Suzuki, Ruriko</td>
<td>1512-P, 1854-P, 1905-P, 1914-P</td>
</tr>
<tr>
<td>Suzuki, Ryo</td>
<td>2385-PUB</td>
</tr>
<tr>
<td>Suzuki, Yoshiyuki</td>
<td>782-P, 1118-P</td>
</tr>
<tr>
<td>Suzuki, Yuta</td>
<td>736-P</td>
</tr>
<tr>
<td>Svane, Maria S.</td>
<td>1885-P, 1956-P, 2059-P</td>
</tr>
<tr>
<td>Svehlikova, Eva</td>
<td>1941-P, 2086-P</td>
</tr>
<tr>
<td>Svensson, Ann-Marie</td>
<td>131-OR</td>
</tr>
<tr>
<td>Svensson, Michael B.</td>
<td>1960-P</td>
</tr>
<tr>
<td>Swain, Richard S.</td>
<td>352-OR</td>
</tr>
<tr>
<td>Swartzentuber, Jenifer</td>
<td>670-P</td>
</tr>
<tr>
<td>Sweeney, Michael</td>
<td>1136-P</td>
</tr>
<tr>
<td>Syed, Ismail</td>
<td>1838-P</td>
</tr>
<tr>
<td>Szablowski, Carrie J.</td>
<td>1518-P, 2370-PUB</td>
</tr>
<tr>
<td>Szentgyorgyi, Eva M.</td>
<td>1550-P, 1578-P, 1579-P</td>
</tr>
<tr>
<td>Szopa, Magdalena</td>
<td>895-P</td>
</tr>
<tr>
<td>Szerwinski, Nina</td>
<td>897-P</td>
</tr>
<tr>
<td>Szymanska-Garbacz, Elektra</td>
<td>2379-PUB</td>
</tr>
<tr>
<td>Ta, Albert</td>
<td>152-OR, 496-P, 1768-P</td>
</tr>
<tr>
<td>Tabak, Rachel G.</td>
<td>694-P</td>
</tr>
<tr>
<td>Tabara, Yasuhiro</td>
<td>1720-P</td>
</tr>
<tr>
<td>Tabbey, Maegan A.</td>
<td>569-P</td>
</tr>
<tr>
<td>Tabor, Ann</td>
<td>689-P</td>
</tr>
<tr>
<td>Tack, Cornelis</td>
<td>106-OR, 438-P</td>
</tr>
<tr>
<td>Tadedese, Abdisa S.</td>
<td>1023-P</td>
</tr>
<tr>
<td>Tagami, Motoki</td>
<td>625-P</td>
</tr>
<tr>
<td>Taguchi, Koichiro</td>
<td>2002-P</td>
</tr>
<tr>
<td>Tahara, Yumiko</td>
<td>1101-P</td>
</tr>
<tr>
<td>Tahrin, Bettina</td>
<td>2079-P</td>
</tr>
<tr>
<td>Tajima, Naoko</td>
<td>562-P, 787-P, 1224-P</td>
</tr>
<tr>
<td>Tajiri, Yuji</td>
<td>1164-P</td>
</tr>
<tr>
<td>Takács, Róbert</td>
<td>1092-P</td>
</tr>
<tr>
<td>Takagi, Masatoshi</td>
<td>766-P</td>
</tr>
<tr>
<td>Takagi, Satoshi</td>
<td>1700-P</td>
</tr>
<tr>
<td>Takagi, Susumu</td>
<td>500-P</td>
</tr>
<tr>
<td>Takagi, Tokyo</td>
<td>1833-P</td>
</tr>
<tr>
<td>Takahashi, Diana L.</td>
<td>2136-P</td>
</tr>
<tr>
<td>Takahashi, Harumi</td>
<td>2156-P</td>
</tr>
<tr>
<td>Takahashi, Hirokazu</td>
<td>742-P</td>
</tr>
<tr>
<td>Takahashi, Hiroshi</td>
<td>915-P, 1018-P, 1134-P, 2269-PUB</td>
</tr>
<tr>
<td>Takahashi, Jiro</td>
<td>766-P</td>
</tr>
<tr>
<td>Takahashi, Kaoru</td>
<td>674-P, 1892-P</td>
</tr>
<tr>
<td>Takahashi, Kazuhiisa</td>
<td>549-P, 575-P, 1831-P, 2132-P</td>
</tr>
<tr>
<td>Takahashi, Kenichiro</td>
<td>302-OR, 1002-P, 1664-P, 2393-PU</td>
</tr>
<tr>
<td>Takahashi, Kiwamu</td>
<td>1716-P</td>
</tr>
<tr>
<td>Takahashi, Kiyohiko</td>
<td>1862-P</td>
</tr>
<tr>
<td>Takahashi, Masaya</td>
<td>1400-P, 2128-P</td>
</tr>
<tr>
<td>Takahashi, Nobuyuki</td>
<td>100-OR, 1940-P</td>
</tr>
<tr>
<td>Takahashi, Sadao</td>
<td>1903-P</td>
</tr>
<tr>
<td>Takahashi, Sho</td>
<td>257-OR</td>
</tr>
<tr>
<td>Takahashi, Tomomi</td>
<td>673-P</td>
</tr>
<tr>
<td>Takakado, Miki</td>
<td>1528-P, 1720-P</td>
</tr>
<tr>
<td>Takakura, Minaka</td>
<td>1349-P</td>
</tr>
<tr>
<td>Takamine, Hikaru</td>
<td>913-P, 2204-PUB, 2286-PUB</td>
</tr>
<tr>
<td>Takamoto, Iseki</td>
<td>486-P, 2012-P</td>
</tr>
<tr>
<td>Takamura, Toshinari</td>
<td>1152-P</td>
</tr>
<tr>
<td>Takano, Koji</td>
<td>535-P</td>
</tr>
<tr>
<td>Takano, Yuya</td>
<td>913-P, 2204-PUB, 2286-PUB</td>
</tr>
<tr>
<td>Takasawa, Shin</td>
<td>472-P, 595-P</td>
</tr>
<tr>
<td>Takashi, Yuiichi</td>
<td>2102-P</td>
</tr>
<tr>
<td>Takata, Shinjiro</td>
<td>1861-P</td>
</tr>
<tr>
<td>Takata, Yasunori</td>
<td>1528-P, 1720-P</td>
</tr>
<tr>
<td>Takayanagi, Naoko</td>
<td>928-P</td>
</tr>
<tr>
<td>Takebayashi, Kozho</td>
<td>2240-PUB</td>
</tr>
<tr>
<td>Takebe, Satomi</td>
<td>2144-P</td>
</tr>
<tr>
<td>Takeda, Ryouko</td>
<td>736-P</td>
</tr>
<tr>
<td>Takeda, Satoru</td>
<td>1400-P</td>
</tr>
<tr>
<td>Takeda, Shinichi</td>
<td>1910-P</td>
</tr>
<tr>
<td>Takeda, Yasunaga</td>
<td>781-P</td>
</tr>
<tr>
<td>Takeda, Yusuke</td>
<td>476-P, 498-P</td>
</tr>
<tr>
<td>Takeishi, Soichi</td>
<td>1003-P</td>
</tr>
<tr>
<td>Takekoshi, Shido</td>
<td>1003-P</td>
</tr>
<tr>
<td>Takemoto, Minoru</td>
<td>257-OR, 2355-PUB</td>
</tr>
<tr>
<td>Takeno, Kageumi</td>
<td>1512-P, 1854-P, 1905-P, 1914-P</td>
</tr>
<tr>
<td>Taki, Iman</td>
<td>1690-P</td>
</tr>
<tr>
<td>Taki, Kentaro</td>
<td>1224-P</td>
</tr>
</tbody>
</table>
Takiguchi, Tomoko 1950-P
Takikawa, Ineko 529-P
Takiyama, Yumi 90-OR
Takizawa, Toshiaki 1133-P
Taku, Kanako 850-P
Talbot, Octavious 1429-P
Taleb, Amir 667-P
Tam, Charmaine 746-P, 1923-P
Tam, Wing H. 116-OR
Tamaki, Motoyuki 529-P, 2102-P
Tami, Abigail 1820-P
Tan, Alvin Wai Kit 367-OR
Tan, Angeline H.Y. 279-OR
Tan, Florence 2057-P
Tan, Hiangkiat (Jason) 1287-P
Tan, Janet S. 834-P
Tan, Rongshao 613-P
Tan, Xiao 1675-P
Tanabe, Katsuya 2105-P
Tanaka, Akira 1505-P
Tanaka, Kenichi 742-P
Tanaka, Shigeho 775-P
Tanaka, Shou 615-P
Tanaka, Tomoko 255-OR, 1227-P, 1957-P, 1958-P
Tanaka, Yoshihiko 1133-P, 1153-P
Tanaka, Toshiya 1118-P
Tanizawa, Mika 915-P, 2269-PUB
Tanizawa, Yukio 2105-P
Tan, Yi 1750-P
Tang, Wei 237-OR
Tang, Patrick Y. 718-P
Tang, Tricia S. 221-OR, 801-P
Tang, Wei, Sr. 1598-P
Tang, Weifeng 1170-P, 1174-P, 1190-P
Tang, Wenjun 624-P
Tang, Xin 419-P, 834-P
Tang, Yaling 56-OR
Tangelloju, Srikanth 1668-P
Tangjaoenpa, Yanin 1836-P
Tangjittipokin, Watip 1721-P
Tangkitikasem, Naithakan 627-P
Tangren, Jessica S. 1440-P
Tanai, Hisanori 415-P, 673-P
Tanigawa, Takeshi 1720-P
Taniguchi, Satoshi 529-P
Taniguchi, Yukiko 2308-PUB
Tanithara, Fuminori 2102-P
Tanino, Fumihito 1118-P
Tanizawa, Mika 915-P, 2269-PUB
Tanizawa, Yukio 2105-P
Tao, Anh 1736-P, 1923-P
Tao, Rongya 184-OR, 1873-P
Tapi, German 136-OR
Tarasenko, Lisa 1132-P
Tardivo, Stefano 2359-PUB
Tarnow, Lise 105-OR, 638-P
Taskaeva, Lilia 511-P, 2055-P
Taskiran, Bengur 2234-PUB
Tate, Donna 198-OR
Tatsuno, Ichiro 615-P
Tatsuoka, Hisato 2306-PUB
Taufeule, Paul V. 1884-P
Tann, Jawahar L. 1640-P
Tavakoli, Mitra 555-P, 580-P
Taveras, Elsie M. 137-OR
Taylor, Christopher A. 763-P
Taylor, Jessica L. 1757-P, 2014-P
Taylor, Roy 40-OR, 42-OR, 291-OR, 1834-P
Taylor, Stephanie D. 2273-PUB
Tchernof, Andre 150-OR
Teague, April M. 1401-P, 1411-P
Teare, Julian P. 2097-P
Tedeschi, Anna 2222-PUB
Tedla, Fasika 486-P, 489-P, 611-P, 1597-P
Teede, Helena 1612-P
Teich, Trevor 394-P
Teixeira, Cassiano 768-P
Tekola-Ayele, Fasil 18-OR, 1434-P
Telega, Grzegorz 1289-P
Tel, Vaishali 1165-P, 1513-P, 1516-P
Temple, Karla A. 1643-P, 1644-P
Templin, Andrew T. 82-OR, 2107-P
Temprano, Marcellina 1472-P, 1574-P
Teng, Sophie 305-OR
Teunagels, Norbert 1861-P
Tenouasse, Sylvie 946-P, 947-P
Tentolouris, Nikolaos 997-P, 1014-P, 1028-P, 1048-P
Teo, Edmund P. 809-P
Teoh, Hwee 330-OR
Terada, Kazuo 2253-PUB
Terada, Yoshio 1673-P

OR: Oral, P: Poster, PUB: Published Only
<table>
<thead>
<tr>
<th>Tonneijck, Lennart</th>
<th>1060-P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonolo, Giancarlo</td>
<td>599-P, 993-P</td>
</tr>
<tr>
<td>Topor, Lisa S.</td>
<td>1378-P</td>
</tr>
<tr>
<td>Torjman, Marc C.</td>
<td>980-P</td>
</tr>
<tr>
<td>Torky, Ahmed</td>
<td>1353-P</td>
</tr>
<tr>
<td>Tortone, Elisabetta</td>
<td>1457-P</td>
</tr>
<tr>
<td>Toro, Alliyson</td>
<td>242-OR, 607-P</td>
</tr>
<tr>
<td>Tosaki, Takahiro</td>
<td>680-P, 902-P, 2304-PUB</td>
</tr>
<tr>
<td>Toscano, Marco</td>
<td>2088-P, 2345-PUB</td>
</tr>
<tr>
<td>Toschi, Elena</td>
<td>62-OR, 380-P, 405-P, 921-P, 931-P, 959-P</td>
</tr>
<tr>
<td>Toshima, Masahiro</td>
<td>766-P</td>
</tr>
<tr>
<td>Toth, Peter P.</td>
<td>332-OR, 416-P, 1679-P</td>
</tr>
<tr>
<td>Totomirova, Tzvetelina</td>
<td>954-P, 2378-PUB</td>
</tr>
<tr>
<td>Touaty, Colette E.</td>
<td>636-P</td>
</tr>
<tr>
<td>Tourkmani, Ayla</td>
<td>559-P, 2458-PUB</td>
</tr>
<tr>
<td>Touyz, Rhian M.</td>
<td>505-P</td>
</tr>
<tr>
<td>Tov, Naveh</td>
<td>235-OR</td>
</tr>
<tr>
<td>Townsend, Raymond</td>
<td>2121-P</td>
</tr>
<tr>
<td>Townsend, Shannon E.</td>
<td>1082-P</td>
</tr>
<tr>
<td>Toshima, Masahiro</td>
<td>766-P</td>
</tr>
<tr>
<td>Trouva, Anastasia</td>
<td>1436-P</td>
</tr>
<tr>
<td>Trouvas, Dimitris</td>
<td>1436-P</td>
</tr>
<tr>
<td>Trucco, Massimo</td>
<td>30-OR</td>
</tr>
<tr>
<td>True, Mark W.</td>
<td>816-P</td>
</tr>
<tr>
<td>Truong, Nguyen</td>
<td>2018-P</td>
</tr>
<tr>
<td>Tryggestad, Jeanie B.</td>
<td>268-OR, 1411-P</td>
</tr>
<tr>
<td>Ts, Boochandran</td>
<td>1204-P</td>
</tr>
<tr>
<td>Tsai, Andy</td>
<td>936-P</td>
</tr>
<tr>
<td>Tsai, Lan-Feng</td>
<td>78-OR, 79-OR, 1067-P, 1070-P</td>
</tr>
<tr>
<td>Tsai, Michael Y.</td>
<td>1437-P, 1462-P, 1552-P, 1560-P</td>
</tr>
<tr>
<td>Tsai, Pai-Jong</td>
<td>1404-P</td>
</tr>
<tr>
<td>Tsai, Tsung-Huang</td>
<td>2036-P, 2429-PUB</td>
</tr>
<tr>
<td>Tsarova, Tatiana</td>
<td>922-P</td>
</tr>
<tr>
<td>Tsatsoulis, Agathocles</td>
<td>2410-PUB</td>
</tr>
<tr>
<td>Tsay, John</td>
<td>88-OR</td>
</tr>
<tr>
<td>Tscherter, Otto</td>
<td>364-OR</td>
</tr>
<tr>
<td>Tse, Hubert M.</td>
<td>29-OR</td>
</tr>
<tr>
<td>Tse, Josephine M.</td>
<td>517-P, 520-P, 538-P, 600-P</td>
</tr>
<tr>
<td>Tsegka, Katerina G.</td>
<td>545-P, 1237-P, 1305-P</td>
</tr>
<tr>
<td>Tseng, Chihong</td>
<td>168-OR</td>
</tr>
<tr>
<td>Tseng, Chin-Hsiao</td>
<td>1622-P</td>
</tr>
<tr>
<td>Tseng, Chin-Lin</td>
<td>403-P</td>
</tr>
<tr>
<td>Tseng, Yu-Hua</td>
<td>38-OR, 46-OR, 273-OR, 277-OR, 286-OR, 1765-P, 2022-P</td>
</tr>
<tr>
<td>Tsiki, Joanna</td>
<td>219-OR</td>
</tr>
<tr>
<td>Tsimihodimos, Vasilios</td>
<td>485-P</td>
</tr>
<tr>
<td>Tsimikas, Alexia</td>
<td>2326-PUB</td>
</tr>
<tr>
<td>Tsomos, Effie</td>
<td>488-P, 541-P</td>
</tr>
<tr>
<td>Tsoukas, Michael</td>
<td>210-OR, 1193-P</td>
</tr>
<tr>
<td>Tsuibo, Hiroki</td>
<td>1003-P</td>
</tr>
<tr>
<td>Tsuchiya, Kyochiro</td>
<td>1993-P</td>
</tr>
<tr>
<td>Tsuchiya, Takafuli</td>
<td>2240-PUB</td>
</tr>
<tr>
<td>Tsuda, Kinsuke</td>
<td>878-P</td>
</tr>
<tr>
<td>Tsui, Emma K.</td>
<td>1678-P</td>
</tr>
<tr>
<td>Tsukihara, Laura</td>
<td>1136-P</td>
</tr>
<tr>
<td>Tsujikawa, Hiroki</td>
<td>595-P</td>
</tr>
<tr>
<td>Tsuneoka, Youko</td>
<td>1484-P</td>
</tr>
<tr>
<td>Tsunoda, Tatsuhiko</td>
<td>1349-P</td>
</tr>
<tr>
<td>Tsutsumi, Yuya</td>
<td>1950-P</td>
</tr>
<tr>
<td>Tsutsumi, Chiharu</td>
<td>100-OR</td>
</tr>
<tr>
<td>Tsutsumi, Shuichi</td>
<td>270-OR</td>
</tr>
<tr>
<td>Tsuzura, Reika</td>
<td>2208-PUB</td>
</tr>
<tr>
<td>Tubbs, Emily</td>
<td>81-OR</td>
</tr>
<tr>
<td>Tuccinardi, Dario</td>
<td>716-P, 2094-P</td>
</tr>
<tr>
<td>Tucker, Katherine L.</td>
<td>1596-P</td>
</tr>
<tr>
<td>Tufro, Alda</td>
<td>526-P</td>
</tr>
<tr>
<td>Tuke, Marcus</td>
<td>23-OR</td>
</tr>
<tr>
<td>Tullier, Mary A.</td>
<td>1357-P</td>
</tr>
<tr>
<td>Tumurbaatar, Batbayar</td>
<td>1410-P</td>
</tr>
<tr>
<td>Tumyan, Anna</td>
<td>124-OR, 1077-P</td>
</tr>
<tr>
<td>Tuomi, Lisa L.</td>
<td>601-P</td>
</tr>
<tr>
<td>Tuomi, Tiina</td>
<td>1537-P</td>
</tr>
<tr>
<td>Tuomilehto, Jaakko</td>
<td>1533-P</td>
</tr>
<tr>
<td>Tura, Andrea</td>
<td>294-OR, 2057-P</td>
</tr>
<tr>
<td>Turchin, Alexander</td>
<td>1520-P, 2101-P</td>
</tr>
<tr>
<td>Turco, Salvatore</td>
<td>993-P</td>
</tr>
<tr>
<td>Turcotte, Eric E.</td>
<td>150-OR</td>
</tr>
</tbody>
</table>

**ABSTRACT AUTHOR INDEX**
Turk, Norman 168-OR
Turka, Joanne F. 702-P
Turki, Yassir 686-P
Turley, Christine B. 1253-P
Tutkunkardas, Deniz 391-P
Tuttle, Edward 1331-P
Tuttle, Katherine R. 1066-P
Tuvdendorj, Demidmaa R. 1410-P
Uchida, Daigaku 257-OR
Uchida, Takayasu 418-P
Uchigata, Yasuko 1700-P, 2208-PUB
Uddin, Fareed 2395-PUB
Uff, Mikael 377-P
Uñasco-Cantero, Álvaro 302-P
Umezawa, Tomohiro 1897-P
Umezawa, Yutaka 143-P
Umezu, Junko 673-P
Umezu, Yuko 424-P
Umezuka, Hisato 963-P
Umekwe, Nkiru A. 2296-PUB
Umezu, Masahiko 873-P
Umekawa, Tatsuya 1916-P
Umezawa, Naoko 256-P
Umezawa, Shinobu 1540-P
Unanue, Emil R. 95-OR
Unterseite, Christian 721-P
Unger, Jeff 1082-P
Un, Joon-Ho 289-P
Unai, Angel 1611-P
Unbehaun, Alexander 1486-P
Unbehaun, Martin 1546-P
Unbehaun, Thierry 1486-P
Underkofler, Chantal 1182-P
Upadhyay, Laxmi 448-P, 541-P
Upala, Sikarin 1684-P
Uppal, Vikas 1362-P
Uppal, Vipul 1362-P
Uppal, Vikas 1362-P
Uppal, Vikas 1362-P
Urakaze, Masaharu 766-P
Urano, Fumihiko 269-OR, 2112-P, 2114-P
Urbina, Elaine M. 441-P
Url, Jasmin 1821-P, 2086-P, 2309-PUB
Urrutia, Maria A. 1070-P, 1237-P
Ushigome, Emi 774-P
Ushiki, Takashi 547-P
Uste, Alejandro 2158-P
Usategui, Ana 1294-P
Usen, Linda 1093-P
Usui, Isao 360-OR, 1749-P, 1849-P, 1990-P
Usui, Ryota 2306-PUB
Ut, Anjusha 574-P, 2209-PUB
Utsunomiya, Kazunori 476-P, 498-P, 543-P, 915-P,
1018-P, 1134-P, 1177-P, 1224-P, 1610-P, 2205-PUB,
2269-PUB
Utumatiwishima, Jean N. 1503-P
Utzschneider, Kristina 1643-P, 1644-P, 1661-P, 1811-P,
1813-P, 1822-P
Uwaili, Gabriel 2296-PUB
Uzoigwe-Smith, Chioma 684-P
Vaccarino, Fernando 2131-PUB
Vacher, Véronique 1001-P
Vaccioni, Marco 764-P
Vadhera, Aisha 1256-P
Vahel, Maria 586-P
Vaidya, Dhananjay 306-OR
Vajda, Eric G. 73-OR, 1117-P
Vajravelu, Mary Ellen 1498-P
Vakharia, Janaki D. 1378-P
Valderramos, Martin, Sr. 371-OR
Valencia, Willy Marcos 1468-P, 1470-P
Valensi, Paul 1435-P, 2084-P, 2189-PUB
Valente, Angelica M.M. 2360-PUB
Valentino, Joe 71-OR, 1809-P, 1922-P
Valenzuela, Evana 1546-P
Valenzuela, Jessica M. 219-OR, 1396-P
Vallés, Michael 250-OR, 2235-PUB
van Baar, Annieke C.G. 1137-P
van Cauter, Eve 1643-P, 1644-P
Van Dessel, Kristof P.S. 1540-P
van Dyke, Thomas E. 1585-P
van Gaal, Luc 1093-P, 1206-P, 1540-P
van Gemert, Theresa 773-P, 822-P
van Hall, Gerrit 295-OR, 1885-P
van Hinsbergh, Victor W.M. 68-OR
van Horn, Linda 119-OR
Van Houten, Holly 381-P, 1652-P
van Kimmenade, Roland 1526-P
van Meijel, Lian 106-OR
van Pelt, Michael 633-P
VanPelt, Michael D. 633-P
<table>
<thead>
<tr>
<th>Author</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vantyghem, Marie-Christine</td>
<td>2143-P</td>
</tr>
<tr>
<td>VanWormer, Jeffrey</td>
<td>764-P</td>
</tr>
<tr>
<td>Varatharajah, Sharlini</td>
<td>60-OR</td>
</tr>
<tr>
<td>Vardarajan, Badri N.</td>
<td>1709-P</td>
</tr>
<tr>
<td>Varghese, Mita</td>
<td>282-OR, 2021-P</td>
</tr>
<tr>
<td>Varma, Sanskriti</td>
<td>2468-PUB</td>
</tr>
<tr>
<td>Varming, Annemarie R.</td>
<td>875-P</td>
</tr>
<tr>
<td>Varsavsky, Andrea</td>
<td>936-P</td>
</tr>
<tr>
<td>Varshney, Arushi</td>
<td>1706-P</td>
</tr>
<tr>
<td>Varthakavi, Premkta K.</td>
<td>1316-P</td>
</tr>
<tr>
<td>Vasconcelos, Izabella T.</td>
<td>2192-PUB</td>
</tr>
<tr>
<td>Vasey, Joe</td>
<td>2285-PUB</td>
</tr>
<tr>
<td>Vasquez, Diego A., Sr.</td>
<td>2185-PUB</td>
</tr>
<tr>
<td>Vassilopoulos, Areti</td>
<td>219-OR</td>
</tr>
<tr>
<td>Vassy, Jason L.</td>
<td>868-P</td>
</tr>
<tr>
<td>Vasunilashorn, Sarinnapha</td>
<td>2363-PUB</td>
</tr>
<tr>
<td>Vatner, Daniel F.</td>
<td>149-OR, 1766-P</td>
</tr>
<tr>
<td>Vatner, Dorothy E.</td>
<td>757-P</td>
</tr>
<tr>
<td>Vatner, Stephen F.</td>
<td>757-P</td>
</tr>
<tr>
<td>Vaz, Cherie Lisa</td>
<td>2070-P</td>
</tr>
<tr>
<td>Vazeou, Andriani</td>
<td>312-OR, 401-P, 545-P, 1078-P, 1237-P, 1587-P, 1818-P</td>
</tr>
<tr>
<td>Vega, Gloria L.</td>
<td>2064-P</td>
</tr>
<tr>
<td>Vega, Rick B.</td>
<td>1907-P</td>
</tr>
<tr>
<td>Velasco, Kelly M.</td>
<td>1824-P</td>
</tr>
<tr>
<td>Velayoudom Cephise, Fritz-Line</td>
<td>450-P</td>
</tr>
<tr>
<td>Velayutham, Vallimayil</td>
<td>542-P</td>
</tr>
<tr>
<td>Velazquez, Julieta</td>
<td>943-P</td>
</tr>
<tr>
<td>Veleba, Jiri</td>
<td>465-P</td>
</tr>
<tr>
<td>Velebova, Katerina</td>
<td>465-P</td>
</tr>
<tr>
<td>Velho, Gilberto</td>
<td>2220-PUB, 2221-PUB</td>
</tr>
<tr>
<td>Vella, Adrian</td>
<td>1808-P, 1812-P, 1953-P</td>
</tr>
<tr>
<td>Vellanki, Priyathamia</td>
<td>312-OR, 401-P, 545-P, 1078-P, 1237-P, 1587-P, 1818-P</td>
</tr>
<tr>
<td>Venditti, Elizabeth M.</td>
<td>134-OR</td>
</tr>
<tr>
<td>Vera Lorenti, Fanny E.</td>
<td>526-P</td>
</tr>
<tr>
<td>Veras, Mariana</td>
<td>223-OR</td>
</tr>
<tr>
<td>Verbeeten, Kate</td>
<td>1372-P</td>
</tr>
<tr>
<td>Verbovoy, Andrey F.</td>
<td>1131-P</td>
</tr>
<tr>
<td>Vercruysse, Frank</td>
<td>1191-P</td>
</tr>
<tr>
<td>Vergara, Ariana</td>
<td>1846-P</td>
</tr>
<tr>
<td>Verier, Odile</td>
<td>933-P</td>
</tr>
<tr>
<td>Verma, Ritu</td>
<td>1498-P</td>
</tr>
<tr>
<td>Vernon, Ashley H.</td>
<td>1833-P</td>
</tr>
<tr>
<td>Veron, Delma</td>
<td>526-P</td>
</tr>
<tr>
<td>Veron, Dolores</td>
<td>526-P</td>
</tr>
<tr>
<td>Verrijken, An</td>
<td>1540-P</td>
</tr>
<tr>
<td>Vesco, Kimberly</td>
<td>1407-P, 1408-P</td>
</tr>
<tr>
<td>Vespasiani, Giacomo</td>
<td>916-P</td>
</tr>
<tr>
<td>Vestgaard, Marianne</td>
<td>1431-P, 1452-P</td>
</tr>
<tr>
<td>Vestri, Catherine S.</td>
<td>1978-P</td>
</tr>
<tr>
<td>Vettere, Amedeo</td>
<td>49-OR</td>
</tr>
<tr>
<td>Veves, Aristidis</td>
<td>647-P</td>
</tr>
<tr>
<td>Vezina, Anick</td>
<td>2346-PUB</td>
</tr>
<tr>
<td>Vidal, Josep</td>
<td>1095-P</td>
</tr>
<tr>
<td>Vieira de Abreu, Adriana</td>
<td>104-OR, 393-P</td>
</tr>
<tr>
<td>Vienneau, Todd</td>
<td>65-OR</td>
</tr>
<tr>
<td>Vierra, Nicholas C.</td>
<td>2172-P</td>
</tr>
<tr>
<td>Vigers, Tim B.</td>
<td>1521-P, 1531-P</td>
</tr>
<tr>
<td>Vigersky, Robert</td>
<td>920-P, 953-P</td>
</tr>
<tr>
<td>Vignolo, Paulina</td>
<td>1137-P</td>
</tr>
<tr>
<td>Vijayakumar, Pavithra</td>
<td>2-OR</td>
</tr>
<tr>
<td>Vilches-Flores, Alfonso</td>
<td>2173-P</td>
</tr>
<tr>
<td>Vilhelmsen, Monica</td>
<td>1352-P</td>
</tr>
<tr>
<td>Viljoen, Adie</td>
<td>1083-P</td>
</tr>
<tr>
<td>Villarreal, Jose A.</td>
<td>1460-P</td>
</tr>
<tr>
<td>Villarreal-Ponce, Alvaro</td>
<td>634-P, 644-P</td>
</tr>
<tr>
<td>Villegas, Guillermo A.</td>
<td>526-P</td>
</tr>
<tr>
<td>Vincent, Kelly P.</td>
<td>1716-P</td>
</tr>
<tr>
<td>Vincent, Lauren</td>
<td>1315-P</td>
</tr>
<tr>
<td>Vinik, Aaron I.</td>
<td>58-OR</td>
</tr>
<tr>
<td>Vintila, Madalina</td>
<td>2410-PUB</td>
</tr>
<tr>
<td>Violante, Rafael</td>
<td>1206-P</td>
</tr>
<tr>
<td>Virella, Gabriel</td>
<td>430-P</td>
</tr>
<tr>
<td>Viroslav, Hannah L.</td>
<td>1381-P</td>
</tr>
<tr>
<td>Virostko, Jack</td>
<td>233-OR</td>
</tr>
<tr>
<td>Visentin, Roberto</td>
<td>72-OR</td>
</tr>
<tr>
<td>Vishweswaramurthy, Ashwini</td>
<td>346-OR, 979-P</td>
</tr>
<tr>
<td>Viswanathan, Lavenya</td>
<td>1078-P</td>
</tr>
<tr>
<td>Viswanathan, Vijay</td>
<td>1316-P, 2207-PUB</td>
</tr>
<tr>
<td>Vittori, Alessandro</td>
<td>1383-P, 2222-PUB</td>
</tr>
<tr>
<td>Vlasakova, Zuzana</td>
<td>1974-P, 2449-PUB</td>
</tr>
<tr>
<td>Vlcek, Miroslav</td>
<td>2082-P</td>
</tr>
<tr>
<td>Vlychou, Marianna</td>
<td>1592-P</td>
</tr>
<tr>
<td>Vogeli, Jo M.</td>
<td>882-P, 885-P, 887-P</td>
</tr>
<tr>
<td>Vogler, Noah</td>
<td>1702-P</td>
</tr>
<tr>
<td>Vogt, Kyle R.</td>
<td>48-OR</td>
</tr>
<tr>
<td>Vojtišková, Alžběta</td>
<td>1747-P</td>
</tr>
<tr>
<td>Volek, Jeff</td>
<td>293-OR</td>
</tr>
<tr>
<td>Vollmer, Sebastian</td>
<td>1511-P</td>
</tr>
<tr>
<td>Vomund, Anthony N.</td>
<td>95-OR</td>
</tr>
<tr>
<td>von Eynatten, Maximilian</td>
<td>524-P, 1346-P</td>
</tr>
<tr>
<td>Vonberg, Andrew D.</td>
<td>318-OR</td>
</tr>
<tr>
<td>Voortman, Trudy</td>
<td>1480-P, 1495-P</td>
</tr>
<tr>
<td>Vora, Jiten</td>
<td>1582-P</td>
</tr>
<tr>
<td>Vorobyev, Sergey V.</td>
<td>1242-P</td>
</tr>
<tr>
<td>Vrazic, Hvoje</td>
<td>1273-P</td>
</tr>
<tr>
<td>Vs, Shivaram</td>
<td>723-P, 884-P, 1059-P</td>
</tr>
<tr>
<td>Vu, Giang</td>
<td>1688-P</td>
</tr>
<tr>
<td>Vu, Huyen T.</td>
<td>1481-P</td>
</tr>
<tr>
<td>Vu, Thuy D.</td>
<td>2179-PUB</td>
</tr>
<tr>
<td>Vukelic, Katarina</td>
<td>2287-PUB</td>
</tr>
<tr>
<td>Vukojecic, Valentina</td>
<td>2278-PUB</td>
</tr>
<tr>
<td>Vupputuri, Suma</td>
<td>1124-P, 1259-P</td>
</tr>
</tbody>
</table>
Vyzantiadis, Timoleon-Achilleas 2447-PUB
Wada, Jun 33-OR
Wada, Nobuhiro 486-P
Wada, Tsutomu 1851-P, 1991-P, 2005-P
Wada, Yoshiharu 1178-P
Wadley, Glenn D. 789-P
Wadwa, R. Paul 234-OR, 1255-P, 1373-P, 1389-P
Waghdhare, Swati 2377-PUB, 2417-PUB
Wagle, Sonali S. 1418-P
Wagmüller, Moritz 295-OR
Wagner, Ana B. 64-OR, 758-P
Wagner, Bridget 49-OR
Wagner, David V. 214-OR, 805-P, 881-P
Wagner, Julie 216-OR
Wagner, Michael 2028-P, 805-P, 881-P
Wagner, Michael J. 56-OR
Wagner, Nicole 387-P
Wagner, Robert 364-OR, 1717-P, 1819-P, 1867-P
Wahab, Abdul 2085-P
Wahl, Matthew 856-P
Wahlqvist, Peter 978-P
Wainstein, Julio, Sr. 908-P
Waise, T.M. Zaved 1948-P
Walkey, Helen C. 1696-P
Wallace, Jamie 175-OR
Wallace, Jane 692-P, 924-P, 925-P
Wallia, Amisha 1125-P
Wallston, Kenneth 825-P
Walter, Laura 1403-P
Walter, Mary 1713-P, 1814-P
Walter, Peter J. 1837-P
Walters, Elliot 111-OR
Walton, Christopher 2071-P
Walus-Miarka, Malgorzata 2217-PUB
Wambach, Jennifer A. 269-OR
Wan, Jing 531-P
Wan, Wen 8-OR, 1324-P
Wan, Xuesi 1044-P, 1045-P
Wanders, Desiree 2031-P
Wang, Baile 2027-P
Wang, Bing 945-P
Wang, Changjiang 1069-P
Wang, Chaofan 1301-P
Wang, Chen 1850-P
Wang, Chih-Hao 46-OR, 273-OR, 356-OR, 2022-P
Wang, Chunmei 1796-P
Wang, Chunqing 34-OR
Wang, Dan 17-OR
Wang, Di 1236-P
Wang, Feng 1069-P
Wang, Guang 429-P
Wang, Guoxiao 274-OR
Wang, Heqiong 545-P, 1078-P
Wang, Hongdong 457-P, 1727-P
Wang, Hongjun 1741-P, 2113-P
Wang, Hongwei 2461-PUB
Wang, Huajie 1794-P
Wang, Jing 151-OR, 247-OR, 1345-P, 1433-P, 1895-P
Wang, Jingjing 1741-P, 2113-P
Wang, Jingya 1442-P
Wang, Jinping 130-OR, 1654-P
Wang, Jiun-Jie 26-OR
Wang, Jiun-Ling 1614-P
Wang, Kai 471-P
Wang, Leishen 1345-P, 1433-P
Wang, Li 1144-P, 1291-P
Wang, Linghao 1232-P, 1233-P
Wang, Na 1162-P
Wang, Nan 2432-PUB
Wang, Nasui 367-OR
Wang, Nian 1240-P
Wang, Ningjian 1602-P, 1996-P
Wang, Paul 55-OR
Wang, Peili 1086-P
Wang, Peng 1433-P
Wang, Ping H. 152-OR, 496-P, 1768-P
Wang, Qiang 1672-P
Wang, Qinghua 1750-P
Wang, Richard 138-OR
Wang, Tongtong 1618-P, 1628-P, 2381-PUB
Wang, Wei 1310-P, 1312-P, 1313-P
Wang, Xiaoli 1121-P
Wang, Xiaolin 1856-P
Wang, Xing 97-OR, 532-P
Wang, Xingchun 2058-P, 2060-P, 2067-P, 2068-P, 2455-PUB, 2457-PUB
<table>
<thead>
<tr>
<th>Name</th>
<th>OR/Poster/PUB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang, Xinhui</td>
<td>117-OR, 227-OR, 344-OR</td>
</tr>
<tr>
<td>Wang, Xinxiao</td>
<td>2419-PUB</td>
</tr>
<tr>
<td>Wang, Xinrui</td>
<td>278-OR</td>
</tr>
<tr>
<td>Wang, Xuanchun</td>
<td>278-OR</td>
</tr>
<tr>
<td>Wang, Ya-Di</td>
<td>2004-P</td>
</tr>
<tr>
<td>Wang, Yan</td>
<td>331-OR</td>
</tr>
<tr>
<td>Wang, Yanfei</td>
<td>1698-P</td>
</tr>
<tr>
<td>Wang, Yanjun</td>
<td>501-P</td>
</tr>
<tr>
<td>Wang, Yanru</td>
<td>779-P, 2413-PUB</td>
</tr>
<tr>
<td>Wang, Yao</td>
<td>2249-PUB</td>
</tr>
<tr>
<td>Wang, Yixin</td>
<td>421-P, 1121-P, 1728-P, 2195-PUB</td>
</tr>
<tr>
<td>Wang, You</td>
<td>643-P</td>
</tr>
<tr>
<td>Wang, Yu</td>
<td>1894-P</td>
</tr>
<tr>
<td>Wang, Yuanping</td>
<td>35-OR</td>
</tr>
<tr>
<td>Wang, Yueshu</td>
<td>97-OR</td>
</tr>
<tr>
<td>Wang, Yufan</td>
<td></td>
</tr>
<tr>
<td>Warden, Christoph</td>
<td>524-P</td>
</tr>
<tr>
<td>Ward, Glenn</td>
<td>986-P</td>
</tr>
<tr>
<td>Ward, Peter A.</td>
<td>1737-P</td>
</tr>
<tr>
<td>Wardelmann, Kristina</td>
<td>1801-P</td>
</tr>
<tr>
<td>Wardian, Jana L.</td>
<td>650-P, 816-P, 1268-P, 2069-P</td>
</tr>
<tr>
<td>Warner, Jay L.</td>
<td>978-P</td>
</tr>
<tr>
<td>Warnick, Jennifer</td>
<td>846-P, 847-P</td>
</tr>
<tr>
<td>Warrier, Rohit</td>
<td>389-P</td>
</tr>
<tr>
<td>Warters, Martin</td>
<td>688-P, 1022-P</td>
</tr>
<tr>
<td>Waseda, Naoko</td>
<td>1187-P</td>
</tr>
<tr>
<td>Washington, Kellie</td>
<td>1114-P</td>
</tr>
<tr>
<td>Wasiak, Sylwia</td>
<td>1136-P</td>
</tr>
<tr>
<td>Wasserfall, Clive</td>
<td>1543-P, 1967-P</td>
</tr>
<tr>
<td>Wasserman, Rachel M.</td>
<td>217-OR</td>
</tr>
<tr>
<td>Wassermann, Karsten</td>
<td>347-OR</td>
</tr>
<tr>
<td>Watanabe, Ai</td>
<td>495-P</td>
</tr>
<tr>
<td>Watanabe, Chizuru</td>
<td>782-P</td>
</tr>
<tr>
<td>Watanabe, Eri</td>
<td>1991-P, 2005-P</td>
</tr>
<tr>
<td>Watanabe, Kazuhsa</td>
<td>1994-P</td>
</tr>
<tr>
<td>Watanabe, Naoko</td>
<td>2080-P</td>
</tr>
<tr>
<td>Watanabe, Takao</td>
<td>1666-P</td>
</tr>
<tr>
<td>Watarai, Atsuko</td>
<td>562-P, 565-P</td>
</tr>
<tr>
<td>Watson, David A.</td>
<td>1370-P, 1384-P, 1387-P, 1388-P</td>
</tr>
<tr>
<td>Watson, Karol</td>
<td>1574-P</td>
</tr>
<tr>
<td>Watson, Nina</td>
<td>650-P</td>
</tr>
<tr>
<td>Watt, Gordon P.</td>
<td>2391-PUB</td>
</tr>
<tr>
<td>Watts, Sharon A.</td>
<td>1285-P</td>
</tr>
<tr>
<td>Waugh, Kathleen</td>
<td>136-OR, 182-OR</td>
</tr>
<tr>
<td>Way, James</td>
<td>1997-P, 1998-P</td>
</tr>
<tr>
<td>Way, Kimberley L.</td>
<td>743-P</td>
</tr>
<tr>
<td>Weatherly, Jake</td>
<td>907-P</td>
</tr>
<tr>
<td>Weaver, Jessica R.</td>
<td>58-OR</td>
</tr>
<tr>
<td>Weaver, Rita</td>
<td>1078-P</td>
</tr>
<tr>
<td>Weber, David R.</td>
<td>1498-P</td>
</tr>
<tr>
<td>Weber, Katharina S.</td>
<td>822-P</td>
</tr>
<tr>
<td>Weber, Sarah R.</td>
<td>608-P</td>
</tr>
<tr>
<td>Wedekind, Lauren E.</td>
<td>1713-P</td>
</tr>
<tr>
<td>Weedon, Michael N.</td>
<td>23-OR, 264-OR</td>
</tr>
<tr>
<td>Wegner, Daniel J.</td>
<td>269-OR</td>
</tr>
<tr>
<td>Wehbe, Mohamed</td>
<td>985-P</td>
</tr>
<tr>
<td>Wei, Cheryl</td>
<td>1181-P</td>
</tr>
<tr>
<td>Wei, Jingkai</td>
<td>1682-P</td>
</tr>
<tr>
<td>Wei, Qiao</td>
<td>1121-P</td>
</tr>
<tr>
<td>Wei, Shuguang</td>
<td>1777-P</td>
</tr>
<tr>
<td>Weigensberg, Marc</td>
<td>1393-P</td>
</tr>
<tr>
<td>Weigert, Cora</td>
<td>1856-P, 1867-P</td>
</tr>
<tr>
<td>Weihrauch-Blüher, Susann</td>
<td>1355-P</td>
</tr>
<tr>
<td>Weil, Henry F.</td>
<td>218-OR</td>
</tr>
<tr>
<td>Weinger, Katie</td>
<td>826-P</td>
</tr>
<tr>
<td>Weir, Natalie L.</td>
<td>1552-P, 1560-P</td>
</tr>
<tr>
<td>Weir-McCall, Jonathan</td>
<td>1238-P</td>
</tr>
<tr>
<td>Weisman, Alanna</td>
<td>10-OR, 517-P, 520-P, 538-P, 560-P, 600-P, 2357-PUB</td>
</tr>
<tr>
<td>Weisman, Harry</td>
<td>1254-P</td>
</tr>
<tr>
<td>Weiss, Jeremy</td>
<td>420-P</td>
</tr>
<tr>
<td>Weiß, Jürgen</td>
<td>1801-P</td>
</tr>
<tr>
<td>Weitgasser, Raimund</td>
<td>518-P</td>
</tr>
<tr>
<td>Weitz, Jonathan</td>
<td>190-OR, 197-OR, 2118-P</td>
</tr>
<tr>
<td>Wells, Andrew D.</td>
<td>1705-P, 1714-P</td>
</tr>
<tr>
<td>Wells, Derrick</td>
<td>30-OR</td>
</tr>
<tr>
<td>Welsh, John</td>
<td>899-P</td>
</tr>
<tr>
<td>Welsh, Paul</td>
<td>1834-P</td>
</tr>
<tr>
<td>Weltman, Arthur</td>
<td>754-P, 1774-P</td>
</tr>
<tr>
<td>Wen, Xin</td>
<td>1351-P</td>
</tr>
<tr>
<td>Wende, Adam R.</td>
<td>1978-P</td>
</tr>
<tr>
<td>Weng, Sharon</td>
<td>1998-P</td>
</tr>
<tr>
<td>Wennberg, Maria</td>
<td>771-P</td>
</tr>
<tr>
<td>Wentworth, John</td>
<td>230-OR</td>
</tr>
<tr>
<td>Werneck de Castro, Joao</td>
<td>2170-P</td>
</tr>
<tr>
<td>Werner, Erika</td>
<td>1427-P</td>
</tr>
<tr>
<td>Wernstedt Asterholm, Ingrid</td>
<td>329-OR, 2431-PUB</td>
</tr>
<tr>
<td>Wertli, Maria M.</td>
<td>350-OR</td>
</tr>
<tr>
<td>Wess, Jürgen</td>
<td>1767-P, 1769-P, 2034-P</td>
</tr>
<tr>
<td>Wess, Chea</td>
<td>1511-P</td>
</tr>
<tr>
<td>Wessel, Jennifer</td>
<td>24-OR, 1724-P</td>
</tr>
<tr>
<td>West, William A.</td>
<td>2296-PUB</td>
</tr>
<tr>
<td>Westen, Sarah C.</td>
<td>719-P, 846-P, 847-P</td>
</tr>
<tr>
<td>Westenfeld, Ralf</td>
<td>284-OR</td>
</tr>
<tr>
<td>Westenfelder, Christof</td>
<td>1746-P</td>
</tr>
<tr>
<td>Westfall, Emily</td>
<td>977-P</td>
</tr>
<tr>
<td>Westfledt, Elizabeth</td>
<td>1496-P</td>
</tr>
<tr>
<td>Wetterneck, Tosha B.</td>
<td>1380-P</td>
</tr>
<tr>
<td>Wewer Albrchtsen, Nicolai J.</td>
<td>43-OR, 147-OR, 1968-P, 2156-P</td>
</tr>
<tr>
<td>Wexler, Deborah J.</td>
<td>587-P, 1182-P</td>
</tr>
<tr>
<td>Whaley, Christopher</td>
<td>1330-P</td>
</tr>
<tr>
<td>Whaley-Connell, Adam</td>
<td>2008-P</td>
</tr>
</tbody>
</table>
Yalamanchi, Sadasiva Rao 1019-P
Yalamanchili, Sandhya 2390-PUB
Yale, Jean Francois 210-OR
Yamada, Eiji 2204-PUB
Yamada, Eijiro 515-P
Yamada, Kentaro 1164-P
Yamada, Masayo 1466-P, 2204-PUB
Yamada, Mika 154-OR, 1903-P, 1906-P
Yamada, Misuzu Y. 2102-P
Yamada, Satoru 2253-PUB
Yamada, Shinsuke 2074-P
Yamada, Takaho 444-P, 637-P, 1154-P, 1176-P, 1488-P
Yamada, Yuichiro 563-P, 565-P, 566-P, 567-P
Yamamoto, Hirotaka 1966-P
Yamamoto, Masashi 2355-PUB
Yamamoto, Naomune 1110-P
Yamamoto, Shin 1581-P, 1609-P, 1666-P
Yamamoto, Takeshi 604-P, 2385-PUB
Yamamoto‑Honda, Ritsuko 1683-P, 2368-PUB
Yamamotoya, Takeshi 604-P, 2385-PUB
Yamashita, Kaoru 772-P
Yamauchi, Akiyo 472-P, 595-P
Yamauchi, Jun 322-OR, 334-OR
Yamauchi, Keishi 1667-P
Yamauchi, Mototaka 2240-PUB
Yamauchi, Yoshimasa 270-OR, 1128-P, 1349-P, 2012-P, 2080-P
Yamazaki, Hiroki 604-P, 2385-PUB
Yamazaki, Hiroyuki 1133-P
Yamazaki, Katsuya 808-P
Yamazaki, Masahiro 762-P, 774-P, 850-P, 1180-P
Yamazaki, Yuko 422-P, 423-P, 443-P
Yan, Cen 224-OR
Yan, Chunhua 224-OR
Yan, Chuin 634-P
Yan, Hui 1875-P, 1880-P, 1883-P, 2441-PUB, 2442-PUB
Yan, Jinhua 860-P, 1301-P, 1731-P, 2350-PUB
Yan, Qingtao 1794-P
Yan, Zihan 327-OR, 2158-P
Yanagisawa, Miyuki 827-P, 1831-P
Yanagisawa, Ryosuke 539-P
Yanai, Kazuhiko 1832-P
Yang, Almira J. 1270-P
Yang, Cui 1759-P
Yang, Goeun 1200-P, 1202-P
Yang, Jiawen 342-OR
Yang, Jin 1200-P, 2302-PUB
Yang, Jing 2001-P
Yang, Jinkui 605-P
Yang, Juxiang 1162-P
Yang, Qian 1847-P
Yang, Qinglin 1748-P
Yang, Li 512-P
Yang, Shaoing 779-P, 2413-PUB
Yang, Shuang 701-P
Yang, Yao 999-P
Yang, Tao 265-OR, 2106-P
Yang, Tung-Lin 445-P
Yang, Wanbo 1875-P, 2441-PUB, 2442-PUB
Yang, Yen-Hsuan 1874-P
Yang, Yongjie 374-OR, 1796-P, 2038-P
Yang, Ziyu 880-P
Yang, Ziyu 1777-P
Yanni, Paul J. II 151-OR, 1895-P
Yano, Masao 2369-PUB
Yano, Wataru 1133-P
Yao, Bin 1033-P, 1301-P, 1731-P
Yao, Qiang X. 1734-P
Yao, Qing 336-OR
Yao, Zhiwen 1734-P
Yaron, Marianna 908-P
Yashin, Anatoly I. 1709-P
Yasuda, Takuma 1469-P
Yasui, Akira 2127-P
Yasui, Atsutaka 1150-P
Yasunari, Yoshi 32-OR
Yau, Daphne 2131-P
Yau, Suk Yu 2249-PUB
Yavelberg, Loren 744-P
Ye, Cheng 320-OR
Ye, Cheng 320-OR
Ye, Cheng 320-OR
Ye, Cheng 320-OR
Ye, Cheng 320-OR
<table>
<thead>
<tr>
<th>Ye, Jianping</th>
<th>1995-P, 2451-PUB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ye, Lu</td>
<td>1642-P</td>
</tr>
<tr>
<td>Ye, Weiwei</td>
<td>1728-P</td>
</tr>
<tr>
<td>Ye, Wen</td>
<td>703-P</td>
</tr>
<tr>
<td>Ye, Zi</td>
<td>1314-P</td>
</tr>
<tr>
<td>Yeaw, Jason</td>
<td>1267-P</td>
</tr>
<tr>
<td>Yee, Curtis</td>
<td>1257-P</td>
</tr>
<tr>
<td>Yeh, Wen-I</td>
<td>96-OR</td>
</tr>
<tr>
<td>Yeh, Yi-Chun</td>
<td>1665-P</td>
</tr>
<tr>
<td>Yenchitsomanus, Pa-Thai</td>
<td>1721-P</td>
</tr>
<tr>
<td>Yeoh, Ester</td>
<td>1198-P, 2408-PUB</td>
</tr>
<tr>
<td>Yeow, Toh Peng</td>
<td>2057-P</td>
</tr>
<tr>
<td>Yeralkar, Disha</td>
<td>2366-PUB</td>
</tr>
<tr>
<td>Yerramilli, Aparna</td>
<td>1041-P</td>
</tr>
<tr>
<td>Yesharim, Rachel</td>
<td>1286-P</td>
</tr>
<tr>
<td>Yeung, Man Yi</td>
<td>1634-P</td>
</tr>
<tr>
<td>Yi, Fanchao</td>
<td>70-OR, 740-P</td>
</tr>
<tr>
<td>Yigit, Sevket</td>
<td>1382-P</td>
</tr>
<tr>
<td>Yikun, Li</td>
<td>2453-PUB</td>
</tr>
<tr>
<td>Yildirim, Emre</td>
<td>1081-P, 1083-P</td>
</tr>
<tr>
<td>Yin, Hongshan</td>
<td>1917-P</td>
</tr>
<tr>
<td>Yin, Ping</td>
<td>1576-P</td>
</tr>
<tr>
<td>Yin, Ruiji</td>
<td>224-OR, 1759-P</td>
</tr>
<tr>
<td>Yin, Tingting</td>
<td>1344-P</td>
</tr>
<tr>
<td>Yoo, Sang-Ku</td>
<td>1158-P, 2053-P</td>
</tr>
<tr>
<td>Yoo, Soon Jib</td>
<td>477-P, 1908-P</td>
</tr>
<tr>
<td>Yoon, Ji Sung</td>
<td>1508-P</td>
</tr>
<tr>
<td>Yoon, Ji Won</td>
<td>266-OR</td>
</tr>
<tr>
<td>Yoon, John</td>
<td>2374-PUB</td>
</tr>
<tr>
<td>Yoon, Juwhan</td>
<td>2026-P</td>
</tr>
<tr>
<td>Yoon, Sung-Hwa</td>
<td>2026-P</td>
</tr>
<tr>
<td>Yorek, Mark A.</td>
<td>59-OR</td>
</tr>
<tr>
<td>Yoshida, Akira</td>
<td>1115-P, 1154-P, 1156-P, 1176-P</td>
</tr>
<tr>
<td>Yoshida, Chiisa</td>
<td>1187-P</td>
</tr>
<tr>
<td>Yoshida, Ken</td>
<td>1994-P</td>
</tr>
<tr>
<td>Yoshida, Mami</td>
<td>1110-P</td>
</tr>
<tr>
<td>Yoshida, Masakazu</td>
<td>1748-P</td>
</tr>
<tr>
<td>Yoshida, Osamu</td>
<td>1666-P</td>
</tr>
<tr>
<td>Yoshida, Shigeru</td>
<td>1110-P</td>
</tr>
<tr>
<td>Yoshida, Sumiko</td>
<td>529-P, 2102-P</td>
</tr>
<tr>
<td>Yoshida, Yohei</td>
<td>1087-P</td>
</tr>
<tr>
<td>Yoshikawa, Sukumori</td>
<td>1848-P</td>
</tr>
<tr>
<td>Yoshikawa, Takeo</td>
<td>1832-P</td>
</tr>
<tr>
<td>Yoshimura, Kuniko</td>
<td>1637-P</td>
</tr>
<tr>
<td>Yoshimura, Ran</td>
<td>2208-PUB</td>
</tr>
<tr>
<td>Yoshimura, Yukio</td>
<td>597-P, 1561-P</td>
</tr>
<tr>
<td>Yoshinaga, Kayo</td>
<td>1635-P</td>
</tr>
<tr>
<td>Yoshino, Hitoshi</td>
<td>1118-P</td>
</tr>
<tr>
<td>Yoshino, Sonomi</td>
<td>535-P</td>
</tr>
<tr>
<td>Yoshizumi, Masanori</td>
<td>472-P</td>
</tr>
<tr>
<td>You, Jee Young</td>
<td>39-OR</td>
</tr>
<tr>
<td>Younes, Naji</td>
<td>1661-P, 1811-P, 1822-P</td>
</tr>
<tr>
<td>Young, Andrew A.</td>
<td>1959-P, 1998-P</td>
</tr>
<tr>
<td>Young, Clipper</td>
<td>829-P</td>
</tr>
<tr>
<td>Young, Deborah R.</td>
<td>1538-P</td>
</tr>
<tr>
<td>Young, Jamey</td>
<td>1876-P</td>
</tr>
<tr>
<td>Young, Natalie</td>
<td>353-OR</td>
</tr>
<tr>
<td>Youngkin, Erin M.</td>
<td>885-P, 1386-P, 1391-P</td>
</tr>
<tr>
<td>Yousef, Shahwar</td>
<td>343-OR</td>
</tr>
<tr>
<td>Youvera, Marlon</td>
<td>1517-P</td>
</tr>
<tr>
<td>Yu, Caiguo</td>
<td>2129-P</td>
</tr>
<tr>
<td>Yu, Chack-Yung</td>
<td>1337-P, 1360-P</td>
</tr>
<tr>
<td>Yu, Chaoyu</td>
<td>1663-P</td>
</tr>
<tr>
<td>Yu, Guoliang</td>
<td>1121-P</td>
</tr>
<tr>
<td>Yu, Jeremy</td>
<td>1397-P, 1399-P, 1405-P, 1409-P</td>
</tr>
<tr>
<td>Yu, Liping</td>
<td>182-OR, 265-OR, 1887-P, 1928-P</td>
</tr>
<tr>
<td>Yu, Maria</td>
<td>1007-P, 1071-P, 1264-P</td>
</tr>
<tr>
<td>Yu, Seung Hee</td>
<td>432-P</td>
</tr>
<tr>
<td>Yu, Xuefeng</td>
<td>333-OR</td>
</tr>
<tr>
<td>Yu, Yongmei</td>
<td>1757-P, 2014-P</td>
</tr>
<tr>
<td>Yu, Yun, Sr.</td>
<td>1598-P</td>
</tr>
<tr>
<td>Yu, Zhijie M.</td>
<td>1433-P</td>
</tr>
<tr>
<td>Yuan, Shasha</td>
<td>2129-P</td>
</tr>
<tr>
<td>Yuan, Shen Yuan</td>
<td>417-P, 2178-PUB</td>
</tr>
<tr>
<td>Yuan, Xiaodan</td>
<td>759-P</td>
</tr>
<tr>
<td>Yuan, Xin</td>
<td>1736-P</td>
</tr>
<tr>
<td>Yuchi, Yixing</td>
<td>1833-P</td>
</tr>
<tr>
<td>Yue, Dennis</td>
<td>593-P</td>
</tr>
<tr>
<td>Yu-Isenberg, Kristina</td>
<td>725-P, 726-P, 1114-P</td>
</tr>
<tr>
<td>Yunhong, Wu</td>
<td>2186-PUB</td>
</tr>
<tr>
<td>Yuzefovich, Larysa</td>
<td>1783-P</td>
</tr>
<tr>
<td>Zafar, Mohammad Ishaq</td>
<td>2155-P</td>
</tr>
<tr>
<td>Zaghloul, Norann A.</td>
<td>54-OR, 1358-P</td>
</tr>
<tr>
<td>Zararia, Oana</td>
<td>748-P, 1509-P, 1567-P, 2054-P</td>
</tr>
<tr>
<td>Zaharieva, Desi</td>
<td>65-OR</td>
</tr>
<tr>
<td>Zahedpour Anaraki, Sara</td>
<td>448-P, 541-P</td>
</tr>
<tr>
<td>Zaheer, Sidra</td>
<td>2395-PUB</td>
</tr>
<tr>
<td>Zajdenverg, Lenita</td>
<td>1112-P</td>
</tr>
<tr>
<td>Zakaria, Anadil F.</td>
<td>355-OR</td>
</tr>
<tr>
<td>Zakhary, Bishoy L.</td>
<td>1625-P</td>
</tr>
<tr>
<td>Zanardini, Anna</td>
<td>898-P</td>
</tr>
<tr>
<td>Zane, Doris</td>
<td>1997-P, 1998-P</td>
</tr>
<tr>
<td>Zanella, Teresinha</td>
<td>606-P</td>
</tr>
</tbody>
</table>

**OR**: Oral  **P**: Poster  **PUB**: Published Only
<table>
<thead>
<tr>
<th>Name</th>
<th>ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhao, Tingkun</td>
<td>1794-P</td>
</tr>
<tr>
<td>Zhao, Xinjie</td>
<td>1856-P</td>
</tr>
<tr>
<td>Zhao, Yinan</td>
<td>2468-PUB</td>
</tr>
<tr>
<td>Zhao, Yu</td>
<td>1201-P</td>
</tr>
<tr>
<td>Zhao, Yuanjun</td>
<td>608-P</td>
</tr>
<tr>
<td>Zhao, Zhenxiang</td>
<td>1648-P</td>
</tr>
<tr>
<td>Zheng, Hui</td>
<td>14-OR, 299-OR</td>
</tr>
<tr>
<td>Zheng, Jia</td>
<td>64-OR</td>
</tr>
<tr>
<td>Zheng, Jie</td>
<td>632-P, 640-P, 2242-PUB</td>
</tr>
<tr>
<td>Zheng, Juan</td>
<td>1314-P, 2155-P</td>
</tr>
<tr>
<td>Zheng, Peilin</td>
<td>1698-P</td>
</tr>
<tr>
<td>Zheng, Qin</td>
<td>265-OR</td>
</tr>
<tr>
<td>Zheng, Xiaoying</td>
<td>85-OR</td>
</tr>
<tr>
<td>Zheng, Xueying</td>
<td>880-P, 1290-P, 1301-P, 2350-PUB</td>
</tr>
<tr>
<td>Zheng, Xuqin</td>
<td>265-OR</td>
</tr>
<tr>
<td>Zheng, Yaguang</td>
<td>826-P</td>
</tr>
<tr>
<td>Zheng, Yi</td>
<td>155-OR, 1843-P</td>
</tr>
<tr>
<td>Zheng, Yujiao</td>
<td>2419-PUB</td>
</tr>
<tr>
<td>Zhong, Judy</td>
<td>181-OR</td>
</tr>
<tr>
<td>Zhong, Ling</td>
<td>1732-P</td>
</tr>
<tr>
<td>Zhong, Yuxiang</td>
<td>16-OR, 920-P</td>
</tr>
<tr>
<td>Zhou, Aimin</td>
<td>1880-P</td>
</tr>
<tr>
<td>Zhou, Danxia</td>
<td>1930-P</td>
</tr>
<tr>
<td>Zhou, Donglei</td>
<td>2058-P, 2060-P</td>
</tr>
<tr>
<td>Zhou, Fenghua</td>
<td>1875-P</td>
</tr>
<tr>
<td>Zhou, Hongwen</td>
<td>265-OR</td>
</tr>
<tr>
<td>Zhou, Hongyi</td>
<td>2001-P</td>
</tr>
<tr>
<td>Zhou, Jianbo</td>
<td>605-P</td>
</tr>
<tr>
<td>Zhou, Jin</td>
<td>437-P</td>
</tr>
<tr>
<td>Zhou, Jing</td>
<td>224-OR, 1872-P</td>
</tr>
<tr>
<td>Zhou, Joseph</td>
<td>1985-P</td>
</tr>
<tr>
<td>Zhou, Lingli</td>
<td>1197-P</td>
</tr>
<tr>
<td>Zhou, Liwei</td>
<td>484-P</td>
</tr>
<tr>
<td>Zhou, Luping</td>
<td>92-OR, 499-P</td>
</tr>
<tr>
<td>Zhou, Peng</td>
<td>1838-P</td>
</tr>
<tr>
<td>Zhou, Qiao</td>
<td>325-OR</td>
</tr>
<tr>
<td>Zhou, Rong</td>
<td>919-P</td>
</tr>
<tr>
<td>Zhou, Shi-Sheng</td>
<td>783-P, 1607-P</td>
</tr>
<tr>
<td>Zhou, Tao</td>
<td>121-OR, 1555-P, 1580-P</td>
</tr>
<tr>
<td>Zhou, Xilin</td>
<td>1245-P</td>
</tr>
<tr>
<td>Zhou, Yue</td>
<td>2431-PUB</td>
</tr>
<tr>
<td>Zhou, Yiming</td>
<td>783-P, 1607-P</td>
</tr>
<tr>
<td>Zhou, Yingsheng</td>
<td>2468-PUB</td>
</tr>
<tr>
<td>Zhou, Yongwen</td>
<td>2350-PUB</td>
</tr>
<tr>
<td>Zhu, Chunfang</td>
<td>1996-P</td>
</tr>
<tr>
<td>Zhu, Dalong</td>
<td>1201-P, 1344-P, 2349-PUB, 2453-PUB, 2454-PUB</td>
</tr>
<tr>
<td>Zhu, Hui</td>
<td>1850-P</td>
</tr>
<tr>
<td>Zhu, Jia</td>
<td>11-OR, 1385-P</td>
</tr>
<tr>
<td>Zhu, Ling</td>
<td>809-P</td>
</tr>
<tr>
<td>Zhu, Lu</td>
<td>1767-P</td>
</tr>
<tr>
<td>Zhu, Meng</td>
<td>265-OR</td>
</tr>
<tr>
<td>Zhu, Ping</td>
<td>613-P</td>
</tr>
<tr>
<td>Zhu, Wanling</td>
<td>1088-P</td>
</tr>
<tr>
<td>Zhu, Yeyi</td>
<td>1417-P, 1462-P, 1538-P</td>
</tr>
<tr>
<td>Zhu, Yu, Jr.</td>
<td>2197-PUB</td>
</tr>
<tr>
<td>Zhuge, Ronghua</td>
<td>2163-P</td>
</tr>
<tr>
<td>Zhumaliyeva, Vera A.</td>
<td>2223-PUB</td>
</tr>
<tr>
<td>Zhyzhneuskaya, Sviatiana V.</td>
<td>40-OR, 42-OR, 1834-P</td>
</tr>
<tr>
<td>Zia, Zahra</td>
<td>2177-PUB</td>
</tr>
<tr>
<td>Ziegler, Dan</td>
<td>63-OR, 579-P, 2054-P</td>
</tr>
<tr>
<td>Ziegler, Ralph</td>
<td>971-P, 972-P</td>
</tr>
<tr>
<td>Ziemann, Mark</td>
<td>2107-P</td>
</tr>
<tr>
<td>Zierath, Juleen</td>
<td>1784-P</td>
</tr>
<tr>
<td>Zijlstra, Eric</td>
<td>305-OR, 998-P</td>
</tr>
<tr>
<td>Zikry, Magdy</td>
<td>1514-P</td>
</tr>
<tr>
<td>Zilov, Alexey</td>
<td>577-P</td>
</tr>
<tr>
<td>Zimmer, Daniel</td>
<td>1207-P</td>
</tr>
<tr>
<td>Zimmer, Zachary</td>
<td>1142-P</td>
</tr>
<tr>
<td>Zimmermann, Alan G.</td>
<td>1066-P</td>
</tr>
<tr>
<td>Zimet, Paul Z.</td>
<td>1533-P</td>
</tr>
<tr>
<td>Zincavage, Rebekah</td>
<td>851-P, 854-P</td>
</tr>
<tr>
<td>Zinzuwadia, Padmanabah</td>
<td>1327-P</td>
</tr>
<tr>
<td>Zisser, Howard</td>
<td>351-OR, 1011-P</td>
</tr>
<tr>
<td>Zmora, Rachel</td>
<td>396-P</td>
</tr>
<tr>
<td>Zmuda, Joseph M.</td>
<td>1681-P, 1709-P, 2100-P</td>
</tr>
<tr>
<td>Zocchi, Elena</td>
<td>2279-PUB</td>
</tr>
<tr>
<td>Zoghibi, Marouan</td>
<td>1082-P</td>
</tr>
<tr>
<td>Zois, Nora E.</td>
<td>466-P, 502-P</td>
</tr>
<tr>
<td>Zong, Ai lun</td>
<td>2468-PUB</td>
</tr>
<tr>
<td>Zonszein, Joel</td>
<td>448-P, 541-P</td>
</tr>
<tr>
<td>Zook, Jessica</td>
<td>1303-P</td>
</tr>
<tr>
<td>Zordano, Olivia</td>
<td>223-OR</td>
</tr>
<tr>
<td>Zou, Meina</td>
<td>504-P, 506-P</td>
</tr>
<tr>
<td>Zou, Mengchen</td>
<td>635-P</td>
</tr>
<tr>
<td>Zou, Shaozhou</td>
<td>497-P</td>
</tr>
<tr>
<td>Zou, Zhong-Mei</td>
<td>1654-P</td>
</tr>
<tr>
<td>Zoungas, Sofia</td>
<td>707-P, 1697-P</td>
</tr>
<tr>
<td>Zoupas, Christos</td>
<td>1436-P</td>
</tr>
<tr>
<td>Zraick, Vivien</td>
<td>987-P, 995-P</td>
</tr>
<tr>
<td>Zraika, Sakeneh</td>
<td>82-OR, 1815-P, 1825-P, 2107-P</td>
</tr>
<tr>
<td>Zuccotti, Gianvincenzo</td>
<td>1231-P</td>
</tr>
<tr>
<td>Zucker, Inbar</td>
<td>636-P</td>
</tr>
<tr>
<td>Zuijdewijk, Caroline S.</td>
<td>1550-P, 1578-P, 1579-P</td>
</tr>
<tr>
<td>Zukowska-Szczepanowska, Ewa</td>
<td>1896-P</td>
</tr>
<tr>
<td>Zuniga, Julie A.</td>
<td>652-P</td>
</tr>
<tr>
<td>Zupa, Margaret</td>
<td>103-OR, 691-P</td>
</tr>
<tr>
<td>Zweck, Elric</td>
<td>284-OR</td>
</tr>
</tbody>
</table>
Corporate Symposia

The following programs are planned and conducted by the corporate community in conjunction with the 78th Scientific Sessions. They provide attendees with additional education and information opportunities.

Events are open to a limited number of attendees, and registration is on a first-come, first-served basis. If you pre-registered for an event(s), you received a ticket(s) with your badge. Visit Assisted Registration located in the Level 1 Lobby to check event availability or to register for additional symposia.

Please remember the following when reserving/attending a Corporate Symposia:

- Seats are limited. Sign-up for only those events you plan to attend.
- If you change your mind about attending, return the ticket to Registration.
- Arrive 15 minutes before the scheduled start time to guarantee entrance. Symposia planners reserve the right to allow walk-ins to fill vacant seats.
- If a symposium was sold out when you registered, check at the door 15 minutes prior to the event to see if space has become available.

Please Note:

- Corporate symposia held in conjunction with the 78th Scientific Sessions are not part of the official ADA Scientific Sessions program.
- Program content and continuing education credit (if applicable) are the sole responsibility of the corporate supporters.
- For more information regarding a symposium and/or to inquire about continuing education for the event, contact the corporate supporters directly.

FRIDAY, JUNE 22, 2018

6:30 p.m.-9:10 p.m.

The Foundational Role of Physiologic, Long-Acting Basal Insulin—Optimizing the Safety-Efficacy Equation in Vulnerable Patients with Type 2 Diabetes

Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes

(6:30 p.m.-7:00 p.m.—Dinner/7:00 p.m.-9:10 p.m.—Program)

This program will focus on the role, indications, guidelines, and evidence supporting optimal approaches to early use, dosing, switching to, and intensification of physiologic, long-acting basal insulin therapy for type 2 diabetes, and when appropriate, in combination with other therapies; and, provide an individualized and patient needs-specific “evidence-based roadmap,” consistent with ADA/EASD position.

Location: Hyatt Regency Orlando, Regency Ballroom O-R

Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
6:30 p.m.-9:15 p.m.
The Mechanistic and Therapeutic Rationale for Dual SGLT1/2 Inhibition in Adults with Type 1 Diabetes
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes
(6:30 p.m.-7:00 p.m.—Dinner/7:00 p.m.-9:15 p.m.—Program)
This CME activity will focus on the role, indications, guidelines, and evidence supporting optimal approaches for improving comprehensive glycemic management, HbA1c target goal attainment, safety, and metabolic optimizing by using agents with mechanistic complementarity with insulin, including those therapies acting through dual SGLT1/2 inhibition, in adults with type 1 diabetes mellitus.

Location: Hyatt Regency Orlando, Regency Ballroom S-V
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net

6:30 p.m.-9:30 p.m.
Los Avances más Recientes en el Manejo de la Diabetes Tipo 2—Un Enfoque más Preciso
Jointly sponsored by The University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education
Supported by an unrestricted educational grant from Novo Nordisk A/S
(6:30 p.m.-6:45 p.m.—Registration and Buffet Dinner/6:45 p.m.-9:30 p.m.—Educational Program)
La prevalencia global de la diabetes tipo 2 ha alcanzado proporciones epidémicas, exponiendo a un gran porcentaje de la población Latina/Hispana a serias complicaciones de riesgo de vida. La iniciación a tiempo y la intensificación de tratamientos basados en guías terapéuticas pueden mejorar el control glucémico y demorar la prevención de problemas de salud, incluyendo complicaciones cardiovasculares. Este simposio proveerá a los participantes con avances recientes y enfocados sobre el mejor manejo del tratamiento de la diabetes tipo 2.

Location: Hyatt Regency Orlando, Plaza International Ballroom D-G
Contacts: Mark Vinciguerra/E-mail: mark.vinciguerra@utsouthwestern.edu
Jane Savio/E-mail: jane.savio@worldwidediabetes.org

6:45 p.m.-9:15 p.m.
The Nexus of NASH and Type 2 Diabetes Mellitus—The Emerging Role of the Diabetologist
Jointly provided by Postgraduate Institute for Medicine (PIM) and Integritas Communications
Supported by an educational grant from Gilead Sciences, Inc.
(6:45 p.m.-7:15 p.m.—Registration and Dinner/7:15 p.m.-9:15 p.m.—Educational Activity)
This Interactive Exchange™ symposium examines the overlapping type 2 diabetes and fatty liver disease epidemics, focusing on diabetologists’ essential roles in identifying and managing cases of nonalcoholic steatohepatitis (NASH). Key topics include pathophysiologic links among obesity, diabetes, and NASH; updated diagnostic guidelines; and evidence for current and emerging NASH therapies.

Location: Hyatt Regency Orlando, Plaza International Ballroom H-K
Contact: Katie Anderton/E-mail: kanderton@integritasgrp.com
SATURDAY, JUNE 23, 2018

5:30 a.m.-7:45 a.m.
Continuous Glucose Monitoring Category Update—Clinical Outcomes, New Technologies, and Therapeutic Dosing
Sponsored by CogniMed
Supported by an educational grant from Dexcom

- Outcomes from the Ihart, HypoDE, DiaMonD, GOLD, Impact, and Replace Study.
- Review of new near term commercial continuous glucose monitoring systems.
- Discuss how to guide patients to dose continuous glucose monitoring in real time.

Location: Hyatt Regency Orlando, Regency Ballroom O-R
Contact: Jeffrey Rosenberg/E-mail: info@cgmeducation.net

5:30 a.m.-7:45 a.m.
Clinician Update—New Options and Strategies for Cardiovascular Risk Reduction in Diabetes
Sponsored by Medtelligence, LLC
Supported by an educational grant from Amarin Pharma Inc.

This CME program will provide attendees with recent advances in our understanding of the complex interrelationship of cardiovascular disease and type 2 diabetes. The multidisciplinary faculty and symposium participants will work through complex issues that challenge health care providers in caring for patients who often have elevated atherogenic cholesterol and triglycerides, many (or most) of whom have been sub-optimally managed.

Location: Hyatt Regency Orlando, Plaza International Ballroom D-G
Contact: Milly Marte/E-mail: mmarte@medtelligence.net

6:15 p.m.-9:15 p.m.
Multi-Mechanistic, Insulin-Based Approaches for Achieving HbA1c/PPG Targets and Optimizing Safety in Challenging Patients with Type 2 Diabetes
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi Diabetes
(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-9:15 p.m.—Program)

This CME activity will focus on the role, indications, guidelines, and evidence supporting “multi-mechanistic” approaches to early use, conversion to, and titration of combination insulin therapy and fixed ratio GLP-combinations; as well as the use of insulin-based formulations in fixed-ratio combination with GLP-1 receptor agonists to optimize metabolic and compliance end points.

Location: Hyatt Regency Orlando, Regency Ballroom O-R
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net
6:15 p.m.-9:15 p.m.

The Landmark Evidence and Clinical Rationale for PCSK9 Inhibition in the Diabetic Patient
Sponsored by CMEducation Resources
Supported by an educational grant from Sanofi and Regeneron

(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-9:15 p.m.—Program)

This CME activity will focus on landmark clinical cardiovascular outcomes trials, mechanisms of atherosclerotic heart disease, new ACC/ECDP Task Force Guidelines for non-statin-based LDL reduction, novel LDL targets and therapies, and new translational dimensions of applying new cardiovascular outcome data in PCSK9-mediated LDL reduction to the diabetic population.

Location: Hyatt Regency Orlando, Regency Ballroom S-V
Contact: Milo Falcon/E-mail: milo.falcon@pharmatecture.net

6:15 p.m.-9:15 p.m.

Innovations in Diabetic Wound Healing
Sponsored by Healogics
Supported by an educational grant from Healogics and Oreganogenesis

In this session, leading experts in wound care will present information on identification, treatment, and healing of diabetic foot ulcers. Join us for a discussion around innovations in wound healing therapies, including standards of care and the use of advanced therapies.

Location: Hyatt Regency Orlando, Plaza International Ballroom D-G
Contact: Hanna Gordon/E-mail: hanna.gordon@healogics.com

6:15 p.m.-9:15 p.m.

Free Style Libre Flash Continuous Glucose Monitoring System—Clinical, Real-World, and Patient Perspectives
Sponsored by Abbott Diabetes Care
Supported by an educational grant from Abbott Diabetes Care

Panel Discussion:
Chair of the Symposium: Dr. Bernard Zinman; Use of Flash Continuous Glucose Monitoring and the Ambulatory Glucose Profile in Clinical Practice: Dr. Irl Hirsch; SELFY & IMPACT: Improved Clinical Outcomes in Teens and Young Adults: Dr. Kurt Midyett; Insights from Real-World Use of Flash Continuous Glucose Monitoring: Dr. Ramzi Ajjan; Patient Perspectives on Flash Continuous Glucose Monitoring: Kelly Close.

Location: Hyatt Regency Orlando, Plaza International Ballroom H-K
Contact: Katherine Bowen/E-mail: katherine.bowen@abbott.com
SUNDAY, JUNE 24, 2018

5:30 a.m.-7:45 a.m.

Recognizing the Risk—Addressing and Improving Cardiovascular Outcomes in Diabetic Kidney Disease (DKD)

Sponsored by Med-IQ
Supported by an educational grant from Bayer Health Care Pharmaceuticals, Inc.

The proposed accredited symposium will address the current research on cardiorenal pathophysiology among those with underlying diabetes as well as associated risk factors and investigational treatment strategies for patients with DKD. The symposium will be sponsored and accredited for 2.0 AMA PRA category 1 credits™, by Med-IQ.

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R

**Contact:** Whitney Stevens/E-mail: wstevens@med-iq.com

6:45 p.m.-8:45 p.m.

Reducing Cardiovascular Risk in Type 2 Diabetes—What I Do and Why

Sponsored by Clinical Care Options, LLC
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC

(6:45 p.m.-7:15 p.m.—Registration and Dinner/7:15 p.m.-8:45 p.m.—Program)

In this highly interactive program, a panel of expert faculty members will walk you through their individual approaches to selecting appropriate type 2 diabetes mellitus therapy based on clinical trial results and real-world evidence evaluating the impact of therapies on cardiovascular risk.

**Location:** Hyatt Regency Orlando, Regency Ballroom O-R

**Contact:** Amy Goldman/E-mail: agoldman@clinicaloptions.com

6:45 p.m.-8:45 p.m.

Multifaceted Approaches to Treating Type 2 Diabetes—Individualization Is Key

Provided by Vindico Medical Education
Supported by an educational grant from Merck & Co., Inc.

(6:45 p.m.-7:15 p.m.—Registration and Dinner/7:15 p.m.-8:45 p.m.—CME-Certified Activity)

This educational activity will feature expert faculty discussing the effective use of therapeutic strategies in redefining the need to individualize treatment with a patient-first approach and assessing new as well as emerging clinical evidence to improve glycemic control, reducing cardiovascular risk.

**Location:** Hyatt Regency Orlando, Regency Ballroom S-V

**Contact:** Kristin Riday/E-mail: kriday@vindicomeded.com
6:45 p.m.-9:15 p.m.

**Pointed Discussions—Clinical Conversations about Reducing Cardiovascular Risks in Patients with Type 2 Diabetes Mellitus Using Newer Options in Injectable Antihyperglycemic Therapy**

*Sponsored by Institute for Medical and Nursing Education*

*Supported by an educational grant from Novo Nordisk Inc.*

(6:45 p.m.-7:15 p.m.—Registration and Dinner/7:15 p.m.-9:15 p.m.—Program)

This CME/CE certified 2-hour dinner program will be implemented using an interactive, video driven, case-based format. Expert faculty will briefly present key educational points, discuss clinically relevant cases, and address participants’ questions regarding the benefits, limitations, and practical aspects of new and existing options in injectable therapy for the management of type 2 diabetes mellitus.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom H-K

**Contact:** Amy Carbonara/E-mail: amy.carbonara@imne.com

6:45 p.m.-9:45 p.m.

**The Right Recipe for Achieving Postprandial Glucose Control—To Inhale or Inject?**

*Sponsored by Medscape*

*Supported by an educational grant from MannKind Corporation*

This live, interactive symposium will guide participants through a comprehensive diabetes management, including a detailed look at how inhaled insulin can be used to improve patient outcomes. The “diabetic chef” will prepare an example meal in between sessions, walking guests through the recipe, ingredient selection, cooking tips, and more.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G

**Contact:** Robert Zorzi/E-mail: rzorzi@medscape.net

**MONDAY, JUNE 25, 2018**

6:45 p.m.-8:45 p.m.

**Treating Diabetic Dyslipidemia—A Deep Dive into PCSK9 Inhibitors**

*Provided by Vindico Medical Education*

*Supported by an educational grant from Amgen, Inc.*

(6:45 p.m.-7:15 p.m.—Registration and Dinner/7:15 p.m.-8:45 p.m.—CME-Certified Activity)

This educational activity will review the latest data regarding the management of dyslipidemia in patients with diabetes, as well as assess the newly released data regarding the safety, efficacy, and reduction in adverse cardiovascular outcomes with PCSK9 inhibitor therapy.

**Location:** Hyatt Regency Orlando, Plaza International Ballroom D-G

**Contact:** Kristin Riday/E-mail: kriday@vindicomeded.com
6:45 p.m.-9:45 p.m.

Medical Crossfire®—Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm
Sponsored by Physicians’ Education Resource (PER)
Supported by an educational grant from Janssen Pharmaceuticals, Inc.

Through a Medical Crossfire®, faculty will provide expert interpretation and guidance on the impact and clinical application of recent cardiovascular outcomes trials for achieving glycemic control with SGLT2 inhibitors. Participant interactivity and Infograph-ed™ will be included to better understand and incorporate cardiometabolic risk-reduction strategies into practice.

Location: Hyatt Regency Orlando, Regency Ballroom O-R  
Contact: Katie Pierson/E-mail: kpierson@permedical.com

6:45 p.m.-9:45 p.m.

Improving Obesity Care—A Practical Guide to Engaging and Treating Patients
Sponsored by The Endocrine Society
Supported by an educational grant from Novo Nordisk Inc.
(6:45 p.m.-7:15 p.m.—Dinner/7:15 p.m.-9:45 p.m.—Program)

This interactive CME activity will focus on patient-centered strategies to long-term weight loss maintenance, barriers to initiating and maintaining care, and evidence-based guidelines in selecting pharmacotherapy to treat patients. The symposium is accredited for 2.5 AMA PRA Category 1 Credits™ and 2.5 ABIM MOC Points and is chaired by Dr. Robert Kushner.

Location: Hyatt Regency Orlando, Regency Ballroom S-V  
Contact: Cassandra Destin/E-mail: cdestin@endocrine.org
Product Theaters

Product Theaters, located within the Exhibit Hall, offer informative sessions focusing on products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for healthcare professionals only with practices relevant to the presented information.

Light refreshments provided by the ADA will be served to the first 300 attendees.

SATURDAY, JUNE 23, 2018

10:15 a.m.-11:00 a.m.
Continuous Glucose Monitoring Reinvented—Introducing the FreeStyle Libre System
Presented by Abbott

Introducing the FreeStyle Libre System. Simple accurate, and more affordable* continuous glucose monitoring for your patients.


* Based on the manufacturer’s list price of the FreeStyle Libre system. The actual cost to you may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

Presenters: W. Reid Litchfield, MD, FACE, ECNU, FRCP
Desert Endocrinology
Nevada Thyroid Institute
Henderson, NV

Special Guest Speaker

Location: Product Theater 1 (Booth 173)

10:15 a.m.-11:00 a.m.
Cardiovascular Disease Burden in the U.S. and Clinical Evaluation of VASCEPA® (Icosapent Ethyl)
Presented by Amarin Pharma, Inc.

Hear from an expert about cardiovascular disease burden in the U.S. and clinical evaluation of VASCEPA® (icosapent ethyl). Despite the benefits of LDL-C lowering, many patients on statin therapy remain at risk. In this presentation, new data and perspectives on the role of high triglycerides as a marker of increased cardiovascular risk in patients with statin-controlled LDL-C will be discussed. The clinical development program and safety for pure EPA VASCEPA® will be reviewed.

Presenter: Eliot A. Brinton, MD
President
Utah Lipid Center
Salt Lake City, UT

Location: Product Theater 2 (Booth 1472)
10:15 a.m.-11:00 a.m.

**Introducing a New Era in Glucose Monitoring—The Eversense® Continuous Glucose Monitoring System**

*Presented by Senseonics*

The world’s first long-term implantable continuous glucose monitoring system.

Based on novel fluorescence technology, Eversense® provides continuous real-time readings up to 3 months with a single sensor. Get a first look at the product technology, which includes a wearable smart transmitter that can be taken on or off and provides discreet vibratory glucose alerts. Learn about the clinical performance resulting in sustained accuracy over the 3-month wear period. During this session, you will hear from clinicians and patients discussing first-hand experience with the technology. At the conclusion of the presentations, there will be a Q&A session. You don’t want to miss this panel of industry experts and current Eversense® users!

**Moderator:** Steven Edelman, MD  
Division of Endocrinology and Metabolism  
University of California, San Diego  
Founder/Director  
Taking Care Of Your Diabetes (TCOYD)  
San Diego, CA

**Presenters:**  
E. Lynne Kelley, MD, FACS  
Chief Medical Officer  
Senseonics, Inc  
Germantown, MD  
Timothy S. Bailey, MD, FACE, FACP, CPI  
President and CEO  
AMCR Institute, Inc.  
Escondido, CA  
Jenine Yager Stone, MSN, FNP-C  
Assistant Director, Clinical Research  
AMCR Institute, Inc.  
Escondido, CA  
Tobias Schulte  
Eversense® User

**Location:** Product Theater 3 (Booth 202)
12:15 p.m.-1:15 p.m.

**Jardiance® (Empagliflozin) Tablets—Evolving Clinical Development**  
*Presented by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA*

This program will discuss recent data from the ongoing Jardiance® clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for Jardiance®. Attendees will also have the opportunity to ask the faculty questions about the data presented.

**Presenters:** Leigh Perreault, MD  
Associate Professor of Medicine  
Division of Endocrinology, Metabolism, and Diabetes  
Affiliate Center for Global Health  
University of Colorado Anschutz Medical Campus  
Associate Professor of Epidemiology  
Colorado School of Public Health  
Boulder, CO  
Pam R. Taub, MD, FACC  
Associate Professor of Medicine  
University of California, San Diego Health System  
San Diego, CA

**Location:** Product Theater 1 (Booth 173)

12:15 p.m.-1:15 p.m.

**The Role of GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Management**  
*Presented by AstraZeneca Pharmaceuticals*

This presentation will review the important role of glucagon-like peptide-1 (GLP-1) in physiologic glucose regulation and the mechanism of GLP-1 receptor agonists in addressing the core defects of type 2 diabetes. The clinical efficacy, safety, and potential place in therapy of a once-weekly, GLP-1 receptor agonist, prefilled autoinjector will be discussed. In addition, there will be a live demonstration of the autoinjector.

**Presenter:** Robert S. Busch, MD  
Albany Medical College  
Albany, NY

**Location:** Product Theater 2 (Booth 1472)

12:15 p.m.-1:15 p.m.

**Developments in GLP-1 Treatment Options for Adults with Type 2 Diabetes**  
*Presented by Novo Nordisk A/S*

**Presenter:** James R. Gavin III, MD, PhD  
Clinical Professor of Medicine  
Emory University School of Medicine  
Chief Medical Officer  
Healing Our Village, Inc.  
Atlanta, GA

**Location:** Product Theater 3 (Booth 202)
2:45 p.m.-3:30 p.m.

Evaluating the Impact of a Safety Outcomes Trial—Incidence of Major Adverse Cardiovascular Events and Clinical Importance of Severe Hypoglycemia for Type 2 Diabetes Patients Requiring a Long-Acting Insulin

**Presented by Novo Nordisk A/S**

**Presenter:** Helena W. Rodbard, MD, FACP, MACE  
Medical Director  
Endocrine and Metabolic Consultants  
Rockville, MD

**Location:** Product Theater 2 (Booth 1472)

2:45 p.m.-3:30 p.m.

**Introducing the New Dexcom G6—Simple, Accurate, Effective**

**Presented by Dexcom**

Introduction and review of the new Dexcom G6 Continuous Glucose Monitoring System.

Dexcom G6 CGM technology features accuracy, usability, and product enhancement.

Dexcom G6 pivotal trial data, patient experience, and training best practices.

**Presenters:**  
Jake Leach  
Senior Vice President, Research and Development  
Dexcom  
San Diego, CA

Keri Leone, MS, RD, CDE  
Senior Director, Global Professional Education  
Dexcom  
San Diego, CA

R. Paul Wadwa, MD  
Associate Professor of Pediatrics  
University of Colorado School of Medicine  
Medical Director, Pediatric Clinic,  
Barbara Davis Center for Childhood Diabetes  
Aurora, CO

**Location:** Product Theater 3 (Booth 202)

---

**SUNDAY, JUNE 24, 2018**

10:15 a.m.-11:00 a.m.

**Praluent® (Alirocumab) Injection—The Time to Treat Is Now**

**Presented by Sanofi-Regeneron**

**Presenter:** Kenneth Feingold, MD  
Professor of Medicine  
University of California, San Francisco  
San Francisco, CA

**Location:** Product Theater 1 (Booth 173)
10:15 a.m.-11:00 a.m.

**Criticality of LDL-C Lowering in Patients with Diabetes Mellitus**
*Presented by Amgen*

**Presenter:** Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
University of Miami Miller School of Medicine
The Center for Diabetes and Endocrine Care
Ft. Lauderdale, FL

**Location:** Product Theater 2 (Booth 1472)

---

10:15 a.m.-11:00 a.m.

**The Guardian™ Connect Continuous Glucose Monitoring System—Utilizing Predictive Alerts and Data Backed Insights to Help with Diabetes Management**
*Presented by Medtronic*

Please join us and learn how predictive alerts and data backed insights of the Guardian™ Connect Smart CGM system can help you and your patients with diabetes management. Presentation will include a system overview, real-world data, case studies, and best practices.

**Presenters:** Timothy S. Bailey, MD, FACE, CPI
President and CEO
AMCR Institute, Inc.
Clinical Associate Professor of Medicine
University of California, San Diego
Escondido, CA

Huzefa Neemuchwala, PhD, MBA
Senior Director, Data and Digital Information
Medtronic Diabetes
Northridge, CA

**Location:** Product Theater 3 (Booth 202)

---

12:30 p.m.-1:30 p.m.

**Pneumococcal Disease in Adults Aged <65 Years with Diabetes or Other Select Chronic Conditions**
*Presented by Merck & Co., Inc.*

Describe pneumococcal disease in adults aged <65 years with diabetes or other select chronic conditions. Review CDC recommendations for pneumococcal vaccination in this population.

**Location:** Product Theater 1 (Booth 173)

---

12:30 p.m.-1:30 p.m.

**Improving Glycemic Control in Type 1 Diabetes—The Role of Insulin-Independent Pathways**
*Presented by Lexicon Pharmaceuticals and Sanofi*

**Presenter:** Yehuda Handelsman, MD, FACP, FNLA, MACE
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA

**Location:** Product Theater 2 (Booth 1472)
12:30 p.m.-1:30 p.m.

Severe Hypertriglyceridemia and Pancreatitis—Including Familial Chylomicronemia Syndrome (FCS) in Your Differential Diagnosis
Presented by Akcea Therapeutics

This program provides clinicians with information on Familial Chylomicronemia Syndrome (FCS), a disease in which inherited defects result in the accumulation of chylomicrons in the plasma causing acute pancreatitis and sequelae which can impact daily life including recurrent pain, recurrent acute pancreatitis, and permanent pancreatic damage.

Is a patient like this in your practice?
- Severe, refractory hypertriglyceridemia
  - TG>880 mg/dL
  - Not responsive to standard triglyceride-lowering therapies
- No secondary causes of hypertriglyceridemia
- One or more of:
  - History of pancreatitis
  - History of recurrent abdominal pain without other explainable cause

Objectives for attending clinicians include:
- Differentiate the FCS patient from patients with secondary causes of hypertriglyceridemia
- Appreciate the importance of FCS diagnosis
- Understand the value of connecting FCS patients to educational resources and the FCS patient community

Presenter: Richard L. Dunbar, MD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Location: Product Theater 3 (Booth 202)

3:00 p.m.-3:45 p.m.

Basal Insulin Treatment Considerations in Adult Patients with Type 2 Diabetes Mellitus
Presented by Sanofi

Presenter: Carol H. Wysham, MD
Clinical Professor of Medicine
University of Washington
Spokane, WA

Location: Product Theater 1 (Booth 173)
3:00 p.m.-3:45 p.m.

Closing the Loop with Blood Glucose Meters—Supporting Current Continuous Glucose Monitoring and Future Therapies
Presented by Ascensia Diabetes Care

As diabetes management solutions continue to evolve, for all people with diabetes, the use of Blood Glucose Meters (BGM) play an integral role in supporting other technologies such as Continuous Glucose Monitors (CGM), Flash Glucose Monitors (FGM), Hybrid Closed-Loop System (HCLS) (such as the Medtronic MiniMed™ 670G), and Artificial Pancreas Device Systems (APDS). This session will discuss these technologies and the role of BGM within each.

**Presenter:** Steven Edelman, MD
Division of Endocrinology and Metabolism
University of California, San Diego
Founder/Director
Taking Care Of Your Diabetes (TCOYD)
San Diego, CA

**Location:** Product Theater 3 (Booth 202)

---

MONDAY, JUNE 25, 2018

10:15 a.m.-11:00 a.m.

MiniMed™ 670G System—Increasing Time In Range with Automated Insulin Delivery
Presented by Medtronic

Please join us and learn how the MiniMed™ 670G system has changed the way we are managing time in range for patients with type 1 diabetes. Presentation will include real-world data, case studies, and best practices.

**Presenters:** Jennifer Sherr, MD, PhD
Pediatric Endocrinologist, Associate Professor
Yale School of Medicine
New Haven, CT

Anders L. Carlson, MD
Medical Director
International Diabetes Center at Park Nicollet
Minneapolis, MN

**Location:** Product Theater 1 (Booth 173)

---

10:15 a.m.-11:00 a.m.

Repatha® (Evolocumab)—Putting It into Practice
Presented by Amgen

Join Eliot A. Brinton, MD, FAHA, FNLA, as he conducts an educational presentation on the importance of Repatha® (evolocumab). Hear about his experience with Repatha® and the options available for appropriate patients.

**Presenter:** Eliot A. Brinton, MD, FAHA, FNLA
President
Utah Lipid Center
Salt Lake City, UT

**Location:** Product Theater 2 (Booth 1472)
12:30 p.m.-1:30 p.m.

**The Omnipod® DASH™ System—Simplifying Insulin Delivery for Your Patients and Practice**

*Presented by Insulet Corporation*

Learn how the Omnipod® DASH™ Insulin Management System will build on the simplicity and ease-of-use of the existing Omnipod® System platform leveraging its tubeless, waterproof design to address the needs of people with insulin-dependent diabetes. The Omnipod® DASH™ System includes the Pod that will remain unchanged in size with Bluetooth® technology for greater connectivity to the Personal Diabetes Manager (PDM) as well as to the compatible Contour® NEXT One Blood Glucose (BG) Meter. The new, slimmer PDM will feature a color touchscreen interface and will enable discreet insulin delivery with a few finger taps. A new suite of iOS mobile applications will give users and their caregivers quick and easy access to their insulin therapy information on their smartphones. The Omnipod® DASH™ system will also be compatible with Insulet Provided Glooko for easy data upload, improved care team collaboration, and access to meaningful data context which will allow for informed diabetes management decisions. Come to our Product Theater to learn more about the Omnipod® DASH™ System and Insulet’s commitment to reducing the burden of diabetes for health care providers, users, and their caregivers.

Caution: Pending 510(k) clearance. Not available for sale in the U.S.

**Presenters:** Trang Ly, MBBS, FRACP, PhD  
Senior Vice President and Medical Director  
Insulet Corporation  
Billerica, MA

Daniel DeSalvo, MD  
Assistant Professor of Pediatrics of Diabetes & Endocrinology  
Baylor College of Medicine/Texas Children’s Hospital  
Houston, TX

**Location:** Product Theater 1 (Booth 173)

---

12:30 p.m.-1:30 p.m.

**A Treatment Option for Adults with Type 2 Diabetes**

*Presented by Merck & Co., Inc.*

Review select prescribing information for a type 2 diabetes therapeutic option.

**Presenter:** Lance Sloan, MD, FACE, FASN  
Private Practice  
Lufkin, TX

**Location:** Product Theater 2 (Booth 1472)
Listed below are the exhibitors for the 78th Scientific Sessions along with their booth numbers and a brief description of the products and services they provide. Exhibitors are also listed by product category at the end of this section.

Abbott  
**Booth 712**
Abbott is a global leader in rapid diagnostic tests that deliver the right care, at the right time. Our comprehensive portfolio of tests for infectious disease, cardiometabolic disease, and toxicology provide fast, reliable, and actionable information that help improve quality of care and enable better clinical and economic health outcomes.

Abbott Laboratories  
**Booth 602**
Abbott believes people with diabetes should enjoy active lives, so we develop innovative products to help people with diabetes manage their health more effectively and comfortably. Our groundbreaking sensing technology is revolutionizing how people monitor glucose and providing physicians with more data to make better informed treatment decisions.

ACCUSPLIT, Make A Difference Programs  
**Booth 873**
ACCUSPLIT certified accurate for research pedometers will start your DPP clients on the road to wellness. Stanford Meta Study shows pedometer users increase physical activity by 26.9%. It’s all about ACCURACY…it’s in our name!

AEGLE Palette  
**Booth 715**
For people with diabetes and their clinicians who struggle to accurately track nutrients intake, lifestyle data, and health outcomes, Palette—GPS for health—is a platform that connects diet and behavior with health goals and provides insight needed to guide diabetes care and patient education.

Agilent Technologies Inc.  
**Booth 732**
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. Agilent employs about 13,500 people worldwide.

Akcea Therapeutics  
**Booth 513**

Akcea Therapeutics  
**Booth 624**

ALPCO  
**Booth 762**
ALPCO is a leading manufacturer and provider of diabetes and obesity-related assays such as insulin, c-peptide, glucagon, and GLP-1. We offer solutions for investigation in the areas of alpha and beta-cell hormones, adipokines, incretins, satiety hormones, and many more.

Amarin Pharma, Inc.  
**Booth 723**
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa®, visit [www.vascepa.com](http://www.vascepa.com). For more information visit [www.amarincorp.com](http://www.amarincorp.com).

AMCR Institute, Inc.  
**Booth 442**
AMCR Institute is a clinical research center (Ph I-IV) carrying out medical device and bio-pharmaceutical research from feasibility to pivotal in pediatric and adult populations. Expect extensive glucose clamp experience, fast and high-numbers enrollment from a comprehensive proprietary volunteer-database, and additionally, all aspects of human factors testing (formative, summative).
American Association of Clinical Endocrinologists (AACE)  
Booth 972  
The world’s largest collection of practicing clinical endocrinologists, the AACE has designed membership benefits with your professional needs in mind. We offer respected, clinical practice guidelines, discounts on meetings, an array of online educational resources, and free patient materials. To learn more about the benefits of AACE membership, visit www.aace.com/membership.

American Association of Diabetes Educators (AADE)  
Booth 1172  
AADE is a multi-disciplinary professional membership organization dedicated to improving diabetes care through innovative education, management, and support. With more than 14,000 members (nurses, dietitians, pharmacists, exercise specialists, and others) AADE has a vast network of practitioners working with people who have, are affected by, or at risk for diabetes.

American College of Physicians (ACP)/Annals of Internal Medicine  
Booth 1272  
The American College of Physicians is the largest medical specialty organization in the United States, whose goal is to enhance the quality and effectiveness of health care. Stop by booth 1272; register to be an Annals Peer Reviewer, collect clinical topics, and pre-order MKSAP 18 before the July 31 release.

American Council on Exercise (ACE)  
Booth 1273  
The American Council on Exercise (ACE) educates, certifies, and represents more than 75,000 currently certified fitness professionals, health coaches, and other allied health professionals. ACE advocates for a new intersection of fitness and health care, bringing the highly qualified professionals ACE represents into the health care continuum.

American Diabetes Association  
Booth 1453  
Visit the ADA Exhibit at booth 1453 in the Exhibit Hall and get the latest tools to help you and your patients better manage and prevent diabetes. Pick up free copies of our professional journals and Diabetes Forecast®. Learn about the Association’s patient materials and programs, recognized education program, and other professional resources. You’ll also be able to join our Advocacy program’s efforts to bring down barriers for people with diabetes and encourage the funding of diabetes research.

American Podiatric Medical Association (APMA), Inc.  
Booth 1175  
APMA is the premier professional organization representing the nation’s doctors of podiatric medicine (podiatrists). APMA is committed to advancing the profession of podiatric medicine and surgery for the benefit of its members and the public.

Amgen, Inc.  
Booth 1503  
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Ansh Labs LLC  
Booth 1366  
New glucagon regulation assays from Ansh Labs are fueling progress in the study of metabolic disease. A deeper understanding of glycemic control and the pathophysiology of diabetes may lead to safer and more effective treatments. Our assays are accurate, reliable, and highly specific, with a turn-around of approximately 2.5 hours.

Ascensia Diabetes Care  
Booth 542  
Ascensia Diabetes Care is a global specialist diabetes care company. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve lives. Home to the world-renowned CONTOUR®NEXT Portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality.
AstraZeneca
Booth 1203
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas—oncology, cardiovascular and metabolic diseases, and respiratory. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Bayer
Booth 1037
Bayer is a global life sciences leader in cardiopulmonology, hematology, neurology, oncology, and women’s health. Building on a 150-year legacy in health care, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.

BD Medical—Diabetes Care
Booth 653, 658
For nearly 90 years, BD’s culture of innovation and continuous improvement has enhanced the patient experience to enable better diabetes therapy and outcomes. BD pen needles and insulin syringes are designed with leading technology to support earlier initiation and better adherence to injectable therapies, helping diabetes patients live healthier lives.

Bentham Science Publishers Limited
Booth 524
Bentham Science Publishers is a major STM journal and e-book publisher of 130 plus journal titles and over 700 e-books, helping to answer the information needs of the pharmaceutical and biomedical research community.

Best of American Diabetes Association/Encore Medical Education, LLC
Booth 615
Bring the official ADA Scientific Sessions education to clinicians who are unable to be here. Live meetings with ADA faculty, webcasts of the Scientific Sessions presentations and more. For more information, contact ADA’s exclusive representative, Lidia Martin, at lidia.martin@encremeded.com.

Biocytogen LLC
Booth 617
Biocytogen was founded in 2009 and headquartered in Beijing, with two other affiliates in the U.S. and China. Our expertise includes generating customized gene-targeted animal models, supplying immuno-oncology mouse models, and performing preclinical pharmacological/pharmadynamics studies. Our single/double humanized immune checkpoint mouse models are powerful tools for R&D of I-O antibodies and combinational therapies.

Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC
Booth 837
Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA welcome you and look forward to the opportunity to share the latest clinical information on our products. Visit www.us.boehringer-ingelheim.com, follow us on twitter at @boehringerus. Our diabetes alliance also welcomes you to visit www.lilly.com.

Calmoseptine, Inc.
Booth 519
Calmoseptine® Ointment protects and helps heal skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal and vaginal fistulas, and feeding tube site leakage. Calmoseptine® temporarily relieves discomfort and itching. Free samples at our booth!

Center for Hope of the Sierras
Booth 866
Center for Hope of the Sierras provides a setting ideal for healing and recovery for women and men all genders age 7+ suffering from anorexia, bulimia, binge eating, and other eating disorders. We also treat co-occurring disorders such as depression, bipolar disorder, as well as various addictions.

Colgate-Palmolive Co.
Booth 437
Covance Inc.
Booth 1417
Covance and Chiltern, a Covance company, make the drug development business of LabCorp. As the world’s most comprehensive drug development company, we are dedicated to advancing health care through a Designed Around You® experience and delivering Solutions Made Real®. Information on our solutions can be obtained through our website at www.covance.com.

Crown Bioscience
Booth 1615
CrownBio’s metabolic disease portfolio enables our clients to take strategic go/no-go decisions as they progress their therapeutic candidates through various stages of drug development. Our platform of rodent and non-human primates (NHP), to model human diabetes and diabetic complications, is used to predict human efficacy and safety of therapeutic candidates.

Cyagen Biosciences
Booth 1367
Cyagen Biosciences is the world’s leading provider of custom mouse and rat models including transgenic, knockout, knockin, CRISPR, humanization, and more. Cyagen’s sister company, VectorBuilder, offers complete outsourcing for vector construction, cloning, and virus packaging with sequence and titer guarantees, with costs typically less than DIY.

Data Sciences International (DSI)
Booth 1372
Data Sciences International (DSI) is a biomedical research company offering telemetry, instrumentation, software, and services that help advance science. DSIs Continuous Glucose Telemetry line for in vivo studies gives researchers the ability to collect continuous glucose data from freely moving animals, contributing to improved animal welfare and higher quality data.

Dexcom, Inc.
Booth 1237
Dexcom, Inc., headquartered in San Diego, CA, provides continuous glucose monitoring (CGM) products for people with diabetes as young as two years old. The Dexcom G6™ CGM System does not require finger sticks for calibration of diabetes treatment decisions and features customizable alerts that can proactively warn of dangerous highs and lows.

DiabetOmics, Inc.
Booth 623
DiabetOmics, Inc. is a global medical diagnostics company pioneering innovative, non-invasive point-of-care tests for the detection and monitoring of diabetes. Our mission is to advance the health and well-being of people with, or at risk for, diabetes through simple, cost-effective, and easily accessible care.

Dkbmed
Booth 531
ePulmonology Review, a journal club-style series of topic-focused newsletters and paired podcasts that summarizes recent and relevant literature, curated and moderated by expert faculty. Stay current with the world of pulmonology while earning CME/CE credits. Free, online, and available when you are.

Dove Medical Press Ltd.
Booth 864
Dove Medical Press (www.dovepress.com) is an open-access publisher of 90+ peer-reviewed biomedical and scientific journals. We focus on medicine, drug treatment, clinical risk management, outcomes research, and adherence across a breadth of disease states and technologies, biology, and basic sciences.

Dr. Comfort
Booth 415
Dr. Comfort offers the finest quality, best looking diabetic footwear available. In addition, Dr. Comfort features an onsite pedorthic laboratory that offers custom inserts, toe fillers, and various shoe modifications. Combining the best diabetic footwear … with exceptional customer service makes Dr. Comfort America’s premier diabetic footwear brand.

Elsevier
Booth 1267
Elsevier is a global information analytics business that helps institutions and professional’s advance health care, open science, and improve performance for the benefit of humanity. The Lancet is a family of world-class journals committed to improving lives through medical research. The Lancet publishes specialty journals, including The Lancet Diabetes and Endocrinology.
Endocrine Today and Healio.com by SLACK Inc.

Booth 613
Visit booth 613 for your free issue of Endocrine Today—your number one news source for diabetes and endocrine disorders. Endocrine Today delivers the right mix of news reports on clinical issues, socioeconomic topics, industry developments, and so much more! We’re reporting live! Follow what’s trending at www.healio.com/endocrinology.

EOFLOW Co., Ltd.
Booth 423
EOFLOW provides wearable disposable insulin pump product, EOPatch, which talks to continuous glucose sensors. It will be software-upgraded to provide an automatic insulin delivery solution. It is also developing a wearable artificial pancreas system, EOPancreas, integrating a CGMS and an insulin pump into one small module. Looking for distribution partners worldwide.

European Association for the Study of Diabetes (EASD)
Booth 1073
The European Association for the Study of Diabetes e.V. (EASD) is a non-profit, medical scientific Association. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge, and to facilitate its application.

Expo Enterprise, Inc.
Booth 439
We promote medical bracelets.

Fitscript, LLC
Booth 1466
Fitscript’s patented GlucoseZone program is the first digital exercise solution designed specifically for people to manage and control their diabetes. Based on user’s real-time biometrics, GlucoseZone provides individualized guidance to help users lose weight, lower A1c, and reduce their need for medications. Learn more at www.glucosezone.com.

Geisinger
Booth 977
Geisinger serves more than 3 million people in Pennsylvania. Geisinger is nationally recognized for innovative practices and quality care. A mature electronic health record connects a comprehensive network of 13 hospital campuses, two research centers, and nearly 1,600 Geisinger primary and specialty care physicians.

Glenmark Pharmaceuticals Ltd.
Booth 1666
Glenmark is a leading player in the discovery of new molecules. Our generic business services the requirements of developed markets like the United States and Western Europe. With 17 manufacturing facilities and five R&D centers, we are committed to creating “a new way for a new world.”

Glooko
Booth 1137
Glooko is the digital platform that provides insights to improve diabetes management. Compatible with 80+ diabetes devices, Glooko gives patients and providers a unified view of diabetes data, enables both patients and care teams to make data-driven health decisions, and supports patient populations.

Glutalor Medical Inc.
Booth 553
Glutalor Medical, based in west suburban Philadelphia, specializes in the development and manufacturing of advanced continuous glucose monitoring (CGM) devices. Its leading iWel CGM system offers real-time glucose readings and alerts but no inserting devices. It is being used in tens of thousands of patients in other countries.

Glytec, LLC
Booth 1345
Glytec combines evidence-based decision support technologies with expert clinical services to optimize insulin therapies in the hospital and at home. The company’s patented software solutions improve the safety and health of people with diabetes and make insulin a more effective medication option for millions unable to achieve their treatment goals.
Good Measures, LLC  
**Booth 867**  
An innovator in nutrition science, Good Measures tackles disease and prevention in a whole new way: through food. We combine breakthrough technology and clinical coaching to help people improve their health one bite at a time. Our goal: sustainable behavior change through better nutrition.

Hawaiian Moon  
**Booth 630**  
Say goodbye to dry skin with Hawaiian Moon Organic Aloe Cream! It is free of dyes, fragrance, parabens, sulfates, mineral oil, and any other harsh chemicals, including petroleum. Our cream penetrates the skin up to 7 layers deep and absorbs into the skin instantly.

High Point Clinical Trials Center (HPCTC)  
**Booth 419**  
High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since 2008. Our 42,000 ft. facility consists of three unique units for execution of outpatient and inpatient clinical studies. In addition to healthy normal, HPCTC focuses on specialty populations in metabolic diseases, including diabetes, NASH, and renal impairment.

InBody  
**Booth 536**  
In less than 60 seconds, InBody medical-grade DSM-BIA devices provide a convenient and non-invasive assessment of muscle, fat, and body water. Tracking these and other factors such as visceral fat helps health care professionals prevent the onset of diabetes and improve treatments for diabetic patients.

InSphero Inc.  
**Booth 1567**  
InSphero is a drug discovery partner for companies investing in phenotypic 3D cell-based assays. Our 3D InSight™ disease platforms combine scalable 3D technology, standardized tissue models, optimized media, and assay services. Our research partners gain access to our experience developing and applying 3D models for toxicology, metabolic diseases (diabetes/NASH), and oncology.

Insulet Corporation  
**Booth 1603**  
Insulet Corporation is an innovative medical device company. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. The simple, wearable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle.

International Diabetes Center  
**Booth 1274**  
International Diabetes Center at Park Nicollet is a not-for-profit organization whose mission is to improve the lives of people living with diabetes by providing world-class diabetes care, education, and clinical research to meet the needs of people with diabetes, their families, and the health professionals who care for them.

Janssen Pharmaceuticals, Inc.  
**Booth 1522**  
Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, aims to create a world without disease. We bring together the best minds and pursue the most promising science in areas of critical need. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com.

Karger Publishers  
**Booth 631**  
Publications include the book series *Endocrine Development, Frontiers in Diabetes, and Frontiers of Hormone Research* and the journal *Hormone Research in Paediatrics*. Karger will also be presenting information on the topic article, *Package Diabetes*.

KRONUS®, Inc.  
**Booth 636**  
KRONUS®, a leading provider of specialized immunoassay test kits for over 30 years, will be presenting information on test kits useful in the assessment of various organ-specific autoimmune diseases. Please take a few moments to visit our informative exhibit at booth 636 to learn more about our complete product line.
LG Chem
Booth 453
Gemigliptin is the novel molecules in DPP-IV inhibitor class developed by LG Chem. LG Chem has served as Korea’s representative chemical company, contributing to the enhancement of the quality-of-life through continuous technological development, new product introduction, and quality innovation based on its stable growth.

LifeScan
Booth 324
LifeScan, Inc. is a world leader in blood glucose monitoring, and the Johnson & Johnson Diabetes Institute is a global initiative to improve care and better outcomes worldwide through education and training programs. Globally, more than 20 million people depend on OneTouch® brand products to help them manage their diabetes.

LMC | Manna Research
Booth 1266
LMC Healthcare: Canada’s largest specialist group in Diabetes & Endocrinology—50 Endocrinologists, single EMR, 11 centres of excellence managing over 200,000 patients. LMC | Manna Research is an industry leader providing Phase I-IV clinical trial services with access to one of the largest fully owned/operated research site networks in North America.

MannKind Corporation
Booth 403
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products, based on its proprietary Technosphere® technology platform, for people living with diseases such as diabetes and pulmonary arterial hypertension. MannKind is headquartered in Westlake Village, California.

Mary Ann Liebert, Inc.
Booth 713
Diabetes Technology & Therapeutics is the official journal of the advanced technologies and treatments for diabetes and the only peer-reviewed journal providing information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes, comprehensive coverage of cutting-edge technologies, and therapeutics in the field.

Med Angel
Booth 533
Clinical research, computer software, glucose monitors, laboratory research products.

Medscape Diabetes & Endocrinology
Booth 1511
Medscape Diabetes & Endocrinology is the leading online destination for physicians and health care professionals worldwide, offering the latest medical news and expert perspectives as well as essential point-of-care drug and disease information, and continuing medical education in a variety of engaging formats.

Medtronic, Inc.
Booth 639
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. Visit us at www.medtronicdiabetes.com.

Mellitus Health
Booth 730
Based on 50 years of research by Mayer B. Davidson, MD, Mellitus Health’s algorithm-based solution helps clinicians tailor injectable insulin dosing in seconds to markedly lower HbA1c levels within 180 days in many patients, even those with hard-to-manage diabetes. It works with all insulins/combinations and all 125 dosing regimens.

Merck & Co., Inc.
Booth 1437
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases around the world.
Mercodia, Inc.
Booth 1322
Mercodia is an immunoassay developer in CVD/Metabolism since 1991. We have research-use and FDA-validated immunoassays that meet stringent criteria for moving a therapeutic from research to clinic. We are the gold standard for measuring glucagon, giving researchers the tools necessary to identify associations and causal roles for biomarkers in metabolic disease.

Metabolic Endocrine Education Foundation (MEEF)
Booth 973
Metabolic Endocrine Education Foundation (MEEF) sponsors educational activities for professional health providers. This year’s events include the 2nd HiD, July 13-15, 2018, in Philadelphia (www.heartindiabetes.com) and the 16th WCIRDC, November 29-December 1, 2018, in Los Angeles (www.wcir.org). A leading national health foundation devoted to improving patients and public health through education.

Monarch Medical Technologies
Booth 516
Monarch Medical Technologies is the leading provider of precision insulin dosing technology for optimized inpatient glycemic management. Monarch’s EndoTool® Glucose Management System is an FDA-cleared software suite that is user proven and has complex algorithms to model, predict, and adapt dosing recommendations to each patient and their individual responses for more precise and safer insulin therapy.

Monogenic Diabetes Research and Advocacy Project (MDRAP)
Booth 1177
MDRAP is an alliance of patients, health care providers, and scientists dedicated to promoting awareness and diagnosis of monogenic diabetes, which accounts for approximately 1/50 cases of diabetes, or approximately 600,000 people in the United States, in order to assure safe and efficacious treatment.

National Certification Board for Diabetes Educators (NCBDE)
Booth 1174
Established in 1986, NCBDE grants recognition through board certification in the field of diabetes education to individuals who have met eligibility requirements and completed the certification examination for diabetes educators.

National Kidney Foundation (NKF)
Booth 974
The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention, and treatment of kidney disease for hundreds of thousands of health care professionals, millions of patients and their families, and tens of millions of Americans at risk.

NIDDK Information Network (dkNET)
Booth 1176
The NIDDK Information Network (dkNET; www.dknet.org) is a community resource for basic and clinical researchers that provides access to a collection of diverse research resources and associated resource reports. Building on the foundation of Research Resource Identifiers (RRIDs), dkNET also provides services to promote scientific rigor and reproducibility.

NIH-NIDDK
Booth 1173
NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts and supports medical research and translates findings to bring science-based tools and information to patients, health care providers, and the public. NIDDK addresses diabetes, obesity, nutrition; kidney, urologic, and digestive diseases; and some endocrine, metabolic, and blood disorders.

Novo Nordisk
Booth 245
Novo Nordisk, a global health care company, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions to lead longer, healthier lives with fewer limitations. We are working toward a future where fewer people get chronic diseases, everyone is diagnosed, and all patients receive adequate treatment.
Novo Nordisk A/S  
Booth 823, 1143  
Novo Nordisk, a global health care company, has been committed to discovering and developing innovative medicines to help people with serious chronic conditions lead longer, healthier lives with fewer limitations. We’re working toward a future where fewer people get chronic diseases, everyone is diagnosed, and all patients receive adequate treatment.

Office of Minority Health Research Coordination  
Booth 417

One Drop  
Booth 537  
One Drop is an evidence-based and clinically effective platform for diabetes management. The digital health company offers world class diabetes care, direct-to-consumer supplies and services, and mobile computing. One Drop users seamlessly test blood sugar, track health markers, set goals, and stay informed with data-driven insights.

OPTIFAST®/Nestlé Health Science  
Booth 526  
For over 40 years, the OPTIFAST® program has offered an evidence-based, medically monitored, multidisciplinary weight management program incorporating full meal replacement products with behavior and lifestyle modifications. The OPTIFAST® Program, as part of a medically monitored plan, can produce significant weight loss, leading to significant improvements in patients with prediabetes and diabetes.

Organogenesis Inc.  
Booth 616  
Organogenesis Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Owen Mumford  
Booth 446  
Owen Mumford is a leading global manufacturer with 60+ years expertise in the development of medical devices to aid in the treatment of diabetes and other conditions. Owen Mumford's innovative product range features Unistik® capillary sampling solutions, Unifine® pen needles, Autolet® lancing devices, and Unilet® lancets.

Pharmacy Times®  
Booth 512  
Pharmacy Times® is the leading media resource for pharmacists and the pharmacy industry, providing practical clinical and professional information. Visit Pharmacy Times® at www.pharmacytimes.com or on Facebook or Twitter. Pharmacy Times® is published by MJH Associates, Inc., a leading provider of health care media resources, research information, and education.

PIKDARE  
Booth 1223  
Pic Solution, a leading Italian diabetes care brand, presents Insupen 34Gx3, 5mm pen needle, representing the peak of a wide range (33G to 29G). Their Extr3me sharpening technology provides a comfortable injection, while the High Flow Thin Wall cannula enhances the insulin flow. BGMs, syringes, lancets, and foot care products complete the assortment.

Premier Protein  
Booth 1067  
Premier Protein offers a selection of protein shakes and powders that are high in protein and low in calories, fat, and sugar. Our products feature healthy protein that helps curb hunger and fuels your energy for whatever you love to do.

ProSciento, Inc.  
Booth 1667  
ProSciento is a full scope clinical R&D services provider, exclusively focused on diabetes, NASH, and obesity. The company is widely recognized for quality and scientific excellence, extensive experience, and scalable R&D services model—combining deep therapeutic area expertise, strategic planning, and operational execution from preclinical to Phase III readiness.
PTS Diagnostics
Booth 729
Through its People, Technology, and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices.

Research Diets, Inc.
Booth 722
Research Diets, Inc. formulates and produces purified OpenSource Diets® for laboratory animals. Custom diets shipped in 5-7 days. BioDAQ® Food/Liquid Intake Monitor for mice and rats mounts to home cage and records the time, duration, and amount of each meal automatically. BioDAQ NHP monitors food intake of socially housed NHPs.

Sable Systems International, Inc.
Booth 514
Sable Systems is the world’s most trusted provider of equipment for research in metabolic and behavior monitoring. The Promethion System measures food and water intake, food access control, body weight, total activity, running wheel, and temperature every second. The metabolic data is synchronized with all behavior data.

Sanofi and Lexicon Pharmaceuticals, Inc.
Booth 1043
Sanofi and Lexicon are biopharmaceutical companies collaborating to develop and oral medicine for the treatment of type 1 and type 2 diabetes.

Sanofi-Regeneron
Booth 803, 812
Sanofi is dedicated to supporting people through health challenges. We prevent illness with vaccines, and provide innovative treatments to fight pain and ease suffering. Regeneron discovers, develops, manufactures, and commercializes biologic medicines. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies.

Senseonics
Booth 1323, 230
Senseonics, Inc. is a medical device company developing transformative glucose monitoring products that enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Eversense® Continuous Glucose Monitoring (CGM) System is the first implantable CGM that is highly accurate throughout its long sensor life.

Siemens Healthineers
Booth 1231
Siemens Healthineers is committed to becoming the trusted partner of health care providers worldwide, enabling them to improve patient outcomes while reducing costs. We are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services. We are dedicated to helping our partners be successful—clinically, operationally, and financially.

Sinclair Research Center, LLC
Booth 1330
Sinclair Research, a preclinical CRO, offers animal efficacy models, IND enabling toxicology services, and research capabilities to the human pharmaceutical, animal health, and medical device companies. With 20+ years’ experience, Sinclair is the undisputed expert in all breeds of miniswine, we developed and maintain our own research breed, “The Sinclair.”

SOOIL Development Co., Ltd.
Booth 1217
SOOIL Development Co., Ltd. has the 39-year history of insulin pump manufacturing (since 1979) with DANA Insulin Pump. DANA pumps are small, light, accurate, and reliable with versatile connectivity. DANA pumps’ easy accessibility has made a better life for patients worldwide with diabetes.
Springer Healthcare—Medicine Matters
Booth 518
Springer Healthcare provides targeted, innovative educational content through our website Medicine Matters. Our distinguished relationships with KOLs and leading medical societies allows us to offer the latest news, conference coverage, and full journal article access to the Springer Nature portfolio of journals.

Medicine Matters
Science • Knowledge • Patient Care

Studylog Systems, Inc.
Booth 444
2015 Bio-IT Best-of-Show winner and system of choice for most top-twenty pharma/biotech’s, academic/government institutions worldwide, Studylog automates and streamlines animal study workflow, mirroring clinical trials processes, making study management easier, faster and more effective for all stakeholders across an enterprise. Studylog securely preserves study conduct information and results for perpetual use.

Sun Pharma
Booth 612

Tandem Diabetes Care Inc.
Booth 1331
Tandem Diabetes Care is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® Insulin Pump.

The Endocrine Society
Booth 716
We are the largest professional membership organization representing the field of endocrinology. Our global community of 18,000 scientists and clinicians—in all stages of their education and careers—believes in advancing science, medicine, and policy through scientific discovery and a commitment to excellence in treatment and care.

The JAMA Network
Booth 632
Building on a tradition of editorial excellence, the JAMA Network brings JAMA together with 11 specialty journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine. JAMA Network Open is a new, open access, general medical journal that will launch in 2018.

The NASH Education Program
Booth 431
The NASH Education Program is a health care initiative driven in collaboration with an independent and international scientific committee, aimed at producing and disseminating essential medical knowledge about NASH (Nonalcoholic Steatohepatitis). The objective is to develop disease awareness activities targeting multiple audiences (physicians, patients, and families) and address unmet information needs.

Tidepool
Booth 975
Tidepool makes free software for patients and clinicians that integrates data from meters, pumps, and CGMs securely in one place. Tidepool also supports diabetes clinical studies requiring device data and innovative research by licensing anonymized datasets donated by Tidepool users.

TrialNet
Booth 1072
Type 1 Diabetes TrialNet is an international network of researchers from more than 200 medical centers dedicated to studying the detection, prevention, and early treatment of type 1 diabetes. Visit us now at www.diabetestrialnet.org.

Type 2 Diabetes Knowledge Portal
Booth 1075
The T2D Knowledge Portal is an open-access resource for accelerating the translation of data into biological knowledge about the mechanisms by which genetic variation affects type 2 diabetes risk. It draws from a comprehensive, harmonized database of genetic associations and provides complementary data types and analysis tools.
University of Florida, nPOD, HPAP, HANDEL-P
Booth 1074
University of Florida is the home of three human organ donor procurement programs collecting precious and hard to find human pancreas and other tissues for T1D diabetes. These three programs include JDRF nPOD, NIH HPAP, and Helmsley HANDEL-P.

Valeritas Inc.
Booth 523
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes. Valeritas’ flagship product V-Go®, is a simpler and highly effective basal+bolus insulin delivery that is worn like a patch, improves adherence, and can eliminate the need for taking multiple daily shots.

VeroScience
Booth 427
VeroScience is focused on developing therapies to improve human health. A major platform technology is Circadian Neuroendocrine Resetting Therapy, used in Cycloset. Timed daily administration of Cycloset (bromocriptine-QR), a unique insulin sensitizer that works to reduce sympathetic activity, is FDA approved for the treatment of type 2 diabetes.

Virtual Reality Tour of Non-Statin LDL-C-lowering Agents that Decrease Cardiovascular Risk for Patients with Persistent Hypercholesterolemia
Booth 952C
Visit booth 952C in the Exhibit Hall for a virtual reality learning experience where participants will have the opportunity to wear Oculus Virtual Reality headsets and be completely immersed in a 360-degree virtual world inside a blood vessel. The learners will virtually experience what the patient is going through in terms of disease symptoms and treatment effects, which will help them learn the importance of personalized treatment, physician patient communication, and patient-reported outcomes. This learning experience will be broken into several virtual themes including:

- The Role of LDL-C in the pathophysiology of cardiovascular disease.

Voluntis, Inc.
Booth 402
Insulia® provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes while enabling the health care team to remotely monitor their progress. Insulia® is available for people using any brand of basal insulin including Lantus®, Levemir®, Toujeo®, Tresiba® (U-100), and Basaglar®.

Wake Forest
Booth 633
Wake Forest Innovations accelerates the journey from discovery to commercialization. Through open innovation with industry we transform ideas, discoveries, and inventions into valuable health care products. We provide industry access to Wake Forest’s basic science scholarship, proprietary technologies for licensing, and specialized preclinical and clinical research services.

Welch Allyn
Booth 862
Welch Allyn, a leading medical device company and division of Hill-Rom (NYSE: HRC), is your strategic and tactical partner for simple and affordable patient-centered solutions.

RetinaVue™ Network is a simple and affordable teleretinal solution to increase diabetic retinal exam compliance in primary health care settings, improving outcomes and quality measures.

Wiley
Booth 717
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment, and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.
Xeris Pharmaceuticals
Booth 508
Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations. The company’s formulation delivery technology enables ultra-low injection volume, room-temperature stable solutions, or suspensions delivered via commercially available injection or infusion options.
### Exhibitors by Product Category/Booth Number

#### Animal Models
- Biocytogen LLC ......................................................... 617
- Covance Inc. ............................................................... 1417
- Cyagen Biosciences ................................................... 1367
- Data Sciences International (DSI) ................................. 1372
- NIDDK Information Network (dkNET) ......................... 1176
- Research Diets, Inc. .................................................... 722
- Sable Systems International, Inc. ................................. 514
- Sinclair Research Center, LLC ..................................... 1330

#### Biologics Development
- Covance Inc. ............................................................... 1417

#### Body Fat Analyzers
- InBody ............................................................................. 536

#### Cell Lines & DNA
- Biocytogen LLC ......................................................... 617
- Crown Bioscience ........................................................ 1615
- NIDDK Information Network (dkNET) ......................... 1176

#### Certification
- American Council on Exercise (ACE) ............................ 1273
- American Diabetes Association ...................................... 1453
- National Certification Board for Diabetes Educators (NCDDE) ................................................. 1174

#### Clinical Research
- ACCUSPLIT, Make A Difference Programs ....................... 873
- AMCR Institute, Inc. ...................................................... 442
- American Association of Clinical Endocrinologists (AACE) ................................................................. 972
- Covance Inc. ............................................................... 1417
- Glooko ............................................................................ 1137
- High Point Clinical Trials Center (HPCTC) ..................... 419
- International Diabetes Center ........................................ 1274
- LMC I Manna Research .................................................. 1266
- Med Angel ....................................................................... 533
- Medscape Diabetes & Endocrinology ............................ 1511
- National Kidney Foundation (NKF) ................................. 974
- NIH-NIDDK ................................................................. 1173
- Novo Nordisk A/S ........................................................ 823, 1143
- ProSciento, Inc. ............................................................. 1667
- PTS Diagnostics ............................................................ 729
- The Endocrine Society .................................................. 716
- TrialNet ........................................................................... 1072
- VeroScience .................................................................... 427
- Wake Forest .................................................................... 633
- Welch Allyn ..................................................................... 862

#### CME/Online Programs
- American Association of Clinical Endocrinologists (AACE) ................................................................. 972
- American Association of Diabetes Educators (AADE) ................................................................. 1172
- American College of Physicians (ACP)/Annals of Internal Medicine ................................................. 1272
- American Diabetes Association ........................................ 1453
- American Podiatric Medical Association (APMA), Inc. ................................................................. 1175
- Best of American Diabetes Association/Encore Medical Education, LLC ............................................. 615
- Dkbmed ........................................................................... 531
- International Diabetes Center ........................................ 1274
- Medscape Diabetes & Endocrinology ............................ 1511
- Metabolic Endocrine Education Foundation (MEEF) ........................................................................... 973
- National Kidney Foundation (NKF) ................................ 974
- Springer Healthcare—Medicine Matters ........................ 518
- The Endocrine Society ................................................... 716
- The JAMA Network ........................................................ 632

#### Computer Software
- AEGLE Palette ............................................................... 715
- Covance Inc. ............................................................... 1417
- Data Sciences International (DSI) ................................. 1372
- Fitscript, LLC ............................................................... 1466
- Glooko ............................................................................ 1137
- Glytec, LLC ................................................................. 1345
- Med Angel ....................................................................... 533
- Mellitus Health ............................................................... 730
- Monarch Medical Technologies ...................................... 516
- NIDDK Information Network (dkNET) ........................ 1176
- Studylog Systems, Inc. ................................................... 444
- Tidepool ........................................................................... 975
- Type 2 Diabetes Knowledge Portal ................................ 1075
- Voluntis, Inc. ................................................................. 402

#### Diagnostic Equipment
- Abbott ............................................................................ 712
- Covance Inc. ............................................................... 1417
- LifeScan ........................................................................... 324
- Siemens Healthineers ................................................... 1231
- Welch Allyn ..................................................................... 862

#### Dietary Products
- AEGLE Palette ............................................................... 715
- OPTIFAST®/Nestlé Health Science ................................ 526
- Research Diets, Inc. ...................................................... 722

#### Durable Medical Equipment
- LifeScan ........................................................................... 324
- Owen Mumford ............................................................. 446

#### Educational Materials
- AEGLE Palette ............................................................... 715
- American Association of Clinical Endocrinologists (AACE) ................................................................. 972
- American Association of Diabetes Educators (AADE) ................................................................. 1172
- American Council on Exercise (ACE) ............................ 1273
- American Diabetes Association ........................................ 1453
- American Podiatric Medical Association (APMA), Inc. ................................................................. 1175
Data Sciences International (DSI) ................................ 1372
Mercodia, Inc. .............................................................1322
Sanofi-Regeneron ................................................... 803, 812
Novo Nordisk A/S ................................................823, 1143
Mellitus Health ..............................................................730
Medtronic, Inc. .............................................................. 639
Mellitus Health ..............................................................730
Monarch Medical Technologies ................................. 516
Owen Mumford .............................................................446
EOFLOW Co., Ltd. ..........................................................423
SOOIL Development Co., Ltd. .......................................1217
Tandem Diabetes Care Inc. ........................................1331
Tidepool ...............................................................975
Voluntis Inc. .................................................................523
Voluntis, Inc. .................................................................402

**Exercise Equipment**

- ACCUSPLIT, Make A Difference Programs ....................873
- Fitscript, LLC ............................................................1466

**Foot Care/Footwear**

- American Podiatric Medical Association (APMA), Inc. ....1175
- Dr. Comfort ...............................................................415
- LMC I Manna Research ............................................1266
- PIKDARE .................................................................1223

**Glucose Monitors**

- Data Sciences International (DSI) ..............................1372
- Dexcom, Inc. ................................................................1237
- EOFLOW Co., Ltd. ......................................................423
- Glutalar Medical Inc. ...................................................553
- LifeScan .................................................................324
- Med Angel .................................................................533
- Mellitus Health .............................................................730
- One Drop ..................................................................537
- PIKDARE .................................................................1223
- Senseonics ...............................................................1323, 230
- Tidepool .................................................................975

**Immunoassay Kits**

- ALPCO ........................................................................ 762
- Ansh Labs LLC ...........................................................1366
- Crown Bioscience ......................................................1615
- KRONUS®, Inc. ............................................................636
- Mercodia, Inc. .............................................................1322

**Infusion Products**

- Data Sciences International (DSI) ..............................1372
- EOFLOW Co., Ltd. ......................................................423
- Medtronic, Inc. ............................................................. 639

**Injection Aids**

- Medtronic, Inc. ............................................................. 639

**Insulin**

- Mellitus Health .............................................................730
- Novo Nordisk A/S ...................................................... 823, 1143
- Sanofi-Regeneron .......................................................803, 812
- Voluntis, Inc. .................................................................402

**Insulin Delivery**

- BD Medical—Diabetes Care ........................................ 653, 658
- EOFLOW Co., Ltd. ...................................................... 423
- Glytec, LLC .................................................................1345

**In Vitro Diagnostics**

- Alphabio .................................................................1304
- Ansh Labs LLC ...........................................................1366
- Crown Bioscience ......................................................1615
- Mercodia, Inc. .............................................................1322
- PTS Diagnostics ..........................................................729

**Laboratory Research Products**

- ALPCO ........................................................................ 762
- Covance Inc. .............................................................1417
- Cyagen Biosciences ..................................................1367
- InSphero Inc. ..............................................................1567
- Med Angel ...................................................................533
- Mercodia, Inc. .............................................................1322
- PTS Diagnostics ..........................................................729
- Research Diets, Inc. ....................................................722
- Sable Systems International, Inc. .................................514
- Studylog Systems, Inc. ...............................................444

**Laboratory Services**

- Covance Inc. .............................................................1417
- Cyagen Biosciences ..................................................1367
- InSphero Inc. ..............................................................1567
- LMC I Manna Research ............................................1266
- Mercodia, Inc. .............................................................1322

**Lancets**

- One Drop ..................................................................537
- Owen Mumford ...........................................................446
- PIKDARE .................................................................1223

**Market Research**

- Covance Inc. .............................................................1417
- NIH-NIDDK .............................................................1173

**Medical Devices**

- Abbott ................................................................. 712
- Abbott Laboratories ......................................................602
- AEGLE Palette ........................................................... 715
- American College of Physicians (ACP)/
  *Annals of Internal Medicine* ..................................... 1272
- Ascensia Diabetes Care .............................................. 542
- BD Medical—Diabetes Care .......................................653, 658
- Covance Inc. .............................................................1417
- Data Sciences International (DSI) ............................1372
- DiabetOnics, Inc. ..........................................................623
- EOFLOW Co., Ltd. ...................................................... 423
- Glytec, LLC .................................................................1345
- InBody ................................................................. 536
- LifeScan ................................................................. 324
Mellitus Health .......................................................... 730
Monarch Medical Technologies .................................. 516
One Drop ................................................................. 537
Owen Mumford ......................................................... 446
PKDARE .................................................................. 1223
PTS Diagnostics ......................................................... 729
Senseonics ................................................................. 1323, 230
SOOIL Development Co., Ltd. ................................. 1217
Tidepool ................................................................. 975
Valeritas Inc. ............................................................ 523
Voluntis, Inc. ............................................................. 402
Welch Allyn ............................................................... 862

Monitors
AEGLE Palette .......................................................... 715
Data Sciences International (DSI) ............................ 1372
EOFLOW Co., Ltd. ..................................................... 423
Glooko .................................................................. 1137
Medtronic, Inc. ......................................................... 639
Senseonics ................................................................. 1323, 230
Voluntis, Inc. ............................................................. 402

Non-Profit Organizations
American Association of Clinical Endocrinologists (AACE) .............................................................................. 972
American Association of Diabetes Educators (AADE) .................................................................................... 1172
American College of Physicians (ACP)/
Annals of Internal Medicine ........................................ 1272
American Council on Exercise (ACE) ........................... 1273
American Diabetes Association ..................................... 1453
American Pediatric Medical Association (APMA), Inc. ................................................................................... 1175
European Association for the Study of Diabetes (EASD) .................................................................................. 1073
Geisinger .................................................................. 977
International Diabetes Center .................................... 1274
Monogenic Diabetes Research and Advocacy Project (MDRAP) ................................................................. 1177
NIDDK Information Network (dkNET) .......................... 1176
NIH-NIDDK .............................................................. 1173
The Endocrine Society ................................................ 716
The NASH Education Program .................................... 431
Tidepool ................................................................. 975

Online Programs
AEGLE Palette .......................................................... 715
American Association of Clinical Endocrinologists (AACE) .............................................................................. 972
American Council on Exercise (ACE) ........................... 1273
American Diabetes Association ..................................... 1453
Fitscript, LLC ............................................................ 1466
Good Measures, LLC ................................................ 867
LifeScan ................................................................. 324
Medscape Diabetes & Endocrinology ............................ 1511
Mellitus Health .......................................................... 730
NIH-NIDDK .............................................................. 1173
One Drop ................................................................. 537
Springer Healthcare—Medicine Matters .......................... 518
Voluntis, Inc. ............................................................. 402

Other
ACCUSPLIT, Make A Difference Programs .................... 873
AEGLE Palette .......................................................... 715
AMCR Institute, Inc. .................................................. 442
Best of American Diabetes Association/
Encore Medical Education, LLC ................................. 615
Center for Hope of the Sierras ..................................... 866
Cyagen Biosciences .................................................. 1367
Fitscript, LLC ............................................................ 1466
Glytec, LLC ............................................................... 1345
Good Measures, LLC ................................................ 867
NIDDK Information Network (dkNET) .......................... 1176
OPTIFAST®/Nestlé Health Science .................................. 526
Premier Protein ........................................................ 1067
Springer Healthcare—Medicine Matters .......................... 518
Voluntis, Inc. ............................................................. 402
Welch Allyn ............................................................... 862

Patient Services
AEGLE Palette .......................................................... 715
American Association of Clinical Endocrinologists (AACE) .............................................................................. 972
Center for Hope of the Sierras ..................................... 866
Good Measures, LLC ................................................ 867
LMC I Manna Research .............................................. 1266
National Kidney Foundation (NKF) .............................. 974
NIH-NIDDK .............................................................. 1173
Voluntis, Inc. ............................................................. 402

Pharmaceuticals
Amarin Pharma, Inc. .................................................... 723
Amgen, Inc. ................................................................ 1503
AstraZeneca ............................................................. 1203
Bayer ...................................................................... 1037
Glenmark Pharmaceuticals Ltd. .................................... 1666
Janssen Pharmaceuticals, Inc. ...................................... 1522
MannKind Corporation ............................................... 403
Merck & Co., Inc. ....................................................... 1437
Novo Nordisk A/S ....................................................... 823, 1143
Sanofi-Regeneron ..................................................... 803, 812
Sinclair Research Center, LLC ..................................... 1330
VeroScience ............................................................. 427
Xeris Pharmaceuticals ............................................... 508

Professional Services
AMCR Institute, Inc. .................................................. 442
American Diabetes Association ..................................... 1453
Best of American Diabetes Association/
Encore Medical Education, LLC ................................. 615
Center for Hope of the Sierras ..................................... 866
Glytec, LLC ............................................................... 1345
Good Measures, LLC ................................................ 867
International Diabetes Center ..................................... 1274
Medscape Diabetes & Endocrinology ............................ 1511
One Drop ................................................................. 537
PTS Diagnostics ......................................................... 729
The Endocrine Society ................................................ 716
Publications
American Association of Clinical Endocrinologists (AACE) ........................................... 972
American Association of Diabetes Educators (AADE) ............................................. 1172
American College of Physicians (ACP)/Annals of Internal Medicine .......................... 1272
American Diabetes Association .......................................................... 1453
American Podiatric Medical Association (APMA), Inc. ........................................... 1175
Bentham Science Publishers Limited .......................................................... 524
Best of American Diabetes Association/Encore Medical Education, LLC ................. 615
Endocrine Today and Healio.com by SLACK Inc. .................................................. 614
International Diabetes Center .......................................................... 1274
Karger Publishers .................................................................................. 631
LifeScan ............................................................................................... 324
Mary Ann Liebert, Inc. ........................................................................... 713
One Drop .............................................................................................. 537
Pharmacy Times® ................................................................................ 512
Springer Healthcare—Medicine Matters .................................................................. 518
The Endocrine Society ............................................................................ 716
The JAMA Network ................................................................................ 632
Wiley ........................................................................................................ 717

Recruitment
American Association of Clinical Endocrinologists (AACE) ........................................... 972
Geisinger ............................................................................................... 977
LMC | Manna Research ........................................................................ 1266

Research
ACCUSPLIT, Make A Difference Programs .................................................. 873
AEGLE Palette ........................................................................................ 715
AMCR Institute, Inc. ............................................................................. 442
Biocytogen LLC ...................................................................................... 617
Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC .................................. 837, 619
Covance Inc. ........................................................................................... 1417
Crown Bioscience .................................................................................. 1615
Data Sciences International (DSI) ..................................................................... 1372
InSphero Inc. ........................................................................................... 1567
International Diabetes Center ........................................................................ 1274
Medscape Diabetes & Endocrinology ................................................................... 1511
Monogenic Diabetes Research and Advocacy Project (MDRAP) ....................... 1177
National Kidney Foundation (NKF) .................................................................... 974
NIDDK Information Network (dkNET) .................................................................. 1176
NIH-NIDDK .............................................................................................. 1173
Sable Systems International, Inc. ........................................................................ 514
Sinclair Research Center, LLC ......................................................................... 1330
Studylog Systems, Inc. .................................................................................. 444
The Endocrine Society .................................................................................. 716
Tidepool ..................................................................................................... 975
TrialNet ...................................................................................................... 1072
Type 2 Diabetes Knowledge Portal ..................................................................... 1075
University of Florida, nPOD, HPAP, HANDEL-P ............................................. 1074
VeroScience ............................................................................................... 427

Skin Care
Calmoseptine, Inc. ...................................................................................... 519
Hawaiian Moon ......................................................................................... 630

Specialty Reference Laboratories
Ansh Labs LLC .......................................................................................... 1366

Supplies
ACCUSPLIT, Make A Difference Programs .................................................. 873
LifeScan.................................................................................................. 324
One Drop ................................................................................................. 537

Syringes
BD Medical—Diabetes Care ........................................................................ 653, 658
PIKDARE ................................................................................................. 1223

Vision/Eye Care
LMC | Manna Research ............................................................................. 1266
Welch Allyn ............................................................................................... 862

Wound Care
Calmoseptine, Inc. ...................................................................................... 519
Organogenesis Inc. ..................................................................................... 616
It is the ADA’s policy to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All participating planning committee members are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information with which they can make their own judgments.

Gannon, Maureen A., PhD (Chair)
Disclosed no conflict of interest.

Ahmann, Andrew J., MD

Alonso, Laura C., MD
Disclosed no conflict of interest.

Basu, Rita, MD
Research Support: AstraZeneca.

Beck, Joni, PharmD, BC-ADM, CDE
Disclosed no conflict of interest.

Bellin, Melena, MD
Advisory Panel: ARIEL Precision Medicine, Inc., Novo Nordisk Inc.; Research Support: Dompé Pharmaceutical, ViaCyte, Inc.

Benninger, Richard K.P., MD
Disclosed no conflict of interest.

Biddinger, Sudha, MD, PhD
Disclosed no conflict of interest.

Busik, Julia V., PhD
Disclosed no conflict of interest.

Callaghan, Brian C., MD, MS
Consultant: Immune Tolerance Network; Research Support: Impeto Medical.

Caramori, Luiza, MD, MSc
Consultant: Bayer AG; Elcelyx Therapeutics, Inc.; Research Support: Bayer AG.

Feingold, Kenneth, MD

Finck, Brian N., PhD
Board Member: Cirius Therapeutics.

Garcia-Ocaña, Adolfo, PhD
Disclosed no conflict of interest.

Green, Jennifer B., MD

Harris, Michael A., PhD
Consultant: Eli Lilly and Company.

Hevener, Andrea L., PhD
Consultant: Eli Lilly and Company.

Horowitz, Jeffrey F. PhD
Disclosed no conflict of interest.

Hsu, William C., MD
Advisory Panel: Twine Health, Inc.; Board Member: Intarcia Therapeutics, Inc.

Kershaw, Erin E., MD
Consultant: Regeneron Pharmaceuticals, Inc.

Libman, Ingrid M., MD, PhD
Consultant: Novo Nordisk A/S.

Lingvay, Ildiko, MD, MPH, MScS

Lipska, Kasia J., MD, MHS, BS

Liu, George T., DPM, FACFAS
Consultant: Gramercy Extremity Orthopedics.

Mayer-Davis, Elizabeth J., PhD
Disclosed no conflict of interest.

Mohed, Amir, MBBS
Disclosed no conflict of interest.

Osborne, Timothy F., PhD
Disclosed no conflict of interest.

Pietropaolo, Massimo, MD
Disclosed no conflict of interest.
Pollin, Toni I., MS, PhD, CGC  
*Research Support: Regeneron Pharmaceuticals, Inc.*

Rutter, Guy A., PhD  
*Research Support: Servier.*

Seley, Jane Jeffrie, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAADE, FAAN  

Simmons, Rebecca A., MD  
*Disclosed no conflict of interest.*

Songer, Thomas, PhD, MSc, MPH  
*Disclosed no conflict of interest.*

Triplitt, Curtis L., PharmD, CDE  
**Invited Speaker Disclosure Information**

As a provider of continuing education, it is the ADA’s policy to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All participating speakers are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information with which they can make their own judgments.

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajami, Nadim J., PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Ajilore, Olusika, MD, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Albright, Ann L., PhD, RD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Alvarez, Carlos A., PharmD, MSc, MSCS, BCPS</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Aminian, Ali, MD, FACS</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Anderson, Rozalyn M., PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Aragón-Sánchez, F. Javier, MD, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Aroda, Vanita R., MD</td>
<td>Consultant: ADOCIA, Novo Nordisk Inc., Sanofi; Employee: Merck &amp; Co., Inc.; (Spouse/Partner); Other Relationship: American Diabetes Association; Research Support: AstraZeneca, Calibra Medical, Eisai Inc., Novo Nordisk Inc., Sanofi, Theracos, Inc.</td>
</tr>
<tr>
<td>Arslanian, Silva A., MD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Bacha, Fida, MD</td>
<td>Research Support: AstraZeneca, JAEB Center For Health Research, National Institutes of Health, Pediatric Diabetes Consortium.</td>
</tr>
<tr>
<td>Baidal, David, MD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Bailey, Beth, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Bakris, George, MD</td>
<td>Consultant: Abbott, CVRx, Eli Lilly and Company, Johnson &amp; Johnson, Takeda, U.S. Food and Drug Administration; Other Relationship: Forest Labs, Takeda, Medtronic, Relaypsa.</td>
</tr>
<tr>
<td>Ballin, Mary C., GNP-BC, CDE</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Baltrusch, Simone E., PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barbetti, Fabrizio, MD, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barbour, Linda (Lynn) A., MD, MSPH, FACP</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barrés, Romain, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barrett, Eugene J., MD, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barshes, Neal R., MD, MPH</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Barton, Franca B., MS</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Basu, Ananda, MBBS, MD</td>
<td>Advisory Panel: Voluntis France; Research Support: AstraZeneca (Spouse/Partner), Novo Nordisk A/S.</td>
</tr>
<tr>
<td>Battaglia, Manuela, PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
<tr>
<td>Baur, Joseph A., PhD</td>
<td>Disclosed no conflict of interest.</td>
</tr>
</tbody>
</table>
INVITED SPEAKER
DISCLOSURES

Beck, Roy W., MD, PhD

Beigneux, Anne, PhD
Disclosed no conflict of interest.

Beitelshes, Amber L., PharmD, MPH, FAHA, FCCP
Disclosed no conflict of interest.

Bergenstahl, Richard M., MD

Bergman, Richard N., PhD

Bernal-Mizrachi, Ernesto, MD
Disclosed no conflict of interest.

Best, Conor J., MD
Disclosed no conflict of interest.

Beverly, Elizabeth A., PhD
Disclosed no conflict of interest.

Bhatt, Deepak L., MD, MPH

Billings, Liana K., MD, MMSc

Bjornstad, Petter, MD
Consultant: Boehringer Ingelheim GmbH.

Blonde, Lawrence, MD

Bolli, Geremia B., MD
Research Support: Sanofi; Speaker’s Bureau: Menarini Group, Sanofi.

Boucher, Jackie L., MS, RDN
Disclosed no conflict of interest.

Bouchonville, Matthew F., II, MD
Disclosed no conflict of interest.

Bourne, Philip E., PhD, FACMI
Disclosed no conflict of interest.

Brenner, Charles, PhD

Breton, Marc D., PhD
Consultant: Sanofi; Research Support: Ascensia Diabetes Care, Dexcom, Inc., Senseonics; Speaker’s Bureau: Ascensia Diabetes Care, Roche Diabetes Care Health and Digital Solutions; Stock/Shareholder: TypeZero Technologies, Inc.

Brown, Adam, BS
Other Relationship: Ascensia Diabetes Care.

Brown, Todd T., MD, PhD
Advisory Panel: Merck & Co., Inc.

Brüning, Jens C., MD
Disclosed no conflict of interest.

Brusko, Todd M., PhD
Advisory Panel: Caladrius Biosciences, Inc.; Consultant: Merck & Co., Inc., Sanofi-Aventis; Stock/Shareholder: OneVax, LLC.

Buchanan, Thomas A., MD
Disclosed no conflict of interest.

Buckingham, Bruce A., MD

Burgess, Shawn C., PhD
Disclosed no conflict of interest.

Buse, John B., MD, PhD
National Institute of Environmental Health Sciences, NovaTarg, Novo Nordisk A/S, Sanofi, Shenzhen Hightide Biopharmaceutical, Ltd., VTV Therapeutics; Research Support: Boehringer Ingelheim GmbH, Johnson & Johnson Services, Inc., National Center for Advancing Translational Sciences, National Heart, Lung, and Blood Institute, Patient-Centered Outcomes Research Institute, Theracos, Inc.

Butler, Javed, MD, MPH, MBA
Consultant: Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, CVRx, Janssen, Luitpold, Medtronic, Novartis, Relypsa, Vifor, ZS Pharma; Speaker’s Bureau: Janssen Pharmaceuticals, Inc., Novartis.

Butler, Peter C., MD
Disclosed no conflict of interest.

Caballero, A. Enrique, MD
Disclosed no conflict of interest.

Campbell-Thompson, Martha L., DVM, PhD
Disclosed no conflict of interest.

Cao, Lei, PhD
Disclosed no conflict of interest.

Caprio, Sonia, MD
Disclosed no conflict of interest.

Caprioli, Richard, PhD
Disclosed no conflict of interest.

Carlsson Ekander, Lena, MD, PhD
Other Relationship: AstraZeneca, Johnson & Johnson Services, Inc., Merck Sharp & Dohme Corp.

Carpentier, André C., MD

Carroll, Ian, PhD
Disclosed no conflict of interest.

Castle, Jessica R., MD
Advisory Panel: Novo Nordisk Inc.; Consultant: Zealand Pharma A/S.

Chait, Alan, MD
Disclosed no conflict of interest.

Chambers, Wiley A., II, MD
Disclosed no conflict of interest.

Champagne, Catherine M., PhD, RDN, LDN, FADA, FAND, FTOS
Disclosed no conflict of interest.

Chan, Christopher T., MD, FRCPC
Disclosed no conflict of interest.

Chan, David C., MD, PhD
Disclosed no conflict of interest.

Chan, Juliana C.N., MD

Chapman, Rick, PhD, MS
Disclosed no conflict of interest.

Chawla, Ajay, MD, PhD
Disclosed no conflict of interest.

Chen, Danica, PhD
Disclosed no conflict of interest.

Cheng, Alice Y.Y., MD, FRCPC

Cherney, David, MD, PhD

Chiasson, Jean-Louis, MD
Research Support: Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk Inc.

Chopra, Atul, MD, PhD
Disclosed no conflict of interest.

Chowdhury, Tahseen A., MD, FRCP
Disclosed no conflict of interest.

Cinar, Ali, PhD
Disclosed no conflict of interest.

Clements, Jennifer N., PharmD, FCCP, BCPS, CDE, BCACP
Disclosed no conflict of interest.

Cnop, Miriam, MD, PhD
Disclosed no conflict of interest.
Cobelli, Claudio, PhD

Cohen, Robert M., MD
Stock/Shareholder: Bristol-Myers Squibb Company.

Colberg, Sheri R., PhD, FACSM
Disclosed no conflict of interest.

Collins, Sheila, PhD

Collombat, Patrick, PhD
Disclosed no conflict of interest.

Cooper, David K.C., MD, PhD, FRCS
Disclosed no conflict of interest.

Corkey, Barbara E., PhD
Disclosed no conflict of interest.

Courcoulas, Anita P., MD, MPH

Cowie, Catherine C., PhD, MPH
Stock/Shareholder: Novo Nordisk Inc.

Crandall, Jill P., MD
Disclosed no conflict of interest.

Criqui, Michael H., MD, MPH
Disclosed no conflict of interest.

Cypress, Aaron M., MD, PhD, MMSc
Disclosed no conflict of interest.

Czech, Michael P., PhD
Disclosed no conflict of interest.

D’Alessio, David, MD

Dahl-Jørgensen, Knut, MD, PhD
Disclosed no conflict of interest.

Dalgaard, Louise T., PhD, MSc
Employee: Novo Nordisk A/S (Spouse/Partner); Stock/Shareholder: Novo Nordisk A/S, Novo Nordisk A/S (Spouse/Partner).

Dandaona, Paresh, MD

Dassau, Eyal, PhD

Davies, Melanie J., CBE, MB, ChB, MD, FRCP, FRCPG

Davis, Catherine L., PhD
Disclosed no conflict of interest.

Davis, Stephen N., MBBS
Disclosed no conflict of interest.

de Bock, Martin I., FRACP
Disclosed no conflict of interest.

de Groot, Mary, PhD
Consultant: Eli Lilly and Company, Johnson & Johnson Diabetes Institute, LLC.

De León-Crutchlow, Diva D., MD, MSCE
Consultant: ProSciento, XOMA Corporation; Employee: Merck & Co., Inc. (Spouse/Partner); Research Support: Biomarin Corporation, Zealand Pharma A/S.

de Zeeuw, Dick, MD, PhD

Dean, Danielle, PhD
Disclosed no conflict of interest.

Delamater, Alan M., PhD
Disclosed no conflict of interest.

Desai, Tejal, PhD
Stock/Shareholder: Encellin Inc.

Diano, Sabrina, PhD
Disclosed no conflict of interest.

DiMarchi, Richard, PhD
Disclosed no conflict of interest.
Doria, Alessandro, MD, PhD, MPH
Research Support: Sanofi-Aventis.

Doyle, Elizabeth Ann, DNP, APRN, CDE
Speaker's Bureau: Medtronic MiniMed, Inc.

Drucker, Daniel J., MD

Dufort, Matthew, PhD
Disclosed no conflict of interest.

Duke, Danny C., PhD
Disclosed no conflict of interest.

Dukhovny, Dmitry, MD, MPH
Disclosed no conflict of interest.

Dungan, Kathleen M., MD, MPH

Edelstein, Sharon L., ScM
Disclosed no conflict of interest.

Edgerton, Dale S., PhD
Speaker's Bureau: Novo Nordisk A/S.

Ehrenfeld, Jesse, MD, MPH
Disclosed no conflict of interest.

Ehrmann, David A., MD
Disclosed no conflict of interest.

Eiland, Leslie, MD
Disclosed no conflict of interest.

Ejskjaer, Niels, MD, PhD
Disclosed no conflict of interest.

Ellacott, Kate, PhD
Disclosed no conflict of interest.

Elmquist, Joel K., DVM, PhD
Consultant: Janssen Research & Development, Merck Sharp & Dohme Corp.

Ely, Elizabeth K., MS
Disclosed no conflict of interest.

Emanuele, Nicholas V., MD
Speaker's Bureau: Merck & Co., Inc.

Embíl, John M., MD
Disclosed no conflict of interest.

Estall, Jennifer L., PhD
Speaker's Bureau: Eli Lilly and Company.

Everhart, Damian, RN, PhD
Disclosed no conflict of interest.

Evert, Alison B., MS, RD, CDE
Disclosed no conflict of interest.

Farber, Steven A., PhD
Disclosed no conflict of interest.

Farooqui, Sadaf, PhD, FRCP, FMedSci
Disclosed no conflict of interest.

Fawzi, Amani, MD
Disclosed no conflict of interest.

Fedele, David, PhD
Disclosed no conflict of interest.

Feghali, Maisa N., MD
Disclosed no conflict of interest.

Feig, Denice S., MD, MSc, FRCPC
Research Support: Medtronic; Speaker's Bureau: Medtronic.

Fendrick, A. Mark, MD

Fernández-Hernando, Carlos, PhD
Disclosed no conflict of interest.

Ferrannini, Ele, MD
Disclosed no conflict of interest.

Ferrer, Jorge, MD, PhD
Disclosed no conflict of interest.

Fisher, Lawrence, PhD, ABPP
Consultant: Abbott, Eli Lilly and Company, Merck & Co., Inc.

Fisher, Simon J., MD, PhD
Disclosed no conflict of interest.

Flannick, Jason A., PhD
Disclosed no conflict of interest.

Florez, Hermes, MD
Advisory Panel: Sanofi.
Fonseca, Vivian, MD  

Forbes, Shareen, MB, ChB, PhD, FRCP  
Disclosed no conflict of interest.

Forlenza, Gregory P., MD  

Fortmann, Addie L., PhD  
Disclosed no conflict of interest.

Fradkin, Judith E., MD  
Disclosed no conflict of interest.

Frangou, Sophia, MD, MSc, PhD, FRCPsych  
Disclosed no conflict of interest.

Frias, Juan P., MD  

Fridman, Vera, MD  
Disclosed no conflict of interest.

Funai, Katsu, PhD  
Disclosed no conflict of interest.

Furuyama, Kenichiro, MD, PhD  
Disclosed no conflict of interest.

Gandica, Rachelle, MD  
Disclosed no conflict of interest.

Garg, Rajesh, MD  
Disclosed no conflict of interest.

Garland, Theodore, Jr., PhD  
Disclosed no conflict of interest.

Garvey, Katharine C., MD, MPH  
Disclosed no conflict of interest.

Garvey, W. Timothy, MD  

Gavin, Marc A., PhD  
Disclosed no conflict of interest.

Gerstein, Hertzl C., MD, MSc, FRCP  

Gilden, Janice L., MD, MS, FCP, FACE, FAAS  
Research Support: Kowa Company, Ltd.

Girotra, Monica, MD  
Disclosed no conflict of interest.

Goldberg, Ira J., MD  

Golden, Sherita, MD, MHS  
Disclosed no conflict of interest.

Gonder-Frederick, Linda, PhD  
Other Relationship: HFS-Global LLC.

Gonzalez, Frank J., PhD  
Disclosed no conflict of interest.

Goodyear, Laurie J., PhD  
Disclosed no conflict of interest.

Greeley, Siri Atma W., MD, PhD  
Research Support: Novo Nordisk Inc.

Greenlee, M. Carol, MD, FACE, FACP  
Disclosed no conflict of interest.

Gregg, Edward W., PhD  
Disclosed no conflict of interest.

Grice, Elizabeth A., PhD  
Disclosed no conflict of interest.

Griffin, Timothy, PhD  
Disclosed no conflict of interest.

Grunfeld, Carl, MD, PhD  
Omission due to printing deadline. Disclosure will be made onsite.
INVITED SPEAKER DISCLOSURES

Gubitosi-Klug, Rose, MD, PhD
Disclosed no conflict of interest.

Guzzardi, Maria A., PhD
Disclosed no conflict of interest.

Haller, Michael, MD
Disclosed no conflict of interest.

Hamm, Heidi E., PhD
Disclosed no conflict of interest.

Hannon, Tamara S., MD, MS
Consultant: Eli Lilly and Company.

Hardee, Sandra, PharmD, CDE
Disclosed no conflict of interest.

Hasson, Rebecca E., PhD
Disclosed no conflict of interest.

Heerspink, Hiddo Lambers, PhD

Heise, Tim, MD

Heisler, Lora K., PhD
Omission due to printing deadline. Disclosure will be made onsite.

Heisler, Michele, MD, MPA
Disclosed no conflict of interest.

Heller, Simon R., MD, FRCP
Advisory Panel: Boehringer Ingelheim GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi-Aventis, Takeda;


Hensrud, Donald D., MD, MPH
Disclosed no conflict of interest.

Herman, Mark A., MD
Consultant: Alkermes.

Hernandez, Teri L., PhD, RN
Disclosed no conflict of interest.

Herold, Kevan C., MD
Disclosed no conflict of interest.

Herrero-Viñas, Pau, PhD
Other Relationship: Cellnovo, Dexcom, Inc.

Hessler, Danielle M., PhD
Consultant: Eli Lilly and Company.

Hessner, Martin J., PhD
Disclosed no conflict of interest.

Hieronymus, Laura B., DNP, MSED, RN, MLDE, BC-ADM, CDE, FAADE
Disclosed no conflict of interest.

Higgins, John M., MD
Disclosed no conflict of interest.

Hill-Briggs, Felicia, PhD, ABPP
Board Member: American Diabetes Association.

Hinder, Lucy M., PhD
Disclosed no conflict of interest.

Hivert, Marie-France, MD
Disclosed no conflict of interest.

Hofer, Sabine E., MD, PhD
Disclosed no conflict of interest.

Hood, David A., PhD
Disclosed no conflict of interest.

Hood, Korey K., PhD
Consultant: Johnson & Johnson Diabetes Institute, LLC., Lilly Innovation Center; Research Support: Dexcom, Inc.

Horton, Mark B., OD, MD
Disclosed no conflict of interest.

Hsue, Priscilla, MD
Consultant: Gilead Sciences, Inc.; Other Relationship: Merck & Co., Inc.

Hugenschmidt, Christina E., PhD
Disclosed no conflict of interest.

Inturrisi, Maribeth, RN, MS, CNS, CDE
Disclosed no conflict of interest.
Isasi, Carmen R., MD, PhD  
Disclosed no conflict of interest.

Isganaitis, Elvira, MD, MPH  
Omission due to printing deadline. Disclosure will be made onsite.

Itsiopoulos, Catherine, BSc, BSc (Hons), Grad Dip Diet, MPH, PhD, APD, AN  
Disclosed no conflict of interest.

Jacobs, David, PhD  
Advisory Panel: California Walnut Commission; Consultant: California Walnut Commission.

James, David E., PhD  
Research Support: Pfizer Inc.

James, Eddie A., PhD  
Disclosed no conflict of interest.

Janicke, David, PhD, ABPP  
Disclosed no conflict of interest.

Jaser, Sarah S., PhD  
Disclosed no conflict of interest.

Jensen, Michael D., MD  
Consultant: Novo Nordisk A/S; Other Relationship: Novo Nordisk A/S.

Jetty, Anuradha, MPH  
Disclosed no conflict of interest.

Johnson, Mary L., RN, BS, CDE  

Johnson, Suzanne Bennett, PhD  
Disclosed no conflict of interest.

Jorsay, Donna, MS, BSN, CPNP, CNS, CDE, CDTC, BC-ADM  
Consultant: Becton, Dickinson and Company; Stock/Shareholder: Medtronic.

Kahn, C. Ronald, MD  
Advisory Panel: AntriaBio, Inc., CohBar, ERX Therapeutics; Board Member: Kaleo Biosciences.

Kalyani, Rita Rastogi, MD, MHS  
Disclosed no conflict of interest.

Kern, Timothy S., PhD  
Disclosed no conflict of interest.

Kernan, Walter, MD  
Disclosed no conflict of interest.

Khunti, Kamlesh, MD, PhD, FRCGP, FRCP, FMedSci  

Kibbey, Richard G., MD, PhD  
Disclosed no conflict of interest.

Kieffer, Edith C., PhD, MPH  
Disclosed no conflict of interest.

Kiguchi, Misaki, MD, MBA  
Disclosed no conflict of interest.

Kim, Jason K., PhD  
Disclosed no conflict of interest.

Kim, Young-Bum, PhD  
Disclosed no conflict of interest.

Kirkman, M. Sue, MD  
Consultant: National Institutes of Health; Research Support: Bayer AG, Centers for Disease Control and Prevention, National Institutes of Health, Theracos, Inc.

Kirwan, John P., PhD  
Disclosed no conflict of interest.

Klass, Evan, MD  
Disclosed no conflict of interest.

Kliweer, Steven, PhD  
Research Support: Novo Nordisk A/S.

Klonoff, David C., MD  

Knutsen, Patricia, NP-C, RN, MSN, ACNS-BC, CDE  
Omission due to printing deadline. Disclosure will be made onsite.

Kosiborod, Mikhail N., MD  
Kovatchev, Boris P., PhD

Kralli, Anastasia, PhD
Disclosed no conflict of interest.

Krieder, Kathryn Evans, DNP, FNP-BC, BC-ADM
Disclosed no conflict of interest.

Krischer, Jeffrey, PhD
Disclosed no conflict of interest.

Ku, Gregory, MD, PhD
Disclosed no conflict of interest.

Laffel, Lori, MD, MPH
Consultant: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Johnson & Johnson Diabetes Institute, LLC, MannKind Corporation, Novo Nordisk Inc., Roche Diagnostics Corporation, Sanofi US.

Lam, Tony K.T., PhD
Disclosed no conflict of interest.

Lane, Wendy S., MD

Lavery, Lawrence A., DPM

Lee, Chih-Hao, PhD
Disclosed no conflict of interest.

Lee, Christine S., PharmD, PhD
Disclosed no conflict of interest.

Lee, Joyce M., MD, MPH
Consultant: Unitio.

Lewis, Dana M., BA
Consultant: Tandem Diabetes Care, Inc.

Lexchin, Joel, MD
Board Member: Health Action international; Other Relationship: Canadian Institutes of Health Research; Research Support: Canadian Institutes of Health Research, National Health and Medical Research Council of Australia.

Ley, Sylvia H., PhD, RD
Disclosed no conflict of interest.

Li, Xiaoying, MD, PhD
Disclosed no conflict of interest.

Lichtman, Andrew H., MD, PhD
Disclosed no conflict of interest.

Ling, Charlotte, PhD
Disclosed no conflict of interest.

Liu, Feng, MD, PhD
Disclosed no conflict of interest.

Liu, Junli, PhD
Disclosed no conflict of interest.

Lönrot, Maria, MD, PhD
Disclosed no conflict of interest.

Loos, Ruth, PhD
Disclosed no conflict of interest.

Los, Evan A., MD
Disclosed no conflict of interest.

Lovshin, Julie A., MD, PhD

Lynch, Kristian F., PhD
Disclosed no conflict of interest.

Mackay, Dylan, MSc, PhD
Disclosed no conflict of interest.

Maechler, Pierre, PhD
Disclosed no conflict of interest.

Magee, Michelle F., MD, MB, BCh, LRCPsI

Magnuson, Mark A., MD
Disclosed no conflict of interest.

Mamula, Mark J., PhD
Disclosed no conflict of interest.

Mangia, Silvia, PhD
Disclosed no conflict of interest.

Mangione, Carol M., MD, MSPH
Disclosed no conflict of interest.

Manning, Alisa, PhD
Disclosed no conflict of interest.

Manson, Spero M., PhD
Disclosed no conflict of interest.

Marchetti, Piero, MD, PhD
Disclosed no conflict of interest.
Marso, Steven P., MD  

Maryniak, Melinda D., MEd, RD, CDE  
Advisory Panel: Foodicine Health; Consultant: Diabetes What to Know.

Mason, Susan Marshall, PhD, MPH  
Disclosed no conflict of interest.

Mather, Kieren J., MD  

Mathiesen, Elisabeth R., MD, DMSc  
Other Relationship: Novo Nordisk A/S, Novo Nordisk Foundation; Speaker's Bureau: Novo Nordisk A/S.

Mathieu, Chantal, MD, PhD  

Matsuoka, Takaaki, MD, PhD  
Disclosed no conflict of interest.

Matthews, Elizabeth, MPA  
Disclosed no conflict of interest.

McCaffery, Jeanne M., PhD  
Disclosed no conflict of interest.

McCarthy, Mark, MD  

McCurdy, Carrie, PhD  
Disclosed no conflict of interest.

McCowan, Philip C., PhD  

McGuire, Darren K., MD, MHSc  

McIntyre, Roger S., MD, FRCP  
Disclosed no conflict of interest.

Meier, Juris, MD  

Mena, Carlos, MD, FACC, FSCAI  
Disclosed no conflict of interest.

Meneghini, Luigi F., MD, MBA  

Messer, Laurel H., RN, MPH, CDE  
Other Relationship: Medtronic MiniMed, Inc.

Michels, Aaron, MD  
Stock/Shareholder: ImmunoMolecular Therapeutics.

Mike, Leigh Ann, PharmD, BCPS, BCGP  
Disclosed no conflict of interest.

Mingrone, Geltrude, MD, PhD  

Mirmira, Raghavendra G., MD, PhD  
Disclosed no conflict of interest.

Mitri, Joanna, MD, MS  
Consultant: AbbVie Inc. (Spouse/Partner), Biogen (Spouse/Partner), Janssen Pharmaceuticals, Inc. (Spouse/Partner), Merck & Co., Inc. (Spouse/Partner); Research Support: AbbVie Inc. (Spouse/Partner), Gilead Sciences, Inc. (Spouse/Partner), Janssen Pharmaceuticals, Inc. (Spouse/Partner), Kowa Pharmaceuticals America, Inc., National Dairy Council, Takeda Pharmaceuticals U.S.A., Inc. (Spouse/Partner).

Mohan, Viswanathan, MD, PhD, DSc  
Disclosed no conflict of interest.

Mohr, Susanne, PhD  
Disclosed no conflict of interest.
Molitch, Mark E., MD

Monaghan, Maureen, PhD

Morahan, Grant, BSc (Hons), PhD
Disclosed no conflict of interest.

Moran, Antoinette, MD

Morris, Jill, PhD
Disclosed no conflict of interest.

Morrison, William B., MD
Disclosed no conflict of interest.

Mottl, Amy K., MD
Disclosed no conflict of interest.

Murashov, Alexander K., MD, PhD
Omission due to printing deadline. Disclosure will be made onsite.

Murphy, Helen R., MD, FRACP

Myers, Martin G., Jr., MD, PhD

Nadeau, Kristen J., MD, MS
Disclosed no conflict of interest.

Najjar, Sonia M., PhD
Disclosed no conflict of interest.

Nassar, Carine M., MS, RD, CDE
Disclosed no conflict of interest.

Nathan, David M., MD
Research Support: Alere Inc.

Nelson, Robert, MD, PhD
Disclosed no conflict of interest.

Newcomer, John W., MD
Consultant: Alkermes, Indivior, Otsuka Holdings Co., Ltd., Sunovion Pharmaceuticals Inc.; Other Relationship: American Society of Clinical Psychopharmacology, Amgen Inc.; Research Support: JDRF (Spouse/Partner), National Institute of Allergy and Infectious Diseases (Spouse/Partner), National Institutes of Health.

Nicholls, David G., PhD
Disclosed no conflict of interest.

Norris, Jill M., PhD
Disclosed no conflict of interest.

O’Brien, Richard M., PhD
Disclosed no conflict of interest.

O’Tierney-Ginn, Perrie F., PhD
Disclosed no conflict of interest.

Oberholzer, Jose, MD
Other Relationship: CellTrans, Sigilon; Speaker’s Bureau: Novartis Pharmaceuticals Corporation, Sanofi.

Odorico, Jon S., MD, FACS
Advisory Panel: Regenerative Medical Solutions, Inc.; Other Relationship: Regenerative Medical Solutions, Inc.; Stock/Shareholder: Regenerative Medical Solutions, Inc.

Ogden, Cynthia L., PhD
Disclosed no conflict of interest.

Oram, Richard A., MD, PhD
Other Relationship: Randox.

Ozanne, Susan, PhD
Disclosed no conflict of interest.

Papa, Feroz R., MD, PhD
Omission due to printing deadline. Disclosure will be made onsite.

Paraskevas, Steven, MD, PhD
Disclosed no conflict of interest.

Parks, Brian, PhD
Disclosed no conflict of interest.

Parry, Samuel, MD
Disclosed no conflict of interest.

Pasquel, Francisco J., MD, MPH

Patel, Minal R., PhD, MPH
Disclosed no conflict of interest.

Patel, Shivani A., PhD
Disclosed no conflict of interest.

Pavkov, Meda E., MD, PhD
Disclosed no conflict of interest.

Pellizzari, Margaret, MS, MBA, RN, CDE, CDTC
Disclosed no conflict of interest.

Perkins, Bruce A., MD, MPH
Perkowitz, Susie  
Disclosed no conflict of interest.

Perrault, Leigh, MD  

Peters, Edgar J.G., MD, PhD  
Disclosed no conflict of interest.

Phelps, Edward, PhD  
Disclosed no conflict of interest.

Philipson, Louis H., MD, PhD  

Philis-Tsimikas, Athena, MD  

Piatt, Gretchen A., PhD, MPH  
Disclosed no conflict of interest.

Pickering, Matthew, PharmD  

Piette, John D., PhD  
Disclosed no conflict of interest.

Pihoker, Catherine, MD  
Disclosed no conflict of interest.

Pipeleers, Daniel, MD, PhD  
Disclosed no conflict of interest.

Plomgaard, Peter, MD, PhD  
Disclosed no conflict of interest.

Probst, Janice C., PhD  
Disclosed no conflict of interest.

Pullen, Timothy, PhD  
Disclosed no conflict of interest.

Qi, Lu, MD, PhD  
Disclosed no conflict of interest.

Ramchandani, Neesha, PNP, CDE, CDTC  
Disclosed no conflict of interest.

Rangaswami, Janani, MD, FACP  
Disclosed no conflict of interest.

Rasouli, Neda, MD  
Consultant: AstraZeneca, Intarcia Therapeutics, Inc.

Reaven, Peter D., MD  

Remaley, Alan T., MD  
Disclosed no conflict of interest.

Resnick, Barbara, PhD, RN, CRNP  
Disclosed no conflict of interest.

Reusch, Jane E.B., MD  
Board Member: American Diabetes Association; Other Relationship: Sanofi-Aventis; Research Support: AstraZeneca, Merck & Co., Inc.

Reutrakul, Sirimon, MD  
Research Support: Merck Sharp & Dohme Corp.; Speaker’s Bureau: Medtronic, Novo Nordisk Inc.

Rich, Stephen S., PhD  
Disclosed no conflict of interest.

Rckels, Michael R., MD, MS  
Consultant: Hua Medicine, Xeris Pharmaceuticals, Inc.

Ricordi, Camillo, MD  
Disclosed no conflict of interest.

Riley, Andrew, PhD  
Disclosed no conflict of interest.

Rodbard, Helena W., MD  

Roden, Michael, MD  
Consultant: Poxel SA; Research Support: Boehringer Ingelheim GmbH, Danone Nutricia Early Life Nutrition, GlaxoSmithKline plc., Nutricia Advanced Medical Nutrition, Sanofi; Speaker’s Bureau: Boehringer Ingelheim GmbH.

Rodgers, Griffin P., MD  
Disclosed no conflict of interest.
Disclosed no conflict of interest.

Saydah, Sharon, PhD
Disclosed no conflict of interest.

Schneiderman, Neil, PhD
Disclosed no conflict of interest.

Schroeder, Emily B., MD, PhD
Disclosed no conflict of interest.

Scialla, Julia, MD

Segar, Michelle, PhD, MPH
Other Relationship: National Center for Behavioral Sustainability; Speaker’s Bureau: Beaumont Medical Center, Blue Cross and Blue Shield of North Dakota/ South Dakota, Centre for Positive Psychology, Melbourne Australia, Iowa State, Kaiser Permanente, Michigan Health Improvement Alliance, Inc., Resistance Exercise Conference.

Segerstolpe, Åsa, PhD
Disclosed no conflict of interest.

Seggelke, Stacey A., DNP, ACNS-BC, BC-ADM, CDE
Disclosed no conflict of interest.

Selvarajah, Dinesh, MB, ChB, MRCP, PhD
Disclosed no conflict of interest.

Senior, Peter A., MBBS, PhD

Senneville, Eric, MD, PhD
Shah, Amy S., MD  
Disclosed no conflict of interest.

Shah, Nilay D., PhD  
Disclosed no conflict of interest.

Shalev, Anath, MD  
Disclosed no conflict of interest.

Shaw, Jonathan E., MD, FRACP, FRCP (UK), FAAHMS  

Shea, Lonnie D., PhD  
Disclosed no conflict of interest.

Shea, Patricia, MPH, MA  
Disclosed no conflict of interest.

Sherr, Jennifer, MD, PhD  

Shulman, Gerald I., MD, PhD, FACP, MACE  

Siminerio, Linda M., RN, PhD, CDE  
Disclosed no conflict of interest.

Singleton, J. Robinson, MD  
Disclosed no conflict of interest.

Smith, Lois E.H., MD, PhD  
Disclosed no conflict of interest.

Smyth, Hugh, PhD  
Consultant: Nob Hill Therapeutics, Respira Therapeutics; Other Relationship: Via Therapeutics.

Sneddon, Julie B., PhD  
Advisory Panel: Encellin; Consultant: Semma Therapeutics, Inc.

Soleimanpour, Scott A., MD  
Disclosed no conflict of interest.

Soukas, Alexander, MD, PhD  
Disclosed no conflict of interest.

Spangenburg, Espen E., PhD  
Disclosed no conflict of interest.

Speier, Stephan, PhD  
Disclosed no conflict of interest.

Stanford, Kristin I., PhD  
Disclosed no conflict of interest.

Star, Robert A., MD  
Disclosed no conflict of interest.

Steinhauser, Matthew, MD  
Omission due to printing deadline. Disclosure will be made onsite.

Sullivan, Sean D., BSc Pharm, PhD  
Disclosed no conflict of interest.

Sun, Jennifer K., MD, MPH  

Sunahara, Roger K., PhD  
Employee: Pfizer Inc. (Spouse/Partner).

Sundstrom, Jeffrey M., MD, PhD  
Disclosed no conflict of interest.

Sussel, Lori, PhD  
Disclosed no conflict of interest.

Swisa, Avital, PhD  
Disclosed no conflict of interest.

Sylvetsky, Allison, PhD  
Disclosed no conflict of interest.

Tabak, Rachel G.A., PhD, RD  
Other Relationship: Centene Corporation, Envolve PeopleCare.

Tamborlane, William V., MD  

Tarnopolsky, Mark A., MD, PhD, FRCP  
Speaker’s Bureau: Sanofi Genzyme; Stock/Shareholder: Exerkine Corporation.

Tate, Deborah, PhD  
Board Member: Weight Watchers International, Inc.

Tay, Jeannie, PhD  
Disclosed no conflict of interest.

Teplitzky, Lena, MPH  
Omission due to printing deadline. Disclosure will be made onsite.

Thabit, Hood, MD, PhD  
Disclosed no conflict of interest.

Thomas, Celeste C., MD, MS  
Disclosed no conflict of interest.

Thomas, Merlin, MB, ChB, PhD, FRACP  
Thompson, David M., MD
Advisory Panel: Novo Nordisk Inc.

Thorens, Bernard, PhD
Disclosed no conflict of interest.

Tien, Phyllis, MD
Disclosed no conflict of interest.

Tolan, Dean R., PhD
Stock/Shareholder: Colorado Research Partners, LLC.

Tomas, Alejandra, PhD
Disclosed no conflict of interest.

Trence, Dace, MD
Stock/Shareholder: Medtronic, Sanofi-Aventis.

Trief, Paula M., PhD

Tsai, Linus T.-Y., MD, PhD
Disclosed no conflict of interest.

Tsapas, Apostolos, MD, PhD, MSc
Other Relationship: Novartis AG; Research Support: Boehringer Ingelheim GmbH, GlaxoSmithKline plc.

Tse, Hubert M., PhD
Disclosed no conflict of interest.

Tseng, Yu-Hua, PhD

Tsimikas, Sotirios, MD, FACC, FAHA, FSCAI
Consultant: Novo Nordisk Inc. (Spouse/Partner).

Udell, Jacob A., MD, MPH, FRCP

Udler, Miriam, MD, PhD
Disclosed no conflict of interest.

Umpierrez, Guillermo E., MD, CDE, FACP, FACE

Urano, Fumihiko, MD, PhD
Research Support: Eli Lilly and Company; Stock/Shareholder: CytrRx.

Ussar, Siegfried, PhD
Disclosed no conflict of interest.

van Lieshout, Johannes, MD
Disclosed no conflict of interest.

Van Name, Michelle A., MD
Disclosed no conflict of interest.

van Praag, Henriette, PhD
Disclosed no conflict of interest.

van Raalte, Daniël H., MD, PhD

Vantyghem, Marie-Christine, MD, PhD
Board Member: Aegerion Pharmaceuticals; Other Relationship: Elsevier; Research Support: Ipsen Biopharmaceuticals, Inc., Novartis Pharmaceuticals Corporation.

Vatanen, Tommi, PhD
Disclosed no conflict of interest.

Vegas, Arturo J., PhD
Consultant: Sigilon Therapeutics.

Veijola, Riitta, MD, PhD
Advisory Panel: Janssen Research & Development.

Venditti, Elizabeth M., PhD
Disclosed no conflict of interest.

Verma, Anil
Omission due to printing deadline. Disclosure will be made onsite.

Wagner, David V., PhD
Disclosed no conflict of interest.

Wang, Ping H., MD
Disclosed no conflict of interest.

Wanner, Christoph, MD
Board Member: Boehringer Ingelheim GmbH, Sanofi Genzyme.

Wareham, Nicholas, PhD
Disclosed no conflict of interest.

Watt, Matthew J., PhD
Disclosed no conflict of interest.

Weissberg-Benchell, Jill, PhD, CDE
Disclosed no conflict of interest.

Wess, Jürgen, PhD
Disclosed no conflict of interest.

Wexler, Deborah J., MD, MSc
Disclosed no conflict of interest.

Wharam, J. Frank, MB, BCh, BAO, MPH
Disclosed no conflict of interest.

White, Morris F., PhD
Advisory Panel: Housey Pharmaceutical Research Laboratories.
Wiitala, Wyndy L., PhD  
Disclosed no conflict of interest.

Williams, Mark D., MD  
Disclosed no conflict of interest.

Wittmer, Jason B., MD, FCCP  
Disclosed no conflict of interest.

Wolfsdorf, Joseph, MB, BCh  
Other Relationship: A. Menarini Diagnostics, UpToDate, Xeris Pharmaceuticals, Inc.

Wyckoff, Jennifer, MD  
Other Relationship: Inspirata (Spouse/Partner).

Wylie-Rosett, Judith, EdD, RD  
Disclosed no conflict of interest.

Wysham, Carol H., MD  

Wysocki, Tim, PhD, ABPP  
Disclosed no conflict of interest.

Yang, Xia, PhD  
Disclosed no conflict of interest.

Young, Laura A., MD, PhD  
Omission due to printing deadline. Disclosure will be made onsite.

Youssef, Gretchen A., MS, RD, CDE  
Disclosed no conflict of interest.

Yu, Liqing, MD, PhD  
Disclosed no conflict of interest.

Zaidi, Mone, MD, PhD  
Disclosed no conflict of interest.

Zeitler, Philip S., MD, PhD  

Zhou, Changcheng, PhD  
Disclosed no conflict of interest.

Zhu, Zhiming, MD  
Disclosed no conflict of interest.

Zinman, Bernard, MD  

Zorzano, Antonio, PhD  
Disclosed no conflict of interest.
**INDICATIONS AND USAGE:** OZEMPIC® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: OZEMPIC® is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans [see Warnings and Precautions]. OZEMPIC® has not been studied in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin value for early detection of MTC in patients treated with OZEMPIC® [see Contraindications and Warnings and Precautions].

**WARNINGS AND PRECAUTIONS:** Risk of Thyroid C-Cell Tumors: In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure at clinically relevant plasma exposures. It is unknown whether OZEMPIC® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions]. OZEMPIC® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications]. Counsel patients regarding the potential risk for MTC with the use of OZEMPIC® and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC® [see Contraindications and Warnings and Precautions].

**ADVERSE REACTIONS:** The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-Cell Tumors [see Warnings and Precautions]; Pancreatitis [see Warnings and Precautions]; Diabetic Retinopathy Complications [see Warnings and Precautions]; Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions]; Acute Kidney Injury [see Warnings and Precautions]; Worsening of Chronic Kidney Disease [see Warnings and Precautions]. Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Pool of Placebo-Controlled Trials: The data in Table 1 are derived from 2 placebo-controlled trials in patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with OZEMPIC® (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (OZEMPIC® 8.2%, placebo 5.2%) than among patients without a known history of diabetic retinopathy (OZEMPIC® 0.7%, placebo 0.4%). Rapid improvement in glucose control has been associated with a temporarily worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. Never Share an OZEMPIC® Pen Between Patients: OZEMPIC® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: The risk of hypoglycemia is increased when OZEMPIC® is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Patients may require a lower dose of the secretagogue or insulin to reduce the risk of hypoglycemia. In this setting [see Adverse Reactions, Drug Interactions]. Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of OZEMPIC® in patients reporting severe adverse gastrointestinal reactions. Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of OZEMPIC®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity to OZEMPIC® [see Contraindications]. Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with OZEMPIC®. Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with OZEMPIC®.
(eGFR ≥90 mL/min/1.73m²) in 57.2%, mildly impaired (eGFR 60 to 90 mL/min/1.73m²) in 35.9% and moderately impaired (eGFR 30 to 60 mL/min/1.73m²) in 6.9% of patients. Pool of Placebo- and Active-Controlled Trials: The occurrence of adverse reactions was also evaluated in a larger pool of patients with type 2 diabetes participating in 7 placebo- and active-controlled glycemic control trials including two trials in Japanese patients evaluating the use of OZEMPIC® as monotherapy and add-on therapy to oral medications or insulin. In this pool, a total of 3150 patients with type 2 diabetes were treated with OZEMPIC® for a mean duration of 44.9 weeks. Across the treatment arms, the mean age of patients was 57 years, 3.2% were 75 years or older and 57% were male. In these trials, 60% were White, 6% were Black or African American, and 31% were Asian; 16% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes for an average of 8.2 years and had a mean HbA1c of 8.2%. At baseline, 7.8% of the population reported retinopathy. Baseline estimated renal function was normal (eGFR ≥90 mL/min/1.73m²) in 63.1%, mildly impaired (eGFR 60 to 90 mL/min/1.73m²) in 34.3%, and moderately impaired (eGFR 30 to 60 mL/min/1.73m²) in 2.5% of the patients. Common Adverse Reactions: Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of OZEMPIC® in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on OZEMPIC® than on placebo, and occurred in at least 5% of patients treated with OZEMPIC®.

Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC®-Treated Patients with Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Placebo (N=262) %</th>
<th>OZEMPIC® 0.5 mg (N=260) %</th>
<th>OZEMPIC® 1 mg (N=261) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>6.1</td>
<td>15.8</td>
<td>20.3</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2.3</td>
<td>5.0</td>
<td>9.2</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1.9</td>
<td>8.5</td>
<td>8.8</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>4.6</td>
<td>7.3</td>
<td>5.7</td>
</tr>
<tr>
<td>Constipation</td>
<td>1.5</td>
<td>5.0</td>
<td>3.1</td>
</tr>
</tbody>
</table>

In the pool of placebo- and active-controlled trials and in the 2-year cardiovascular outcomes trial, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in Table 1. Gastrointestinal Adverse Reactions: In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving OZEMPIC® than placebo (placebo 15.3%, OZEMPIC® 0.5 mg 32.7%, OZEMPIC® 1 mg 36.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving OZEMPIC® 0.5 mg (31%) and OZEMPIC® 1 mg (38%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5% were associated with OZEMPIC® (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.6%, 0.8%, 0.4%). Other Adverse Reactions: Hypoglycemia: Table 2 summarizes the incidence of events related to hypoglycemia by various definitions in the placebo-controlled trials.

Table 2. Hypoglycemia Adverse Reactions in Placebo-Controlled Trials In Patients with Type 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Monotherapy</th>
<th>Placebo</th>
<th>OZEMPIC® 0.5 mg</th>
<th>OZEMPIC® 1 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>(30 weeks)</td>
<td>N=132</td>
<td>N=132</td>
<td>N=131</td>
</tr>
<tr>
<td>Severe†</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Documented symptomatic (≤70 mg/dL glucose threshold)</td>
<td>0%</td>
<td>1.6%</td>
<td>3.8%</td>
</tr>
<tr>
<td>Severe† or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)</td>
<td>1.6%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Add-on to Basal Insulin with or without Metformin

<table>
<thead>
<tr>
<th>(30 weeks)</th>
<th>N=132</th>
<th>N=132</th>
<th>N=131</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe†</td>
<td>0%</td>
<td>0%</td>
<td>1.5%</td>
</tr>
<tr>
<td>Documented symptomatic (≤70 mg/dL glucose threshold)</td>
<td>15.2%</td>
<td>16.7%</td>
<td>29.8%</td>
</tr>
<tr>
<td>Severe† or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)</td>
<td>5.3%</td>
<td>8.3%</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

"Severe" hypoglycemia adverse reactions are episodes requiring the assistance of another person. Hypoglycemia was more frequent when OZEMPIC® was used in combination with a sulfonylurea [see Warnings and Precautions]. Severe hypoglycemia occurred in 0.8% and 1.2% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Documented symptomatic hypoglycemia occurred in 17.9% and 24.4% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Severe or blood glucose confirmed symptomatic hypoglycemia occurred in 6.5% and 10.4% of patients when OZEMPIC® 0.5 mg and 1 mg, respectively, was co-administered with a sulfonylurea. Injection Site Reactions: In placebo-controlled trials, injection site reactions (e.g., injection-site discomfort, erythema) were reported in 0.2% of OZEMPIC®-treated patients. Increases in Amylase and Lipase: In placebo-controlled trials, patients exposed to OZEMPIC® had a mean increase from baseline in amylase of 13% and lipase of 22%. These changes were not observed in placebo-treated patients. Cholelithiasis: In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with OZEMPIC® 0.5 mg and 1 mg, respectively. Cholelithiasis was not reported in placebo-treated patients. Increases in Heart Rate: In placebo-controlled trials, OZEMPIC® 0.5 mg and 1 mg resulted in a mean increase in heart rate of 2 to 3 beats per minute. There was a mean decrease in heart rate of 0.3 beats per minute in placebo-treated patients. Fatigue, Dysgeusia and Dizziness: Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC® include fatigue, dysgeusia and dizziness. Immunogenicity: Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients treated with OZEMPIC® may develop anti-semaglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to semaglutide in the studies described below cannot be directly compared with the incidence of antibodies in other studies or to other products. Across the placebo- and active-controlled glycemic control trials, 32 (1.0%) OZEMPIC®-treated patients developed anti-drug antibodies (ADAs) to the active ingredient in OZEMPIC® (i.e., semaglutide). Of the 32 semaglutide-treated patients that developed semaglutide ADAs, 19 patients (0.6% of the overall population) developed antibodies cross-reacting with native GLP-1. In the in vitro neutralizing activity of the antibodies is uncertain at this time.

DRUG INTERACTIONS: Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin: The risk of hypoglycemia is increased when OZEMPIC® is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see Warnings and Precautions]. Oral
Medications: OZEMPIC® causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. In clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree. Nonetheless, caution should be exercised when oral medications are concomitantly administered with OZEMPIC®.

USE IN SPECIFIC POPULATIONS: Pregnancy: Risk Summary: There are limited data with semaglutide use in pregnant women to inform a drug–associated risk for adverse developmental outcomes. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. OZEMPIC® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at maternal exposures below the maximum recommended human dose (MRHD) based on AUC. In rabbits and cynomolgus monkeys administered semaglutide during organogenesis, early pregnancy losses and structural abnormalities were observed at below the MRHD (rabbit) and ≥5-fold the MRHD (monkey). These findings coincided with a marked maternal body weight loss in both animal species (see Data). The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c >7 and has been reported to be as high as 20–25% in women with a HbA1c >10. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Clinical Considerations: Disease associated maternal and fetal risk. Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data: Animal Data: In a combined fertility and embryofetal development study in rats, subcutaneous doses of 0.01, 0.03 and 0.09 mg/kg/day (0.1-, 0.4-, and 1.1-fold the MRHD) were administered to males for 4 weeks prior to and throughout mating and to females for 2 weeks prior to mating, and throughout organogenesis to Gestation Day 17. In parental animals, pharmacologically mediated reductions in body weight gain and food consumption were observed at all dose levels. In the offspring, reduced growth and fetuses with visceral (heart blood vessels) and skeletal (cranial bones, vertebra, ribs) abnormalities were observed at the human exposure. In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.0010, 0.0025 or 0.0075 mg/kg/day (0.03-, 0.3-, and 5X human exposure). In a combined fertility and embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (1.0-, 5.2-, and 14.9-fold the MRHD) were administered throughout organogenesis from Gestation Day 16 to 19. Pharmacologically mediated reductions in maternal body weight gain and food consumption were observed at all dose levels. Early pregnancy losses and increased incidences of minor visceral (kidney, liver) and skeletal (sternebra) fetal abnormalities were observed at ≥0.0025 mg/kg/day, at clinically relevant exposures. In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (1.0-, 5.2-, and 14.9-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50. Pharmacologically mediated, marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with the occurrence of sporicardial abnormalities (vertebra, sternebra, ribs) at ≥0.075 mg/kg twice weekly (≥5X human exposure). In a pre- and postnatal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (0.7-, 3.3-, and 7.2-fold the MRHD) were administered from Gestation Day 16 to 140. Pharmacologically mediated marked initial maternal body weight loss and reductions in body weight gain and food consumption coincided with an increase in early pregnancy loss and led to delivery of slightly smaller offspring at ≥0.075 mg/kg twice weekly (≥3X human exposure). Lactation: Risk Summary: There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Semaglutide was present in the milk of lactating rats, however, due to species-specific differences in lactation physiology, the clinical relevance of these data are not clear (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OZEMPIC® and any potential adverse effects on the breastfed infant from OZEMPIC® or from the underlying maternal condition. Data: In lactating rats, semaglutide was detected in milk at levels 3-12 fold lower than in maternal plasma. Females and Males of Reproductive Potential: Discontinue OZEMPIC® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide (see Use in Specific Populations). Pediatric Use: Safety and efficacy of OZEMPIC® have not been established in pediatric patients (younger than 18 years). Geriatric Use: In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC®-treated patients were 65 years of age and over and 102 OZEMPIC®-treated patients (3.2%) patients were 75 years of age and over. In SUSTAIN 6, the cardiovascular outcome trial, 788 (48.0%) OZEMPIC®-treated patients were 65 years of age and over and 157 OZEMPIC®-treated patients (9.6%) patients were 75 years of age and over. No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Renal Impairment: No dose adjustment of OZEMPIC® is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no clinically relevant change in semaglutide pharmacokinetics (PK) was observed. Hepatic Impairment: No dose adjustment of OZEMPIC® is recommended for patients with hepatic impairment. In a study in subjects with different degrees of hepatic impairment, no clinically relevant change in semaglutide pharmacokinetics (PK) was observed. OVERDOSAGE: in the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of OZEMPIC® of approximately 1 week. More detailed information is available upon request. For information about OZEMPIC®, contact: Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ 08536, 1-888-693-6742 Date of Issue: December 2017 Version: 1 Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark OZEMPIC® and NovoFine® are registered trademarks of Novo Nordisk A/S. PATENT INFORMATION: http://novonordisk-us.com/patients/products/product-patents.html © 2018 Novo Nordisk US18OZM00021 4/2018
Indication and Limitations of Use

Ozempic® (semaglutide) injection 0.5 mg or 1 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

- Ozempic® is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- Ozempic® has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Ozempic® is not a substitute for insulin. Ozempic® is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.